PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Alb, JG; Cortese, JD; Phillips, SE; Albin, RL; Nagy, TR; Hamilton, BA; Bankaitis, VA				Alb, JG; Cortese, JD; Phillips, SE; Albin, RL; Nagy, TR; Hamilton, BA; Bankaitis, VA			Mice lacking phosphatidylinositol transfer protein-alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYLOMICRON RETENTION DISEASE; PHOSPHOLIPID TRANSFER PROTEIN; EMBRYONIC STEM-CELLS; TRANSLATIONAL CONTROL; MAST-CELLS; YEAST; CLONING; RAT; ENCEPHALOMYELITIS; COMPLEMENTATION	Phosphatidylinositol transfer proteins (PITPs) regulate the interface between lipid metabolism and cellular functions. We now report that ablation of PITPalpha function leads to aponecrotic spinocerebellar disease, hypoglycemia, and intestinal and hepatic steatosis in mice. The data indicate that hypoglycemia is in part associated with reduced proglucagon gene expression and glycogenolysis that result from pancreatic islet cell defects. The intestinal and hepatic steatosis results from the intracellular accumulation of neutral lipid and free fatty acid mass in these organs and suggests defective trafficking of triglycerides and diacylglycerols from the endoplasmic reticulum. We propose that deranged intestinal and hepatic lipid metabolism and defective proglucagon gene expression contribute to hypoglycemia in PITPalpha(-/-) mice, and that hypoglycemia is a significant contributing factor in the onset of spinocerebellar disease. Taken together, the data suggest an unanticipated role for PITPalpha in with glucose homeostasis and in mammalian endoplasmic reticulum functions that interface with transport of specific luminal lipid cargoes.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Michigan, Sch Med, Dept Neurol, Ann Arbor Vet Affairs Med Ctr GRECC, Ann Arbor, MI 48104 USA; Univ Alabama, Dept Nutr, Birmingham, AL 35294 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Diego	Bankaitis, VA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.			PHILLIPS, SCOTT/0000-0002-5451-0984; Nagy, Tim/0000-0002-2371-7114; Hamilton, Bruce/0000-0001-5599-9139	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS037723, R01NS037723] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK056350, DK56350] Funding Source: Medline; NIGMS NIH HHS [R01 GM086912] Funding Source: Medline; NIMH NIH HHS [R01 MH059207] Funding Source: Medline; NINDS NIH HHS [R56 NS037723, R01 NS037723, NS37723] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguglia U, 2000, ANN NEUROL, V47, P260, DOI 10.1002/1531-8249(200002)47:2<260::AID-ANA21>3.0.CO;2-V; Alb JG, 2002, MOL BIOL CELL, V13, P739, DOI 10.1091/mbc.01-09-0457; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bebo BF, 1996, J NEUROSCI RES, V45, P340; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Fullwood Y, 1999, J BIOL CHEM, V274, P31553, DOI 10.1074/jbc.274.44.31553; GALLI SJ, 1984, PROG ALLERGY, V34, P1; GAUTHIER S, 1983, ANN NEUROL, V14, P591, DOI 10.1002/ana.410140517; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; Levy E, 1996, CLIN INVEST MED, V19, P317; Li XM, 2002, J CELL BIOL, V157, P63, DOI 10.1083/jcb.200201037; LUNA LG, 1968, MANUAL HISTOLOGIC ST, P143; MASCORRO JA, 1986, P 44 ANN M EL MICR S, P222; Milligan SC, 1997, J CELL BIOL, V139, P351, DOI 10.1083/jcb.139.2.351; NAGY TR, 1994, CAN J ZOOL, V72, P1726, DOI 10.1139/z94-233; NELSON DL, 2000, LEHNINGER PRINCIPLES, P729; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; PENDER MP, 1990, ACTA NEUROPATHOL, V80, P172, DOI 10.1007/BF00308921; ROY CC, 1987, GASTROENTEROLOGY, V92, P390, DOI 10.1016/0016-5085(87)90133-8; Sato T, 1968, J Electron Microsc (Tokyo), V17, P158; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; WEIMAR WR, 1982, BRAIN RES, V251, P357, DOI 10.1016/0006-8993(82)90754-5; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Yanagisawa LL, 2002, MOL BIOL CELL, V13, P2193, DOI 10.1091/mbc.01-11-0563; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	42	87	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33501	33518		10.1074/jbc.M303591200	http://dx.doi.org/10.1074/jbc.M303591200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12788952	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000184901800124
J	Ber, I; Shternhall, K; Perl, S; Ohanuna, Z; Goldberg, I; Barshack, I; Benvenisti-Zarum, L; Meivar-Levy, I; Ferber, S				Ber, I; Shternhall, K; Perl, S; Ohanuna, Z; Goldberg, I; Barshack, I; Benvenisti-Zarum, L; Meivar-Levy, I; Ferber, S			Functional, persistent, and extended liver to pancreas transdifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOVIRAL VECTORS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; FACTOR 1-ALPHA; CELL FUNCTION; DIFFERENTIATION; PDX-1; HEPATOCYTES; HNF-1-ALPHA; ACTIVATION	Pancreatic and duodenal homeobox gene-1 (PDX-1) regulates pancreas development during embryogenesis, whereas in the adult it controls beta-cell function. Here we analyze whether PDX-1 functions as a pancreatic differentiation factor and a bona fide master regulator when ectopically expressed in mature fully differentiated liver in vivo. By ectopic and transient PDX-1 expression in liver in vivo, using the first generation recombinant adenoviruses, we demonstrate that PDX-1 induces in liver a wide repertoire of both exocrine and endocrine pancreatic gene expression. Moreover, PDX-1 induces its own expression (auto-induction), which in turn may explain the long lasting nature of the "liver to pancreas" transdifferentiation. Insulin as well glucagon-producing cells are mainly located in the proximity of hepatic central veins, possibly allowing direct hormone release into the bloodstream, without affecting normal hepatic function. Importantly, we demonstrate that hepatic insulin production triggered by Ad-CMV-PDX-1 recombinant adenovirus administration is functional and prevents streptozotocin-induced hyperglycemia in Balb/c mice even 8 months after the initial treatment. We conclude that PDX-1 plays an important instructive role in pancreas differentiation, not only from primitive gut endoderm but also from mature liver. Transconversion of liver to pancreas may serve as a novel approach for generating endocrine-pancreatic tissue that can replace malfunctioning beta-cells in diabetics.	Chaim Sheba Med Ctr, Endocrine Inst, IL-52621 Tel Hashomer, Israel; Meir Med Ctr, IL-44281 Kefar Sava, Israel; Tel Aviv Univ, Sackler Sch Med, IL-67978 Tel Aviv, Israel; Bar Ilan Univ, IL-52900 Ramat Gan, Israel; Chaim Sheba Med Ctr, Inst Pathol, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Bar Ilan University; Chaim Sheba Medical Center	Ferber, S (corresponding author), Chaim Sheba Med Ctr, Endocrine Inst, IL-52621 Tel Hashomer, Israel.	sferber@sheba.health.gov.il	Wilson, Matthew H/K-3193-2013	Ferber, Sarah/0000-0003-2764-2786				Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Christoffels VM, 1999, HEPATOLOGY, V29, P1180, DOI 10.1002/hep.510290413; Dabeva MD, 1997, P NATL ACAD SCI USA, V94, P7356, DOI 10.1073/pnas.94.14.7356; Desmet VJ, 2001, LIVER BIOL PATHOBIOL, P3; Deutsch G, 2001, DEVELOPMENT, V128, P871; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Ferber S, 2000, ISR MED ASSOC J, V2, P32; Fernandes A, 1997, ENDOCRINOLOGY, V138, P1750, DOI 10.1210/en.138.4.1750; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; Gill DR, 2001, GENE THER, V8, P1539, DOI 10.1038/sj.gt.3301561; GUZ Y, 1995, DEVELOPMENT, V121, P11; Horb ME, 2003, CURR BIOL, V13, P105, DOI 10.1016/S0960-9822(02)01434-3; Hui HX, 2002, EUR J ENDOCRINOL, V146, P129, DOI 10.1530/eje.0.1460129; Hussain MA, 2002, J BIOL CHEM, V277, P16028, DOI 10.1074/jbc.M107124200; Jungermann K, 2000, HEPATOLOGY, V31, P255, DOI 10.1002/hep.510310201; KNAACK D, 1994, DIABETES, V43, P1413, DOI 10.2337/diabetes.43.12.1413; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; Krakowski ML, 1999, AM J PATHOL, V154, P683, DOI 10.1016/S0002-9440(10)65315-1; Krones A, 1998, FEBS LETT, V421, P136, DOI 10.1016/S0014-5793(97)01556-1; Lamers WH, 1999, J HISTOCHEM CYTOCHEM, V47, P1507, DOI 10.1177/002215549904701202; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Li XK, 2002, MOL THER, V5, P262, DOI 10.1006/mthe.2002.0543; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; Peeters MJTFDV, 1996, HUM GENE THER, V7, P1693, DOI 10.1089/hum.1996.7.14-1693; REDDY JK, 1984, J CELL BIOL, V98, P2082, DOI 10.1083/jcb.98.6.2082; Roth MD, 2002, J IMMUNOL, V169, P4651, DOI 10.4049/jimmunol.169.8.4651; Roth U, 2002, BIOCHEM J, V365, P223, DOI 10.1042/BJ20020340; SCARPELLI DG, 1981, P NATL ACAD SCI-BIOL, V78, P2577, DOI 10.1073/pnas.78.4.2577; SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326; Seijffers R, 1999, ENDOCRINOLOGY, V140, P3311, DOI 10.1210/en.140.7.3311; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Shih DQ, 2002, P NATL ACAD SCI USA, V99, P3818, DOI 10.1073/pnas.062605899; Soria B, 2001, DIFFERENTIATION, V68, P205, DOI 10.1046/j.1432-0436.2001.680408.x; Tabiin MT, 2001, J AUTOIMMUN, V17, P229, DOI 10.1006/jaut.2001.0539; Varda-Bloom N, 2001, GENE THER, V8, P819, DOI 10.1038/sj.gt.3301472; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Wang X, 2001, AM J PATHOL, V158, P571, DOI 10.1016/S0002-9440(10)63999-5; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3	47	208	223	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31950	31957		10.1074/jbc.M303127200	http://dx.doi.org/10.1074/jbc.M303127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12775714	hybrid			2022-12-25	WOS:000184782100063
J	Wu, C; Ghosh, S				Wu, C; Ghosh, S			Differential phosphorylation of the signal-responsive domain of I kappa B alpha and I kappa B alpha by I kappa B kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS TYPE-1; IKK-BETA SUBUNIT; PERSISTENT ACTIVATION; CRYSTAL-STRUCTURE; MICE LACKING; COMPLEX; EXPRESSION; DEGRADATION; PROTEINS; INACTIVATION	NF-kappaB activity is regulated by its association with the inhibitory IkappaB proteins, among which IkappaBalpha and IkappaBbeta are the most abundant. IkappaB proteins are widely expressed in different cells and tissues and bind to similar combinations of NF-kappaB proteins. The degradation of IkappaB proteins allows nuclear translocation of NF-kappaB and hence plays a critical role in NF-kappaB activation. Previous studies have demonstrated that, although both IkappaB proteins are phosphorylated by the same IkappaB kinase (IKK) complex, and their ubiquitination and degradation following phosphorylation are carried out by the same ubiquitination/degradation machinery, their kinetics of degradation are quite different. To better understand the underlying mechanism of the differences in degradation kinetics, we have carried out a systematic, comparative analysis of the ability of the IKK catalytic subunits to phosphorylate IkappaBalpha and IkappaBbeta. We found that, whereas IKKalpha is a weak kinase for the N-terminal serines of both IkappaB isoforms, IKKbeta is an efficient kinase for those residues in IkappaBalpha. However, IKKbeta phosphorylates the N-terminal serines of IkappaBbeta far less efficiently, thereby providing an explanation for the slower rate of degradation observed for IkappaBbeta. Mutational analysis indicated that the regions around the two N-terminal serines collectively influence the relative phosphorylation efficiency, and no individual residue is critical. These findings provide the first systematic analysis of the ability of IkappaBalpha and IkappaBbeta to serve as substrates for IKKs and help provide a possible explanation for the differential degradation kinetics of IkappaBalpha and IkappaBbeta.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunol Sect, CAB S625,300 Cedar St, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R37-AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bitko V, 1998, J VIROL, V72, P5610, DOI 10.1128/JVI.72.7.5610-5618.1998; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Budde LM, 2002, MOL BIOL CELL, V13, P4179, DOI 10.1091/mbc.01-07-0373; Burke JR, 1999, J BIOL CHEM, V274, P36146, DOI 10.1074/jbc.274.51.36146; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen Y, 2003, J BIOL CHEM, V278, P23101, DOI 10.1074/jbc.M301021200; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malek S, 2003, J BIOL CHEM, V278, P23094, DOI 10.1074/jbc.M301022200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	42	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31980	31987		10.1074/jbc.M304278200	http://dx.doi.org/10.1074/jbc.M304278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791687	hybrid			2022-12-25	WOS:000184782100067
J	Chelikani, P; Carpena, X; Fita, I; Loewen, PC				Chelikani, P; Carpena, X; Fita, I; Loewen, PC			An electrical potential in the access channel of catalases enhances catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; PENICILLIUM-VITALE; PROTEUS-MIRABILIS; CRYSTAL-STRUCTURE; HPII; CLONING; KATE	Substrate H2O2 must gain access to the deeply buried active site of catalases through channels of 30 - 50 Angstrom in length. The most prominent or main channel approaches the active site perpendicular to the plane of the heme and contains a number of residues that are conserved in all catalases. Changes in Val(169), 8 Angstrom from the heme in catalase HPII from Escherichia coli, introducing smaller, larger or polar side chains reduces the catalase activity. Changes in Asp(181), 12 Angstrom from the heme, reduces activity by up to 90% if the negatively charged side chain is removed when Ala, Gln, Ser, Asn, or Ile are the substituted residues. Only the D181E variant retains wild type activity. Determination of the crystal structures of the Glu(181), Ala(181), Ser(181), and Gln(181) variants of HPII reveals lower water occupancy in the main channel of the less active variants, particularly at the position forming the sixth ligand to the heme iron and in the hydrophobic, constricted region adjacent to Val(169). It is proposed that an electrical potential exists between the negatively charged aspartate ( or glutamate) side chain at position 181 and the positively charged heme iron 12 Angstrom distant. The potential field acts upon the electrical dipoles of water generating a common orientation that favors hydrogen bond formation and promotes interaction with the heme iron. Substrate hydrogen peroxide would be affected similarly and would enter the active site oriented optimally for interaction with active site residues.	Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada; CSIC, Inst Biol Mol Barcelona, Barcelona 08034, Spain	University of Manitoba; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Loewen, PC (corresponding author), Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada.	peter_loewen@umanitoba.ca	Fita, Ignasi/R-4515-2019; Carpena, Xavi/J-5877-2017	Fita, Ignasi/0000-0002-7521-2679; Carpena, Xavi/0000-0002-8646-0440; Chelikani, Prashen/0000-0003-1129-7957				Amara P, 2001, PROTEIN SCI, V10, P1927, DOI 10.1110/ps.14201; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRAVO J, 1995, STRUCTURE, V3, P491, DOI 10.1016/S0969-2126(01)00182-4; Bravo J, 1997, PROTEIN SCI, V6, P1016, DOI 10.1002/pro.5560060507; Bravo J, 1999, PROTEINS, V34, P155, DOI 10.1002/(SICI)1097-0134(19990201)34:2<155::AID-PROT1>3.0.CO;2-P; Carpena X, 2003, PROTEINS, V50, P423, DOI 10.1002/prot.10284; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FITA I, 1986, ACTA CRYSTALLOGR B, V42, P497, DOI 10.1107/S0108768186097835; GOUET P, 1995, J MOL BIOL, V249, P933, DOI 10.1006/jmbi.1995.0350; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalko SG, 2001, J AM CHEM SOC, V123, P9665, DOI 10.1021/ja010512t; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Ko TP, 2000, ACTA CRYSTALLOGR D, V56, P241, DOI 10.1107/S0907444999015930; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LOEWEN PC, 1986, BIOCHEM CELL BIOL, V64, P638, DOI 10.1139/o86-088; LOEWEN PC, 1993, BIOCHEMISTRY-US, V32, P10159, DOI 10.1021/bi00089a035; Mate MJ, 1999, J BIOL CHEM, V274, P27717, DOI 10.1074/jbc.274.39.27717; Mate MJ, 1999, J MOL BIOL, V286, P135, DOI 10.1006/jmbi.1998.2453; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; Melik-Adamyan W, 2001, PROTEINS, V44, P270, DOI 10.1002/prot.1092; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; MURSHUDOV GN, 1992, FEBS LETT, V312, P127, DOI 10.1016/0014-5793(92)80919-8; Murshudov GN, 1996, J BIOL CHEM, V271, P8863, DOI 10.1074/jbc.271.15.8863; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; Nicholls P, 2001, ADV INORG CHEM, V51, P51; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; RORTH M, 1967, BIOCHIM BIOPHYS ACTA, V139, P171, DOI 10.1016/0005-2744(67)90124-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMB WC, 1955, HYDROGEN PEROXIDE, P310; Sevinc MS, 1999, PROTEIN SCI, V8, P490, DOI 10.1110/ps.8.3.490; VAINSHTEIN BK, 1981, NATURE, V293, P411, DOI 10.1038/293411a0; VAINSHTEIN BK, 1986, J MOL BIOL, V188, P49, DOI 10.1016/0022-2836(86)90479-1; VONOSSOWSKI I, 1991, J BACTERIOL, V173, P514, DOI 10.1128/jb.173.2.514-520.1991; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31290	31296		10.1074/jbc.M304076200	http://dx.doi.org/10.1074/jbc.M304076200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777389	hybrid			2022-12-25	WOS:000184658800109
J	Palsdottir, H; Lojero, CG; Trumpower, BL; Hunte, C				Palsdottir, H; Lojero, CG; Trumpower, BL; Hunte, C			Structure of the yeast cytochrome bc(1) complex with a hydroxyquinone anion Q(o) site inhibitor bound	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; RIESKE 2FE-2S CLUSTER; UBIHYDROQUINONE OXIDATION; UBIQUINOL OXIDATION; ELECTRON-TRANSFER; QUINOL OXIDATION; BC1 COMPLEX; BINDING; MECHANISM; PROGRAM	Bifurcated electron transfer during ubiquinol oxidation is the key reaction of cytochrome bc(1) complex catalysis. Binding of the competitive inhibitor 5-n-heptyl-6- hydroxy-4,7-dioxobenzothiazole to the Q(o) site of the cytochrome bc(1) complex from Saccharomyces cerevisiae was analyzed by x-ray crystallography. This alkylhydroxydioxobenzothiazole is bound in its ionized form as evident from the crystal structure and confirmed by spectroscopic analysis, consistent with a measured pK(a) = 6.1 of the hydroxy group in detergent micelles. Stabilizing forces for the hydroxyquinone anion inhibitor include a polarized hydrogen bond to the iron-sulfur cluster ligand His(181) and on-edge interactions via weak hydrogen bonds with cytochrome b residue Tyr(279). The hydroxy group of the latter contributes to stabilization of the Rieske protein in the b-position by donating a hydrogen bond. The reported pH dependence of inhibition with lower efficacy at alkaline pH is attributed to the protonation state of His(181) with a pK(a) of 7.5. Glu(272), a proposed primary ligand and proton acceptor of ubiquinol, is not bound to the carbonyl group of the hydroxydioxobenzothiazole ring but is rotated out of the binding pocket toward the heme b(L) propionate A, to which it is hydrogen-bonded via a single water molecule. The observed hydrogen bonding pattern provides experimental evidence for the previously proposed proton exit pathway involving the heme propionate and a chain of water molecules. Binding of the alkyl-6-hydroxy-4,7-dioxobenzothiazole is discussed as resembling an intermediate step of ubiquinol oxidation, supporting a single occupancy model at the Q(o) site.	Max Planck Inst Biophys, Abt Mol Membranbiol, D-60439 Frankfurt, Germany; IPN, Ctr Invest & Estudios Avanzados, Dept Bioquim, Mexico City 07360, DF, Mexico; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Max Planck Society; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Dartmouth College	Hunte, C (corresponding author), Max Planck Inst Biophys, Abt Mol Membranbiol, Marie Curie Str 15, D-60439 Frankfurt, Germany.	carola.hunte@mpibp-frankfurt.mpg.de	Hunte, Carola/E-4071-2015	Hunte, Carola/0000-0002-0826-3986	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartoschek S, 2001, J BIOL CHEM, V276, P35231, DOI 10.1074/jbc.C100365200; Berry EA, 1999, BIOCHEM SOC T, V27, P565, DOI 10.1042/bst0270565; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BOWYER JR, 1982, J BIOL CHEM, V257, P8321; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Covian R, 2002, J BIOL CHEM, V277, P48449, DOI 10.1074/jbc.M208060200; Covian R, 2001, EUR J BIOCHEM, V268, P5783, DOI 10.1046/j.0014-2956.2001.02521.x; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; Desiraju G. R., 1999, WEAK HYDROGEN BOND; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Hubbard SJ., 1993, COMPUTER PROGRAM; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palsdottir H., 2003, MEMBRANE PROTEIN PUR, P191; Samoilova RI, 2002, J BIOL CHEM, V277, P4605, DOI 10.1074/jbc.C100664200; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; TRUMPOWER BL, 1980, J BIOENERG BIOMEMBR, V12, P151, DOI 10.1007/BF00744680; Ullmann GM, 2002, J BIOL INORG CHEM, V7, P632, DOI 10.1007/s00775-002-0342-6; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008; Zhang L, 1999, FEBS LETT, V460, P349, DOI 10.1016/S0014-5793(99)01340-X; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	53	156	165	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31303	31311		10.1074/jbc.M302195200	http://dx.doi.org/10.1074/jbc.M302195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782631	hybrid			2022-12-25	WOS:000184658800111
J	Arsham, AM; Howell, JJ; Simon, MC				Arsham, AM; Howell, JJ; Simon, MC			A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL RIBOSOME ENTRY; INITIATION-FACTOR 2-ALPHA; P70 S6 KINASE; ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; PHOSPHATASE 2A; TRANSLATION INITIATION; EFFICIENT TRANSLATION; BRAIN ISCHEMIA	Hypoxia triggers a reversible inhibition of protein synthesis thought to be important for energy conservation in O-2-deficient environments. The mammalian target of rapamycin (mTOR) pathway integrates multiple environmental cues to regulate translation in response to nutrient availability and stress, suggesting it as a candidate for O-2 regulation. We show here that hypoxia rapidly and reversibly triggers hypophosphorylation of mTOR and its effectors 4E-BP1, p70(S6K), rpS6, and eukaryotic initiation factor 4G. Hypoxic regulation of these translational control proteins is dominant to activation via multiple distinct signaling pathways such as insulin, amino acids, phorbol esters, and serum and is independent of Akt/protein kinase B and AMP-activated protein kinase phosphorylation, ATP levels, ATP:ADP ratios, and hypoxia-inducible factor-1 (HIF-1). Finally, hypoxia appears to repress phosphorylation of translational control proteins in a manner analogous to rapamycin and independent of phosphatase 2A (PP2A) activity. These data demonstrate a new mode of regulation of the mTOR pathway and position this pathway as a powerful point of control by O-2 of cellular metabolism and energetics.	Univ Chicago, Comm Genet, Chicago, IL 60615 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Chicago; University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania	Simon, MC (corresponding author), 438 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021	Arsham, Andrew/0000-0002-5274-8710; Howell, Jessica/0000-0002-9736-5211	PHS HHS [63310] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Althausen S, 2001, J NEUROCHEM, V78, P779, DOI 10.1046/j.1471-4159.2001.00462.x; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Boutilier RG, 2000, COMP BIOCHEM PHYS A, V126, P481, DOI 10.1016/S1095-6433(00)00234-8; Budinger GRS, 1996, AM J PHYSIOL-LUNG C, V270, pL44, DOI 10.1152/ajplung.1996.270.1.L44; Chen D, 1999, MOL CELL BIOL, V19, P4684; Clemens MJ, 2001, PROG MOLEC, V27, P57; de la Vega CM, 2001, BIOCHEM J, V357, P819; de la Vega CM, 2001, NEUROREPORT, V12, P1021, DOI 10.1097/00001756-200104170-00031; DeGracia DJ, 1999, EXP NEUROL, V155, P221, DOI 10.1006/exnr.1998.6986; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Duncan RF, 1999, EUR J BIOCHEM, V265, P728, DOI 10.1046/j.1432-1327.1999.00776.x; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Hand SC, 1998, J EXP BIOL, V201, P1233; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hochachka PW, 2001, COMP BIOCHEM PHYS B, V130, P435, DOI 10.1016/S1096-4959(01)00408-0; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; Janelidze S, 2001, NEUROBIOL DIS, V8, P147, DOI 10.1006/nbdi.2000.0325; Jonassen AK, 2001, CIRC RES, V89, P1191, DOI 10.1161/hh2401.101385; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kimball SR, 2002, CURR OPIN CLIN NUTR, V5, P63, DOI 10.1097/00075197-200201000-00012; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Marbach I, 2001, J BIOL CHEM, V276, P16944, DOI 10.1074/jbc.M100383200; Martin ME, 2000, BIOCHEM J, V351, P327, DOI 10.1042/0264-6021:3510327; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; Mengesdorf T, 2002, EXP NEUROL, V177, P538, DOI 10.1006/exnr.2002.8002; MILLER AG, 1981, J BIOL CHEM, V256, P2433; MILLER AG, 1983, J BIOL CHEM, V258, P3523; Munoz F, 2000, J NEUROCHEM, V75, P2335, DOI 10.1046/j.1471-4159.2000.0752335.x; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; Scheper GC, 1998, BIOCHEM J, V334, P463, DOI 10.1042/bj3340463; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SETA KA, 2002, SCI STKE; Smith RW, 1996, AM J PHYSIOL-REG I, V271, pR897, DOI 10.1152/ajpregu.1996.271.4.R897; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Sullivan JM, 1999, J CEREBR BLOOD F MET, V19, P1010, DOI 10.1097/00004647-199909000-00009; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Turcotte ML, 2002, BRIT J CANCER, V86, P619, DOI 10.1038/sj.bjc.6600087; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200	67	373	388	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29655	29660		10.1074/jbc.M212770200	http://dx.doi.org/10.1074/jbc.M212770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777372	hybrid			2022-12-25	WOS:000184507000035
J	Fessenden, JD; Perez, CF; Goth, S; Pessah, IN; Allen, PD				Fessenden, JD; Perez, CF; Goth, S; Pessah, IN; Allen, PD			Identification of a key determinant of ryanodine receptor type 1 required for activation by 4-chloro-m-cresol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; MOLECULAR-IDENTIFICATION; CALCIUM RELEASE; CAFFEINE; CA-2+; SENSITIVITY; MODULATION; MUTATIONS	4-Chloro-m-cresol (4-CmC) is a potent and specific activator of the intracellular Ca2+ release channel, the ryanodine receptor (RyR). We have previously shown that RyR1 expressed in dyspedic 1B5 myotubes is activated by 4-CmC, whereas RyR3 is not (Fessenden, J. D., Wang, Y., Moore, R. A., Chen, S. R. W., Allen, P. D., and Pessah, I. N. (2000) Biophys. J. 79, 2509-2525). To identify region(s) on RyR1 that are responsible for mediating activation by 4-CmC, we expressed RyR1-RyR3 chimeric proteins in dyspedic 1B5 myotubes and then measured 4-CmC-induced increases in intracellular Ca2+. Substitution of the C-terminal third of RyR1 into RyR3 imparted 4-CmC sensitivity to the resulting chimera, thus suggesting that determinants required for activation by 4-CmC are located in this region. We subdivided the C-terminal third of RyR1 into smaller segments and identified two overlapping regions of RyR1 (amino acids 3769-4180 and 4007-4382) that each imparted 4-CmC sensitivity to RyR3. Substitution of the 173 amino acids of RyR1 common to these two chimeras (amino acids 4007-4180) also weakly restored 4-CmC sensitivity in the resulting chimera. To confirm these findings, we created a complementary set of chimeras containing RyR3 substitutions in RyR1. Substitution of the RyR3 C terminus into RyR1 disrupted 4-CmC sensitivity in the resulting chimera. In addition, substitution of the corresponding RyR3 sequence into positions 4007-4180 of RyR1 disrupted 4-CmC sensitivity. Taken together, these results suggest that essential determinants required for activation of RyR1 by 4-CmC reside within a 173-amino acid region between residues 4007 and 4180.	Brigham & Womens Hosp, Dept Anesthesia Res, Boston, MA 02115 USA; Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis	Fessenden, JD (corresponding author), Brigham & Womens Hosp, Dept Anesthesia Res, 75 Francis St, Boston, MA 02115 USA.	fessenden@zeus.bwh.harvard.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				ABRAMSON JJ, 1988, MOL CELL BIOCHEM, V82, P81; Avila G, 2001, J GEN PHYSIOL, V118, P277, DOI 10.1085/jgp.118.3.277; Baur CP, 2000, ANESTH ANALG, V90, P200, DOI 10.1097/00000539-200001000-00040; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Choisy S, 1999, J PHARMACOL EXP THER, V290, P578; Choisy S, 2000, J PHARMACOL EXP THER, V294, P884; Du GG, 1998, J BIOL CHEM, V273, P31867, DOI 10.1074/jbc.273.48.31867; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Du GG, 2001, BIOCHEM J, V360, P97, DOI 10.1042/0264-6021:3600097; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Girard T, 2001, J BIOL CHEM, V276, P48077, DOI 10.1074/jbc.M107134200; HerrmannFrank A, 1996, BIOCHEM PHARMACOL, V52, P149, DOI 10.1016/0006-2952(96)00175-X; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; Laver DR, 1997, J MEMBRANE BIOL, V156, P213, DOI 10.1007/s002329900202; Lee EH, 2002, BIOPHYS J, V82, p76A; LOPEZ JR, 1988, MUSCLE NERVE, V11, P82; Lopez JR, 2000, ANESTHESIOLOGY, V92, P1799, DOI 10.1097/00000542-200006000-00040; Matyash M, 2001, FASEB J, V15, P84, DOI 10.1096/fj.01-0380fje; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; Richter M, 1997, J BIOL CHEM, V272, P5256, DOI 10.1074/jbc.272.8.5256; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tegazzin V, 1996, ANESTHESIOLOGY, V84, P1380, DOI 10.1097/00000542-199606000-00014; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Westerblad H, 1998, CELL CALCIUM, V24, P105, DOI 10.1016/S0143-4160(98)90078-1; Xiong H, 1998, BIOCHEMISTRY-US, V37, P4804, DOI 10.1021/bi971198b; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192; Zucchi R, 1997, PHARMACOL REV, V49, P1	41	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28727	28735		10.1074/jbc.M303821200	http://dx.doi.org/10.1074/jbc.M303821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12761215	hybrid			2022-12-25	WOS:000184421100048
J	Helliwell, PA; Rumsby, MG; Kellett, GL				Helliwell, PA; Rumsby, MG; Kellett, GL			Intestinal sugar absorption is regulated by phosphorylation and turnover of protein kinase C beta II mediated by phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; GLUCOSE-ABSORPTION; PHOSPHOINOSITIDE 3-KINASE; FRUCTOSE TRANSPORT; RAT JEJUNUM; GLUT2; PDK-1; ACTIVATION; ISOZYMES; INSULIN	Stimulation of intestinal fructose absorption by phorbol 12-myristate 13-acetate (PMA) results from rapid insertion of GLUT2 into the brush-border membrane and correlates with protein kinase C (PKC) betaII activation. We have therefore investigated the role of phosphatidylinositol 3 (PI3)-kinase and mammalian target of rapamycin in the regulation of fructose absorption by PKC betaII phosphorylation. In isolated jejunal loops, stimulation of fructose absorption by PMA was inhibited by preperfusion with wortmannin or rapamycin, which blocked GLUT2 activation and insertion into the brush-border membrane. Antibodies to the last 18 and last 10 residues of the C-terminal region of PKC betaII recognized several species differentially in Western blots. Extensive cleavage of native enzyme (80/78 kDa) to a catalytic domain product of 49 kDa occurred. PMA and sugars provoked turnover and degradation of PKC betaII by dephosphorylation to a 42-kDa species, which was converted to polyubiquitylated species detected at 180 and 250 + kDa. PMA increased the level of the PKC betaII 49-kDa species, which correlates with the GLUT2 level; wortmannin and rapamycin blocked these effects of PMA. Rapamycin and wortmannin inhibited PKC betaII turnover. PI3-kinase, PDK-1, and protein kinase B were present in the brush-border membrane, where their levels were increased by PMA and blocked by the inhibitors. We conclude that GLUT2-mediated fructose absorption is regulated through PI3-kinase and mammalian target of rapamycin-dependent pathways, which control phosphorylation of PKC betaII and its substrate-induced turnover and ubiquitin-dependent degradation. These findings suggest possible mechanisms for short term control of intestinal sugar absorption by insulin and amino acids.	Univ York, Dept Biol, Area 3, York YO10 5YW, N Yorkshire, England	University of York - UK	Kellett, GL (corresponding author), Univ York, Dept Biol, Area 3, York YO10 5YW, N Yorkshire, England.							Au A, 2002, BIOCHEM J, V367, P247, DOI 10.1042/BJ20020393; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; CHEESEMAN CI, 1993, GASTROENTEROLOGY, V105, P1050, DOI 10.1016/0016-5085(93)90948-C; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Corpe CP, 1996, PFLUG ARCH EUR J PHY, V432, P192, DOI 10.1007/s004240050124; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FERRARIS RP, 1990, AM J PHYSIOL-GASTR L, V259, P822; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; GOUYON F, 2002, J CELL BIOL, V58, P274; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Helliwell PA, 2000, BIOCHEM J, V350, P163, DOI 10.1042/0264-6021:3500163; Helliwell PA, 2000, BIOCHEM J, V350, P149, DOI 10.1042/0264-6021:3500149; Helliwell PA, 2002, J PHYSIOL-LONDON, V544, P579, DOI 10.1113/jphysiol.2002.028209; Kang BS, 2000, ONCOGENE, V19, P4263, DOI 10.1038/sj.onc.1203779; Kellett GL, 2000, BIOCHEM J, V350, P155, DOI 10.1042/0264-6021:3500155; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; KELLETT GL, 1984, BIOCHEM J, V219, P1027, DOI 10.1042/bj2191027; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; PAPPENHEIMER JR, 1993, AM J PHYSIOL, V265, pG409, DOI 10.1152/ajpgi.1993.265.3.G409; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PENNINGTON AM, 1994, J PHYSIOL-LONDON, V478, P187, DOI 10.1113/jphysiol.1994.sp020241; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; WOLLEN N, 1988, GUT, V29, P1064, DOI 10.1136/gut.29.8.1064; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	33	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28644	28650		10.1074/jbc.M301479200	http://dx.doi.org/10.1074/jbc.M301479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12766174	hybrid			2022-12-25	WOS:000184421100038
J	Li, XWS; Reddy, MS; Baev, D; Edgerton, M				Li, XWS; Reddy, MS; Baev, D; Edgerton, M			Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; FUNGICIDAL ACTIVITY; HSP70 GENES; FAMILY; WALL; MUTATIONS; MECHANISM; MEMBERS; EXERTS; ATP	Salivary histatins are a family of small histidine-rich peptides with potent antifungal activity. We previously identified a 70-kDa cell envelope protein in Candida albicans and Saccharomyces cerevisiae that mediates binding of histatin (Hst) 5. Isolation of Hst 5-binding protein followed by matrix-assisted laser desorption ionization mass spectrometry analysis identified this protein as the heat shock protein Ssa1p. Ssa protein and Hst 5-binding protein were found to be co-localized on immunoblots of yeast beta-mercaptoethanol cell wall extracts and cytosolic fractions. Yeast two-hybrid analysis showed strong interactions between Ssa1p and both Hst 3 and Hst 5. To assess functional roles of Ssa proteins in the Hst 5 antifungal mechanism in vivo, both binding and fungicidal assays were carried out using S. cerevisiae isogenic SSA1/SSA2 mutants. I-125-Hst 5 binding assays showed saturable binding (K-d = 2.57 x 10(-6) M) with the wild-type SSA1/SSA2 strain; however, Hst 5 binding with the Deltassa1ssa2 double mutant was reduced (K-d = 1.25 x 10(-6) M). Cell wall HSP70 proteins were also diminished, but still detectable, in S. cerevisiae Deltassa1ssa2 cells and are likely to be Ssa3p or Ssa4p. Hst 5 (31 muM) killed 80% of the wild-type cells in fungicidal assays at room temperature. However, only 50-60% killing of the single mutants (Deltassa1 and Deltassa2) was observed, and fungicidal activity was further reduced to 20-30% in the Deltassa1ssa2 double mutant. Incubation of cells under heat shock conditions increased the sensitivity of cells to Hst 5, which correlated with increased Hst 5-binding activity in Deltassa1ssa2 cells, but not in wild-type cells. This study provides evidence for a novel function for yeast Ssa1/2 proteins as cell envelope binding receptors for Hst 5 that mediate fungicidal activity.	SUNY Buffalo, Dept Oral Biol, Sch Dent Med, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Restorat Dent, Sch Dent Med, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Edgerton, M (corresponding author), SUNY Buffalo, Dept Oral Biol, Sch Dent Med, Main St Campus,310 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	edgerto@buffalo.edu			NIDCR NIH HHS [DE10641, R01 DE010641, R01 DE010641-10A1, DE00406] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE010641] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; Baev D, 2002, INFECT IMMUN, V70, P4777, DOI 10.1128/IAI.70.9.4777-4784.2002; Baev D, 2001, MICROBIOL-SGM, V147, P3323, DOI 10.1099/00221287-147-12-3323; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; Breinig F, 2002, CELL, V108, P395, DOI 10.1016/S0092-8674(02)00634-7; Bromuro C, 1998, INFECT IMMUN, V66, P2154, DOI 10.1128/IAI.66.5.2154-2162.1998; Craig E, 1995, COLD SPRING HARB SYM, V60, P441, DOI 10.1101/SQB.1995.060.01.049; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Edgerton M, 2000, ANTIMICROB AGENTS CH, V44, P3310, DOI 10.1128/AAC.44.12.3310-3316.2000; Eroles P, 1997, MICROBIOL-SGM, V143, P313, DOI 10.1099/00221287-143-2-313; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Gyurko C, 2001, ANTON LEEUW INT J G, V79, P297, DOI 10.1023/A:1012070600340; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; Helmerhorst EJ, 2001, J BIOL CHEM, V276, P5643, DOI 10.1074/jbc.M008229200; Helmerhorst EJ, 2001, P NATL ACAD SCI USA, V98, P14637, DOI 10.1073/pnas.141366998; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Koshlukova SE, 1999, J BIOL CHEM, V274, P18872, DOI 10.1074/jbc.274.27.18872; LAVALLE R, 1995, INFECT IMMUN, V63, P4039, DOI 10.1128/IAI.63.10.4039-4045.1995; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; LopezRibot JL, 1996, INFECT IMMUN, V64, P3333; LopezRibot JL, 1996, J BACTERIOL, V178, P4724, DOI 10.1128/jb.178.15.4724-4726.1996; Magliani W, 1997, CLIN MICROBIOL REV, V10, P369, DOI 10.1128/CMR.10.3.369; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NELSON RJ, 1992, GENETICS, V131, P277; OConnell BC, 1996, HUM GENE THER, V7, P2255, DOI 10.1089/hum.1996.7.18-2255; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satyanarayana C, 2000, FEBS LETT, V470, P232, DOI 10.1016/S0014-5793(00)01324-7; Situ H, 1999, J DENT RES, V78, P690, DOI 10.1177/00220345990780020901; Tenovuo J, 1998, ACTA ODONTOL SCAND, V56, P250, DOI 10.1080/000163598428400; Tsai H, 1997, ANTIMICROB AGENTS CH, V41, P2224, DOI 10.1128/AAC.41.10.2224; Tsai HY, 1997, BBA-GEN SUBJECTS, V1336, P367, DOI 10.1016/S0304-4165(97)00076-7; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; Xu YY, 1999, ANTIMICROB AGENTS CH, V43, P2256, DOI 10.1128/AAC.43.9.2256; ZUO Y, 1995, GENE, V161, P87, DOI 10.1016/0378-1119(95)00237-Z	40	130	140	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28553	28561		10.1074/jbc.M300680200	http://dx.doi.org/10.1074/jbc.M300680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12761219	hybrid			2022-12-25	WOS:000184421100028
J	MacAulay, N; Meinild, AK; Zeuthen, T; Gether, U				MacAulay, N; Meinild, AK; Zeuthen, T; Gether, U			Residues in the extracellular loop 4 are critical for maintaining the conformational equilibrium of the gamma-aminobutyric acid transporter-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA COTRANSPORTER RGAT1; DOPAMINE TRANSPORTER; RAT-BRAIN; XENOPUS OOCYTES; STEADY-STATE; BINDING SITE; ION-BINDING; SUBTYPE-A; SODIUM; CURRENTS	We mutated residues Met(345) and Thr(349) in the rat gamma-aminobutyric acid transporter-1 (GAT-1) to histidines (M345H and T349H). These two residues are located four amino acids apart at the extracellular end of transmembrane segment 7 in a region of GAT-1 that we have previously suggested undergoes conformational changes critical for the transport process. The two single mutants and the double mutant (M345H/T349H) were expressed in Xenopus laevis oocytes, and their steady-state and presteady-state kinetics were examined and compared with wild type GAT-1 by using the two-electrode voltage clamp method. Oocytes expressing M345H showed a decrease in apparent GABA affinity, an increase in apparent affinity for Na+, a shift in the charge/voltage (Q/V-m) relationship to more positive membrane potentials, and an increased Li+-induced leak current. Oocytes expressing T349H showed an increase in apparent GABA affinity, a decrease in apparent Na+ affinity, a profound shift in the Q/V-m relationship to more negative potentials, and a decreased Li+-induced leak current. The data are consistent with a shift in the conformational equilibrium of the mutant transporters, with M345H stabilized in an outward-facing conformation and T349H in an inward-facing conformation. These data suggest that the extracellular end of transmembrane domain 7 not only undergoes conformational changes critical for the translocation process but also plays a role in regulating the conformational equilibrium between inward-and outward-facing conformations.	Univ Copenhagen, Div Cellular & Mol Physiol, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Dept Pharmacol, Panum Inst, DK-2200 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	MacAulay, N (corresponding author), Univ Copenhagen, Div Cellular & Mol Physiol, Panum Inst, Dept Med Physiol, 12-5, DK-2200 Copenhagen N, Denmark.		MacAulay, Nanna/AER-7709-2022	MacAulay, Nanna/0000-0002-7800-6600; Gether, Ulrik/0000-0002-0020-3807				Binda F, 2002, FEBS LETT, V512, P303, DOI 10.1016/S0014-5793(02)02271-8; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Bossi E, 2002, J PHYSIOL-LONDON, V541, P343, DOI 10.1113/jphysiol.2001.013457; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; Cao YW, 1998, J NEUROSCI, V18, P7739; Forlani G, 2001, J PHYSIOL-LONDON, V536, P479, DOI 10.1111/j.1469-7793.2001.0479c.xd; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; MacAulay N, 2002, J PHYSIOL-LONDON, V544, P447, DOI 10.1113/jphysiol.2002.022897; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; Penado KMY, 1998, J BIOL CHEM, V273, P28098, DOI 10.1074/jbc.273.43.28098; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Yu N, 1998, FEBS LETT, V426, P174, DOI 10.1016/S0014-5793(98)00333-0	36	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28771	28777		10.1074/jbc.M213023200	http://dx.doi.org/10.1074/jbc.M213023200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12764157	hybrid			2022-12-25	WOS:000184421100054
J	Wu, K; Yamoah, K; Dolios, G; Gan-Erdene, T; Tan, PL; Chen, A; Lee, CG; Wei, N; Wilkinson, KD; Wang, R; Pan, ZQ				Wu, K; Yamoah, K; Dolios, G; Gan-Erdene, T; Tan, PL; Chen, A; Lee, CG; Wei, N; Wilkinson, KD; Wang, R; Pan, ZQ			DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; SCF UBIQUITIN-LIGASE; KAPPA-B-ALPHA; CRYSTAL-STRUCTURE; COP9 SIGNALOSOME; DEUBIQUITINATING ENZYME; CONJUGATION PATHWAY; COMPLEX; CLEAVAGE; FAMILY	Nedd8 activates ubiquitination by increasing the efficiency of polyubiquitin chain assembly through its covalent conjugation to cullin molecules. Here we report the isolation, cloning, and characterization of a novel human Nedd8-specific protease called DEN1. Human DEN1 is encoded by AAH31411.1, a previously uncharacterized protein of 212 amino acids that shares homology with the Ulp1 cysteinyl SUMO deconjugating enzyme family. Recombinant human DEN1, purified from bacteria, selectively binds to Nedd8 and hydrolyzes C-terminal derivatives of Nedd8. Interestingly, DEN1 deconjugates cullin 1 (CUL1)-Nedd8 in a concentration-dependent manner. At a low concentration, DEN1 processes hyper-neddylated CUL1 to yield a mononeddylated form, which presumably contains the Lys720(CUL1)- Nedd8 linkage. At elevated concentrations, DEN1 is able to complete the removal of Nedd8 from CUL1. These activities distinguish DEN1 from the COP9 signalosome, which is capable of efficiently cleaving the Lys-720(CUL1)-Nedd8 conjugate, but lacks Nedd8 C-terminal hydrolytic activity and poorly processes hyperneddylated CUL1. These results suggest a unique role for DEN1 in regulating the modification of cullins by Nedd8.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, New Jersey Med Sch, Newark, NJ 07103 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Emory University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yale University	Pan, ZQ (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.		Wang, Rong/A-8721-2009	Wei, Ning/0000-0001-8827-1320	FOGARTY INTERNATIONAL CENTER [F05TW005461] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R24CA088325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061051, R01GM030308, R01GM066355] Funding Source: NIH RePORTER; FIC NIH HHS [F05 TW05461] Funding Source: Medline; NCI NIH HHS [CA88325] Funding Source: Medline; NIGMS NIH HHS [GM61051, GM30308, GM66355] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; PICKART CM, 1985, J BIOL CHEM, V260, P7903; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-7	41	140	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28882	28891		10.1074/jbc.M302888200	http://dx.doi.org/10.1074/jbc.M302888200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759363	hybrid			2022-12-25	WOS:000184421100067
J	DuHadaway, JB; Du, W; Donover, S; Baker, J; Liu, AX; Sharp, DM; Muller, AJ; Prendergast, GC				DuHadaway, JB; Du, W; Donover, S; Baker, J; Liu, AX; Sharp, DM; Muller, AJ; Prendergast, GC			Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1	ONCOGENE			English	Article						FTI; farnesyltransferase; Ras; RhoB; SV40T antigen; amphiphysin	TUMOR-SUPPRESSOR BIN1; GENE-EXPRESSION; YEAST HOMOLOG; SMALL GTPASE; CELL-CYCLE; KINASE 2; PROTEIN; ACTIN; RAS; MYC	Neoplastic transformation sensitizes many cells to apoptosis. This phenomenon may underlie the therapeutic benefit of many anticancer drugs, but its molecular basis is poorly understood. We have used a selective and potent farnesyltransferase inhibitor (FTI) to probe a mechanism of apoptosis that is peculiarly linked to neoplastic transformation. While nontoxic to untransformed mouse cells, FTI triggers a massive RhoB-dependent, p53-independent apoptosis in mouse cells that are neoplastically transformed. Here we offer evidence that the BAR adapter-encoding tumor suppressor gene Bin1 is required for this transformation-selective death program. Targeted deletion of Bin1 in primary mouse embyro fibroblasts (MEFs) transformed by E1A + Ras did not affect FTI-induced reversion, actin fiber formation, or growth inhibition, but it abolished FTI-induced apoptosis. The previously defined requirement for RhoB in these effects suggests that BinI adapter proteins act downstream or in parallel to RhoB in cell death signaling. The death defect in Bin1 null cells was significant insofar as it abolished FTI efficacy in tumor xenograft assays. p53 deletion did not phenocopy the effects of Bin1 deletion. However, MEFs transformed by SV40 large T antigen + Ras were also resistant to apoptosis by FTI, consistent with other evidence that large T inhibits Bin1-dependent cell death by a p53-independent mechanism. Taken together, the results define a function for Bin1 in apoptosis that is conditional on transformation stress. This study advances understanding of the functions of BAR adapter proteins, which are poorly understood, by revealing genetic interactions with an Rho small GTPase that functions in stress signaling. The frequent losses of Bin1 expression that occur in human breast and prostate cancers may promote tumor progression and limit susceptibility to FTI or other therapeutic agents that exploit the heightened sensitivity of neoplastic cells to apoptosis.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Canc Res Grp, Glenolden, PA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont; The Wistar Institute; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org		Muller, Alexander/0000-0001-7854-6933	NATIONAL CANCER INSTITUTE [R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [CA82222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Balguerie A, 1999, J CELL SCI, V112, P2529; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bon E, 2000, YEAST, V16, P1229, DOI 10.1002/1097-0061(20000930)16:13<1229::AID-YEA618>3.0.CO;2-Q; Breton AM, 1998, CURR GENET, V34, P280, DOI 10.1007/s002940050397; Colwill K, 1999, GENETICS, V152, P881; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Du W, 1999, MOL CELL BIOL, V19, P1831; Du W, 1999, CANCER RES, V59, P4208; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Galderisi U, 1999, J CELL BIOCHEM, V74, P313, DOI 10.1002/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.3.CO;2-Q; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P559, DOI 10.1002/1096-911X(20001201)35:6<559::AID-MPO14>3.3.CO;2-A; Huang HT, 2000, CANCER RES, V60, P6868; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ P, 1998, CELL ADHES COMMUN, V4, P1; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mangues R, 1998, CANCER RES, V58, P1253; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Prendergast GC, 1999, CANCER RES, V59, P5924; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; ZALCMAN G, 1995, ONCOGENE, V10, P1935	53	15	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3578	3588		10.1038/sj.onc.1206481	http://dx.doi.org/10.1038/sj.onc.1206481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789266				2022-12-25	WOS:000183399200008
J	Bristow, RG; Peacock, J; Jang, A; Kim, J; Hill, RP; Benchimol, S				Bristow, RG; Peacock, J; Jang, A; Kim, J; Hill, RP; Benchimol, S			Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53	ONCOGENE			English	Article						p53; sensitivity; MEF; gain of function; metastasis; transformation	OF-FUNCTION MUTATIONS; P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; REPAIR PATHWAYS; CELL-SURVIVAL; MUTANT FORMS; CORE DOMAIN; IN-VITRO; GENE; CHECKPOINT	Tumor cells can acquire aggressive phenotypes secondary to the loss of expression of the wild-type p53 (WTp53) protein or by the gain of function for selected mutant p53 (MTp53) proteins. However, it is unclear as to whether the development of aggressive phenotypes is inter-related. Herein we report the radiosensitivity, chemosensitivity, and in vivo growth characteristics of isogenic p53(-/-) MEF ras-transformants that variably express an MTp53 protein. Initial experiments revealed significant clonal heterogeneity with respect to cellular sensitivity to DNA-damaging agents (i.e. ionizing radiation, ultraviolet radiation, cis-platinum, and methotrexate) within subclones of a pre-existing p53(-/-) MEF cell population. Moreover, this differential sensitivity was also observed within suliclones of p53(-/-) MEF cells transformed with an activated ras allele, suggesting that secondary genetic events and clonal selection, but not cellular transformation per se, may drive the resistance patterns for certain null-p53 tumors. In contrast, uniform resistance was observed following the additional transfection of an MTp53 allele (MTp53pro193) into p53(-/-) MEF transformants and p53(-/-) DP-16 Friend erythroleukemia cells, consistent with a gain of MTp53 function for this allele. Relative tumor growth rate and experimental metastatic ability was not enhanced by MTp53pro193 expression. Our results support the concept that gain of MTp53pro193 function leads to the selection of dominant clones, which may exhibit cellular resistance following cancer therapy.	Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Bristow, RG (corresponding author), Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Radiat Oncol, 610 Univ Ave,Room 5-923, Toronto, ON M5G 2M9, Canada.			Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X; Bristow, Robert/0000-0002-8553-9544				Albor A, 1998, CANCER RES, V58, P2091; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Bristow RG, 1998, ONCOGENE, V16, P1789, DOI 10.1038/sj.onc.1201935; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gangopadhyay S, 2002, EXP CELL RES, V275, P122, DOI 10.1006/excr.2002.5493; Grant SW, 1998, CANCER DETECT PREV, V22, P185, DOI 10.1046/j.1525-1500.1998.0oa18.x; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HSIAO M, 1994, AM J PATHOL, V145, P702; Illidge TM, 2000, CELL BIOL INT, V24, P621, DOI 10.1006/cbir.2000.0557; Iwamoto KS, 1996, CANCER RES, V56, P3862; Iwanaga Y, 2002, CANCER RES, V62, P2618; KIESER A, 1994, ONCOGENE, V9, P963; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; POWELL SN, 1995, CANCER RES, V55, P1643; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; Roth JA, 2001, ACTA ONCOL, V40, P739; Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sigal A, 2000, CANCER RES, V60, P6788; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; STRANO S, 2002, J BIOL CHEM, V13, P13; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Tang W, 1999, CANCER RES, V59, P2562; Tannock IF, 2001, BRIT J CANCER, V84, P100, DOI 10.1054/bjoc.2000.1538; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wiesmueller Lisa, 2001, Journal of Biomedicine and Biotechnology, V1, P7, DOI 10.1155/S1110724301000043	49	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2960	2966		10.1038/sj.onc.1206405	http://dx.doi.org/10.1038/sj.onc.1206405			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771947				2022-12-25	WOS:000182824800011
J	Kimes, AS; Horti, AG; London, ED; Chefer, SI; Contoreggi, C; Ernst, M; Friello, P; Koren, AO; Kurian, V; Matochik, JA; Pavlova, O; Vaupel, DB; Mukhin, AG				Kimes, AS; Horti, AG; London, ED; Chefer, SI; Contoreggi, C; Ernst, M; Friello, P; Koren, AO; Kurian, V; Matochik, JA; Pavlova, O; Vaupel, DB; Mukhin, AG			2-[F-18]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans	FASEB JOURNAL			English	Article						dosimetry; smoking; Alzheimer's disease; Parkinson's disease; non-invasive imaging	ALZHEIMERS-DISEASE; BINDING-SITES; C-11 NICOTINE; PARKINSONS; TRACER; RADIOLIGAND; POSTMORTEM; AFFINITY; SUBUNIT; SMOKING	Noninvasive imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain in vivo is critical for elucidating the role of these receptors in normal brain function and in the pathogenesis of brain disorders. Here we report the first in vivo visualization of human brain areas containing nAChRs by using PET and 2-[F-18]fluoro-3-(2(S)azetidinylmethoxy)pyridine (2-[F-18]FA). We acquired scans from six healthy non-smoking volunteers after i.v. bolus administration of 2-[F-18]FA (1.6 MBq/kg or 0.043 +/- 0.002 mCi/kg). This dose was sufficient for visualizing nAChRs in the thalamus up to 5 h after injection. There were no adverse effects associated with administration of no-carrier-added 2-[F-18]FA (1.3-10 pmol/kg). Consistent with the distribution of nAChRs in human brain, accumulated radioactivity was greatest in thalamus, intermediate in the midbrain, pons, cerebellum, and cortex; and least in white matter. As similar to90% of the injected radioactivity was eliminated via the urine (biological half-life ca. 4 h), the urinary bladder wall received the highest radiation dose. The estimate of radiation dose equivalent to the urinary bladder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multiple studies could be performed in a single subject. The results predict that quantitative PET imaging of nAChRs in human brain with 2-[F-18]FA is feasible.	NIDA, Intramural Res Program, Neuroimaging Res Branch, Baltimore, MD 21224 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Los Angeles, CA USA; NIMH, Intramural Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kimes, AS (corresponding author), NIDA, Intramural Res Program, Neuroimaging Res Branch, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	akimes@intra.nida.nih.gov			NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000405, Z01DA000405] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abreo MA, 1996, J MED CHEM, V39, P817, DOI 10.1021/jm9506884; BERNIER DR, 1994, NUCL MED TECHNOLOGY; Breese CR, 1997, J PHARMACOL EXP THER, V282, P7; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; Chefer SI, 2003, SYNAPSE, V48, P25, DOI 10.1002/syn.10180; Chefer SI, 2000, METMBS'00: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON MATHEMATICS AND ENGINEERING TECHNIQUES IN MEDICINE AND BIOLOGICAL SCIENCES, VOLS I AND II, P409; Chefer SI, 1999, NEUROREPORT, V10, P2715, DOI 10.1097/00001756-199909090-00005; Chefer SI, 1998, LIFE SCI, V63, pPL355, DOI 10.1016/S0024-3205(98)00514-1; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; Court JA, 2000, J CHEM NEUROANAT, V20, P281, DOI 10.1016/S0891-0618(00)00110-1; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Ding YS, 2000, NUCL MED BIOL, V27, P381, DOI 10.1016/S0969-8051(00)00094-9; Dolle F, 1999, J MED CHEM, V42, P2251, DOI 10.1021/jm9910223; Dolle F, 1998, J LABELLED COMPD RAD, V41, P451, DOI 10.1002/(SICI)1099-1344(199805)41:5<451::AID-JLCR111>3.0.CO;2-R; Epping-Jordan MP, 1999, PSYCHOPHARMACOLOGY, V147, P25, DOI 10.1007/s002130051135; Fujita M, 2002, EUR J NUCL MED MOL I, V29, P183, DOI 10.1007/s00259-001-0695-z; Fujita M, 2000, J NUCL MED, V41, P1552; HELLSTROMLINDAH.E, 1994, MOL BRAIN RES, V66, P94; Horti AG, 1998, J LABELLED COMPD RAD, V41, P309, DOI 10.1002/(SICI)1099-1344(199804)41:4<309::AID-JLCR78>3.0.CO;2-I; Horti AG, 1998, NUCL MED BIOL, V25, P599, DOI 10.1016/S0969-8051(98)00031-6; Koren AO, 1998, J MED CHEM, V41, P3690, DOI 10.1021/jm980170a; Loevinger R, 1991, MIRD PRIMER ABSORBED; Lundqvist H, 1998, ALZ DIS ASSOC DIS, V12, P238, DOI 10.1097/00002093-199809000-00018; Marubio LM, 1999, NATURE, V398, P805, DOI 10.1038/19756; MAZIERE M, 1995, BRAIN IMAGING NICOTI, P13; Mukhin AG, 2000, MOL PHARMACOL, V57, P642, DOI 10.1124/mol.57.3.642; Muzic RF, 1998, J NUCL MED, V39, P2048; Newhouse PA, 1997, DRUG AGING, V11, P206, DOI 10.2165/00002512-199711030-00005; NORDBERG A, 1990, J NEURAL TRANSM-PARK, V2, P215, DOI 10.1007/BF02257652; Nordberg A, 1997, DEMENT GERIATR COGN, V8, P78, DOI 10.1159/000106611; NORDBERG A, 1986, NEUROSCI LETT, V72, P115, DOI 10.1016/0304-3940(86)90629-4; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; PAVLOVA OA, 2000, SOC NEUR ABSTR, V26, P627; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Picciotto MR, 2002, J NEUROSCI, V22, P3338; Rasmussen T, 1998, PHARMACOL BIOCHEM BE, V60, P567, DOI 10.1016/S0091-3057(98)00003-3; RINNE JO, 1991, BRAIN RES, V547, P167; Robins L, 1995, DIAGNOSTIC INTERVIEW; Sihver W, 2000, BEHAV BRAIN RES, V113, P143, DOI 10.1016/S0166-4328(00)00209-6; Valette H, 1998, LIFE SCI, V64, pPL93, DOI 10.1016/S0024-3205(98)00573-6; Valette H, 2003, J NEUROCHEM, V84, P105, DOI 10.1046/j.1471-4159.2003.01502.x; Valette H, 1999, J NUCL MED, V40, P1374; VAUPEL DB, 2002, DRUG ALCOHOL DEPEN S, V1, pS187; Warpman U, 1995, NEUROREPORT, V6, P2419, DOI 10.1097/00001756-199511270-00033; Zachary R, 1986, SHIPLEY I LIVING SCA	47	96	97	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1331	+		10.1096/fj.02-0492fje	http://dx.doi.org/10.1096/fj.02-0492fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759330				2022-12-25	WOS:000183165000015
J	Teoh, MLT; Walasek, PJ; Evans, DH				Teoh, MLT; Walasek, PJ; Evans, DH			Leporipoxvirus Cu,Zn-superoxide dismutase (SOD) homologs are catalytically inert decoy proteins that bind copper chaperone for SOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; VACCINIA VIRUS; NUCLEOTIDE-SEQUENCE; METALLOCHAPERONE; CCS; REPLICATION; POXVIRUSES; ANION; GENE; KBP	Many Chordopoxviruses encode catalytically inactive homologs of cellular Cu-Zn superoxide dismutase ( SOD). The biological function of these proteins is unknown, although the proteins encoded by Leporipoxviruses have been shown to promote a slow decline in the level of superoxide dismutase activity in virus-infected cells. To gain more insights into their function, we have further characterized the enzymatic and biochemical properties of a SOD homolog encoded by Shope fibroma virus. Shope fibroma virus SOD has retained the zinc binding properties of its cellular homolog, but cannot bind copper. Site-directed mutagenesis showed that it requires at least four amino acid substitutions to partially restore copper binding activity, but even these changes still did not restore catalytic activity. Reciprocal co-immunoprecipitation experiments showed that recombinant Shope fibroma virus SOD forms very stable complexes with cellular copper chaperones for SOD and these observations were confirmed using glutathione-S-transferase tagged proteins. Similar viral SOD/chaperone complexes were formed in cells infected with a closely related myxoma virus, where we also noted that some of the SOD antigen co-localizes with mitochondrial markers using confocal fluorescence microscopy. About 2% of the viral SOD was subsequently detected in gradient-purified mitochondria extracted from virus-infected cells. These poxviral SOD homologs do not form stable complexes with cellular Cu, Zn-SOD or affect its concentration. We suggest that Leporipoxvirus SOD homologs are catalytically inert decoy proteins that are designed to interfere in the proper metallation and activation of cellular Cu, Zn-SOD. This reaction might be advantageous for tumorigenic poxviruses, since higher levels of superoxide have been proposed to have antiapoptotic and tumorigenic activity.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Evans, DH (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 1-41 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Evans, David H/M-1912-2016	Evans, David H/0000-0001-5871-299X				AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; Almazan F, 2001, J VIROL, V75, P7018, DOI 10.1128/JVI.75.15.7018-7029.2001; Bawden AL, 2000, VIROLOGY, V274, P120, DOI 10.1006/viro.2000.0449; Cameron C, 1999, VIROLOGY, V264, P298, DOI 10.1006/viro.1999.0001; Cao JX, 2002, VIROLOGY, V296, P125, DOI 10.1006/viro.2002.1383; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; CHALLBERG MD, 1979, J BIOL CHEM, V254, P7812; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cunnion KM, 1999, MOL GENET METAB, V67, P278, DOI 10.1006/mgme.1999.2878; DiGiacomo R. F., 1994, The biology of the laboratory rabbit., P171; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; KLUG D, 1972, J BIOL CHEM, V247, P4839; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; MARMOCCHI F, 1975, PHYSIOL CHEM PHYS M, V7, P465; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MILLS EL, 1981, INFECT IMMUN, V32, P1200, DOI 10.1128/IAI.32.3.1200-1205.1981; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Pervaiz S, 2002, BIOCHEM BIOPH RES CO, V290, P1145, DOI 10.1006/bbrc.2001.6274; Quick KL, 2000, J NEUROSCI METH, V97, P139, DOI 10.1016/S0165-0270(00)00179-5; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RYPNIEWSKI WR, 1995, J MOL BIOL, V251, P282, DOI 10.1006/jmbi.1995.0434; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Seet BT, 2002, J LEUKOCYTE BIOL, V72, P24; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMALSKI MD, 1991, VIROLOGY, V184, P149, DOI 10.1016/0042-6822(91)90831-U; Torres AS, 2001, J BIOL CHEM, V276, P38410, DOI 10.1074/jbc.M104790200; WEISS SJ, 1978, AM J HEMATOL, V4, P1, DOI 10.1002/ajh.2830040102; Willer DO, 1999, VIROLOGY, V264, P319, DOI 10.1006/viro.1999.0002; ZHANG WD, 1993, J VIROL, V67, P204, DOI 10.1128/JVI.67.1.204-212.1993	33	31	32	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33175	33184		10.1074/jbc.M300644200	http://dx.doi.org/10.1074/jbc.M300644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12773543	hybrid			2022-12-25	WOS:000184901800084
J	Jensen, BC; Wang, Q; Kifer, CT; Parsons, M				Jensen, BC; Wang, Q; Kifer, CT; Parsons, M			The NOG1 GTP-binding protein is required for biogenesis of the 60 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SIGMA(B); TRYPANOSOMA-BRUCEI; BACILLUS-SUBTILIS; SACCHAROMYCES-CEREVISIAE; NUCLEOLAR PROTEIN; STRESS ACTIVATION; MOLECULAR-CLONING; RNA; GENE; OBG	NOG1 is a nucleolar GTP-binding protein present in eukaryotes ranging from trypanosomes to humans. In this report we demonstrate that NOG1 is functionally linked to ribosome biogenesis. In sucrose density gradients Trypanosoma brucei NOG1 co-sediments with 60 S ribosomal subunits but not with monosomes. 60 S precursor RNAs are co-precipitated with NOG1. Together with the nucleolar localization of NOG1, these data indicate that NOG1 is associated with a precursor particle to the 60 S subunit. Disruption of NOG1 function through RNA interference led to a dramatic decrease in the levels of free 60 S particles and the appearance of an atypical rRNA intermediate in which ITS2 was not cleaved. Overexpression of mutant nog1 with a defect in its GTP binding motif on a wild type background caused a modest defect in 60 S biogenesis and a relative decrease in processing of the large subunit rRNAs. In contrast to the mutant protein, neither the N-terminal half of NOG1, which contains the GTP binding motifs, nor the C-terminal half of NOG1 associated with pre-ribosomal particles, although both localized to the nucleolus.	Seattle Biomed Res Inst, Seattle, WA 98109 USA; Univ Washington, Sch Community Med & Publ Hlth, Dept Pathobiol, Seattle, WA 98195 USA	Center for Infectious Disease Research; University of Washington; University of Washington Seattle	Parsons, M (corresponding author), Seattle Biomed Res Inst, 4 Nickerson St, Seattle, WA 98109 USA.	mparsons@sbri.org		Parsons, Marilyn/0000-0003-3994-8096	NIAID NIH HHS [T32 AI07509, R01 AI31077] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007509, R01AI031077] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; Brecht M, 1998, MOL BIOCHEM PARASIT, V97, P189, DOI 10.1016/S0166-6851(98)00151-0; BRUN R, 1979, ACTA TROP, V36, P289; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; Das A, 1998, J CELL SCI, V111, P2615; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garcia SN, 1999, CELL, V97, P825, DOI 10.1016/S0092-8674(00)80794-1; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; Hartshorne T, 2001, J MOL BIOL, V313, P733, DOI 10.1006/jmbi.2001.5078; Ho JHN, 2000, RNA, V6, P1625, DOI 10.1017/S1355838200001291; Kallstrom G, 2003, MOL CELL BIOL, V23, P4344, DOI 10.1128/MCB.23.12.4344-4355.2003; KLOOTWIJK J, 1989, METHOD ENZYMOL, V180, P96; Kobayashi G, 2001, MOL MICROBIOL, V41, P1037, DOI 10.1046/j.1365-2958.2001.02574.x; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lin B, 1999, J BACTERIOL, V181, P5825, DOI 10.1128/JB.181.18.5825-5832.1999; Maddock J, 1997, J BACTERIOL, V179, P6426, DOI 10.1128/jb.179.20.6426-6431.1997; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Okamoto S, 1997, J BACTERIOL, V179, P170, DOI 10.1128/jb.179.1.170-179.1997; Okamoto S, 1998, MOL MICROBIOL, V30, P107, DOI 10.1046/j.1365-2958.1998.01042.x; Park JH, 2002, MOL BIOCHEM PARASIT, V119, P97, DOI 10.1016/S0166-6851(01)00407-8; Park JH, 2001, J CELL SCI, V114, P173; PARKER HL, 1995, MOL BIOCHEM PARASIT, V69, P269, DOI 10.1016/0166-6851(94)00208-5; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P363, DOI 10.1016/0006-291X(92)91567-A; Scott JM, 2000, J BACTERIOL, V182, P2771, DOI 10.1128/JB.182.10.2771-2777.2000; Scott JM, 1999, J BACTERIOL, V181, P4653, DOI 10.1128/JB.181.15.4653-4660.1999; SKEIKY YAW, 1993, J IMMUNOL, V151, P1; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; VENEMA J, 1995, YEAST, V11, P145, DOI 10.1002/yea.320110206; VIDWANS SJ, 1995, J BACTERIOL, V177, P3308, DOI 10.1128/jb.177.11.3308-3311.1995; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WELSH KM, 1994, J BACTERIOL, P6426; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zanchin NIT, 1997, MOL CELL BIOL, V17, P5001, DOI 10.1128/MCB.17.9.5001; Zhang SY, 2001, J BACTERIOL, V183, P2316, DOI 10.1128/JB.183.7.2316-2321.2001; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	48	72	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32204	32211		10.1074/jbc.M304198200	http://dx.doi.org/10.1074/jbc.M304198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788953	hybrid			2022-12-25	WOS:000184782100094
J	Aoyagi, S; Wade, PA; Hayes, JJ				Aoyagi, S; Wade, PA; Hayes, JJ			Nucleosome sliding induced by the xMi-2 complex does not occur exclusively via a simple twist-diffusion mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; YEAST SWI/SNF COMPLEX; HISTONE-DNA INTERACTIONS; BINDING; CORE; TRANSCRIPTION; MOBILIZATION; DEACETYLATION; DISRUPTION; METHYLATION	ATP-dependent chromatin remodeling complexes can induce the translocation (sliding) of nucleosomes in cis along DNA, but the mechanism by which sliding occurs is not well defined. We previously presented evidence that sliding induced by the human SWI/SNF complex does not occur solely via a proposed "twist-diffusion" mechanism whereby the DNA rotates about its helical axis without displacement from the surface of the nucleosome (Aoyagi, S., and Hayes, J. J. (2002) Mol. Cell. Biol. 22, 7484-7490). Here we examined whether the Xenopus Mi-2 nucleosome remodeling complex induces nucleosome sliding via a twist-diffusion mechanism with nucleosomes assembled onto DNA templates containing branched DNA structures expected to sterically hinder rotation of the DNA helix on the nucleosome surface. We find that the branched DNA-containing nucleosomes undergo xMi-2-catalyzed sliding at a rate and extent identical to that of nucleosomes assembled on native DNA fragments. These results indicate that both the hSWI/SNF and xMi-2 complexes induce nucleosome sliding via a mechanism(s) other than simple twist diffusion and are consistent with models in which the DNA largely maintains its rotational orientation with respect to the histone surface.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	University of Rochester; Emory University	Hayes, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.		Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X	NICHD NIH HHS [5K22HD01238] Funding Source: Medline; NIGMS NIH HHS [R01GM52426] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K22HD001238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyagi S, 2002, MOL CELL BIOL, V22, P3653, DOI 10.1128/MCB.22.11.3653-3662.2002; Aoyagi S, 2002, MOL CELL BIOL, V22, P7484, DOI 10.1128/MCB.22.21.7484-7490.2002; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Blomquist P, 1999, NUCLEIC ACIDS RES, V27, P517, DOI 10.1093/nar/27.2.517; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Chafin DR, 2000, EMBO J, V19, P5492, DOI 10.1093/emboj/19.20.5492; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; KIMBALL A, 1990, J BIOL CHEM, V265, P6544; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Langst G, 2001, J CELL SCI, V114, P2561; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Schnitzler GR, 2001, MOL CELL BIOL, V21, P8504, DOI 10.1128/MCB.21.24.8504-8511.2001; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suto RK, 2003, J MOL BIOL, V326, P371, DOI 10.1016/S0022-2836(02)01407-9; Thiriet C, 1998, J BIOL CHEM, V273, P21352, DOI 10.1074/jbc.273.33.21352; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; van Holde KE., 1989, SPRINGER SERIES MOL; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vitolo JM, 2000, MOL CELL BIOL, V20, P2167, DOI 10.1128/MCB.20.6.2167-2175.2000; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang HB, 2001, NUCLEIC ACIDS RES, V29, P2517, DOI 10.1093/nar/29.12.2517; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Whitehouse I, 2000, BIOCHEM SOC T, V28, P376, DOI 10.1042/0300-5127:0280376; Wolffe A., 1998, CHROMATIN STRUCTURE; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WOLFFE AP, 1993, METH MOL G, V2, P314; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	48	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30562	30568		10.1074/jbc.M304148200	http://dx.doi.org/10.1074/jbc.M304148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12767978	hybrid			2022-12-25	WOS:000184658800020
J	Cheng, BK; Zhu, CX; Ji, CL; Ahumada, A; Tse-Dinh, YC				Cheng, BK; Zhu, CX; Ji, CL; Ahumada, A; Tse-Dinh, YC			Direct interaction between Escherichia coli RNA polymerase and the zinc ribbon domains of DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-LOOP FORMATION; III-ALPHA; TRANSCRIPTION; BINDING; SENSITIVITY; TEMPLATE; AFFINITY	Escherichia coli DNA topoisomerase I (encoded by the topA gene) is important for maintaining steady-state DNA supercoiling and has been shown to influence vital cellular processes including transcription. Topoisomerase I activity is also needed to remove hypernegative supercoiling generated on the DNA template by the progressing RNA polymerase complex during transcription elongation. The accumulation of hypernegative supercoiling in the absence of topoisomerase I can lead to R-loop formation by the nascent transcript and template strand, leading to suppression of transcription elongation. Here we show by affinity chromatography and overlay blotting that E. coli DNA topoisomerase I interacts directly with the RNA polymerase complex. The protein-protein interaction involves the beta' subunit of RNA polymerase and the C-terminal domains of E. coli DNA topoisomerase I, which are homologous to the zinc ribbon domains in a number of transcription factors. This direct interaction can bring the topoisomerase I relaxing activity to the site of transcription where its activity is needed. The zinc ribbon C-terminal domains of other type IA topoisomerases, including mammalian topoisomerase III, may also help link the enzyme activities to their physiological functions, potentially including replication, transcription, recombination, and repair.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Tse-Dinh, YC (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	yuk-ching_tse-dinh@nymc.edu			NIGMS NIH HHS [R01 GM054226, GM54226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 1998, BIOCHEM BIOPH RES CO, V251, P509, DOI 10.1006/bbrc.1998.9500; Ahumada A, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-13; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; Grishin NV, 2000, J MOL BIOL, V299, P1165, DOI 10.1006/jmbi.2000.3841; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Johnson FB, 2000, CANCER RES, V60, P1162; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; Leng FF, 2002, P NATL ACAD SCI USA, V99, P9139, DOI 10.1073/pnas.142002099; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Masse E, 1999, J BIOL CHEM, V274, P16659, DOI 10.1074/jbc.274.23.16659; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Mondal N, 2001, NATURE, V413, P435, DOI 10.1038/35096590; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Seki T, 1998, J BIOL CHEM, V273, P28553, DOI 10.1074/jbc.273.44.28553; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; Tse-Dinh YC, 2000, J BACTERIOL, V182, P829, DOI 10.1128/JB.182.3.829-832.2000; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Y, 2002, J BIOL CHEM, V277, P1203, DOI 10.1074/jbc.M109436200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yigit H, 1999, J BACTERIOL, V181, P3185, DOI 10.1128/JB.181.10.3185-3192.1999; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103; Zhu CX, 1999, METH MOL B, V94, P145; ZHU CX, 1995, BIOCHEM MOL BIOL INT, V35, P375; Zhu CX, 2000, J BIOL CHEM, V275, P5318, DOI 10.1074/jbc.275.8.5318; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	37	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30705	30710		10.1074/jbc.M303403200	http://dx.doi.org/10.1074/jbc.M303403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788950	hybrid			2022-12-25	WOS:000184658800036
J	Mogk, A; Schlieker, C; Friedrich, KL; Schofeld, HJ; Vierling, E; Bukau, B				Mogk, A; Schlieker, C; Friedrich, KL; Schofeld, HJ; Vierling, E; Bukau, B			Refolding of substrates bound to small Hsps relies on a disaggregation reaction mediated most efficiently by ClpB/DnaK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI PROTEINS; MOLECULAR CHAPERONES; MULTICHAPERONE NETWORK; ALPHA-CRYSTALLIN; IN-VIVO; DNAK; AGGREGATION; MACHINERY; SYSTEM	Small heat shock proteins (sHsps) are ubiquitous molecular chaperones that bind denatured proteins in vitro, thereby facilitating their subsequent refolding by ATP-dependent chaperones. The mechanistic basis of this refolding process is poorly defined. We demonstrate that substrates complexed to sHsps from various sources are not released spontaneously. Dissociation and refolding of sHsp bound substrates relies on a disaggregation reaction mediated by the DnaK system, or, more efficiently, by ClpB/DnaK. While the DnaK system alone works for small, soluble sHsp/substrate complexes, ClpB/DnaK-mediated protein refolding is fastest for large, insoluble protein aggregates with incorporated sHsps. Such conditions reflect the situation in vivo, where sHsps are usually associated with insoluble proteins during heat stress. We therefore propose that sHsp function in cellular protein quality control is to promote rapid resolubilization of aggregated proteins, formed upon severe heat stress, by DnaK or ClpB/DnaK.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany; Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Hoffmann La Roche Ag, CH-4070 Basel, Switzerland	Ruprecht Karls University Heidelberg; University of Arizona; Roche Holding	Mogk, A (corresponding author), Univ Heidelberg, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.			Vierling, Elizabeth/0000-0002-0066-4881; Bukau, Bernd/0000-0003-0521-7199	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042762] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM42762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arsene F, 1999, J BACTERIOL, V181, P3552; Bukau B., 1999, MOL CHAPERONES FOLDI, P3; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ehrnsperger M., 1998, STRUCTURE FUNCTION S, P533; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; GIESE KC, 2002, J BIOL CHEM, V23, P23; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; Laskowska E, 1996, BIOCHIMIE, V78, P117, DOI 10.1016/0300-9084(96)82643-5; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Michelini ET, 1999, J BACTERIOL, V181, P4237, DOI 10.1128/JB.181.14.4237-4244.1999; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stewart GR, 2002, MICROBIOL-SGM, V148, P3129, DOI 10.1099/00221287-148-10-3129; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANMONTFORT R, 2002, STRUCTURE FUNCTION S, P59; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	33	216	228	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31033	31042		10.1074/jbc.M303587200	http://dx.doi.org/10.1074/jbc.M303587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788951	hybrid			2022-12-25	WOS:000184658800079
J	Palamakumbura, AH; Sommer, P; Trackman, PC				Palamakumbura, AH; Sommer, P; Trackman, PC			Autocrine growth factor regulation of lysyl oxidase expression in transformed fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; OSTEOBLASTIC MC3T3-E1 CELLS; REFRACTORY PROSTATE-CANCER; LUNG FIBROBLASTS; MESSENGER-RNA; FLUOROMETRIC ASSAY; FIBROGENIC CELLS; DOWN-REGULATION; FACTOR RECEPTOR; HUMAN-MELANOMA	Lysyl oxidase catalyzes oxidative deamination of peptidyl-lysine and hydroxylysine residues in collagens and lysine residues in elastin to form peptidyl aldehydes that are required for the formation of covalent crosslinks in normal extracellular matrix biosynthesis. Lysyl oxidase in addition has tumor suppressor activity, and phenotypic reversion of transformed cell lines is accompanied by increased lysyl oxidase expression. The mechanism of low expression of lysyl oxidase in tumor cells is unknown. The present study investigates the hypothesis that autocrine growth factor pathways maintain low lysyl oxidase expression levels in c-H-ras-transformed fibroblasts (RS485 cell line). Autocrine pathways were blocked with suramin, a general inhibitor of growth factor receptor binding, and resulted in more than a 10-fold increase in lysyl oxidase expression and proenzyme production. This regulation was found to be reversible and occurred at the transcriptional level determined using lysyl oxidase promoter/reporter gene assays. Function blocking anti-fibroblast growth factor-2 (FGF-2) antibody enhanced lysyl oxidase expression in the absence of suramin. Finally, the addition of FGF-2 to suramin-treated cells completely reversed suramin stimulation of lysyl oxidase mRNA levels. Data support that an FGF-2 autocrine pathway inhibits lysyl oxidase transcription in the tumorigenic-transformed RS485 cell line. This finding may be of therapeutic significance and, in addition, provides a new experimental approach to investigate the mechanism of the tumor suppressor activity of lysyl oxidase.	Boston Univ, Goldman Sch Dent Med, Div Oral Biol, Boston, MA 02118 USA; Univ Lyon 1, Inst Biol & Chim Prot, CNRS UMR 5086, F-69367 Lyon 07, France	Boston University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Trackman, PC (corresponding author), Boston Univ, Goldman Sch Dent Med, Div Oral Biol, 700 Albany St,W-210, Boston, MA 02118 USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NIDCR NIH HHS [DE11004, DE12425, DE12209] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012209, R29DE011004, R03DE012425, R01DE011004] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abdiu A, 1999, CANCER LETT, V146, P189, DOI 10.1016/S0304-3835(99)00260-8; Arnaud E, 1999, MOL CELL BIOL, V19, P505; BOAK AM, 1994, AM J RESP CELL MOL, V11, P751, DOI 10.1165/ajrcmb.11.6.7946403; Choung J, 1998, J CELL BIOCHEM, V71, P254, DOI 10.1002/(SICI)1097-4644(19981101)71:2<254::AID-JCB10>3.3.CO;2-L; Cirillo A, 2001, CELL TISSUE RES, V304, P323, DOI 10.1007/s004410100355; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; Csiszar K, 1996, MOL BIOL REP, V23, P97, DOI 10.1007/BF00424435; Davol PA, 1999, CANCER, V86, P1733, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1733::AID-CNCR15>3.0.CO;2-H; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; Dhar S, 2000, EUR J CANCER, V36, P803, DOI 10.1016/S0959-8049(00)00024-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Feres EJ, 1996, J BIOL CHEM, V271, P6411, DOI 10.1074/jbc.271.11.6411; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Fujiuchi S, 1997, ONCOLOGY, V54, P134; Fukumoto M, 2000, ANTICANCER RES, V20, P4059; Garcia-Schurmann JM, 1999, UROLOGY, V53, P535, DOI 10.1016/S0090-4295(98)00544-5; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giampuzzi M, 2003, BBA-PROTEINS PROTEOM, V1647, P239, DOI 10.1016/S1570-9639(03)00058-X; Giampuzzi M, 2003, BBA-PROTEINS PROTEOM, V1647, P245, DOI 10.1016/S1570-9639(03)00059-1; Giampuzzi M, 2001, J BIOL CHEM, V276, P29226, DOI 10.1074/jbc.M101695200; GREEN RS, 1995, LAB INVEST, V73, P476; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; Hong HH, 2002, J PERIODONTOL, V73, P145, DOI 10.1902/jop.2002.73.2.145; Hong HH, 1999, LAB INVEST, V79, P1655; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; Kagan HM, 2000, ACTA TROP, V77, P147, DOI 10.1016/S0001-706X(00)00128-5; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; LAROCCA RV, 1990, J CLIN ENDOCR METAB, V71, P497; LAROCCA RV, 1990, J STEROID BIOCHEM, V37, P893, DOI 10.1016/0960-0760(90)90439-R; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; Lossos IS, 2000, LIFE SCI, V67, P2873, DOI 10.1016/S0024-3205(00)00865-1; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mietz H, 1998, BRIT J OPHTHALMOL, V82, P816, DOI 10.1136/bjo.82.7.816; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; Mirza MR, 1997, ACTA ONCOL, V36, P171, DOI 10.3109/02841869709109226; MURPHY PR, 1995, MOL CELL ENDOCRINOL, V114, P193, DOI 10.1016/0303-7207(95)96800-W; Nellaiappan K, 2000, J CELL BIOCHEM, V79, P576, DOI 10.1002/1097-4644(20001215)79:4<576::AID-JCB60>3.0.CO;2-A; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Ren CZ, 1998, CANCER RES, V58, P1285; Reynaud C, 1999, CELL MOL BIOL, V45, P1237; Roy R, 1996, J CELL BIOCHEM, V62, P411, DOI 10.1002/(SICI)1097-4644(199609)62:3<411::AID-JCB11>3.0.CO;2-L; Ryan CW, 2002, CANCER CHEMOTH PHARM, V50, P1, DOI 10.1007/s00280-002-0458-y; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; Small EJ, 2000, J CLIN ONCOL, V18, P1440, DOI 10.1200/JCO.2000.18.7.1440; SOMMER P, 1993, LAB INVEST, V69, P460; Song SH, 2001, CANCER RES, V61, P6145; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Song YL, 2000, ARTERIOSCL THROM VAS, V20, P982, DOI 10.1161/01.ATV.20.4.982; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Sullivan KA, 1997, BRAIN RES, V744, P199, DOI 10.1016/S0006-8993(96)01078-5; Tan RSP, 1996, CANCER RES, V56, P2417; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Trivedy C, 1999, J ORAL PATHOL MED, V28, P246; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; VYTASEK R, 1982, ANAL BIOCHEM, V120, P243, DOI 10.1016/0003-2697(82)90342-6; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Zanghi JA, 2000, BIOTECHNOL PROGR, V16, P319, DOI 10.1021/bp0000353	76	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30781	30787		10.1074/jbc.M305238200	http://dx.doi.org/10.1074/jbc.M305238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788924	hybrid			2022-12-25	WOS:000184658800046
J	Shu, LM; Shayman, JA				Shu, LM; Shayman, JA			Src kinase mediates the regulation of phospholipase C-gamma activity by glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; CAVEOLAE-LIKE DOMAINS; PHOSPHORYLATION CASCADE; INOSITOL TRISPHOSPHATE; SIGNAL-TRANSDUCTION; LOW-DENSITY; CELLS; LOCALIZATION; ACTIVATION; ASSOCIATION	Glucosylceramide-based glycosphingolipids have been previously demonstrated to regulate negatively the formation of inositol 1,4,5-trisphosphate by phospholipase C-gamma1. In the present study, the depletion of endogenous glucosylceramide by D-t-EtDO-P4 in cultured ECV304 cells induced autophosphorylation of Src kinase at tyrosine residue 418 within the catalytic loop and dephosphorylation of Src kinase at tyrosine residues 529 within the carboxyl-terminal regulatory region. Phosphotransferase activities of Src kinase were also induced in the glucosylceramide-depleted cells. c-Src kinase activity and phosphorylations at Src Tyr-418 and epidermal growth factor (EGF) receptor Tyr-1068 were significantly enhanced by bradykinin in response to 100 nM D-t-EtDO-P4 compared with control cells. The phosphorylation and dephosphorylation on Tyr-418 and Tyr-529 residues of c-Src were reversed by treatment of 4-amino-5-(4-chlorophenyl)-7-t-butyl( pyrazolo)[3,4-d] pyrimidine (PP2), an inhibitor of Src kinase, in control cells. Glucosylceramide-depleted cells resisted treatment with PP2, and both phosphorylation of Tyr-418 and dephosphorylation of Tyr-529 induced by depletion of glucosylceramide were maintained. Compared with untreated cells, tyrosine phosphorylation of phospholipase C-gamma1 was enhanced by EGF stimulation in glucosylceramide-depleted cells, associated with enhanced tyrosine phosphorylation of the EGF receptor at inhibitor, PP2, significantly blocked EGF-induced tyrosine phosphorylation of phospholipase C-gamma1 in control cells, whereas in glucosylceramide-depleted cells, suppression of Src kinase activity by PP2 toward EGF-induced tyrosine phosphorylation of phospholipase C-gamma1 was less significant. Thus the activation of Src kinase by depletion of glucosylceramide-based glycosphingolipids in cultured ECV304 cells is a critical upstream event in the activation of phospholipase C-gamma1.	Univ Michigan, Dept Internal Med, Div Nephrol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Dept Internal Med, Div Nephrol, Sch Med, Box 0676,Rm 1560 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [R01-DK55823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; GOUY H, 1995, J IMMUNOL, V155, P5160; Hakomori S, 2003, CURR OPIN HEMATOL, V10, P16, DOI 10.1097/00062752-200301000-00004; Hiraoka M, 2002, J BIOL CHEM, V277, P10090, DOI 10.1074/jbc.M111977200; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MAHDIYOUN S, 1992, ARCH BIOCHEM BIOPHYS, V292, P506, DOI 10.1016/0003-9861(92)90023-P; MILJAN EA, 2002, SCI STKE; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; Myers SJ, 1999, ATHEROSCLEROSIS, V143, P389, DOI 10.1016/S0021-9150(98)00331-1; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shu LM, 2002, J BIOL CHEM, V277, P18447, DOI 10.1074/jbc.M111363200; Shu LM, 2000, ARCH BIOCHEM BIOPHYS, V373, P83, DOI 10.1006/abbi.1999.1553; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; Toselli M, 2001, J PHYSIOL-LONDON, V536, P361, DOI 10.1111/j.1469-7793.2001.0361c.xd; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4	28	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31419	31425		10.1074/jbc.M303783200	http://dx.doi.org/10.1074/jbc.M303783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12771140	hybrid			2022-12-25	WOS:000184658800125
J	Spitalny, P; Thomm, M				Spitalny, P; Thomm, M			Analysis of the open region and of DNA-protein contacts of archaeal RNA polymerase transcription complexes during transition from initiation to elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER CLEARANCE; IN-VITRO; MECHANISM; TRANSLOCATION; BINDING; HYBRID	The archaeal transcriptional machinery is polymerase II (pol II)-like but does not require ATP or TFIIH for open complex formation. We have used enzymatic and chemical probes to follow the movement of Pyrococcus RNA polymerase (RNAP) along the glutamate dehydrogenase gene during transcription initiation and transition to elongation. RNAP was stalled between registers +5 and +20 using C-minus cassettes. The upstream edge of RNAP was in close contact with the archaeal transcription factors TATA box-binding protein/transcription factor B in complexes stalled at position +5. Movement of the downstream edge of the RNAP was not detected by exonuclease III footprinting until register +8. A first structural transition characterized by movement of the upstream edge of RNAP was observed at registers +6/+7. A major transition was observed at registers +10/+11. In complexes stalled at these positions also the downstream edge of RNA polymerase started translocation, and reclosure of the initially open complex occurred indicating promoter clearance. Between registers +11 and +20 both RNAP and transcription bubble moved synchronously with RNA synthesis. The distance of the catalytic center to the front edge of the exo III footprint was similar to12 nucleotides in all registers. The size of the RNA-DNA hybrid in an early archaeal elongation complex was estimated between 9 and 12 nucleotides. For complexes stalled between positions +10 and +20 the size of the transcription bubble was around 17 nucleotides. This study shows characteristic mechanistic properties of the archaeal system and also similarities to prokaryotic RNAP and pol II.	Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	University of Kiel	Thomm, M (corresponding author), Univ Regensburg, Lehrstuhl Mikrobiol, Univ Str 31, D-93053 Regensburg, Germany.	Michael.Thomm@Biologie.Uni-Regensburg.de						Bartlett MS, 2000, NAT STRUCT BIOL, V7, P782, DOI 10.1038/79020; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 1998, P NATL ACAD SCI USA, V95, P15218, DOI 10.1073/pnas.95.26.15218; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; CAI H, 1987, J BIOL CHEM, V262, P298; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Dahlke I, 2002, NUCLEIC ACIDS RES, V30, P701, DOI 10.1093/nar/30.3.701; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; Fiedler U, 2000, BIOESSAYS, V22, P316, DOI 10.1002/(SICI)1521-1878(200004)22:4<316::AID-BIES2>3.0.CO;2-B; Fiedler U, 2001, NUCLEIC ACIDS RES, V29, P2706, DOI 10.1093/nar/29.13.2706; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hausner W, 2001, J BACTERIOL, V183, P3025, DOI 10.1128/JB.183.10.3025-3031.2001; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; HEUMANN H, 1997, NUCL ACIDS MOL BIOL, V11, P151; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; JIANG Y, 1993, J BIOL CHEM, V268, P6535; Kahl BF, 2000, J MOL BIOL, V299, P75, DOI 10.1006/jmbi.2000.3743; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; VANHIPPEL PH, 1992, TRANSCRIPTION REGULA, P179; Vierke G, 2003, J BIOL CHEM, V278, P18, DOI 10.1074/jbc.M209250200; Yan M, 1997, EMBO J, V16, P7457, DOI 10.1093/emboj/16.24.7457; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	36	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30497	30505		10.1074/jbc.M303633200	http://dx.doi.org/10.1074/jbc.M303633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783891	hybrid			2022-12-25	WOS:000184658800013
J	Dhawan, S; Dua, M; Chishti, AH; Hanspal, M				Dhawan, S; Dua, M; Chishti, AH; Hanspal, M			Ankyrin peptide blocks falcipain-2-mediated malaria parasite release from red blood cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	44th Annual Meeting of the American-Society-of-Hematology	DEC 06-10, 2002	PHILADELPHIA, PENNSYLVANIA	Amer Soc Hematol			FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; RECOMBINANT FALCIPAIN-2; PROTEASE INHIBITORS; CYSTEINE PROTEINASE; HOST ERYTHROCYTE; EXPRESSION; IDENTIFICATION; MEROZOITES; INVASION	Falcipain-2 (FP-2) is a dual-function protease that cleaves hemoglobin at the early trophozoite stage and erythrocyte membrane ankyrin and protein 4.1 at the late stages of parasite development. FP-2-mediated cleavage of ankyrin and protein 4.1 is postulated to cause membrane instability facilitating parasite release in vivo. To test this hypothesis, here we have determined the precise peptide sequence at the hydrolysis site of ankyrin to develop specific inhibitor(s) of FP-2. Mass spectrometric analysis of the hydrolysis products showed that FP-2-mediated cleavage of ankyrin occurred immediately after arginine 1,210. A 10-mer peptide (ankyrin peptide, AnkP) containing the cleavage site completely inhibited the FP-2 enzyme activity in vitro and abolished all of the known functions of FP-2. To determine the effect of this peptide on the growth and development of P. falciparum, the peptide was delivered into intact parasite-infected red blood cells (RBCs) via the Antennapedia homeoprotein internalization domain. Growth and maturation of trophozoites and schizonts was markedly inhibited in the presence of the fused AnkP peptide. < 10% of new ring-stage parasites were detected compared with the control sample. Together, our results identify a specific peptide derived from the spectrin-binding domain of ankyrin that blocks late-stage malaria parasite development in RBCs. Confocal microscopy with FP-2-specific antibodies demonstrated the proximity of the enzyme in apposition with the RBC membrane, further corroborating the proposed function of FP-2 in the cleavage of RBC skeletal proteins.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Biomed Res,Div Hematol Res,ACH 406, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University	Hanspal, M (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Biomed Res,Div Hematol Res,ACH 406, Boston, MA 02135 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051445, R01HL060152, R56HL051445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050600] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51445, HL 60152] Funding Source: Medline; NIAID NIH HHS [AI 50600] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; ALEY SB, 1986, PARASITOLOGY, V92, P511, DOI 10.1017/S0031182000065410; Alves LC, 2001, MOL BIOCHEM PARASIT, V116, P1, DOI 10.1016/S0166-6851(01)00290-0; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; BANYAL HS, 1981, J PARASITOL, V67, P623, DOI 10.2307/3280435; Clavijo CA, 1998, MEM I OSWALDO CRUZ, V93, P115, DOI 10.1590/S0074-02761998000100022; DEGUERCY A, 1990, MOL BIOCHEM PARASIT, V38, P233, DOI 10.1016/0166-6851(90)90026-I; Dua M, 2001, MOL BIOCHEM PARASIT, V116, P95, DOI 10.1016/S0166-6851(01)00306-1; GINSBURG H, 1983, MOL BIOCHEM PARASIT, V8, P177, DOI 10.1016/0166-6851(83)90008-7; GLASER T, 1994, P NATL ACAD SCI USA, V91, P7879, DOI 10.1073/pnas.91.17.7879; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; HALL TG, 1987, J BIOL CHEM, V262, P10537; Hanspal M, 2002, BLOOD, V100, P1048, DOI 10.1182/blood-2002-01-0101; Hanspal M, 2002, MOL BIOCHEM PARASIT, V122, P227, DOI 10.1016/S0166-6851(02)00104-4; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LI WL, 1991, MOL BIOCHEM PARASIT, V49, P157, DOI 10.1016/0166-6851(91)90138-V; LYON JA, 1986, J IMMUNOL, V136, P2245; Raphael P, 2000, MOL BIOCHEM PARASIT, V110, P259, DOI 10.1016/S0166-6851(00)00283-8; ROSENTHAL PJ, 1989, MOL BIOCHEM PARASIT, V35, P177, DOI 10.1016/0166-6851(89)90120-5; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; SHERMAN IW, 1985, PARASITOLOGY, V91, P609, DOI 10.1017/S0031182000062843; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Walsh M, 2002, BLOOD, V99, P3439, DOI 10.1182/blood.V99.9.3439; Winograd E, 1999, PARASITOL RES, V85, P621, DOI 10.1007/s004360050606	31	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30180	30186		10.1074/jbc.M305132200	http://dx.doi.org/10.1074/jbc.M305132200			7	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775709	hybrid			2022-12-25	WOS:000184507000096
J	Kruljac-Letunic, A; Moelleken, J; Kallin, A; Wieland, F; Blaukat, A				Kruljac-Letunic, A; Moelleken, J; Kallin, A; Wieland, F; Blaukat, A			The tyrosine kinase Pyk2 regulates Arf1 activity by phosphorylation and inhibition of the Arf-GTPase-activating protein ASAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; NUCLEOTIDE EXCHANGE; PLECKSTRIN HOMOLOGY; FOCAL ADHESIONS; PHOSPHOLIPASE-D; CHOLERA-TOXIN; SH3 DOMAINS; BINDING; SRC; BETA	Proline-rich tyrosine kinase 2 (Pyk2), a non-receptor tyrosine kinase structurally related to focal adhesion kinase, has been implicated in the regulation of mitogen-activated protein kinase cascades and ion channels, the induction of apoptosis, and in the modulation of the cytoskeleton. In order to understand how Pyk2 signaling mediates these diverse cellular functions, we performed a yeast two-hybrid screening using the C-terminal part of Pyk2 that contains potential protein-protein interaction sites as bait. A prominent binder of Pyk2 identified by this method was the Arf-GTPase-activating protein ASAP1. Pyk2-ASAP1 interaction was confirmed in pull-down as well as in co-immunoprecipitation experiments, and contact sites were mapped to the proline-rich regions of Pyk2 and the SH3 domain of ASAP1. Pyk2 directly phosphorylates ASAP1 on tyrosine residues in vitro and increases ASAP1 tyrosine phosphorylation when co-expressed in HEK293T cells. Phosphorylation of tyrosine 308 and 782 affects the phosphoinositide binding profile of ASAP1, and fluorimetric Arf-GTPase assays with purified proteins revealed an inhibition of ASAP1 GTPase-activating protein activity by Pyk2-mediated tyrosine phosphorylation. We therefore provide evidence for a functional interaction between Pyk2 and ASAP1 and a regulation of ASAP1 and hence Arf1 activity by Pyk2-mediated tyrosine phosphorylation.	Heidelberg Univ, Inst Pharmacol, D-69120 Heidelberg, Germany; Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ludwig Institute for Cancer Research	Blaukat, A (corresponding author), Merck KGaA, Oncol Res Darmstadt, A25-R501,Frankfurter Str 250, D-64293 Darmstadt, Germany.	Andree.Blaukat@merck.de						Andreev J, 1999, MOL CELL BIOL, V19, P2338; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Aoto H, 2002, CELL STRUCT FUNCT, V27, P47, DOI 10.1247/csf.27.47; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DOWLER S, 2002, SCI STKE, V129, pPL6; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Gavin AC, 2003, CURR OPIN CHEM BIOL, V7, P21, DOI 10.1016/S1367-5931(02)00007-8; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Nakamura T, 2002, FEBS LETT, V521, P190, DOI 10.1016/S0014-5793(02)02861-2; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; WEERNINK PAO, 2000, N-S ARCH PHARMACOL, V363, pR62; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	39	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29560	29570		10.1074/jbc.M302278200	http://dx.doi.org/10.1074/jbc.M302278200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771146	hybrid			2022-12-25	WOS:000184507000023
J	Rutkowski, DT; Ott, CM; Polansky, JR; Lingappa, VR				Rutkowski, DT; Ott, CM; Polansky, JR; Lingappa, VR			Signal sequences initiate the pathway of maturation in the endoplasmic reticulum lumen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASCENT POLYPEPTIDES; SECRETORY PROTEINS; ER MEMBRANE; TRANSLOCATION CHANNEL; PRION PROTEIN; BETA-SUBUNIT; RECOGNITION; COMPLEX; GLYCOSYLATION; PEPTIDASE	An interaction between an N-terminal signal sequence and the translocon leads to the initiation of protein translocation into the endoplasmic reticulum lumen. Subsequently, folding and modification of the substrate rapidly ensue. The close temporal coordination of these processes suggests that they may be structurally and functionally coordinated as well. Here we show that information encoded in the hydrophobic domain of a signal sequence influences the timing and efficiency of at least two steps in maturation, namely N-linked glycosylation and signal sequence cleavage. We demonstrate that these consequences correlate with and likely stem from the nature of the initial association made between the signal sequence and the translocon during the initiation of translocation. We propose a model by which these maturational events are controlled by the signal sequence-translocon interaction. Our work demonstrates that the pathway taken by a nascent chain through post-translational maturation depends on information encoded in its signal sequence.	Univ Calif San Francisco, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol & Med, San Francisco, CA 94143 USA.			Rutkowski, Thomas/0000-0001-6586-4449; Lingappa, Vishwanath R./0000-0003-0962-6571				Anjos S, 2002, J BIOL CHEM, V277, P46478, DOI 10.1074/jbc.M206894200; Chen XM, 2001, J BIOL CHEM, V276, P2411, DOI 10.1074/jbc.M007723200; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; Li Y, 2000, VIROLOGY, V272, P417, DOI 10.1006/viro.2000.0357; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; Lingappa VR, 2002, BIOESSAYS, V24, P741, DOI 10.1002/bies.10130; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; Sambrook J., 2002, MOL CLONING LAB MANU; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211	38	55	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30365	30372		10.1074/jbc.M302117200	http://dx.doi.org/10.1074/jbc.M302117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771148	hybrid			2022-12-25	WOS:000184507000117
J	McKay, TR; Bell, S; Tenev, T; Stoll, V; Lopes, R; Lemoine, NR; McNeish, IA				McKay, TR; Bell, S; Tenev, T; Stoll, V; Lopes, R; Lemoine, NR; McNeish, IA			Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy	ONCOGENE			English	Article						survivin; caspase; ovarian carcinoma; gene therapy	ADENOVIRUS-MEDIATED TRANSFER; CASPASE ACTIVATION; DIRECT INHIBITOR; CANCER-CELLS; IN-VIVO; APOPTOSIS; PROTEIN; DEATH; IAP; PATHWAY	Increased survivin expression is a negative prognostic marker in many tumours, including ovarian cancer. We show here that ovarian carcinoma cells upregulate survivin transcription in response to increased expression of the proapoptotic protein procaspase 3. We have utilized this observation in a combination gene therapy strategy using adenoviral constructs expressing the dominant-negative mutant survivin T34A (Ad Survivin T34A) and procaspase 3 (Ad Caspase 3) in ovarian carcinoma cell lines. Transfection of ovarian carcinoma cells with Ad Survivin T34A induces apoptosis via a caspase 9-mediated pathway that is not affected by cell cycle block prior to G2/M. Ad Survivin T34A-induced apoptosis can be significantly enhanced by cotransfection with Ad Caspase 3, and the combination of Ad Survivin T34A and Ad Caspase 3 leads to a significant increase in survival in a murine intraperitoneal ovarian carcinoma model with some long-term survivors. This suggests that inhibiting endogenous survivin activity while also delivering high levels of procaspase 3 allow proteolytic cleavage and activation of the terminal caspase cascade leading to tumour cell death.	Hammersmith Hosp, Imperial Coll Sch Med, Canc Res UK Mol Oncol Unit, London W12 0NN, England	Cancer Research UK; Imperial College London	McNeish, IA (corresponding author), Hammersmith Hosp, Canc Res UK Mol Oncol Unit, MRC Cyclotron Bldg, London W12 0HS, England.			Tenev, Tencho/0000-0001-8762-1069; McNeish, Iain/0000-0002-9387-7586; McKay, Tristan/0000-0002-9128-9115				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Blanc-Brude OP, 2002, NAT MED, V8, P987, DOI 10.1038/nm750; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dong Z, 2002, BIOCHEM J, V364, P413, DOI 10.1042/BJ20011431; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ikeguchi M, 2002, ONCOL REP, V9, P1121; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; McNeish IA, 2001, CANCER GENE THER, V8, P308, DOI 10.1038/sj.cgt.7700305; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645; Shariat SF, 2001, CANCER RES, V61, P2562; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Shinoura N, 2000, EXP CELL RES, V256, P423, DOI 10.1006/excr.2000.4848; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Silke J, 2001, J CELL SCI, V114, P1821; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Tenev T, 2001, CELL DEATH DIFFER, V8, P256, DOI 10.1038/sj.cdd.4400808; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wall NR, 2003, CANCER RES, V63, P230; Yamabe K, 1999, GENE THER, V6, P1952, DOI 10.1038/sj.gt.3301041; Yoshitake T, 2000, J MATER SCI LETT, V19, P537, DOI 10.1023/A:1006722205010; Zhao J, 2000, J CELL SCI, V113, P4363; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	46	37	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3539	3547		10.1038/sj.onc.1206417	http://dx.doi.org/10.1038/sj.onc.1206417			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789262	Bronze			2022-12-25	WOS:000183399200004
J	Bader, S; Walker, M; McQueen, HA; Sellar, R; Oei, E; Wopereis, S; Zhu, YH; Peter, A; Bird, AP; Harrison, DJ				Bader, S; Walker, M; McQueen, HA; Sellar, R; Oei, E; Wopereis, S; Zhu, YH; Peter, A; Bird, AP; Harrison, DJ			MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers	ONCOGENE			English	Article						18q21 gene mutations; colon cancer; lung cancer	CPG-BINDING-PROTEIN; HISTONE DEACETYLASE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; DROSOPHILA-TRITHORAX; MESSENGER-RNA; ALL-1 GENE; DOMAIN; EXPRESSION; DCC	The genes MBD1 and MBD2 encode methyl-CpG binding proteins that suppress transcription from methylated promoters. In contrast, CGBP encodes a protein that binds promoters containing unmethylated CpG and stimulates transcription. All three are located on human chromosome 18q21, a region of frequent loss of heterozygosity in several cancers. These genes therefore represent candidate tumour suppressor genes, whose loss of function could affect the normal regulation of gene expression, whether by lack of complete suppression of genes normally silenced (via loss of MBD1 and MBD2) or by some loss of activation of genes normally expressed (via loss of CGBP), either way contributing to the tumorigenic phenotype. We have confirmed by fluorescent in situ hybridization that MBD1 and MBD2 bracket the DCC locus giving a gene order of MBD1/CGBP-DCC 5'-DCC 3'-MBD2. Mutation analyses by single-stranded conformation polymorphism in colon and lung cancer cell lines and primary tumours revealed a small number of mutations, suggesting only a limited role of these genes in human tumorigenesis.	Univ Edinburgh, Mol Med Ctr, Div Pathol, Sir Alastair Currie Canc Res UK Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Life Sci Technol, NL-7500 KB Enschede, Netherlands	University of Edinburgh; University of Edinburgh	Bader, S (corresponding author), Univ Edinburgh, Mol Med Ctr, Div Pathol, Sir Alastair Currie Canc Res UK Labs, Edinburgh EH4 2XU, Midlothian, Scotland.	s.bader@ed.ac.uk	McQueen, Heather/AAS-3294-2020	McQueen, Heather/0000-0002-4228-6081; Bird, Adrian/0000-0002-8600-0372; harrison, david/0000-0001-9041-9988				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Carlone DL, 2001, MOL CELL BIOL, V21, P7601, DOI 10.1128/MCB.21.22.7601-7606.2001; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cross SH, 1999, NUCLEIC ACIDS RES, V27, P2099, DOI 10.1093/nar/27.10.2099; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; Fabre M, 1999, INT J CANCER, V81, P799, DOI 10.1002/(SICI)1097-0215(19990531)81:5<799::AID-IJC22>3.3.CO;2-N; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 1999, MOL CELL BIOL, V19, P6415; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Muller-Tidow C, 2001, BRIT J CANCER, V85, P1168, DOI 10.1054/bjoc.2001.2041; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; SHISEKI M, 1994, CANCER RES, V54, P5643; TAKAI K, 1998, CANCER RES, V58, P3700; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	46	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3506	3510		10.1038/sj.onc.1206574	http://dx.doi.org/10.1038/sj.onc.1206574			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776203				2022-12-25	WOS:000183128500018
J	Wu, WC; Shu, XD; Hovsepyan, H; Mosteller, RD; Broek, D				Wu, WC; Shu, XD; Hovsepyan, H; Mosteller, RD; Broek, D			VEGF receptor expression and signaling in human bladder tumors	ONCOGENE			English	Article						VEGF; sphingosine kinase; bladder tumor	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; VASCULAR-PERMEABILITY FACTOR; SPHINGOSINE KINASE; GENE-PRODUCT; IN-VITRO; CELLS; ACTIVATION; CANCER; RAS	Overexpression of vascular endothelial growth factor receptors (VEGFRs) has been reported in a variety of tumor types. Here we find that 11 out of the 14 bladder tumor cell tines examined express one or more VEGF receptors. Analysis of the T24 bladder tumor cell line reveals a functional autocrine loop involving VEGF and the Flk-1 receptor. Blocking VEGF expression in T24 cells results in a decrease in DNA synthesis. The Flk-1 receptor in T24 cells is phosphorylated in response to VEGF-121 or VEGF-165, and an Flk-1 inhibitor blocks VEGF to ERK signaling. We report that VEGF stimulation of T24 cells results in activation of H- and N-Ras and this is dependent on cellular sphingosine kinase I (SPK1) activity. Previously, we found VEGF-induced activation of Ras appears to be independent of a Ras-guanine nucleotide exchange factors (GEFs). Here we report that sphingosine can stimulate Ras-GTPase activating protein (GAP) activity in vitro, and sphingosine-I-phosphate (SPP) can block the stimulatory effects of sphingosine. We present a model where the balance between sphingosine and SPP regulates Ras-GAP activity such that stimulation of SPK1 favors downregulation of Ras-GAP and thereby the activation of Ras proteins. These data highlight a VEGF pathway that may be involved in the survival and proliferation of bladder tumor cells as well as other tumor cell types.	Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California	Broek, D (corresponding author), Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.				NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1995, METHOD ENZYMOL, V255, P161; BROWN LF, 1993, AM J PATHOL, V143, P1255; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Crew JP, 1997, CANCER RES, V57, P5281; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrer FA, 1999, UROLOGY, V54, P567, DOI 10.1016/S0090-4295(99)00156-9; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Liu B, 1995, BIOCHEM BIOPH RES CO, V217, P721, DOI 10.1006/bbrc.1995.2832; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; ObergWelsh C, 1997, MOL CELL ENDOCRINOL, V126, P125, DOI 10.1016/S0303-7207(96)03977-9; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Strawn LM, 1996, CANCER RES, V56, P3540; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Veikkola T, 2000, CANCER RES, V60, P203; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	35	127	141	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3361	3370		10.1038/sj.onc.1206285	http://dx.doi.org/10.1038/sj.onc.1206285			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776187				2022-12-25	WOS:000183128500002
J	Botelho, MG; Gralle, M; Oliveira, CLP; Torriani, I; Ferreira, ST				Botelho, MG; Gralle, M; Oliveira, CLP; Torriani, I; Ferreira, ST			Folding and stability of the extracellular domain of the human amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; ALZHEIMERS-DISEASE; BETA-SECRETASE; GUANIDINE-HYDROCHLORIDE; INHIBITORY-ACTIVITY; CRYSTAL-STRUCTURE; BUNDLE PROTEIN; CELL; DENATURATION; CLEAVAGE	The beta-amyloid peptide (Abeta), the major component of the senile plaques found in the brains of Alzheimer's disease patients, is derived from proteolytic processing of a transmembrane glycoprotein known as the amyloid precursor protein (APP). Human APP exists in various isoforms, of which the major ones contain 695, 751, and 770 amino acids. Proteolytic cleavage of APP by alpha- or beta-secretases releases the extracellular soluble fragments sAPPalpha or sAPPbeta, respectively. Despite the fact that sAPPalpha plays important roles in both physiological and pathological processes in the brain, very little is known about its structure and stability. We have recently presented a structural model of sAPPalpha(695) obtained from small-angle x-ray scattering measurements (Gralle, M., Botelho, M. M., Oliveira, C. L. P., Torriani, I., and Ferreira, S. T. ( 2002) Biophys. J. 83, 3513 - 3524). We now report studies on the folding and stabilities of sAPPalpha(695) and sAPPalpha(770). The combined use of intrinsic fluorescence, 4-4'-Dianilino-1,1' binaphthyl-5,5'-disulfonic acid ( bis-ANS) fluorescence, circular dichroism, differential ultraviolet absorption, and small-angle x-ray scattering measurements of the equilibrium unfolding of sAPPalpha(695) and sAPPalpha(770) by GdnHCl and urea revealed multistep folding pathways for both sAPPalpha isoforms. Such stepwise folding processes may be related to the identification of distinct structural domains in the three-dimensional model of sAPPalpha. Furthermore, the relatively low stability of the native state of sAPPalpha suggests that conformational plasticity may play a role in allowing APP to interact with a number of distinct physiological ligands.	Univ Fed Rio de Janeiro, Dept Med Biochem, BR-21944590 Rio De Janeiro, Brazil; UNICAMP, Inst Fis Gleb Wataghin, BR-13084971 Campinas, SP, Brazil; Lab Nacl Luz Sincrotron, BR-13084970 Campinas, SP, Brazil	Universidade Federal do Rio de Janeiro; Universidade Estadual de Campinas; Laboratorio Nacional de Luz Sincrotron (LNLS)	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Dept Med Biochem, BR-21944590 Rio De Janeiro, Brazil.		Caarls, Michelle Botelho/T-7976-2019; Torriani, Iris L/E-5686-2010; Ferreira, Sergio/AAZ-1576-2020; Oliveira, Cristiano L P/B-4403-2008; Gralle, Matthias/B-9005-2014	Ferreira, Sergio/0000-0001-7160-9866; Oliveira, Cristiano L P/0000-0002-3426-6507; 				Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; Chapeaurouge A, 2001, J BIOL CHEM, V276, P14861, DOI 10.1074/jbc.M009622200; De Felice FG, 2002, CELL MOL NEUROBIOL, V22, P545, DOI 10.1023/A:1021832302524; De Strooper B, 2000, J CELL SCI, V113, P1857; DEBYE P, 1947, J PHYS COLLOID CHEM, V51, P18, DOI 10.1021/j150451a002; DONIACH S, 1995, J MOL BIOL, V254, P960, DOI 10.1006/jmbi.1995.0668; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Glatter O., 1982, SMALL ANGLE X RAY SC; Gralle M, 2002, BIOPHYS J, V83, P3513, DOI 10.1016/S0006-3495(02)75351-4; Guo J, 1998, INVEST OPHTH VIS SCI, V39, P292; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Heber S, 2000, J NEUROSCI, V20, P7951; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Hoffmann J, 1999, J HISTOCHEM CYTOCHEM, V47, P373, DOI 10.1177/002215549904700311; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Martins SM, 2002, EUR J BIOCHEM, V269, P5484, DOI 10.1046/j.1432-1033.2002.03248.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MONERA OD, 1994, PROTEIN SCI, V3, P1984, DOI 10.1002/pro.5560031110; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; MUROGA Y, 1992, MACROMOLECULES, V25, P3385, DOI 10.1021/ma00039a012; POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792; Rassoulzadegan M, 1998, EMBO J, V17, P4647, DOI 10.1093/emboj/17.16.4647; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDBRINK R, 1994, J BIOL CHEM, V269, P14227; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Semisotnov GV, 1996, J MOL BIOL, V262, P559, DOI 10.1006/jmbi.1996.0535; Sester M, 2000, J BIOL CHEM, V275, P3645, DOI 10.1074/jbc.275.5.3645; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; TENDIAN SW, 1995, BIOCHEMISTRY-US, V34, P6464, DOI 10.1021/bi00019a028; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; YORK SS, 1978, BIOCHEMISTRY-US, V9, P1038	49	19	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34259	34267		10.1074/jbc.M303189200	http://dx.doi.org/10.1074/jbc.M303189200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12796495	hybrid			2022-12-25	WOS:000185047500081
J	Caloca, MJ; Zugaza, JL; Bustelo, XR				Caloca, MJ; Zugaza, JL; Bustelo, XR			Exchange factors of the RasGRP family mediate Ras activation in the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTORS; PLASMA-MEMBRANE; C1 DOMAIN; N-RAS; K-RAS; H-RAS; MICE; PROTEINS; ENDOCYTOSIS; DEFECTS	H-Ras and N-Ras become activated both at the plasma membrane and in endomembrane structures such as the Golgi apparatus. This compartmentalized activation is relevant from a signaling standpoint, because effector molecules can become activated differently depending on the region of the cell where Ras proteins are activated. An unsolved question in this new regulatory mechanism is the understanding of how Ras proteins become activated in endomembranes. To approach this problem, we have studied the subcellular distribution and activities of a number of Ras guanosine nucleotide exchange factors. Our results indicate that Ras activation at the plasma membrane and endoplasmic reticulum is an unspecific process that can be achieved by most Ras activators. In contrast, GTP loading of Ras at the Golgi is only induced by members of the Ras guanosine nucleotide releasing protein family. In agreement with these observations, Ras guanosine nucleotide releasing proteins are the only Ras activators showing localization in the Golgi. These results indicate that the compartmentalized activation of effector pathways by Ras proteins depends not only on the specific localization of the GTPases but also in the availability of GDP/GTP exchange factors capable of activating Ras proteins in specific subcellular compartments.	Univ Salamanca, Consejo Super Invest Cient, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, Consejo Super Invest Cient, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, Consejo Super Invest Cient, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.		Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022; Caloca, María-José/K-9357-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671; Caloca, Maria-Jose/0000-0002-1003-2685	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NCI NIH HHS [CA7373501] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BUSTELO XR, 1994, ONCOGENE, V9, P2405; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Dasgupta B, 2003, CURR OPIN GENET DEV, V13, P20, DOI 10.1016/S0959-437X(02)00015-1; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Lakkis MM, 1999, DEV BIOL, V212, P80, DOI 10.1006/dbio.1999.9327; Lorenzo PS, 2001, CANCER RES, V61, P943; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rojas JM, 1999, ONCOGENE, V18, P1651, DOI 10.1038/sj.onc.1202483; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; van der Eb A J, 1980, Methods Enzymol, V65, P826; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200	26	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33465	33473		10.1074/jbc.M302807200	http://dx.doi.org/10.1074/jbc.M302807200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12782630	hybrid			2022-12-25	WOS:000184901800120
J	Kanazawa, N; Tashiro, K; Inaba, K; Miyachi, Y				Kanazawa, N; Tashiro, K; Inaba, K; Miyachi, Y			Dendritic cell immunoactivating receptor, a novel C-type lectin immunoreceptor, acts as an activating receptor through association with Fc receptor gamma chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID CELLS; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; INHIBITORY MOTIF; SURFACE-RECEPTOR; CUTTING EDGE; CLONING; NK; BEARING; COMPLEX	An increasing number of C-type lectin receptors are being discovered on dendritic cells, but their signaling abilities and underlying mechanisms require further definition. Among these, dendritic cell immunoreceptor (DCIR) induces negative signals through an inhibitory immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic tail. Here we identify a novel C-type lectin receptor, dendritic cell immunoactivating receptor (DCAR), whose extracellular lectin domain is highly homologous to that of DCIR. DCAR is expressed similarly in tissues to DCIR, but its short cytoplasmic portion lacks signaling motifs like ITIM. However, a positively charged arginine residue is present in the transmembrane region of the DCAR, which may explain its association with Fc receptor gamma chain and its stable expression on the cell surface. Furthermore, cross- linking of DCAR in the presence of gamma chain activates calcium mobilization and tyrosine phosphorylation of cellular proteins. These signals are mediated by the immunoreceptor tyrosine-based activating motif (ITAM) of the gamma chain. Thus, DCAR is closely related to DCIR, but it introduces activating signals into antigen-presenting cells through its physical and functional association with ITAM-bearing gamma chain. The identification of this activating immunoreceptor provides an example of signaling via a dendritic cell-expressed C-type lectin receptor.	Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068507, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Div System Life Sci, Immunobiol Lab, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Kanazawa, N (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068507, Japan.	nkanazaw@kuhp.kyoto-u.ac.jp	Kanazawa, Nobuo/AAM-7353-2021	Kanazawa, Nobuo/0000-0003-3000-9711				Arce I, 2001, EUR J IMMUNOL, V31, P2733, DOI 10.1002/1521-4141(200109)31:9<2733::AID-IMMU2733>3.0.CO;2-X; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; Bakker ABH, 2000, IMMUNITY, V13, P345, DOI 10.1016/S1074-7613(00)00034-0; Bakker ABH, 2000, HUM IMMUNOL, V61, P18, DOI 10.1016/S0198-8859(99)00160-3; Bakker ABH, 1999, P NATL ACAD SCI USA, V96, P9792, DOI 10.1073/pnas.96.17.9792; Balch SG, 1998, J BIOL CHEM, V273, P18656, DOI 10.1074/jbc.273.29.18656; Bates EEM, 1999, J IMMUNOL, V163, P1973; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; DAERON M, 1992, J IMMUNOL, V149, P1365; Daws MR, 2001, EUR J IMMUNOL, V31, P783, DOI 10.1002/1521-4141(200103)31:3<783::AID-IMMU783>3.0.CO;2-U; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Dzionek A, 2001, J EXP MED, V194, P1823, DOI 10.1084/jem.194.12.1823; Engering A, 2002, TRENDS IMMUNOL, V23, P480, DOI 10.1016/S1471-4906(02)02296-2; Fernandes MJ, 1999, CANCER RES, V59, P2709; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Gergely J, 1999, IMMUNOL LETT, V68, P3, DOI 10.1016/S0165-2478(99)00024-3; Gibbins JM, 2002, TRENDS CARDIOVAS MED, V12, P213, DOI 10.1016/S1050-1738(02)00164-0; Hofer E, 2001, IMMUNOL REV, V181, P5, DOI 10.1034/j.1600-065X.2001.1810101.x; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JONES B, 1986, J IMMUNOL, V136, P348; Kanazawa N, 2002, J INVEST DERMATOL, V118, P261, DOI 10.1046/j.0022-202x.2001.01633.x; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P43, DOI 10.1016/0952-7915(92)90122-U; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Lebecque S, 2000, VACCINE, V18, P1603, DOI 10.1016/S0264-410X(99)00493-4; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; Masumoto M, 1999, J IMMUNOL, V163, P5039; Nakajima H, 1999, J IMMUNOL, V162, P5; NUMA F, 1995, CANCER RES, V55, P4676; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Taylor L S, 2000, Rev Immunogenet, V2, P204; Tomasello E, 2000, IMMUNITY, V13, P355, DOI 10.1016/S1074-7613(00)00035-2; Tomasello E, 2000, EUR J IMMUNOL, V30, P2147, DOI 10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1; Trowsdale J, 2001, IMMUNITY, V15, P363, DOI 10.1016/S1074-7613(01)00197-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vely F, 1997, J IMMUNOL, V159, P2075; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730	47	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32645	32652		10.1074/jbc.M304226200	http://dx.doi.org/10.1074/jbc.M304226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12777403	hybrid			2022-12-25	WOS:000184901800022
J	Amazit, L; Alj, Y; Tyagi, RK; Chauchereau, A; Loosfelt, H; Pichon, C; Pantel, J; Guinchard, EF; Leclerc, P; Milgrom, E; Guiochon-Mantel, A				Amazit, L; Alj, Y; Tyagi, RK; Chauchereau, A; Loosfelt, H; Pichon, C; Pantel, J; Guinchard, EF; Leclerc, P; Milgrom, E; Guiochon-Mantel, A			Subcellular localization and mechanisms of nucleocytoplasmic trafficking of steroid receptor coactivator-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; HUMAN ANDROGEN RECEPTOR; NUCLEAR EXPORT SIGNAL; PROGESTERONE-RECEPTOR; THYROID-HORMONE; TRANSCRIPTIONAL COACTIVATOR; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; COREPRESSOR COMPLEXES; BIPARTITE-TYPE	Steroid hormone receptors are ligand-stimulated transcription factors that modulate gene transcription by recruiting coregulators to gene promoters. Subcellular localization and dynamic movements of transcription factors have been shown to be one of the major means of regulating their transcriptional activity. In the present report we describe the subcellular localization and the dynamics of intracellular trafficking of steroid receptor coactivator 1 (SRC-1). After its synthesis in the cytoplasm, SRC-1 is imported into the nucleus, where it activates transcription and is subsequently exported back to the cytoplasm. In both the nucleus and cytoplasm, SRC-1 is localized in speckles. The characterization of SRC-1 nuclear localization sequence reveals that it is a classic bipartite signal localized in the N-terminal region of the protein, between amino acids 18 and 36. This sequence is highly conserved within the other members of the p160 family. Additionally, SRC-1 nuclear export is inhibited by leptomycin B. The region involved in its nuclear export is localized between amino acids 990 and 1038. It is an unusually large domain differing from the classic leucine-rich NES sequences. Thus SRC-1 nuclear export involves either an alternate type of NES or is dependent on the interaction of SRC-1 with a protein, which is exported through the crm1/exportin pathway. Overall, the intracellular trafficking of SRC-1 might be a mechanism to regulate the termination of hormone action, the interaction with other signaling pathways in the cytoplasm and its degradation.	Hop Bicetre, INSERM, AP HP, Lab Hormonol & Biol Mol, F-94275 Le Kremlin Bicetre, France; Inst Federat Rech Bicetre, F-94276 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Guiochon-Mantel, A (corresponding author), Hop Bicetre, INSERM, AP HP, Lab Hormonol & Biol Mol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.		Guiochon-Mantel, Anne S/S-8408-2018; CHAUCHEREAU, Anne/B-1074-2009; Chauchereau, Anne/N-8880-2016; Pantel, Jacques/C-6563-2014	Guiochon-Mantel, Anne S/0000-0003-1737-1409; Chauchereau, Anne/0000-0001-9447-3797; Pantel, Jacques/0000-0002-9015-6281				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Chen YM, 1999, P NATL ACAD SCI USA, V96, P4443, DOI 10.1073/pnas.96.8.4443; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DeFranco Donald B., 1999, Cell Biochemistry and Biophysics, V30, P1, DOI 10.1007/BF02737882; DEITCH AD, 1982, J HISTOCHEM CYTOCHEM, V30, P967, DOI 10.1177/30.9.6182188; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Ikuta T, 2000, J BIOCHEM, V127, P503, DOI 10.1093/oxfordjournals.jbchem.a022633; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1999, MOL CELL BIOL, V19, P6323; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; Laudet V, 2001, NUCL RECEPTOR FACTS; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; LOGEAT F, 1983, P NATL ACAD SCI-BIOL, V80, P6456, DOI 10.1073/pnas.80.21.6456; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MADSEN P, 1986, J CELL BIOL, V103, P2083, DOI 10.1083/jcb.103.6.2083; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; NARDULLI AM, 1986, ENDOCRINOLOGY, V119, P2038, DOI 10.1210/endo-119-5-2038; Nazareth LV, 1999, MOL ENDOCRINOL, V13, P2065, DOI 10.1210/me.13.12.2065; ONATE SA, 1995, SCIENCE, V270, P1354; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Qutob MS, 2002, MOL CELL BIOL, V22, P6611, DOI 10.1128/MCB.22.18.6611-6626.2002; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Soling A, 2002, FEBS LETT, V527, P153, DOI 10.1016/S0014-5793(02)03201-5; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tobey R A, 1973, Methods Cell Biol, V6, P67, DOI 10.1016/S0091-679X(08)60048-5; TOBEY RA, 1970, J CELL BIOL, V46, P151, DOI 10.1083/jcb.46.1.151; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/me.15.4.501	82	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32195	32203		10.1074/jbc.M300730200	http://dx.doi.org/10.1074/jbc.M300730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791702	hybrid			2022-12-25	WOS:000184782100093
J	Basora, N; Boulay, G; Bilodeau, L; Rousseau, E; Payet, MD				Basora, N; Boulay, G; Bilodeau, L; Rousseau, E; Payet, MD			20-hydroxyeicosatetraenoic acid (20-HETE) activates mouse TRPC6 channels expressed in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CA2+-PERMEABLE CATION CHANNEL; RECEPTOR POTENTIAL CHANNELS; LIGHT-SENSITIVE CHANNELS; SMOOTH-MUSCLE CELLS; SF9 INSECT CELLS; ARACHIDONIC-ACID; CA2+ ENTRY; RESISTANCE ARTERIES; PHOSPHOLIPASE-C	In the present study, we show that the eicosanoid compound, 20-hydroxyeicosatetraenoic acid (20-HETE), an important arachidonic acid metabolite, activates mouse TRPC6 in a stable, overexpressing HEK293 cell line, Hek-t6.11. Application of 20-HETE rapidly induced an inward, non-selective current in whole-cell recordings, which was inhibited by N-methyl-D-glucamine, 1.8 mM Ca2+, and 100 muM Gd3+ but remained unaffected by flufenamate and indomethacin. The current-voltage relationship obtained at low concentrations of 20-HETE (1-10 muM) demonstrated slight inward rectification, whereas the highest concentration of 20-HETE tested ( 30 muM) showed outward rectification, as shown previously for these channels using 100 muM 1-oleoyl-2-acetyl-sn-glycerol. Dose-response curves indicate that 20-HETE activated TRPC6 channels with an EC50 = 0.8 muM. Single channel analysis using inside-out patches revealed that 20-HETE increased open probability of mouse TRPC6 channels similar to3-fold, and this was in a membrane-delimited fashion. Interestingly, 20-HETE did not provoke changes in intracellular Ca2+ concentrations. Thus, we have identified an arachidonic acid metabolite, 20-HETE, as a novel activator for a TRP family member, TRPC6.	Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Basora, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, 3001 12th Ave N, Fleurimont, PQ J1H 5N4, Canada.		Boulay, Guylain/D-9773-2010					Benoit C, 2001, AM J PHYSIOL-LUNG C, V280, pL965, DOI 10.1152/ajplung.2001.280.5.L965; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birks EK, 1997, AM J PHYSIOL-LUNG C, V272, pL823, DOI 10.1152/ajplung.1997.272.5.L823; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Frisbee JC, 2001, AM J PHYSIOL-HEART C, V280, pH1066, DOI 10.1152/ajpheart.2001.280.3.H1066; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Jacobs ER, 2001, AM J PHYSIOL-HEART C, V280, pH1, DOI 10.1152/ajpheart.2001.280.1.H1; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; KRAUSE E, 1996, J BIOL CHEM, V271, P35253; Lee CH, 2002, AM J PHYSIOL-HEART C, V282, pH1571, DOI 10.1152/ajpheart.01035.2001; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Roman RJ, 2000, CLIN EXP PHARMACOL P, V27, P855, DOI 10.1046/j.1440-1681.2000.03349.x; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Roman RJ, 1999, NEWS PHYSIOL SCI, V14, P238; Salvail D, 1998, AM J PHYSIOL-LUNG C, V275, pL432, DOI 10.1152/ajplung.1998.275.3.L432; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tao L, 2000, AM J PHYSIOL-LUNG C, V279, pL722, DOI 10.1152/ajplung.2000.279.4.L722; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Walker RL, 2001, AM J PHYSIOL-CELL PH, V280, pC1184, DOI 10.1152/ajpcell.2001.280.5.C1184; Welsh DG, 2002, CIRC RES, V90, P248, DOI 10.1161/hh0302.105662; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zeldin DC, 1996, ARCH BIOCHEM BIOPHYS, V330, P87, DOI 10.1006/abbi.1996.0229; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228, DOI 10.1152/ajpregu.1996.270.1.R228; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	48	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31709	31716		10.1074/jbc.M304437200	http://dx.doi.org/10.1074/jbc.M304437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794071	hybrid			2022-12-25	WOS:000184782100032
J	Giovannone, B; Lee, E; Laviola, L; Giorgino, F; Cleveland, KA; Smith, RJ				Giovannone, B; Lee, E; Laviola, L; Giorgino, F; Cleveland, KA; Smith, RJ			Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPANDED POLYGLUTAMINE STRETCHES; SRC HOMOLOGY 2; SH2 DOMAIN; PLECKSTRIN HOMOLOGY; BINDING-PROTEIN; INTERACTS; FAMILY; IDENTIFICATION; CLONING; TRANSFORMATION	Grb10 is a protein that binds to the intracellular domains of activated tyrosine kinase receptors, including insulin-like growth factor (IGF-I) and insulin receptors. This occurs through the interaction of two C-terminal Grb10 motifs (BPS and Src homology domains) with receptor phosphotyrosine residues. Published data from transfection/overexpression studies support both positive and negative regulatory effects of Grb10, thus leaving its physiological role unclear. Because Grb10 has the structure of an adapter protein, the objective of this study was to determine whether Grb10 links other proteins to IGF-I receptors and thus modulates IGF-I signaling. Using yeast two-hybrid screening, the N terminus of Grb10 was shown to interact with two novel proteins, designated GIGYF1 ((G) under bar rb10 (i) under bar nteracting (GYF) under bar protein (1) under bar) and GIGYF2. Mutation analysis indicates that a 17-amino acid sequence in GIGYF1 and GIGYF2, homologous to the GYF domain described previously, binds to tandem proline-rich regions in the N terminus of Grb10. In IGF-I receptor- expressing R+ fibroblasts, there is detectable binding of a Myc-tagged fragment of GIGYF1 to Grb10 in the basal state. Stimulation with IGF-I results in increased binding of GIGYF1 to Grb10 and transient binding of both Grb10 and GIGYF1 to IGF-I receptors, presumably via the adapter function of Grb10. At later time points, GIGYF1 dissociates, but Grb10 remains linked to IGF-I receptors. Overexpression of the Grb10 binding fragment of GIGYF1 in R+ cells results in a significant increase in IGF-I-stimulated receptor tyrosine phosphorylation. In conclusion, we have identified two members of a novel protein family, which become transiently linked to IGF-I receptors by the Grb10 adapter protein following IGF-I stimulation. Grb10 and GIGYFs may act cooperatively to regulate receptor signaling.	Brown Univ, Rhode Isl Hosp, Hallett Ctr Diabet & Endocrinol, Providence, RI 02903 USA; Univ Bari, Dept Emergency & Organ Transplantat Internal Med, I-70124 Bari, Italy	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Universita degli Studi di Bari Aldo Moro	Smith, RJ (corresponding author), Brown Univ, Rhode Isl Hosp, Hallett Ctr Diabet & Endocrinol, 1 Hoppin St,Suite 200, Providence, RI 02903 USA.	rsmith4@lifespan.org	Giorgino, Francesco/K-7262-2016	Giorgino, Francesco/0000-0001-7372-2678; Giovannone, Barbara/0000-0003-3143-1922; Laviola, Luigi/0000-0001-8860-5845	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043038] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43038] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; Glockner G, 1998, GENOME RES, V8, P1060; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Morrione A, 2000, INT J MOL MED, V5, P151; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shimohata T, 2000, NEUROPATHOLOGY, V20, P326, DOI 10.1046/j.1440-1789.2000.00350.x; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wilson MD, 2001, NUCLEIC ACIDS RES, V29, P1352, DOI 10.1093/nar/29.6.1352; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727	41	83	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31564	31573		10.1074/jbc.M211572200	http://dx.doi.org/10.1074/jbc.M211572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12771153	hybrid			2022-12-25	WOS:000184782100016
J	Jiang, ZY; He, ZH; King, BL; Kuroki, T; Opland, DM; Suzuma, K; Suzuma, I; Ueki, K; Kulkarni, RN; Khan, CR; King, GL				Jiang, ZY; He, ZH; King, BL; Kuroki, T; Opland, DM; Suzuma, K; Suzuma, I; Ueki, K; Kulkarni, RN; Khan, CR; King, GL			Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE B; GLUCOSE-TRANSPORT; DIABETIC-RETINOPATHY; CELLULAR MECHANISMS; GENE-EXPRESSION; POTENTIAL ROLE; NITRIC-OXIDE; ACTIVATION; AKT	The effects of insulin on vascular endothelial growth factor (VEGF) expression in cultured vascular cells and in angiogenesis were characterized. Insulin increased VEGF mRNA levels in mouse aortic smooth muscle cells from 10(-9) to 10(-7) M with an initial peak of 3.7-fold increases at 1 h and a second peak of 2.8-fold after 12 h. The first peak of VEGF expression was inhibited by LY294002, an inhibitor of phosphatidylinositol (PI)3-kinase, and by the overexpression of dominant negative forms of p85 subunit of PI 3-kinase or Akt. Inhibitors of MEK kinase, PD98059, or overexpression of dominant negative forms of Ras was ineffective. In contrast, the chronic effect of insulin on VEGF expression was partially inhibited by both LY294002 or PD98059 as well as by the overexpression of dominant negatives of PI 3-kinase or Ras. The importance of PI 3-kinase-Akt pathway on VEGF expression was confirmed in mouse aortic smooth muscle cells isolated from insulin receptor substrate -1 knockout (IRS-1(-/-)) mice that showed parallel reductions of 46-49% in insulin-stimulated VEGF expression and PI 3-kinase-Akt activation. Insulin-induced activation of PI 3-kinase-Akt on hypoxia-induced VEGF expression and neovascularization was reduced by 40% in the retina of neonatal hypoxia model using IRS-1(-/-) mice. Thus, unlike other cells, insulin can regulate VEGF expression by both IRS-1/PI 3-kinase-Akt cascade and Ras-MAPK pathways in aortic smooth muscle cells. The in vivo results provide direct evidence that insulin can modulate hypoxia-induced angiogenesis via reduction in VEGF expression in vivo.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	King, GL (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	george.king@joslin.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053105] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK53105] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALLEN LA, 1986, EXP EYE RES, V43, P679, DOI 10.1016/S0014-4835(86)80034-3; [Anonymous], 1995, DIABETES, V44, P968; Baron AD, 1999, AM J CARDIOL, V84, p25J; Bermont L, 2001, J CLIN ENDOCR METAB, V86, P363, DOI 10.1210/jc.86.1.363; Castro C, 2003, J BIOL CHEM, V278, P4482, DOI 10.1074/jbc.M204716200; Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143; CLERMONT AC, 1994, INVEST OPHTH VIS SCI, V35, P981; Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229; FEENER EP, 1997, LANCET S1, V350, P9; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Haffner SM, 2000, NEW ENGL J MED, V342, P1040, DOI 10.1056/NEJM200004063421408; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Jiang ZY, 1999, DIABETES, V48, P1120, DOI 10.2337/diabetes.48.5.1120; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P3281; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Obata T, 1996, CIRC RES, V79, P1167, DOI 10.1161/01.RES.79.6.1167; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Senthil D, 2002, BIOCHEM J, V368, P49, DOI 10.1042/BJ20020137; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; STANDLEY PR, 1994, AM J HYPERTENS, V7, P357, DOI 10.1093/ajh/7.4.357; Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Waltenberger J, 2001, CARDIOVASC RES, V49, P554, DOI 10.1016/S0008-6363(00)00228-5; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	41	84	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31964	31971		10.1074/jbc.M303314200	http://dx.doi.org/10.1074/jbc.M303314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12775712	hybrid			2022-12-25	WOS:000184782100065
J	Navratil, AM; Bliss, SP; Berghorn, KA; Haughian, JM; Farmerie, TA; Graham, JK; Clay, CM; Roberson, MS				Navratil, AM; Bliss, SP; Berghorn, KA; Haughian, JM; Farmerie, TA; Graham, JK; Clay, CM; Roberson, MS			Constitutive localization of the gonadotropin-releasing hormone (GnRH) receptor to low density membrane microdomains is necessary for GnRH signaling to ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; PROTEIN-COUPLED RECEPTOR; ALPHA-T3-1 CELL-LINE; PLASMA-MEMBRANE; BETA-ARRESTIN; LIPID RAFTS; KINASE-C; MOLECULAR MECHANISMS; MEDIATED ACTIVATION; TERMINAL TAIL	Specialized membrane microdomains known as lipid rafts are thought to contribute to G-protein coupled receptor (GPCR) signaling by organizing receptors and their cognate signaling molecules into discrete membrane domains. To determine if the GnRHR, an unusual member of the GPCR superfamily, partitions into lipid rafts, homogenates of alphaT3-1 cells expressing endogenous GnRHR or Chinese hamster ovary cells expressing an epitope-tagged GnRHR were fractionated through a sucrose gradient. We found the GnRHR and c-raf kinase constitutively localized to low density fractions independent of hormone treatment. Partitioning of c-raf kinase into lipid rafts was also observed in whole mouse pituitary glands. Consistent with GnRH induced phosphorylation and activation of c-raf kinase, GnRH treatment led to a decrease in the apparent electrophoretic mobility of c-raf kinase that partitioned into lipid rafts compared with unstimulated cells. Cholesterol depletion of alphaT3-1 cells using methyl-beta-cyclodextrin disrupted GnRHR but not c-raf kinase association with rafts and shifted the receptor into higher density fractions. Cholesterol depletion also significantly attenuated GnRH but not phorbol ester-mediated activation of extracellular signal-related kinase (ERK) and c-fos gene induction. Raft localization and GnRHR signaling to ERK and c-Fos were rescued upon repletion of membrane cholesterol. Thus, the organization of the GnRHR into low density membrane microdomains appears critical in mediating GnRH induced intracellular signaling.	Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA	Colorado State University; Cornell University	Clay, CM (corresponding author), Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA.	colin.clay@colostate.edu						Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Elion EA, 2001, J CELL SCI, V114, P3967; Evans JJ, 1997, ENDOCRINOLOGY, V138, P2049, DOI 10.1210/en.138.5.2049; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAMERNIK DL, 1986, ENDOCRINOLOGY, V119, P2704, DOI 10.1210/endo-119-6-2704; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Hislop JN, 2001, J BIOL CHEM, V276, P39685, DOI 10.1074/jbc.M104542200; Hoessli DC, 2000, GLYCOCONJUGATE J, V17, P191, DOI 10.1023/A:1026585006064; Horvat RD, 2001, MOL ENDOCRINOL, V15, P695, DOI 10.1210/me.15.5.695; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; Kokubo H, 2003, BRAIN RES, V965, P83, DOI 10.1016/S0006-8993(02)04140-9; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; MASON AJ, 1986, SCIENCE, V234, P1372, DOI 10.1126/science.3097822; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; McArdle C. A., 2002, Archives of Physiology and Biochemistry, V110, P113, DOI 10.1076/apab.110.1.113.893; McArdle CA, 1999, MOL CELL ENDOCRINOL, V151, P129, DOI 10.1016/S0303-7207(99)00024-6; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Millar R, 2001, P NATL ACAD SCI USA, V98, P9636, DOI 10.1073/pnas.141048498; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; Munshi UM, 2001, EUR J BIOCHEM, V268, P1631, DOI 10.1046/j.1432-1033.2001.02032.x; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Neill JD, 2001, BIOCHEM BIOPH RES CO, V282, P1012, DOI 10.1006/bbrc.2001.4678; Nelson S, 1999, ENDOCRINOLOGY, V140, P950, DOI 10.1210/en.140.2.950; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Tensen C, 1997, EUR J BIOCHEM, V243, P134, DOI 10.1111/j.1432-1033.1997.0134a.x; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; WAGNER TOF, 1979, BIOL REPROD, V20, P140, DOI 10.1095/biolreprod20.2.140; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	68	115	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31593	31602		10.1074/jbc.M304273200	http://dx.doi.org/10.1074/jbc.M304273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791688	hybrid			2022-12-25	WOS:000184782100019
J	Tovich, PR; Oko, RJ				Tovich, PR; Oko, RJ			Somatic histones are components of the perinuclear theca in bovine spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COMPOSITION; SPERM HEAD; OOCYTE ACTIVATION; BASIC-PROTEINS; NUCLEAR PROTEINS; RAT SPERMATIDS; CORE HISTONES; MOUSE SPERM; CENP-A; CHROMATIN	The perinuclear theca is a non-ionic detergent-resistant, electron-dense layer surrounding the condensed nucleus of mammalian sperm. The known proteins originating from the perinuclear theca have implicated the structure in a variety of important cellular processes during spermiogenesis and fertilization. Nonetheless, the composition of the perinuclear theca remains largely unexplored. We have isolated a group of low molecular mass (14-19 kDa) perinuclear theca-derived proteins from acrosome-depleted bovine sperm heads by salt (1 M KCl) extraction and have identified them as core somatic histones. N-terminal sequencing and immunoblotting with anti-histone antibodies confirmed the presence of both intact and proteolytically cleaved somatic histones H3, H2B, H2A, and H4. Identical proteins were isolated using 2% SDS or 1 N HCl extractions. Subsequent acid and SDS extractions of intact bovine sperm revealed the presence of all four intact histone subtypes, with minimal proteolysis. Two-dimensional acid/urea/Triton-SDS-PAGE, coupled with immunoblotting analysis, confirmed the somatic nature of these perinuclear theca-derived histones. Estimates of the abundance of perinuclear theca-derived histones showed that up to 0.2 pg per sperm of each histone subtype was present. Immunogold labeling at the ultrastructural level localized all four core somatic histones to the postacrosomal sheath region of bovine epididymal sperm, when probed with affinity-purified anti-histone antibodies. Little immunoreactivity was detected in residual perinuclear theca structures following the extractions. Taken together, these findings indicate the unprecedented and stable localization of non-nuclear somatic histones in bovine sperm perinuclear theca.	Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Oko, RJ (corresponding author), Queens Univ, Dept Anat & Cell Biol, Botterell Hall, Kingston, ON K7L 3N6, Canada.	ro3@post.queensu.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aul RB, 2002, DEV BIOL, V242, P268, DOI 10.1006/dbio.2002.0575; Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; BARTLEY J, 1970, J BIOL CHEM, V245, P4286; BEDFORD JM, 1974, J EXP ZOOL, V188, P137, DOI 10.1002/jez.1401880203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breed WG, 2000, BIOL REPROD, V63, P629, DOI 10.1095/biolreprod63.2.629; BUCCI LR, 1984, J BIOL CHEM, V259, P8840; Chen HY, 1998, J BIOL CHEM, V273, P13165, DOI 10.1074/jbc.273.21.13165; CLERMONT Y, 1990, ANAT RECORD, V227, P447, DOI 10.1002/ar.1092270408; COURTENS JL, 1981, REPROD NUTR DEV, V21, P467, DOI 10.1051/rnd:19810312; COURTENS JL, 1976, J ULTRA MOL STRUCT R, V57, P54, DOI 10.1016/S0022-5320(76)80054-8; DAVIE JR, 1982, ANAL BIOCHEM, V120, P276, DOI 10.1016/0003-2697(82)90348-7; Eddy E. M., 1994, P29; FAULKNER RD, 1987, BIOL REPROD, V36, P471, DOI 10.1095/biolreprod36.2.471; GARNER DL, 1971, BIOL REPROD, V4, P93, DOI 10.1093/biolreprod/4.1.93; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20662; GERSHEY EL, 1968, J BIOL CHEM, V243, P5018; GOLDBERG RB, 1977, DIFFERENTIATION, V7, P167, DOI 10.1111/j.1432-0436.1977.tb01508.x; GRIMES SR, 1986, COMP BIOCHEM PHYS B, V83, P495, DOI 10.1016/0305-0491(86)90285-3; GRIMES SR, 1983, ARCH BIOCHEM BIOPHYS, V221, P108, DOI 10.1016/0003-9861(83)90126-1; GUSSE M, 1986, BIOCHIM BIOPHYS ACTA, V884, P124, DOI 10.1016/0304-4165(86)90235-7; Hazzouri M, 2000, EUR J CELL BIOL, V79, P950, DOI 10.1078/0171-9335-00123; Herrada G, 1997, J CELL SCI, V110, P1543; HESS H, 1993, J CELL BIOL, V122, P1043, DOI 10.1083/jcb.122.5.1043; Hewitson L, 1999, NAT MED, V5, P431, DOI 10.1038/7430; Hoffmann P, 1978, Methods Cell Biol, V17, P1, DOI 10.1016/S0091-679X(08)61130-9; Kierszenbaum AL, 2002, MOL REPROD DEV, V63, P1, DOI 10.1002/mrd.10179; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; Kimura Y, 1998, BIOL REPROD, V58, P1407, DOI 10.1095/biolreprod58.6.1407; KISTLER WS, 1973, J BIOL CHEM, V248, P4532; KLYSZEJKOSTEFAN.L, 1989, HISTONES OTHER BASIC, P17; Korley R, 1997, BIOL REPROD, V57, P1426, DOI 10.1095/biolreprod57.6.1426; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; LALLI M, 1981, AM J ANAT, V160, P419, DOI 10.1002/aja.1001600406; LAVITRANO M, 1989, CELL, V57, P717, DOI 10.1016/0092-8674(89)90787-3; Lecuyer C, 2000, BIOL REPROD, V63, P1801, DOI 10.1095/biolreprod63.6.1801; LIEW CC, 1970, NATURE, V226, P414, DOI 10.1038/226414a0; LONGO FJ, 1987, J CELL BIOL, V105, P1105, DOI 10.1083/jcb.105.3.1105; Manandhar G, 2003, BIOL REPROD, V68, P655, DOI 10.1095/biolreprod.102.006098; MARUSHIGE K, 1976, BIOCHEMISTRY-US, V15, P2047, DOI 10.1021/bi00655a004; MARUSHIGE Y, 1983, BIOCHIM BIOPHYS ACTA, V761, P48, DOI 10.1016/0304-4165(83)90361-6; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MEISTRICH ML, 1978, FED PROC, V37, P2522; OBRIEN DA, 1980, DEV BIOL, V75, P386, DOI 10.1016/0012-1606(80)90171-2; OKO R, 1995, MICROSC RES TECHNIQ, V32, P520, DOI 10.1002/jemt.1070320605; OKO R, 1988, BIOL REPROD, V39, P673, DOI 10.1095/biolreprod39.3.673; OKO R, 1994, DEV BIOL, V166, P235, DOI 10.1006/dbio.1994.1310; OKO R, 1994, BIOL REPROD, V50, P1000, DOI 10.1095/biolreprod50.5.1000; OKO R, 2001, ANDROLOGY 21 CENTURY, P37; Oko RJ, 1995, REPROD FERT DEVELOP, V7, P777, DOI 10.1071/RD9950777; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PALMER DK, 1990, CHROMOSOMA, V100, P32, DOI 10.1007/BF00337600; Perry ACF, 1999, SCIENCE, V284, P1180, DOI 10.1126/science.284.5417.1180; Platz R D, 1977, Methods Cell Biol, V16, P297; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; SCHMITT MC, 1994, BIOL REPROD, V51, P239, DOI 10.1095/biolreprod51.2.239; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Sutovsky P, 1997, DEV BIOL, V188, P75, DOI 10.1006/dbio.1997.8618; Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P362, DOI 10.1002/jemt.10350; TANPHAICHITR N, 1978, EXP CELL RES, V117, P347, DOI 10.1016/0014-4827(78)90148-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; Zalensky AO, 2002, J BIOL CHEM, V277, P43474, DOI 10.1074/jbc.M206065200; ZANI M, 1995, EXP CELL RES, V217, P57, DOI 10.1006/excr.1995.1063	68	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32431	32438		10.1074/jbc.M303786200	http://dx.doi.org/10.1074/jbc.M303786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12777396	hybrid			2022-12-25	WOS:000184782100123
J	Drin, G; Cottin, S; Blanc, E; Rees, AR; Temsamani, J				Drin, G; Cottin, S; Blanc, E; Rees, AR; Temsamani, J			Studies on the internalization mechanism of cationic cell-penetrating peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; ANTENNAPEDIA HOMEODOMAIN; 3RD HELIX; MANNOSE-6-PHOSPHATE RECEPTORS; ANTIMICROBIAL PEPTIDES; PROTEIN TRANSDUCTION; PLASMA-MEMBRANE; LIPID-BILAYERS; PANTP PEPTIDE; TRANSFERRIN	A great deal of data has been amassed suggesting that cationic peptides are able to translocate into eucaryotic cells in a temperature-independent manner. Although such peptides are widely used to promote the intracellular delivery of bioactive molecules, the mechanism by which this cell-penetrating activity occurs still remains unclear. Here, we present an in vitro study of the cellular uptake of peptides, originally deriving from protegrin (the SynB peptide vectors), that have also been shown to enhance the transport of drugs across the blood-brain barrier. In parallel, we have examined the internalization process of two lipid-interacting peptides, SynB5 and pAntp-(43-58), the latter corresponding to the translocating segment of the Antennapedia homeodomain. We report a quantitative study of the time- and dose-dependence of internalization and demonstrate that these peptides accumulate inside vesicular structures. Furthermore, we have examined the role of endocytotic pathways in this process using a variety of metabolic and endocytosis inhibitors. We show that the internalization of these peptides is a temperature- and energy-dependent process and that endosomal transport is a key component of the mechanism. Altogether, our results suggest that SynB and pAntp-(43-58) peptides penetrate into cells by an adsorptive-mediated endocytosis process rather than temperature- independent translocation.	Parc Sci Georges Besse, Synt Em, F-30000 Nimes, France; Inst Genet Mol, Synt Em, F-34293 Montpellier 5, France	Universite de Montpellier	Temsamani, J (corresponding author), Parc Sci Georges Besse, Synt Em, F-30000 Nimes, France.	jtemsamani@syntem.com		DRIN, Guillaume/0000-0002-3484-4581				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; BERCZI A, 1993, EUR J BIOCHEM, V213, P427, DOI 10.1111/j.1432-1033.1993.tb17778.x; Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1984, J CELL BIOL, V99, P320, DOI 10.1083/jcb.99.1.320; Chaloin L, 1997, BIOCHEMISTRY-US, V36, P11179, DOI 10.1021/bi9708491; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Dathe M, 1996, BIOCHEMISTRY-US, V35, P12612, DOI 10.1021/bi960835f; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drin G, 2002, BBA-BIOMEMBRANES, V1559, P160, DOI 10.1016/S0005-2736(01)00447-3; Drin G, 2001, BIOCHEMISTRY-US, V40, P1824, DOI 10.1021/bi002019k; Drin G, 2001, EUR J BIOCHEM, V268, P1304, DOI 10.1046/j.1432-1327.2001.01997.x; Dunican DJ, 2001, BIOPOLYMERS, V60, P45, DOI 10.1002/1097-0282(2001)60:1<45::AID-BIP1003>3.3.CO;2-0; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4; JIN MJ, 1993, J BIOL CHEM, V268, P18390; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819; Lindberg M, 2001, BIOCHEMISTRY-US, V40, P3141, DOI 10.1021/bi0008985; Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2; Mangoni ME, 1996, FEBS LETT, V383, P93, DOI 10.1016/0014-5793(96)00236-0; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Mazel M, 2001, ANTI-CANCER DRUG, V12, P107, DOI 10.1097/00001813-200102000-00003; Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rousselle C, 2000, MOL PHARMACOL, V57, P679, DOI 10.1124/mol.57.4.679; Rousselle C, 2002, J DRUG TARGET, V10, P309, DOI 10.1080/10611860290031886; Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124; Scheller A, 1999, J PEPT SCI, V5, P185, DOI 10.1002/(SICI)1099-1387(199904)5:4<185::AID-PSC184>3.0.CO;2-9; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; Sokolov Y, 1999, BBA-BIOMEMBRANES, V1420, P23, DOI 10.1016/S0005-2736(99)00086-3; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; SWANSON J, 1989, FLUORESCENCE MICROSC, P137; Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jbc.M208762200; THATTE HS, 1994, J CELL PHYSIOL, V160, P345, DOI 10.1002/jcp.1041600216; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Vidal P, 1998, J MEMBRANE BIOL, V162, P259, DOI 10.1007/s002329900363; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010	58	430	450	0	88	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31192	31201		10.1074/jbc.M303938200	http://dx.doi.org/10.1074/jbc.M303938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783857	hybrid			2022-12-25	WOS:000184658800097
J	Ito, K; Uyeda, TQP; Suzuki, Y; Sutoh, K; Yamamoto, K				Ito, K; Uyeda, TQP; Suzuki, Y; Sutoh, K; Yamamoto, K			Requirement of domain-domain interaction for conformational change and functional ATP hydrolysis in myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MYOSIN; X-RAY STRUCTURES; SMOOTH-MUSCLE MYOSIN; MOTOR DOMAIN; CRYSTAL-STRUCTURE; MOLECULAR MOTORS; HEAVY-MEROMYOSIN; LIGHT-CHAIN; ADP RELEASE; LEVER ARM	Coordination between the nucleotide-binding site and the converter domain of myosin is essential for its ATP-dependent motor activities. To unveil the communication pathway between these two sites, we investigated contact between side chains of Phe-482 in the relay helix and Gly-680 in the SH1-SH2 helix. F482A myosin, in which Phe-482 was changed to alanine with a smaller side chain, was not functional in vivo. In vitro, F482A myosin did not move actin filaments and the Mg2+-ATPase activity of F482A myosin was hardly activated by actin. Phosphate burst and tryptophan fluorescence analyses, as well as fluorescence resonance energy transfer measurements to estimate the movements of the lever arm domain, indicated that the transition from the open state to the closed state, which precedes ATP hydrolysis, is very slow. In contrast, F482A/G680F doubly mutated myosin was functional in vivo and in vitro. The fact that a larger side chain at the 680th position suppresses the defects of F482A myosin suggests that the defects are caused by insufficient contact between side chains of Ala-482 and Gly-680. Thus, the contact between these two side chains appears to play an important role in the coordinated conformational changes and subsequent ATP hydrolysis.	Chiba Univ, Dept Biol, Inage Ku, Chiba 2638522, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Lab, Tsukuba, Ibaraki 3058562, Japan; Univ Tokyo, Dept Life Sci, Grad Sch Arts & Sci, Tokyo 1538902, Japan	Chiba University; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Ito, K (corresponding author), Chiba Univ, Dept Biol, Inage Ku, Chiba 2638522, Japan.	kohjiito@bio.s.chiba-u.ac.jp	Ito, Kohji/K-8441-2017	Ito, Kohji/0000-0001-9573-432X				Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Batra R, 1999, BIOCHEMISTRY-US, V38, P6126, DOI 10.1021/bi982251e; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; COOKE R, 1984, ADV EXP MED BIOL, V170, P413; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; DASGUPTA G, 1992, BIOCHEMISTRY-US, V31, P1836, DOI 10.1021/bi00121a036; DELOZANNE A, 1987, METHOD CELL BIOL, V28, P489; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Giese KC, 1997, BIOCHEMISTRY-US, V36, P8465, DOI 10.1021/bi963141f; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; Gulick AM, 2000, J BIOL CHEM, V275, P398, DOI 10.1074/jbc.275.1.398; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Liu X, 2000, BIOCHEM BIOPH RES CO, V271, P75, DOI 10.1006/bbrc.2000.2582; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; Patterson B, 1998, GENETICS, V149, P1799; Patterson B, 2000, METHODS, V22, P299, DOI 10.1006/meth.2000.1082; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Ruff C, 2001, NAT STRUCT BIOL, V8, P226, DOI 10.1038/84962; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; Sasaki N, 2003, BIOCHEMISTRY-US, V42, P90, DOI 10.1021/bi026051l; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith JL, 1996, EMBO J, V15, P6075, DOI 10.1002/j.1460-2075.1996.tb00996.x; SPRINGER ML, 1994, DEVELOPMENT, V120, P2651; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Uyeda TQP, 2002, BIOCHEMISTRY-US, V41, P9525, DOI 10.1021/bi026177i; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537	52	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31049	31057		10.1074/jbc.M304138200	http://dx.doi.org/10.1074/jbc.M304138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12756255	hybrid			2022-12-25	WOS:000184658800081
J	Torres, J; Rodriguez, J; Myers, MP; Valiente, M; Graves, JD; Tonks, NK; Pulido, R				Torres, J; Rodriguez, J; Myers, MP; Valiente, M; Graves, JD; Tonks, NK; Pulido, R			Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3 - Implications for the control of protein stability and PTEN-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAIN; CELL-SURVIVAL; PTEN/MMAC1; APOPTOSIS; GENE; FORM	PTEN phosphatase is one of the most commonly targeted tumor suppressors in human cancers and a key regulator of cell growth and apoptosis. We have found that PTEN is cleaved by caspase-3 at several target sites, located in unstructured regions within the C terminus of the molecule. Cleavage of PTEN was increased upon TNFalpha-cell treatment and was negatively regulated by phosphorylation of the C-terminal tail of PTEN by the protein kinase CK2. The proteolytic PTEN fragments displayed reduced protein stability, and their capability to interact with the PTEN interacting scaffolding protein S-SCAM/MAGI-2 was lost. Interestingly, S-SCAM/MAGI-2 was also cleaved by caspase-3. Our findings suggest the existence of a regulatory mechanism of protein stability and PTEN-protein interactions during apoptosis, executed by caspase-3 in a PTEN phosphorylation-regulated manner.	Inst Invest Citological Caja Ahorros Valencia, Valencia 46010, Spain; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Washington, Dept Immunol, Med Ctr, Seattle, WA 98195 USA	Cold Spring Harbor Laboratory; University of Washington; University of Washington Seattle	Pulido, R (corresponding author), Inst Invest Citological Caja Ahorros Valencia, Amadeo Saboya 4, Valencia 46010, Spain.	rpulido@ochoa.fib.es	Torres, Josema/F-7070-2013	Torres, Josema/0000-0001-6906-7164; Pulido, Rafael/0000-0001-9100-248X	NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline; NIGMS NIH HHS [GM55989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Caselli A, 2002, BIOCHEM BIOPH RES CO, V296, P692, DOI 10.1016/S0006-291X(02)00928-2; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1997, CANCER RES, V57, P2124; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yaginuma Y, 2000, MOL CARCINOGEN, V27, P110, DOI 10.1002/(SICI)1098-2744(200002)27:2<110::AID-MC6>3.0.CO;2-E; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200	31	112	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30652	30660		10.1074/jbc.M212610200	http://dx.doi.org/10.1074/jbc.M212610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788938	hybrid, Green Published			2022-12-25	WOS:000184658800030
J	Wang, X; Khadpe, J; Hu, BC; Iliakis, G; Wang, Y				Wang, X; Khadpe, J; Hu, BC; Iliakis, G; Wang, Y			An overactivated ATR/CHK1 pathway is responsible for the prolonged G(2) accumulation in irradiated AT cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE CHECKPOINT RESPONSE; STRAND BREAK REPAIR; S-PHASE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; HOMOLOGOUS RECOMBINATION; KU AFFECTS; CYCLE CHECKPOINTS; CELLULAR-RESPONSE; ATR PROTEIN	Induction of checkpoint responses in G(1), S, and G(2) phases of the cell cycle after exposure of cells to ionizing radiation (IR) is essential for maintaining genomic integrity. Ataxia telangiectasia mutated (ATM) plays a key role in initiating this response in all three phases of the cell cycle. However, cells lacking functional ATM exhibit a prolonged G(2) arrest after IR, suggesting regulation by an ATM-independent checkpoint response. The mechanism for this ataxia telangiectasia (AT)-independent G(2)-checkpoint response remains unknown. We report here that the G(2) checkpoint in irradiated human AT cells derives from an overactivation of the ATR/CHK1 pathway. Chk1 small interfering RNA abolishes the IR-induced prolonged G(2) checkpoint and radiosensitizes AT cells to killing. These results link the activation of ATR/CHK1 with the prolonged G(2) arrest in AT cells and show that activation of this G(2) checkpoint contributes to the survival of AT cells.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Univ Essen Med Sch, Inst Med Radiat Biol, D-45122 Essen, Germany	Jefferson University; University of Duisburg Essen	Wang, Y (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Thompson Bldg,B1,1020 Sansom St, Philadelphia, PA 19107 USA.	ya.wang@mail.tju.edu			NCI NIH HHS [P30-CA56036, R25 CA48010, CA42026, CA76203, CA56706] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042026, R29CA076203, P30CA056036, R01CA056706, R25CA048010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; BEALL EL, 1994, P NATL ACAD SCI USA, V91, P12681, DOI 10.1073/pnas.91.26.12681; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Liu QH, 2000, GENE DEV, V14, P1448; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McKay BC, 2002, DNA REPAIR, V1, P811, DOI 10.1016/S1568-7864(02)00109-X; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Takai H, 2000, GENE DEV, V14, P1439; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TATSUKA M, 1989, MUTAT RES, V214, P321; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Wang HC, 2003, RADIAT RES, V159, P420, DOI 10.1667/0033-7587(2003)159[0420:CCNESH]2.0.CO;2; Wang HY, 2002, CANCER RES, V62, P2483; Wang X, 2003, RADIAT RES, V159, P426, DOI 10.1667/0033-7587(2003)159[0426:CIRIIO]2.0.CO;2; Wang X, 2002, CANCER RES, V62, P6031; Wang Y, 2000, GENE DEV, V14, P927; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou XY, 2002, CANCER RES, V62, P1598; Zhou XY, 2002, ONCOGENE, V21, P6377, DOI 10.1038/sj.onc.1205782	59	58	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30869	30874		10.1074/jbc.M301876200	http://dx.doi.org/10.1074/jbc.M301876200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12791699	hybrid			2022-12-25	WOS:000184658800058
J	Christiano, C; Chini, S; Chen, J				Christiano, C; Chini, S; Chen, J			Human claspin is required for replication checkpoint control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; EARLY EMBRYONIC LETHALITY; CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; RADIOSENSITIZING AGENT; IONIZING-RADIATION; PROTEIN-KINASE; S-CHECKPOINT; HUMAN CHK1; ATR	Claspin is a newly identified protein that regulates Chk1 activation in Xenopus. In the present study we investigated the role of human Claspin in the DNA damage/replication checkpoint in mammalian cells. We observed that human Claspin is a cell cycle regulated protein that peaks at S/G(2) phase. Claspin localizes in the nuclei, but it only associates with Chk1 following replication stress or other types of DNA damage. In addition, Claspin is phosphorylated in response to replication stress, and this phosphorylation appears to be required for its association with Chk1. Moreover, Claspin interacts with the checkpoint proteins ATR and Rad9. Given that both the ATR and Rad9-Rad1-Hus1 complexes are involved in Chk1 activation, it is possible that Claspin works as an adaptor molecule bringing these molecules together. Using small interfering RNA technology, we have shown that down-regulation of Claspin expression inhibits Chk1 activation in response to replication stress. More importantly, down-regulation of Claspin augments the premature chromatin condensation induced by hydroxyurea, inhibits the UV-induced reduction of DNA synthesis, and decreases cell survival. Taken together, these data imply a potentially critical role for Claspin in replication checkpoint control in mammalian cells.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic	Chen, J (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [R01CA089239, R01CA092312] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89239, CA92312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Brown EJ, 2000, GENE DEV, V14, P397; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Busby EC, 2000, CANCER RES, V60, P2108; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; SANCHEZ Y, 1997, SCIENCE, V277, P497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Takai H, 2000, GENE DEV, V14, P1439; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	38	198	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30057	30062		10.1074/jbc.M301136200	http://dx.doi.org/10.1074/jbc.M301136200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766152	hybrid			2022-12-25	WOS:000184507000082
J	Laurine, E; Lafitte, D; Gregoire, C; Seree, E; Loret, E; Douillard, S; Michel, B; Briand, C; Verdier, JM				Laurine, E; Lafitte, D; Gregoire, C; Seree, E; Loret, E; Douillard, S; Michel, B; Briand, C; Verdier, JM			Specific binding of dehydroepiandrosterone to the N terminus of the microtubule-associated protein MAP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; NERVOUS-SYSTEM; RAT-BRAIN; IN-VITRO; NEUROSTEROIDS; PHOSPHORYLATION; EXPRESSION; PREDICTION	The effect of neurosteroids is mediated through their membrane or nuclear receptors. However, no dehydroepiandrosterone ( DHEA)-specific receptors have been evidenced so far in the brain. In this paper, we showed by isothermal titration calorimetry that the DHEA specifically binds to the dendritic brain microtubule-associated protein MAP2C with an association constant of 2.7 x 10(7) M-1 and at a molar ratio of 1: 1. By partial tryptic digestions and mass spectrometry analysis, we found that the binding involved the N-terminal region of MAP2C. Interestingly, MAP2C displays homologies with 17beta-hydroxysteroid dehydrogenase 1, an enzyme required for estrogen synthesis. Based on these sequence homologies and on the x-ray structure of the DHEA-binding pocket of 17beta-hydroxysteroid dehydrogenase 1, we modeled the complex of DHEA with MAP2C. The binding of DHEA to MAP2C involved specific hydrogen bonds that orient the steroid into the pocket. This work suggests that DHEA can directly influence brain plasticity via MAP2C binding. It opens interesting ways for understanding the role of DHEA in the brain.	Univ Montpellier 2, Ecole Prat Hautes Etud, F-34095 Montpellier 05, France; Fac Pharm Marseille, CNRS, UMR 6032, F-13385 Marseille 05, France; Hop St Marguerite, Unite Neurogeriatr, F-13385 Marseille 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Verdier, JM (corresponding author), Univ Montpellier 2, Ecole Prat Hautes Etud, Pl Eugene Bataillon,CC94, F-34095 Montpellier 05, France.	verdier@univ-montp2.fr		VERDIER, Jean-Michel/0000-0002-7252-1556; lafitte, daniel/0000-0001-9921-7522				Alexa A, 2002, BIOCHEMISTRY-US, V41, P12427, DOI 10.1021/bi025916s; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; Barbier P, 1998, BIOCHEMISTRY-US, V37, P758, DOI 10.1021/bi970568t; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; BERLING B, 1994, EUR J CELL BIOL, V64, P120; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boucher M, 1999, CELL MOTIL CYTOSKEL, V42, P257, DOI 10.1002/(SICI)1097-0169(1999)42:4<257::AID-CM1>3.0.CO;2-B; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; CHARRIEREBERTRAND C, 1991, J NEUROCHEM, V56, P385, DOI 10.1111/j.1471-4159.1991.tb08163.x; CORPECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P4704, DOI 10.1073/pnas.78.8.4704; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Gamblin TC, 1996, BIOCHEMISTRY-US, V35, P12576, DOI 10.1021/bi961135d; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Gonzalez-Billault C, 2002, J NEUROSCI RES, V67, P713, DOI 10.1002/jnr.10161; GREER J, 1991, METHOD ENZYMOL, V202, P239; Han Q, 2000, J BIOL CHEM, V275, P1105, DOI 10.1074/jbc.275.2.1105; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; HERNANDEZ MA, 1986, EUR J BIOCHEM, V154, P41, DOI 10.1111/j.1432-1033.1986.tb09356.x; HOBOHM U, 1994, PROTEIN SCI, V3, P522; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; KALCHEVA N, 1995, P NATL ACAD SCI USA, V92, P10894, DOI 10.1073/pnas.92.24.10894; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; KINDLER S, 1990, J BIOL CHEM, V265, P19679; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; Lim RWL, 2000, J BIOL CHEM, V275, P20578, DOI 10.1074/jbc.M001887200; Malmendal A, 2003, BIOCHEM BIOPH RES CO, V301, P136, DOI 10.1016/S0006-291X(02)02989-3; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Marx CE, 2000, BRAIN RES, V871, P104, DOI 10.1016/S0006-8993(00)02452-5; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; Murakami K, 2000, P NATL ACAD SCI USA, V97, P3579, DOI 10.1073/pnas.97.7.3579; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; Robel P, 1995, CRIT REV NEUROBIOL, V9, P383; ROSEMBLATT M, 1989, FEBS LETT, V252, P91, DOI 10.1016/0014-5793(89)80895-6; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsutsui K, 2000, NEUROSCI RES, V36, P261, DOI 10.1016/S0168-0102(99)00132-7; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1	43	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29979	29986		10.1074/jbc.M303242200	http://dx.doi.org/10.1074/jbc.M303242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775713	hybrid			2022-12-25	WOS:000184507000072
J	Wang, LK; Ho, CK; Pei, Y; Shuman, S				Wang, LK; Ho, CK; Pei, Y; Shuman, S			Mutational analysis of bacteriophage T4 RNA ligase 1 - Different functional groups are required for the nucleotidyl transfer and phosphodiester bond formation steps of the ligation reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DNA-LIGASE; CAPPING ENZYME; CRYSTAL-STRUCTURE; ADENYLYLATION SITE; COVALENT CATALYSIS; NICK RECOGNITION; ACTIVE-SITES; DOMAIN; GENE; MUTAGENESIS	T4 RNA ligase 1 (Rnl1) exemplifies an ATP-dependent RNA ligase family that includes fungal tRNA ligase (Trl1) and a putative baculovirus RNA ligase. Rnl1 acts via a covalent enzyme-AMP intermediate generated by attack of Lys-99 Nzeta on the alpha phosphorus of ATP. Mutation of Lys-99 abolishes ligase activity. Here we tested the effects of alanine mutations at 19 conserved positions in Rnl1 and thereby identified 9 new residues essential for ligase activity: Arg-54, Lys-75, Phe-77, Gly-102, Lys-119, Glu-227, Gly-228, Lys-240, and Lys-242. Seven of the essential residues are located within counterparts of conserved nucleotidyltransferase motifs I ((99)KEDG(102)), Ia ((SK119)-S-118), IV ((227)EGYVA(231)), and V ((HFKIK242)-H-238) that comprise the active sites of DNA ligases, RNA capping enzymes, and T4 RNA ligase 2. Three other essential residues, Arg-54, Lys-75 and Phe-77, are located upstream of the AMP attachment site within a conserved domain unique to the Rnl1-like ligase family. We infer a shared evolutionary history and active site architecture in Rnl1 ( a tRNA repair enzyme) and Trl1 ( a tRNA splicing enzyme). We determined structure-activity relationships via conservative substitutions and examined mutational effects on the isolated steps of Rnl1 adenylylation ( step 1) and phosphodiester bond formation ( step 3). Lys-75, Lys-240, and Lys-242 were found to be essential for step 1 and overall ligation of 5'-phosphorylated RNA but not for phosphodiester bond formation. These results suggest that the composition of the Rnl1 active site is different during steps 1 and 3. Mutations at Arg-54 and Lys-119 abolished the overall RNA ligation reaction without affecting steps 1 and 3. Arg-54 and Lys-119 are thereby implicated as specific catalysts of the RNA adenylation reaction ( step 2) of the ligation pathway.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Ho, KIong/GPP-6051-2022; Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BAYMILLER J, 1994, GENE, V142, P129, DOI 10.1016/0378-1119(94)90367-0; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Doherty AJ, 2000, J MOL BIOL, V296, P43, DOI 10.1006/jmbi.1999.3423; Durantel D, 1998, J GEN VIROL, V79, P629, DOI 10.1099/0022-1317-79-3-629; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; MODRICH P, 1973, J BIOL CHEM, V267, P8117; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; RAND KN, 1984, EMBO J, V3, P397, DOI 10.1002/j.1460-2075.1984.tb01819.x; SAWAYA R, 2003, IN PRESS BIOCHEMISTR; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	42	44	44	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29454	29462		10.1074/jbc.M304320200	http://dx.doi.org/10.1074/jbc.M304320200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766156	hybrid			2022-12-25	WOS:000184507000009
J	Yu, CR; Mahdi, RM; Ebong, S; Vistica, BP; Gery, I; Egwuagu, CE				Yu, CR; Mahdi, RM; Ebong, S; Vistica, BP; Gery, I; Egwuagu, CE			Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; LINEAGE COMMITMENT; SOCS PROTEINS; INTERLEUKIN-2; RECEPTOR; EXPRESSION; INDUCTION; DIFFERENTIATION; BINDING; GFI-1B	Suppressors of cytokine signaling (SOCS) have been implicated in regulation of T-cell activation and cytokine-mediated differentiation of T-helper cells. In this study we have characterized the pattern of SOCS expression in naive and activated primary T-helper cells, examined whether expression of SOCS genes is regulated by cytokine or T-cell receptor signaling, and analyzed the function of SOCS in differentiated T-cells. We show that SOCS1, SOCS2, SOCS3, CIS ((c) under bar ytokine-(i) under bar nduced (S) under bar H2 protein) genes are constitutively expressed in naive T-helper cells, with SOCS3 being the most abundant. Antigen stimulation of naive T-helper cells down-regulates SOCS3 expression and concomitantly up-regulates SOCS1, SOCS2, and CIS gene transcription, suggesting that SOCS genes are regulated differentially by T-cell activation. Down-regulation of SOCS3 expression is subsequently followed by gradual increase in SOCS3 level and corresponding decline in interleukin 2 (IL-2) secretion. In fact, SOCS3 mRNA levels are inversely correlated with the amount of IL-2 secretion and proliferative responses of differentiating T-helper cells, suggesting mutually antagonistic effects of SOCS3 and IL-2 and feedback regulation of T-cell activation by SOCS3. Furthermore, the degree of SOCS3 inhibition is antigen concentration-dependent and is mediated in part by growth factor independence-1, a T-cell transcription factor that regulates S-phase entry in T-cells. Forced overexpression of SOCS3 inhibits proliferation of T-helper cells, whereas depletion of endogenous SOCS3 by antisense SOCS3 cDNA enhances T-cell receptor- and cytokine-induced proliferation. Taken together, these results suggest a role for SOCS3 in maintaining T-helper cells in a quiescent state. Transient inhibition of SOCS3 by antigen stimulation may therefore be essential in allowing activation of resting T-cells.	NEI, Mol Immunol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Egwuagu, CE (corresponding author), NEI, Mol Immunol Sect, Immunol Lab, NIH, Bldg 10,Rm 10N116,10 Ctr Dr, Bethesda, MD 20892 USA.	emeka@helix.nih.gov		Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [Z01EY000069, ZIAEY000069] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Banerjee A, 2002, J IMMUNOL, V168, P4277, DOI 10.4049/jimmunol.168.9.4277; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Egwuagu CE, 1999, J IMMUNOL, V162, P510; Glimcher LH, 2000, GENE DEV, V14, P1693; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Jegalian AG, 2002, J BIOL CHEM, V277, P2345, DOI 10.1074/jbc.M105575200; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; KAYE J, 1984, LYMPHOKINE RES, V3, P175; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kim SJ, 2002, INVEST OPHTH VIS SCI, V43, P758; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 2003, J EXP MED, V197, P425, DOI 10.1084/jem.20020939; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; O'Shea JJ, 2002, NAT IMMUNOL, V3, P506, DOI 10.1038/ni0602-506; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Seki Y, 2002, P NATL ACAD SCI USA, V99, P13003, DOI 10.1073/pnas.202477099; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Wurster AL, 2002, MOL CELL BIOL, V22, P117, DOI 10.1128/MCB.22.1.117-126.2002; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309	34	88	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29752	29759		10.1074/jbc.M300489200	http://dx.doi.org/10.1074/jbc.M300489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12783879	hybrid			2022-12-25	WOS:000184507000046
J	Das, R; Mahabeleshwar, GH; Kundu, GC				Das, R; Mahabeleshwar, GH; Kundu, GC			Osteopontin stimulates cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE-B; PHOSPHOINOSITIDE 3-KINASE; PROMATRIX METALLOPROTEINASE-2; CONSTITUTIVE ACTIVATION; INDEPENDENT GROWTH; MELANOMA-CELLS; MESSENGER-RNA; TUMOR; AKT	We have recently reported that osteopontin (OPN) induces nuclear factor kappaB (NFkappaB)-mediated promatrix metalloproteinase-2 activation through IkappaBalpha/IKK signaling pathways and that curcumin (diferulolylmethane) down-regulates these pathways (Philip, S., and Kundu, G. C. (2003) J. Biol. Chem. 278, 14487-14497). However, the molecular mechanism by which upstream kinases regulate the OPN-induced NFkappaB activation and urokinase type plasminogen activator (uPA) secretion in human breast cancer cells is not well defined. Here we report that OPN induces the phosphatidylinositol 3'-kinase (PI 3'-kinase) activity and phosphorylation of Akt in highly invasive MDA-MB-231 and low invasive MCF-7 cells. The OPN-induced Akt phosphorylation was inhibited when cells were transfected with a dominant negative mutant of the p85 domain of PI 3-kinase (Deltap85) and enhanced when cells were transfected with an activated form of PI 3-kinase (p110CAAX), indicating that PI 3'-kinase is involved in Akt phosphorylation. OPN enhances the interaction between IkappaBalpha kinase (IKK) and phosphorylated Akt. OPN also induces NFkappaB activation through phosphorylation and degradation of IkappaBalpha by inducing the IKK activity. However, both pharmacological (wortmannin and LY294002) and genetic (Deltap85) inhibitors of PI 3'-kinase inhibited OPN-induced Akt phosphorylation, IKK activity, and NFkappaB activation through phosphorylation and degradation of IkappaBalpha. OPN also enhances uPA secretion, cell motility, and extracellular matrix invasion. Furthermore, cells transfected with Deltap85 or the super-repressor form of IkappaBalpha suppressed the OPN-induced uPA secretion and cell motility, whereas cells transfected with p110CAAX enhanced these effects. Pretreatment of cells with PI 3-kinase inhibitors or NFkappaB inhibitory peptide (SN-50) reduced the OPN-induced uPA secretion, cell motility, and invasion. To our knowledge, this is first report that OPN induces NFkappaB activity and uPA secretion by activating PI 3'kinase/Akt/IKK-mediated signaling pathways and further demonstrates a functional molecular link between OPN-induced PI 3'kinase-dependent Akt phosphorylation and NFkappaB-mediated uPA secretion, and all of these ultimately control the motility of breast cancer cells.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BROWN LF, 1994, AM J PATHOL, V145, P610; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Frandsen TL, 2001, CANCER RES, V61, P532; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Liaw L, 1998, J CLIN INVEST, V101, P1468; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; Nakanishi K, 2002, CANCER RES, V62, P2971; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; RIZZO MT, 1994, CANCER RES, V54, P2611; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 2001, BREAST CANCER RES TR, V70, P197, DOI 10.1023/A:1013095329825; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; van der Pluijm G, 1997, LAB INVEST, V77, P665	56	142	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28593	28606		10.1074/jbc.M303445200	http://dx.doi.org/10.1074/jbc.M303445200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12771144	hybrid			2022-12-25	WOS:000184421100033
J	Feng, JQ; Xing, LP; Zhang, JH; Zhao, M; Horn, D; Chan, J; Boyce, BF; Harris, SE; Mundy, GR; Chen, D				Feng, JQ; Xing, LP; Zhang, JH; Zhao, M; Horn, D; Chan, J; Boyce, BF; Harris, SE; Mundy, GR; Chen, D			NF-kappa B specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; TISSUE-SECTIONS; MOUSE; PROMOTER; TRANSCRIPTION; CHONDROGENESIS; SYSTEM; LIMB	Bone morphogenetic protein-2 (BMP-2) regulates growth plate chondrogenesis during development and postnatal bone growth, but the control mechanisms of BMP-2 expression in growth plate chondrocytes are unknown. Here we have used both in vitro and in vivo approaches to demonstrate that transcription factor, NF-kappaB, regulates BMP-2 gene expression in chondrocytes. Two putative NF-kappaB response elements were found in the -2712/+165 region of the BMP-2 gene. Co-transfection of mutant I-kappaBalpha expression plasmids with BMP-2 promoter-luciferase reporters into TMC-23 chondrocyte cell line suppressed BMP-2 transcription. Mutations in NF-kappaB response elements in the BMP-2 gene lead to decreases in BMP-2 promoter activity. Electrophoretic mobility shift assay using nuclear extracts from TMC-23 chondrocytic cells revealed that the NF-kappaB subunits p50 and p65 bound to the NF-kappaB response elements of the BMP-2 gene. Thus, NF-kappaB may positively regulate BMP-2 gene transcription. Consistent with these findings, expression of BMP-2 mRNA was significantly reduced in growth plate chondrocytes in NF-kappaB p50/p52 dKO mice, which associated with decreased numbers of 5-bromo-2'-deoxyuridine (BrdUrd)-positive cells in the proliferating zone of growth plate in these mice. Therefore, in postnatal growth plate chondrocytes, expression of BMP-2 is regulated by NF-kappaB, which may play an important role in chondrogenesis.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA	University of Texas System; University of Texas Health San Antonio; University of Missouri System; University of Missouri Kansas City; University of Rochester	Chen, D (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,Mail Code 7762, San Antonio, TX 78229 USA.		Chan, Jeannie/B-5060-2013		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048697, R03AR048920, R21AR049305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE013480] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR49305, AR48697, R03 AR048920, AR43150, AR048920] Funding Source: Medline; NIDCR NIH HHS [DE13480] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430; FENG JQ, 1994, BBA-GENE STRUCT EXPR, V1218, P221, DOI 10.1016/0167-4781(94)90017-5; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Lazik A, 1996, TRENDS GENET, V12, P445, DOI 10.1016/0168-9525(96)99999-0; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; SHAMIM H, 1999, MOL EMBRYOLOGY METHO; Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; WU RL, 1994, J BIOL CHEM, V269, P28450; Xu C, 1998, IN VITRO CELL DEV-AN, V34, P359; Yazaki Y, 1998, ANTICANCER RES, V18, P2339	22	102	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29130	29135		10.1074/jbc.M212296200	http://dx.doi.org/10.1074/jbc.M212296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759356	hybrid			2022-12-25	WOS:000184421100097
J	Ding, Y; Xu, G; Yang, MJ; Yao, M; Gao, GF; Wang, LF; Zhang, W; Rao, ZH				Ding, Y; Xu, G; Yang, MJ; Yao, M; Gao, GF; Wang, LF; Zhang, W; Rao, ZH			Crystal structure of the ectodomain of human Fc alpha RI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORY RECEPTOR; AFFINITY RECEPTOR; LIGAND-BINDING; KILLER-CELL; IGA; IDENTIFICATION; DOMAIN; GENE; RESIDUES; FRAGMENT	Human FcalphaRI (CD89) is the receptor specific for IgA, an immunoglobulin that is abundant in mucosa and is also found in high concentrations in serum. Although FcalphaRI is an immunoglobulin Fc receptor (FcR), it differs in many ways from FcRs for other immunoglobulin classes. The genes of most FcRs are located on chromosome 1 at 1q21-23, whereas FcalphaRI is on chromosome 19, at 19q13.4, a region called the leukocyte receptor complex, because it is clustered with several leukocyte receptor families including killer cell inhibitory receptors (KIRs) and leukocyte Ig-like receptors (LIRs). The amino acid sequence of FcalphaRI shares only 20% homology with other FcRs but it has around 35% homology with its neighboring LIRs and KIRs. In this work, we analyzed the crystal structure of the ectodomain of FcalphaRI and examined structure similarities between FcalphaRI and KIR2DL1, KIR2DL2 and LIR-1. Our data show that FcalphaRI, KIRs, and LIRs share a common hydrophobic core in their interdomain interface, and FcalphaRI is evolutionally closer to LIR than KIR.	Chinese Acad Med Sci, Inst Basic Med Sci, Peking Union Med Coll, Beijing 100005, Peoples R China; Tsinghua Univ, Minist Educ Prot Sci Lab, Beijing 100084, Peoples R China; Tsinghua Univ, Struct Biol Lab, Beijing 100084, Peoples R China; Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido, Japan	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Tsinghua University; Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Hokkaido University	Zhang, W (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Peking Union Med Coll, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	wzhang@pumc.edu.cn; raozh@xtal.tsinghua.edu.cn	Gao, George Fu/ABD-5229-2021; yao, min/F-5287-2011; Rao, Zihe/HCH-6944-2022	yao, min/0000-0003-1687-5904; Yang, Maojun/0000-0002-6798-3094				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; Chapman TL, 2000, IMMUNITY, V13, P727, DOI 10.1016/S1074-7613(00)00071-6; Davis RS, 2002, IMMUNOL REV, V190, P123, DOI 10.1034/j.1600-065X.2002.19009.x; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; GALLA JH, 1995, KIDNEY INT, V47, P377, DOI 10.1038/ki.1995.50; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Hulett MD, 1998, MOL IMMUNOL, V35, P989, DOI 10.1016/S0161-5890(98)00069-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; Klungland H, 1997, MAMM GENOME, V8, P300, DOI 10.1007/s003359900425; KREMER EJ, 1992, HUM GENET, V89, P107, DOI 10.1007/BF00207054; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; MAZENGERA RL, 1990, BIOCHEM J, V272, P159, DOI 10.1042/bj2720159; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Morton HC, 1999, J EXP MED, V189, P1715; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; Powell MS, 1999, IMMUNOL LETT, V68, P17, DOI 10.1016/S0165-2478(99)00025-5; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2002, BIOCHEM SOC T, V30, P481, DOI 10.1042/bst0300481; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; Storset AK, 2003, EUR J IMMUNOL, V33, P980, DOI 10.1002/eji.200323710; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Volz A, 2001, IMMUNOL REV, V181, P39, DOI 10.1034/j.1600-065X.2001.1810103.x; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; ZHANG GP, 1995, J IMMUNOL, V155, P1534	35	25	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27966	27970		10.1074/jbc.C300223200	http://dx.doi.org/10.1074/jbc.C300223200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12783876	hybrid			2022-12-25	WOS:000184242700080
J	Shonukan, T; Bagayogo, I; McCrea, PD; Chao, M; Hempstead, B				Shonukan, T; Bagayogo, I; McCrea, PD; Chao, M; Hempstead, B			Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin	ONCOGENE			English	Article						fascin; melanoma; migration; NGF; p75(NTR)	NERVE GROWTH-FACTOR; HEPARAN-SULFATE SUBPOPULATIONS; INVASION SELECTED ENHANCEMENT; NF-KAPPA-B; RECEPTOR; P75; BINDING; ACTIVATION; TRK; STIMULATION	Expression of the p75 neurotrophin receptor (p75(NTR)) in primary melanomas is associated with deeply invasive lesions. In turn, there is expression of high levels of neurotrophins at the invasion front of normal tissue adjacent to brain metastases, thus implicating this growth factor-receptor system in melanoma tumorigenesis. The neurotrophins nerve growth factor (NGF) and neurotrophin-3 (NT-3) are potent chemotactic agents for human melanoma cells which express p75(NTR)in vitro. Here we show that the actin-bundling protein fascin specifically interacts with p75(NTR) in an NGF-dependent manner by co-immunoprecipitation and colocalization in melanoma cells that express the two proteins endogenously. In addition, expression of a fascin point mutant at the serine phosphorylation site (serine 39) regulating actin binding abrogates neurotrophin-induced migration. These results suggest a causal role for NGF-mediated dephosphorylation of serine 39 on fascin in mediating actin binding and subsequent melanoma cell migration.	Univ Miami, Sch Med, Dept Med, Div Hematol Oncol,Sylvester Canc Ctr, Miami, FL 33136 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Skirball Inst Biomol Med, Dept Cell Biol, Mol Neurobiol Program, New York, NY 10016 USA	University of Miami; Cornell University; University of Texas System; UTMD Anderson Cancer Center	Shonukan, T (corresponding author), Univ Miami, Sch Med, Dept Med, Div Hematol Oncol,Sylvester Canc Ctr, Pap 110,M-877,1550 NW 10th Ave, Miami, FL 33136 USA.	oshonukan@med.miami.edu		Chao, Moses/0000-0002-6969-3744	NIGMS NIH HHS [R01 GM052112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BRYAN J, 1986, METHOD ENZYMOL, V134, P13; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; Gallo G, 1998, J NEUROSCI, V18, P5403, DOI 10.1523/JNEUROSCI.18-14-05403.1998; Iwamoto S, 1996, J AM ACAD DERMATOL, V35, P725, DOI 10.1016/S0190-9622(96)90728-8; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P99, DOI 10.1038/jidsymp.1997.19; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Nicolson GL, 1995, CANCER METAST REV, V14, P303, DOI 10.1007/BF00690600; Ono S, 1997, J BIOL CHEM, V272, P2527; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; OTTO JJ, 1980, CELL MOTIL CYTOSKEL, V1, P31, DOI 10.1002/cm.970010104; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	28	83	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3616	3623		10.1038/sj.onc.1206561	http://dx.doi.org/10.1038/sj.onc.1206561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789270				2022-12-25	WOS:000183399200012
J	Walters, DK; French, JD; Arendt, BK; Jelinek, DF				Walters, DK; French, JD; Arendt, BK; Jelinek, DF			Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex	ONCOGENE			English	Article						ErbB3; interferon-alpha; multiple myeloma	EPIDERMAL GROWTH-FACTOR; MULTIPLE-MYELOMA; RECEPTOR; INTERLEUKIN-6; ACTIVATION; CARCINOMA; PATHWAYS; LEUKEMIA; THERAPY; CANCER	We have previously demonstrated that the responsiveness of multiple myeloma (MM) cells to interferon-alpha (IFN-alpha) stimulation is variable, with an atypical growth response displayed by some cells. Here we report the ability of IFN-alpha to induce tyrosine phosphorylation of a 180 kDa band in the KAS-6/1 MM cell line, which is growth responsive to IFN-alpha. Further characterization demonstrated that this band corresponds to ErbB3. To our knowledge, this is the first report of ErbB3 expression in a cell type of the hematopoietic lineage. Although ErbB receptors have been shown to crosscommunicate with various other receptors, our results show for the first time that the IFN-alpha: receptor can crosscommunicate with ErbB3. To address the significance of these observations, we transfected ErbB3-negative DP-6 MM cells with ErbB3 and used siRNA to silence ErbB3 in the KAS-6/1 cell line. Although IFN-alpha transactivated ErbB3 in the DP-6 transfectants, it did not confer growth responsiveness to IFN-alpha. Interestingly, silencing ErbB3 expression in the KAS-6/1 cells decreased the overall growth response to IFN-alpha and to interleukin-6. These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Jelinek, DF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA62228, CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA062228, R01CA062228, P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arora T, 1999, J IMMUNOL, V162, P3289; BLADE J, 1991, BRIT J HAEMATOL, V79, P523, DOI 10.1111/j.1365-2141.1991.tb08068.x; BREGMAN MD, 1986, INT J CELL CLONING, V4, P224, DOI 10.1002/stem.5530040401; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; French JD, 2002, LEUKEMIA, V16, P1189, DOI 10.1038/sj.leu.2402516; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; JOURDAN M, 1991, J IMMUNOL, V147, P4402; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pestka Sidney, 1997, Seminars in Oncology, V24, P18; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; SALMON SE, 1991, SEMIN ONCOL, V18, P33; SAWAMURA M, 1992, BRIT J HAEMATOL, V82, P631, DOI 10.1111/j.1365-2141.1992.tb06484.x; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Walters DK, 2002, ANTISENSE NUCLEIC A, V12, P411, DOI 10.1089/108729002321082483; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	23	14	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3598	3607		10.1038/sj.onc.1206512	http://dx.doi.org/10.1038/sj.onc.1206512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789268				2022-12-25	WOS:000183399200010
J	Heliez, C; Baricault, L; Barboule, N; Valette, A				Heliez, C; Baricault, L; Barboule, N; Valette, A			Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells	ONCOGENE			English	Article						paclitaxel; p21 localization and phosphorylation	CYCLE ARREST; MICROTUBULE DISRUPTION; MITOTIC EXIT; P53; APOPTOSIS; G(1); P21(WAF1); INHIBITOR; G1; OVEREXPRESSION	CKI p21 is a regulator of cellular responses to microtubule damage induced by drugs such as paclitaxel (PTX). It mediates the G1 4N arrest postactivation of the spindle assembly checkpoint and protects cancer cells against PTX-induced cytotoxicity. We demonstrated here that low doses of PTX that are unable to activate the spindle assembly checkpoint, upregulate p21 by a p53-dependent pathway and induce its translocation to the cytoplasm. This cytoplasmic accumulation of p21 resulted from an AKT-dependent p21 phosphorylation leading to an association of p21 with 14-3-3. Furthermore, the cytoplasmic p21 accumulation observed in PTX-treated cells was inhibited by LY 294002, a specific PI-3 kinase inhibitor or by the expression of a dominant-negative AKT mutant. However, the kinase activity of AKT was unchanged in PTX-treated cells, suggesting that low doses of PTX could regulate p21 phosphorylation via inhibition of its dephosphorylation. As a functional consequence, we found that cytoplasmic accumulation of the phosphorylated form of p21 prevents the inhibitory effect of p21, enabling these cells to escape to the p53-dependent GI/S and G2/M checkpoints.	Univ Toulouse 3, CNRS, UMR 5088, IFR 109,LBCMCP, F-31062 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Valette, A (corresponding author), Univ Toulouse 3, CNRS, UMR 5088, IFR 109,LBCMCP, Bat 4R3B1,118 Route Narbonne, F-31062 Toulouse 4, France.	valette@cict.fr	Baricault, Laurent/G-3396-2017					Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blajeski AL, 2002, J CLIN INVEST, V110, P91, DOI 10.1172/JCI200213275; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen JG, 2002, CANCER RES, V62, P1935; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gorospe M, 1999, GENE EXPRESSION, V7, P377; HARPER JW, 1993, CELL, V75, P805; Jordan MA, 1996, CANCER RES, V56, P816; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stewart ZA, 1999, CANCER RES, V59, P3831; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Torres K, 1998, CANCER RES, V58, P3620; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	33	54	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3260	3268		10.1038/sj.onc.1206409	http://dx.doi.org/10.1038/sj.onc.1206409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761496				2022-12-25	WOS:000183040000008
J	Kovar, H; Pospisilova, S; Jug, G; Printz, D; Gadner, H				Kovar, H; Pospisilova, S; Jug, G; Printz, D; Gadner, H			Response of Ewing tumor cells to forced and activated p53 expression	ONCOGENE			English	Article						Ewing's sarcoma; apoptosis; p53; EWS-FLI1; irradiation	P53-DEPENDENT GROWTH ARREST; WILD-TYPE P53; PROGNOSTIC IMPACT; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; ANTICANCER AGENTS; ADENOVIRUS E1A; PROTEIN-KINASE; CYCLE ARREST; C-MYC	The EWS-FLI1 transcription factor is consistently expressed in 85% of Ewing tumors (EFT). In heterologous cells, EWS-FLI1 induces p53-dependent cell cycle arrest or apoptosis. It has been speculated that the p53 tumor suppressor pathway may be generally compromised in EFT despite only rare p53 mutations. In order to test for functional integrity of this pathway, we have investigated a series of EFT cell lines that differ from each other with respect to their endogenous p53 and INK4A gene status for their response to ectopic p53 expression and to stimulation of endogenous p53 activity by X-ray treatment. Significant interindividual and intratumoral variations in the apoptotic propensity of EFT cell lines to transient expression of ectopic p53 were observed, which was independent of the level of p53 expression. In cell lines with a low apoptotic incidence, apoptosis was delayed and the surviving fraction showed a prolonged growth arrest. Complete resistance to p53-induced apoptosis in two cell lines established from the same patient was associated with a high BCL2/BAX ratio and low levels of APAF1. Sensitivity to X-rays showed a trend towards a higher apoptotic rate in wild-type (wt) p53 expressing than in p53 mutant cells. However, one wt p53-expressing EFT cell line was completely refractory to irradiation-stimulated cell death despite high apoptotic responsiveness to ectopic p53. No difference in Ser15 phosphorylation and the transcriptional activation of p53 targets was observed in wt p53 EFT cell lines irrespective of the induction of cell death or growth arrest. All together, our results demonstrate that despite significant variability in the outcome, cell death or cell cycle arrest, the p53 downstream pathway and the DNA damage signaling pathway are functionally intact in EFT.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	Saint Anna Children's Hospital	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.		Pospisilova, Sarka/D-7200-2012	Pospisilova, Sarka/0000-0001-7136-2680; Kovar, Heinrich/0000-0001-6873-9109				Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Di Como CJ, 1998, ONCOGENE, V16, P2527; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gorgoulis VG, 1998, BRIT J CANCER, V77, P374, DOI 10.1038/bjc.1998.60; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Hadano S, 1999, MAMM GENOME, V10, P757; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hattinger CM, 1999, GENE CHROMOSOME CANC, V24, P243, DOI 10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1995, ONCOGENE, V11, P1409; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2000, CANCER RES, V60, P1557; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; Lahti J M, 1995, Prog Cell Cycle Res, V1, P329; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKEON C, 1988, CANCER RES, V48, P4307; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; OConnor PM, 1997, CANCER RES, V57, P4285; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PARK DJ, 1994, ONCOGENE, V9, P1899; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RENZING J, 1995, ONCOGENE, V10, P1865; Sanchez-Prieto R, 1999, NAT MED, V5, P1076, DOI 10.1038/12516; Sollazzo MR, 1999, TUMORI, V85, P167, DOI 10.1177/030089169908500304; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; VECCHIO G, 1989, ONCOGENE, V4, P897; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	57	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3193	3204		10.1038/sj.onc.1206391	http://dx.doi.org/10.1038/sj.onc.1206391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761489				2022-12-25	WOS:000183040000001
J	Jourdan, M; Veyrune, JL; De Vos, J; Redal, N; Couderc, G; Klein, B				Jourdan, M; Veyrune, JL; De Vos, J; Redal, N; Couderc, G; Klein, B			A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells	ONCOGENE			English	Article						myeloma; IL-6; apoptosis; Mcl-1	HUMAN MULTIPLE-MYELOMA; INTERLEUKIN-6 TRANSGENIC MICE; BCL-2 FAMILY; B-CELLS; MONOCLONAL-ANTIBODIES; CHROMOSOME 1Q21; PLASMA-CELLS; EXPRESSION; LINES; APOPTOSIS	Interleukin-6 (IL-6) is a major survival factor for malignant plasma cells involved in multiple myeloma. Using an RNase protection assay, we looked for gene expression of 10 anti- and proapoptotic Bcl-2-family proteins in 12 IL-6-dependent human myeloma cell lines (HMCL). A high Mcl-1 gene expression was found in all HMCLs and the other genes were variably expressed. Out of the 10 Bcl-2-family members, only the Mcl-1 gene was regulated by IL-6. Upon starvation of IL-6, Mcl-1 gene expression decreased in association with myeloma cell apoptosis and was upregulated after adding IL-6 again in association with myeloma cell survival. A constitutive Mcl-1 expression was induced with an Mcl-1-GFP retrovirus in two IL-6-dependent HMCLs. The Mcl-1 HMCLs have a marked reduced apoptosis upon IL-6 starvation compared to HMCLs transduced with control GFP retrovirus and may grow without adding IL-6. These data emphasize the major role of Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.	INSERM, U475, F-34197 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34197 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	De Vos, John/A-5703-2010	De Vos, John/0000-0003-1880-4130				Bae J, 2001, APOPTOSIS, V6, P319, DOI 10.1023/A:1011319901057; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; CRAIG RW, 1994, GENOMICS, V23, P457, DOI 10.1006/geno.1994.1523; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; HAMILTON MS, 1991, LEUKEMIA, V5, P768; Harada N, 1998, LEUKEMIA, V12, P1817, DOI 10.1038/sj.leu.2401168; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Keung YK, 1998, CANCER GENET CYTOGEN, V106, P135, DOI 10.1016/S0165-4608(97)00316-6; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 2003, BIOL MULTIPLE MYELOM; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Le Baccon P, 2001, GENE CHROMOSOME CANC, V32, P250, DOI 10.1002/gcc.1189; Liautard J, 1997, CYTOKINE, V9, P233, DOI 10.1006/cyto.1996.0159; LOKHORST HM, 1994, BLOOD, V84, P2269; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; PETTERSSON M, 1992, BLOOD, V79, P495; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; SHIMIZU S, 1989, J EXP MED, V169, P339, DOI 10.1084/jem.169.1.339; Spets H, 1997, BRIT J HAEMATOL, V98, P126, DOI 10.1046/j.1365-2141.1997.1903004.x; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; UCHIYAMA H, 1993, BLOOD, V82, P3712; Westendorf JJ, 1996, LEUKEMIA, V10, P866; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; ZHANG XG, 1994, BLOOD, V83, P3654; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	42	124	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2950	2959		10.1038/sj.onc.1206423	http://dx.doi.org/10.1038/sj.onc.1206423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771946	Green Submitted, Green Accepted			2022-12-25	WOS:000182824800010
J	Zeller, C; Hinzmann, B; Seitz, S; Prokoph, H; Burkhard-Goettges, E; Fischer, J; Jandrig, B; Schwarz, LE; Rosenthal, A; Scherneck, S				Zeller, C; Hinzmann, B; Seitz, S; Prokoph, H; Burkhard-Goettges, E; Fischer, J; Jandrig, B; Schwarz, LE; Rosenthal, A; Scherneck, S			SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer	ONCOGENE			English	Article						breast cancer; LOH analysis; 6q24.3; tumor suppressor genes; SAM; SH3	OVARIAN-CANCER; CELL-LINES; ALLELIC LOSS; IN-SITU; PROTEIN; CARCINOMA; 6Q; IDENTIFICATION; SUSCEPTIBILITY; REGION	Loss of heterozygosity (LOH) and in silico expression analysis were applied to identify genes significantly downregulated in breast cancer within the genomic interval 6q23-25. Systematic comparison of candidate EST sequences with genomic sequences from this interval revealed the genomic structure of a potential target gene on 6q24.3, which we called SAM and SH3 domain containing I (SASH1). Loss of the gene-internal marker D6S311, found in 30% of primary breast cancer, was significantly correlated with poor survival and increase in tumor size. Two SASH1 transcripts of approximately 4.4 and 7.5 kb exist and are predominantly transcribed in the human breast, lung, thyroid, spleen, placenta and thymus. In breast cancer cell tines, SASH1 is only expressed at low levels. SASH1 is downregulated in the majority (74%) of breast tumors in comparison with corresponding normal breast epithelial tissues. In addition, SASH1 is also downregulated in tumors of the lung and thyroid. Analysis of the protein domain structure revealed that SASH1 is a member of a recently described family of SH3/SAM adapter molecules and thus suggests a role in signaling pathways. We assume that SASH1 is a new tumor suppressor gene possibly involved in tumorigenesis of breast and other solid cancers. We were unable to find mutations in the coding region of the gene in primary breast cancers showing LOH within the critical region. We therefore hypothesize that other mechanisms as for instance methylation of the promoter region of SASH1 are responsible for the loss of expression of SASH1 in primary and metastatic breast cancer.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13125 Berlin, Germany; MetaGen Pharmaceut GmbH, D-13347 Berlin, Germany; Robert Roessle Hosp, Dept Med Informat, D-13122 Berlin, Germany; Robert Roessle Hosp, Dept Surg & Surg Oncol, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Zeller, C (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, Robert Roessle Str 10, D-13125 Berlin, Germany.	c.zeller@mdc-berlin.de						Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Barghorn A, 2001, AM J PATHOL, V158, P1903, DOI 10.1016/S0002-9440(10)64658-5; Beer S, 2001, BBA-GENE STRUCT EXPR, V1520, P89, DOI 10.1016/S0167-4781(01)00242-1; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Claudio J, 2001, ONCOGENE, V20, P5373, DOI 10.1038/sj.onc.1204698; de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; Hofmann W, 2002, INT J CANCER, V97, P472, DOI 10.1002/ijc.1626; Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Pagotto U, 2000, CANCER RES, V60, P6794; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Sachs L, 1992, ANGEW STAT, V7; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Srikantan V, 1999, INT J CANCER, V84, P331, DOI 10.1002/(SICI)1097-0215(19990621)84:3<331::AID-IJC23>3.0.CO;2-J; Stallmach I, 2002, VIRCHOWS ARCH, V440, P77, DOI 10.1007/s004280100523; Theile M, 1996, ONCOGENE, V13, P677; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Uchida T, 2001, BIOCHEM BIOPH RES CO, V288, P137, DOI 10.1006/bbrc.2001.5722; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; WURSTERHILL DH, 1984, CANCER GENET CYTOGEN, V13, P303, DOI 10.1016/0165-4608(84)90075-X; YOO HW, 1993, GENOMICS, V15, P21, DOI 10.1006/geno.1993.1005; Zhang YM, 1998, HUM GENET, V103, P727; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	40	107	115	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2972	2983		10.1038/sj.onc.1206474	http://dx.doi.org/10.1038/sj.onc.1206474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771949				2022-12-25	WOS:000182824800013
J	Kaimori, J; Takenaka, M; Nakajima, H; Hamano, T; Horio, M; Sugaya, T; Ito, T; Hori, M; Okubo, K; Imai, E				Kaimori, J; Takenaka, M; Nakajima, H; Hamano, T; Horio, M; Sugaya, T; Ito, T; Hori, M; Okubo, K; Imai, E			Induction of glia maturation factor-beta in proximal tubular cells leads to vulnerability to oxidative injury through the p38 pathway and changes in antioxidant enzyme activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; F-ACTIN CYTOSKELETON; HYDROGEN-PEROXIDE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; GENE-EXPRESSION; CU,ZN-SUPEROXIDE DISMUTASE; OXYGEN RADICALS; PROTEIN-KINASE	Proteinuria is an independent risk factor for progression of renal diseases. Glia maturation factor-beta (GMF-beta), a 17-kDa brain-specific protein originally purified as a neurotrophic factor from brain, was induced in renal proximal tubular (PT) cells by proteinuria. To examine the role of GMF-beta in PT cells, we constructed PT cell lines continuously expressing GMF-beta. The PT cells overexpressing GMF-beta acquired susceptibility to cell death upon stimulation with tumor necrosis factor-alpha and angiotensin II, both of which are reported to cause oxidative stress. GMF-beta overexpression also promoted oxidative insults by H2O2, leading to the reorganization of F-actin as well as apoptosis in non-brain cells (not only PT cells, but also NIH 3T3 cells). The measurement of intracellular reactive oxygen species in the GMF-beta-overexpressing cells showed a sustained increase in H2O2 in response to tumor necrosis factor-alpha, angiotensin II, and H2O2 stimuli. The sustained increase in H2O2 was caused by an increase in the activity of the H2O2-producing enzyme copper/zinc-superoxide dismutase, a decrease in the activities of the H2O2-reducing enzymes catalase and glutathione peroxidase, and a depletion of the content of the cellular glutathione peroxidase substrate GSH. The p38 pathway was significantly involved in the sustained oxidative stress to the cells. Taken together, the alteration of the antioxidant enzyme activities, in particular the peroxide-scavenging deficit, underlies the susceptibility to cell death in GMF-beta-overexpressing cells. In conclusion, we suggest that the proteinuria induction of GMF-beta in renal PT cells may play a critical role in the progression of renal diseases by enhancing oxidative injuries.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Osaka 5650871, Japan; Cmic Co Ltd, Tokyo 1410022, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan	Osaka University; Osaka University; CMIC Holdings Co Ltd; Kyushu University	Takenaka, M (corresponding author), Kobe Womens Univ, Grad Sch Life Sci, 2-1 Higashi Suma Aoyama, Kobe, Hyogo 6548585, Japan.	masaru@suma.kobe-wu.ac.jp	Hamano, TAKAYUKI/AAZ-4837-2021	Hamano, TAKAYUKI/0000-0002-2100-9106				AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Back SA, 1998, J NEUROSCI, V18, P6241; Banan A, 2000, GUT, V46, P830, DOI 10.1136/gut.46.6.830; Banan A, 2001, AM J PHYSIOL-GASTR L, V280, pG1234, DOI 10.1152/ajpgi.2001.280.6.G1234; Banan A, 2001, FREE RADICAL BIO MED, V30, P287, DOI 10.1016/S0891-5849(00)00471-8; BOSCH EP, 1989, J NEUROSCI, V9, P3690; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; EDDY AA, 1989, AM J PATHOL, V135, P719; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fiorentini C, 1999, FEBS LETT, V453, P124, DOI 10.1016/S0014-5793(99)00706-1; Hannken T, 1998, KIDNEY INT, V54, P1923, DOI 10.1046/j.1523-1755.1998.00212.x; HINSHAW DB, 1991, ARCH BIOCHEM BIOPHYS, V288, P311, DOI 10.1016/0003-9861(91)90200-3; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; Kaimori JY, 2002, AM J KIDNEY DIS, V39, P948, DOI 10.1053/ajkd.2002.32768; KAPLAN R, 1991, J NEUROCHEM, V57, P483, DOI 10.1111/j.1471-4159.1991.tb03777.x; LIM R, 1987, DEV BRAIN RES, V33, P93, DOI 10.1016/0165-3806(87)90179-9; LIM R, 1995, BIOCHEM BIOPH RES CO, V211, P928, DOI 10.1006/bbrc.1995.1901; Lim R, 1998, NEUROCHEM RES, V23, P1445, DOI 10.1023/A:1020715126326; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; LIM R, 1987, DEV BRAIN RES, V33, P49, DOI 10.1016/0165-3806(87)90175-1; MOCALI A, 1995, EXP CELL RES, V216, P388, DOI 10.1006/excr.1995.1049; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; Nagasawa Y, 2000, KIDNEY INT, V57, P717, DOI 10.1046/j.1523-1755.2000.00894.x; Nakajima H, 2002, KIDNEY INT, V61, P1577, DOI 10.1046/j.1523-1755.2002.00300.x; Nishiwaki A, 2001, MOL BRAIN RES, V95, P103, DOI 10.1016/S0169-328X(01)00252-2; Okubo K, 1991, DNA Seq, V2, P137, DOI 10.3109/10425179109039684; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; OMANN GM, 1994, ARCH BIOCHEM BIOPHYS, V308, P407, DOI 10.1006/abbi.1994.1057; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Pinto-Sietsma SJ, 2000, J AM SOC NEPHROL, V11, P1882, DOI 10.1681/ASN.V11101882; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Ruggenenti P, 1998, J AM SOC NEPHROL, V9, P2336; Ruggenenti P, 1997, Kidney Int Suppl, V63, pS54; Shenoy UV, 1999, ENDOCRINOLOGY, V140, P500, DOI 10.1210/en.140.1.500; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Su B, 2001, CIRC RES, V89, P39, DOI 10.1161/hh1301.093615; Sutherland MW, 1997, FREE RADICAL RES, V27, P283, DOI 10.3109/10715769709065766; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; Takenaka M, 1998, KIDNEY INT, V53, P562, DOI 10.1046/j.1523-1755.1998.00808.x; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; VIBERTI GC, 1982, LANCET, V1, P1430; WANG BR, 1992, BRAIN RES, V591, P1, DOI 10.1016/0006-8993(92)90971-B; Wang WS, 2001, J AM SOC NEPHROL, V12, P1422, DOI 10.1681/ASN.V1271422; Wissing D, 1998, FREE RADICAL BIO MED, V25, P57, DOI 10.1016/S0891-5849(98)00043-4; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; YAMANOUCHI M, 2000, Patent No. 0073791; Ying WZ, 2000, KIDNEY INT, V58, P2007, DOI 10.1111/j.1523-1755.2000.00373.x; Zaheer A, 1997, J BIOL CHEM, V272, P5183, DOI 10.1074/jbc.272.8.5183; ZAHEER A, 1993, J NEUROCHEM, V60, P914, DOI 10.1111/j.1471-4159.1993.tb03237.x; Zaheer A, 2001, NEUROCHEM RES, V26, P1293, DOI 10.1023/A:1014241300179; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zoja C, 1999, EXP NEPHROL, V7, P420	60	40	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33519	33527		10.1074/jbc.M301552200	http://dx.doi.org/10.1074/jbc.M301552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12791701	hybrid			2022-12-25	WOS:000184901800125
J	Maertens, G; Cherepanov, P; Pluymers, W; Busschots, K; De Clercq, E; Debyser, Z; Engelborghs, Y				Maertens, G; Cherepanov, P; Pluymers, W; Busschots, K; De Clercq, E; Debyser, Z; Engelborghs, Y			LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 PREINTEGRATION COMPLEXES; CENTRAL DNA FLAP; CARBOXYL-TERMINAL DOMAINS; GROWTH-FACTOR LEDGF/P75; VIRAL MATRIX PROTEIN; AMINO-ACID-RESIDUES; NONDIVIDING CELLS; BINDING DOMAIN; IN-VITRO	We have reported that human immunodeficiency virus type 1 (HIV-1) integrase (IN) forms a specific nuclear complex with human lens epithelium-derived growth factor/transcription co-activator p75 (LEDGF/p75) protein. We now studied the IN-LEDGF/p75 interaction and nuclear import of IN in living cells using fusions of IN and LEDGF/p75 with enhanced green fluorescent protein and far-red fluorescent protein HcRed1. We show that both the N-terminal zinc binding domain and the central core domains of IN are involved in the interaction with LEDGF/p75. Both domains are essential for nuclear localization of IN as well as for the association of IN with condensed chromosomes during mitosis. However, upon overexpression of LEDGF/p75, the core domain fragment of IN was recruited to the nuclei and mitotic chromosomes with a distribution pattern characteristic of the full-length protein, indicating that it harbors the main determinant for interaction with LEDGF/p75. Although the C-terminal domain of IN was dispensable for nuclear/chromosomal localization, a fusion of the C-terminal IN fragment with enhanced green fluorescent protein was found exclusively in the nucleus, with a diffuse nuclear/nucleolar distribution, suggesting that the C-terminal domain may also play a role in the nuclear import of IN. In contrast to LEDGF/p75, its alternative splice variant, p52, did not interact with HIV-1 IN in vitro and in living cells. Finally, RNA interference-mediated knock-down of endogenous LEDGF/p75 expression abolished nuclear/chromosomal localization of IN. We conclude, therefore, that the interaction with LEDGF/p75 accounts for the karyophilic properties and chromosomal targeting of HIV-1 IN.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium	KU Leuven; KU Leuven	Debyser, Z (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.		Maertens, Goedele/D-8628-2015; Cherepanov, Peter P/F-6859-2010; debyser, zeger/H-1310-2013	Maertens, Goedele/0000-0002-1963-8026; Cherepanov, Peter P/0000-0002-0634-538X; De Clercq, Erik/0000-0002-2985-8890; debyser, zeger/0000-0002-3982-1565				Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Brown P. O., 1997, P161; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; Bushman FD, 1997, J VIROL, V71, P458, DOI 10.1128/JVI.71.1.458-464.1997; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Cherepanov P, 1997, MOL PHARMACOL, V52, P771, DOI 10.1124/mol.52.5.771; Cherepanov P, 1999, NUCLEIC ACIDS RES, V27, P2202, DOI 10.1093/nar/27.10.2202; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Dvorin JD, 2002, J VIROL, V76, P12087, DOI 10.1128/JVI.76.23.12087-12096.2002; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; EMILIANI S, 2003, 10 C RETR OPP INF BO; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Fouchier RAM, 1999, ADV VIRUS RES, V52, P275, DOI 10.1016/S0065-3527(08)60302-4; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fradkov AF, 2002, BIOCHEM J, V368, P17, DOI 10.1042/BJ20021191; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; GONZALEZ R, 2002, DIGITAL IMAGE PROCES, P693; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Limon A, 2002, J VIROL, V76, P12078, DOI 10.1128/JVI.76.23.12078-12086.2002; Limon A, 2002, J VIROL, V76, P10598, DOI 10.1128/JVI.76.21.10598-10607.2002; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; Nakajima N, 2001, J VIROL, V75, P7944, DOI 10.1128/JVI.75.17.7944-7955.2001; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Petit C, 2000, J VIROL, V74, P7119, DOI 10.1128/JVI.74.15.7119-7126.2000; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; van den Ent FMI, 1998, J VIROL, V72, P3916, DOI 10.1128/JVI.72.5.3916-3924.1998; Van Maele B, 2003, J VIROL, V77, P4685, DOI 10.1128/JVI.77.8.4685-4694.2003; Vercammen J, 2002, J BIOL CHEM, V277, P38045, DOI 10.1074/jbc.M205842200; Vodicka Marie A., 2001, Somatic Cell and Molecular Genetics, V26, P35, DOI 10.1023/A:1021022629126; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Woodward CL, 2003, J VIROL, V77, P4516, DOI 10.1128/JVI.77.8.4516-4527.2003; Xie WW, 2001, MOL CELL BIOL, V21, P6606, DOI 10.1128/MCB.21.19.6606-6614.2001; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	69	400	414	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33528	33539		10.1074/jbc.M303594200	http://dx.doi.org/10.1074/jbc.M303594200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796494	hybrid			2022-12-25	WOS:000184901800126
J	Schoeffler, AJ; Ruiz, CR; Joubert, AM; Yang, XM; LiCata, VJ				Schoeffler, AJ; Ruiz, CR; Joubert, AM; Yang, XM; LiCata, VJ			Salt modulates the stability and lipid binding affinity of the adipocyte lipid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; PROLIFERATOR-ACTIVATED RECEPTORS; INSULIN-RESISTANCE; 1-ANILINO-8-NAPHTHALENE SULFONATE; ELECTROSTATIC INTERACTIONS; TRANSACTIVATION; HYPERTENSION; MEMBRANES; MECHANISM; OBESITY	Adipocyte lipid-binding protein (ALBP or aP2) is an intracellular fatty acid-binding protein that is found in adipocytes and macrophages and binds a large variety of intracellular lipids with high affinity. Although intracellular lipids are frequently charged, biochemical studies of lipid-binding proteins and their interactions often focus most heavily on the hydrophobic aspects of these proteins and their interactions. In this study, we have characterized the effects of KCl on the stability and lipid binding properties of ALBP. We find that added salt dramatically stabilizes ALBP, increasing its DeltaG of unfolding by 3 - 5 kcal/mol. At 37 degreesC salt can more than double the stability of the protein. At the same time, salt inhibits the binding of the fluorescent lipid 1-anilinonaphthalene-8- sulfonate (ANS) to the protein and induces direct displacement of the lipid from the protein. Thermodynamic linkage analysis of the salt inhibition of ANS binding shows a nearly 1: 1 reciprocal linkage: i.e. one ion is released from ALBP when ANS binds, and vice versa. Kinetic experiments show that salt reduces the rate of association between ANS and ALBP while simultaneously increasing the dissociation rate of ANS from the protein. We depict and discuss the thermodynamic linkages among stability, lipid binding, and salt effects for ALBP, including the use of these linkages to calculate the affinity of ANS for the denatured state of ALBP and its dependence on salt concentration. We also discuss the potential molecular origins and potential intracellular consequences of the demonstrated salt linkages to stability and lipid binding in ALBP.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	LiCata, VJ (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.		Richard, Allison/N-1987-2017	Schoeffler, Allyn/0000-0002-7112-409X				ARAKAWA T, 1990, BIOCHEMISTRY-US, V29, P1924, DOI 10.1021/bi00459a037; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Berg JP, 1997, EUR J ENDOCRINOL, V136, P467, DOI 10.1530/eje.0.1360467; BERNASCONI CF, 1976, RELAXATION KINETICS, P11; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Datta K, 2003, J BIOL CHEM, V278, P5694, DOI 10.1074/jbc.M208133200; DONOVAN DS, 1993, AM J PHYSIOL, V264, pE730, DOI 10.1152/ajpendo.1993.264.5.E730; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Garner MH, 2002, J MEMBRANE BIOL, V187, P97, DOI 10.1007/s00232-001-0155-5; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; Grimaldi PA, 2001, PROG LIPID RES, V40, P269, DOI 10.1016/S0163-7827(01)00005-4; Helledie T, 2000, J LIPID RES, V41, P1740; Helledie T, 2002, MOL CELL BIOCHEM, V239, P157, DOI 10.1023/A:1020538404612; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; INGLESE J, 1989, J MED CHEM, V32, P937, DOI 10.1021/jm00125a002; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Layne MD, 2001, FASEB J, V15, P2733, DOI 10.1096/fj.01-0374fje; LiCata VJ, 1998, PROTEINS, V33, P577, DOI 10.1002/(SICI)1097-0134(19981201)33:4<577::AID-PROT10>3.0.CO;2-2; LODISH H, 1999, MOL CELL BIOL, P585; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; MATARESE V, 1988, J BIOL CHEM, V263, P14544; Matulis D, 1998, BIOPHYS J, V74, P422, DOI 10.1016/S0006-3495(98)77799-9; Matulis D, 1999, BIOPOLYMERS, V49, P451, DOI 10.1002/(SICI)1097-0282(199905)49:6<451::AID-BIP3>3.0.CO;2-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishimura C, 2001, BIOCHEMISTRY-US, V40, P2113, DOI 10.1021/bi000861k; Ogihara T, 2001, DIABETES, V50, P573, DOI 10.2337/diabetes.50.3.573; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1988, BIOCHEMISTRY-US, V27, P3242, DOI 10.1021/bi00409a018; Perrella MA, 2001, FASEB J, V15, P1774, DOI 10.1096/fj.01-0017fje; Resnick LM, 2001, HYPERTENSION, V38, P709, DOI 10.1161/01.HYP.38.3.709; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; SCHELLMAN JA, 1987, ANNU REV BIOPHYS BIO, V16, P115, DOI 10.1146/annurev.bb.16.060187.000555; Simpson MA, 1998, BIOCHEMISTRY-US, V37, P10980, DOI 10.1021/bi980507a; Smith ER, 1999, J BIOL CHEM, V274, P35325, DOI 10.1074/jbc.274.50.35325; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Stewart JM, 2000, CELL MOL LIFE SCI, V57, P1345, DOI 10.1007/PL00000620; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Timasheff S N, 1995, Methods Mol Biol, V40, P253; Von Hippel P. H., 1969, STRUCTURE STABILITY, P417; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; XU Z, 1991, J BIOL CHEM, V226, P14367	52	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33268	33275		10.1074/jbc.M304955200	http://dx.doi.org/10.1074/jbc.M304955200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12794068	hybrid			2022-12-25	WOS:000184901800095
J	Thoden, JB; Holden, HM				Thoden, JB; Holden, HM			Molecular structure of galactokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GALACTOSE METABOLISM; ESCHERICHIA-COLI; UDP-GALACTOSE; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; MEVALONATE KINASE; SUGAR BINDING; MUTAROTASE; MECHANISM; PROGRAM; COMPLEX	Galactokinase plays a key role in normal galactose metabolism by catalyzing the ATP-dependent phosphorylation of alpha-D-galactose to galactose 1-phosphate. In humans, mutations in the galactokinase gene can lead to the diseased state referred to as Type II galactosemia. Here we describe the three-dimensional structure of galactokinase from Lactococcus lactis determined to 2.1-Angstrom resolution. As expected from amino acid sequence alignments, galactokinase adopts a similar topology to that observed for members of the GHMP superfamily. The N-terminal domain is characterized by a five-stranded mixed beta-sheet while the C-terminal motif is dominated by two distinct four-stranded anti-parallel beta-sheets. The structure was solved in the presence of alpha-D-galactose and inorganic phosphate. These ligands are wedged between the N- and C-terminal domains. Amino acid side chains responsible for anchoring the sugar ligand to the protein include Arg(36), Glu(42), Asp(45), Asp(183), and Tyr(233). Both Arg(36) and Asp(183) are strictly conserved in the amino acid sequences available in the literature thus far for galactokinases. Interestingly, the carboxylate side chain of Asp(183) is positioned within 3.5 Angstrom of the C-1 hydroxyl group of galactose, whereas the guanidinium group of Arg(36) is situated between both the C-1 hydroxyl group and the inorganic phosphate. Most likely these residues play key roles in catalysis. The structure of galactokinase described here serves as a model for understanding the functional consequences of point mutations known to result in Type II galactosemia in humans.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARD FJ, 1966, BIOCHEM J, V101, P70, DOI 10.1042/bj1010070; BORK P, 1993, PROTEIN SCI, V2, P31; Bosch AM, 2002, J INHERIT METAB DIS, V25, P629, DOI 10.1023/A:1022875629436; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DEY PM, 1983, EUR J BIOCHEM, V136, P155, DOI 10.1111/j.1432-1033.1983.tb07720.x; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; Romanowski MJ, 2002, PROTEINS, V47, P568, DOI 10.1002/prot.10118; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P20854, DOI 10.1074/jbc.M201415200; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; Timson DJ, 2003, EUR J BIOCHEM, V270, P1767, DOI 10.1046/j.1432-1033.2003.03538.x; Timson DJ, 2002, BIOCHEM J, V363, P515, DOI 10.1042/0264-6021:3630515; Timson DJ, 2002, BIOCHIMIE, V84, P265, DOI 10.1016/S0300-9084(02)01399-8; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WALKER DG, 1968, BIOCHEM J, V108, P169, DOI 10.1042/bj1080169; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; WILSON DB, 1969, J BIOL CHEM, V244, P2137; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	31	58	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33305	33311		10.1074/jbc.M304789200	http://dx.doi.org/10.1074/jbc.M304789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796487	hybrid			2022-12-25	WOS:000184901800100
J	Brookes, PS; Kraus, DW; Shiva, S; Doeller, JE; Barone, MC; Patel, RP; Lancaster, JR; Darley-Usmar, V				Brookes, PS; Kraus, DW; Shiva, S; Doeller, JE; Barone, MC; Patel, RP; Lancaster, JR; Darley-Usmar, V			Control of mitochondrial respiration by NO center dot, effects of low oxygen and respiratory state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; NITRIC-OXIDE; OXIDATIVE-PHOSPHORYLATION; REVERSIBLE INHIBITION; CHAIN; HEART; TRANSDUCTION; MEMBRANES; KINETICS; DISEASES	Nitric oxide (NOcircle) inhibits mitochondrial respiration by binding to the binuclear heme alpha(3)/Cu-B center in cytochrome c oxidase. However, the significance of this reaction at physiological O-2 levels (5-10 muM) and the effects of respiratory state are unknown. In this study mitochondrial respiration, absorption spectra, [O-2], and [NOcircle] were measured simultaneously at physiological O-2 levels with constant O-2 delivery, to model in vivo respiratory dynamics. Under these conditions NOcircle inhibited mitochondrial respiration with an IC50 of 0.14+/-0.01 muM in state 3 versus 0.31+/-0.04 muM in state 4. Spectral data indicate that the higher sensitivity of state 3 respiration to NOcircle is due to greater control over respiration by an NOcircle-dependent spectral species in the respiratory chain in this state. These results are discussed in the context of regulation of respiration by NOcircle in vivo and its implications for the control of vessel-parenchymal O-2 gradients.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Darley-Usmar, V (corresponding author), Univ Alabama, Dept Pathol, Bmr-2,901 19th St S, Birmingham, AL 35294 USA.		Darley-Usmar, Victor/F-7656-2010	Patel, Rakesh/0000-0002-1526-4303; Brookes, Paul/0000-0002-8639-8413; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013395] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL7014601] Funding Source: Medline; NIAAA NIH HHS [AA13395] Funding Source: Medline; NIDDK NIH HHS [DK46935] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Borutaite V, 1996, BIOCHEM J, V315, P295, DOI 10.1042/bj3150295; Brookes P, 2002, FREE RADICAL BIO MED, V32, P370, DOI 10.1016/S0891-5849(01)00805-X; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brookes PS, 2001, J MOL CELL CARDIOL, V33, P69, DOI 10.1006/jmcc.2000.1276; Brookes PS, 2002, METHOD ENZYMOL, V359, P305; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Brown GC, 2000, ACTA PHYSIOL SCAND, V168, P667, DOI 10.1046/j.1365-201x.2000.00718.x; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; COLE RP, 1982, J APPL PHYSIOL, V53, P1116, DOI 10.1152/jappl.1982.53.5.1116; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; Forstner H., 1983, POLAROGRAPHIC OXYGEN, P321, DOI [10.1007/978-3-642-81863-9_28, DOI 10.1007/978-3-642-81863-9_28]; GAYESKI TEJ, 1991, AM J PHYSIOL, V260, pH522, DOI 10.1152/ajpheart.1991.260.2.H522; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; GROEN AK, 1982, J BIOL CHEM, V257, P2754; HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Loke KE, 1999, CIRCULATION, V100, P1291, DOI 10.1161/01.CIR.100.12.1291; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mazat JP, 1997, MOL CELL BIOCHEM, V174, P143, DOI 10.1023/A:1006875517267; Okada S, 1996, PHYSIOL CHEM PHYS ME, V28, P69; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Rossignol R, 2000, BIOCHEM J, V347, P45, DOI 10.1042/0264-6021:3470045; Sarti P, 2000, BIOCHEM BIOPH RES CO, V274, P183, DOI 10.1006/bbrc.2000.3117; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Territo PR, 2001, J BIOL CHEM, V276, P2586, DOI 10.1074/jbc.M002923200; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169	31	96	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31603	31609		10.1074/jbc.M211784200	http://dx.doi.org/10.1074/jbc.M211784200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788936	hybrid			2022-12-25	WOS:000184782100020
J	Jin, QM; van Eynde, A; Beullens, M; Roy, N; Thiel, G; Stalmans, W; Bollen, M				Jin, QM; van Eynde, A; Beullens, M; Roy, N; Thiel, G; Stalmans, W; Bollen, M			The protein phosphatase-1 (PP1) regulator, nuclear inhibitor of PP1 (NIPP1), interacts with the polycomb group protein, embryonic ectoderm development (EED), and functions as a transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; H3 LYSINE-27 METHYLATION; GROUP GENE EED; RNA-BINDING; EVOLUTIONARY CONSERVATION; BIOLOGICAL-ACTIVITY; KINASE-A; PHOSPHORYLATION; DROSOPHILA; COMPLEX	The nuclear protein NIPP1 (nuclear inhibitor of protein Ser/Thr phosphatase-1) interacts with the splicing factors SAP155 and CDC5L and is involved in a late step of spliceosome assembly. In addition, NIPP1 is an interactor of protein phosphatase-1 and a COOH-terminal NIPP1 fragment displays an RNase E like endoribonuclease activity. A yeast two-hybrid screening resulted in the identification of the Polycomb group protein EED (embryonic ectoderm development), an established transcriptional repressor, as a novel NIPP1 interactor. NIPP1 only interacted with full-length EED, whereas two EED interaction domains were mapped to the central and COOH-terminal thirds of NIPP1. The NIPP1-EED interaction was potentiated by the binding of (d)G-rich nucleic acids to the central domain of NIPP1. Nucleic acids also decreased the potency of NIPP1 as an inhibitor of PP1, but they did not prevent the formation of a ternary NIPP1.EED.PP1 complex. EED had no effect on the function of NIPP1 as a splicing factor or as an endoribonuclease. However, similar to EED, NIPP1 acted as a transcriptional repressor of targeted genes and this NIPP1 effect was mediated by the EED interaction domain. Also, the histone deacetylase 2 was present in a complex with NIPP1. Our data are in accordance with a role for NIPP1 as a DNA-targeting protein for EED and associated chromatin-modifying enzymes.	Katholieke Univ Leuven, Div Biochem, Fac Med, B-3000 Louvain, Belgium; Univ Saarland, Dept Med Biochem & Mol Biol, Sch Med, D-66241 Homburg, Germany	KU Leuven; Saarland University	Bollen, M (corresponding author), Katholieke Univ Leuven, Div Biochem, Fac Med, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.ac.be						BEULLENS M, 1993, J BIOL CHEM, V268, P13172; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Boudrez A, 2002, J BIOL CHEM, V277, P31834, DOI 10.1074/jbc.M204427200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Faust C, 1998, DEVELOPMENT, V125, P4495; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Jagiello I, 1997, J BIOL CHEM, V272, P22067, DOI 10.1074/jbc.272.35.22067; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Jin QM, 1999, BIOCHEM J, V342, P13, DOI 10.1042/0264-6021:3420013; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; LANGE R, 1995, DNA CELL BIOL, V14, P971, DOI 10.1089/dna.1995.14.971; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Ng J, 1997, MOL CELL BIOL, V17, P6663, DOI 10.1128/MCB.17.11.6663; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; PARK IK, 1994, J BIOL CHEM, V269, P944; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; Raaphorst FM, 2001, TRENDS IMMUNOL, V22, P682, DOI 10.1016/S1471-4906(01)02082-8; Rudenko A, 2003, EMBO REP, V4, P59, DOI 10.1038/sj.embor.embor712; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; Schumacher A, 1998, GENOMICS, V54, P79, DOI 10.1006/geno.1998.5509; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Thiel G, 2001, BIOL CHEM, V382, P891, DOI 10.1515/BC.2001.111; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; Tie F, 2001, DEVELOPMENT, V128, P275; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Van Eynde A, 1999, EUR J BIOCHEM, V261, P291, DOI 10.1046/j.1432-1327.1999.00272.x; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Wang JB, 2002, MAMM GENOME, V13, P493, DOI 10.1007/s00335-002-2182-7; WANG M, 1994, P NATL ACAD SCI USA, V91, P10591, DOI 10.1073/pnas.91.22.10591; Wu DY, 2002, J BIOL CHEM, V277, P27706, DOI 10.1074/jbc.M200955200	48	28	34	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30677	30685		10.1074/jbc.M302273200	http://dx.doi.org/10.1074/jbc.M302273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788942	hybrid			2022-12-25	WOS:000184658800033
J	Yang, RY; Cui, LY; Hou, YX; Riordan, JR; Chang, XB				Yang, RY; Cui, LY; Hou, YX; Riordan, JR; Chang, XB			ATP binding to the first nucleotide binding domain of multidrug resistance-associated protein plays a regulatory role at low nucleotide concentration, whereas ATP hydrolysis at the second plays a dominant role in ATP-dependent leukotriene C4 transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; S-CONJUGATE TRANSPORT; CATALYTIC CYCLE; VINCRISTINE TRANSPORT; ABC TRANSPORTERS; MRP GENE; CELLS; GLUTATHIONE; SITES; C-4	Multidrug resistance-associated protein (MRP1) transports solutes in an ATP dependent manner by utilizing its two nonequivalent nucleotide binding domains (NBDs) to bind and hydrolyze ATP. The two NBDs possess different properties (Gao, M., Cui, H. R., Loe, D. W., Grant, C. E., Almquist, K. C., Cole, S. P., and Deeley, R. G. (2000) J. Biol. Chem. 275, 13098-13108; Hou, Y., Cui, L., Riordan, J. R., and Chang, X. (2000) J. Biol. Chem. 275, 20280-20287) and may play different roles during solute transport. We now report that NBD1 has moderately higher affinity for ATP than NBD2. The consequence of this difference is that the overall K-d value for wild-type MRP1 is mainly determined by ATP binding at NBD1. This conclusion is supported by the following: 1) mutation of the cysteine residue at 682 to alanine (C682A) in Walker A motif in NBD1 decreases the K-d value, indicating increased affinity for ATP; 2) mutation of the alanine residue at 1331 to cysteine (A1331C) in the Walker A motif of NBD2 does not have an effect on the K-d value; and 3) photolabeling of the protein with a cysteine residue in the Walker A motif of NBD1 is much more sensitive to N-ethylmaleimide modification than the protein with a cysteine residue in the Walker A motif of NBD2. In contrast, the K-m for ATP in support of LTC4 transport is mainly determined by ATP hydrolysis at NBD2. This conclusion is supported by the following: 1) although mutation of A1331C does not have an effect on the K-d value, the K-m values measured from LTC4 transport by proteins with this mutation in NBD2 are much higher than the proteins with wild-type NBD2, implying that the A1331C mutation affects ATP binding/hydrolysis at NBD2; and 2) ATP-dependent LTC4 transport by the protein with a cysteine residue in the Walker A motif of NBD2 is much more sensitive to N-ethylmaleimide modification than the protein with a cysteine residue in the Walker A motif of NBD1. Our previous results indicated that ATP binding at NBD1 at low concentration enhanced ATP binding/hydrolysis at NBD2. All of these results support the notion that ATP binding at NBD1 at low concentration plays a more important regulatory role than the binding at high ATP concentration and that ATP hydrolysis at NBD2 plays a dominant role in the ATP-dependent LTC4 transport.	Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Mayo Fdn, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Chang, XB (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Mayo Fdn, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	xbchang@mayo.edu			NCI NIH HHS [CA89078] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089078] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui LY, 2001, ARCH BIOCHEM BIOPHYS, V392, P153, DOI 10.1006/abbi.2001.2441; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GEORGES E, 1993, J BIOL CHEM, V268, P1792; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2003, J BIOL CHEM, V278, P3599, DOI 10.1074/jbc.M210480200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Keppler D, 1996, ADV ENZYME REGUL, V36, P17, DOI 10.1016/0065-2571(95)00011-9; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Muller M, 1996, J HEPATOL, V24, P100; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Senior AE, 1998, METHOD ENZYMOL, V292, P514; Sharom FJ, 1998, BIOCHEM CELL BIOL, V76, P695, DOI 10.1139/bcb-76-5-695; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Vigano C, 2002, J BIOL CHEM, V277, P5008, DOI 10.1074/jbc.M107928200; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3	44	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30764	30771		10.1074/jbc.M304118200	http://dx.doi.org/10.1074/jbc.M304118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783859	hybrid			2022-12-25	WOS:000184658800044
J	de Keyzer, J; van der Does, C; Kloosterman, TG; Driessen, AJM				de Keyzer, J; van der Does, C; Kloosterman, TG; Driessen, AJM			Direct demonstration of ATP-dependent release of SecA from a translocating preprotein by surface plasmon resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SECA; PROTEIN-TRANSLOCATION; PRECURSOR PROTEINS; MEMBRANE-VESICLES; KINETIC-ANALYSIS; CATALYTIC CYCLE; BINDING; SECYEG; REGION; RECONSTITUTION	Translocase mediates the transport of preproteins across the inner membrane of Escherichia coli. SecA binds with high affinity to the membrane-embedded protein-conducting SecYEG complex and serves as both a receptor for secretory proteins and as an ATP-driven molecular motor. Cycles of ATP binding and hydrolysis by SecA drive the progressive movement of the preprotein across the membrane. Surface plasmon resonance allows an online monitoring of protein interactions. Here we report on the kinetic analysis of the interaction between SecA and the membrane-embedded SecYEG complex. Immobilization of membrane vesicles containing overproduced SecYEG on the Biacore Pioneer L1 chip allows the detection of high affinity SecA binding to the SecYEG complex and online monitoring of the translocation of the secretory protein proOmpA. SecA binds tightly to the SecYEG . proOmpA complex and is released only upon ATP hydrolysis. The results provide direct evidence for a model in which SecA cycles at the SecYEG complex during translocation.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 1999, J BIOL CHEM, V274, P23868, DOI 10.1074/jbc.274.34.23868; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nagamori S, 2002, J BIOCHEM, V132, P629, DOI 10.1093/oxfordjournals.jbchem.a003266; Nakatogawa H, 2000, J BIOL CHEM, V275, P33209, DOI 10.1074/jbc.C000550200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Snyders S, 1997, J BIOL CHEM, V272, P11302; TANI K, 1990, J BIOL CHEM, V265, P17341; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102	42	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29581	29586		10.1074/jbc.M303490200	http://dx.doi.org/10.1074/jbc.M303490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771143	hybrid, Green Published			2022-12-25	WOS:000184507000025
J	Dong, JF; Moake, JL; Bernardo, A; Fujikawa, K; Ball, C; Nolasco, L; Lopez, JA; Cruz, MA				Dong, JF; Moake, JL; Bernardo, A; Fujikawa, K; Ball, C; Nolasco, L; Lopez, JA; Cruz, MA			ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; VONWILLEBRAND-FACTOR MULTIMERS; GLYCOPROTEIN IB-ALPHA; IX-V COMPLEX; SHEAR-STRESS; BINDING SITE; FACTOR-VIII; FACTOR VWF; PLASMA	Thrombotic thrombocytopenic purpura is caused by congenital or acquired deficiency of ADAMTS-13, a metalloprotease that cleaves the endothelium-derived ultra-large multimers of von Willebrand factor (ULVWF). The proteolysis converts hyper-reactive and thrombogenic ULVWF into smaller and less adhesive plasma forms. Activity of ADAMTS-13 is usually measured in a static system under non-physiological conditions that require protein denaturation and prolonged incubation. We have demonstrated previously that ULVWF multimers, upon release from endothelial cells, form platelet-decorated string-like structures that are rapidly cleaved by ADAMTS-13. Here we report the direct interaction between ADAMTS-13 and VWF under both static and flowing conditions. ADAMTS-13-coated beads adhered to both immobilized VWF and ULVWF strings presented by stimulated endothelial cells. These beads adhered to VWF under both venous (2.5 dynes/cm(2)) and arterial (30 dynes/cm(2)) shear stresses. We then demonstrated that ADAMTS-13 beads adhered to immobilized recombinant VWF-A1 and -A3 domains, but soluble metalloprotease bound preferentially to the A3 domain, suggesting that the VWF A3 domain may be the primary docking site for the metalloprotease. We suggest that tensile stresses imposed by fluid shear stretch endothelial bound ULVWF multimers to expose binding sites within the A domains for circulating ADAMTS-13. The bound enzyme then cleaves within the A2 domain that lies in close proximity and releases smaller VWF multimers into the plasma. Once released, these cleaved VWF fragments become inaccessible for the metalloprotease to prevent further cleavage.	Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Rice Univ, Cox Lab Bioengn, Houston, TX 77251 USA	Baylor College of Medicine; Baylor College of Medicine; University of Washington; University of Washington Seattle; Rice University	Dong, JF (corresponding author), Baylor Coll Med, Dept Med, Thrombosis Res Sect, BCM286,N1319,1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL065967, R01HL071895] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL65967, HL71895] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Arya M, 2002, BLOOD, V99, P3971, DOI 10.1182/blood-2001-11-0060; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cruz MA, 2000, J BIOL CHEM, V275, P19098, DOI 10.1074/jbc.M002292200; Cruz MA, 2002, BLOOD, V100, p259A; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DENT JA, 1991, J CLIN INVEST, V88, P774, DOI 10.1172/JCI115376; Dong JF, 2000, J BIOL CHEM, V275, P27663; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1996, ANN HEMATOL, V72, P341, DOI 10.1007/s002770050184; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Kroll MH, 1996, BLOOD, V88, P1525; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Lopez J A, 1997, Curr Opin Hematol, V4, P323; Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; OLSON JD, 1983, THROMB RES, V32, P115, DOI 10.1016/0049-3848(83)90023-3; Remuzzi G, 2002, BLOOD, V100, P778, DOI 10.1182/blood-2001-12-0166; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; RUGGERI ZM, 1992, THROMB HAEMOSTASIS, V67, P594; RUGGERI ZM, 1981, BLOOD, V57, P1140; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; TSAI HM, 1994, BLOOD, V83, P2171; TSAI HM, 1991, BRIT J HAEMATOL, V79, P239, DOI 10.1111/j.1365-2141.1991.tb04528.x; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Tsai HM, 2002, J MOL MED, V80, P639, DOI 10.1007/s00109-002-0369-8; WAGNER DD, 1983, J BIOL CHEM, V258, P2065; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200	37	142	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29633	29639		10.1074/jbc.M301385200	http://dx.doi.org/10.1074/jbc.M301385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775718	hybrid			2022-12-25	WOS:000184507000032
J	Oinuma, KI; Hashimoto, Y; Konishi, K; Goda, M; Noguchi, T; Higashibata, H; Kobayashi, M				Oinuma, KI; Hashimoto, Y; Konishi, K; Goda, M; Noguchi, T; Higashibata, H; Kobayashi, M			Novel aldoxime dehydratase involved in carbon-nitrogen triple bond synthesis of Pseudomonas chlororaphis B23 - Sequencing, gene expression, purification, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOCOCCUS-RHODOCHROUS J1; MASS NITRILE HYDRATASE; CYANOGENIC GLUCOSIDE DHURRIN; PHENYLACETALDOXIME DEHYDRATASE; MOLECULAR CHARACTERIZATION; ISONITRILE HYDRATASE; ESCHERICHIA-COLI; REACTION-PRODUCT; STRAIN OXB-1; BACILLUS SP	Analysis of the nitrile hydratase gene cluster involved in nitrile metabolism of Pseudomonas chlororaphis B23 revealed that it contains one open reading frame encoding aldoxime dehydratase upstream of the amidase gene. The amino acid sequence deduced from this open reading frame shows similarity (32% identity) with that of Bacillus phenylacetaldoxime dehydratase (Kato, Y., Nakamura, K., Sakiyama, H., Mayhew, S. G., and Asano, Y. (2000) Biochemistry 39, 800-809). The gene product expressed in Escherichia coli catalyzed the dehydration of aldoxime into nitrile. The Pseudomonas aldoxime dehydratase (OxdA) was purified from the E. coli transformant and characterized. OxdA shows an absorption spectrum with a Soret peak that is characteristic of heme, demonstrating that it is a hemoprotein. For its activity, this enzyme required a reducing reagent, Na2S2O4, but did not require FMN, which is crucial for the Bacillus enzyme. The enzymatic reaction was found to be catalyzed when the heme iron of the enzyme was in the ferrous state. Calcium as well as iron was included in the enzyme. OxdA reduced by Na2S2O4 had a molecular mass of 76.2 kDa and consisted of two identical subunits. The kinetic parameters of OxdA indicated that aliphatic aldoximes are more effective substrates than aromatic aldoximes. A variety of spectral shifts in the absorption spectra of OxdA were observed upon the addition of each of various compounds (i.e. redox reagents and heme ligands). Moreover, the addition of the substrate to OxdA gave a peak that would be derived from the intermediate in the nitrile synthetic reaction. P. chlororaphis B23 grew and showed the OxdA activity when cultured in a medium containing aldoxime as the sole carbon and nitrogen source. Together with these findings, Western blotting analysis of the extracts using anti-OxdA antiserum revealed that OxdA is responsible for the metabolism of aldoxime in vivo in this strain.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Inst Sci Mat, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Kobayashi, M (corresponding author), Univ Tsukuba, Inst Appl Biochem, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.		Noguchi, Takumi/I-7105-2014	HIGASHIBATA, Hiroki/0000-0001-7416-5316				AMADE P, 1994, J ANTIBIOT, V47, P201, DOI 10.7164/antibiotics.47.201; ASANO Y, 1980, AGR BIOL CHEM TOKYO, V44, P2251, DOI 10.1080/00021369.1980.10864311; Bak S, 2001, PLANT CELL, V13, P101, DOI 10.1105/tpc.13.1.101; Bak S, 1998, PLANT MOL BIOL, V36, P393, DOI 10.1023/A:1005915507497; Bak S, 2001, PLANT PHYSIOL, V127, P108, DOI 10.1104/pp.127.1.108; BARTLING D, 1994, P NATL ACAD SCI USA, V91, P6021, DOI 10.1073/pnas.91.13.6021; BOUCHER JL, 1994, BIOCHEMISTRY-US, V33, P7811, DOI 10.1021/bi00191a008; CISKANIK LM, 1995, APPL ENVIRON MICROB, V61, P998, DOI 10.1128/AEM.61.3.998-1003.1995; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEMASTER EG, 1992, J ORG CHEM, V57, P5074, DOI 10.1021/jo00045a014; Endo I, 1999, TRENDS BIOTECHNOL, V17, P244, DOI 10.1016/S0167-7799(99)01303-7; Falk JE, 1964, PORPHYRINS METALLOPO, P240; Goda M, 2002, J BIOL CHEM, V277, P45860, DOI 10.1074/jbc.M208571200; Goda M, 2001, J BIOL CHEM, V276, P23480, DOI 10.1074/jbc.M007856200; Hann EC, 1999, BIOORGAN MED CHEM, V7, P2239, DOI 10.1016/S0968-0896(99)00157-1; Hansen CH, 2001, J BIOL CHEM, V276, P24790, DOI 10.1074/jbc.M102637200; Hansen CH, 2001, J BIOL CHEM, V276, P11078, DOI 10.1074/jbc.M010123200; HELMLINGER J, 1987, PHYTOCHEMISTRY, V26, P615, DOI 10.1016/S0031-9422(00)84751-2; Hull AK, 2000, P NATL ACAD SCI USA, V97, P2379, DOI 10.1073/pnas.040569997; Kahn RA, 1997, PLANT PHYSIOL, V115, P1661, DOI 10.1104/pp.115.4.1661; Kato Y, 2000, BIOCHEMISTRY-US, V39, P800, DOI 10.1021/bi991598u; Kato Y, 2000, APPL ENVIRON MICROB, V66, P2290, DOI 10.1128/AEM.66.6.2290-2296.2000; Kato Y, 1999, EUR J BIOCHEM, V263, P662, DOI 10.1046/j.1432-1327.1999.00535.x; Kato Y, 1998, ARCH MICROBIOL, V170, P85, DOI 10.1007/s002030050618; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9; KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714; Kobayashi M, 2000, CURR OPIN CHEM BIOL, V4, P95, DOI 10.1016/S1367-5931(99)00058-7; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042; KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746; Kobayashi M, 1998, NAT BIOTECHNOL, V16, P733, DOI 10.1038/nbt0898-733; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOBAYASHI M, 1994, FEMS MICROBIOL LETT, V120, P217, DOI 10.1016/0378-1097(94)90474-X; Komeda H, 1996, P NATL ACAD SCI USA, V93, P4267, DOI 10.1073/pnas.93.9.4267; Komeda H, 1996, J BIOL CHEM, V271, P15796, DOI 10.1074/jbc.271.26.15796; Komeda H, 1996, P NATL ACAD SCI USA, V93, P10572, DOI 10.1073/pnas.93.20.10572; KUMAR SA, 1963, ARCH BIOCHEM BIOPHYS, V103, P516, DOI 10.1016/0003-9861(63)90446-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHADEVAN S, 1973, ANNU REV PLANT PHYS, V24, P69, DOI 10.1146/annurev.pp.24.060173.000441; MAHADEVAN S, 1963, ARCH BIOCHEM BIOPHYS, V100, P557, DOI 10.1016/0003-9861(63)90127-9; Maniatis T., 1989, MOL CLONING LAB MANU; NAGASAWA T, 1987, EUR J BIOCHEM, V162, P691, DOI 10.1111/j.1432-1033.1987.tb10692.x; NAGASAWA T, 1989, EXPERIENTIA, V45, P1066, DOI 10.1007/BF01950160; NISHIYAMA M, 1991, J BACTERIOL, V173, P2465, DOI 10.1128/jb.173.8.2465-2472.1991; Normanly J, 1997, PLANT CELL, V9, P1781, DOI 10.1105/tpc.9.10.1781; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; Popescu VC, 2001, BIOCHEMISTRY-US, V40, P7984, DOI 10.1021/bi010198f; RAJAGOPAL P, 1972, PLANTA, V103, P45; Reintanz B, 2001, PLANT CELL, V13, P351, DOI 10.1105/tpc.13.2.351; SIBBESEN O, 1995, AMINO ACIDS THEIR DE, P227; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; UNDERHILL EW, 1967, EUR J BIOCHEM, V2, P61, DOI 10.1111/j.1432-1033.1967.tb00106.x; Xie SX, 2001, BIOSCI BIOTECH BIOCH, V65, P2666, DOI 10.1271/bbb.65.2666; Yamada H, 2001, CHEM REC, V1, P152; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	61	60	61	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29600	29608		10.1074/jbc.M211832200	http://dx.doi.org/10.1074/jbc.M211832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773527	hybrid			2022-12-25	WOS:000184507000028
J	Petegnief, V; Friguls, B; Sanfeliu, C; Sunol, C; Planas, AM				Petegnief, V; Friguls, B; Sanfeliu, C; Sunol, C; Planas, AM			Transforming growth factor-alpha attenuates N-methyl-D-aspartic acid toxicity in cortical cultures by preventing protein synthesis inhibition through an Erk1/2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; SIGNAL-TRANSDUCTION PATHWAYS; REDUCES INFARCT VOLUME; NEUROTROPHIC FACTOR; INDUCED APOPTOSIS; NEURONAL INJURY; CALCIUM INFLUX; BRAIN ISCHEMIA; CELL-CULTURE; TGF-ALPHA	Transforming growth factor-alpha(TGF-alpha), a ligand of the epidermal growth factor receptor, reduces the infarct size after focal cerebral ischemia in rat, but the molecular basis underlying the protection is unknown. Excitotoxicity and global inhibition of translation are acknowledged to contribute significantly to the ischemic damage. Here we studied whether TGF-alpha can rescue neurons from excitotoxicity in vitro and how it affects calcium homeostasis, protein synthesis, and the associated Akt and extracellular signal-regulated kinase 1/2 (Erk1/2) intracellular signaling pathways in mixed neuronglia cortical cultures. We found that 100 ng/ml TGF-alpha attenuated neuronal cell death induced by a 30-min exposure to 35 muM N-methyl-D-aspartic acid ( NMDA) ( as it reduced lactate dehydrogenase release, propidium iodide staining, and caspase-3 activation) and decreased the elevation of intracellular Ca2+ elicited by NMDA. TGF-alpha induced a prompt and sustained phosphorylation of Erk1/2 and prevented the loss of Akt-P induced by NMDA 3 h after exposure. The protective effect of TGF-alpha was completely prevented by PD 98059, an inhibitor of the Erk1/2 pathway. Studies of incorporation of [H-3] leucine into proteins showed that NMDA decreased the rate of protein synthesis, and TGF-alpha attenuated this effect. TGF-alpha stimulated the phosphorylation of the eukaryotic initiation factor 4E (eIF4E) but did not affect eIF2alpha, two proteins involved in translation regulation. PD 98059 abrogated the TGF-alpha effect on eIF4E. Our data demonstrate that TGF-alpha exerts a neuroprotective action against NMDA toxicity, in which Erk1/2 activation plays a key role, and suggest that the underlying mechanisms involve recovery of translation inhibition, mediated at least in part by eIF4E phosphorylation.	IDIBAPS, CSIC, Inst Invest Biomed Barcelona, Dept Farmacol & Toxicol, Barcelona 08036, Spain; IDIBAPS, CSIC, Inst Invest Biomed Barcelona, Dept Neuroquim, Barcelona 08036, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Petegnief, V (corresponding author), IDIBAPS, CSIC, Inst Invest Biomed Barcelona, Dept Farmacol & Toxicol, Barcelona 08036, Spain.	vpefat@iibb.csic.es	SUNOL, CRISTINA/K-8302-2014; Planas, Anna M/J-5991-2014; Sanfeliu, Coral/G-9926-2015; Petegnief, Valerie/L-3402-2014	SUNOL, CRISTINA/0000-0001-9367-8483; Planas, Anna M/0000-0002-6147-1880; Sanfeliu, Coral/0000-0002-9004-1206; Petegnief, Valerie/0000-0002-2782-1891				Alcazar A, 1997, J NEUROCHEM, V69, P1703; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Alirezaei M, 1999, J BIOL CHEM, V274, P32433, DOI 10.1074/jbc.274.45.32433; Alirezaei M, 2001, J NEUROCHEM, V76, P1080, DOI 10.1046/j.1471-4159.2001.00105.x; Borg J, 2002, J NEUROSCI RES, V70, P180, DOI 10.1002/jnr.10404; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; CHALAZONITIS A, 1992, J NEUROSCI, V12, P583; Chihab R, 1998, J NEUROCHEM, V71, P1177; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de la Vega CM, 2001, NEUROREPORT, V12, P1021, DOI 10.1097/00001756-200104170-00031; DeGracia DJ, 1996, J NEUROCHEM, V67, P2005; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Friguls B, 2002, NEUROBIOL DIS, V11, P443, DOI 10.1006/nbdi.2002.0553; Friguls B, 2001, NEUROREPORT, V12, P3381, DOI 10.1097/00001756-200110290-00046; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hata R, 2000, J CEREBR BLOOD F MET, V20, P937, DOI 10.1097/00004647-200006000-00006; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Junier MP, 2000, PROG NEUROBIOL, V62, P443, DOI 10.1016/S0301-0082(00)00017-4; Justicia C, 1999, J CEREBR BLOOD F MET, V19, P128, DOI 10.1097/00004647-199902000-00002; Justicia C, 2001, J CEREBR BLOOD F MET, V21, P1097, DOI 10.1097/00004647-200109000-00007; KEEN RE, 1989, J CEREBR BLOOD F MET, V9, P429, DOI 10.1038/jcbfm.1989.67; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; Kleijn M, 2000, BIOCHEM J, V347, P399, DOI 10.1042/0264-6021:3470399; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Marin P, 1997, J NEUROSCI, V17, P3445; Martin ME, 2000, BIOCHEM J, V351, P327, DOI 10.1042/0264-6021:3510327; Mengesdorf T, 2001, BIOCHEM J, V356, P805, DOI 10.1042/0264-6021:3560805; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; NOWAK TS, 1985, J NEUROCHEM, V44, P487, DOI 10.1111/j.1471-4159.1985.tb05440.x; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Paschen W, 2000, BRAIN RES BULL, V53, P409, DOI 10.1016/S0361-9230(00)00369-5; Petegnief V, 2001, NEUROSCIENCE, V104, P223, DOI 10.1016/S0306-4522(01)00046-X; PLANAS AM, 1992, J CEREBR BLOOD F MET, V12, P603, DOI 10.1038/jcbfm.1992.84; Quevedo C, 2000, J BIOL CHEM, V275, P19192, DOI 10.1074/jbc.M000238200; Quevedo C, 2002, BIOCHEM BIOPH RES CO, V291, P560, DOI 10.1006/bbrc.2002.6479; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Sawhney RS, 2002, J BIOL CHEM, V277, P75, DOI 10.1074/jbc.M103268200; Singer CA, 1999, J NEUROSCI, V19, P2455; SMITH CB, 1988, P NATL ACAD SCI USA, V85, P9341, DOI 10.1073/pnas.85.23.9341; SUNOL C, 1988, ANAL CHEM, V60, P649, DOI 10.1021/ac00158a009; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Tenneti L, 1998, J NEUROCHEM, V71, P946; Thomas CE, 2000, BRAIN RES, V884, P163, DOI 10.1016/S0006-8993(00)02834-1; Valencia A, 2001, J NEUROSCI RES, V64, P284, DOI 10.1002/jnr.1077.abs; Verkhratsky A, 2000, BRAIN RES REV, V32, P380, DOI 10.1016/S0165-0173(99)00093-4; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004	55	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29552	29559		10.1074/jbc.M300661200	http://dx.doi.org/10.1074/jbc.M300661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771152	hybrid			2022-12-25	WOS:000184507000022
J	Fischer, M; You, M; Matsumoto, M; Crabb, DW				Fischer, M; You, M; Matsumoto, M; Crabb, DW			Peroxisome proliferator-activated receptor alpha ( PPAR alpha) agonist treatment reverses PPAR alpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOLIC LIVER-DISEASE; ACETYL-COA CARBOXYLASE; FATTY-ACID SYNTHESIS; ADAPTIVE RESPONSE; BINDING PROTEIN; BETA-OXIDATION; RATS; MECHANISM; INCREASE; GENE	Proper function of the peroxisome proliferator-activated receptor alpha ( PPARalpha) is essential for the regulation of hepatic fatty acid metabolism. Fatty acid levels are increased in liver during the metabolism of ethanol and should activate PPARalpha. However, recent in vitro data showed that ethanol metabolism inhibited the function of PPARalpha. We now report that ethanol feeding impairs fatty acid catabolism in the liver in part via blocking PPARalpha-mediated responses in C57BL/6J mice. Ethanol feeding decreased PPARalpha/retinoid X receptor alpha binding in electrophoretic mobility shift assay of liver nuclear extracts. mRNAs for PPAR-regulated genes were reduced ( long chain and medium chain acyl-CoA dehydrogenases) or failed to be induced (acyl-CoA oxidase, liver carnitine palmitoyl-CoA transferase, very long chain acyl-CoA synthetase, very long chain acyl-CoA dehydrogenase) in livers of the ethanol-fed animals, and ethanol feeding did not increase the rate of fatty acid beta-oxidation. Wy14,643, a PPARalpha agonist, restored the DNA binding activity of PPARalpha/retinoid X receptor alpha, induced mRNA levels of PPARalpha target genes, stimulated the rate of fatty acid beta-oxidation, and prevented fatty liver in ethanol-fed animals. Impairment of PPARalpha function during ethanol consumption contributes to the development of alcoholic fatty liver, which can be overcome by Wy14,643.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Mol Biol, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Crabb, DW (corresponding author), Indiana Univ, Sch Med, Dept Med, 545 Barnhill Dr,Emerson Hall 317, Indianapolis, IN 46202 USA.	dcrabb@iupui.edu	You, Min/I-4973-2012	You, Min/0000-0003-1977-3479	NIAAA NIH HHS [P50 AA07611, AA06463] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007611] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Baraona E, 1998, RECENT DEV ALCOHOL, V14, P97, DOI 10.1007/0-306-47148-5_5; Beigneux AP, 2000, J BIOL CHEM, V275, P16390, DOI 10.1074/jbc.M000953200; BHAGWANDEEN BS, 1987, J PATHOL, V152, P47, DOI 10.1002/path.1711520107; BOCOS C, 1995, J STEROID BIOCHEM, V53, P1; CASTELLI WP, 1977, LANCET, V2, P153; Crabb D W, 1993, Recent Dev Alcohol, V11, P207; Diehl AM, 2001, ALCOHOL CLIN EXP RES, V25, p8S, DOI 10.1111/j.1530-0277.2001.tb02368.x; Everett L, 2000, LIVER, V20, P191, DOI 10.1034/j.1600-0676.2000.020003191.x; Flavell DM, 2000, DIABETOLOGIA, V43, P673, DOI 10.1007/s001250051357; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Galli A, 2001, J BIOL CHEM, V276, P68, DOI 10.1074/jbc.M008791200; GRUNNET N, 1986, ALCOHOL CLIN EXP RES, V10, pS64, DOI 10.1111/j.1530-0277.1986.tb05182.x; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jarvelainen HA, 1999, HEPATOLOGY, V29, P1503, DOI 10.1002/hep.510290508; JAUHONEN P, 1982, ALCOHOL CLIN EXP RES, V6, P350, DOI 10.1111/j.1530-0277.1982.tb04990.x; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Lacquemant C, 2000, DIABETES METAB, V26, P393; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LIEBER CS, 1989, HEPATOLOGY, V10, P501, DOI 10.1002/hep.1840100417; Ma XL, 1999, AM J MED, V106, P70, DOI 10.1016/S0002-9343(98)00361-1; MA XL, 1993, HEPATOLOGY, V18, P1247; MARSMAN DS, 1988, CANCER RES, V48, P6739; MARZO A, 1970, KLIN WOCHENSCHR, V48, P949, DOI 10.1007/BF01487639; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Motomura K, 2001, AM J PHYSIOL-ENDOC M, V281, pE420, DOI 10.1152/ajpendo.2001.281.3.E420; Munday MR, 1999, ADV ENZYME REGUL, V39, P205, DOI 10.1016/S0065-2571(98)00016-8; Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; PANCHENKO LF, 1987, EXPERIENTIA, V43, P580, DOI 10.1007/BF02143593; PIGNON JP, 1987, HEPATOLOGY, V7, P865, DOI 10.1002/hep.1840070512; RABINOWITZ JL, 1991, ALCOHOL, V8, P241, DOI 10.1016/0741-8329(91)90289-9; Roglans N, 2001, BIOCHEM PHARMACOL, V62, P803, DOI 10.1016/S0006-2952(01)00701-8; Sapone A, 2000, PHARMACOGENETICS, V10, P321, DOI 10.1097/00008571-200006000-00006; SPRITZ N, 1966, P SOC EXP BIOL MED, V121, P147; Tai ES, 2002, ARTERIOSCL THROM VAS, V22, P805, DOI 10.1161/01.ATV.0000012302.11991.42; Uesugi T, 2001, HEPATOLOGY, V34, P101, DOI 10.1053/jhep.2001.25350; Wan YJY, 2001, HEPATOL RES, V19, P117, DOI 10.1016/S1386-6346(00)00089-9; WAN YJY, 1994, LIFE SCI, V56, P307, DOI 10.1016/0024-3205(94)00953-8; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; WILLIAMS HE, 1984, MED CLIN N AM, V68, P33, DOI 10.1016/S0025-7125(16)31239-1; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; You M, 2002, J BIOL CHEM, V277, P29342, DOI 10.1074/jbc.M202411200	47	208	228	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27997	28004		10.1074/jbc.M302140200	http://dx.doi.org/10.1074/jbc.M302140200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12791698	hybrid			2022-12-25	WOS:000184242700084
J	Li, YJ; Song, RL; Korkola, JE; Archer, MC; Ben-David, Y				Li, YJ; Song, RL; Korkola, JE; Archer, MC; Ben-David, Y			Cyclin D1 is necessary but not sufficient for anchorage-independent growth of rat mammary tumor cells and is associated with resistance of the Copenhagen rat to mammary carcinogenesis	ONCOGENE			English	Article						mammary carcinogenesis; anoikis; cyclin D1; beta-catenin	INTESTINAL EPITHELIAL-CELLS; BETA-CATENIN; BREAST-CANCER; ACTIVATED RAS; OVEREXPRESSION; EXPRESSION; LINES; GENE; PROGRESSION; ERYTHROLEUKEMIA	To identify genes associated with the resistance of Copenhagen (Cop) rats to mammary carcinogenesis, we infused a retrovirus harboring v-Ha-ras directly into the main mammary ducts of resistant F1 rats from a cross between Cop and susceptible Wistar Furth (WIT) rats. Adenocarcinomas formed in approximately 50% of infused glands. Cell lines derived from these tumors were clonal, but did not share a common viral integration site, suggesting that a high level of v-Ha-ras expression was able to overcome resistance in the F1 rats. Some of the cell lines were able to grow in soft agar, but a significant number did not display anchorage-independent growth. These growth characteristics were independent of v-Ha-ras expression levels. The ability to grow in soft agar was associated with the size of tumors induced by injecting the cells into nude mice, and showed a striking positive association with the expression of cyclin D1. Furthermore, while resistance to anchorage-independent growth was fully overcome by transfection of cyclin D1 in some clones, in the others the effect was partial. A similar pattern of cyclin D1 upregulation and growth in soft agar was also observed when the cells were transfected with an active form of beta-catenin. Hybrid cells from the somatic fusion of an anchorage-dependent to an anchorage-independent clone did not grow in soft agar. These results suggest that while a high expression level of cyclin D1 is necessary for anchorage-independent growth in all clones, it is not sufficient for full growth capacity in soft agar, raising the possibility that the loss of a tumor suppressor gene in the cell lines is required to fully confer anchorage-independent growth. Our anchorage-dependent and independent rat mammary tumor-derived cell lines may recapitulate the resistance and susceptibility of Cop and WF rats, respectively, to mammary carcinogenesis that could facilitate the identification of breast cancer susceptibility genes.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Nutrit Sci, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave,Res Bldg,Room S218, Toronto, ON M4N 3M5, Canada.			, James/0000-0002-0030-6216				Bani MR, 1996, CANCER RES, V56, P3075; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BESTWICK RK, 1985, J VIROL, V56, P660, DOI 10.1128/JVI.56.3.660-664.1985; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; FILMUS J, 1994, ONCOGENE, V9, P3627; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GOULD MN, 1989, GENES SIGNAL TRANSDU, P19; HAN EKH, 1995, ONCOGENE, V10, P953; JIANG W, 1993, ONCOGENE, V8, P3447; Korkola J E, 1999, Breast Cancer Res, V1, P88, DOI 10.1186/bcr18; Korkola JE, 1999, CARCINOGENESIS, V20, P221, DOI 10.1093/carcin/20.2.221; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PRICE JE, 1990, CANCER RES, V50, P717; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; RUDLAND PS, 1986, DEV BIOL, V113, P388, DOI 10.1016/0012-1606(86)90174-0; Russo J, 2000, J MAMMARY GLAND BIOL, V5, P187, DOI 10.1023/A:1026443305758; Shepel LA, 1998, GENETICS, V149, P289; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Teodori L, 2000, IN VITRO CELL DEV-AN, V36, P153; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG BC, 1991, CANCER RES, V51, P5298; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wood GA, 2002, CARCINOGENESIS, V23, P1, DOI 10.1093/carcin/23.1.1; Zhou Q, 2000, BREAST CANCER RES TR, V59, P27, DOI 10.1023/A:1006370603147; Zhou Q, 2001, CANCER LETT, V162, P3, DOI 10.1016/S0304-3835(00)00657-1	37	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3452	3462		10.1038/sj.onc.1206411	http://dx.doi.org/10.1038/sj.onc.1206411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776197				2022-12-25	WOS:000183128500012
J	Matsuda, A; Suzuki, Y; Honda, G; Muramatsu, S; Matsuzaki, O; Nagano, Y; Doi, T; Shimotohno, K; Harada, T; Nishida, E; Hayashi, H; Sugano, S				Matsuda, A; Suzuki, Y; Honda, G; Muramatsu, S; Matsuzaki, O; Nagano, Y; Doi, T; Shimotohno, K; Harada, T; Nishida, E; Hayashi, H; Sugano, S			Large-scale identification and characterization of human genes that activate NF-kappa B and MAPK signaling pathways	ONCOGENE			English	Article						full-length cDNA; signaling pathways; NF-kappa B; MAPK; oligo-capping	UBIQUITIN-PROTEIN LIGASE; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; LYMPHOID-TISSUE; KINASE; EXPRESSION; APOPTOSIS; CELLS; CARCINOMA; MEDIATORS	We have carried out a large-scale identification and characterization of human genes that activate the NF-kappaB and MARK signaling pathways. We constructed full-length cDNA libraries using the oligo-capping method and prepared an arrayed cDNA pool consisting of 150 000 cDNAs randomly isolated from the libraries. For analysis of the NF-kappaB signaling pathway, we introduced each of the cDNAs into human embryonic kidney 293 cells and examined whether it activated the transcription of a luciferase reporter gene driven by a promoter containing the consensus NF-kappaB binding sites. In total, we identified 299 cDNAs that activate the NF-kappaB pathway, and we classified them into 83 genes, including 30 characterized activator genes of the NF-kappaB pathway, 28 genes whose involvement in the NF-kappaB pathways have not been characterized and 25 novel genes. We then carried out a similar analysis for the identification of genes that activate the MARK pathway, utilizing the same cDNA resource. We assayed 145 000 cDNAs and identified 57 genes that activate the MARK pathway. Interestingly, 27 genes were overlapping between the NF-kappaB and the MAPK pathways, which may indicate that these genes play cross-talking roles between these two pathways.	ASAHI KASEI Corp, Hlth Care Co, Life Sci Res Inst, Biol Lab, Fuji, Shizuoka 4168501, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Struct Anal,Minato Ku, Tokyo 1088639, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Asahi Kasei Corporation; University of Tokyo; Kyoto University; Kyoto University	Matsuda, A (corresponding author), ASAHI KASEI Corp, Hlth Care Co, Life Sci Res Inst, Biol Lab, 2-1 Samejima, Fuji, Shizuoka 4168501, Japan.	matsuda.ab@om.asahi-kasei.co.jp	Doi, Takahiro/ABA-5913-2021	Doi, Takahiro/0000-0001-8133-558X				Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bannai H., 2001, Proceedings of the Fourteenth International Florida Artificial Intelligence Research Society Conference, P233; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barstead R, 2001, CURR OPIN CHEM BIOL, V5, P63, DOI 10.1016/S1367-5931(00)00173-3; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Dong G, 2001, CANCER RES, V61, P4797; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; ISHIKAWA J, 1995, GENOMICS, V26, P527, DOI 10.1016/0888-7543(95)80171-H; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Liu HX, 2001, BLOOD, V98, P1182, DOI 10.1182/blood.V98.4.1182; MARUYAMA K, 1994, GENE, V138, P171; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Ohtomo T, 1999, BIOCHEM BIOPH RES CO, V258, P583, DOI 10.1006/bbrc.1999.0683; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	47	316	371	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3307	3318		10.1038/sj.onc.1206406	http://dx.doi.org/10.1038/sj.onc.1206406			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761501				2022-12-25	WOS:000183040000013
J	Telmer, PG; Shilton, BH				Telmer, PG; Shilton, BH			Insights into the conformational equilibria of maltose-binding protein by analysis of high affinity mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSPORT-SYSTEMS; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; LIGAND-BINDING; MATHEMATICAL TREATMENT; PERIPLASMIC RECEPTORS; MEMBRANE-COMPONENTS; BACTERIAL TRANSPORT; UNLIGANDED FORM; CHEMOTAXIS	The affinity of maltose-binding protein (MBP) for maltose and related carbohydrates was greatly increased by removal of groups in the interface opposite the ligand binding cleft. The wild-type protein has a K-D of 1200 nM for maltose; mutation of residues Met-321 and Gln-325, both to alanine, resulted in a K-D for maltose of 70 nM; deletion of 4 residues, Glu-172, Asn-173, Lys-175, and Tyr-176, which are part of a poorly ordered loop, results in a K-D for maltose of 110 nM. Combining the mutations yields an increased affinity for maltodextrins and a K-D of 6 nM for maltotriose. Comparison of ligand binding by the mutants, using surface plasmon resonance spectroscopy, indicates that decreases in the off-rate are responsible for the increased affinity. Small-angle x-ray scattering was used to demonstrate that the mutations do not significantly affect the solution conformation of MBP in either the presence or absence of maltose. The crystal structures of selected mutants showed that the mutations do not cause significant structural changes in either the closed or open conformation of MBP. These studies show that interactions in the interface opposite the ligand binding cleft, which we term the "balancing interface," are responsible for modulating the affinity of MBP for its ligand. Our results are consistent with a model in which the ligand-bound protein alternates between the closed and open conformations, and removal of interactions in the balancing interface decreases the stability of the open conformation, without affecting the closed conformation.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Shilton, BH (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	bshilton@uwo.ca	Shilton, Brian H/A-6667-2011		NCRR NIH HHS [RR-08630] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCPA, 1994, ACTA CRYSTALLOGR D, V50, P760; CORMACK B, 1987, CURRENT PROTOCOLS MO; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Dempsey BR, 2002, J MOL BIOL, V315, P831, DOI 10.1006/jmbi.2001.5279; Doring K, 1999, EUR J BIOCHEM, V266, P477, DOI 10.1046/j.1432-1327.1999.00880.x; Evdokimov AG, 2001, J MOL BIOL, V305, P891, DOI 10.1006/jmbi.2000.4202; Evenas J, 2001, J MOL BIOL, V309, P961, DOI 10.1006/jmbi.2001.4695; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Koshland DE, 2002, J BIOL CHEM, V277, P46841, DOI 10.1074/jbc.R200014200; LAKIWICZ JR, 1983, PRINCIPLES FLUORESCE; MARTINEAU P, 1990, J MOL BIOL, V214, P337, DOI 10.1016/0022-2836(90)90165-I; Marvin JS, 2001, NAT STRUCT BIOL, V8, P795, DOI 10.1038/nsb0901-795; Marvin JS, 2001, P NATL ACAD SCI USA, V98, P4955, DOI 10.1073/pnas.091083898; MERINO G, 1995, J THEOR BIOL, V177, P171, DOI 10.1006/jtbi.1995.0236; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Mizoue LS, 2002, CURR OPIN STRUC BIOL, V12, P459, DOI 10.1016/S0959-440X(02)00348-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEU HC, 1965, J BIOL CHEM, V240, P3685; OTWINOWSKI Z, 1994, ACTA CRYSTALLOGR D, V50, P760; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Robyt J., 1998, ESSENTIALS CARBOHYDR; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; Shilton BH, 1996, J MOL BIOL, V264, P364, DOI 10.1006/jmbi.1996.0646; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; [No title captured]	41	78	81	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34555	34567		10.1074/jbc.M301004200	http://dx.doi.org/10.1074/jbc.M301004200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12794084	hybrid			2022-12-25	WOS:000185047500117
J	Arnette, D; Gibson, TB; Lawrence, MC; January, B; Khoo, S; McGlynn, K; Vanderbilt, CA; Cobb, MH				Arnette, D; Gibson, TB; Lawrence, MC; January, B; Khoo, S; McGlynn, K; Vanderbilt, CA; Cobb, MH			Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GLUCAGON-LIKE PEPTIDE-1; STIMULATED INSULIN-SECRETION; CA2+-INDUCED CA2+ RELEASE; GROWTH-FACTOR RECEPTOR; CYCLIC ADP-RIBOSE; INTRACELLULAR CA2+; INOSITOL TRISPHOSPHATE; GENE-TRANSCRIPTION; TYROSINE PHOSPHORYLATION	We showed previously that ERK1/2 were activated by glucose and amino acids in pancreatic beta cells. Here we examine and compare signaling events that are necessary for ERK1/2 activation by glucose and other stimuli in beta cells. We find that agents that interrupt Ca2+ signaling by a variety of mechanisms interfere with glucose- and glucagon-like peptide (GLP-1)-stimulated ERK1/2 activity. In particular, calmodulin antagonists, FK506, and cyclosporin, immunosuppressants that inhibit the calcium-dependent phosphatase calcineurin, suppress ERK1/2 activation by both glucose and GLP-1. Ca2+ signaling from intracellular stores is also essential for ERK1/2 activation, because thapsigargin blocks ERK1/2 activation by glucose or GLP-1. The glucose-sensitive mechanism is distinct from that used by phorbol ester or insulin to stimulate ERK1/2 but shares common features with that used by GLP-1.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055310] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55310] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; AIZAWA T, 1995, LIFE SCI, V57, P1375, DOI 10.1016/0024-3205(95)02095-Z; Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; Arredouani A, 2002, DIABETES, V51, P3245, DOI 10.2337/diabetes.51.11.3245; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bandyopadhyay A, 2000, BIOCHEM J, V352, P61, DOI 10.1042/0264-6021:3520061; Bandyopadhyay G, 2000, J BIOL CHEM, V275, P40817, DOI 10.1074/jbc.M007920200; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; Bocker D, 2001, Int J Exp Diabetes Res, V2, P233, DOI 10.1155/EDR.2001.233; Bode HP, 1999, ENDOCRINOLOGY, V140, P3919, DOI 10.1210/en.140.9.3919; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Fuhrer DK, 2001, DIABETES OBES METAB, V3, P393, DOI 10.1046/j.1463-1326.2001.00150.x; Fukunaga K, 1996, NEUROCHEM INT, V28, P343, DOI 10.1016/0197-0186(95)00097-6; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Gromada J, 2001, J PHYSIOL-LONDON, V535, P519, DOI 10.1111/j.1469-7793.2001.00519.x; Hagar RE, 2000, CELL MOL LIFE SCI, V57, P1938, DOI 10.1007/PL00000674; HEROLD KC, 1993, TRANSPLANTATION, V55, P186, DOI 10.1097/00007890-199301000-00035; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; Lawrence MC, 2001, MOL ENDOCRINOL, V15, P1758, DOI 10.1210/me.15.10.1758; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Lester LB, 2001, ENDOCRINOLOGY, V142, P1218, DOI 10.1210/en.142.3.1218; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu YJ, 1996, ARCH BIOCHEM BIOPHYS, V334, P295, DOI 10.1006/abbi.1996.0458; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Maechler P, 1999, J BIOL CHEM, V274, P12583, DOI 10.1074/jbc.274.18.12583; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mitterdorfer J, 1998, J BIOENERG BIOMEMBR, V30, P319, DOI 10.1023/A:1021933504909; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Paul-Pletzer K, 2002, J BIOL CHEM, V277, P34918, DOI 10.1074/jbc.M205487200; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; Redmon JB, 1996, J CLIN INVEST, V98, P2786, DOI 10.1172/JCI119105; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTSON RP, 1986, DIABETES, V35, P1016, DOI 10.2337/diabetes.35.9.1016; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shin D M, 2000, Adv Dent Res, V14, P12; SIHRA TS, 1995, NEUROPHARMACOLOGY, V34, P731, DOI 10.1016/0028-3908(95)00051-7; Summers SA, 2000, INT J OBESITY, V24, pS67, DOI 10.1038/sj.ijo.0801509; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xu SC, 1997, MOL ENDOCRINOL, V11, P1618, DOI 10.1210/me.11.11.1618; Zawalich WS, 1996, PFLUG ARCH EUR J PHY, V432, P589, DOI 10.1007/s004240050174; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	71	102	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32517	32525		10.1074/jbc.M301174200	http://dx.doi.org/10.1074/jbc.M301174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12783880	hybrid			2022-12-25	WOS:000184901800007
J	Foeger, N; Schmid, EM; Skern, T				Foeger, N; Schmid, EM; Skern, T			Human rhinovirus 2 2A(pro) recognition of eukaryotic initiation factor 4GI - Involvement of an exosite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; MOUTH-DISEASE VIRUS; PRO-ARG CHLOROMETHYLKETONE; RHINOVIRUS 2A PROTEINASE; TRANSLATION INITIATION; CRYSTAL-STRUCTURE; PICORNAVIRAL PROTEINASES; ACTIVE-SITE; IN-VITRO; CLEAVAGE	The 2A proteinase (2A(pro)) of human rhinovirus 2 is a cysteine proteinase with a unique chymotrypsin-like fold. During viral replication, 2A(pro) performs self-processing by cleaving between its own N terminus and the C terminus of the preceding protein, VP1. Subsequently, 2Apro cleaves the two isoforms of the cellular protein, eukaryotic initiation factor (eIF) 4G. We have previously shown that HRV2 2A(pro) can directly bind to eIF4G isoforms. Here we demonstrate using deletion mutants of eIF4GI that HRV2 2A(pro) requires eIF4GI amino acids 600 - 674 for binding; however, the amino acids at the cleavage site, Arg(681) down arrow Gly, are not required. The HRV2 2A(pro) binding domain for eIF4GI was identified by site-directed mutagenesis. Specifically, mutations Leu(17) --> Arg and Asp(35) --> Glu severely impaired HRV2 2A(pro) binding and thus processing of eIF4GI in rabbit reticulocyte lysates; self-processing, however, was not affected. Alanine scanning analysis further identified the loop containing residues Tyr(32), Ser(33), and Ser(34) as important for eIF4GI binding. Although Asp(35) is part of the catalytic triad, most of the eIF4GI binding domain lies in a unique exosite structure absent from other chymotrypsin-like enzymes and is distinct from the substrate binding cleft. The exosite represents a novel virulence determinant that may allow the development of specific inhibitors for HRV2 2A(pro).	Univ Vienna, Vienna Bioctr,Univ Dept,Max F Perutz Labs, Dept Biochem Med, Div Biochem, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Skern, T (corresponding author), Univ Vienna, Vienna Bioctr,Univ Dept,Max F Perutz Labs, Dept Biochem Med, Div Biochem, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.		Foeger, Nicole/L-2620-2019; Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500; Foeger, Nicole/0000-0001-7775-7325				Banner DW, 2000, NATURE, V404, P449, DOI 10.1038/35006540; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; Brown CC, 1996, J VIROL, V70, P5638, DOI 10.1128/JVI.70.8.5638-5641.1996; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; Ehrenfeld Ellie, 2002, P159; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Foeger N, 2002, J BIOL CHEM, V277, P44300, DOI 10.1074/jbc.M208006200; Glaser W, 2000, FEBS LETT, V480, P151, DOI 10.1016/S0014-5793(00)01928-1; Glaser W, 2003, J VIROL, V77, P5021, DOI 10.1128/JVI.77.8.5021-5025.2003; Gradi A, 2003, J VIROL, V77, P5026, DOI 10.1128/JVI.77.8.5026-5029.2003; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Guarne A, 1998, EMBO J, V17, P7469, DOI 10.1093/emboj/17.24.7469; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; Kanno T, 2001, VIRUS RES, V80, P101, DOI 10.1016/S0168-1702(01)00341-0; King AMQ, 1999, VIRUS TAXONOMY, P657; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuechler Ernst, 2002, P301; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Petersen JFW, 1999, EMBO J, V18, P5463, DOI 10.1093/emboj/18.20.5463; READ RJ, 1983, BIOCHEMISTRY-US, V22, P4420, DOI 10.1021/bi00288a012; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Sakoda Y, 2001, J VIROL, V75, P10643, DOI 10.1128/JVI.75.22.10643-10650.2001; Seipelt J, 2000, J BIOL CHEM, V275, P20084, DOI 10.1074/jbc.275.26.20084; Skern Tim, 2002, P199; Sommergruber W, 1997, VIROLOGY, V234, P203, DOI 10.1006/viro.1997.8595; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8; Zamora Miguel, 2002, P313	40	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33200	33207		10.1074/jbc.M304007200	http://dx.doi.org/10.1074/jbc.M304007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12791690	hybrid			2022-12-25	WOS:000184901800087
J	Ho, DT; Bardwell, AJ; Abdollahi, M; Bardwell, L				Ho, DT; Bardwell, AJ; Abdollahi, M; Bardwell, L			A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ANTHRAX LETHAL FACTOR; PROTEIN-KINASE KINASE-4; N-TERMINAL KINASE; C-JUN; TUMOR-SUPPRESSOR; IN-VITRO; ACTIVATION; PHOSPHORYLATION; GENE	Specific docking interactions between MAPKs and their activating MAPK kinases (MKKs or MEKs) are crucial for efficient and accurate signal transmission. Here, we report the identification of a MAPK-docking site, or "D-site," in the N terminus of human MKK4/JNKK1. This docking site conforms to the consensus sequence for known D-sites in other MKKs and contains the first of the two cleavage sites for anthrax lethal factor protease that have been found in the N terminus of MKK4. This docking site was both necessary and sufficient for the high affinity binding of the MAPKs JNK1, JNK2, JNK3, p38alpha, and p38beta to MKK4. Mutations that altered conserved residues in this docking site reduced JNK/p38 binding. In addition, a peptide version of this docking site, as well as a peptide version of the JNK-binding site of the JIP-1 scaffold protein, inhibited both MKK4/JNK binding and MKK4-mediated phosphorylation of JNK1. These same peptides also inhibited JNK2-mediated phosphorylation of c-Jun and ATF2, suggesting that transcription factors, MKK4, and the JIP scaffold compete for docking to JNK. Finally, the selectivity of the MKK4, MEK1, and MEK2 D-sites for JNK versus ERK was quantified. The MEK1 and MEK2 D-sites displayed a strong selectivity for their cognate MAPK (ERK2) versus a non-cognate MAPK (JNK). In contrast, the MKK4 D-site exhibited only limited selectivity for JNK versus ERK.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Bardwell, L (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 5205 McGaugh Hall, Irvine, CA 92697 USA.	bardwell@uci.edu	Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060366] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060366-04, GM60366, R01 GM060366] Funding Source: Medline; NLM NIH HHS [LM07443, T15 LM007443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bishopric Nanette H., 2001, Current Opinion in Pharmacology, V1, P141, DOI 10.1016/S1471-4892(01)00032-7; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kieran MW, 1999, ONCOGENE, V18, P6647, DOI 10.1038/sj.onc.1203057; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mayer BJ, 2001, J CELL SCI, V114, P1253; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; O'Rourke L, 2003, ACCOUNTS CHEM RES, V36, P410, DOI 10.1021/ar020167s; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Teng DHF, 1997, CANCER RES, V57, P4177; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yoshida BA, 1999, CANCER RES, V59, P5483; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	57	86	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32662	32672		10.1074/jbc.M304229200	http://dx.doi.org/10.1074/jbc.M304229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12788955	Green Accepted, hybrid			2022-12-25	WOS:000184901800024
J	Ammosova, T; Jerebtsova, M; Beullens, M; Voloshin, Y; Ray, PE; Kumar, A; Bollen, M; Nekhai, S				Ammosova, T; Jerebtsova, M; Beullens, M; Voloshin, Y; Ray, PE; Kumar, A; Bollen, M; Nekhai, S			Nuclear protein phosphatase-1 regulates HIV-1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; C-TERMINAL DOMAIN; P-TEFB; HIGH-AFFINITY; TAT PROTEIN; NIPP1; PHOSPHORYLATION; BINDING; ELONGATION	We recently reported that protein phosphatase 1 (PP1) dephosphorylates RNA polymerase II C-terminal repeats and regulates HIV-1 transcription in vitro. Here we provide evidence that PP1 is also required for Tat-induced HIV-1 transcription and for viral replication in cultured cells. Inhibition of PP1 by overexpression of nuclear inhibitor of PP1 (NIPP1) inhibited Tat-induced HIV-1 transcription in transient transfection assays. A mutant of NIPP1 that was defective in binding to PP1 did not have this effect. Also the co-expression of PP1gamma reversed the inhibitory effect of NIPP1. Adeno-associated virus-mediated delivery of NIPP1 significantly reduced HIV-1 transcription induced by Tat-expressing adenovirus in CD4+ HeLa cells that contained an integrated HIV-1 promoter ( HeLa MAGI cells). In addition, infection of HeLa MAGI cells with adeno-associated virus-NIPP1 prior to the infection with HIV-1 significantly reduced the level of HIV-1 replication. Our results indicate that PP1 might be a host cell factor that is required for HIV-1 viral transcription. Therefore, nuclear PP1 may represent a novel target for anti-HIV-1 therapeutics.	Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Dept Biochem & Mol Biol, Washington, DC 20059 USA; Childrens Natl Med Ctr, Washington, DC 20010 USA; George Washington Univ, Dept Biochem & Mol Biol, Washington, DC 20037 USA; Catholic Univ Louvain, Fac Med, Div Biochem, B-3000 Louvain, Belgium	Howard University; Howard University; Children's National Health System; George Washington University; Universite Catholique Louvain	Nekhai, S (corresponding author), Howard Univ, Ctr Sickle Cell Dis, 2121 Georgia Ave NW, Washington, DC 20059 USA.		Ammosova, Tatiana/J-7564-2018; Ammosova, Tatiana/HIA-0704-2022; Wilson, Matthew H/K-3193-2013; , nekhai/AFO-2652-2022; , nekhai/AAW-3105-2021; Voloshin, Yan Z./E-8545-2014	Ammosova, Tatiana/0000-0001-8777-1032; Voloshin, Yan Z./0000-0003-2823-6560	NHLBI NIH HHS [R01 HL055605, UH1 HL03679, R01 HL55605] Funding Source: Medline; NIAID NIH HHS [R21 AI056973, R21 AI056973-01, R21 AI 156973-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK49414] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679, R01HL055605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056973] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bensaude O, 1999, BIOCHEM CELL BIOL, V77, P249, DOI 10.1139/bcb-77-4-249; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Bharucha DC, 2002, VIROLOGY, V296, P6, DOI 10.1006/viro.2002.1438; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Boudrez A, 2002, J BIOL CHEM, V277, P31834, DOI 10.1074/jbc.M204427200; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; DAVIS AR, 1996, CURRENT PROTOCOLS HU; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Jagiello I, 2000, J CELL SCI, V113, P3761; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Jin QM, 1999, BIOCHEM J, V342, P13, DOI 10.1042/0264-6021:3420013; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Parker L, 2002, BIOCHEM J, V368, P789, DOI 10.1042/BJ20020582; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Verhoef K, 1999, J VIROL, V73, P2781, DOI 10.1128/JVI.73.4.2781-2789.1999; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8	30	38	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32189	32194		10.1074/jbc.M300521200	http://dx.doi.org/10.1074/jbc.M300521200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788939	hybrid			2022-12-25	WOS:000184782100092
J	Chung, MK; Lee, H; Caterina, MJ				Chung, MK; Lee, H; Caterina, MJ			Warm temperatures activate TRPV4 in mouse 308 keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-EVOKED ACTIVATION; ROOT GANGLION NEURONS; RECEPTOR-LIKE PROTEIN; VANILLOID RECEPTOR-1; CAPSAICIN-RECEPTOR; CATION CHANNEL; MICE LACKING; ION-CHANNEL; EXTRACELLULAR CALCIUM; NOCICEPTIVE NEURONS	Mammalian survival requires constant monitoring of environmental and body temperature. Recently, several members of the transient receptor potential vanilloid (TRPV) subfamily of ion channels have been identified that can be gated by increases in temperature into the warm (TRPV3 and TRPV4) or painfully hot (TRPV1 and TRPV2) range. In rodents, TRPV3 and TRPV4 proteins have not been detected in sensory neurons but are highly expressed in skin epidermal keratinocytes. Here, we show that in response to warm temperatures (>32degreesC), the mouse 308 keratinocyte cell line exhibits nonselective transmembrane cationic currents and Ca2+ influx. Both TRPV3 and TRPV4 are expressed in 308 cells. However, the warmth-evoked responses we observe most closely resemble those mediated by recombinant TRPV4 on the basis of their electrophysiological properties and sensitivity to osmolarity and the phorbol ester, 4alpha-phorbol-12,13-didecanoate. Together, these data support the notion that keratinocytes are capable of detecting modest temperature elevations, strongly suggest that TRPV4 participates in these responses, and define a system for the cell biological analysis of warmth transduction.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Caterina, MJ (corresponding author), 725 N Wolfe St, Baltimore, MD 21205 USA.	caterina@jhmi.edu	Chung, Man-Kyo/S-7433-2019	Chung, Man-Kyo/0000-0001-7637-1148; , Hyosang/0000-0002-3200-8678				Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Birder LA, 2001, P NATL ACAD SCI USA, V98, P13396, DOI 10.1073/pnas.231243698; Boels K, 2001, J CELL SCI, V114, P3599; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guler AD, 2002, J NEUROSCI, V22, P6408; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Inoue K, 2002, BIOCHEM BIOPH RES CO, V291, P124, DOI 10.1006/bbrc.2002.6393; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Marshall ICB, 2003, BRIT J PHARMACOL, V138, P172, DOI 10.1038/sj.bjp.0705003; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Nagy I, 1999, NEUROSCIENCE, V88, P995, DOI 10.1016/S0306-4522(98)00535-1; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PILLAI S, 1991, J CELL PHYSIOL, V146, P94, DOI 10.1002/jcp.1041460113; Pottosin II, 1999, BIOPHYS J, V77, P1973, DOI 10.1016/S0006-3495(99)77038-4; Romanovsky AA, 2002, J APPL PHYSIOL, V92, P2667, DOI 10.1152/japplphysiol.01173.2001; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Southall MD, 2003, J PHARMACOL EXP THER, V304, P217, DOI 10.1124/jpet.102.040675; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wisnoskey BJ, 2003, BIOCHEM J, V372, P517, DOI 10.1042/BJ20021574; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; YUSPA SH, 1988, ANN NY ACAD SCI, V548, P191, DOI 10.1111/j.1749-6632.1988.tb18806.x; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; YUSPA SH, 1983, J INVEST DERMATOL, V81, pS162, DOI 10.1111/1523-1747.ep12540999	49	191	212	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32037	32046		10.1074/jbc.M303251200	http://dx.doi.org/10.1074/jbc.M303251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783886	hybrid			2022-12-25	WOS:000184782100074
J	Georgel, PT; Horowitz-Scherer, RA; Adkins, N; Woodcock, CL; Wade, PA; Hansen, JC				Georgel, PT; Horowitz-Scherer, RA; Adkins, N; Woodcock, CL; Wade, PA; Hansen, JC			Chromatin compaction by human MeCP2 - Assembly of novel secondary chromatin structures in the absence of DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG BINDING DOMAIN; TRANSCRIPTIONAL REPRESSOR MECP2; RETT-SYNDROME MUTATIONS; IN-VITRO; HISTONE DEACETYLASE; PROTEIN MECP2; COMPLEX; GENE; LOCALIZATION; ARCHITECTURE	MeCP2 is a transcriptional repressor that contains an N-terminal methylated DNA-binding domain, a central transcription regulation domain, and a C-terminal domain of unknown function. Whereas current models of MeCP2 function evoke localized recruitment of histone deacetylases to specific methylated regions of the genome, it is unclear whether MeCP2 requires DNA methylation to bind to chromatin or whether MeCP2 binding influences chromatin structure in the absence of other proteins. To address these issues, we have characterized the complexes formed between MeCP2 and biochemically defined nucleosomal arrays. At molar ratios near 1 MeCP2/nucleosome, unmethylated nucleosomal arrays formed both extensively condensed ellipsoidal particles and oligomeric suprastructures. Furthermore, MeCP2-mediated chromatin compaction occurred in the absence of monovalent or divalent cations, in distinct contrast to all other known chromatin-condensing proteins. Analysis of specific missense and nonsense MeCP2 mutants indicated that the ability to condense chromatin resides in region(s) of the protein other than the methylated DNA-binding domain. These data demonstrate that MeCP2 assembles novel secondary chromatin structures independent of DNA modification and suggest that the ability of MeCP2 to silence chromatin may be related in part to its effects on large-scale chromatin organization.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Marshall Univ, Dept Biol Sci, Huntington, WV 25755 USA; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	Emory University; University of Texas System; University of Texas Health San Antonio; Marshall University; University of Massachusetts System; University of Massachusetts Amherst	Wade, PA (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.		Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X	NICHD NIH HHS [5K22HD01238] Funding Source: Medline; NIGMS NIH HHS [GM43786, GM45916] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K22HD001238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916, R01GM043786] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BEDNAR J, 1995, J CELL BIOL, V131, P1365, DOI 10.1083/jcb.131.6.1365; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Georgel PT, 2001, P NATL ACAD SCI USA, V98, P8584, DOI 10.1073/pnas.151258798; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; Horowitz RA, 1997, J STRUCT BIOL, V120, P353, DOI 10.1006/jsbi.1997.3921; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Lee SSJ, 2001, BRAIN DEV-JPN, V23, pS138; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; Vacca M, 2001, J MOL MED, V78, P648, DOI 10.1007/s001090000155; Van den Veyver IB, 2001, BRAIN DEV-JPN, V23, pS147, DOI 10.1016/S0387-7604(01)00376-X; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Woodcock CL, 1998, METHOD CELL BIOL, V53, P167; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172	39	241	249	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32181	32188		10.1074/jbc.M305308200	http://dx.doi.org/10.1074/jbc.M305308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788925	hybrid			2022-12-25	WOS:000184782100091
J	Stehlik, C; Hayashi, H; Pio, F; Godzik, A; Reed, JC				Stehlik, C; Hayashi, H; Pio, F; Godzik, A; Reed, JC			CARD6 is a modulator of NF-kappa B activation by Nod1- and Cardiak-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; INDUCED-PROXIMITY MODEL; CONTAINING APAF1-LIKE PROTEIN; FAMILY-MEMBER; REGULATES ACTIVATION; SIGNALING PATHWAYS; CROHNS-DISEASE; MALT LYMPHOMA; APOPTOSIS; INHIBITOR	We cloned a novel cDNA derived from the CARD6 gene locus on chromosome 5p12 of 311 amino acids in length. By immunoprecipitation we detected specific binding of this CARD6-encoding protein to Nod1 (CARD4), Cardiak (Rip2/Rick), NAC (NALP1/DEFCAP/CARD7), and TUCAN (CARD8/Cardinal/NDPP/Dakar), caspase recruitment domain (CARD)-containing proteins implicated in NF-kappaB and caspase-1 activation but not to other CARD family proteins. Cardiak and Nod1 (but not other CARD proteins) also exhibited opposing effects on CARD6 protein phosphorylation and expression, providing further evidence of functional interactions among these proteins in cells. In transfection experiments, the CARD6 protein suppressed NF-kappaB induction by Nod1 or Cardiak but did not interfere with NF-kappaB activation by the CARD-containing adapter protein Bcl10 or the cytokine tumor necrosis factor-alpha, demonstrating specificity of CARD6 for Nod-1 and Cardiak-dependent pathways. In contrast to its effects on Nod1- and Cardiak-dependent NF-kappaB activation, CARD6 did not interfere with caspase-1-dependent interleukin-1beta secretion induced by Cardiak or Nod1. CARD6 also did not affect caspase activation and apoptosis induced by overexpression of Fas, Bax, or other pro-apoptotic stimuli. Thus, CARD6 represents a selective modulator of NF-kappaB activation by Cardiak and Nod1, adding to the repertoire of CARD-family proteins implicated in inflammatory responses and innate immunity.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org	Godzik, Adam/A-7279-2009; Stehlik, Christian/AAG-2132-2021; Godzik, Adam/AAW-1467-2020	Godzik, Adam/0000-0002-2425-852X; Stehlik, Christian/0000-0002-3782-2484; Godzik, Adam/0000-0002-2425-852X; Hayashi, Hideki/0000-0003-4585-6542; pio, frederic/0000-0003-2050-847X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Fiorentino L, 2002, J BIOL CHEM, V277, P35333, DOI 10.1074/jbc.M200446200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Li WZ, 2000, BIOINFORMATICS, V16, P1105, DOI 10.1093/bioinformatics/16.12.1105; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pathan N, 2001, J BIOL CHEM, V276, P32220, DOI 10.1074/jbc.M100433200; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulze-Osthoff K, 2000, CELL DEATH DIFFER, V7, P1025, DOI 10.1038/sj.cdd.4400752; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Yoo NJ, 2002, BIOCHEM BIOPH RES CO, V299, P652, DOI 10.1016/S0006-291X(02)02714-6; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang H, 2002, INT J ONCOL, V20, P1035; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	63	54	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31941	31949		10.1074/jbc.M300009200	http://dx.doi.org/10.1074/jbc.M300009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12775719	hybrid			2022-12-25	WOS:000184782100062
J	Tanner, GJ; Francki, KT; Abrahams, S; Watson, JM; Larkin, PJ; Ashton, AR				Tanner, GJ; Francki, KT; Abrahams, S; Watson, JM; Larkin, PJ; Ashton, AR			Proanthocyanidin biosynthesis in plants - Purification of legume leucoanthocyanidin reductase and molecular cloning of its cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ENZYME; LEUCOCYANIDIN; EXPRESSION; CONVERSION; CULTURES; ENCODES; BANYULS; GENE	Leucoanthocyanidin reductase (LAR) catalyzes the synthesis of catechin, an initiating monomer of condensed tannin or proanthocyanidin (PA) synthesis, from 3,4-cis-leucocyanidin and thus is the first committed step in PA biosynthesis. The enzyme was purified to near homogeneity from PA-rich leaves of the legume Desmodium uncinatum (Jacq.) DC, partially sequenced and the corresponding cDNA cloned. The identity of the enzyme was confirmed by expressing active recombinant LAR in Escherichia coli and in tobacco and white clover. The enzyme is a monomer of 43 kDa (382 amino acids) and is most active synthesizing catechin (specific activity of similar to10 mumol min(-1) mg of protein(-1)) but also synthesizes afzelechin and gallocatechin. LAR is most closely related to the isoflavone reductase group of plant enzymes that are part of the Reductase-Epimerase-Dehydrogenase ( RED) family of proteins. Unlike all other plant isoflavone reductase homologues that are about 320 amino acids long, LAR has an additional 65-amino acid C-terminal extension whose function is not known. Curiously, although Arabidopsis makes PA, there is no obvious LAR orthologue in the Arabidopsis genome. This may be because Arabidopsis seems to produce only an epicatechin, rather than a dual catechin/epicatechin-based PA similar to many other plants.	CSIRO Plant Ind, Canberra, ACT 2601, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Tanner, GJ (corresponding author), CSIRO Plant Ind, GPO Box 1600, Canberra, ACT 2601, Australia.	greg.tanner@csiro.au; tony.ashton@csiro.au	Tanner, Greg J/A-3210-2010; Larkin, Philip J/A-9468-2008; Larkin, Philip/AAU-3195-2021; Ashton, Anthony R/A-2721-2010	Larkin, Philip J/0000-0002-2608-1924; Larkin, Philip/0000-0002-2608-1924; Ashton, Anthony R/0000-0001-5649-2882				Abrahams S, 2002, PLANT PHYSIOL, V130, P561, DOI 10.1104/pp.006189; ASHTON AR, 1978, BIOCHEM J, V175, P501, DOI 10.1042/bj1750501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; Debeaujon I, 2001, PLANT CELL, V13, P853, DOI 10.1105/tpc.13.4.853; DEBLOCK M, 1984, EMBO J, V3, P1681, DOI 10.1002/j.1460-2075.1984.tb02032.x; Devic M, 1999, PLANT J, V19, P387, DOI 10.1046/j.1365-313X.1999.00529.x; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; Gang DR, 1999, J BIOL CHEM, V274, P7516, DOI 10.1074/jbc.274.11.7516; HARBORNE JB, 1996, FLAVONOIDS ADV RES 1, P23; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Joseph R, 1998, AUST J PLANT PHYSIOL, V25, P271, DOI 10.1071/PP97068; KRISTIANSEN KN, 1986, CARLSBERG RES COMMUN, V51, P51, DOI 10.1007/BF02907995; LABESSE G, 1994, BIOCHEM J, V304, P95, DOI 10.1042/bj3040095; Larkin PJ, 1996, TRANSGENIC RES, V5, P325, DOI 10.1007/BF01968942; Li YG, 1996, J SCI FOOD AGR, V70, P89, DOI 10.1002/(SICI)1097-0010(199601)70:1&lt;89::AID-JSFA470&gt;3.0.CO;2-N; Lunn JE, 2000, P NATL ACAD SCI USA, V97, P12914, DOI 10.1073/pnas.230430197; Mulichak AM, 1999, P NATL ACAD SCI USA, V96, P13097, DOI 10.1073/pnas.96.23.13097; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schunmann PHD, 2003, FUNCT PLANT BIOL, V30, P443, DOI 10.1071/FP02166; SCOPES RK, 1994, PROTEIN PURIFICATION, P210; Singh S, 1997, PHYTOCHEMISTRY, V44, P425, DOI 10.1016/S0031-9422(96)00415-3; Skadhauge B, 1997, AM J BOT, V84, P494, DOI 10.2307/2446026; STAFFORD HA, 1984, PLANT PHYSIOL, V76, P184, DOI 10.1104/pp.76.1.184; TAM JP, 1984, PEPTIDE ANTIGENS PRA, P83; TANNER GJ, 1993, ANAL BIOCHEM, V209, P274, DOI 10.1006/abio.1993.1119; TANNER GJ, 2000, ACIAR P, V92; TIEMANN K, 1991, EUR J BIOCHEM, V200, P751, DOI 10.1111/j.1432-1033.1991.tb16241.x; Xie DY, 2003, SCIENCE, V299, P396, DOI 10.1126/science.1078540	31	276	314	5	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31647	31656		10.1074/jbc.M302783200	http://dx.doi.org/10.1074/jbc.M302783200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788945	hybrid			2022-12-25	WOS:000184782100025
J	Vaidyanathan, H; Ramos, JW				Vaidyanathan, H; Ramos, JW			RSK2 activity is regulated by its interaction with PEA-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH EFFECTOR DOMAIN; PROTEIN-KINASE-C; ERK MAP KINASE; HISTONE H3; FOS GENE; PHOSPHORYLATION; ASTROCYTES; ACTIVATION; APOPTOSIS; IDENTIFICATION	The ERK MAP (mitogen-activated protein) kinase cascade modulates many cellular processes including transcription, adhesion, growth, survival, and proliferation. One target substrate of ERK involved in regulating transcription is the p90 ribosomal S6 kinase (RSK) isozyme, RSK2. Here we demonstrate that a small death effector domain-containing protein called PEA-15 binds RSK2. RSK2 and PEA-15 ((p) under bar hosphoprotein (e) under bar nriched in astrocytes, (15) under bar kDa) co-precipitated from cells and were colocalized in the cytoplasm. Furthermore, purified PEA-15 bound in vitro translated RSK2, suggesting that these proteins interact directly. PEA-15 does not bind to RSK1 and therefore exhibits some binding specificity. RSK2 binds the COOH terminus of PEA-15 and does not interact with its NH2-terminal death effector domain. We show that this interaction has functional consequences including the inhibition of RSK2-dependent CREB transcription. PEA-15 expression also blocks histone H3 phosphorylation, an RSK2-dependent event that may contribute to effects on gene expression. These results can be attributed to two effects of PEA-15 on RSK2. First, PEA-15 blocks nuclear accumulation of RSK2 after epidermal growth factor stimulation. Second, PEA-15 inhibits RSK2 kinase activity by 50%. A mutant of PEA-15 that binds RSK2 but is localized to the nucleus had no effect on RSK2-dependent transcription. Interestingly, this mutant also did not affect RSK2 kinase activity. This may indicate that cytoplasmic retention of RSK2 is also required for PEA-15 to impair kinase activity. PEA-15 does not alter ERK phosphorylation of RSK2 and is not itself a substrate of RSK2. Hence the effects of PEA-15 on RSK2 represent a novel mechanism for the regulation of RSK2-mediated signaling.	Rutgers State Univ, Nelson Biol Labs, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Ramos, JW (corresponding author), Rutgers State Univ, Nelson Biol Labs, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.		Ramos, Joe/G-4074-2010	Ramos, Joe/0000-0002-9708-2115	NCI NIH HHS [CA93849-01, R01 CA093849, R01 CA093849-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093849, R56CA093849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bruning JC, 2000, P NATL ACAD SCI USA, V97, P2462, DOI 10.1073/pnas.97.6.2462; Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gutkind J.S, 2000, SCI STKE; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Hu SM, 1997, J BIOL CHEM, V272, P9621; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Kubes M, 1998, J NEUROCHEM, V71, P1307; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhang Y, 2002, J BIOL CHEM, V277, P19042, DOI 10.1074/jbc.M112442200	33	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32367	32372		10.1074/jbc.M303988200	http://dx.doi.org/10.1074/jbc.M303988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12796492	hybrid			2022-12-25	WOS:000184782100115
J	Wilkinson, SR; Horn, D; Prathalingam, SR; Kelly, JM				Wilkinson, SR; Horn, D; Prathalingam, SR; Kelly, JM			RNA interference identifies two hydroperoxide metabolizing enzymes that are essential to the bloodstream form of the African trypanosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOTHIONE REDUCTASE; OXIDATIVE STRESS; DEVELOPMENTAL REGULATION; CRITHIDIA-FASCICULATA; ASCORBATE PEROXIDASE; MITOCHONDRIAL; GLUTATHIONE; TRYPAREDOXIN; LEISHMANIA; EXPRESSION	Detoxification of hydroperoxides in trypanosomes is mediated by a series of linked redox pathways that are dependent on the parasite-specific thiol trypanothione for reducing equivalents. These pathways are characterized by differences in subcellular location, electron transport molecules, and substrate specificity. To determine the functional significance of the enzymes involved, we have used a tetracycline-inducible RNA interference system to down-regulate expression of each of the corresponding transcripts in bloodstream form Trypanosoma brucei. We have identified two peroxidases, a cytosolic peroxiredoxin (TbCPX) and a member of the non-selenium glutathione-dependent peroxidase family (TbGPXI), that appear to be essential for the viability of this clinically relevant stage of the parasite life cycle. The addition of tetracycline to the cultures resulted in a major reduction in mRNA levels and enzyme activity, a dramatic fall in growth rate, and significant cell death. Furthermore, within 20 h of adding tetracycline, cells in which the cytosolic peroxiredoxin transcript was targeted were found to be 16-fold more susceptible to killing by exogenous hydrogen peroxide. We also observed that knockdown of the tryparedoxin TbT-PNI, a thioredoxin-like protein that facilitates electron transport to both TbCPX and TbGPXI, resulted in a reduction in growth rate. These experiments therefore identify redox pathways that are essential for oxidative defense in T. brucei and validate the corresponding peroxidases as targets for drug design.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Wilkinson, SR (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	shane.wilkinson@lshtm.ac.uk		Horn, David/0000-0001-5173-9284				Alphey MS, 1999, J BIOL CHEM, V274, P25613, DOI 10.1074/jbc.274.36.25613; Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Baier M, 2000, PLANT PHYSIOL, V124, P823, DOI 10.1104/pp.124.2.823; BIENEN EJ, 1991, MOL BIOCHEM PARASIT, V45, P185, DOI 10.1016/0166-6851(91)90085-K; Castro H, 2002, FREE RADICAL BIO MED, V33, P1563, DOI 10.1016/S0891-5849(02)01088-2; Castro H, 2002, FREE RADICAL BIO MED, V33, P1552, DOI 10.1016/S0891-5849(02)01089-4; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Drozdz M, 2002, EMBO J, V21, P1791, DOI 10.1093/emboj/21.7.1791; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; EASTERBY JS, 1982, METHOD ENZYMOL, V90, P11; Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FEAGIN JE, 1985, P NATL ACAD SCI USA, V82, P3380, DOI 10.1073/pnas.82.10.3380; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; Guerra-Giraidez C, 2002, J CELL SCI, V115, P2651; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hofmann B, 2001, BIOL CHEM, V382, P459, DOI 10.1515/BC.2001.056; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; Hunter WN, 1997, PARASITOLOGY, V114, pS17, DOI 10.1017/S0031182097008962; Ingram AK, 2000, MOL BIOCHEM PARASIT, V111, P309, DOI 10.1016/S0166-6851(00)00322-4; Jimenez A, 1997, PLANT PHYSIOL, V114, P275, DOI 10.1104/pp.114.1.275; KELLY JM, 1993, EUR J BIOCHEM, V218, P29, DOI 10.1111/j.1432-1033.1993.tb18348.x; Krauth-Siegel RL, 2002, METHOD ENZYMOL, V347, P259; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; KrauthSiegel RL, 1996, MOL BIOCHEM PARASIT, V80, P203, DOI 10.1016/0166-6851(96)02689-8; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; Montemartini Marisa, 2000, Biofactors, V11, P65; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Moutiez M, 1997, BIOCHEM J, V322, P43, DOI 10.1042/bj3220043; MOUTIEZ M, 1995, BIOCHEM J, V310, P433, DOI 10.1042/bj3100433; Mullen RT, 1997, PLANT J, V12, P313, DOI 10.1046/j.1365-313X.1997.12020313.x; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P291, DOI 10.1016/0166-6851(81)90062-1; OPPERDOES FR, 1993, BIOCHIMIE, V75, P231, DOI 10.1016/0300-9084(93)90081-3; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Parsons M, 2001, MOL BIOCHEM PARASIT, V115, P19, DOI 10.1016/S0166-6851(01)00261-4; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; Rizhsky L, 2002, PLANT J, V32, P329, DOI 10.1046/j.1365-313X.2002.01427.x; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; Steinert P, 2000, BIOL CHEM, V381, P211, DOI 10.1515/BC.2000.028; Tetaud E, 1998, MOL BIOCHEM PARASIT, V96, P111, DOI 10.1016/S0166-6851(98)00120-0; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Tovar J, 1998, MOL MICROBIOL, V29, P653, DOI 10.1046/j.1365-2958.1998.00968.x; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2002, P NATL ACAD SCI USA, V99, P13453, DOI 10.1073/pnas.202422899; Wilkinson SR, 2002, BIOCHEM J, V364, P787, DOI 10.1042/BJ20020038; Wilkinson SR, 2000, BIOCHEM J, V352, P755, DOI 10.1042/0264-6021:3520755; Willekens H, 1997, EMBO J, V16, P4806, DOI 10.1093/emboj/16.16.4806; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; YAMAGUCHI K, 1995, PLANT CELL PHYSIOL, V36, P1157, DOI 10.1093/oxfordjournals.pcp.a078862; Zoraghi R, 2002, P NATL ACAD SCI USA, V99, P4343, DOI 10.1073/pnas.062716599	66	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31640	31646		10.1074/jbc.M303035200	http://dx.doi.org/10.1074/jbc.M303035200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791697	hybrid			2022-12-25	WOS:000184782100024
J	Yang, ZZ; Tschopp, O; Hemmings-Mieszczak, M; Feng, JH; Brodbeck, D; Perentes, E; Hemmings, BA				Yang, ZZ; Tschopp, O; Hemmings-Mieszczak, M; Feng, JH; Brodbeck, D; Perentes, E; Hemmings, BA			Protein kinase B alpha/Akt1 regulates placental development and fetal growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; ORGAN GROWTH; AKT; CELLS; ACTIVATION; DIFFERENTIATION; AKT1/PKB-ALPHA; ANGIOGENESIS; DISRUPTION	Protein kinase Balpha (PKBalpha/Akt1) is implicated in the regulation of metabolism, transcription, cell survival, angiogenesis, cell migration, growth, and tumorigenesis. Previously, it was reported that PKBalpha-deficient mice are small with increased neonatal mortality (Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., and Birnbaum, M. J. ( 2001) J. Biol. Chem. 276, 38349 - 38352 and Chen, W. S., Xu, P. Z., Gottlob, K., Chen, M. L., Sokol, K., Shiyanova, T., Roninson, I., Wenig, W., Suzuki, R., Tobe, K., Kadowaki, T., and Hay, N. ( 2001) Genes Dev. 15, 2203 2208). Here we show that PKBalpha is widely expressed in placenta including all types of trophoblast and vascular endothelial cells. Pkbalpha(-/-) placentae display significant hypotrophy, with marked reduction of the decidual basalis and nearly complete loss of glycogen-containing cells in the spongiotrophoblast, and exhibit decreased vascularization. Pkbalpha(-/-) placentae also show significant reduction of phosphorylation of PKB and endothelial nitric-oxide synthase. These defects may cause placental insufficiency, fetal growth impairment, and neonatal mortality. These data represent the first evidence for the role of PKBalpha and endothelial nitric-oxide synthase in regulating placental development and provide an animal model for intrauterine growth retardation.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Novartis Pharma AG, CH-4056 Basel, Switzerland; Novartis Pharma AG, Preclin Safety, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis; Novartis	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	hemmings@fmi.ch	Tschopp, Oliver/H-7545-2018	Tschopp, Oliver/0000-0002-7733-7934				Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; Anthony RV, 2001, BIOCHEM SOC T, V29, P42, DOI 10.1042/0300-5127:0290042; BELLACOSA A, 1993, ONCOGENE, V8, P745; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cross JC, 2002, MOL CELL ENDOCRINOL, V187, P207, DOI 10.1016/S0303-7207(01)00703-1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duplain H, 2001, CIRCULATION, V104, P342, DOI 10.1161/01.CIR.104.3.342; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Han Victor K. M., 2001, Current Opinion in Pharmacology, V1, P632, DOI 10.1016/S1471-4892(01)00108-4; Hefler LA, 2001, BIOL REPROD, V64, P666, DOI 10.1095/biolreprod64.2.666; Ihle JN, 2000, CELL, V102, P131, DOI 10.1016/S0092-8674(00)00017-9; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kamei T, 2002, MOL ENDOCRINOL, V16, P1469, DOI 10.1210/me.16.7.1469; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Limbourg FP, 2002, J CLIN INVEST, V110, P1729, DOI 10.1172/JCI200215481; Lopez MF, 1996, ENDOCRINOLOGY, V137, P2100, DOI 10.1210/en.137.5.2100; LUO Z, 2002, J CLIN INVEST, V106, P493; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Okada S, 2001, TRENDS MOL MED, V7, P126, DOI 10.1016/S1471-4914(01)01933-5; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Pardi G, 2002, PLACENTA, V23, pS136, DOI 10.1053/plac.2002.0802; *PERK LIF SCI, 1997, ABI PRISM 7700 US B, V2; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Prada JA, 1998, EUR J CLIN NUTR, V52, pS21; Rathjen J, 2001, CURR OPIN GENET DEV, V11, P587, DOI 10.1016/S0959-437X(00)00237-9; Regnault TRH, 2002, PLACENTA, V23, pS119, DOI 10.1053/plac.2002.0792; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; van Kleffens M, 1998, MOL CELL ENDOCRINOL, V140, P129, DOI 10.1016/S0303-7207(98)00041-0; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	47	301	322	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32124	32131		10.1074/jbc.M302847200	http://dx.doi.org/10.1074/jbc.M302847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783884	hybrid			2022-12-25	WOS:000184782100084
J	Daines, MO; Andrews, RP; Chen, WG; El-Zayaty, SA; Hershey, GKK				Daines, MO; Andrews, RP; Chen, WG; El-Zayaty, SA; Hershey, GKK			DNA binding activity of cytoplasmic phosphorylated Stat6 is masked by an interaction with a detergent-sensitive factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL TRANSDUCER; GENE-EXPRESSION; NUCLEAR EXPORT; IL-4; ACTIVATION; INHIBITION; RESPONSES; IMPORTIN	Signal transducer and activator of transcription (Stat) 6 is vital to interleukin (IL)-4 and IL-13 responses and the generation of Th2 immunity. We investigated the cellular location of phosphorylated Stat6 and Stat6 DNA binding activity in A201.1 murine B cells and primary splenocytes. Phosphorylated Stat6 was present in cytoplasmic and nuclear extracts from IL-4-treated cells. Confocal microscopy confirmed the presence of phosphorylated Stat6 in the cytoplasm of IL-4-treated cells. In contrast, Stat6 DNA binding activity was present in nuclear extracts, but not in cytoplasmic extracts. Thus, cytoplasmic extracts from IL-4-stimulated cells were devoid of Stat6 DNA binding activity despite the presence of phosphorylated Stat6. Addition of cytoplasmic extracts to nuclear extracts did not inhibit Stat6 DNA binding present in the nuclear extracts. Detergent treatment restored Stat6 DNA binding activity in cytoplasmic extracts of IL-4-stimulated cells. Thus, DNA binding activity of cytoplasmic phosphorylated Stat6 is masked by a factor dissociable by detergent treatment.	Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@chmcc.org		Daines, Michael/0000-0003-2464-9034				Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Andrews RP, 2001, J IMMUNOL, V166, P1716, DOI 10.4049/jimmunol.166.3.1716; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Losman JA, 1999, J IMMUNOL, V162, P3770; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Venkataraman C, 1999, J IMMUNOL, V162, P4053	26	11	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30971	30974		10.1074/jbc.M301094200	http://dx.doi.org/10.1074/jbc.M301094200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777374	hybrid			2022-12-25	WOS:000184658800071
J	Honbou, K; Suzuki, NN; Horiuchi, M; Niki, T; Taira, T; Ariga, H; Inagaki, F				Honbou, K; Suzuki, NN; Horiuchi, M; Niki, T; Taira, T; Ariga, H; Inagaki, F			The crystal structure of DJ-1, a protein related to male fertility and bParkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANTHRANILATE SYNTHASE; CATALYTIC TRIAD; SP22; FERTILIZATION; RESOLUTION; GLUTAMINE; CATALASE; PROGRAM; REVEALS	DJ-1 is a multifunctional protein that plays essential roles in tissues with higher order biological functions such as the testis and brain. DJ-1 is related to male fertility, and its level in sperm decreases in response to exposure to sperm toxicants. DJ-1 has also been identified as a hydroperoxide-responsive protein. Recently, a mutation of DJ-1 was found to be responsible for familial Parkinson's disease. Here, we present the crystal structure of DJ-1 refined to 1.95-Angstrom resolution. DJ-1 forms a dimer in the crystal, and the monomer takes a flavodoxin-like Rossmann-fold. DJ-1 is structurally most similar to the monomer subunit of protease I, the intracellular cysteine protease from Pyrococcus horikoshii, and belongs to the Class I glutamine amidotransferase-like superfamily. However, DJ-1 contains an additional alpha-helix at the C-terminal region, which blocks the putative catalytic site of DJ-1 and appears to regulate the enzymatic activity. DJ-1 may induce conformational changes to acquire catalytic activity in response to oxidative stress.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University; Japan Science & Technology Agency (JST); Hokkaido University	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, N-12,W-6, Sapporo, Hokkaido 0600812, Japan.		Ariga, Hiroyoshi/B-5895-2013; Horiuchi, Masataka/D-5491-2012; Noda, Nobuo/P-1397-2015	Ariga, Hiroyoshi/0000-0001-7384-2143; Noda, Nobuo/0000-0002-6940-8069				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bravo J, 1999, PROTEINS, V34, P155, DOI 10.1002/(SICI)1097-0134(19990201)34:2<155::AID-PROT1>3.0.CO;2-P; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBILLAU C, 1997, TURBO FRODO VERSION; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Horvath MM, 2001, PROTEINS, V42, P230, DOI 10.1002/1097-0134(20010201)42:2<230::AID-PROT100>3.3.CO;2-A; Klinefelter GR, 2002, J ANDROL, V23, P48, DOI 10.1002/jand.2002.23.1.48; Klinefelter GR, 1997, J ANDROL, V18, P139; Knochel T, 1999, P NATL ACAD SCI USA, V96, P9479, DOI 10.1073/pnas.96.17.9479; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Spraggon G, 2001, P NATL ACAD SCI USA, V98, P6021, DOI 10.1073/pnas.111150298; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Welch JE, 1998, J ANDROL, V19, P385	29	172	184	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31380	31384		10.1074/jbc.M305878200	http://dx.doi.org/10.1074/jbc.M305878200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12796482	hybrid			2022-12-25	WOS:000184658800120
J	Kifor, O; Kifor, I; Moore, FD; Butters, RR; Brown, EM				Kifor, O; Kifor, I; Moore, FD; Butters, RR; Brown, EM			m-Calpain colocalizes with the calcium-sensing receptor (CaR) in caveolae in parathyroid cells and participates in degradation of the CaR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSFECTED HEK293 CELLS; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; EXTRACELLULAR DOMAIN; STRUCTURAL BASIS; FAMILY; ACTIVATION; SECRETION; RELEASE	The calcium-sensing receptor (CaR) is a G protein-coupled, seven-transmembrane receptor and resides within caveolin-rich membrane domains in bovine parathyroid cells. The proenzyme of calpain 2 (m-calpain) is a heterodimeric calcium-dependent cysteine protease consisting of catalytic and regulatory subunits. The effects of calcium on the enzyme include activation, autolysis, and subunit dissociation. Here, we examine the potential role of caveolin-1 and caveolae in regulating the cellular distribution and function of m-calpain in parathyroid cells. We show that the inactive heterodimeric forms of m-calpain are concentrated in caveolin-rich membrane fractions prepared from parathyroid cells incubated with low extracellular calcium (Ca-o(2+)). In contrast, in cells incubated with 3 mM Ca-o(2+), which activates the CaR and increases intracellular calcium, there is a reduction in m-calpain in association with an increase in CaR protein and phosphorylated protein kinase C alpha and beta in caveolin-rich fractions. To assess the impact of activation of calpain on CaR protein in caveolar fractions, we analyzed the effects of m-calpain on the CaR. Activation of the CaR with high Ca-o(2+) induced the release of lower molecular weight fragments of the receptor into the cell culture medium, and calpain inhibitors blocked this effect. Moreover, the fragments of the CaR as well as caveolin-1, m-calpain, and alkaline phosphatase were localized in membrane vesicles shed by parathyroid cells, supporting the association of these proteins in living cells. Treatment of CaR proteins in vitro with m-calpain also resulted in the appearance of lower molecular weight fragments of the CaR. Our data suggest that localization of m-calpain within caveolae may contribute to maintenance of the enzyme in an inactive state and that m-calpain may also contribute to the regulation of CaR levels.	Brigham & Womens Hosp, Div Endocrine Hypertens, Membrane Biol Program, Harvard Med Sch, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Harvard Med Sch, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kifor, O (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Membrane Biol Program, Harvard Med Sch, 221 Longwood Ave, Boston, MA 02115 USA.				NIDDK NIH HHS [DK52005, DK48330, DK41415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048330, R01DK052005, R01DK041415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Brown EM, 1999, VITAM HORM, V55, P1; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Civenni G, 1998, BLOOD, V91, P1784, DOI 10.1182/blood.V91.5.1784.1784_1784_1792; CONG JY, 1989, J BIOL CHEM, V264, P10096; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Daman A, 2001, MOL CELL BIOCHEM, V223, P159, DOI 10.1023/A:1017939116715; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Khorchid A, 2002, NAT STRUCT BIOL, V9, P239, DOI 10.1038/nsb0402-239; Kifor O, 2001, AM J PHYSIOL-RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; KIFOR O, 1990, J BONE MINER RES, V5, P1003; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; MITCHEL JB, 1997, J BIOL CHEM, V272, P18522; MORRISSEY JJ, 1988, AM J PHYSIOL, V254, pE63, DOI 10.1152/ajpendo.1988.254.1.E63; Murthy KS, 2000, J BIOL CHEM, V275, P30211, DOI 10.1074/jbc.M002194200; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; RACKE FK, 1994, AM J PHYSIOL, V267, pE429, DOI 10.1152/ajpendo.1994.267.3.E429; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Reyes-Cruz G, 2001, J BIOL CHEM, V276, P32145, DOI 10.1074/jbc.M102977200; Rong YQ, 2001, J NEUROCHEM, V79, P382, DOI 10.1046/j.1471-4159.2001.00565.x; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; TAYLOR DD, 1983, BIOCHEM BIOPH RES CO, V113, P470, DOI 10.1016/0006-291X(83)91749-7; WATSON PH, 1995, J MOL ENDOCRINOL, V15, P61, DOI 10.1677/jme.0.0150061; WILD P, 1995, MICROSC RES TECHNIQ, V32, P120, DOI 10.1002/jemt.1070320207; XIE MS, 1995, BIOCHEM J, V305, P529, DOI 10.1042/bj3050529	57	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31167	31176		10.1074/jbc.M303377200	http://dx.doi.org/10.1074/jbc.M303377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783889	hybrid			2022-12-25	WOS:000184658800094
J	Luciakova, K; Barath, P; Poliakova, D; Persson, A; Nelson, BD				Luciakova, K; Barath, P; Poliakova, D; Persson, A; Nelson, BD			Repression of the human adenine nucleotide translocase-2 gene in growth-arrested human diploid cells - The role of nuclear factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND INVOLUTION; CYCLE-DEPENDENT GENES; ADP/ATP TRANSLOCASE; DIFFERENTIAL REGULATION; MOLECULAR-CLONING; HUMAN-LYMPHOCYTES; SILENCER ELEMENT; BINDING-PROTEINS; MAMMALIAN-CELLS; DNA-REPLICATION	Adenine nucleotide translocase-2 (ANT2) catalyzes the exchange of ATP for ADP across the mitochondrial membrane, thus playing an important role in maintaining the cytosolic phosphorylation potential required for cell growth. Expression of ANT2 is activated by growth stimulation of quiescent cells and is down-regulated when cells become growth-arrested. In this study, we address the mechanism of growth arrest repression. Using a combination of transfection, in vivo dimethyl sulfate mapping, and in vitro DNase I mapping experiments, we identified two protein-binding elements (Go-1 and Go-2) that are responsible for growth arrest of ANT2 expression in human diploid fibroblasts. Proteins that bound the Go elements were purified and identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry as members of the NF1 family of transcription factors. Chromatin immunoprecipitation analysis showed that NF1 was bound to both Go-1 and Go-2 in quiescent human diploid cells in vivo, but not in the same cells stimulated to growth by serum. NF1 binding correlated with the disappearance of ANT2 transcripts in quiescent cells. Furthermore, overexpression of NF1-A, -C, and -X in NIH3T3 cells repressed expression of an ANT2-driven reporter gene construct. Two additional putative repressor elements in the ANT2 promoter, an Sp1 element juxtaposed to the transcription start site and a silencer centered at nucleotide -332, did not appear to contribute to growth arrest repression. Thus, enhanced binding of NF1 is a key step in the growth arrest repression of ANT2 transcription. To our knowledge, this is the first report showing a role for NF1 in growth arrest.	Slovak Acad Sci, Canc Res Inst, Bratislava 83391, Slovakia; Univ Stockholm, Arrhenius Lab, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Univ Stockholm, Canc Res Inst, Dept Cell Biol, S-10691 Stockholm, Sweden	Slovak Academy of Sciences; Stockholm University; Stockholm University	Luciakova, K (corresponding author), Slovak Acad Sci, Canc Res Inst, Vlarska 7, Bratislava 83391, Slovakia.		Barath, Peter/T-7563-2019	Barath, Peter/0000-0001-7330-955X				ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; AUSUBEL FM, 1994, CURRERNT PROTOCOLS M; Barath P, 1999, EXP CELL RES, V248, P583, DOI 10.1006/excr.1999.4432; Barath P, 1999, J BIOL CHEM, V274, P3378, DOI 10.1074/jbc.274.6.3378; BATTINI R, 1987, J BIOL CHEM, V262, P4355; Bisgrove DA, 2000, J BIOL CHEM, V275, P30668, DOI 10.1074/jbc.M003828200; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chaudhry AZ, 1999, J BIOL CHEM, V274, P7072, DOI 10.1074/jbc.274.11.7072; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dorner A, 1999, BBA-BIOMEMBRANES, V1417, P16, DOI 10.1016/S0005-2736(98)00245-4; DORNER A, 1997, FEBS LETT, V414, P258; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Gao B, 1998, J BIOL CHEM, V273, P31784, DOI 10.1074/jbc.273.48.31784; Gao B, 1996, MOL CELL BIOL, V16, P5997; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KACZMAREK L, 1985, BIOCHEM BIOPH RES CO, V133, P410, DOI 10.1016/0006-291X(85)90921-0; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; Kane R, 2002, J BIOL CHEM, V277, P25893, DOI 10.1074/jbc.M202469200; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; Kraus RJ, 2001, VIROLOGY, V287, P89, DOI 10.1006/viro.2001.1024; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; KU DH, 1990, J BIOL CHEM, V265, P16060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Liu YC, 1997, J BIOL CHEM, V272, P10739; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Nakamura M, 2001, HYPERTENSION, V37, P419, DOI 10.1161/01.HYP.37.2.419; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; Norquay LD, 2001, BIOCHEM J, V354, P387, DOI 10.1042/0264-6021:3540387; Osada S, 1997, J BIOCHEM, V121, P355; Osada S, 1997, BIOCHEM BIOPH RES CO, V238, P744, DOI 10.1006/bbrc.1997.7382; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; *PROM, 1991, PROM PROT APPL GUID; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; SZABO P, 1995, J BIOL CHEM, V270, P10212, DOI 10.1074/jbc.270.17.10212; WEINMANN AM, 2000, METHODS, V26, P37; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; Zaid A, 1999, J BIOENERG BIOMEMBR, V31, P129, DOI 10.1023/A:1005499727732; Zaid A, 2001, EUR J BIOCHEM, V268, P5497, DOI 10.1046/j.0014-2956.2001.02453.x; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	71	32	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30624	30633		10.1074/jbc.M303530200	http://dx.doi.org/10.1074/jbc.M303530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777383	hybrid			2022-12-25	WOS:000184658800027
J	McMahan, RH; Watson, L; Meza-Romero, R; Burrows, GG; Bourdette, DN; Buenafe, AC				McMahan, RH; Watson, L; Meza-Romero, R; Burrows, GG; Bourdette, DN; Buenafe, AC			Production, characterization, and immunogenicity of a soluble rat single chain T cell receptor specific for an encephalitogenic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; V-BETA-GENES; ALPHA-BETA; IMMUNODOMINANT EPITOPE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TRANSGENIC MICE; IMMUNE-RESPONSE	The encephalitogenic rat T cell clone C14 recognizes the myelin basic protein 69-89 peptide in the context of the RT1B major histocompatibility complex (MHC) class II molecule. Modeling of the C14 TCR molecule indicated that previously identified CDR3 motifs are likely to be central to interaction with MHC class II-presented peptide. Here we report the cloning and expression of C14-derived single chain TCR (scTCR) molecules in an Escherichia coli expression system. The recombinant molecule consists of the Valpha2 domain connected to the Vbeta8.2 domain via a 15-residue linker. Soluble C14 scTCR was purified using conventional chromatography techniques and refolded by a rapid dilution procedure. C14 scTCR was able to bind soluble rat MHC class II molecules bearing covalently coupled Gp-BP-(69-89) peptide, as analyzed using surface plasmon resonance. Immune recognition of the C14 scTCR protein as an antigen revealed that limited regions of the TCR may be more likely to induce responsiveness.	Oregon Hlth & Sci Univ, Dept Neurol, Tykeson MS Res Lab, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Dept Neuroimmunol Res, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Buenafe, AC (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, Tykeson MS Res Lab, UHS-46,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035207, R01NS041965] Funding Source: NIH RePORTER; NINDS NIH HHS [NS041965, NS35207] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ALVORD EC, 1984, EXPT ALLERGIC ENCEPH, P523; Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; Buenafe AC, 1996, J NEUROSCI RES, V44, P562; BUENAFE AC, 1994, J IMMUNOL, V153, P386; Buenafe AC, 1997, J NEUROSCI RES, V47, P489, DOI 10.1002/(SICI)1097-4547(19970301)47:5<489::AID-JNR4>3.0.CO;2-D; BUENAFE AC, 1987, MOL IMMUNOL, V24, P401, DOI 10.1016/0161-5890(87)90013-7; Buenafe AC, 1997, J IMMUNOL, V158, P5472; BURNS FR, 1989, J EXP MED, V169, P27, DOI 10.1084/jem.169.1.27; Burrows GG, 2000, J IMMUNOL, V164, P6366, DOI 10.4049/jimmunol.164.12.6366; Burrows GG, 1999, PROTEIN ENG, V12, P771, DOI 10.1093/protein/12.9.771; CHLUBA J, 1989, EUR J IMMUNOL, V19, P279, DOI 10.1002/eji.1830190210; CHOU YK, 1989, J NEUROSCI RES, V22, P181, DOI 10.1002/jnr.490220211; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Degano M, 2000, IMMUNITY, V12, P251, DOI 10.1016/S1074-7613(00)80178-8; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gregoire C, 1996, EUR J IMMUNOL, V26, P2410, DOI 10.1002/eji.1830261022; Hare BJ, 1999, NAT STRUCT BIOL, V6, P574; He XL, 2002, IMMUNITY, V17, P83, DOI 10.1016/S1074-7613(02)00340-0; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; Jesson MI, 1998, INT IMMUNOL, V10, P27, DOI 10.1093/intimm/10.1.27; Khandekar SS, 1997, J BIOL CHEM, V272, P32190, DOI 10.1074/jbc.272.51.32190; KUCHROO VK, 1991, PATHOBIOLOGY, V59, P305, DOI 10.1159/000163668; KUMAR V, 1995, J IMMUNOL, V154, P1941; KUMAR V, 1993, J EXP MED, V178, P909, DOI 10.1084/jem.178.3.909; Kumar V, 1997, J IMMUNOL, V159, P5150; KURUCZ I, 1993, P NATL ACAD SCI USA, V90, P3830, DOI 10.1073/pnas.90.9.3830; LOHSE AW, 1992, SPRINGER SEMIN IMMUN, V14, P179; Offner H, 1998, J IMMUNOL, V161, P2178; OFFNER H, 1993, J IMMUNOL, V151, P506; Pecorari F, 1999, J MOL BIOL, V285, P1831, DOI 10.1006/jmbi.1998.2422; Plaksin D, 1997, J IMMUNOL, V158, P2218; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; ROSLONIEC EF, 1995, J IMMUNOL, V155, P4504; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; Zang YCQ, 2000, J IMMUNOL, V164, P4011, DOI 10.4049/jimmunol.164.8.4011; ZHANG JW, 1995, J IMMUNOL, V155, P5868	52	7	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30961	30970		10.1074/jbc.M300628200	http://dx.doi.org/10.1074/jbc.M300628200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773544	hybrid			2022-12-25	WOS:000184658800070
J	Punter, FA; Glerum, DM				Punter, FA; Glerum, DM			Mutagenesis reveals a specific role for Cox17p in copper transport to cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SHUTTLE VECTORS; C-OXIDASE; SACCHAROMYCES-CEREVISIAE; RESTRICTION SITES; YEAST; PROTEIN; GENES; SCO1P; PURIFICATION; METABOLISM	The provision of copper to cytochrome oxidase is one of the requisite steps in the assembly of the holoenzyme. Several proteins are involved in this process including Cox17p, Sco1p, and Cox11p. Cox17p, an 8-kDa protein, is the only molecule thought to be involved in shuttling copper from the cytoplasm into mitochondria. Given the small size of Cox17p, we have taken a random and site-directed mutagenesis approach to studying structure-function relationships in Cox17p. Mutations have been generated in 70% of the Cox17p amino acid residues, with only a small subset leading to a detectable respiration-deficient phenotype. We have characterized the respiration-deficient cox17 mutants and found in addition to the expected cytochrome oxidase deficiency, a specific lack of Cox2p and the presence of a misassembled cytochrome oxidase in a subset of mutants. These results suggest that Cox17p is involved upstream of Sco1p in delivering copper specifically to subunit 2 of cytochrome oxidase and predict the existence of a subunit 1-specific copper chaperone.	Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	University of Alberta	Glerum, DM (corresponding author), Univ Alberta, Dept Med Genet, 8-33 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Glerum, Moira/AHD-3271-2022					Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Dameron CT, 1998, AM J CLIN NUTR, V67, p1091S, DOI 10.1093/ajcn/67.5.1091S; Denning DP, 2002, J BIOL CHEM, V277, P33447, DOI 10.1074/jbc.M203499200; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Mochizuki M, 1999, J BIOL CHEM, V274, P33403, DOI 10.1074/jbc.274.47.33403; MYERS AM, 1987, J BIOL CHEM, V262, P3388; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schricker R, 2002, J BIOL CHEM, V277, P28757, DOI 10.1074/jbc.M201561200; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Xu H, 1999, BIOTECHNIQUES, V27, P1102, DOI 10.2144/99276bm02	27	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30875	30880		10.1074/jbc.M302358200	http://dx.doi.org/10.1074/jbc.M302358200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788943	hybrid			2022-12-25	WOS:000184658800059
J	Tomita, A; Buchholz, DR; Obata, K; Shi, YB				Tomita, A; Buchholz, DR; Obata, K; Shi, YB			Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PLZF-RAR-ALPHA; HISTONE DEACETYLASE COMPLEX; ACUTE MYELOID-LEUKEMIA; N-COR; NUCLEAR RECEPTORS; MOLECULAR PATHOGENESIS; PML; CHROMATIN; SMRT	Fusion proteins of retinoic acid receptor alpha (RARalpha) with promyelocytic leukemia protein (PML-RARalpha) or with promyelocytic leukemia zinc finger protein (PLZF-RARalpha) are associated with and likely responsible for the development of acute promyelocytic leukemia. These oncoproteins retain the ability to bind DNA and retinoic acid through the RARalpha moiety. This enables them to repress RARalpha target genes in the absence of retinoic acid, but the underlying mechanisms remain to be investigated. Here we use the frog oocyte system to study transcriptional regulation by PML-RARalpha and PLZF-RARalpha in the context of chromatin. We first show that the endogenous corepressor N-CoR forms a complex with TBLR1 (transducin beta-like protein 1-related protein) and that both N-CoR and TBLR1 can interact with unliganded PML-RARalpha and PLZF-RARalpha in vivo. Using chromatin immunoprecipitation, we demonstrate that both oncoproteins recruit TBLR1, as well as N-CoR, to its target promoter, leading to histone deacetylation and transcriptional repression. Furthermore, expression of a dominant negative N-CoR that contains the TBLR1-interacting domain blocks transcription repression by unliganded PML-RARalpha and PLZF-RARalpha. Thus, our studies provide in vivo evidence for targeted recruitment of N-CoR-TBLR1 complexes by PML-RARalpha and PLZF-RARalpha in transcriptional repression in the context of chromatin.	NICHD, Unit Mol Morphogenesis, LGRD, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shi, YB (corresponding author), NICHD, Unit Mol Morphogenesis, LGRD, NIH, Bldg 18 T,Rm 106, Bethesda, MD 20892 USA.		Obata, Keiko/E-2019-2012	Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Duprez E, 1999, J CELL SCI, V112, P381; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glass CK, 2000, GENE DEV, V14, P121; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2000, GENE DEV, V14, P1048; Guidez F, 2000, BLOOD, V96, P2557; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hsia SCV, 2001, CELL RES, V11, P8, DOI 10.1038/sj.cr.7290061; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jepsen K, 2002, J CELL SCI, V115, P689; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; Jones PL, 2001, J BIOL CHEM, V276, P8807, DOI 10.1074/jbc.C000879200; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laudet V., 2002, NUCL RECEPTOR FACTS; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Minucci S, 1998, MOL ENDOCRINOL, V12, P315, DOI 10.1210/me.12.3.315; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sachs LM, 2002, MOL CELL BIOL, V22, P8527, DOI 10.1128/MCB.22.24.8527-8538.2002; Shi YB, 2001, CELL RES, V11, P245, DOI 10.1038/sj.cr.7290093; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; WARRELL RPJ, 1993, NEW ENGL J MED, V324, P177; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	58	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30788	30795		10.1074/jbc.M303309200	http://dx.doi.org/10.1074/jbc.M303309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12794076	hybrid			2022-12-25	WOS:000184658800047
J	Belmokhtar, CA; Hillion, J; Dudognon, C; Fiorentino, S; Flexor, M; Lanotte, M; Segal-Bendirdjian, E				Belmokhtar, CA; Hillion, J; Dudognon, C; Fiorentino, S; Flexor, M; Lanotte, M; Segal-Bendirdjian, E			Apoptosome-independent pathway for apoptosis - Biochemical analysis of APAF-1 defects and biological outcomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; STRESS-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; WD-40 REPEAT REGION; BCL-X-L; CASPASE ACTIVATION; GRANZYME-B; MITOCHONDRIAL CONTROL; PROCASPASE-9 ACTIVATION; OVARIAN-CANCER	Induction and execution of apoptosis programs are generally believed to be mediated through a hierarchy of caspase activation. By using two cellular variants obtained from the L1210 cell line (L1210/S and L1210/0), we have shown previously that staurosporine induces apoptotic cell death through both caspase-dependent and caspase-independent pathways. Both pathways normally coexisted in L1210/S cells, whereas L1210/0 cells lacked the ability to activate caspases despite the confirmed presence of both procaspase-3 and -9. Here we show that this defect in caspase activation is not due to mechanisms such as an absence of cytochrome c release, the expression of non-functional caspases, or the presence of an endogenous inhibitor but results from the loss of apoptosis protease activator protein-1 (APAF-1) expression. This absence of APAF-1 protein results from multiple alterations at both genomic and transcriptional levels. However, although this lack of APAF-1 delays the apoptotic program, it does not hamper its execution. Importantly, in these cells, apoptosis develops not only in an APAF-1-independent way but also in the absence of caspase-3 and -9 activation. Altogether these findings provide evidence that apoptosis may occur through alternative signaling pathways independent of APAF-1 expression and totally dissociated from any caspase processing. Therefore, the L1210/0 variant subline provides a valuable tool for the elucidation of these pathways.	Hop St Louis, Ctr G Hayem, INSERM, U496, F-75010 Paris, France; Hop St Louis, Ctr G Hayem, INSERM, U462, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Segal-Bendirdjian, E (corresponding author), Hop St Louis, Ctr G Hayem, INSERM, U496, 1 Ave Claude Vellefaux, F-75010 Paris, France.		fiorentino, susana/R-8700-2016	fiorentino, susana/0000-0002-4664-0682; Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BURCHENAL JH, 1977, CANCER RES, V37, P4098; CAPECCHI MR, 1974, P NATL ACAD SCI USA, V71, P4732, DOI 10.1073/pnas.71.12.4732; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deas O, 1998, J IMMUNOL, V161, P3375; EASTMAN A, 1981, BIOCHEM PHARMACOL, V30, P2721, DOI 10.1016/0006-2952(81)90546-3; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fu WN, 2003, ONCOGENE, V22, P451, DOI 10.1038/sj.onc.1206147; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Heibein JA, 1999, J IMMUNOL, V163, P4683; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu JR, 2002, CANCER RES, V62, P924; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Sambrook J., 2002, MOL CLONING LAB MANU; SEGALBENDIRDJIAN E, 1995, EXP CELL RES, V218, P201, DOI 10.1006/excr.1995.1148; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; VandeCraen M, 1997, EUR J IMMUNOL, V27, P1296, DOI 10.1002/eji.1830270535; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	68	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29571	29580		10.1074/jbc.M302924200	http://dx.doi.org/10.1074/jbc.M302924200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773531	hybrid			2022-12-25	WOS:000184507000024
J	Butt, AJ; Dickson, KA; McDougall, F; Baxter, RC				Butt, AJ; Dickson, KA; McDougall, F; Baxter, RC			Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIPROLIFERATIVE ACTION; INDUCED APOPTOSIS; SURFACE BINDING; MAMMARY-GLAND; EXPRESSION; IGFBP-5; RECEPTOR; DEATH; P53; MITOGENESIS	The role of insulin-like growth factor-binding protein (IGFBP)-5 in human breast cancer cell growth is unclear. We determined the effects of IGFBP-5 expression on the growth of human breast cancer cell lines in vivo and in vitro. Expression of IGFBP-5, both by stable transfection and adenoviral-mediated infection, was inhibitory to the growth of MDA-MB-231 and Hs578T human breast cancer cells over a 13-day period. IGFBP-5 expression resulted in a G(2)/M cell cycle arrest and the induction of apoptosis in both cell lines, an effect that was abrogated in the presence of the broad-spectrum caspase inhibitor, z-VAD-fmk. IGFBP-5-induced apoptosis was associated with a transcriptional increase in expression of the proapoptotic regulator bax and decrease in the anti-apoptotic bcl-2 compared with vector controls. Secreted IGFBP-5 when added exogenously to breast cancer cells was not internalized and had no effect on cell growth or apoptosis, suggesting that IGFBP-5 may elicit its inhibitory effects via a novel, intracrine mechanism. In athymic nude mice, stable expression of IGFBP-5 significantly inhibited both the formation and growth of tumors derived from MDA-MB-231 cells. IGFBP-5-expressing tumors also had a significantly elevated level of bax mRNA and decreased levels of bcl-2 mRNA compared with vector tumors. These data suggest that IGFBP-5 is a potent growth inhibitor and proapoptotic agent in human breast cancer cells via modulation of cell cycle regulation and apoptotic mediators.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Butt, AJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	abutt@med.usyd.edu.au	Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Butt, Alison/0000-0002-6216-5105; McDougall, Fiona/0000-0001-8669-9702				Allan GJ, 2000, ANAT EMBRYOL, V202, P1, DOI 10.1007/PL00008239; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; Baxter RC, 2002, J CLIN ENDOCR METAB, V87, P271, DOI 10.1210/jc.87.1.271; BEILHARZ EJ, 1993, MOL BRAIN RES, V18, P209, DOI 10.1016/0169-328X(93)90191-Q; Besnard N, 1996, BIOL REPROD, V55, P1356, DOI 10.1095/biolreprod55.6.1356; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Chan TW, 2001, CLIN CANCER RES, V7, P2545; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; Delhanty PJD, 1998, ENDOCRINOLOGY, V139, P260, DOI 10.1210/en.139.1.260; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; FIGUEROA JA, 1992, BREAST CANCER RES TR, V22, P81, DOI 10.1007/BF01833336; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Firth SM, 1999, PROTEIN EXPRES PURIF, V16, P202, DOI 10.1006/prep.1999.1075; Firth SM, 2001, ENDOCRINOLOGY, V142, P2147, DOI 10.1210/en.142.5.2147; Higo H, 1997, BIOCHEM BIOPH RES CO, V239, P706, DOI 10.1006/bbrc.1997.7499; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Miyake H, 2000, CANCER RES, V60, P3058; Monget P, 1998, J CELL PHYSIOL, V177, P13, DOI 10.1002/(SICI)1097-4652(199810)177:1<13::AID-JCP2>3.0.CO;2-H; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; OH YM, 1993, J BIOL CHEM, V268, P14964; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Perks CM, 1999, J CELL BIOCHEM, V75, P652, DOI 10.1002/(SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0; Perks CM, 2000, J CELL BIOCHEM, V80, P248; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Roschier M, 2001, J NEUROCHEM, V76, P11, DOI 10.1046/j.1471-4159.2001.00002.x; Rozen F, 1999, INT J ONCOL, V15, P589; Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; YEE D, 1994, J NATL CANCER I, V86, P1785, DOI 10.1093/jnci/86.23.1785	44	115	120	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29676	29685		10.1074/jbc.M301965200	http://dx.doi.org/10.1074/jbc.M301965200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777377	hybrid			2022-12-25	WOS:000184507000038
J	Rachow, A; Gauss-Muller, V; Probst, C				Rachow, A; Gauss-Muller, V; Probst, C			Homogenous hepatitis A virus particles - Proteolytic release of the assembly signal 2A from procapsids by factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CAPSID PROTEIN VP1; CHICK-EMBRYO; STRUCTURAL PROTEINS; MENGO-VIRUS; CLEAVAGE; IDENTIFICATION; POLYPROTEIN; MATURATION; CELLS	Among the picornaviridae, hepatitis A virus (HAV) is unique in that its assembly is driven by domain 2A of P1-2A, the precursor of the structural proteins (Probst, C., Jecht, M., and Gauss-Muller, V. (1999) J. Biol. Chem. 274, 4527-4531). Whereas infected individuals excrete in stool mature HAV capsids with VP1 as the major structural protein, its C-terminal extended form VP1-2A is the main component of immature procapsids produced in HAV-infected cells in culture. Obviously, a postassembly proteolytic step is required to remove the primary assembly signal 2A from VP1-2A of procapsids. Mutants of VP1-2A were expressed in COS7 cells to determine the cleavage site in VP1-2A and to test for the cleavage potential of viral and host proteinases (factor Xa and thrombin). Site-specific in vitro cleavage by factor Xa and thrombin occurred in procapsids that contained VP1-2A with engineered cognate cleavage sites for these proteinases. Interestingly, factor Xa but not thrombin liberated mature VP1 also from native procapsids in an assembly-dependent manner. The data show that domain 2A, which is required for pentamerization of its precursor polypeptides and thus for the primary step of HAV assembly, is removed from the surface of immature procapsid by a host proteinase. Moreover, our data open a novel avenue to produce homogenous HAV particles from recombinant intermediates by in vitro treatment with exogenously added proteases such as factor Xa or thrombin.	Univ Luebeck, Inst Med Mol Biol, D-23538 Lubeck, Germany; November AG, D-91056 Erlangen, Germany	University of Lubeck	Gauss-Muller, V (corresponding author), Univ Luebeck, Inst Med Mol Biol, D-23538 Lubeck, Germany.							Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; ANDERSON DA, 1990, J VIROL, V64, P5284, DOI 10.1128/JVI.64.11.5284-5289.1990; Beneduce F, 2002, ANTIVIR RES, V55, P369, DOI 10.1016/S0166-3542(02)00073-6; BISHOP NE, 1993, VIROLOGY, V197, P616, DOI 10.1006/viro.1993.1636; BOEGE U, 1989, VIROLOGY, V168, P409, DOI 10.1016/0042-6822(89)90284-5; BOROVEC SV, 1993, J VIROL, V67, P3095, DOI 10.1128/JVI.67.6.3095-3102.1993; Cohen L, 2002, J VIROL, V76, P7495, DOI 10.1128/JVI.76.15.7495-7505.2002; DOTZAUER A, 1995, VIROLOGY, V213, P671; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUSSMULLER V, 1986, VIROLOGY, V155, P732, DOI 10.1016/0042-6822(86)90234-5; Gentile F, 2002, J BIOL CHEM, V277, P44050, DOI 10.1074/jbc.M206761200; Gosert R, 1996, J GEN VIROL, V77, P247, DOI 10.1099/0022-1317-77-2-247; GOTOH B, 1990, EMBO J, V9, P4189, DOI 10.1002/j.1460-2075.1990.tb07643.x; Graff J, 1999, J VIROL, V73, P6015, DOI 10.1128/JVI.73.7.6015-6023.1999; HARMON SA, 1995, J VIROL, V69, P5576, DOI 10.1128/JVI.69.9.5576-5581.1995; Jecht M, 1998, VIROLOGY, V252, P218, DOI 10.1006/viro.1998.9451; JIA XY, 1993, VIROLOGY, V193, P515, DOI 10.1006/viro.1993.1157; KRISHNASWAMY S, 1990, J MOL BIOL, V211, P803, DOI 10.1016/0022-2836(90)90077-Y; Kusov Y, 1999, J VIROL, V73, P9867, DOI 10.1128/JVI.73.12.9867-9878.1999; KUSOV YY, 1992, J VIROL, V66, P6794, DOI 10.1128/JVI.66.11.6794-6796.1992; KUSOV YY, 1992, J MED VIROL, V37, P220, DOI 10.1002/jmv.1890370313; LEE WM, 1993, J VIROL, V67, P2110, DOI 10.1128/JVI.67.4.2110-2122.1993; Martin A, 1999, J VIROL, V73, P6220, DOI 10.1128/JVI.73.8.6220-6227.1999; MARTIN A, 1995, VIROLOGY, V213, P213, DOI 10.1006/viro.1995.1561; OGASAWARA T, 1992, EMBO J, V11, P467, DOI 10.1002/j.1460-2075.1992.tb05076.x; Probst C, 1999, J BIOL CHEM, V274, P4527, DOI 10.1074/jbc.274.8.4527; Probst C, 1998, J VIROL, V72, P8013, DOI 10.1128/JVI.72.10.8013-8020.1998; Probst C, 1997, J VIROL, V71, P3288, DOI 10.1128/JVI.71.4.3288-3292.1997; SCHULTHEISS T, 1994, VIROLOGY, V198, P275, DOI 10.1006/viro.1994.1030; SCHULTHEISS T, 1995, J VIROL, V69, P1727, DOI 10.1128/JVI.69.3.1727-1733.1995; Smyth MS, 2000, ARCH VIROL, V145, P1473, DOI 10.1007/s007050070104; SUZUKI H, 1991, FEBS LETT, V283, P281, DOI 10.1016/0014-5793(91)80608-6; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03	33	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29744	29751		10.1074/jbc.M300454200	http://dx.doi.org/10.1074/jbc.M300454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12782637	hybrid, Green Submitted			2022-12-25	WOS:000184507000045
J	Suzuki, M; Ueno, N; Kuroiwa, A				Suzuki, M; Ueno, N; Kuroiwa, A			Hox proteins functionally cooperate with the GC box-binding protein system through distinct domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOOT-GENITAL SYNDROME; LOCUS-CONTROL REGION; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HOMEODOMAIN PROTEINS; HOMEOTIC TRANSFORMATION; GENE-EXPRESSION; CPG ISLAND; SP1; HOMEOBOX	Hox genes encode a transcriptional factor that plays a key role in regulating position-specific cartilage pattern formation. We found that Hoxa-13 and Hoxd-13, which are members of the Abd-B subfamily of Hox genes and are crucial for the autopod development of the limb, stimulate transcription from the Bmp-4 promoter. This stimulation was dependent on the GC box within the promoter and independent of the putative Hox protein binding site. The stimulation by HoxA-13 was remarkably enhanced by cotransfection with members of a family of zinc finger GC box binding transcriptional factors including Sp1. The stimulation was suppressed by another Abd-B Hox protein, HoxA-11, indicating that each Abd-B Hox protein has a different effect on the target genes through the Sp1 system. We have identified multiple functional domains involved in transcriptional regulation, including three independent transcriptional activation domains (ADs) in HoxA-13. AD1 and AD3 in helices 1 and 2 of the homeodomain individually cooperate with Sp1-dependent stimulation. The homeodomain is also required for cooperation of the AD with Sp1. By contrast, AD2 strongly activates transcription in an Sp1-independent manner only when the homeodomain has been removed. These observations indicate that HoxA-13 regulates transcription through multiple pathways. In addition, we found that a helix 3 mutation of the HoxA-13 homeodomain behaves as a dominant negative form.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Natl Inst Basic Biol, Dept Dev Biol, Okazaki, Aichi 4448585, Japan	Nagoya University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Kuroiwa, A (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.			Ueno, Naoto/0000-0002-8375-2317; Kuroiwa, Atsushi/0000-0001-7710-4041				Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHARIOT A, 1995, BIOCHEM BIOPH RES CO, V215, P713, DOI 10.1006/bbrc.1995.2522; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; Florence B, 1998, GENETICS, V150, P1497; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Goodman FR, 2000, AM J HUM GENET, V67, P197, DOI 10.1086/302961; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; Komuves LG, 2000, DEV DYNAM, V218, P636; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KURIHARA T, 1993, BIOCHEM BIOPH RES CO, V192, P1049, DOI 10.1006/bbrc.1993.1523; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Murakami M, 1997, GENE, V202, P23, DOI 10.1016/S0378-1119(97)00468-X; MURPHY SP, 1988, P NATL ACAD SCI USA, V85, P5587, DOI 10.1073/pnas.85.15.5587; Nelson CE, 1996, DEVELOPMENT, V122, P1449; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; Ronshaugen M, 2002, NATURE, V415, P914, DOI 10.1038/nature716; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Shetty S, 1999, BIOCHEM J, V339, P751, DOI 10.1042/0264-6021:3390751; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yamamoto M, 1998, DEVELOPMENT, V125, P1325; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0; Zakany J, 1997, P NATL ACAD SCI USA, V94, P13695, DOI 10.1073/pnas.94.25.13695; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	58	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30148	30156		10.1074/jbc.M303932200	http://dx.doi.org/10.1074/jbc.M303932200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771139	hybrid			2022-12-25	WOS:000184507000093
J	Tokuraku, K; Matsushima, K; Matui, T; Nakagawa, H; Katsuki, M; Majima, R; Kotani, S				Tokuraku, K; Matsushima, K; Matui, T; Nakagawa, H; Katsuki, M; Majima, R; Kotani, S			The number of repeat sequences in microtubule-associated protein 4 affects the microtubule surface properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL DIFFERENCES; BINDING DOMAINS; TAU ISOFORMS; REGION; EXPRESSION; MOUSE; MAP-2; SITE; IDENTIFICATION; DIGESTION	The microtubule-binding domain of MAP4, a ubiquitous microtubule-associated protein, contains a Repeat region with tandemly organized repeat sequences. In this study, we focused on the variations of the Repeat region, and searched for MAP4 isoforms with diverse Repeat region organizations. We successfully isolated four types of MAP4 cDNAs, which differed from each other in both the number and the arrangement of the repeat sequences, from a single source (bovine adrenal gland). To examine the functional differences among the isoforms, we prepared the microtubule-binding domain polypeptides of three of the four isoforms, and examined their activities. The isoform fragments showed similar degrees of microtubule assembly promoting activity and microtubule binding affinity. This result suggested that the Repeat region variation is not important for the control of microtubule dynamics, which is believed to be the main function of MAPs. On the other hand, the microtubule bundle-forming activity differed among the isoform fragments. The bundle formation was augmented by increasing the number of repeat sequences in the fragments. Based on these results, we propose the hypothesis that the role of the MAP4 isoforms is to regulate the surface charge of microtubules.	Miyakonojo Natl Coll Technol, Dept Sci & Chem Engn, 473-1 Yoshio Cho, Miyazaki 8858567, Japan; Kyushu Inst Technol, Dept Biochem Engn & Sci, Fac Comp Sci & Syst Engn, Fukuoka 8208502, Japan; RIKEN, Brain Sci Inst, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Kyushu Institute of Technology; RIKEN	Tokuraku, K (corresponding author), Miyakonojo Natl Coll Technol, Dept Sci & Chem Engn, 473-1 Yoshio Cho, Miyazaki 8858567, Japan.	tokuraku@miyakonojo-nct.ac.jp	Tokuraku, Kiyotaka/D-4542-2014	Tokuraku, Kiyotaka/0000-0002-7747-4808				AIZAWA H, 1988, J BIOL CHEM, V263, P7703; AIZAWA H, 1991, J BIOL CHEM, V266, P9841; AIZAWA H, 1990, J BIOL CHEM, V265, P13849; AIZAWA H, 1987, J BIOL CHEM, V262, P3782; AIZAWA H, 1989, J BIOL CHEM, V264, P5885; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; CHAPIN SJ, 1991, J CELL SCI, V98, P27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; DORSEY TE, 1977, ANAL BIOCHEM, V78, P156, DOI 10.1016/0003-2697(77)90019-7; DRUBIN DG, 1984, J CELL BIOL, V98, P1090, DOI 10.1083/jcb.98.3.1090; Dustin P., 1984, MICROTUBULES; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; Iida J, 2002, J MOL BIOL, V320, P97, DOI 10.1016/S0022-2836(02)00402-3; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KALCHEVA N, 1995, P NATL ACAD SCI USA, V92, P10894, DOI 10.1073/pnas.92.24.10894; Katsuki M, 1997, FEBS LETT, V418, P35, DOI 10.1016/S0014-5793(97)01342-2; Katsuki M, 2000, EUR J BIOCHEM, V267, P7193, DOI 10.1046/j.1432-1327.2000.01822.x; KINDLER S, 1990, J BIOL CHEM, V265, P19679; KOTANI S, 1986, EUR J BIOCHEM, V156, P23, DOI 10.1111/j.1432-1033.1986.tb09543.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; TERASAKI AG, 1995, J CELL SCI, V108, P857; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Tokuraku K, 1999, EUR J BIOCHEM, V259, P158, DOI 10.1046/j.1432-1327.1999.00019.x; Tokuraku K, 1999, EUR J BIOCHEM, V264, P996, DOI 10.1046/j.1432-1327.1999.00710.x; TOKURAKU K, 2002, RRD BIOCHEM 1, V3, P315; Utton MA, 2001, J BIOL CHEM, V276, P34288, DOI 10.1074/jbc.M011384200; VALLEE RB, 1977, J BIOL CHEM, V252, P377; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEST RR, 1991, J BIOL CHEM, V266, P21886; WICHE G, 1991, INT REV CYTOL, V124, P217; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	45	23	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29609	29618		10.1074/jbc.M302186200	http://dx.doi.org/10.1074/jbc.M302186200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773533	hybrid			2022-12-25	WOS:000184507000029
J	Naylor, MJ; Ginsburg, E; Iismaa, TP; Vonderhaar, BK; Wynick, D; Ormandy, CJ				Naylor, MJ; Ginsburg, E; Iismaa, TP; Vonderhaar, BK; Wynick, D; Ormandy, CJ			The neuropeptide galanin augments lobuloalveolar development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND DEVELOPMENT; GROWTH-HORMONE; PROGESTERONE-RECEPTOR; MOLECULAR-CLONING; TRANSGENIC MICE; BREAST-CANCER; WISTAR RATS; PROLACTIN; GENE; MOUSE	Mammary lobuloalveolar development during pregnancy is controlled by ovarian sex steroids and pituitary prolactin release. In organ culture these hormones are incapable of reproducing the density and size of lobuloalveoli seen in mice, suggesting the existence of other undiscovered factors. We showed previously that galanin knockout mice fail to lactate sufficiently for pup survival following their first pregnancy. Here we demonstrate that prolactin treatment of galanin knockout mice allows pup survival but does not completely rescue lobuloalveolar development or reduced milk protein expression. When galanin was used in combination with prolactin in mammary organ culture, larger and more numerous lobules were produced than with prolactin alone. Galanin alone produced sustained activation of STAT5a and the induction of milk protein expression but did not induce lobulogenesis. Examination of the transcriptional interaction between galanin and prolactin using oligonucleotide microarrays demonstrated synergistic and antagonistic modes of interaction between these hormones. These data establish a new role for galanin as a hormone augmenting mammary development during pregnancy in concert with prolactin.	St Vincents Hosp, Garvan Inst Med Res, Dev Grp, Canc Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Neurobiol Program, Sydney, NSW 2010, Australia; NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Bristol, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Bristol	Ormandy, CJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Dev Grp, Canc Res Program, Sydney, NSW 2010, Australia.		Ormandy, Chris/G-4165-2014	Ormandy, Christopher/0000-0002-2504-7919	NATIONAL CANCER INSTITUTE [ZIABC008226, Z01BC008226] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Cai A, 1999, ENDOCRINOLOGY, V140, P4955, DOI 10.1210/en.140.11.4955; Chen TJ, 1998, ENDOCRINOLOGY, V139, P609, DOI 10.1210/en.139.2.609; Cunha GR, 1997, J MAMMARY GLAND BIOL, V2, P393, DOI 10.1023/A:1026303630843; El-Salhy M, 2002, REGUL PEPTIDES, V108, P55, DOI 10.1016/S0167-0115(02)00106-4; Gallego MI, 2001, DEV BIOL, V229, P163, DOI 10.1006/dbio.2000.9961; Ginsburg E., 2000, METHODS MAMMARY GLAN, P147; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Hadsell DL, 2000, J MAMMARY GLAND BIOL, V5, P19, DOI 10.1023/A:1009559014703; Hadsell DL, 2002, J DAIRY SCI, V85, P365, DOI 10.3168/jds.S0022-0302(02)74083-6; HANDWERGER S, 1991, ENDOCR REV, V12, P329, DOI 10.1210/edrv-12-4-329; Holmes FE, 2000, P NATL ACAD SCI USA, V97, P11563, DOI 10.1073/pnas.210221897; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; IISHI H, 1995, INT J CANCER, V61, P861, DOI 10.1002/ijc.2910610619; IISHI H, 1994, CANCER RES, V54, P3167; Iishi H, 1998, INT J CANCER, V75, P396, DOI 10.1002/(SICI)1097-0215(19980130)75:3<396::AID-IJC12>3.0.CO;2-7; Iismaa T P, 1999, Results Probl Cell Differ, V26, P257; Kerr BJ, 2000, EUR J NEUROSCI, V12, P793, DOI 10.1046/j.1460-9568.2000.00967.x; Kokaia M, 2001, P NATL ACAD SCI USA, V98, P14006, DOI 10.1073/pnas.231496298; Mazarati AM, 2000, J NEUROSCI, V20, P6276, DOI 10.1523/JNEUROSCI.20-16-06276.2000; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Muller WJ, 2001, J MAMMARY GLAND BIOL, V6, P1, DOI 10.1023/A:1009540813521; MURAKAMI Y, 1989, ENDOCRINOLOGY, V124, P1224, DOI 10.1210/endo-124-3-1224; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; O'Meara G, 2000, P NATL ACAD SCI USA, V97, P11569, DOI 10.1073/pnas.210254597; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Ormandy CJ, 1998, CANCER RES, V58, P1353; OTTLECZ A, 1988, P NATL ACAD SCI USA, V85, P9861, DOI 10.1073/pnas.85.24.9861; PLAUT K, 1993, ENDOCRINOLOGY, V133, P1843, DOI 10.1210/en.133.4.1843; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; Tonner E, 2002, DEVELOPMENT, V129, P4547; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; VRONTAKIS ME, 1992, ENDOCRINOLOGY, V130, P458, DOI 10.1210/en.130.1.458; Wang SK, 1997, J BIOL CHEM, V272, P31949, DOI 10.1074/jbc.272.51.31949; Wynick D, 1998, P NATL ACAD SCI USA, V95, P12671, DOI 10.1073/pnas.95.21.12671	41	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29145	29152		10.1074/jbc.M303746200	http://dx.doi.org/10.1074/jbc.M303746200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759342	hybrid			2022-12-25	WOS:000184421100099
J	del Alamo, M; Neira, JL; Mateu, MG				del Alamo, M; Neira, JL; Mateu, MG			Thermodynamic dissection of a low affinity protein- protein interface involved in human immunodeficiency virus assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 CAPSID PROTEIN; CONFORMATIONAL STABILITY; DIMERIZATION DOMAIN; MUTATIONAL ANALYSIS; FUNCTIONAL EPITOPE; CRYSTAL-STRUCTURE; DIMER INTERFACE; TERMINAL DOMAIN; BINDING-SITE; EARLY STEPS	Homo-dimerization of the capsid protein CA of human immunodeficiency virus through its C-terminal domain constitutes an early crucial step in the virion assembly pathway and a potential target for antiviral inhibitors. We have truncated to alanine the 20 amino acid side chains per monomer that participate in intersubunit contacts at the CA dimer interface and analyzed their individual energetic contribution to protein association and stability. About half of the side chains in the contact epitope are critically involved in the energetic epitope as their truncation essentially prevented dimerization. However, dimerization affinity is kept low partly because of the presence of interfacial side chains whose individual truncation improves affinity by 2-20-fold. Many side chains at the interface are energetically important also for the folding of a monomeric intermediate and for its conformational rearrangement during dimerization. The thermodynamic description of this low affinity interface (dissociation constant of similar to10 muM) was compared with those obtained for the other protein-protein interfaces, nearly all of them of much higher affinity, that have been systematically analyzed by mutation. The results reveal differences that may have been evolutionary selected and that may be exploited for the design of an effective interfacial inhibitor of human immunodeficiency virus assembly.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Miguel Hernandez, Ctr Biol Mol & Celular, Alicante 03206, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Universidad Miguel Hernandez de Elche	Mateu, MG (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Mateu, Mauricio/ABF-2146-2021; Neira, Jose/ABF-4210-2021	Mateu, Mauricio/0000-0002-2915-1529; Neira, Jose Luis/0000-0002-4933-0428; del Alamo, Marta/0000-0002-8254-9990				BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016; Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Borsetti A, 1998, J VIROL, V72, P9313, DOI 10.1128/JVI.72.11.9313-9317.1998; Cartier C, 1999, J BIOL CHEM, V274, P19434, DOI 10.1074/jbc.274.27.19434; Castro MJM, 1996, BIOCHEMISTRY-US, V35, P11435, DOI 10.1021/bi960515w; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P7981, DOI 10.1021/bi980148j; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P9266, DOI 10.1021/bi980270i; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Darling PJ, 2000, BIOCHEMISTRY-US, V39, P11500, DOI 10.1021/bi000935s; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Jin ZM, 1999, J MOL BIOL, V286, P83, DOI 10.1006/jmbi.1998.2443; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Khorasanizadeh S, 1999, J MOL BIOL, V291, P491, DOI 10.1006/jmbi.1999.2986; Kingston RL, 2000, STRUCTURE, V8, P617, DOI 10.1016/S0969-2126(00)00148-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lanman J, 2003, J MOL BIOL, V325, P759, DOI 10.1016/S0022-2836(02)01245-7; Lanman J, 2002, J VIROL, V76, P6900, DOI 10.1128/JVI.76.14.6900-6908.2002; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; Li S, 2000, NATURE, V407, P409, DOI 10.1038/35030177; Mateu MG, 2002, J MOL BIOL, V318, P519, DOI 10.1016/S0022-2836(02)00091-8; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P5145, DOI 10.1021/bi00070a025; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; Valdes R Jr, 1979, Methods Enzymol, V61, P125; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WANG CT, 1993, J VIROL, V67, P4264, DOI 10.1128/JVI.67.7.4264-4273.1993; Worthylake DK, 1999, ACTA CRYSTALLOGR D, V55, P85, DOI 10.1107/S0907444998007689; Wrobel JA, 2000, AIDS RES HUM RETROV, V16, P2049, DOI 10.1089/088922200750054783; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	50	59	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27923	27929		10.1074/jbc.M304466200	http://dx.doi.org/10.1074/jbc.M304466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12761222	hybrid			2022-12-25	WOS:000184242700075
J	Conticello, SG; Kowalsman, ND; Jacobsen, C; Yudkovsky, G; Sato, K; Elazar, Z; Petersen, CM; Aronheim, A; Fainzilber, M				Conticello, SG; Kowalsman, ND; Jacobsen, C; Yudkovsky, G; Sato, K; Elazar, Z; Petersen, CM; Aronheim, A; Fainzilber, M			The prodomain of a secreted hydrophobic mini-protein facilitates its export from the endoplasmic reticulum by hitchhiking on sorting receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; QUALITY-CONTROL; CONOTOXIN; VESICLES; TRANSPORT; MEMBRANE; BINDING; BRAIN; EXIT	Misfolded secretory proteins are retained in the endoplasmic reticulum ( ER) by quality control mechanisms targeted to exposed hydrophobic surfaces. Paradoxically, certain conotoxins expose extensive hydrophobic surfaces upon folding to their bioactive structures. How then can such secreted mini-proteins traverse the secretory pathway? Here we show that secretion of the hydrophobic conotoxin-TxVI is strongly dependent on its propeptide domain, which enhances TxVI export from the ER. The propeptide domain interacts with sorting receptors from the sortilin Vps10p domain family. The sortilin-TxVI interaction occurs in the ER, and sortilin facilitates export of TxVI from the ER to the Golgi. Thus, the prodomain in a secreted hydrophobic protein acts as a tag that can facilitate its ER export by a hitchhiking mechanism.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus, Denmark; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Mol Genet, IL-31096 Haifa, Israel; Fukuoka Womens Univ, Higashi Ku, Fukuoka 8138529, Japan	Weizmann Institute of Science; Aarhus University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Fainzilber, M (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Conticello, Silvestro/G-9113-2011	Conticello, Silvestro/0000-0002-4244-1846; Fainzilber, Mike/0000-0001-8173-8557; Aronheim, Ami/0000-0002-8575-4092				Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; Hampe W, 1999, DEVELOPMENT, V126, P4077; Heurgue-Hamard V, 2000, EMBO J, V19, P2701, DOI 10.1093/emboj/19.11.2701; Jacobsen L, 2001, J BIOL CHEM, V276, P22788, DOI 10.1074/jbc.M100857200; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P14761, DOI 10.1021/bi001506x; Kohno T, 2002, J BIOL CHEM, V277, P36387, DOI 10.1074/jbc.M206833200; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; PriceCarter M, 1996, BIOCHEMISTRY-US, V35, P15547, DOI 10.1021/bi9615755; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; ROTHMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P780, DOI 10.1073/pnas.77.2.780; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x	20	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26311	26314		10.1074/jbc.C300141200	http://dx.doi.org/10.1074/jbc.C300141200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12771154	hybrid			2022-12-25	WOS:000184155700003
J	Schraets, D; Lehmann, T; Dingermann, T; Marschalek, R				Schraets, D; Lehmann, T; Dingermann, T; Marschalek, R			MLL-mediated transcriptional gene regulation investigated by gene expression profiling	ONCOGENE			English	Article						MLL; expression profiling; development; differential gene expression	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTO-ONCOPROTEIN MLL; GROWTH-FACTOR-BETA; CELL-LINE; TRANSMEMBRANE-4 SUPERFAMILY; MOUSE EMBRYO; CDNA CLONING; ALL1 GENE; IN-VITRO; BINDING	The human mixed lineage leukemia (MLL) gene is involved in about 50 different chromosomal translocations, associated with the disease phenotype of acute leukemia. However, the normal function of MLL is less understood. Homozygous knockouts of murine Mll were embryonal lethal, while heterozygous disruption led to aberrant hox gene expression associated with skeletal malformations, growth retardation, and impaired hematopoiesis. To understand MLL functions on the molecular level, gene expression profiling experiments were performed with a pair of murine cell lines (MLL+/+ and MLL-/-). Microarray hybridization experiments revealed 197 potential target genes that are differentially expressed, providing new and important clues about MLL functions.	Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, Marie Curie Str 9, D-60439 Frankfurt, Germany.		Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Alward WLM, 2000, AM J OPHTHALMOL, V130, P107, DOI 10.1016/S0002-9394(00)00525-0; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Attardi LD, 2000, GENE DEV, V14, P704; Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Cavodeassi F, 2001, DEVELOPMENT, V128, P2847; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Cimino G, 1998, HAEMATOLOGICA, V83, P350; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gopalakrishnan R, 2001, ENDOCRINOLOGY, V142, P4379, DOI 10.1210/en.142.10.4379; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Hanashima C, 2002, J NEUROSCI, V22, P6526; Henkel GW, 2002, INT IMMUNOL, V14, P723, DOI 10.1093/intimm/dxf040; Hosokawa Y, 1999, NEUROSCI RES, V35, P281, DOI 10.1016/S0168-0102(99)00093-0; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Iida K, 1997, DEVELOPMENT, V124, P4627; Irikura VM, 2002, J IMMUNOL, V169, P393, DOI 10.4049/jimmunol.169.1.393; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Lee KKH, 2001, DEV BIOL, V234, P188, DOI 10.1006/dbio.2001.0249; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lochner K, 1996, CANCER RES, V56, P2171; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Meins M, 2001, J NEUROSCI, V21, P8830, DOI 10.1523/JNEUROSCI.21-22-08830.2001; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Pasqualetti M, 2001, NAT GENET, V29, P34, DOI 10.1038/ng702; PERRIS R, 1993, DEV DYNAM, V198, P135, DOI 10.1002/aja.1001980207; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Spandorfer SD, 2000, AM J REPROD IMMUNOL, V43, P6, DOI 10.1111/j.8755-8920.2000.430102.x; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Toft DJ, 2001, P NATL ACAD SCI USA, V98, P13055, DOI 10.1073/pnas.231364798; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yagami K, 1999, J CELL BIOL, V147, P1097, DOI 10.1083/jcb.147.5.1097; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; YonedaKato N, 1996, ONCOGENE, V12, P265; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	67	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3655	3668		10.1038/sj.onc.1206438	http://dx.doi.org/10.1038/sj.onc.1206438			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789274				2022-12-25	WOS:000183399200016
J	Stoecklin, G; Gross, B; Ming, XF; Moroni, C				Stoecklin, G; Gross, B; Ming, XF; Moroni, C			A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA	ONCOGENE			English	Article						ARE; interleukin-3; MRNA decay; tristetraprolin; zinc-finger protein	INTERLEUKIN-3 MESSENGER-RNA; ACTIVATED PROTEIN-KINASE; MAST-CELLS; DEGRADATION PATHWAY; STABILITY FACTOR; CANCER CELLS; GM-CSF; ELEMENTS; TRISTETRAPROLIN; STABILIZATION	The occurrence of pathologically stable mRNAs of protooncogenes, growth factors and cyclins has been proposed to contribute to experimental and human oncogenesis. In normal resting cells, mRNAs containing an AU-rich element (ARE) in their 3' untranslated region are subjected to rapid degradation. Tristetraprolin (TTP) is an RNA-binding zinc-finger protein that promotes decay of ARE-containing mRNAs. Here we report that TTP acts as a potent tumor suppressor in a v-H-ras-dependent mast cell tumor model, where tumors express abnormally stable interleukin-3 (IL-3) mRNA as part of an oncogenic autocrine loop. Premalignant v-H-ras cells were transfected with TTP and injected into syngeneic mice. TTP expression delayed tumor progression by 4 weeks, and late appearing tumors escaped suppression by loss of TTP. When transfected into a fully established tumor line, TTP reduced cloning efficiency in vitro and growth of the inoculated cells in vivo. Transgenic TTP interfered with the autocrine loop by enhancing the degradation of IL-3 mRNA with concomitant reduction of IL-3 secretion. Our data establish the ARE as an antioncogenic target in a model situation, underline the importance of mRNA stabilization in oncogenesis and show for the first time that tumor suppression can be achieved by interfering with mRNA turnover.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.			Stoecklin, Georg/0000-0001-9284-9834				AGHIB DF, 1990, ONCOGENE, V5, P707; ALGATE PA, 1993, ONCOGENE, V8, P1221; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Gouble A, 2002, CANCER RES, V62, P1489; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirsch HH, 1996, GROWTH FACTORS, V13, P99, DOI 10.3109/08977199609034570; HIRSCH HH, 1995, J BIOL CHEM, V270, P20629, DOI 10.1074/jbc.270.35.20629; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Nabors LB, 2001, CANCER RES, V61, P2154; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; ROSS HJ, 1991, BLOOD, V77, P1787; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Stoecklin G, 2001, RNA, V7, P1578; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200	44	93	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3554	3561		10.1038/sj.onc.1206418	http://dx.doi.org/10.1038/sj.onc.1206418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789264				2022-12-25	WOS:000183399200006
J	Srinivasan, RS; de Erkenez, AC; Hemenway, CS				Srinivasan, RS; de Erkenez, AC; Hemenway, CS			The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor	ONCOGENE			English	Article						oncogenic fusion proteins; alternative RNA splicing; gene repression; leukemia cell lines	ACUTE MYELOID-LEUKEMIA; DROSOPHILA-TRITHORAX; NUCLEAR-PROTEIN; HUMAN HOMOLOG; MLL; GENE; POLYCOMB; 11Q23; ENL; TRANSLOCATIONS	The mixed lineage leukemia (MLL) gene at chromosome band 11q23 is commonly involved in reciprocal translocations that are detected in acute leukemias. Evidence suggests that the resulting MLL fusion genes contribute to leukemogenesis. AF9 is a common MLL fusion partner in acute myeloid leukemia. The AF9 protein functions as a transcriptional activator in artificial reporter gene assays and a structurally related protein in yeast, ANC1/TFG3, is a component of the SWI/SNF complex. Apart from these observations, little is known about the biologic function of AF9 in mammals. We have found that a recently described transcriptional repressor, BCL-6 corepressor (BCoR), interacts with the carboxy-terminus of AF9. The interaction of AF9 with BCoR has been confirmed by independent in vitro and in vivo protein-binding studies. The BCoR gene is expressed as several alternatively spliced transcripts. AF9 only binds BCoR isoforms that contain a unique 34 aa sequence located in the mid-portion of the protein. In artificial reporter gene assays, a BCoR isoform that binds AF9 efficiently suppresses AF9 transcriptional activity, while a nonbinding isoform does not. These results indicate that different isoforms of BCoR have unique biologic properties and that cell function may be partly determined by the different isoforms that are present within the cell.	Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Mol & Cellular Biol Program, Dept Pediat, New Orleans, LA 70112 USA	Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Tulane Canc Ctr, 1430 Tulane Ave,SL-37, New Orleans, LA 70112 USA.	chemenw@tulane.edu			NATIONAL CANCER INSTITUTE [K01CA078318] Funding Source: NIH RePORTER; NCI NIH HHS [CA78318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOWNING JR, 1996, MOL GENETICS THERAPY; Erfurth F, 2000, BLOOD, V96, p700A; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Huynh KD, 2000, GENE DEV, V14, P1810; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Joh T, 1996, ONCOGENE, V13, P1945; Kuwada N, 2001, CANCER RES, V61, P2665; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Ono R, 2002, CANCER RES, V62, P333; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUBNITZ JE, 1994, BLOOD, V84, P1747; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; WELCH MD, 1994, MOL BIOL CELL, V5, P617, DOI 10.1091/mbc.5.6.617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	38	63	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3395	3406		10.1038/sj.onc.1206361	http://dx.doi.org/10.1038/sj.onc.1206361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776190				2022-12-25	WOS:000183128500005
J	Knuefermann, C; Lu, Y; Liu, BL; Jin, WD; Liang, K; Wu, L; Schmidt, M; Mills, GB; Mendelsohn, J; Fan, Z				Knuefermann, C; Lu, Y; Liu, BL; Jin, WD; Liang, K; Wu, L; Schmidt, M; Mills, GB; Mendelsohn, J; Fan, Z			HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells	ONCOGENE			English	Article						HER2; PI-3K; Akt; chemotherapy; breast cancer	SERINE-THREONINE KINASE; NF-KAPPA-B; V-HA-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; OVARIAN-CANCER; GROWTH-FACTORS; AKT2 ONCOGENE; INHIBITION; PROTEIN	Growth factor receptor-mediated signal transduction has been implicated in conferring resistance to conventional chemotherapy on cancer cells. In this study, we delineated a pathway that involves HER2/PI-3K/Akt in mediating multidrug resistance in human breast cancer cells. We found that the cell lines that express both HER2 and HER3 appear to have a higher phosphorylation level of Akt (activated Akt). Transfection of HER2 in MCF7 breast cancer cells that express. HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin). Selective inhibition of PI-3K or Akt activity with their respective dominant-negative expression vectors sensitized the cells to the induction of apoptosis by the chemotherapeutic agents. We further demonstrated that MCF7 cells expressing a constitutively active Akt, in which the phospholipid-interactive PH domain of Akt was replaced by a farnesylation sequence for, constitutive membrane anchorage (DeltaPH-Akt1-farn), showed a similar increased resistance to the chemotherapeutic agents. Our results suggest that activation of AM by HER2/PI-3K plays an important role in conferring a broad-spectrum chemoresistance on breast cancer cells and that Akt may therefore be a novel molecular target for therapies that would improve the outcome of patients with breast cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 36, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 36, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA082716] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA82716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DEL PL, 1997, SCIENCE, V278, P687; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Liu AX, 1998, CANCER RES, V58, P2973; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ozes ON, 1999, NATURE, V401, P82; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun M, 2001, CANCER RES, V61, P5985; Teng DHF, 1997, CANCER RES, V57, P5221; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	25	360	383	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3205	3212		10.1038/sj.onc.1206394	http://dx.doi.org/10.1038/sj.onc.1206394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761490				2022-12-25	WOS:000183040000002
J	Schneiderhan, N; Budde, A; Zhang, YP; Brune, B				Schneiderhan, N; Budde, A; Zhang, YP; Brune, B			Nitric oxide induces phosphorylation of p53 and impairs nuclear export	ONCOGENE			English	Article						p53-ubiquitination; Mdm2; nucleo-cytoplasmic; shuttling; leptomycin; heterokaryon analysis	RING-FINGER DOMAIN; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; DNA-BINDING; IN-VIVO; MDM2; DEGRADATION; ACTIVATION; PROTEIN; SIGNAL	The tumor suppressor p53 accumulates under diverse stress conditions and affects cell cycle progression and/or apoptosis. This has been exemplified for endogenously produced or exogenously supplied nitric oxide (NO) and thus accounts at least in part for pathophysiological signaling of that bioactive molecule, although detailed mechanisms remain to be elucidated. By using luciferase reporter assays, we show that NO stabilized a transcriptionally active p53 protein. Considering that p53 is targeted by murine double minute (Mdm2) for ubiquitination and subsequent proteasomal degradation and knowing that this interaction is impaired by, for example, UV-treatment with concomitant stabilization of p53 we questioned the p53/Mdm2 interaction in the presence of NO. Although p53 became phosphorylated at serine 15 under the impact of NO, coimmunoprecipitation with Mdm2 and ubiquitination remained intact, thus excluding any interference of NO with this pathway. The importance of N-terminal p53 phosphorylation was verified with p53 mutants where the first six serine residues have been converted to alanine, and which do not accumulate in response to NO. Regulation of p53 stability can be also achieved by affecting nuclear-cytoplasmic shuttling and it was presented that leptomycin B, an inhibitor of nuclear export, caused p53 accumulation. Cell fractionation and immunofluorescence staining following NO-treatment revealed predominant nuclear accumulation of p53 in close association with serine 15-phosphorylation, which suggests impaired nuclear-cytoplasmic shuttling. This was verified by heterokaryon analysis. We conclude that attenuated nuclear export contributes to stabilization and activation of p53 under the influence of NO.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany	University of Kaiserslautern; University of Texas System; UTMD Anderson Cancer Center; University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, Erwin Schrodinger Str, D-67663 Kaiserslautern, Germany.	BRUENE@rhrk.uni-kl.de			NCI NIH HHS [K01 CA087580] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA087580] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brune B, 2001, CELL SIGNAL, V13, P525, DOI 10.1016/S0898-6568(01)00175-9; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Davis DW, 2000, J EXP MED, V192, P857, DOI 10.1084/jem.192.6.857; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottifredi V, 2001, SCIENCE, V292, P1851, DOI 10.1126/science.1062238; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsuoka M, 2001, BIOCHEM BIOPH RES CO, V282, P1120, DOI 10.1006/bbrc.2001.4700; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MIYASHITA T, 1995, CELL, V80, P293; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang F, 2000, J LEUKOCYTE BIOL, V68, P916; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	58	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2857	2868		10.1038/sj.onc.1206431	http://dx.doi.org/10.1038/sj.onc.1206431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771937				2022-12-25	WOS:000182824800001
J	Mack, JA; Abramson, SR; Ben, YX; Coffin, JC; Rothrock, JK; Maytin, EV; Hascall, VC; Largman, C; Stelnicki, EJ				Mack, JA; Abramson, SR; Ben, YX; Coffin, JC; Rothrock, JK; Maytin, EV; Hascall, VC; Largman, C; Stelnicki, EJ			Hoxb13 knockout adult skin exhibits high levels of hyaluronan and enhanced wound healing	FASEB JOURNAL			English	Article						transcription factor; fetal scarless wound healing; differentiation	HOMEODOMAIN PROTEIN; FETAL WOUNDS; DIFFERENTIATION; EXPRESSION; GENE; GROWTH; MOUSE; MICROANALYSIS; KERATINOCYTES; PROLIFERATION	In contrast to adult cutaneous wound repair, early gestational fetal cutaneous wounds heal by a process of regeneration, resulting in little or no scarring. Previous studies indicate that down-regulation of HoxB13, a member of the highly conserved family of Hox transcription factors, occurs during fetal scarless wound healing. No down-regulation was noted in adult wounds. Here, we evaluate healing of adult cutaneous wounds in Hoxb13 knockout (KO) mice, hypothesizing that loss of Hoxb13 in adult skin should result in enhanced wound healing. Tensiometry was used to measure the tensile strength of incisional wounds over a 60-day time course; overall, Hoxb13 KO wounds are significantly stronger than wild-type (WT). Histological evaluation of incisional wounds shows that 7-day-old Hoxb13 KO wounds are significantly smaller and that 60-day-old Hoxb13 KO wounds exhibit a more normal collagen architecture compared with WT wounds. We also find that excisional wounds close at a faster rate in Hoxb13 KO mice. Biochemical and histochemcial analyses show that Hoxb13 KO skin contains significantly elevated levels of hyaluronan. Because higher levels of hyaluronan and enhanced wound healing are characteristics of fetal skin, we conclude that loss of Hoxb13 produces a more "fetal-like" state in adult skin.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, Cleveland, OH 44195 USA; Cleveland Clin Florida, Dept Res, Weston, FL USA; Nova SE Univ, Coll Dent Med, Ft Lauderdale, FL 33314 USA; Cleveland Clin Fdn, Dept Dermatol, Cleveland, OH 44195 USA; Vet Affairs Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Nova Southeastern University; Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Mack, JA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	mackj@ccf.org						AN G, 1993, J BIOL CHEM, V268, P10977; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; Chang PY, 1998, BIOCHEM BIOPH RES CO, V248, P749, DOI 10.1006/bbrc.1998.9076; CHISAKA O, 1991, NATURE, V350, P458; Coleman PJ, 2002, BBA-GEN SUBJECTS, V1571, P173, DOI 10.1016/S0304-4165(02)00213-1; Cowherd RM, 1997, BIOCHEM BIOPH RES CO, V237, P470, DOI 10.1006/bbrc.1997.7160; DECRAEN MV, 1998, CELL DEATH DIFFER, V5, P838; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Economides KD, 2003, DEV BIOL, V256, P317, DOI 10.1016/S0012-1606(02)00137-9; ESTES JM, 1993, J PEDIATR SURG, V28, P1227, DOI 10.1016/S0022-3468(05)80303-3; Gardiner DM, 1998, AM ZOOL, V38, P659; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Komuves LG, 2000, DEV DYNAM, V218, P636; Komuves LG, 2002, DEV DYNAM, V224, P58, DOI 10.1002/dvdy.10085; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KUJAWA MJ, 1983, DEV BIOL, V99, P277, DOI 10.1016/0012-1606(83)90277-4; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LEVENSON SM, 1965, ANN SURG, V161, P293, DOI 10.1097/00000658-196502000-00019; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; LONGAKER MT, 1990, J PEDIATR SURG, V25, P63, DOI 10.1016/S0022-3468(05)80165-4; MANAK JR, 1994, DEVELOPMENT, P61; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; McCallion RL, 1996, MOL CELLULAR BIOL WO, P561; Packer AI, 2000, MECH DEVELOP, V99, P153, DOI 10.1016/S0925-4773(00)00471-8; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Sonoda M, 1997, AM J SPORT MED, V25, P755, DOI 10.1177/036354659702500606; Sonoda M, 2000, AM J SPORT MED, V28, P90, DOI 10.1177/03635465000280012801; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; Stelnicki EJ, 1998, J INVEST DERMATOL, V111, P57, DOI 10.1046/j.1523-1747.1998.00238.x; Su DM, 2001, DEV BIOL, V236, P316, DOI 10.1006/dbio.2001.0342; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1	43	72	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1352	+		10.1096/fj.02-0959fje	http://dx.doi.org/10.1096/fj.02-0959fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759339				2022-12-25	WOS:000183165000018
J	Barbieri, MA; Kong, C; Chen, PI; Horazdovsky, BF; Stahl, PD				Barbieri, MA; Kong, C; Chen, PI; Horazdovsky, BF; Stahl, PD			The Src homology 2 domain of Rin1 mediates its binding to the epidermal growth factor receptor and regulates receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; LIGAND-INDUCED INTERNALIZATION; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; ENDOSOME FUSION; KINASE-ACTIVITY; A431 CELLS; IN-VITRO	Activated epidermal growth factor receptors (EGFRs) recruit intracellular proteins that mediate receptor signaling and endocytic trafficking. Rin1, a multifunctional protein, has been shown to regulate EGFR internalization (1). Here we show that EGF stimulation induces a specific, rapid, and transient membrane recruitment of Rin1 and that recruitment is dependent on the Src homology 2 (SH2) domain of Rin1. Immunoprecipitation of EGFR is accompanied by co-immunoprecipitation of Rin1 in a time- and ligand-dependent manner. Association of Rin1 and specifically the SH2 domain of Rin1 with the EGFR was dependent on tyrosine phosphorylation of the intracellular domain of the EGFR. The recruitment of Rin1, observed by light microscopy, indicated that although initially cytosolic, Rin1 was recruited to both plasma membrane and endosomes following EGF addition. Moreover, the expression of the SH2 domain of Rin1 substantially impaired the internalization of EGF without affecting internalization of transferrin. Finally, we found that Rin1 co-immunoprecipitated with a number of tyrosine kinase receptors but not with cargo endocytic receptors. These results indicate that Rin1 provides a link via its SH2 domain between activated tyrosine kinase receptors and the endocytic pathway through the recruitment and activation of Rab5a.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Ctr Canc, Rochester, MN 55905 USA	Washington University (WUSTL); Mayo Clinic; Mayo Clinic	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Campus Box 8228, St Louis, MO 63110 USA.		Stahl, Philip/D-6315-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035884, R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20015, AI35884] Funding Source: Medline; NIDDK NIH HHS [2P60DK20579] Funding Source: Medline; NIGMS NIH HHS [GM55301, GM42259] Funding Source: Medline; CSR NIH HHS [IRG5801045-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CSR NIH HHS		Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Clague MJ, 2001, J CELL SCI, V114, P3075; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; de Melker AA, 2001, J CELL SCI, V114, P2167; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; KIM JW, 1990, J BIOL CHEM, V265, P3940; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Li GP, 1997, J BIOL CHEM, V272, P10337; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; Martinu L, 2002, J BIOL CHEM, V277, P50996, DOI 10.1074/jbc.M204869200; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; Park WY, 2001, ANN NY ACAD SCI, V928, P79; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Sakaguchi K, 2001, BIOCHEM BIOPH RES CO, V282, P1154, DOI 10.1006/bbrc.2001.4680; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; Sanjay A., 2001, SCI STKE; Sato K, 2000, GENES CELLS, V5, P749, DOI 10.1046/j.1365-2443.2000.00358.x; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Sorkina T, 1999, J CELL SCI, V112, P317; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; WAHL MI, 1990, J BIOL CHEM, V265, P3944; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wells A, 1999, CELL MOTIL CYTOSKEL, V44, P227, DOI 10.1002/(SICI)1097-0169(199912)44:4<227::AID-CM1>3.0.CO;2-B; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	56	69	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32027	32036		10.1074/jbc.M304324200	http://dx.doi.org/10.1074/jbc.M304324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783862	hybrid			2022-12-25	WOS:000184782100073
J	Leopold, JA; Walker, J; Scribner, AW; Voetsch, B; Zhang, YY; Loscalzo, AJ; Stanton, RC; Loscalzo, J				Leopold, JA; Walker, J; Scribner, AW; Voetsch, B; Zhang, YY; Loscalzo, AJ; Stanton, RC; Loscalzo, J			Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LINKED GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; INHIBITION; CELLS; OVEREXPRESSION; SUPEROXIDE; ACTIVATION; EXPRESSION; GENERATION; VIVO	Glucose-6-phosphate dehydrogenase (G6PD), the first enzyme of the pentose phosphate pathway, is the principal intracellular source of NADPH. NADPH is utilized as a cofactor by vascular endothelial cell nitric-oxide synthase (eNOS) to generate nitric oxide (NO.). To determine whether G6PD modulates NO.-mediated angiogenesis, we decreased G6PD expression in bovine aortic endothelial cells using an antisense oligodeoxynucleotide to G6PD or increased G6PD expression by adenoviral gene transfer, and we examined vascular endothelial growth factor (VEGF)-stimulated endothelial cell proliferation, migration, and capillary-like tube formation. Deficient G6PD activity was associated with a significant decrease in endothelial cell proliferation, migration, and tube formation, whereas increased G6PD activity promoted these processes. VEGF-stimulated eNOS activity and NO. production were decreased significantly in endothelial cells with deficient G6PD activity and enhanced in G6PD-overexpressing cells. In addition, G6PD-deficient cells demonstrated decreased tyrosine phosphorylation of the VEGF receptor Flk-1/ KDR, Akt, and eNOS compared with cells with normal G6PD activity, whereas overexpression of G6PD enhanced phosphorylation of Flk-1/KDR, Akt, and eNOS. In the Pretsch mouse, a murine model of G6PD deficiency, vessel outgrowth from thoracic aorta segments was impaired compared with C3H wild-type mice. In an in vivo Matrigel angiogenesis assay, cell migration into the plugs was inhibited significantly in G6PD-deficient mice compared with wild-type mice, and gene transfer of G6PD restored the wild-type phenotype in G6PD-deficient mice. These findings demonstrate that G6PD modulates angiogenesis and may represent a novel angiogenic regulator.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Leopold, JA (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 700 Albany St,CABR W-507, Boston, MA 02118 USA.	Jane.Leopold@bmc.org	Loscalzo, Joseph/ABD-8980-2021; Stanton, Robert C/AAG-7584-2020	Stanton, Robert C/0000-0002-3056-1277	NHLBI NIH HHS [P50 HL55993, HL61795, HL58976, HL04399] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004399, R01HL058976, R01HL061795, P50HL055993, R37HL061795] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4; Burbridge MF, 2001, METH MOLEC MED, V46, P185, DOI 10.1385/1-59259-143-4:185; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DiMonaco M, 1997, BRIT J CANCER, V75, P589, DOI 10.1038/bjc.1997.102; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; KUGLER P, 1994, J HISTOCHEM CYTOCHEM, V42, P1317, DOI 10.1177/42.10.7523487; Kuo WY, 1998, FREE RADICAL BIO MED, V24, P1130, DOI 10.1016/S0891-5849(97)00413-9; Leopold JA, 2003, ARTERIOSCL THROM VAS, V23, P411, DOI 10.1161/01.ATV.0000056744.26901.BA; Leopold JA, 2001, FASEB J, V15, P1771, DOI 10.1096/fj.00-0893fje; Lucerna M, 2003, J BIOL CHEM, V278, P11433, DOI 10.1074/jbc.M204937200; Mei JJM, 1998, CANCER LETT, V129, P191, DOI 10.1016/S0304-3835(98)00102-5; Noiri E, 1996, AM J PHYSIOL-CELL PH, V270, pC794, DOI 10.1152/ajpcell.1996.270.3.C794; PANT N, 1995, HUM EXP TOXICOL, V14, P889, DOI 10.1177/096032719501401106; PRETSCH W, 1988, BIOCHEM GENET, V26, P89, DOI 10.1007/BF00555491; Sanders S, 1997, MUTAT RES-FUND MOL M, V374, P79, DOI 10.1016/S0027-5107(96)00222-9; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tsai KJ, 1998, FEBS LETT, V436, P411, DOI 10.1016/S0014-5793(98)01174-0; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Zhang YY, 2002, BIOCHEM J, V361, P267, DOI 10.1042/0264-6021:3610267; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Zollner S, 2000, ENDOTHELIUM-NEW YORK, V7, P169	28	116	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32100	32106		10.1074/jbc.M301293200	http://dx.doi.org/10.1074/jbc.M301293200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12777375	hybrid			2022-12-25	WOS:000184782100081
J	Myers, JC; Li, DQ; Amenta, PS; Clark, CC; Nagaswami, C; Weisel, JW				Myers, JC; Li, DQ; Amenta, PS; Clark, CC; Nagaswami, C; Weisel, JW			Type XIX collagen purified from human umbilical cord is characterized by multiple sharp kinks delineating collagenous subdomains and by intermolecular aggregates via globular, disulfide-linked, and heparin-binding amino termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; LAMININ G-LIKE; ELECTRON-MICROSCOPY; N-PROTEINASE; CELLS; THROMBOSPONDIN-1; DOMAIN; CHAIN; SUBSTITUTION; ORGANIZATION	Type XIX collagen was discovered from the sequence of rhabdomyosarcoma cDNA clones. The chain is composed of a 268-residue amino terminus, an 832-residue discontinuous collagenous region, and a 19-residue carboxyl peptide. Light microscopy immunohistochemistry of adult human tissues demonstrated that type XIX is localized in vascular, neuronal, mesenchymal, and some epithelial basement membrane zones. It also appears to be involved in events linked to skeletal myogenesis. In this report, we have presented the first direct evidence for the molecular structure of type XIX collagen. Using human umbilical cord, native type XIX was purified by neutral salt extraction and by ion exchange and antibody affinity chromatography. Type XIX was found to represent only similar to10(-6%) of the dry weight of tissue, making it by far the least abundant collagen ever isolated. Transmission electron microscopy after rotary shadowing revealed the appearance of rodlike structures with multiple sharp bends, a small nodule at one end of the molecule, and a total length of 240 nm. Domain-specific antibodies were used to identify the nodule as the non-collagenous amino terminus, whereas the location of most kinks corresponds to major interruptions separating the five collagenous subdomains. More than half of the type XIX molecules observed were present in oligomers of different size and complexity, resulting from association of the amino-terminal domains. Biochemical analysis demonstrated that these supramolecular aggregates are dependent upon and/or stabilized by intermolecular disulfide cross-links and that the globular amino terminus contains a high affinity, heparin-binding site. The polymorphic conformational states of this rare collagen, and its ability to self-assemble into a higher order structure provide focal points for future determination of biologically significant functions in cell-cell and/or cell-matrix interactions.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, New Brunswick, NJ 08903 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center	Myers, JC (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 909 Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL30954] Funding Source: Medline; NIAMS NIH HHS [AR20553] Funding Source: Medline; NIGMS NIH HHS [GM64777] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064777] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Amenta PS, 2003, J PATHOL, V199, P298, DOI 10.1002/path.1303; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BROWM JC, 1995, INT ARCH ALLERGY IMM, V107, P484, DOI 10.1159/000237090; Bruckner-Tuderman L, 1998, J MOL MED-JMM, V76, P226, DOI 10.1007/s001090050213; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; EYDEN BP, 1994, J SUBMICR CYTOL PATH, V26, P347; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; Forlino A, 1998, MATRIX BIOL, V17, P575, DOI 10.1016/S0945-053X(98)90109-3; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; FURUTO DK, 1987, METHOD ENZYMOL, V144, P41; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hirako Y, 1996, J BIOL CHEM, V271, P13739, DOI 10.1074/jbc.271.23.13739; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; INOGUCHI K, 1995, J BIOCHEM-TOKYO, V117, P137, DOI 10.1093/oxfordjournals.jbchem.a124700; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P79, DOI 10.1006/bbrc.1999.1638; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Li DQ, 2000, J BIOL CHEM, V275, P22339, DOI 10.1074/jbc.M000519200; LIGHTFOOT SJ, 1992, J BIOL CHEM, V267, P25521; Merle B, 1997, J CELL BIOCHEM, V67, P75; MEYER FA, 1996, EXTRACELLULAR MATRIX, V1, P443; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; MYERS JC, 1993, GENE, V123, P211, DOI 10.1016/0378-1119(93)90126-N; MYERS JC, 1994, J BIOL CHEM, V269, P18549; Myers JC, 1997, AM J PATHOL, V151, P1729; Myers JC, 1999, EXP CELL RES, V253, P587, DOI 10.1006/excr.1999.4642; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nanaev AK, 1997, PLACENTA, V18, P53, DOI 10.1016/S0143-4004(97)90071-0; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; Sato K, 2002, J BIOL CHEM, V277, P37678, DOI 10.1074/jbc.M205347200; Sumiyoshi H, 2001, DEV DYNAM, V220, P155, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1099>3.3.CO;2-N; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; Weisel JW, 2001, BIOCHEMISTRY-US, V40, P10424, DOI 10.1021/bi010556e; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S	56	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32047	32057		10.1074/jbc.M304629200	http://dx.doi.org/10.1074/jbc.M304629200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788917	hybrid			2022-12-25	WOS:000184782100075
J	Ruiz-Ruiz, C; Robledo, G; Cano, E; Redondo, JM; Lopez-Rivas, A				Ruiz-Ruiz, C; Robledo, G; Cano, E; Redondo, JM; Lopez-Rivas, A			Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; DRUG-INDUCED APOPTOSIS; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; CD95-MEDIATED APOPTOSIS; FAS/APO-1 EXPRESSION; IONIZING-RADIATION; CANCER-THERAPY; IMMUNE ESCAPE; CYCLE ARREST	Death receptor CD95 gene expression is frequently low in human breast tumors and is up-regulated by genotoxic treatments in a p53-dependent manner. We have evaluated the relative contribution of promoter and intronic p53 consensus sites to the regulation of the human CD95 gene in breast tumor cells following doxorubicin treatment. Deletion constructs of the promoter region and site-directed mutagenesis of p53 consensus sites in a fragment spanning 1448 bp of the 5'-promoter demonstrate that these sites are not involved in the observed up-regulation of the CD95 gene upon doxorubicin treatment. In contrast, a p53 consensus site located within the first intron of CD95 gene is absolutely required for the inducible expression of CD95 upon genotoxic treatment in breast tumor cells. Analysis of the transcriptional activity of the two most common p53 mutants found in human breast tumors that are associated with resistance to doxorubicin reveals that these mutations completely eliminate the ability of p53 protein to transactivate CD95 gene expression. On the other hand, Bcl-2 overexpression albeit preventing doxorubicin-induced apoptosis, has no effect on p53-mediated CD95 up-regulation in breast tumor cells. Altogether, these results indicate the lack of involvement of p53 consensus sites of the CD95 promoter region and the pivotal role of intronic p53-responsive element in the regulation of human CD95 gene expression in breast tumor cells. Our results also suggest that in breast cancer patients with certain mutations in the p53 gene, expression of death receptor CD95 in response to genotoxic treatments could be severely compromised.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.		Cano, Eva/A-2049-2010; Redondo, Juan Miguel/H-6351-2015; Ruiz-Ruiz, Carmen/I-8792-2017; Lopez-Rivas, Abelardo/E-5115-2015	Cano, Eva/0000-0003-2750-6135; Redondo, Juan Miguel/0000-0001-5779-9122; Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BARTEK J, 1990, ONCOGENE, V5, P893; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Gronbaek K, 1998, BLOOD, V92, P3018; Higaki K, 1996, AM J PATHOL, V149, P429; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Keane MM, 1996, CANCER RES, V56, P4791; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lee SH, 1999, CANCER RES, V59, P3068; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maecker HL, 2002, CANCER CELL, V2, P139, DOI 10.1016/S1535-6108(02)00095-8; McCloskey DE, 1996, RECENT PROG HORM RES, V51, P493; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Muschen M, 1999, J PATHOL, V189, P378, DOI 10.1002/(SICI)1096-9896(199911)189:3<378::AID-PATH439>3.0.CO;2-D; Muschen M, 2001, INT J CANCER, V92, P309; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; Rosen D, 2000, J IMMUNOL, V164, P3229, DOI 10.4049/jimmunol.164.6.3229; RUDERT F, 1995, DNA CELL BIOL, V14, P931, DOI 10.1089/dna.1995.14.931; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; von Reyher U, 1998, CANCER RES, V58, P526; Walczak H, 2000, CANCER RES, V60, P3051; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; Zhang B, 2002, CANCER RES, V62, P450	64	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31667	31675		10.1074/jbc.M304397200	http://dx.doi.org/10.1074/jbc.M304397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788915	hybrid			2022-12-25	WOS:000184782100027
J	Barrette-Ng, IH; Ng, KKS; Cherney, MM; Pearce, G; Ghani, U; Ryan, CA; James, MNG				Barrette-Ng, IH; Ng, KKS; Cherney, MM; Pearce, G; Ghani, U; Ryan, CA; James, MNG			Unbound form of tomato inhibitor-II reveals interdomain flexibility and conformational variability in the reactive site loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; TRYPSIN-INHIBITOR; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; 3RD DOMAIN; CRYSTALLOGRAPHIC REFINEMENT; MOLECULAR-STRUCTURE; TERNARY COMPLEX; BOVINE TRYPSIN; LEAVES	The Potato II (Pot II) family of proteinase inhibitors plays important roles in the constitutive and inducible defense of plants against predation by a wide range of pests. The structural basis of inhibition by a multidomain Pot II family inhibitor was revealed recently by the structure of the ternary complex between the two-headed tomato inhibitor-II (TI-II) and two molecules of subtilisin Carlsberg. Here we report the 2.15-Angstrom resolution crystal structure of the unbound form of TI-II that reveals significant conformational flexibility in the absence of bound proteinase molecules. The four independent copies of unbound TI-II in the asymmetric unit of the unit cell display a range of different conformations when compared with the bound form of the inhibitor, most strikingly in the orientations of the inhibitory domains and in the conformations of the reactive site loops. One of the two linker segments ( residues 74 to 79) between the two domains as well as the adjacent beta-strand in Domain I ( residues 80-85) is well ordered in all four copies of the unbound inhibitor, even though this region appeared to be disordered in the structure of the ternary complex. Conformational flexibility seen in the reactive site loops of unbound TI-II suggests a mechanism by which the inhibitor can balance the need for tight binding with the need for broad inhibitory function.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Institute for Work & Health; University of Alberta; University of Calgary; Washington State University	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Rm 4-29,Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	michael.james@ualberta.ca	Ghani, Usman/X-6644-2019	Ng, Kenneth K.S./0000-0001-7280-8445; Ghani, Usman/0000-0003-0776-9528				Antcheva N, 1996, BBA-PROTEIN STRUCT M, V1298, P95, DOI 10.1016/S0167-4838(96)00121-5; Apostoluk W, 1998, PROTEINS, V32, P459, DOI 10.1002/(SICI)1097-0134(19980901)32:4<459::AID-PROT5>3.0.CO;2-B; ATKINSON AH, 1993, PLANT CELL, V5, P203, DOI 10.1105/tpc.5.2.203; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALANDIN T, 1995, PLANT MOL BIOL, V27, P1197, DOI 10.1007/BF00020893; Barrette-Ng IH, 2003, J BIOL CHEM, V278, P24062, DOI 10.1074/jbc.M302020200; BODE W, 1985, EUR J BIOCHEM, V147, P387, DOI 10.1111/j.1432-1033.1985.tb08762.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; BOULTER D, 1989, BIOTECHNOL ADV, V7, P489, DOI 10.1016/0734-9750(89)90720-9; BROADWAY RM, 1986, J INSECT PHYSIOL, V32, P673, DOI 10.1016/0022-1910(86)90108-3; BROWN WE, 1984, BIOCHEMISTRY-US, V23, P3418, DOI 10.1021/bi00310a006; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYANT J, 1976, BIOCHEMISTRY-US, V15, P3418, DOI 10.1021/bi00661a004; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; Duan XL, 1996, NAT BIOTECHNOL, V14, P494, DOI 10.1038/nbt0496-494; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; FUJINAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P4868, DOI 10.1073/pnas.79.16.4868; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREENBLATT HM, 1989, J MOL BIOL, V205, P201, DOI 10.1016/0022-2836(89)90376-8; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; KEIL M, 1986, NUCLEIC ACIDS RES, V14, P5641, DOI 10.1093/nar/14.14.5641; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Koepke J, 2000, J MOL BIOL, V298, P477, DOI 10.1006/jmbi.2000.3677; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; Lee MCS, 1999, NAT STRUCT BIOL, V6, P526, DOI 10.1038/9293; Li L, 2002, P NATL ACAD SCI USA, V99, P6416, DOI 10.1073/pnas.072072599; LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x; Marchetti S, 2000, THEOR APPL GENET, V101, P519, DOI 10.1007/s001220051511; MCPHALEN CA, 1987, BIOCHEMISTRY-US, V26, P261, DOI 10.1021/bi00375a036; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NIELSEN KJ, 1994, J MOL BIOL, V242, P231, DOI 10.1006/jmbi.1994.1575; NIELSEN KJ, 1995, BIOCHEMISTRY-US, V34, P14304, DOI 10.1021/bi00044a007; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZAWA K, 1966, J BIOL CHEM, V241, P3955; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, 1993, PLANT PHYSIOL, V102, P639, DOI 10.1104/pp.102.2.639; PEARCE G, 1988, PLANTA, V175, P527, DOI 10.1007/BF00393075; PLUNKETT G, 1982, ARCH BIOCHEM BIOPHYS, V213, P463, DOI 10.1016/0003-9861(82)90572-0; Raj SSS, 2002, J BIOCHEM, V132, P927, DOI 10.1093/oxfordjournals.jbchem.a003306; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; READ RJ, 1986, PROTEINASE INHIBITOR, V12, P301; RICHARDSON M, 1979, FEBS LETT, V104, P322, DOI 10.1016/0014-5793(79)80843-1; Ryan CA, 2002, P NATL ACAD SCI USA, V99, P6519, DOI 10.1073/pnas.112196499; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; STIEKEMA WJ, 1988, PLANT MOL BIOL, V11, P255, DOI 10.1007/BF00027383; SUZUKI A, 1993, J MOL BIOL, V234, P722, DOI 10.1006/jmbi.1993.1622; TAYLOR BH, 1993, PLANT MOL BIOL, V23, P1005, DOI 10.1007/BF00021815; THORNBURG RW, 1987, P NATL ACAD SCI USA, V84, P744, DOI 10.1073/pnas.84.3.744; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	62	27	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31391	31400		10.1074/jbc.M304562200	http://dx.doi.org/10.1074/jbc.M304562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788916	hybrid			2022-12-25	WOS:000184658800122
J	Eisenhaure, TM; Francis, SA; Willison, LD; Coughlin, SR; Lerner, DJ				Eisenhaure, TM; Francis, SA; Willison, LD; Coughlin, SR; Lerner, DJ			The Rho guanine nucleotide exchange factor Lsc homo-oligomerizes and is negatively regulated through domains in its carboxyl terminus that are absent in novel splenic isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; COILED-COILS; P115 RHOGEF; FAMILY GTPASES; PROTEIN; IDENTIFICATION; ACTIVATION; EXPRESSION; P190RHOGEF; MECHANISM	Rho GTPases control fundamental cellular processes, including cytoskeletal reorganization and transcription. Rho guanine nucleotide exchange factors (GEFs) compose a large (> 65) and diverse family of related proteins that activate Rho GTPases. Lsc/p115-RhoGEF is a Rho-specific GEF required for normal B and T lymphocyte function. Despite its essential role in lymphocytes, Lsc/p115-RhoGEF signaling in vivo is not well understood. To define Lsc/p115-RhoGEF signaling pathways in vivo, we set out to identify proteins that interact with regulatory regions of Lsc. The 146-amino acid C terminus of Lsc contains a predicted coiled-coil domain, and we demonstrated that deletion of this C terminus confers a gain of function in vivo. Surprisingly, a yeast two-hybrid screen for proteins that interact with this regulatory C terminus isolated a larger C-terminal fragment of Lsc itself. Co-immunoprecipitation experiments in mammalian cells demonstrated that Lsc specifically homo-oligomerizes and that the coiled-coil domain in the C terminus is required for homo-oligomerization. Mutagenesis experiments revealed that homo-oligomerization and negative regulation are distinct functions of the C terminus. Two novel isoforms of Lsc found in the spleen lack portions of this C terminus, including the coiled-coil domain. Importantly, the C termini of both isoforms confer a gain of function and eliminate homo-oligomerization. These results define two important features of Lsc signaling. First, Lsc homo-oligomerizes and is negatively regulated through domains in its C terminus; and second, functionally distinct isoforms of Lsc lacking these domains are present in the spleen.	Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Cornell University; Cornell University; University of California System; University of California San Francisco	Lerner, DJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Rm A356,510 E 70th St, New York, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004080] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04080] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Canete-Soler R, 2001, J BIOL CHEM, V276, P32046, DOI 10.1074/jbc.M104104200; *CLONT, 2001, YEAST PROT HDB; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; GLANTZ S, 1987, PRIMER BI STAT; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Harlow E., 1999, USING ANTIBODIES LAB; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Koh CG, 2001, J CELL SCI, V114, P4239; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Park B, 2002, J BIOL CHEM, V277, P45361, DOI 10.1074/jbc.M202447200; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Russell MW, 2002, GENE, V282, P237, DOI 10.1016/S0378-1119(01)00795-8; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sourdive DJD, 1997, NUCLEIC ACIDS RES, V25, P1476, DOI 10.1093/nar/25.8.1476; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; VAN AL, 1997, GENE DEV, V11, P2295; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200; Zhang H, 1999, CURR BIOL, V9, P1271, DOI 10.1016/S0960-9822(99)80511-9; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	56	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30975	30984		10.1074/jbc.M303277200	http://dx.doi.org/10.1074/jbc.M303277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773540	hybrid			2022-12-25	WOS:000184658800072
J	Miura, S; Kai, Y; Ono, M; Ezaki, O				Miura, S; Kai, Y; Ono, M; Ezaki, O			Overexpression of peroxisome proliferator-activated receptor gamma coactivator-1 alpha down-regulates GLUT4 mRNA in skeletal muscles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; NUCLEAR RESPIRATORY FACTORS; GLUCOSE-TRANSPORT; TRANSGENIC MICE; GENE-EXPRESSION; MITOCHONDRIAL BIOGENESIS; TRANSCRIPTION FACTOR; PGC-1; EXERCISE; LOCALIZATION	Exercise training increases mitochondria and GLUT4 in skeletal muscles. Recent studies indicate that an increased expression of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) by exercise may promote mitochondrial biogenesis and fatty acid oxidation. To examine whether increased PGC-1alpha expression was also responsible for an increase of GLUT4 expression, transgenic mice that overexpress PGC-1alpha in skeletal muscles driven by a human alpha-skeletal actin promoter were made. PGC-1alpha was overexpresssed in skeletal muscles including type I and II fiber-rich muscles but not in the heart. With an increase of PGC-1alpha mRNA, type II fiber-rich muscles were redder, and genes of mitochondrial oxidative metabolism were up-regulated in skeletal muscles, whereas the expression of GLUT4 mRNA was unexpectedly downregulated. In parallel with a decrease of GLUT4 mRNA, an impairment of glycemic control after intraperitoneal insulin administration was observed. Thus, an increase of PGC-1alpha plays a role in increasing mitochondrial biogenesis and fatty acid oxidation but not in increasing GLUT4 mRNA in skeletal muscles.	Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, Tokyo 1628636, Japan	National Institute of Health & Nutrition - Japan	Ezaki, O (corresponding author), Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.		Miura, Shinji/K-6516-2013	Miura, Shinji/0000-0001-8806-9763				Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; BOOTH FW, 1997, HDB PHYSL 12, P1075; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Ezaki O, 1997, BIOCHEM BIOPH RES CO, V241, P1, DOI 10.1006/bbrc.1997.7587; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; Ikeda S, 2002, BIOCHEM BIOPH RES CO, V296, P395, DOI 10.1016/S0006-291X(02)00883-5; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Price TB, 1996, P NATL ACAD SCI USA, V93, P5329, DOI 10.1073/pnas.93.11.5329; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; REN JM, 1993, J BIOL CHEM, V268, P16113; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SAMBROOK J, 1989, MOL CLONING LAB MANU, P187; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Tortorella LL, 2002, AM J PHYSIOL-ENDOC M, V283, pE514, DOI 10.1152/ajpendo.00092.2002; Tsunoda N, 2000, BIOCHEM BIOPH RES CO, V267, P744, DOI 10.1006/bbrc.1999.2031; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	31	114	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31385	31390		10.1074/jbc.M304312200	http://dx.doi.org/10.1074/jbc.M304312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777397	hybrid			2022-12-25	WOS:000184658800121
J	Mottet, D; Dumont, V; Deccache, Y; Demazy, C; Ninane, N; Raes, M; Michiels, C				Mottet, D; Dumont, V; Deccache, Y; Demazy, C; Ninane, N; Raes, M; Michiels, C			Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta pathway in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; INITIATION-FACTOR EIF2B; NF-KAPPA-B; GLYCOGEN-SYNTHASE; FACTOR 1-ALPHA; FACTOR-I; SIGNALING PATHWAY; PC12 CELLS; FACTOR (HIF)-1-ALPHA	Hypoxia initiates an intracellular signaling pathway leading to the activation of the transcription factor hypoxia-inducible factor-1 (HIF-1). HIF-1 activity is regulated through different mechanisms involving stabilization of HIF-1alpha, phosphorylations, modifications of redox conditions, and interactions with coactivators. However, it appears that some of these steps can be cell type-specific. Among them, the involvement of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in the regulation of HIF-1 by hypoxia remains controversial. Here, we investigated the activation state of PI3K/Akt/glycogen synthase kinase 3beta(GSK3beta) in HepG2 cells. Increasing incubation times in hypoxia dramatically decreased both the phosphorylation of Akt and the inhibiting phosphorylation of GSK3beta. The PI3K/Akt pathway was necessary for HIF-1alpha stabilization early during hypoxia. Indeed, its inhibition was sufficient to decrease HIF-1alpha protein level after 5-h incubation in hypoxia. However, longer exposure (16 h) in hypoxia resulted in a decreased HIF-1alpha protein level compared with early exposure (5 h). At that time, Akt was no longer present or active, which resulted in a decrease in the inhibiting phosphorylation of GSK3beta on Ser-9 and hence in an increased GSK3beta activity. GSK3 inhibition reverted the effect of prolonged hypoxia on HIF-1alpha protein level; more stabilized HIF-1alpha was observed as well as increased HIF-1 transcriptional activity. Thus, a prolonged hypoxia activates GSK3beta, which results in decreased HIF-1alpha accumulation. In conclusion, hypoxia induced a biphasic effect on HIF-1alpha stabilization with accumulation in early hypoxia, which depends on an active PI3K/Akt pathway and an inactive GSK3beta, whereas prolonged hypoxia results in the inactivation of Akt and activation of GSK3beta, which then down-regulates the HIF-1 activity through down-regulation of HIF-1alpha accumulation.	Univ Namur, Lab Biochem & Cellular Biol, B-5000 Namur, Belgium	University of Namur	Michiels, C (corresponding author), Univ Namur, Lab Biochem & Cellular Biol, 61 Rue Bruxelles, B-5000 Namur, Belgium.							Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; ARSHAM AM, 2002, J BIOL CHEM; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Blancher C, 2001, CANCER RES, V61, P7349; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen EY, 2001, CANCER RES, V61, P2429; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Feldser D, 1999, CANCER RES, V59, P3915; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mora A, 2002, CELL SIGNAL, V14, P557, DOI 10.1016/S0898-6568(01)00282-0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Richard DE, 2000, J BIOL CHEM, V275, P26765; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	54	256	272	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31277	31285		10.1074/jbc.M300763200	http://dx.doi.org/10.1074/jbc.M300763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12764143	hybrid			2022-12-25	WOS:000184658800107
J	Guo, YP; Kotova, E; Chen, ZS; Lee, K; Hopper-Borge, E; Belinsky, MG; Kruh, GD				Guo, YP; Kotova, E; Chen, ZS; Lee, K; Hopper-Borge, E; Belinsky, MG; Kruh, GD			MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2 ',3 '-dideoxycytidine and 9 '-(2 '-phosphonylmethoxyethyl) adenine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISSEMINATED COLORECTAL-CANCER; ORGANIC ANION TRANSPORTER; THYMIDYLATE SYNTHASE GENE; DEPENDENT EXPORT PUMP; EPITHELIAL-CELL LINE; ESCHERICHIA-COLI; SMOOTH-MUSCLE; NITRIC-OXIDE; PROTEIN 5; AMP	MRP8 (ABCC11) is a recently identified cDNA that has been assigned to the multidrug resistance-associated protein (MRP) family of ATP-binding cassette transporters, but its functional characteristics have not been determined. Here we examine the functional properties of the protein using transfected LLC-PK1 cells. It is shown that ectopic expression of MRP8 reduces basal intracellular levels of cAMP and cGMP and enhances cellular extrusion of cyclic nucleotides in the presence or absence of stimulation with forskolin or SIN-1A. Analysis of the sensitivity of MRP8-overexpressing cells revealed that they are resistant to a range of clinically relevant nucleotide analogs, including the anticancer fluoropyrimidines 5'-fluorouracil (similar to3-fold), 5'-fluoro-2'-deoxyuridine (similar to5-fold), and 5'-fluoro- 5'-deoxyuridine (similar to3-fold), the anti-human immunodeficiency virus agent 2', 3'-dideoxycytidine (similar to6-fold) and the anti-hepatitis B agent 9'-(2'-phosphonylmethoxynyl) adenine (PMEA) (similar to5-fold). By contrast, increased resistance was not observed for several natural product chemotherapeutic agents. In accord with the notion that MRP8 functions as a drug efflux pump for nucleotide analogs, MRP8-transfected cells exhibited reduced accumulation and increased efflux of radiolabeled PMEA. In addition, it is shown by the use of in vitro transport assays that MRP8 is able to confer resistance to fluoropyrimidines by mediating the MgATP-dependent transport of 5'-fluoro- 2'-deoxyuridine monophosphate, the cytotoxic intracellular metabolite of this class of agents, but not of 5'-fluorouracil or 5'-fluoro- 2'-deoxyuridine. We conclude that MRP8 is an amphipathic anion transporter that is able to efflux cAMP and cGMP and to function as a resistance factor for commonly employed purine and pyrimidine nucleotide analogs.	Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kruh, GD (corresponding author), Fox Chase Canc Ctr, Div Med Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Kotova, Elena/V-3767-2019	Chen, Zhe-Sheng/0000-0002-8289-097X	NATIONAL CANCER INSTITUTE [U01CA073728, P30CA006927, R01CA073728] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA73728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BRUNTON LL, 1988, METHOD ENZYMOL, V159, P83; BRUNTON LL, 1979, J BIOL CHEM, V254, P9714; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; COPUR S, 1995, BIOCHEM PHARMACOL, V49, P1419, DOI 10.1016/0006-2952(95)00067-A; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; FEHR TF, 1990, J BIOL CHEM, V265, P10974; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GOLDENBAUM PE, 1979, J BACTERIOL, V140, P459, DOI 10.1128/JB.140.2.459-467.1979; HAMET P, 1989, J BIOL CHEM, V264, P12364; HEASLEY LE, 1985, MOL PHARMACOL, V27, P60; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; JOHNSTON PG, 1995, CANCER RES, V55, P1407; Kruh GD, 2001, J BIOENERG BIOMEMBR, V33, P493, DOI 10.1023/A:1012827221844; Ladner RD, 2000, CANCER RES, V60, P3493; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai LQ, 2002, BIOCHEM J, V361, P497, DOI 10.1042/0264-6021:3610497; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; Leichman CG, 1997, J CLIN ONCOL, V15, P3223, DOI 10.1200/JCO.1997.15.10.3223; LEIER I, 1994, J BIOL CHEM, V269, P27807; Lenz HJ, 1998, CLIN CANCER RES, V4, P1243; Lenz HJ, 1996, J CLIN ONCOL, V14, P176, DOI 10.1200/JCO.1996.14.1.176; Millul V, 1996, AM J PHYSIOL-CELL PH, V270, pC1051, DOI 10.1152/ajpcell.1996.270.4.C1051; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; PODEVIN RA, 1980, BIOCHIM BIOPHYS ACTA, V629, P135, DOI 10.1016/0304-4165(80)90272-X; SAIER MH, 1975, J BIOL CHEM, V250, P7593; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schultz C, 1998, BIOCHEMISTRY-US, V37, P1161, DOI 10.1021/bi9713409; STARRETT JE, 1994, J MED CHEM, V37, P1857, DOI 10.1021/jm00038a015; STEINBERG RA, 1979, J CELL PHYSIOL, V100, P579, DOI 10.1002/jcp.1041000319; STREWLER GJ, 1984, AM J PHYSIOL, V246, pC224, DOI 10.1152/ajpcell.1984.246.3.C224; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133595; Wang X, 2003, MOL PHARMACOL, V63, P65, DOI 10.1124/mol.63.1.65; Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200; Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WOODS M, 1991, BIOCHEM PHARMACOL, V41, P385, DOI 10.1016/0006-2952(91)90535-D; Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886	44	207	221	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29509	29514		10.1074/jbc.M304059200	http://dx.doi.org/10.1074/jbc.M304059200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764137	hybrid			2022-12-25	WOS:000184507000016
J	Li, XD; Ikebe, M				Li, XD; Ikebe, M			Two functional heads are required for full activation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; LIGHT CHAIN KINASE; HEAVY-MEROMYOSIN; 2-HEADED STRUCTURE; MOTOR; SUBFRAGMENT-1; DOMAIN; PROTEOLYSIS; FRAGMENTS; BINDING	The motor activity of smooth muscle myosin II is regulated by the regulatory light chain phosphorylation, but it is not understood how phosphorylation activates motor activity. To address this question, we produced asymmetric heavy meromyosin (HMM), which is composed of a wild-type (WT) heavy chain and a mutant heavy chain having no motor activity (i.e. S236T or G457A). The actin-activated ATPase activities ( V-max) of asymmetric HMMs were only 21.8 and 8.4% of the wildtype HMM for S236A/WT HMM and G456A/WT HMM, respectively. If the two heads of HMM are independent for their ATPase activities, asymmetric HMM should show 50% of the activity of wild-type HMM; however, the activity of asymmetric HMM was much lower than the expected value. The results suggest that the activity of the wild-type head is attenuated by the presence of inactive head. Consistently, the actin-gliding velocity of the asymmetric HMM (i.e. S236T/ WT or G457A/WT) was less than one-fifth of the wild-type HMM. The present study supports an idea that the two heads of smooth muscle myosin II interact with each other and the presence of two active heads is required for full activation.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NHLBI NIH HHS [HL61426] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Ikebe M, 1998, BIOCHEMISTRY-US, V37, P13285, DOI 10.1021/bi981130b; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1986, J BIOL CHEM, V261, P36; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Li XD, 1998, J BIOL CHEM, V273, P27404, DOI 10.1074/jbc.273.42.27404; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 2000, J BIOL CHEM, V275, P41273, DOI 10.1074/jbc.M008310200; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Tanaka H, 1998, BIOPHYS J, V75, P1886, DOI 10.1016/S0006-3495(98)77629-5; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; WHITE HD, 1993, BIOCHEMISTRY-US, V32, P9859, DOI 10.1021/bi00088a042; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328	28	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29435	29441		10.1074/jbc.M301784200	http://dx.doi.org/10.1074/jbc.M301784200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12759357	hybrid			2022-12-25	WOS:000184507000007
J	Prasad, R; Bebenek, K; Hou, E; Shock, DD; Beard, WA; Woodgate, R; Kunkel, TA; Wilson, SH				Prasad, R; Bebenek, K; Hou, E; Shock, DD; Beard, WA; Woodgate, R; Kunkel, TA; Wilson, SH			Localization of the deoxyribose phosphate lyase active site in human DNA polymerase iota by controlled proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; MOUSE HOMOLOGS; GENE ENCODES; IN-VITRO; BETA; MUTAGENESIS; ETA; REPLICATION	Human DNA polymerase iota (pol iota) is a member of the Y-family of low fidelity lesion bypass DNA polymerases. In addition to a probable role in DNA lesion bypass, this enzyme has recently been shown to be required for somatic hypermutation in human B-cells. We found earlier that human pol iota has deoxyribose phosphate (dRP) lyase activity and unusual specificity for activity during DNA synthesis, suggesting involvement in specialized forms of base excision repair (BER). Here, mapping of the domain structure of human pol iota by controlled proteolysis revealed that the enzyme has a 48-kDa NH2-terminal domain and a protease resistant 40-kDa "core domain" spanning residues Met(79) to similar toMet(445). A covalently crosslinked pol iota-DNA complex, representing a trapped intermediate in the dRP lyase reaction, was subjected to controlled proteolysis. Cross-linking was mapped to the 40-kDa core domain, indicating that the dRP lyase active site is in this region. To further evaluate the BER capacity of the enzyme, the dRP lyase and DNA polymerase activities were characterized on DNA substrates representing BER intermediates, and we found that pol iota was able to complement the in vitro single-nucleotide BER deficiency of a DNA polymerase beta null cell extract.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NICHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wilson, SH (corresponding author), 111 TW Alexander Dr,POB 12233,MD B2-06, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158, Z01ES065070, ZIAES065070, ZIAES050158] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0; Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Cann IKO, 1999, GENETICS, V152, P1249; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Kannouche P, 2003, EMBO J, V22, P1223, DOI 10.1093/emboj/7595006; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	35	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29649	29654		10.1074/jbc.M305399200	http://dx.doi.org/10.1074/jbc.M305399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777390	hybrid			2022-12-25	WOS:000184507000034
J	Wada, T; Kuzuyama, T; Satoh, S; Kuramitsu, S; Yokoyama, S; Unzai, S; Tame, JRH; Park, SY				Wada, T; Kuzuyama, T; Satoh, S; Kuramitsu, S; Yokoyama, S; Unzai, S; Tame, JRH; Park, SY			Crystal structure of 4-(cytidine 5 '-diphospho)-2-C-methyl-D-erythritol kinase, an enzyme in the non-mevalonate pathway of isoprenoid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; NONMEVALONATE PATHWAY; 2-C-METHYL-D-ERYTHRITOL 4-PHOSPHATE; FUNCTIONAL-CHARACTERIZATION; CATALYTIC RESIDUES; ACTIVE-SITE; BIOSYNTHESIS; PROTEIN; IDENTIFICATION; HEXOKINASE	The crystal structure of the enzyme 4-(cytidine 5'-diphospho)- 2-C-methyl-D-erythritol (CDP-ME) kinase from the thermophilic bacterium Thermus thermophilus HB8 has been determined at 1.7-Angstrom resolution. This enzyme catalyzes phosphorylation of the 2-hydroxyl group of CDP-ME, the fourth step of the non-mevalonate pathway, which is essential for isoprenoid biosynthesis in several pathogenic microorganisms. Since this pathway is absent in humans, it is an important target for the development of novel antimicrobial compounds. The structure of the enzyme is similar to the structures of mevalonate kinase and homoserine kinase, members of the GHMP superfamily. Lys(8) and Asp(125) are active site residues in mevalonate kinase that also appear to play a catalytic role in CDP-ME kinase. Both the mevalonate and the non-mevalonate pathways therefore involve closely related kinases with similar mechanisms. Assaying the enzyme showed that CDP-ME kinase will phosphorylate CDP-ME but not 4-(uridine 5'-diphospho)-2-C-methyl-D-erythritol, indicating the substrate pyrimidine moiety is involved in important interactions with the enzyme.	Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN Yokohama Inst, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; RIKEN Harima Inst, Sayo, Hyogo 6795148, Japan	Yokohama City University; University of Tokyo; RIKEN; University of Tokyo; RIKEN	Park, SY (corresponding author), Yokohama City Univ, Prot Design Lab, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	park@tsurumi.yokohama-cu.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kuzuyama, Tomohisa/0000-0002-7221-5858				Adachi S, 2001, NUCL INSTRUM METH A, V467, P711, DOI 10.1016/S0168-9002(01)00472-7; Aleshin AE, 2000, J MOL BIOL, V296, P1001, DOI 10.1006/jmbi.1999.3494; Altincicek B, 2002, FEBS LETT, V532, P437, DOI 10.1016/S0014-5793(02)03726-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; Bonanno JB, 2001, P NATL ACAD SCI USA, V98, P12896, DOI 10.1073/pnas.181466998; BORK P, 1993, PROTEIN SCI, V2, P31; Cho YK, 2001, J BIOL CHEM, V276, P12573, DOI 10.1074/jbc.M011478200; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kollas AK, 2002, FEBS LETT, V532, P432, DOI 10.1016/S0014-5793(02)03725-0; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; Kuzuyama T, 2002, BIOSCI BIOTECH BIOCH, V66, P1619, DOI 10.1271/bbb.66.1619; Kuzuyama T, 2000, TETRAHEDRON LETT, V41, P2925, DOI 10.1016/S0040-4039(00)00295-1; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; Kuzuyama T, 2000, TETRAHEDRON LETT, V41, P703, DOI 10.1016/S0040-4039(99)02143-7; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; Lange BM, 1999, P NATL ACAD SCI USA, V96, P13714, DOI 10.1073/pnas.96.24.13714; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Luttgen H, 2000, P NATL ACAD SCI USA, V97, P1062, DOI 10.1073/pnas.97.3.1062; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; Potter D, 1997, J BIOL CHEM, V272, P25449, DOI 10.1074/jbc.272.41.25449; QURESHI N, 1981, BIOSYNTHESIS ISOPREN, V1, P47; Rohdich F, 2000, P NATL ACAD SCI USA, V97, P8251, DOI 10.1073/pnas.140209197; Rohdich F, 2002, P NATL ACAD SCI USA, V99, P1158, DOI 10.1073/pnas.032658999; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Romanowski MJ, 2002, PROTEINS, V47, P568, DOI 10.1002/prot.10118; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	38	53	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30022	30027		10.1074/jbc.M304339200	http://dx.doi.org/10.1074/jbc.M304339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771135	hybrid			2022-12-25	WOS:000184507000077
J	Antos, CL; McKinsey, TA; Dreitz, M; Hollingsworth, LM; Zhang, CL; Schreiber, K; Rindt, H; Gorczynski, RJ; Olson, EN				Antos, CL; McKinsey, TA; Dreitz, M; Hollingsworth, LM; Zhang, CL; Schreiber, K; Rindt, H; Gorczynski, RJ; Olson, EN			Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE-3-BETA; CARDIAC-HYPERTROPHY; IN-VIVO; PRESSURE-OVERLOAD; GENE-EXPRESSION; TRICHOSTATIN-A; ANTITUMOR-ACTIVITY; POTENTIAL ROLE; PROTEIN SIR2	Postnatal cardiac myocytes respond to stress signals by hypertrophic growth and activation of a fetal gene program. Recently, we showed that class II histone deacetylases (HDACs) suppress cardiac hypertrophy, and mice lacking the class II HDAC, HDAC9, are sensitized to hypertrophic signals. To further define the roles of HDACs in cardiac hypertrophy, we analyzed the effects of HDAC inhibitors on the responsiveness of primary cardiomyocytes to hypertrophic agonists. Paradoxically, HDAC inhibitors imposed a dose-dependent blockade to hypertrophy and fetal gene activation. We conclude that distinct HDACs play positive or negative roles in the control of cardiomyocyte hypertrophy. HDAC inhibitors are currently being tested in clinical trials as anti-cancer agents. Our results suggest that these inhibitors may also hold promising clinical value as therapeutics for cardiac hypertrophy and heart failure.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Myogen Inc, Westminster, CO 80021 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.		Antos, Christopher L/E-8171-2010					ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941; Butler LM, 2000, CANCER RES, V60, P5165; Butler LM, 2001, CLIN CANCER RES, V7, P962; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Furumai R, 2002, CANCER RES, V62, P4916; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harding VB, 2001, P NATL ACAD SCI USA, V98, P5809, DOI 10.1073/pnas.091102398; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hassig CA, 1997, CHEM BIOL, V4, P783, DOI 10.1016/S1074-5521(97)90111-3; Hill JA, 2000, CIRCULATION, V101, P2863, DOI 10.1161/01.CIR.101.24.2863; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kuwahara K, 2001, MOL CELL BIOL, V21, P2085, DOI 10.1128/MCB.21.6.2085-2097.2001; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Marmorstein R, 2001, STRUCTURE, V9, P1127, DOI 10.1016/S0969-2126(01)00690-6; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; SUGITA K, 1992, CANCER RES, V52, P168; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Woodcock EA, 2002, J BIOL CHEM, V277, P22734, DOI 10.1074/jbc.M110405200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200	61	211	223	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28930	28937		10.1074/jbc.M303113200	http://dx.doi.org/10.1074/jbc.M303113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12761226	hybrid			2022-12-25	WOS:000184421100072
J	Funabara, D; Watabe, S; Mooers, SU; Narayan, S; Dudas, C; Hartshorne, DJ; Siegman, MJ; Butler, TM				Funabara, D; Watabe, S; Mooers, SU; Narayan, S; Dudas, C; Hartshorne, DJ; Siegman, MJ; Butler, TM			Twitchin from molluscan catch muscle - Primary structure and relationship between site-specific phosphorylation and mechanical function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERTEBRATE SMOOTH-MUSCLE; BINDING-PROTEIN-C; LIGHT-CHAIN KINASE; MYOSIN-BINDING; ACTIN-FILAMENTS; CARDIAC MYOSIN; MYBP-C; SKELETAL; FORCE; IDENTIFICATION	The phosphorylation state of the myosin thick filament-associated mini-titin, twitchin, regulates catch force maintenance in molluscan smooth muscle. The full-length cDNA for twitchin from the anterior byssus retractor muscle of the mussel Mytilus was obtained using PCR and 5' rapid amplification of cDNA ends, and its derived amino acid sequence showed a large molecule (similar to 530 kDa) with a motif arrangement as follows: (Ig)(11)(IgFn(2))(2)Ig(Fn)(3)Ig(Fn)(2)Ig(Fn)(3)(Ig)(2)(Fn)(2)(Ig)(2) FnKinase( Ig)(4). Other regions of note include a 79-residue sequence between Ig domains 6 and 7 ( from the N terminus) in which more than 60% of the residues are Pro, Glu, Val, or Lys and between the 7th and 8th Ig domains, a DFRXXL motif similar to that thought to be necessary for high affinity binding of myosin light chain kinase to F-actin. Two major phosphorylation sites, i.e. D1 and D2, were located in linker regions between Ig domains 7 and 8 and Ig domains 21 and 22, respectively. Correlation of the phosphorylation state of twitchin, using antibodies specific to D1 and D2, with mechanical properties suggested that phosphorylation of both D1 and D2 is required for relaxation from the catch state.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA; Univ Tokyo, Lab Aquat Mol Biol & Biotechnol, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Jefferson University; University of Tokyo; University of Arizona	Butler, TM (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042758] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 42758] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHAZI RK, 1974, PFLUG ARCH EUR J PHY, V349, P19, DOI 10.1007/BF00587913; Alyonycheva TN, 1997, J BIOL CHEM, V272, P20866, DOI 10.1074/jbc.272.33.20866; Asara JM, 1999, J AM SOC MASS SPECTR, V10, P35, DOI 10.1016/S1044-0305(98)00129-9; BAGUET F, 1968, J PHYSIOL-LONDON, V198, P127, DOI 10.1113/jphysiol.1968.sp008597; BAYLISS WM, 1927, PRINCIPLES GEN PHYSL, P534; Bozler E, 1930, J PHYSIOL-LONDON, V69, P442, DOI 10.1113/jphysiol.1930.sp002662; Butler TM, 1998, BIOPHYS J, V75, P1904, DOI 10.1016/S0006-3495(98)77631-3; Butler TM, 2001, BIOPHYS J, V80, P415, DOI 10.1016/S0006-3495(01)76024-9; Calaghan SC, 2000, J PHYSIOL-LONDON, V528, P151, DOI 10.1111/j.1469-7793.2000.00151.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE RA, 1972, COMP BIOCHEM PHYSIOL, V43, P321, DOI 10.1016/0300-9629(72)90191-0; Funabara D, 2001, BIOCHEMISTRY-US, V40, P2087, DOI 10.1021/bi0022691; Gruen M, 1999, FEBS LETT, V453, P254, DOI 10.1016/S0014-5793(99)00727-9; HOFMANN PA, 1991, J PHYSIOL-LONDON, V439, P701, DOI 10.1113/jphysiol.1991.sp018689; HOFMANN PA, 1991, J GEN PHYSIOL, V97, P1141, DOI 10.1085/jgp.97.6.1141; ISHII N, 1989, SCIENCE, V243, P1367, DOI 10.1126/science.2922614; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kulke M, 2001, CIRC RES, V89, P874, DOI 10.1161/hh2201.099453; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YH, 2000, J BIOL CHEM, V275, P10989, DOI 10.1074/jbc.275.15.10989; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MOERMAN DG, 1982, CELL, V29, P773, DOI 10.1016/0092-8674(82)90439-1; Mohamed AS, 1998, ARCH BIOCHEM BIOPHYS, V358, P313, DOI 10.1006/abbi.1998.0857; NAUSS KM, 1966, BIOCHEM Z, V345, P173; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; PARNAS J, 1919, PFLUGERS ARCH, V131, P441; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; Siegman MJ, 1997, J MUSCLE RES CELL M, V18, P655, DOI 10.1023/A:1018683823020; Siegman MJ, 1998, P NATL ACAD SCI USA, V95, P5383, DOI 10.1073/pnas.95.9.5383; Smith L, 1999, J BIOL CHEM, V274, P29433, DOI 10.1074/jbc.274.41.29433; Smith L, 2000, FEBS LETT, V480, P298, DOI 10.1016/S0014-5793(00)01931-1; TWAROG BM, 1972, COMP BIOCHEM PHYSIOL, V43, P331, DOI 10.1016/0300-9629(72)90192-2; VIBERT P, 1993, J MUSCLE RES CELL M, V14, P598, DOI 10.1007/BF00141557; VONUEXKULL J, 1919, Z BIOL, V58, P305; Wang Z, 1997, P NATL ACAD SCI USA, V94, P11899, DOI 10.1073/pnas.94.22.11899; Yamada A, 2001, P NATL ACAD SCI USA, V98, P6635, DOI 10.1073/pnas.111585098	39	46	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29308	29316		10.1074/jbc.M303272200	http://dx.doi.org/10.1074/jbc.M303272200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756258	hybrid			2022-12-25	WOS:000184421100116
J	Ha, KS; Kim, KM; Kwon, YG; Bai, SK; Nam, WD; Yoo, YM; Kim, PKM; Chung, HT; Billiar, TR; Kim, YM				Ha, KS; Kim, KM; Kwon, YG; Bai, SK; Nam, WD; Yoo, YM; Kim, PKM; Chung, HT; Billiar, TR; Kim, YM			Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation	FASEB JOURNAL			English	Article						caspase; mitochondria; cytochrome c; Bad phosphorylation; protein kinase G	ALPHA-INDUCED APOPTOSIS; AKT PROTEIN-KINASE; MEDIATED APOPTOSIS; CYTOCHROME-C; SYMPATHETIC NEURONS; DISTINCT MECHANISMS; PARKINSONS-DISEASE; DEATH; NECROSIS; SURVIVAL	Nitric oxide (NO) functions not only as an important signaling molecule in the brain by producing cGMP, but also regulates neuronal cell apoptosis. The mechanism by which NO regulates apoptosis is unclear. In this study, we demonstrated that NO, produced either from the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) or by transfection of neuronal NO synthase, suppressed 6-hydroxydopamine (6-OHDA)-induced apoptosis in PC12 cells by inhibiting mitochondrial cytochrome c release, caspase-3 and -9 activation, and DNA fragmentation. This protection was significantly reversed by the soluble guanylyl cyclase inhibitor 1H-(1,2,4)-oxadiazole[4,3-a]quinoxalon-1-one, indicating that cGMP is a key mediator in NO-mediated anti-apoptosis. Moreover, the membrane-permeable cGMP analog 8-Br-cGMP inhibited 6-OHDA-induced apoptosis. These anti-apoptotic effects of SNAP and 8-Br-cGMP were suppressed by cGMP-dependent protein kinase G (PKG) inhibitor KT5823, indicating that PKG is a downstream signal mediator in the suppression of apoptosis by NO and cGMP. Both SNAP and 8-Br-cGMP induced endogenous Akt activation and Bad phosphorylation, resulting in the inhibition of Bad translocation to mitochondria; these effects were inhibited by KT5823 and the phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and Wortmannin. Our data suggest that the NO/cGMP pathway suppresses 6-OHDA-induced PC12 cell apoptosis by suppressing the mitochondrial apoptosis signal via PKG/PI3K/Akt-dependent Bad phosphorylation.	Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Vasc Syst Res Ctr, Chunchon, Kangwon Do, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; Wonkwang Univ, Sch Med, Dept Microbiol & Immunol, Iksan, Chonbuk, South Korea	Kangwon National University; Kangwon National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wonkwang University	Kim, YM (corresponding author), Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon, Kangwon Do, South Korea.	ymkim@kangwon.ac.kr	Ha, Kwon-Soo/AAU-4417-2020	Ha, Kwon-Soo/0000-0002-4219-1787				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEL PL, 1997, SCIENCE, V278, P687; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Estevez AG, 1998, J NEUROSCI, V18, P923; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Estevez AG, 1998, J NEUROSCI, V18, P3708; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hengartner MO, 2001, NATURE, V412, P27, DOI 10.1038/35083663; HILL IE, 1995, BRAIN RES, V676, P398, DOI 10.1016/0006-8993(95)00145-G; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lotharius J, 1999, J NEUROSCI, V19, P1284; McDonald L J, 1995, Adv Pharmacol, V34, P263; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Ozes ON, 1999, NATURE, V401, P82; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; RICHTERLANDSBERG C, 1994, J NEUROCHEM, V63, P2202; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Tariq M, 2001, BRAIN RES BULL, V54, P77, DOI 10.1016/S0361-9230(00)00427-5; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	50	137	148	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1036	1047		10.1096/fj.02-0738com	http://dx.doi.org/10.1096/fj.02-0738com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773486				2022-12-25	WOS:000183818000007
J	Yegutkin, GG; Samburski, SS; Jalkanen, S				Yegutkin, GG; Samburski, SS; Jalkanen, S			Soluble purine-converting enzymes circulate in human blood and regulate extracellular ATP level via counteracting pyrophosphatase and phosphotransfer reactions	FASEB JOURNAL			English	Article						purine metabolism; human serum; soluble nucleotide kinases; adenosine	VASCULAR ENDOTHELIAL-CELLS; LIVER PLASMA-MEMBRANES; ADENOSINE-DEAMINASE; ECTO-ATPASE; NUCLEOTIDE PYROPHOSPHOHYDROLASE; NUCLEOSIDE DIPHOSPHOKINASE; INORGANIC PYROPHOSPHATE; HUMAN SERUM; METABOLISM; 5'-NUCLEOTIDASE	Extracellular ATP and other purines play a crucial role in the vasculature, and their turnover is selectively governed by a network of ectoenzymes expressed both on endothelial and hematopoietic cells. By studying the whole pattern of purine metabolism in human serum, we revealed the existence of soluble enzymes capable of both inactivating and transphosphorylating circulating purines. Evidence for this was obtained by using independent assays, including chromatographic analyses with H-3-labeled and unlabeled nucleotides and adenosine, direct transfer of gamma-terminal phosphate from [gamma-P-32]ATP to NDP/AMP, and bioluminescent measurement of ATP metabolism. Based on substrate-specificity and competitive studies, we identified three purine-inactivating enzymes in human serum, nucleotide pyrophosphatase (EC 3.6.1.9), 5'-nucleotidase (EC 3.1.3.5), and adenosine deaminase (EC 3.5.4.4), whereas an opposite ATP-generating pathway is represented by adenylate kinase (EC 2.7.4.3) and NDP kinase (EC 2.7.4.6). Comparative kinetic analysis revealed that the V-max values for soluble nucleotide kinases significantly exceed those of counteracting nucleotidases, whereas the apparent K-m values for serum enzymes were fairly comparable and varied within a range of 40-70 mumol/l. Identification of soluble enzymes contributing, along with membrane-bound ectoenzymes, to the active cycling between circulating ATP and other purines provides a novel insight into the regulatory mechanisms of purine homeostasis in the blood.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Microbiol, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; University of Turku; Finland National Institute for Health & Welfare	Yegutkin, GG (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.	gennady.yegutkin@utu.fi	Yegutkin, Gennady G./K-3815-2014	Yegutkin, Gennady G./0000-0001-6684-7982				Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Aldrich MB, 2000, BIOCHEM BIOPH RES CO, V272, P311, DOI 10.1006/bbrc.2000.2773; BEUKERS MW, 1993, BIOCHEM PHARMACOL, V46, P1959, DOI 10.1016/0006-2952(93)90637-C; Burnstock G, 2002, CLIN MED, V2, P45, DOI 10.7861/clinmedicine.2-1-45; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Cardenal A, 1998, J RHEUMATOL, V25, P2175; Cardenal A, 1996, ARTHRITIS RHEUM, V39, P252, DOI 10.1002/art.1780390211; Chan ESL, 2002, ARTHRITIS RES, V4, P266, DOI 10.1186/ar419; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; CRACK BE, 1994, BRIT J PHARMACOL, V113, P1432, DOI 10.1111/j.1476-5381.1994.tb17157.x; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Grobben B, 2000, BRIT J PHARMACOL, V130, P139, DOI 10.1038/sj.bjp.0703289; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Marcus AJ, 2001, ARTERIOSCL THROM VAS, V21, P178, DOI 10.1161/01.ATV.21.2.178; MEGHJI P, 1995, BIOCHEM J, V308, P725, DOI 10.1042/bj3080725; Park W, 1996, J RHEUMATOL, V23, P1233; Pinsky DJ, 2002, J CLIN INVEST, V109, P1031, DOI 10.1172/JCI200210649; Ralevic V, 1998, PHARMACOL REV, V50, P413; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; ROBSON S, 2000, EMERGING THER TARGET, V4, P155; Rutsch F, 2001, AM J PATHOL, V158, P543, DOI 10.1016/S0002-9440(10)63996-X; SIMMONDS RJ, 1981, J CHROMATOGR, V226, P369, DOI 10.1016/S0378-4347(00)86071-5; Spychala J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X; SUNDERMAN FW, 1990, ANN CLIN LAB SCI, V20, P123; Terkeltaub RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; UNGERER JPJ, 1992, CLIN CHEM, V38, P1322; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Yegutkin GG, 1997, BIOCHEMISTRY-MOSCOW+, V62, P619; Yegutkin GG, 2000, BBA-BIOMEMBRANES, V1466, P234, DOI 10.1016/S0005-2736(00)00165-6; Yegutkin GG, 1998, BBA-BIOMEMBRANES, V1373, P227, DOI 10.1016/S0005-2736(98)00108-4; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; Zimmermann H, 1999, NAT MED, V5, P987, DOI 10.1038/12419; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	42	78	79	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1328	+		10.1096/fj.02-1136fje	http://dx.doi.org/10.1096/fj.02-1136fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759341				2022-12-25	WOS:000183165000014
J	Le Gurun, S; Martin, D; Formenton, A; Maechler, P; Caille, D; Waeber, G; Meda, P; Haefliger, JA				Le Gurun, S; Martin, D; Formenton, A; Maechler, P; Caille, D; Waeber, G; Meda, P; Haefliger, JA			Connexin-36 contributes to control function of insulin-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; K-ATP CHANNELS; CA2+ OSCILLATIONS; ISLET CELLS; SECRETION; GLUCOSE; EXPRESSION; OVEREXPRESSION; ESTABLISHMENT; PROTEINS	Connexin-36 (Cx36) is a gap junction protein expressed by the insulin-producing beta-cells. We investigated the contribution of this protein in normal beta-cell function by using a viral gene transfer approach to alter Cx36 content in the insulin-producing line of INS-1E cells and rat pancreatic islets. Transcripts for Cx43, Cx45, and Cx36 were detected by reverse transcriptase-PCR in freshly isolated pancreatic islets, whereas only a transcript for Cx36 was detected in INS-1E cells. After infection with a sense viral vector, which induced de novo Cx36 expression in the Cx-defective HeLa cells we used to control the transgene expression, Western blot, immunofluorescence, and freeze-fracture analysis showed a large increase of Cx36 within INS-1E cell membranes. In contrast, after infection with an antisense vector, Cx36 content was decreased by 80%. Glucose-induced insulin release and insulin content were decreased, whether infected INS-1E cells expressed Cx36 levels that were largely higher or lower than those observed in wild-type control cells. In both cases, basal insulin secretion was unaffected. Comparable observations on basal secretion and insulin content were made in freshly isolated rat pancreatic islets. The data indicate that large changes in Cx36 alter insulin content and, at least in INS-1E cells, also affect glucose-induced insulin release.	Univ Lausanne Hosp, Dept Internal Med, Lausanne 1011, Switzerland; Univ Geneva, Dept Med, Geneva 1211 4, Switzerland; Univ Geneva, Dept Morphol, Geneva 1211 4, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Geneva	Haefliger, JA (corresponding author), CHU Vaudois, Lab Mol Biol 19 135S, Dept Internal Med, Rue Bugnon 46, Lausanne 1011, Switzerland.			Maechler, Pierre/0000-0002-2005-1433; Waeber, Gerard/0000-0003-4193-788X; Haefliger, Jacques-Antoine/0000-0003-2732-1667	NIDDK NIH HHS [DK-63443] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063443] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; Belluardo N, 2000, BRAIN RES, V865, P121, DOI 10.1016/S0006-8993(00)02300-3; BERGSTEN P, 1995, AM J PHYSIOL-ENDOC M, V268, pE282, DOI 10.1152/ajpendo.1995.268.2.E282; BOSCO D, 1991, ENDOCRINOLOGY, V129, P3157, DOI 10.1210/endo-129-6-3157; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Calabrese A, 2003, DIABETES, V52, P417, DOI 10.2337/diabetes.52.2.417; Caton D, 2003, J CELL SCI, V116, P2285, DOI 10.1242/jcs.00442; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Charollais A, 2000, J CLIN INVEST, V106, P235, DOI 10.1172/JCI9398; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; Condorelli DF, 2000, BRAIN RES REV, V32, P72, DOI 10.1016/S0165-0173(99)00068-5; CSETE ME, 1995, TRANSPLANTATION, V59, P263, DOI 10.1097/00007890-199501270-00019; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Garcia-Ocana A, 2003, J BIOL CHEM, V278, P343, DOI 10.1074/jbc.M207848200; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; Hamid M, 2001, CELL TRANSPLANT, V10, P153; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; Jonkers FC, 1999, J PHYSIOL-LONDON, V520, P839, DOI 10.1111/j.1469-7793.1999.00839.x; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; MEDA P, 1990, J CLIN INVEST, V86, P759, DOI 10.1172/JCI114772; Meda P, 1996, ANN ENDOCRINOL-PARIS, V57, P481; MEDA P, 1993, ENDOCRINOLOGY, V133, P2371, DOI 10.1210/en.133.5.2371; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nakazaki M, 2002, J PHYSIOL-LONDON, V540, P781; NIELSEN JH, 1979, DIABETOLOGIA, V16, P97, DOI 10.1007/BF01225457; Richard G, 2000, EXP DERMATOL, V9, P77, DOI 10.1034/j.1600-0625.2000.009002077.x; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Rubi B, 2002, BIOCHEM J, V364, P219, DOI 10.1042/bj3640219; Rubi B, 2001, J BIOL CHEM, V276, P36391, DOI 10.1074/jbc.M104999200; SCHAACK J, 1995, J VIROL, V69, P3920, DOI 10.1128/JVI.69.6.3920-3923.1995; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; Serre-Beinier V, 2000, DIABETES, V49, P727, DOI 10.2337/diabetes.49.5.727; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Spray DC, 1998, CIRC RES, V83, P679, DOI 10.1161/01.RES.83.6.679; Tawadros T, 2002, J CELL SCI, V115, P385; VOZZI C, 1995, J CELL BIOL, V131, P1561, DOI 10.1083/jcb.131.6.1561; Vozzi C, 2001, REPRODUCTION, V122, P619, DOI 10.1530/reprod/122.4.619; WHITE TW, 1995, KIDNEY INT, V48, P1148, DOI 10.1038/ki.1995.398; White TW, 1996, J BIOENERG BIOMEMBR, V28, P339, DOI 10.1007/BF02110110; WOLLHEIM CB, 1990, METHOD ENZYMOL, V192, P223; WOLLHEIM CB, 1990, METHOD ENZYMOL, V192, P188	46	48	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37690	37697		10.1074/jbc.M212382200	http://dx.doi.org/10.1074/jbc.M212382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12766175				2022-12-25	WOS:000185437200085
J	Fittipaldi, A; Ferrari, A; Zoppe, M; Arcangeli, C; Pellegrini, V; Beltram, F; Giacca, M				Fittipaldi, A; Ferrari, A; Zoppe, M; Arcangeli, C; Pellegrini, V; Beltram, F; Giacca, M			Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ISCHEMIC BRAIN INJURY; NF-KAPPA-B; HEPARAN-SULFATE; TRANSDUCTION DOMAIN; PLASMA-MEMBRANE; CHOLERA-TOXIN; ENDOPLASMIC-RETICULUM; DELIVERY; INTERNALIZATION	The transactivator protein of human immunodeficiency virus type 1 Tat has the unique property of mediating the delivery of large protein cargoes into the cells when present in the extracellular milieu. Here we show that Tat fusion proteins are internalized by the cells through a temperature-dependent endocytic pathway that originates from cell membrane lipid rafts and follows caveolar endocytosis. These conclusions are supported by the study of the slow kinetics of the internalization of Tat endosomes, by their resistance to nonionic detergents, the colocalization of internalized Tat with markers of caveolar endocytosis, and the impairment of the internalization process by drugs that disrupt lipid rafts or disturb caveolar trafficking. These results are of interest for all those who exploit Tat as a vehicle for transcellular protein delivery.	Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy; Ist Nazl Fis Nucl, NEST, I-56100 Pisa, Italy; Scuola Normale Super Pisa, I-56100 Pisa, Italy; CNR, Ist Fisiol Clin, I-56100 Pisa, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); Istituto Nazionale di Fisica Nucleare (INFN); Scuola Normale Superiore di Pisa; Consiglio Nazionale delle Ricerche (CNR)	Giacca, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Padriciano 99, I-34012 Trieste, Italy.	giacca@icgeb.org	Arcangeli, Caterina/AFR-1728-2022; Giacca, Mauro/J-9287-2016; Beltram, Fabio/L-9486-2019	Arcangeli, Caterina/0000-0002-5459-1024; Giacca, Mauro/0000-0003-2927-7225; Beltram, Fabio/0000-0002-6081-436X; ZOPPE', Monica/0000-0003-4590-0718				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Cao GD, 2002, J NEUROSCI, V22, P5423; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Datta K, 2001, CANCER RES, V61, P1768; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FERRARI A, 2003, IN PRESS MOL THER; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FUJIMOTO T, 1995, J CELL SCI, V108, P7; Ghezzi S, 2000, BIOCHEM BIOPH RES CO, V270, P992, DOI 10.1006/bbrc.2000.2523; Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587; Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002; Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Sacchetti A, 2001, J CELL BIOCHEM, P117; Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393; Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simpson JC, 1996, EXP CELL RES, V229, P447, DOI 10.1006/excr.1996.0390; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Tasciotti E, 2003, CANCER GENE THER, V10, P64, DOI 10.1038/sj.cgt.7700526; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wacker I, 1997, J CELL SCI, V110, P1453; Wang HY, 2002, J CLIN INVEST, V109, P1463, DOI 10.1172/JCI200215399; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466	62	375	409	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34141	34149		10.1074/jbc.M303045200	http://dx.doi.org/10.1074/jbc.M303045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12773529	hybrid			2022-12-25	WOS:000185047500067
J	Ahn, HC; Ohkubo, T; Iwai, S; Morikawa, K; Lee, BJ				Ahn, HC; Ohkubo, T; Iwai, S; Morikawa, K; Lee, BJ			Interaction of T4 endonuclease V with DNA - Importance of the flexible loop regions in protein-DNA interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 ENDONUCLEASE-V; NUCLEAR-MAGNETIC-RESONANCE; EXCISION-REPAIR ENZYME; SITE-DIRECTED MUTAGENESIS; N-15 NMR RELAXATION; MODEL-FREE APPROACH; SYN THYMINE DIMER; PYRIMIDINE DIMER; CIS-SYN; BACKBONE DYNAMICS	T4 endonuclease V (T4 endo V), a thymine dimer-specific DNA repair enzyme, and its interaction with DNA were investigated by nuclear magnetic resonance (NMR) spectroscopy. Backbone resonance assignment, chemical shift mapping, and N-15 relaxation measurements were employed to the free and DNA-bound enzymes. The secondary structure and the tertiary fold of T4 endo V in solution were consistent with those from the crystallographic study. The backbone H-1 and N-15 chemical shift perturbation upon the addition of DNA without a lesion revealed that the residues including Arg(3), Arg(22)-Arg(26), Lys(45)-Phe(60), and Lys(86)-Thr(88) participate in DNA binding. However, when DNA with a lesion was added to the enzyme and concomitantly the catalytic reaction was completed, the resonances of Arg(22), Glu(23), and Arg(26), which constitute the catalytic active site, and the resonance of Thr(88), were perturbed in a different manner. The region around Lys(45)-Ser(47) was found to be involved in DNA binding, which have not been reported elsewhere. The backbone relaxation measurements of the free and DNA-bound enzymes indicated that two loop regions, Lys(45)-Phe(60) and Lys(86)-Asp(92), show the high degree of backbone flexibility. These results imply that two flexible loop regions may play an important role in DNA binding and in scanning along DNA duplex to search the thymine dimer sites in UV-damaged DNA.	Seoul Natl Univ, Coll Pharm, Natl Res Lab MPS, Seoul 151742, South Korea; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Biomol Engn Res Inst, Osaka 5680874, Japan	Seoul National University (SNU); Osaka University	Lee, BJ (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab MPS, San 56-1, Seoul 151742, South Korea.		Lee, Bong-Jin/AAQ-1609-2020	Lee, Bong-Jin/0000-0001-7896-2961				Ahn HC, 2002, J BIOMOL NMR, V22, P383, DOI 10.1023/A:1014982001056; Buchko GW, 1999, BIOCHEMISTRY-US, V38, P15116, DOI 10.1021/bi991755p; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOBSON ML, 1989, MUTAT RES, V218, P49; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; Dong J, 2000, BIOCHEMISTRY-US, V39, P13241, DOI 10.1021/bi001437m; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FREIDBURG E, 1971, J BACTERIOL, V106, P500; Furuta M, 1997, APPL ENVIRON MICROB, V63, P1551, DOI 10.1128/AEM.63.4.1551-1556.1997; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GRUNSKIN EA, 1986, J BIOL CHEM, V261, P2696; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KEMMINK J, 1987, EUR J BIOCHEM, V162, P37, DOI 10.1111/j.1432-1033.1987.tb10538.x; LATHAM KA, 1995, J BACTERIOL, V177, P5166, DOI 10.1128/jb.177.17.5166-5168.1995; Lee AL, 1997, BIOCHEMISTRY-US, V36, P14306, DOI 10.1021/bi970830y; LEE BJ, 1994, BIOCHEMISTRY-US, V33, P57, DOI 10.1021/bi00167a008; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MACMILLAN S, 1981, J VIROL, V40, P211; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; McCullough AK, 1998, J BIOL CHEM, V273, P13136, DOI 10.1074/jbc.273.21.13136; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; Nyaga SG, 1997, BIOCHEMISTRY-US, V36, P4080, DOI 10.1021/bi962218x; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; Shiota S, 1997, P NATL ACAD SCI USA, V94, P593, DOI 10.1073/pnas.94.2.593; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069; YASUDA S, 1970, P NATL ACAD SCI USA, V67, P1839, DOI 10.1073/pnas.67.4.1839	46	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30985	30992		10.1074/jbc.M210939200	http://dx.doi.org/10.1074/jbc.M210939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783877	hybrid			2022-12-25	WOS:000184658800073
J	Brevet, A; Chen, J; Commans, S; Lazennec, C; Blanquet, S; Plateau, P				Brevet, A; Chen, J; Commans, S; Lazennec, C; Blanquet, S; Plateau, P			Anticodon recognition in evolution - Switching tRNA specificity of an aminoacyl-tRNA synthetase by site-directed peptide transplantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-MODIFIED ENZYMES; ASPARAGINYL-TRANSFER-RNA; GLUTAMINYL-TRANSFER-RNA; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; BINDING DOMAIN; CRYSTAL-STRUCTURE; DISCRIMINATOR BASE; IDENTITY ELEMENTS; TRANSITION-STATE	The highly conserved aspartyl-, asparaginyl-, and lysyl-tRNA synthetases compose one subclass of amino-acyl-tRNA synthetases, called IIb. The three enzymes possess an OB-folded extension at their N terminus. The function of this extension is to specifically recognize the anticodon triplet of the tRNA. Three-dimensional models of bacterial aspartyl- and lysyl-tRNA synthetases complexed to tRNA indicate that a rigid scaffold of amino acid residues along the five beta-strands of the OB-fold accommodates the base U at the center of the anticodon. The binding of the adjacent anticodon bases occurs through interactions with a flexible loop joining strands 4 and 5 (L(45)). As a result, a switching of the specificity of lysyl-tRNA synthetase from tRNA(Lys) (anticodon UUU) toward tRNA(Asp) (GUC) could be attempted by transplanting the small loop L(45) of aspartyl- tRNA synthetase inside lysyl-tRNA synthetase. Upon this transplantation, lysyl-tRNA synthetase loses its capacity to aminoacylate tRNA(Lys). In exchange, the chimeric enzyme acquires the capacity to charge tRNA(Asp) with lysine. Upon giving the tRNA(Asp) substrate the discriminator base of tRNA(Lys), the specificity shift is improved. The change of specificity was also established in vivo. Indeed, the transplanted lysyl-tRNA synthetase succeeds in suppressing a missense Lys --> Asp mutation inserted into the beta-lactamase gene. These results functionally establish that sequence variation in a small peptide region of subclass IIb aminoacyl-tRNA synthetases contributes to specification of nucleic acid recognition. Because this peptide element is not part of the core catalytic structure, it may have evolved independently of the active sites of these synthetases.	Ecole Polytech, Biochim Lab, CNRS, UMR 7654, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, Biochim Lab, CNRS, UMR 7654, F-91128 Palaiseau, France.	plateau@botrytis.polytechnique.fr						Agrawal V, 2001, BMC Struct Biol, V1, P5, DOI 10.1186/1472-6807-1-5; AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; Auld DS, 1996, EMBO J, V15, P1142, DOI 10.1002/j.1460-2075.1996.tb00452.x; Becker HD, 1996, BIOCHEMISTRY-US, V35, P7447, DOI 10.1021/bi9601058; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; BLANQUET S, 1974, EUR J BIOCHEM, V44, P343, DOI 10.1111/j.1432-1033.1974.tb03491.x; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; BREVET A, 1995, J BIOL CHEM, V270, P14439, DOI 10.1074/jbc.270.24.14439; Briand C, 2000, J MOL BIOL, V299, P1051, DOI 10.1006/jmbi.2000.3819; Brodersen DE, 2002, J MOL BIOL, V316, P725, DOI 10.1006/jmbi.2001.5359; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Charron C, 2003, EMBO J, V22, P1632, DOI 10.1093/emboj/cdg148; COMMANS S, 1995, BIOCHEMISTRY-US, V34, P8180, DOI 10.1021/bi00025a025; COMMANS S, 1995, J MOL BIOL, V253, P100, DOI 10.1006/jmbi.1995.0539; Commans S, 1998, J MOL BIOL, V278, P801, DOI 10.1006/jmbi.1998.1711; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Eriani G, 1999, J MOL BIOL, V291, P761, DOI 10.1006/jmbi.1999.3012; Feng L, 2003, P NATL ACAD SCI USA, V100, P5676, DOI 10.1073/pnas.0631525100; FRUGIER M, 1994, BIOCHEMISTRY-US, V33, P9912, DOI 10.1021/bi00199a013; Gale AJ, 1996, BIOCHEMISTRY-US, V35, P608, DOI 10.1021/bi9520904; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; GUAN Y, 1995, PROTEIN SCI, V4, P187; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; Ibba M, 1997, P NATL ACAD SCI USA, V94, P14383, DOI 10.1073/pnas.94.26.14383; Ibba M, 1999, P NATL ACAD SCI USA, V96, P418, DOI 10.1073/pnas.96.2.418; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; LAWRENCE F, 1973, EUR J BIOCHEM, V36, P234, DOI 10.1111/j.1432-1033.1973.tb02905.x; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; LI SH, 1993, J BIOL CHEM, V268, P18335; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; Moulinier L, 2001, EMBO J, V20, P5290, DOI 10.1093/emboj/20.18.5290; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAMEKI N, 1992, BIOCHEM BIOPH RES CO, V189, P856, DOI 10.1016/0006-291X(92)92282-3; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; Raczniak G, 2001, J BIOL CHEM, V276, P45862, DOI 10.1074/jbc.M109494200; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Sauter C, 2000, J MOL BIOL, V299, P1313, DOI 10.1006/jmbi.2000.3791; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHMITT E, 1993, J MOL BIOL, V233, P615, DOI 10.1006/jmbi.1993.1540; SHIMIZU M, 1992, J MOL EVOL, V35, P436; Soll D, 2000, P NATL ACAD SCI USA, V97, P14224, DOI 10.1073/pnas.97.26.14224; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; Terada T, 2002, NAT STRUCT BIOL, V9, P257, DOI 10.1038/nsb777; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tumbula-Hansen D, 2002, J BIOL CHEM, V277, P37184, DOI 10.1074/jbc.M204767200; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wei RR, 2001, J BIOL CHEM, V276, P28380, DOI 10.1074/jbc.M102444200	66	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30927	30935		10.1074/jbc.M302618200	http://dx.doi.org/10.1074/jbc.M302618200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12766171	hybrid			2022-12-25	WOS:000184658800066
J	Chen, M; Abele, R; Tampe, R				Chen, M; Abele, R; Tampe, R			Peptides induce ATP hydrolysis at both subunits of the transporter associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; BINDING CASSETTE TRANSPORTER; VIRUS PROTEIN ICP47; MYOSIN MOTOR DOMAIN; MHC CLASS-I; NUCLEOTIDE-BINDING; ABC TRANSPORTER; ALUMINUM FLUORIDE; TRANSITION-STATE; MOLECULAR-MECHANISM	The transporter associated with antigen processing ( TAP) plays a key role in the adaptive immune response by pumping antigenic peptides into the endoplasmic reticulum for subsequent loading of major histocompatibility complex class I molecules. TAP is a heterodimer consisting of TAP1 and TAP2. Each subunit is composed of a transmembrane domain and a nucleotide-binding domain, which energizes the peptide transport. To analyze ATP hydrolysis of each subunit we developed a method of trapping 8-azido-nucleotides to TAP in the presence of phosphate transition state analogs followed by photocross-linking, immunoprecipitation, and high resolution SDS-PAGE. Strikingly, trapping of both TAP subunits by beryllium fluoride is peptide-specific. The peptide concentration required for half-maximal trapping is identical for TAP1 and TAP2 and directly correlates with the peptide binding affinity. Only a background level of trapping was observed for low affinity peptides or in the presence of the herpes simplex viral protein ICP47, which specifically blocks peptide binding to TAP. Importantly, the peptide-induced trapped state is reached after ATP hydrolysis and not in a backward reaction of ADP binding and trapping. In the trapped state, TAP can neither bind nor exchange nucleotides, whereas peptide binding is not affected. In summary, these data support the model that peptide binding induces a conformation that triggers ATP hydrolysis in both subunits of the TAP complex within the catalytic cycle.	Goethe Univ Frankfurt, Inst Biochem, Bioctr, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Goethe Univ Frankfurt, Inst Biochem, Bioctr, Marie Curie Str 9, D-60439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; Arora S, 2001, P NATL ACAD SCI USA, V98, P7241, DOI 10.1073/pnas.131132198; Cai J, 2002, BIOCHEMISTRY-US, V41, P8058, DOI 10.1021/bi012082p; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Daumke O, 2001, EUR J BIOCHEM, V268, P4776, DOI 10.1046/j.1432-1327.2001.02406.x; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Kyritsis C, 2001, J BIOL CHEM, V276, P48031, DOI 10.1074/jbc.M108528200; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MARUTA S, 1993, J BIOL CHEM, V268, P7093; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 2002, J MOL BIOL, V324, P965, DOI 10.1016/S0022-2836(02)01148-8; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Neumann L, 1999, J MOL BIOL, V294, P1203, DOI 10.1006/jmbi.1999.3329; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Park S, 1999, BBA-PROTEIN STRUCT M, V1430, P127, DOI 10.1016/S0167-4838(98)00262-3; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Sankaran B, 1997, FEBS LETT, V417, P119, DOI 10.1016/S0014-5793(97)01268-4; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Saveanu L, 2001, J BIOL CHEM, V276, P22107, DOI 10.1074/jbc.M011221200; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; van Endert PM, 2002, TRENDS BIOCHEM SCI, V27, P454, DOI 10.1016/S0968-0004(02)02090-X; van Endert PM, 1999, J BIOL CHEM, V274, P14632, DOI 10.1074/jbc.274.21.14632; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; Wittinghofer A, 1997, CURR BIOL, V7, pR682, DOI 10.1016/S0960-9822(06)00355-1	57	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29686	29692		10.1074/jbc.M302757200	http://dx.doi.org/10.1074/jbc.M302757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777379	hybrid			2022-12-25	WOS:000184507000039
J	Echave, P; Tamarit, J; Cabiscol, E; Ros, J				Echave, P; Tamarit, J; Cabiscol, E; Ros, J			Novel antioxidant role of alcohol dehydrogenase E from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; OXIDATIVE STRESS; ADHE GENE; SACCHAROMYCES-CEREVISIAE; ETHANOL DEHYDROGENASE; HYDROGEN-PEROXIDE; PROPANEDIOL OXIDOREDUCTASE; SUPEROXIDE-DISMUTASE; ZYMOMONAS-MOBILIS; PROTECTIVE ROLE	Alcohol dehydrogenase E (AdhE) is an Fe-enzyme that, under anaerobic conditions, is involved in dissimilation of glucose. The enzyme is also present under aerobic conditions, its amount is about one-third and its activity is only one-tenth of the values observed under anaerobic conditions. Nevertheless, its function in the presence of oxygen remained ignored. The data presented in this paper led us to propose that the enzyme has a protective role against oxidative stress. Our results indicated that cells deleted in adhE gene could not grow aerobically in minimal media, were extremely sensitive to oxidative stress and showed division defects. In addition, compared with wild type, mutant cells displayed increased levels of internal peroxides (even higher than those found in a DeltakatG strain) and increased protein carbonyl content. This pleiotropic phenotype disappeared when the adhE gene was reintroduced into the defective strain. The purified enzyme was highly reactive with hydrogen peroxide (with a K-i of 5 muM), causing inactivation due to a metal-catalyzed oxidation reaction. It is possible to prevent this reactivity to hydrogen peroxide by zinc, which can replace the iron atom at the catalytic site of AdhE. This can also be achieved by addition of ZnSO4 to cell cultures. In such conditions, addition of hydrogen peroxide resulted in reduced cell viability compared with that obtained without the Zn treatment. We therefore propose that AdhE acts as a H2O2 scavenger in Escherichia coli cells grown under aerobic conditions.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Av Rovira Roure 44, Lleida 25198, Spain.	joaquim.ros@cmb.udl.es	Tamarit, Jordi/C-6316-2008; Cabiscol, Elisa/A-4584-2009; ROS, Joaquim/ABG-7487-2020; Ros, Joaquim/A-7507-2010	Tamarit, Jordi/0000-0003-3227-6928; Cabiscol, Elisa/0000-0003-2795-7999; ROS, Joaquim/0000-0003-0901-8648; 				Aristarkhov A, 1996, J BACTERIOL, V178, P4327, DOI 10.1128/jb.178.14.4327-4332.1996; BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; Cabiscol E, 2002, J BIOL CHEM, V277, P44531, DOI 10.1074/jbc.M206525200; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHEN YM, 1991, J BACTERIOL, V173, P8009, DOI 10.1128/jb.173.24.8009-8013.1991; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; CLARK D, 1980, J BACTERIOL, V141, P177, DOI 10.1128/JB.141.1.177-183.1980; CLARK DP, 1989, FEMS MICROBIOL LETT, V63, P223, DOI 10.1111/j.1574-6968.1989.tb03398.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DARI R, 1982, BIOCHIMIE, V64, P6273; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Echave P, 2002, P NATL ACAD SCI USA, V99, P4626, DOI 10.1073/pnas.072504199; Espinosa A, 2001, J BIOL CHEM, V276, P20136, DOI 10.1074/jbc.M101349200; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HUISMAN O, 1984, P NATL ACAD SCI-BIOL, V81, P4490, DOI 10.1073/pnas.81.14.4490; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; Jakubowski W, 2000, FREE RADICAL BIO MED, V28, P659, DOI 10.1016/S0891-5849(99)00266-X; KESSLER D, 1992, J BIOL CHEM, V267, P18073; KESSLER D, 1991, FEBS LETT, V281, P59, DOI 10.1016/0014-5793(91)80358-A; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; LAURELL CB, 1966, ANAL BIOCHEM, V97, P145; LEONARDO MR, 1993, J BACTERIOL, V175, P870, DOI 10.1128/JB.175.3.870-878.1993; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; MATAYOSHI S, 1989, J GEN MICROBIOL, V135, P525; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7571; Membrillo-Hernandez J, 2000, J BIOL CHEM, V275, P33869, DOI 10.1074/jbc.M005464200; Mikulskis A, 1997, J BACTERIOL, V179, P7129, DOI 10.1128/jb.179.22.7129-7134.1997; MILLER JH, 1972, EXPT MOL GENETICS, P190; NOMURA S, 1989, MICROBIOL IMMUNOL, V33, P23, DOI 10.1111/j.1348-0421.1989.tb01494.x; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; Obinger C, 1997, ARCH BIOCHEM BIOPHYS, V342, P58, DOI 10.1006/abbi.1997.9988; Obradors N, 1998, EUR J BIOCHEM, V258, P207, DOI 10.1046/j.1432-1327.1998.2580207.x; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; SAK BD, 1989, P NATL ACAD SCI USA, V86, P3271, DOI 10.1073/pnas.86.9.3271; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Tamarit J, 1997, J BACTERIOL, V179, P1102, DOI 10.1128/jb.179.4.1102-1104.1997; Tang Y, 2002, MICROBIOL-SGM, V148, P1027, DOI 10.1099/00221287-148-4-1027; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; YAMATO M, 1995, MICROBIOL IMMUNOL, V39, P255, DOI 10.1111/j.1348-0421.1995.tb02198.x; Yamato M, 1998, J GEN APPL MICROBIOL, V44, P173, DOI 10.2323/jgam.44.173; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	54	87	92	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30193	30198		10.1074/jbc.M304351200	http://dx.doi.org/10.1074/jbc.M304351200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12783863	Green Published, hybrid			2022-12-25	WOS:000184507000098
J	Isas, JM; Patel, DR; Jao, C; Jayasinghe, S; Cartailler, JP; Haigler, HT; Langen, R				Isas, JM; Patel, DR; Jao, C; Jayasinghe, S; Cartailler, JP; Haigler, HT; Langen, R			Global structural changes in annexin 12 - The roles of phospholipid, Ca2+, and pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID-BILAYERS; XII; MEMBRANE; FORM; MITOCHONDRIA; LOCALIZATION; CARDIOLIPIN; MICROSCOPY; VESICLES; BINDING	Ca2+-dependent membrane interaction has long been recognized as a general property of the annexin (ANX) family of proteins. More recently, it has become clear that ANXs can also undergo Ca2+-independent membrane interactions at mildly acidic pH. Here we use site-directed spin labeling in combination with circular dichroism and biochemical labeling methods to compare the structure and membrane topography of these two different membrane-bound forms of ANX12. Our results reveal strong similarities between the solution structure and the structure of the Ca2+-dependent membrane-bound form at neutral pH. In contrast, all Ca2+-independent membrane interactions tested resulted in large scale conformational changes and membrane insertion. Pairs of spin labels that were in close proximity across the interface of different domains of the protein in both the soluble and Ca2+-dependent membrane form were > 25 Angstrom apart in the Ca2+-independent membrane-bound form. Despite these major conformational changes, the overall secondary structure content did not appear to be strongly altered and ANX12 remained largely helical. Thus, Ca2+-independent membrane interaction leads to massive refolding but not unfolding. Refolding did not occur at low pH in the absence of membranes but occurred within a few seconds after phospholipid vesicles were added. The phospholipid composition of the vesicles was an important modulator of Ca2+-independent membrane interaction. For example, cardiolipin-containing vesicles induced Ca2+-independent membrane interaction even at near neutral pH, thereby raising the possibility that lipid composition could induce relatively rapid Ca2+-independent membrane interaction in vivo.	Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA; Univ So Calif, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of Southern California; University of Southern California; University of California System; University of California Irvine	Langen, R (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Cartailler, Jean-Philippe/D-2543-2010; Haigler, Harry/C-3788-2011	Cartailler, Jean-Philippe/0000-0002-0312-2391; 	NIGMS NIH HHS [GM 63915, GM 55651] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063915, R01GM055651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; BERLINER LJ, 1982, ANAL BIOCHEM, V119, P450, DOI 10.1016/0003-2697(82)90612-1; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; Diakonova M, 1997, J CELL SCI, V110, P1199; Freed JH, 1976, SPIN LABELING THEORY; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Mailliard WS, 1997, BIOCHEMISTRY-US, V36, P9045, DOI 10.1021/bi970749v; Megli FM, 2000, BIOCHEMISTRY-US, V39, P5534, DOI 10.1021/bi992779z; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; PULA G, 1990, FEBS LETT, V277, P53, DOI 10.1016/0014-5793(90)80808-V; RAINTEAU D, 1995, FEBS LETT, V360, P80, DOI 10.1016/0014-5793(95)00087-P; Rand JH, 1999, NEW ENGL J MED, V340, P1035, DOI 10.1056/NEJM199904013401310; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Reviakine I, 2000, J STRUCT BIOL, V131, P234, DOI 10.1006/jsbi.2000.4286; Reviakine I, 1998, J STRUCT BIOL, V121, P356, DOI 10.1006/jsbi.1998.4003; SCHLAEPFER DD, 1992, J BIOL CHEM, V267, P9529; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SHIN YK, 1993, SCIENCE, V64, P642; Sokolov Y, 2000, J GEN PHYSIOL, V115, P571, DOI 10.1085/jgp.115.5.571; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783	31	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30227	30234		10.1074/jbc.M301228200	http://dx.doi.org/10.1074/jbc.M301228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12756261	hybrid			2022-12-25	WOS:000184507000103
J	Liang, Y; Du, F; Sanglier, S; Zhou, BR; Xia, Y; Van Dorsselaer, A; Maechling, C; Kilhoffer, MC; Haiech, J				Liang, Y; Du, F; Sanglier, S; Zhou, BR; Xia, Y; Van Dorsselaer, A; Maechling, C; Kilhoffer, MC; Haiech, J			Unfolding of rabbit muscle creatine kinase induced by acid - A study using electrospray ionization mass spectrometry, isothermal titration calorimetry, and fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT-INDUCED FORMATION; MOLTEN GLOBULE STATE; CYTOCHROME-C; GUANIDINIUM CHLORIDE; PROTEIN INTERACTIONS; EQUILIBRIUM; PH; ENZYME; THERMODYNAMICS; CONFORMATIONS	Electrospray ionization mass spectrometry, isothermal titration calorimetry (ITC), fluorescence spectroscopy, and glutaraldehyde cross-linking SDS-PAGE have been used to study the unfolding of rabbit muscle creatine kinase (MM-CK) induced by acid. The mass spectrometric experiments show that MM-CK is unfolded gradually when titrated with acid. MM-CK is a dimer (the native state) at pH 7.0 and becomes an equilibrium mixture of the dimer and a partially folded monomer (the intermediate) between pH 6.7 and 5.0. The dimeric protein becomes an equilibrium mixture of the intermediate and an unfolded monomer (the unfolded state) between pH 5.0 and 3.0 and is almost fully unfolded at pH 3.0 reached. The results from a "phase diagram" method of fluorescence show that the conformational transition between the native state and the intermediate of MM-CK occurs in the pH range of 7.0-5.2, and the transition between the intermediate and the unfolded state of the protein occurs between pH 5.2 and 3.0. The intrinsic molar enthalpy changes for formation of the unfolded state of MM-CK induced by acid at 15.0, 25.0, 30.0, and 37.0 degreesC have been determined by ITC. A large positive molar heat capacity change of the unfolding, 8.78 kcal mol(-1) K-1, at all temperatures examined indicates that hydrophobic interaction is the dominant driving force stabilizing the native structure of MM-CK. Combining the results from these four methods, we conclude that the acid-induced unfolding of MM-CK follows a "three-state" model and that the intermediate state of the protein is a partially folded monomer.	Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China; Univ Strasbourg, Ecole Europeenne Chim Polymeres & Mat, CNRS, UMR 7509, F-67087 Strasbourg, France; Univ Strasbourg 1, Fac Pharm, CNRS, UMR 7034, F-67401 Illkirch Graffenstaden, France	Wuhan University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Liang, Y (corresponding author), Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.	liangyi@whu.edu.cn	Liang, Yi/V-1396-2017; Maechling, Clarisse/D-8214-2012; haiech, jacques J/F-2890-2010; Zhou, Bing-Rui/D-4766-2009	Liang, Yi/0000-0002-7349-8300; Cianferani, Sarah/0000-0003-4013-4129; haiech, jacques/0000-0003-2908-8053; Zhou, Bing-Rui/0000-0002-5375-7977				Ahmad N, 1998, BIOCHEMISTRY-US, V37, P16765, DOI 10.1021/bi9811720; Ayed A, 1998, RAPID COMMUN MASS SP, V12, P339, DOI 10.1002/(SICI)1097-0231(19980415)12:7<339::AID-RCM163>3.0.CO;2-6; Babu KR, 2001, J AM SOC MASS SPECTR, V12, P317, DOI 10.1016/S1044-0305(00)00226-9; Bakhtiar R, 2000, MUTAGENESIS, V15, P415, DOI 10.1093/mutage/15.5.415; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BHAKUNI V, 1991, BIOCHEMISTRY-US, V30, P5055, DOI 10.1021/bi00234a031; Bushmarina NA, 2001, CHEMBIOCHEM, V2, P813, DOI 10.1002/1439-7633(20011105)2:11<813::AID-CBIC813>3.0.CO;2-W; Chang JY, 2002, FEBS LETT, V511, P73, DOI 10.1016/S0014-5793(01)03284-7; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Dobo A, 2001, ANAL CHEM, V73, P4763, DOI 10.1021/ac010713f; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; Fan YX, 1998, PROTEIN SCI, V7, P2631, DOI 10.1002/pro.5560071217; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Grandori R, 2001, J MASS SPECTROM, V36, P918, DOI 10.1002/jms.193; Griffiths WJ, 2001, BIOCHEM J, V355, P545, DOI 10.1042/bj3550545; Griko YV, 1999, PROTEIN SCI, V8, P554; GROSS M, 1995, BIOCHEMISTRY-US, V34, P10350, DOI 10.1021/bi00033a005; HAMADA D, 1994, P NATL ACAD SCI USA, V91, P10325, DOI 10.1073/pnas.91.22.10325; Hamada D, 1995, THERMOCHIM ACTA, V266, P385, DOI 10.1016/0040-6031(95)02444-1; Hearn MTW, 2002, ANAL CHEM, V74, P1467, DOI 10.1021/ac0104173; Jamin M, 2000, PROTEIN SCI, V9, P1340, DOI 10.1110/ps.9.7.1340; Konermann L, 1998, J AM SOC MASS SPECTR, V9, P1248, DOI 10.1016/S1044-0305(98)00103-2; Konermann L, 1998, RAPID COMMUN MASS SP, V12, P435, DOI 10.1002/(SICI)1097-0231(19980430)12:8<435::AID-RCM181>3.0.CO;2-F; Konermann L, 1997, BIOCHEMISTRY-US, V36, P12296, DOI 10.1021/bi971266u; Konermann L, 2001, ANAL CHEM, V73, P4836, DOI 10.1021/ac010545r; Krupakar J, 1999, BIOCHEM J, V338, P273, DOI 10.1042/0264-6021:3380273; Kuznetsova IM, 2002, BBA-PROTEIN STRUCT M, V1596, P138, DOI 10.1016/S0167-4838(02)00212-1; Kuznetsova IM, 2002, BIOCHEMISTRY-US, V41, P13127, DOI 10.1021/bi026412x; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Leydier C, 1998, BIOCHEMISTRY-US, V37, P17579, DOI 10.1021/bi981828p; Liang Y, 2002, EUR J BIOCHEM, V269, P2851, DOI 10.1046/j.1432-1033.2002.02948.x; Liang Y, 2001, THERMOCHIM ACTA, V376, P123, DOI 10.1016/S0040-6031(01)00573-1; Liang Y, 2001, EUR J BIOCHEM, V268, P4183, DOI 10.1046/j.1432-1327.2001.02330.x; Liang Y, 2000, THERMOCHIM ACTA, V348, P41, DOI 10.1016/S0040-6031(00)00355-5; Liu L, 2000, BIOPHYS CHEM, V84, P239, DOI 10.1016/S0301-4622(00)00130-7; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; Mazon H, 2002, BIOCHEMISTRY-US, V41, P9646, DOI 10.1021/bi025893h; Perraut C, 1998, PROTEINS, V32, P43, DOI 10.1002/(SICI)1097-0134(19980701)32:1<43::AID-PROT6>3.0.CO;2-F; PFEIL W, 1986, FEBS LETT, V198, P287, DOI 10.1016/0014-5793(86)80422-7; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; Pramanik BN, 1998, J MASS SPECTROM, V33, P911, DOI 10.1002/(SICI)1096-9888(1998100)33:10<911::AID-JMS737>3.0.CO;2-5; PUTNEY S, 1984, J BIOL CHEM, V259, P14317; RAIMBAULT C, 1995, EUR J BIOCHEM, V234, P570, DOI 10.1111/j.1432-1033.1995.570_b.x; Ramstrom H, 2003, J BIOL CHEM, V278, P1174, DOI 10.1074/jbc.M209052200; Rao JK, 1998, FEBS LETT, V439, P133; Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c; Rogniaux H, 2001, ANAL BIOCHEM, V291, P48, DOI 10.1006/abio.2000.4975; Sasahara K, 1999, J MOL BIOL, V291, P693, DOI 10.1006/jmbi.1999.2982; Sogbein OO, 2000, J AM SOC MASS SPECTR, V11, P312, DOI 10.1016/S1044-0305(99)00149-X; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Tame JRH, 1998, BIOCALORIMETRY, P27; Todd MJ, 2001, ANAL BIOCHEM, V296, P179, DOI 10.1006/abio.2001.5218; TSOU CL, 1993, SCIENCE, V262, P380, DOI 10.1126/science.8211158; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Webb TI, 2001, PROTEINS, V42, P269, DOI 10.1002/1097-0134(20010201)42:2<269::AID-PROT140>3.0.CO;2-Y; Zhang YL, 1998, BIOCHEM BIOPH RES CO, V246, P609, DOI 10.1006/bbrc.1998.8673; Zhu L, 2001, BIOCHEM BIOPH RES CO, V285, P857, DOI 10.1006/bbrc.2001.5248; Zhu L, 2001, BBA-PROTEIN STRUCT M, V1544, P320, DOI 10.1016/S0167-4838(00)00244-2	59	61	63	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30098	30105		10.1074/jbc.M304050200	http://dx.doi.org/10.1074/jbc.M304050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771138	hybrid			2022-12-25	WOS:000184507000087
J	Qin, H; Shao, Q; Igdoura, SA; Alaoui-Jamali, MA; Laird, DW				Qin, H; Shao, Q; Igdoura, SA; Alaoui-Jamali, MA; Laird, DW			Lysosomal and proteasomal degradation play distinct roles in the life cycle of Cx43 in gap junctional intercellular communication-deficient and -competent breast tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR TRAFFICKING; PROTEIN-DEGRADATION; MAMMALIAN-CELLS; CONNEXIN GENES; PHOSPHORYLATION; MECHANISM; TURNOVER; DELIVERY; GROWTH; ENDOCYTOSIS	The present study was designed to determine the specific roles played by lysosomes and proteasomes in the degradation of Cx43 in both gap junctional intercellular communication-deficient MDA-MB-231 and -competent BICR-M1R(k) cells. In MDA-MB-231 cells, immunolocalization and brefeldin A protein transport blocking studies revealed that there was a propensity for newly synthesized Cx43 to be transported to lysosomes. On the other hand, light and electron microscopic analysis of BICR-M1R(k) cells showed that Cx43 gap junctions were prevalent with a subpopulation of intracellular Cx43 localized to lysosomes. In both cell types, Western blots revealed a notable increase in total cellular Cx43 in response to lysosome inhibitors. Interestingly, lactacystin inhibition of proteosomal degradation in MDA-MB-231 cells resulted in a marked increase in phosphorylated Cx43 at the expense of non-phosphorylated Cx43, and this change corresponded with an increase in "oversized" gap junction plaques. In BICR-M1R(k) cells, lactacystin treatment partially prevented the BFA-induced loss of gap junctions. Together, our data suggests that lysosomes play a key role in not only degrading internalized gap junction in BICR-M1R(k) cells but also in degrading Cx43 delivered from early secretory compartments to lysosomes in MDA-MB-231 cells. Overall proteasomal degradation regulates the stability of phosphorylated Cx43 and appears to promote the internalization of Cx43 from the cell surface.	Univ Western Ontario, Dept Anat & Cell Biol, Ctr Gap Junct Res, London, ON N6A 5C1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L85 4L8, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L85 4L8, Canada; McGill Univ, Dept Med Pharmacol & Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada	Western University (University of Western Ontario); McMaster University; McMaster University; McGill University; Lady Davis Institute; McGill University	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Ctr Gap Junct Res, London, ON N6A 5C1, Canada.		Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015	Laird, Dale W/0000-0002-4568-3285; 				Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Benaroudj N, 2001, BIOCHIMIE, V83, P311, DOI 10.1016/S0300-9084(01)01244-5; Berthoud VM, 2000, METHODS, V20, P180, DOI 10.1006/meth.1999.0935; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; Galipeau J, 1999, CANCER RES, V59, P2384; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; Gehrmann J, 2000, J CARDIOVASC ELECTR, V11, P354, DOI 10.1111/j.1540-8167.2000.tb01806.x; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Jordan K, 2001, J CELL SCI, V114, P763; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 1996, J BIOENERG BIOMEMBR, V28, P311, DOI 10.1007/BF02110107; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Matsuyama W, 2001, J HUM GENET, V46, P307, DOI 10.1007/s100380170064; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; NAUS CCG, 1993, EXP CELL RES, V206, P72, DOI 10.1006/excr.1993.1122; Nicholson BJ, 2000, BRAZ J MED BIOL RES, V33, P369, DOI 10.1590/S0100-879X2000000400002; OKO R, 1993, J CELL BIOL, V123, P809, DOI 10.1083/jcb.123.4.809; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; QIN H, 2001, CELL COMMUN ADHES, V8, P1; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Thomas MA, 2003, J CELL SCI, V116, P2213, DOI 10.1242/jcs.00440; Ulrich HD, 2002, CURR TOP MICROBIOL, V268, P137; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	41	121	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30005	30014		10.1074/jbc.M300614200	http://dx.doi.org/10.1074/jbc.M300614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12767974	hybrid			2022-12-25	WOS:000184507000075
J	Neff, L; Zeisel, M; Druet, V; Takeda, K; Klein, JP; Sibilia, J; Wachsmann, D				Neff, L; Zeisel, M; Druet, V; Takeda, K; Klein, JP; Sibilia, J; Wachsmann, D			ERK1/2- and JNKs-dependent synthesis of Interleukins 6 and 8 by fibroblast-like synoviocytes stimulated with protein I/II, a modulin from oral streptococci, requires focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; MAP KINASE; INTEGRIN; ACTIVATION; INVOLVEMENT; INVASION	Protein I/II, a pathogen-associated molecular pattern from oral streptococci, is a potent inducer of interleukin-6 (IL-6) and IL-8 synthesis and release from fibroblast-like synoviocytes (FLSs), cells that are critically involved in joint inflammation. This synthesis implicates ERK 1/2 and JNKs as well as AP-1-binding activity and nuclear translocation of NF-kappaB. The mechanisms by which protein I/II activates MAPKs remain, however, elusive. Because focal adhesion kinase (FAK) was proposed to play a role in signaling to MAPKs, we examined its ability to contribute to the MAPKs-dependent synthesis of IL-6 and IL-8 in response to protein I/II. We used FAK-/- fibroblasts as well as FAK+/+ fibroblasts and FLSs transfected with FRNK, a dominant negative form of FAK. The results demonstrate that IL-6 and IL-8 release in response to protein I/II was strongly inhibited in both protein I/II-stimulated FAK-/- and FRNK-transfected cells. Cytochalasin D, which inhibits protein I/II-induced phosphorylation of FAK (Tyr-397), had no effect either on activation of ERK 1/2 and JNKs or on IL-6 and IL-8 release. Taken together, these results indicate that IL-6 and IL-8 release by protein I/II- activated FLSs is regulated by FAK independently of Tyr-397 phosphorylation.	Univ Louis Pasteur Strasbourg 1, INSERM, Fac Pharm,U392, Lab Immunol & Biochim Bacterienne, F-67400 Illkirch Graffenstaden, France; Hop Univ Strasbourg, Dept Rhumatol, F-67400 Illkirch Graffenstaden, France; Univ Louis Pasteur Strasbourg 1, Fac Pharm, CNRS, UMR 7034, F-67400 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wachsmann, D (corresponding author), Univ Louis Pasteur Strasbourg 1, INSERM, Fac Pharm,U392, Lab Immunol & Biochim Bacterienne, 74 Route Rhin, F-67400 Illkirch Graffenstaden, France.		Zeisel, Mirjam B/E-9205-2016	Zeisel, Mirjam B/0000-0003-1606-0131; Sibilia, Jean/0000-0002-1601-4795				Al-Okla S, 1999, CELL MICROBIOL, V1, P157, DOI 10.1046/j.1462-5822.1999.00016.x; Alrutz MA, 1998, P NATL ACAD SCI USA, V95, P13658, DOI 10.1073/pnas.95.23.13658; ARNETT FC, 1988, ARTHRITIS RHEUM, V3, P315; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chatenay-Rivauday C, 1998, MOL MICROBIOL, V29, P39, DOI 10.1046/j.1365-2958.1998.00881.x; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; DECHANET J, 1994, EUR J IMMUNOL, V24, P3222, DOI 10.1002/eji.1830241247; Gemba T, 2002, J BIOL CHEM, V277, P907, DOI 10.1074/jbc.M109690200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannone G, 2002, J BIOL CHEM, V277, P26364, DOI 10.1074/jbc.M203952200; GOURIEUX B, 2000, FEMS IMMUNOL MED MIC, V1280, P1; Gustavsson A, 2002, J CELL SCI, V115, P2669; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; Hauck CR, 2001, CANCER RES, V61, P7079; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Ilic D, 1997, J CELL SCI, V110, P401; Ishibashi Y, 2001, MICROB PATHOGENESIS, V30, P279, DOI 10.1006/mpat.2001.0432; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Lai KMV, 2000, GENE DEV, V14, P1132; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Mortier E, 2001, CELL SIGNAL, V13, P901, DOI 10.1016/S0898-6568(01)00226-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muller-Ladner U, 2000, CURR OPIN RHEUMATOL, V12, P186, DOI 10.1097/00002281-200005000-00005; Natarajan K, 2002, INVEST OPHTH VIS SCI, V43, P2685; Neff L, 2001, CELL MICROBIOL, V3, P703, DOI 10.1046/j.1462-5822.2001.00148.x; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Rawadi G, 1998, J IMMUNOL, V160, P1330; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Scherle PA, 1998, J IMMUNOL, V161, P5681; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; Tachado SD, 1996, J IMMUNOL, V156, P1897; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vernier A, 1996, INFECT IMMUN, V64, P3016, DOI 10.1128/IAI.64.8.3016-3022.1996; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; Yilmaz O, 2002, CELL MICROBIOL, V4, P305, DOI 10.1046/j.1462-5822.2002.00192.x; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	49	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27721	27728		10.1074/jbc.M212065200	http://dx.doi.org/10.1074/jbc.M212065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12761229	hybrid			2022-12-25	WOS:000184242700050
J	Levine, JJ; Stimson-Crider, KM; Vertino, PM				Levine, JJ; Stimson-Crider, KM; Vertino, PM			Effects of methylation on expression of TMS1/ASC in human breast cancer cells	ONCOGENE			English	Article						DNA methylation; methyltransferase; apoptosis; ASC; gene regulation; transcription	RECRUITMENT DOMAIN PROTEIN; DNA METHYLATION; CPG ISLAND; GENE; TRANSCRIPTION; REPRESSION; PROMOTER; HYPERMETHYLATION; LEUKEMIA; COMPLEX	Gene silencing associated with aberrant methylation of promoter region CpG islands is one mechanism in which tumor suppressor genes are inactivated in human cancers. Recently, we identified a novel gene, Target of Methylation-associated Silencing-1 (TMS1) (also called ASC), which is aberrantly methylated and silenced in human breast cancers. To further investigate the mechanism of TMS1 silencing, we defined the transcription initiation site and detailed the DNA methylation pattern of the TMS1 CpG island in normal breast epithelial cells, breast cancer cell lines, and primary tumors. We find that in normal cells, the TMS1 CpG island lies within a 1.2kb unmethylated domain, the 5' boundary of which is in close proximity to the transcription initiation site. In breast cancer cell lines, this boundary appeared to be unstable in that methylation tended to accumulate in the 5' end of the CpG island relative to normal epithelial cells. In contrast, the 3' methylation boundary remained intact. Gene silencing was not correlated with the methylation of specific CpG sites nor the inability to transactivate the TMS1 promoter, but was correlated with the percentage of alleles in the population exhibiting dense methylation across the entire CpG island. Using 5-aza-deoxycytidine to reactivate TMS1 in methylated and silent cell lines, and a cassette methylation strategy to determine the impact of methylation on different parts of the promoter, we find that demethylation of a small region immediately surrounding the transcription start site is critical to TMS1 expression. Our data support the idea that gene silencing and dense methylation are tightly coupled events that affect individual chromosomal copies of TMS1 in an all-or-none manner. The transition to this stably repressed state may be facilitated by spreading of methylation into the proximal promoter and direct effects of methylation on TMS1 transcription.	Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Vertino, PM (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, 1365-B Clifton Rd NE,Room B5119, Atlanta, GA 30322 USA.	pvertin@emory.edu		Crider, Krista/0000-0001-6997-5955	NCI NIH HHS [1R01 CA77337] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conway KE, 2000, CANCER RES, V60, P6236; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Dammann R, 2001, CANCER RES, V61, P3105; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Han L, 2001, MOL CELL BIOL, V21, P3416, DOI 10.1128/MCB.21.10.3416-3424.2001; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kass Stefan U., 1993, Biochemical Society Transactions, V21, p9S; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kinoshita H, 2000, CANCER RES, V60, P3623; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Mann JR, 2000, CRIT REV EUKAR GENE, V10, P241; Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; McConnell BB, 2000, CANCER RES, V60, P6243; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WANG L, 2002, J BIOL CHEM, V17, P17; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	40	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3475	3488		10.1038/sj.onc.1206430	http://dx.doi.org/10.1038/sj.onc.1206430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776200				2022-12-25	WOS:000183128500015
J	Ozaki, T; Watanabe, KI; Nakagawa, T; Miyazaki, K; Takahashi, M; Nakagawara, A				Ozaki, T; Watanabe, KI; Nakagawa, T; Miyazaki, K; Takahashi, M; Nakagawara, A			Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB	ONCOGENE			English	Article						p53; pRB; p73; RACK1; two-hybrid	PROTEIN-KINASE-C; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; MAMMALIAN-CELLS; CANCER TISSUES; BETA-SUBUNIT; APOPTOSIS; GENE; SUMO-1	The newly identified p53-related gene, p73, encodes a nuclear transcription factor. Unlike p53, p73 has various isoforms with different NH2- and COOH-terminal tails. p73alpha with the longest COOH-terminal extension is most abundantly expressed in many tissues and cells among those splicing isoforms of p73 and the COON-terminal region appears to have an autoregulatory function. To isolate and characterize the cellular protein(s) that interacts with the unique COOH-terminal region of p73alpha, we employed a yeast two-hybrid screen with a human fetal brain and 293 cell cDNA libraries. We identified the receptor for activated C kinase (RACK1) as a new member of p73alpha-binding proteins. The interaction was confirmed by coimmunoprecipitation experiments, whereas RACK1 did not interact with p53 or p73beta. Ectopic overexpression of RACK1 in SAOS-2 cells reduced the p73alpha-mediated transcription from the p53/ p73-responsive promoters, and inhibited the p73alpha-dependent apoptosis. On the other hand, the p53-dependent transcriptional activation as well as apoptosis was unaffected in the presence of RACK1. Furthermore, we found that pRB physically bound to RACK1, and repressed the RACK1-dependent inhibition of p73alpha. Taken together, our observations suggest that pRB diminishes the RACK1-mediated inhibition of p73alpha activity through the interaction with RACK1.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan	Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.							Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen CL, 2000, CLIN CANCER RES, V6, P3910; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Ozaki T, 1999, CANCER RES, V59, P5902; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Shaw P, 1996, ONCOGENE, V12, P921; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	60	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3231	3242		10.1038/sj.onc.1206382	http://dx.doi.org/10.1038/sj.onc.1206382			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761493				2022-12-25	WOS:000183040000005
J	Boulanger, A; McLemore, P; Copeland, NG; Gilbert, DJ; Jenkins, NA; Yu, SS; Gentleman, S; Redmond, TM				Boulanger, A; McLemore, P; Copeland, NG; Gilbert, DJ; Jenkins, NA; Yu, SS; Gentleman, S; Redmond, TM			Identification of beta-carotene 15,15 '-monooxygenase as a peroxisome proliferator-activated receptor target gene	FASEB JOURNAL			English	Article						carotenoids; retinoids; transcriptional regulation; promoter; RXR	RETINOL-BINDING PROTEIN; RAT SMALL-INTESTINE; RNA POLYMERASE-II; BETA,BETA-CAROTENE 15,15'-DIOXYGENASE; DIFFERENTIAL REGULATION; X-RECEPTOR; EXPRESSION; ENZYME; ALPHA; CLEAVAGE	beta-Carotene 15,15'-monooxygenase (BCM) catalyzes the first step of vitamin A biosynthesis from provitamin A carotenoids. We wished to determine the factors underlying the transcriptional regulation of this gene. After cloning of the 40 kilobase pair (kbp) mouse Bcm gene and determination of its genomic organization, analysis of the 2 kb 5'-flanking region showed several putative transcription factor binding sites including TATA box, a peroxisome proliferator response element (PPRE), AP2, and bHLH. The 2 kb fragment drove specific luciferase gene expression in vitro only in cell lines that express BCM (TC7, PF11, and monkey retinal pigment epithelium). Nucleotides -41 to +163, and -60 to +163 drove basal and specific Bcm transcriptional activity, respectively. Site-directed mutagenesis and gel shift experiments demonstrate that PPRE was essential for Bcm promoter specificity and that the peroxisome proliferator activated receptor (PPAR) gamma (PPARgamma) specifically binds to this element. Furthermore, cotransfection experiments and pharmacological treatments in vitro, using the specific PPARgamma agonists LY17883 and ciglitazone, demonstrate that the PPRE element confers peroxisome proliferator responsiveness via the PPARgamma and retinoid X receptor-alpha heterodimer. Treatment of mice with the PPARalpha/gamma agonist WY14643 increases BCM protein expression in liver. Thus PPAR is a key transcription factor for the transcriptional regulation of the Bcm gene, suggesting a broader function for PPARs in the regulation of carotenoid metabolism metabolism that is consistent with their established role in neutral lipid metabolism and transport.	NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mouse Canc Genet Program, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Redmond, TM (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Rm 339,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.	redmond@helix.nih.gov		Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Bhatti RA, 2003, INVEST OPHTH VIS SCI, V44, P44, DOI 10.1167/iovs.02-0167; Bok D, 1999, NEURON, V23, P412, DOI 10.1016/S0896-6273(00)80791-6; Calvo S, 1996, DEV GENET, V19, P169, DOI 10.1002/(SICI)1520-6408(1996)19:2<169::AID-DVG9>3.3.CO;2-T; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong D, 1998, BIOCHEMISTRY-US, V37, P10691, DOI 10.1021/bi980561r; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; During A, 1998, BIOCHEM BIOPH RES CO, V249, P467, DOI 10.1006/bbrc.1998.9160; Duszka C, 1996, J NUTR, V126, P2550, DOI 10.1093/jn/126.10.2550; ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x; GODA T, 1993, BIOCHIM BIOPHYS ACTA, V1168, P153; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; Montano AM, 2000, BBA-MOL BASIS DIS, V1500, P323, DOI 10.1016/S0925-4439(99)00119-2; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Nagao A, 1996, ARCH BIOCHEM BIOPHYS, V328, P57, DOI 10.1006/abbi.1996.0142; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; ONG DE, 1987, J BIOL CHEM, V262, P2729; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; Peters JM, 1998, CARCINOGENESIS, V19, P1989, DOI 10.1093/carcin/19.11.1989; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Suruga K, 1999, ARCH BIOCHEM BIOPHYS, V362, P159, DOI 10.1006/abbi.1998.1018; Tajima S, 2001, COMP BIOCHEM PHYS B, V128, P425, DOI 10.1016/S1096-4959(00)00347-X; Takase S, 2000, BRIT J NUTR, V84, pS217, DOI 10.1079/096582197388572; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; vanVliet T, 1996, J NUTR, V126, P499, DOI 10.1093/jn/126.2.499; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2001, P NATL ACAD SCI USA, V98, P1130, DOI 10.1073/pnas.031576398; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476	49	80	86	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1304	+		10.1096/fj.02-0690fje	http://dx.doi.org/10.1096/fj.02-0690fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759335				2022-12-25	WOS:000183165000024
J	Grosch, S; Tegeder, I; Schilling, K; Maier, T; Niederberger, E; Geisslinger, G				Grosch, S; Tegeder, I; Schilling, K; Maier, T; Niederberger, E; Geisslinger, G			Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers	FASEB JOURNAL			English	Article						G(1)-phase block; apoptosis; colon cancer; flurbiprofen; enantiomer	R-FLURBIPROFEN; CYCLOOXYGENASE-2 INHIBITOR; PROSTAGLANDIN SYNTHESIS; RHEUMATOID-ARTHRITIS; D1 EXPRESSION; APOPTOSIS; PROLIFERATION; TRANSCRIPTION; SURVIVAL; CANCER	The unselective cyclooxygenase (COX) inhibitor S-flurbiprofen and its-in terms of COX-inhibition-"inactive" enantiomer R-flurbiprofen have been previously found to inhibit tumor development and growth in various animal models. The underlying mechanisms are unknown. Here, we show that both R- and S-flurbiprofen reduce survival of three colon cancer cell lines, which differ in the expression of COX-2 (HCT-15, no COX-2; Caco-2, inducible COX-2; and HT-29, constitutive COX-2). The IC50 for S- and R-flurbiprofen ranged from 250 to 450 muM. Both flurbiprofen enantiomers induced apoptosis in all three cell lines as indicated by DNA- and PARP-cleavage. In addition, R- and S-flurbiprofen caused a G(1)-cell cycle block. The latter was associated with an activation of c-Jun N-terminal kinase (JNK), an increase of the DNA binding activity of the transcription factor AP-1 and down-regulation of cyclin D1 expression. Western blot analysis, as well as supershift experiments, revealed that the AP-1 activation was associated with a change of AP-1 composition toward an increase of JunB. The JNK inhibitor SP600125 antagonized R- and S-flurbiprofen-induced AP-1 DNA binding, suppression of cyclin D1 expression, and the G(1)-cell cycle block. However, JNK inhibition had no effect on flurbiprofen-induced apoptosis. Hence, the cell cycle arrest is obviously mediated, at least in part, through JNK-activation, whereas R- and S-flurbiprofen-induced apoptosis is largely independent of JNK. Although in vitro effects of R- and S-flurbiprofen were indistinguishable, only R-flurbiprofen inhibited HCT-15 tumor growth in nude mice, suggesting the involvement of additional in vivo targets, which are differently affected by R- and S-flurbiprofen.	Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Grosch, S (corresponding author), Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	groesch@em.uni-frankfurt.de	Groesch, Sabine/H-4251-2018; Tegeder, Irmgard/AAM-2246-2020; Tegeder, Irmgard/AAM-2266-2020	Groesch, Sabine/0000-0002-7262-6307; Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025				Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BENNETT A, 1982, BRIT J CANCER, V45, P762, DOI 10.1038/bjc.1982.118; BENNETT A, 1979, PROSTAGLANDINS, V17, P179, DOI 10.1016/0090-6980(79)90037-6; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Damiens E, 2000, Prog Cell Cycle Res, V4, P219; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; GEISSLINGER G, 1992, J CHROMATOGR-BIOMED, V573, P163, DOI 10.1016/0378-4347(92)80492-9; Geisslinger G, 1996, J CLIN PHARMACOL, V36, P513, DOI 10.1002/j.1552-4604.1996.tb05041.x; Grosch S, 1999, BIOCHEM BIOPH RES CO, V261, P859, DOI 10.1006/bbrc.1999.1125; Leaper D J, 1980, Adv Prostaglandin Thromboxane Res, V6, P591; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lin SK, 2001, MOL PHARMACOL, V60, P768; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552-4604.1996.tb05043.x; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Niculescu AB, 1998, MOL CELL BIOL, V18, P1763, DOI 10.1128/MCB.18.3.1763; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Rossat J, 1999, CLIN PHARMACOL THER, V66, P76, DOI 10.1016/S0009-9236(99)70056-1; Schmassmann A., 1998, AM J MED, V104, p[43S, 79S], DOI DOI 10.1016/S0002-9343(97)00211-8; Schmassmann Adrian, 1998, American Journal of Medicine, V104, p43S, DOI 10.1016/S0002-9343(97)00211-8; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Tegeder I, 2001, FASEB J, V15, P595, DOI 10.1096/fasebj.15.3.595; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; Wechter WJ, 2000, CANCER RES, V60, P2203; Wechter WJ, 1997, CANCER RES, V57, P4316; Wechter WJ, 2000, LIFE SCI, V66, P745, DOI 10.1016/S0024-3205(99)00645-1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	43	44	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1316	+		10.1096/fj.02-0919fje	http://dx.doi.org/10.1096/fj.02-0919fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759338				2022-12-25	WOS:000183165000020
J	Liew, R; MacLeod, KT; Collins, P				Liew, R; MacLeod, KT; Collins, P			Novel stimulatory actions of the phytoestrogen genistein: effects on the gain of cardiac excitation-contraction coupling	FASEB JOURNAL			English	Article						cardiac myocyte; cell shortening; calcium transient; sarcoplasmic reticulum; myofilament calcium sensitivity	TYROSINE KINASE INHIBITOR; VASCULAR SMOOTH-MUSCLE; CA2+ SENSITIVITY; PHOSPHATASE INHIBITORS; REGIONAL DIFFERENCES; MEMBRANE CURRENTS; SOY ISOFLAVONES; CALCIUM CURRENT; RABBIT; RELAXATION	Genistein, a phytoestrogen found abundantly in soy products, is thought to be cardioprotective, partly through its ability to act as a natural Ca2+ channel antagonist. However, the precise nature and significance of such direct cardiac actions remain obscure. We investigated the hypothesis that genistein exerts important additional actions on cardiac excitation-contraction coupling (ECC). Genistein acutely increased cell shortening and the Ca2+ transient in field stimulated guinea-pig ventricular myocytes despite potently inhibiting the L-type Ca2+ current, I-Ca,I-L. The specific phosphotyrosine phosphatase inhibitor, bpV(phen), diminished the stimulatory effects of genistein on myocyte contractility, suggesting that the mechanism partly involved tyrosine kinase inhibition. Genistein increased sarcoplasmic reticulum (SR) Ca2+ load as measured with a caffeine pulse in Na+-free/Ca2+-free solution. Furthermore, in the continued presence of caffeine, genistein increased the time constant of decline of the caffeine-induced Ca2+ transient, implying impaired sarcolemmal Na+/Ca2+ exchanger function. Tetanization studies in intact myocytes revealed that 43% of cells exhibited increased myofilament Ca2+ sensitivity in the presence of genistein. These findings demonstrate novel cardiac actions of genistein on the SR Ca2+ load, Na+/Ca2+ exchanger, and myofilament Ca2+ sensitivity, which result in an overall increase in myocyte contractility and consequently the gain of ECC.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiac Med, London SW3 6LY, England	Imperial College London	Liew, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiac Med, Dovehouse St, London SW3 6LY, England.	r.liew@imperial.ac.uk	MacLeod, Kenneth/GWU-8940-2022					ADLERCREUTZ H, 1990, SCAND J CLIN LAB INV, V50, P3, DOI 10.3109/00365519009085798; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; Anthony MS, 1998, AM J CLIN NUTR, V68, p1390S, DOI 10.1093/ajcn/68.6.1390S; ARTAUDWILD SM, 1993, CIRCULATION, V88, P2771, DOI 10.1161/01.CIR.88.6.2771; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; BERS DM, 1995, AM J PHYSIOL-CELL PH, V268, pC271, DOI 10.1152/ajpcell.1995.268.1.C271; BERS DM, 1989, CIRC RES, V65, P334, DOI 10.1161/01.RES.65.2.334; CHAMUNORWA JP, 1995, PFLUG ARCH EUR J PHY, V430, P195, DOI 10.1007/BF00374650; Chiang CE, 2002, J BIOMED SCI, V9, P321, DOI 10.1007/BF02256587; Chiang CE, 1996, BIOCHEM BIOPH RES CO, V223, P598, DOI 10.1006/bbrc.1996.0941; Chin-Dusting JPF, 2001, BRIT J PHARMACOL, V133, P595, DOI 10.1038/sj.bjp.0704088; Eisner DA, 2000, CIRC RES, V87, P1087, DOI 10.1161/01.RES.87.12.1087; Figtree GA, 2000, J AM COLL CARDIOL, V35, P1977, DOI 10.1016/S0735-1097(00)00645-8; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; Hongo K, 1998, PFLUG ARCH EUR J PHY, V436, P639, DOI 10.1007/s004240050683; Hool LC, 1998, CIRC RES, V83, P33, DOI 10.1161/01.RES.83.1.33; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL666, DOI 10.1152/ajplung.2001.280.4.L666; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Kurzer MS, 2002, J NUTR, V132, p570S, DOI 10.1093/jn/132.3.570S; LAB MJ, 1990, CIRC RES, V66, P585, DOI 10.1161/01.RES.66.3.585; LEWARTOWSKI B, 1993, J MOL CELL CARDIOL, V25, P23, DOI 10.1006/jmcc.1993.1004; Lewis JG, 2002, STEROIDS, V67, P25, DOI 10.1016/S0039-128X(01)00129-5; Liggins J, 2000, BRIT J NUTR, V84, P717; Liu HY, 1997, CAN J PHYSIOL PHARM, V75, P1058, DOI 10.1139/cjpp-75-9-1058; MACLEOD KT, 1991, J PHYSIOL-LONDON, V444, P481, DOI 10.1113/jphysiol.1991.sp018889; Main MC, 1998, EXP PHYSIOL, V83, P747, DOI 10.1113/expphysiol.1998.sp004156; Mazur W, 1998, BAILLIERE CLIN ENDOC, V12, P729, DOI 10.1016/S0950-351X(98)80013-X; Mishra Santosh K., 2000, Cardiovascular Research, V46, P539, DOI 10.1016/S0008-6363(00)00049-3; Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297; Obayashi K, 1999, PFLUG ARCH EUR J PHY, V438, P269, DOI 10.1007/s004240050909; Paillart C, 1997, J PHARMACOL EXP THER, V280, P521; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Sato A, 2000, METHOD FIND EXP CLIN, V22, P25, DOI 10.1358/mf.2000.22.1.795816; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1333S, DOI 10.1093/ajcn/68.6.1333S; Setchell KDR, 2001, J AM COLL NUTR, V20, p354S, DOI 10.1080/07315724.2001.10719168; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; Shuba LM, 1996, BRIT J PHARMACOL, V119, P335, DOI 10.1111/j.1476-5381.1996.tb15991.x; Sims C, 2000, MOL PHARMACOL, V58, P1213, DOI 10.1124/mol.58.6.1213; SMIRNOV SV, 1995, CIRC RES, V76, P310, DOI 10.1161/01.RES.76.2.310; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STEUSLOFF A, 1995, ARCH BIOCHEM BIOPHYS, V320, P236, DOI 10.1016/0003-9861(95)90005-5; Tanabe S, 1999, AM J PHYSIOL-HEART C, V277, pH826, DOI 10.1152/ajpheart.1999.277.2.H826; Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223; Walker HA, 2001, CIRCULATION, V103, P258, DOI 10.1161/01.CIR.103.2.258; Wang H, 2001, EUR J PHARMACOL, V424, P91, DOI 10.1016/S0014-2999(01)01125-6; Wang YG, 1998, AM J PHYSIOL-HEART C, V275, pH204, DOI 10.1152/ajpheart.1998.275.1.H204; Watts SW, 1996, J VASC RES, V33, P288, DOI 10.1159/000159156; Yokoshiki H, 1996, J MOL CELL CARDIOL, V28, P807, DOI 10.1006/jmcc.1996.0075	51	22	23	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1307	+		10.1096/fj.02-0760fje	http://dx.doi.org/10.1096/fj.02-0760fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759336				2022-12-25	WOS:000183165000017
J	Staykova, MA; Berven, LA; Cowden, WB; Willenborg, DO; Crouch, MF				Staykova, MA; Berven, LA; Cowden, WB; Willenborg, DO; Crouch, MF			Nitric oxide induces polarization of actin in encephalitogenic T cells and inhibits their in vitro transendothelial migration in a p70S6 kinase-independent manner	FASEB JOURNAL			English	Article						T lymphocyte migration; CNS microvascular endothelial cells; autoimmune encephalomyelitis; F-actin	BRAIN ENDOTHELIAL-CELLS; LYMPHOCYTE MIGRATION; IN-VITRO; HUMAN NEUTROPHILS; ADP-RIBOSYLATION; NADPH OXIDASE; EXPRESSION; ACTIVATION; SYNTHASE; SHAPE	Nitric oxide (NO) inhibits both actively induced and transferred autoimmune encephalomyelitis. To explore potential mechanisms, we examined the ability of NO to inhibit migration of T lymphoblasts through both collagen matrices and monolayers of rat brain endothelial cells. The NO donor 1-hydroxy-2-oxo-3, 3-bis (2-aminoethyl)-1-triazene (HOBAT) inhibited migration in a concentration-dependent manner. NO pretreatment of T cells inhibited migration through untreated endothelial cells, but NO pretreatment of endothelial cells had no inhibitory effect on untreated T cells. Therefore NO's migration inhibitory action was mediated through its effect on T cells and not endothelial cells. HOBAT did not inhibit migration by inducing T-cell death but rather by polarizing the T cells, resulting in a morphology suggestive of migrating cells. P70S6 kinase, shown to have a role in NO-induced migration inhibition in fibroblasts, had no role in the inhibitory effect of NO on T-cell migration. Thus, HOBAT did not alter p70S6K activity nor did rapamycin, a specific inhibitor of p70S6K, inhibit HOBAT-induced T-cell morphological changes or T-cell migration. We suggest that NO-induced morphological changes result in T cells with predefined migratory directionality, thus limiting the ability of these cells to respond to other migratory signals.	Canberra Hosp, Neurosci Res Unit, Canberra, ACT, Australia; Australian Natl Univ, Sch Med, Canberra, ACT, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Australian National University; Canberra Hospital; Australian National University; Australian National University; John Curtin School of Medical Research	Staykova, MA (corresponding author), Neurosci Res Unit, Bldg 10,Level 6,Yamba Dr, Garran, ACT 2606, Australia.	maria.staykova@anu.edu.au						Balyasnikova IV, 2000, J CEREBR BLOOD F MET, V20, P688, DOI 10.1097/00004647-200004000-00006; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Berven LA, 1999, BIOCHEM BIOPH RES CO, V266, P352, DOI 10.1006/bbrc.1999.1833; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; CLANCY R, 1995, J LEUKOCYTE BIOL, V58, P196, DOI 10.1002/jlb.58.2.196; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; Cowden WB, 1998, J NEUROIMMUNOL, V88, P1, DOI 10.1016/S0165-5728(98)00040-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; FRIEDL P, 1995, J IMMUNOL, V154, P4973; Friedl P, 1998, EUR J IMMUNOL, V28, P2331, DOI 10.1002/(SICI)1521-4141(199808)28:08<2331::AID-IMMU2331>3.0.CO;2-C; Friedl P, 2001, J LEUKOCYTE BIOL, V70, P491; Hokari R, 1998, GASTROENTEROLOGY, V115, P618, DOI 10.1016/S0016-5085(98)70141-6; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; Jun CD, 1996, CELL IMMUNOL, V174, P25, DOI 10.1006/cimm.1996.0290; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kroncke KD, 2001, INT IMMUNOPHARMACOL, V1, P1407, DOI 10.1016/S1567-5769(01)00087-X; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Loitto VM, 2000, J CELL PHYSIOL, V182, P402, DOI 10.1002/(SICI)1097-4652(200003)182:3<402::AID-JCP11>3.0.CO;2-D; LUDOWYK PA, 1993, J NEUROIMMUNOL, V48, P121, DOI 10.1016/0165-5728(93)90184-Z; Magazine HI, 2000, J IMMUNOL, V165, P102, DOI 10.4049/jimmunol.165.1.102; Matheny HE, 2000, J IMMUNOL, V164, P6550, DOI 10.4049/jimmunol.164.12.6550; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; PABST R, 1988, IMMUNOL TODAY, V9, P43, DOI 10.1016/0167-5699(88)91258-3; RAINE CS, 1980, LAB INVEST, V43, P150; ROTZINGER S, 1995, LIFE SCI, V56, P1321, DOI 10.1016/0024-3205(94)00083-2; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Shoker AS, 1997, MOL CELL BIOCHEM, V171, P75, DOI 10.1023/A:1006815430622; Staykova M, 2000, J NEUROPATH EXP NEUR, V59, P120, DOI 10.1093/jnen/59.2.120; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; TERADA LS, 1991, J CELL PHYSIOL, V148, P191, DOI 10.1002/jcp.1041480202; Tudor KSRS, 2001, CYTOKINE, V15, P196, DOI 10.1006/cyto.2001.0922; van der Goes A, 2001, FASEB J, V15, P1852, DOI 10.1096/fj.00-0881fje; Zech JC, 1998, INVEST OPHTH VIS SCI, V39, P1600; Zettl UK, 1997, CELL IMMUNOL, V178, P1, DOI 10.1006/cimm.1997.1113	40	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1337	+		10.1096/fj.02-0577fje	http://dx.doi.org/10.1096/fj.02-0577fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759332				2022-12-25	WOS:000183165000023
J	Soh, JW; Weinstein, IB				Soh, JW; Weinstein, IB			Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; REGULATORY DOMAIN; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; RESPONSE ELEMENT; DELTA; EXPRESSION; INDUCTION; CELLS; FOS; JUN	Although protein kinase C (PKC) has been implicated in cell cycle progression, cell proliferation, and tumor promotion, the precise roles of specific isoforms in these processes is not clear. Therefore, we constructed and analyzed a series of expression vectors that encode hemagglutinin-tagged wild type (WT), constitutively active mutants (DeltaNPS and CAT), and dominant negative mutants of PKCs alpha, beta1, beta2, gamma, delta, epsilon, eta, zeta, and iota. Cyclin D1 promoter reporter assays done in serum-starved NIH3T3 cells indicated that the constitutively active mutants of PKC-alpha and PKC-epsilon were the most potent activators of this reporter, whereas the constitutively active mutant of PKC-delta inhibited its activity. Transient transfection studies with a series of 5'-deleted cyclin D1 promoter constructs showed that the proximal 964-base region, which contains AP-1, SP1, and CRE enhancer elements, is required for activation of the cyclin D1 promoter by PKC-alpha. Deletion of the AP-1 enhancer element located at position - 954 upstream from the initiation site abolished PKC-alpha-dependent activation of cyclin D1 expression. Deletion of the SP1 or CRE enhancer elements did not have any effect. A dominant negative mutant of c-Jun inhibited activation of the cyclin D1 promoter in a concentration-dependent manner, providing further evidence that AP-1 activity is required for activation of the cyclin D1 promoter by PKC-alpha and PKC-epsilon. The constitutively active mutants of PKC-alpha and PKC-epsilon also activated c-fos, c-jun, and cyclin E promoter activity. Furthermore, NIH3T3 cells that stably express the constitutively active mutants of PKC-alpha or PKC-epsilon displayed increased expression of endogenous cyclins D1 and E and faster growth rates. These results provide evidence that the activation of PKC-alpha or PKC-epsilon in mouse fibroblasts can play an important role in enhancing cell cycle progression and cell proliferation.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Soh, JW (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, HHSC-1509,701 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [CA-26056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026056, R01CA026056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; Cacace AM, 1996, ONCOGENE, V13, P2517; Corbalan-Garcia S, 1999, BIOCHEM J, V337, P513, DOI 10.1042/0264-6021:3370513; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GAUTHIERROUVIERE C, 1992, ONCOGENE, V7, P363; Geng Y, 1996, ONCOGENE, V12, P1173; Grunicke H H, 1992, Semin Cancer Biol, V3, P351; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Li LW, 1999, MOL CELL BIOL, V19, P8547; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; OSADA S, 1990, J BIOL CHEM, V265, P22434; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; Pepio AM, 2001, J BIOL CHEM, V276, P3846, DOI 10.1074/jbc.M006339200; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soh JW, 1999, MOL CELL BIOL, V19, P1313; TANG YM, 1990, NUCLEIC ACIDS RES, V18, P5310, DOI 10.1093/nar/18.17.5310; Yan SC, 2001, J CELL PHYSIOL, V186, P338, DOI 10.1002/1097-4652(2000)9999:9999<000::AID-JCP1032>3.0.CO;2-B	41	167	171	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34709	34716		10.1074/jbc.M302016200	http://dx.doi.org/10.1074/jbc.M302016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12794082	hybrid			2022-12-25	WOS:000185047500132
J	Morrow, VA; Foufelle, F; Connell, JMC; Petrie, JR; Gould, GW; Salt, IP				Morrow, VA; Foufelle, F; Connell, JMC; Petrie, JR; Gould, GW; Salt, IP			Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; AKT; SYNTHASE; ISOFORMS; AICAR; ISOPROTERENOL	Recent studies have indicated that endothelial nitricoxide synthase (eNOS) is regulated by reversible phosphorylation in intact endothelial cells. AMP-activated protein kinase (AMPK) has previously been demonstrated to phosphorylate and activate eNOS at Ser-1177 in vitro, yet the function of AMPK in endothelium is poorly characterized. We therefore determined whether activation of AMPK with 5'-aminoimidazole-4-carboxamide ribonucleoside (AICAR) stimulated NO production in human aortic endothelial cells. AICAR caused the time- and dose-dependent stimulation of AMPK activity, with a concomitant increase in eNOS Ser-1177 phosphorylation and NO production. AMPK was associated with immunoprecipitates of eNOS, yet this was unaffected by increasing concentrations of AICAR. AICAR also caused the time- and dose-dependent stimulation of protein kinase B phosphorylation. To confirm that the effects of AICAR were indeed mediated by AMPK, we utilized adenovirus-mediated expression of a dominant negative AMPK mutant. Expression of dominant negative AMPK attenuated AICAR-stimulated AMPK activity, eNOS Ser-1177 phosphorylation and NO production and was without effect on AICAR-stimulated protein kinase B Ser-473 phosphorylation or NO production stimulated by insulin or A23187. These data suggest that AICAR-stimulated NO production is mediated by AMPK as a consequence of increased Ser-1177 phosphorylation of eNOS. We propose that stimuli that result in the acute activation of AMPK activity in endothelial cells stimulate NO production, at least in part due to phosphorylation and activation of eNOS. Regulation of endothelial AMPK therefore provides an additional mechanism by which local vascular tone may be controlled.	Univ Glasgow, Henry Wellcome Lab Cell Biol, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Western Infirm, Div Cardiovasc & Med Sci, Gardiner Inst, Glasgow G11 6NT, Lanark, Scotland; Ctr Biomed Cordeliers, INSERM, U465, F-75270 Paris 06, France	University of Glasgow; University of Glasgow; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Salt, IP (corresponding author), Univ Glasgow, Henry Wellcome Lab Cell Biol, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	isalt001@udcf.gla.ac.uk		Gould, Gwyn/0000-0001-6571-2875; Salt, Ian/0000-0003-0055-3724; FOUFELLE, Fabienne/0000-0002-0752-622X; s, hema/0000-0002-3440-9475				Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buhl ES, 2002, DIABETES, V51, P2199, DOI 10.2337/diabetes.51.7.2199; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dagher Z, 1999, BIOCHEM BIOPH RES CO, V265, P112, DOI 10.1006/bbrc.1999.1635; Dagher Z, 2001, CIRC RES, V88, P1276, DOI 10.1161/hh1201.092998; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fiedler M, 2001, DIABETOLOGIA, V44, P2180, DOI 10.1007/s001250100027; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, PROTEIN PHOSPHORYLAT, P201; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Ido Y, 2002, DIABETES, V51, P159, DOI 10.2337/diabetes.51.1.159; Iglesias MA, 2002, DIABETES, V51, P2886, DOI 10.2337/diabetes.51.10.2886; Isenovic E, 2002, METABOLISM, V51, P380, DOI 10.1053/meta.2002.30525; Kim F, 2001, AM J PHYSIOL-CELL PH, V280, pC1057, DOI 10.1152/ajpcell.2001.280.5.C1057; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lounsbury KM, 2000, FREE RADICAL BIO MED, V28, P1362, DOI 10.1016/S0891-5849(00)00222-7; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MONCADA S, 1991, PHARMACOL REV, V43, P109; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Song XM, 2002, DIABETOLOGIA, V45, P56, DOI 10.1007/s125-002-8245-8; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Steenbergen C, 2002, BASIC RES CARDIOL, V97, P276, DOI 10.1007/s00395-002-0364-9; Vecchione C, 2002, DIABETES, V51, P168, DOI 10.2337/diabetes.51.1.168; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Wojtaszewski JFP, 2000, J PHYSIOL-LONDON, V528, P221, DOI 10.1111/j.1469-7793.2000.t01-1-00221.x; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	52	281	292	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31629	31639		10.1074/jbc.M212831200	http://dx.doi.org/10.1074/jbc.M212831200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791703	hybrid			2022-12-25	WOS:000184782100023
J	Torbett, NE; Casamassima, A; Parker, PJ				Torbett, NE; Casamassima, A; Parker, PJ			Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL INTEGRITY; PROTEIN-KINASE; SMALL GTPASE; CATALYTIC DOMAIN; RHO; IDENTIFICATION; STRESS; PRK1; PKN; EXPRESSION	Protein kinase N 1 (PKN1), which in part resembles yeast protein kinase C, has been shown to be under the control of Rho GTPases and 3-phosphoinositide-dependent kinase 1 (PDK1). We show here that green fluorescent protein-tagged PKN1 has the ability to translocate in a reversible manner to a vesicular compartment following hyperosmotic stress. PKN1 kinase activity is not necessary for this translocation, and in fact the PKN inhibitor HA1077 is also shown to induce PKN1 vesicle accumulation. PKN1 translocation is dependent on Rac1 activation, although the GTPase binding HR1abc domain is not sufficient for this recruitment. The PKN1 kinase domain, however, localizes constitutively to this compartment, and we demonstrate that this behavior is selective for PKNs. Associated with vesicle recruitment, PKN1 is shown to undergo activation loop phosphorylation and activation. It is established that this activation pathway involves PDK1, which is shown to be recruited to this PKN1-positive compartment upon hyperosmotic stress. Taken together, our findings present a pathway for the selective hyperosmotic-induced Rac1-dependent PKN1 translocation and PDK1-dependent activation.	Canc Res UK, London Res Inst, Prot Phosphorylat Lab, London WC2A 3PX, England	Cancer Research UK	Parker, PJ (corresponding author), Canc Res UK, London Res Inst, Prot Phosphorylat Lab, 44 Lincolns Inn Fileds, London WC2A 3PX, England.	parkerp@cancer.org.uk	Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alonso-Monge R, 2001, MOL MICROBIOL, V41, P717, DOI 10.1046/j.1365-2958.2001.02549.x; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Arellano M, 1999, J CELL SCI, V112, P3569; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Edwards YS, 1998, AM J PHYSIOL-LUNG C, V275, pL670, DOI 10.1152/ajplung.1998.275.4.L670; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Morales MP, 2000, BIOCHEM BIOPH RES CO, V270, P1029, DOI 10.1006/bbrc.2000.2550; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Sengar AS, 1997, MOL CELL BIOL, V17, P3508, DOI 10.1128/MCB.17.7.3508; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sumioka K, 2000, INVEST OPHTH VIS SCI, V41, P29; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V278, pC102, DOI 10.1152/ajpcell.2000.278.1.C102	41	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32344	32351		10.1074/jbc.M303532200	http://dx.doi.org/10.1074/jbc.M303532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783890	hybrid			2022-12-25	WOS:000184782100112
J	Coros, CJ; Sekino, Y; Baker, TA; Chaconas, G				Coros, CJ; Sekino, Y; Baker, TA; Chaconas, G			Effect of mutations in the C-terminal domain of Mu B on DNA binding and interactions with Mu A transposase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSPOSITION; BACTERIOPHAGE-MU; STRAND-TRANSFER; ESCHERICHIA-COLI; CONSERVATIVE INTEGRATION; TARGET IMMUNITY; END-PRODUCTS; PROTEIN; CLEAVAGE; COMPLEX	Bacteriophage Mu transposition requires two phage-encoded proteins, the transposase, Mu A, and an accessory protein, Mu B. Mu B is an ATP-dependent DNA-binding protein that is required for target capture and target immunity and is an allosteric activator of transpososome function. The recent NMR structure of the C-terminal domain of Mu B (Mu B223-312) revealed that there is a patch of positively charged residues on the solvent-exposed surface. This patch may be responsible for the nonspecific DNA binding activity displayed by the purified Mu B223-312 peptide. We show that mutations of three lysine residues within this patch completely abolish nonspecific DNA binding of the C-terminal peptide (Mu B223-312). To determine how this DNA binding activity affects transposition we mutated these lysine residues in the full-length protein. The full-length protein carrying all three mutations was deficient in both strand transfer and allosteric activation of transpososome function but retained ATPase activity. Peptide binding studies also revealed that this patch of basic residues within the C-terminal domain of Mu B is within a region of the protein that interacts directly with Mu A. Thus, we conclude that this protein segment contributes to both DNA binding and protein-protein contacts with the Mu transposase.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	University of Calgary; Western University (University of Western Ontario); University of Calgary; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Chaconas, G (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	chaconas@ucalgary.ca			NIGMS NIH HHS [R01 GM049224, R01 GM049224-11, GM49224] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049224] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; Bird LE, 1999, BBA-GENE STRUCT EXPR, V1444, P424, DOI 10.1016/S0167-4781(99)00024-X; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1981, J MOL BIOL, V150, P341, DOI 10.1016/0022-2836(81)90551-9; CHACONAS G, 1983, VIROLOGY, V128, P48, DOI 10.1016/0042-6822(83)90317-3; CHACONAS G, 1985, CELL, V41, P857, DOI 10.1016/S0092-8674(85)80066-0; Chaconas George, 2002, P384; Coros CJ, 2001, J MOL BIOL, V310, P299; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DARZINS A, 1988, P NATL ACAD SCI USA, V85, P6826, DOI 10.1073/pnas.85.18.6826; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; HARSHEY RM, 1984, COLD SPRING HARB SYM, V49, P273, DOI 10.1101/SQB.1984.049.01.032; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; Hung LH, 2000, EMBO J, V19, P5625, DOI 10.1093/emboj/19.21.5625; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kobryn K, 2002, MOL CELL, V10, P659, DOI 10.1016/S1097-2765(02)00596-8; Krementsova E, 1998, J BIOL CHEM, V273, P31358, DOI 10.1074/jbc.273.47.31358; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LIEBART JC, 1982, P NATL ACAD SCI-BIOL, V79, P4362, DOI 10.1073/pnas.79.14.4362; LIM WA, 1991, METHOD ENZYMOL, V208, P196; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; Millner A, 1998, J MOL BIOL, V275, P233, DOI 10.1006/jmbi.1997.1446; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; Naigamwalla DZ, 1997, EMBO J, V16, P5227, DOI 10.1093/emboj/16.17.5227; Naigamwalla DZ, 1998, J MOL BIOL, V282, P265, DOI 10.1006/jmbi.1998.2011; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; Namgoong SY, 1998, J MOL BIOL, V275, P221, DOI 10.1006/jmbi.1997.1466; Neuwald AF, 1999, GENOME RES, V9, P27; Roldan LAS, 2001, MOL MICROBIOL, V40, P141, DOI 10.1046/j.1365-2958.2001.02364.x; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; TEPLOW DB, 1988, J BIOL CHEM, V263, P10851; Wang ZG, 1996, J BIOL CHEM, V271, P9619, DOI 10.1074/jbc.271.16.9619; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; Wu ZG, 1997, J MOL BIOL, V267, P132, DOI 10.1006/jmbi.1996.0854; WU ZG, 1992, J BIOL CHEM, V267, P9552; WU ZG, 1994, J BIOL CHEM, V269, P28829; Yamauchi M, 1998, EMBO J, V17, P5509, DOI 10.1093/emboj/17.18.5509	54	4	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31210	31217		10.1074/jbc.M303693200	http://dx.doi.org/10.1074/jbc.M303693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12791691	hybrid			2022-12-25	WOS:000184658800099
J	Pankevych, H; Korkhov, V; Freissmuth, M; Nanoff, C				Pankevych, H; Korkhov, V; Freissmuth, M; Nanoff, C			Truncation of the A(1) adenosine receptor reveals distinct roles of the membrane-proximal carboxyl terminus in receptor folding and G protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; 4TH CYTOPLASMIC LOOP; BETA-GAMMA-SUBUNITS; ALPHA-SUBUNITS; A(1)-ADENOSINE RECEPTOR; CONSTITUTIVE ACTIVITY; BETA-2-ADRENERGIC RECEPTOR; SUBCELLULAR FRACTIONATION; ENDOPLASMIC-RETICULUM; RAPID DEGRADATION	The carboxyl terminus (C-tail) of G protein-coupled receptors is divergent in length and structure and may represent an individualized cytoplasmic domain. By progressively truncating the A(1) adenosine receptor, a G(i/o)-coupled receptor with short cytoplasmic stretches, we identify two inherent functions of the C-tail, namely a role in receptor export from the endoplasmic reticulum (ER) and a role in G protein coupling. Deletion of the last 22 and 26 amino acids (of 36) reduced and completely abolished surface expression of the receptor, respectively. The severely truncated receptors were retained in the ER and failed to bind ligands. If overexpressed, even a substantial portion of the full-length receptor was retained in the ER in a form that was not functional. These data indicate that folding is rate limiting in export from the ER and that the proximal segment of the carboxyl terminus provides a docking site for the machinery involved in folding and quality control. In addition, the proximal portion is also important in G protein coupling. This latter role was unmasked when the distal portion of the C-tail (the extreme 18 amino acids, including a palmitoylated cysteine) had been removed; the resulting receptor was functional and transferred the agonist-mediated signal more efficiently than the full-length receptor. Signaling was enhanced because the coupling affinity increased (by 3-fold), which translated into a higher agonist potency. Thus, the distal portion of the carboxyl terminus provides for an autoinhibitory restraint, presumably by folding back and preventing G protein access to the proximal part of the C-tail.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	University of Vienna	Nanoff, C (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Gurtel 13A, A-1090 Vienna, Austria.			nanoff, christian/0000-0002-8857-2470; Korkhov, Volodymyr/0000-0002-0962-9433; Freissmuth, Michael/0000-0001-9398-1765				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fialka I, 1997, ELECTROPHORESIS, V18, P2582, DOI 10.1002/elps.1150181414; Fukushima Y, 1997, J BIOL CHEM, V272, P19464, DOI 10.1074/jbc.272.31.19464; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Gimelbrant AA, 1999, J NEUROCHEM, V72, P2301, DOI 10.1046/j.1471-4159.1999.0722301.x; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; Klinger M, 2002, CELL SIGNAL, V14, P99, DOI 10.1016/S0898-6568(01)00235-2; Klinger M, 2002, N-S ARCH PHARMACOL, V366, P287, DOI 10.1007/s00210-002-0617-z; Krause G, 2000, MOL PHARMACOL, V57, P232; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mielke T, 2002, BIOCHEMISTRY-US, V41, P7875, DOI 10.1021/bi011862v; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NANOFF C, 1989, J CARDIOVASC PHARM, V13, P198, DOI 10.1097/00005344-198902000-00004; Nanoff C, 1997, NEUROPHARMACOLOGY, V36, P1211, DOI 10.1016/S0028-3908(97)00135-4; NANOFF C, 1995, MOL PHARMACOL, V48, P806; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palmer TM, 1996, J BIOL CHEM, V271, P15272, DOI 10.1074/jbc.271.25.15272; PARKER EM, 1991, J BIOL CHEM, V266, P9987; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Pasquali C, 1999, J CHROMATOGR B, V722, P89, DOI 10.1016/S0378-4347(98)00314-4; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Perroy J, 2001, J BIOL CHEM, V276, P45800, DOI 10.1074/jbc.M106876200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Ponimaskin EG, 2002, J BIOL CHEM, V277, P2534, DOI 10.1074/jbc.M106529200; Ren HZ, 1995, MOL PHARMACOL, V48, P975; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Sarrio S, 2000, MOL CELL BIOL, V20, P5164, DOI 10.1128/MCB.20.14.5164-5174.2000; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; STILES GL, 1985, J BIOL CHEM, V261, P10639; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; WARD CL, 1994, J BIOL CHEM, V269, P25710; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a	67	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30283	30293		10.1074/jbc.M212918200	http://dx.doi.org/10.1074/jbc.M212918200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764156	hybrid			2022-12-25	WOS:000184507000108
J	Zhou, N; Xiao, H; Li, TK; Nur-E-Kamal, A; Liu, LF				Zhou, N; Xiao, H; Li, TK; Nur-E-Kamal, A; Liu, LF			DNA damage-mediated apoptosis induced by selenium compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II-ALPHA; REDUCED EXPRESSION; HISTONE H2AX; CELL-CYCLE; ATM; GROWTH; PROTECT; CANCER; CHEMOPREVENTION; ACTIVATION	Selenium ( Se) compounds, which are the most extensively studied cancer chemopreventive agents, induce apoptotic death of tumor cells. In the current study, we show that selenite-induced apoptosis involves DNA damage. We showed that selenite-induced apoptosis as evidenced by cleavage of poly( ADP-ribose) polymerase was reduced in NIH 3T3 cells treated with ATM small interfering RNA, suggesting the involvement of the DNA damage regulator ATM. Consistent with ATM/ATR involvement, selenite was also shown to stimulate Ser-139 phosphorylation of the ATM/ATR substrate H2AX. Selenite-induced apoptosis was shown to involve DNA topoisomerase II (Top II) as selenite-induced apoptosis was reduced in Top II-deficient HL-60/MX2 cells and in HL-60 cells co-treated with the Top II catalytic inhibitor ICRF-193. Using purified human recombinant Top II, selenite was shown to induce reversible Top II cleavage complexes in vitro. In the aggregate, these results suggest that selenite-induced apoptosis, which involves ATM/ATR and Top II, is likely to be because of DNA damage.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	lliu@umdnj.edu		Liu, Leroy/0000-0001-9396-763X; LI, TSAI-KUN/0000-0003-0393-2340	NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39662] Funding Source: Medline; NIGMS NIH HHS [GM 27731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; HARKER WG, 1991, BIOCHEMISTRY-US, V30, P9953, DOI 10.1021/bi00105a020; HARKER WG, 1995, CANCER RES, V55, P1707; Harrison PR, 1997, BIOMED ENVIRON SCI, V10, P235; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ip C, 2000, ANTICANCER RES, V20, P4179; ISHIDA R, 1991, CANCER RES, V51, P4909; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LU JX, 1995, BIOCHEM PHARMACOL, V50, P213, DOI 10.1016/0006-2952(95)00119-K; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; MILNER JA, 1981, CANCER RES, V41, P1652; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; NEVE J, 1995, J TRACE ELEM MED BIO, V9, P65, DOI 10.1016/S0946-672X(11)80013-1; POSNER GH, 1994, J MED CHEM, V37, P170, DOI 10.1021/jm00027a021; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sehested M, 1998, CANCER RES, V58, P1460; SHAMBERGER RJ, 1969, CAN MED ASSOC J, V100, P682; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart MS, 1999, FREE RADICAL BIO MED, V26, P42, DOI 10.1016/S0891-5849(98)00147-6; Subramanian D, 2000, METH MOL B, V95, P137; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; TANABE K, 1991, CANCER RES, V51, P4903; Wang HM, 2001, J BIOL CHEM, V276, P15990, DOI 10.1074/jbc.M011143200; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; WASSERMAN RA, 1993, CANCER RES, V53, P3591; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; Wei YM, 2001, MUTAT RES-GEN TOX EN, V490, P113, DOI 10.1016/S1383-5718(00)00149-2; Xiao H, 2003, P NATL ACAD SCI USA, V100, P5205, DOI 10.1073/pnas.0935978100; Zhong WX, 2001, CANCER RES, V61, P7071	50	125	132	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29532	29537		10.1074/jbc.M301877200	http://dx.doi.org/10.1074/jbc.M301877200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766154	hybrid			2022-12-25	WOS:000184507000019
J	Paxian, M; Bauer, I; Rensing, H; Jaeschke, H; Mautes, AEM; Kolb, SA; Wolf, B; Stockhausen, A; Jeblick, S; Bauer, M				Paxian, M; Bauer, I; Rensing, H; Jaeschke, H; Mautes, AEM; Kolb, SA; Wolf, B; Stockhausen, A; Jeblick, S; Bauer, M			Recovery of hepatocellular ATP and "pericentral apoptosis" after hemorrhage and resuscitation	FASEB JOURNAL			English	Article						necrosis; apoptosis; necrapoptosis; liver; ATP; oxygen free radicals	MITOCHONDRIAL PERMEABILITY TRANSITION; HEPATIC ISCHEMIA-REPERFUSION; NECROSIS FACTOR-ALPHA; CASPASE INHIBITOR; CELL-DEATH; RADICAL SCAVENGER; ORGAN INJURY; SHOCK; RATS; LIVER	Progressive liver dysfunction contributes significantly to the development of multiple organ failure after trauma/hemorrhage. This study tested the relative impact of necrotic and apoptotic cell death in a graded model of hemorrhagic shock (mean arterial blood pressure = 35 +/- 5 mmHg for 1, 2, or 3 h, followed by 2 h, 1 h, or no resuscitation, respectively) in rats. Prolonged periods of hemorrhagic hypotension (3 h) were paralleled by a profound decrease of hepatic ATP levels and occurrence of pericentral necrosis. Resuscitation after shorter periods of hemorrhagic hypotension resulted in restoration of tissue ATP whereas hepatocellular function as assessed by indocyanine green clearance remained depressed (49.9 +/- 1.6 mL/(min . kg) at baseline, 28.8 +/- 1.2 mL/(min . kg) after 2 h of resuscitation; P<0.05). Under these conditions, induction of caspase activity and DNA fragmentation were observed in pericentral hepatocytes that could be prevented by the radical scavenger tempol. Pretreatment with z-Val-Ala-Asp(O-methyl)-flouromethylketone prevented de novo expression of caspase-generated cytokeratin 18, DNA fragmentation, and depression of hepatocellular indocyanine green clearance. These data suggest that prolonged low flow/hypoxia induces ATP depletion and pericentral necrosis and restoration of oxygen supply and ATP levels after shorter periods of low flow ischemia propagate programmed cell death or "pericentral apoptosis."	Univ Saarland, Dept Anesthesiol & Crit Care Med, D-66421 Homburg, Germany; Univ Saarland, Neurosurg Res Lab, D-66421 Homburg, Germany; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland	Saarland University; Saarland University; University of Arkansas System; University of Arkansas Medical Sciences; University of Zurich; University Zurich Hospital	Bauer, M (corresponding author), Univ Saarland, Dept Anesthesiol & Crit Care Med, D-66421 Homburg, Germany.	aimbau@uniklinik-saarland.de	Jaeschke, Hartmut/J-6285-2013	Bauer, Michael/0000-0002-1521-3514				BAUER M, 1995, CRIT CARE MED, V23, P316, DOI 10.1097/00003246-199502000-00018; Bauer M, 1996, AM J PHYSIOL-GASTR L, V271, pG929, DOI 10.1152/ajpgi.1996.271.5.G929; BYNUM TE, 1979, DIGEST DIS SCI, V24, P129, DOI 10.1007/BF01324740; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; DEITCH EA, 1994, SHOCK, V1, P141, DOI 10.1097/00024382-199402000-00010; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gujral JS, 2001, HEPATOLOGY, V33, P397, DOI 10.1053/jhep.2001.22002; Jaeschke H, 2000, TOXICOL APPL PHARM, V169, P77, DOI 10.1006/taap.2000.9035; Leach M, 1998, BRIT J PHARMACOL, V125, P817, DOI 10.1038/sj.bjp.0702123; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; MARZI I, 1995, SHOCK, V3, P27, DOI 10.1097/00024382-199503010-00004; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McDonald MC, 1999, FREE RADICAL BIO MED, V27, P493, DOI 10.1016/S0891-5849(99)00100-8; McGuire GM, 1996, FREE RADICAL BIO MED, V20, P189, DOI 10.1016/0891-5849(95)02028-4; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Paxian M, 2001, SHOCK, V15, P438, DOI 10.1097/00024382-200115060-00005; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; Shimizu S, 1996, CANCER RES, V56, P2161; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	32	72	74	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					993	1002		10.1096/fj.02-0624com	http://dx.doi.org/10.1096/fj.02-0624com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773482				2022-12-25	WOS:000183818000003
J	Senchenko, V; Liu, J; Braga, E; Mazurenko, N; Loginov, W; Seryogin, Y; Bazov, I; Protopopov, A; Kisseljov, FL; Kashuba, V; Lerman, MI; Klein, G; Zabarovsky, ER				Senchenko, V; Liu, J; Braga, E; Mazurenko, N; Loginov, W; Seryogin, Y; Bazov, I; Protopopov, A; Kisseljov, FL; Kashuba, V; Lerman, MI; Klein, G; Zabarovsky, ER			Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas	ONCOGENE			English	Article						quantitative real-time PCR; human chromosome 3p; tumor suppressor genes; NotI linking clone; loss of heterozygosity; cervical carcinoma	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; LUNG-CANCER; 3P DELETIONS; SHORT ARM; INTRAEPITHELIAL NEOPLASIA; EPIGENETIC INACTIVATION; ALLELIC LOSS; HETEROZYGOSITY; FREQUENT	We report chromosome 3p deletion mapping of 32 cervical carcinoma (CC) biopsies using 26 microsatellite markers located in frequently deleted 3p regions to detect loss of heterozygosity and homozygous loss. In addition, two STS markers (NLJ-003 and NL3-001) located in the 3p21.3 telomeric (3p21.3T) and 3p21.3 centromeric (3p21.3C) regions, respectively, were used for quantitative real-time PCR as TaqMan probes. We show that quantitative real-time PCR is reliable and sensitive and allows discriminating between 0, 1 and 2 marker copies per human genome. For the first time, frequent (five of 32 cases, i.e. 15.6%) homozygous deletions were demonstrated in CCs in both 3p21.3T and 3p21.3C regions. The smallest region homozygously deleted in 3p21.3C was located between D3S1568 (CACNA2D2 gene) and D3S4604 (SEMA3F gene) and contains 17 genes previously defined as lung cancer candidate Tumor suppressor genes (TSG(s)). The smallest region homozygously deleted in 3p21.3T was flanked by D3S1298 and NL1-024 (D3S4285), excluding DLEC1 and MYD88 as candidate TSGs involved in cervical carcinogenesis. Overall, this region contains five potential candidates, namely GOLGA4, APRG1, ITGA9, HYA22 and VILL, which need to be analysed. The data showed that aberrations of either NLJ-003 or NL3-001 were detected in 29 cases (90.6%) and most likely have a synergistic effect (P<0.01). The study also demonstrated that aberrations in 3p21.3 were complex and in addition to deletions, may involve gene amplification as well. The results strongly suggest that 3p21.3T and 3p21.3C regions harbor genes involved in the origin and/or development of CCs and imply that those genes might be multiple TSG(s).	Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Russian Acad Sci, Ctr Bioengn, Moscow 117312, Russia; Russian State Genet Ctr, Moscow 113545, Russia; Russian Acad Med Sci, Blokhin Canc Res Ctr, Moscow 115478, Russia; NCI, Canc Causing Genes Sect, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Karolinska Institutet; Research Center of Biotechnology RAS; Russian Academy of Sciences; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Zabarovsky, ER (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Senchenko, Vera N/C-8992-2014; Loginov, Vytaliy/J-9738-2018; Braga, Eleonora A./P-5574-2016; Kashuba, Vladimir/AAO-7742-2020; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017	Senchenko, Vera N/0000-0002-3119-515X; Loginov, Vytaliy/0000-0003-2668-8096; Kashuba, Vladimir I/0000-0001-9416-8282; Bazov, Igor/0000-0003-4388-1656; Braga, Eleonora/0000-0001-5188-4094	PHS HHS [N01-C0-56000] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; ANGELONI D, 2001, SOURCEBOOK ASBESTOS, V23, P169; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Boulay JL, 1999, BIOTECHNIQUES, V27, P228, DOI 10.2144/99272bm03; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Braga E, 1999, FEBS LETT, V454, P215, DOI 10.1016/S0014-5793(99)00807-8; Braga E. A., 1997, Molekulyarnaya Biologiya (Moscow), V31, P985; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cairns JP, 1998, CLIN CANCER RES, V4, P441; Chiang PW, 1999, CLIN CANCER RES, V5, P1381; Daigo Y, 1999, DNA Res, V6, P37, DOI 10.1093/dnares/6.1.37; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; de Nooij-van Dalen AG, 1998, GENE CHROMOSOME CANC, V21, P30, DOI 10.1002/(SICI)1098-2264(199801)21:1<30::AID-GCC5>3.0.CO;2-9; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Fouret PJ, 1998, PATHOBIOLOGY, V66, P306, DOI 10.1159/000028038; Guo ZM, 2000, INT J CANCER, V86, P518, DOI 10.1002/(SICI)1097-0215(20000515)86:4<518::AID-IJC12>3.0.CO;2-Y; Guo ZM, 1998, ANTICANCER RES, V18, P707; Guo ZM, 2001, MODERN PATHOL, V14, P54, DOI 10.1038/modpathol.3880256; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Helland A, 2000, INT J CANCER, V88, P217; Herzog CR, 2001, MOL CARCINOGEN, V30, P159, DOI 10.1002/mc.1024; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Kashuba VI, 1999, GENE, V239, P259, DOI 10.1016/S0378-1119(99)00411-4; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kisseljov F, 1996, INT J CANCER, V69, P484, DOI 10.1002/(SICI)1097-0215(19961220)69:6<484::AID-IJC12>3.3.CO;2-G; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Larson AA, 1997, CANCER RES, V57, P4082; Larson AA, 1997, CANCER RES, V57, P4171; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lerman MI, 2000, CANCER RES, V60, P6116; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; LIVAK KJ, 1995, PCR METH APPL, V4, P357; MANTEL N, 1967, CANCER RES, V27, P209; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Mazurenko N, 1999, ONCOL REP, V6, P859; Muller CY, 1998, J NATL CANCER I, V90, P433, DOI 10.1093/jnci/90.6.433; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Protopopov A, 2003, CANCER RES, V63, P404; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; Rader JS, 1996, ONCOGENE, V13, P2737; SAMOYLOVA EV, 1995, INT J CANCER, V61, P337, DOI 10.1002/ijc.2910610311; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Varella-Garcia M, 1998, CANCER RES, V58, P4701; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1997, CANCER RES, V57, P3154; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	52	51	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2984	2992		10.1038/sj.onc.1206429	http://dx.doi.org/10.1038/sj.onc.1206429			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771950				2022-12-25	WOS:000182824800014
J	Deng, YP; Bhattacharya, S; Swamy, OR; Tandon, RC; Wang, Y; Janda, R; Riedel, H				Deng, YP; Bhattacharya, S; Swamy, OR; Tandon, RC; Wang, Y; Janda, R; Riedel, H			Growth factor receptor-binding protein 10 (Grb10) as a partner of phosphatidylinositol 3-kinase in metabolic insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; GLUCOSE-TRANSPORTER TRANSLOCATION; GLYCOGEN-SYNTHASE ACTIVATION; SRC HOMOLOGY-2 DOMAIN; P70 S6 KINASE; SIGNALING PATHWAY; 3T3-L1 ADIPOCYTES; ADAPTER PROTEIN; SH2 DOMAIN; PLECKSTRIN HOMOLOGY	The regulation of the metabolic insulin response by mouse growth factor receptor-binding protein 10 (Grb10) has been addressed in this report. We find mouse Grb10 to be a critical component of the insulin receptor (IR) signaling complex that provides a functional link between IR and p85 phosphatidylinositol (PI) 3-kinase and regulates PI 3-kinase activity. This regulatory mechanism parallels the established link between IR and p85 via insulin receptor substrate (IRS) proteins. A direct association was demonstrated between Grb10 and p85 but was not observed between Grb10 and IRS proteins. In addition, no effect of mouse Grb10 was observed on the association between IRS-1 and p85, on IRS-1-associated PI 3-kinase activity, or on insulin-mediated activation of IR or IRS proteins. A critical role of mouse Grb10 was observed in the regulation of PI 3-kinase activity and the resulting metabolic insulin response. Dominant-negative Grb10 domains, in particular the SH2 domain, eliminated the metabolic response to insulin in differentiated 3T3-L1 adipocytes. This was consistently observed for glycogen synthesis, glucose and amino acid transport, and lipogenesis. In parallel, the same metabolic responses were substantially elevated by increased levels of Grb10. A similar role of Grb10 was confirmed in mouse L6 cells. In addition to the SH2 domain, the Pro-rich amino-terminal region of Grb10 was implicated in the regulation of PI 3-kinase catalytic activity. These regulatory roles of Grb10 were extended to specific insulin mediators downstream of PI 3-kinase including PKB/Akt, glycogen synthase kinase, and glycogen synthase. In contrast, a regulatory role of Grb10 in parallel insulin response pathways including p70 S6 kinase, ubiquitin ligase Cbl, or mitogen-activated protein kinase p38 was not observed. The dissection of the interaction of mouse Grb10 with p85 and the resulting regulation of PI 3-kinase activity should help elucidate the complexity of the IR signaling mechanism.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Riedel, H (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.		Bhattacharya, Sujoy/AAD-2253-2022	Bhattacharya, Sujoy/0000-0003-4443-9691; Deng, Youping/0000-0002-5951-8213	NATIONAL CANCER INSTITUTE [R01CA077873] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angrist M, 1998, ONCOGENE, V17, P3065, DOI 10.1038/sj.onc.1202226; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; CARIOU B, 2004, IN PRESS FRONT BIOSC, V9; Cattanach BM, 1998, CYTOGENET CELL GENET, V80, P41, DOI 10.1159/000014955; CHANG PY, 1995, J BIOL CHEM, V270, P29928; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Giorgetti-Peraldi S, 2001, ONCOGENE, V20, P3959, DOI 10.1038/sj.onc.1204520; Giovannone B, 2003, J BIOL CHEM, V278, P31564, DOI 10.1074/jbc.M211572200; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hikichi T, 2003, NUCLEIC ACIDS RES, V31, P1398, DOI 10.1093/nar/gkg232; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Jerome CA, 1997, GENOMICS, V40, P215, DOI 10.1006/geno.1996.4535; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; Kayali AG, 1998, J BIOL CHEM, V273, P13808, DOI 10.1074/jbc.273.22.13808; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; McCann JA, 2001, BIOCHEM BIOPH RES CO, V286, P943, DOI 10.1006/bbrc.2001.5500; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; McDowell HE, 1998, FEBS LETT, V441, P15, DOI 10.1016/S0014-5793(98)01508-7; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; Mori K, 2003, DIABETES, V52, pA308; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 2000, INT J MOL MED, V5, P151; Mounier C, 2001, MOL CELL ENDOCRINOL, V173, P15, DOI 10.1016/S0303-7207(00)00439-1; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Riedel H, 2000, ONCOGENE, V19, P39, DOI 10.1038/sj.onc.1203253; RIEDEL H, 2004, IN PRESS FRONT BIOSC, V9; RIEDEL H, 2001, INSULIN SIGNALING CU, P89; Robbins PB, 2002, BIOTECHNIQUES, V33, P190, DOI 10.2144/02331dd02; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHEN T, 2004, IN PRESS FRONT BIOSC, V9; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Stein EG, 2003, J BIOL CHEM, V278, P13257, DOI 10.1074/jbc.M212026200; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Vidal M, 1999, J MOL BIOL, V290, P717, DOI 10.1006/jmbi.1999.2899; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VONHORN DJ, 1994, J BIOL CHEM, V269, P29; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	81	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39311	39322		10.1074/jbc.M304599200	http://dx.doi.org/10.1074/jbc.M304599200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12783867	hybrid			2022-12-25	WOS:000185713800008
J	Banchio, C; Schang, LM; Vance, DE				Banchio, C; Schang, LM; Vance, DE			Activation of CTP : phosphocholine cytidylyltransferase alpha expression during the S phase of the cell cycle is mediated by the transcription factor Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; RAT-LIVER; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE METABOLISM; ENHANCER FACTOR-4; BINDING PROTEINS; MAMMALIAN-CELLS; GENE; IDENTIFICATION; PHOSPHORYLATION	An essential step during cell division is induction of phosphatidylcholine biosynthesis. In this pathway, CTP: phosphocholine cytidylyltransferase alpha (CTalpha) plays an important regulatory role. Previous studies (Golfman, L. S., Bakovic, M., and Vance, D. E. (2001) J. Biol. Chem. 276, 43688-43692) demonstrated that CTalpha mRNA accumulates during S phase in preparation for cellular mitosis. We now demonstrate that increased binding of the transcription factor Sp1 to the proximal promoter of CTalpha is responsible for increased transcription during the S phase. The Sp1 binding element present in position -67/-62 is essential for activation, and the Sp1 site in position -31/-9 is required to enhance transcription. Inhibition of Sp1 expression by RNA interference abolished the enhanced expression of CTalpha. Immunoprecipitation studies demonstrated that Sp1 interacts with cyclin E, cyclin A, and cyclin-dependent kinase 2 during the S phase. We conclude that Sp1 binding to the CTalpha proximal promoter is necessary to enhance transcription during the S phase. This is the first elucidation of a mechanism by which expression of a key enzyme in phospholipid biosynthesis is regulated during the cell cycle.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.			Schang, Luis Maria/0000-0002-5789-8590				AMSTRONG SA, 1997, J BIOL CHEM, V272, P13489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; HOUWELING M, 1997, BIOCHIM BIOPHYS ACTA, V1546, P7; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kast HR, 2001, J LIPID RES, V42, P1266; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Ridgway ND, 2003, BIOCHEM J, V372, P811, DOI 10.1042/BJ20030252; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sugimoto H, 2003, J BIOL CHEM, V278, P19716, DOI 10.1074/jbc.M301590200; Sugimoto H, 2001, J BIOL CHEM, V276, P12338, DOI 10.1074/jbc.M100090200; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TERCE F, 1994, J LIPID RES, V35, P2130; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354	42	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32457	32464		10.1074/jbc.M304810200	http://dx.doi.org/10.1074/jbc.M304810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794070	hybrid			2022-12-25	WOS:000184782100126
J	Polek, TC; Talpaz, M; Darnay, BG; Spivak-Kroizman, T				Polek, TC; Talpaz, M; Darnay, BG; Spivak-Kroizman, T			TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR - Evidence for a second TWEAK receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; OSTEOCLAST DIFFERENTIATION; MULTIPLE PATHWAYS; ENDOTHELIAL-CELLS; FACTOR FAMILY; LIGAND; DEATH; TNF; RANK	Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor family that is implicated in apoptosis, proliferation, migration, and inflammation. We describe our findings showing that TWEAK mediated the differentiation of RAW264.7(RAW) monocyte/macrophage cells into multinuclear, functional osteoclasts. The effect of TWEAK was direct and not mediated by the receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL) as shown by the use of TWEAK- or RANKL-neutralizing antibodies and by osteoprotegerin, a decoy receptor for RANKL. Recently, fibroblast growth factor-inducible 14 (Fn14) was suggested to be a receptor for TWEAK. We show that the Fn14/TWEAK receptor (TweakR) was not responsible for the osteoclastic effect of TWEAK on RAW cells. Flow cytometry analysis did not reveal the expression of Fn14/TweakR on RAW cells. Moreover, Fn14/TweakR-neutralizing antibodies did not block TWEAK- induced RAW cell differentiation into osteoclasts. This indicated that a second TweakR, TweakR2, exists on RAW cells and is responsible for mediating TWEAK- induced differentiation. We next compared the signaling pathways that are activated by the two receptors. TWEAK binding to TweakR2 activated the NF-kappaB, mitogen-activated protein kinase and c-Jun N-terminal kinase signaling cascades in RAW cells. In contrast, TWEAK binding to Fn14/TweakR activated the NF-kappaB and c-Jun N-terminal kinase pathways but induced only a weak activation of MAPK in HT-29 human colon adenocarcinoma cells expressing endogenous Fn14/TweakR. We propose that the biological effects of TWEAK are mediated by binding to one of at least two distinct receptors that induce differential activation of downstream signaling pathways.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Cytokine Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Spivak-Kroizman, T (corresponding author), Unit 143,1515 Holcombe Blvd, Houston, TX 77030 USA.			Talpaz, Moshe/0000-0003-3361-3981				Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chicheportiche Y, 2002, ARTHRITIS RES, V4, P126, DOI 10.1186/ar388; Chung JY, 2002, J CELL SCI, V115, P679; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Desplat-Jego S, 2002, J NEUROIMMUNOL, V133, P116, DOI 10.1016/S0165-5728(02)00368-5; Han SY, 2003, BIOCHEM BIOPH RES CO, V305, P789, DOI 10.1016/S0006-291X(03)00852-0; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Jakubowski A, 2002, J CELL SCI, V115, P267; Kaplan MJ, 2002, J IMMUNOL, V169, P6020, DOI 10.4049/jimmunol.169.10.6020; Kaptein A, 2000, FEBS LETT, V485, P135, DOI 10.1016/S0014-5793(00)02219-5; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1	36	136	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32317	32323		10.1074/jbc.M302518200	http://dx.doi.org/10.1074/jbc.M302518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794080	hybrid			2022-12-25	WOS:000184782100109
J	Kessl, JJ; Lange, BB; Merbitz-Zahradnik, T; Zwicker, K; Hill, P; Meunier, B; Palsdottir, H; Hunte, C; Meshnick, S; Trumpower, BL				Kessl, JJ; Lange, BB; Merbitz-Zahradnik, T; Zwicker, K; Hill, P; Meunier, B; Palsdottir, H; Hunte, C; Meshnick, S; Trumpower, BL			Molecular basis for atovaquone binding to the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; RHODOPSEUDOMONAS-SPHAEROIDES; SACCHAROMYCES-CEREVISIAE; TOXOPLASMA-GONDII; ELECTRON-TRANSFER; B GENE; RESISTANCE; MUTATIONS; SITE; MITOCHONDRIAL	Atovaquone is a substituted 2-hydroxynaphthoquinone that is used therapeutically to treat Plasmodium falciparum malaria, Pneumocystis carinii pneumonia, and Toxoplasma gondii toxoplasmosis. It is thought to act on these organisms by inhibiting the cytochrome bc(1) complex. We have examined the interaction of atovaquone with the bc1 complex isolated from Saccharomyces cerevisiae, a surrogate, nonpathogenic fungus. Atovaquone inhibits the bc(1) complex competitively with apparent K(i) = 9 nM, raises the midpoint potential of the Rieske iron-sulfur protein from 285 to 385 mV, and shifts the g values in the EPR spectrum of the Rieske center. These results indicate that atovaquone binds to the ubiquinol oxidation pocket of the bc(1) complex, where it interacts with the Rieske iron-sulfur protein. A computed energy-minimized structure for atovaquone liganded to the yeast bc(1) complex suggests that a phenylalanine at position 275 of cytochrome b in the bovine bc(1) complex, as opposed to leucine at the equivalent position in the yeast enzyme, is responsible for the decreased sensitivity of the bovine bc(1) complex (K(i) = 80 nM) to atovaquone. When a L275F mutation was introduced into the yeast cytochrome b, the sensitivity of the yeast enzyme to atovaquone decreased (K(i) = 100 nM) with no loss in activity, confirming that the L275F exchange contributes to the differential sensitivity of these two species to atovaquone. These results provide the first molecular description of how atovaquone binds to the bc(1) complex and explain the differential inhibition of the fungal versus mammalian enzymes.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Frankfurt Klinikum, ZBC, D-60590 Frankfurt, Germany; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Max Planck Inst Biophys, D-60439 Frankfurt, Germany; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Dartmouth College; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of London; University College London; Max Planck Society; University of North Carolina; University of North Carolina Chapel Hill	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Hunte, Carola/E-4071-2015; Kessl, Jacques/AAV-2526-2021; Kessl, Jacques/J-6073-2015	Hunte, Carola/0000-0002-0826-3986; Meunier, Brigitte/0000-0002-6988-4663	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46966] Funding Source: Medline; NIGMS NIH HHS [GM20379] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAUJO FG, 1991, ANTIMICROB AGENTS CH, V35, P293, DOI 10.1128/AAC.35.2.293; BOEHM P, 1981, J MED CHEM, V24, P295, DOI 10.1021/jm00135a011; BOWYER JR, 1980, BIOCHIM BIOPHYS ACTA, V592, P445, DOI 10.1016/0005-2728(80)90091-2; BOWYER JR, 1982, J BIOL CHEM, V257, P8321; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Covian R, 2002, J BIOL CHEM, V277, P48449, DOI 10.1074/jbc.M208060200; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; FLETCHER R, 1987, PRACTICAL METHODS OP, P54; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; HEHRE WJ, 1998, BRIEF GUIDE MOL MECH, P7; HILL P, 2003, IN PRESS ANTIMICROBI; HUDSON AT, 1991, DRUG EXP CLIN RES, V17, P427; HUGHES WT, 1995, J INFECT DIS, V172, P1042, DOI 10.1093/infdis/172.4.1042; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; JACOBS DAH, 1977, STATE ART NUMERICAL, P256; Kazanjian P, 2001, J INFECT DIS, V183, P819, DOI 10.1086/318835; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; KUNZE B, 1984, J ANTIBIOT, V37, P454, DOI 10.7164/antibiotics.37.454; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MAROTI P, 1995, NAT STRUCT BIOL, V2, P1057, DOI 10.1038/nsb1295-1057; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McFadden DC, 2000, MOL BIOCHEM PARASIT, V108, P1, DOI 10.1016/S0166-6851(00)00184-5; NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Sampogna RV, 1996, BIOPHYS J, V71, P1165, DOI 10.1016/S0006-3495(96)79320-7; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Syafruddin D, 1999, MOL BIOCHEM PARASIT, V104, P185, DOI 10.1016/S0166-6851(99)00148-6; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Walker DJ, 1998, J INFECT DIS, V178, P1767, DOI 10.1086/314509; WENDEL WB, 1946, FED PROC, V5, P406	35	123	130	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31312	31318		10.1074/jbc.M304042200	http://dx.doi.org/10.1074/jbc.M304042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12791689	hybrid, Green Published			2022-12-25	WOS:000184658800112
J	Kundrat, L; Martins, J; Stith, L; Dunbrack, RL; Jaffe, EK				Kundrat, L; Martins, J; Stith, L; Dunbrack, RL; Jaffe, EK			A structural basis for half-of-the-sites metal binding revealed in Drosophila melanogaster porphobilinogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; 5-AMINOLEVULINATE DEHYDRATASE; ARTIFICIAL GENE; MECHANISM; ACID; INHIBITION	Porphobilinogen synthase (PBGS) proteins fall into several distinct groups with different metal ion requirements. Drosophila melanogaster porphobilinogen synthase (DmPBGS) is the first non-mammalian metazoan PBGS to be characterized. The sequence shows the determinants for two zinc binding sites known to be present in both mammalian and yeast PBGS, proteins that differ in the exhibition of half-of-the-sites metal binding. The pH-dependent activity of DmPBGS is uniquely affected by zinc. A tight binding catalytic zinc binds at 0.5/subunit with a K-d well below muM. A second inhibitory zinc exhibits a K-d of similar to5 muM and appears to bind at a stoichiometry of 1/subunit. A molecular model of DmPBGS suggests that the inhibitory zinc is located at a subunit interface using Cys-219 and His-10 as ligands. Zinc binding to this previously unknown inhibitory site is proposed to inhibit opening of the active site lid. As predicted, the DmPBGS mutant H10F is active but is not inhibited by zinc. H10F binds a catalytic zinc at 0.5/ subunit and binds a second nonessential and noninhibitory zinc at 0.5/ subunit. This result reveals a structural basis for half-of-the-sites metal binding that is consistent with a reciprocating motion model for function of oligomeric PBGS.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 333 Cottman Ave, Philadelphia, PA 19111 USA.		Dunbrack, Roland/ABG-7141-2020	Dunbrack, Roland/0000-0001-7674-6667	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BEVAN DR, 1980, J BIOL CHEM, V255, P2030; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; COPELAND RA, 1995, BIOORG MED CHEM LETT, V5, P1947, DOI 10.1016/0960-894X(95)00330-V; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Dunbrack RL, 1999, PROTEINS, P81; Erskine PT, 2000, ACTA CRYSTALLOGR D, V56, P421, DOI 10.1107/S0907444900000597; Erskine PT, 1997, NAT STRUCT BIOL, V4, P1025, DOI 10.1038/nsb1297-1025; Erskine PT, 2001, J MOL BIOL, V312, P133, DOI 10.1006/jmbi.2001.4947; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Jaffe EK, 2003, CHEM BIOL, V10, P25, DOI 10.1016/S1074-5521(02)00296-X; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; JAFFE EK, 1984, J BIOL CHEM, V259, P5032; JAFFE EK, 1992, BIOCHEMISTRY-US, V31, P2113, DOI 10.1021/bi00122a032; Jaffe EK, 2000, J BIOL CHEM, V275, P2619, DOI 10.1074/jbc.275.4.2619; Jaffe EK, 2002, J BIOL CHEM, V277, P19792, DOI 10.1074/jbc.M201486200; Jaffe EK, 2001, J BIOL CHEM, V276, P1531, DOI 10.1074/jbc.M007663200; Kervinen J, 2001, BIOCHEMISTRY-US, V40, P8227, DOI 10.1021/bi010656k; Kervinen J, 2000, BIOCHEMISTRY-US, V39, P9018, DOI 10.1021/bi000620c; Shoolingin-Jordan PM, 1998, BIOCHEM SOC T, V26, P326, DOI 10.1042/bst0260326	21	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31325	31330		10.1074/jbc.M304124200	http://dx.doi.org/10.1074/jbc.M304124200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12794073	hybrid			2022-12-25	WOS:000184658800114
J	Cao, C; Leng, YM; Kufe, D				Cao, C; Leng, YM; Kufe, D			Catalase activity is regulated by c-Abl and Arg in the oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; INDUCED APOPTOSIS; CU,ZN-SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR; CELL-DEATH; LIFE-SPAN; ACTIVATION; DNA; MITOCHONDRIA; GENERATION	The Abl family of mammalian non-receptor tyrosine kinases includes c-Abl and Arg. Recent studies have demonstrated that c-Abl and Arg are activated in the response of cells to oxidative stress. This work demonstrates that catalase, a major effector of the cellular defense against H2O2, interacts with c-Abl and Arg. The results show that H2O2 induced binding of c-Abl and Arg to catalase. The SH3 domains of c-Abl and Arg bound directly to catalase at a (PFNP)-F-293 site. c-Abl and Arg phosphorylated catalase at Tyr(231) and Tyr(386) in vitro and in the response of cells to H2O2. The functional significance of the interaction is supported by the demonstration that cells deficient in both c-Abl and Arg exhibit substantial increases in H2O2 levels. In addition, c-abl(-/-) arg(-/-) cells exhibited a marked increase in H2O2-induced apoptosis compared with that found in the absence of either kinase. These findings indicate that c-Abl and Arg regulate catalase and that this signaling pathway is of importance to apoptosis in the oxidative stress response.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Beijing Inst Biotechnol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA42802, CA49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639, R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RADI R, 1991, J BIOL CHEM, V266, P22028; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1996, ONCOGENE, V13, P193; Yabuki M, 1999, FREE RADICAL BIO MED, V26, P325, DOI 10.1016/S0891-5849(98)00203-2; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	44	141	143	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29667	29675		10.1074/jbc.M301292200	http://dx.doi.org/10.1074/jbc.M301292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777400	hybrid			2022-12-25	WOS:000184507000037
J	He, ZG; Rezende, LF; Willcox, S; Griffith, JD; Richardson, CC				He, ZG; Rezende, LF; Willcox, S; Griffith, JD; Richardson, CC			The carboxyl-terminal domain of bacteriophage T7 single-stranded DNA-binding protein modulates DNA binding and interaction with T7 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE 2.5 PROTEIN; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; UNWINDING PROTEIN; REPLICATION; SEQUENCE; HELICASE; PURIFICATION; STIMULATION; MECHANISM	Gene 2.5 of bacteriophage T7 is an essential gene that encodes a single-stranded DNA-binding protein (gp2.5). Previous studies have demonstrated that the acidic carboxyl terminus of the protein is essential and that it mediates multiple protein-protein interactions. A screen for lethal mutations in gene 2.5 uncovered a variety of essential amino acids, among which was a single amino acid substitution, F232L, at the carboxyl-terminal residue. gp2.5-F232L exhibits a 3-fold increase in binding affinity for single-stranded DNA and a slightly lower affinity for T7 DNA polymerase when compared with wild type gp2.5. gp2.5-F232L stimulates the activity of T7 DNA polymerase and, in contrast to wild-type gp2.5, promotes strand displacement DNA synthesis by T7 DNA polymerase. A carboxyl-terminal truncation of gene 2.5 protein, gp2.5-Delta26C, binds single-stranded DNA 40-fold more tightly than the wild-type protein and cannot physically interact with T7 DNA polymerase. gp2.5-Delta26C is inhibitory for DNA synthesis catalyzed by T7 DNA polymerase on single-stranded DNA, and it does not stimulate strand displacement DNA synthesis at high concentration. The biochemical and genetic data support a model in which the carboxyl-terminal tail modulates DNA binding and mediates essential interactions with T7 DNA polymerase.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.		He, Zheng-Guo/P-3647-2014		NIGMS NIH HHS [GM 54397] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Griffith J D, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 1, P215; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; LOW RL, 1982, J BIOL CHEM, V257, P6242; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MYERS TW, 1988, J BIOL CHEM, V263, P17006; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; Pajunen MI, 2001, J BACTERIOL, V183, P1928, DOI 10.1128/JB.183.6.1928-1937.2001; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; Rezende LF, 2002, J BIOL CHEM, V277, P50643, DOI 10.1074/jbc.M207359200; REZENDE LF, 2003, IN PRESS J BIOL CHEM, V278; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RIGLER MN, 1995, J BIOL CHEM, V270, P8910, DOI 10.1074/jbc.270.15.8910; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SCHMITT MP, 1987, J MOL BIOL, V193, P479, DOI 10.1016/0022-2836(87)90261-0; SIGAL N, 1972, P NATL ACAD SCI USA, V69, P3537, DOI 10.1073/pnas.69.12.3537; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Tabor S., 1996, Richardson, Method for Nucleic Acid Hybridization Using Single-stranded DNA Binding Protein, Patent No. 5534407; TALOR J, 1994, METHODS MOL BIOL DNA, V30, P263; Trakselis MA, 2001, TRENDS BIOCHEM SCI, V26, P566, DOI 10.1016/S0968-0004(01)01929-6; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; WEINER JH, 1975, J BIOL CHEM, V250, P1972; Wu M, 1999, J MOL BIOL, V286, P1107, DOI 10.1006/jmbi.1999.2541; Yu M, 2001, J BACTERIOL, V183, P1862, DOI 10.1128/JB.183.6.1862-1869.2001	51	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29538	29545		10.1074/jbc.M304318200	http://dx.doi.org/10.1074/jbc.M304318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766155	hybrid			2022-12-25	WOS:000184507000020
J	Pierrel, F; Hernandez, HL; Johnson, MK; Fontecave, M; Atta, M				Pierrel, F; Hernandez, HL; Johnson, MK; Fontecave, M; Atta, M			MiaB protein from Thermotoga maritima - Characterization of an extremely thermophilic tRNA-methylthiotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; MAGNETIC CIRCULAR-DICHROISM; IRON-SULFUR CLUSTER; IN-VITRO SYNTHESIS; ESCHERICHIA-COLI; RESONANCE RAMAN; BIOTIN SYNTHASE; SPECTROSCOPIC CHARACTERIZATION; SALMONELLA-TYPHIMURIUM; RADICAL MECHANISMS	In Escherichia coli, the MiaB protein catalyzes the methylthiolation of N-6-isopentenyl adenosine in tRNAs, the last reaction step during biosynthesis of 2-methylthio-N-6-isopentenyl adenosine ( ms(2)i(6)A-37). For the first time the thermophilic bacterium Thermotoga maritima is shown here to contain such a MiaB tRNA-modifying enzyme, named MiaBTm, and to synthesize ms(2)i(6)A-37 as demonstrated by an analysis of modified nucleosides from tRNA hydrolysates. The corresponding gene (TM0653) was identified by sequence similarity to the miaB gene cloned and expressed in E. coli. MiaBTm was purified to homogeneity and thoroughly characterized by biochemical and spectroscopic methods. It is a monomer of 443 residues with a molecular mass of 50,710 kilodaltons. Its amino acid sequence shares the CysXXX-CysXXCys sequence with MiaB from E. coli as well as with biotin synthase and lipoate synthase. This sequence was shown to be essential for chelation of an iron-sulfur center and for activity in these enzymes. As isolated, MiaBTm contains both iron and sulfide and an apoprotein form can coordinate up to 4 iron and 4 sulfur atoms per polypeptide chain. UV-visible absorption, resonance Raman, variable temperature magnetic circular dichroism, and EPR spectroscopy of MiaBTm indicate the presence of a [ 4Fe-4S](+2/+1) cluster under reducing and anaerobic conditions, whereas [3Fe-4S](+1) and [2Fe-2S](+2) forms are generated under aerobic conditions. The redox potential of the [4Fe-4S](+2/+1) transition is - 495 +/- 10 mV ( versus the normal hydrogen electrode). Finally, the expression of MiaBTm from T. maritima in an E. coli mutant strain lacking functional miaB gene allowed production of ms(2)i(6)A-37. These results provide further information on the enzymes involved in methylthiolation of tRNAs.	Univ Grenoble 1, Commissariat Energie Atom Grenoble, DRDC CB, Ctr Redox Biol,Lab Chim & Biochim,CNRS,UMR 5047, F-38054 Grenoble 09, France; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Atta, M (corresponding author), Univ Grenoble 1, Commissariat Energie Atom Grenoble, DRDC CB, Ctr Redox Biol,Lab Chim & Biochim,CNRS,UMR 5047, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mohamed.atta@cea.fr	PIERREL, Fabien/M-6016-2014	PIERREL, Fabien/0000-0003-2083-3002	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRIS PF, 1975, NUCLEIC ACIDS RES, V2, P691, DOI 10.1093/nar/2.5.691; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anantharaman V, 2001, FEMS MICROBIOL LETT, V197, P215, DOI 10.1111/j.1574-6968.2001.tb10606.x; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BJORK GR, 1996, ESCHERICHIA COLI SAL, P861; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; BJORK RG, 1998, MODIFICATION EDITING, P471; BJORK RG, 1995, TRNA STRUCTURE BIOSY, P23; Bocchetta M, 2000, J MOL EVOL, V50, P366, DOI 10.1007/s002399910040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brereton PS, 1999, BIOCHEMISTRY-US, V38, P10594, DOI 10.1021/bi990671d; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Crouse BR, 1996, BIOCHEMISTRY-US, V35, P16222, DOI 10.1021/bi9620114; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; DROZDZEWSKI PM, 1988, APPL SPECTROSC, V42, P1575, DOI 10.1366/0003702884429841; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; ERICSON JU, 1991, J MOL BIOL, V218, P509, DOI 10.1016/0022-2836(91)90697-5; ESBERG B, 1995, J BACTERIOL, V177, P1967, DOI 10.1128/jb.177.8.1967-1975.1995; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; FU WG, 1991, FEBS LETT, V284, P165, DOI 10.1016/0014-5793(91)80676-T; FU WG, 1992, J BIOL CHEM, V267, P15502; GEFTER ML, 1969, BIOCHEM BIOPH RES CO, V36, P435, DOI 10.1016/0006-291X(69)90583-X; Gehrke CW, 1990, J CHROMATOGRAPHY LIB, pA3; GROSJEAN H, 1985, NUCLEIC ACIDS RES, V13, P5697, DOI 10.1093/nar/13.15.5697; HAGEN WR, 1989, EUR J BIOCHEM, V182, P523, DOI 10.1111/j.1432-1033.1989.tb14859.x; Hewitson KS, 2002, J BIOL INORG CHEM, V7, P83, DOI 10.1007/s007750100268; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Johnson M. K., 1988, METAL CLUSTERS PROTE, P326; Johnson MK, 1998, PURE APPL CHEM, V70, P939, DOI 10.1351/pac199870040939; JOHNSON MK, 1983, J AM CHEM SOC, V105, P6671, DOI 10.1021/ja00360a022; Johnson MK, 1999, ADV INORG CHEM, V47, P1, DOI 10.1016/S0898-8838(08)60076-8; Johnson MK, 1982, IRON SULFUR PROTEINS, P367; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; Marquet A, 2001, VITAM HORM, V61, P51; MEYER J, 1994, BIOCHEMISTRY-US, V33, P13642, DOI 10.1021/bi00250a014; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; Moore JA, 1997, BIOCHEMISTRY-US, V36, P604, DOI 10.1021/bi962225l; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Mulliez E, 2001, BIOCHEMISTRY-US, V40, P3730, DOI 10.1021/bi001746c; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; ONATE YA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P113, DOI 10.1016/0167-4838(93)90237-L; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; ROSENBERG AH, 1969, J MOL BIOL, V46, P581, DOI 10.1016/0022-2836(69)90197-1; Soderberg T, 2000, BIOCHEMISTRY-US, V39, P6546, DOI 10.1021/bi992775u; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Spiro T. G., 1988, RESONANCE RAMAN SPEC, P523; SPIRO TG, 1982, IRON SULFUR PROTEINS, P407; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; Winkler ME, 1998, MODIFICATION EDITING, P441	70	54	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29515	29524		10.1074/jbc.M301518200	http://dx.doi.org/10.1074/jbc.M301518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766153	hybrid			2022-12-25	WOS:000184507000017
J	Seufferheld, M; Vieira, MCF; Ruiz, FA; Rodrigues, CO; Moreno, SNJ; Docampo, R				Seufferheld, M; Vieira, MCF; Ruiz, FA; Rodrigues, CO; Moreno, SNJ; Docampo, R			Identification of organelles in bacteria similar to acidocalcisomes of unicellular eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING PYROPHOSPHATASE; VACUOLAR H+-PYROPHOSPHATASE; INORGANIC PYROPHOSPHATASE; PUMPING PYROPHOSPHATASE; RHODOSPIRILLUM-RUBRUM; VOLUTIN-GRANULES; POLYPHOSPHATE; EXPRESSION; K+; FLUORESCENCE	Acidocalcisomes are acidic calcium storage compartments described in several unicellular eukaryotes, including trypanosomatid and apicomplexan parasites, algae, and slime molds. In this work, we report that the volutin granules of Agrobacterium tumefaciens possess properties similar to the acidocalcisomes. Transmission electron microscopy revealed that each intracellular granule was surrounded by a membrane. X-ray microanalysis of the volutin granules showed large amounts of phosphorus, magnesium, potassium, and calcium. Calcium in the volutin granules increased when the bacteria were incubated at high extracellular calcium concentration. Immunofluorescence and immunoelectron microscopy, using antisera raised against peptide sequences conserved in the A. tumefaciens proton pyrophosphatase, indicated localization in intracellular vacuoles. Purification of the volutin granules using iodixanol density gradients indicated a preferential localization of the pyrophosphatase activity in addition to high concentrations of phosphate, pyrophosphate, short- and long-chain polyphosphate, but lack of markers of the plasma membrane. The pyrophosphatase activity was potassium-insensitive and inhibited by the pyrophosphate analogs, amynomethylenediphosphonate and imidodiphosphate, by dicyclohexylcarbodiimide, and by the thiol reagent N-ethylmaleimide. Polyphosphate was also localized to the volutin granules by 4', 6'-diamino-2-phenylindole staining. The organelles were acidic, as demonstrated by staining with LysoSensor blue DND-167, a dye especially used to detect very acidic compartments in cells, and cycloprodigiosin, a compound isolated from a marine bacterium that has been shown to uncouple proton pyrophosphatase activity acting as a chloride/proton symport. The results suggest that acidocalcisomes arose before the prokaryotic and eukaryotic lineages diverged.	Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015	NIAID NIH HHS [AI23259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN RA, 1980, CAN J MICROBIOL, V26, P912, DOI 10.1139/m80-158; Belogurov GA, 2002, J BIOL CHEM, V277, P49651, DOI 10.1074/jbc.M210341200; Belogurov GA, 2002, J BIOL CHEM, V277, P22209, DOI 10.1074/jbc.M202951200; Cannon GC, 2001, APPL ENVIRON MICROB, V67, P5351, DOI 10.1128/AEM.67.12.5351-5361.2001; COHENBAZIRE G, 1963, BACTERIAL PHOTOSYNTH, P89; Damste JSS, 2002, NATURE, V419, P708, DOI 10.1038/nature01128; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Drozdowicz YM, 2000, PLANT PHYSIOL, V123, P353, DOI 10.1104/pp.123.1.353; DUBOCHET J, 1983, J BACTERIOL, V155, P381, DOI 10.1128/JB.155.1.381-390.1983; Glasauer S, 2002, SCIENCE, V295, P117, DOI 10.1126/science.1066577; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; HASE E, 1963, PLANT CELL PHYSL TOK, V4, P619; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; JACOBSON L, 1982, BIOCHEM J, V201, P473, DOI 10.1042/bj2010473; Jensen Thomas E., 1993, P7; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Lin HJ, 2001, ANAL BIOCHEM, V294, P118, DOI 10.1006/abio.2001.5155; Lindsay MR, 2001, ARCH MICROBIOL, V175, P413, DOI 10.1007/s002030100280; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Maeshima M, 1999, PLANT CELL PHYSIOL, V40, P439, DOI 10.1093/oxfordjournals.pcp.a029560; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Meyer A., 1904, BOT Z, V62, P113; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; NYREN P, 1991, BIOCHEMISTRY-US, V30, P2883, DOI 10.1021/bi00225a022; ORMEROD WE, 1958, J GEN MICROBIOL, V19, P271, DOI 10.1099/00221287-19-2-271; Perez-Castineira JR, 2002, BIOCHEM BIOPH RES CO, V294, P567, DOI 10.1016/S0006-291X(02)00517-X; Perez-Castineira JR, 2001, FEBS LETT, V496, P6, DOI 10.1016/S0014-5793(01)02390-0; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RANDAHL H, 1979, EUR J BIOCHEM, V102, P251, DOI 10.1111/j.1432-1033.1979.tb06287.x; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; ROSENBERG H, 1966, EXP CELL RES, V41, P397, DOI 10.1016/S0014-4827(66)80147-7; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; SHIVELY JM, 1974, ANNU REV MICROBIOL, V28, P167, DOI 10.1146/annurev.mi.28.100174.001123; Simon R.D., 1987, CYANOBACTERIA, P199; WIAME JM, 1947, BIOCHIM BIOPHYS ACTA, V1, P234, DOI 10.1016/0006-3002(47)90137-6; Woese CR, 2002, P NATL ACAD SCI USA, V99, P8742, DOI 10.1073/pnas.132266999	46	117	123	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29971	29978		10.1074/jbc.M304548200	http://dx.doi.org/10.1074/jbc.M304548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12783865	hybrid			2022-12-25	WOS:000184507000071
J	Boivin, B; Chevalier, D; Villeneuve, LR; Rousseau, E; Allen, BG				Boivin, B; Chevalier, D; Villeneuve, LR; Rousseau, E; Allen, BG			Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-KINASE-C; EPIDERMAL-GROWTH-FACTOR; CYTOSOLIC PHOSPHOLIPASE A(2); ANGIOTENSIN-II; BINDING-SITES; SARCOPLASMIC-RETICULUM; COUPLED RECEPTORS; ADENYLATE-CYCLASE; INSULIN BINDING; TYROSINE KINASE	Endothelins are thought to act through two specific, plasmalemmal G protein-coupled receptor subtypes, ETAR and ETBR. However, in subfractionated cardiac membranes, ETAR immunoreactivity was detected only in the plasma membrane whereas ETBR immunoreactivity was detected predominantly in membranes of intracellular origin. Confocal microscopy demonstrated the presence of intracellular ETAR and ETBR in ventricular myocytes. ETAR were primarily on plasma membrane (surface membranes and transverse-tubules) and to a lesser extent on the nucleus while ETBR localized primarily to the nuclei. Western blot analysis of nuclei isolated from the heart indicated the presence of endothelin receptors: both ETAR and ETBR copurified with nucleoporin 62, whereas markers of endoplasmic reticulum and Golgi membranes were depleted. Radioligand binding studies revealed that isolated nuclei contain specific [I-125] ET-1 binding sites. Specific [I-125] ET-1 binding was reduced by 70-80% using the ETAR-selective antagonist BQ610 and 20-30% using the ETBR-specific antagonist BQ788. IRL-1620, an ETBR-specific agonist, also reduced [I-125] ET-1 binding. Furthermore, ET-1 and IRL-1620 altered the incorporation of P-32 into nuclear proteins and caused a transient increase in nuclear Ca2+ concentration. Hence, cardiac nuclei possess both ETAR and ETBR subtypes, which are functional with respect to ligand binding and are coupled to signaling mechanisms within the nuclear membrane.	Inst Cardiol Montreal, Ctr Rech, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med & Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada; Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada	Universite de Montreal; Institut de Cardiologie de Montreal; Universite de Montreal; Universite de Montreal; University of Sherbrooke	Allen, BG (corresponding author), Inst Cardiol Montreal, Ctr Rech, 5000 Rue Belanger, Montreal, PQ H1T 1C8, Canada.	allen@icm.umontreal.ca	Allen, Bruce G/B-4693-2008	Allen, Bruce G/0000-0001-9000-9495; Boivin, Benoit/0000-0003-3306-5970	Canadian Institutes of Health Research [14725] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Abe Y, 2000, J BIOL CHEM, V275, P8664, DOI 10.1074/jbc.275.12.8664; Abrenica B, 2000, CELL CALCIUM, V28, P127, DOI 10.1054/ceca.2000.0137; Allen BG, 2003, CAN J PHYSIOL PHARM, V81, P95, DOI 10.1139/Y02-155; Allen BG, 2000, J MOL CELL CARDIOL, V32, P2379, DOI 10.1006/jmcc.2000.1268; AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; Ballard C, 1996, J MOL CELL CARDIOL, V28, P11, DOI 10.1006/jmcc.1996.0002; BAYDOUN AR, 1989, J CARDIOVASC PHARM, V13, pS193, DOI 10.1097/00005344-198900135-00054; BELCHEVA M, 1993, J NEUROSCI, V13, P104; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Bian LJ, 1998, EUR J BIOCHEM, V253, P545, DOI 10.1046/j.1432-1327.1998.2530545.x; Bkaily G, 2000, J CARDIOVASC PHARM, V36, pS414, DOI 10.1097/00005344-200036051-00121; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; CARPENTIER JL, 1986, EXP CELL RES, V166, P312, DOI 10.1016/0014-4827(86)90479-9; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; Chevalier D, 2000, BIOCHEMISTRY-US, V39, P6145, DOI 10.1021/bi9928389; CHUN MY, 1995, J BIOL CHEM, V270, P10855, DOI 10.1074/jbc.270.18.10855; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; CODY RJ, 1992, CIRCULATION, V85, P504, DOI 10.1161/01.CIR.85.2.504; CONCAS V, 1989, J HYPERTENS, V7, pS96, DOI 10.1097/00004872-198900076-00044; D'Santos CS, 1999, CURR BIOL, V9, P437, DOI 10.1016/S0960-9822(99)80193-6; Davenport AP, 2002, PHARMACOL REV, V54, P219, DOI 10.1124/pr.54.2.219; Dawn B, 2001, J MOL CELL CARDIOL, V33, P161, DOI 10.1006/jmcc.2000.1291; Devadason PSS, 1997, BRIT J PHARMACOL, V121, P253, DOI 10.1038/sj.bjp.0701126; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Ergul A, 2000, AM J PHYSIOL-HEART C, V278, pH2050, DOI 10.1152/ajpheart.2000.278.6.H2050; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fareh J, 1996, CIRC RES, V78, P302, DOI 10.1161/01.RES.78.2.302; Fatima S, 2003, J CELL SCI, V116, P353, DOI 10.1242/jcs.00242; FIRTH JD, 1990, CLIN SCI, V79, P221, DOI 10.1042/cs0790221; FIRTH JD, 1990, CLIN SCI, V13, pS193; FRIEDLAENDER MM, 1993, AM J PHYSIOL, V264, pF845, DOI 10.1152/ajprenal.1993.264.5.F845; FUJITANI Y, 1993, J PHARMACOL EXP THER, V267, P683; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Grantcharova E, 2002, J BIOL CHEM, V277, P43933, DOI 10.1074/jbc.M208407200; Grasl-Kraupp B, 2002, HEPATOLOGY, V35, P1372, DOI 10.1053/jhep.2002.33203; Guihard G, 1997, FEBS LETT, V414, P89, DOI 10.1016/S0014-5793(97)00949-6; HAGIWARA H, 1991, J CARDIOVASC PHARM, V17, pS117, DOI 10.1097/00005344-199100177-00030; HilalDandan R, 1997, J PHARMACOL EXP THER, V281, P267; HILALDANDAN R, 1994, MOL PHARMACOL, V45, P1183; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HOLT SJ, 1994, BIOCHEM PHARMACOL, V47, P117, DOI 10.1016/0006-2952(94)90444-8; HORVAT A, 1978, J CELL PHYSIOL, V97, P37, DOI 10.1002/jcp.1040970106; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; Husain S, 1998, BBA-LIPID LIPID MET, V1392, P127, DOI 10.1016/S0005-2760(98)00011-3; INUI M, 1988, J BIOL CHEM, V263, P10843; IRVINE RF, 2002, SCI STKE; ISHIKAWA T, 1988, PFLUG ARCH EUR J PHY, V413, P108, DOI 10.1007/BF00581239; ISHIKAWA T, 1991, CIRC RES, V69, P918, DOI 10.1161/01.RES.69.4.918; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; KARNE S, 1993, J BIOL CHEM, V268, P19126; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KUSHNARYOV VM, 1985, P NATL ACAD SCI USA, V82, P3281, DOI 10.1073/pnas.82.10.3281; LANINI L, 1992, J BIOL CHEM, V267, P11548; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; LIU Y, 1992, AM J PHYSIOL, V262, pC941, DOI 10.1152/ajpcell.1992.262.4.C941; LOVENBERG W, 1990, NEUROCHEM RES, V15, P407, DOI 10.1007/BF00969926; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; Lugnier C, 1999, BBA-GEN SUBJECTS, V1472, P431, DOI 10.1016/S0304-4165(99)00145-2; Lui PPY, 1998, PFLUG ARCH EUR J PHY, V435, P357, DOI 10.1007/s004240050523; Marti U, 2001, THYROID, V11, P137, DOI 10.1089/105072501300042785; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; Nguyen QT, 1998, CIRCULATION, V98, P2323, DOI 10.1161/01.CIR.98.21.2323; Oie E, 1997, AM J PHYSIOL-HEART C, V273, pH1727; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Paasche JD, 2001, J BIOL CHEM, V276, P34041, DOI 10.1074/jbc.M103243200; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512; RABEN DM, 1994, J MEMBRANE BIOL, V142, P1; RE RN, 1984, J HYPERTENSION S3, V2, P271; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SADOSHIMA J, 1995, CIRC RES, V76, P1; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sanchez R, 2002, J CARDIOVASC PHARM, V39, P652, DOI 10.1097/00005344-200205000-00005; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1991, HYPERTENSION, V17, P856, DOI 10.1161/01.HYP.17.6.856; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SOKOLOVSKY M, 1993, BIOCHEM BIOPH RES CO, V196, P32, DOI 10.1006/bbrc.1993.2212; SOKOLOVSKY M, 1993, RECEPTOR CHANNEL, V1, P295; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V191, P823, DOI 10.1006/bbrc.1993.1291; TAKAI M, 1992, BIOCHEM BIOPH RES CO, V184, P953, DOI 10.1016/0006-291X(92)90683-C; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TAKASUKA T, 1992, J BIOCHEM-TOKYO, V112, P396, DOI 10.1093/oxfordjournals.jbchem.a123911; Talbodec A, 2000, MOL PHARMACOL, V57, P797, DOI 10.1124/mol.57.4.797; Thomas PB, 1996, AM J PHYSIOL-HEART C, V271, pH2629, DOI 10.1152/ajpheart.1996.271.6.H2629; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; VANHEUGTEN HAA, 1994, J MOL CELL CARDIOL, V26, P1081, DOI 10.1006/jmcc.1994.1128; Vann LR, 1997, BIOCHEM J, V327, P569; VIGNERI R, 1978, J BIOL CHEM, V253, P2098; WATANABE T, 1989, J CARDIOVASC PHARM, V13, pS108, DOI 10.1097/00005344-198900135-00027; WATANABE TX, 1989, J CARDIOVASC PHARM, V13, pS207, DOI 10.1097/00005344-198900135-00059; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; WUWONG JR, 1994, BBA-MOL CELL RES, V1224, P288, DOI 10.1016/0167-4889(94)90202-X; Yamamoto S, 1998, MICROSC RES TECHNIQ, V40, P479, DOI 10.1002/(SICI)1097-0029(19980301)40:6<479::AID-JEMT8>3.0.CO;2-K; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YANKNER BA, 1979, P NATL ACAD SCI USA, V76, P1269, DOI 10.1073/pnas.76.3.1269	107	123	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29153	29163		10.1074/jbc.M301738200	http://dx.doi.org/10.1074/jbc.M301738200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756260	hybrid			2022-12-25	WOS:000184421100100
J	Laszlo, GS; Nathanson, NM				Laszlo, GS; Nathanson, NM			Src family kinase-independent signal transduction and gene induction by leukemia inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EMBRYONIC STEM-CELLS; EPIDERMAL-GROWTH-FACTOR; CNTF RECEPTOR COMPLEX; DNA-BINDING ACTIVITY; TYROSINE PHOSPHORYLATION; ONCOSTATIN-M; CYTOKINE RECEPTORS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE	Members of the interleukin-6 (IL-6) family of cytokines exert their biological effects via binding to their cognate ligand-binding receptor subunit on a target cell. The subsequent recruitment of the common signal transducer glycoprotein 130 and activation of the JAK/STAT and SHP-2/Ras/mitogen-activated protein kinase (MAPK) pathways are responsible for the majority of cellular responses elicited by IL-6 cytokines. Several types of experiments suggest that the Src family of kinases (SFK) also participates in IL-6 family cytokine-mediated signaling events. SYF cells, which lack expression of SFKs Src, Yes, and Fyn, were used to determine the role of SFKs in IL-6 family cytokine signaling and gene induction. SYF and wild type (WT) control fibroblasts displayed similar activation of signaling intermediates following stimulation with leukemia inhibitory factor (LIF). LIF-stimulated tyrosine phosphorylation of SHP-2 and subsequent activation of MAPK in SYF cells were identical to that seen in LIF-stimulated WT cells. Both LIF-stimulated tyrosine phosphorylation of STAT1 and STAT3, as well as LIF-stimulated DNA binding activity of STAT-containing nuclear complexes were indistinguishable when compared in SYF and WT cells. In addition, the phosphatidylinositol 3-kinase-sensitive Akt kinase and p38 MAPK were activated by LIF in both SYF and WT cells. Furthermore, LIF-stimulated expression of c-fos, egr-1, and suppressor of cytokine signaling-3 was retained in SYF cells. The IL-6 family cytokine oncostatin M was also capable of activating MAPK, STAT3, STAT1, Akt, and p38 in both WT and SYF cells. These results demonstrate that IL-6 family cytokines can activate a full repertoire of signaling pathways and induce gene expression independent of SFKs.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.				NIGMS NIH HHS [GM07018] Funding Source: Medline; NINDS NIH HHS [NS30410] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bartoe JL, 2000, J NEUROCHEM, V74, P2021, DOI 10.1046/j.1471-4159.2000.0742021.x; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hamilton SE, 2001, J BIOL CHEM, V276, P15850, DOI 10.1074/jbc.M011563200; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Iwamoto T, 2000, ONCOGENE, V19, P4795, DOI 10.1038/sj.onc.1203829; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kodama H, 1997, CIRC RES, V81, P656; Kumar P, 2001, J BIOL CHEM, V276, P21039, DOI 10.1074/jbc.M009099200; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; MARSHALL MK, 1994, ENDOCRINOLOGY, V135, P141, DOI 10.1210/en.135.1.141; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PETERSON SR, 1995, CANCER RES, V55, P4651; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Van Wagoner NJ, 2000, J NEUROCHEM, V75, P563, DOI 10.1046/j.1471-4159.2000.0750563.x; Vara JAF, 2001, MOL BIOL CELL, V12, P2171, DOI 10.1091/mbc.12.7.2171; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; WANG XY, 1995, J BIOL CHEM, V270, P27999; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wyke AW, 1996, CELL SIGNAL, V8, P131, DOI 10.1016/0898-6568(95)02038-1; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	72	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27750	27757		10.1074/jbc.M303670200	http://dx.doi.org/10.1074/jbc.M303670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12764151	hybrid			2022-12-25	WOS:000184242700054
J	Atlas, E; Bojanowski, K; Mehmi, I; Lupu, R				Atlas, E; Bojanowski, K; Mehmi, I; Lupu, R			A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity	ONCOGENE			English	Article						HRG; mutants; drug resistance; doxorubicin; estrogen dependence; antiestrogen resistance; breast cancer	TOPOISOMERASE-II; GROWTH-FACTOR; ESTROGEN-RECEPTOR; EXPRESSION; APOPTOSIS; INDUCTION; ONCOGENE; LINE; DIFFERENTIATION; PROLIFERATION	Heregulin (HRG) is an activator of the erbB2-, erbB3- and erB4-(erbB-2/3/4) signaling pathway. Transfection of full-length HRG cDNA into the estrogen (E2)-dependent cell line MCF-7 promoted an invasive E2-independent phenotype, as well as persistent activation of the erbB-2/3/4 receptors. Moreover, HRG expression in MCF-7 cells renders the cells sensitive to the topoisomerase 11 inhibitor doxorubicin (Doxo). In an attempt to dissociate the tumorigenic effect of HRG from the sensitizing effect to chemotherapy, we constructed a structural deletion mutant of HRG. Transfection of the deletion mutant of HRG described in this study (HRG/M) into MCF-7 cells resulted in the dissociation of the tumor-promoting activity of HRG from the sensitization to Doxo, that is, although the cells did not become more aggressive or E2-independent they became more sensitive to Doxo. HRG/M was unable to autophosphorylate the erbB receptors and did not affect the level of MAPK phosphorylation. Furthermore, the intracellular localization of the protein was different from that of the full-length protein. Our data show that the HRG/M sequences are sufficient to sensitize MCF-7 cells to Doxo, and provide evidence that this sensitization is independent of erbB2 activation.	Northwestern Univ, Evanston NW Healthcare Res Inst, Evanston, IL 60201 USA	Northwestern University	Lupu, R (corresponding author), Northwestern Univ, Evanston NW Healthcare Res Inst, 1001 Univ Pl,2650 Ridge Ave, Evanston, IL 60201 USA.							Alper O, 2000, INT J CANCER, V88, P566, DOI 10.1002/1097-0215(20001115)88:4<566::AID-IJC8>3.0.CO;2-D; Aoyama M, 1998, BIOCHEM J, V336, P727, DOI 10.1042/bj3360727; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Harris LN, 2001, CLIN CANCER RES, V7, P1497; Hijazi MM, 2000, INT J ONCOL, V17, P629; Keir M, 2000, STEM CELLS, V18, P422, DOI 10.1634/stemcells.18-6-422; Krane IM, 1996, ONCOGENE, V12, P1781; Lessor T, 1998, J CELL BIOCHEM, V70, P587, DOI 10.1002/(SICI)1097-4644(19980915)70:4<587::AID-JCB14>3.0.CO;2-E; Li WL, 1996, ONCOGENE, V12, P2473; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Matsumoto Y, 1999, J NEURO-ONCOL, V45, P37, DOI 10.1023/A:1006346624083; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Talukder AH, 2000, CANCER RES, V60, P276; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2000, CANCER RES, V60, P5603; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; Xiong SB, 2001, CANCER RES, V61, P1727	27	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3441	3451		10.1038/sj.onc.1206410	http://dx.doi.org/10.1038/sj.onc.1206410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776196				2022-12-25	WOS:000183128500011
J	Dang, DT; Chen, XM; Feng, J; Torbenson, M; Dang, LH; Yang, VW				Dang, DT; Chen, XM; Feng, J; Torbenson, M; Dang, LH; Yang, VW			Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity	ONCOGENE			English	Article						Kruppel-like factor 4; tumorigenecity; RKO; colorectal cancer	ZINC-FINGER PROTEIN; CARCINOMA CELLS; GENE-EXPRESSION; IN-VIVO; TRANSCRIPTION; DIFFERENTIATION; GROWTH; GKLF; PROLIFERATION; PROGRESSION	Kruppel-like factor 4 (KLF4) is a zinc-finger-containing transcription factor, the expression of which is enriched in the postmitotic cells of the intestinal epithelium. KLF4 is a target gene of the tumor suppressor adenomatous polyposis coli (APC). We sought to determine the role of KLF4 in suppressing the tumorigenecity of RKO colon cancer cells, which do not express KLF4. We utilized an established system in RKO cells, in which an inducible promoter controls expression of KLF4. Four independent assays were used to assess the effects of KLF4 induction on tumor cells. We find that KLF4 overexpression reduces colony formation, cell migration and invasion, and in vivo tumorigenecity. The mechanism of action of KLF4 does not involve apoptosis. These findings, along with our previous findings that KLF4 induces G1/S arrest, suggest that KLF4 is a cell cycle checkpoint protein that can reduce tumorigenecity of colon cancer cells.	Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Johns Hopkins University; Emory University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Emory University	Dang, DT (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, 720 Rutland Ave,Ross 918, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, K08DK059970] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197, R01 CA084197-04, CA84197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230-06, DK52230, DK59970, K08 DK059970, R01 DK052230] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Behr R, 2002, MECH DEVELOP, V115, P167, DOI 10.1016/S0925-4773(02)00127-2; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Katz JP, 2002, DEVELOPMENT, V129, P2619; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Luo J, 2002, PROSTATE, V51, P189, DOI 10.1002/pros.10087; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Panigada M, 1999, MECH DEVELOP, V81, P103, DOI 10.1016/S0925-4773(98)00237-8; Pouliot N, 2001, EXP CELL RES, V266, P1, DOI 10.1006/excr.2001.5197; Rigas A, 2002, CANCER INVEST, V20, P657, DOI 10.1081/CNV-120002491; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Suh E, 1996, MOL CELL BIOL, V16, P619; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	31	133	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3424	3430		10.1038/sj.onc.1206413	http://dx.doi.org/10.1038/sj.onc.1206413			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776194	Green Accepted			2022-12-25	WOS:000183128500009
J	Biggs, PJ; Vogel, H; Sage, M; Martin, LA; Donehower, LA; Bradley, A				Biggs, PJ; Vogel, H; Sage, M; Martin, LA; Donehower, LA; Bradley, A			Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity	ONCOGENE			English	Article						p53; tumorigenicity; chromosome 11 deletion; loss of heterozygosity; mouse cancer model	CANCER; BREAST; GENE; SUSCEPTIBILITY; MICE; MUTATIONS; DELETIONS; GENOME; TUMORS; BRCA1	Most tumour suppressor genes (TSGs) have been found through linkage studies in cancer predisposed families where the mutations have a high penetrance, for example, the breast cancer genes BRCA1 and BRCA2. Loss of heterozygosity (LOH) analyses of sporadic breast tumours indicate that there are many other putative TSGs yet to be identified. One such locus is proximal to BRCA1 on human chromosome 17q21. In an attempt to isolate this putative TSG, we have assessed a portion of the orthologous region on mouse chromosome 11 for its tumorigenic potential using segmental haploidy in combination with a p53 mutation. Two populations of animals were studied, with the deleted region being either on the same (cis) or on the homologous chromosome (trans) to a targeted mutant p53 allele. The deficiency elevated the tumour susceptibility of p53 heterozygous mice and modified the tumour spectrum, but only when the deficiency was in trans with the p53 mutation. Even though the genotype of these mice is identical, allelic phasing affects both the tumour spectrum and progression.	Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	Wellcome Trust Sanger Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Bradley, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England.	abradley@sanger.ac.uk	Biggs, Patrick Jon/H-3355-2014	Biggs, Patrick Jon/0000-0002-0285-4101; Bradley, Allan/0000-0002-2349-8839; Vogel, Otto Hannes/0000-0002-0960-3508				Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Bradley A, 1998, INT J DEV BIOL, V42, P943; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Liu PT, 1998, GENETICS, V150, P1155; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Osborne RJ, 2000, CANCER RES, V60, P3706; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J; Su H, 2000, NAT GENET, V24, P92, DOI 10.1038/71756; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949	27	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3288	3296		10.1038/sj.onc.1206384	http://dx.doi.org/10.1038/sj.onc.1206384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761499				2022-12-25	WOS:000183040000011
J	Hayano, T; Yanagida, M; Yamauchi, Y; Shinkawa, T; Isobe, T; Takahashi, N				Hayano, T; Yanagida, M; Yamauchi, Y; Shinkawa, T; Isobe, T; Takahashi, N			Proteomic analysis of human Nop56p-associated pre-ribosomal ribonucleoprotein complexes - Possible link between Nop56p and the nucleolar protein treacle responsible for Treacher Collins syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-BINDING-PROTEINS; SIGNAL RECOGNITION PARTICLE; ESSENTIAL YEAST PROTEIN; TRANS-ACTING FACTORS; OPEN READING FRAMES; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; GENE-PRODUCT; IN-VITRO; NUCLEOTIDE-SEQUENCE	Nop56p is a component of the box C/D small nucleolar ribonucleoprotein complexes that direct 2'-O-methylation of pre-rRNA during its maturation. Genetic analyses in yeast have shown that Nop56p plays important roles in the early steps of pre-rRNA processing. However, its precise function remains elusive, especially in higher eukaryotes. Here we describe the proteomic characterization of human Nop56p (hNop56p)-associated pre-ribosomal ribonucleoprotein complexes. Mass spectrometric analysis of purified pre-ribosomal ribonucleoprotein complexes identified 61 ribosomal proteins, 16 trans-acting factors probably involved in ribosome biogenesis, and 29 proteins whose function in ribosome biogenesis is unknown. Identification of pre-rRNA species within hNop56p-associated pre-ribosomal ribonucleoprotein complexes, coupled with the known functions of yeast orthologs of the probable trans-acting factors identified in human, demonstrated that hNop56p functions in the early to middle stages of 60 S subunit synthesis in human cells. Interestingly, the nucleolar phosphoprotein treacle, which is responsible for the craniofacial disorder associated with Treacher Collins syndrome, was found to be a constituent of hNop56p-associated pre-rRNP complexes. The association of hNop56p and treacle within the complexes was independent of rRNA integrity, indicating a direct interaction. In addition, the protein compositions of the treacle-associated and hNop56p- associated pre-ribosomal ribonucleoprotein complexes were very similar, suggesting functional similarities between these two complexes with respect to ribosome biogenesis in human cells.	Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Tokyo 1838509, Japan; Minist Educ Culture Sports Sci & Technol Japan, Pioneer Res Genome Frontier, Integrated Proteom Syst Project, Tokyo, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Tokyo 1920397, Japan	Tokyo University of Agriculture & Technology; Tokyo Metropolitan University	Takahashi, N (corresponding author), Tokyo Univ Agr & Technol, Dept Appl Biol Sci, 3-5-8 Saiwai Cho, Tokyo 1838509, Japan.	ntakahas@cc.tuat.ac.jp	TAKAHASHI, Nobuhiro/G-1129-2013; Isobe, Toshiaki/Q-9279-2017					Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; ALLEN BS, 1991, GENOMICS, V10, P486, DOI 10.1016/0888-7543(91)90337-E; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; [Anonymous], 1996, Nat Genet, V12, P130; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BERGES T, 1994, EMBO J, V13, P3136, DOI 10.1002/j.1460-2075.1994.tb06612.x; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; BOU G, 1993, YEAST, V9, P1349, DOI 10.1002/yea.320091209; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; Brogna S, 2002, MOL CELL, V10, P93, DOI 10.1016/S1097-2765(02)00565-8; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHANG TH, 1990, P NATL ACAD SCI USA, V87, P1571, DOI 10.1073/pnas.87.4.1571; Charpentier AH, 2000, CANCER RES, V60, P5977; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DATAR KV, 1993, NUCLEIC ACIDS RES, V21, P439, DOI 10.1093/nar/21.3.439; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dixon J, 1997, GENOME RES, V7, P223, DOI 10.1101/gr.7.3.223; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Edwards SJ, 1997, AM J HUM GENET, V60, P515; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; ELLIS EM, 1993, GENE, V132, P175, DOI 10.1016/0378-1119(93)90193-7; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; FAZEN LE, 1967, AM J DIS CHILD, V113, P405, DOI 10.1001/archpedi.1967.02090190051001; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Fujiyama S, 2002, J BIOL CHEM, V277, P23773, DOI 10.1074/jbc.M201181200; Gall JG, 2000, ANNU REV CELL DEV BI, V16, P273, DOI 10.1146/annurev.cellbio.16.1.273; Garcia-Planells J, 2000, GENETICA, V109, P275, DOI 10.1023/A:1017596312331; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GHISOLFI L, 1990, MOL BIOL REP, V14, P113, DOI 10.1007/BF00360437; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Gladwin AJ, 1996, HUM MOL GENET, V5, P1533, DOI 10.1093/hmg/5.10.1533; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GORLIN RJ, 1990, SYNDROMES HEAD NECK, P799; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Hadjiolov A.A., 1976, Progress Biophys Molec Biol, V31, P95; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HONORE B, 1994, GENE, V151, P291, DOI 10.1016/0378-1119(94)90673-4; Huang S, 2000, J STRUCT BIOL, V129, P233, DOI 10.1006/jsbi.2000.4247; Huber MD, 2000, J BIOL CHEM, V275, P28764, DOI 10.1074/jbc.M000594200; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Isaac C, 2000, MOL BIOL CELL, V11, P3061, DOI 10.1091/mbc.11.9.3061; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; Johnston M, 1997, NATURE, V387, P87, DOI 10.1038/387s087; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES KL, 1975, J PEDIATR-US, V86, P84, DOI 10.1016/S0022-3476(75)80709-8; KANEDA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3158, DOI 10.1073/pnas.81.10.3158; KAO PN, 1994, J BIOL CHEM, V269, P20691; Keough R, 1999, GENOMICS, V62, P483, DOI 10.1006/geno.1999.6035; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KONDO K, 1992, J BIOL CHEM, V267, P16252; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lange TS, 2000, MOL BIOL CELL, V11, P2419, DOI 10.1091/mbc.11.7.2419; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LEE CG, 1992, J BIOL CHEM, V267, P4398; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Marsh KL, 1998, HUM MOL GENET, V7, P1795, DOI 10.1093/hmg/7.11.1795; MEIER UT, 1992, CELL, V70, P127; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MIWA T, 1990, NUCLEIC ACIDS RES, V18, P4263, DOI 10.1093/nar/18.14.4263; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Nikolakaki E, 2001, J BIOL CHEM, V276, P40175, DOI 10.1074/jbc.M104755200; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Omer AD, 2002, P NATL ACAD SCI USA, V99, P5289, DOI 10.1073/pnas.082101999; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pederson T, 2000, J CELL BIOL, V148, P1091, DOI 10.1083/jcb.148.6.1091; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; PERRY RP, 1976, ANNU REV BIOCHEM, V45, P605, DOI 10.1146/annurev.bi.45.070176.003133; Politz JC, 2000, P NATL ACAD SCI USA, V97, P55, DOI 10.1073/pnas.97.1.55; POSWILLO D, 1975, BRIT J ORAL SURG, V13, P1, DOI 10.1016/0007-117X(75)90019-0; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Rieger M, 1997, YEAST, V13, P1077, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1077::AID-YEA152>3.0.CO;2-Y; RUSSELL I, 1995, EUR J CELL BIOL, V66, P293; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; Saito H, 1996, CYTOGENET CELL GENET, V72, P191, DOI 10.1159/000134186; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; SKALA J, 1995, YEAST, V11, P1421, DOI 10.1002/yea.320111410; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STRUB K, 1989, P NATL ACAD SCI USA, V86, P9747, DOI 10.1073/pnas.86.24.9747; SU LS, 1993, GENE DEV, V7, P735, DOI 10.1101/gad.7.5.735; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; Tollervey D, 1996, SCIENCE, V273, P1056, DOI 10.1126/science.273.5278.1056; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; Tsujii R, 2000, GENES CELLS, V5, P543, DOI 10.1046/j.1365-2443.2000.00346.x; UEYAMA H, 1984, MOL CELL BIOL, V4, P1073, DOI 10.1128/MCB.4.6.1073; Valdez BC, 1996, NUCLEIC ACIDS RES, V24, P1220, DOI 10.1093/nar/24.7.1220; VANDENBOL M, 1994, YEAST, V10, pS25, DOI 10.1002/yea.320100004; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354; Welch PJ, 2000, GENOMICS, V66, P274, DOI 10.1006/geno.2000.6230; WELLS J, 1995, FEBS LETT, V358, P119, DOI 10.1016/0014-5793(94)01403-N; WILEY MJ, 1983, ACTA ANAT, V116, P180; Winokur ST, 1998, HUM MOL GENET, V7, P1947, DOI 10.1093/hmg/7.12.1947; Wise CA, 1997, P NATL ACAD SCI USA, V94, P3110, DOI 10.1073/pnas.94.7.3110; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453; Yamamoto T, 1996, GENE, V173, P281, DOI 10.1016/0378-1119(96)00020-0; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yanagida M, 2000, ELECTROPHORESIS, V21, P1890; Yang YF, 2000, MOL BIOL CELL, V11, P567, DOI 10.1091/mbc.11.2.567; YU Y, 1995, DNA CELL BIOL, V14, P411, DOI 10.1089/dna.1995.14.411; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769	137	103	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34309	34319		10.1074/jbc.M304304200	http://dx.doi.org/10.1074/jbc.M304304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12777385	hybrid			2022-12-25	WOS:000185047500087
J	Bieganowski, P; Brenner, C				Bieganowski, P; Brenner, C			The reported human NADsyn2 is ammonia-dependent NAD synthetase from a pseudomonad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOPYRIDINE NUCLEOTIDE; CRYSTAL-STRUCTURE; BIOSYNTHESIS; GLUTAMINE; IDENTIFICATION; MOLECULE; ENZYMES	Nicotinamide-adenine dinucleotide (NAD(+)) synthetases catalyze the last step in NAD(+) metabolism in the de novo, import, and salvage pathways that originate from tryptophan (or aspartic acid), nicotinic acid, and nicotinamide, respectively, and converge on nicotinic acid mononucleotide. NAD(+) synthetase converts nicotinic acid adenine dinucleotide to NAD(+) via an adenylylated intermediate. All of the known eukaryotic NAD(+) synthetases are glutamine-dependent, hydrolyzing glutamine to glutamic acid to provide the attacking ammonia. In the prokaryotic world, some NAD(+) synthetases are glutamine-dependent, whereas others can only use ammonia. Earlier, we noted a perfect correlation between presence of a domain related to nitrilase and glutamine dependence and then proved in the accompanying paper (Bieganowski, P., Pace, H. C., and Brenner, C. (2003) J. Biol. Chem. 278, 33049-33055) that the nitrilase-related domain is an essential, obligate intramolecular, thiol-dependent glutamine amidotransferase in the yeast NAD(+) synthetase, Qns1. Independently, human NAD(+) synthetase was cloned and shown to depend on Cys-175 for glutamine-dependent but not ammonia-dependent NAD(+) synthetase activity. Additionally, it was claimed that a 275 amino acid open reading frame putatively amplified from human glioma cell line LN229 encodes a human ammonia-dependent NAD(+) synthetase and this was speculated largely to mediate NAD(+) synthesis in human muscle tissues. Here we establish that the so-called NADsyn2 is simply ammonia-dependent NAD(+) synthetase from Pseudomonas, which is encoded on an operon with nicotinic acid phosphoribosyltransferase and, in some Pseudomonads, with nicotinamidase.	Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA	Jefferson University	Brenner, C (corresponding author), Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA.	charles.brenner@dartmouth.edu	Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [P01 CA077738-040003, CA77738, P01 CA077738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bieganowski P, 2003, J BIOL CHEM, V278, P33049, DOI 10.1074/jbc.M302257200; Brenner C, 2002, CURR OPIN STRUC BIOL, V12, P775, DOI 10.1016/S0959-440X(02)00387-1; Cantoni R, 1998, J BACTERIOL, V180, P3218, DOI 10.1128/JB.180.12.3218-3221.1998; Cross SH, 2000, MAMM GENOME, V11, P373, DOI 10.1007/s003350010071; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Hara N, 2003, J BIOL CHEM, V278, P10914, DOI 10.1074/jbc.M209203200; Nagai K, 1996, BIOL PHARM BULL, V19, P873; Nakai T, 2000, STRUCTURE, V8, P729, DOI 10.1016/S0969-2126(00)00160-X; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pace HC, 2001, GENOME BIOL, V2; PREISS J, 1958, J BIOL CHEM, V233, P488; PREISS J, 1958, J BIOL CHEM, V233, P493; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; SPENCER RL, 1967, J BIOL CHEM, V242, P385; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	20	16	17	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33056	33059		10.1074/jbc.M302276200	http://dx.doi.org/10.1074/jbc.M302276200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12777395	hybrid			2022-12-25	WOS:000184901800070
J	Gourlay, LJ; Bhella, D; Kelly, SM; Price, NC; Lindsay, JG				Gourlay, LJ; Bhella, D; Kelly, SM; Price, NC; Lindsay, JG			Structure-function analysis of recombinant substrate protein 22 kDa (SP-22) - A mitochondrial 2-Cys peroxiredoxin organized as a decameric toroid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; BOVINE ADRENAL-CORTEX; MAMMALIAN PEROXIREDOXIN; CRYSTAL-STRUCTURE; OXIDATIVE STRESS; ELECTRON-MICROSCOPY; DEHYDROGENASE; THIOREDOXIN; PEROXIDE; PROTEINS	Bovine mitochondrial SP-22 is a member of the peroxiredoxin family of peroxidases. It belongs to the peroxiredoxin 2-Cys subgroup containing three cysteines at positions 47, 66, and 168. The cloning and overexpression in Escherichia coli of recombinant wild type SP-22 and its three cysteine mutants (C47S, C66S, and C168S) are reported. Purified His-tagged SP-22 was fully active with Cys-47 being confirmed as the catalytic residue. The enzyme forms a stable decameric toroid consisting of five basic dimeric units containing intermolecular disulfide bonds linking the catalytically active Cys-47 of one subunit and Cys-168 of the adjacent monomer. The disulfide bonds are not required for overall structural integrity. The toroidal units have average external and internal diameters of 15 and 7 nm, respectively, and can form stacks in a lateral arrangement of two or three rings. C47S had a pronounced tendency to stack in long tubular structures containing up to 60 rings. Further unusual structural features are the presence of radial spikes projecting from the external surface and ordered electron-dense material within the central cavity of the toroid.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow	Lindsay, JG (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland.		Bhella, David/J-8514-2012	Bhella, David/0000-0003-2096-8310; GOURLAY, LOUISE JANE/0000-0002-6369-2230; Kelly, Sharon/0000-0002-3516-1387	Medical Research Council [MC_U130115834] Funding Source: Medline; MRC [MC_U130115834] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Bunik V, 1999, PROTEIN SCI, V8, P65; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; Gibson GE, 2000, NEUROCHEM INT, V36, P97, DOI 10.1016/S0197-0186(99)00114-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Harris JR, 2001, BBA-PROTEIN STRUCT M, V1547, P221, DOI 10.1016/S0167-4838(01)00184-4; HARRIS JR, 1991, J ELECTRON MICR TECH, V18, P269; Hiroi T, 1996, DNA SEQUENCE, V6, P239, DOI 10.3109/10425179609008449; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindner Peter, 1992, Methods (Orlando), V4, P41, DOI 10.1016/1046-2023(92)90055-D; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Peshenko IV, 2001, FREE RADICAL BIO MED, V31, P292, DOI 10.1016/S0891-5849(01)00579-2; RADI R, 1991, J BIOL CHEM, V266, P22028; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; WATABE S, 1995, BIOCHEM BIOPH RES CO, V213, P1010, DOI 10.1006/bbrc.1995.2229; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; WATABE S, 1993, J BIOCHEM-TOKYO, V113, P672, DOI 10.1093/oxfordjournals.jbchem.a124101; Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901; WHITE MF, 1993, BIOCHEM J, V291, P479, DOI 10.1042/bj2910479; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	39	41	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32631	32637		10.1074/jbc.M303862200	http://dx.doi.org/10.1074/jbc.M303862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12773537	hybrid			2022-12-25	WOS:000184901800020
J	Relou, IAM; Gorter, G; Ferreira, IA; van Rijn, HJM; Akkerman, JWN				Relou, IAM; Gorter, G; Ferreira, IA; van Rijn, HJM; Akkerman, JWN			Platelet endothelial cell adhesion molecule-1 (PECAM-1) inhibits low density lipoprotein-induced signaling in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; BINDING-SITES; OKADAIC ACID; ACTIVATION; KINASE; PHOSPHORYLATION; RECEPTOR; CD31; COLLAGEN; AGGREGATION	At physiological concentrations, low density lipoprotein (LDL) increases the sensitivity of platelets to aggregation- and secretion-inducing agents without acting as an independent activator of platelet functions. LDL sensitizes platelets by inducing a transient activation of p38(MAPK), a Ser/Thr kinase that is activated by the simultaneous phosphorylation of Thr(180) and Tyr(182) and is an upstream regulator of cytosolic phospholipase A(2) (cPLA(2)). A similar transient phosphorylation of p38MAPK is induced by a peptide mimicking amino acids 3359-3369 in apoB100 called the B-site. Here we report that the transient nature of p38(MAPK) activation is caused by platelet endothelial cell adhesion molecule 1 (PECAM-1), a receptor with an immunoreceptor tyrosine-based inhibitory motif. PECAM-1 activation by cross-linking induces tyrosine phosphorylation of PECAM-1 and a fall in phosphorylated p38(MAPK) and cPLA(2). Interestingly, LDL and the B-site peptide also induce tyrosine phosphorylation of PECAM-1, and studies with immunoprecipitates indicate the involvement of c-Src. Inhibition of the Ser/Thr phosphatases PP1/PP2A (okadaic acid) makes the transient p38(MAPK) activation by LDL and the B-site peptide persistent. Inhibition of Tyr-phosphatases (vanadate) increases Tyr-phosphorylated PECAM-1 and blocks the activation of p38(MAPK). Together, these findings suggest that, following a first phase in which LDL, through its B-site, phosphorylates and thereby activates p38(MAPK), a second phase is initiated in which LDL activates PECAM-1 and induces dephosphorylation of p38(MAPK) via activation of the Ser/Thr phosphatases PP1/PP2A.	Univ Med Ctr Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Clin Chem, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University	Akkerman, JWN (corresponding author), Univ Med Ctr Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, POB 85500, NL-3508 GA Utrecht, Netherlands.							ANDREWS HE, 1987, BIOCHEM J, V242, P559, DOI 10.1042/bj2420559; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cao MY, 1998, J BIOL CHEM, V273, P15765, DOI 10.1074/jbc.273.25.15765; Cicmil M, 2002, BLOOD, V99, P137, DOI 10.1182/blood.V99.1.137; Cicmil M, 2000, J BIOL CHEM, V275, P27339; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; CURTISS LK, 1984, BLOOD, V64, P365; DeLisser H M, 1993, Curr Top Microbiol Immunol, V184, P37; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; Guselnikov SV, 2002, IMMUNOGENETICS, V54, P87, DOI 10.1007/s00251-002-0436-x; Hackeng CM, 1999, ARTERIOSCL THROM VAS, V19, P239, DOI 10.1161/01.ATV.19.2.239; Hackeng CM, 1999, J BIOL CHEM, V274, P384, DOI 10.1074/jbc.274.1.384; Hackeng CM, 2000, BIOCHEM J, V349, P231, DOI 10.1042/0264-6021:3490231; Hackeng CM, 1999, THROMB HAEMOSTASIS, V82, P1749, DOI 10.1055/s-0037-1614909; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Henshall TL, 2001, J IMMUNOL, V166, P3098, DOI 10.4049/jimmunol.166.5.3098; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Jones KL, 2001, BLOOD, V98, P1456, DOI 10.1182/blood.V98.5.1456; MALLE E, 1994, PLATELETS, V5, P70, DOI 10.3109/09537109409005516; MODDERMAN PW, 1994, BIOCHEM J, V299, P613, DOI 10.1042/bj2990613; Newman DK, 2001, BLOOD, V97, P2351, DOI 10.1182/blood.V97.8.2351; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Newton-Nash DK, 1999, J IMMUNOL, V163, P682; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Patil S, 2001, BLOOD, V97, P1727, DOI 10.1182/blood.V97.6.1727; PEDRENO J, 1992, ARTERIOSCLER THROMB, V12, P1353, DOI 10.1161/01.ATV.12.11.1353; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Relou IAM, 2003, BIOCHEM J, V369, P407, DOI 10.1042/BJ20020410; Relou IAM, 2002, THROMB HAEMOSTASIS, V87, P880; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; SURYA II, 1993, AM HEART J, V125, P272, DOI 10.1016/0002-8703(93)90096-R; SURYA II, 1992, BIOCHIM BIOPHYS ACTA, V1165, P19, DOI 10.1016/0005-2760(92)90070-C; VANWILLIGEN G, 1994, ARTERIOSCLER THROMB, V14, P41, DOI 10.1161/01.ATV.14.1.41; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131	41	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32638	32644		10.1074/jbc.M212675200	http://dx.doi.org/10.1074/jbc.M212675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12775720	hybrid			2022-12-25	WOS:000184901800021
J	Tesic, M; Marsh, JA; Cullinan, SB; Gaber, RF				Tesic, M; Marsh, JA; Cullinan, SB; Gaber, RF			Functional interactions between Hsp90 and the co-chaperones Cns1 and Cpr7 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TETRATRICOPEPTIDE REPEAT PROTEIN; CYCLOSPORINE-A-BINDING; STEROID-RECEPTOR; GLUCOCORTICOID-RECEPTOR; ATPASE ACTIVITY; CYCLOPHILIN; DOMAIN; FKBP52; IDENTIFICATION	Hsp90 complexes contain a class of co-chaperones characterized by a tetratricopeptide repeat (TPR) domain, which mediates binding to a carboxyl-terminal EEVD region in Hsp90. Among Hsp90 TPR co-chaperones in Saccharomyces cerevisiae, only Cns1 is essential. The amino terminus of Cns1, which harbors the TPR domain, is sufficient for viability when overexpressed. In a screen for temperature-sensitive alleles of CNS1, we identified mutations resulting in substitutions of conserved residues in the TPR domain. Mutations in CNS1 disrupt in vitro and in vivo interaction with Hsp90 and reduce Hsp90 function, indicating that Cns1 is a bona fide co-chaperone. Genetic interactions between CNS1 and another Hsp90 co-chaperone, CPR7, suggest that the two co-chaperones share an essential role in the cell. Although both the TPR and the isomerase domains of the cyclophilin Cpr7 are required for viability of cns1 mutant cells, this requirement does not depend on the catalytic function of the isomerase domain. Instead, hydrophilic residues on the surface of this domain appear to be important for the common Cns1.Cpr7 function. Although both co-chaperones interact with Hsp90 primarily through the carboxyl terminus (EEVD), Cns1 and Cpr7 are mostly found in complexes distinct from Hsp90. EEVD is required for normal growth in cns1 mutant cells, demonstrating for the first time in vivo requirement for this conserved region of Hsp90. Overall, our findings reveal a considerable degree of complexity in the interactions not only between Hsp90 and its co-chaperones, but also among the co-chaperones themselves.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Gaber, RF (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, OT Hogan Biol Sci Bldg,2-100,2205 Tech Dr, Evanston, IL 60208 USA.	r-gaber@northwestern.edu						Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648; BAUR A, 1993, YEAST, V9, P289, DOI 10.1002/yea.320090308; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; DEBOER M, 1994, BLOOD, V83, P531, DOI 10.1182/blood.V83.2.531.bloodjournal832531; Dolinski KJ, 1998, MOL CELL BIOL, V18, P7344, DOI 10.1128/MCB.18.12.7344; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Louvion JF, 1998, MOL BIOL CELL, V9, P3071, DOI 10.1091/mbc.9.11.3071; Louvion JF, 1996, P NATL ACAD SCI USA, V93, P13937, DOI 10.1073/pnas.93.24.13937; Marsh JA, 1998, MOL CELL BIOL, V18, P7353, DOI 10.1128/MCB.18.12.7353; Mayr C, 2000, J BIOL CHEM, V275, P34140, DOI 10.1074/jbc.M005251200; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pirkl F, 2001, J MOL BIOL, V308, P795, DOI 10.1006/jmbi.2001.4595; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Warth R, 1997, BIOL CHEM, V378, P381, DOI 10.1515/bchm.1997.378.5.381; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	56	40	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32692	32701		10.1074/jbc.M304315200	http://dx.doi.org/10.1074/jbc.M304315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12788914	hybrid			2022-12-25	WOS:000184901800027
J	Yaghootfam, A; Schestag, F; Dierks, T; Gieselmann, V				Yaghootfam, A; Schestag, F; Dierks, T; Gieselmann, V			Recognition of arylsulfatase A and B by the UDP-N-acetylglucosamine : lysosomal enzyme N-acetylglucosamine-phosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASN-LINKED OLIGOSACCHARIDES; LYSINE-BASED STRUCTURE; MANNOSE PHOSPHORYLATION; PROCATHEPSIN-D; ACTIVE-SITE; CATHEPSIN-D; EXPRESSION; SULFATASE; RESIDUES; AMINO	The critical step for sorting of lysosomal enzymes is the recognition by a Golgi-located phosphotransferase. The topogenic structure common to all lysosomal enzymes essential for this recognition is still not well defined, except that lysine residues seem to play a critical role. Here we have substituted surface-located lysine residues of lysosomal arylsulfatases A and B. In lysosomal arylsulfatase A only substitution of lysine residue 457 caused a reduction of phosphorylation to 33% and increased secretion of the mutant enzyme. In contrast to critical lysines in various other lysosomal enzymes, lysine 457 is not located in an unstructured loop region but in a helix. It is not strictly conserved among six homologous lysosomal sulfatases. Based on three-dimensional structure comparison, lysines 497 and 507 in arylsulfatase B are in a similar position as lysine 457 of arylsulfatase A. Also, the position of oligosaccharide side chains phosphorylated in arylsulfatase A is similar in arylsulfatase B. Despite the high degree of structural homology between these two sulfatases substitution of lysines 497 and 507 in arylsulfatase B has no effect on the sorting and phosphorylation of this sulfatase. Thus, highly homologous lysosomal arylsulfatases A and B did not develop a single conserved phosphotransferase recognition signal, demonstrating the high variability of this signal even in evolutionary closely related enzymes.	Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany; Univ Gottingen, Dept Biochem 2, Inst Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	University of Bonn; University of Gottingen	Gieselmann, V (corresponding author), Univ Bonn, Inst Physiol Chem, Nussallee 11, D-53115 Bonn, Germany.		Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Bresciani R, 1996, EUR J BIOCHEM, V238, P669, DOI 10.1111/j.1432-1033.1996.0669w.x; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Lukong KE, 1999, BIOCHEMISTRY-US, V38, P73, DOI 10.1021/bi981324r; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; PETERS C, 1990, J BIOL CHEM, V265, P3374; Schierau A, 1999, J BIOL CHEM, V274, P3651, DOI 10.1074/jbc.274.6.3651; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SCHOREY JS, 1995, J CELL SCI, V108, P2007; SOMMERLADE HJ, 1994, J BIOL CHEM, V269, P20977; SOMMERLADE HJ, 1994, BIOCHEM J, V297, P123, DOI 10.1042/bj2970123; STEIN C, 1989, J BIOL CHEM, V264, P1252; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; Waldow A, 1999, J BIOL CHEM, V274, P12284, DOI 10.1074/jbc.274.18.12284	30	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32653	32661		10.1074/jbc.M304865200	http://dx.doi.org/10.1074/jbc.M304865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12783870	hybrid			2022-12-25	WOS:000184901800023
J	Fassett, JT; Tobolt, D; Nelsen, CJ; Albrecht, JH; Hansen, LK				Fassett, JT; Tobolt, D; Nelsen, CJ; Albrecht, JH; Hansen, LK			The role of collagen structure in mitogen stimulation of ERK, cyclin D1 expression, and G(1)-S progression in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; SIGNAL-REGULATED KINASE; CELL-CYCLE; PHOSPHATIDYLINOSITOL 3-KINASE; DNA-SYNTHESIS; TRANSIENT EXPRESSION; IN-VITRO; ACTIVATION; PROTEIN	Adhesion to type 1 collagen can elicit different cellular responses dependent upon whether the collagen is in a fibrillar form ( gel) or monomeric form ( film). Hepatocytes adherent to collagen film spread extensively, express cyclin D1, and increase DNA synthesis in response to epidermal growth factor, whereas hepatocytes adherent to collagen gel have increased differentiated function, but lower DNA synthesis. The signaling mechanisms by which different forms of type I collagen modulate cell cycle progression are unknown. When ERK MAP kinase activation was analyzed in hepatocytes attached to collagen film, two peaks of ERK activity were demonstrated. Only the second peak, which correlated with an increase of cyclin D1, was required for G(1)-S progression. Notably, this second peak of ERK activity was absent in cells adherent to collagen gel, but not required in the presence of exogenous cyclin D1. Expression of activated mutants of the Ras/Raf/MEK signaling pathway in cells adherent to collagen gel restored ERK phosphorylation and DNA synthesis, but differentially affected cell shape. Although Ras, Raf, and MEK all increased expression of cyclin D1 on collagen film, only Ras and Raf significantly up-regulated cyclin D1 levels on collagen gel. These results demonstrate that adhesion to polymerized collagen induces growth arrest by inhibiting the Ras/ERK-signaling pathway to cyclin D1 required in late G(1).	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center	Hansen, LK (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.	hanse066@tc.umn.edu		Fassett, John/0000-0003-4591-6875; Hansen, Linda/0000-0003-3651-0419	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045371, R01DK054921] Funding Source: NIH RePORTER; NCI NIH HHS [CA09138] Funding Source: Medline; NIDDK NIH HHS [2R01-DK45371, DK54921] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 1999, J CELL SCI, V112, P695; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Awata R, 1998, J GASTROEN HEPATOL, V13, pS55; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; De Smet K, 2001, BIOCHEM PHARMACOL, V61, P1293, DOI 10.1016/S0006-2952(01)00612-8; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; ETIENNE PL, 1988, ONCOGENE RES, V3, P255; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gomez-Lechon MJ, 1998, J CELL PHYSIOL, V177, P553, DOI 10.1002/(SICI)1097-4652(199812)177:4<553::AID-JCP6>3.0.CO;2-F; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; Hansen LK, 1999, J CELL SCI, V112, P2971; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klesse LJ, 1998, J NEUROSCI, V18, P10420; KNIGHT J, 1984, ULTRASTRUCT PATHOL, V7, P133, DOI 10.3109/01913128409141470; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; Lahti JM, 1997, J BIOL CHEM, V272, P10859; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lora JM, 1998, HEPATOLOGY, V28, P1095, DOI 10.1002/hep.510280426; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; Nelsen CJ, 2001, CANCER RES, V61, P8564; Page K, 2000, AM J RESP CELL MOL, V23, P436, DOI 10.1165/ajrcmb.23.4.3953; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; ROJKIND M, 1976, P NATL ACAD SCI USA, V73, P539, DOI 10.1073/pnas.73.2.539; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088; SAND TE, 1987, J CELL PHYSIOL, V131, P141, DOI 10.1002/jcp.1041310202; SAWADA N, 1986, EXP CELL RES, V167, P458, DOI 10.1016/0014-4827(86)90186-2; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Schwartz MA, 2001, J CELL SCI, V114, P2553; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEYER JM, 1977, J CLIN INVEST, V59, P241, DOI 10.1172/JCI108634; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Thoresen GH, 1999, CELL BIOL INT, V23, P13, DOI 10.1006/cbir.1998.0314; Tombes RM, 1998, BIOCHEM J, V330, P1451; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; WU KJ, 1994, J BIOL CHEM, V269, P1177; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	73	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31691	31700		10.1074/jbc.M300899200	http://dx.doi.org/10.1074/jbc.M300899200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794085	hybrid			2022-12-25	WOS:000184782100030
J	Yamamoto, H; Shevde, NK; Warrier, A; Plum, LA; DeLuca, HF; Pike, JW				Yamamoto, H; Shevde, NK; Warrier, A; Plum, LA; DeLuca, HF; Pike, JW			2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D-3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; DISTINCT CONFORMATIONAL-CHANGES; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; COACTIVATOR INTERACTION; TRANSCRIPTIONAL ACTIVATION; PEPTIDE ANTAGONISTS; RESPONSE ELEMENT; BONE-RESORPTION; 20-EPI ANALOGS	2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D-3 (2MD) is a highly potent analog of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) whose actions are mediated through the vitamin D receptor (VDR). In this report, we have replicated this increased potency of 2MD in vitro using osteoblastic cells and explored its underlying molecular mechanism. 2MD stimulates the expression of several vitamin D-sensitive genes including 25-hydroxyvitamin D-3-24 hydroxylase (Cyp24), osteopontin and receptor activator of NFkappaB ligand and suppresses osteoprotegerin at concentrations two logs lower than that for 1,25(OH)(2)D-3. 2MD is also more potent in stimulating transfected chimeric reporter genes under either Cyp24 or the osteocalcin promoter control. Enhanced potency is retained regardless of medium serum content. Interestingly, the uptake of both 1,25(OH)(2)D-3 and 2MD into cells is similar, as is their rapid association with the VDR. This indicates that comparable levels of occupied VDR do not elicit equivalent levels of transactivation. Using chromatin immunoprecipitation (ChIP), however, we observed a strong correlation between DNA-bound receptor and the level of induced transcription suggesting a 2MD-induced increase in affinity of the VDR for DNA. Additional studies using a mammalian two-hybrid system and ChIP indicate that 2MD is also more potent in promoting interaction with RXR and the coactivators SRC-1 and DRIP205. Finally, protease digestion studies revealed a unique VDR conformation in the presence of 2MD. These studies suggest that the molecular mechanism of 2MD potency is due to its ability to promote enhanced levels of specific DNA binding by the VDR and could suggest possible explanations for the tissue- and gene-selective actions of 2MD.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Pike, JW (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052453] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52453] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Beckman MJ, 1998, PROGR MED CHEM, V35, P1, DOI 10.1016/S0079-6468(08)70033-X; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; BINDERUP L, 1997, VITAMIN D, P127; BROWN AJ, 1997, VITAMIN D, P1027; Carlberg C, 2003, J CELL BIOCHEM, V88, P274, DOI 10.1002/jcb.10337; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; COOK NE, 1984, ENDOCR REV, V10, P294; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; James AJ, 2002, MOL ENDOCRINOL, V16, P2692, DOI 10.1210/me.2001-0281; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KISSMEYER AM, 1991, BIOCHEM PHARMACOL, V41, P1601, DOI 10.1016/0006-2952(91)90160-7; Kittaka A, 2003, CHEM PHARM BULL, V51, P357; Kraichely DM, 1999, J BIOL CHEM, V274, P14352, DOI 10.1074/jbc.274.20.14352; Kubodera N, 2003, J CELL BIOCHEM, V88, P286, DOI 10.1002/jcb.10346; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Morony S, 1999, J BONE MINER RES, V14, P1478, DOI 10.1359/jbmr.1999.14.9.1478; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NORMAN AW, 1995, J CELL BIOCH S, V22, P218; OZONO K, 1990, J BIOL CHEM, V265, P21881; Pathrose P, 2002, J BONE MINER RES, V17, P2196, DOI 10.1359/jbmr.2002.17.12.2196; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Pike ACW, 2000, BIOCHEM SOC T, V28, P396, DOI 10.1042/0300-5127:0280396; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1983, J BIOL CHEM, V258, P8554; Pike JW, 2002, ADV RENAL REPLACE TH, V9, P168, DOI 10.1053/jarr.2002.34845; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Shevde NK, 2002, P NATL ACAD SCI USA, V99, P13487, DOI 10.1073/pnas.202471299; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sicinski RR, 1998, J MED CHEM, V41, P4662, DOI 10.1021/jm9802618; SONE T, 1991, J BIOL CHEM, V266, P23296; Thompson PD, 2001, J MOL ENDOCRINOL, V27, P211, DOI 10.1677/jme.0.0270211; Tocchini-Valentini G, 2001, P NATL ACAD SCI USA, V98, P5491, DOI 10.1073/pnas.091018698; Vaisanen S, 1999, EUR J BIOCHEM, V261, P706, DOI 10.1046/j.1432-1327.1999.00318.x; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yang W, 1999, J BIOL CHEM, V274, P16838, DOI 10.1074/jbc.274.24.16838; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	52	86	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31756	31765		10.1074/jbc.M304737200	http://dx.doi.org/10.1074/jbc.M304737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12796488	hybrid			2022-12-25	WOS:000184782100037
J	Armoni, M; Kritz, N; Harel, C; Bar-Yoseph, F; Chen, H; Quon, MJ; Karnieli, E				Armoni, M; Kritz, N; Harel, C; Bar-Yoseph, F; Chen, H; Quon, MJ; Karnieli, E			Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; DIABETES-MELLITUS; GENE-EXPRESSION; IN-VIVO; RAT; ADIPOGENESIS; LIGAND; KINASE	The synthetic thiazolidinedione ligands of peroxisome proliferator-activated receptor-gamma (PPARgamma) improve insulin sensitivity in type II diabetes and induce GLUT4 mRNA expression in fat and muscle. However, the molecular mechanisms involved are still unclear. We studied the regulatory effects of PPARgamma and its ligands on GLUT4 gene expression in primary rat adipocytes and CHO-K1 cells cotransfected with PPARgamma and the GLUT4 promoter reporter. PPARgamma1 and PPARgamma2 repressed the activity of the GLUT4 promoter in a dose-dependent manner. Whereas this repression was augmented by the natural ligand 15Delta-prostaglandin J(2), it was completely alleviated by rosiglitazone (Rg). Ligand binding-defective mutants PPARgamma1-L468A/E471A and PPARgamma2-L496A/E499A retained the repression effect, which was unaffected by Rg, whereas the PPARgamma2-S112A mutant exhibited a 50% reduced capacity to repress GLUT4 promoter activity. The -66/+163 bp GLUT4 promoter region was sufficient to mediate PPARgamma inhibitory effects. The PPARgamma/retinoid X receptor-alpha heterodimer directly bound to this region, whereas binding was abolished in the presence of Rg. Thus, we show that PPARgamma represses transcriptional activity of the GLUT4 promoter via direct and specific binding of PPARgamma/retinoid X receptor-alpha to the GLUT4 promoter. This effect requires an intact Ser(112) phosphorylation site on PPARgamma and is completely alleviated by Rg, acting via its ligand-binding domain. These data suggest a novel mechanism by which Rg exerts its antidiabetic effects via detaching PPARgamma from the GLUT4 gene promoter, thus leading to increased GLUT4 expression and enhanced insulin sensitivity.	Rambam Med Ctr, Inst Endocrinol Diabet & Metab, Unit Mol Endocrinol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Fac Med, IL-31096 Haifa, Israel; NIH, NCCAM, Bethesda, MD 20892 USA	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Armoni, M (corresponding author), Rambam Med Ctr, Inst Endocrinol Diabet & Metab, Unit Mol Endocrinol, IL-31096 Haifa, Israel.		Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Armoni M, 2002, J CLIN ENDOCR METAB, V87, P5312, DOI 10.1210/jc.2002-020318; ARMONI M, 1995, ENDOCRINOLOGY, V136, P3292, DOI 10.1210/en.136.8.3292; ARMONI M, 1987, J CLIN ENDOCR METAB, V65, P1141, DOI 10.1210/jcem-65-6-1141; Balfour JAB, 1999, DRUGS, V57, P921; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Beamer BA, 1997, BIOCHEM BIOPH RES CO, V233, P756, DOI 10.1006/bbrc.1997.6540; Camp HS, 1997, J BIOL CHEM, V272, P10811; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GARVEY WT, 1992, DIABETES CARE, V15, P396, DOI 10.2337/diacare.15.3.396; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; Glass CK, 2000, GENE DEV, V14, P121; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; Henry RR, 1997, ENDOCRIN METAB CLIN, V26, P553, DOI 10.1016/S0889-8529(05)70267-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KARNIELI E, 1981, J CLIN INVEST, V68, P811, DOI 10.1172/JCI110318; KARNIELI E, 1987, DIABETES, V36, P925, DOI 10.2337/diabetes.36.8.925; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1996, DNA TRANSFER CULTURE, V4, P93; SAMBROOK J, 1989, MOL CLON LAB MANUAL; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Spencer CM, 1997, DRUGS, V54, P89, DOI 10.2165/00003495-199754010-00010; Spiegelman B M, 1997, Eur J Med Res, V2, P457; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230	37	102	107	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30614	30623		10.1074/jbc.M304654200	http://dx.doi.org/10.1074/jbc.M304654200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777391	hybrid			2022-12-25	WOS:000184658800026
J	Choi-Rhee, E; Cronan, JE				Choi-Rhee, E; Cronan, JE			The biotin carboxylase-biotin carboxyl carrier protein complex of Escherichia coli acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; SUBUNIT; GENES; CARBOXYLTRANSFERASE; PURIFICATION; ENZYME; DOMAIN; APO; EXPRESSION; SYSTEM	Escherichia coli acetyl-CoA carboxylase (ACC) is composed of four different protein molecules. These proteins form a large but very unstable complex. Hints of a sub-complex between the biotin carboxylase (BC) and biotin carboxyl carrier protein (BCCP) subunits have been reported in the literature, but the complex was not isolated and thus the protein stoichiometry could not be determined. We report isolation of the BC.BCCP complex. By use of affinity chromatography using two different affinity tags it was shown that the complex consists of a two BCCP molecules per BC molecule. The molar ratio in the complex is the same as the ratio of the subunit proteins synthesized in vivo. We conclude that the complex consists of a dimer of BC plus four BCCP molecules instead of the 2BC.2BCCP complex previously assumed. This subunit ratio allows two conflicting models of the ACC mechanism to be rectified. We also report that the N-terminal 30 or so residues of BCCP are responsible for the interaction of BCCP with BC and that the BC.BCCP complex is a substrate for biotinylation in vitro.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, B103 Chem & Life Sci Lab,601 S Goodwin Ave, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1968, P NATL ACAD SCI USA, V59, P561, DOI 10.1073/pnas.59.2.561; ALBERTS AW, 1972, ENZYMES, V6, P37; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BEST EA, 1993, J BACTERIOL, V175, P6881, DOI 10.1128/jb.175.21.6881-6889.1993; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Cronan JE, 2002, J BIOL CHEM, V277, P22520, DOI 10.1074/jbc.M201249200; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Cronan JE, 2001, J BIOL CHEM, V276, P37355, DOI 10.1074/jbc.M106353200; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Fall R R, 1975, Methods Enzymol, V35, P17; FALL RR, 1976, BIOCHIM BIOPHYS ACTA, V450, P475, DOI 10.1016/0005-2760(76)90022-9; FALL RR, 1972, J BIOL CHEM, V247, P8005; FALL RR, 1971, P NATL ACAD SCI USA, V68, P1512, DOI 10.1073/pnas.68.7.1512; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; Janiyani K, 2001, J BIOL CHEM, V276, P29864, DOI 10.1074/jbc.M104102200; Kwon K, 2000, PROTEIN SCI, V9, P1530, DOI 10.1110/ps.9.8.1530; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; MARINI P, 1995, J BACTERIOL, V177, P7003, DOI 10.1128/jb.177.23.7003-7006.1995; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; Reverdatto S, 1999, PLANT PHYSIOL, V119, P961, DOI 10.1104/pp.119.3.961; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; Sapan CV, 1999, BIOTECHNOL APPL BIOC, V29, P99; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WOOD HG, 1980, J BIOL CHEM, V255, P7397; WOOD HG, 1985, ANN NY ACAD SCI, V447, P1, DOI 10.1111/j.1749-6632.1985.tb18422.x; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f; ZABIN I, 1970, LACTOSE OPERON, P27	34	68	101	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30806	30812		10.1074/jbc.M302507200	http://dx.doi.org/10.1074/jbc.M302507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12794081	hybrid			2022-12-25	WOS:000184658800049
J	Milne, TJ; Abbenante, G; Tyndall, JDA; Halliday, J; Lewis, RJ				Milne, TJ; Abbenante, G; Tyndall, JDA; Halliday, J; Lewis, RJ			Isolation and characterization of a cone snail protease with homology to CRISP proteins of the pathogenesis-related protein superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE SIMILARITY; VENOM ALLERGEN; GENE; PREDICTION; PEPTIDES; DATABASE	The pathogenesis-related (PR) protein superfamily is widely distributed in the animal, plant, and fungal kingdoms and is implicated in human brain tumor growth and plant pathogenesis. The precise biological activity of PR proteins, however, has remained elusive. Here we report the characterization, cloning and structural homology modeling of Tex31 from the venom duct of Conus textile. Tex31 was isolated to >95% purity by activity-guided fractionation using a para-nitroanilide substrate based on the putative cleavage site residues found in the propeptide precursor of conotoxin TxVIA. Tex31 requires four residues including a leucine N-terminal of the cleavage site for efficient substrate processing. The sequence of Tex31 was determined using two degenerate PCR primers designed from N-terminal and tryptic digest Edman sequences. A BLAST search revealed that Tex31 was a member of the PR protein superfamily and most closely related to the CRISP family of mammalian proteins that have a cysteine-rich C-terminal tail. A homology model constructed from two PR proteins revealed that the likely catalytic residues in Tex31 fall within a structurally conserved domain found in PR proteins. Thus, it is possible that other PR proteins may also be substrate-specific proteases.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Queensland Univ Technol, Ctr Mol Biotechnol, Sch Life Sci, Brisbane, Qld 4001, Australia	University of Queensland; Queensland University of Technology (QUT)	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard/T-8763-2019; Lewis, Richard J/E-8674-2013; tyndall, joel/C-2803-2008; Milne, Trudy J/G-2630-2011	Lewis, Richard/0000-0003-3470-923X; Lewis, Richard J/0000-0003-3470-923X; tyndall, joel/0000-0003-0783-1635; 				Abbenante G, 2000, LETT PEPT SCI, V7, P347, DOI 10.1023/A:1013016323676; *ACC INC, 2001, INS MOD ENV; ALEWOOD PF, 1990, PEPTIDES, P174; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTONIW JF, 1980, PHYTOPATHOL Z, V98, P331; Bogyo M, 1998, NATURE, V396, P625, DOI 10.1038/25238; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EBERSPAECHER U, 1995, MOL REPROD DEV, V42, P157, DOI 10.1002/mrd.1080420205; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Fernandez C, 1997, J MOL BIOL, V266, P576, DOI 10.1006/jmbi.1996.0772; Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160; KASAHARA M, 1989, GENOMICS, V5, P527, DOI 10.1016/0888-7543(89)90019-0; Laskowski RA, 1996, PROTEIN SCI, V5, P2438; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; LINDERSTROMLANG K, 1947, NATURE, V159, P807, DOI 10.1038/159807a0; LU G, 1993, J IMMUNOL, V150, P2823; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MOCHCAMORALES J, 1990, TOXICON, V28, P299, DOI 10.1016/0041-0101(90)90065-F; MURPHY EV, 1995, GENE, V159, P131, DOI 10.1016/0378-1119(95)00061-A; Nakai K, 2001, J STRUCT BIOL, V134, P103, DOI 10.1006/jsbi.2001.4378; Neurath H, 1999, P NATL ACAD SCI USA, V96, P10962, DOI 10.1073/pnas.96.20.10962; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olivera BM, 1999, CURR OPIN NEUROBIOL, V9, P772, DOI 10.1016/S0959-4388(99)00033-1; Rich T, 1996, GENE, V180, P125, DOI 10.1016/S0378-1119(96)00431-3; SCHUREN FHJ, 1993, J GEN MICROBIOL, V139, P2083, DOI 10.1099/00221287-139-9-2083; SOMORIN O, 1979, J BIOCHEM-TOKYO, V85, P157, DOI 10.1093/oxfordjournals.jbchem.a132305; Szyperski T, 1998, P NATL ACAD SCI USA, V95, P2262, DOI 10.1073/pnas.95.5.2262; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x	32	185	196	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31105	31110		10.1074/jbc.M304843200	http://dx.doi.org/10.1074/jbc.M304843200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12759345	hybrid			2022-12-25	WOS:000184658800087
J	Suo, ZM; Wu, M; Citron, BA; Gao, CH; Festoff, BW				Suo, ZM; Wu, M; Citron, BA; Gao, CH; Festoff, BW			Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BRAIN; THROMBOMODULIN; INFLAMMATION; MECHANISMS; INJURY	We have previously reported that thrombin, the ultimate serine protease in the coagulation cascades, is a proinflammatory agent that causes proliferation and activation of brain microglial cells. However, participation of its principal receptor, the protease-activated receptor 1 (PAR1) appears to be limited to promoting microglial proliferation and not induction of inflammatory mediators. In the present study, we now report that thrombin action in promoting inflammatory mediators from brain microglia is mediated through another thrombin receptor, PAR4. Here we show that the PAR4 agonist peptide (PAR4AP, GYPGKF), but not the PAR1AP (TRAP, SFLLRN), induced tumor necrosis factor-alpha (TNF-alpha) production not only in cultured murine microglial cells in vitro but also in rat cortex in vivo. Down-regulation of PAR4 expression in microglial cultures by a specific antisense, but not a sense, oligonucleotide reduced PAR4AP- induced TNF-alpha. Mechanistic studies indicated that, in comparison with PAR1 signaling, prolonged increase of [Ca2+](i) and phosphorylation of p44/42 mitogen-activated protein kinases, as well as NFkappaB activation may be responsible for PAR4AP-induced TNF-alpha production in microglia. Taken together, these results demonstrate that PAR4 activation mediates the potentially detrimental effects of thrombin on microglia, implying that perspectives of exploiting PAR1 as a potential anti-inflammatory target should be shifted toward PAR4 as a much more specific therapeutic target in brain inflammatory conditions associated with neurotrauma and neurodegenerations.	Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, Kansas City, MO 64128 USA; Vet Affairs Med Ctr, Mol Biol Res Lab, Kansas City, MO 64128 USA; Vet Affairs Med Ctr, Neurobiol Res Lab, Kansas City, MO 64128 USA; Univ Kansas, Dept Neurol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Pharmacol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Toxicol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Therapeut, Sch Med, Kansas City, KS 66170 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Suo, ZM (corresponding author), Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	zsuo@kumc.edu						AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FESTOFF BW, 1997, NEUROPROTECTIVE SIGN, P221; FESTOFF BW, 1992, HDB AMYOTROPHIC LATE, V12, P661; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Mollison J, 2002, J FAM PLAN REPROD H, V28, P101, DOI 10.1783/147118902101196072; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Pindon A, 1997, GLIA, V19, P259, DOI 10.1002/(SICI)1098-1136(199703)19:3<259::AID-GLIA8>3.0.CO;2-U; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Ruscher K, 2000, J BIOTECHNOL, V78, P163, DOI 10.1016/S0168-1656(00)00207-8; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Sarker KP, 1999, THROMB HAEMOSTASIS, V82, P1071, DOI 10.1055/s-0037-1614331; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Strukova SM, 2001, BIOCHEMISTRY-MOSCOW+, V66, P8, DOI 10.1023/A:1002869310180; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	36	89	101	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31177	31183		10.1074/jbc.M302137200	http://dx.doi.org/10.1074/jbc.M302137200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12775717	hybrid			2022-12-25	WOS:000184658800095
J	Tao, X; Tong, L				Tao, X; Tong, L			Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACEPTION-ASSOCIATED PROTEIN-1; ESCHERICHIA-COLI; INTRACELLULAR PROTEASE; ANOMALOUS DIFFRACTION; MOLECULAR REPLACEMENT; GENE; ALPHA; IDENTIFICATION; EXPRESSION; RESOLUTION	We report the crystal structure at 1.8-Angstrom resolution of human DJ-1, which has been linked to early onset Parkinson's disease. The monomer of DJ-1 contains the alpha/beta-fold that is conserved among members of the DJ-1/ThiJ/ PfpI superfamily. However, the structure also contains an extra helix at the C terminus, which mediates a novel mode of dimerization for the DJ-1 proteins. A putative active site has been identified near the dimer interface, and the residues Cys-106, His-126, and Glu-18 may play important roles in the catalysis by this protein. Studies with the disease-causing L166P mutant suggest that the mutation has disrupted the C-terminal region and the dimerization of the protein. The DJ-1 proteins may function only as dimers. The Lys to Arg mutation at residue 130, the site of sumoylation of DJ-1, has minimal impact on the structure of the protein.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Tong, Liang/0000-0002-0563-6468	NIAID NIH HHS [AI49475] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049475] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bravo J, 1999, PROTEINS, V34, P155, DOI 10.1002/(SICI)1097-0134(19990201)34:2<155::AID-PROT1>3.0.CO;2-P; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066; Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1; Halio SB, 1996, J BACTERIOL, V178, P2605, DOI 10.1128/jb.178.9.2605-2612.1996; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horvath MM, 2001, PROTEINS, V42, P230, DOI 10.1002/1097-0134(20010201)42:2<230::AID-PROT100>3.3.CO;2-A; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Mizote T, 1999, MICROBIOL-UK, V145, P495, DOI 10.1099/13500872-145-2-495; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niki T, 2003, MOL CANCER RES, V1, P247; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wagenfeld A, 2000, J ANDROL, V21, P954; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Welch JE, 1998, J ANDROL, V19, P385	40	194	214	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31372	31379		10.1074/jbc.M304221200	http://dx.doi.org/10.1074/jbc.M304221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12761214	hybrid			2022-12-25	WOS:000184658800119
J	Chou, CC; Forouhar, F; Yeh, YH; Shr, HL; Wang, C; Hsiao, CD				Chou, CC; Forouhar, F; Yeh, YH; Shr, HL; Wang, C; Hsiao, CD			Crystal structure of the C-terminal 10-kDa subdomain of Hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; MOLECULAR CHAPERONE HSC70; SUBSTRATE-BINDING DOMAIN; PEPTIDE-BINDING; UNFOLDED PROTEINS; ESCHERICHIA-COLI; SELF-ASSOCIATION; ATPASE; KINETICS; HSP70	The 70-kDa heat shock proteins (Hsp70), including the cognates (Hsc70), are molecular chaperones that prevent misfolding and aggregation of polypeptides in cells under both normal and stressed conditions. They are composed of two major structural domains: an N-terminal 44-kDa ATPase domain and a C-terminal 30-kDa substrate binding domain. The 30-kDa domain can be divided into an 18-kDa subdomain and a 10-kDa subdomain. Here we report the crystal structure of the 10-kDa subdomain of rat Hsc70 at 3.45 Angstrom. Its helical region adopted a helix-loop-helix fold. This conformation is different from the equivalent subdomain of DnaK, the bacterial homologue of Hsc70. Moreover, in the crystalline state, the 10-kDa subdomain formed dimers. The results of gel filtration chromatography further supported the view that this subdomain was self-associated. Upon gel filtration, Hsc70 was found to exist as a mixture of monomers, dimers, and oligomers, but the 60-kDa fragment was predominantly found to exist as monomers. These findings suggest that the alpha-helical region of the 10-kDa subdomain dictates the chaperone self-association.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan	Hsiao, CD (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	mbhsiao@ccvax.sinica.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Hsiao, Chwan-Deng/D-7327-2013	Hsiao, Chwan-Deng/0000-0002-7012-1532; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; Chou CC, 2001, ACTA CRYSTALLOGR D, V57, P1928, DOI 10.1107/S090744490101722X; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Fouchaq B, 1999, EUR J BIOCHEM, V259, P379, DOI 10.1046/j.1432-1327.1999.00053.x; Ha JH, 1997, J BIOL CHEM, V272, P27796, DOI 10.1074/jbc.272.44.27796; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; Harlt F.U., 1996, NATURE, V381, P571; HOHFELD J, 1995, CELL, V83, P589; Hu SM, 1996, ARCH BIOCHEM BIOPHYS, V332, P163, DOI 10.1006/abbi.1996.0328; Hu SM, 2002, ARCH BIOCHEM BIOPHYS, V407, P135, DOI 10.1016/S0003-9861(02)00515-5; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Wu SJ, 2001, BIOCHEM J, V359, P419, DOI 10.1042/0264-6021:3590419; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	34	47	50	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30311	30316		10.1074/jbc.M304563200	http://dx.doi.org/10.1074/jbc.M304563200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773536	hybrid			2022-12-25	WOS:000184507000111
J	Xiao, JH; Ghosn, C; Hinchman, C; Forbes, C; Wang, J; Snider, N; Cordrey, A; Zhao, Y; Chandraratna, RAS				Xiao, JH; Ghosn, C; Hinchman, C; Forbes, C; Wang, J; Snider, N; Cordrey, A; Zhao, Y; Chandraratna, RAS			Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR; CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; EXPRESSION; ACTIVATION; GROWTH; GENE; MUTANT; MICE; CARCINOMA	beta-catenin is a component of stable cell adherent complexes whereas its free form functions as a transcription factor that regulate genes involved in oncogenesis and metastasis. Free beta-catenin is eliminated by two adenomatous polyposis coli (APC)-dependent proteasomal degradation pathways regulated by glycogen synthase kinase 3beta (GSK3beta) or p53-inducible Siah-1. Dysregulation of beta-catenin turnover consequent to mutations in critical genes of the APC-dependent pathways is implicated in cancers such as colorectal cancer. We have identified a novel retinoid X receptor (RXR)-mediated APC-independent pathway in the regulation of beta-catenin. In this proteasomal pathway, RXR agonists induce degradation of beta-catenin and RXRalpha and repress beta-catenin-mediated transcription. In vivo, beta-catenin interacts with RXRalpha in the absence of ligand, but RXR agonists enhanced the interaction. RXR agonist action was not impaired by GSK3beta inhibitors or deletion of the GSK3beta-targeted sequence from beta-catenin. In APC- and p53-mutated colorectal cancer cells, RXR agonists still inactivated endogenous beta-catenin via RXRalpha. Interestingly, deletion of the RXRalpha A/B region abolished ligand-induced beta-catenin degradation but not RXRalpha-mediated transactivation. RXRalpha-mediated inactivation of oncogenic beta-catenin paralleled a reduction in cell proliferation. These results suggest a potential role for RXR and its agonists in the regulation of beta-catenin turnover and related biological events.	Allergan Pharmaceut Inc, Restinoid Res, Dept Biol, Irvine, CA 92623 USA; Allergan Pharmaceut Inc, Restinoid Res, Dept Chem, Irvine, CA 92623 USA; Allergan Pharmaceut Inc, Restinoid Res, Dept Biol, Irvine, CA 92623 USA	AbbVie; Allergan; AbbVie; Allergan; AbbVie; Allergan	Xiao, JH (corresponding author), Allergan Pharmaceut Inc, Restinoid Res, Dept Biol, Irvine, CA 92623 USA.			Wang, Jenny W/0000-0003-0217-7275				ABARZUA P, 1995, CANCER RES, V55, P3490; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadoret A, 2001, CANCER RES, V61, P3245; Celli G, 1996, EXP CELL RES, V226, P273, DOI 10.1006/excr.1996.0228; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen RH, 2001, CANCER RES, V61, P4445; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dussault I, 2003, J BIOL CHEM, V278, P7027, DOI 10.1074/jbc.M209863200; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Green DW, 2001, J SURG RES, V101, P16, DOI 10.1006/jsre.2001.6241; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Johnson AT, 1999, BIOORGAN MED CHEM, V7, P1321, DOI 10.1016/S0968-0896(99)00055-3; Kajino Y, 2001, PATHOL INT, V51, P543, DOI 10.1046/j.1440-1827.2001.01231.x; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu T, 2002, J BIOL CHEM, V277, P30887, DOI 10.1074/jbc.M203852200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Osburn DL, 2001, MOL CELL BIOL, V21, P4909, DOI 10.1128/MCB.21.15.4909-4918.2001; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Roh H, 2001, CANCER RES, V61, P6563; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Vuligonda V, 2001, J MED CHEM, V44, P2298, DOI 10.1021/jm0100584; Westin S, 2000, ADV PHARMACOL, V47, P89; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x	42	132	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29954	29962		10.1074/jbc.M304761200	http://dx.doi.org/10.1074/jbc.M304761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771132	hybrid			2022-12-25	WOS:000184507000069
J	Zhao, A; Lew, JL; Huang, L; Yu, JH; Zhang, T; Hrywna, Y; Thompson, JR; de Pedro, N; Blevins, RA; Pelaez, F; Wright, SD; Cui, JS				Zhao, A; Lew, JL; Huang, L; Yu, JH; Zhang, T; Hrywna, Y; Thompson, JR; de Pedro, N; Blevins, RA; Pelaez, F; Wright, SD; Cui, JS			Human kininogen gene is transactivated by the farnesoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; ORPHAN NUCLEAR RECEPTOR; SALT EXPORT PUMP; BILE-ACIDS; HIGH-SENSITIVITY; CELL-ADHESION; PROTEIN GENE; PLASMA; FXR; IDENTIFICATION	Human kininogen belongs to the plasma kallikrein-kinin system. High molecular weight kininogen is the precursor for two-chain kinin-free kininogen and bradykinin. It has been shown that the two-chain kinin-free kininogen has the properties of anti-adhesion, antiplatelet aggregation, and anti-thrombosis, whereas bradykinin is a potent vasodilator and mediator of inflammation. In this study we show that the human kininogen gene is strongly up-regulated by agonists of the farnesoid X receptor (FXR), a nuclear receptor for bile acids. In primary human hepatocytes, both the endogenous FXR agonist chenodeoxycholate and synthetic FXR agonist GW4064 increased kininogen mRNA with a maximum induction of 8-10-fold. A more robust induction of kininogen expression was observed in HepG2 cells, where kininogen mRNA was increased by chenodeoxycholate or GW4064 up to 130-140-fold as shown by real time PCR. Northern blot analysis confirmed the up-regulation of kininogen expression by FXR agonists. To determine whether kininogen is a direct target of FXR, we examined the sequence of the kininogen promoter and identified a highly conserved FXR response element (inverted repeat, IR-1) in the proximity of the kininogen promoter (-66/-54). FXR/RXRalpha heterodimers specifically bind to this IR-1. A construct of a minimal promoter with the luciferase reporter containing this IR-1 was transactivated by FXR. Deletion or mutation of this IR-1 abolished FXR-mediated promoter activation, indicating that this IR-1 element is responsible for the promoter transactivation by FXR. We conclude that kininogen is a novel and direct target of FXR, and bile acids may play a role in the vasodilation and anti-coagulation processes.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Bioinformat, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Profiling, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Madrid 28027, Spain	Merck & Company; Merck & Company; Merck & Company; Merck & Company	Cui, JS (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000,RY80W-107, Rahway, NJ 07065 USA.		Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Asakura S, 1998, J BIOCHEM-TOKYO, V124, P473, DOI 10.1093/oxfordjournals.jbchem.a022138; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; Batzoglou S, 2000, GENOME RES, V10, P950, DOI 10.1101/gr.10.7.950; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 2002, J BIOL CHEM, V277, P32677, DOI 10.1074/jbc.M204010200; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; Cui J, 2002, J BIOL CHEM, V277, P25963, DOI 10.1074/jbc.M200824200; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; FONG D, 1991, HUM GENET, V87, P189, DOI 10.1007/BF00204179; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GERMAN D, 1989, DIGEST DIS SCI, V34, P1770, DOI 10.1007/BF01540057; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MAJIMA M, 1993, HYPERTENSION, V22, P705, DOI 10.1161/01.HYP.22.5.705; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MARGOLIUS HS, 1995, HYPERTENSION, V26, P221, DOI 10.1161/01.HYP.26.2.221; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; NISHIKAWA K, 1992, BLOOD, V80, P1980; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; Tu H, 2000, TRENDS CARDIOVAS MED, V10, P30, DOI 10.1016/S1050-1738(00)00043-8; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Willson TM, 2001, MED RES REV, V21, P513, DOI 10.1002/med.1023; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zhao YQ, 2001, AM J PHYSIOL-HEART C, V280, pH1821, DOI 10.1152/ajpheart.2001.280.4.H1821	45	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28765	28770		10.1074/jbc.M304568200	http://dx.doi.org/10.1074/jbc.M304568200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12761213	hybrid			2022-12-25	WOS:000184421100053
J	David, MD; Bertoglio, J; Pierre, J				David, MD; Bertoglio, J; Pierre, J			Functional characterization of IL-13 receptor alpha 2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression	ONCOGENE			English	Article						cytokine receptors; gene regulation; transcription factors; cytokines; keratinocytes	MESSENGER-RNA; HUMAN B; HUMAN MONOCYTES; GAMMA-CHAIN; INTERLEUKIN-13; PROTEIN; CLONING; CELLS; ACTIVATION; BINDING	Interleukin (IL)-4 and IL-13 are two structurally and functionally related cytokines that have overlapping but also distinct biological activities. One of the components of the IL-13 receptor, the alpha2 chain (IL-13Ralpha2), has been reported to downregulate the cell responsiveness to IL-13, without affecting IL-4 signaling. Here, we report that TNFalpha synergizes with either IL-4 or IL-13 in inducing the IL-13Ralpha2 chain at both the mRNA and protein levels in the HaCaT human keratinocyte cell line. Further studies by 5'RACE identified as yet undescribed exonic sequences of the IL-13Ralpha2 5'UTR, provided evidence for the expression of alternatively spliced IL-13Ralpha2 transcripts and defined the transcription start of the IL-13Ralpha2 gene. A 1.5 kb region upstream of the first exon of the IL-13Ralpha2 gene displayed basal promoter activity when inserted in a reporter plasmid and transiently transfected in HaCaT cells. This promoter activity was further increased in response to IL-4 and IL-13. Furthermore, by electrophoretic mobility shift assay and site-directed mutagenesis, we showed that the IL-4/IL-13-induced promoter activity depended upon a positively acting STAT6 response element. Finally, TNFalpha was shown to potentiate IL-4/IL-13-induced IL-13Ralpha2 promoter activity when the same reporter construct was studied in stably but not in transiently transfected cells. These results suggest that the synergistic effect of TNFalpha on IL-4/IL-13-induced IL-13Ralpha2 expression is dependent upon chromatin re-modeling events.	Fac Pharm Chatenay Malabry, U461, INSERM, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pierre, J (corresponding author), Fac Pharm Chatenay Malabry, U461, INSERM, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	josiane.pierre@cep.u-psud.fr	David, Muriel/F-9592-2012	David, Muriel/0000-0003-1392-2701				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; Debinski W, 1999, INT J ONCOL, V15, P481; Debinski W, 1999, CLIN CANCER RES, V5, P985; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Feng NP, 1998, LAB INVEST, V78, P591; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guo DQ, 1998, J IMMUNOL, V160, P2742; Guo JA, 1997, GENOMICS, V42, P141, DOI 10.1006/geno.1997.4628; Hart PH, 1999, J LEUKOCYTE BIOL, V66, P575, DOI 10.1002/jlb.66.4.575; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Jeannin P, 1997, J BIOL CHEM, V272, P15613, DOI 10.1074/jbc.272.25.15613; Kambayashi T, 1996, CELL IMMUNOL, V171, P153, DOI 10.1006/cimm.1996.0186; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Maini A, 1997, J UROLOGY, V158, P948, DOI 10.1016/S0022-5347(01)64369-6; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Ogata H, 1998, J BIOL CHEM, V273, P9864, DOI 10.1074/jbc.273.16.9864; Pesu M, 2002, J BIOL CHEM, V277, P38254, DOI 10.1074/jbc.M201427200; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang JG, 1997, J BIOL CHEM, V272, P9474	43	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3386	3394		10.1038/sj.onc.1206352	http://dx.doi.org/10.1038/sj.onc.1206352			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776189				2022-12-25	WOS:000183128500004
J	Ruivenkamp, C; Hermsen, M; Postma, C; Klous, A; Baak, J; Meijer, G; Demant, P				Ruivenkamp, C; Hermsen, M; Postma, C; Klous, A; Baak, J; Meijer, G; Demant, P			LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21	ONCOGENE			English	Article						PTPRJ; colorectal cancer; LOH; CGH; 18q12-21	MOUSE	Recently, the gene PTPRJ (protein tyrosine phosphatase receptor type J) was identified as the candidate gene for the mouse colon cancer susceptibility locus Scc1. Its human homologue PTPRJ is frequently deleted in several cancer types, including colorectal cancer. To elucidate the role of PTPRJ loss in different stages of colorectal cancer and in its pathways of progression, we expanded the previously published comparative genomic hybridization results with novel data on loss of heterozygosity (LOH) at the PTPRJ locus. We identified a strong association between the LOH of PTPRJ and the loss of chromosomal region 18q12-21 (P=0.009). This observation is specific for progressed colorectal adenomas, suggesting that an interaction between LOH of PTPRJ and loss of 18q12-21 may be involved in the development of a more progressed form of adenomas.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands	Netherlands Cancer Institute; Vrije Universiteit Amsterdam	Demant, P (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	P.demant@nki.nl						Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen MAJA, 1996, HUM PATHOL, V27, P342, DOI 10.1016/S0046-8177(96)90106-9; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MOEN CJA, 1992, ONCOGENE, V7, P563; Moustakas A, 2001, J CELL SCI, V114, P4359; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243	9	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3472	3474		10.1038/sj.onc.1206246	http://dx.doi.org/10.1038/sj.onc.1206246			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776199				2022-12-25	WOS:000183128500014
J	Klein, A; Guhl, E; Tzeng, YJ; Fuhrhop, J; Levrero, M; Graessmann, M; Graessmann, A				Klein, A; Guhl, E; Tzeng, YJ; Fuhrhop, J; Levrero, M; Graessmann, M; Graessmann, A			HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53	ONCOGENE			English	Article						HBX; transgenic animals; ME-cell immortalization; cyclin D1; differentiation; tumor formation	HEPATITIS-B VIRUS; CELLULAR DNA-REPAIR; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; P53-INDUCED APOPTOSIS; GENE; MICE; ANTIGEN; LIVER; HEPATOCARCINOGENESIS	Transgenic mice, which selectively express the WAP-HBX transgene in mammary gland epithelial cells (ME-cells), were established in order to elucidate the consequences of HBX gene expression on organ differentiation, cell death program and tumor development. Transgene expression was demonstrable by RT-PCR, Northern and Western blot analysis during pregnancy, lactation and after weaning. HBX synthesis neither affect mammary gland differentiation nor apoptosis in ME-cells. Although breast cancer formation was rare in WAP-HBX animals (<1%), WAP-HBX.p53+/- hybrid animals developed breast tumors at an increased rate (12/85) after a latency period of 8-18 months. We also show here for the first time that HBX can immortalize ME-cells generated from mammary gland tissue segments in a p53-independent fashion. HBX causes cyclin D1 gene overexpression during early pregnancy, and this is maintained in ME-cells isolated either from mammary gland or from breast tumors. Intranuclear cyclin D1 accumulation also occurs in the absence of external growth factors and the BrdU incorporation rate remains high under serum starvation conditions. Finally, both cyclin D1 induction and HBX mitotic activity are dependent on p38 and c-Jun N-terminal kinase, but not on MEK-1 kinase activity.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Univ Roma La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy	Free University of Berlin; Tzu Chi University; Sapienza University Rome	Graessmann, A (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.		Klein, Andreas/AAG-4506-2021; Levrero, Massimo/G-5680-2016	Klein, Andreas/0000-0002-3496-7215; Levrero, Massimo/0000-0002-4978-0875				Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAGANI TA, 1990, CARCINOGENESIS, V11, P953, DOI 10.1093/carcin/11.6.953; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goetz F, 2001, ONCOGENE, V20, P2325, DOI 10.1038/sj.onc.1204355; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kim YC, 1998, WATER SCI TECHNOL, V38, P1, DOI 10.1016/S0273-1223(98)00671-4; Kohzato N, 2001, HEPATOL RES, V21, P27, DOI 10.1016/S1386-6346(00)00150-9; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Madden CR, 2000, J VIROL, V74, P5266, DOI 10.1128/JVI.74.11.5266-5272.2000; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NATOLI G, 1994, ONCOGENE, V9, P2837; Pollicino T, 1998, BIOMED PHARMACOTHER, V52, P363, DOI 10.1016/S0753-3322(99)80003-1; Sambrook J., 2002, MOL CLONING LAB MANU; Santarelli R, 1996, ONCOGENE, V12, P495; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Terradillos O, 2002, ONCOGENE, V21, P377, DOI 10.1038/sj.onc.1205110; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1995, CANCER RES, V55, P6012	45	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2910	2919		10.1038/sj.onc.1206539	http://dx.doi.org/10.1038/sj.onc.1206539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771941				2022-12-25	WOS:000182824800005
J	Hochbaum, D; Tanos, T; Ribeiro-Neto, F; Altschuler, D; Coso, OA				Hochbaum, D; Tanos, T; Ribeiro-Neto, F; Altschuler, D; Coso, OA			Activation of JNK by Epac is independent of its activity as a rap guanine nucleotide exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS RAC1; MAP KINASE; SIGNAL-TRANSDUCTION; STRESS; PATHWAY; CAMP; PHOSPHORYLATION; CDC42; GTP; SUBUNIT	Guanine nucleotide exchange factors ( GEFs) and their associated GTP-binding proteins (G-proteins) are key regulatory elements in the signal transduction machinery that relays information from the extracellular environment into specific intracellular responses. Among them, the MAPK cascades represent ubiquitous downstream effector pathways. We have previously described that, analogous to the Ras-dependent activation of the Erk-1/2 pathway, members of the Rho family of small G-proteins activate the JNK cascade when GTP is loaded by their corresponding GEFs. Searching for novel regulators of JNK activity we have identified Epac ( exchange protein activated by cAMP) as a strong activator of JNK-1. Epac is a member of a growing family of GEFs that specifically display exchange activity on the Rap subfamily of Ras small G-proteins. We report here that while Epac activates the JNK severalfold, a constitutively active (G12V) mutant of Rap1b does not, suggesting that Rap-GTP is not sufficient to transduce Epac-dependent JNK activation. Moreover, Epac signaling to the JNKs was not blocked by inactivation of endogenous Rap, suggesting that Rap activation is not necessary for this response. Consistent with these observations, domain deletion mutant analysis shows that the catalytic GEF domain is dispensable for Epac-mediated activation of JNK. These studies identified a region overlapping the Ras exchange motif domain as critical for JNK activation. Consistent with this, an isolated Ras exchange motif domain from Epac is sufficient to activate JNK. We conclude that Epac signals to the JNK cascade through a new mechanism that does not involve its canonical catalytic action, i.e. Rap-specific GDP/GTP exchange. This represents not only a novel way to activate the JNKs but also a yet undescribed mechanism of downstream signaling by Epac.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol & Biol Mol & Celular, Lab Fisiol & Biol Mol, RA-1428 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, IFYBINE, RA-1428 Buenos Aires, DF, Argentina; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Coso, OA (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol & Biol Mol & Celular, Lab Fisiol & Biol Mol, RA-1428 Buenos Aires, DF, Argentina.	ocoso@fbmc.fcen.uba.ar		Tanos, Tamara/0000-0002-3217-3104; Hochbaum, Daniel/0000-0001-6387-7529				ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2000, FR MOLEC B, V24, P67; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gutkind J.S, 2000, SCI STKE; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rooij J., 2000, J BIOL CHEM, V275, P20829; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; YAN MH, 1994, NATURE, V372, P798; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	37	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33738	33746		10.1074/jbc.M305208200	http://dx.doi.org/10.1074/jbc.M305208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12783872	hybrid			2022-12-25	WOS:000185047500018
J	Pearce, FG; Andrews, TJ				Pearce, FG; Andrews, TJ			The relationship between side reactions and slow inhibition of ribulose-bisphosphate carboxylase revealed by a loop 6 mutant of the tobacco enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTANT; TIGHT-BINDING INHIBITOR; RIBULOSEBISPHOSPHATE CARBOXYLASE; 1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; ACTIVE-SITE; XYLULOSE 1,5-BISPHOSPHATE; BETA-ELIMINATION; CARBON-DIOXIDE; CATALYTIC SITE	The first directed mutant of a higher plant ribulosebisphosphate carboxylase/oxygenase (Rubisco), constructed by chloroplast transformation, is catalytically impaired but still able to support the plant's photosynthesis and growth (Whitney, S. M., von Caemmerer, S., Hudson, G. S., and Andrews, T.J. (1999) Plant Physiol. 121, 579-588). This mutant enzyme has a Leu to Val substitution at residue 335 in the flexible loop 6 of the large subunit, which closes over the substrate during catalysis. Its active site was intact, as judged by its barely impaired competency in the initial enolization step of the reaction sequence, and its ability to bind tightly the intermediate analog, 2'-carboxy-D-arabinitol-1,5-bisphosphate. Prompted by observations that the mutant enzyme displayed much less slow inhibition during catalysis in vitro than the wild type, its tendency to catalyze side reactions and its response to the slow inhibitor D-xylulose-1,5-bisphosphate were studied. The lessening in slow inhibition was not caused by reduced production of inhibitory side products. Except for pyruvate production, these reactions were strongly enhanced by the mutation, as was the ability to catalyze the carboxylation of D-xylulose-1,5-bisphosphate. Rather, reduced inhibition was the result of lessened sensitivity to these inhibitors. The slow isomerization phase that characterizes inhibition of the wild-type enzyme by D-xylulose-1,5-bisphosphate was completely eliminated by the mutation, and the mutant was more adept than the wild type in catalyzing the benzylic acid-type rearrangement of D-glycero-2,3-pentodiulose1,5-bisphosphate (produced by oxidation of the substrate, D-ribulose-1,5-bisphosphate). These observations are consistent with increased flexibility of loop 6 induced by the mutation, and they reveal the underlying mechanisms by which the side reactions cause slow inhibition.	Australian Natl Univ, Res Sch Biol Sci, Mol Plant Physiol Grp, Canberra, ACT 2601, Australia	Australian National University	Andrews, TJ (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Mol Plant Physiol Grp, POB 475, Canberra, ACT 2601, Australia.			Pearce, Frederick/0000-0002-2683-0331				Andersson I, 2003, ARCH BIOCHEM BIOPHYS, V414, P130, DOI 10.1016/S0003-9861(03)00164-4; ANDREWS TJ, 1991, J BIOL CHEM, V266, P9447; Andrews TJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P159, DOI 10.1016/S0003-9861(03)00100-0; ANDREWS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P3660, DOI 10.1073/pnas.81.12.3660; BERRY JA, 1987, P NATL ACAD SCI USA, V84, P734, DOI 10.1073/pnas.84.3.734; BYRNE WL, 1954, BIOCHIM BIOPHYS ACTA, V14, P495, DOI 10.1016/0006-3002(54)90229-2; CHEN YR, 1995, J BIOL CHEM, V270, P11741, DOI 10.1074/jbc.270.20.11741; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1383, DOI 10.1104/pp.93.4.1383; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; Flachmann R, 1997, PLANT PHYSIOL, V114, P131, DOI 10.1104/pp.114.1.131; GUTTERIDGE S, 1986, NATURE, V324, P274, DOI 10.1038/324274a0; HARPEL MR, 1995, BIOCHEMISTRY-US, V34, P11296, DOI 10.1021/bi00035a039; Harpel MR, 1996, BIOCHEMISTRY-US, V35, P13865, DOI 10.1021/bi962184t; Hernandez JM, 1996, J BACTERIOL, V178, P347, DOI 10.1128/jb.178.2.347-356.1996; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; Kane HJ, 1998, PLANT PHYSIOL, V117, P1059, DOI 10.1104/pp.117.3.1059; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUNG SD, 1980, METHODS ENZYMOL    C, V69, P326; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1994, J BIOL CHEM, V269, P11114; LEE EH, 1993, J BIOL CHEM, V268, P26583; LILLEY RM, 1974, BIOCHIM BIOPHYS ACTA, V358, P226, DOI 10.1016/0005-2744(74)90274-5; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; LORING HS, 1956, J AM CHEM SOC, V78, P3724, DOI 10.1021/ja01596a048; MCCURRY SD, 1977, J BIOL CHEM, V252, P8344; Mizohata E, 2003, BIOCHEM BIOPH RES CO, V301, P591, DOI 10.1016/S0006-291X(02)03057-7; Morell MK, 1997, J BIOL CHEM, V272, P5445, DOI 10.1074/jbc.272.9.5445; MORELL MK, 1994, J BIOL CHEM, V269, P8091; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; Parry MAJ, 2003, J EXP BOT, V54, P1321, DOI 10.1093/jxb/erg141; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; Roy Harry, 2000, VVolume 9, P53; SCHLOSS JV, 1988, J BIOL CHEM, V263, P4145; SEEMANN JR, 1985, P NATL ACAD SCI USA, V82, P8024, DOI 10.1073/pnas.82.23.8024; SERVAITES JC, 1985, ARCH BIOCHEM BIOPHYS, V238, P154, DOI 10.1016/0003-9861(85)90151-1; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; Uemura K, 1998, PLANT CELL PHYSIOL, V39, P212, DOI 10.1093/oxfordjournals.pcp.a029359; VANDYK DE, 1986, BIOCHEMISTRY-US, V25, P5145, DOI 10.1021/bi00366a024; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579; YOKOTA A, 1991, PLANT CELL PHYSIOL, V32, P755; Zhu GH, 1998, PHOTOSYNTH RES, V55, P67, DOI 10.1023/A:1005989012003; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	53	57	58	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32526	32536		10.1074/jbc.M305493200	http://dx.doi.org/10.1074/jbc.M305493200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12783874	hybrid			2022-12-25	WOS:000184901800008
J	Huster, D; Lutsenko, S				Huster, D; Lutsenko, S			The distinct roles of the N-terminal copper-binding sites in regulation of catalytic activity of the Wilson's disease protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTING ATPASE ATP7B; P-TYPE ATPASE; DEPENDENT TRAFFICKING; DOMAIN; EXPRESSION; MECHANISM; MUTATION; CELLS; MOTIF	Wilson's disease protein (WNDP) is a copper-transporting ATPase essential for normal distribution of copper in human cells. Recent studies demonstrate that copper regulates WNDP through several mechanisms. Six metal-binding sites (MBS) at the N terminus of WNDP are predicted to be involved in copper-dependent regulation of WNDP; however, specific roles of MBS remain poorly understood. To address this issue, we generated WNDP variants with mutations or truncation in the N-terminal region and characterized their functional properties. We show that copper cooperatively stimulates catalytic activity of WNDP and that this effect requires the presence of both MBS5 and MBS6. Mutations of MBS6 or MBS1-5 result in non-cooperative activation of the enzyme by copper, whereas the deletion of MBS1-4 does not abolish cooperativity. Our data further suggest that MBS5 and MBS6 together regulate the affinity of the intramembrane-binding site(s) for copper. Analysis of the copper-dependent stimulation of catalytic phosphorylation demonstrate that the MBS6 and MBS1-5 mutants have a 7-8-fold lower EC50 for copper activation, suggesting that their affinity for copper is increased. This conclusion is confirmed by a markedly decreased inhibition of these mutants by a copper chelator bathocuproine disulphonate. In contrast, deletion of MBS1-4 does not affect the affinity of sites important for catalytic phosphorylation. Rather, the MBS1-4 region appears to control access of copper to the functionally important metal-binding sites. The implications of these findings for intracellular regulation of WNDP are discussed.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.				NIDDK NIH HHS [DK55719] Funding Source: Medline; NIGMS NIH HHS [1-P01-GM067166-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bal N, 2003, BIOCHEM J, V369, P681, DOI 10.1042/BJ20021416; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; DiDonato M, 1999, ADV EXP MED BIOL, V448, P165; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Jensen PY, 1999, BBA-PROTEIN STRUCT M, V1434, P103, DOI 10.1016/S0167-4838(99)00161-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 1997, ANN NY ACAD SCI, V834, P155, DOI 10.1111/j.1749-6632.1997.tb52246.x; Mercer JFB, 2003, BIOMETALS, V16, P175, DOI 10.1023/A:1020719016675; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Tsivkovskii R, 2003, J BIOL CHEM, V278, P13302, DOI 10.1074/jbc.M300034200; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Vanderwerf SM, 2001, J BIOL CHEM, V276, P36289, DOI 10.1074/jbc.M102055200; Voskoboinik I, 2002, ADV PROTEIN CHEM, V60, P123; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258	29	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32212	32218		10.1074/jbc.M305408200	http://dx.doi.org/10.1074/jbc.M305408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794172	hybrid			2022-12-25	WOS:000184782100095
J	Barsukov, IL; Prescot, A; Bate, N; Patel, B; Floyd, DN; Bhanji, N; Bagshaw, CR; Letinic, K; Di Paolo, G; De Camilli, P; Roberts, GCK; Critchley, DR				Barsukov, IL; Prescot, A; Bate, N; Patel, B; Floyd, DN; Bhanji, N; Bagshaw, CR; Letinic, K; Di Paolo, G; De Camilli, P; Roberts, GCK; Critchley, DR			Phosphatidylinositol phosphate kinase type 1 gamma and beta(1)-Integrin cytoplasmic domain bind to the same region in the talin FERM domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEIN TALIN; C-TERMINAL REGIONS; VINCULIN-BINDING; CELL-ADHESION; FUNCTIONAL DOMAINS; INTEGRIN BINDING; FOCAL ADHESIONS; ACTIN-BINDING; STRESS FIBERS; SITES	Talin is an essential component of focal adhesions that couples beta-integrin cytodomains to F-actin and provides a scaffold for signaling proteins. Recently, the integrin beta(3) cytodomain and phosphatidylinositol phosphate (PIP) kinase type 1gamma (a phosphatidylinositol 4,5-bisphosphate-synthesizing enzyme) were shown to bind to the talin FERM domain (subdomain F3). We have characterized the PIP kinase-binding site by NMR using a N-15-labeled talin F2F3 polypeptide. A PIP kinase peptide containing the minimal talin-binding site formed a 1:1 complex with F2F3, causing a substantial number of chemical shift changes. In particular, two of the three Arg residues (Arg(339) and Arg(358)), four of eight Ile residues, and one of seven Val residues in F3 were affected. Although a R339A mutation did not affect the exchange kinetics, R358A or R358K mutations markedly weakened binding. The K-d for the interaction determined by Trp fluorescence was 6 muM, and the R358A mutation increased the K-d to 35 muM. Comparison of these results with those of the crystal structure of a beta(3)-integrin cytodomain talin F2F3 chimera shows that both PIP kinase and integrins bind to the same surface of the talin F3 subdomain. Indeed, binding of talin present in rat brain extracts to a glutathione S-transferase integrin beta(1)-cytodomain polypeptide was inhibited by the PIP kinase peptide. The results suggest that ternary complex formation with a single talin FERM domain is unlikely, although both integrins and PIP kinase may bind simultaneously to the talin anti-parallel dimer.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	University of Leicester; Howard Hughes Medical Institute; Yale University; Yale University	Critchley, DR (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.		Bagshaw, Clive R./L-5484-2019	Bagshaw, Clive R./0000-0002-5396-153X; Roberts, Gordon/0000-0001-6200-1373				ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bolton SJ, 1997, CELL MOTIL CYTOSKEL, V36, P363; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hemler M. E., 1999, GUIDEBOOK EXTRACELLU, P196; Hemmings L, 1996, J CELL SCI, V109, P2715; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; Liddington RC, 2003, CURR BIOL, V13, pR94, DOI 10.1016/S0960-9822(03)00035-6; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; Manes S, 1999, MOL CELL BIOL, V19, P3125; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; McCann RO, 1999, BIOCHEM BIOPH RES CO, V266, P135, DOI 10.1006/bbrc.1999.1776; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; NIGGLI V, 1994, EUR J BIOCHEM, V224, P951, DOI 10.1111/j.1432-1033.1994.00951.x; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Schmidt JM, 1999, ARCH BIOCHEM BIOPHYS, V366, P139, DOI 10.1006/abbi.1999.1204; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Weernink PAO, 2000, EUR J BIOCHEM, V267, P5237, DOI 10.1046/j.1432-1327.2000.01599.x; Winkler J, 1997, EUR J BIOCHEM, V243, P430, DOI 10.1111/j.1432-1033.1997.0430a.x; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	48	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31202	31209		10.1074/jbc.M303850200	http://dx.doi.org/10.1074/jbc.M303850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782621	hybrid			2022-12-25	WOS:000184658800098
J	Boot-Handford, RP; Tuckwell, DS; Plumb, DA; Rock, CF; Poulsom, R				Boot-Handford, RP; Tuckwell, DS; Plumb, DA; Rock, CF; Poulsom, R			A novel and highly conserved collagen (pro alpha 1(XXVII)) with a unique expression pattern and unusual molecular characteristics establishes a new clade within the vertebrate fibrillar collagen family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; IDENTIFICATION; DUPLICATION; EVOLUTION; MATRICES; SEQUENCE; MEMBER; HYDRA; BONE	The type XXVII collagen gene codes for a novel vertebrate fibrillar collagen that is highly conserved in man, mouse, and fish (Fugu rubripes). The proalpha1(XXVII) chain has a domain structure similar to that of the type B clade chains (alpha1(V), alpha3(V), alpha1(XI), and alpha2(XI)). However, compared with other vertebrate fibrillar collagens (types I, II, III, V, and XI), type XXVII collagen has unusual molecular features such as no minor helical domain, a major helical domain that is short and interrupted, and a short chain selection sequence within the NC1 domain. Proalpha1(XXVII) mRNA is 9 kb and expressed by chondrocytes but also by a variety of epithelial cell layers in developing tissues including stomach, lung, gonad, skin, cochlear, and tooth. By Western blotting, type XXVII antisera recognized multiple bands of 240 110 kDa in tissue extracts and collagenous bands of 150 140 kDa in the conditioned medium of the differentiating chondrogenic ATDC5 cell line. Phylogenetic analyses revealed that type XXVII, together with the closely related type XXIV collagen gene, form a new, third clade (type C) within the vertebrate fibrillar collagen family. Furthermore, the exon structure of the type XXVII collagen gene is similar to, but distinct from, those of the genes coding for the type A or B clade proalpha chains.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Canc Res UK, Histopathol Unit, London WC2A 3PX, England	University of Manchester; Cancer Research UK	Boot-Handford, RP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford, Manchester M13 9PT, Lancs, England.			Boot-Handford, Raymond/0000-0002-6167-8419				AYAD S, 1998, EXTRACELLULAR MATRIX, P43; Bailey WJ, 1997, MOL BIOL EVOL, V14, P843, DOI 10.1093/oxfordjournals.molbev.a025825; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Chen YW, 2001, MATRIX BIOL, V20, P589, DOI 10.1016/S0945-053X(01)00169-X; Chu M., 2002, CONNECTIVE TISSUE IT, P223, DOI [10.1002/0471221929.ch2(ii), DOI 10.1002/0471221929.CH2(II)]; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Deutzmann R, 2000, DEVELOPMENT, V127, P4669; Felsenstein J., 1993, PHYLOGENETIC INFEREN; FICHARD A, 1994, MATRIX BIOL, V14, P515; Fowler SJ, 2000, J BIOL CHEM, V275, P39589, DOI 10.1074/jbc.M005871200; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Holland PWH, 1999, SEMIN CELL DEV BIOL, V10, P541, DOI 10.1006/scdb.1999.0335; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Poulsom R, 1998, EUR J HISTOCHEM, V42, P121; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Sicot FX, 1997, EUR J BIOCHEM, V246, P50, DOI 10.1111/j.1432-1033.1997.00050.x; Taylor JS, 2001, PHILOS T R SOC B, V356, P1661, DOI 10.1098/rstb.2001.0975; Tuckwell D, 2002, MATRIX BIOL, V21, P63, DOI 10.1016/S0945-053X(01)00176-7	25	104	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31067	31077		10.1074/jbc.M212889200	http://dx.doi.org/10.1074/jbc.M212889200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12766169	hybrid			2022-12-25	WOS:000184658800083
J	Hatsuzawa, K; Lang, T; Fasshauer, D; Bruns, D; Jahn, R				Hatsuzawa, K; Lang, T; Fasshauer, D; Bruns, D; Jahn, R			The R-SNARE motif of tomosyn forms SNARE core complexes with syntaxin 1 and SNAP-25 and down-regulates exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; NERVE GROWTH-FACTOR; MEMBRANE-FUSION; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; CRYSTAL-STRUCTURE; IDENTIFICATION; DROSOPHILA; HOMOLOG; RELEASE	Tomosyn is a 130-kDa syntaxin-binding protein that contains a large N-terminal domain with WD40 repeats and a C-terminal domain homologous to R-SNAREs. Here we show that tomosyn forms genuine SNARE core complexes with the SNAREs syntaxin 1 and SNAP-25. In vitro studies with recombinant proteins revealed that complex formation proceeds from unstructured monomers to a stable four-helical bundle. The assembled complex displayed features typical for SNARE core complexes, including a profound hysteresis upon unfolding-refolding transitions. No stable complexes were formed between the SNARE motif of tomosyn and either syntaxin or SNAP-25 alone. Furthermore, both native tomosyn and its isolated C-terminal domain competed with synaptobrevin for binding to endogenous syntaxin and SNAP-25 on inside-out sheets of plasma membranes. Tomosyn-SNARE complexes were effectively disassembled by the ATPase N-ethylmaleimide-sensitive factor together with its cofactor alpha-SNAP. Moreover, the C-terminal domain of tomosyn was as effective as the cytoplasmic portion of synaptobrevin in inhibiting evoked exocytosis in a cell-free preparation derived from PC12 cells. Similarly, overexpression of tomosyn in PC12 cells resulted in a massive reduction of exocytosis, but the release parameters of individual exocytotic events remained unchanged. We conclude that tomosyn is a soluble SNARE that directly competes with synaptobrevin in the formation of SNARE complexes and thus may function in down-regulating exocytosis.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany.		Fasshauer, Dirk/B-1563-2013	Fasshauer, Dirk/0000-0002-1040-4282; Jahn, Reinhard/0000-0003-1542-3498				Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Avery J, 2000, J CELL BIOL, V148, P317, DOI 10.1083/jcb.148.2.317; Bruns D, 2000, NEURON, V28, P205, DOI 10.1016/S0896-6273(00)00097-0; Bruns D, 1998, METHOD ENZYMOL, V296, P593; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chen YA, 2001, J BIOL CHEM, V276, P26680, DOI 10.1074/jbc.M103522200; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kim YS, 2002, INT J ONCOL, V20, P1219; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TATA F, 1993, DEVELOPMENT, P139; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yokoyama S, 1999, BIOCHEM BIOPH RES CO, V256, P218, DOI 10.1006/bbrc.1999.0300	33	98	105	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31159	31166		10.1074/jbc.M305500200	http://dx.doi.org/10.1074/jbc.M305500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782620	Green Published, hybrid			2022-12-25	WOS:000184658800093
J	Yen, HCS; Espiritu, C; Chang, EC				Yen, HCS; Espiritu, C; Chang, EC			Rpn5 is a conserved proteasome subunit and required for proper proteasome localization and assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26 S PROTEASE; FISSION YEAST; REGULATORY PARTICLE; ATPASE SUBUNIT; GENE; DEGRADATION; MITOSIS; COMPLEXES; EFFICIENT; INTERACTS	Proper function of the 26 S proteasome requires assembly of the regulatory complex, which is composed of the lid and base subcomplexes. We characterized Rpn5, a lid subunit, in fission yeast. We show that Rpn5 associates with the proteasome rpn5. Deletion (rpn5Delta) exacerbates the growth defects in proteasome mutants, leading to mitotic abnormalities, which correlate with accumulation of polyubiquitinated proteins, such as Cut2/securin. Rpn5 expression is tightly controlled; both overexpression and deletion of rpn5 impair proteasome functions. The proteasome is assembled around the inner nuclear membrane in wild-type cells; however, in rpn5Delta cells, proteasome subunits are improperly assembled and/or localized. In the lid mutants, Rpn5 is mislocalized in the cytosol, while in the base mutants, Rpn5 can enter the nucleus, but is left in the nucleoplasm, and not assembled into the nuclear membrane. These results suggest that Rpn5 is a dosage-dependent proteasome regulator and plays a role in mediating proper proteasome assembly. Moreover, the Rpn5 assembly may be a cooperative process that involves at least two steps: 1) nuclear import and 2) subsequent assembly into the nuclear membrane. The former step requires other components of the lid, while the latter requires the base. Human Rpn5 rescues the phenotypes associated with rpn5Delta and is incorporated into the yeast proteasome, suggesting that Rpn5 functions are highly conserved.	Baylor Coll Med, Methodist Hosp, Dept Mol & Cellular Biol, Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Chang, EC (corresponding author), Baylor Coll Med, Methodist Hosp, Dept Mol & Cellular Biol, Breast Ctr, Houston, TX 77030 USA.	echang@breastcenter.tmc.edu	Yen, Hsueh-Chi Sherry/AAA-3907-2021	Yen, Hsueh-Chi Sherry/0000-0003-3511-4414	NATIONAL CANCER INSTITUTE [R01CA090464] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA90464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfa C., 1993, EXPT FISSION YEAST; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; Berry LD, 1999, MOL CELL BIOL, V19, P2535; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lehmann A, 2002, J MOL BIOL, V317, P401, DOI 10.1006/jmbi.2002.5443; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Penney M, 1998, J BIOL CHEM, V273, P23938, DOI 10.1074/jbc.273.37.23938; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Saito A, 1997, GENE, V203, P241, DOI 10.1016/S0378-1119(97)00524-6; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Wilkinson CRM, 1997, J BIOL CHEM, V272, P25768, DOI 10.1074/jbc.272.41.25768; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370	31	31	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30669	30676		10.1074/jbc.M302093200	http://dx.doi.org/10.1074/jbc.M302093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783882	hybrid			2022-12-25	WOS:000184658800032
J	Lock, LS; Frigault, MM; Saucier, C; Park, M				Lock, LS; Frigault, MM; Saucier, C; Park, M			Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the met receptor kinase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; DOCKING PROTEIN GAB1; GRB2 BINDING-SITE; EPITHELIAL MORPHOGENESIS DOWNSTREAM; SIGNAL-REGULATED KINASE; IRS-1 PTB DOMAIN; TYROSINE KINASE; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-TRANSFORMATION	The Gab1 docking protein forms a platform for the assembly of a multiprotein signaling complex downstream from receptor tyrosine kinases. In general, recruitment of Gab1 occurs indirectly, via the adapter protein Grb2. In addition, Gab1 interacts with the Met/hepatocyte growth factor receptor in a Grb2-independent manner. This interaction requires a Met binding domain (MBD) in Gab1 and is essential for Met-mediated epithelial morphogenesis. The Gab1 MBD has been proposed to act as a phosphotyrosine binding domain that binds Tyr-1349 in the Met receptor. We show that a 16-amino acid motif within the Gab1 MBD is sufficient for interaction with the Met receptor, suggesting that it is unlikely that the Gab1 MBD forms a structured domain. Alternatively, the structural integrity of the Met receptor, and residues upstream of Tyr-1349 located in the C-terminal lobe of the kinase domain, are required for Grb2-independent interaction with the Gab1 MBD. Moreover, the substitution of Tyr-1349 with an acidic residue allows for the recruitment of the Gab1 MBD and for phosphorylation of Gab1. We propose that Gab1 and the Met receptor interact in a novel manner, such that the activated kinase domain of Met and the negative charge of phosphotyrosine 1349 engage the Gab1 MBD as an extended peptide ligand.	McGill Univ, Ctr Hlth, Dept Biochem, Mol Oncol Grp H5 10, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp H5 10, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Mol Oncol Grp H5 10, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Dept Biochem, Mol Oncol Grp H5 10, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	morag@molonc.mcgill.ca	Saucier, Caroline/Q-9250-2019	Saucier, Caroline/0000-0001-7678-9886				Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bausenwein BS, 2000, MECH DEVELOP, V90, P205, DOI 10.1016/S0925-4773(99)00252-X; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HURLEY JH, 1992, BIOPOLYMERS, V32, P1443, DOI 10.1002/bip.360321104; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Lamorte L, 2002, J BIOL CHEM, V277, P37904, DOI 10.1074/jbc.M201743200; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nollau P, 2001, P NATL ACAD SCI USA, V98, P13531, DOI 10.1073/pnas.241215998; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Saxton TM, 2001, CURR BIOL, V11, P662, DOI 10.1016/S0960-9822(01)00198-1; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Van Obberghen E, 2001, EUR J CLIN INVEST, V31, P966, DOI 10.1046/j.1365-2362.2001.00896.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	64	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30083	30090		10.1074/jbc.M302675200	http://dx.doi.org/10.1074/jbc.M302675200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766170	hybrid			2022-12-25	WOS:000184507000085
J	Suzuki, T; Muto, S; Miyamoto, S; Aizawa, K; Horikoshi, M; Nagai, R				Suzuki, T; Muto, S; Miyamoto, S; Aizawa, K; Horikoshi, M; Nagai, R			Functional interaction of the DNA-binding transcription factor Sp1 through its DNA-binding domain with the histone chaperone TAF-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING FACTOR-I; REPLICATION FACTOR; ADENOVIRUS GENOME; NUCLEAR RECEPTORS; 3 FINGERS; COACTIVATOR; MECHANISM; COMPLEXES; TEMPLATE; HOMOLOG	Transcription involves molecular interactions between general and regulatory transcription factors with further regulation by protein-protein interactions (e.g. transcriptional cofactors). Here we describe functional interaction between DNA-binding transcription factor and histone chaperone. Affinity purification of factors interacting with the DNA-binding domain of the transcription factor Sp1 showed Sp1 to interact with the histone chaperone TAF-I, both alpha and beta isoforms. This interaction was specific as Sp1 did not interact with another histone chaperone CIA nor did other tested DNA-binding regulatory factors (MyoD, NFkappaB, p53) interact with TAF-I. Interaction of Sp1 and TAF-I occurs both in vitro and in vivo. Interaction with TAF-I results in inhibition of DNA-binding, and also likely as a result of such, inhibition of promoter activation by Sp1. Collectively, we describe interaction between DNA-binding transcription factor and histone chaperone which results in negative regulation of the former. This novel regulatory interaction advances our understanding of the mechanisms of eukaryotic transcription through DNA-binding regulatory transcription factors by protein-protein interactions, and also shows the DNA-binding domain to mediate important regulatory interactions.	Univ Tokyo, Dept Cardiovasc Med, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Clin Bioinformat, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dev Biol Lab, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Corp, Horikoshi Gene Selector Project, Exploratory Res Adv Technol ERATO, Tsukuba, Ibaraki 3002635, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Suzuki, T (corresponding author), Univ Tokyo, Dept Cardiovasc Med, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	torusuzu-tky@umin.ac.jp; nagai-tky@umin.ac.jp		Suzuki, Toru/0000-0002-8371-664X				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Ando S, 2002, MOL CELL BIOL, V22, P2229, DOI 10.1128/MCB.22.7.2229-2241.2002; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HAI TW, 1998, CELL, V54, P1043; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; MATSUMOTO K, 1995, J BIOL CHEM, V270, P9645, DOI 10.1074/jbc.270.16.9645; Matsumoto K, 1999, FEBS LETT, V463, P285, DOI 10.1016/S0014-5793(99)01632-4; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Munakata T, 2000, GENES CELLS, V5, P221, DOI 10.1046/j.1365-2443.2000.00319.x; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; WAGNER S, 1994, CURR OPIN CELL BIOL, V6, P410, DOI 10.1016/0955-0674(94)90034-5; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	47	41	41	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28758	28764		10.1074/jbc.M302228200	http://dx.doi.org/10.1074/jbc.M302228200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759364	hybrid			2022-12-25	WOS:000184421100052
J	Oshiro, MM; Watts, GS; Wozniak, RJ; Junk, DJ; Munoz-Rodriguez, JL; Domann, FE; Futscher, BW				Oshiro, MM; Watts, GS; Wozniak, RJ; Junk, DJ; Munoz-Rodriguez, JL; Domann, FE; Futscher, BW			Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression	ONCOGENE			English	Article						methylation; p53; tumor suppressor; azacytidine; breast cancer; maspin	HUMAN BREAST CARCINOMAS; CLONAL CHROMOSOME-ABNORMALITIES; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; CELL-LINES; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; BINDING PROTEIN; MASPIN GENE; CANCER	p53 is an important transcriptional regulator that is frequently mutated in cancer. Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters. Despite the transcriptional repression of these genes by aberrant DNA methylation, restoration of p53 resulted in the partial reactivation of both genes. This reactivation is a result of wt p53 binding to its consensus DNA-binding sites within the MASPIN and DSC3 promoters, stimulating histone acetylation, and enhancing chromatin accessibility of their promoters. Interestingly, wt p53 alone did not affect the methylation status of either promoter, suggesting that p53 itself can partially overcome the repressive barrier of DNA methylation. Pharmacologic inhibition of DNA methylation with 5-aza-2'-deoxycytidine in combination with restoration of wt p53 status resulted in a synergistic reactivation of these genes to near-normal levels. These results suggest that cancer treatments that target both genetic and epigenetic facets of gene regulation may be a useful strategy towards the therapeutic transcriptional reprogramming of cancer cells.	Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Iowa; University of Iowa	Futscher, BW (corresponding author), Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA.		Rodríguez, Jose Manuel JMMR Muñoz/A-7323-2016	Rodríguez, Jose Manuel JMMR Muñoz/0000-0002-4688-6420; Junk, Damian/0000-0002-9251-3799; Domann, Frederick/0000-0002-0489-2179	NCI NIH HHS [P30 CA023074] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan J, 1998, CANCER RES, V58, P5009; Klus GT, 2001, INT J ONCOL, V19, P169; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Seftor REB, 1998, CANCER RES, V58, P5681; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Streuli CH, 2002, BREAST CANCER RES, V4, P137, DOI 10.1186/bcr437; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhao RB, 2000, GENE DEV, V14, P981; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	44	77	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3624	3634		10.1038/sj.onc.1206545	http://dx.doi.org/10.1038/sj.onc.1206545			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789271				2022-12-25	WOS:000183399200013
J	Kunzmann, S; Mantel, PY; Wohlfahrt, JG; Akdis, M; Blaser, K; Schmidt-Weber, CB				Kunzmann, S; Mantel, PY; Wohlfahrt, JG; Akdis, M; Blaser, K; Schmidt-Weber, CB			Histamine enhances TGF-beta 1-mediated suppression of Th2 responses	FASEB JOURNAL			English	Article						transforming growth factor beta 1; CD4(+) T cells; cAMP/PKA pathway; nucleofection	GROWTH-FACTOR-BETA; T-CELL; PROTEIN-KINASE; ALLERGIC DISEASES; HUMAN LYMPHOCYTES; FUNCTIONAL-CHARACTERIZATION; 2 PARTS; RECEPTOR; EXPRESSION; IDENTIFICATION	Susceptibility of T cells to TGF-beta1 produced by regulatory T cells has an important impact on the induction and maintenance of peripheral tolerance and therefore on the development of autoimmunity, cancer, and allergy. Histamine not only mediates the deleterious effects of allergic reactions, it can also modulate the Th1/Th2 cell balance. We demonstrate that histamine dose-dependently enhanced TGF-beta1-mediated suppression and TGF-beta1 responsiveness of CD4(+) T cells. This effect was mediated by the histamine 2 receptor (H2R), as demonstrated by receptor-specific agonists and antagonists. Furthermore, the histamine effect on TGF-beta1 responsiveness was cAMP/PKA dependent. This pathway is activated by the H2R, which is preferentially expressed on Th2 cells. Thus a higher additive effect of histamine on TGF-beta1 responsiveness was found in Th2 cells compared with Th1 cells. In fact, findings are confirmed by analysis of cytokine regulation, since activation of the H2R/cAMP pathway promoted TGF-beta1-mediated IL-4 inhibition but was ineffective in suppressing IFN-gamma. These results demonstrate that histamine supports TGF-beta1 susceptibility of T cells. Moreover, Th2 cells are more affected by histamine-enhanced TGF-beta1 suppression, which is particularly important for the regulation of allergen-specific T cells in allergic immune responses.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Schmidt-Weber, CB (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	csweber@siaf.unizh.ch	Schmidt-Weber, Carsten B./AAU-1621-2021; Mantel, Pierre-Yves/N-3065-2015; Akdis, Cezmi/AAV-4844-2020	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Mantel, Pierre-Yves/0000-0001-9526-9309; Akdis, Cezmi/0000-0001-8020-019X				ADAMS GK, 1979, J IMMUNOL, V122, P555; Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Bachert C, 2002, ALLERGY, V57, P287, DOI 10.1034/j.1398-9995.2002.1r3542.x; Bitzer M, 2000, GENE DEV, V14, P187; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; DelValle J, 1997, AM J PHYSIOL-GASTR L, V273, pG987, DOI 10.1152/ajpgi.1997.273.5.G987; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Drutel G, 2001, MOL PHARMACOL, V59, P1; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P85, DOI 10.1067/mai.2002.124770a; HAAKSMA EEJ, 1990, PHARMACOL THERAPEUT, V47, P73, DOI 10.1016/0163-7258(90)90046-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL SJ, 1990, PHARMACOL REV, V42, P45; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEMP BE, 1975, BIOCHEM J, V145, P241, DOI 10.1042/bj1450241; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; MURRAY AW, 1972, BIOCHEM J, V129, P995, DOI 10.1042/bj1290995a; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Poluektova LY, 1999, IMMUNOPHARMACOLOGY, V41, P77, DOI 10.1016/S0162-3109(98)00057-5; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Schmidt-Weber Carsten B, 2002, Curr Allergy Asthma Rep, V2, P259, DOI 10.1007/s11882-002-0028-8; Schmidt-Weber CB, 2002, ALLERGY, V57, P762, DOI 10.1034/j.1398-9995.2002.02158.x; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smit MJ, 1999, CLIN EXP ALLERGY, V29, P19, DOI 10.1046/j.1365-2222.1999.00008.x; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; ZHENG T, 1994, J IMMUNOL, V153, P4742; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434	39	77	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1089	1095		10.1096/fj.02-1008com	http://dx.doi.org/10.1096/fj.02-1008com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773491				2022-12-25	WOS:000183818000012
J	Ilangovan, R; Marshall, WL; Hua, YM; Zhou, JH				Ilangovan, R; Marshall, WL; Hua, YM; Zhou, JH			Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; DROSOPHILA-MELANOGASTER CELLS; MOTOR-NEURON PROTEIN; CASPASE DRONC; CYTOCHROME-C; DEATH; GENE; DIAP1; GRIM; ORTHOLOGUE	Spinal muscular atrophy is an autosomal recessive motor neuron degenerative disorder, caused by the loss of telomeric copy of the survival motor neuron gene (SMN1). To better understand how motor neurons are targeted in Spinal muscular atrophy patients, it is important to study the role of SMN protein in cell death. In this report, we employed RNA interference (RNAi) to study the loss-of-function of SMN in Drosophila S2 cells. A 601-base pair double-stranded RNA (dsRNA) of Drosophila SMN (dSMN) was used for silencing the dSMN. Our data indicate that dSMN RNAi resulted in more than 90% reduction of both RNA and protein. Further analysis of S2 cells by cell death ELISA and flow cytometry assays revealed that reduction of dSMN expression significantly increased apoptosis. The cell death mediated by SMN depletion is caspase-dependent and specifically due to the activation of the endogenous caspases, DRONC and DRICE. Significantly, the effect of dSMN RNAi was reversed by a peptide caspase inhibitor, Z-VAD-fmk. These results suggest that dSMN is involved in signal pathways of apoptotic cell death in Drosophila. Hence, the model system of reduced SMN expression by RNAi in Drosophila could be exploited for identification of therapeutic targets.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Zhou, JH (corresponding author), Univ Massachusetts, Sch Med, Dept Med, 364 Plantat St,LRB325, Worcester, MA 01605 USA.		Hua, Yimin/U-6911-2018	Hua, Yimin/0000-0003-0905-7989	NINDS NIH HHS [NS-41665] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041665] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dodds E, 2001, FEBS LETT, V495, P31, DOI 10.1016/S0014-5793(01)02330-4; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Earnshaw WC, 1999, NATURE, V397, P387, DOI 10.1038/17015; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; King MA, 2002, CYTOMETRY, V49, P28, DOI 10.1002/cyto.10141; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Miguel-Aliaga I, 2000, FEBS LETT, V486, P99, DOI 10.1016/S0014-5793(00)02243-2; Monani UR, 2000, HUM MOL GENET, V9, P2451, DOI 10.1093/hmg/9.16.2451; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Paushkin S, 2000, J BIOL CHEM, V275, P23841, DOI 10.1074/jbc.M001441200; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Vitali T, 1999, HUM MOL GENET, V8, P2525, DOI 10.1093/hmg/8.13.2525; Volbracht C, 2001, MOL MED, V7, P36, DOI 10.1007/BF03401837; Vyas S, 2002, HUM MOL GENET, V11, P2751, DOI 10.1093/hmg/11.22.2751; Wang J, 2001, J BIOL CHEM, V276, P9599, DOI 10.1074/jbc.M009162200; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Young PJ, 2002, J BIOL CHEM, V277, P2852, DOI 10.1074/jbc.M108769200; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	49	40	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30993	30999		10.1074/jbc.M303763200	http://dx.doi.org/10.1074/jbc.M303763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783893	hybrid			2022-12-25	WOS:000184658800074
J	Pikas, DS; Brown, EL; Gurusiddappa, S; Lee, LY; Xu, Y; Hook, M				Pikas, DS; Brown, EL; Gurusiddappa, S; Lee, LY; Xu, Y; Hook, M			Decorin-binding sites in the adhesin DbpA from Borrelia burgdorferi - A synthetic peptide approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME-DISEASE SPIROCHETE; REPEAT PROTEIN FAMILY; HUMAN PLATELETS; IDENTIFICATION; ARTHRITIS; EXPRESSION; LIGAND; GENE; PROTEOGLYCANS; ADHERENCE	Lyme disease is caused by the spirochete Borrelia burgdorferi following transmission from infected Ixodes ticks to human hosts. Following colonization of the skin, spirochetes can disseminate throughout the body, resulting in complications that can include ocular, cardiac, neural, and skeletal disease. We have previously shown that B. burgdorferi expresses two closely related decorin-binding adhesins (DbpA and DbpB) of the MSCRAMM (microbial surface component recognizing adhesive matrix molecule) type that can mediate bacterial attachment to extracellular matrices in the host. Furthermore, three Lys residues in DbpA appear to be critical for the binding of DbpA to decorin. We have now characterized the interaction of DbpA and decorin further by using a synthetic peptide approach. We synthesized a panel of peptides that spanned the DbpA sequence and examined their ability to inhibit the binding of intact DbpA to decorin. From these studies, we identified a decorin-binding peptide that lost this activity if the sequence was either scrambled or if a critical Lys residue was chemically modified. A minimal decorin-binding peptide was identified by examining a set of truncated peptides. One peptide is proposed to contain the primary decorin-binding site in DbpA. By comparing the amino acid sequences of 29 different DbpA homologs from different B. burgdorferi sensu lato isolates, we discovered that the identified decorin-binding sequence was quite variable. Therefore, we synthesized a new panel of peptides containing the putative decorin-binding sequence of the different DbpA homologs. All of these peptides were active in our decorin-binding assay, and consensus decorin binding motifs are discussed.	Texas A&M Univ, Hlth Sci Ctr, Albert B Alkek Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Hook, M (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Albert B Alkek Inst Biosci & Technol, Ctr Extracellular Matrix Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.				NIAMS NIH HHS [AR-44415] Funding Source: Medline; ODCDC CDC HHS [CCU618387] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); ODCDC CDC HHS; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Brown EL, 1999, J BIOL CHEM, V274, P26272, DOI 10.1074/jbc.274.37.26272; Brown EL, 2001, J CLIN INVEST, V107, P845, DOI 10.1172/JCI11692; Carroll JA, 2000, INFECT IMMUN, V68, P6677, DOI 10.1128/IAI.68.12.6677-6684.2000; Casjens S, 2000, J MOL MICROB BIOTECH, V2, P401; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COBURN J, 1993, P NATL ACAD SCI USA, V90, P7059, DOI 10.1073/pnas.90.15.7059; Coburn J, 1999, MOL MICROBIOL, V34, P926, DOI 10.1046/j.1365-2958.1999.01654.x; COBURN J, 1994, INFECT IMMUN, V62, P5559, DOI 10.1128/IAI.62.12.5559-5567.1994; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DATTWYLER RJ, 1987, ARTHRITIS RHEUM, V30, P448, DOI 10.1002/art.1780300414; Deutsch D, 2002, CONNECT TISSUE RES, V43, P425, DOI 10.1080/03008200290001186; Eicken C, 2001, J BIOL CHEM, V276, P10010, DOI 10.1074/jbc.M010062200; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Guo BP, 1998, MOL MICROBIOL, V30, P711, DOI 10.1046/j.1365-2958.1998.01103.x; GUO BP, 1995, INFECT IMMUN, V63, P3467, DOI 10.1128/IAI.63.9.3467-3472.1995; Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hubalek Z, 1997, EUR J EPIDEMIOL, V13, P951, DOI 10.1023/A:1007426304900; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; ISHII N, 1995, MICROBIOL IMMUNOL, V39, P929, DOI 10.1111/j.1348-0421.1995.tb03295.x; Liang FT, 2002, J EXP MED, V196, P275, DOI 10.1084/jem.20020770; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Ornstein K, 2002, SCAND J INFECT DIS, V34, P341, DOI 10.1080/00365540110080313; Parveen N, 2000, MOL MICROBIOL, V35, P1220, DOI 10.1046/j.1365-2958.2000.01792.x; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Revel AT, 2002, P NATL ACAD SCI USA, V99, P1562, DOI 10.1073/pnas.032667699; Roberts WC, 1998, INFECT IMMUN, V66, P5275, DOI 10.1128/IAI.66.11.5275-5285.1998; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; Trollmo C, 2001, J IMMUNOL, V166, P5286, DOI 10.4049/jimmunol.166.8.5286; Weis JJ, 2002, CURR OPIN RHEUMATOL, V14, P399, DOI 10.1097/00002281-200207000-00011	38	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30920	30926		10.1074/jbc.M303979200	http://dx.doi.org/10.1074/jbc.M303979200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12761224	hybrid			2022-12-25	WOS:000184658800065
J	Rosovitz, MJ; Schuck, P; Varughese, M; Chopra, AP; Mehra, V; Singh, Y; McGinnis, LM; Leppla, SH				Rosovitz, MJ; Schuck, P; Varughese, M; Chopra, AP; Mehra, V; Singh, Y; McGinnis, LM; Leppla, SH			Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; BACILLUS-ANTHRACIS; LETHAL FACTOR; MAMMALIAN-CELLS; I-DOMAIN; CRYSTAL-STRUCTURE; INTEGRIN; SURFACE; COMPONENT; COLLAGEN	A panel of variants with alanine substitutions in the small loop of anthrax toxin protective antigen domain 4 was created to determine individual amino acid residues critical for interactions with the cellular receptor and with a neutralizing monoclonal antibody, 14B7. Substituted protective antigen proteins were analyzed by cellular cytotoxicity assays, and their interactions with antibody were measured by plasmon surface resonance and analytical ultracentrifugation. Residue Asp(683) was the most critical for cell binding and toxicity, causing an similar to1000-fold reduction in toxicity, but was not a large factor for interactions with 14B7. Substitutions in residues Tyr(681), Asn(682), and Pro(686) also reduced toxicity significantly, by 10-100-fold. Of these, only Asn(682) and Pro(686) were also critical for interactions with 14B7. However, residues Lys(684), Leu(685), Leu(687), and Tyr(688) were critical for 14B7 binding without greatly affecting toxicity. The K684A and L685A variants exhibited wild type levels of toxicity in cell culture assays; the L687A and Y688A variants were reduced only 1.5- and 5-fold, respectively.	NIAID, Microbial Pathogenesis Sect, NIH, Bethesda, MD 20892 USA; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA; Inst Genom & Integrat Biol, Delhi 110007, India	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB)	Leppla, SH (corresponding author), NIAID, Microbial Pathogenesis Sect, NIH, Bldg 30,Rm 303,MSC 4350, Bethesda, MD 20892 USA.	Leppla@nih.gov	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000929, ZIAAI000929] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Ahuja N, 2001, BIOCHEM BIOPH RES CO, V287, P542, DOI 10.1006/bbrc.2001.5613; ARORA N, 1992, J BIOL CHEM, V267, P15542; BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brossier F, 1999, INFECT IMMUN, V67, P964, DOI 10.1128/IAI.67.2.964-967.1999; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; Kar SR, 2000, ANAL BIOCHEM, V285, P135, DOI 10.1006/abio.2000.4748; Khanna H, 2001, FEMS MICROBIOL LETT, V199, P27; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; Legge GB, 2002, PROTEINS, V48, P151, DOI 10.1002/prot.10134; Leppla SH, 2002, J CLIN INVEST, V110, P141, DOI [10.1172/JCI200216204, 10.1172/JCI0216204]; LEPPLA SH, 2000, BACTERIAL PROTEIN TO; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; Little SF, 1996, MICROBIOL-SGM, V142, P707, DOI 10.1099/13500872-142-3-707; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Maynard JA, 2002, NAT BIOTECHNOL, V20, P597, DOI 10.1038/nbt0602-597; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2001, J BACTERIOL, V183, P2111, DOI 10.1128/JB.183.6.2111-2116.2001; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nassi S, 2002, BIOCHEMISTRY-US, V41, P1445, DOI 10.1021/bi0119518; NOSKOV AN, 1996, MOL GEN MIKROBIOL VI, V6, P16; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Ramirez DM, 2002, J IND MICROBIOL BIOT, V28, P232, DOI 10.1038/sj/jim/700239; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SCHUCK P, 2000, CURRENT PROTOCOLS IM; SCHUCK P, 1999, CURRENT PROTOCOLS PR; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SINGH Y, 1994, J BIOL CHEM, V269, P29039; St Croix B, 2000, SCIENCE, V289, P1197; STANLEY JL, 1961, J GEN MICROBIOL, V26, P49, DOI 10.1099/00221287-26-1-49; Stanley P, 1998, J BIOL CHEM, V273, P3358, DOI 10.1074/jbc.273.6.3358; Svedberg T, 1940, THE ULTRACENTRIFUGE; Svitel J, 2003, BIOPHYS J, V84, P4062, DOI 10.1016/S0006-3495(03)75132-7; Varughese M, 1999, INFECT IMMUN, V67, P1860; Varughese M, 1998, MOL MED, V4, P87, DOI 10.1007/BF03401732	51	116	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30936	30944		10.1074/jbc.M301154200	http://dx.doi.org/10.1074/jbc.M301154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12771151	hybrid			2022-12-25	WOS:000184658800067
J	Yamazaki, Y; Kubota, H; Nozaki, M; Nagata, K				Yamazaki, Y; Kubota, H; Nozaki, M; Nagata, K			Transcriptional regulation of the cytosolic chaperonin theta subunit gene, Cctq, by Ets domain transcription factors Elk-1, Sap-1a, and net in the absence of serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX FACTORS ELK-1; ACTIVATING FACTOR; PROTEIN; BINDING; EXPRESSION; TARGET; GROWTH; INDUCTION; INTERACTS; FAMILY	The chaperonin-containing t-complex polypeptide 1 (CCT) is a molecular chaperone that facilitates protein folding in eukaryotic cytosol, and the expression of CCT is highly dependent on cell growth. We show here that transcription of the gene encoding the theta subunit of mouse CCT, Cctq, is regulated by the ternary complex factors (TCFs), Elk-1, Sap-1a, and Net (Sap-2). Reporter gene assay using HeLa cells indicated that the Cctq gene promoter contains a cis-acting element of the CCG-GAAGT sequence (CQE1) at -36 bp. The major CQE1-binding proteins in HeLa cell nuclear extract was recognized by anti-Elk-1 or anti-Sap-1a antibodies in electrophoretic mobility shift assay, and recombinant Elk-1, Sap-1a, or Net specifically recognized CQE1. The CQE1-dependent transcriptional activity in HeLa cells was virtually abolished by overexpression of the DNA binding domains of TCFs. Overexpression of full-length TCFs with Ras indicated that exogenous TCFs can regulate the CQE1-dependent transcription in a Ras-dependent manner. PD98059, an inhibitor of MAPK, significantly repressed the CQE1-dependent transcription. However, no serum response factor was detected by electrophoretic mobility shift assay using the CQE1 element. These results indicate that transcription of the Cctq gene is regulated by TCFs under the control of the Ras/MAPK pathway, probably independently of serum response factor.	Kyoto Univ, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan; Kyoto Univ, CREST JST, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068397, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Sci Lab Anim Expt, Osaka 565, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Osaka University	Kubota, H (corresponding author), Kyoto Univ, Dept Mol & Cellular Biol, Sakyo Ku, 53 Shogoin Kawaharacho, Kyoto 6068397, Japan.	hkubota@frontier.kyoto-u.ac.jp						Adachi K, 1999, ENDOCRINOLOGY, V140, P618, DOI 10.1210/en.140.2.618; Ayadi A, 2001, MECH DEVELOP, V102, P205, DOI 10.1016/S0925-4773(01)00289-1; Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; Gebauer M, 1998, J BIOL CHEM, V273, P29475, DOI 10.1074/jbc.273.45.29475; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; HENIKOFF S, 1984, GENE, V3, P351; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kubota H, 1999, FEBS LETT, V461, P125, DOI 10.1016/S0014-5793(99)01437-4; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kubota H, 1999, EUR J BIOCHEM, V262, P492, DOI 10.1046/j.1432-1327.1999.00405.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Srikakulam R, 1999, J BIOL CHEM, V274, P27265, DOI 10.1074/jbc.274.38.27265; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Yokota S, 2000, EUR J BIOCHEM, V267, P1658, DOI 10.1046/j.1432-1327.2000.01157.x; Yokota S, 2001, EUR J BIOCHEM, V268, P4664, DOI 10.1046/j.1432-1327.2001.02393.x; Yokota S, 2001, CELL STRESS CHAPERON, V6, P345, DOI 10.1379/1466-1268(2001)006<0345:IEOCCC>2.0.CO;2; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070	53	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30642	30651		10.1074/jbc.M212242200	http://dx.doi.org/10.1074/jbc.M212242200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788937	hybrid			2022-12-25	WOS:000184658800029
J	Bos, IGA; Lubbers, YTP; Roem, D; Abrahams, JP; Hack, CE; Eldering, E				Bos, IGA; Lubbers, YTP; Roem, D; Abrahams, JP; Hack, CE; Eldering, E			The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ANGIONEUROTIC-EDEMA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PLASMA PROTEINASE-INHIBITORS; REACTIVE-SITE LOOP; HUMAN C1 INHIBITOR; STRUCTURAL BASIS; CL-INHIBITOR; ALPHA(1)-PROTEINASE INHIBITOR; C1-ESTERASE INHIBITOR; PROTEASE INHIBITORS	C1-inhibitor (C1-Inh) is a serine protease inhibitor ( serpin) with a unique, non-conserved N-terminal domain of unknown function. Genetic deficiency of C1-Inh causes hereditary angioedema. A novel type of mutation (Delta3) in exon 3 of the C1-Inh gene, resulting in deletion of Asp(62)-Thr(116) in this unique domain, was encountered in a hereditary angioedema pedigree. Because the domain is supposedly not essential for inhibitory activity, the unexpected loss-of-function of this deletion mutant was further investigated. The Delta3 mutant and three additional mutants starting at Pro(76), Gly(98), and Ser(115), lacking increasing parts of the N-terminal domain, were produced recombinantly. C1-Inh(76) and C1-Inh(98) retained normal conformation and interaction kinetics with target proteases. In contrast, C1-Inh(115) and Delta3, which both lack the connection between the serpin and the nonserpin domain via two disulfide bridges, were completely non-functional because of a complex-like and multimeric conformation, as demonstrated by several criteria. The Delta3 mutant also circulated in multimeric form in plasma from affected family members. The C1-Inh mutant reported here is unique in that deletion of an entire amino acid stretch from a domain not shared by other serpins leads to a loss-of-function. The deletion in the unique N-terminal domain results in a "multimerization phenotype" of C1-Inh, because of diminished stability of the central beta-sheet. This phenotype, as well as the location of the disulfide bridges between the serpin and the non-serpin domain of C1-Inh, suggests that the function of the N-terminal region may be similar to one of the effects of heparin in antithrombin III, maintenance of the metastable serpin conformation.	CLB, Sanquin Res, Dept Immunopathol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; Leiden Inst Chem, NL-2333 CC Leiden, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Clin Chem, NL-1081 HV Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Bos, IGA (corresponding author), CLB, Sanquin Res, Dept Immunopathol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		Abrahams, Jan Pieter/AAE-4319-2020; Levi, Marcel/AAZ-8559-2020; Abrahams, Jan Pieter/G-7287-2016	Abrahams, Jan Pieter/0000-0001-8216-1868; Abrahams, Jan Pieter/0000-0001-8216-1868				AULAK KS, 1993, J BIOL CHEM, V268, P18088; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; Bos IGA, 2003, BBA-PROTEINS PROTEOM, V1648, P75, DOI 10.1016/S1570-9639(03)00107-9; Bos IGA, 2002, IMMUNOBIOLOGY, V205, P518, DOI 10.1078/0171-2985-00151; Bos IGAC, 2001, INT IMMUNOPHARMACOL, V1, P1583, DOI 10.1016/S1567-5769(01)00073-X; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 2001, THROMB HAEMOSTASIS, V86, P14; CARTER PE, 1991, EUR J BIOCHEM, V197, P301, DOI 10.1111/j.1432-1033.1991.tb15911.x; CHAN JYC, 1977, BIOCHEM BIOPH RES CO, V74, P150, DOI 10.1016/0006-291X(77)91387-0; CHANG WS, 1995, THESIS CAMBRIDGE U C; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; COUTINHO M, 1994, J IMMUNOL, V153, P3648; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DYKES DD, 1988, ELECTROPHORESIS, V9, P359, DOI 10.1002/elps.1150090803; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; ELDERING E, 1992, J BIOL CHEM, V267, P7013; ELDERING E, 1988, J BIOL CHEM, V263, P11776; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LINDO VS, 1995, BRIT J HAEMATOL, V89, P589, DOI 10.1111/j.1365-2141.1995.tb08368.x; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NILSSON T, 1982, BIOCHIM BIOPHYS ACTA, V705, P271, DOI 10.1016/0167-4838(82)90188-1; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; NUIJENS JH, 1988, BLOOD, V72, P1841; NUIJENS JH, 1987, IMMUNOLOGY, V61, P387; PATSTON PA, 1995, FEBS LETT, V368, P401, DOI 10.1016/0014-5793(95)00694-5; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; PIXLEY RA, 1985, J BIOL CHEM, V260, P1723; QUASTEL M, 1983, J CLIN INVEST, V71, P1041, DOI 10.1172/JCI110831; RENT R, 1976, CLIN EXP IMMUNOL, V23, P264; SCHAPIRA M, 1985, Complement, V2, P111; SCHAPIRA M, 1982, J CLIN INVEST, V69, P462, DOI 10.1172/JCI110470; SCHOENBERGER OL, 1989, FEBS LETT, V259, P165, DOI 10.1016/0014-5793(89)81519-4; SIM RB, 1979, FEBS LETT, V97, P111, DOI 10.1016/0014-5793(79)80063-0; Simonovic I, 2000, BBA-PROTEIN STRUCT M, V1481, P97, DOI 10.1016/S0167-4838(00)00115-1; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Storm D, 1997, J BIOL CHEM, V272, P31043, DOI 10.1074/jbc.272.49.31043; VANDERGRAAF F, 1983, J CLIN INVEST, V71, P149, DOI 10.1172/JCI110743; Verpy E, 1996, AM J HUM GENET, V59, P308; VERPY E, 1995, J CLIN INVEST, V95, P350, DOI 10.1172/JCI117663; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WRIGHT HT, 1994, FEBS LETT, V348, P14, DOI 10.1016/0014-5793(94)00568-0; Wuillemin WA, 1997, J IMMUNOL, V159, P1953; WUILLEMIN WA, 1995, BLOOD, V85, P1517, DOI 10.1182/blood.V85.6.1517.bloodjournal8561517; Zahedi R, 1996, J BIOL CHEM, V271, P24307, DOI 10.1074/jbc.271.39.24307; Zuraw BL, 2000, J ALLERGY CLIN IMMUN, V105, P541, DOI 10.1067/mai.2000.104780	65	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29463	29470		10.1074/jbc.M302977200	http://dx.doi.org/10.1074/jbc.M302977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773530	Green Published, hybrid			2022-12-25	WOS:000184507000010
J	Okino, N; He, XX; Gatt, S; Sandhoff, K; Ito, M; Schuchman, EH				Okino, N; He, XX; Gatt, S; Sandhoff, K; Ito, M; Schuchman, EH			The reverse activity of human acid ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH CDNA; ALKALINE CERAMIDASE; MOLECULAR-CLONING; NEUTRAL CERAMIDASE; SACCHAROMYCES-CEREVISIAE; ENZYMATIC-HYDROLYSIS; PURIFICATION	An overexpression system was recently developed to produce and purify recombinant, human acid ceramidase. In addition to ceramide hydrolysis, the purified enzyme was able to catalyze ceramide synthesis using [C-14] lauric acid and sphingosine as substrates. Herein we report detailed characterization of this acid ceramidase-associated "reverse activity" and provide evidence that this reaction occurs in situ as well as in vitro. The pH optimum of the reverse reaction was similar to5.5, as compared with similar to4.5 for the hydrolysis reaction. Non-ionic detergents and zinc cations inhibited the activity, whereas most other cations were stimulatory. Of note, sphingomyelin also was very inhibitory toward this reaction, whereas the anionic lipids, phosphatidic acid and phosphatidylserine, were stimulatory. Of various sphingosine stereoisomers tested in the reverse reaction, only the natural, D-erythro form could efficiently serve as a substrate. Using D-erythro-sphingosine and lauric acid as substrates, the reaction followed normal Michaelis-Menten kinetics. The K-m and V-max values toward sphingosine were 23.75 muM and 208.3 pmol/mug/h, respectively, whereas for lauric acid they were 73.76 muM and 232.5 pmol/mug/h, respectively. Importantly, the reverse activity was reduced in cell lysates from a Farber disease patient to the same extent as the acid ceramidase activity. Furthermore, when 12-(N-methyl-N-(7-nitrobenz-2- oxa-1,3-diazol-4-yl)) (NBD)-conjugated lauric acid and sphingosine were added to cultured lymphoblasts from a Farber disease patient in the presence of fumonisin B ( 1), the conversion to NBD-ceramide was reduced similar to30% when compared with normal cells. These data provide important new information on human acid ceramidase and further document its central role in sphingolipid metabolism.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Kyushu Univ, Dept Biosci & Biotechnol, Fukuoka 8128581, Japan; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Icahn School of Medicine at Mount Sinai; Kyushu University; Hebrew University of Jerusalem; University of Bonn	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498,1425 Madison Ave,Rm 14-20A, New York, NY 10029 USA.	Edward.Schuchman@mssm.edu	Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818	FIC NIH HHS [5R03 TW 01372] Funding Source: Medline; NIDDK NIH HHS [R01 DK54830] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054830] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar J, 2001, HUM MUTAT, V17, P199, DOI 10.1002/humu.5; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; DAGAN A, 1999, SPHINGOLIPID METAB B, P293; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; GATT S, 1963, J BIOL CHEM, V238, P3131; GATT S, 1966, J BIOL CHEM, V241, P3724; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; He XX, 1999, ANAL BIOCHEM, V274, P264, DOI 10.1006/abio.1999.4284; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Kita K, 2000, BBA-MOL CELL BIOL L, V1485, P111, DOI 10.1016/S1388-1981(00)00029-9; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Linke, 2001, METABOLIC MOL BASES, P3573; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Pyne Susan, 2002, Subcell Biochem, V36, P245; Sawai H, 1999, CHEM PHYS LIPIDS, V102, P141, DOI 10.1016/S0009-3084(99)00082-1; Spiegel S, 1998, BIOCHEMISTRY-MOSCOW+, V63, P69; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462	32	99	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29948	29953		10.1074/jbc.M303310200	http://dx.doi.org/10.1074/jbc.M303310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764132	hybrid			2022-12-25	WOS:000184507000068
J	Perret, S; Eble, JA; Siljander, PRM; Merle, C; Farndale, RW; Theisen, M; Ruggiero, F				Perret, S; Eble, JA; Siljander, PRM; Merle, C; Farndale, RW; Theisen, M; Ruggiero, F			Prolyl hydroxylation of collagen type I is required for efficient binding to integrin alpha(1)beta(1) and platelet glycoprotein VI but not to alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-BETA-1 INTEGRIN; DEPENDENT ADHESION; CELL-ADHESION; RECEPTOR; ACTIVATION; RECOGNITION; DOMAIN; SEQUENCE; SITE; EXPRESSION	Collagen is a potent adhesive substrate for cells, an event essentially mediated by the integrins alpha(1)beta(1) and alpha(2)beta(1). Collagen fibrils also bind to the integrin alpha(2)beta(1) and the platelet receptor glycoprotein VI to activate and aggregate platelets. The distinct triple helical recognition motifs for these receptors, GXOGER and (GPO)(n), respectively, all contain hydroxyproline. Using unhydroxylated collagen I produced in transgenic plants, we investigated the role of hydroxyproline in the receptor-binding properties of collagen. We show that alpha(2)beta(1) but not alpha(1)beta(1) mediates cell adhesion to unhydroxylated collagen. Soluble recombinant alpha(1)beta(1) binding to unhydroxylated collagen is considerably reduced compared with bovine collagens, but binding can be restored by prolyl hydroxylation of recombinant collagen. We also show that platelets use alpha(2)beta(1) to adhere to the unhydroxylated recombinant molecules, but the adhesion is weaker than on fully hydroxylated collagen, and the unhydroxylated collagen fibrils fail to aggregate platelets. Prolyl hydroxylation is thus required for binding of collagen to platelet glycoprotein VI and to cells by alpha(1)beta(1). These observations give new insights into the molecular basis of collagen-receptor interactions and offer new selective applications for the recombinant unhydroxylated collagen I.	CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 7, France; Munster Univ Hosp, Dept Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Meristem Therapeut, Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); University of Munster; University of Cambridge	Ruggiero, F (corresponding author), CNRS, UMR 5086, Inst Biol & Chim Prot, IFR128 Biosci Lyon Gerland,7 Passage Vercors, F-69367 Lyon 7, France.	f.ruggiero@ibcp.fr		Siljander, Pia/0000-0003-2326-5821; RUGGIERO, Florence/0000-0003-2915-5359				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Barnes M. J, 1982, COLLAGEN HLTH DISEAS, P179; Barnes MJ, 1996, BIOPOLYMERS, V40, P383, DOI 10.1002/(SICI)1097-0282(1996)40:4<383::AID-BIP4>3.0.CO;2-S; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLLER BS, 1989, BLOOD, V74, P182; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Gardner H, 1999, J CELL SCI, V112, P263; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Jung SM, 2000, TRENDS CARDIOVAS MED, V10, P285, DOI 10.1016/S1050-1738(01)00064-0; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Kehrel B, 1998, BLOOD, V91, P491; KEHREL B, 1988, BLOOD, V71, P1074; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KIELTY CM, 1992, CONNECTIVE TISSUE IT, P103; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Merle C, 2002, FEBS LETT, V515, P114, DOI 10.1016/S0014-5793(02)02452-3; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Niedergang F, 2000, BIOCHEM BIOPH RES CO, V273, P246, DOI 10.1006/bbrc.2000.2940; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; Perret S, 2001, J BIOL CHEM, V276, P43693, DOI 10.1074/jbc.M105507200; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Ruggiero F, 2000, FEBS LETT, V469, P132, DOI 10.1016/S0014-5793(00)01259-X; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Siljander P, 1999, ARTERIOSCL THROM VAS, V19, P3033, DOI 10.1161/01.ATV.19.12.3033; SILJANDER PRM, 2002, PLATELETS THROMBOTIC, P158; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VOGEL W, 2000, FASEB J, V13, P77; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	42	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29873	29879		10.1074/jbc.M304073200	http://dx.doi.org/10.1074/jbc.M304073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771137	hybrid			2022-12-25	WOS:000184507000060
J	Schmidt, K; Glaser, G; Wernig, A; Wegner, M; Rosorius, O				Schmidt, K; Glaser, G; Wernig, A; Wegner, M; Rosorius, O			Sox8 is a specific marker for muscle satellite cells and inhibits myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SOX10; AUTOSOMAL SEX REVERSAL; TERMINAL DIFFERENTIATION; CAMPOMELIC DYSPLASIA; STEM-CELLS; GENE; SRY; MOUSE; MUTATIONS; PROTEIN	Sox8 belongs to a family of transcription regulators characterized by a unique DNA-binding domain known as the high mobility group box. Many Sox proteins play fundamental roles in vertebrate development and differentiation processes. Expression of Sox8 is strong during embryonic muscle development and gradually declines postnatally. In this study, we report that in adult skeletal muscle Sox8 is confined to satellite cells. Downregulation during myogenic differentiation was also detected in cell culture systems and occurred in parallel with down-regulation of the related Sox9. Overexpression of Sox8 or Sox9 on the other hand disrupted myoblasts in their ability to form myotubes. Concomitantly, expression of MyoD and myogenin decreased and basal as well as MyoD-induced activities of the myogenin promoter were strongly reduced in a Sox8-dependent manner. Our data suggest that Sox8 acts as a specific negative regulator of skeletal muscle differentiation, possibly by interfering with the function of myogenic basic helix-loop-helix proteins.	Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany; Univ Bonn, Inst Physiol & Neurophysiol, D-53111 Bonn, Germany	University of Erlangen Nuremberg; University of Bonn	Wegner, M (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	m.wegner@biochem.uni-erlangen.de; rosorius@biochem.uni-erlangen.de		Wegner, Michael/0000-0002-4586-3294; Schmidt, Katy/0000-0003-4727-8854				Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Beranger F, 2000, J BIOL CHEM, V275, P16103, DOI 10.1074/jbc.275.21.16103; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Gasca S, 2002, P NATL ACAD SCI USA, V99, P11199, DOI 10.1073/pnas.172383099; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; Hogan B, 1994, MANIPULATING MOUSE E; IRINTCHEV A, 1994, DEV DYNAM, V199, P326, DOI 10.1002/aja.1001990407; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; MANSOUR S, 1995, J MED GENET, V32, P415, DOI 10.1136/jmg.32.6.415; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Ohe K, 2002, P NATL ACAD SCI USA, V99, P1146, DOI 10.1073/pnas.022645899; Paratore C, 2001, DEVELOPMENT, V128, P3949; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Pfeifer D, 2000, GENOMICS, V63, P108, DOI 10.1006/geno.1999.6060; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Rehberg S, 2002, MOL CELL BIOL, V22, P5826, DOI 10.1128/MCB.22.16.5826-5834.2002; Rosorius O, 1999, J CELL SCI, V112, P2369; Rosorius O, 2000, J BIOL CHEM, V275, P12061, DOI 10.1074/jbc.275.16.12061; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Schepers GE, 2000, NUCLEIC ACIDS RES, V28, P1473, DOI 10.1093/nar/28.6.1473; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Seale P, 2001, DEV CELL, V1, P333, DOI 10.1016/S1534-5807(01)00049-1; Sock E, 2001, MOL CELL BIOL, V21, P6951, DOI 10.1128/MCB.21.20.6951-6959.2001; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X	37	66	69	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29769	29775		10.1074/jbc.M301539200	http://dx.doi.org/10.1074/jbc.M301539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12782625	hybrid			2022-12-25	WOS:000184507000048
J	Wykes, SM; Krawetz, SA				Wykes, SM; Krawetz, SA			The structural organization of sperm chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SPERMATOZOA; NUCLEAR MATRIX; DNA; DOMAIN; GENE; EVOLUTION; GENOME; SEQUENCE	The packaging of the male haploid genome within the differentiating spermatid nucleus is facilitated by small basic nuclear proteins called protamines. Although the majority of the DNA in human sperm chromatin is bound by these proteins, a small percentage retains a nucleosomal-like component. These histone-enriched regions may possess enhanced nuclease sensitivity and have been postulated to designate certain genes involved in early embryogenesis. We have shown previously that the chromatin domain containing the two human protamines PRM1 and PRM2 and the transition protein TNP2 forms a DNase I-sensitive conformation in pachytene spermatocytes, a requisite event prior to the haploid expression of its members in round spermatids (Kramer, J. A, McCarrey, J., Djakiew, D., and Krawetz, S. A. ( 1998) Development 125, 4749 - 4755). Interestingly, this configuration persists in mature spermatozoa subsequent to the transcriptional silencing of the locus. It was therefore postulated that the retained, enhanced DNase I-sensitive conformation of the PRM1-->PRM2--> TNP2 domain in human sperm may be preferentially histone-enriched. To address this tenet, we examined the chromatin structure of the human PRM1--> PRM2-->TNP2 domain using a PCR-based assay. The results show that this retained, enhanced DNase I sensitive domain reflects an enrichment of histones at discrete regions across the locus. In addition, a similar examination of other genes and repetitive sequences suggests the non-random distribution of histones and protamines within the sperm nucleus. A discussion of these results and their functional significance is presented.	Wayne State Univ, Sch Med, Dept Obstet & Gynecol, CS Mott Ctr, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Inst Comp Sci, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Krawetz, SA (corresponding author), Wayne State Univ, Sch Med, Dept Obstet & Gynecol, CS Mott Ctr, 275 E Hancock, Detroit, MI 48201 USA.	steve@compbio.med.wayne.edu	krawetz, stephen/GQQ-3308-2022		NICHD NIH HHS [HD23126] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023126] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Banerjee S, 1998, MOL REPROD DEV, V50, P474, DOI 10.1002/(SICI)1098-2795(199808)50:4&lt;474::AID-MRD11&gt;3.0.CO;2-2; BELLVE AR, 1988, BIOCHEMISTRY-US, V27, P2890, DOI 10.1021/bi00408a034; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; Cho C, 2001, NAT GENET, V28, P82, DOI 10.1038/ng0501-82; CHOUDHARY SK, 1995, J BIOL CHEM, V270, P8755, DOI 10.1074/jbc.270.15.8755; Cremer T, 2000, CRIT REV EUKAR GENE, V10, P179; FRIEDMAN J, 1992, NATL MED SERIES INDE, P1; Gardiner-Garden M, 1998, MOL CELL BIOL, V18, P3350, DOI 10.1128/MCB.18.6.3350; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20662; KLEMM U, 1991, HUM GENET, V87, P635; Kramer JA, 1998, DEVELOPMENT, V125, P4749; Kramer JA, 1998, J EXP ZOOL, V282, P245, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2<245::AID-JEZ26>3.0.CO;2-R; Kramer JA, 1996, J BIOL CHEM, V271, P11619, DOI 10.1074/jbc.271.20.11619; MCKAY DJ, 1986, EUR J BIOCHEM, V156, P5, DOI 10.1111/j.1432-1033.1986.tb09540.x; NELSON JE, 1993, J BIOL CHEM, V268, P2932; ONYANGO P, 2002, P NATL ACAD SCI USA, V99, P10243; PIRHONEN A, 1990, BIOCHIM BIOPHYS ACTA, V1039, P177, DOI 10.1016/0167-4838(90)90183-G; Pittoggi C, 1999, J CELL SCI, V112, P3537; QUERALT R, 1995, J MOL EVOL, V40, P601, DOI 10.1007/BF00160507; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; Sotolongo B, 2000, J CELL BIOCHEM, P23; Steger K, 1999, ANAT EMBRYOL, V199, P471, DOI 10.1007/s004290050245; TANPHAICHITR N, 1978, EXP CELL RES, V117, P347, DOI 10.1016/0014-4827(78)90148-9; Ward WS, 1999, BIOL REPROD, V60, P702, DOI 10.1095/biolreprod60.3.702; WARD WS, 1989, CHROMOSOMA, V98, P153, DOI 10.1007/BF00329678; Zalenskaya IA, 2000, BIOCHEM BIOPH RES CO, V279, P213, DOI 10.1006/bbrc.2000.3917; ZALENSKY AO, 1995, CHROMOSOMA, V103, P577	28	234	250	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29471	29477		10.1074/jbc.M304545200	http://dx.doi.org/10.1074/jbc.M304545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775710	hybrid			2022-12-25	WOS:000184507000011
J	Nihalani, D; Wong, HN; Holzman, LB				Nihalani, D; Wong, HN; Holzman, LB			Recruitment of JNK to JIP1 and JNK-dependent JIP1 phosphorylation regulates JNK module dynamics and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; SIGNAL-TRANSDUCTION; SCAFFOLD PROTEIN; INDUCED APOPTOSIS; MAP KINASES; PATHWAY; JUN; COMPONENTS; YEAST; STE5	JIP1 is a scaffold protein that assembles and facilitates the activation of the mixed lineage kinase-dependent JNK module. Results of earlier work led us to propose a model for JIP1-JNK complex regulation that predicts that under basal conditions, JIP1 maintains DLK in a monomeric, unphosphorylated, and catalytically inactive state. Upon appropriate module stimulation, JNK-JIP1 binding affinity increases and DLK-JIP1 affinity decreases. Dissociation of DLK from JIP1 results in subsequent DLK oligomerization, autophosphorylation, and ultimately module activation. Our previous published results suggested the hypothesis that recruitment of JNK to JIP1 and phosphorylation of JIP1 by JNK is prerequisite for activation of the JNK module (Nihalani, D., Meyer, D., Pajni, S., and Holzman, L. B. (2001) EMBO J. 20, 3447-3458). The present study corroborated this hypothesis by demonstrating that JNK binding to JIP1 is necessary for stimulus-induced dissociation of DLK from JIP1, for DLK oligomerization, and for JNK activation. After mapping JNK-dependent JIP1 phosphorylation sites and testing their functional significance, it was observed that phosphorylation by JNK of JIP1 on Thr-103 and not other phosphorylated JIP1 residues is necessary for the regulation of DLK association with JIP1, DLK activation, and subsequent module activation. A refined model of JIP1-JNK module regulation is presented in which JNK phosphorylation of JIP1 is necessary prior to module activation.	Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Holzman, LB (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, 1560 MSRB II, Ann Arbor, MI 48109 USA.	lholzman@umich.edu	nihalani, deepak/AAK-9453-2020	Holzman, Lawrence/0000-0002-8961-234X	PHS HHS [DO-52788] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barancik M, 1999, J CARDIOVASC PHARM, V34, P182, DOI 10.1097/00005344-199908000-00002; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; CHOI KY, 1994, CELL, V78, P499; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINTEN JA, 1994, GENETICS, V138, P609; RAABE T, 2002, SCI STKE, pPE28; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rincon Mercedes, 1997, Genes and Function, V1, P51; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Takino T, 2002, ONCOGENE, V21, P6488, DOI 10.1038/sj.onc.1205840; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	47	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28694	28702		10.1074/jbc.M304212200	http://dx.doi.org/10.1074/jbc.M304212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756254	hybrid			2022-12-25	WOS:000184421100044
J	Xing, YQ; Musi, N; Fujii, N; Zou, LQ; Luptak, I; Hirshman, MF; Goodyear, LJ; Tian, R				Xing, YQ; Musi, N; Fujii, N; Zou, LQ; Luptak, I; Hirshman, MF; Goodyear, LJ; Tian, R			Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha 2 subunit of AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; RAT-HEART; ISCHEMIA; GLYCOLYSIS; TRANSPORT; PHOSPHORYLATION; CONTRACTION; STIMULATION; SUBFAMILY; EXERCISE	AMP-activated protein kinase (AMPK) is an energy-sensing enzyme that plays a pivotal role in regulating cellular metabolism for sustaining energy homeostasis under stress conditions. Activation of AMPK has been observed in the heart during acute and chronic stresses, but its functional role has not been completely understood because of the lack of effective activators and inhibitors of this kinase in the heart. We generated transgenic mice (TG) with cardiac-specific overexpression of a dominant negative mutant of the AMPK alpha2 catalytic subunit to clarify the functional role of this kinase in myocardial ischemia. In isolated perfused hearts subjected to a 10-min ischemia, AMPK alpha2 activity in wild type (WT) increased substantially ( by 4.5-fold), whereas AMPK alpha2 activity in TG was similar to the level of WT at base line. Basal AMPK alpha1 activity was unchanged in TG and increased normally during ischemia. Ischemia stimulated a 2.5-fold increase in 2-deoxyglucose uptake over base line in WT, whereas the inactivation of AMPK alpha2 in TG significantly blunted this response. Using P-31 NMR spectroscopy, we found that ATP depletion was accelerated in TG hearts during no-flow ischemia, and these hearts developed left ventricular dysfunction manifested by an early and more rapid increase in left ventricular end-diastolic pressure. The exacerbated ATP depletion could not be attributed to impaired glycolytic ATP synthesis because TG hearts consumed slightly more glycogen during this period of no-flow ischemia. Thus, AMPK alpha2 is necessary for maintaining myocardial energy homeostasis during ischemia. It is likely that the functional role of AMPK in myocardial energy metabolism resides both in energy supply and utilization.	Brigham & Womens Hosp, Nucl Magnet Resonance Lab Physiol Chem, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Joslin Diabet Ctr, Dept Med, Div Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Tian, R (corresponding author), NMR Lab Physiol Chem, 221 Longwood Ave,Rm 252, Boston, MA 02115 USA.	rtian@rics.bwh.harvard.edu	Tian, Rong/ABH-1383-2020; Fujii, Nobuharu/J-2724-2014	Tian, Rong/0000-0002-3676-3830; Fujii, Nobuharu/0000-0002-0974-3033; Luptak, Ivan/0000-0001-7498-7694				Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; BAK MI, 1994, J CLIN INVEST, V93, P40, DOI 10.1172/JCI116974; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Depre C, 1998, EUR J BIOCHEM, V258, P277, DOI 10.1046/j.1432-1327.1998.2580277.x; Egert S, 1999, CIRC RES, V84, P1407; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; GIBBS CL, 1980, CIRC RES, V47, P408, DOI 10.1161/01.RES.47.3.408; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; Opie L. H., 1998, HEART PHYSL CELL CIR, P295; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; POLIMENI PI, 1988, J MOL CELL CARDIOL, V20, P15, DOI 10.1016/S0022-2828(88)80175-5; Raymond R, 1998, CIRCULATION, V98, P2180, DOI 10.1161/01.CIR.98.20.2180; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; SUGA H, 1990, PHYSIOL REV, V70, P247, DOI 10.1152/physrev.1990.70.2.247; Tian R, 2001, CIRCULATION, V103, P2961, DOI 10.1161/01.CIR.103.24.2961; Tian R, 2001, CIRCULATION, V104, P1664, DOI 10.1161/hc4001.097183; Tong HY, 2000, J BIOL CHEM, V275, P11981, DOI 10.1074/jbc.275.16.11981; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000	34	182	197	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28372	28377		10.1074/jbc.M303521200	http://dx.doi.org/10.1074/jbc.M303521200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12766162	hybrid			2022-12-25	WOS:000184421100005
J	Li, YP; Lecker, SH; Chen, YL; Waddell, ID; Goldberg, AL; Reid, MB				Li, YP; Lecker, SH; Chen, YL; Waddell, ID; Goldberg, AL; Reid, MB			TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E2(20k)	FASEB JOURNAL			English	Article						cachexia; catabolism; atrophy; cytokines; nuclear factor kappa B	TUMOR-NECROSIS-FACTOR; END RULE PATHWAY; KAPPA-B ACTIVATION; GENE-EXPRESSION; PROTEASOME PATHWAY; HEART-FAILURE; BEARING RATS; PROTEIN LOSS; CACHEXIA; ENZYME	In some inflammatory diseases, TNF-alpha is thought to stimulate muscle catabolism via an NF-kappaB-dependent process that increases ubiquitin conjugation to muscle proteins. The transcriptional mechanism of this response has not been determined. Here we studied the potential role of UbcH2, a ubiquitin carrier protein and homologue of murine E2(20k). We find that UbcH2 is constitutively expressed by human skeletal and cardiac muscles, murine limb muscle, and cultured myotubes. TNF-alpha stimulates UbcH2 expression in mouse limb muscles in vivo and in cultured myotubes. The UbcH2 promoter region contains a functional NF-kappaB binding site; NF-kappaB binding to this sequence is increased by TNF-alpha stimulation. A dominant negative inhibitor of NF-kappaB activation blocks both UbcH2 up-regulation and the increase in ubiquitin-conjugating activity stimulated by TNF-alpha. In extracts from TNF-alpha-treated myotubes, ubiquitin-conjugating activity is limited by UbcH2 availability; activity is inhibited by an antiserum to UbcH2 or a dominant negative mutant of UbcH2 and is enhanced by wild-type UbcH2. Thus, UbcH2 upregulation is a novel response to TNF-alpha/NF-kappaB signaling in skeletal muscle that appears to be essential for the increased ubiquitin conjugation induced by this cytokine.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; AstraZeneca, Alderley Pk SK10 4TG, Cheshire, England; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA	Baylor College of Medicine; Harvard University; Beth Israel Deaconess Medical Center; AstraZeneca; Harvard University; Harvard Medical School	Reid, MB (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,Suite 520B, Houston, TX 77030 USA.	reid@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59878] Funding Source: Medline; NIDDK NIH HHS [DK02707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Anker SD, 1999, CURR OPIN CARDIOL, V14, P211, DOI 10.1097/00001573-199905000-00004; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; FAGEN JM, 1987, BIOCHEM J, V243, P335; Farber MO, 2000, NEUROL CLIN, V18, P245, DOI 10.1016/S0733-8619(05)70188-2; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GARCIAMARTINEZ C, 1994, BIOCHEM BIOPH RES CO, V201, P682, DOI 10.1006/bbrc.1994.1754; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hasselgren PO, 2001, ANN SURG, V233, P9, DOI 10.1097/00000658-200101000-00003; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; KAISER P, 1994, J BIOL CHEM, V269, P8797; Kaiser P, 1995, FEBS LETT, V377, P193, DOI 10.1016/0014-5793(95)01323-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2001, FASEB J, V15, P1413, DOI 10.1096/fj.00-0632fje; Lin YQ, 2002, J BIOL CHEM, V277, P21913, DOI 10.1074/jbc.M109398200; LIU YC, 1990, BIOTECHNIQUES, V9, P558; Llovera M, 1998, CANCER LETT, V133, P83, DOI 10.1016/S0304-3835(98)00216-X; Llovera M, 1996, BIOCHEM BIOPH RES CO, V221, P653, DOI 10.1006/bbrc.1996.0651; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; Moldawer LL, 1998, SEMIN ONCOL, V25, P73; Moynihan TP, 1998, GENOMICS, V51, P124, DOI 10.1006/geno.1998.5257; NAKASHIMA J, 1995, CANCER RES, V55, P4881; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; TESSITORE L, 1993, BRIT J CANCER, V67, P15, DOI 10.1038/bjc.1993.4; Tisdale MJ, 1999, J NUTR, V129, p243S, DOI 10.1093/jn/129.1.243S; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Vary T C, 1998, Curr Opin Clin Nutr Metab Care, V1, P217, DOI 10.1097/00075197-199803000-00013; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; WEFES I, 1995, GENE, V163, P321, DOI 10.1016/0378-1119(95)00374-F; WEFES I, 1995, P NATL ACAD SCI USA, V92, P4982, DOI 10.1073/pnas.92.11.4982; Zar JH, 1974, BIOSTATISTICAL ANAL	47	153	160	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1048	1057		10.1096/fj.02-0759com	http://dx.doi.org/10.1096/fj.02-0759com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773487				2022-12-25	WOS:000183818000008
J	Espinosa, L; Ingles-Esteve, J; Aguilera, C; Bigas, A				Espinosa, L; Ingles-Esteve, J; Aguilera, C; Bigas, A			Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FATE; TRANSCRIPTIONAL COACTIVATOR; NEURONAL DIFFERENTIATION; NUCLEAR TRANSLOCATION; SIGNALING PATHWAYS; MAMMALIAN NOTCH; DROSOPHILA; WINGLESS; EXPRESSION; ACTIVATION	Phosphorylation of Notch proteins has been indirectly correlated with Notch activation and nuclear translocation as well as cellular transformation. There is evidence that the Wnt signaling pathway, which results in glycogen synthase kinase-3beta (GSK-3beta) inhibition, cross-talks with the Notch pathway. In this study, we show that GSK-3beta is able to bind and phosphorylate Notch2 in vitro and in vivo. We identify three specific phosphorylation sites in the Notch2 serine/threoninerich domain that are dependent on GSK-3beta activity. Phosphorylation of the serine/threonine-rich domain has been shown previously to be crucial in regulating cytokine-specific cell differentiation. Coimmunoprecipitation experiments show that full-length Notch2 binds more efficiently than intracellular Notch2 to GSK3beta. Nevertheless, only the processed Notch2 is a substrate for the kinase, thus suggesting that GSK-3beta-dependent phosphorylation may be specifically regulating the activated Notch molecule. Consistent with this, GSK-3beta inhibits the transcriptional activation of Notch target genes both in vitro and in vivo, whereas lithium chloride treatment or Wnt-1 overexpression that results in GSK-3beta inhibition leads to the up-regulation of the Hes-1 promoter. Together, our results suggest that cross-talk between Notch and Wnt pathways may be partially mediated by specific regulation of GSK-3beta-dependent Notch phosphorylation.	Ctr Mol Oncol, Inst Ric Oncol, Hosp, Barcelona 08907, Spain		Bigas, A (corresponding author), Ctr Mol Oncol, Inst Ric Oncol, Hosp, Gran Via Km 2-7, Barcelona 08907, Spain.	abigas@iro.es	Bigas, Anna/A-7457-2014	Bigas, Anna/0000-0003-4801-6899				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Brennan K, 1999, DEV BIOL, V216, P210, DOI 10.1006/dbio.1999.9502; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Egan SE, 1998, CURR TOP MICROBIOL, V228, P273; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Foltz DR, 2001, BIOCHEM BIOPH RES CO, V286, P484, DOI 10.1006/bbrc.2001.5421; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Ingles-Esteve J, 2001, J BIOL CHEM, V276, P44873, DOI 10.1074/jbc.M104703200; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Koyano-Nakagawa N, 1999, MOL CELL NEUROSCI, V14, P327, DOI 10.1006/mcne.1999.0783; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; Wesley CS, 2000, J BIOL CHEM, V275, P9099, DOI 10.1074/jbc.275.13.9099; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	45	257	269	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32227	32235		10.1074/jbc.M304001200	http://dx.doi.org/10.1074/jbc.M304001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794074	hybrid			2022-12-25	WOS:000184782100097
J	Masters, KM; Parkhurst, KM; Daugherty, MA; Parkhurst, LJ				Masters, KM; Parkhurst, KM; Daugherty, MA; Parkhurst, LJ			Native human TATA-binding protein simultaneously binds and bends promoter DNA without a slow isomerization step or TFIIB requirement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DEPENDENT DIFFERENCES; RECOGNITION; MECHANISM	The association of TATA-binding protein (TBP) with promoter DNA is central to the initiation and regulation of eukaryotic protein synthesis. Our laboratory has previously conducted detailed investigations of this interaction using yeast TBP and seven consensus and variant TATA sequences. We have now investigated this key interaction using human TBP and the TATA sequence from the adenovirus major late promoter (AdMLP). Recombinant native human protein was used together with fluorescently labeled DNA, allowing real time data acquisition in solution. We find that the wild-type hTBP-DNA(AdMLP) reaction is characterized by high affinity (K-d = 5 nM), simultaneous binding and DNA bending, and rapid formation of a stable human TBP-DNA complex having DNA bent similar to100degrees. These data allow, for the first time, a direct comparison of the reactions of the full-length, native human and yeast TBPs with a consensus promoter, studied under identical conditions. The general reaction characteristics are similar for the human and yeast proteins, although the details differ and the hTBP(wt)-induced bend is more severe. This directly measured hTBP(wt)-DNA(AdMLP) interaction differs fundamentally from a recently published hTBP(wt)-DNA(AdMLP) model characterized by low affinity (muM) binding and an unstable complex requiring either a 30-min isomerization or TFIIB to achieve DNA bending. Possible sources of these significant differences are discussed.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University of Nebraska System; University of Nebraska Lincoln; University of Vermont	Parkhurst, KM (corresponding author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.	kparkhurst1@unl.edu; lparkhurst1@unl.edu			NCRR NIH HHS [RR15635] Funding Source: Medline; NIGMS NIH HHS [GM59346] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059346] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FORSTER T, 1949, Z NATURFORSCH A, V4, P321; FORSTER VT, 1967, COMPR BIOCHEM, V2, P157; Hardwidge PR, 2002, BIOCHEMISTRY-US, V41, P7732, DOI 10.1021/bi020213w; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; Jameson DM, 1998, BIOPHYS J, V75, P419, DOI 10.1016/S0006-3495(98)77528-9; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; Parkhurst LJ, 2001, PRACT SPECTROSC SERI, V25, P5; Parkhurst LJ, 2001, BIOPOLYMERS, V61, P180; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Petri V, 1998, BIOCHEMISTRY-US, V37, P15842, DOI 10.1021/bi981072u; Powell RM, 2002, J BIOL CHEM, V277, P7776, DOI 10.1074/jbc.M110147200; Powell RM, 2001, J BIOL CHEM, V276, P29782, DOI 10.1074/jbc.M104099200; Pugh B F, 1995, Methods Mol Biol, V37, P359; STARR DB, 1995, J MOL BIOL, V250, P434; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; Wu JO, 2001, J BIOL CHEM, V276, P14623, DOI 10.1074/jbc.M004401200; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7	30	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31685	31690		10.1074/jbc.M305201200	http://dx.doi.org/10.1074/jbc.M305201200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791683	hybrid			2022-12-25	WOS:000184782100029
J	Fourie, AM; Coles, F; Moreno, V; Karlsson, L				Fourie, AM; Coles, F; Moreno, V; Karlsson, L			Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; METALLOPROTEASE-DISINTEGRIN; FAMILY MEMBER; CELL-SURFACE; IN-VIVO; EXPRESSION; METARGIDIN; DOMAIN; INTEGRIN; LOCATION	The ADAM family of disintegrin metalloproteases plays important roles in "ectodomain shedding," the process by which biologically active, soluble forms of cytokines, growth factors, and their receptors are released from membrane-bound precursors. Whereas ADAM8, ADAM15, and MDC-L (ADAM28) are expressed in specific cell types and tissues, their in vivo functions and substrates are not known. By screening a library of synthetic peptides as potential substrates, we show that soluble recombinant forms of these enzymes have similar proteolytic substrate specificity, clearly distinct from that of ADAM17 (TNFalpha-converting enzyme). A number of tumor necrosis factor (TNF) family proteins and CD23 were screened as potential substrates for ectodomain cleavage. We found that ADAM8, ADAM15, and MDC-L, but not ADAM17, catalyzed ectodomain shedding of CD23, the low affinity IgE receptor. ADAM8-dependent, soluble CD23 release required proteolytically active ADAM8, and a physical association of ADAM8 was observed with the membrane-bound form of CD23. The ADAM8-dependent release of sCD23 and the endogenous release from B cell lines could be similarly inhibited by a hydroxamic acid, metalloprotease inhibitor compound. We conclude that ADAM8 could contribute to ectodomain shedding of CD23 and may thus be a potential target for therapeutic intervention in allergy and inflammation.	Johnson & Johnson Pharmaceut Res & Dev, LLC, San Diego, CA 92121 USA	Johnson & Johnson; Johnson & Johnson USA	Fourie, AM (corresponding author), Johnson & Johnson Pharmaceut Res & Dev, LLC, 3210 Merryfield Row, San Diego, CA 92121 USA.							Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Bohm BB, 1999, ARTHRITIS RHEUM, V42, P1946, DOI 10.1002/1529-0131(199909)42:9<1946::AID-ANR21>3.0.CO;2-E; Bonnefoy JY, 1996, IMMUNOL TODAY, V17, P418, DOI 10.1016/0167-5699(96)10054-2; Choi SJ, 2001, J BONE MINER RES, V16, P814, DOI 10.1359/jbmr.2001.16.5.814; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; Haidl ID, 2002, GENE, V283, P163, DOI 10.1016/S0378-1119(01)00871-X; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Howard L, 2001, FEBS LETT, V498, P82, DOI 10.1016/S0014-5793(01)02506-6; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Kataoka M, 1997, J BIOL CHEM, V272, P18209, DOI 10.1074/jbc.272.29.18209; Marolewski AE, 1998, BIOCHEM J, V333, P573, DOI 10.1042/bj3330573; Martin J, 2002, J BIOL CHEM, V277, P33683, DOI 10.1074/jbc.M200988200; Moss ML, 2001, DRUG DISCOV TODAY, V6, P417, DOI 10.1016/S1359-6446(01)01738-X; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; Roberts CM, 1999, J BIOL CHEM, V274, P29251, DOI 10.1074/jbc.274.41.29251; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schlomann U, 2000, J NEUROSCI, V20, P7964; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Sekut L, 1998, Expert Opin Investig Drugs, V7, P1825, DOI 10.1517/13543784.7.11.1825; SMITH RA, 1987, J BIOL CHEM, V262, P6951; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Wheeler DJ, 1998, IMMUNOLOGY, V95, P105; Yoshiyama K, 1997, GENOMICS, V41, P56, DOI 10.1006/geno.1997.4607; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	29	145	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30469	30477		10.1074/jbc.M213157200	http://dx.doi.org/10.1074/jbc.M213157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777399	hybrid			2022-12-25	WOS:000184658800010
J	Karumbati, AS; Deshpande, RA; Jilani, A; Vance, JR; Ramotar, D; Wilson, TE				Karumbati, AS; Deshpande, RA; Jilani, A; Vance, JR; Ramotar, D; Wilson, TE			The role of yeast DNA 3 '-phosphatase Tpp1 and Rad1/Rad10 endonuclease in processing spontaneous and induced base lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; I COVALENT COMPLEXES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; EXCISION-REPAIR; STRAND BREAKS; FPG PROTEIN; GENE; GLYCOSYLASE; DAMAGE	Tpp1 is a DNA 3'-phosphatase in Saccharomyces cerevisiae that is believed to act during strand break repair. It is homologous to one domain of mammalian polynucleotide kinase/3'-phosphatase. Unlike in yeast, we found that Tpp1 could confer resistance to methylmethane sulfonate when expressed in bacteria that lack abasic endonuclease/3'-phosphodiesterase function. This species difference was due to the absence of delta-lyase activity in S. cerevisiae, since expression of bacterial Fpg conferred Tpp1-dependent resistance to methylmethane sulfonate in yeast lacking the abasic endonucleases Apn1 and Apn2. In contrast, beta-only lyases increased methylmethane sulfonate sensitivity independently of Tpp1, which was explained by the inability of Tpp1 to cleave 3', alpha,beta-unsaturated aldehydes. In parallel experiments, mutations of TPP1 and RAD1, encoding part of the Rad1/Rad10 3'-flap endonuclease, caused synthetic growth defects in yeast strains lacking Apn1. In contrast, Fpg expression led to a partial rescue of apn1 apn2 rad1 synthetic lethality by converting lesions into Tpp1-cleavable 3'-phosphates. The collected experiments reveal a profound toxicity of strand breaks with irreparable 3' blocking lesions, and extend the function of the Rad1/Rad10 salvage pathway to 3'-phosphates. They further demonstrate a role for Tpp1 in repairing endogenously created 3'-phosphates. The source of these phosphates remains enigmatic, however, because apn1 tpp1 rad1 slow growth could be correlated with neither the presence of a yeast delta-lyase, the activity of the 3'-phosphate-generating enzyme Tdp1, nor levels of endogenous oxidation.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Montreal, Hop Maisonneuve Rosemont, Ctr Rech, Montreal, PQ H1T 2M4, Canada; Plantaceutica Inc, Res Triangle Pk, NC 27709 USA	University of Michigan System; University of Michigan; Universite de Montreal	Wilson, TE (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	wilsonte@umich.edu		Deshpande, Rajashree/0000-0001-5728-716X	NATIONAL CANCER INSTITUTE [R01CA090911] Funding Source: NIH RePORTER; NCI NIH HHS [CA-90911] Funding Source: Medline; NHLBI NIH HHS [5T32HL07157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Betti M, 2001, J BIOL CHEM, V276, P18038, DOI 10.1074/jbc.M010648200; Brachmann CB, 1998, YEAST, V14, P115; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHATTERJEE IB, 1991, INDIAN J BIOCHEM BIO, V28, P233; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Fang J, 2003, FREE RADICAL BIO MED, V34, P478, DOI 10.1016/S0891-5849(02)01328-X; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Girard PM, 1997, BIOCHIMIE, V79, P559, DOI 10.1016/S0300-9084(97)82004-4; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Guibourt N, 2000, BIOCHIMIE, V82, P59, DOI 10.1016/S0300-9084(00)00357-6; Guillet M, 2002, EMBO J, V21, P2833, DOI 10.1093/emboj/21.11.2833; Hongay C, 2002, EMBO J, V21, P4114, DOI 10.1093/emboj/cdf415; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; Jilani A, 2002, BIOCHEMISTRY-US, V41, P7688, DOI 10.1021/bi012213m; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Krokan HE, 1997, BIOCHEM J, V325, P1; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Maris AF, 2001, CURR GENET, V39, P137, DOI 10.1007/s002940100194; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Meijer M, 2002, J BIOL CHEM, V277, P4050, DOI 10.1074/jbc.M109383200; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Newcomb TG, 1998, CONT CANC RES, P65; Petrucco S, 2002, J BIOL CHEM, V277, P23675, DOI 10.1074/jbc.M201411200; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RAMOTAR D, 1991, MOL MICROBIOL, V5, P149, DOI 10.1111/j.1365-2958.1991.tb01835.x; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Vance JR, 2001, MOL CELL BIOL, V21, P7191, DOI 10.1128/MCB.21.21.7191-7198.2001; Vance JR, 2001, J BIOL CHEM, V276, P15073, DOI 10.1074/jbc.M011075200; von Sonntag C, 1991, Basic Life Sci, V58, P287; Wilson DM, 1998, CONT CANC RES, P29; WILSON III, 2003, FRONT BIOSCI, V8, pD963; Wilson TE, 2002, GENETICS, V162, P677; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xiao W, 2001, MUTAT RES-DNA REPAIR, V487, P137, DOI 10.1016/S0921-8777(01)00113-6; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	49	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31434	31443		10.1074/jbc.M304586200	http://dx.doi.org/10.1074/jbc.M304586200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783866	hybrid			2022-12-25	WOS:000184658800127
J	Li, RA; Hui, K; French, RJ; Sato, K; Henrikson, CA; Tomaselli, GF; Marban, E				Li, RA; Hui, K; French, RJ; Sato, K; Henrikson, CA; Tomaselli, GF; Marban, E			Dependence of mu-conotoxin block of sodium channels on ionic strength but not on the permeating [Na(+)] - Implications for the distinctive mechanistic interactions between Na(+) and K(+) channel pore-blocking toxins and their molecular targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; CHARYBDOTOXIN BLOCK; SELECTIVITY FILTER; BINDING-SITE; GIIIA; VOLTAGE; PEPTIDE; LOCALIZATION; DISCRIMINATE; VESTIBULE	mu-Conotoxins (mu-CTXs) are Na(+) channel-blocking, 22-amino acid peptides produced by the sea snail Conus geographus. Although K(+) channel pore-blocking toxins show specific interactions with permeant ions and strong dependence on the ionic strength (mu), no such dependence has been reported for mu-CTX and Na(+) channels. Such properties would offer insight into the binding and blocking mechanism of mu-CTX as well as functional and structural properties of the Na+ channel pore. Here we studied the effects of mu and permeant ion concentration ([Na(+)]) on mu-CTX block of rat skeletal muscle (mu1, Na(v)1.4) Na(+) channels. mu-CTX sensitivity of wild-type and E758Q channels increased significantly (by similar to20-fold) when mu was lowered by substituting external Na(+) with equimolar sucrose (from 140 to 35 mM Na(+)); however, toxin block was unaltered (p > 0.05) when mu was maintained by replacement of [Na(+)] with N-methyl-D-glucamine (NMG(+)), suggesting that the enhanced sensitivity at low mu was not due to reduction in [Na(+)]. Single-channel recordings identified the association rate constant, k(on), as the primary determinant of the changes in affinity (k(on) increased 40- and 333-fold for mu-CTX D2N/R13Q and D12N/R13Q, respectively, when symmetric 200 mM Na(+) was reduced to 50 mM). In contrast, dissociation rates changed <2-fold for the same derivatives under the same conditions. Experiments with additional mu-CTX derivatives identified toxin residues Arg-1, Arg-13, and Lys-16 as important contributors to the sensitivity external mu. Taken together, our findings indicate that mu-CTX block of Na(+) channels depends critically on mu but not specifically on [Na(+)], contrasting with the known behavior of pore-blocking K(+) channel toxins. These findings suggest that different degrees of ion interaction, underlying the fundamental conduction mechanisms of Na(+) and K(+) channels, are mirrored in ion interactions with pore-blocking toxins.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Fukuoka Womens Univ, Fukuoka 8138529, Japan	Johns Hopkins University; University of Calgary	French, RJ (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.	french@ucalgary.ca	Marban, Eduardo/GWC-8514-2022; Li, Ronald/E-9833-2010		NHLBI NIH HHS [R01 HL-50411, R01 HL-52768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050411, R01HL052768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; BEGENISICH T, 1981, J GEN PHYSIOL, V77, P489, DOI 10.1085/jgp.77.5.489; Chahine M, 1995, RECEPTOR CHANNEL, V3, P161; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; French R J, 1999, Methods Enzymol, V294, P575; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; French RJ, 1997, SER CENT ES, P67; FRENCH RJ, 1994, J GEN PHYSIOL, V103, P447, DOI 10.1085/jgp.103.3.447; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Hui KY, 2002, J GEN PHYSIOL, V119, P45, DOI 10.1085/jgp.119.1.45; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Li RA, 2002, BIOPHYS J, V82, p85A; Li RA, 2002, FEBS LETT, V511, P159, DOI 10.1016/S0014-5793(01)03316-6; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; Li RA, 2001, BIOCHEMISTRY-US, V40, P6002, DOI 10.1021/bi010077f; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Li RK, 2000, J BIOL CHEM, V275, P27551; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MILLER C, 1990, BIOCHEMISTRY-US, V29, P5320, DOI 10.1021/bi00474a016; MOCZYDLOWSKI E, 1993, BIOPHYS J, V64, P1051, DOI 10.1016/S0006-3495(93)81459-0; NAKAMURA H, 1983, EXPERIENTIA, V39, P590, DOI 10.1007/BF01971110; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; RAVINDRAN A, 1992, BIOPHYS J, V61, P494, DOI 10.1016/S0006-3495(92)81854-4; SATO K, 1991, J BIOL CHEM, V266, P16989; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; Yamagishi T, 2001, J GEN PHYSIOL, V118, P171, DOI 10.1085/jgp.118.2.171	39	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30912	30919		10.1074/jbc.M301039200	http://dx.doi.org/10.1074/jbc.M301039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12764145	hybrid			2022-12-25	WOS:000184658800064
J	Sorescu, GP; Sykes, M; Weiss, D; Platt, MO; Saha, A; Hwang, J; Boyd, N; Boo, YC; Vega, JD; Taylor, WR; Jo, H				Sorescu, GP; Sykes, M; Weiss, D; Platt, MO; Saha, A; Hwang, J; Boyd, N; Boo, YC; Vega, JD; Taylor, WR; Jo, H			Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; GENE-EXPRESSION; KAPPA-B; ATHEROSCLEROSIS; KINASE; ACTIVATION; FLOW; PHOSPHORYLATION; LOCALIZATION; INHIBITION	Atherosclerosis is now viewed as an inflammatory disease occurring preferentially in arterial regions exposed to disturbed flow conditions, including oscillatory shear stress (OS), in branched arteries. In contrast, the arterial regions exposed to laminar shear (LS) are relatively lesion-free. The mechanisms underlying the opposite effects of OS and LS on the inflammatory and atherogenic processes are not clearly understood. Here, through DNA microarrays, protein expression, and functional studies, we identify bone morphogenic protein 4 (BMP4) as a mechanosensitive and pro-inflammatory gene product. Exposing endothelial cells to OS increased BMP4 protein expression, whereas LS decreased it. In addition, we found BMP4 expression only in the selective patches of endothelial cells overlying foam cell lesions in human coronary arteries. The same endothelial patches also expressed higher levels of intercellular cell adhesion molecule-1 (ICAM-1) protein compared with those of non-diseased areas. Functionally, we show that OS and BMP4 induced ICAM-1 expression and monocyte adhesion by a NFkappaB-dependent mechanism. We suggest that BMP4 is a mechanosensitive, inflammatory factor playing a critical role in early steps of atherogenesis in the lesion-prone areas.	Georgia Tech Res Inst, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Div Cardiol, Atlanta, GA 30322 USA; Emory Univ, Dept Surg, Atlanta, GA 30322 USA	University System of Georgia; Georgia Institute of Technology; Emory University; Emory University	Jo, H (corresponding author), Georgia Tech Res Inst, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA.	hanjoong.jo@bme.gatech.edu	Platt, Manu/ABY-6057-2022; Jo, Hanjoong/L-6216-2019	Jo, Hanjoong/0000-0003-1833-372X; Boo, Yong Chool/0000-0001-9895-2066	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071014, R01HL070531, R01HL067413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67413, HL70531, HL71014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Breuss JM, 2002, CIRCULATION, V105, P633, DOI 10.1161/hc0502.102966; Brooks AR, 2002, PHYSIOL GENOMICS, V9, P27, DOI 10.1152/physiolgenomics.00075.2001; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Cejna M, 2002, RADIOLOGY, V223, P702, DOI 10.1148/radiol.2233011002; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chen BPC, 2001, PHYSIOL GENOMICS, V7, P55, DOI 10.1152/physiolgenomics.2001.7.1.55; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Dale L, 1999, BIOESSAYS, V21, P751, DOI 10.1002/(SICI)1521-1878(199909)21:9<751::AID-BIES6>3.0.CO;2-I; Davies PF, 2002, BIORHEOLOGY, V39, P299; De Caestecker M, 2001, RESPIR RES, V2, P193; Dhore CR, 2001, ARTERIOSCL THROM VAS, V21, P1998, DOI 10.1161/hq1201.100229; Endres M, 1997, STROKE, V28, P77, DOI 10.1161/01.STR.28.1.77; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Huang Y, 2002, J IMMUNOL, V169, P2627, DOI 10.4049/jimmunol.169.5.2627; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; KEVIL CG, 2001, AM J PHYSIOL-CELL PH, V281, P8955; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; Napoli C, 2002, CIRCULATION, V105, P1360, DOI 10.1161/01.CIR.0000013090.96919.FA; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; TSAO PS, 1995, CIRCULATION, V92, P3513, DOI 10.1161/01.CIR.92.12.3513; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Zahler S, 2000, FASEB J, V14, P555, DOI 10.1096/fasebj.14.3.555; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	38	239	244	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31128	31135		10.1074/jbc.M300703200	http://dx.doi.org/10.1074/jbc.M300703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12766166	hybrid			2022-12-25	WOS:000184658800090
J	Koshkin, A; Nunn, CM; Djordjevic, S; de Montellano, PRO				Koshkin, A; Nunn, CM; Djordjevic, S; de Montellano, PRO			The mechanism of mycobacterium tuberculosis alkylhydroperoxidase AhpD as defined by mutagenesis, crystallography, and kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISONIAZID RESISTANCE; ANTIOXIDANT DEFENSE; CATALASE PEROXIDASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; THIOREDOXIN; SENSITIVITY; ACTIVATION; ETHIONAMIDE; REDUCTASE	AhpD, a protein with two cysteine residues, is required for physiological reduction of the Mycobacterium tuberculosis alkylhydroperoxidase AhpC. AhpD also has an alkylhydroperoxidase activity of its own. The AhpC/ AhpD system provides critical antioxidant protection, particularly in the absence of the catalase-peroxidase KatG, which is suppressed in most isoniazid-resistant strains. Based on the crystal structure, we proposed recently a catalytic mechanism for AhpD involving a proton relay in which the Glu(118) carboxylate group, via His(137) and a water molecule, deprotonates the catalytic residue Cys(133) ( Nunn, C. M., Djordjevic, S., Hillas, P. J., Nishida, C., and Ortiz de Montellano, P. R. ( 2002) J. Biol. Chem. 277, 20033 - 20040). A possible role for His(132) in subsequent formation of the Cys(133)-Cys(130) disulfide bond was also noted. To test this proposed mechanism, we have expressed the H137F, H137Q, H132F, H132Q, E118F, E118Q, C133S, and C130S mutants of AhpD, determined the crystal structures of the H137F and H132Q mutants, estimated the pK(a) values of the cysteine residues, and defined the kinetic properties of the mutant proteins. The collective results strongly support the proposed catalytic mechanism for AhpD.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of London; University College London; University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM56531] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056531] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baulard AR, 2000, J BIOL CHEM, V275, P28326; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; Deretic V, 1996, NAT BIOTECHNOL, V14, P1557, DOI 10.1038/nbt1196-1557; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Hillas PJ, 2000, J BIOL CHEM, V275, P18801, DOI 10.1074/jbc.M001001200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keshavjee S, 2000, JAMA-J AM MED ASSOC, V283, P1201, DOI 10.1001/jama.283.9.1201; LeMaster DM, 1997, J BIOL CHEM, V272, P29998, DOI 10.1074/jbc.272.48.29998; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Menchise V, 2001, BIOCHEM J, V359, P65, DOI 10.1042/0264-6021:3590065; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nunn CM, 2002, J BIOL CHEM, V277, P20033, DOI 10.1074/jbc.M200864200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Poole LB, 2002, METHOD ENZYMOL, V348, P122, DOI 10.1016/S0076-6879(02)48632-6; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; ROUSEL A, 2000, TURBO MANUAL; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Zhang Y, 1996, P NATL ACAD SCI USA, V93, P13212, DOI 10.1073/pnas.93.23.13212; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zhang ZP, 1999, ARCH BIOCHEM BIOPHYS, V363, P19, DOI 10.1006/abbi.1998.1056	38	36	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29502	29508		10.1074/jbc.M303747200	http://dx.doi.org/10.1074/jbc.M303747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761216	hybrid			2022-12-25	WOS:000184507000015
J	Park, SW; Wei, LN				Park, SW; Wei, LN			Regulation of c-myc gene by nitric oxide via inactivating NF-kappa B complex in P19 mouse embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTOR GENE; PROTEIN-KINASE; NEOPLASTIC PHENOTYPE; SELECTIVE NITRATION; RETINOIC ACID; BREAST-CANCER; TRANSCRIPTION; ACTIVATION; EXPRESSION; PHOSPHORYLATION	Nitric oxide (NO) may regulate gene expression by directly modifying redox state-sensitive residues of transcription factors. Here we show that the NO donor, sodium nitroprusside (SNP), rapidly represses c-myc gene transcription in a protein synthesis-independent manner in P19 embryonal carcinoma cells by inactivation of NF-kappaB. SNP treatment reduces the DNA binding ability of the constitutively active NF-kappaB heterodimer, p65/p50, and its consequent transactivation of the c-myc promoter. Repression can be blocked by the peroxynitrite scavenger, deferoxamine, but not by dithiothreitol, which triggers reduction of S-nitrosylated residues. In HEK293 cells, where tumor necrosis factor-alpha can activate NF-kappaB, SNP likewise suppresses the binding of the active NF-kappaB complex, restoring the binding of the repressive p50/p50 homodimer complex. This effect of SNP in HEK293 cells is also blocked by deferoxamine. Chromatin immunoprecipitation analysis of SNP-treated P19 cells reveals reduced association of p65, but not of p50, with the promoter region of the endogenous c-myc gene. SNP-induced p65 dissociation was associated with the recruitment of histone deacetylase 1 and 2 to the endogenous c-myc gene promoter and the subsequent deacetylation of its chromatin histone. This study is the first to demonstrate that NO modulates the transcriptional activity of the c-myc gene promoter by dissociating the active form of NF-kappaB and replacing it with a repressive NF-kappaB complex, correlated with the recruitment of gene-silencing histone deacetylases. In light of findings that NF-kappaB stimulates Myc oncoprotein expression in cancers, our findings suggest that NO should be investigated as a prospective therapeutic cancer agent.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	weixx009@tc.umn.edu		Park, Sung Wook/0000-0002-3393-8826	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060521, R01DK054733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190, P50DA011806, K02DA013926] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11806, DA13926, DA11190] Funding Source: Medline; NIDDK NIH HHS [DK60521, DK 54733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Colasanti M, 2000, BRAIN RES BULL, V52, P155, DOI 10.1016/S0361-9230(00)00262-8; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Dang CV, 1999, MOL CELL BIOL, V19, P1; delaTorre A, 1999, J IMMUNOL, V162, P4101; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Haqqani AS, 2002, J BIOL CHEM, V277, P3614, DOI 10.1074/jbc.M105730200; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hu XL, 2001, J BIOL CHEM, V276, P4597, DOI 10.1074/jbc.M005477200; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Li JH, 2002, J BIOL CHEM, V277, P39967, DOI 10.1074/jbc.M200840200; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; Park SW, 2002, J NEUROSCI, V22, P7941; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; Ratsch A, 2002, EXP CELL RES, V273, P12, DOI 10.1006/excr.2001.5429; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; RHEE KS, 1994, J BIOL CHEM, V269, P17035; Schindler H, 2001, INT IMMUNOPHARMACOL, V1, P1443, DOI 10.1016/S1567-5769(01)00089-3; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yamamoto T, 2002, J NEURAL TRANSM, V109, P1, DOI 10.1007/s702-002-8232-1; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	60	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29776	29782		10.1074/jbc.M303306200	http://dx.doi.org/10.1074/jbc.M303306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12783888	hybrid			2022-12-25	WOS:000184507000049
J	Ichihashi, N; Kurokawa, K; Matsuo, M; Kaito, C; Sekimizu, K				Ichihashi, N; Kurokawa, K; Matsuo, M; Kaito, C; Sekimizu, K			Inhibitory effects of basic or neutral phospholipid on acidic phospholipid-mediated dissociation of adenine nucleotide bound to DnaA protein, the initiator of chromosomal DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; STAPHYLOCOCCUS-AUREUS; BACILLUS-SUBTILIS; CELL-MEMBRANE; IN-VIVO; ORIGIN; ATP; IDENTIFICATION; PURIFICATION; LIPIDS	DnaA protein activity, the initiator of chromosomal DNA replication in bacteria, is regulated by acidic phospholipids such as phosphatidylglycerol ( PG) or cardiolipin ( CL) via facilitation of the exchange reaction of bound adenine nucleotide. Total lipid isolated from exponentially growing Staphylococcus aureus cells facilitated the release of ATP bound to S. aureus DnaA protein, whereas that from stationary phase cells was inert. Fractionation of total lipid from stationary phase cells revealed that the basic phospholipid, lysylphosphatidylglycerol (LPG), inhibited PG- or CL-facilitated release of ATP from DnaA protein. There was an increase in LPG concentration during the stationary phase. A fraction of the total lipid from stationary phase cells of an integrational deletion mprF mutant, in which LPG was lost, facilitated the release of ATP from DnaA protein. A zwitterionic phospholipid, phosphatidylethanolamine, also inhibited PG- facilitated ATP release. These results indicate that interaction of DnaA protein with acidic phospholipids might be regulated by changes in the phospholipid composition of the cell membrane at different growth stages. In addition, the mprF mutant exhibited an increased amount of origin per cell in vivo, suggesting that LPG is involved in regulating the cell cycle event(s).	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Sekimizu, K (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 3-1,7 Chome, Tokyo 1130033, Japan.		Ichihashi, Norikazu/AAY-6897-2020; Kaito, Chikara/W-1815-2019; Kaito, Chikara/G-1248-2017	Kaito, Chikara/0000-0002-2895-3386; Kaito, Chikara/0000-0002-2895-3386				Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COOPER S, 1968, J MOL BIOL, V31, P519, DOI 10.1016/0022-2836(68)90425-7; CROOKE E, 1992, J BIOL CHEM, V267, P16779; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; ENTEZAMI AA, 1987, J CHROMATOGR, V387, P323, DOI 10.1016/S0021-9673(01)94535-2; FISCHER W, 1978, BIOCHIM BIOPHYS ACTA, V528, P288, DOI 10.1016/0005-2760(78)90018-8; Fischer W, 1998, J BACTERIOL, V180, P2950, DOI 10.1128/JB.180.11.2950-2957.1998; FRALICK JA, 1991, MOL GEN GENET, V229, P175, DOI 10.1007/BF00272153; FUKUOKA T, 1990, J BIOCHEM-TOKYO, V107, P732, DOI 10.1093/oxfordjournals.jbchem.a123117; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; HOUTSMUL.UM, 1965, BIOCHIM BIOPHYS ACTA, V106, P564, DOI 10.1016/0005-2760(65)90072-X; Inoue R, 2001, MOL GENET GENOMICS, V266, P564, DOI 10.1007/s004380100564; Katayama H, 1997, BIOL PHARM BULL, V20, P820; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Katayama T, 2001, MOL MICROBIOL, V41, P9, DOI 10.1046/j.1365-2958.2001.02483.x; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; KAWANAMI J, 1968, BIOCHIM BIOPHYS ACTA, V152, P808; KENWARD MA, 1979, J APPL BACTERIOL, V47, P489, DOI 10.1111/j.1365-2672.1979.tb01210.x; Kikuchi S, 2000, J BACTERIOL, V182, P371, DOI 10.1128/JB.182.2.371-376.2000; Kitchen JL, 1999, BIOCHEMISTRY-US, V38, P6213, DOI 10.1021/bi982733q; Kobayashi G, 2001, MOL MICROBIOL, V41, P1037, DOI 10.1046/j.1365-2958.2001.02574.x; Kornberg A., 1992, DNA REPLICATION; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; Lindsay JA, 2001, MICROBIOL-SGM, V147, P1259, DOI 10.1099/00221287-147-5-1259; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majka J, 1997, J BACTERIOL, V179, P2426, DOI 10.1128/jb.179.7.2426-2432.1997; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1996, J BIOL CHEM, V271, P3633; MIZUSHIMA T, 1992, BIOCHEM J, V285, P503, DOI 10.1042/bj2850503; Newman G, 2000, J BACTERIOL, V182, P2604, DOI 10.1128/JB.182.9.2604-2610.2000; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Schaper S, 2000, J MOL BIOL, V299, P655, DOI 10.1006/jmbi.2000.3764; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1994, CHEM PHYS LIPIDS, V73, P223, DOI 10.1016/0009-3084(94)90183-X; SHAW N, 1968, BIOCHEM J, V107, P329, DOI 10.1042/bj1070329; Skarstad K, 1995, METHOD ENZYMOL, V262, P604; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; STEELE G, 1975, INT J CANCER, V15, P180, DOI 10.1002/ijc.2910150203; Sueoka N, 1998, PROG NUCLEIC ACID RE, V59, P35; WHITE DC, 1967, J BACTERIOL, V94, P1854, DOI 10.1128/JB.94.6.1854-1867.1967; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; Yamamoto K, 2002, J BIOCHEM, V131, P219, DOI 10.1093/oxfordjournals.jbchem.a003091; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; Zawilak A, 2001, NUCLEIC ACIDS RES, V29, P2251, DOI 10.1093/nar/29.11.2251; Zheng WD, 2001, EMBO J, V20, P1164, DOI 10.1093/emboj/20.5.1164	52	60	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28778	28786		10.1074/jbc.M212202200	http://dx.doi.org/10.1074/jbc.M212202200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12767975	hybrid			2022-12-25	WOS:000184421100055
J	King, KE; Ponnamperuma, RM; Yamashita, T; Tokino, T; Lee, LA; Young, MF; Weinberg, WC				King, KE; Ponnamperuma, RM; Yamashita, T; Tokino, T; Lee, LA; Young, MF; Weinberg, WC			Delta Np63 alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes	ONCOGENE			English	Article						Delta Np63 alpha; p63; p53 homologues; keratinocytes; epidermal differentiation	SQUAMOUS-CELL CARCINOMAS; P53 GENE DOSAGE; MALIGNANT PROGRESSION; P53-RELATED PROTEIN; SPONTANEOUS TUMORS; P63 EXPRESSION; CORE DOMAIN; P73; HOMOLOG; APOPTOSIS	DeltaNp63 is overexpressed in squamous carcinomas where it is associated with proliferation and is believed to enhance cell growth by blocking p53-mediated transactivation. In normal epithelium, DeltaNp63alpha protein expression is abundant in basal cells and decreases with differentiation. To explore the biological consequences of DeltaNp63alpha overexpression in relation to squamous carcinogenesis, we evaluated its effect on normal squamous differentiation and p53 transactivation function in keratinocytes. Forced overexpression of DeltaNp63alpha in primary murine keratinocytes in vitro inhibits morphological differentiation induced by elevated extracellular [Ca2+], abrogates Ca2+-induced growth arrest, and blocks expression of maturation-specific proteins keratin 10 and filaggrin. This suggests that DeltaNp63 overexpression in squamous carcinomas may serve to maintain the basal cell phenotype and promote cell survival. DeltaNp63alpha blocks transactivation of p53 responsive reporter constructs mediated by endogenous or exogenous p53 at 17 h postinfection, as expected. However, at 41 h, when p53-mediated transactivation is diminished, DeltaNp63alpha: enhances transactivation of these reporter constructs by 2.2-12-fold over control. Maximal DeltaNp63alpha-induced transactivation requires intact p53 responsive elements, but is independent of cellular p53 status. This positive transcriptional function of DeltaNp63alpha appears to be cell-type specific, as it is not observed in primary dermal fibroblasts or Saos-2 cells. These findings support DeltaNp63alpha as a master regulator of keratinocyte differentiation, and suggest a novel function of this protein in the maintenance of epithelial homeostasis.	US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Sapporo Med Univ, Sch Med, Sapporo, Hokkaido 0608556, Japan; Univ Colorado, Sch Med, Denver, CO 80262 USA; Denver Hlth Med Ctr, Denver, CO 80262 USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); Sapporo Medical University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Weinberg, WC (corresponding author), US FDA, Ctr Biol Evaluat & Res, 29 Lincoln Dr,HFM-564,Bldg 29B,Room 3NN04, Bethesda, MD 20892 USA.		Weinberg, Wendy/A-8920-2009; Tokino, Takashi/AAI-9887-2021	Young, Marian F/0000-0003-0929-8854	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bamberger C, 2001, FEBS LETT, V501, P121, DOI 10.1016/S0014-5793(01)02643-6; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Dellavalle RP, 2001, J DERMATOL SCI, V27, P82, DOI 10.1016/S0923-1811(01)00105-0; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Glickman JN, 2001, HUM PATHOL, V32, P1157, DOI 10.1053/hupa.2001.28951; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Lee LA, 1999, J INVEST DERMATOL, V113, P146, DOI 10.1046/j.1523-1747.1999.00651.x; Liefer KM, 2000, CANCER RES, V60, P4016; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Reis JS, 2002, J CUTAN PATHOL, V29, P517, DOI 10.1034/j.1600-0560.2002.290902.x; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shimada A, 1999, CANCER RES, V59, P2781; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	49	128	133	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3635	3644		10.1038/sj.onc.1206536	http://dx.doi.org/10.1038/sj.onc.1206536			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789272				2022-12-25	WOS:000183399200014
J	Oikawa, S; Murakami, K; Kawanishi, S				Oikawa, S; Murakami, K; Kawanishi, S			Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis	ONCOGENE			English	Article						DNA damage; homocysteine; 8-oxo-7, 8-dihydro-2 '-deoxyguanosine; hydrogen peroxide; singlet oxygen	TOTAL PLASMA HOMOCYSTEINE; NESTED CASE-CONTROL; SINGLET OXYGEN; HORDALAND HOMOCYSTEINE; HYDROGEN-PEROXIDE; COLORECTAL-CANCER; STRANDED-DNA; RISK-FACTORS; MALE SMOKERS; FOLATE	Homocysteine is considered to be an important risk factor for cancer as well as cardiovascular diseases. To clarify whether homocysteine has potential carcinogenicity, we investigated formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), which is known to be correlated with the incidence of cancer, induced by homocysteine in human cultured cell lines. Homocysteine increased the amount of 8-oxodG in human leukemia cell line HL-60, whereas the amount of 8-oxodG in its hydrogen peroxide (H2O2)-resistant clone HP100 was not increased. We investigated the mechanism for oxidative DNA damage by homocysteine using P-32-labeled DNA fragments obtained from human tumor suppressor genes and a protooncogene. There were two mechanisms by which homocysteine caused DNA damage in the presence of Cu(II). A low concentration of homocysteine (20 muM) frequently induced piperidine-labile sites at thymine residues, whereas a high concentration of homocysteine (100 muM) resulted in damage principally to guanine residues. Catalase inhibited DNA damage by 20 muM homocysteine, indicating the participation of H2O2, but was ineffective in preventing DNA damage by 100 muM homocysteine. Experiments using a singlet oxygen probe showed that 100 muM homocysteine enhanced chemiluminescence intensity in deuterium oxide more than that in H2O. These results indicated that the metal-dependent DNA damage through H2O2 is likely to be a more relevant mechanism for homocysteine carcinogenicity.	Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan	Mie University	Kawanishi, S (corresponding author), Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan.							Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; Blom HJ, 1998, AM J CLIN NUTR, V67, P188, DOI 10.1093/ajcn/67.2.188; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHIU SM, 1995, BIOCHEMISTRY-US, V34, P2653, DOI 10.1021/bi00008a032; CHUMAKOV P, 1990, X54156 EMBL DAT LIB; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P317, DOI 10.1016/0003-9861(91)90366-Q; DIZDAROGLU M, 1990, BIOCHEMISTRY-US, V29, P8447, DOI 10.1021/bi00488a035; El-Khairy L, 1999, AM J CLIN NUTR, V70, P1016; EPE B, 1991, CHEM-BIOL INTERACT, V80, P239, DOI 10.1016/0009-2797(91)90086-M; Fenech M, 1998, CARCINOGENESIS, V19, P1163, DOI 10.1093/carcin/19.7.1163; Fenech MF, 1997, CARCINOGENESIS, V18, P1329, DOI 10.1093/carcin/18.7.1329; Glynn SA, 1996, CANCER EPIDEM BIOMAR, V5, P487; Gray RG, 2000, LANCET, V355, P1588; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Guttormsen AB, 1996, J CLIN INVEST, V98, P2174, DOI 10.1172/JCI119024; Hall DB, 1998, BIOCHEMISTRY-US, V37, P15933, DOI 10.1021/bi981750c; HALL RD, 1989, J BIOL CHEM, V264, P7900; Heijmans BT, 1999, EUR J HUM GENET, V7, P197, DOI 10.1038/sj.ejhg.5200283; Huschtscha LI, 1998, CANCER RES, V58, P3508; ITO K, 1993, J BIOL CHEM, V268, P13221; Kark JD, 1999, ANN INTERN MED, V131, P321, DOI 10.7326/0003-4819-131-5-199909070-00002; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASUGAI I, 1992, LEUKEMIA RES, V16, P173, DOI 10.1016/0145-2126(92)90129-U; Kato I, 1999, BRIT J CANCER, V79, P1917, DOI 10.1038/sj.bjc.6690305; KAWANISHI S, 1991, BIOCHEMISTRY-US, V30, P3069, DOI 10.1021/bi00226a013; KAWANISHI S, 1986, J BIOL CHEM, V261, P6090; Langman LJ, 1999, CRIT REV CL LAB SCI, V36, P365, DOI 10.1080/10408369991239231; Linder MC, 2001, MUTAT RES-FUND MOL M, V475, P141, DOI 10.1016/S0027-5107(01)00076-8; LINDIG BA, 1980, J AM CHEM SOC, V102, P5590, DOI 10.1021/ja00537a030; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; Martinez ME, 1999, CANCER RES, V59, P5181; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; Miller H, 2000, BIOCHEMISTRY-US, V39, P1029, DOI 10.1021/bi991789x; Murata M, 2000, J BIOL CHEM, V275, P2003, DOI 10.1074/jbc.275.3.2003; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Oikawa S, 1998, BBA-GENE STRUCT EXPR, V1399, P19, DOI 10.1016/S0167-4781(98)00092-X; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PRYOR WA, 1978, BIOCHEM BIOPH RES CO, V81, P498, DOI 10.1016/0006-291X(78)91562-0; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schneede J, 2000, SEMIN THROMB HEMOST, V26, P263, DOI 10.1055/s-2000-8471; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEVILLA MD, 1987, BIOCHEM BIOPH RES CO, V144, P1037, DOI 10.1016/S0006-291X(87)80068-2; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Stevenson C, 1999, CHEM RES TOXICOL, V12, P38, DOI 10.1021/tx980158l; Stolzenberg-Solomon RZ, 1999, JNCI-J NATL CANCER I, V91, P535, DOI 10.1093/jnci/91.6.535; Tada-Oikawa S, 2000, METHOD ENZYMOL, V319, P331; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; Theophanides T, 2002, CRIT REV ONCOL HEMAT, V42, P57, DOI 10.1016/S1040-8428(02)00007-0; Thomson SW, 2000, NUTRITION, V16, P411, DOI 10.1016/S0899-9007(00)00284-7; TUITE EM, 1993, J PHOTOCH PHOTOBIO B, V21, P103, DOI 10.1016/1011-1344(93)80173-7; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298	58	63	65	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3530	3538		10.1038/sj.onc.1206440	http://dx.doi.org/10.1038/sj.onc.1206440			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789261				2022-12-25	WOS:000183399200003
J	Monsinjon, T; Gasque, P; Chan, P; Ischenko, A; Brady, JJ; Fontaine, M				Monsinjon, T; Gasque, P; Chan, P; Ischenko, A; Brady, JJ; Fontaine, M			Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells	FASEB JOURNAL			English	Article						C3aR; C5aR; MAP kinases	ALTERNATIVE PATHWAY PROTEINS; RECEPTOR MESSENGER-RNA; MOLECULAR-CLONING; CELLULAR EXPRESSION; NONMYELOID CELLS; EFFECTOR PHASE; FACTOR-H; INTERLEUKIN-8; NEUTROPHILS; IDENTIFICATION	C3a and C5a anaphylatoxins are cytokine-like polypeptides generated during complement (C) system activation and released at the inflammatory site. They exert several biological activities through binding to the G-protein-coupled receptors C3aR and C5aR, respectively. Cloning and Northern blot experiments have indicated that both receptors are expressed by myeloid as well as nonmyeloid cells (e.g., endothelial and epithelial cells). To better understand the roles of C anaphylatoxins during inflammation, we investigated their effects on the expression of cytokine and chemokine genes by cultured human umbilical cord endothelial cells (HUVEC). HUVEC constitutively expressed both anaphylatoxin receptors, and addition of physiological concentrations of C3a or C5a (nM range) caused a strong up-regulation of IL-8, IL-1beta, and RANTES mRNA in a time- and dose-dependent manner. Conversely, a decrease in IL-6 mRNA was observed, but only with C5a stimulation. These variations in mRNA levels were inhibited by pretreatment with anti-C5aR and anti-C3aR antibodies as well as pertussis toxin, indicating that G-proteins are involved in anaphylatoxin-activated signal transduction pathways. Finally, we showed that C3a and C5a both strongly activate downstream MAP kinase signaling pathways (p44 and p42 Erk kinases).	Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Cardiff CF14 4XN, S Glam, Wales; Univ Rouen, INSERM, U519, Immunol Lab, F-76821 Mont St Aignan, France; Res Inst Highly Pure Biopreparat, St Petersburg, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Gasque, P (corresponding author), Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Tenovus Bldg, Cardiff CF14 4XN, S Glam, Wales.	Tiphaine_Monsinj@hotmail.com; gasque@cardiff.ac.uk		monsinjon, Tiphaine/0000-0001-6959-5522				Abe K, 2001, KIDNEY INT, V60, P137, DOI 10.1046/j.1523-1755.2001.00780.x; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; BROOIMANS RA, 1989, J IMMUNOL, V142, P2024; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; COULPIER M, 1995, CLIN EXP IMMUNOL, V101, P142; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; DAUCHEL H, 1990, EUR J IMMUNOL, V20, P1669, DOI 10.1002/eji.1830200808; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; Erdei A, 1997, EXP CLIN IMMUNOGENET, V14, P16; Fayyazi A, 2000, IMMUNOLOGY, V99, P38, DOI 10.1046/j.1365-2567.2000.00911.x; Foreman KE, 1996, INFLAMMATION, V20, P1, DOI 10.1007/BF01487740; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Fukuoka Y, 1998, J IMMUNOL, V161, P2977; Fukuoka Y, 1998, BIOCHEM BIOPH RES CO, V242, P663, DOI 10.1006/bbrc.1997.8034; Fukuoka Y, 2001, CURR EYE RES, V23, P320, DOI 10.1076/ceyr.23.5.320.5437; Gasque P, 1998, J IMMUNOL, V160, P3543; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 1997, AM J PATHOL, V150, P31; Grant EP, 2002, J EXP MED, V196, P1461, DOI 10.1084/jem.20020205; HAEFFNERCAVAILLON N, 1987, J IMMUNOL, V139, P794; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Hollmann TJ, 1998, MOL IMMUNOL, V35, P137, DOI 10.1016/S0161-5890(98)00021-2; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Ikeda K, 1997, THROMB HAEMOSTASIS, V77, P394; Ischenko A, 1998, J NEUROCHEM, V71, P2487; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Langeggen H, 2001, INFLAMMATION, V25, P83, DOI 10.1023/A:1007162320882; Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962; MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Monsinjon T, 2001, FEBS LETT, V487, P339, DOI 10.1016/S0014-5793(00)02320-6; Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377; Nilsson G, 1996, J IMMUNOL, V157, P1693; NORGAUER J, 1993, EUR J BIOCHEM, V217, P289, DOI 10.1111/j.1432-1033.1993.tb18245.x; Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; Sayah S, 1999, J NEUROCHEM, V72, P2426, DOI 10.1046/j.1471-4159.1999.0722426.x; Schieferdecker HL, 1997, FEBS LETT, V406, P305, DOI 10.1016/S0014-5793(97)00292-5; Schlaf G, 2003, HISTOL HISTOPATHOL, V18, P299, DOI 10.14670/HH-18.299; Schraufstatter IU, 2002, J IMMUNOL, V169, P2102, DOI 10.4049/jimmunol.169.4.2102; Shushakova N, 2002, J CLIN INVEST, V110, P1823, DOI 10.1172/JCI200216577; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stahel PF, 1997, J IMMUNOL, V159, P861; Takayama A, 1996, PHYS PLASMAS, V3, P3, DOI 10.1063/1.871832; Tornetta MA, 1997, J IMMUNOL, V158, P5277; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; Wolff B, 1998, J EXP MED, V188, P1757, DOI 10.1084/jem.188.9.1757	58	182	188	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1003	1014		10.1096/fj.02-0737com	http://dx.doi.org/10.1096/fj.02-0737com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773483				2022-12-25	WOS:000183818000004
J	Andreozzi, F; Melillo, RM; Carlomagno, F; Oriente, F; Miele, C; Fiory, F; Santopietro, S; Castellone, MD; Beguinot, F; Santoro, M; Formisano, P				Andreozzi, F; Melillo, RM; Carlomagno, F; Oriente, F; Miele, C; Fiory, F; Santopietro, S; Castellone, MD; Beguinot, F; Santoro, M; Formisano, P			Protein kinase C alpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase	ONCOGENE			English	Article						protein kinase C; tyrosine; phorbol; oncogene; thyroid; familial; papillary; signaling; carcinoma	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN; PHOSPHORYLATION; RAS; PROTOONCOGENE; PATHWAYS; MUSCLE; DELTA	We have studied the role of protein kinase C (PKC) in signaling of the RET tyrosine kinase receptor. By using a chimeric receptor (E/R) in which RET kinase can be tightly controlled by the addition of epidermal growth factor (EGF), we have found that RET triggering induces a strong increase of PKCalpha, PKCdelta and PKCzeta activity and that PKCalpha, not PKCdelta and PKCzeta, forms a ligand-dependent protein complex with E/R. We have identified tyrosine 1062 in the RET carboxyl-terminal tail as the docking site for PKCalpha. Block of PKC activity by bisindolytmaleimide or chronic phorbol esters treatment decreased EGF-induced serine/threonine phosphorylation of E/R, while it caused a similarly sized increase of EGF-induced E/R tyrosine kinase activity and mitogenic signaling. Conversely, acute phorbol esters treatment, which promotes PKC activity, increased the levels of E/R serine/threonine phosphorylation and significantly decreased its phosphotyrosine content. A threefold reduction of tyrosine phosphorylation levels of the constitutively active RET/MEN2A oncoprotein was observed upon coexpression with PKCalpha. We conclude that RET binds to and activates PKCalpha. PKCalpha, in turn, causes RET phosphorylation and downregulates RET tyrosine kinase and downstream signaling, thus functioning as a negative feedback loop to modulate RET activity.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via S Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; melillo, rosa marina/O-5255-2015; Andreozzi, Francesco/J-4073-2018; ORIENTE, Francesco/J-6652-2018	MELILLO, Rosa Marina/0000-0002-9233-5275; Formisano, Pietro/0000-0001-7020-6870; Andreozzi, Francesco/0000-0001-9375-1513; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; De Vita G, 2000, CANCER RES, V60, P3727; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; FARESE RV, 1988, BIOCHEM J, V256, P175, DOI 10.1042/bj2560175; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Iwashita T, 1996, ONCOGENE, V12, P481; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Ponder BAJ, 1999, CANCER RES, V59, p1736S; PREISS J, 1986, J BIOL CHEM, V261, P8597; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; Seedorf K, 1995, ANN NY ACAD SCI, V766, P459, DOI 10.1111/j.1749-6632.1995.tb26694.x; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	36	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2942	2949		10.1038/sj.onc.1206475	http://dx.doi.org/10.1038/sj.onc.1206475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771945				2022-12-25	WOS:000182824800009
J	Tutt, A; Connor, F; Bertwistle, D; Kerr, P; Peacock, J; Ross, G; Ashworth, A				Tutt, A; Connor, F; Bertwistle, D; Kerr, P; Peacock, J; Ross, G; Ashworth, A			Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity	ONCOGENE			English	Article							HOMOLOGY-DIRECTED REPAIR; CENTROSOME AMPLIFICATION; BREAST-CANCER; MUTATION; P53; INSTABILITY; MICE; RECOMBINATION; MAINTENANCE; DEFICIENT	Carriers of mutations in the BRCA2 gene are at a highly elevated risk of breast and other cancers. The BRCA2 gene encodes a very large protein thought to play a role in DNA repair. To examine the effect of mutation of BRCA2 on sensitivity to ionizing radiation, we used a previously described mouse model system (Brca2(Tr)) in which the Brca2 open reading frame is truncated. Mouse embryo fibroblasts carrying this mutation have a proliferative defect, which we show here can be substantially rescued by genetic ablation of p53. Proliferating Brca2(Tr/Tr)/p53(-/-) cells, like Brca2(Tr/Tr) cells, show genomic instability. We used the clonogenic survival assay, which depends on the ability of cells to proliferate, to examine the cell cycle dependence of radiation sensitivity of Brca2(Tr/Tr)/p53(-/-) compared to p53(-/-) and wild-type cells. This showed that the Brca2 mutation had little effect on cells irradiated in quiescence but sensitized proliferating cells to ionizing radiation on a p53(-/-) background. These results suggest that the major role of Brca2 in mediating cell survival after irradiation is in the S and G(2) phases of the cell cycle.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.			Tutt, Andrew/0000-0001-8715-2901				Bertwistle D, 1997, CANCER RES, V57, P5485; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gretarsdottir S, 1998, CANCER RES, V58, P859; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Steel G. G., 1997, BASIC CLIN RADIOBIOL, P40; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	19	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2926	2931		10.1038/sj.onc.1206522	http://dx.doi.org/10.1038/sj.onc.1206522			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771943				2022-12-25	WOS:000182824800007
J	Lamb, HK; Leslie, K; Dodds, AL; Nutley, M; Cooper, A; Johnson, C; Thompson, P; Stammers, DK; Hawkins, AR				Lamb, HK; Leslie, K; Dodds, AL; Nutley, M; Cooper, A; Johnson, C; Thompson, P; Stammers, DK; Hawkins, AR			The negative transcriptional regulator NmrA discriminates between oxidized and reduced dinucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN METABOLITE REPRESSION; ASPERGILLUS-NIDULANS NMRA; NADP-DEPENDENT ENZYMES; NEUROSPORA-CRASSA; DNA-BINDING; MOLECULAR-DYNAMICS; MESSENGER-RNA; FACTOR AREA; PROTEIN; GENE	NmrA, a transcription repressor involved in the regulation of nitrogen metabolism in Aspergillus nidulans, is a member of the short-chain dehydrogenase reductase superfamily. Isothermal titration calorimetry and differential scanning calorimetry have been used to show NmrA binds NAD(+) and NADP(+) with similar affinity ( average K-D 65 muM) but has a greatly reduced affinity for NADH and NADPH (average K-D 6.0 mM). The structure of NmrA in a complex with NADP(+) reveals how repositioning a His-37 side chain allows the different conformations of NAD(+) and NADP(+) to be accommodated. Modeling NAD(P) H into NmrA indicated that steric clashes, attenuation of electrostatic interactions, and loss of aromatic ring stacking can explain the differing affinities of NAD(P)(+)/NAD(P) H. The ability of NmrA to discriminate between the oxidized and reduced forms of the dinucleotides may be linked to a possible role in redox sensing. Isothermal titration calorimetry demonstrated that NmrA and a C-terminal fragment of the GATA transcription factor AreA interacted with a 1: 1 stoichiometry and an apparent K-D of 0.26 muM. NmrA was unable to bind the nitrogen metabolite repression signaling molecules ammonium or glutamine.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	Newcastle University - UK; University of Oxford; University of Glasgow	Stammers, DK (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Catherine Cookson Bldg,Framington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	daves@strubi.ox.ac.uk; a.r.hawkins@ncl.ac.uk	Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343				Andrianopoulos A, 1998, J BACTERIOL, V180, P1973, DOI 10.1128/JB.180.7.1973-1977.1998; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carugo O, 1997, PROTEINS, V28, P29, DOI 10.1002/(SICI)1097-0134(199705)28:1<29::AID-PROT3>3.3.CO;2-C; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cooper A., 1999, PROTEIN C T, P217; Cooper A, 2000, PROTEIN LIGAND INTER; DAVIS MA, 1987, P NATL ACAD SCI USA, V84, P3753, DOI 10.1073/pnas.84.11.3753; DEBUSK RM, 1984, J BACTERIOL, V160, P493, DOI 10.1128/JB.160.2.493-498.1984; DUNNCOLEMAN NS, 1979, J BACTERIOL, V139, P697, DOI 10.1128/JB.139.2.697-700.1979; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; GROVE G, 1981, J BIOL CHEM, V256, P463; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Klaholz BP, 2002, STRUCTURE, V10, P1197, DOI 10.1016/S0969-2126(02)00828-6; Lamb HK, 1996, MICROBIOL-UK, V142, P1477, DOI 10.1099/13500872-142-6-1477; Lamb HK, 1996, BIOCHEM J, V313, P941, DOI 10.1042/bj3130941; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; Maniatis T., 1982, MOL CLONING LAB MANU; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Morozov IY, 2001, MOL MICROBIOL, V42, P269, DOI 10.1046/j.1365-2958.2001.02636.x; Muro-Pastor MI, 1999, EMBO J, V18, P1584, DOI 10.1093/emboj/18.6.1584; Nichols CE, 2001, ACTA CRYSTALLOGR D, V57, P1722, DOI 10.1107/S090744490101410X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Platt A, 1996, EMBO J, V15, P2791, DOI 10.1002/j.1460-2075.1996.tb00639.x; PUNT PJ, 1995, MOL CELL BIOL, V15, P5688; Reddy SG, 1996, BIOCHEMISTRY-US, V35, P13294, DOI 10.1021/bi9615809; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Wilson RA, 1998, MICROBIOL MOL BIOL R, V62, P586, DOI 10.1128/MMBR.62.3.586-596.1998; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XIAO XD, 1995, BIOCHEMISTRY-US, V34, P8861, DOI 10.1021/bi00027a038; YOUNG JL, 1991, BIOCHEM GENET, V29, P447	41	64	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32107	32114		10.1074/jbc.M304104200	http://dx.doi.org/10.1074/jbc.M304104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12764138	hybrid			2022-12-25	WOS:000184782100082
J	Roberts, SA; Wildner, GF; Grass, G; Weichsel, A; Ambrus, A; Rensing, C; Montfort, WR				Roberts, SA; Wildner, GF; Grass, G; Weichsel, A; Ambrus, A; Rensing, C; Montfort, WR			A labile regulatory copper ion lies near the T1 copper site in the multicopper oxidase CueO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HUMAN CERULOPLASMIN; RESISTANCE; PROTEIN; PCO; HOMEOSTASIS; TOLERANCE; LACCASE	CueO, a multicopper oxidase, is part of the copper-regulatory cue operon in Escherichia coli, is expressed under conditions of copper stress and shows enhanced oxidase activity when additional copper is present. The 1.7-Angstrom resolution structure of a crystal soaked in CuCl2 reveals a Cu(II) ion bound to the protein 7.5 Angstrom from the T1 copper site in a region rich in methionine residues. The trigonal bipyramidal coordination sphere is unusual, containing two methionine sulfur atoms, two aspartate carboxylate oxygen atoms, and a water molecule. Asp-439 both ligates the labile copper and hydrogen-bonds to His-443, which ligates the T1 copper. This arrangement may mediate electron transfer from substrates to the T1 copper. Mutation of residues bound to the labile copper results in loss of oxidase activity and of copper tolerance, confirming a regulatory role for this site. The methionine-rich portion of the protein, which is similar to that of other proteins involved in copper homeostasis, does not display additional copper binding. The type 3 copper atoms of the trinuclear cluster in the structure are bridged by a chloride ion that completes a square planar coordination sphere for the T2 copper atom but does not affect oxidase activity.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Soil Water & Environm Sci, Tucson, AZ 85721 USA; Ruhr Univ Bochum, Lehrstuhl Biochem Pflanzen, D-44780 Bochum, Germany	University of Arizona; University of Arizona; Ruhr University Bochum	Montfort, WR (corresponding author), 1041 E Lowell St, Tucson, AZ 85721 USA.	montfort@email.arizona.edu	Ambrus, Attila/O-4301-2017; Grass, Gregor/A-9981-2009; Rensing, Christopher/D-3947-2011	Ambrus, Attila/0000-0001-6014-3175; Grass, Gregor/0000-0002-8002-7718; Rensing, Christopher/0000-0002-5012-7953	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058727] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07707] Funding Source: Medline; NHLBI NIH HHS [HL62969] Funding Source: Medline; NIGMS NIH HHS [GM58727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Arnesano F, 2002, STRUCTURE, V10, P1337, DOI 10.1016/S0969-2126(02)00858-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand T, 2002, BIOCHEMISTRY-US, V41, P7325, DOI 10.1021/bi0201318; Brown MA, 2002, FEBS LETT, V520, P8, DOI 10.1016/S0014-5793(02)02652-2; BROWN NL, 1995, MOL MICROBIOL, V17, P1153, DOI 10.1111/j.1365-2958.1995.mmi_17061153.x; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; Crichton RR, 2001, BIOMETALS, V14, P99, DOI 10.1023/A:1016710810701; Culotta V.C., 2001, METABOLIC MOL BASES, P3105; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Faham S, 1999, ACTA CRYSTALLOGR D, V55, P379, DOI 10.1107/S0907444998010464; Franke S, 2003, J BACTERIOL, V185, P3804, DOI 10.1128/JB.185.13.3804-3812.2003; Grass G, 2001, BIOCHEM BIOPH RES CO, V286, P902, DOI 10.1006/bbrc.2001.5474; Grass G, 2001, J BACTERIOL, V183, P2145, DOI 10.1128/JB.183.6.2145-2147.2001; Hakulinen N, 2002, NAT STRUCT BIOL, V9, P601, DOI 10.1038/nsb823; Huffman DL, 2002, BIOCHEMISTRY-US, V41, P10046, DOI 10.1021/bi0259960; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Kim C, 2001, J BACTERIOL, V183, P4866, DOI 10.1128/JB.183.16.4866-4875.2001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee SM, 2002, BIOCHEM BIOPH RES CO, V295, P616, DOI 10.1016/S0006-291X(02)00726-X; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Wernimont AK, 2003, J BIOL INORG CHEM, V8, P185, DOI 10.1007/s00775-002-0404-9	37	127	129	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31958	31963		10.1074/jbc.M302963200	http://dx.doi.org/10.1074/jbc.M302963200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794077	hybrid			2022-12-25	WOS:000184782100064
J	Kawamura, S; Miyamoto, S; Brown, JH				Kawamura, S; Miyamoto, S; Brown, JH			Initiation and transduction of stretch-induced RhoA and Rac1 activation through caveolae - Cytoskeletal regulation of ERK translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CARDIAC-HYPERTROPHY; RAT VENTRICULAR MYOCYTES; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; LIPID RAFTS; ACTIN CYTOSKELETON; MEMBRANE DOMAINS; ENOS ACTIVATION; H-RAS; MUSCLE	The Rho family small GTPases play a crucial role in mediating cellular responses to stretch. However, it remains unclear how force is transduced to Rho signaling pathways. We investigated the effect of stretch on the activation and caveolar localization of RhoA and Rac1 in neonatal rat cardiomyocytes. In unstretched cardiomyocytes, RhoA and Rac1 were detected in both caveolar and non-caveolar fractions as assessed using detergent-free floatation analysis. Stretching myocytes for 4 min activated RhoA and Rac1. By 15 min of stretch, RhoA and Rac1 had dissociated from caveolae, and there was decreased coprecipitation of RhoA and Rac1 with caveolin-3. To determine whether compartmentation of RhoA and Rac1 within caveolae was necessary for stretch signaling, we disrupted caveolae with methyl beta-cyclodextrin (MbetaCD). Treatment with 5 mM MbetaCD for 1 h dissociated both RhoA and Rac1 from caveolae. Under this condition, stretch failed to activate RhoA or Rac1. Stretch-induced actin cytoskeletal organization was concomitantly impaired. Interestingly the ability of stretch to activate extracellular signal-regulated kinase (ERK) was unaffected by MbetaCD treatment, but ERK translocation to the nucleus was impaired. Stretch-induced hypertrophy was also inhibited. Actin cytoskeletal disruption with cytochalasin-D also prevented stretch from increasing nuclear ERK, whereas actin polymerization with jasplakinolide restored nuclear translocation of activated ERK in the presence of MbetaCD. We suggest that activation of RhoA or Rac1, localized in a caveolar compartment, is essential for sensing externally applied force and transducing this signal to the actin cytoskeleton and ERK translocation.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu	Miyamoto, Shigeki/L-4004-2019		NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028143, P01HL046345, R01HL028143] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 2002, HYPERTENSION, V39, P233, DOI 10.1161/hy0202.102699; Aikawa R, 2001, BIOCHEM BIOPH RES CO, V289, P901, DOI 10.1006/bbrc.2001.6068; Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Doyle DD, 2000, CIRC RES, V87, P480; DULHUNTY AF, 1975, J PHYSIOL-LONDON, V250, P513, DOI 10.1113/jphysiol.1975.sp011068; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1999, ANN NY ACAD SCI, V874, P11, DOI 10.1111/j.1749-6632.1999.tb09220.x; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, J BIOL CHEM, V273, P30249, DOI 10.1074/jbc.273.46.30249; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Ingram AJ, 2000, J BIOL CHEM, V275, P40301, DOI 10.1074/jbc.M007018200; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kim MK, 2002, INT J ARTIF ORGANS, V25, P33, DOI 10.1177/039139880202500106; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Numaguchi K, 1999, CIRC RES, V85, P5; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Park DS, 2002, AM J PATHOL, V160, P2207, DOI 10.1016/S0002-9440(10)61168-6; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Ueyama T, 2000, J MOL CELL CARDIOL, V32, P947, DOI 10.1006/jmcc.2000.1135; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Woodman SE, 2002, J BIOL CHEM, V277, P38988, DOI 10.1074/jbc.M205511200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yarbrough TL, 2002, CIRC RES, V90, P443, DOI 10.1161/hh0402.105177	41	162	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31111	31117		10.1074/jbc.M300725200	http://dx.doi.org/10.1074/jbc.M300725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777392	hybrid			2022-12-25	WOS:000184658800088
J	Fay, N; Inoue, YJ; Bousset, L; Taguchi, H; Melki, R				Fay, N; Inoue, YJ; Bousset, L; Taguchi, H; Melki, R			Assembly of the yeast prion Ure2p into protein fibrils - Thermodynamic and kinetic characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMATION IN-VITRO; SACCHAROMYCES-CEREVISIAE; AMYLOID FORMATION; DISEASE; CONFORMATION; ALZHEIMERS; ANALOG; STATES	The [URE3] phenotype in Saccharomyces cerevisiae propagates by a prion mechanism, involving the aggregation of the normally soluble and highly helical protein Ure2. Previous data have shown that the protein spontaneously forms in vitro long, straight, insoluble fibrils at neutral pH that are similar to amyloids in that they bind Congo red and show green-yellow birefringence and have an increased resistance to proteolysis. These fibrils are not amyloids as they are devoid of a cross-beta core. Here we further document the mechanism of assembly of Ure2p into fibrils. The critical concentration for Ure2p assembly is measured, and the minimal size of the nuclei that are the precursors of Ure2p fibrils is determined. Our data indicate that the assembly process is irreversible. As a consequence, the critical concentration is very low. By analyzing the elongation rates of preformed fibrils and combining the results with single-fiber imaging experiments of a variant Ure2p labeled by fluorescent dyes, we reveal the polarity of the fibrils and differences in the elongation rates at their ends. These results bring novel insight in the process of Ure2p assembly into fibrils and the mechanism of propagation of yeast prions.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Melki, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.		Inoue, Yuji/B-5267-2013; Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Inoue, Yuji/0000-0002-2932-4733; Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, MICROBES INFECT, V4, P461, DOI 10.1016/S1286-4579(02)01561-7; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; CARLIER MF, 1978, BIOCHEMISTRY-US, V17, P1908, DOI 10.1021/bi00603a017; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 1997, GENETICS, V147, P507; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Inoue Y, 2001, J BIOL CHEM, V276, P35227, DOI 10.1074/jbc.C100304200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Oosawa F., 1975, THERMODYNAMICS POLYM; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Quintas A, 2001, J BIOL CHEM, V276, P27207, DOI 10.1074/jbc.M101024200; Rai R, 2003, J BIOL CHEM, V278, P12826, DOI 10.1074/jbc.M212186200; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Staniforth RA, 2001, EMBO J, V20, P4774, DOI 10.1093/emboj/20.17.4774; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; [No title captured]	38	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30199	30205		10.1074/jbc.M303000200	http://dx.doi.org/10.1074/jbc.M303000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777380	hybrid			2022-12-25	WOS:000184507000099
J	Potente, M; Fisslthaler, B; Busse, R; Fleming, I				Potente, M; Fisslthaler, B; Busse, R; Fleming, I			11,12-epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; TRANSCRIPTION FACTOR FKHR; EPOXYEICOSATRIENOIC ACIDS; ARACHIDONIC-ACID; SMOOTH-MUSCLE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; KINASE; OVEREXPRESSION; METABOLITES	Cytochrome P450-derived epoxyeicosatrienoic acids (EETs) stimulate endothelial cell proliferation and angiogenesis. In this study, we investigated the involvement of the forkhead box, class O (FOXO) family of transcription factors and their downstream target p27(Kip1) in EET-induced endothelial cell proliferation. Incubation of human umbilical vein endothelial cells with 11,12-EET induced a time- and dose-dependent decrease in p27(Kip1) protein expression, whereas p21(Cip1) was not significantly affected. This effect on p27(Kip1) protein was associated with decreased mRNA levels as well as p27(Kip1) promoter activity. 11,12-EET also stimulated the time- dependent phosphorylation of Akt and of the forkhead factors FOXO1 and FOXO3a, effects prevented by the phosphatidylinositol 3-kinase inhibitor LY 294002. Transfection of endothelial cells with either a dominant-negative or an "Akt-resistant"/constitutively active FOXO3a mutant reversed the 11,12-EET-induced down-regulation of p27(Kip1), whereas transfection of a constitutive active Akt decreased p27(Kip1) expression independently of the presence or absence of 11,12-EET. To determine whether these effects are involved in EET-induced proliferation, endothelial cells were transfected with the 11,12-EET-generating epoxygenase CYP2C9. Transfection of CYP2C9 elicited endothelial cell proliferation and this effect was inhibited in cells co-transfected with CYP2C9 and either a dominant-negative Akt or constitutively active FOXO3a. Reducing FOXO expression using RNA interference, on the other hand, attenuated p27(Kip1) expression and stimulated endothelial cell proliferation. These results indicate that EET-induced endothelial cell proliferation is associated with the phosphatidylinositol 3-kinase/Akt-dependent phosphorylation and inactivation of FOXO factors and the subsequent decrease in expression of the cyclin-dependent kinase inhibitor p27(Kip1).	Univ Frankfurt Klinikum, Inst Kardiovask Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovask Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	fleming@em.uni-frankfurt.de	Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Potente, Michael/0000-0002-5689-0036				Boehm M, 2001, CIRCULATION, V103, P2879, DOI 10.1161/01.CIR.103.24.2879; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Chen JR, 2000, J BIOL CHEM, V275, P13789, DOI 10.1074/jbc.275.18.13789; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fleming I, 2001, PFLUG ARCH EUR J PHY, V442, P511, DOI 10.1007/s004240100565; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Fleming I, 2001, CIRC RES, V89, P753, DOI 10.1161/hh2101.099268; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Li PL, 1997, HYPERTENSION, V29, P262, DOI 10.1161/01.HYP.29.1.262; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Michaelis UR, 2003, FASEB J, V17, P770, DOI 10.1096/fj.02-0640fje; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Munzenmaier DH, 2000, AM J PHYSIOL-HEART C, V278, pH1163, DOI 10.1152/ajpheart.2000.278.4.H1163; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Node K, 2001, J BIOL CHEM, V276, P15983, DOI 10.1074/jbc.M100439200; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Snyder GD, 2002, AM J PHYSIOL-HEART C, V283, pH1936, DOI 10.1152/ajpheart.00321.2002; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Sun JX, 2002, CIRC RES, V90, P1020, DOI 10.1161/01.RES.0000017727.35930.33; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Wong PYK, 2000, PROSTAG OTH LIPID M, V62, P321, DOI 10.1016/S0090-6980(00)00079-4; Yang BC, 2001, MOL PHARMACOL, V60, P310, DOI 10.1124/mol.60.2.310	49	141	157	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29619	29625		10.1074/jbc.M305385200	http://dx.doi.org/10.1074/jbc.M305385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773534	hybrid			2022-12-25	WOS:000184507000030
J	Little, R; Dixon, R				Little, R; Dixon, R			The amino-terminal GAF domain of Azotobacter vinelandii NifA binds 2-oxoglutarate to resist inhibition by NifL under nitrogen-limiting conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATION; REGULATORY PROTEIN; IN-VITRO; AZOSPIRILLUM-BRASILENSE; KLEBSIELLA-PNEUMONIAE; SENSOR NIFL; P-II; COMPLEX	The expression of genes required for the synthesis of molybdenum nitrogenase in Azotobacter vinelandii is controlled by the NifL-NifA transcriptional regulatory complex in response to nitrogen, carbon, and redox status. Activation of nif gene expression by the transcriptional activator NifA is inhibited by direct protein-protein interaction with NifL under conditions unfavorable for nitrogen fixation. We have recently shown that the NifL-NifA system responds directly to physiological concentrations of 2-oxoglutarate, resulting in relief of NifA activity from inhibition by NifL under conditions when fixed nitrogen is limiting. The inhibitory activity of NifL is restored under conditions of excess combined nitrogen through the binding of the signal transduction protein Av GlnK to the carboxyl-terminal domain of NifL. The amino-terminal domain of NifA comprises a GAF domain implicated in the regulatory response to NifL. A truncated form of NifA lacking this domain is not responsive to 2-oxoglutarate in the presence of NifL, suggesting that the GAF domain is required for the response to this ligand. Using isothermal titration calorimetry, we demonstrate stoichiometric binding of 2-oxoglutarate to both the isolated GAF domain and the full-length A. vinelandii NifA protein with a dissociation constant of similar to60 muM. Limited proteolysis experiments indicate that the binding of 2-oxoglutarate increases the susceptibility of the GAF domain to trypsin digestion and also prevents NifL from protecting these cleavage sites. However, protection by NifL is restored when the non-modified (non-uridylylated) form of Av GlnK is also present. Our results suggest that the binding of 2-oxoglutarate to the GAF domain of NifA may induce a conformational change that prevents inhibition by NifL under conditions when fixed nitrogen is limiting.	John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dixon, R (corresponding author), John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.			Dixon, Ray/0000-0002-6348-639X	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000016] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Arsene F, 1996, J BACTERIOL, V178, P4830, DOI 10.1128/jb.178.16.4830-4838.1996; Barrett J, 2001, MOL MICROBIOL, V39, P480, DOI 10.1046/j.1365-2958.2001.02243.x; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; EYDMANN T, 1995, J BACTERIOL, V177, P1186, DOI 10.1128/jb.177.5.1186-1195.1995; He LH, 1998, J BACTERIOL, V180, P6661, DOI 10.1128/JB.180.24.6661-6667.1998; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; Hopper S, 1996, J BACTERIOL, V178, P199, DOI 10.1128/jb.178.1.199-203.1996; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12802, DOI 10.1021/bi980666u; Jiang P, 1999, J BACTERIOL, V181, P1906, DOI 10.1128/JB.181.6.1906-1911.1999; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Korsa I, 1997, J BACTERIOL, V179, P41, DOI 10.1128/jb.179.1.41-45.1997; LIANG YY, 1992, FEMS MICROBIOL LETT, V100, P113, DOI 10.1111/j.1574-6968.1992.tb05691.x; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; Money T, 2001, J BACTERIOL, V183, P1359, DOI 10.1128/JB.183.4.1359-1368.2001; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Muro-Pastor MI, 2001, J BIOL CHEM, V276, P38320; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; Reyes-Ramirez F, 2002, J BACTERIOL, V184, P6777, DOI 10.1128/JB.184.24.6777-6785.2002; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; Rudnick P, 2002, J BACTERIOL, V184, P812, DOI 10.1128/JB.184.3.812-820.2002; Schmitz RA, 1997, FEMS MICROBIOL LETT, V157, P313, DOI 10.1111/j.1574-6968.1997.tb12791.x; SENIOR PJ, 1975, J BACTERIOL, V123, P407, DOI 10.1128/JB.123.2.407-418.1975; Soderback E, 1998, MOL MICROBIOL, V28, P179, DOI 10.1046/j.1365-2958.1998.00788.x; Tanigawa R, 2002, P NATL ACAD SCI USA, V99, P4251, DOI 10.1073/pnas.072587199; Vazquez-Bermudez MF, 2002, FEBS LETT, V512, P71, DOI 10.1016/S0014-5793(02)02219-6; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	36	71	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28711	28718		10.1074/jbc.M301992200	http://dx.doi.org/10.1074/jbc.M301992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759352	hybrid			2022-12-25	WOS:000184421100046
J	Vaandrager, AB; Hogema, BM; Edixhoven, M; van den Burg, CMM; Bot, AGM; Klatt, P; Ruth, P; Hofmann, F; Van Damme, J; Vandekerckhove, J; de Jonge, HR				Vaandrager, AB; Hogema, BM; Edixhoven, M; van den Burg, CMM; Bot, AGM; Klatt, P; Ruth, P; Hofmann, F; Van Damme, J; Vandekerckhove, J; de Jonge, HR			Autophosphorylation of cGMP-dependent protein kinase type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITION; LOCALIZATION; INHIBITION; EXPRESSION; INCREASES; CLONING; CAMP	Cyclic nucleotides are shown to stimulate the autophosphorylation of type II cGMP-dependent protein kinase (cGK) on multiple sites. Mass spectrometric based analyses, using a quadrupole time-of-flight-mass spectrometry instrument revealed that cGMP stimulated the in vitro phosphorylation of residues Ser(110) and Ser(114), and, at a slow rate, of Ser(126) and Thr(109) or Ser(117), all located in the autoinhibitory region. In addition Ser(445) was found to be phosphorylated in a cGMP-dependent manner, whereas Ser(110) and Ser(97) were already pre-phosphorylated to a large extent in Sf9 cells. cGMP-dependent phosphorylation of cGK II was also demonstrated in intact COS-1 cells and intestinal epithelium. Substitution of most of the potentially autophosphorylated residues for alanines largely abolished the cGMP stimulation of the autophosphorylation. Prolonged autophosphorylation of purified recombinant cGK II in vitro resulted in a 40-50% increase in basal kinase activity, but its maximal cGMP-stimulated activity and the EC50 for cGMP remained unaltered. Mutation of the major phosphorylatable serines 110, 114, and 445 into "phosphorylation-mimicking" glutamates had no effect on the kinetic parameters of cGK II. However, replacing the slowly autophosphorylated residue Ser(126) by Glu rendered cGK II constitutively active. These results show that the fast phase of cyclic nucleotide-stimulated autophosphorylation of cGK II has a relatively small feed forward effect on its activity, whereas the secondary phase, presumably involving Ser(126) phosphorylation, may generate a constitutively active form of the enzyme.	Erasmus Univ, Dept Biochem, Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium	Erasmus University Rotterdam; Erasmus MC; Utrecht University; Ghent University	Vaandrager, AB (corresponding author), Erasmus Univ, Dept Biochem, Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands.	A.B.Vaandrager@vet.uu.nl		Vaandrager, Arie/0000-0001-9394-9239				AITKEN A, 1994, BIOCHIM BIOPHYS ACTA, V790, P219; Busch JL, 2002, J BIOL CHEM, V277, P34048, DOI 10.1074/jbc.M202761200; Cha BY, 2001, GASTROENTEROLOGY, V120, pA85; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Gambaryan S, 2002, BIOCHEM BIOPH RES CO, V293, P1438, DOI 10.1016/S0006-291X(02)00412-6; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hofmann F, 2000, J CELL SCI, V113, P1671; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; Taylor MK, 2002, J BIOL CHEM, V277, P37242, DOI 10.1074/jbc.M202060200; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Vaandrager AB, 1997, J BIOL CHEM, V272, P11816, DOI 10.1074/jbc.272.18.11816; Wagner C, 1998, J CLIN INVEST, V102, P1576, DOI 10.1172/JCI4044; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915	26	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28651	28658		10.1074/jbc.M303699200	http://dx.doi.org/10.1074/jbc.M303699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12764134	hybrid			2022-12-25	WOS:000184421100039
J	Schulenberg, B; Aggeler, R; Beechem, JM; Capaldi, RA; Patton, WF				Schulenberg, B; Aggeler, R; Beechem, JM; Capaldi, RA; Patton, WF			Analysis of steady-state protein phosphorylation in mitochondria using a novel fluorescent phosphosensor dye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-POLYACRYLAMIDE GELS; BOVINE HEART; COMPLEX-I; DEPENDENT PHOSPHORYLATION; SUBUNIT; KINASE; PHOSPHOPROTEINS; IDENTIFICATION; NADH	The phosphorylation of mitochondrial proteins is pivotal to the regulation of respiratory activity in the cell and to signaling pathways leading to apoptosis, as well as for other vital mitochondrial processes. A number of protein kinases have been identified in mitochondria but the physiological substrates for many of these remain unknown or poorly understood. By necessity, most studies of mitochondrial phosphoproteins to date have been conducted using in vitro incorporation of P-32. However, proteins that are highly phosphorylated from in situ reactions are not necessarily detected by this approach. In this study, a new small molecule fluorophore has been employed to characterize steady-state levels of mitochondrial phosphoproteins. The dye is capable of sensitive detection of phosphorylated amino acid residues in proteins separated by gel electrophoresis. When the fluorescent dye is combined with a total protein stain in a sequential gel staining procedure, the phosphorylated proteins can be visualized in the same gel as the total proteins. To optimize resolution of the proteins in mitochondria, a previously described sucrose gradient fractionation method was employed prior to gel electrophoresis. Phosphorylated proteins, as defined by the fluorescence of the phosphosensor, were excised from the gels and identified by peptide mass fingerprinting. One novel and prominent phosphoprotein identified in this manner was determined to be the 42-kDa subunit of mitochondrial complex I.	Mol Probes Inc, Proteom Sect, Eugene, OR 97402 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Patton, WF (corresponding author), Mol Probes Inc, Proteom Sect, 29851 Willow Creek Rd, Eugene, OR 97402 USA.				NATIONAL CANCER INSTITUTE [R33CA093292] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NCI NIH HHS [1 R33 CA093292-01] Funding Source: Medline; NHLBI NIH HHS [HL24526] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Berggren K, 2000, ELECTROPHORESIS, V21, P2509, DOI 10.1002/1522-2683(20000701)21:12<2509::AID-ELPS2509>3.3.CO;2-0; Berggren KN, 2002, PROTEOMICS, V2, P486, DOI 10.1002/1615-9861(200205)2:5<486::AID-PROT486>3.0.CO;2-X; BYFORD MF, 1991, BIOCHEM J, V280, P261, DOI 10.1042/bj2800261; Bykova NV, 2003, FEBS LETT, V540, P141, DOI 10.1016/S0014-5793(03)00250-3; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Corso M, 2001, PLACENTA, V22, P432, DOI 10.1053/plac.2001.0672; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; Hart C, 2003, ELECTROPHORESIS, V24, P599, DOI 10.1002/elps.200390070; Hojlund K, 2003, J BIOL CHEM, V278, P10436, DOI 10.1074/jbc.M212881200; Hu VW, 2002, FASEB J, V16, P1456, DOI 10.1096/fj.02-0142fje; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; Kaufmann H, 2001, PROTEOMICS, V1, P194, DOI 10.1002/1615-9861(200102)1:2<194::AID-PROT194>3.3.CO;2-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200; Patton WF, 2002, CURR OPIN CHEM BIOL, V6, P63, DOI 10.1016/S1367-5931(01)00284-8; PIEDIMONTE G, 1986, J CELL BIOCHEM, V32, P113, DOI 10.1002/jcb.240320204; Salvi M, 2002, BBA-MOL CELL RES, V1589, P181, DOI 10.1016/S0167-4889(02)00174-X; Sardanelli AM, 1995, FEBS LETT, V377, P470, DOI 10.1016/0014-5793(95)01407-1; Sardanelli AM, 1996, FEBS LETT, V396, P276, DOI 10.1016/0014-5793(96)01112-X; Scacco S, 2000, J BIOL CHEM, V275, P17578, DOI 10.1074/jbc.M001174200; Smilansky Z, 2001, ELECTROPHORESIS, V22, P1616, DOI 10.1002/1522-2683(200105)22:9<1616::AID-ELPS1616>3.0.CO;2-Z; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBERG T, 2003, IN PRESS PROTEOMICS; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Technikova-Dobrova Z, 2001, BIOCHEMISTRY-US, V40, P13941, DOI 10.1021/bi011066p; TECHNIKOVADOBROVA Z, 1994, FEBS LETT, V350, P187, DOI 10.1016/0014-5793(94)00760-8; Thomson M, 2002, CELL MOL LIFE SCI, V59, P213, DOI 10.1007/s00018-002-8417-7; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yamaguchi M, 2000, EUR J BIOCHEM, V267, P329, DOI 10.1046/j.1432-1327.2000.00999.x; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	33	190	198	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27251	27255		10.1074/jbc.C300189200	http://dx.doi.org/10.1074/jbc.C300189200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12759343	hybrid			2022-12-25	WOS:000184155700121
J	Barnes, H; Ackermann, EJ; van der Geer, P				Barnes, H; Ackermann, EJ; van der Geer, P			v-Src induces Shc binding to tyrosine 63 in the cytoplasmic domain of the LDL receptor-related protein 1	ONCOGENE			English	Article						phosphorylation; kinase; PTB domain; signal transduction	DENSITY-LIPOPROTEIN RECEPTOR; GROWTH-FACTOR; C-SRC; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; FAMILY KINASES; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; PP60C-SRC	We recently observed that the LDL receptor-related protein 1 (LRP-1) is tyrosine phosphorylated in v-Src-transformed cells. Using a GST-fusion protein containing the cytoplasmic domain of LRP-1, we show that LRP-1 is a direct substrate for v-Src in vitro. To study LRP-1 phosphorylation in vivo, we constructed an LRP-1 mini-receptor composed of the beta chain linked at the aminoterminus to a Myc epitope (Myc-LRPbeta). When expressed together with v-Src, Myc-LRPbeta becomes phosphorylated on tyrosine. Of the four tyrosine residues present in the cytoplasmic domain of LRP-1, only Tyr 63 is phosphorylated by v-Src in vivo or in vitro. Using fibroblasts deficient in Src, Yes and Fyn, we were able to show that there are multiple kinases present in the cell that can phosphorylate LRP-1. Tyrosine-phosphorylated LRP-1 associates with Shc, a PTB and SH2 domain containing signaling protein that is involved in the activation of Ras. Binding of the purified Shc PTB domain to Tyr 63 containing peptides shows that the interaction between LRP-1 and She is direct. We found that DAB, a PTB domain containing signaling protein that is involved in signaling by LDL receptor-related proteins in the nervous system, did not bind to full-length LRP-1. Our observations suggest that LRP-1 may be involved in normal and malignant signal transduction through a direct interaction with Shc adaptor proteins.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Neurogenet Inc, La Jolla, CA 92037 USA	University of California System; University of California San Diego	van der Geer, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	geer@ucsd.edu			NATIONAL CANCER INSTITUTE [R29CA078629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA78629] Funding Source: Medline; NIDDK NIH HHS [DK 07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Gellner K, 1999, GENOME RES, V9, P251; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lai KMV, 2000, GENE DEV, V14, P1132; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; NIMPF J, 1994, J BIOL CHEM, V269, P212; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3589	3597		10.1038/sj.onc.1206504	http://dx.doi.org/10.1038/sj.onc.1206504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789267				2022-12-25	WOS:000183399200009
J	del Rincon, SV; Rousseau, C; Samanta, R; Miller, WH				del Rincon, SV; Rousseau, C; Samanta, R; Miller, WH			Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway	ONCOGENE			English	Article						retinoic acid; IRS-1; IGF; AKT; breast cancer	BREAST-CANCER CELLS; INSULIN-RECEPTOR SUBSTRATE-1; FACTOR-I RECEPTOR; FACTOR-BINDING PROTEIN-3; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC IMPLICATIONS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; CYCLIN D1	In the MCF-7 breast cancer cell line, insulin-like growth factors (IGFs) are known to elicit antiproliferative actions via the insulin receptor substrate-1 (IRS-1)/PI 3-kinase/AKT pathway. All-trans retinoic acid (RA) is a potent inhibitor of MCF-7 cell proliferation, but the mechanism by which growth regulation is achieved remains unclear. We investigated the effects of RA on the regulation of the IGF-IR and its key signaling elements: IRS-1, IRS-2, and SHC. Treatment of MCF-7 cells with RA caused a significant reduction in IRS-1 protein and tyrosine phosphorylation levels at a concentration and time consistent with RA-mediated growth inhibition. IRS-1 regulation is selective, as RA did not influence IRS-2 or SHC levels. Downstream signaling events were also selectively reduced, as RA abrogated IGF-I-stimulated AKT activation but did not alter erk1/2 activation. To confirm the importance of IRS-1 regulation by RA, we examined the response to RA in MCF-7 cells overexpressing IGF-IR and IRS-1. RA resistance was observed in MCF-7 cells overexpressing IRS-I but not IGF-IR. This suggests that RA-mediated growth inhibition requires the selective downregulation of IRS-1 and AKT. Therapeutic agents targeting the IRS-1/PI 3-kinase/AKT pathway may enhance the cytostatic effects of RA in breast cancer, since overexpression of IRS-1 and AKT have been reported in primary breast tumors.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Miller, WH (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.							Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allen LF, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34049; Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; ANZANO MA, 1994, CANCER RES, V54, P4614; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Chang Q, 2002, CANCER RES, V62, P6035; CULLEN KJ, 1990, CANCER RES, V50, P48; DE LUCA LM, 1991, FASEB J, V5, P2924; DeVente JE, 1996, J BIOL CHEM, V271, P32276, DOI 10.1074/jbc.271.50.32276; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dragnev K H, 2000, Oncologist, V5, P361, DOI 10.1634/theoncologist.5-5-361; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Guruswamy S, 2001, JNCI-J NATL CANCER I, V93, P516, DOI 10.1093/jnci/93.7.516; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Ishibashi K, 2001, J CLIN INVEST, V107, P1193, DOI 10.1172/JCI11753; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; JONES PF, 1991, NATURE, V376, P599; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174/1568026023393318; LI XS, 1994, EXP CELL RES, V211, P68, DOI 10.1006/excr.1994.1060; Li YW, 2002, CLIN CANCER RES, V8, P2369; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Moon RC, 1997, BREAST CANCER RES TR, V46, P181, DOI 10.1023/A:1005995925246; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Rosenauer A, 1998, CANCER RES, V58, P5110; Rozen F, 1999, INT J ONCOL, V15, P589; RUBIN M, 1994, CANCER RES, V54, P6549; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Salerno M, 1999, INT J CANCER, V81, P299; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; SPORN MB, 1994, RETINOIDS BIOL CHEM, P573; Straker SM, 2001, REV ENGL STUD, V52, P1; Sueoka N, 1999, CANCER RES, V59, P3838; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; Taouis M, 1998, MOL CELL ENDOCRINOL, V137, P177, DOI 10.1016/S0303-7207(97)00245-1; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Torrisi R, 2001, DRUGS, V61, P909, DOI 10.2165/00003495-200161070-00002; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Wang Q, 2000, CANCER RES, V60, P2040; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Xie SP, 1997, J ENDOCRINOL, V154, P495, DOI 10.1677/joe.0.1540495; Xie SP, 1999, EUR J CANCER, V35, P1717, DOI 10.1016/S0959-8049(99)00200-2; Yakes FM, 2002, CANCER RES, V62, P4132; Yoshida H, 1996, CANCER RES, V56, P2945; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	74	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3353	3360		10.1038/sj.onc.1206485	http://dx.doi.org/10.1038/sj.onc.1206485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776186	Green Submitted			2022-12-25	WOS:000183128500001
J	Budunova, IV; Kowalczyk, D; Perez, P; Yao, YJ; Jorcano, JL; Slaga, TJ				Budunova, IV; Kowalczyk, D; Perez, P; Yao, YJ; Jorcano, JL; Slaga, TJ			Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis	ONCOGENE			English	Article						glucocorticoid receptor; transgenic mice; skin carcinogenesis; NF-kappa B	NF-KAPPA-B; TRANSGENIC TG.AC MICE; CELL-CYCLE; TRANSCRIPTION FACTORS; TUMOR PROMOTION; ONCOGENIC RAS; ORNITHINE DECARBOXYLASE; PAPILLOMA DEVELOPMENT; DNA-BINDING; EXPRESSION	Glucocorticoids are effective inhibitors of epidermal proliferation and skin tumorigenesis. Glucocorticoids affect cellular functions via glucocorticoid receptor (GR), a well-known transcription factor. Recently, we generated skin-targeted transgenic mice overexpressing GR under control of the keratin5 promoter (K5-GR mice). To test the hypothesis that GR plays a role as a tumor suppressor in skin, we bred K5-GR transgenic mice with Tg.AC transgenic mice, which express v-Ha-ras oncogene in the skin, and compared the susceptibility of F1 offspring to TPA-induced skin carcinogenesis. GR overexpression in the epidermis dramatically inhibited skin tumor development. In K5-GR/ras+ double transgenic mice papillomas developed later and the average number of tumors per animal was 15% (in males) and 40% (in females) of the number seen in wild type (w.t./ras+) littermates. In addition, the papillomas in w.t./ras+ animals were eight to nine times larger. GR overexpression resulted in a decrease in keratinocyte proliferation combined with a modest increase in apoptosis and differentiation of keratinocytes in K5-GR/ras+ papillomas. Our data clearly indicate that interference of GR transgenic protein with nuclear factor kappa B (NF-kappaB) transcription factor had resulted in NF-kappaB blockage in K5-GR/ras + tumors. We discuss the role of NF-kappaB blockage in tumor-suppressor effect of GR.	AMC Canc Res Ctr, Denver, CO 80214 USA; CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain; CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain	AMC Cancer Research Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Budunova, IV (corresponding author), AMC Canc Res Ctr, 1600 Pierce St, Denver, CO 80214 USA.	budunovai@amc.org	Perez, Paloma/K-8841-2017	Perez, Paloma/0000-0002-7166-2824	NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-79065-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Binder RL, 1998, CANCER RES, V58, P4314; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cannon RE, 1997, MOL CARCINOGEN, V20, P108, DOI 10.1002/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; DIGIOVANNI J, 1992, CARCINOGENESIS, V13, P525, DOI 10.1093/carcin/13.4.525; DIGIOVANNI J, 1988, CARCINOGENESIS, V9, P1445, DOI 10.1093/carcin/9.8.1445; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FISCHER SM, 1989, CANCER RES, V49, P6693; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HENNINGS H, 1987, MULTISTEP MODELS CAR, P59; Honchel R, 2001, MOL CARCINOGEN, V30, P99, DOI 10.1002/1098-2744(200102)30:2<99::AID-MC1018>3.3.CO;2-Z; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Ma SH, 1997, GENE EXPRESSION, V6, P361; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; NESNOW S, 1986, ENVIRON HEALTH PERSP, V68, P19, DOI 10.1289/ehp.866819; Park JH, 2001, INT J ONCOL, V18, P997; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Perez P, 2001, FASEB J, V15, P2030, DOI 10.1096/fj.00-0772fje; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHWARZ JA, 1977, CHEM-BIOL INTERACT, V17, P331, DOI 10.1016/0009-2797(77)90096-5; SLAGA TJ, 1984, MODELS MECH ETIOLOGY, P497; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spiegelman VS, 1997, MOL CARCINOGEN, V20, P99, DOI 10.1002/(SICI)1098-2744(199709)20:1<99::AID-MC11>3.0.CO;2-4; STRAWHECKER JM, 1992, CARCINOGENESIS, V13, P2075, DOI 10.1093/carcin/13.11.2075; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; Terada Y, 2001, KIDNEY INT, V59, P1706, DOI 10.1046/j.1523-1755.2001.0590051706.x; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; VERMA AK, 1983, CANCER RES, V43, P3045	56	28	29	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3279	3287		10.1038/sj.onc.1206383	http://dx.doi.org/10.1038/sj.onc.1206383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761498				2022-12-25	WOS:000183040000010
J	Most, P; Remppis, A; Pleger, ST; Loffler, E; Ehlermann, P; Bernotat, J; Kleuss, C; Heierhorst, J; Ruiz, P; Witt, H; Karczewski, P; Mao, L; Rockman, HA; Duncan, SJ; Katus, HA; Koch, WJ				Most, P; Remppis, A; Pleger, ST; Loffler, E; Ehlermann, P; Bernotat, J; Kleuss, C; Heierhorst, J; Ruiz, P; Witt, H; Karczewski, P; Mao, L; Rockman, HA; Duncan, SJ; Katus, HA; Koch, WJ			Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ALPHA PROTEIN; CARDIAC SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CA2+ RELEASE; MICE; GENE; HYPERTROPHY; EXPRESSION; RECEPTOR; FAILURE	S100A1, a Ca2+-sensing protein of the EF-hand family, is most highly expressed in myocardial tissue, and cardiac S100A1 overexpression in vitro has been shown to enhance myocyte contractile properties. To study the physiological consequences of S100A1 in vivo, transgenic mice were developed with cardiac-restricted overexpression of S100A1. Characterization of two independent transgenic mouse lines with similar to4-fold overexpression of S100A1 in the myocardium revealed a marked augmentation of in vivo basal cardiac function that remained elevated after beta-adrenergic receptor stimulation. Contractile function and Ca2+ handling properties were increased in ventricular cardiomyocytes isolated from S100A1 transgenic mice. Enhanced cellular Ca2+ cycling by S100A1 was associated both with increased sarcoplasmic reticulum Ca2+ content and enhanced sarcoplasmic reticulum Ca2+-induced Ca2+ release, and S100A1 was shown to associate with the cardiac ryanodine receptor. No alterations in beta-adrenergic signal transduction or major cardiac Ca2+-cycling proteins occurred, and there were no signs of hypertrophy with chronic cardiac S100A1 overexpression. Our findings suggest that S100A1 plays an important in vivo role in the regulation of cardiac function perhaps through interacting with the ryanodine receptor. Because S100A1 protein expression is downregulated in heart failure, increasing S100A1 expression in the heart may represent a novel means to augment contractility.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Univ Heidelberg, Med Univ Klin & Poliklin 3, D-69115 Heidelberg, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Max Delbruck Zentrum, D-13125 Berlin, Germany; Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA	Duke University; Ruprecht Karls University Heidelberg; Free University of Berlin; St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Duke University	Koch, WJ (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 2606, Durham, NC 27710 USA.		Noppinger, Patricia Ruiz/AAH-1753-2019; Ruiz Noppinger, Patricia/D-6418-2014	Noppinger, Patricia Ruiz/0000-0001-5617-8965; Ruiz Noppinger, Patricia/0000-0001-5617-8965; Heierhorst, Jorg/0000-0003-2789-9514	NHLBI NIH HHS [R01 HL56205, R01 HL61690] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056205, R01HL061690] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AdachiAkahane S, 1997, J GEN PHYSIOL, V109, P717, DOI 10.1085/jgp.109.6.717; Asahi M, 2000, J BIOL CHEM, V275, P15034, DOI 10.1074/jbc.275.20.15034; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Ehlermann P, 2000, BBA-MOL BASIS DIS, V1500, P249, DOI 10.1016/S0925-4439(99)00106-4; Ehlermann P, 2001, GEN PHYSIOL BIOPHYS, V20, P203; FANO G, 1989, FEBS LETT, V248, P9, DOI 10.1016/0014-5793(89)80421-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HAIMOTO H, 1988, EUR J BIOCHEM, V171, P409, DOI 10.1111/j.1432-1033.1988.tb13805.x; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Iaccarino G, 1998, AM J PHYSIOL-HEART C, V275, pH1298, DOI 10.1152/ajpheart.1998.275.4.H1298; Ito K, 2001, CIRC RES, V89, P422, DOI 10.1161/hh1701.095522; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KATO K, 1986, J NEUROCHEM, V46, P1555, DOI 10.1111/j.1471-4159.1986.tb01776.x; KNAUS HG, 1992, P NATL ACAD SCI USA, V89, P3586, DOI 10.1073/pnas.89.8.3586; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Kohout TA, 2001, CIRCULATION, V104, P2485, DOI 10.1161/hc4501.098933; KUO WN, 1986, CYTOBIOS, V46, P139; Lalli MJ, 2001, CIRC RES, V89, P160; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Most P, 2003, J BIOL CHEM, V278, P26356, DOI 10.1074/jbc.M303338200; Most P, 2001, P NATL ACAD SCI USA, V98, P13889, DOI 10.1073/pnas.241393598; Muth JN, 2001, CIRCULATION, V103, P140; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Remppis A, 1996, BBA-MOL CELL RES, V1313, P253, DOI 10.1016/0167-4889(96)00097-3; REMPPIS A, 2002, BASIC RES CARDIOL, V97; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHWARTZ A, 1973, AM J CARDIOL, V32, P407, DOI 10.1016/S0002-9149(73)80031-1; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Treves S, 1997, BIOCHEMISTRY-US, V36, P11496, DOI 10.1021/bi970160w; Tsoporis JN, 1998, J CLIN INVEST, V102, P1609, DOI 10.1172/JCI3077; Tsoporis JN, 2003, MOL CELL BIOCHEM, V242, P27, DOI 10.1023/A:1021148503861; Wang ZL, 2001, ACTA CRYSTALLOGR D, V57, P882, DOI 10.1107/S0907444901005273; Wolff MR, 1996, J CLIN INVEST, V98, P167, DOI 10.1172/JCI118762; ZIMMER DB, 1991, CELL MOTIL CYTOSKEL, V20, P325, DOI 10.1002/cm.970200408	41	101	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33809	33817		10.1074/jbc.M301788200	http://dx.doi.org/10.1074/jbc.M301788200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12777394	hybrid			2022-12-25	WOS:000185047500026
J	Xue, YZ; Fares, H; Grant, B; Li, Z; Rose, AM; Clark, SG; Skolnik, EY				Xue, YZ; Fares, H; Grant, B; Li, Z; Rose, AM; Clark, SG; Skolnik, EY			Genetic analysis of the myotubularin family of phosphatases in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-PHOSPHATE; MEMBRANE; MYOPATHY; PROTEINS; YEAST; DOMAIN; PHOSPHOINOSITIDES; TRAFFICKING; MUTATIONS; 3-KINASE	Myotubularins (MTMs) constitute a large family of lipid phosphatases that specifically dephosphorylate phosphatidylinositol (3) P. MTM1 and MTM2 are mutated in X-linked myotubular myopathy and Charcot-Marie-Tooth disease ( type 4B), respectively, although the mechanisms whereby MTM dysfunction leads to these diseases is unknown. To gain insight into MTM function, we undertook the study of MTMs in the nematode Caenorhabditis elegans, which possesses representative homologues of the four major subgroups of MTMs identified in mammals. As in mammals, we found that C. elegans MTMs mediate distinct functions. let-512 (vps34) encodes the C. elegans homologue of the yeast and mammalian homologue of the phosphatidylinositol 3-kinase Vps34. We found that reduction of mtm-6 (F53A2.8) function by RNA inhibition rescued the larval lethality of let-512 ( vps34) mutants and that the reduction of mtm-1 (Y110A7A. 5) activity by RNA inhibition rescued the endocytosis defect of let-512 animals. Together, these observations provide genetic evidence that MTMs negatively regulate phosphatidylinositol ( 3) P levels. Analysis of MTM expression patterns using transcriptional green fluorescence protein reporters demonstrated that these two MTMs exhibit mostly nonoverlapping expression patterns and that MTM-green fluorescence protein fusion proteins are localized to different subcellular locations. These observations suggest that some of the different functions of MTMs might, in part, be a consequence of unique expression and localization patterns. However, our finding that at least three C. elegans MTMs play essential roles in coelomocyte endocytosis, a process that also requires VPS34, indicates that MTMs do not simply turn off VPS34 but unexpectedly also function as positive regulators of biological processes.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med, New York, NY 10016 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada	New York University; New York University; University of Arizona; Rutgers State University New Brunswick; University of British Columbia	Skolnik, EY (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.			Grant, Barth/0000-0002-5943-8336	NIDDK NIH HHS [DK49207] Funding Source: Medline; NIGMS NIH HHS [F32 GM019167, F32 GM019167-01, GM58573, F32 GM019167-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058573, F32GM019167] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; BRENNER S, 1974, GENETICS, V77, P71; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; CLARK SG, 1994, GENETICS, V137, P987; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P483, DOI 10.1016/S0968-0004(00)01664-9; Fares H, 2001, GENETICS, V159, P133; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kim SA, 2002, J BIOL CHEM, V277, P4526, DOI 10.1074/jbc.M111087200; Laporte J, 1997, HUM MOL GENET, V6, P1505, DOI 10.1093/hmg/6.9.1505; Laporte J, 2002, J CELL SCI, V115, P3105; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Laporte J, 2001, TRENDS GENET, V17, P221, DOI 10.1016/S0168-9525(01)02245-4; McDowall JS, 1997, MOL GEN GENET, V255, P60, DOI 10.1007/s004380050475; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Roggo L, 2002, EMBO J, V21, P1673, DOI 10.1093/emboj/21.7.1673; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 2001, SEMIN CELL DEV BIOL, V12, P193, DOI 10.1006/scdb.2000.0236; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wishart MJ, 2001, CURR OPIN CELL BIOL, V13, P172, DOI 10.1016/S0955-0674(00)00195-2; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7	31	55	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34380	34386		10.1074/jbc.M303259200	http://dx.doi.org/10.1074/jbc.M303259200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12788949	hybrid			2022-12-25	WOS:000185047500095
J	Berrisford, JM; Akerboom, J; Turnbull, AP; de Geus, D; Sedelnikova, SE; Staton, I; McLeod, CW; Verhees, CH; van der Oost, J; Rice, DW; Baker, PJ				Berrisford, JM; Akerboom, J; Turnbull, AP; de Geus, D; Sedelnikova, SE; Staton, I; McLeod, CW; Verhees, CH; van der Oost, J; Rice, DW; Baker, PJ			Crystal structure of Pyrococcus furiosus phosphoglucose isomerase - Implications for substrate binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR FERMENTATION; PROTEIN; ENZYME; EVOLUTION; OPERATION; ALIGNMENT; PATHWAY	Phosphoglucose isomerase (PGI) catalyzes the reversible isomerization between D-fructose 6-phosphate and D-glucose 6-phosphate as part of the glycolytic pathway. PGI from the Archaea Pyrococcus furiosus (Pfu) was crystallized, and its structure was determined by x-ray diffraction to a 2-Angstrom resolution. Structural comparison of this archaeal PGI with the previously solved structures of bacterial and eukaryotic PGIs reveals a completely different structure. Each subunit of the homodimeric Pfu PGI consists of a cupin domain, for which the overall structure is similar to other cupin domain-containing proteins, and includes a conserved transition metal-binding site. Biochemical data on the recombinant enzyme suggests that Fe2+ is bound to Pfu PGI. However, as catalytic activity is not strongly influenced either by the replacement of Fe2+ by a range of transition metals or by the presence or absence of the bound metal ion, we suggest that the metal may not be directly involved in catalysis but rather may be implicated in substrate recognition.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Wageningen & Res Ctr, Dept Agrotechnol & Food Sci, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Univ Sheffield, Dept Chem, Ctr Analyt Sci, Sheffield S3 7HF, S Yorkshire, England	University of Sheffield; Wageningen University & Research; University of Sheffield	Baker, PJ (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	p.baker@sheffield.ac.uk	van+der+Oost, John/Y-2548-2019	Berrisford, John/0000-0003-4442-5871; Baker, Patrick/0000-0003-1995-5643				AKERBOOM J, 2003, IN PRESS ACTA CRYS D; Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cleasby A, 1996, NAT STRUCT BIOL, V3, P470, DOI 10.1038/nsb0596-470; Davies C, 2003, ACTA CRYSTALLOGR D, V59, P453, DOI 10.1107/S0907444902023387; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Giraud MF, 2000, NAT STRUCT BIOL, V7, P398; GRINDLEY HM, 1993, J MOL BIOL, V229, P707, DOI 10.1006/jmbi.1993.1074; Hansen T, 2001, J BACTERIOL, V183, P3428, DOI 10.1128/JB.183.11.3428-3435.2001; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jeong JJ, 2003, FEBS LETT, V535, P200, DOI 10.1016/S0014-5793(02)03900-5; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEUNER A, 1990, ARCH MICROBIOL, V153, P205, DOI 10.1007/BF00247822; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P5412, DOI 10.1073/pnas.96.10.5412; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Verhees CH, 2001, J BIOL CHEM, V276, P40926, DOI 10.1074/jbc.M104603200; VERTIANI C, 1998, P NATL ACAD SCI USA, V95, P12300; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036; Woo EJ, 2002, EMBO J, V21, P2877, DOI 10.1093/emboj/cdf291; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	37	31	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33290	33297		10.1074/jbc.M305170200	http://dx.doi.org/10.1074/jbc.M305170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796486	hybrid			2022-12-25	WOS:000184901800098
J	Guan, ZW; Kamatani, D; Kimura, S; Iyanagi, T				Guan, ZW; Kamatani, D; Kimura, S; Iyanagi, T			Mechanistic studies on the intramolecular one-electron transfer between the two flavins in the human neuronal nitric-oxide synthase and inducible nitric-oxide synthase flavin domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; REDUCTASE DOMAIN; CYTOCHROME-P450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; P-450 REDUCTASE; CALMODULIN; NADPH; FAD	Neuronal nitric-oxide synthase ( nNOS) differs from inducible NOS (iNOS) in both its dependence on the intracellular Ca(2+) concentration and the production rate of NO. To investigate what difference(s) exist between the two NOS flavin domains at the electron transfer level, we isolated the recombinant human NOS flavin domains, which were co-expressed with human calmodulin (CaM). The flavin semiquinones, FADH(.) and FMNH(.), in both NOSs participate in the regulation of one-electron transfer within the flavin domain. Each semiquinone can be identified by a characteristic absorption peak at 520 nm (Guan, Z.-W., and Iyanagi, T. (2003) Arch. Biochem. Biophys. 412, 65-76). NADPH reduction of the FAD and FMN redox centers by the CaM-bound flavin domains was studied by stopped-flow and rapid scan spectrometry. Reduction of the air-stable semiquinone (FAD-FMNH(.)) of both domains with NADPH showed that the extent of conversion of FADH(2)/FMNH(.) to FADH(.)/FMNH(2) in the iNOS flavin domain was greater than that of the nNOS flavin domain. The reduction of both oxidized domains (FAD-FMN) with NADPH resulted in the initial formation of a small amount of disemiquinone, which then decayed. The rate of intramolecular electron transfer between the two flavins in the iNOS flavin domain was faster than that of the nNOS flavin domain. In addition, the formation of a mixture of the two- and four-electron-reduced states in the presence of excess NADPH was different for the two NOS flavin domains. The data indicate a more favorable formation of the active intermediate FMNH(2) in the iNOS flavin domain.	Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima, Hyogo 6781279, Japan	University of Hyogo	Iyanagi, T (corresponding author), Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima, Hyogo 6781279, Japan.	iyanagi@sci.himeji-tech.ac.jp						ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; BACKES WL, 1988, J BIOL CHEM, V263, P247; BHATTACHARYYA AK, 1991, BIOCHEMISTRY-US, V30, P759, DOI 10.1021/bi00217a027; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRITZMCKIBBIN P, 2003, ANAL BIOCHEM, V57, P87; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Guan ZW, 2003, ARCH BIOCHEM BIOPHYS, V412, P65, DOI 10.1016/S0003-9861(03)00009-2; GUAN ZW, 2002, FLAVIN FLAVOPROTEINS, P563; Gutierrez A, 2002, BIOCHEMISTRY-US, V41, P4626, DOI 10.1021/bi0159433; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; Kimura S, 2003, J BIOL CHEM, V278, P3580, DOI 10.1074/jbc.M209838200; KLATT P, 1993, J BIOL CHEM, V268, P14781; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; Kobayashi K, 2001, J BIOL CHEM, V276, P39864, DOI 10.1074/jbc.M102537200; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Matsuda H, 2000, BBA-BIOENERGETICS, V1459, P106, DOI 10.1016/S0005-2728(00)00117-1; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; OPRIAN DD, 1982, J BIOL CHEM, V257, P8935; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; Shen AL, 1996, BIOCHEMISTRY-US, V35, P9451, DOI 10.1021/bi960587n; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wang Y, 1997, J BIOL CHEM, V272, P11392; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	52	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30859	30868		10.1074/jbc.M301929200	http://dx.doi.org/10.1074/jbc.M301929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777376	hybrid			2022-12-25	WOS:000184658800057
J	Martin, LA; Farmer, I; Johnston, SRD; Ali, S; Marshall, C; Dowsett, M				Martin, LA; Farmer, I; Johnston, SRD; Ali, S; Marshall, C; Dowsett, M			Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; RIBOSOMAL S6 KINASE; ESTRADIOL HYPERSENSITIVITY; ANTIESTROGEN RESISTANCE; PHOSPHORYLATION; EXPRESSION; INSULIN; BINDING	The mechanisms involved in resistance to estrogen deprivation are of major importance for optimal patient therapy and the development of new drugs. Long term culture of MCF-7 cells in estrogen (E2)-depleted medium (long term estrogen deprivation; LTED) results in hypersensitivity to E2 coinciding with elevated levels of estrogen receptor (ER) alpha phosphorylated on Ser(118) and MAPK, together with several of its downstream targets associated previously with ERalpha phosphorylation. Our data suggest elevated MAPK activity results from enhanced ERBB2 expression in the LTED cells versus the wild-type (wt), and treatment with the tyrosine kinase inhibitor ZD1839 revealed increased sensitivity in both transcription and proliferation assays. Similarly the MEK inhibitor U0126 decreased transcription and proliferation in the LTED cells and reduced their sensitivity to the proliferative effects of E2, while having no effect on the wt. However, the complete suppression of MAPK activity in the LTED cells did not inhibit ERalpha Ser(118) phosphorylation suggesting that ER activity remained ligand-dependant. The LTED cells also expressed elevated levels of insulin-like growth factor-1R, and inhibition of phosphatidylinositol 3-kinase activity with LY294002 reduced basal ERalpha transactivation by 70% in the LTED cells compared with the wt. However, LY294002 had no effect on ERalpha Ser(118) phosphorylation. These data suggest that although elevated levels of MAPK occur during LTED and influence the phenotype, this is unlikely to be the sole pathway operating to achieve adaptation.	Inst Canc Res, Acad Dept Biochem, London SW3 6JJ, England; Royal Marsden Hosp, Dept Med, London SW3 6JJ, England; Inst Canc Res, Chester Beatty Labs, Div Cell & Mol Biol, London SW3 6JB, England; Hammersmith Hosp, Imperial Coll Sch Med, Dept Med, London W12 0NN, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Martin, LA (corresponding author), Inst Canc Res, Acad Dept Biochem, London SW3 6JJ, England.		Martin, Lesley-Ann/AAA-1841-2020; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen LC, 1999, GENET ENG NEWS, V19, P11; Clarke R, 2001, J STEROID BIOCHEM, V76, P71, DOI 10.1016/S0960-0760(00)00193-X; Coutts AS, 1998, CANCER RES, V58, P4071; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Dowsett M, 1996, ACTA ONCOL, V35, P91, DOI 10.3109/02841869609083979; DUBIK D, 1992, ONCOGENE, V7, P1587; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GEE JM, 2001, ASCO, V20, P71; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Jeng MH, 2000, BREAST CANCER RES TR, V62, P167, DOI 10.1023/A:1006406030612; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kyo S, 1999, CANCER RES, V59, P5917; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Lobenhofer EK, 2000, J STEROID BIOCHEM, V75, P11, DOI 10.1016/S0960-0760(00)00132-1; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moasser MM, 2001, CANCER RES, V61, P7184; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Murphy LC, 2000, CANCER RES, V60, P6266; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Panno ML, 1996, J CANCER RES CLIN, V122, P745, DOI 10.1007/BF01209122; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Song RX, 2002, MOL CELL ENDOCRINOL, V193, P29, DOI 10.1016/S0303-7207(02)00093-X; Stephen RL, 2001, J BIOL CHEM, V276, P40080, DOI 10.1074/jbc.M105892200; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132	50	256	264	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30458	30468		10.1074/jbc.M305226200	http://dx.doi.org/10.1074/jbc.M305226200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12775708	hybrid			2022-12-25	WOS:000184658800009
J	Raijmakers, R; Egberts, WV; van Venrooij, WJ; Pruijn, GJM				Raijmakers, R; Egberts, WV; van Venrooij, WJ; Pruijn, GJM			The association of the human PM/Scl-75 autoantigen with the exosome is dependent on a newly identified N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SCLERODERMA OVERLAP SYNDROME; MESSENGER-RNA TURNOVER; HUMAN PM-SCL; RIBOSOMAL-RNA; YEAST EXOSOME; COMPLEX; COMPONENTS; SUBUNITS; AUTOANTIBODIES	The exosome is a complex of 3' --> 5' exoribonucleases that functions in a variety of cellular processes, all concerning the processing or degradation of RNA. Paradoxically, the previously described cDNA for the human autoantigenic exosome subunit PM/Scl-75 (Alderuccio, F., Chan, E. K., and Tan, E. M. (1991) J. Exp. Med. 173, 941-952) encodes a polypeptide that failed to interact with the exosome complex. Here, we describe the cloning of a more complete cDNA for PM/Scl-75 encoding 84 additional amino acids at its N terminus. We show that only the longer polypeptide is able to associate with the exosome complex. This interaction is most likely mediated by protein-protein interactions with two other exosome subunits, hRrp46p and hRrp41p, one of which was confirmed in a mammalian two-hybrid system. In addition we show that the putative nuclear localization signal present in the C-terminal region of PM/Scl-75 is sufficient, although not essential for nuclear localization of the protein. Moreover, the deletion of this element abrogated the nucleolar accumulation of PM/Scl-75, although its association with the exosome was not disturbed. This suggests that this basic element of PM/Scl-75 plays a role in targeting the exosome to the nucleolus.	Univ Nijmegen, Dept Biochem, Nijmegen Ctr Mol Life Sci, NL-6525 GA Nijmegen, Netherlands	Radboud University Nijmegen	Pruijn, GJM (corresponding author), Univ Nijmegen, Dept Biochem 161, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Raijmakers, Reinout/A-3045-2010; Pruijn, Ger/D-6664-2012	Raijmakers, Reinout/0000-0001-6316-6663; 				ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bliskovski V, 2000, GENOMICS, V64, P106, DOI 10.1006/geno.2000.6118; BLUTHNER M, 1992, J EXP MED, V176, P973, DOI 10.1084/jem.176.4.973; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Briggs MW, 1998, J BIOL CHEM, V273, P13255, DOI 10.1074/jbc.273.21.13255; Brouwer R, 2002, ARTHRITIS RES, V4, P134, DOI 10.1186/ar389; Brouwer R, 2001, ARTHRITIS RES, V3, P102, DOI 10.1186/ar147; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; GE Q, 1992, J CLIN INVEST, V90, P559, DOI 10.1172/JCI115895; GELPI C, 1990, CLIN EXP IMMUNOL, V81, P59; Grosshans H, 2001, J CELL BIOL, V153, P745, DOI 10.1083/jcb.153.4.745; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Raijmakers R, 2002, J MOL BIOL, V323, P653, DOI 10.1016/S0022-2836(02)00947-6; Raijmakers R, 2002, J MOL BIOL, V315, P809, DOI 10.1006/jmbi.2001.5265; REIMER G, 1986, J IMMUNOL, V137, P3802; van Eenennaam H, 2001, MOL BIOL CELL, V12, P3680, DOI 10.1091/mbc.12.11.3680; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Yang XF, 2002, CANCER RES, V62, P5517	26	24	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30698	30704		10.1074/jbc.M302488200	http://dx.doi.org/10.1074/jbc.M302488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788944	Green Published, hybrid			2022-12-25	WOS:000184658800035
J	Wang, JM; Chen, QS; Corne, J; Zhu, Z; Lee, CG; Bhandari, V; Homer, RJ; Elias, JA				Wang, JM; Chen, QS; Corne, J; Zhu, Z; Lee, CG; Bhandari, V; Homer, RJ; Elias, JA			Pulmonary expression of leukemia inhibitory factor induces B cell hyperplasia and confers protection in hyperoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR ANTAGONIST; FACTOR LIF; AIRWAY INFLAMMATION; OXYGEN-TOXICITY; TRANSGENIC MICE; SEPTIC SHOCK; LUNG INJURY; IN-VITRO; INTERLEUKIN-6; INDUCTION	Leukemia inhibitory factor (LIF) is produced by a large number of pulmonary cells in response to diverse stimuli. Exaggerated levels of LIF have also been detected in the adult respiratory distress syndrome and other disorders. The biologic effects of LIF in the lung, however, have not been elucidated. To define the respiratory effects of LIF, we generated transgenic mice in which human LIF was selectively targeted to the mature lung. In these mice, transgene activation caused an impressive increase in bronchoalveolar lavage (BAL) cellularity with a significant increase in BAL and tissue B lymphocytes. LIF also conferred protection in 100% O-2 where it decreased alveolar-capillary protein leak and enhanced survival. This protective effect was associated with the induction of interleukin (IL)-6 mRNA and protein. LIF transgenic mice with a null mutation in IL-6 were more sensitive to the toxic effects of 100% O-2 than LIF-transgenic animals with a wild-type IL-6 locus. These studies demonstrate that LIF induces B cell hyperplasia and confers protection in hyperoxic acute lung injury. They also demonstrate that LIF induces IL-6 and that the protective effects of LIF are mediated, in part, via this inductive event. LIF may be an important regulator of B cell-mediated responses and oxidant injury in the lung.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Vet Affairs Connecticut Hlth Care Syst, Pathol & Lab Med Serv, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Elias, JA (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, Dept Internal Med, Room 44-C,300 Cedar St, New Haven, CT 06520 USA.	jack.elias@yale.edu	Bhandari, Vineet/AAS-3365-2020; Lee, Chun Geun/AAC-2838-2021; homer, robert/P-3884-2019	homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658				Azari MF, 2001, BRAIN RES, V922, P144, DOI 10.1016/S0006-8993(01)03156-0; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; BROWN MA, 1994, CYTOKINE, V6, P300, DOI 10.1016/1043-4666(94)90027-2; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; ELIAS JA, 1994, AM J PHYSIOL, V266, pL426, DOI 10.1152/ajplung.1994.266.4.L426; Fujii T, 2001, AM J RESP CELL MOL, V25, P265, DOI 10.1165/ajrcmb.25.3.4445; Fukada K, 1997, GROWTH FACTORS, V14, P279, DOI 10.3109/08977199709021526; Gruson D, 1998, INTENS CARE MED, V24, P366, DOI 10.1007/s001340050582; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ikezono T, 1997, BBA-MOL CELL RES, V1355, P121, DOI 10.1016/S0167-4889(96)00122-X; JORDAN M, 1995, J IMMUNOL, V154, P4081; Jorens PG, 1996, CYTOKINE, V8, P873, DOI 10.1006/cyto.1996.9999; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; Knight D, 1997, BRIT J PHARMACOL, V120, P883, DOI 10.1038/sj.bjp.0700965; Knight D, 2001, PULM PHARMACOL THER, V14, P169, DOI 10.1006/pupt.2001.0282; Knight DA, 1999, AM J RESP CELL MOL, V20, P834, DOI 10.1165/ajrcmb.20.4.3429; Kozawa O, 2002, CELL SIGNAL, V14, P311, DOI 10.1016/S0898-6568(01)00248-0; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289, DOI 10.1165/ajrcmb.22.3.3690; Lass A, 2001, FERTIL STERIL, V76, P1091, DOI 10.1016/S0015-0282(01)02878-3; Malaval L, 2001, J CELL BIOCHEM, P63; Moran CS, 1997, J VASC RES, V34, P378, DOI 10.1159/000159246; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; SHINGU M, 1995, BRIT J RHEUMATOL, V34, P101; SMITH LJ, 1985, J LAB CLIN MED, V106, P269; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; TILG H, 1994, BLOOD, V83, P113; Tofaris GK, 2002, J NEUROSCI, V22, P6696; ULICH TR, 1994, AM J PHYSIOL-LUNG C, V267, pL442, DOI 10.1152/ajplung.1994.267.4.L442; Wang F, 2002, J MOL CELL CARDIOL, V34, P1309, DOI 10.1006/jmcc.2002.2059; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; WARE CB, 1995, DEVELOPMENT, V121, P1283; WARING P, 1992, J CLIN INVEST, V90, P2031, DOI 10.1172/JCI116083; WARING PM, 1995, P NATL ACAD SCI USA, V92, P1337, DOI 10.1073/pnas.92.5.1337; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Yoon HJ, 1999, J IMMUNOL, V162, P7461; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	40	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31226	31232		10.1074/jbc.M301820200	http://dx.doi.org/10.1074/jbc.M301820200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782633	hybrid			2022-12-25	WOS:000184658800101
J	Beck, S; Lambeau, G; Scholz-Pedretti, K; Gelb, MH; Janssen, MJW; Edwards, SH; Wilton, DC; Pfeilschifter, J; Kaszkin, M				Beck, S; Lambeau, G; Scholz-Pedretti, K; Gelb, MH; Janssen, MJW; Edwards, SH; Wilton, DC; Pfeilschifter, J; Kaszkin, M			Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A(2) (sPLA(2))-IIA expression in mesangial cells by an autocrine loop involving sPLA(2) and peroxisome proliferator-activated receptor alpha activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; GROUP-II; GROUP-V; ACUTE-PANCREATITIS; HUMAN NEUTROPHILS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; GROUP-X; BINDING	In rat mesangial cells, exogenously added secreted phospholipases A(2) (sPLA(2)s) potentiate the expression of pro-inflammatory sPLA(2)-IIA first induced by cytokines like tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta. The transcriptional pathway mediating this effect is, however, unknown. Because products of PLA(2) activity are endogenous activators of peroxisome proliferator-activated receptor alpha (PPARalpha), we postulated that sPLA(2)s mediate their effects on sPLA(2)-IIA expression via sPLA(2) activity and subsequent PPARalpha activation. This study shows that various sPLA(2)s, including venom enzymes, human sPLA(2)-IIA, and wild-type and catalytically inactive H48Q mutant of porcine pancreatic sPLA(2)-IB, enhance the TNFalpha-induced sPLA(2)-IIA expression at the mRNA and protein levels. In cells transfected with luciferase sPLA(2)-IIA promoter constructs, sPLA(2)s are active only when the promoter contains a functional PPRE-1 site. The effect of exogenous sPLA(2)s is also blocked by the PPARalpha inhibitor MK886. Interestingly, the expression of sPLA(2)-IIA induced by TNFalpha alone is also attenuated by MK886, by the sPLA(2)-IIA inhibitor LY311727, by heparinase, which prevents the binding of sPLA(2)-IIA to heparan sulfate proteoglycans, and by the specific cPLA(2)-alpha inhibitor pyrrolidine-1. Together, these data indicate that sPLA(2)-IIA released from mesangial cells by TNFalpha stimulates its own expression via an autocrine loop involving cPLA(2) and PPARalpha. This signaling pathway is also used by exogenously added sPLA(2)s including pancreatic sPLA(2)-IB and is distinct from that used by TNFalpha.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Ctr Pharmacol, D-60590 Frankfurt, Germany; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; Univ Washington, Dept Chem & Biochem, Seattle, WA 98195 USA; Acad Med Ctr, Dept Clin Chem, NL-1100 DD Amsterdam, Netherlands; Univ Southampton, Div Biochem & Mol Biol, Sch Biol Sci, Southampton SO16 7PX, Hants, England	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Washington; University of Washington Seattle; University of Amsterdam; Academic Medical Center Amsterdam; University of Southampton	Kaszkin, M (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Ctr Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	kaszkin@em.uni-frankfurt.de	Lambeau, Gerard/GRJ-5624-2022	gelb, michael/0000-0001-7000-5219; Lambeau, Gerard/0000-0002-9239-518X				Baek SH, 2001, EUR J IMMUNOL, V31, P2709, DOI 10.1002/1521-4141(200109)31:9<2709::AID-IMMU2709>3.0.CO;2-3; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bidgood MJ, 2000, J IMMUNOL, V165, P2790, DOI 10.4049/jimmunol.165.5.2790; Calabrese C, 2000, ALLERGY, V55, P27, DOI 10.1034/j.1398-9995.2000.00504.x; Connolly S, 2002, J MED CHEM, V45, P1348, DOI 10.1021/jm011050x; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Edwards SH, 2002, BIOCHEMISTRY-US, V41, P15468, DOI 10.1021/bi020485z; Fayard JM, 1998, J CELL SCI, V111, P985; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GHOMASHCHI F, 2001, BIOCHIM BIOPHYS ACTA, V1513, P1; Guan YF, 2001, KIDNEY INT, V60, P14, DOI 10.1046/j.1523-1755.2001.00766.x; Guidet B, 1996, INFECTION, V24, P103, DOI 10.1007/BF01713312; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hernandez M, 2002, CIRC RES, V90, P38, DOI 10.1161/hh0102.102978; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; Janssen MJW, 1999, PROTEIN ENG, V12, P497, DOI 10.1093/protein/12.6.497; Kehrer JP, 2001, BIOCHEM J, V356, P899, DOI 10.1042/0264-6021:3560899; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kinoshita E, 1997, FEBS LETT, V407, P343, DOI 10.1016/S0014-5793(97)00373-6; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; Kitadokoro K, 1998, J BIOCHEM, V123, P619; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LIANOS EA, 1993, J LIPID MEDIATOR, V6, P333; Mandal AK, 2001, FASEB J, V15, P1834, DOI 10.1096/fj.00-0831fje; MARKI F, 1986, BIOCHIM BIOPHYS ACTA, V879, P149, DOI 10.1016/0005-2760(86)90097-4; Motoyoshi M, 2001, INT J PANCREATOL, V29, P69, DOI 10.1385/IJGC:29:2:069; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Nevalainen TJ, 1999, HEPATO-GASTROENTEROL, V46, P2731; Partrick DA, 2001, CRIT CARE MED, V29, P989, DOI 10.1097/00003246-200105000-00020; PFEILSCHIFTER J, 1993, EUR J CLIN PHARMACOL, V44, pS7, DOI 10.1007/BF01428384; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; Sartipy P, 2000, CIRC RES, V86, P707, DOI 10.1161/01.RES.86.6.707; Schaefer L, 1998, KIDNEY INT, V54, P1529, DOI 10.1046/j.1523-1755.1998.00149.x; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SCHALKWIJK CG, 1993, FEBS LETT, V333, P339, DOI 10.1016/0014-5793(93)80683-L; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Scholz-Pedretti K, 2000, BRIT J PHARMACOL, V130, P1183, DOI 10.1038/sj.bjp.0703419; Scholz-Pedretti K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133611; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Specty O, 2001, FEBS LETT, V490, P88, DOI 10.1016/S0014-5793(00)02414-5; SUGIURA T, 1995, FEBS LETT, V370, P141, DOI 10.1016/0014-5793(95)00810-V; Tada K, 1998, J IMMUNOL, V161, P5008; Takasaki J, 1996, J LEUKOCYTE BIOL, V60, P174, DOI 10.1002/jlb.60.2.174; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; Triggiani M, 2000, J IMMUNOL, V164, P4908, DOI 10.4049/jimmunol.164.9.4908; Uhl W, 1997, GUT, V40, P386, DOI 10.1136/gut.40.3.386; Urasaki T, 2000, INFLAMM RES, V49, P177, DOI 10.1007/s000110050578; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; van der Helm HA, 2000, BBA-MOL CELL BIOL L, V1484, P215, DOI 10.1016/S1388-1981(00)00021-4; VICKERS PJ, 1995, J LIPID MEDIAT CELL, V12, P185, DOI 10.1016/0929-7855(95)00018-L; Wada A, 1997, BBA-LIPID LIPID MET, V1345, P99, DOI 10.1016/S0005-2760(96)00158-0; WALKER G, 1995, FEBS LETT, V364, P218, DOI 10.1016/0014-5793(95)00402-U; Yokota Y, 1999, BBA-MOL CELL BIOL L, V1438, P213, DOI 10.1016/S1388-1981(99)00053-0; Yuan CJ, 2000, CANCER RES, V60, P1084; Zallen G, 1998, ARCH SURG-CHICAGO, V133, P1229, DOI 10.1001/archsurg.133.11.1229; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	68	81	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29799	29812		10.1074/jbc.M211763200	http://dx.doi.org/10.1074/jbc.M211763200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12782627	hybrid			2022-12-25	WOS:000184507000052
J	Gong, PF; Cederbaum, AI; Nieto, N				Gong, PF; Cederbaum, AI; Nieto, N			Increased expression of cytochrome P450 2E1 induces heme oxygenase-1 through ERK MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; GENE-EXPRESSION; OXIDATIVE STRESS; CYP2E1 OVEREXPRESSION; TRANSCRIPTION FACTORS; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; RAT-LIVER; INJURY; CYTOTOXICITY	The inducible form of heme oxygenase (HO-1) is increased during oxidative injury, and this may be an important defense mechanism against such injury. Cytochrome P450 2E1 (CYP2E1) generates reactive oxygen species and promotes lipid peroxidation. In this study induction of HO-1 by CYP2E1 and the possible role of mitogen-activated protein kinase ( MAPK) in this process were evaluated. HO-1 induction was observed in the livers of chronic alcohol-fed mice or pyrazole-treated rats, conditions known to elevate CYP2E1 levels. Increased levels of HO-1 were observed in HepG2 cells overexpressing CYP2E1 (E47 cells) compared with control HepG2 cells or HepG2 cells expressing CYP3A4. Expression of CYP2E1 in HepG2 cells transcriptionally activated the HO-1 gene, increasing HO-1 mRNA and protein expression and activity of a HO-1 reporter construct. CYP2E1 inhibitors and catalase blocked the increased production of reactive oxygen species as well as HO-1 induction. Increasing oxidative stress by the addition of arachidonic acid or depletion of glutathione further increased HO-1 induction. The phosphorylated form of ERK MAPK but not that of p38 or JNK MAPK was increased in E47 cells compared with the control C34 HepG2 cells. PD98059, a specific inhibitor of ERK MAPK, blocked the activity of a HO-1 reporter in E47 cells but not in C34 cells. These results suggest that increased CYP2E1 activity leads to induction of the HO-1 gene, and the ERK MAPK pathway is important in mediating this process. This induction may serve as an adaptive mechanism to protect the E47 cells against the CYP2E1-dependent oxidative stress.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NIAAA NIH HHS [AA 03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA003312, R56AA003312] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Agarwal A, 1998, J AM SOC NEPHROL, V9, P1990; Akagi R, 2002, JPN J PHARMACOL, V88, P127, DOI 10.1254/jjp.88.127; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1539, DOI 10.1016/S0891-5849(01)00743-2; Chen C., 1997, New Review of Hypermedia and Multimedia, V3, P67, DOI 10.1080/13614569708914684; Chen JX, 2001, PHARMACOL RES, V43, P63, DOI 10.1006/phrs.2000.0753; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Dennery PA, 2000, CURR TOP CELL REGUL, V36, P181; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Favatier F, 2001, BIOCHEM J, V353, P475, DOI 10.1042/0264-6021:3530475; FEIERMAN DE, 1989, CHEM RES TOXICOL, V2, P359, DOI 10.1021/tx00012a002; Fogg S, 1999, AM J RESP CELL MOL, V20, P797, DOI 10.1165/ajrcmb.20.4.3477; Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; KYLE ME, 1988, J BIOL CHEM, V263, P3784; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Mari M, 2001, HEPATOLOGY, V33, P652, DOI 10.1053/jhep.2001.22521; Mari R, 2000, J BIOL CHEM, V275, P15563; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; Pratico D, 1998, J INVEST MED, V46, P51; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; Takahashi S, 1998, CELL BIOCHEM FUNCT, V16, P183, DOI 10.1002/(SICI)1099-0844(199809)16:3<183::AID-CBF784>3.0.CO;2-0; Takahashi S, 2003, INT J MOL MED, V11, P57; Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev; Wu CC, 2001, FOOD CHEM TOXICOL, V39, P563, DOI 10.1016/S0278-6915(00)00171-X; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Wu DF, 2001, ALCOHOL CLIN EXP RES, V25, P619, DOI 10.1097/00000374-200104000-00021; WU DF, 1993, J PHARMACOL EXP THER, V264, P1468; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082	42	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29693	29700		10.1074/jbc.M304728200	http://dx.doi.org/10.1074/jbc.M304728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777398	hybrid			2022-12-25	WOS:000184507000040
J	Kehoe, LE; Snidwongse, J; Courvalin, P; Rafferty, JB; Murray, IA				Kehoe, LE; Snidwongse, J; Courvalin, P; Rafferty, JB; Murray, IA			Structural basis of Synercid (R) (quinupristin-dalfopristin) resistance in gram-positive bacterial pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLTRANSFERASE; GENE; CHLORAMPHENICOL; VIRGINIAMYCIN; SEQUENCE; PROGRAM; STREPTOGRAMINS; PARAMETERS; BOND	Synercid(R), a new semisynthetic streptogramin-derived antibiotic containing dalfopristin and quinupristin, is used in treatment of life-threatening infections caused by glycopeptide-resistant Enterococcus faecium and other bacterial pathogens. However, dissemination of genes encoding virginiamycin acetyltransferases, enzymes that confer resistance to streptogramins, threatens to limit the medical utility of the quinupristin-dalfopristin combination. Here we present structures of virginiamycin acetyltransferase D (VatD) determined at 1.8 Angstrom resolution in the absence of ligands, at 2.8 Angstrom resolution bound to dalfopristin, and at 3.0 Angstrom resolution in the presence of acetyl-coenzyme A. Dalfopristin is bound by VatD in a similar conformation to that described previously for the streptogramin virginiamycin M1. However, specific interactions with the substrate are altered as a consequence of a conformational change in the pyrollidine ring that is propagated to adjacent constituents of the dalfopristin macrocycle. Inactivation of dalfopristin involves acetyl transfer from acetylcoenzyme A to the sole (O-18) hydroxy group of the antibiotic that lies close to the side chain of the strictly conserved residue, His-82. Replacement of residue 82 by alanine is accompanied by a fall in specific activity of > 10(5)-fold, indicating that the imidazole moiety of His-82 is a major determinant of catalytic rate enhancement by VatD. The structure of the VatD-dalfopristin complex can be used to predict positions where further structural modification of the drug might preclude enzyme binding and thereby circumvent Synercid(R) resistance.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Inst Pasteur, Unite Agents Antibacteriens, F-75015 Paris, France	University of Sheffield; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Murray, IA (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Ct,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	i.a.murray@sheffield.ac.uk		Rafferty, John/0000-0003-1183-7474				AARESTRUP FM, 2001, ANTIMICROB AGENTS CH, V45, P3223; ALLIGNET J, 1993, GENE, V130, P91, DOI 10.1016/0378-1119(93)90350-C; ALLIGNET J, 1992, GENE, V117, P45, DOI 10.1016/0378-1119(92)90488-B; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamas-Jacques N, 1999, J APPL MICROBIOL, V87, P939, DOI 10.1046/j.1365-2672.1999.00955.x; Batard E, 2002, ANTIMICROB AGENTS CH, V46, P2174, DOI 10.1128/AAC.46.7.2174-2178.2002; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P10363, DOI 10.1021/bi980759b; BOUNINE JP, 1999, Patent No. 5994338; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cocito C, 1997, J ANTIMICROB CHEMOTH, V39, P7, DOI 10.1093/jac/39.suppl_1.7; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERSHT AR, 1986, PHILOS T R SOC A, V317, P305, DOI 10.1098/rsta.1986.0041; Henney JE, 1999, JAMA-J AM MED ASSOC, V282, P1613, DOI 10.1001/jama.282.17.1613; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leclercq R, 1998, LANCET, V352, P591, DOI 10.1016/S0140-6736(05)79570-2; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murray IA, 1997, ANTIMICROB AGENTS CH, V41, P1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RENDEFOURNIER R, 1993, ANTIMICROB AGENTS CH, V37, P2119, DOI 10.1128/AAC.37.10.2119; Roberts MC, 1999, ANTIMICROB AGENTS CH, V43, P2823, DOI 10.1128/AAC.43.12.2823; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; SNIDWONGSE J, 2002, THESIS U SHEFFIELD S; Sugantino M, 2002, BIOCHEMISTRY-US, V41, P2209, DOI 10.1021/bi011991b; Thal LA, 1999, J ANTIMICROB CHEMOTH, V43, P171, DOI 10.1093/jac/43.2.171; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	41	31	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29963	29970		10.1074/jbc.M303766200	http://dx.doi.org/10.1074/jbc.M303766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771141	hybrid			2022-12-25	WOS:000184507000070
J	van Buul, JD; Voermans, C; van Gelderen, J; Anthony, EC; van der Schoot, CE; Hordijk, PL				van Buul, JD; Voermans, C; van Gelderen, J; Anthony, EC; van der Schoot, CE; Hordijk, PL			Leukocyte-endothelium interaction promotes SDF-1-dependent polarization of CXCR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; BONE-MARROW; VASCULAR ENDOTHELIUM; CHEMOKINE SDF-1; CD34(+) CELLS; LEADING-EDGE; SHEAR-FLOW; TRANSENDOTHELIAL MIGRATION; CHEMOATTRACTANT RECEPTOR; LYMPHOCYTE MIGRATION	Chemokine-driven migration is accompanied by polarization of the cell body and of the intracellular signaling machinery. The extent to which chemokine receptors polarize during chemotaxis is currently unclear. To analyze the distribution of the chemokine receptor CXCR4 during SDF-1 (CXCL12)-induced chemotaxis, we retrovirally expressed a CXCR4-GFP fusion protein in the CXCR4-deficient human hematopoietic progenitor cell line KG1a. This KG1a CXCR4-GFP cell line showed full restoration of SDF-1 responsiveness in assays detecting activation of ERK1/2 phosphorylation, actin polymerization, adhesion to endothelium under conditions of physiological flow, and (transendothelial) chemotaxis. When adhered to cytokine-activated endothelium in the absence of SDF-1, CXCR4 did not localize to the leading edge of the cell but was uniformly distributed over the plasma membrane. In contrast, when SDF-1 was immobilized on cytokine-activated endothelium, the CXCR4-GFP receptors that were present on the cell surface markedly redistributed to the leading edge of migrating cells. In addition, CXCR4-GFP co-localized with lipid rafts in the leading edge of SDF-1 stimulated cells, at the sites of contact with the endothelial surface. Inhibition of lipid raft formation prevents SDF-1-dependent migration, internalization of CXCR4, and polarization to the leading edge of CXCR4, indicating that CXCR4 surface expression and signaling requires lipid rafts. These data show that SDF-1, immobilized on activated human endothelium, induces polarization of CXCR4 to the leading edge of migrating cells, revealing co-operativity between chemokine and substrate in the control of cell migration.	SLB, Sanquin Res, Dept Expt Immunohematol, NL-1066 CX Amsterdam, Netherlands; Landsteinder Lab, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1066 CX Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Hordijk, PL (corresponding author), SLB, Sanquin Res, Dept Expt Immunohematol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		van Buul, Jaap D/AAJ-4371-2021; Voermans, Carlijn/GPP-3405-2022	van Buul, Jaap D/0000-0003-0054-7949; Hordijk, Peter/0000-0002-3348-078X				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Alonso MA, 2001, J CELL SCI, V114, P3957; Baribaud F, 2001, J VIROL, V75, P8957, DOI 10.1128/JVI.75.19.8957-8967.2001; Cinamon G, 2001, J LEUKOCYTE BIOL, V69, P860; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; MCKAY DA, 1991, J CELL SCI, V100, P437; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Mohle R, 1999, ANN NY ACAD SCI, V872, P176, DOI 10.1111/j.1749-6632.1999.tb08463.x; Netelenbos T, 2001, EXP HEMATOL, V29, P884, DOI 10.1016/S0301-472X(01)00653-1; Nieto M, 1997, J EXP MED, V186, P153, DOI 10.1084/jem.186.1.153; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Pelletier AJ, 2000, BLOOD, V96, P2682; Quesenberry PJ, 1998, P NATL ACAD SCI USA, V95, P15155, DOI 10.1073/pnas.95.26.15155; Riviere C, 1999, BLOOD, V93, P1511, DOI 10.1182/blood.V93.5.1511.405k02_1511_1523; ROOD PM, 2000, EUR J CLIN INVEST, V30, P473; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shamri R, 2002, J BIOL CHEM, V277, P40027, DOI 10.1074/jbc.M206806200; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; Ulfman LH, 1999, J IMMUNOL, V163, P343; van Buul JD, 2002, J IMMUNOL, V168, P588, DOI 10.4049/jimmunol.168.2.588; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; Voermans C, 2000, STEM CELLS, V18, P435, DOI 10.1634/stemcells.18-6-435; Voermans C, 1999, EXP HEMATOL, V27, P1806, DOI 10.1016/S0301-472X(99)00113-7; Voermans C, 2001, EXP HEMATOL, V29, P1456, DOI 10.1016/S0301-472X(01)00740-8; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365	39	83	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30302	30310		10.1074/jbc.M304764200	http://dx.doi.org/10.1074/jbc.M304764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766157	hybrid			2022-12-25	WOS:000184507000110
J	Alanen, HI; Williamson, RA; Howard, MJ; Lappi, AK; Jantti, HP; Rautio, SM; Kellokumpu, S; Ruddock, LW				Alanen, HI; Williamson, RA; Howard, MJ; Lappi, AK; Jantti, HP; Rautio, SM; Kellokumpu, S; Ruddock, LW			Functional characterization of ERp18, a new endoplasmic reticulum-located thioredoxin superfamily member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; MULTIPLE SEQUENCE ALIGNMENT; ESCHERICHIA-COLI THIOREDOXIN; BOND FORMATION; LUMENAL PROTEIN; LIVING CELLS; DSBA; FAMILY; YEAST; PATHWAY	Native disulfide bond formation in the endoplasmic reticulum is a critical process in the maturation of many secreted and outer membrane proteins. Although a large number of proteins have been implicated in this process, it is clear that our current understanding is far from complete. Here we describe the functional characterization of a new 18-kDa protein (ERp18) related to protein-disulfide isomerase. We show that ERp18 is located in the endoplasmic reticulum and that it contains a single catalytic domain with an unusual CGAC active site motif and a probable insertion between beta(3) and alpha(3) of the thioredoxin fold. From circular dichroism and NMR measurements, ERp18 is well structured and undergoes only a minor conformational change upon dithioldisulfide exchange in the active site. Guanidinium chloride denaturation curves indicate that the reduced form of the protein is more stable than the oxidized form, suggesting that it is involved in disulfide bond formation. Furthermore, in vitro ERp18 possesses significant peptide thiol-disulfide oxidase activity, which is dependent on the presence of both active site cysteine residues. This activity differs from that of the human PDI family in that under standard assay conditions it is limited by substrate oxidation and not by enzyme reoxidation. A putative physiological role for Erp18 in native disulfide bond formation is discussed.	Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Kent	Ruddock, LW (corresponding author), Univ Oulu, Bioctr Oulu, POB 3000, FIN-90014 Oulu, Finland.			Howard, Mark/0000-0002-0762-2887; Kinnunen, Sini/0000-0003-1592-8306; Ruddock, Lloyd/0000-0002-6247-686X				ALANEN HI, 2003, IN PRESS ANTIOXID RE; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BLANK J, IN PRESS ANTIOXID RE; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Couprie J, 1998, PROTEIN SCI, V7, P2065, DOI 10.1002/pro.5560071003; CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; Depiereux E, 1997, COMPUT APPL BIOSCI, V13, P249; DYSON HJ, 1991, BIOCHEMISTRY-US, V30, P4262, DOI 10.1021/bi00231a023; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; Guddat LW, 1997, PROTEIN SCI, V6, P1893, DOI 10.1002/pro.5560060910; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Hu SH, 1997, J MOL BIOL, V268, P137, DOI 10.1006/jmbi.1997.0940; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Ruddock LW, 1996, BIOCHEM J, V315, P1001, DOI 10.1042/bj3151001; Ruoppolo M, 1996, BIOCHEMISTRY-US, V35, P13636, DOI 10.1021/bi960755b; Sargsyan E, 2002, J BIOL CHEM, V277, P17009, DOI 10.1074/jbc.M200539200; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972	45	71	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28912	28920		10.1074/jbc.M304598200	http://dx.doi.org/10.1074/jbc.M304598200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12761212	hybrid			2022-12-25	WOS:000184421100070
J	Vogt, S; Grosse, R; Schultz, G; Offermanns, S				Vogt, S; Grosse, R; Schultz, G; Offermanns, S			Receptor-dependent RhoA activation in G(12)/G(13)-deficient cells - Genetic evidence for an involvement of G(q)/G(11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; NEURITE RETRACTION; G(12) FAMILY; P115 RHOGEF; PDZ-RHOGEF; G-ALPHA(12); ADHESION; GTPASE; LARG	The small GTPase RhoA is involved in the regulation of various cellular functions like the remodeling of the actin cytoskeleton and the induction of transcriptional activity. G-protein-coupled receptors (GPCRs), which are able to activate G(q)/G(11) and G(12)/G(13) are major upstream regulators of RhoA activity, and G(12)/G(13) have been shown to couple GPCRs to the activation of Rho by regulating the activity of a subfamily of RhoGEF proteins. However, the possible contribution of G(q)/G(11) to the regulation of RhoA activity via GPCRs is controversial. We have used a genetic approach to study the role of heterotrimeric G-proteins in the activation of RhoA via endogenous GPCRs. In pertussis toxin-treated G(alpha12)/G(alpha13)-deficient as well as in Galpha(q)/Galpha(11)-deficient mouse embryonic fibroblasts (MEFs), in which coupling of receptors is restricted to G(q)/G(11) and G(12)/G(13), respectively, receptor activation results in Rho activation. Rho activation induced by receptor agonists via G(q)/G(11) occurs with lower potency than Rho activation via G(12)/G(13). Activation of RhoA via G(q)/G(11) is not affected by the phospholipase-C blocker U73122 or the Ca2+-chelator BAPTA, but can be blocked by a dominant-negative mutant of the RhoGEF protein LARG. Our data clearly show that G(12)/G(13) as well as G(q)/G(11) alone can couple GPCRs to the rapid activation of RhoA. G(q)/G(11)-mediated RhoA activation occurs independently of phospholipase C-beta and appears to involve LARG.	Heidelberg Univ, Inst Pharmacol, D-69120 Heidelberg, Germany; Free Univ Berlin, Inst Pharmacol, D-14195 Berlin, Germany	Ruprecht Karls University Heidelberg; Free University of Berlin	Offermanns, S (corresponding author), Heidelberg Univ, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	Stefan.Offermanns@urz.uni-heidelberg.de	Vogt, Stephan/AAQ-7456-2021; Offermanns, Stefan/L-3313-2017	Grosse, Robert/0000-0002-3380-5273; Offermanns, Stefan/0000-0001-8676-6805				Aasheim HC, 1997, ONCOGENE, V14, P1747, DOI 10.1038/sj.onc.1200994; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Dutt P, 2002, FEBS LETT, V531, P565, DOI 10.1016/S0014-5793(02)03625-6; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	41	162	164	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28743	28749		10.1074/jbc.M304570200	http://dx.doi.org/10.1074/jbc.M304570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12771155	hybrid			2022-12-25	WOS:000184421100050
J	Russo, M; Palumbo, R; Mupo, A; Tosto, M; Iacomino, G; Scognamiglio, A; Tedesco, I; Galano, G; Russo, GL				Russo, M; Palumbo, R; Mupo, A; Tosto, M; Iacomino, G; Scognamiglio, A; Tedesco, I; Galano, G; Russo, GL			Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase C alpha	ONCOGENE			English	Article						quercetin; PKC alpha; CD95/Fas/Apol; flavonoids; HPB-ALL; apoptosis	PHOSPHOINOSITIDE 3-KINASE; DOWN-REGULATION; DNA-SYNTHESIS; DEATH DOMAIN; COLON-CANCER; IN-VITRO; FAS; INHIBITION; GROWTH; PKC	We previously demonstrated that quercetin, a naturally occurring flavonoid with strong antioxidant properties, was able to enhance programmed cell death in HPB-acute lymphoblastic leukemia (ALL) cell line, derived from a human tymoma, when associated with the agonistic antiCD95 monoclonal antibody. Here, we report that HPBALL cells are normally resistant to Cd95-mediated apoptosis, and quercetin is able to sensitize this cell line through a mechanism independent of its antioxidant properties. In fact, other compounds structurally and functionally similar to quercetin, when associated with anti-CD95 antibody did not induce any CD95-mediated apoptosis, still maintaining their antioxidant capacity. We found that quercetin effects are mediated by the activation of PKCalpha. Treatment of HPB-ALL cells with quercetin slightly decreased PKCa activity, but when the flavonoid was associated with anti-CD95, the kinase activity increased by 12-fold with respect to the treatment with quercetin. In addition, overexpression of PKCalpha induced programmed cell death in the absence of any additional stimulus, while a kinase-defective mutant of PKCalpha was ineffective. Our data confirm the involvement of specific PKC isoforms in CD95 signaling and suggest, for the first time, that quercetin targets this pathway increasing apoptogenic response in a cell line resistant to CD95-mediated apoptosis.	CNR, Ist Sci Alimentaz, I-83100 Avellino, Italy; Staz Zool Anton Dohrn, I-80121 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); Stazione Zoologica Anton Dohrn di Napoli	Russo, GL (corresponding author), CNR, Ist Sci Alimentaz, Via Roma 52 A-C, I-83100 Avellino, Italy.	russogl@inwind.it	Russo, Maria/AAJ-9424-2020; russo, maria/E-8585-2011; RUSSO, GIAN LUIGI/GQB-0962-2022; Iacomino, Giuseppe/AAV-2456-2021	russo, maria/0000-0001-8385-9184; IACOMINO, GIUSEPPE/0000-0001-5231-2231; PALUMBO, ROSANNA/0000-0002-3858-4529; Mupo, Annalisa/0000-0002-2771-0462; RUSSO, GIAN LUIGI/0000-0001-9321-1613				Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Alberts DS, 1999, CANCER RES, V59, P4743; ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; AVILA MA, 1994, CANCER RES, V54, P2424; Avila MA, 1996, ADV EXP MED BIOL, V401, P101; BORS W, 1990, METHOD ENZYMOL, V186, P343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEBATIN KM, 1995, LEUKEMIA, V9, P815; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Ferrandina G, 1998, INT J CANCER, V77, P747, DOI 10.1002/(SICI)1097-0215(19980831)77:5<747::AID-IJC14>3.0.CO;2-Z; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Galati G, 2000, Drug Metabol Drug Interact, V17, P311; Gamet-Payrastre L, 1999, GEN PHARMACOL-VASC S, V32, P279, DOI 10.1016/S0306-3623(98)00220-1; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; Goldberg DM, 1996, ANAL CHEM, V68, P1688, DOI 10.1021/ac951083i; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAGIWARA M, 1988, BIOCHEM PHARMACOL, V37, P2987; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ishikawa Y, 2000, BIOCHEM BIOPH RES CO, V279, P629, DOI 10.1006/bbrc.2000.4016; Iwao K, 1999, BBA-GEN SUBJECTS, V1427, P112, DOI 10.1016/S0304-4165(99)00007-0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; JARVIS WD, 1994, CANCER RES, V54, P1707; Kang TB, 1997, BIOCHEM PHARMACOL, V54, P1013, DOI 10.1016/S0006-2952(97)00260-8; Kang ZC, 1999, NUTR CANCER, V35, P175, DOI 10.1207/S15327914NC352_12; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krammer PH, 1998, ADV CANCER RES, V75, P251, DOI 10.1016/S0065-230X(08)60744-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larocca LM, 1997, INT J CANCER, V73, P75, DOI 10.1002/(SICI)1097-0215(19970926)73:1<75::AID-IJC13>3.0.CO;2-4; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Le Marchand L, 2000, JNCI-J NATL CANCER I, V92, P154, DOI 10.1093/jnci/92.2.154; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921; Mandil R, 2001, CANCER RES, V61, P4612; Middleton E, 1986, FLAVONOIDS ADV RES 1, V1993, P619; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; MORIKAWA S, 1978, INT J CANCER, V21, P166, DOI 10.1002/ijc.2910210207; Mouria M, 2002, INT J CANCER, V98, P761, DOI 10.1002/ijc.10202; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Noroozi M, 2000, EUR J CLIN NUTR, V54, P143, DOI 10.1038/sj.ejcn.1600908; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Plaumann B, 1996, ONCOGENE, V13, P1605; Ranelletti FO, 2000, INT J CANCER, V85, P438, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt;438::AID-IJC22&gt;3.0.CO;2-F; Reddy BS, 2000, CANCER EPIDEM BIOMAR, V9, P239; Rong Y, 2000, ANTICANCER RES, V20, P4339; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Russo M, 1999, FEBS LETT, V462, P322, DOI 10.1016/S0014-5793(99)01544-6; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; STAVRIC B, 1994, CLIN BIOCHEM, V27, P319, DOI 10.1016/0009-9120(94)00039-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Weber G, 1999, ADV ENZYME REGUL, V39, P51, DOI 10.1016/S0065-2571(98)00027-2; Weisburger JH, 2000, AM J CLIN NUTR, V71, p1710S, DOI 10.1093/ajcn/71.6.1710S; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381	73	58	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3330	3342		10.1038/sj.onc.1206493	http://dx.doi.org/10.1038/sj.onc.1206493			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761503				2022-12-25	WOS:000183040000015
J	Brezniceanu, ML; Volp, K; Bosse, S; Solbach, C; Lichter, P; Joos, S; Zornig, M				Brezniceanu, ML; Volp, K; Bosse, S; Solbach, C; Lichter, P; Joos, S; Zornig, M			HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma	FASEB JOURNAL			English	Article						high-mobility group box protein; apoptosis; Bak	DNA-BINDING DOMAIN; CYTOCHROME-C; CASPASE ACTIVATION; CHROMATIN PROTEIN; APOPTOTIC CHANGES; ENHANCES BINDING; BAX; GENE; MITOCHONDRIA; RELEASE	Apoptosis is a fundamental biological process used to eliminate unwanted cells in a multicellular organism. An increasing number of regulatory proteins have been identified that either promote or inhibit apoptosis. For tumors to arise, apoptosis must be blocked in the transformed cells, for example by mutational overexpression of anti-apoptotic proteins, which represent attractive target proteins for molecular therapy strategies. In a functional yeast survival screen designed to select new anti-apoptotic mammalian genes, we have identified the chromosomal high-mobility group box-1 protein (HMGB1) as an inhibitor of yeast cell death induced by the pro-apoptotic Bcl-2 family member Bak. The C-terminal 33 amino acids of HMGB1 are dispensable for this inhibitory function. HMGB1 is also able to protect mammalian cells against different death stimuli including ultraviolet radiation, CD95-, TRAIL-, Casp-8-, and Bax-induced apoptosis. We found high HMGB1 protein levels in human primary breast carcinoma. Hmgb1 RNA levels are changing during different stages of mouse mammary gland development and are particularly low during lactation and involution. These data suggest that HMGB1 may participate in the regulation of mammary gland apoptosis and that its high expression level promotes tumor growth because of its anti-apoptotic properties.	Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Klin Gynakol & Geburtshilfe, D-60590 Frankfurt, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Zornig, M (corresponding author), Chemotherapeut Forschungsinst, Georg Speyer Haus,Paul Ehrlich St 42-44, D-60596 Frankfurt, Germany.	zoernig@em.uni-frankfurt.de	li, tao/B-2402-2008					Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Chiappetta G, 1996, ONCOGENE, V13, P2439; Conradt B, 2002, NAT CELL BIOL, V4, pE139, DOI 10.1038/ncb0602-e139; Damiano JS, 2002, CURR CANCER DRUG TAR, V2, P37, DOI 10.2174/1568009023334033; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Flohr AM, 2001, ANTICANCER RES, V21, P3881; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Greenhalf W, 1999, YEAST, V15, P1307, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1307::AID-YEA455>3.3.CO;2-V; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Gutierrez-Puente Y, 2002, SEMIN ONCOL, V29, P71, DOI 10.1053/sonc.2002.34058; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawkins CJ, 2001, APOPTOSIS, V6, P331, DOI 10.1023/A:1011329917895; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; Kawahara N, 1996, CANCER RES, V56, P5330; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Mitsouras K, 2002, MOL CELL BIOL, V22, P4390, DOI 10.1128/MCB.22.12.4390-4401.2002; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pasheva EA, 2002, INT J BIOCHEM CELL B, V34, P87, DOI 10.1016/S1357-2725(01)00096-6; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Romine LE, 1998, MOL ENDOCRINOL, V12, P664, DOI 10.1210/me.12.5.664; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Shaham S, 1998, CELL, V92, P425, DOI 10.1016/S0092-8674(00)80934-4; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thatte U, 1997, DRUGS, V54, P511, DOI 10.2165/00003495-199754040-00002; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Travers A, 2000, CURR OPIN STRUC BIOL, V10, P102, DOI 10.1016/S0959-440X(99)00056-1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; Xiang YY, 1997, INT J CANCER, V74, P1; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	64	174	207	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1295	+		10.1096/fj.02-0621fje	http://dx.doi.org/10.1096/fj.02-0621fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759333				2022-12-25	WOS:000183165000022
J	Bieganowski, P; Pace, HC; Brenner, C				Bieganowski, P; Pace, HC; Brenner, C			Eukaryotic NAD(+) synthetase Qns1 contains an essential, obligate intramolecular thiol glutamine amidotransferase domain related to nitrilase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DIPHOSPHOPYRIDINE NUCLEOTIDE; INTRAGENIC COMPLEMENTATION; CALORIE RESTRICTION; CRYSTAL-STRUCTURE; LIFE-SPAN; PROTEIN; GENE; BIOSYNTHESIS; IDENTIFICATION	NAD(+) is an essential co-enzyme for redox reactions and is consumed in lysine deacetylation and poly(ADP-ribosyl) ation. NAD(+) synthetase catalyzes the final step in NAD(+) synthesis in the well characterized de novo, salvage, and import pathways. It has been long known that eukaryotic NAD(+) synthetases use glutamine to amidate nicotinic acid adenine dinucleotide while many purified prokaryotic NAD(+) synthetases are ammonia-dependent. Earlier, we discovered that glutamine-dependent NAD(+) synthetases contain N-terminal domains that are members of the nitrilase superfamily and hypothesized that these domains function as glutamine amidotransferases for the associated synthetases. Here we show yeast glutamine-dependent NAD(+) synthetase Qns1 requires both the nitrilase-related active-site residues and the NAD(+) synthetase active-site residues for function in vivo. Despite failure to complement the lethal phenotype of qns1 disruption, the former mutants retain ammonia-dependent NAD(+) synthetase activity in vitro, whereas the latter mutants retain basal glutaminase activity. Moreover, the two classes of mutants fail to trans-complement despite forming a stable heteromultimer in vivo. These data indicate that the nitrilase-related domain in Qns1 is the fourth independently evolved glutamine amidotransferase domain to have been identified in nature and that glutamine-dependence is an obligate phenomenon involving intramolecular transfer of ammonia over a predicted distance of 46 Angstrom from one active site to another within Qns1 monomers.	Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA	Jefferson University	Brenner, C (corresponding author), Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA.	charles.brenner@dartmouth.edu	Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [P01 CA077738, P01 CA077738-040003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell SD, 2002, SCIENCE, V296, P148, DOI 10.1126/science.1070506; Bera AK, 2000, J BIOL CHEM, V275, P7975, DOI 10.1074/jbc.275.11.7975; Bieganowski P, 2003, J BIOL CHEM, V278, P33056, DOI 10.1074/jbc.M302276200; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brachmann CB, 1998, YEAST, V14, P115; Brenner C, 2002, CURR OPIN STRUC BIOL, V12, P775, DOI 10.1016/S0959-440X(02)00387-1; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cantoni R, 1998, J BACTERIOL, V180, P3218, DOI 10.1128/JB.180.12.3218-3221.1998; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Ghosh S, 1996, GENE, V176, P249, DOI 10.1016/0378-1119(96)00260-0; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Hara N, 2003, J BIOL CHEM, V278, P10914, DOI 10.1074/jbc.M209203200; Kaiser C., 1994, METHODS YEAST GENETI; KLEM TJ, 1993, BIOCHEMISTRY-US, V32, P5177, DOI 10.1021/bi00070a029; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIEB M, 1976, MOL GEN GENET, V146, P291, DOI 10.1007/BF00701253; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pace HC, 2001, GENOME BIOL, V2; PREISS J, 1958, J BIOL CHEM, V233, P488; PREISS J, 1958, J BIOL CHEM, V233, P493; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Rizzi M, 1998, STRUCTURE, V6, P1129, DOI 10.1016/S0969-2126(98)00114-2; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCER RL, 1967, J BIOL CHEM, V242, P385; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Yu B, 2000, CELL MOL LIFE SCI, V57, P1637, DOI 10.1007/PL00000646; YU CK, 1972, J BIOL CHEM, V247, P4794; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	37	55	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33049	33055		10.1074/jbc.M302257200	http://dx.doi.org/10.1074/jbc.M302257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12771147	hybrid			2022-12-25	WOS:000184901800069
J	Corti, C; Clarkson, RWE; Crepaldi, L; Sala, CF; Xuereb, JH; Ferraguti, F				Corti, C; Clarkson, RWE; Crepaldi, L; Sala, CF; Xuereb, JH; Ferraguti, F			Gene structure of the human metabotropic glutamate receptor 5 and functional analysis of its multiple promoters in neuroblastoma and astroglioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; TISSUE-SPECIFIC EXPRESSION; MGLUR5 MESSENGER-RNA; NF-KAPPA-B; RAT-BRAIN; DEVELOPMENTAL EXPRESSION; ALTERNATIVE PROMOTER; GENOMIC ORGANIZATION; REACTIVE ASTROCYTES; CORTICAL ASTROCYTES	The metabotropic glutamate receptor 5 (mGluR5) has a discrete tissue expression mainly limited to neural cells. Expression of mGluR5 is developmentally regulated and undergoes dramatic changes in association with neuropathological disorders. We report the complete genomic structure of the mGluR5 gene, which is composed of 11 exons and encompasses similar to563 kbp. Three clusters of multiple transcription initiation sites located on three distinct exons (IA, IB, and II), which undergo alternative splicing, have been identified. The 5'-flanking regions of these exons were isolated and, using a luciferase reporter gene assay, shown to possess active promoter elements in SKN-MC neuroblastoma and U178-MG astroglioma cells. Promoter IA was characterized by a CpG island; promoter IB contained a TATA box, and promoter II possessed three active Oct-1-binding sites. Preferential luciferase activity was observed in SKN-MC concomitant with differential DNA binding activity to several responsive elements, including CREB, Oct-1, C/EBP, and Brn-2. Exposure to growth factors produced enhanced expression of promoters IB and II in astroglioma cells and activation of NF-kappaB. These results suggest that alternative 5'-splicing and usage of multiple promoters may contribute regulatory mechanisms for tissue- and context-specific expression of the mGluR5 gene.	Univ Innsbruck, Dept Pharmacol, A-6020 Innsbruck, Austria; Univ Cambridge, Dept Pathol, Cambridge Brain Bank Lab, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; GlaxoSmithKline Med Res Ctr, Psychiat Ctr Excellence Drug Discovery, Dept Biol, I-37135 Verona, Italy	University of Innsbruck; University of Cambridge; University of Cambridge; GlaxoSmithKline	Ferraguti, F (corresponding author), Univ Innsbruck, Dept Pharmacol, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	francesco.ferraguti@uibk.ac.at	Francesco, Ferraguti/AAD-3422-2020; Clarkson, Richard/A-7505-2010	Francesco, Ferraguti/0000-0002-3843-5857; Corti, Corrado/0000-0002-7876-9114; clarkson, richard/0000-0001-7389-8673				Abe S, 2001, NEUROPSYCHOPHARMACOL, V25, P173, DOI 10.1016/S0893-133X(00)00250-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200; Aronica E, 2000, EUR J NEUROSCI, V12, P2333, DOI 10.1046/j.1460-9568.2000.00131.x; Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bates B, 2002, MOL BRAIN RES, V109, P18, DOI 10.1016/S0169-328X(02)00458-8; Brice NL, 2002, DIABETOLOGIA, V45, P242, DOI 10.1007/s00125-001-0750-0; Cai ZH, 2000, GLIA, V29, P70, DOI 10.1002/(SICI)1098-1136(20000101)29:1<70::AID-GLIA7>3.0.CO;2-V; Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Corti C, 2001, BIOCHEM BIOPH RES CO, V286, P381, DOI 10.1006/bbrc.2001.5391; Corti C, 2000, J NEUROGENET, V14, P207, DOI 10.3109/01677060009084499; Devon RS, 2001, MOL PSYCHIATR, V6, P311, DOI 10.1038/sj.mp.4000848; Ferraguti F, 2001, EXP BRAIN RES, V137, P1, DOI 10.1007/s002210000633; Frati C, 2000, J CELL PHYSIOL, V183, P364, DOI 10.1002/(SICI)1097-4652(200006)183:3<364::AID-JCP9>3.3.CO;2-O; Freeman WM, 2001, NEUROSCIENCE, V108, P371, DOI 10.1016/S0306-4522(01)00432-8; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; Ghosh PK, 1997, DEV BRAIN RES, V102, P1, DOI 10.1016/S0165-3806(97)00066-7; Griffin C, 1998, ENDOCRINOLOGY, V139, P4614, DOI 10.1210/en.139.11.4614; Hashimoto T, 1997, EUR J NEUROSCI, V9, P1226, DOI 10.1111/j.1460-9568.1997.tb01477.x; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Joo A, 2001, MOL PSYCHIATR, V6, P186, DOI 10.1038/sj.mp.4000841; Kraus J, 1998, FEBS LETT, V428, P165, DOI 10.1016/S0014-5793(98)00520-1; Liu MT, 2000, J NEUROSCI, V20, P3200, DOI 10.1523/JNEUROSCI.20-09-03200.2000; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Mao LM, 2001, SYNAPSE, V41, P230, DOI 10.1002/syn.1080; MILLER S, 1995, J NEUROSCI, V15, P6103; MINAKAMI R, 1995, J NEUROCHEM, V65, P1536; Minoshima T, 1999, J BIOCHEM-TOKYO, V126, P889, DOI 10.1093/oxfordjournals.jbchem.a022531; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; Nakahara K, 1997, J NEUROCHEM, V69, P1467; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; NEDIVI E, 1992, J NEUROSCI, V12, P691; Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Ogbourne S, 1998, BIOCHEM J, V331, P1; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Reese MG, 1995, GENOME SCI TECHNOLOG, V1, P45; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Riedel G, 2000, NEUROPHARMACOLOGY, V39, P1943, DOI 10.1016/S0028-3908(00)00037-X; Romano C, 1996, J COMP NEUROL, V367, P403, DOI 10.1002/(SICI)1096-9861(19960408)367:3<403::AID-CNE6>3.0.CO;2-9; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Shigemoto R, 2000, HAND CHEM N, V18, P63; Smialowska M, 2002, NEUROPHARMACOLOGY, V42, P1016, DOI 10.1016/S0028-3908(02)00062-X; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; Storto M, 2001, J ENDOCRINOL, V170, P71, DOI 10.1677/joe.0.1700071; Sugitani Y, 2002, GENE DEV, V16, P1760, DOI 10.1101/gad.978002; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Ueda Y, 1997, J NEUROSCI, V17, P3014; Ulas J, 2000, GLIA, V30, P352, DOI 10.1002/(SICI)1098-1136(200006)30:4<352::AID-GLIA40>3.0.CO;2-6; VANDENPOL AN, 1995, J COMP NEUROL, V362, P134, DOI 10.1002/cne.903620108; Walker K, 2001, NEUROPHARMACOLOGY, V40, P10, DOI 10.1016/S0028-3908(00)00114-3; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; Yamaguchi S, 1998, J NEUROCHEM, V71, P60; Yatsushiro S, 1999, NEUROREPORT, V10, P1599, DOI 10.1097/00001756-199905140-00038	63	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33105	33119		10.1074/jbc.M212380200	http://dx.doi.org/10.1074/jbc.M212380200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12783878	hybrid			2022-12-25	WOS:000184901800076
J	Gulberti, S; Gigleux, SF; Mulliert, G; Aubry, A; Netter, P; Magdalou, J; Ouzzine, M				Gulberti, S; Gigleux, SF; Mulliert, G; Aubry, A; Netter, P; Magdalou, J; Ouzzine, M			The functional glycosyltransferase signature sequence of the human beta 1,3-glucuronosyltransferase is a XDD motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; MOLECULAR-CLONING; BIOSYNTHESIS; STRUCTURE/FUNCTION; PROTEOGLYCANS; EXPRESSION; REQUIRES; SULFATE; BINDING; DONOR	The human beta1,3-glucuronosyltransferase I (GlcAT-I) is the key enzyme responsible for the completion of glycosaminoglycan-protein linkage tetrasaccharide of proteoglycans (GlcAbeta1,3Galbeta1,3Galbeta1,4Xylbeta1-O-serine). We have investigated the role of aspartate residues Asp(194)-Asp(195)- Asp(196) corresponding to the glycosyltransferase DXD signature motif, in GlcAT-I function by UDP binding experiments, kinetic analyses, and site-directed mutagenesis. We presented the first evidence that Mn2+ is not only essential for GlcAT-I activity but is also required for cosubstrate binding. In agreement, kinetic studies were consistent with a metal-activated enzyme model whereby activation probably occurs via binding of a Mn2+.UDP-GlcA complex to the enzyme. Mutational analysis showed that the Asp(194)-Asp(195)-Asp(196) motif is a major element of the UDP/Mn2+ binding site. Furthermore, determination of the individual role of each aspartate showed that substitution of Asp(195) as well as Asp(196) to alanine strongly impaired GlcAT-I activity, whereas Asp(194) replacement produced only a moderate alteration of the enzyme activity. These findings along with molecular modeling and three-dimensional structure comparison of the GlcAT-I catalytic center with that of the Bacillus subtilis glycosyltransferase SpsA provided evidence that the interactions of Asp(195) with the ribose moiety of UDP and of Asp(196) with the metal cation Mn2+ were crucial for GlcAT-I function. Altogether, these results indicated that, similarly to the SpsA enzyme, the nucleotide binding site of GlcAT-I contains a XDD motif rather than a DXD motif.	Univ Nancy 1, CNRS, UMR 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France; Univ Nancy 1, CNRS, UMR 7036, Fac Sci, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Lorraine	Gigleux, SF (corresponding author), Univ Nancy 1, CNRS, UMR 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France.	sfg@medecine.uhp-nancy.fr; ouzzine@medecine.uhp-nancy.fr	Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950; GULBERTI, Sandrine/0000-0002-9378-4697				Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Case DAPD, 1999, AMBER 6; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krautwurst H, 2002, BIOCHEMISTRY-US, V41, P12763, DOI 10.1021/bi026241w; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JG, 2001, GLYCOBIOLOGY, V11, P217, DOI 10.1093/glycob/11.3.217; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Ouzzine M, 2000, MOL PHARMACOL, V58, P1609, DOI 10.1124/mol.58.6.1609; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Ouzzine M, 2002, J BIOL CHEM, V277, P25439, DOI 10.1074/jbc.M201912200; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; Petrova P, 2001, EUR J BIOCHEM, V268, P5365, DOI 10.1046/j.0014-2956.2001.02469.x; Prydz K, 2000, J CELL SCI, V113, P193; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; Segel IH., 1975, ENZYME KINETICS, P227; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Susan-Resiga D, 2003, J BIOL CHEM, V278, P12660, DOI 10.1074/jbc.M300257200; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	36	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32219	32226		10.1074/jbc.M207899200	http://dx.doi.org/10.1074/jbc.M207899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794088	hybrid			2022-12-25	WOS:000184782100096
J	Spazierer, D; Fuchs, P; Proll, V; Janda, L; Oehler, S; Fischer, I; Hauptmann, R; Wiche, G				Spazierer, D; Fuchs, P; Proll, V; Janda, L; Oehler, S; Fischer, I; Hauptmann, R; Wiche, G			Epiplakin gene analysis in mouse reveals a single exon encoding a 725-kDa protein with expression restricted to epithelial tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT ASSOCIATION; EPIDERMAL CORNIFIED ENVELOPE; CYTOSKELETAL LINKER PROTEIN; CULTURED-CELLS; PLECTIN; DESMOPLAKIN; BINDING; PERIPLAKIN; ENVOPLAKIN; VIMENTIN	Based on cDNA cloning and sequencing, human epiplakin has been classified as a member of the plakin protein family of cytolinkers. We report here the characterization of the mouse epiplakin gene locus and the isolation of full-length mouse epiplakin cDNA using BAC vectors. We found that the protein is encoded by a single remarkably large exon (>20 kb) that consists of a series of 0.8-1.5-kb-long DNA repeats, eight of which are virtually identical. Consequently, mouse epiplakin contains 16 plakin repeat domains, three more than reported for the human protein and eight more than predicted for the mouse protein based on the contig characterized by the Mouse Genome Sequencing Consortium. Using antibodies raised to a highly conserved repeating epiplakin sequence domain, we show that the protein in cells is expressed in its full length (725 kDa), and we provide evidence that the size of human epiplakin previously may have been underestimated. In addition we show on transcript and protein levels that epiplakin is restricted to epithelial tissues and that its gene maps to mouse chromosome 15 (human chromosome 8). This study lays the groundwork for future genetic approaches aimed at defining the biological role of this unique protein.	Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Cell Biol, A-1030 Vienna, Austria; Boehringer Ingelheim Austria, Dept Exploratory Res, A-1121 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Boehringer Ingelheim	Wiche, G (corresponding author), Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Cell Biol, A-1030 Vienna, Austria.	wiche@abc.univie.ac.at	Janda, Lubomir/D-8048-2012; WICHE, Gerhard/AAA-3227-2021	Fuchs, Peter/0000-0003-3933-7674; Wiche, Gerhard/0000-0001-9550-5463; Janda, Lubomir/0000-0002-5406-4208				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andra K, 2003, J INVEST DERMATOL, V120, P189, DOI 10.1046/j.1523-1747.2003.12027.x; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARTWRIGHT E, 2000, QIAGEN NEWS, P18; Choi HJ, 2002, NAT STRUCT BIOL, V9, P612, DOI 10.1038/nsb818; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; Eger A, 1997, J CELL SCI, V110, P1307; Fuchs P, 1999, HUM MOL GENET, V8, P2461, DOI 10.1093/hmg/8.13.2461; Fujiwara S, 2001, J BIOL CHEM, V276, P13340, DOI 10.1074/jbc.M011386200; FUJIWARA S, 1994, DERMATOLOGY, V189, P120, DOI 10.1159/000246950; Fujiwara S, 1996, J INVEST DERMATOL, V106, P1125, DOI 10.1111/1523-1747.ep12340171; GREEN KJ, 1990, J BIOL CHEM, V265, P11406; Guermeur Y., 1997, THESIS U PARIS 6, P6; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Janda L, 2001, BIOESSAYS, V23, P1064, DOI 10.1002/bies.1151; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; Liu CG, 1996, P NATL ACAD SCI USA, V93, P4278, DOI 10.1073/pnas.93.9.4278; Maatta A, 2001, MOL CELL BIOL, V21, P7047, DOI 10.1128/MCB.21.20.7047-7053.2001; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; Pulkkinen L, 1996, HUM MOL GENET, V5, P1539, DOI 10.1093/hmg/5.10.1539; Roper K, 2002, J CELL SCI, V115, P4215, DOI 10.1242/jcs.00157; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STAPPENBECK TS, 1993, J CELL BIOL, V123, P123; Steinbock FA, 2000, J CELL SCI, V113, P483; Steinert PM, 2000, J CELL BIOL, V151, pF5, DOI 10.1083/jcb.151.2.F5; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5	47	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31657	31666		10.1074/jbc.M303055200	http://dx.doi.org/10.1074/jbc.M303055200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791695	hybrid			2022-12-25	WOS:000184782100026
J	Tsutsumi, S; Yanagawa, T; Shimura, T; Fukumori, T; Hogan, V; Kuwano, H; Raz, A				Tsutsumi, S; Yanagawa, T; Shimura, T; Fukumori, T; Hogan, V; Kuwano, H; Raz, A			Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; S-PHASE KINASE; GROWTH-FACTOR; CYCLIN D1; FACTOR-RECEPTOR; PHOSPHOHEXOSE ISOMERASE; GENE-EXPRESSION; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; RETINOBLASTOMA PROTEIN	Autocrine motility factor (AMF)/phosphoglucose isomerase (PGI; EC 5.3.1.9) is a housekeeping cytosolic enzyme that plays a key role in both glycolysis and gluconeogenesis pathways. AMF/PGI is also a multifunctional protein that displays cytokine properties, eliciting mitogenic, motogenic, and differentiation activities, and has been implicated in tumor progression and metastasis. Because little is known about AMF/PGI-dependent signaling in general and during tumorigenesis in particular, we sought to study its effect on the cell cycle. To elucidate the functional role of PGI, we stably transfected its cDNA into NIH/3T3 and BALB/c 3T3-A31 fibroblasts. Ectopic overexpression of PGI results in the acquisition of a transformed phenotype associated with an acceleration of G(1) to S cell cycle transition. These were manifested by up-regulation of cyclin D1 expression and cyclin-dependent kinase activity and down-regulation of the cyclin-dependent kinase inhibitor p27(Kip1). The reduced p27(Kip1) protein expression level in PGI-overexpressing cells could be restored to control levels by treatment with proteasome inhibitor. PGI-overexpressing cells also exhibited elevated expression of Skp2 involved in p27(Kip1) ubiquitination and elevation in the levels of retinoblastoma protein hyperphosphorylation. Thus, we may conclude that the overexpression of AMF/PGI enhances cell proliferation together with up-regulation of cyclin/cyclin-dependent kinase activities and down-regulation of p27(Kip1), whereas the induction of 3T3 fibroblast transformation by PGI is regulated by the retinoblastoma protein pathway.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Gunma Univ, Grad Sch Med, Dept Gen Surg Sci Surg 1, Maebashi, Gumma 3718511, Japan	Barbara Ann Karmanos Cancer Institute; Wayne State University; Gunma University	Raz, A (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, 110 E Warren Ave, Detroit, MI 48201 USA.				NCI NIH HHS [CA-51714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Funasaka T, 2002, INT J CANCER, V101, P217, DOI 10.1002/ijc.10617; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; GUIRGUIS R, 1990, J OCCUP ENVIRON MED, V32, P846, DOI 10.1097/00043764-199009000-00017; Hamelers IHL, 2002, J BIOL CHEM, V277, P47645, DOI 10.1074/jbc.M208727200; HARRISON RA, 1974, ANAL BIOCHEM, V61, P500, DOI 10.1016/0003-2697(74)90417-5; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; JIANG W, 1993, ONCOGENE, V8, P3447; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; JORDAN MA, 1992, J CELL SCI, V102, P401; Kudo Y, 2001, CANCER RES, V61, P7044; Lee JS, 2001, CURR EYE RES, V23, P69, DOI 10.1076/ceyr.23.1.69.5421; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; MARUYAMA K, 1995, INT J CANCER, V64, P316, DOI 10.1002/ijc.2910640506; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NABI IR, 1992, CANCER METAST REV, V11, P5, DOI 10.1007/BF00047599; NAKAMORI S, 1994, CANCER-AM CANCER SOC, V74, P1855, DOI 10.1002/1097-0142(19941001)74:7<1855::AID-CNCR2820740705>3.0.CO;2-1; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Niinaka Y, 1998, CANCER RES, V58, P2667; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Page K, 1999, AM J RESP CELL MOL, V20, P1294, DOI 10.1165/ajrcmb.20.6.3597; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7; SILLETTI S, 1993, BIOCHEM BIOPH RES CO, V194, P446, DOI 10.1006/bbrc.1993.1840; Takanami I, 1998, TUMOR BIOL, V19, P384, DOI 10.1159/000030031; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsutsumi S, 2003, CANCER RES, V63, P242; Tsutsumi S, 2002, CANCER RES, V62, P4484; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Watanabe H, 1996, CANCER RES, V56, P2960; WATANABE H, 1991, J BIOL CHEM, V266, P13442; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZVIBEL I, 1985, INT J CANCER, V36, P261, DOI 10.1002/ijc.2910360220	65	46	52	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32165	32172		10.1074/jbc.M304537200	http://dx.doi.org/10.1074/jbc.M304537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783864	hybrid			2022-12-25	WOS:000184782100089
J	Grbovic, OM; Mathews, PM; Jiang, Y; Schmidt, SD; Dinakar, R; Summers-Terio, NB; Ceresa, BP; Nixon, RA; Cataldo, AM				Grbovic, OM; Mathews, PM; Jiang, Y; Schmidt, SD; Dinakar, R; Summers-Terio, NB; Ceresa, BP; Nixon, RA; Cataldo, AM			Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and A beta production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SECRETASE CLEAVAGE; TRANS-GOLGI NETWORK; SPORADIC ALZHEIMERS-DISEASE; SMALL GTPASE RAB5; DISINTEGRIN METALLOPROTEASE; SUBCELLULAR-LOCALIZATION; APOLIPOPROTEIN-E; ENDOSOME FUSION; IN-VITRO; PRESENILIN-1	We previously identified abnormalities of the endocytic pathway in neurons as the earliest known pathology in sporadic Alzheimer's disease (AD) and Down's syndrome brain. In this study, we modeled aspects of these AD-related endocytic changes in murine L cells by overexpressing Rab5, a positive regulator of endocytosis. Rab5-transfected cells exhibited abnormally large endosomes immunoreactive for Rab5 and early endosomal antigen 1, resembling the endosome morphology seen in affected neurons from AD brain. The levels of both Abeta40 and Abeta42 in conditioned medium were increased more than 2.5-fold following Rab5 overexpression. In Rab5 overexpressing cells, the levels of beta-cleaved amyloid precursor protein (APP) carboxyl-terminal fragments (betaCTF), the rate-limiting proteolytic intermediate in Abeta generation, were increased up to 2-fold relative to APP holoprotein levels. An increase in beta-cleaved soluble APP relative to alpha-cleaved soluble APP was also observed following Rab5 overexpression. betaCTFs were co-localized by immunolabeling to vesicular compartments, including the early endosome and the trans-Golgi network. These results demonstrate a relationship between endosomal pathway activity, betaCTF generation, and Abeta production. Our findings in this model system suggest that the endosomal pathology seen at the earliest stage of sporadic AD may contribute to APP proteolysis along a beta-amyloidogenic pathway.	Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, Orangeburg, NY 10962 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; McLean Hosp, Mailman Res Ctr, Lab Mol Neuropathol, Belmont, MA 02478 USA; Harvard Univ, Sch Med, Dept Psychiat & Neuropathol, Boston, MA 02115 USA	Nathan Kline Institute for Psychiatric Research; New York University; New York University; University of Oklahoma System; University of Oklahoma Health Sciences Center; Harvard University; McLean Hospital; Harvard University; Harvard Medical School	Grbovic, OM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, R1121,1275 York Ave, New York, NY 10021 USA.		Schmidt, Stephen/B-5398-2012; Schmidt, Stephen/AAC-6967-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS045357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017617, R29AG014726] Funding Source: NIH RePORTER; NIA NIH HHS [AG17617, AG14726] Funding Source: Medline; NINDS NIH HHS [NS045357] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Cataldo A, 2001, ANN NEUROL, V50, P661, DOI 10.1002/ana.1254.abs; CATALDO A, 2000, NEUROBIOL AGING S65, V293, P293; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Cataldo AM, 1996, J NEUROSCI, V16, P186; Cedazo-Minguez A, 2001, J CELL MOL MED, V5, P254, DOI 10.1111/j.1582-4934.2001.tb00159.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Gandy S, 1999, TRENDS ENDOCRIN MET, V10, P273, DOI 10.1016/S1043-2760(99)00166-6; GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; HYMAN BT, 1992, PROG CLIN BIOL RES, V379, P123; Islam K, 1997, AM J PATHOL, V151, P265; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; MANN DMA, 1987, J NEUROL SCI, V80, P79, DOI 10.1016/0022-510X(87)90223-1; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; Mathews PM, 2002, J BIOL CHEM, V277, P5299, DOI 10.1074/jbc.M108161200; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Petanceska SS, 2000, J NEUROCHEM, V74, P1878, DOI 10.1046/j.1471-4159.2000.0741878.x; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Vandermeeren M, 2001, NEUROSCI LETT, V315, P145, DOI 10.1016/S0304-3940(01)02369-2; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANNOSTRAND WE, 1989, NATURE, V341, P546; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	72	182	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31261	31268		10.1074/jbc.M304122200	http://dx.doi.org/10.1074/jbc.M304122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12761223	hybrid			2022-12-25	WOS:000184658800105
J	Hirsila, M; Koivunen, P; Gunzler, V; Kivirikko, KI; Myllyharju, J				Hirsila, M; Koivunen, P; Gunzler, V; Kivirikko, KI; Myllyharju, J			Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; HIF-ALPHA; PROTEIN; HYDROXYLATION; HIF-1-ALPHA; COLLAGEN; COMPLEX; FAMILY; DOMAIN; VHL	The hypoxia-inducible factors (HIFs) play a central role in oxygen homeostasis. Hydroxylation of one or two critical prolines by specific hydroxylases (P4Hs) targets their HIF-alpha subunits for proteasomal degradation. By studying the three human HIF-P4Hs, we found that the longest and shortest isoenzymes have major transcripts encoding inactive polypeptides, which suggest novel regulation by alternative splicing. Recombinant HIF-P4Hs expressed in insect cells required peptides of more than 8 residues, distinct differences being found between isoenzymes. All the HIF-P4Hs hydroxylated peptides corresponding to Pro(564) in HIF-1alpha, whereas a Pro(402) peptide had 20-50-fold K-m values for two isoenzymes but was not hydroxylated by the shortest isoenzyme at all; this difference was not explained by the two prolines being in a -Pro(402)-Ala- and -Pro(564)-Tyr- sequence. All the HIF-P4Hs-hydroxylated peptides corresponding to two of three potential sites in HIF-2alpha and one in HIF-3alpha. The K-m values for O-2 were slightly above its atmospheric concentration, indicating that the HIF-P4Hs are effective oxygen sensors. Small molecule inhibitors of collagen P4Hs also inhibited the HIF-P4Hs, but with distinctly different K-i values, indicating that it should be possible to develop specific inhibitors for each class of P4Hs and possibly even for the individual HIF-P4Hs.	Oulu Univ, Collagen Res Unit, Dept Med Biochem & Mol Biol, Bioctr Oulu, FIN-90014 Oulu, Finland; FibroGen Inc, San Francisco, CA 94080 USA	University of Oulu; FibroGen	Myllyharju, J (corresponding author), Oulu Univ, Collagen Res Unit, Dept Med Biochem & Mol Biol, Bioctr Oulu, POB 5000, FIN-90014 Oulu, Finland.							BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fedele Anthony O, 2002, Mol Interv, V2, P229, DOI 10.1124/mi.2.4.229; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	30	618	657	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30772	30780		10.1074/jbc.M304982200	http://dx.doi.org/10.1074/jbc.M304982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788921	hybrid			2022-12-25	WOS:000184658800045
J	Kim, H; Yang, PR; Catanuto, P; Verde, F; Lai, H; Du, HY; Chang, F; Marcus, S				Kim, H; Yang, PR; Catanuto, P; Verde, F; Lai, H; Du, HY; Chang, F; Marcus, S			The kelch repeat protein, Tea1, is a potential substrate target of the p21-activated kinase, Shk1, in the fission yeast, Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; SH3 DOMAIN PROTEIN; CELL POLARITY; SACCHAROMYCES-CEREVISIAE; XENOPUS OOCYTES; HUMAN HOMOLOG; GAMMA-PAK; ALPHA-PAK; ACTIVATION; GROWTH	The p21-activated kinase (PAK) homolog, Shk1, is a critical component of a multifunctional Ras/Cdc42/PAK complex required for viability, polarized growth and cell shape, and sexual differentiation in the fission yeast, Schizosaccharomyces pombe. Substrate targets of the Shk1 kinase have not previously been described. Here we show that the S. pombe cell polarity factor, Tea1, is directly phosphorylated by Shk1 in vitro. We demonstrate further that Tea1 is phosphorylated in S. pombe cells and that its level of phosphorylation is significantly reduced in cells defective in Shk1 function. Consistent with a role for Tea1 as a potential downstream effector of Shk1, we show that a tea1 null mutation rescues the Shk1 hyperactivity-induced lethal phenotype caused by loss of function of the essential Shk1 inhibitor, Skb15. All phenotypes associated with Skb15 loss, including defects in actin cytoskeletal organization, chromosome segregation, and cytokinesis, are suppressed by tea1Delta, suggesting that Tea1 is a potential mediator of multiple Shk1 functions. S. pombe cells carrying a weak hypomorphic allele of shk1 together with a tea1Delta mutation exhibit a cytokinesis defective phenotype that is significantly more severe than that observed in the respective single mutants, providing evidence that Shk1 and Tea1 cooperate to regulate cytokinesis. In addition, we show that S. pombe cells carrying the orb2-34 allele of shk1 exhibit a pattern of monopolar growth similar to that observed in tea1Delta cells, suggesting that Shk1 and Tea1 may regulate one or more common processes involved in the regulation of polarized cell growth. Taken together, our results strongly implicate Tea1 as a potential substrate-effector of the Shk1 kinase.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Miami; Columbia University	Marcus, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	smarcus@mdacc.tmc.edu			NIGMS NIH HHS [R01GM53239, R01GM56836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239, R01GM056836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C, 1993, EXPT FISSION YEAST L; Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Arellano M, 2002, CURR BIOL, V12, P751, DOI 10.1016/S0960-9822(02)00821-7; Bao SL, 2001, J BIOL CHEM, V276, P14549, DOI 10.1074/jbc.C100096200; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Chang E, 1999, MOL CELL BIOL, V19, P8066; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Glynn JM, 2001, CURR BIOL, V11, P836, DOI 10.1016/S0960-9822(01)00235-4; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Le Goff X, 1999, CURR GENET, V35, P571, DOI 10.1007/s002940050455; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARKS J, 1986, J CELL SCI, P229; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MITCHISON JM, 1985, J CELL SCI, V75, P357; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Papadaki P, 2002, MOL CELL BIOL, V22, P4598, DOI 10.1128/MCB.22.13.4598-4606.2002; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Qyang YB, 2002, MOL MICROBIOL, V44, P325, DOI 10.1046/j.1365-2958.2002.02882.x; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rose MD., 1990, METHODS YEAST GENETI; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sawin KE, 1999, CURR BIOL, V9, P1335, DOI 10.1016/S0960-9822(00)80058-5; Sawin KE, 1998, J CELL BIOL, V142, P457, DOI 10.1083/jcb.142.2.457; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1998, J BIOL CHEM, V273, P18490, DOI 10.1074/jbc.273.29.18490; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Sokol NS, 1999, CURR BIOL, V9, P1221, DOI 10.1016/S0960-9822(99)80502-8; Velichkova M, 2002, CELL MOTIL CYTOSKEL, V51, P147, DOI 10.1002/cm.10025; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Xia CZ, 2001, P NATL ACAD SCI USA, V98, P6174, DOI 10.1073/pnas.101137298; Yang PR, 1998, J BIOL CHEM, V273, P18481, DOI 10.1074/jbc.273.29.18481; Yang PR, 1999, J BIOL CHEM, V274, P36052, DOI 10.1074/jbc.274.51.36052	51	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30074	30082		10.1074/jbc.M302609200	http://dx.doi.org/10.1074/jbc.M302609200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764130	hybrid			2022-12-25	WOS:000184507000084
J	Littlejohn, TK; Takikawa, O; Truscott, RJW; Walker, MJ				Littlejohn, TK; Takikawa, O; Truscott, RJW; Walker, MJ			Asp(274) and His(346) are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL CIRCULAR-DICHROISM; AMINO-ACID-SEQUENCE; L-TRYPTOPHAN 2,3-DIOXYGENASES; DIOXYGENASE-LIKE-MYOGLOBIN; QUINOLINIC ACID; INTERFERON-GAMMA; INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY; CEREBROSPINAL-FLUID; NUCLEOTIDE-SEQUENCE; KYNURENINE PATHWAY	L-Tryptophan is the least abundant essential amino acid in humans. Indoleamine 2,3-dioxgyenase (IDO) is a cytosolic heme protein which, together with the hepatic enzyme tryptophan 2,3-dioxygenase, catalyzes the first and rate-limiting step in the major pathway of tryptophan metabolism, the kynurenine pathway. The physiological role of IDO is not fully understood but is of great interest, because IDO is widely distributed in human tissues, can be up-regulated via cytokines such as interferon-gamma, and can thereby modulate the levels of tryptophan, which is vital for cell growth. To identify which amino acid residues are important in substrate or heme binding in IDO, site-directed mutagenesis of conserved residues in the IDO gene was undertaken. Because it had been proposed that a histidine residue might be the proximal heme ligand in IDO, mutation to alanine of the three highly conserved histidines His(16), His(303), and His(346) was conducted. Of these, only His(346) was shown to be essential for heme binding, indicating that this histidine residue may be the proximal ligand and suggesting that neither His(303) nor His(16) act as the proximal ligand. Site-directed mutagenesis of Asp(274) also compromised the ability of IDO to bind heme. This observation indicates that Asp(274) may coordinate to heme directly as the distal ligand or is essential in maintaining the conformation of the heme pocket.	Univ Wollongong, Dept Biol Sci, Wollongong, NSW 2522, Australia; Univ Wollongong, Dept Chem, Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia	University of Wollongong; University of Wollongong	Walker, MJ (corresponding author), Univ Wollongong, Dept Biol Sci, Wollongong, NSW 2522, Australia.	mark_walker@uow.edu.au	Walker, Mark J./F-6940-2011	Stutchbury, Tamantha/0000-0001-9308-4562; Walker, Mark/0000-0001-7423-2769				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Aquilina JA, 1997, EXP EYE RES, V64, P727, DOI 10.1006/exer.1996.0258; Botting NP, 1995, CHEM SOC REV, V24, P401, DOI 10.1039/cs9952400401; Brew BJ, 1996, J NEUROVIROL, V2, P152, DOI 10.3109/13550289609146877; BURKE F, 1995, INT J CANCER, V60, P115, DOI 10.1002/ijc.2910600117; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DAI W, 1990, BIOCHEM BIOPH RES CO, V168, P1, DOI 10.1016/0006-291X(90)91666-G; Dias S, 1998, INT J CANCER, V75, P151, DOI 10.1002/(SICI)1097-0215(19980105)75:1<151::AID-IJC23>3.0.CO;2-I; HABARAOHKUBO A, 1991, GENE, V105, P221, DOI 10.1016/0378-1119(91)90154-4; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; HIRATA F, 1977, J BIOL CHEM, V252, P4637; ISHIMURA Y, 1970, J BIOL CHEM, V245, P3593; Kawamichi K, 1998, J PROTEIN CHEM, V17, P651, DOI 10.1007/BF02780966; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Littlejohn TK, 2000, PROTEIN EXPRES PURIF, V19, P22, DOI 10.1006/prep.2000.1214; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; Pan TL, 2000, TRANSPL IMMUNOL, V8, P189, DOI 10.1016/S0966-3274(00)00024-1; Reinhard JF, 1998, NEUROCHEM RES, V23, P661, DOI 10.1023/A:1022438822023; SAITO K, 1991, LIFE SCI, V49, P527, DOI 10.1016/0024-3205(91)90070-R; SAITO K, 1991, BRAIN RES, V540, P353, DOI 10.1016/0006-8993(91)90536-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanni LA, 1998, AM J PATHOL, V152, P611; SARDAR AM, 1995, NEUROSCI LETT, V187, P9, DOI 10.1016/0304-3940(95)11324-P; SHIMIZU T, 1978, J BIOL CHEM, V253, P4700; SONO M, 1980, J BIOL CHEM, V255, P1339; SONO M, 1990, BIOCHEMISTRY-US, V29, P1451, DOI 10.1021/bi00458a016; SONO M, 1984, BIOCHIM BIOPHYS ACTA, V789, P170, DOI 10.1016/0167-4838(84)90202-4; STONE TW, 1985, NEUROSCIENCE, V15, P597, DOI 10.1016/0306-4522(85)90063-6; STUTCHBURY GM, 1993, EXP EYE RES, V57, P149, DOI 10.1006/exer.1993.1110; SUZUKI T, 1992, J MOL BIOL, V228, P698, DOI 10.1016/0022-2836(92)90854-D; Suzuki T, 1998, J PROTEIN CHEM, V17, P817, DOI 10.1023/A:1020782403070; SUZUKI T, 1994, J PROTEIN CHEM, V13, P9, DOI 10.1007/BF01891987; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAKIKAWA O, 1986, J BIOL CHEM, V261, P3648; TAKIKAWA O, 1990, J IMMUNOL, V145, P1246; TONE S, 1990, NUCLEIC ACIDS RES, V18, P367, DOI 10.1093/nar/18.2.367; Truscott RJW, 2000, OPHTHALMIC RES, V32, P185, DOI 10.1159/000055612; UCHIDA K, 1983, J BIOL CHEM, V258, P2526; UCHIDA K, 1983, J BIOL CHEM, V258, P2519; Widner B, 1999, ADV EXP MED BIOL, V467, P133; Widner B, 2000, J NEURAL TRANSM, V107, P343, DOI 10.1007/s007020050029; YOSHIDA R, 1979, P NATL ACAD SCI USA, V76, P4084, DOI 10.1073/pnas.76.8.4084; YOSHIDA R, 1978, P NATL ACAD SCI USA, V75, P3998, DOI 10.1073/pnas.75.8.3998; Yu WG, 1996, INT IMMUNOL, V8, P855, DOI 10.1093/intimm/8.6.855	46	59	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29525	29531		10.1074/jbc.M301700200	http://dx.doi.org/10.1074/jbc.M301700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766158	hybrid			2022-12-25	WOS:000184507000018
J	Schwender, J; Ohlrogge, JB; Shachar-Hill, Y				Schwender, J; Ohlrogge, JB; Shachar-Hill, Y			A flux model of glycolysis and the oxidative pentosephosphate pathway in developing Brassica napus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; PENTOSE-PHOSPHATE PATHWAY; DEVELOPING SEEDS; PYRUVATE-KINASE; PHOSPHOENOLPYRUVATE CARBOXYLASE; ASPARTATE-AMINOTRANSFERASE; SUBCELLULAR-LOCALIZATION; GAS-CHROMATOGRAPHY; MOLECULAR-CLONING; TRIOSE PHOSPHATE	Developing oilseeds synthesize large quantities of triacylglycerol from sucrose and hexose. To understand the fluxes involved in this conversion, a quantitative metabolic flux model was developed and tested for the reaction network of glycolysis and the oxidative pentose phosphate pathway (OPPP). Developing Brassica napus embryos were cultured with [U-C-13(6)] glucose, [1-C-13] glucose, [6-C-13] glucose, [U-C-13(12)] sucrose, and/or [1,2-C-13(2)] glucose and the labeling patterns in amino acids, lipids, sucrose, and starch were measured by gas chromatography/ mass spectrometry and NMR. Data were used to verify a reaction network of central carbon metabolism distributed between the cytosol and plastid. Computer simulation of the steady state distribution of isotopomers in intermediates of the glycolysis/OPPP network was used to fit metabolic flux parameters to the experimental data. The observed distribution of label in cytosolic and plastidic metabolites indicated that key intermediates of glycolysis and OPPP have similar labeling in these two compartments, suggesting rapid exchange of metabolites between these compartments compared with net fluxes into end products. Cycling between hexose phosphate and triose phosphate and reversible transketolase velocity were similar to net glycolytic flux, whereas reversible transaldolase velocity was minimal. Flux parameters were overdetermined by analyzing labeling in different metabolites and by using data from different labeling experiments, which increased the reliability of the findings. Net flux of glucose through the OPPP accounts for close to 10% of the total hexose influx into the embryo. Therefore, the reductant produced by the OPPP accounts for at most 44% of the NADPH and 22% of total reductant needed for fatty acid synthesis.	Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University	Schwender, J (corresponding author), Michigan State Univ, Dept Plant Biol, Wilson Dr, E Lansing, MI 48824 USA.	Schwend2@msu.edu	Schwender, Jorg/P-2282-2014; Shachar-Hill, Yair/B-6165-2013	Schwender, Jorg/0000-0003-1350-4171; Shachar-Hill, Yair/0000-0001-8793-5084				AGRAWAL PK, 1971, CAN J BOTANY, V49, P267, DOI 10.1139/b71-044; ANDERSON LE, 1981, BIOCHEM BIOPH RES CO, V99, P1199, DOI 10.1016/0006-291X(81)90746-4; Asokanthan PS, 1997, PHYSIOL PLANTARUM, V101, P353, DOI 10.1034/j.1399-3054.1997.1010215.x; Bao XM, 1998, PLANT PHYSIOL, V118, P183, DOI 10.1104/pp.118.1.183; Bao XM, 2000, PLANT J, V22, P39, DOI 10.1046/j.1365-313x.2000.00712.x; Beckles DM, 2001, PLANT PHYSIOL, V125, P818, DOI 10.1104/pp.125.2.818; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; daSilva PMFR, 1997, PLANTA, V203, P480, DOI 10.1007/s004250050217; DASNEVES HJC, 1987, J CHROMATOGR, V392, P249, DOI 10.1016/S0021-9673(01)94270-0; Dauner M, 2000, BIOTECHNOL PROGR, V16, P642, DOI 10.1021/bp000058h; Debnam PM, 1999, J EXP BOT, V50, P1653, DOI 10.1093/jexbot/50.340.1653; DENNIS DT, 1989, CUR TOP PL, V2, P120; DIEUAIDENOUBHANI M, 1995, J BIOL CHEM, V270, P13147, DOI 10.1074/jbc.270.22.13147; Domergue F, 1999, OCL-OL CORPS GRAS LI, V6, P101; Eastmond P, 1996, J EXP BOT, V47, P1763, DOI 10.1093/jxb/47.11.1763; Eastmond PJ, 1998, J EXP BOT, V49, P1105, DOI 10.1093/jexbot/49.324.1105; Eastmond PJ, 2000, PLANT PHYSIOL, V122, P767, DOI 10.1104/pp.122.3.767; Eastmond PJ, 1997, PLANT PHYSIOL, V114, P851, DOI 10.1104/pp.114.3.851; Edwards S, 1998, PLANT PHYSIOL, V116, P1073, DOI 10.1104/pp.116.3.1073; Eicks M, 2002, PLANT PHYSIOL, V128, P512, DOI 10.1104/pp.010576; Fernie AR, 2001, PLANTA, V212, P250, DOI 10.1007/s004250000386; Fernie AR, 2001, PLANT PHYSIOL, V125, P1967, DOI 10.1104/pp.125.4.1967; FOLCH J, 1957, J BIOL CHEM, V226, P497; Follstad BD, 1998, EUR J BIOCHEM, V252, P360, DOI 10.1046/j.1432-1327.1998.2520360.x; GEER BW, 1979, BIOCHEM GENET, V17, P881, DOI 10.1007/BF00504310; Gupta R, 1996, J BIOSCIENCE, V21, P819, DOI 10.1007/BF02704723; Gupta R, 1996, J PLANT BIOCHEM BIOT, V5, P127, DOI 10.1007/BF03262998; Gupta R, 1997, INDIAN J BIOCHEM BIO, V34, P288; Hartwell J, 1996, PLANTA, V200, P107, DOI 10.1007/BF00196656; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Hill LM, 2000, BIOCHEM SOC T, V28, P667, DOI 10.1042/BST0280667; HILL LM, 2003, PLANT PHYSL, V131; Ho CL, 1999, J BIOL CHEM, V274, P11007, DOI 10.1074/jbc.274.16.11007; Ireland RJ, 1999, BOOK SOIL P, P49; KANG F, 1994, PLANT J, V6, P795, DOI 10.1046/j.1365-313X.1994.6060795.x; Kang F, 1996, PLANTA, V199, P321; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; KATZ J, 1966, J BIOL CHEM, V241, P727; KATZ J, 1960, J BIOL CHEM, V235, P2165; Ke J, 2000, PLANT PHYSIOL, V123, P497, DOI 10.1104/pp.123.2.497; King SP, 1998, AUST J PLANT PHYSIOL, V25, P377, DOI 10.1071/PP97157; King SP, 1997, PLANT PHYSIOL, V114, P31; King SP, 1997, PLANT PHYSIOL, V114, P153, DOI 10.1104/pp.114.1.153; Kubis SE, 2000, BIOCHEM SOC T, V28, P665, DOI 10.1042/BST0280665; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Liepman AH, 2003, PLANT PHYSIOL, V131, P215, DOI 10.1104/pp.011460; MEHTA M, 1995, J PLANT BIOCHEM BIOT, V4, P11, DOI 10.1007/BF03262943; MURPHY DJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P86, DOI 10.1016/0167-4781(91)90156-G; MURPHY DJ, 1989, J PLANT PHYSIOL, V135, P63, DOI 10.1016/S0176-1617(89)80225-1; NEESE RA, 1994, AM J PHYSIOL-ENDOC M, V267, pE1023, DOI 10.1152/ajpendo.1994.267.6.E1023; Neuhaus HE, 2000, ANNU REV PLANT PHYS, V51, P111, DOI 10.1146/annurev.arplant.51.1.111; NORTON G, 1989, OIL CROPS WORLD, P165; OHLROGGE JB, 1979, P NATL ACAD SCI USA, V76, P1194, DOI 10.1073/pnas.76.3.1194; Ohta D, 2000, PLANT PHYSIOL, V122, P907, DOI 10.1104/pp.122.3.907; Rontein D, 2002, J BIOL CHEM, V277, P43948, DOI 10.1074/jbc.M206366200; Roscher A, 2000, J BIOTECHNOL, V77, P81, DOI 10.1016/S0168-1656(99)00209-6; Ruuska SA, 2002, PLANT CELL, V14, P1191, DOI 10.1105/tpc.000877; SANGWAN RS, 1992, PLANTA, V187, P198, DOI 10.1007/BF00201938; SCHEIBE R, 1991, PLANT PHYSIOL, V96, P1, DOI 10.1104/pp.96.1.1; Schmidt K, 1997, BIOTECHNOL BIOENG, V55, P831, DOI 10.1002/(SICI)1097-0290(19970920)55:6<831::AID-BIT2>3.0.CO;2-H; SCHNARRENBERGER C, 1995, PLANT PHYSIOL, V108, P609, DOI 10.1104/pp.108.2.609; SCHULTZ CJ, 1995, PLANT J, V7, P61, DOI 10.1046/j.1365-313X.1995.07010061.x; Schwender J, 2002, PLANT PHYSIOL, V130, P347, DOI 10.1104/pp.004275; SHACHARHILL Y, 1996, NUCL MAGNETIC RESONA, P196; SHELDON PS, 1992, BIOCHIM BIOPHYS ACTA, V1120, P151, DOI 10.1016/0167-4838(92)90263-D; SINGAL HR, 1995, J BIOSCIENCE, V20, P49, DOI 10.1007/BF02711580; SINGAL HR, 1987, PLANT PHYSIOL, V83, P1043, DOI 10.1104/pp.83.4.1043; Singh BK, 1999, BOOKS SOIL PLANT ENV, P227; Singh DK, 2000, INDIAN J BIOCHEM BIO, V37, P51; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; Szyperski T, 1998, Q REV BIOPHYS, V31, P41, DOI 10.1017/S0033583598003412; Talwar G, 1996, PHOTOSYNTHETICA, V32, P221; Thelen JJ, 2002, METAB ENG, V4, P12, DOI 10.1006/mben.2001.0204; Thom E, 1998, PLANTA, V204, P226, DOI 10.1007/s004250050251; White JA, 2000, PLANT PHYSIOL, V124, P1582, DOI 10.1104/pp.124.4.1582; WHITFIELD HV, 1993, PHYTOCHEMISTRY, V32, P255, DOI 10.1016/S0031-9422(00)94977-X; Wiechert W, 2001, METAB ENG, V3, P265, DOI 10.1006/mben.2001.0188; Wilkie SE, 1998, PROTEIN EXPRES PURIF, V12, P381, DOI 10.1006/prep.1997.0845; Wittmann C, 1999, BIOTECHNOL BIOENG, V62, P739, DOI 10.1002/(SICI)1097-0290(19990320)62:6<739::AID-BIT13>3.0.CO;2-E	79	204	213	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29442	29453		10.1074/jbc.M303432200	http://dx.doi.org/10.1074/jbc.M303432200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12759349	hybrid			2022-12-25	WOS:000184507000008
J	Zelenina, M; Bondar, AA; Zelenin, S; Aperia, A				Zelenina, M; Bondar, AA; Zelenin, S; Aperia, A			Nickel and extracellular acidification inhibit the water permeability of human aquaporin-3 in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNELS; SECRETION; TRANSPORT; HISTIDINE; RESIDUES; AQP3; LOCALIZATION; CYSTEINE-189; SUBUNIT; BINDING	Nickel is a common cause of pneumoconiosis. Here, we show that nickel inactivates aquaporin (AQP)-3, the water channel expressed apically in epithelial cells of human terminal airways. Human AQP3 was transiently transfected into human lung cells, and water permeability was measured in transfected and neighboring untransfected cells. Incubation with NiCl2 rapidly, dose-dependently, and reversibly decreased water permeability in AQP3-expressing cells. Acidification of the extracellular medium also caused rapid, dose-dependent, and reversible inhibition of AQP3. Sensitivity of AQP3 to nickel was lower at alkaline pH than at neutral and acidic pH. Cells transfected with human AQP4 and AQP5, which are also expressed in airway epithelia, were insensitive to nickel and extracellular acidification. Zinc and cadmium, other common causes of pneumoconiosis, had no effect on the water permeability of AQP3. Three extracellular residues, Trp(128), Ser(152), and His(241), were responsible for the blocking effect of nickel on human AQP3. Ser(152) was identified as a common site for nickel and pH sensitivity. His(53), Tyr(124), and His(154) were also involved in regulation of AQP3 by extracellular pH. In addition, the aromatic side chain of His(154) was shown to be important for the water permeability of AQP3. Our results imply that nickel and extracellular pH may modulate lung water clearance and that defective water clearance may be an early component of nickel-induced lung disease.	Karolinska Inst, Dept Woman & Child Hlth, S-17176 Stockholm, Sweden; Russian Acad Sci, Siberian Branch, Inst Cytol & Genet, Lab Physiol Genet, Novosibirsk 630090, Russia; Russian Acad Sci, Siberian Branch, Novosibirsk Bioorgan Chem Inst, Grp Funct Genom, Novosibirsk 630090, Russia	Karolinska Institutet; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences	Aperia, A (corresponding author), Q2 09 Astrid Lindgren Childrens Hosp, S-17176 Stockholm, Sweden.	anita.aperia@ks.se	Bondar, Alexander/AAA-7087-2020	Bondar, Alexander/0000-0001-9181-0487				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Aiba S, 1999, J INVEST DERM SYMP P, V4, P158, DOI 10.1038/sj.jidsp.5640201; Audicana Maria Teresa, 2002, Am J Contact Dermat, V13, P3, DOI 10.1053/ajcd.2002.29945; Bar-Or D, 2001, EUR J BIOCHEM, V268, P42, DOI 10.1046/j.1432-1327.2001.01846.x; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; Ermler U, 1998, CURR OPIN STRUC BIOL, V8, P749, DOI 10.1016/S0959-440X(98)80095-X; Fischer H, 2002, AM J PHYSIOL-CELL PH, V282, pC736, DOI 10.1152/ajpcell.00369.2001; GORDON SE, 1995, NEURON, V14, P177; GROSZ V, 2001, AM J PHYSIOL, V281, pG247; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Jayaraman S, 2001, AM J PHYSIOL-CELL PH, V281, pC1504, DOI 10.1152/ajpcell.2001.281.5.C1504; Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154; Kelleher P, 2000, ENVIRON HEALTH PERSP, V108, P685, DOI 10.2307/3454405; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuwahara M, 1997, BIOCHEMISTRY-US, V36, P13973, DOI 10.1021/bi9711442; Li HY, 2002, ANN THORAC SURG, V73, P1253, DOI 10.1016/S0003-4975(02)03381-7; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Matsuzaki T, 1999, J HISTOCHEM CYTOCHEM, V47, P1275, DOI 10.1177/002215549904701007; Moore M, 2000, EXP EYE RES, V70, P557, DOI 10.1006/exer.1999.0814; NEMERY B, 1990, EUR RESPIR J, V3, P202; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; Perchenet L, 2001, J MEMBRANE BIOL, V183, P51, DOI 10.1007/s00232-001-0052-y; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Schafer T, 2001, ALLERGY, V56, P1192, DOI 10.1034/j.1398-9995.2001.00086.x; Schultz LW, 1998, BIOCHEMISTRY-US, V37, P8886, DOI 10.1021/bi972766q; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Sweeney M, 2002, J APPL PHYSIOL, V92, P1594, DOI 10.1152/japplphysiol.00722.2001; TANG XS, 1993, BIOCHEMISTRY-US, V32, P13742, DOI 10.1021/bi00212a045; Verkman AS, 2000, AM J PHYSIOL-LUNG C, V278, pL867, DOI 10.1152/ajplung.2000.278.5.L867; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002	43	90	98	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30037	30043		10.1074/jbc.M302206200	http://dx.doi.org/10.1074/jbc.M302206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773542	hybrid			2022-12-25	WOS:000184507000079
J	Jin, ES; Uyeda, K; Kawaguchi, T; Burgess, SC; Malloy, CR; Sherry, AD				Jin, ES; Uyeda, K; Kawaguchi, T; Burgess, SC; Malloy, CR; Sherry, AD			Increased hepatic fructose 2,6-bisphosphate after an oral glucose load does not affect gluconeogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTPRANDIAL HYPERGLYCEMIA; LIVER; RATS; FRUCTOSE-1,6-BISPHOSPHATASE; INHIBITION; ISOTOPOMER; METABOLISM; PRECURSORS; (H2O)-H-2; DISPOSAL	The generally accepted metabolic concept that fructose 2,6-bisphosphate (Fru-2,6-P-2) inhibits gluconeogenesis by directly inhibiting fructose 1,6-bisphosphatase is based entirely on in vitro observations. To establish whether gluconeogenesis is indeed inhibited by Fru-2,6-P-2 in intact animals, a novel NMR method was developed using [U-C-13] glucose and (H2O)-H-2 as tracers. The method was used to estimate the sources of plasma glucose from gastric absorption of oral [U-C-13] glucose, from gluconeogenesis, and from glycogen in 24-h fasted rats. Liver Fru-2,6-P-2 increased similar to10-fold shortly after the glucose load, reached a maximum at 60 min, and then dropped to base-line levels by 150 min. The gastric contribution to plasma glucose reached similar to 50% at 30 min after the glucose load and gradually decreased thereafter. Although the contribution of glycogen to plasma glucose was small, glucose formed from gluconeogenesis was substantial throughout the study period even when liver Fru-2,6-P-2 was high. Liver glycogen repletion was also brisk throughout the study period, reaching similar to 30 mumol/g at 3 h. These data demonstrate that Fru-2,6-P-2 does not inhibit gluconeogenesis significantly in vivo.	Univ Texas, SW Med Ctr, Dept Radiol, Mary Nell & Ralph B Rogers Magnet Resonance Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Vet Affairs N Texas Hlth Care Syst, Dallas, TX 75216 USA; Univ Texas, Dept Chem, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; University of Texas System; University of Texas Dallas	Sherry, AD (corresponding author), Univ Texas, SW Med Ctr, Dept Radiol, Mary Nell & Ralph B Rogers Magnet Resonance Ctr, 5801 Forest Pk Rd, Dallas, TX 75235 USA.	dean.sherry@utsouthwestern.edu	; Sherry, Dean/P-2348-2018	Malloy, Craig/0000-0001-5077-0642; Sherry, Dean/0000-0001-7150-8301	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034557, R01HL034557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-02584] Funding Source: Medline; NHLBI NIH HHS [HL-34557] Funding Source: Medline; NIDDK NIH HHS [DK-16194] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergmeyer H.U., 1974, METHOD ENZYMAT AN, V4, P2267; Burgess SC, 2001, ANAL BIOCHEM, V289, P187, DOI 10.1006/abio.2000.4930; Cahill GF., 1976, GLUCONEOGENESIS ITS, P515; Choi IY, 2002, EUR J BIOCHEM, V269, P4418, DOI 10.1046/j.1432-1033.2002.03125.x; Delarue J, 1996, AM J PHYSIOL-ENDOC M, V270, pE353, DOI 10.1152/ajpendo.1996.270.2.E353; DOHM GL, 1983, BIOCHEM MED METAB B, V30, P157, DOI 10.1016/0006-2944(83)90082-0; Ekberg K, 1999, DIABETES, V48, P292, DOI 10.2337/diabetes.48.2.292; FERRANNINI E, 1985, DIABETES, V34, P580, DOI 10.2337/diabetes.34.6.580; FERRANNINI E, 1988, METABOLISM, V37, P79, DOI 10.1016/0026-0495(88)90033-9; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382; HUE L, 1984, BIOCHEM J, V218, P165, DOI 10.1042/bj2180165; Jones JG, 2001, AM J PHYSIOL-ENDOC M, V281, pE848, DOI 10.1152/ajpendo.2001.281.4.E848; Jones JG, 2001, MAGN RESON MED, V45, P156, DOI 10.1002/1522-2594(200101)45:1<156::AID-MRM1020>3.0.CO;2-Z; KATZ J, 1993, J BIOL CHEM, V268, P25509; Keppler D, 1994, METHOD ENZYMAT AN, P1127; KITAJIMA S, 1983, J BIOL CHEM, V258, P7352; KRUSZYNSKA YT, 1993, J CLIN INVEST, V91, P1057, DOI 10.1172/JCI116263; KUWAJIMA M, 1986, J BIOL CHEM, V261, P2632; KUWAJIMA M, 1982, BIOCHEM BIOPH RES CO, V104, P84, DOI 10.1016/0006-291X(82)91943-X; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; Lawson JWR, 1976, GLUCONEOGENESIS ITS; Livesey G, 1998, AM J PHYSIOL-ENDOC M, V275, pE717, DOI 10.1152/ajpendo.1998.275.4.E717; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; MITRAKOU A, 1990, DIABETES, V39, P1381, DOI 10.2337/diabetes.39.11.1381; MORIWAKI T, 1963, ENDOCRINOLOGY, V72, P134, DOI 10.1210/endo-72-1-134; NIEWOEHNER CB, 1984, AM J PHYSIOL, V246, pE89, DOI 10.1152/ajpendo.1984.246.1.E89; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; PEREZLLAMAS F, 1992, ARCH INT PHYSIOL BIO, V100, P335, DOI 10.3109/13813459209000722; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1981, J BIOL CHEM, V256, P1489; SMADJA C, 1990, BIOCHEM J, V270, P505, DOI 10.1042/bj2700505; Staehr P, 2002, DIABETES OBES METAB, V4, P215, DOI 10.1046/j.1463-1326.2002.00177.x; STRYER L, 1995, BIOCHEMISTRY-US, P575; THOMAS H, 1986, ANAL BIOCHEM, V154, P50, DOI 10.1016/0003-2697(86)90494-X; VANHERCK H, 1991, LAB ANIM, V25, P325, DOI 10.1258/002367791780809931; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Wu CD, 2002, AM J PHYSIOL-ENDOC M, V282, pE38, DOI 10.1152/ajpendo.2002.282.1.E38; Wu CD, 2001, J CLIN INVEST, V107, P91, DOI 10.1172/JCI11103	40	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28427	28433		10.1074/jbc.M302134200	http://dx.doi.org/10.1074/jbc.M302134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12764148	hybrid			2022-12-25	WOS:000184421100012
J	Lekmine, F; Uddin, S; Sassano, A; Parmar, S; Brachmann, SM; Majchrzak, B; Sonenberg, N; Hay, N; Fish, EN; Platanias, LC				Lekmine, F; Uddin, S; Sassano, A; Parmar, S; Brachmann, SM; Majchrzak, B; Sonenberg, N; Hay, N; Fish, EN; Platanias, LC			Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT1 SERINE PHOSPHORYLATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; MAMMALIAN TARGET; TYROSINE PHOSPHORYLATION; MEDIATES PHOSPHORYLATION; GENE-EXPRESSION; MICE LACKING; MAP KINASE	The Type I IFN receptor-generated signals required for initiation of mRNA translation and, ultimately, induction of protein products that mediate IFN responses, remain unknown. We have previously shown that IFNalpha and IFNbeta induce phosphorylation of insulin receptor substrate proteins and downstream engagement of the phosphatidylinositol (PI) 3'-kinase pathway. In the present study we provide evidence for the existence of a Type I IFN-dependent signaling cascade activated downstream of PI 3'-kinase, involving p70 S6 kinase. Our data demonstrate that p70 S6K is rapidly phosphorylated on threonine 421 and serine 424 and is activated during treatment of cells with IFNalpha or IFNbeta. Such activation of p70 S6K is blocked by pharmacological inhibitors of the PI 3'-kinase or the FKBP 12-rapamycin-associated protein/mammalian target of rapamycin (FRAP/mTOR). Consistent with this, the Type I IFN-dependent phosphorylation/activation of p70 S6K is defective in embryonic fibroblasts from mice with targeted disruption of the p85alpha and p85beta subunits of the PI 3'-kinase (p85alpha-/-beta-/-). Treatment of sensitive cell lines with IFNalpha or IFNbeta also results in phosphorylation/inactivation of the 4E-BP-1 repressor of mRNA translation. Such 4E-BP1 phosphorylation is also PI3'-kinase-dependent and rapamycin-sensitive, indicating that the Type I IFN-inducible activation of PI3'-kinase and FRAP/mTOR results in dissociation of 4E-BP1 from the eukaryotic initiation factor-4E (eIF4E) complex. Altogether, our data establish that the Type I IFN receptor-activated PI 3'-kinase pathway mediates activation of the p70 S6 kinase and inactivation of 4E-BP1, to regulate mRNA translation and induction of Type I IFN responses.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Toronto, Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 3E2, Canada; Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Chicago; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Free University of Berlin; McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks St,Olson 8250, Chicago, IL 60611 USA.	l-platanias@northwestern.edu		Uddin, Shahab/0000-0003-1886-6710				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BELCHAM C, 1999, CURR BIOL, V9, P93; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; FALCOFF E, 1973, J VIROL, V12, P421, DOI 10.1128/JVI.12.3.421-430.1973; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; FRIEDMAN RM, 1972, J VIROL, V10, P1184, DOI 10.1128/JVI.10.6.1184-1198.1972; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Garber K, 2001, J NATL CANCER I, V93, P1517, DOI 10.1093/jnci/93.20.1517; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gonalons E, 1998, J IMMUNOL, V161, P1837; Grammer TC, 1996, CANCER SURV, V27, P271; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; KERR IM, 1974, NATURE, V250, P57, DOI 10.1038/250057a0; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Prejean C, 2001, J IMMUNOL, V167, P4553, DOI 10.4049/jimmunol.167.8.4553; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; UDDIN S, 1999, HAEMA, V2, P192; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Verma A, 2002, LEUKEMIA LYMPHOMA, V43, P703, DOI 10.1080/10428190290016782; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; Weinstein SL, 2000, J LEUKOCYTE BIOL, V67, P405, DOI 10.1002/jlb.67.3.405; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	82	99	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27772	27780		10.1074/jbc.M301364200	http://dx.doi.org/10.1074/jbc.M301364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12759354	hybrid, Green Published			2022-12-25	WOS:000184242700057
J	Boilard, E; Bourgoin, SG; Bernatchez, C; Poubelle, PE; Surette, ME				Boilard, E; Bourgoin, SG; Bernatchez, C; Poubelle, PE; Surette, ME			Interaction of low molecular weight group IIA phospholipase A(2) with apoptotic human T cells: role of heparan sulfate proteoglycans	FASEB JOURNAL			English	Article						lymphocytes; apoptosis; IIA phospholipase A(2); heparan sulfate proteoglycan; arachidonic acid; arthritis	ARACHIDONIC-ACID RELEASE; REGULATORY FUNCTIONS; HUMAN NEUTROPHILS; GROUP IB; BINDING; MEMBRANE; RECEPTOR; IDENTIFICATION; DIVERSITY; PROTEIN	Human group IIA phospholipase A(2) (hIIA PLA(2)) is a 14 kDa secreted enzyme associated with inflammatory diseases. A newly discovered property of hIIA PLA(2) is the binding affinity for the heparan sulfate proteoglycan (HSPG) glypican-1. In this study, the binding of hIIA PLA(2) to apoptotic human T cells was investigated. Little or no exogenous hIIA PLA(2) bound to CD3-activated T cells but significant binding was measured on activated T cells induced to undergo apoptosis by anti-CD95. Binding to early apoptotic T cells was greater than to late apoptotic cells. The addition of heparin and the hydrolysis of HSPG by heparinase III only partially inhibited hIIA PLA(2) binding to apoptotic cells, suggesting an interaction with both HSPG and other binding protein(s). Two low molecular weight HSPG were coimmunoprecipitated with hIIA PLA(2) from apoptotic T cells, but not from living cells. Treatment of CD95-stimulated T cells with hIIA PLA(2) resulted in the release of arachidonic acid but not oleic acid from cells and this release was blocked by heparin and heparinase III. Altogether, these results suggest a role for hIIA PLA(2) in the release of arachidonic acid from apoptotic cells through interactions with HSPG and its potential implication in the progression of inflammatory diseases.	Pilot Therapeut Inc, Charleston, SC 29492 USA; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; Ctr Hosp Univ Quebec, Ctr Rech Rhumatol & Immunol, Ctr Rech, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Surette, ME (corresponding author), Pilot Therapeut Inc, 2000 Daniel Isl Dr,Suite 440, Charleston, SC 29492 USA.	MarcS@pilott.com	Surette, Marc/AAW-1078-2021	Bourgoin, Sylvain/0000-0001-9779-0368				ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Fonteh AN, 1998, BBA-LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005-2760(98)00079-4; Gensler TJ, 2001, J AUTOIMMUN, V16, P59, DOI 10.1006/jaut.2000.0464; Gilbert C, 2002, J IMMUNOL METHODS, V261, P85, DOI 10.1016/S0022-1759(01)00553-1; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HART DA, 1975, J IMMUNOL, V115, P871; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; Janssen MJW, 1999, BBA-MOL CELL BIOL L, V1440, P59, DOI 10.1016/S1388-1981(99)00122-5; Jiang JZ, 2002, AM J PATHOL, V160, P667, DOI 10.1016/S0002-9440(10)64886-9; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kretz-Rommel A, 2001, CELL IMMUNOL, V208, P125, DOI 10.1006/cimm.2001.1774; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lernmark A, 2001, J CLIN INVEST, V108, P1091, DOI 10.1172/JCI200114234; Lilja I, 2000, CLIN CHEM LAB MED, V38, P1231, DOI 10.1515/CCLM.2000.194; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nevalainen TJ, 2000, BBA-MOL CELL BIOL L, V1488, P83, DOI 10.1016/S1388-1981(00)00112-8; Nielson KH, 2000, BBA-MOL CELL BIOL L, V1484, P163, DOI 10.1016/S1388-1981(00)00004-4; Ozgen U, 2000, CYTOMETRY, V42, P74, DOI 10.1002/(SICI)1097-0320(20000215)42:1<74::AID-CYTO11>3.0.CO;2-6; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Vincent A, 1999, PATHOL RES PRACT, V195, P535, DOI 10.1016/S0344-0338(99)80002-8; WALL JR, 1993, J ENDOCRINOL INVEST, V16, P863, DOI 10.1007/BF03348946; Wilson HA, 1999, J BIOL CHEM, V274, P11494, DOI 10.1074/jbc.274.17.11494; Yokota Y, 2000, FEBS LETT, V478, P187, DOI 10.1016/S0014-5793(00)01848-2; ZAMAI L, 1993, CYTOMETRY, V14, P891, DOI 10.1002/cyto.990140807; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	54	42	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1068	1080		10.1096/fj.02-0938com	http://dx.doi.org/10.1096/fj.02-0938com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773489				2022-12-25	WOS:000183818000010
J	Kunapuli, P; Somerville, R; Still, IH; Cowell, JK				Kunapuli, P; Somerville, R; Still, IH; Cowell, JK			ZNF198 protein, involved in rearrangement in myeloproliferative disease, forms complexes with the DNA repair-associated HHR6A/6B and RAD18 proteins	ONCOGENE			English	Article						ZNF198; myeloproliferative disease; post replication repair; RAD6; RAD18	UBIQUITIN-CONJUGATING ENZYME; GROWTH-FACTOR RECEPTOR-1; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; DISORDER FUSES; YEAST RAD6; GENE RAD6; TRANSLOCATION; CHROMOSOME-13; BINDING	A highly specific t(8;13)(p11;q12) translocation has been consistently identified in bone marrow cells from patients with an atypical myeloproliferative disease that is associated with peripheral blood eosinophila and T- or B-cell leukemias. In all patients analysed to date, the translocation event results in a chimeric gene in which the atypical zinc-finger domain of ZNF198 is fused to the N-terminal end of the catalytic domain of the FGFR1 receptor tyrosine kinase. To understand more about the consequences of this rearrangement we have investigated the normal function of the ZNF198 gene. Using yeast two-hybrid analysis we identified HHR6 as a protein binding partner an confirmed this using immunoprecipitation studies. The ZNF198/FGFRI fusion protein also binds to HHR6. We demonstrate here that the human RAD18 is also present in the ZNF198/HHR6 protein complex, although it does not coimmunoprecipitate with the fusion kinase. Cells expressing the fusion kinase gene show a marked increased sensitivity to UVB irradiation, suggesting that it acts in a dominant-negative way to affect DNA repair. These observations support the idea that ZNF198, through its interaction with HHR6 and RAD18, may be involved in the DNA repair process.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA	Roswell Park Cancer Institute; Cleveland Clinic Foundation	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA076167] Funding Source: NIH RePORTER; NCI NIH HHS [CA76167, P30 CA16056-26] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRUZZO LV, 1992, AM J SURG PATHOL, V16, P236, DOI 10.1097/00000478-199203000-00003; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BAUMANN H, 2003, IN PRESS J BIOL CHEM; Chervin RD, 2000, SLEEP MED, V1, P21, DOI 10.1016/S1389-9457(99)00009-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KEMPSKI H, 1995, GENE CHROMOSOME CANC, V12, P283, DOI 10.1002/gcc.2870120408; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; Shekhar MPV, 2002, CANCER RES, V62, P2115; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; SMEDLEY D, 1999, NEOPLASIA, V1, P249; Still IH, 1997, BLOOD, V90, P3136, DOI 10.1182/blood.V90.8.3136; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; van der Laan R, 2000, GENOMICS, V69, P86, DOI 10.1006/geno.2000.6220; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847	29	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3417	3423		10.1038/sj.onc.1206408	http://dx.doi.org/10.1038/sj.onc.1206408			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776193				2022-12-25	WOS:000183128500008
J	Luo, RZ; Fang, XJ; Marquez, R; Liu, SY; Mills, GB; Liao, WSL; Yu, YH; Bast, RC				Luo, RZ; Fang, XJ; Marquez, R; Liu, SY; Mills, GB; Liao, WSL; Yu, YH; Bast, RC			ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers	ONCOGENE			English	Article						ARHI; tumor suppressor gene; GTP-binding protein; GTPase; mutagenesis; protein function; Ras superfamily	TUMOR-SUPPRESSOR GENE; GTPASE-ACTIVATING PROTEIN; BIOCHEMICAL-PROPERTIES; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; RHO-FAMILY; DOMAIN; FARNESYLATION; ASSOCIATION; MEMBRANE	Our group recently identified Ras homolog member I (ARHI), a novel maternally imprinted tumor suppressor gene that encodes a 26kDa GTP-binding protein with high homology to Ras and Rap. Unlike other Ras family members, ARHI exhibits several unusual structural and functional properties. ARHI contains a unique 34 amino-acid extension at the N-terminus, and differs from Ras in residues critical for GTPase activity and in its putative effector domain. Like Ras, ARHI can bind to GTP with high affinity but has low intrinsic GTPase activity. In addition, while Ras is an oncogene, ARHI functions as an inhibitor for cell growth. 12 Phosphorus labeling showed that ARHI is maintained in a constitutively activated GTP-bound state in resting cells, possibly because of impaired GTPase activity. ARHI is associated at the cell membrane through its prenylation at the C-terminal cysteine residue. Mutation of the conserved CAAX box at the C-terminus led to a loss of its membrane association and a decreased ability to inhibit cell growth. Conversion of Ser(51) to Asn decreased GTP binding and reduced ARHI's biological activity. Mutation of Ala(46) to Val increased the ability of ARHI to inhibit cell growth, associated with a further decrease of its intrinsic GTPase activity. Moreover, conversion of residues in ARHI that are conserved in the Ras family for GTPase activity partially restored the GTPase activity in ARHI. Most strikingly, deletion of ARHI's unique N-terminal extension nearly abolished its inhibitory effect on cell growth, suggesting its importance in ARHI's inhibitory function. Thus, ARHI is a unique Ras family member that retains basic small GTPase function, but exhibits many unusual features. In contrast to most other Ras family members, ARHI has a long N-terminal extension, modest GTPase activity, and constitutive GTP binding in resting cells. Furthermore, unlike the Ras oncogene, ARHI inhibits cell growth, and loss of its expression in cells may contribute to the development of breast and ovarian cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Rm Y7-5821,Box 355, Houston, TX 77030 USA.	rbast@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA80957, CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1995, METHOD ENZYMOL, V225, P161; BOUNE HR, 1991, NATURE, V349, P117; Chen JM, 1996, J PROTEIN CHEM, V15, P511, DOI 10.1007/BF01908532; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fiegen D, 2002, FEBS LETT, V525, P100, DOI 10.1016/S0014-5793(02)03094-6; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Foster R, 1996, MOL CELL BIOL, V16, P2689; Garavini H, 2002, BIOCHEMISTRY-US, V41, P6303, DOI 10.1021/bi025651h; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; HALL A, 1986, J BIOL CHEM, V261, P963; Hofemeister H, 2000, MOL BIOL CELL, V11, P3233, DOI 10.1091/mbc.11.9.3233; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Patton SE, 1998, CANCER RES, V58, P2253; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SUNYER T, 1984, J BIOL CHEM, V259, P5447; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Xu FJ, 2000, CANCER RES, V60, P4913; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	41	83	89	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2897	2909		10.1038/sj.onc.1206380	http://dx.doi.org/10.1038/sj.onc.1206380			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771940				2022-12-25	WOS:000182824800004
J	Oosterhoff, JK; Penninkhof, F; Brinkmann, AO; Grootegoed, JA; Blok, LJ				Oosterhoff, JK; Penninkhof, F; Brinkmann, AO; Grootegoed, JA; Blok, LJ			REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells	ONCOGENE			English	Article						REPS2; POB1; prostate cancer; internalization; EGF signalling	RAL-BINDING PROTEIN-1; CLATHRIN-MEDIATED ENDOCYTOSIS; PUTATIVE EFFECTOR PROTEIN; GTPASE; IDENTIFICATION; INVOLVEMENT; PATHWAYS; COMPLEX; RLIP76; GENES	During progression of prostate cancer, cellular changes occur, leading to a transition from androgen-dependent to androgen-independent growth. One aspect of this transition is a switch from androgens to growth factors, like epidermal growth factor (EGF), as primary regulators of proliferation. We examined the involvement of REPS2/POB1 in this process. REPS2/POB1 is an EH domain-containing protein, reported to be involved in signalling via RatBP1 and to play a role in endocytosis of EGF receptors. Furthermore, the protein is relatively highly expressed in androgen-dependent as compared to androgen-independent human prostate cancer cell lines and xenografts. Next to the known REPS2/POB1 protein, an open reading frame encoding REPS2/POB1, with 139 additional amino-acid residues at the NH2-terminus, was cloned and found to be expressed in prostate cancer cells. Overexpression, by transient transfection, of both forms of REPS2/POB1 in prostate cancer cell lines, induced apoptosis within 48 h. At shorter time intervals after transfection, signalling towards a TPA response element luciferase reporter was found to be inhibited. From these experiments, it is concluded that REPS2/POB1, through its influence on the Ral signalling pathway, is involved in growth factor signalling. Decreased expression of REPS2/POB1 during progression of prostate cancer may therefore result in loss of control of growth factor signalling and consequently in loss of control of cell proliferation.	Erasmus Univ, Erasmus MC, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Blok, LJ (corresponding author), Erasmus Univ, Erasmus MC, Dept Reprod & Dev, POB 1738, NL-3000 DR Rotterdam, Netherlands.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chang GTG, 1997, CANCER RES, V57, P4075; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JANSSEN T, 1995, PROSTATE, V27, P277, DOI 10.1002/pros.2990270507; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Osada M, 1999, MOL CELL BIOL, V19, P6333; Park SH, 1995, ONCOGENE, V11, P2349; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Russell PJ, 1998, CLIN CHEM, V44, P705; VANSTEENBRUGGE GJ, 1991, J STEROID BIOCHEM, V40, P207, DOI 10.1016/0960-0760(91)90184-7; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086	23	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2920	2925		10.1038/sj.onc.1206397	http://dx.doi.org/10.1038/sj.onc.1206397			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771942				2022-12-25	WOS:000182824800006
J	Zwaka, TP; Torzewski, J; Hoeflich, A; Dejosez, M; Kaiser, S; Hombach, V; Jehle, PM				Zwaka, TP; Torzewski, J; Hoeflich, A; Dejosez, M; Kaiser, S; Hombach, V; Jehle, PM			The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop	FASEB JOURNAL			English	Article						arteriosclerosis; cell death; inflammation; C5b-9; growth factors	C-REACTIVE PROTEIN; HUMAN ATHEROSCLEROTIC PLAQUES; HUMAN CORONARY-ARTERIES; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-I; UNSENSITIZED CELLS; MEDIATED LYSIS; SUBLYTIC C5B-9; PROLIFERATION; RESTENOSIS	Two counteracting processes determine accumulation of human vascular smooth muscle cells (SMCs) in atherosclerotic lesions: cell proliferation and apoptosis. SMCs synthesize insulin-like growth factor-1 (IGF-1), which potently inhibits apoptosis. The terminal complement complex C5b-9 interacts with SMCs in early human atherogenesis. In this study, we investigated whether C5b-9 may activate the IGF-1 system in SMCs, resulting in the inhibition of SMC apoptosis. C5b-9 generation on SMCs in vitro markedly reduced CD95-mediated apoptosis as assessed by flowcytometric analysis of annexin V binding and in caspase 3 assays. C5b-9 induced both significant IGF-1 release and up-regulation of IGF-1 binding sites in SMCs. Immunoneutralization of IGF-1 with a monoclonal IGF-1 antibody abolished the antiapoptotic effects of C5b-9. We conclude that C5b-9 inhibits apoptosis in SMCs by inducing an autocrine IGF-1 loop. This mechanism may contribute to the accumulation of SMCs in early human atherosclerotic lesions.	Univ Ulm, Dept Internal Med 2, D-89069 Ulm, Germany; Univ Munich, Gene Ctr, Inst Mol Anim Breeding, D-80539 Munich, Germany; Creatogen AG, Augsburg, Germany	Ulm University; University of Munich	Torzewski, J (corresponding author), Univ Ulm, Dept Internal Med Cardiol 2, Robert Koch Str 8, D-89081 Ulm, Germany.	jan.torzewski@medizin.uni-ulm.de		Hoeflich, Andreas/0000-0003-2018-2836; Torzewski, Jan/0000-0003-4959-7293				Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; Buono C, 2002, CIRCULATION, V105, P3025, DOI 10.1161/01.CIR.0000019584.04929.83; Dashiell SM, 2000, GLIA, V30, P187, DOI 10.1002/(SICI)1098-1136(200004)30:2<187::AID-GLIA8>3.0.CO;2-7; Dejosez M, 2000, CELL DEATH DIFFER, V7, P1127, DOI 10.1038/sj.cdd.4400746; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Hila S, 2001, GLIA, V36, P58, DOI 10.1002/glia.1095; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Jehle PM, 1999, HORM METAB RES, V31, P97, DOI 10.1055/s-2007-978705; Kockx MM, 2000, J PATHOL, V190, P267, DOI 10.1002/(SICI)1096-9896(200002)190:3<267::AID-PATH523>3.0.CO;2-A; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; LACHMANN PJ, 1970, J EXP MED, V131, P643, DOI 10.1084/jem.131.4.643; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; Niculescu F, 1999, MOL IMMUNOL, V36, P949, DOI 10.1016/S0161-5890(99)00117-0; Niculescu F, 1999, ATHEROSCLEROSIS, V142, P47, DOI 10.1016/S0021-9150(98)00185-3; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1993, AM J PATHOL, V143, P987; Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x; Schmiedt W, 1998, ARTERIOSCL THROM VAS, V18, P1790, DOI 10.1161/01.ATV.18.11.1790; SEIFERT PS, 1988, ATHEROSCLEROSIS, V73, P91, DOI 10.1016/0021-9150(88)90030-5; Soane L, 1999, J IMMUNOL, V163, P6132; THOMPSON RA, 1970, J EXP MED, V131, P629, DOI 10.1084/jem.131.4.629; Torzewski J, 1996, ARTERIOSCL THROM VAS, V16, P673, DOI 10.1161/01.ATV.16.5.673; Torzewski J, 1998, ARTERIOSCL THROM VAS, V18, P1386, DOI 10.1161/01.ATV.18.9.1386; Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7; Torzewski M, 1997, ARTERIOSCL THROM VAS, V17, P2448, DOI 10.1161/01.ATV.17.11.2448; Viedt C, 2000, FASEB J, V14, P2370; von Wichert G, 2000, CANCER RES, V60, P4573; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Zhang YX, 1999, ATHEROSCLEROSIS, V145, P375, DOI 10.1016/S0021-9150(99)00105-7; Zwaka TP, 2001, CIRCULATION, V103, P1194; Zwaka TP, 2002, AM J PATHOL, V161, P449, DOI 10.1016/S0002-9440(10)64201-0	37	27	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1346	+		10.1096/fj.02-0814fje	http://dx.doi.org/10.1096/fj.02-0814fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759337				2022-12-25	WOS:000183165000016
J	Sax, JK; El-Deiry, WS				Sax, JK; El-Deiry, WS			Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; ADAPTER PROTEINS; CELL-CYCLE; P53; RECEPTOR; FAMILY; INHIBITOR; DEATH; KILLER/DR5	The role of p53 in tumor suppression partly relies on its ability to transcriptionally regulate target genes involved in the initiation of cell cycle arrest or the activation of programmed cell death. In recent years many genes have been identified as p53-regulated genes; however, no single target gene has been shown to be required for the full apoptotic effect. We have identified TRAF4 as a p53-regulated gene in a microarray screen using a Murine 11K Affymetrix GeneChip hybridized with cRNA from the p53 temperature-sensitive cell line, Vm10. TRAF4 is a member the TRAF family of adaptor proteins that mediate cellular signaling by binding to various members of the tumor necrosis family receptor superfamily and interleukin-1/Toll-like receptor superfamily. In contrast to its other family members, TRAF4 has not been shown to bind to a member of the tumor necrosis factor receptor superfamily in vivo, nor has it been shown to regulate signaling pathways common to its other family members. Therefore the role of TRAF4 in a signaling pathway has not yet been established and requires further study. TRAF4 is specifically regulated by p53 in response to temperature sensitive p53, overexpression of p53 by use of an adenovirus, and stabilization of p53 in response to DNA damage. The murine TRAF4 promoter contains a functional p53 DNA-binding site similar to1 kilobase upstream of the initiating methionine. TRAF4 localizes to the cytoplasm and appears to remain in the cytoplasm following DNA damage. Interestingly, the overexpression of TRAF4 induces apoptosis and suppresses colony formation. These data suggest a correlation that the orphan adaptor protein TRAF4 may play a role in p53-mediated proapoptotic signaling in the response to cellular stress.	Univ Penn, Sch Med, Dept Med,Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol,Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet,Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med,Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Attardi LD, 2000, GENE DEV, V14, P704; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chung JY, 2002, J CELL SCI, V115, P679; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Glauner H, 2002, EUR J BIOCHEM, V269, P4819, DOI 10.1046/j.1432-1033.2002.03180.x; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Krajewska M, 1998, AM J PATHOL, V152, P1549; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Masson R, 1998, MECH DEVELOP, V71, P187, DOI 10.1016/S0925-4773(97)00192-5; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Shiels H, 2000, AM J PATHOL, V157, P679, DOI 10.1016/S0002-9440(10)64578-6; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	46	48	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36435	36444		10.1074/jbc.M303191200	http://dx.doi.org/10.1074/jbc.M303191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12788948	hybrid			2022-12-25	WOS:000185318300072
J	Cristillo, AD; Nie, LH; Macri, MJ; Bierer, BE				Cristillo, AD; Nie, LH; Macri, MJ; Bierer, BE			Cloning and characterization of N4WBP5A, an inducible, cyclosporine-sensitive, Nedd4-binding protein in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; WW DOMAIN; LIDDLES-SYNDROME; IMMUNE-SYSTEM; LIGASE NEDD4; UBIQUITINATION; FAMILY; IDENTIFICATION; MICE; ITCH	We have cloned and characterized a human cDNA, designated N4WBP5A, that belongs to the family of Nedd4-binding proteins. We originally identified N4WBP5A as an unknown expressed sequence tag (AA770150) represented in a cDNA microarray analysis that was up-regulated upon activation of T cells and inhibited by cell treatment with the calcineurin phosphatase inhibitors, cyclosporine (CsA) and tacrolimus (FK506). The predicted N4WBP5A amino acid sequence of 242 amino acid residues reveals an open reading frame of 729 nucleotides with a corresponding molecular mass of 27.1 kDa. Detection of N4WBP5A mRNA by reverse transcription-PCR was consistent with the induction of N4WBP5A following mitogenic stimulation of T lymphocytes and inhibition by CsA. Immunoblot analysis revealed endogenous N4WBP5A protein to be up-regulated following T cell activation and inhibited by CsA. This regulation of N4WBP5A mRNA expression differed from that of its homologue (51% identical; 65% similar) N4WBP5. Like N4WBP5, however, expression of epitope-tagged N4WBP5A indicated that the protein is localized predominantly to the Golgi network. Here we show by co-precipitation experiments that N4WBP5A interacts with the WW domains of Nedd4, an E3 ubiquitin ligase. Taken together, our data suggest that N4WBP5A may play a regulatory role in modulating Nedd4 activity at the level of the Golgi apparatus in T lymphocytes.	NHLBI, Lab Lymphocyte Biol, NIH, Bethesda, MD 20892 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Dana-Farber Cancer Institute	Bierer, BE (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	bbierer@partners.org		Bierer, Barbara/0000-0001-6448-8170				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P44, DOI 10.1093/nar/29.1.44; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Ciechanover A, 2000, J CELL BIOCHEM, P40; Cristillo AD, 2002, J BIOL CHEM, V277, P4465, DOI 10.1074/jbc.M108598200; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9	26	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34587	34597		10.1074/jbc.M304723200	http://dx.doi.org/10.1074/jbc.M304723200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12796489	hybrid			2022-12-25	WOS:000185047500120
J	Sun, H; Hu, XQ; Moradel, EM; Weight, FF; Zhang, L				Sun, H; Hu, XQ; Moradel, EM; Weight, FF; Zhang, L			Modulation of 5-HT3 receptor-mediated response and trafficking by activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; NEUROTRANSMITTER RELEASE; FUNCTIONAL EXPRESSION; SYNAPTIC-TRANSMISSION; NMDA RECEPTORS; F-ACTIN; PHOSPHORYLATION; POTENTIATION; INTERNALIZATION; AGONISTS	Modulation of neurotransmitter-gated membrane ion channels by protein kinase C (PKC) has been the subject of a number of studies. However, less is known about PKC modulation of the serotonin type 3 (5-HT3) receptor, a ligand-gated membrane ion channel that can mediate fast synaptic transmission in the central and peripheral nervous system. Here, we show that PKC potentiated 5-HT3 receptor-mediated current in Xenopus oocytes expressing 5- HT3A receptors and mouse N1E-115 neuroblastoma cells. In addition, using a specific antibody directed to the extracellular N-terminal domain of the 5- HT3A receptor, treatment with the PKC activator, 4beta-phorbol 12-myristate 13-acetate (PMA), significantly increased surface immunofluorescence. PKC also increased the amount of 5- HT3A receptor protein in the cell membrane without affecting the amount receptor protein in the total cell extract. The magnitude of PMA potentiation of 5-HT3A receptor-mediated responses is correlated with the magnitude of PMA enhancement of the receptor abundance in the cell surface membrane. PMA potentiation is unlikely to occur via direct phosphorylation of the 5- HT3A receptor protein since the potentiation was not affected by point mutation of each of the putative sites for PKC phosphorylation. However, preapplication of phalloidin, which stabilizes the actin polymerization, significantly inhibited PMA potentiation of 5-HT-activated responses in both N1E-115 cells and oocytes expressing 5-HT3A receptors. On the other hand, latrunculin-A, which destabilizes actin cytoskeleton, enhanced the PMA potentiation of 5- HT3A receptors. The observations suggest that PKC can modulate 5- HT3A receptor function and trafficking through an F-actin-dependent mechanism.	NIAAA, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Zhang, L (corresponding author), NIAAA, Mol & Cellular Neurobiol Lab, NIH, Pk Bldg,Rm 150, Bethesda, MD 20892 USA.	lzhang@niaaa.nih.gov		Zhang, Lubo/0000-0002-9386-8938	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allison DW, 1998, J NEUROSCI, V18, P2423; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chapell R, 1998, J BIOL CHEM, V273, P32595, DOI 10.1074/jbc.273.49.32595; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Coultrap SJ, 2002, RECEPTOR CHANNEL, V8, P63, DOI 10.1080/10606820212397; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Emerit MB, 2002, MOL CELL NEUROSCI, V20, P110, DOI 10.1006/mcne.2002.1133; Filippova N, 2000, MOL PHARMACOL, V57, P847; Filippova N, 1999, J PHYSIOL-LONDON, V518, P385, DOI 10.1111/j.1469-7793.1999.0385p.x; GRANT KA, 1995, DRUG ALCOHOL DEPEN, V38, P155, DOI 10.1016/0376-8716(95)01120-N; Hanna MC, 2000, J NEUROCHEM, V75, P240, DOI 10.1046/j.1471-4159.2000.0750240.x; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HOPE AG, 1993, EUR J PHARM-MOLEC PH, V245, P187, DOI 10.1016/0922-4106(93)90128-V; Hubbard PC, 2000, MOL BRAIN RES, V81, P101, DOI 10.1016/S0169-328X(00)00138-8; Kim CH, 1999, J NEUROSCI, V19, P4314; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Lankiewicz S, 2000, RECEPTOR CHANNEL, V7, P9; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; Liao GY, 2001, MOL PHARMACOL, V59, P960, DOI 10.1124/mol.59.5.960; Liu QS, 1999, J NEUROSCI, V19, P10280; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Morales M, 2002, J NEUROSCI, V22, P6732; Morales M, 2001, J COMP NEUROL, V438, P163, DOI 10.1002/cne.1307; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; Nakhost A, 1998, J NEUROCHEM, V71, P1221; Shoop RD, 2000, J NEUROSCI, V20, P4021; SIGEL E, 1994, J BIOL CHEM, V269, P8204; Skeberdis VA, 2001, NEUROPHARMACOLOGY, V40, P856, DOI 10.1016/S0028-3908(01)00005-3; Spier AD, 1999, MOL BRAIN RES, V67, P221; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; Trifaro JM, 2000, BIOCHIMIE, V82, P339, DOI 10.1016/S0300-9084(00)00193-0; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; UCHIYAMA M, 1994, MOL BRAIN RES, V24, P295, DOI 10.1016/0169-328X(94)90142-2; van Hooft JA, 2000, TRENDS NEUROSCI, V23, P605, DOI 10.1016/S0166-2236(00)01662-3; vanHooft JA, 1996, BRIT J PHARMACOL, V117, P839; VANHOOFT JA, 1995, RECEPTOR CHANNEL, V3, P7; vanHooft JA, 1997, J RECEPT SIGNAL TR R, V17, P267, DOI 10.3109/10799899709036608; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Wagner DA, 1999, NEUROSCI LETT, V272, P187, DOI 10.1016/S0304-3940(99)00524-8; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zeitz KP, 2002, J NEUROSCI, V22, P1010, DOI 10.1523/JNEUROSCI.22-03-01010.2002; ZHANG L, 1995, NEUROREPORT, V6, P1464, DOI 10.1097/00001756-199507100-00025; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zheng X, 1997, J NEUROSCI, V17, P8676; Zheng X, 1999, P NATL ACAD SCI USA, V96, P15262, DOI 10.1073/pnas.96.26.15262	50	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34150	34157		10.1074/jbc.M303584200	http://dx.doi.org/10.1074/jbc.M303584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12791692	hybrid			2022-12-25	WOS:000185047500068
J	Masuda, K; Shima, H; Katagiri, C; Kikuchi, K				Masuda, K; Shima, H; Katagiri, C; Kikuchi, K			Activation of ERK induces phosphorylation of MAPK phosphatase-7, a JNK specific phosphatase, at Ser-446	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-KINASE; C-JUN; SUBSTRATE RECOGNITION; DOCKING SITE; TRANSCRIPTION FACTORS; CATALYTIC ACTIVATION; S6 KINASE; DOMAIN; P38	We previously showed that MKP-7 suppresses MAPK activation in COS-7 cells in the order of selectivity, JNKmuch greater thanp38>ERK, but interacts with ERK as well as JNK and p38. In this study we found that, when expressed in COS-7 cells with HA-ERK2, the mobility of FLAG-MKP-7 was decreased on SDS-PAGE gels depending on several stimuli, including phorbol 12-myristate 13-acetate, fetal bovine serum, epidermal growth factor, H2O2, and ionomycin. By using U0126, a MEK inhibitor, and introducing several point mutations, we demonstrated that this upward mobility shift is because of phosphorylation and identified Ser-446 of MKP-7 as the phosphorylation site targeted by ERK activation. To determine how MKP-7 interacts with MAPKs, we identified three domains in MKP-7 required for interaction with MAPKs, namely, putative MAP kinase docking domains (D-domain) I and II and a long COOH-terminal stretch unique to MKP-7. The D-domain I is required for interaction with ERK and p38, whereas the D-domain II is required for interaction with JNK and p38, which is likely to be important for MKP-7 to suppress JNK and p38 activations. The COOH-terminal stretch of MKP-7 was shown to determine JNK preference for MKP-7 by masking MKP-7 activity toward p38 and is a domain bound by ERK. These data strongly suggested that Ser-446 of MKP-7 is phosphorylated by ERK.	Hokkaido Univ, Inst Med Genet,Div Biochem Oncol & Immunol, Sect Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Shima, H (corresponding author), Hokkaido Univ, Inst Med Genet,Div Biochem Oncol & Immunol, Sect Biochem Oncol & Immunol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.		Katagiri, Chiaki/AAW-6901-2020					Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chen YR, 2000, INT J ONCOL, V16, P651; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DAI TN, 1995, ONCOGENE, V10, P849; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Hall JF, 2000, P NATL ACAD SCI USA, V97, P14022, DOI 10.1073/pnas.97.26.14022; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Nakamura K, 2002, J BIOCHEM, V132, P463, DOI 10.1093/oxfordjournals.jbchem.a003244; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; Tamura S, 2002, EUR J BIOCHEM, V269, P1060, DOI 10.1046/j.0014-2956.2002.02754.x; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; THEODOSIOU A, 2002, GENOME BIOL, V3; Todd JL, 2002, ONCOGENE, V21, P2573, DOI 10.1038/sj.onc.1205344; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200	56	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32448	32456		10.1074/jbc.M213254200	http://dx.doi.org/10.1074/jbc.M213254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794087	hybrid			2022-12-25	WOS:000184782100125
J	Richard, CL; Tandon, A; Sloan, NR; Kranz, RG				Richard, CL; Tandon, A; Sloan, NR; Kranz, RG			RNA polymerase subunit requirements for activation by the enhancer-binding protein Rhodobacter capsulatus NtrC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; ESCHERICHIA-COLI; ALPHA-SUBUNIT; TRANSCRIPTIONAL ACTIVATOR; IN-VITRO; OMEGA-SUBUNIT; RHODOPSEUDOMONAS-CAPSULATA; NITROGEN-FIXATION; GENE-EXPRESSION; CROSS-LINKING	Rhodobacter capsulatus NtrC is an enhancer-binding protein that activates transcription of the R. capsulatus sigma(70) RNA polymerase, but does not activate the Escherichia coli sigma(70)-RNA polymerase at the nifA1 promoter. We utilized R. capsulatus: E. coli hybrid RNA polymerases assembled in vitro to investigate the subunits required for protein-protein interaction with RcNtrC at the nifA1mut1 promoter. Assembly of core Rcalphabetabeta' or hybrid RNA polymerases containing the Rcbetabeta' subunits absolutely require the inclusion of an omega subunit, with the Ecomega subunit only partially promoting RNA polymerase assembly. The RcalphaEcbetabeta' RNA polymerase is not activated by RcNtrC. Moreover, a mutant form of the Rcalpha lacking the alpha C-terminal domain, when assembled with the Rcbetabeta'omega and sigma(70) subunits, is activated by RcNtrC. These results suggest that the R. capsulatus alpha subunit is not important for RcNtrC interaction. All hybrid RNA polymerases that contained the Rcbeta' were activated by RcNtrC, suggesting that the Rcbeta' subunit plays an important role. It is proposed that RcNtrC recruits R. capsulatus sigma(70)-RNA polymerase to the promoter through interaction with Rcbeta'. RcNtrC interacts with RNA polymerase from a unique position, with dimers centered at -118 bp from the start site. Placing the RcNtrC tandem binding sites on the opposite face of the helix (-113 bp) completely abolished transcription activation. Moving the RcNtrC tandem binding sites 20 bp closer to or further from the promoter significantly reduced activation, again suggesting unique spatial constraints on how RcNtrC interacts with the R. capsulatus RNA polymerase.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Kranz, RG (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.			Tandon, Animesh/0000-0001-9769-8801				AVTGES P, 1985, MOL GEN GENET, V201, P363, DOI 10.1007/BF00331324; Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; Bowman WC, 1998, GENE DEV, V12, P1884, DOI 10.1101/gad.12.12.1884; BURGESS RR, 1969, J BIOL CHEM, V244, P6168; Cullen PJ, 1997, J BIOL CHEM, V272, P27266, DOI 10.1074/jbc.272.43.27266; Cullen PJ, 1996, J BIOL CHEM, V271, P6530, DOI 10.1074/jbc.271.11.6530; Dove SL, 1998, GENE DEV, V12, P745, DOI 10.1101/gad.12.5.745; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; FOSTERHARTNETT D, 1994, J BACTERIOL, V176, P6175, DOI 10.1128/jb.176.20.6175-6187.1994; FOSTERHARTNETT D, 1994, J BACTERIOL, V176, P5171, DOI 10.1128/jb.176.16.5171-5176.1994; GAO J, 1991, J BACTERIOL, V173, P394, DOI 10.1128/jb.173.1.394-397.1991; GENTRY DR, 1993, BIOCHEMISTRY-US, V32, P11224, DOI 10.1021/bi00092a036; Ghosh P, 2001, EUR J BIOCHEM, V268, P4621, DOI 10.1046/j.1432-1327.2001.02381.x; He YP, 1999, J BIOL CHEM, V274, P10840, DOI 10.1074/jbc.274.16.10840; KRANZ RG, 1990, MOL MICROBIOL, V4, P1793, DOI 10.1111/j.1365-2958.1990.tb02027.x; LAWLEY B, 1995, J BACTERIOL, V177, P238, DOI 10.1128/jb.177.1.238-241.1995; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; Lohrke SM, 1999, J BACTERIOL, V181, P4533, DOI 10.1128/JB.181.15.4533-4539.1999; Lohrke SM, 2001, J BACTERIOL, V183, P3704, DOI 10.1128/JB.183.12.3704-3711.2001; Masepohl B, 2001, J BACTERIOL, V183, P637, DOI 10.1128/JB.183.2.637-643.2001; Mencia M, 1998, J MOL BIOL, V275, P177, DOI 10.1006/jmbi.1997.1463; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; Mukherjee K, 1999, EUR J BIOCHEM, V266, P228, DOI 10.1046/j.1432-1327.1999.00848.x; Mukherjee K, 1997, EUR J BIOCHEM, V247, P884, DOI 10.1111/j.1432-1033.1997.00884.x; Peck MC, 2002, J BACTERIOL, V184, P3808, DOI 10.1128/JB.184.14.3808-3814.2002; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Savery NJ, 2002, J BACTERIOL, V184, P2273, DOI 10.1128/JB.184.8.2273-2280.2002; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; Steffen P, 1998, J BACTERIOL, V180, P1567, DOI 10.1128/JB.180.6.1567-1569.1998; Stevens AM, 1999, J BACTERIOL, V181, P4704, DOI 10.1128/JB.181.15.4704-4707.1999; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; Vicente M, 1999, MOL MICROBIOL, V33, P8, DOI 10.1046/j.1365-2958.1999.01445.x; Wang YK, 1997, MOL MICROBIOL, V26, P373, DOI 10.1046/j.1365-2958.1997.5851955.x; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Yang J, 1996, J BACTERIOL, V178, P6389, DOI 10.1128/jb.178.21.6389-6393.1996; YEN HC, 1977, ARCH BIOCHEM BIOPHYS, V181, P411, DOI 10.1016/0003-9861(77)90246-6; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	41	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31701	31708		10.1074/jbc.M304430200	http://dx.doi.org/10.1074/jbc.M304430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794072	hybrid			2022-12-25	WOS:000184782100031
J	Ahern, GP				Ahern, GP			Activation of TRPV1 by the satiety factor oleoylethanolamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR VR1; VANILLOID RECEPTOR; MESSENGER-RNA; DORSAL-ROOT; SUBTYPE 1; PAIN; ANANDAMIDE; RAT; EXPRESSION; MECHANISM	The fatty acid oleoylethanolamide (OEA) is a satiety factor that excites peripheral vagal sensory nerves, but the mechanism by which this occurs and the molecular targets of OEA are unclear. In this study the ability of OEA to modulate the capsaicin receptor (TRPV1) was explored. OEA alone did not activate TRPV1 expressed in Xenopus oocytes under control conditions, but produced a differential modulation of agonist-evoked responses. OEA enhanced proton-gated TRPV1 currents, inhibited anandamide-evoked currents and had no effect on capsaicin-evoked responses. Following stimulation of protein kinase C (PKC), OEA alone directly activated TRPV1 channel with an EC50 of similar to2 muM at room temperature. This effect was due to direct phosphorylation of TRPV1 because no responses to OEA were observed with mutant channels lacking critical PKC phosphorylation sites, S502A/S800A. In sensory neurons, OEA-induced Ca2+ rises that were selective for capsaicin-sensitive cells, inhibited by the TRPV1 blocker, capsazepine, and occurred in a PKC-dependent manner. Further, after PKC stimulation, OEA activated TRPV1 channels in cell-free patches suggesting a direct mode of action. Thus, TRPV1 represents a potential target for OEA and may contribute to the excitatory action of OEA on sensory nerves.	Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA	Georgetown University	Ahern, GP (corresponding author), Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA.	gpa3@georgetown.edu						Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bray GA, 2000, P NUTR SOC, V59, P373, DOI 10.1017/S0029665100000422; Broberger C, 2001, BRAIN RES, V903, P128, DOI 10.1016/S0006-8993(01)02468-4; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Gomez R, 2002, J NEUROSCI, V22, P9612; Jonsson KO, 2001, BRIT J PHARMACOL, V133, P1263, DOI 10.1038/sj.bjp.0704199; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Michael GJ, 1999, J NEUROSCI, V19, P1844; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Piomelli D, 1998, NEUROBIOL DIS, V5, P462, DOI 10.1006/nbdi.1998.0221; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smart D, 2002, BRIT J PHARMACOL, V136, P452, DOI 10.1038/sj.bjp.0704732; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	21	192	211	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30429	30434		10.1074/jbc.M305051200	http://dx.doi.org/10.1074/jbc.M305051200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12761211	hybrid			2022-12-25	WOS:000184658800005
J	Heath, MJ; Derebail, SS; Gorelick, RJ; DeStefano, JJ				Heath, MJ; Derebail, SS; Gorelick, RJ; DeStefano, JJ			Differing roles of the N- and C-terminal zinc fingers in human immunodeficiency virus nucleocapsid protein-enhanced nucleic acid annealing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; STRAND TRANSFER-REACTIONS; RNA PACKAGING SIGNAL; PRIMER BINDING-SITE; STRONG-STOP DNA; STEM-LOOP SL2; IN-VITRO; REVERSE TRANSCRIPTION; CHAPERONE ACTIVITY; VIRAL-DNA	The replication process of human immunodeficiency virus requires a number of nucleic acid annealing steps facilitated by the hybridization and helix-destabilizing activities of human immunodeficiency virus nucleocapsid (NC) protein. NC contains two CCHC zinc finger motifs numbered 1 and 2 from the N terminus. The amino acids surrounding the CCHC residues differ between the two zinc fingers. Assays were preformed to investigate the activities of the fingers by determining the effect of mutant and wild-type proteins on annealing of 42-nucleotide RNA and DNA complements. The mutants 1.1 NC and 2.2 NC had duplications of the N- and C-terminal zinc fingers in positions 1 and 2. The mutant 2.1 NC had the native zinc fingers with their positions switched. Annealing assays were completed with unstructured and highly structured oligonucleotide complements. 2.2 NC had a near wild-type level of annealing of unstructured nucleic acids, whereas it was completely unable to stimulate annealing of highly structured nucleic acids. In contrast, 1.1 NC was able to stimulate annealing of both unstructured and structured substrates, but to a lesser degree than the wild-type protein. Results suggest that finger 1 has a greater role in unfolding of strong secondary structures, whereas finger 2 serves an accessory role that leads to a further increase in the rate of annealing.	Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA; NCI, AIDS Vaccine Program, SAIC Frederick Inc, Frederick, MD 21702 USA	University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	DeStefano, JJ (corresponding author), Univ Maryland, Dept Mol Genet & Cell Biol, Bldg 231, College Pk, MD 20742 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051140, R01GM051140] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NIGMS NIH HHS [R01 GM051140, GM51140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Amarasinghe GK, 2000, J MOL BIOL, V299, P145, DOI 10.1006/jmbi.2000.3710; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; Brule F, 2002, RNA, V8, P8, DOI 10.1017/S1355838202010981; Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; Carteau S, 1997, J VIROL, V71, P6225, DOI 10.1128/JVI.71.8.6225-6229.1997; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10041, DOI 10.1073/pnas.89.21.10041; COFFIN JM, 1997, RETROVIRUSES, P51; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; De Guzman RN, 1998, BIOPOLYMERS, V48, P181, DOI 10.1002/(SICI)1097-0282(1998)48:2<181::AID-BIP7>3.0.CO;2-L; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; Fisher RJ, 1998, J VIROL, V72, P1902, DOI 10.1128/JVI.72.3.1902-1909.1998; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; Golinelli MP, 2001, VIROLOGY, V285, P278, DOI 10.1006/viro.2001.0970; Gorelick RJ, 1999, VIROLOGY, V256, P92, DOI 10.1006/viro.1999.9629; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Hargittai MRS, 2001, J MOL BIOL, V312, P985, DOI 10.1006/jmbi.2001.5021; HENDERSON LE, 1990, J MED PRIMATOL, V19, P411; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hsu M, 2000, NUCLEIC ACIDS RES, V28, P1724, DOI 10.1093/nar/28.8.1724; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; KHAN R, 1994, J BIOL CHEM, V269, P22538; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; MULLER G, 1994, J MOL BIOL, V242, P422, DOI 10.1006/jmbi.1994.1592; Novere N.L., 2001, BIOINFORMATICS, V17, P1226; OMICHINSKI JG, 1991, FEBS LETT, V292, P25, DOI 10.1016/0014-5793(91)80825-N; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Raja A, 1999, BIOCHEMISTRY-US, V38, P5178, DOI 10.1021/bi9828019; REIN A, 1994, J VIROL, V68, P6124, DOI 10.1128/JVI.68.9.6124-6129.1994; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; Shehu-Xhilaga M, 2001, J VIROL, V75, P9156, DOI 10.1128/JVI.75.19.9156-9164.2001; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; Takahashi K, 2001, J BIOL CHEM, V276, P31274, DOI 10.1074/jbc.M104577200; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; Trubetskoy AM, 1999, J VIROL, V73, P3477, DOI 10.1128/JVI.73.4.3477-3483.1999; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8; Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521; Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	76	49	49	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30755	30763		10.1074/jbc.M303819200	http://dx.doi.org/10.1074/jbc.M303819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783894	hybrid			2022-12-25	WOS:000184658800043
J	Matsushima, Y; Matsumura, K; Ishii, S; Inagaki, H; Suzuki, T; Matsuda, Y; Beck, K; Kitagawa, Y				Matsushima, Y; Matsumura, K; Ishii, S; Inagaki, H; Suzuki, T; Matsuda, Y; Beck, K; Kitagawa, Y			Functional domains of chicken mitochondrial transcription factor a for the maintenance of mitochondrial DNA copy number in lymphoma cell line DT40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE RNA-POLYMERASE; HMG-BOX PROTEIN; SPECIFICITY FACTOR; FACTOR-A; SACCHAROMYCES-CEREVISIAE; PROMOTER RECOGNITION; YEAST MITOCHONDRIA; BINDING PROPERTIES; INITIATION SITES; SIGMA-FACTORS	Nuclear and mitochondrial (mt) forms of chicken mt transcription factor A (c-TFAM) generated by alternative splicing of a gene (c-tfam) were cloned. c-tfam mapped at 6q1.1-q1.2 has similar exon/intron organization as mouse tfam except that the first exons encoding the nuclear and the mt form-specific sequences were positioned oppositely. When cDNA encoding the nuclear form was transiently expressed in chicken lymphoma DT40 cells after tagging at the C terminus with c-Myc, the product was localized into nucleus, whereas the only endogenous mt form of DT40 cells was immunostained exclusively within mitochondria. c-TFAM is most similar to Xenopus (xl-) TFAM in having extended C-terminal regions in addition to two high mobility group (HMG) boxes, a linker region between them, and a C-terminal tail, also found in human and mouse TFAM. Similarities between c- and xl-TFAM are higher in linker and C-terminal regions than in HMG boxes. Disruption of both tfam alleles in DT40 cells prevented proliferation. The tfam(+)/tfam(-) cells showed a 50 and 40-60% reduction of mtDNA and its transcripts, respectively. Expression of exogenous wild type c- tfam cDNA in the tfam(+)/tfam(-) cells increased mtDNA up to 4-fold in a dose-dependent manner, whereas its transcripts increased only marginally. A deletion mutant lacking the first HMG box lost this activity, whereas only marginal reduction of the activity was observed in a deletion mutant at the second HMG box. Despite the essential role of the C-terminal tail in mtDNA transcription demonstrated in vitro, deletion of c-TFAM at this region reduced the activity of maintenance of the mtDNA level only by 50%. A series of deletion mutant at the tail region suggested stimulatory and suppressive sequences in this region for the maintenance of mtDNA level.	Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Courses Regulat Biol Signals, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Courses Appl Mol Biosci, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Natl Inst Adv Ind Sci & Technol, Neurosci Res Inst, Tsukuba, Ibaragi 3058566, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University; National Institute of Advanced Industrial Science & Technology (AIST)	Kitagawa, Y (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.		Inagaki, Hidetoshi/J-9071-2018; Beck, Konrad/AAX-1351-2020	Inagaki, Hidetoshi/0000-0001-7820-3420; Beck, Konrad/0000-0001-5098-9484				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTOSHECHKIN I, 1995, MOL CELL BIOL, V15, P7032; Antoshechkin I, 1997, EMBO J, V16, P3198, DOI 10.1093/emboj/16.11.3198; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2910, DOI 10.1128/MCB.8.7.2910; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2917, DOI 10.1128/MCB.8.7.2917; Bogenhagen DF, 1996, J BIOL CHEM, V271, P12036; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Carrodeguas JA, 1996, GENE EXPRESSION, V6, P219; CHANG DD, 1986, MOL CELL BIOL, V6, P1446, DOI 10.1128/MCB.6.5.1446; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; Cliften PF, 1997, GENE DEV, V11, P2897, DOI 10.1101/gad.11.21.2897; Cliften PF, 2000, MOL CELL BIOL, V20, P7013, DOI 10.1128/MCB.20.18.7013-7023.2000; DAIRAGHI DJ, 1995, J MOL BIOL, V249, P11, DOI 10.1006/jmbi.1995.9889; DESJARDINS P, 1990, J MOL BIOL, V212, P599, DOI 10.1016/0022-2836(90)90225-B; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; KING TC, 1987, J BIOL CHEM, V262, P6204; LABBE D, 1991, J BIOL CHEM, V266, P10844; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; STOLZENBURG F, 1992, NUCLEIC ACIDS RES, V20, P4927, DOI 10.1093/nar/20.18.4927; TAKEDA S, 1992, P NATL ACAD SCI USA, V89, P4023, DOI 10.1073/pnas.89.9.4023; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x	56	37	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31149	31158		10.1074/jbc.M303842200	http://dx.doi.org/10.1074/jbc.M303842200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12759347	Green Accepted, hybrid			2022-12-25	WOS:000184658800092
J	Sweeney, SM; DiLullo, G; Slater, SJ; Martinez, J; Iozzo, RV; Lauer-Fields, JL; Fields, GB; Antonio, JDS				Sweeney, SM; DiLullo, G; Slater, SJ; Martinez, J; Iozzo, RV; Lauer-Fields, JL; Fields, GB; Antonio, JDS			Angiogenesis in collagen I requires alpha(2)beta(1) ligation of a GFP* GER sequence and possibly p38 MAPK activation and focal adhesion disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-CYCLE PROGRESSION; ALPHA-V INTEGRINS; PROTEIN-KINASE-C; TUBE FORMATION; VITRO ANGIOGENESIS; SIGNAL-TRANSDUCTION; MOLECULAR ARCHITECTURE; BINDING-SITES; MICE LACKING	Angiogenesis depends on proper collagen biosynthesis and cross-linking, and type I collagen is an ideal angiogenic scaffold, although its mechanism is unknown. We examined angiogenesis using an assay wherein confluent monolayers of human umbilical vein endothelial cells were overlain with collagen in a serum-free defined medium. Small spaces formed in the cell layer by 2 h, and cells formed net-like arrays by 6-8 h and capillary-like lumens by 24 h. Blocking of alpha(2)beta(1), but not alpha(1) or alpha(v)beta(3) integrin function halted morphogenesis. We found that a triple-helical, homotrimeric peptide mimetic of a putative alpha(2)beta(1) binding site: alpha(1) (I) 496-507 GARGERGFP*GER (where single-letter amino acid nomenclature is used, P*=hydroxyproline) inhibited tube formation, whereas a peptide carrying another putative site: alpha(1) (I) 127-138 GLP*GERGRP*GAP* or control peptides did not. A chemical inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), SB202190, blocked tube formation, and p38 MAPK activity was increased in collagen-treated cultures, whereas targeting MAPK kinase (MEK), focal adhesion kinase (FAK), or phosphatidylinositol 3-kinase (PI3K) had little effect. Collagen-treated cells had fewer focal adhesions and 3- to 5-fold less activated FAK. Thus capillary morphogenesis requires endothelial alpha(2)beta(1) integrin engagement of a single type I collagen integrin-binding site, possibly signaling via p38 MAPK and focal adhesion disassembly/FAK inactivation.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Anat, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Florida Atlantic Univ, Charles E Schmidt Coll Sci, Dept Chem & Biochem, Boca Raton, FL 33431 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; State University System of Florida; Florida Atlantic University	Antonio, JDS (corresponding author), Thomas Jefferson Univ, Cardeza Fdn, Dept Med, 813 Curits,1015 Walnut St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA77402, R01CA47282] Funding Source: Medline; NHLBI NIH HHS [HL53590] Funding Source: Medline; NIBIB NIH HHS [EB00289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077402, R01CA047282] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053590, R29HL053590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; Chen CS, 1997, IN VITRO CELL DEV-AN, V33, P796; Chen CS, 1998, J DERMATOL SCI, V16, P208, DOI 10.1016/S0923-1811(97)00054-6; Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5; COTTAPEREIRA G, 1980, J CELL PHYSIOL, V102, P183, DOI 10.1002/jcp.1041020209; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; Deroanne CF, 1996, EXP CELL RES, V224, P215, DOI 10.1006/excr.1996.0131; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOUSER L, 1991, J BIOL CHEM, V266, P18345; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Funahashi Y, 2002, CANCER RES, V62, P6116; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Hippenstiel S, 2000, BLOOD, V95, P3044; Ilan N, 1998, J CELL SCI, V111, P3621; INGBER D, 1988, LAB INVEST, V59, P44; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; JACKSON CJ, 1994, EXP CELL RES, V215, P294, DOI 10.1006/excr.1994.1345; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Klekotka PA, 2001, J BIOL CHEM, V276, P32353, DOI 10.1074/jbc.M101921200; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Kuzuya M, 1999, EXP CELL RES, V248, P498, DOI 10.1006/excr.1999.4422; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; LEVENE CI, 1984, ATHEROSCLEROSIS, V52, P59, DOI 10.1016/0021-9150(84)90156-4; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; NICOSIA RF, 1990, LAB INVEST, V63, P115; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SANANTONIO JD, 1992, J CELL PHYSIOL, V150, P8; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; Tanaka K, 1999, JPN J CANCER RES, V90, P647, DOI 10.1111/j.1349-7006.1999.tb00796.x; TSOPANOGLOU NE, 1994, J VASC RES, V31, P195, DOI 10.1159/000159044; Whelan MC, 2003, J BIOL CHEM, V278, P327, DOI 10.1074/jbc.M207554200; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656; Zutter MM, 1999, AM J PATHOL, V155, P927, DOI 10.1016/S0002-9440(10)65192-9	65	121	130	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30516	30524		10.1074/jbc.M304237200	http://dx.doi.org/10.1074/jbc.M304237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788934	hybrid			2022-12-25	WOS:000184658800015
J	Jiang, HM; Daniels, PJ; Andrews, GK				Jiang, HM; Daniels, PJ; Andrews, GK			Putative zinc-sensing zinc fingers of metal-response element-binding transcription factor-1 stabilize a metal-dependent chromatin complex on the endogenous metallothionein-I promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MTF-1; GENE-EXPRESSION; DNA-BINDING; FUNCTIONAL-HETEROGENEITY; STRAIN DIFFERENCES; OXIDATIVE STRESS; HEAVY-METALS; CADMIUM; CELLS; MICE	The metalloregulatory functions of metal-response element-binding transcription factor-1 (MTF-1) have been mapped, in part, to its six highly conserved zinc fingers. Here we examined the ability of zinc finger deletion mutants of mouse MTF-1 to regulate the endogenous metallothionein-I (MT-I) gene in cells lacking endogenous MTF-1. MTF-1 knockout mouse embryo fibroblasts were transfected with expression vectors for FLAG-tagged MTF-1 (MTF-1(flag)) or finger deletion mutants of MTF-1(flag) and then assayed for metal induction of MT-I gene expression, nuclear translocation, and in vitro DNA-binding activity of MTF-1 and its stable association with the endogenous chromosomal MT-I promoter. Intact MTF-1(flag) restored metal responsiveness of the MT-I gene, underwent nuclear translocation, displayed increased in vitro DNA binding in response to zinc and less so to cadmium, and rapidly formed a stable complex with the MT-I promoter chromatin in response to both of these metals. In contrast, although deletion of finger 1, fingers 5 and 6, or finger 6 only had variable effects on the nuclear localization and in vitro DNA-binding activity of MTF-1, each of these finger-deletion mutants severely attenuated metal-induced MTF-1 binding to the MT-I promoter chromatin and activation of the endogenous MT-I gene. These results demonstrated that the metal-induced recruitment of MTF-1 to the MT-I promoter is a rate-limiting step in its metalloregulatory function and that an intact zinc finger domain is required for this recruitment. During the course of these studies, it was discovered that mouse MTF-1 is polymorphic. The impact of these polymorphisms on MTF-1 metalloregulatory functions is discussed.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Mail Stop 330,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	gandrews@kumc.edu			NICHD NIH HHS [F32 HD40705] Funding Source: Medline; NIEHS NIH HHS [ES05704] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD040705] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS GK, 1987, NUCLEIC ACIDS RES, V15, P5461, DOI 10.1093/nar/15.13.5461; Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; Apuy JL, 2001, BIOCHEMISTRY-US, V40, P15164, DOI 10.1021/bi0112208; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Bittel DC, 2000, J BIOL CHEM, V275, P37194, DOI 10.1074/jbc.M003863200; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Daniels PJ, 2002, NUCLEIC ACIDS RES, V30, P3130, DOI 10.1093/nar/gkf432; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Giedroc DP, 2001, J BIOL CHEM, V276, P42322, DOI 10.1074/jbc.M106517200; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; Habeebu SS, 2001, TOXICOL APPL PHARM, V177, P200, DOI 10.1006/taap.2001.9311; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hovland DN, 1999, TERATOLOGY, V60, P13, DOI 10.1002/(SICI)1096-9926(199907)60:1<13::AID-TERA6>3.0.CO;2-B; King LM, 1998, ARCH TOXICOL, V72, P650, DOI 10.1007/s002040050556; Koizumi S, 2000, J CELL PHYSIOL, V185, P464, DOI 10.1002/1097-4652(200012)185:3<464::AID-JCP18>3.0.CO;2-4; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; LIU J, 1992, TOXICOLOGY, V75, P51, DOI 10.1016/0300-483X(92)90125-X; Liu J, 2001, TOXICOL APPL PHARM, V176, P1, DOI 10.1006/taap.2001.9262; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Maur AAD, 1999, BIOL CHEM, V380, P175, DOI 10.1515/BC.1999.026; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; Otsuka F, 2000, BBA-GENE STRUCT EXPR, V1492, P330, DOI 10.1016/S0167-4781(00)00110-X; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Saydam N, 2002, J BIOL CHEM, V277, P20438, DOI 10.1074/jbc.M110631200; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Yu CW, 1997, FEBS LETT, V420, P69, DOI 10.1016/S0014-5793(97)01489-0	41	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30394	30402		10.1074/jbc.M303598200	http://dx.doi.org/10.1074/jbc.M303598200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764133	hybrid			2022-12-25	WOS:000184507000120
J	Kim, AH; Sasaki, T; Chao, MV				Kim, AH; Sasaki, T; Chao, MV			JNK-interacting protein 1 promotes Akt1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; GROWTH-FACTORS; SCAFFOLD	Members of the JNK pathway are organized together by virtue of interactions with JNK interacting protein 1 (JIP1), a scaffold protein. Here we have investigated the possibility that JIP1 may also affect the catalytic activity of Akt1, a serine/threonine kinase that has been implicated in multiple cellular processes, including survival and proliferation. JIP1 expression enhanced Akt1 kinase activity in a dose-dependent manner following serum starvation in 293 cells. Cellular activation of Akt1 following stimulation with low concentrations of insulin-like growth factor (IGF-1) was elevated in the presence of JIP1. JIP1 expression also prolonged Akt1 stimulation after a short IGF-1 pulse. The mechanism of JIP1-mediated Akt1 activation involved JIP1 protein binding to the Akt1 pleckstrin homology domain, which in turn promoted the phosphorylation of the activation T-loop of Akt1 by phosphoinositide-dependent kinase-1. These results suggest that, in certain cellular contexts, JIP1 may act as an Akt1 scaffold, which regulates the enzymatic activity of Akt1. This study also indicates that JIP1 expression can exert signaling effects independent of JNK activity.	NYU, Med Ctr, Sch Med,Skirball Inst Biomol Med, Dept Cell Biol,Mol Neurobiol Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Biol, Dept Physiol,Mol Neurobiol Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Biol, Dept Neurosci,Mol Neurobiol Program, New York, NY 10016 USA; Akita Univ, Sch Med, 21st Century Ctr Excellence Program, Akita 0108543, Japan	New York University; New York University; New York University; Akita University	Chao, MV (corresponding author), NYU, Med Ctr, Sch Med,Skirball Inst Biomol Med, Dept Cell Biol,Mol Neurobiol Program, 540 1st Ave,Rm 5-15, New York, NY 10016 USA.		Kim, Albert H./HGF-0057-2022	Sasaki, Takehiko/0000-0003-1837-3748; Chao, Moses/0000-0002-6969-3744	NCI NIH HHS [CA56490] Funding Source: Medline; NICHD NIH HHS [HD23315] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHAN TO, 2001, SCI STKE; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Sarmiere PD, 2001, MOL CELL NEUROSCI, V18, P320, DOI 10.1006/mcne.2001.1021; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	42	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29830	29836		10.1074/jbc.M305349200	http://dx.doi.org/10.1074/jbc.M305349200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12783873	hybrid			2022-12-25	WOS:000184507000056
J	Ilbert, M; Mejean, V; Giudici-Orticoni, MT; Samama, JP; Iobbi-Nivol, C				Ilbert, M; Mejean, V; Giudici-Orticoni, MT; Samama, JP; Iobbi-Nivol, C			Involvement of a mate chaperone (TorD) in the maturation pathway of molybdoenzyme TorA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-OXIDE REDUCTASE; DIMETHYL-SULFOXIDE REDUCTASE; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; SHEWANELLA-MASSILIA; ANGSTROM RESOLUTION; MOLECULAR ANALYSIS; ELECTRON-TRANSFER	As many prokaryotic molybdoenzymes, the trimethylamine oxide reductase ( TorA) of Escherichia coli requires the insertion of a bis(molybdopterin guanine dinucleotide) molybdenum cofactor in its catalytic site to be active and translocated to the periplasm. We show in vitro that the purified apo form of TorA was activated weakly when an appropriate bis( molybdopterin guanine dinucleotide) molybdenum source was provided, whereas addition of the TorD chaperone increased apo-TorA activation up to 4-fold, allowing maturation of most of the apoprotein. We demonstrate that TorD alone is sufficient for the efficient activation of apoTorA by performing a minimal in vitro assay containing only the components for the cofactor synthesis, apoTorA and TorD. Interestingly, incubation of apoTorA with TorD before cofactor addition led to a significant increase of apoTorA activation, suggesting that TorD acts on apoTorA before cofactor insertion. This result is consistent with the fact that TorD binds to apoTorA and probably modifies its conformation in the absence of cofactor. Therefore, we propose that TorD is involved in the first step of TorA maturation to make it competent to receive the cofactor.	CNRS, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, F-13402 Marseille 20, France; CNRS, Lab Bioenerget & Ingn Prot, Inst Biol Struct & Microbiol, F-13402 Marseille, France; Inst Genet & Biol Mol & Cellulaire, Dept Biol & Genome Struct, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Iobbi-Nivol, C (corresponding author), CNRS, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Ilbert, marianne/ABG-5015-2021	ilbert, marianne/0000-0002-9070-2334; Mejean, Vincent/0000-0001-6533-5846				Berks BC, 2000, BBA-BIOENERGETICS, V1459, P325, DOI 10.1016/S0005-2728(00)00168-7; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; Dos Santos JP, 1998, J MOL BIOL, V284, P421, DOI 10.1006/jmbi.1998.2155; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gon S, 2001, J BIOL CHEM, V276, P11545, DOI 10.1074/jbc.M008875200; Gon S, 2002, J BACTERIOL, V184, P1262, DOI 10.1128/JB.184.5.1262-1269.2002; Gon S, 2001, P NATL ACAD SCI USA, V98, P11615, DOI 10.1073/pnas.211330598; Gon S, 2000, J BACTERIOL, V182, P5779, DOI 10.1128/JB.182.20.5779-5786.2000; Hasona A, 2001, ARCH MICROBIOL, V175, P178, DOI 10.1007/s002030100252; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; IOBBINIVOL C, 2000, HDB METALLOPROTEINS, P1063; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; McDevitt CA, 2002, MOL MICROBIOL, V44, P1575, DOI 10.1046/j.1365-2958.2002.02978.x; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Mouncey NJ, 1997, J BACTERIOL, V179, P7617, DOI 10.1128/jb.179.24.7617-7624.1997; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Ribbe MW, 2001, P NATL ACAD SCI USA, V98, P5521, DOI 10.1073/pnas.101119498; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; SANTINI CL, 1992, J BACTERIOL, V174, P7934, DOI 10.1128/JB.174.24.7934-7940.1992; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Shaw AL, 1996, BBA-BIOENERGETICS, V1276, P176, DOI 10.1016/0005-2728(96)00092-8; Shaw AL, 1999, MICROBIOL-UK, V145, P1409, DOI 10.1099/13500872-145-6-1409; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; Tranier S, 2003, STRUCTURE, V11, P165, DOI 10.1016/S0969-2126(03)00008-X; Tranier S, 2002, PROTEIN SCI, V11, P2148, DOI 10.1110/ps.0202902; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6	39	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28787	28792		10.1074/jbc.M302730200	http://dx.doi.org/10.1074/jbc.M302730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12766163	hybrid			2022-12-25	WOS:000184421100056
J	Mirza, A; Wu, Q; Wang, LQ; McClanahan, T; Bishop, WR; Gheyas, F; Ding, W; Hutchins, B; Hockenberry, T; Kirschmeier, P; Greene, JR; Liu, SX				Mirza, A; Wu, Q; Wang, LQ; McClanahan, T; Bishop, WR; Gheyas, F; Ding, W; Hutchins, B; Hockenberry, T; Kirschmeier, P; Greene, JR; Liu, SX			Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression	ONCOGENE			English	Article						p53; transcription; microarray; chromatin immunoprecipitation; bioinformatics	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; INHIBITS TRANSCRIPTION; PROMOTER; REPRESSION; ACTIVATION; EXPRESSION; ELEMENT; TRANSACTIVATION	The temporal gene expression profile during the entire process of apoptosis and cell cycle progression in response to p53 in human ovarian cancer cells was explored with cDNA microarrays representing 33 615 individual human genes. A total of 1501 genes (4.4%) were found to respond to p53 (approximately 80% of these were repressed by p53) using 2.5-fold change as a cutoff. It was anticipated that most of p53 responsive genes resulted from the secondary effect of p53 expression at late stage of apoptosis. To delineate potential p53 direct and indirect target genes during the process of apoptosis and cell cycle progression, microarray data were combined with global p53 DNA-binding site analysis. Here we showed that 361 out of 1501 p53 responsive genes contained p53 consensus DNA-binding sequence(s) in their regulatory region, approximately 80% of which were repressed by p53. This is the first time that a large number of p53-repressed genes have been identified to contain p53 consensus DNA-binding sequence(s) in their regulatory region. Hierarchical cluster analysis of these genes revealed distinct temporal expression patterns of transcriptional activation and repression by p53. More genes were activated at early time points, while more repressed genes were found after the onset of apoptosis. A small-scale quantitative chromatin immunoprecipitation analysis indicated that in vivo p53-DNA interaction was detected in eight out of 10 genes, most of which were repressed by p53 at the early onset of apoptosis, suggesting that a portion of p53 target genes in the human genome could be negatively regulated by p53 via sequence-specific DNA binding. The approaches and genes described here should aid the understanding of global gene regulatory network of p53.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Human Genom Res Dept, Kenilworth, NJ 07033 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Schering Plough Corp, Res Inst, Biostat Grp, Kenilworth, NJ 07033 USA; Canji Inc, San Diego, CA 92121 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Schering Plough Corporation	Liu, SX (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd,K-15-4 4600, Kenilworth, NJ 07033 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaluzova M, 2000, BBA-GENE STRUCT EXPR, V1491, P20, DOI 10.1016/S0167-4781(00)00015-4; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P525, DOI 10.1146/annurev.physiol.60.1.525; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2000, CANCER GENE THER, V7, P1469, DOI 10.1038/sj.cgt.7700257; Wu Q, 2002, J BIOL CHEM, V277, P36329, DOI 10.1074/jbc.M204962200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhao RB, 2000, GENE DEV, V14, P981	40	142	143	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3645	3654		10.1038/sj.onc.1206477	http://dx.doi.org/10.1038/sj.onc.1206477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789273				2022-12-25	WOS:000183399200015
J	Wang, WS; Chen, PM; Hsiao, HL; Ju, SY; Su, Y				Wang, WS; Chen, PM; Hsiao, HL; Ju, SY; Su, Y			Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells	ONCOGENE			English	Article						thymosin beta-4; SW480; E-cadherin; beta-catenin; c-Myc; malignancy	ACTIN-SEQUESTERING PEPTIDE; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; EPITHELIAL-CELLS; PROSTATE-CANCER; CATENIN COMPLEX; BREAST-CANCER; E-CADHERIN; EXPRESSION; CYTOSKELETON	Thymosin beta-4 (Tbeta-4), a small peptide originally isolated from calf thymus, modulates the formation of F-actin microfilaments by sequestering the monomeric G-actin. Recent studies have shown that overexpression of the Tbeta-4 gene occurs not only in many human carcinomas but also in the highly metastatic melanomas and fibrosarcomas. However, little is known about the specific growth advantages acquired by different tumors from this genetic abnormality. To address the above questions, Tbeta-4-overexpressing human colon carcinoma (SW480) cells were established by stable transfection and their phenotypic changes were monitored. We found that both the morphology and the cortical actin cytoskeleton of SW480 cells were altered by Tbeta-4 overexpression. Moreover, both cellular level and that distributed over the intercellular junctions of the E-cadherin were decreased in the Tbeta-4 overexpressers, which were accompanied by a twofold increase in their saturation densities. Meanwhile, these cells also exhibited an increased ability to form colonies in soft agar. Interestingly, a dramatic increase of growth rate was detected in the Tbeta-4 overexpressers, which might be attributed to an accelerated proliferation induced by c-Myc that was activated by nuclear beta-catenin. Finally, a motility increase of these cells was demonstrated by two independent migration assays, which was accompanied by an enhanced focal contact. Taken together, our data suggest that the drastic growth property and motility changes of the SW480 cells overexpressing Tbeta-4 gene are due mainly to a deregulated cell-cell adhesion arisen from the downregulation of E-cadherin, plus uncontrolled cell proliferation owing to the upregulation of beta-catenin, both resulted from a breakdown of actin microfilaments caused by the overexpression of this G-actin sequestering peptide.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan; Natl Yang Ming Univ, Coll Life Sci, Inst Pharmacol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tv						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Barker N, 2000, BIOESSAYS, V22, P961; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Califano D, 1998, CANCER RES, V58, P823; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Chakravarti A, 2000, UROLOGY, V55, P635, DOI 10.1016/S0090-4295(00)00462-3; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gold JS, 1997, MODERN PATHOL, V10, P1106; Golla R, 1997, CELL MOTIL CYTOSKEL, V38, P187, DOI 10.1002/(SICI)1097-0169(1997)38:2<187::AID-CM7>3.0.CO;2-4; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Lee SH, 2001, ONCOGENE, V20, P6700, DOI 10.1038/sj.onc.1204683; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LOW TLK, 1982, J BIOL CHEM, V257, P1000; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakanishi K, 2002, CANCER RES, V62, P2971; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P307, DOI 10.1002/cm.970310407; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sardi I, 2002, INT J MOL MED, V9, P541; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sellin JH, 2001, CANCER RES, V61, P2899; Sosne G, 2002, CURR EYE RES, V24, P268, DOI 10.1076/ceyr.24.4.268.8414; Su Y, 2000, MOL CELL BIOCHEM, V203, P163, DOI 10.1023/A:1007020619788; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tang RY, 1997, J VIROL METHODS, V65, P153, DOI 10.1016/S0166-0934(97)02176-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VARNUMFINNEY B, 1994, J CELL BIOL, V127, P1071, DOI 10.1083/jcb.127.4.1071; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WETERMAN MAJ, 1993, INT J CANCER, V53, P278, DOI 10.1002/ijc.2910530218; Xie D, 2002, INT J ONCOL, V21, P499; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103	57	71	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3297	3306		10.1038/sj.onc.1206404	http://dx.doi.org/10.1038/sj.onc.1206404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761500				2022-12-25	WOS:000183040000012
J	Sokolowski, M; Scott, JE; Heaney, RP; Patel, AH; Clements, JB				Sokolowski, M; Scott, JE; Heaney, RP; Patel, AH; Clements, JB			Identification of herpes simplex virus RNAs that interact specifically with regulatory protein ICP27 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST 3-HYBRID SYSTEM; NUCLEAR EXPORT SIGNAL; MESSENGER-RNA; TYPE-1 ICP27; RGG BOX; MACROMOLECULAR-SYNTHESIS; ALPHA PROTEIN-ICP27; BINDING-ACTIVITY; IE63 PROTEIN; GENE	Herpes simplex virus type 1 (HSV-1) protein ICP27 has an essential regulatory role during viral replication, in part by post-transcriptional control of gene expression, and has a counterpart in all herpes viruses sequenced so far. Although much is known about the functions of this signature herpesvirus protein, little is known about its RNA binding capabilities; ICP27 interacts with specificity for a subset of intronless HSV-1 RNAs and poly( G), through its RGG box. We performed an in vivo yeast three-hybrid screen of an HSV-1 genomic library, searching for ICP27 interacting RNAs. Comparable with a yeast genomic screen, 24 of 55 single inserts mapped to antisense strands of HSV-1 transcribed regions or non-transcribed regions. The 31 HSV-1 sense RNAs identified were 35 to 225 nucleotides in length and interacted with preferred specificity for ICP27 as compared with an unrelated RNA-binding protein. They map to 10 monocistronic and 10 polycistronic transcripts of all kinetic classes and represent 28 open reading frames encoding predominantly essential viral proteins with roles in viral DNA replication and virion maturation. Several studies show regulatory effects by ICP27 on the majority of these transcripts, consistent with its regulation of the early-late switch in the HSV-1 life cycle. Deletion of the ICP27 RGG box and the ICP27 M15 mutation, both lethal in virus, abolished or severely reduced the ICP27-RNA interactions, indicating their biological relevance. The study facilitates continued study of gene regulation by ICP27 by further defining its interactions with viral RNAs.	Univ Glasgow, Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; Univ Glasgow, Inst Biomed Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow; University of Glasgow	Clements, JB (corresponding author), Univ Glasgow, Inst Virol, MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.			Sokolowski, Marcus/0000-0003-3931-1810				Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; BROWN CR, 1995, J VIROL, V69, P7187, DOI 10.1128/JVI.69.11.7187-7195.1995; Bryant HE, 2001, J VIROL, V75, P4376, DOI 10.1128/JVI.75.9.4376-4385.2001; Bryant HE, 2000, J VIROL, V74, P11322, DOI 10.1128/JVI.74.23.11322-11328.2000; Chen IHB, 2002, J VIROL, V76, P12877, DOI 10.1128/JVI.76.24.12877-12889.2002; CUNNINGHAM C, 1993, VIROLOGY, V197, P116, DOI 10.1006/viro.1993.1572; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Donnelly M, 2001, J VIROL, V75, P2566, DOI 10.1128/JVI.75.6.2566-2574.2001; HARDY WR, 1994, J VIROL, V68, P7790, DOI 10.1128/JVI.68.12.7790-7799.1994; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; HONESS RW, 1975, P NATL ACAD SCI USA, V72, P1276, DOI 10.1073/pnas.72.4.1276; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; Ingram A, 1996, J GEN VIROL, V77, P1847, DOI 10.1099/0022-1317-77-8-1847; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Jean S, 2001, VIROLOGY, V283, P273, DOI 10.1006/viro.2001.0902; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; Lengyel J, 2002, J VIROL, V76, P11866, DOI 10.1128/JVI.76.23.11866-11879.2002; Lindberg A, 2002, VIROLOGY, V294, P189, DOI 10.1006/viro.2001.1301; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; McGregor F, 1996, J VIROL, V70, P1931, DOI 10.1128/JVI.70.3.1931-1940.1996; MCLAUCHLAN J, 1992, J VIROL, V66, P6939, DOI 10.1128/JVI.66.12.6939-6945.1992; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; Mears WE, 1998, VIROLOGY, V242, P128, DOI 10.1006/viro.1997.9006; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; MILLER JH, 1979, J MOL BIOL, V131, P223, DOI 10.1016/0022-2836(79)90074-3; Panagiotidis CA, 1997, J VIROL, V71, P1547, DOI 10.1128/JVI.71.2.1547-1557.1997; Phelan A, 1998, SEMIN VIROL, V8, P309, DOI 10.1006/smvy.1997.0133; PHELAN A, 1993, P NATL ACAD SCI USA, V90, P9056, DOI 10.1073/pnas.90.19.9056; Phelan A, 1996, J VIROL, V70, P5255, DOI 10.1128/JVI.70.8.5255-5265.1996; Phelan A, 1997, J GEN VIROL, V78, P3327, DOI 10.1099/0022-1317-78-12-3327; Putz U, 1996, NUCLEIC ACIDS RES, V24, P4838, DOI 10.1093/nar/24.23.4838; RICE SA, 1990, J VIROL, V64, P1704, DOI 10.1128/JVI.64.4.1704-1715.1990; RICE SA, 1994, J VIROL, V68, P823, DOI 10.1128/JVI.68.2.823-833.1994; RICE SA, 1993, J VIROL, V67, P1778, DOI 10.1128/JVI.67.4.1778-1787.1993; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; SACKS WR, 1985, J VIROL, V55, P796, DOI 10.1128/JVI.55.3.796-805.1985; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; SANDRIGOLDIN RM, 1995, J VIROL, V69, P6063, DOI 10.1128/JVI.69.10.6063-6076.1995; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SEKULOVICH RE, 1988, J VIROL, V62, P4510, DOI 10.1128/JVI.62.12.4510-4522.1988; Sengupta DJ, 1999, RNA, V5, P596, DOI 10.1017/S1355838299002113; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHATLAND T, 2000, NUCLEIC ACIDS RES, V28, pE93; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Soliman TM, 1997, J VIROL, V71, P9188, DOI 10.1128/JVI.71.12.9188-9197.1997; Soliman TM, 2000, J VIROL, V74, P7600, DOI 10.1128/JVI.74.16.7600-7609.2000; Stingley SW, 2000, J VIROL, V74, P9916, DOI 10.1128/JVI.74.21.9916-9927.2000; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Uprichard SL, 1996, J VIROL, V70, P1969, DOI 10.1128/JVI.70.3.1969-1980.1996; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; WAGNER EK, 1999, ENCY VIROLOGY, P686; WILCOX KW, 1980, I J VIROL, V71, P167; Zhang BL, 2000, METHOD ENZYMOL, V318, P399; Zhou CH, 2002, J VIROL, V76, P5893, DOI 10.1128/JVI.76.12.5893-5904.2002	58	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33540	33549		10.1074/jbc.M302063200	http://dx.doi.org/10.1074/jbc.M302063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12783881	hybrid			2022-12-25	WOS:000184901800127
J	Lauritzen, I; Zanzouri, M; Honore, E; Duprat, F; Ehrengruber, MU; Lazdunski, M; Patel, AJ				Lauritzen, I; Zanzouri, M; Honore, E; Duprat, F; Ehrengruber, MU; Lazdunski, M; Patel, AJ			K+-dependent cerebellar granule neuron apoptosis - Role of task leak K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; ELEVATED POTASSIUM; CELL-DEATH; SURVIVAL; DEPOLARIZATION; VOLUME; BRAIN; PH; DIFFERENTIATION	Rat mature cerebellar granule, unlike hippocampal neurons, die by apoptosis when cultured in a medium containing a physiological concentration of K+ but survive under high external K+ concentrations. Cell death in physiological K+ parallels the developmental expression of the TASK-1 and TASK-3 subunits that encode the pH-sensitive standing outward K+ current IKso. Genetic transfer of the TASK subunits in hippocampal neurons, lacking IKso, induces cell death, while their genetic inactivation protects cerebellar granule neurons. Neuronal death of cultured rat granule neurons is also prevented by conditions that specifically reduce K+ efflux through the TASK-3 channels such as extracellular acidosis and ruthenium red. TASK leak K+ channels thus play an important role in K+-dependent apoptosis of cerebellar granule neurons in culture.	Inst Paul Hamel, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Zurich	Patel, AJ (corresponding author), Inst Paul Hamel, CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Lauritzen, Inger/AFF-7261-2022; Lauritzen, Inger/AAE-9927-2022; Duprat, Fabrice/D-1221-2013	Duprat, Fabrice/0000-0001-8774-1220; lauritzen, inger/0000-0002-2011-1387; HONORE, Eric/0000-0002-8007-0919				Barbuti A, 2002, AM J PHYSIOL-HEART C, V282, pH2024, DOI 10.1152/ajpheart.00956.2001; Bayliss DA, 2001, RESP PHYSIOL, V129, P159, DOI 10.1016/S0034-5687(01)00288-2; BENNETT MR, 1979, BRAIN RES, V173, P549, DOI 10.1016/0006-8993(79)90250-6; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; CHALAZONITIS A, 1980, DEV BIOL, V78, P173, DOI 10.1016/0012-1606(80)90327-9; Czirjak G, 2002, J BIOL CHEM, V277, P5426, DOI 10.1074/jbc.M107138200; Czirjak G, 2003, MOL PHARMACOL, V63, P646, DOI 10.1124/mol.63.3.646; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; Daniels M, 2002, MOL CELL NEUROSCI, V19, P281, DOI 10.1006/mcne.2001.1070; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Fujikawa N, 2000, EUR J NEUROSCI, V12, P1838, DOI 10.1046/j.1460-9568.2000.00072.x; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Han J, 2002, J PHYSIOL-LONDON, V542, P431, DOI 10.1113/jphysiol.2002.017590; Hartness ME, 2001, J BIOL CHEM, V276, P26499, DOI 10.1074/jbc.M010357200; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Karschin C, 2001, MOL CELL NEUROSCI, V18, P632, DOI 10.1006/mcne.2001.1045; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lauritzen I, 1997, J NEUROCHEM, V69, P1570; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; Lossi L, 2002, NEUROSCIENCE, V112, P509, DOI 10.1016/S0306-4522(02)00112-4; Lundstrom K, 2001, HISTOCHEM CELL BIOL, V115, P83, DOI 10.1007/s004180000223; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Meadows HJ, 2001, NEUROPHARMACOLOGY, V40, P551, DOI 10.1016/S0028-3908(00)00189-1; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Mu D, 2003, CANCER CELL, V3, P297, DOI 10.1016/S1535-6108(03)00054-0; Nadeau H, 2000, J NEUROPHYSIOL, V84, P1062, DOI 10.1152/jn.2000.84.2.1062; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; PATEL AJ, 2001, TRENDS NEUROSCI, V2, P422; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PHILLIPSON OT, 1975, BRAIN RES, V90, P273, DOI 10.1016/0006-8993(75)90307-8; Plant LD, 2002, STROKE, V33, P2324, DOI 10.1161/01.STR.0000027440.68031.B0; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; SCOTT BS, 1977, J CELL PHYSIOL, V91, P305, DOI 10.1002/jcp.1040910215; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Trimarchi JR, 2002, AM J PHYSIOL-CELL PH, V282, pC588, DOI 10.1152/ajpcell.00365.2001; Wang HZ, 2002, CANCER RES, V62, P4843; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Yu SP, 2000, P NATL ACAD SCI USA, V97, P9360, DOI 10.1073/pnas.97.17.9360; Yuan A, 2003, NEURON, V37, P765, DOI 10.1016/S0896-6273(03)00096-5; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	62	161	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32068	32076		10.1074/jbc.M302631200	http://dx.doi.org/10.1074/jbc.M302631200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783883	hybrid			2022-12-25	WOS:000184782100077
J	Arnan, C; Saperas, N; Prieto, C; Chiva, M; Ausio, J				Arnan, C; Saperas, N; Prieto, C; Chiva, M; Ausio, J			Interaction of nucleoplasmin with core histones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SPERM CHROMATIN; CRYSTAL-STRUCTURE; EGG EXTRACTS; NUCLEOSOME; PROTEIN; COMPLEXES; OCTAMER; NUCLEI; DECONDENSATION	Nucleoplasmin is one of the most abundant proteins in Xenopus laevis oocytes, and it has been involved in the chromatin remodeling that takes place immediately after fertilization. This molecule has been shown to be responsible for the removal of the sperm-specific proteins and deposition of somatic histones onto the male pronuclear chromatin. To better understand the latter process, we have used sedimentation velocity, sedimentation equilibrium, and sucrose gradient fractionation analysis to show that the pentameric form of nucleoplasmin binds to a histone octamer equivalent consisting of equal amounts of the four core histones, H2A, H2B, H3, and H4, without any noticeable preference for any of these proteins. Removal of the histone N-terminal "tail" domains or the major C-terminal polyglutamic tracts of nucleoplasmin did not alter these binding properties. These results indicate that interactions other than those electrostatic in nature ( likely hydrophobic) also play a critical role in the formation of the complex between the negatively charged nucleoplasmin and positively charged histones. Although the association of histones with nucleoplasmin may involve some ionic interactions, the interaction process is not electrostatically driven.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Politecn Catalunya, Escola Tecn Super Engn Ind Barcelona, Dept Engn Quim, E-08028 Barcelona, Spain; Univ Barcelona, Fac Med, Dept Ciencias Fisiol 2, E-08907 Barcelona, Spain	University of Victoria; Universitat Politecnica de Catalunya; University of Barcelona	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055,Petch Bldg 220, Victoria, BC V8W 3P6, Canada.		Arnan, Carme/H-5153-2015; saperas, núria/P-7213-2015	Arnan, Carme/0000-0002-7431-2088; saperas, núria/0000-0002-5419-7502				Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; CHUNG SY, 1978, P NATL ACAD SCI USA, V75, P1680, DOI 10.1073/pnas.75.4.1680; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; ITOH T, 1993, DEV GROWTH DIFFER, V35, P59; Karantza V, 2001, BIOCHEMISTRY-US, V40, P13114, DOI 10.1021/bi0110140; KASINSKY HE, 1989, HISTONES OTHER BASIC, P74; KATAGIRI C, 1994, INT J DEV BIOL, V38, P209; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Namboodiri VMH, 2003, STRUCTURE, V11, P175, DOI 10.1016/S0969-2126(03)00007-8; OHSUMI K, 1991, DEV BIOL, V148, P295, DOI 10.1016/0012-1606(91)90338-4; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PHILIP M, 1979, P NATL ACAD SCI USA, V76, P5178, DOI 10.1073/pnas.76.10.5178; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; Prieto C, 2002, BIOCHEMISTRY-US, V41, P7802, DOI 10.1021/bi020120e; RICE P, 1995, BIOCHEMISTRY-US, V34, P7563, DOI 10.1021/bi00023a001; RuizLara SA, 1996, EUR J BIOCHEM, V240, P186, DOI 10.1111/j.1432-1033.1996.0186h.x; Saperas N, 1999, ARCH BIOCHEM BIOPHYS, V361, P135, DOI 10.1006/abbi.1998.0965; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; THOMAS JO, 1977, J MOL BIOL, V116, P769, DOI 10.1016/0022-2836(77)90270-4; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X	39	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31319	31324		10.1074/jbc.M305560200	http://dx.doi.org/10.1074/jbc.M305560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12791680	hybrid, Green Published			2022-12-25	WOS:000184658800113
J	Dyall, SD; Lester, DC; Schneider, RE; Delgadillo-Correa, MG; Plumper, E; Martinez, A; Koehler, CM; Johnson, PJ				Dyall, SD; Lester, DC; Schneider, RE; Delgadillo-Correa, MG; Plumper, E; Martinez, A; Koehler, CM; Johnson, PJ			Trichomonas vaginalis Hmp35, a putative pore-forming hydrogenosomal membrane protein, can form a complex in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; RING FINGER DOMAIN; INTERMEMBRANE SPACE; CARRIER FAMILY; INNER MEMBRANE; IMPORT; EVOLUTION; EUKARYOTES; GENE; TRANSLOCATION	An abundant integral membrane protein, Hmp35, has been isolated from hydrogenosomes of Trichomonas vaginalis. This protein has no known homologue and exists as a stable 300-kDa complex, termed HMP35, in membranes of the hydrogenosome. By using blue native gel electrophoresis, we found the HMP35 complex to be stable in 2 M NaCl and up to 5 M urea. The endogenous Hmp35 protein was largely protease-resistant. The protein has a predominantly beta-sheet structure and predicted transmembrane domains that may form a pore. Interestingly, the protein has a high number of cysteine residues, some of which are arranged in motifs that resemble the RING finger, suggesting that they could be coordinating zinc or another divalent cation. Our data show that Hmp35 forms one intramolecular but no intermolecular disulfide bonds. We have isolated the HMP35 complex by expressing a His-tagged Hmp35 protein in vivo followed by purification with nickel-agarose beads. The purified 300-kDa complex consists of mostly Hmp35 with lesser amounts of 12-, 25-27-, and 32-kDa proteins. The stoichiometry of proteins in the complex indicates that Hmp35 exists as an oligomer. Hmp35 can be targeted heterologously into yeast mitochondria, despite the lack of homology with any yeast protein, demonstrating the compatibility of mitochondrial and hydrogenosomal protein translocation machineries.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Johnson, PJ (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.				NIAID NIH HHS [AI27857, AI07323] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027857, R37AI027857, R29AI027857] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akhmanova A, 1998, NATURE, V396, P527, DOI 10.1038/25023; Biagini GA, 1997, FEMS MICROBIOL LETT, V155, P133, DOI 10.1016/S0378-1097(97)00333-9; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Bradley PJ, 1997, EMBO J, V16, P3484, DOI 10.1093/emboj/16.12.3484; Bui ETN, 1996, MOL BIOCHEM PARASIT, V76, P305, DOI 10.1016/0166-6851(96)02567-4; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; Clemens DL, 2000, MOL BIOCHEM PARASIT, V106, P307, DOI 10.1016/S0166-6851(99)00220-0; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Dekker PJT, 1996, BIOL CHEM, V377, P535; Delgadillo MG, 1997, P NATL ACAD SCI USA, V94, P4716, DOI 10.1073/pnas.94.9.4716; Dyall SD, 2000, BIOLOGY OF PARASITISM, P169; Dyall SD, 2000, CURR OPIN MICROBIOL, V3, P404, DOI 10.1016/S1369-5274(00)00112-0; Dyall SD, 2000, MOL CELL BIOL, V20, P2488, DOI 10.1128/MCB.20.7.2488-2497.2000; Embley TM, 2003, PHILOS T R SOC B, V358, P191, DOI 10.1098/rstb.2002.1190; FENCHEL T, 1995, ECOLOGY EVOLUTION AN; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Guthrie C, 1991, GUIDE YEAST GENETICS; Hardie KR, 1996, MOL MICROBIOL, V22, P967, DOI 10.1046/j.1365-2958.1996.01539.x; Hausler T, 1997, EUR J CELL BIOL, V73, P240; Heinz C, 2003, J BIOL CHEM, V278, P8678, DOI 10.1074/jbc.M212280200; Herrmann JM, 2003, TRENDS MICROBIOL, V11, P74, DOI 10.1016/S0966-842X(02)00033-1; Horner DS, 2002, TRENDS BIOCHEM SCI, V27, P148, DOI 10.1016/S0968-0004(01)02053-9; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LAHTI CJ, 1991, MOL BIOCHEM PARASIT, V46, P307, DOI 10.1016/0166-6851(91)90055-B; Liston DR, 1999, MOL CELL BIOL, V19, P2380; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; McFadden GI, 1999, CURR OPIN PLANT BIOL, V2, P513, DOI 10.1016/S1369-5266(99)00025-4; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rigobello MP, 2001, BIOCHEM J, V356, P567, DOI 10.1042/0264-6021:3560567; RIZZUTO R, 1991, BIOCHIM BIOPHYS ACTA, V1129, P100, DOI 10.1016/0167-4781(91)90220-G; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; Tachezy J, 2001, MOL BIOL EVOL, V18, P1919, DOI 10.1093/oxfordjournals.molbev.a003732; Tamm LK, 2001, J BIOL CHEM, V276, P32399, DOI 10.1074/jbc.R100021200; van der Giezen M, 2002, EMBO J, V21, P572, DOI 10.1093/emboj/21.4.572; Vidakovic MS, 1996, J BIOL CHEM, V271, P14734, DOI 10.1074/jbc.271.25.14734; Yuan YP, 1998, BIOINFORMATICS, V14, P285, DOI 10.1093/bioinformatics/14.3.285; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	58	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30548	30561		10.1074/jbc.M304032200	http://dx.doi.org/10.1074/jbc.M304032200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12766161	hybrid			2022-12-25	WOS:000184658800019
J	Marshall, TW; Link, KA; Petre-Draviam, CE; Knudsen, KE				Marshall, TW; Link, KA; Petre-Draviam, CE; Knudsen, KE			Differential requirement of SWI/SNF for androgen receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEXES; INDEPENDENT PROSTATE-CANCER; CELL-CYCLE ARREST; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; ENDOCRINE TREATMENT; MOLECULAR-BIOLOGY	The androgen receptor (AR) is a ligand-dependent transcription factor whose activity is required for prostate cancer proliferation. Because ablation of AR activity is a critical goal of prostate cancer therapy, much emphasis has been placed on understanding the accessory proteins that regulate AR function in the prostate. Several co-activators have been shown to be required for full AR activity, including histone acetyl-transferases and TRAP/mediator complexes. SWI/SNF comprises a family of large, multisubunit complexes present in the cell, which contain one of two core ATPases required for nucleosome re-positioning, BRG1 or hBRM. We investigated the specific requirement of the SWI/SNF core ATPases for AR function. Using cells deficient in both BRG1 and hBRM, we show that activation of one AR target promoter, prostate-specific antigen (PSA), requires SWI/SNF chromatin remodeling for activity. A second AR target promoter, probasin, maintained a low level of activation in the absence of SWI/SNF. AR stimulation on the probasin core promoter could be partially induced with BRG1, but hBRM strongly stimulated AR activity. The PSA promoter was only induced by the restoration of hBRM. In contrast, ligand-dependent activation of the estrogen receptor was equally stimulated by BRG1 or hBRM. We demonstrate that the addition of a known enhancer region to the core PSA promoter bypasses the requirement for SWI/SNF on the PSA promoter, indicating that elements upstream of specific proximal promoters can impact the influence of the SWI/SNF complex on target gene activation. Addition of the enhancer to the probasin core promoter failed to impact the SWI/SNF requirement. In summary, SWI/SNF function potently regulates core AR target gene promoter activation, with a preference for hBRM-containing complexes. These studies highlight a role for the enhancer in altering the impact of SWI/SNF action and suggest a disparity in AR target genes for SWI/SNF requirement.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knudsen, KE (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.			Knudsen, Karen/0000-0002-1301-890X				Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Bourachot B, 1999, MOL CELL BIOL, V19, P3931; Brinkmann AO, 2000, ADV PHARMACOL, V47, P317; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; Catalona WJ, 1999, CA-CANCER J CLIN, V49, P282, DOI 10.3322/canjclin.49.5.282; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; Desjardins C, 1978, J Anim Sci, V47 Suppl 2, P56; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Glass CK, 2000, GENE DEV, V14, P121; Gregory CW, 2001, CANCER RES, V61, P4315; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; Jia L, 2003, MOL CANCER RES, V1, P385; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; King IFG, 2001, NATURE, V414, P858, DOI 10.1038/414858a; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Klotz Laurence, 2000, Cancer, V88, P3009, DOI 10.1002/1097-0142(20000615)88:12+<3009::AID-CNCR17>3.0.CO;2-E; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Miyamoto H, 2002, J BIOL CHEM, V277, P4609, DOI 10.1074/jbc.M108312200; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Pirtskhalaishvili G, 2001, CANCER PRACT, V9, P295, DOI 10.1046/j.1523-5394.2001.96009.x; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; SANTEN RJ, 1992, J CLIN ENDOCR METAB, V75, P685, DOI 10.1210/jc.75.3.685; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Singh P, 2001, J BIOL CHEM, V276, P13762, DOI 10.1074/jbc.M100137200; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; STEARNS ME, 1992, LAB INVEST, V67, P540; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Young JC, 2002, NAT STRUCT BIOL, V9, P640, DOI 10.1038/nsb0902-640; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287	70	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30605	30613		10.1074/jbc.M304582200	http://dx.doi.org/10.1074/jbc.M304582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12775722	hybrid			2022-12-25	WOS:000184658800025
J	Liu, LB; Omata, W; Kojima, I; Shibata, H				Liu, LB; Omata, W; Kojima, I; Shibata, H			Insulin recruits GLUT4 from distinct compartments via distinct traffic pathways with differential microtubule dependence in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; FAT-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; VESICLE TRAFFICKING; STORAGE-VESICLES; PLASMA-MEMBRANE; TRANSLOCATION; PROTEIN	In the present study, we investigated the physiological significance of the microtubules in the subcellular localization and trafficking of GLUT4 in rat primary adipocytes. Morphological and biochemical analyses revealed a dose- and time-dependent disruption of the microtubules by treatment with nocodazole. With nearly complete disruption of the microtubules, the insulin-stimulated glucose transport activity was inhibited by 55%. This inhibition was concomitant with a comparable inhibition of GLUT4 translocation measured by the subcellular fractionation and the cell-surface GLUT4 labeling by trypsin cleavage. In addition, the time-course of insulin stimulation of the glucose transport activity was significantly delayed by microtubule disruption (t(1/2) were 7 and 2.3 min in nocodazole-treated and control cells, respectively), while the rate of GLUT4 endocytosis was little affected. The impaired insulin-stimulated glucose transport activity was not fully restored to the level in control cells by blocking GLUT4 endocytosis, suggesting that the inhibition was due to the existence of a microtubule-dependent subpopulation in the insulin-responsive GLUT4 pool. On the other hand, nocodazole partially inhibited insulin-induced translocation of the insulin-regulated aminopeptidase and the vesicle-associated membrane protein (VAMP)-2 without affecting GLUT1 and VAMP-3. In electrically permeabilized adipocytes, the insulin-stimulated glucose transport was inhibited by 40% by disruption of the microtubules whereas that stimulated with GTPgammaS was not affected. Intriguingly, the two reagents stimulated glucose transport to the comparable level by disruption of the microtubules. These data suggest that insulin recruits GLUT4 to the plasma membrane from at least two distinct intracellular compartments via distinct traffic routes with differential microtubule dependence in rat primary adipocytes.	Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Maebashi, Gumma 3718512, Japan	Gunma University	Shibata, H (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.		Liu, Libin/ABH-6019-2020	Liu, Libin/0000-0001-5056-1517				BALDINI G, 1991, J BIOL CHEM, V266, P4037; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DANOWSKI BA, 1989, J CELL SCI, V93, P255; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; EZAKI O, 1982, J BIOL CHEM, V257, P4306; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Fontana E, 2002, HORM METAB RES, V34, P165, DOI 10.1055/s-2002-23191; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KONO T, 1975, J BIOL CHEM, V250, P7826; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Lee YC, 1998, METABOLISM, V47, P1468, DOI 10.1016/S0026-0495(98)90071-3; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Malide D, 2000, J CELL SCI, V113, P4203; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; OKA Y, 1988, J BIOL CHEM, V263, P13432; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Park JG, 2001, J BIOL CHEM, V276, P47751, DOI 10.1074/jbc.C100524200; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SHIBATA H, 1991, ARCH BIOCHEM BIOPHYS, V285, P97, DOI 10.1016/0003-9861(91)90333-E; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; STAGSTED J, 1993, J BIOL CHEM, V268, P22809; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103	46	40	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30157	30169		10.1074/jbc.M301511200	http://dx.doi.org/10.1074/jbc.M301511200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12782634	hybrid			2022-12-25	WOS:000184507000094
J	Petoukhov, MV; Svergun, DI; Konarev, PV; Ravasio, S; van den Heuvel, RHH; Curti, B; Vanoni, MA				Petoukhov, MV; Svergun, DI; Konarev, PV; Ravasio, S; van den Heuvel, RHH; Curti, B; Vanoni, MA			Quaternary structure of Azospirillum brasilense NADPH-dependent glutamate synthase in solution as revealed by synchrotron radiation x-ray scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR FLAVOPROTEIN; DIHYDROPYRIMIDINE DEHYDROGENASE; BIOLOGICAL MACROMOLECULES; CATALYTIC-PROPERTIES; BIOPOLYMERS; CRYSTAL; ENZYMES; CENTERS; PROGRAM; SUBUNIT	Azospirillum brasilense glutamate synthase (GltS) is the prototype of bacterial NADPH-dependent enzymes, a class of complex iron-sulfur flavoproteins essential in ammonia assimilation processes. The catalytically active GltS alphabeta holoenzyme and its isolated alpha and beta subunits (162 and 52 kDa, respectively) were analyzed using synchrotron radiation x-ray solution scattering. The GltS alpha subunit and alphabeta holoenzyme were found to be tetrameric in solution, whereas the beta subunit was a mixture of monomers and dimers. Ab initio low resolution shapes restored from the scattering data suggested that the arrangement of subunits in the (alphabeta)(4) holoenzyme is similar to that in the tetrameric alpha(4) complex and that beta subunits occupy the periphery of the holoenzyme. The structure of alpha(4) was further modeled using the available crystallographic coordinates of the monomeric alpha subunit assuming P222 symmetry. To model the entire alphabeta holoenzyme, a putative alphabeta protomer was constructed from the coordinates of the alpha subunit and those of the N-terminal region of porcine dihydropyrimidine dehydrogenase, which is similar to the beta subunit. Rigid body refinement yielded a model of GltS with an arrangement of alpha subunits similar to that in alpha(4), but displaying contacts also between beta subunits belonging to adjacent protomers. The holoenzyme model allows for independent catalytic activity of the alphabeta protomers, which is consistent with the available biochemical evidence.	Univ Milan, Dept Fisiol & Biochim Gen, I-20133 Milan, Italy; European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy	University of Milan; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of Pavia	Vanoni, MA (corresponding author), Univ Milan, Dept Fisiol & Biochim Gen, Via Celoria 26, I-20133 Milan, Italy.		Petoukhov, Maxim V/R-7371-2016; Konarev, Petr V/W-1380-2017; Vanoni, Maria/AAP-2089-2021	Petoukhov, Maxim V/0000-0001-6760-4595; Vanoni, Maria/0000-0001-7213-732X; Konarev, Petr/0000-0002-5606-1596; Svergun, Dmitri/0000-0003-0830-5696				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Binda C, 2000, STRUCTURE, V8, P1299, DOI 10.1016/S0969-2126(00)00540-2; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dobritzsch D, 2001, EMBO J, V20, P650, DOI 10.1093/emboj/20.4.650; EDMONDS AR, 1957, ANGULAR MOMENTUM QUA, V4, P53; Feigin L.A., 1987, STRUCTURE ANAL SMALL; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; Hagen WR, 2000, EUR J BIOCHEM, V267, P3640, DOI 10.1046/j.1432-1327.2000.01393.x; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Ravasio S, 2001, BIOCHEMISTRY-US, V40, P5533, DOI 10.1021/bi0100889; Rosenbaum K, 1998, BIOCHEMISTRY-US, V37, P17598, DOI 10.1021/bi9815997; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Stabile H, 2000, EUR J BIOCHEM, V267, P2720, DOI 10.1046/j.1432-1327.2000.01289.x; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P297, DOI 10.1074/jbc.275.1.297; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; Svergun DI, 1997, PROTEINS, V27, P110; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; SVERGUN DI, 1994, ACTA CRYSTALLOGR A, V50, P391, DOI 10.1107/S0108767393013492; Temple SJ, 1998, TRENDS PLANT SCI, V3, P51, DOI 10.1016/S1360-1385(97)01159-X; van den Heuvel RHH, 2002, J BIOL CHEM, V277, P24579, DOI 10.1074/jbc.M202541200; VANONI MA, 1992, BIOCHEMISTRY-US, V31, P4613, DOI 10.1021/bi00134a011; Vanoni MA, 1996, EUR J BIOCHEM, V236, P937, DOI 10.1111/j.1432-1033.1996.00937.x; Vanoni MA, 1998, BIOCHEMISTRY-US, V37, P1828, DOI 10.1021/bi972342w; Vanoni MA, 1999, CELL MOL LIFE SCI, V55, P617, DOI 10.1007/s000180050319; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	33	23	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29933	29939		10.1074/jbc.M304147200	http://dx.doi.org/10.1074/jbc.M304147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777402	hybrid			2022-12-25	WOS:000184507000066
J	Jean, L; Hackett, F; Martin, SR; Blackman, MJ				Jean, L; Hackett, F; Martin, SR; Blackman, MJ			Functional characterization of the propeptide of Plasmodium falciparum subtilisin-like protease-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEROZOITE SURFACE PROTEIN-1; CIRCULAR-DICHROISM SPECTRA; INTRAMOLECULAR CHAPERONE; SERINE-PROTEASE; PRO-SUBTILISIN; INHIBITION; PEPTIDES; ACTIVATION; COMPLEX; FURIN	Erythrocyte invasion by the malaria merozoite is prevented by serine protease inhibitors. Various aspects of the biology of Plasmodium falciparum subtilisin-like protease-1 (PfSUB-1), including the timing of its expression and its apical location in the merozoite, suggest that this enzyme is involved in invasion. Recombinant PfSUB-1 expressed in a baculovirus system is secreted in the p54 form, noncovalently bound to its cognate propeptide, p31. To understand the role of p31 in PfSUB-1 maturation, we examined interactions between p31 and both recombinant and native enzymes. CD analyses revealed that recombinant p31 (rp31)possesses significant secondary structure on its own, comparable with that of folded propeptides of some bacterial subtilisins. Kinetic studies demonstrated that rp31 is a fast binding, high affinity inhibitor of PfSUB-1. Inhibition of two bacterial subtilisins by rp31 was much less effective, with inhibition constants 49-60-fold higher than that for PfSUB-1. Single (at the P4 or P1 position) or double (at P4 and P1 positions) point mutations of residues within the C-terminal region of rp31 had little effect on its inhibitory activity, and truncation of 11 residues from the rp31 C terminus substantially reduced, but did not abolish, inhibition. None of these modifications prevented binding to the PfSUB-1 catalytic domain or rendered the propeptide susceptible to proteolytic digestion by PfSUB-1. These studies provide new insights into the function of the propeptide in PfSUB-1 activation and shed light on the structural requirements for interaction with the catalytic domain.	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Blackman, MJ (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.			Jean, Letitia/0000-0002-6450-7148				Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Barale JC, 1999, P NATL ACAD SCI USA, V96, P6445, DOI 10.1073/pnas.96.11.6445; Basak A, 2003, BIOCHEM J, V373, P231, DOI 10.1042/BJ20030120; Blackman Michael J., 2000, Current Drug Targets, V1, P59, DOI 10.2174/1389450003349461; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BLACKMAN MJ, 1993, MOL BIOCHEM PARASIT, V62, P103, DOI 10.1016/0166-6851(93)90182-W; Blackman MJ, 2002, BIOCHEMISTRY-US, V41, P12244, DOI 10.1021/bi0263661; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; Chowdhury SF, 2002, J MED CHEM, V45, P5321, DOI 10.1021/jm020238t; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; CUMIN F, 1985, J BIOL CHEM, V260, P9154; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; DLUZEWSKI AR, 1986, EXP PARASITOL, V62, P416, DOI 10.1016/0014-4894(86)90050-0; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; EVIN G, 1984, P NATL ACAD SCI-BIOL, V81, P48, DOI 10.1073/pnas.81.1.48; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; FUSEK M, 1991, FEBS LETT, V287, P160, DOI 10.1016/0014-5793(91)80040-A; Hackett F, 1999, MOL BIOCHEM PARASIT, V103, P183, DOI 10.1016/S0166-6851(99)00122-X; Howard RF, 1998, MOL BIOCHEM PARASIT, V92, P111, DOI 10.1016/S0166-6851(97)00238-7; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; Huang HW, 1997, PROTEIN ENG, V10, P1227, DOI 10.1093/protein/10.10.1227; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; KESSLER E, 1994, J BIOL CHEM, V269, P22726; Kojima S, 1997, FEBS LETT, V411, P128, DOI 10.1016/S0014-5793(97)00678-9; Kojima S, 1998, J MOL BIOL, V277, P1007, DOI 10.1006/jmbi.1998.1671; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; Markaryan A, 1996, J BACTERIOL, V178, P2211, DOI 10.1128/jb.178.8.2211-2215.1996; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Sajid M, 2000, J BIOL CHEM, V275, P631, DOI 10.1074/jbc.275.1.631; Shinde U, 1996, ADV EXP MED BIOL, V379, P147; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, BIOCHEMISTRY-US, V38, P10814, DOI 10.1021/bi990516z; Tangrea MA, 2001, BIOCHEMISTRY-US, V40, P5488, DOI 10.1021/bi0026472; *WHO, 1999, REP INF DIS; Withers-Martinez C, 2002, J BIOL CHEM, V277, P29698, DOI 10.1074/jbc.M203088200; Yabuta Y, 2001, J BIOL CHEM, V276, P44427, DOI 10.1074/jbc.M107573200	47	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28572	28579		10.1074/jbc.M303827200	http://dx.doi.org/10.1074/jbc.M303827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12764150	hybrid			2022-12-25	WOS:000184421100030
J	Li, JP; Gong, F; Hagner-McWhirter, A; Forsberg, E; Abrink, M; Kisilevsky, R; Zhang, X; Lindahl, U				Li, JP; Gong, F; Hagner-McWhirter, A; Forsberg, E; Abrink, M; Kisilevsky, R; Zhang, X; Lindahl, U			Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCANS; MICE; BIOSYNTHESIS; DROSOPHILA; WINGLESS; ENZYME	The glycosaminoglycan, heparan sulfate (HS), binds proteins to modulate signaling events in embryogenesis. All identified protein-binding HS epitopes contain L-iduronic acid ( IdoA). We report that targeted disruption of the murine D-glucuronyl C5-epimerase gene results in a structurally altered HS lacking IdoA. The corresponding phenotype is lethal, with renal agenesis, lung defects, and skeletal malformations. Unexpectedly, major organ systems, including the brain, liver, gastrointestinal tract, skin, and heart, appeared normal. We find that IdoA units are essential for normal kidney, lung, and skeletal development, albeit with different requirement for 2-O-sulfation. By contrast, major early developmental events known to critically depend on heparan sulfate apparently proceed normally even in the absence of IdoA.	Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, SE-75123 Uppsala, Sweden; Queens Univ, Dept Pathol, Richardson Lab, Kingston, ON K7L 3N6, Canada; Huddinge Univ Hosp, Karolinska Inst, Novum, Neurotec Dept,Div Mol Neuropharmacol, S-14186 Huddinge, Sweden	Uppsala University; Queens University - Canada; Karolinska Institutet	Li, JP (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, Box 582, SE-75123 Uppsala, Sweden.		Åbrink, Magnus/AAK-8346-2020	Abrink, Magnus/0000-0002-1335-3927				Baeg GH, 2001, DEVELOPMENT, V128, P87; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Crawford BE, 2001, J BIOL CHEM, V276, P21538, DOI 10.1074/jbc.M100880200; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Li JP, 2001, J BIOL CHEM, V276, P20069, DOI 10.1074/jbc.M011783200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, DEVELOPMENT, V126, P3715; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2002, BBA-GEN SUBJECTS, V1573, P319, DOI 10.1016/S0304-4165(02)00399-9; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336	23	165	173	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28363	28366		10.1074/jbc.C300219200	http://dx.doi.org/10.1074/jbc.C300219200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12788935	hybrid			2022-12-25	WOS:000184421100003
J	Szule, JA; Jarvis, SE; Hibbert, JE; Spafford, JD; Braun, JEA; Zamponni, GW; Wessel, GM; Coorssen, JR				Szule, JA; Jarvis, SE; Hibbert, JE; Spafford, JD; Braun, JEA; Zamponni, GW; Wessel, GM; Coorssen, JR			Calcium-triggered membrane fusion proceeds independently of specific presynaptic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; SEA-URCHIN EGG; SNARE COMPLEX; N-TYPE; CA2+ CHANNELS; T-SNARE; EXOCYTOSIS; SYNTAXIN; BINDING; CELLS	Complexes of specific presynaptic proteins have been hypothesized to drive or catalyze the membrane fusion steps of exocytosis. Here we use a stage-specific preparation to test the roles of SNAREs, synaptotagmin, and SNARE-binding proteins in the mechanism of Ca2+-triggered membrane fusion. Excess exogenous proteins, sufficient to block SNARE interactions, did not inhibit either the Ca2+ sensitivity, extent, or kinetics of fusion. In contrast, despite a limited effect on SNARE and synaptotagmin densities, treatments with high doses of chymotrypsin markedly inhibited fusion. Conversely, low doses of chymotrypsin had no effect on the Ca2+ sensitivity or extent of fusion but did alter the kinetic profile, indicating a more direct involvement of other proteins in the triggered fusion pathway. SNAREs, synaptotagmin, and their immediate binding partners are critical to exocytosis at a stage other than membrane fusion, although they may still influence the triggered steps.	Univ Calgary, Hlth Sci Ctr, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; Brown Univ, Dept Biochem Mol Biol & Cellular Biol, Providence, RI 02912 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Brown University	Coorssen, JR (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada.			Hibbert, Julie/0000-0002-8839-3966; Zamponi, Gerald W./0000-0002-0644-9066				BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Blank PS, 2001, J GEN PHYSIOL, V118, P145, DOI 10.1085/jgp.118.2.145; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Conner S, 1997, MOL REPROD DEV, V48, P106; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Coorssen JR, 2002, ANAL BIOCHEM, V307, P54, DOI 10.1016/S0003-2697(02)00015-5; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Coorssen JR, 2003, J CELL SCI, V116, P2087, DOI 10.1242/jcs.00374; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Hohenstein AC, 2001, BIOCHEM BIOPH RES CO, V285, P167, DOI 10.1006/bbrc.2001.5141; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2002, J BIOL CHEM, V277, P44399, DOI 10.1074/jbc.M206902200; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; JARVIS SE, 2002, THESIS U CALGARY CAL; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Matos MF, 2000, EUR J CELL BIOL, V79, P377, DOI 10.1078/0171-9335-00063; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; Nie ZP, 1999, J NEUROSCI, V19, P10270; Ninomiya Y, 1996, J BIOL CHEM, V271, P17751, DOI 10.1074/jbc.271.30.17751; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stanley EF, 1997, TRENDS NEUROSCI, V20, P404, DOI 10.1016/S0166-2236(97)01091-6; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tahara M, 1998, J BIOL CHEM, V273, P33667, DOI 10.1074/jbc.273.50.33667; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; Vogel SS, 1996, J CELL BIOL, V134, P329, DOI 10.1083/jcb.134.2.329; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yang Y, 2002, P NATL ACAD SCI USA, V99, P17060, DOI 10.1073/pnas.242624699; Zimmerberg J, 2000, BIOCHIMIE, V82, P303, DOI 10.1016/S0300-9084(00)00215-7	44	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24251	24254		10.1074/jbc.C300197200	http://dx.doi.org/10.1074/jbc.C300197200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12764142	hybrid			2022-12-25	WOS:000183824800003
J	Hoare, K; Hoare, S; Smith, OM; Kalmaz, G; Small, D; May, WS				Hoare, K; Hoare, S; Smith, OM; Kalmaz, G; Small, D; May, WS			Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling	ONCOGENE			English	Article						embryonic stem (ES) cells; nonreceptor protein tyrosine kinase (NRPTK); apoptosis; Ras; green fluorescent protein (GFP)	EMBRYONIC STEM-CELLS; HEMATOPOIETIC-CELLS; GTPASE ACTIVITY; GROWTH-FACTOR; PROTEIN-KINASES; MOUSE EMBRYOS; SH2 DOMAINS; IN-VITRO; BINDING; TRANSDUCTION	Kinase of embryonic stem cells (Kos1), a nonreceptor protein tyrosine kinase (NRPTK), was identified and cloned from differentiating murine embryonic stem cells. Kos1 is localized on mouse chromosome 11 that corresponds to human chromosome 17p13.1 and is homologous to Tnk1, Ack1 and Ack2, making it a new member of the Ack family of NRPTKs. Kos1 is a ubiquitously expressed 47-kDa protein with autotyrosine kinase activity that is developmentally regulated during embryogenesis. Kos1 is also upregulated following IL3 withdrawal from factor-dependent murine NSF/N1.H7 cells that undergo apoptosis, suggesting a role in growth inhibition. Stable overexpression of Kos1 inhibits growth of NIH 3T3 cells, while the kinase-dead Kos1(CN) promotes cell growth in both liquid culture and soft agar. In addition, forced expression of Kos1 inhibits Ras activity in an indirect mechanism that results in the downregulation of the Ras-Raf1-MAPK growth pathway. Furthermore, overexpression of Kos1 in NCI-H82 lung cancer cells that express oncogenic Ha-Ras(G12V) inhibits cell growth under reduced serum (0.5%) conditions in close association with the upregulation of the Ras inhibitor, Rap1A. Collectively, these data support a negative regulatory role for Kos1 in regulating the Ras-Raf1-MAPK growth pathway by a mechanism that requires its autotyrosine kinase activity.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Johns Hopkins Univ, Sch Med, Dept Oncol & Pediat, Baltimore, MD 21287 USA	State University System of Florida; University of Florida; University of Texas System; University of Texas Medical Branch Galveston; Johns Hopkins University	May, WS (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd, Gainesville, FL 32610 USA.			Small, Donald/0000-0002-3072-243X	NCI NIH HHS [CA44649] Funding Source: Medline; NHLBI NIH HHS [HL5408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Avraham H, 2000, J HEMATOTH STEM CELL, V9, P425, DOI 10.1089/152581600419080; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hoehn GT, 1996, ONCOGENE, V12, P903; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sambrook J., 1989, MOL CLONING, pA1; SATOH T, 1995, METHOD ENZYMOL, V255, P149; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; Sem KP, 2002, MOL CELL BIOL, V22, P3685, DOI 10.1128/MCB.22.11.3685-3697.2002; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1995, SCIENCE, V267, P1701; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILES MV, 1991, DEVELOPMENT, V111, P259; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516; YANG JJ, 1998, MOL CELL BIOL, V17, P3850; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200	68	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3562	3577		10.1038/sj.onc.1206480	http://dx.doi.org/10.1038/sj.onc.1206480			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789265				2022-12-25	WOS:000183399200007
J	Steinman, RA; Wentzel, A; Lu, YL; Stehle, C; Grandis, JR				Steinman, RA; Wentzel, A; Lu, YL; Stehle, C; Grandis, JR			Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2	ONCOGENE			English	Article						Stat3 (signal transducer and activator of; transcription-2) cdk2; confluence; cyclin-dependent; kinase; protein transduction	GROWTH IN-VIVO; KINASE INHIBITOR P27(KIP1); CARCINOMA-CELLS; PLASMA-MEMBRANE; NECK-CANCER; TGF-ALPHA; HEAD; DIFFERENTIATION; APOPTOSIS; PROTEIN	The signal transducing protein Stat3 activates gene transcription in cells in response to multiple cytokines. Constitutive activation of Stat3 has been observed in solid tumors including head and neck squamous cell carcinoma. Stat3 activation in cancer has been associated with autocrine stimulatory loops and is believed to convey a growth advantage to cells. We now demonstrate ligand-independent activation of Stat3 by high cell density in multiple cancer cell lines. Activation of Stat3 is associated with anti proliferative rather than proliferative conditions. Interference with cdk2 activity upregulates Stat3 phosphorylation and Stat3-directed DNA-binding activity. Our data supports a model in which Stat3 activity is partially suppressed by cdk2 in growing cells and derepressed upon cell confluence.	Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Steinman, RA (corresponding author), Hillman Canc Ctr, Suite 2,18 UPCI Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.				NCI NIH HHS [R01CA77308] Funding Source: Medline; NHLBI NIH HHS [R01HL65172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077308] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chapman RS, 2000, ADV EXP MED BIOL, V480, P129; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Dimanche-Boitrel MT, 1998, INT J CANCER, V77, P796, DOI 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2-Z; Endo S, 2000, GENE THER, V7, P1906, DOI 10.1038/sj.gt.3301315; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garrido C, 1997, CANCER RES, V57, P2661; Gaulin JF, 2000, J BIOL CHEM, V275, P16658, DOI 10.1074/jbc.275.22.16658; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; LI L, 2002, J BIOL CHEM, V21, P21; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Steinman RA, 1999, LEUKEMIA, V13, P54, DOI 10.1038/sj.leu.2401253; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Wang S, 1999, J GASTROINTEST SURG, V3, P200, DOI 10.1016/S1091-255X(99)80034-1; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200; Xie B, 2001, J BIOL CHEM, V276, P19512, DOI 10.1074/jbc.M009063200; Yaroslavskiy BB, 2001, MOL MED, V7, P49, DOI 10.1007/BF03401838; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	42	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3608	3615		10.1038/sj.onc.1206523	http://dx.doi.org/10.1038/sj.onc.1206523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789269				2022-12-25	WOS:000183399200011
J	Mikola, M; Kero, J; Nilson, JH; Keri, RA; Poutanen, M; Huhtaniemi, I				Mikola, M; Kero, J; Nilson, JH; Keri, RA; Poutanen, M; Huhtaniemi, I			High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter Simian virus 40 T-antigen fusion gene	ONCOGENE			English	Article						LH; adrenal and gonadal tumorigenesis; inhibin	IMMUNOREACTIVE INHIBIN; POSTMENOPAUSAL WOMEN; ACTIVATING MUTATION; OVARIAN-TUMORS; SERUM INHIBIN; CELL TUMORS; GONADOTROPIN; RECEPTOR; PROTEIN; CANCER	Transgenic (TG) mice expressing the Simian virus 40 T-antigen under the control of the murine inhibin-a promoter (Inhalpha/Tag) develop granulosa and Leydig cell tumors at the age of 5-6 months, with 100% penetrance. When these mice are gonadectomized, they develop adrenocortical tumors. Suppression of gonadotropin secretion inhibits the tumorigenesis in the gonads of intact animals and in the adrenals after gonadectomy. To study further the role of luteinizing hormone (LH) in gonadal and adrenal tumorigenesis, a double TG mouse model was generated by crossing the Inha/Tag mice with mice producing constitutively elevated levels of LH (bLHbeta-CTP mice). Our results show that in double TG mice (bLHbeta-CTP/Inhalpha/Tag), gonadal tumorigenesis starts earlier and progresses faster than in Inha/Tag mice. Both ovarian and testicular tumors were histologically comparable with the tumors found in Inhalpha/Tag mice. In addition, adrenal tumorigenesis was found in intact double TG females, but not in Inha/Tag females. Inhibin-a and LH receptor (LHR) were highly expressed in tumorigenic gonadal tissues, and the elevated LH levels were shown to be associated with ectopic LHR and high inhibin-a expression in the female adrenals. We conclude that in the Inhalpha/Tag tumor mouse model, elevated LH levels act as a tumor promoter, advancing gonadal and adrenal tumorigenesis.	Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	University of Turku; University of Turku; Case Western Reserve University	Huhtaniemi, I (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Du Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@ic.ac.uk	Keri, Ruth/ABF-2209-2021; kero, jukka/G-3448-2014; Poutanen, Matti/I-1700-2018	Keri, Ruth/0000-0002-1640-3088; kero, jukka/0000-0001-8767-7222; Poutanen, Matti/0000-0002-8953-1734; Ahtiainen, Maarit/0000-0002-3263-2307				ADELSON MD, 1993, CLIN OBSTET GYNECOL, V36, P690, DOI 10.1097/00003081-199309000-00025; Ala-Fossi SL, 2000, EUR J GYNAECOL ONCOL, V21, P187; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEJONG FH, 1990, J STEROID BIOCHEM, V37, P863, DOI 10.1016/0960-0760(90)90433-L; DING YQ, 1989, ACTA ENDOCRINOL-COP, V121, P46, DOI 10.1530/acta.0.1210046; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GAYTAN F, 1994, J ENDOCRINOL, V142, P527, DOI 10.1677/joe.0.1420527; Gocze PM, 1997, GYNECOL ONCOL, V65, P143, DOI 10.1006/gyno.1997.4635; HEALY DL, 1993, NEW ENGL J MED, V329, P1539, DOI 10.1056/NEJM199311183292104; Herath CB, 2001, J ANDROL, V22, P838; Hogan B, 1994, MANIPULATING MOUSE E; HUHTANIEMI I, 1994, EUR J ENDOCRINOL, V130, P25, DOI 10.1530/eje.0.1300025; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; HUHTANIEMI IT, 1981, ENDOCRINOLOGY, V109, P588, DOI 10.1210/endo-109-2-588; Iczkowski KA, 1998, MODERN PATHOL, V11, P774; Illingworth PJ, 1996, J CLIN ENDOCR METAB, V81, P1321, DOI 10.1210/jc.81.4.1321; Kananen K, 1997, ENDOCRINOLOGY, V138, P3521, DOI 10.1210/en.138.8.3521; Kananen K, 1996, MOL CELL ENDOCRINOL, V119, P135, DOI 10.1016/0303-7207(96)03802-6; KANANEN K, 1995, MOL ENDOCRINOL, V9, P616, DOI 10.1210/me.9.5.616; Kananen K, 1996, MOL ENDOCRINOL, V10, P1667, DOI 10.1210/me.10.12.1667; Keri RA, 2000, P NATL ACAD SCI USA, V97, P383, DOI 10.1073/pnas.97.1.383; Kero J, 2000, J CLIN INVEST, V105, P633, DOI 10.1172/JCI7716; Kuhn B, 1999, BIOCHEMISTRY-US, V38, P12490, DOI 10.1021/bi990755m; Kumar TR, 1999, MOL ENDOCRINOL, V13, P851, DOI 10.1210/me.13.6.851; Kumar TR, 1996, ENDOCRINOLOGY, V137, P4210, DOI 10.1210/en.137.10.4210; LambertMesserlian GM, 1997, GYNECOL ONCOL, V65, P512, DOI 10.1006/gyno.1997.4719; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Mikola MK, 2001, J ENDOCRINOL, V170, P79, DOI 10.1677/joe.0.1700079; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; NEUMANN F, 1991, MUTAT RES, V248, P341, DOI 10.1016/0027-5107(91)90067-X; NISWENDER GD, 1968, P SOC EXP BIOL MED, V128, P807; Owens GE, 2002, MOL ENDOCRINOL, V16, P1230, DOI 10.1210/me.16.6.1230; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; Rahman NA, 2001, BIOL REPROD, V64, P1122, DOI 10.1095/biolreprod64.4.1122; Rilianawati, 2000, J ENDOCRINOL, V166, P77, DOI 10.1677/joe.0.1660077; Rilianawati, 1998, MOL ENDOCRINOL, V12, P801, DOI 10.1210/me.12.6.801; RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322; Rulli SB, 2002, ENDOCRINOLOGY, V143, P4084, DOI 10.1210/en.2002-220490; SIMON WE, 1983, J NATL CANCER I, V70, P839; Toppari J, 1998, APMIS, V106, P101, DOI 10.1111/j.1699-0463.1998.tb01325.x; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; VUORENTO T, 1989, SCAND J CLIN LAB INV, V49, P395, DOI 10.3109/00365518909089113; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; WIMALASENA J, 1992, GYNECOL ONCOL, V46, P345, DOI 10.1016/0090-8258(92)90230-G; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	52	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3269	3278		10.1038/sj.onc.1206518	http://dx.doi.org/10.1038/sj.onc.1206518			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761497				2022-12-25	WOS:000183040000009
J	Kalafatis, M; Beck, DO; Mann, KG				Kalafatis, M; Beck, DO; Mann, KG			Structural requirements for expression of factor Va activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; COAGULATION FACTOR-V; THROMBIN-CATALYZED ACTIVATION; ANION-BINDING EXOSITE; HEPARIN COFACTOR-II; BOVINE FACTOR-V; FACTOR-XA; HEAVY-CHAIN; BLOOD-COAGULATION; PROTHROMBINASE COMPLEX	Thrombin activated factor Va (factor V-IIa, residues 1-709 and 1546-2196) has an apparent dissociation constant (K-d,K-app) for factor Xa within prothrombinase of similar to0.5 nM. A protease (NN) purified from the venom of the snake Naja nigricollis nigricollis, cleaves human factor V at Asp(697), Asp(1509), and Asp(1514) to produce a molecule (factor V-NN) that is composed of a M-r 100,000 heavy chain (amino acid residues 1-696) and a M-r 80,000 light chain (amino acid residues 1509/1514-2196). Factor V-NN, has a K-d,K-app for factor Xa of 4 nM and reduced clotting activity. Cleavage of factor V-IIa by NN at Asp(697) results in a cofactor that loses similar to60-80% of its clotting activity. An enzyme from Russell's viper venom (RVV) cleaves human factor V at Arg(1018) and Arg(1545) to produce a M-r 150,000 heavy chain and M-r 74,000 light chain (factor V-RVV, residues 1-1018 and 1546-2196). The RVV species has affinity for factor Xa and clotting activity similar to the thrombin-activated factor Va. Cleavage of factor V-NN at Arg(1545) by alpha-thrombin (factor V-NN/IIa) or RVV ( factor V-NN/RVV) leads to enhanced affinity of the cofactor for factor Xa (K(d,app)similar to0.5 nM). A synthetic peptide containing the last 13 residues from the heavy chain of factor Va (amino acid sequence 697-709, D13R) was found to be a competitive inhibitor of prothrombinase with respect to prothrombin. The peptide was also found to specifically interact with thrombin-agarose. These data demonstrate that 1) cleavage at Arg(1545) and formation of the light chain of factor V-IIa is essential for high affinity binding and function of factor Xa within prothrombinase and 2) a binding site for prothrombin is contributed by amino acid residues 697-709 of the heavy chain of the cofactor.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University System of Ohio; Cleveland State University; Cleveland Clinic Foundation; University of Vermont	Kalafatis, M (corresponding author), Cleveland State Univ, Dept Chem, 2121 Euclid Ave,Sci Bldg SR370, Cleveland, OH 44115 USA.				NHLBI NIH HHS [R37 HL34757] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ANNAMALAI AE, 1987, BLOOD, V70, P139; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Brummel KE, 2002, BLOOD, V100, P148, DOI 10.1182/blood.V100.1.148; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; ESMON CT, 1979, J BIOL CHEM, V254, P964; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; Grimm DR, 2001, CELL MOL LIFE SCI, V58, P148, DOI 10.1007/PL00000775; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HASSAN MI, 1985, THESIS AIN SHAMS U C; HJORT P, 1955, J LAB CLIN MED, V46, P89; Hockin MF, 2002, J BIOL CHEM, V277, P18322, DOI 10.1074/jbc.M201173200; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Jesty J, 1976, Methods Enzymol, V45, P95; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1993, BLOOD, V81, P704; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; Kalafatis M, 2001, J BIOL CHEM, V276, P18614, DOI 10.1074/jbc.M007134200; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kalafatis M, 1998, J BIOL CHEM, V273, P8459, DOI 10.1074/jbc.273.14.8459; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1982, J BIOL CHEM, V257, P3963; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMPTE MF, 1994, J BIOL CHEM, V269, P1905; LEE CD, 1989, BLOOD, V73, P185; LIN WH, 1992, J BIOL CHEM, V267, P2876; LIU LW, 1991, J BIOL CHEM, V266, P16977; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MONKOVIC DD, 1990, J BIOL CHEM, V265, P17132; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SEGEL IH, 1993, ENZYME KINETICS, P203; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TRACY PB, 1981, J BIOL CHEM, V256, P743; TUCKER MM, 1983, J BIOL CHEM, V258, P1210; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; WEBER G, 1992, PROTEIN INTERACTIONS, P15; WU QY, 1994, J BIOL CHEM, V269, P3725; Yang TL, 1998, BLOOD, V91, P4593, DOI 10.1182/blood.V91.12.4593.412a02_4593_4599	83	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33550	33561		10.1074/jbc.M303153200	http://dx.doi.org/10.1074/jbc.M303153200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12788947	Green Published, hybrid			2022-12-25	WOS:000184901800128
J	Shirahama-Noda, K; Yamamoto, A; Sugihara, K; Hashimoto, N; Asano, M; Nishimura, M; Hara-Nishimura, I				Shirahama-Noda, K; Yamamoto, A; Sugihara, K; Hashimoto, N; Asano, M; Nishimura, M; Hara-Nishimura, I			Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOCYTOCHEMICAL LOCALIZATION; RAT-KIDNEY; MOLECULAR-CLONING; ACTIVATION; LEGUMAIN; ENZYME; CELLS; PROTEIN; GENE; MOUSE	Asparaginyl endopeptidase (AEP)/legumain, an asparagine-specific cysteine proteinase in animals, is an ortholog of plant vacuolar processing enzyme (VPE), which processes the exposed asparagine residues of various vacuolar proteins. In search for its physiological role in mammals, here we generated and characterized AEP-deficient mice. Although their body weights were significantly reduced, they were normally born and fertile. In the wild-type kidney where the expression of AEP was exceedingly high among various organs, the localization of AEP was mainly found in the lamp-2-positive late endosomes in the apical region of the proximal tubule cells. In these cells of AEP-deficient mice, the lamp-2-positive membrane structures were found to be greatly enlarged. These aberrant lysosomes, merged with the late endosomes, accumulated electron-dense and membranous materials. Furthermore, the processing of the lysosomal proteases, cathepsins B, H, and L, from the single-chain forms into the two-chain forms was completely defected in the deficient mice. Thus, the AEP deficiency caused the accumulation of macromolecules in the lysosomes, highlighting a pivotal role of AEP in the endosomal/lysosomal degradation system.	Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Kansai Med Univ, Dept Physiol, Moriguchi, Osaka 5708506, Japan; Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa 9208640, Japan	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kansai Medical University; Kanazawa University	Hara-Nishimura, I (corresponding author), Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan.	ihnishi@gr.bot.kyoto-u.ac.jp		Nishimura, Mikio/0000-0001-7960-9721				Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; Chen JM, 1998, BIOCHEM J, V335, P111, DOI 10.1042/bj3350111; Choi SJ, 2001, J BONE MINER RES, V16, P1804, DOI 10.1359/jbmr.2001.16.10.1804; Christensen EI, 1998, INT REV CYTOL, V180, P237; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; Dawson G, 2000, J NEUROSCI RES, V60, P133, DOI 10.1002/(SICI)1097-4547(20000415)60:2<133::AID-JNR1>3.0.CO;2-3; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Halfon S, 1998, FEBS LETT, V438, P114, DOI 10.1016/S0014-5793(98)01281-2; HARAHISHIMURA I, 1993, PLANT J, V4, P793, DOI 10.1046/j.1365-313X.1993.04050793.x; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; Hiraiwa N, 1999, FEBS LETT, V447, P213, DOI 10.1016/S0014-5793(99)00286-0; Hiraiwa N, 1997, PLANT J, V12, P819, DOI 10.1046/j.1365-313X.1997.12040819.x; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIRSCHKE H, 1998, LYOSOSOMAL CYSTEINE; KOH S, 1993, J NEUROCYTOL, V22, P995, DOI 10.1007/BF01218356; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Kuroyanagi M, 2002, PLANT CELL PHYSIOL, V43, P143, DOI 10.1093/pcp/pcf035; Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; Sly WS, 2002, P NATL ACAD SCI USA, V99, P5760, DOI 10.1073/pnas.102175599; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; Tanaka T, 1996, CYTOGENET CELL GENET, V74, P120, DOI 10.1159/000134397; TOWATARI T, 1988, FEBS LETT, V236, P57, DOI 10.1016/0014-5793(88)80285-0; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yamamoto A, 1996, J CELL SCI, V109, P1727; Yamane T, 2002, BBA-PROTEIN STRUCT M, V1596, P108, DOI 10.1016/S0167-4838(02)00209-1; YOKOTA S, 1985, J HISTOCHEM CYTOCHEM, V33, P191, DOI 10.1177/33.3.2579120; YOKOTA S, 1986, HISTOCHEMISTRY, V85, P223, DOI 10.1007/BF00494808; YOKOTA S, 1986, J HISTOCHEM CYTOCHEM, V34, P899, DOI 10.1177/34.7.3519753; YOKOTA S, 1988, HISTOCHEMISTRY, V90, P277, DOI 10.1007/BF00495971	41	161	163	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33194	33199		10.1074/jbc.M302742200	http://dx.doi.org/10.1074/jbc.M302742200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12775715	hybrid			2022-12-25	WOS:000184901800086
J	Sanz, MA; Tsang, WY; Willems, EM; Grivell, LA; Lemire, BD; van der Spek, H; Nijtmans, LGJ				Sanz, MA; Tsang, WY; Willems, EM; Grivell, LA; Lemire, BD; van der Spek, H; Nijtmans, LGJ			The mitochondrial prohibitin complex is essential for embryonic viability and germline function in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; SACCHAROMYCES-CEREVISIAE; GENOMIC ANALYSIS; GENE-EXPRESSION; PROTEIN; MEMBRANE; CELLS; ELECTROPHORESIS; INTERFERENCE	Prohibitins in eukaryotes consist of two subunits (PHB1 and PHB2) that together form a high molecular weight complex in the mitochondrial inner membrane. The evolutionary conservation and the ubiquitous expression in mammalian tissues of the prohibitin complex suggest an important function among eukaryotes. The PHB complex has been shown to play a role in the stabilization of newly synthesized subunits of mitochondrial respiratory enzymes in the yeast Saccharomyces cerevisiae. We have used Caenorhabditis elegans as model system to study the role of the PHB complex during development of a multicellular organism. We demonstrate that prohibitins in C. elegans form a high molecular weight complex in the mitochondrial inner membrane similar to that of yeast and humans. By using RNA-mediated gene inactivation, we show that PHB proteins are essential during embryonic development and are required for somatic and germline differentiation in the larval gonad. We further demonstrate that a deficiency in PHB proteins results in altered mitochondrial biogenesis in body wall muscle cells. This paper reports a strong loss of function phenotype for prohibitin gene inactivation in a multicellular organism and shows for the first time that prohibitins serve an essential role in mitochondrial function during organismal development.	Univ Amsterdam, Swammerdam Inst Life Sci, Mol Biol Sect, NL-1098 SJ Amsterdam, Netherlands; Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Canadian Inst Hlth Res, Edmonton, AB T6G 2H7, Canada; Univ Med Ctr Nijmegen, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands	University of Amsterdam; Institute for Work & Health; University of Alberta; Radboud University Nijmegen	Sanz, MA (corresponding author), Univ Amsterdam, Swammerdam Inst Life Sci, Mol Biol Sect, Kruislaan 318, NL-1098 SJ Amsterdam, Netherlands.	artal@science.uva.nl	Nijtmans, L.G.J./L-4549-2015; Artal-Sanz, Marta/J-6186-2012	Artal-Sanz, Marta/0000-0003-1126-0492; Tsang, William/0000-0002-1584-616X				Back JW, 2002, PROTEIN SCI, V11, P2471, DOI 10.1110/ps.0212602; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Birner R, 2003, MOL BIOL CELL, V14, P370, DOI 10.1091/mbc.E02-05-0263; Braeckman BP, 2002, MECH AGEING DEV, V123, P105, DOI 10.1016/S0047-6374(01)00331-1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHOONGKITTAWORN NM, 1993, BIOL REPROD, V49, P300, DOI 10.1095/biolreprod49.2.300; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EVELETH DD, 1986, NUCLEIC ACIDS RES, V14, P6169, DOI 10.1093/nar/14.15.6169; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kayser EB, 2001, J BIOL CHEM, V276, P20551, DOI 10.1074/jbc.M011066200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Nijtmans LGJ, 2001, FEBS LETT, V498, P46, DOI 10.1016/S0014-5793(01)02447-4; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Snedden WA, 1997, PLANT MOL BIOL, V33, P753, DOI 10.1023/A:1005737026289; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Tanno S, 1997, JPN J CANCER RES, V88, P1155, DOI 10.1111/j.1349-7006.1997.tb00344.x; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Tsang WY, 2002, BIOCHEM BIOPH RES CO, V291, P8, DOI 10.1006/bbrc.2002.6394; Tsang WY, 2001, J BIOL CHEM, V276, P32240, DOI 10.1074/jbc.M103999200; Van Voorhies WA, 1999, P NATL ACAD SCI USA, V96, P11399, DOI 10.1073/pnas.96.20.11399; VANDENBOGERT C, 1988, EXP CELL RES, V178, P143, DOI 10.1016/0014-4827(88)90385-0; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684	41	158	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32091	32099		10.1074/jbc.M304877200	http://dx.doi.org/10.1074/jbc.M304877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794069	hybrid, Green Published			2022-12-25	WOS:000184782100080
J	Sugishima, M; Sakamoto, H; Higashimoto, Y; Noguchi, M; Fukuyama, K				Sugishima, M; Sakamoto, H; Higashimoto, Y; Noguchi, M; Fukuyama, K			Crystal structure of rat heme oxygenase-1 in complex with biliverdin-iron chelate - Conformational change of the distal helix during the heme cleavage reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC ALPHA-HYDROXYHEME; REDUCING EQUIVALENT; GENE-EXPRESSION; DEGRADATION; VERDOHEME; SYSTEM; REQUIREMENT; ACTIVATION; CONVERSION; OXIDATION	The crystal structure of rat heme oxygenase-1 in complex with biliverdin-iron chelate (biliverdin(Fe)-HO-1), the immediate precursor of the final product, biliverdin, has been determined at a 2.4-Angstrom resolution. The electron density in the heme pocket clearly showed that the tetrapyrrole ring of heme is cleaved at the alpha-meso edge. Like the heme bound to HO-1, biliverdin-iron chelate is located between the distal and proximal helices, but its accommodation state seems to be less stable in light of the disordering of the solvent-exposed propionate and vinyl groups. The middle of the distal helix is shifted away from the center of the active site in biliverdin(Fe)-HO-1, increasing the size of the heme pocket. The hydrogen-bonding interaction between Glu-29 and Gln-38, considered to restrain the orientation of the proximal helix in the heme-HO-1 complex, was lost in biliverdin(Fe)-HO-1, leading to relaxation of the helix. Biliverdin has a distorted helical conformation; the lactam oxygen atom of its pyrrole ring-A interacted with Asp-140 through a hydrogen-bonding solvent network. Because of the absence of a distal water ligand, the iron atom is five-coordinated with His-25 and four pyrrole nitrogen atoms. The coordination geometry deviates considerably from a square pyramid, suggesting that the iron may be readily dissociated. We speculate that the opened conformation of the heme pocket facilitates sequential product release, first iron then biliverdin, and that because of biliverdin's increased flexibility, iron release triggers its slow dissociation.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan	Osaka University; Kurume University	Fukuyama, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.		Sakamoto, Hiroshi/A-3181-2011; Sugishima, Masakazu/B-1049-2010; Sugishima, Masakazu/M-2773-2019	Sugishima, Masakazu/0000-0002-0840-4929; Sugishima, Masakazu/0000-0002-0840-4929; Higashimoto, Yuichiro/0000-0003-1382-8598				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BALCH AL, 1993, J AM CHEM SOC, V115, P9056, DOI 10.1021/ja00073a022; Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; BEALE SI, 1994, CIBA F SYMP, V180, P156; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cary SPL, 2001, J CLIN INVEST, V107, P1071, DOI 10.1172/JCI12823; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Koerner R, 1998, J AM CHEM SOC, V120, P9246, DOI 10.1021/ja980558v; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Migita CT, 1999, BBA-PROTEIN STRUCT M, V1432, P203; Pereira PJB, 2001, NAT STRUCT BIOL, V8, P215, DOI 10.1038/84948; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sakamoto H, 1999, J BIOL CHEM, V274, P18196, DOI 10.1074/jbc.274.26.18196; Sakamoto H, 2002, EUR J BIOCHEM, V269, P5231, DOI 10.1046/j.1432-1033.2002.03230.x; Scapagnini G, 2002, BRAIN RES, V954, P51, DOI 10.1016/S0006-8993(02)03338-3; Schmitt MP, 1999, J BACTERIOL, V181, P5330, DOI 10.1128/JB.181.17.5330-5340.1999; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SHELDRICK WS, 1976, J CHEM SOC P1, V2, P1457; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; SUGISHIMA M, 2003, IN PRESS BIOCHEMISTR; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; WAGNER UG, 1995, J MOL BIOL, V247, P326, DOI 10.1006/jmbi.1994.0142; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418	45	49	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32352	32358		10.1074/jbc.M303682200	http://dx.doi.org/10.1074/jbc.M303682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794075	hybrid			2022-12-25	WOS:000184782100113
J	Larsen, C; Malte, H; Weber, RE				Larsen, C; Malte, H; Weber, RE			ATP-induced reverse temperature effect in isohemoglobins from the endothermic porbeagle shark (Lamna nasus)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUNA SWIMMING PERFORMANCE; LARGE WATER TUNNEL; OXYGEN EQUILIBRIA; CARCHARODON-CARCHARIAS; WHITE SHARK; SQUALUS-ACANTHIAS; ANGUILLA-ANGUILLA; EFFECT HEMOGLOBIN; BODY-TEMPERATURE; THUNNUS-THYNNUS	The evolutionary convergence of endothermic tunas and lamnid sharks is unique. Their heat exchanger-mediated endothermy represents an interesting example of the evolutionary pressure associated with this specific characteristic. To assess the implications of endothermy for gas transport and the possible contribution of hemoglobin (Hb), we investigated the effect of temperature on the oxygen equilibria of purified isohemoglobin components V and III from the porbeagle shark (Lamna nasus). In the absence of ATP the effect of temperature on oxygen affinity is normal in both Hb III (P-50 = 0.9 and 2.2 torr at 10 and 26 degreesC, respectively) and Hb V (P-50 = 1.5 and 2.5 torr at 10 and 26 degreesC, respectively). In the presence of this effector P-50 decreases with increasing temperature in both components (P-50 at 10 and 26 degreesC = 9.9 and 8.4 torr (Hb III), respectively, and 9.6 and 7.4 torr (Hb V), respectively. The reverse temperature effect in the presence of ATP will reduce the risk of oxygen loss from the arterial to the venous blood by lowering the oxygen tension gradient between the blood vessels. The mechanism behind the reverse temperature effect resembles that found in the bluefin tuna (Thunnus thynnus), an endothermic teleost, thus evidencing further convergent evolution.	Aarhus Univ, Dept Zoophysiol, Inst Biol Sci, DK-8000 Aarhus, Denmark	Aarhus University	Malte, H (corresponding author), Aarhus Univ, Dept Zoophysiol, Inst Biol Sci, Bldg 131, DK-8000 Aarhus, Denmark.		Malte, Hans/J-6018-2013					Altringham JD, 1997, J EXP BIOL, V200, P2617; ANDERSEN ME, 1973, J BIOL CHEM, V248, P331; Anderson SD, 2001, COPEIA, P794; Bernal D, 2001, COMP BIOCHEM PHYS A, V129, P695, DOI 10.1016/S1095-6433(01)00333-6; BLOCK BA, 1994, ENVIRON BIOL FISH, V40, P283, DOI 10.1007/BF00002518; BLOCK BA, 1993, SCIENCE, V260, P210, DOI 10.1126/science.8469974; Burne R. H., 1923, Philosophical Transactions of the Royal Society London B, V212, P209; CAREY FG, 1973, SCI AM, V228, P36, DOI 10.1038/scientificamerican0273-36; CAREY FG, 1971, AM ZOOL, V11, P137; CAREY FG, 1981, PHYSIOL ZOOL, V54, P334, DOI 10.1086/physzool.54.3.30159948; CAREY FG, 1969, COMP BIOCHEM PHYSIOL, V28, P205, DOI 10.1016/0010-406X(69)91336-X; CAREY FG, 1982, COPEIA, P254; CAREY FG, 1969, COMP BIOCHEM PHYSIOL, V28, P199, DOI 10.1016/0010-406X(69)91335-8; CAREY GF, 1977, BIOCHEM BIOPH RES CO, V78, P1376; CECH JJ, 1984, J EXP BIOL, V109, P21; DEWAR H, 1994, J EXP BIOL, V192, P33; DEWAR H, 1994, J EXP BIOL, V192, P13; DICKSON KA, 1995, ENVIRON BIOL FISH, V42, P65, DOI 10.1007/BF00002352; DOBSON GP, 1986, PHYSIOL ZOOL, V59, P150, DOI 10.1086/physzool.59.2.30156028; Fago A, 1997, J BIOL CHEM, V272, P15628, DOI 10.1074/jbc.272.25.15628; FAGO A, 1995, J BIOL CHEM, V270, P18897, DOI 10.1074/jbc.270.32.18897; Goldman KJ, 1997, J COMP PHYSIOL B, V167, P423, DOI 10.1007/s003600050092; GRAHAM JB, 1975, FISH B-NOAA, V73, P219; Graham JB, 2000, ZOOL J LINN SOC-LOND, V129, P419, DOI 10.1111/j.1096-3642.2000.tb00612.x; HAZARD ES, 1984, AM ZOOL, V24, pA120; HOLLAND KN, 1994, ENVIRON BIOL FISH, V40, P319, DOI 10.1007/BF00002520; IKEDASAITO M, 1983, J MOL BIOL, V168, P673, DOI 10.1016/S0022-2836(83)80308-8; IMAI K, 1973, BIOCHEMISTRY-US, V12, P798, DOI 10.1021/bi00729a003; Imai K., 1982, ALLOSTERIC EFFECTS H; JENSEN FB, 1987, J COMP PHYSIOL B, V157, P137, DOI 10.1007/BF00692357; JONES DR, 1986, J EXP BIOL, V120, P201; MCCOSKER JE, 1987, COPEIA, P195; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PENNELLY RR, 1975, COMP BIOCHEM PHYS B, V52, P83, DOI 10.1016/0305-0491(75)90119-4; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; ROSSIFANELLI A, 1960, NATURE, V186, P895, DOI 10.1038/186895a0; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1995, J MOL BIOL, V251, P703, DOI 10.1006/jmbi.1995.0466; WEBER RE, 1988, ANNU REV PHYSIOL, V50, P161, DOI 10.1146/annurev.ph.50.030188.001113; WEBER RE, 1983, J EXP BIOL, V103, P109; Weber RE, 2000, HEMOGLOBIN FUNCTION IN VERTEBRATES, P23; WELLS RMG, 1983, J EXP BIOL, V103, P95; WYMAN J, 1977, J MOL BIOL, V109, P195, DOI 10.1016/S0022-2836(77)80029-6	43	22	22	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30741	30747		10.1074/jbc.M301930200	http://dx.doi.org/10.1074/jbc.M301930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773532	hybrid			2022-12-25	WOS:000184658800041
J	Mao, CG; Xu, RJ; Szulc, ZM; Bielawski, J; Becker, KP; Bielawska, A; Galadari, SH; Hu, W; Obeid, LM				Mao, CG; Xu, RJ; Szulc, ZM; Bielawski, J; Becker, KP; Bielawska, A; Galadari, SH; Hu, W; Obeid, LM			Cloning and characterization of a mouse endoplasmic reticulum alkaline ceramidase - An enzyme that preferentially regulates metabolism of very long chain ceramides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID CERAMIDASE; MOLECULAR-CLONING; NEUTRAL CERAMIDASE; SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS-AERUGINOSA; PURIFICATION; SYNTHASE; DISEASE; SPHINGOMYELINASE; NEUTRAL/ALKALINE	Ceramidases deacylate ceramides, important intermediates in the metabolic pathway of sphingolipids. In this study, we report the cloning and characterization of a novel mouse alkaline ceramidase (maCER1) with a highly restricted substrate specificity. maCER1 consists of 287 amino acids, and it has a 28 and 32% identity to the Saccharomyces alkaline ceramidases (YPC1p and YDC1p) and the human alkaline phytoceramidase, respectively. Reverse transcriptase-PCR analysis demonstrated that maCER1 was predominantly expressed in skin. maCER1 was localized to the endoplasmic reticulum as revealed by immunocytochemistry. In vitro biochemical characterization determined that maCER1 hydrolyzed D-erythro-ceramide exclusively but not D-erythro-dihydroceramide or D-ribo-phytoceramide. Similar to other alkaline ceramidases, maCER1 had an alkaline pH optimum of 8.0, and it was activated by Ca2+ but inhibited by Zn2+, Cu2+, and Mn2+. maCER1 was also inhibited by sphingosine, one of its products. Metabolic labeling studies showed that overexpression of maCER1 caused a decrease in the incorporation of radiolabeled dihydrosphingosine into ceramide and complex sphingolipids but led to a concomitant increase in sphingosine-1-P (S1P) in HeLa cells. Mass measurement showed that overexpression of maCER1 selectively lowered the cellular levels of D-erythro-C-24:1-ceramide, but not other ceramide species and caused an increase in the levels of S1P. Taken together, these data suggest that maCER1 is a novel alkaline ceramidase with a stringent substrate specificity and that maCER1 is selectively expressed in skin and may have a role in regulating the levels of bioactive lipids ceramide and S1P, as well as complex sphingolipids.	Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; United Arab Emirates University	Mao, CG (corresponding author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 114 Doughty St,Rm 605 STB,POB 250779, Charleston, SC 29425 USA.		Galadari, Sehamuddin/AAK-6039-2020; xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847	NCRR NIH HHS [1P20RR017677-01] Funding Source: Medline; NIGMS NIH HHS [GM62887-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABENOZA P, 1987, ULTRASTRUCT PATHOL, V11, P397, DOI 10.3109/01913128709048433; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Doering T, 2002, J LIPID RES, V43, P1727, DOI 10.1194/jlr.M200208-JLR200; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; el Bawab Samer, 2002, Subcell Biochem, V36, P187; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hwang O, 2001, MOL PHARMACOL, V59, P1249, DOI 10.1124/mol.59.5.1249; Kita K, 2000, BBA-MOL CELL BIOL L, V1485, P111, DOI 10.1016/S1388-1981(00)00029-9; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Macheleidt O, 2002, J INVEST DERMATOL, V119, P166, DOI 10.1046/j.1523-1747.2002.01833.x; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; MARCHESINI S, 1990, CHEM PHYS LIPIDS, V53, P165, DOI 10.1016/0009-3084(90)90042-P; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Obeid L.M., 2001, J BIOL CHEM, V16, P16; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Pyne Susan, 2002, Subcell Biochem, V36, P245; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Uchida Y, 2002, J LIPID RES, V43, P1293, DOI 10.1194/jlr.M100442-JLR200; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200	30	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31184	31191		10.1074/jbc.M303875200	http://dx.doi.org/10.1074/jbc.M303875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783875	hybrid			2022-12-25	WOS:000184658800096
J	Mizuno, K; Suzuki, A; Hirose, T; Kitamura, K; Kutsuzawa, K; Futaki, M; Amano, Y; Ohno, S				Mizuno, K; Suzuki, A; Hirose, T; Kitamura, K; Kutsuzawa, K; Futaki, M; Amano, Y; Ohno, S			Self-association of PAR-3-mediated by the conserved N-terminal domain contributes to the development of epithelial tight junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-POLARITY; MAMMALIAN HOMOLOG; DIRECT BINDING; COMPLEX; APKC; CDC42; POLARIZATION; ADHESION; LINKS	PAR-3 is a scaffold-like PDZ-containing protein that forms a complex with PAR-6 and atypical protein kinase C (PAR-3-atypical protein kinase C-PAR-6 complex) and contributes to the establishment of cell polarity in a wide variety of biological contexts. In mammalian epithelial cells, it localizes to tight junctions, the most apical end of epithelial cell-cell junctions, and contributes to the formation of functional tight junctions. However, the mechanism by which PAR-3 localizes to tight junctions and contributes to their formation remains to be clarified. Here we show that the N-terminal conserved region, CR1-(1-86), and the sequence 937-1,024 are required for its recruitment to the most apical side of the cell-cell contact region in epithelial Madin-Darby canine kidney cells. We also show that CR1 self-associates to form an oligomeric complex in vivo and in vitro. Further, overexpression of CR1 in Madin-Darby canine kidney cells disturbs the distribution of atypical protein kinase C and PAR-6 as well as PAR-3 and delays the formation of functional tight junctions. These results support the notion that the CR1- mediated self-association of the PAR-3-containing protein complex plays a role during the formation of functional tight junctions.	Yokohama City Univ, Dept Biol Mol, Sch Med, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Yokohama City University	Ohno, S (corresponding author), Yokohama City Univ, Dept Biol Mol, Sch Med, Kanazawa Ku, Fuku Ura 3-9, Yokohama, Kanagawa 2360004, Japan.		Hirose, Tomonori/M-8872-2019; Ohno, Shigeo/B-1768-2010; Hirose, Tomonori/F-6015-2010	Hirose, Tomonori/0000-0003-2428-0919; Ohno, Shigeo/0000-0002-1294-5269; Hirose, Tomonori/0000-0003-2428-0919				Bilder D, 2001, TRENDS GENET, V17, P511, DOI 10.1016/S0168-9525(01)02407-6; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fang CM, 2001, CELL RES, V11, P223, DOI 10.1038/sj.cr.7290090; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harris BZ, 2001, J CELL SCI, V114, P3219; Hirose T, 2002, J CELL SCI, V115, P2485; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johansson AS, 2000, J CELL SCI, V113, P3267; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Nagai-Tamai Y, 2002, GENES CELLS, V7, P1161, DOI 10.1046/j.1365-2443.2002.00590.x; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V268, P530, DOI 10.1006/bbrc.2000.2167; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Suzuki A, 2002, J CELL SCI, V115, P3565, DOI 10.1242/jcs.00032; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; YONEMURA S, 1995, J CELL SCI, V108, P127	29	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31240	31250		10.1074/jbc.M303593200	http://dx.doi.org/10.1074/jbc.M303593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12756256	hybrid			2022-12-25	WOS:000184658800103
J	Pojer, F; Kahlich, R; Kammerer, B; Li, SM; Heide, L				Pojer, F; Kahlich, R; Kammerer, B; Li, SM; Heide, L			CloR, a bifunctional non-heme iron oxygenase involved in clorobiocin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ESCHERICHIA-COLI; VANCOMYCIN GROUP; ALDOLASE; NOVOBIOCIN; ENZYME; GENE; HYDROXYBENZOATE; DIOXYGENASE; PROTEINS	The aminocoumarin antibiotics novobiocin and clorobiocin contain a 3-dimethylallyl-4-hydroxybenzoate (3DMA-4HB) moiety. The biosynthesis of this moiety has now been identified by biochemical and molecular biological studies. CloQ from the clorobiocin biosynthetic gene cluster in Streptomyces roseochromogenes DS 12976 has recently been identified as a 4-hydroxyphenylpyruvate-3-dimethylallyltransferase. In the present study, the enzyme CloR was overexpressed in Escherichia coli, purified, and identified as a bifunctional non-heme iron oxygenase, which converts 3-dimethylallyl-4-hydroxyphenylpyruvate (3DMA-4HPP) via 3-dimethylallyl-4-hydroxymandelic acid (3DMA-4HMA) to 3DMA-4HB by two consecutive oxidative decarboxylation steps. In O-18(2) labeling experiments we showed that two oxygen atoms are incorporated into the intermediate 3DMA-4HMA in the first reaction step, but only one further oxygen is incorporated into the final product 3DMA-4HB during the second reaction step. CloR does not show sequence similarity to known oxygenases. It apparently presents a novel member of the diverse family of the non-heme iron (II) and alpha-ketoacid-dependent oxygenases, with 3DMA-4HPP functioning both as an alpha-keto acid and as a hydroxylation substrate. The reaction catalyzed by CloR represents a new pathway for the formation of benzoic acids in nature.	Univ Tubingen, D-72076 Tubingen, Germany; Univ Tubingen, Inst Pharmakol & Toxikol, Klin Pharmakol Abt, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Heide, L (corresponding author), Univ Tubingen, Morgenstelle 8, D-72076 Tubingen, Germany.	heide@uni-tuebingen.de		Heide, Lutz/0000-0001-7809-7453				Abd El-Mawla AMA, 2002, PLANTA, V214, P727, DOI 10.1007/s004250100657; Berger U., 1978, J CHROMATOGR LIB, V15, P101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVERT RT, 1972, J PHARM PHARMACOL, V24, P972, DOI 10.1111/j.2042-7158.1972.tb08929.x; Chen HW, 2001, CHEM BIOL, V8, P301, DOI 10.1016/S1074-5521(01)00009-6; Choroba OW, 2000, J AM CHEM SOC, V122, P5389, DOI 10.1021/ja000076v; DREYER MK, 1993, J MOL BIOL, V231, P549, DOI 10.1006/jmbi.1993.1307; Dreyer MK, 1996, J MOL BIOL, V259, P458, DOI 10.1006/jmbi.1996.0332; Gasson MJ, 1998, J BIOL CHEM, V273, P4163, DOI 10.1074/jbc.273.7.4163; GLUSENKAMP KH, 1986, J ORG CHEM, V51, P4481; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Hertweck C, 2000, TETRAHEDRON, V56, P9115, DOI 10.1016/S0040-4020(00)00765-1; Hubbard BK, 2000, CHEM BIOL, V7, P931, DOI 10.1016/S1074-5521(00)00043-0; Kampranis SC, 1999, BIOCHEMISTRY-US, V38, P1967, DOI 10.1021/bi982320p; Kominek L A, 1975, Methods Enzymol, V43, P502; KOMINEK LA, 1974, DEV IND MICROBIOL, V15, P60; Kroemer M, 2002, ACTA CRYSTALLOGR D, V58, P824, DOI 10.1107/S0907444902004614; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafitte D, 2002, BIOCHEMISTRY-US, V41, P7217, DOI 10.1021/bi0159837; Lanoot B, 2002, INT J SYST EVOL MICR, V52, P823, DOI [10.1099/ijs.0.02008-0, 10.1099/00207713-52-3-823]; Li SM, 1998, TETRAHEDRON LETT, V39, P2717, DOI 10.1016/S0040-4039(98)00386-4; LOSCHER R, 1994, PLANT PHYSIOL, V106, P271, DOI 10.1104/pp.106.1.271; Luo Y, 2001, BIOCHEMISTRY-US, V40, P14763, DOI 10.1021/bi0112513; Maxwell A, 2003, CURR TOP MED CHEM, V3, P283, DOI 10.2174/1568026033452500; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; MELZER M, 1994, BBA-LIPID LIPID MET, V1212, P93, DOI 10.1016/0005-2760(94)90193-7; MONTECALVO MA, 1995, ANTIMICROB AGENTS CH, V39, P794, DOI 10.1128/AAC.39.3.794; Pojer F, 2003, P NATL ACAD SCI USA, V100, P2316, DOI 10.1073/pnas.0337708100; Pojer F, 2002, MICROBIOL-SGM, V148, P3901, DOI 10.1099/00221287-148-12-3901; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Que L, 2000, NAT STRUCT BIOL, V7, P182, DOI 10.1038/73270; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Rappa G, 2000, ONCOL RES, V12, P113, DOI 10.3727/096504001108747585; Rohde JU, 2003, SCIENCE, V299, P1037, DOI 10.1126/science.299.5609.1037; Sambrook J, 2001, MOL CLONING LAB MANU; Serre L, 1999, STRUCTURE, V7, P977, DOI 10.1016/S0969-2126(99)80124-5; SIEBERT M, 1994, MICROBIOL-SGM, V140, P897, DOI 10.1099/00221287-140-4-897; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Walsh CT, 2002, CHEMBIOCHEM, V3, P125; Wehmeier UF, 2001, FEMS MICROBIOL LETT, V197, P53, DOI 10.1111/j.1574-6968.2001.tb10582.x	40	43	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30661	30668		10.1074/jbc.M303190200	http://dx.doi.org/10.1074/jbc.M303190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777382	hybrid			2022-12-25	WOS:000184658800031
J	Shi, JX; Tai, K; McCammon, JA; Taylor, P; Johnson, DA				Shi, JX; Tai, K; McCammon, JA; Taylor, P; Johnson, DA			Nanosecond dynamics of the mouse acetylcholinesterase Cys(69)-Cys(96) omega loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-RUGOSA LIPASE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; COMPLEX; SPECIFICITY; SIMULATION; FASCICULIN; RESIDUES; BINDING; PROTEIN	The paradox of high substrate turnover occurring within the confines of a deep, narrow gorge through which acetylcholine must traverse to reach the catalytic site of acetylcholinesterase has suggested the existence of transient gorge enlargements that would enhance substrate accessibility. To establish a foundation for the experimental study of transient fluctuations in structure, site-directed labeling in conjunction with time-resolved fluorescence anisotropy were utilized to assess the possible involvement of the omega loop (Omega loop), a segment that forms the outer wall of the gorge. Specifically, the flexibility of three residues (L76C, E81C, and E84C) in the Cys(69)-Cys(96) Omega loop and one residue (Y124C) across the gorge from the Omega loop were studied in the absence and presence of two inhibitors of different size, fasciculin and huperzine. Additionally, to validate the approach molecular dynamics was employed to simulate anisotropy decay of the side chains. The results show that the Omega loop residues are significantly more mobile than the non-loop residue facing the interior of the gorge. Moreover, fasciculin, which binds at the mouth of the gorge, well removed from the active site, decreases the mobility of 5-((((2-acetyl)amino)ethyl)amino) naphthalene-1-sulfonic acid reporter groups attached to L76C and Y124C but increases the mobility of the reporter groups attached to E81C and E84C. Huperzine, which binds at the base of active-site gorge, has no effect on the mobility of reporter groups attached to L76C and Y124C but increases the mobility of the reporter groups attached to E81C and E84C. Besides showing that fluctuations of the Omega loop residues are not tightly coupled, the results indicate that residues in the Omega loop exhibit distinctive conformational fluctuations and therefore are likely to contribute to transient gorge enlargements in the non-liganded enzyme.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Riverside	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.		Tai, Kaihsu/A-1465-2013; McCammon, J. Andrew/AAG-1832-2021	Tai, Kaihsu/0000-0002-4979-7060; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R37GM018360] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42-ES10337] Funding Source: Medline; NIGMS NIH HHS [R37-GM18360, T32-GM07752] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; Gangal M, 1999, P NATL ACAD SCI USA, V96, P12394, DOI 10.1073/pnas.96.22.12394; Gangal M, 1998, BIOCHEMISTRY-US, V37, P13728, DOI 10.1021/bi980560z; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; ICHIYE T, 1983, BIOCHEMISTRY-US, V22, P2884, DOI 10.1021/bi00281a017; KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1; Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, P321; Marchot P, 1996, PROTEIN SCI, V5, P672; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Shen TY, 2002, ACCOUNTS CHEM RES, V35, P332, DOI 10.1021/ar010025i; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; STEINER RF, 1991, TOPICS FLUORESCENCE, P13; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tai K, 2001, BIOPHYS J, V81, P715, DOI 10.1016/S0006-3495(01)75736-0; Wlodek ST, 1997, J AM CHEM SOC, V119, P9513, DOI 10.1021/ja971226d; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	24	40	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30905	30911		10.1074/jbc.M303730200	http://dx.doi.org/10.1074/jbc.M303730200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12759360	hybrid			2022-12-25	WOS:000184658800063
J	Seigneuret, M; Garnier-Suillerot, A				Seigneuret, M; Garnier-Suillerot, A			A structural model for the open conformation of the mdr1 P-glycoprotein based on the MsbA crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; NUCLEOTIDE-BINDING SITES; DISULFIDE CROSS-LINKING; MULTIDRUG TRANSPORTER; ABC TRANSPORTERS; SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; TRANSMEMBRANE HELICES; ELECTRON-MICROSCOPY; FUNCTIONAL-ANALYSIS	The validity of the structure of the Escherichia coli MsbA lipid transporter as a model from the mdr1 P-glycoprotein has been evaluated. Comparative sequence analyses, motif search and secondary structure prediction indicated that each of the two P-glycoprotein halves is structurally similar to the MsbA monomer and also suggested that the open dimer structure is valid for P-glycoprotein. Homology modeling was used to predict the structure of P-glycoprotein using MsbA as a template. The resulting modeled structure allowed a detailed study of the interactions between the intracellular domain and the nucleotide binding domain and suggested that these contacts are involved in mediating the coupling between nucleotide binding domain conformational changes and transmembrane helices reorientation during transport. In P-glycoprotein, the internal chamber open to the inner leaflet and the inner medium is significantly different in size and charge than in MsbA. These differences can be related to those of the transported substrates. Moreover an ensemble of 20 conserved aromatic residues appears to border the periphery of each side of the chamber in P-glycoprotein. These may be important for size selection and proper positioning of drugs for transport. The relevance of the modeled conformation to P-gp function is discussed.	Univ Paris 06, Lab Physochim Biomol & Cellulaire, CNRS, UMR 7033, Paris, France; Univ Paris 13, Lab Physochim Biomol & Cellulaire, CNRS, UMR 7033, Bobigny, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Universite Paris 13	Seigneuret, M (corresponding author), Inst Cochin Genet Mol, Dept Biol Cellulaire, 22 Rue Mechain, F-75014 Paris, France.							Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Campbell JD, 2003, BIOCHEMISTRY-US, V42, P3666, DOI 10.1021/bi027337t; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Eilers M, 2002, BIOPHYS J, V82, P2720, DOI 10.1016/S0006-3495(02)75613-0; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Higgins CF, 2001, SCIENCE, V293, P1782, DOI 10.1126/science.1065588; Hrycyna CA, 1998, BIOCHEMISTRY-US, V37, P13660, DOI 10.1021/bi9808823; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwan T, 1998, BIOCHEMISTRY-US, V37, P3337, DOI 10.1021/bi972680x; Kwan T, 2000, MOL PHARMACOL, V58, P37, DOI 10.1124/mol.58.1.37; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Liang J, 2002, CURR OPIN CHEM BIOL, V6, P878, DOI 10.1016/S1367-5931(02)00393-9; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1996, J BIOL CHEM, V268, P5; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; McDonald MK, 1997, J BACTERIOL, V179, P7638, DOI 10.1128/jb.179.24.7638-7643.1997; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otto M, 2001, RES MICROBIOL, V152, P351, DOI 10.1016/S0923-2508(01)01206-2; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; POELARENDS GJ, 2002, BIOCHIM BIOPHYS ACTA, V1555, P13; Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sakamoto K, 2001, J BACTERIOL, V183, P5371, DOI 10.1128/JB.183.18.5371-5375.2001; Salerno M, 2002, BIOCHEM PHARMACOL, V63, P1471, DOI 10.1016/S0006-2952(02)00895-X; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Small DM, 2003, P NATL ACAD SCI USA, V100, P4, DOI 10.1073/pnas.0237205100; Song JM, 2001, MOL PHARMACOL, V60, P254, DOI 10.1124/mol.60.2.254; Taguchi Y, 1997, FEBS LETT, V413, P142, DOI 10.1016/S0014-5793(97)00899-5; Thomas PJ, 2001, NAT STRUCT BIOL, V8, P920, DOI 10.1038/nsb1101-920; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; van Veen HW, 2001, RES MICROBIOL, V152, P365, DOI 10.1016/S0923-2508(01)01208-6; VRIEND G, 1990, J MOL GRAPHICS, V8, P526; Yang AS, 2000, J MOL BIOL, V301, P679, DOI 10.1006/jmbi.2000.3974; Zhou Y, 1999, MOL CELL BIOL, V19, P1450	66	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30115	30124		10.1074/jbc.M302443200	http://dx.doi.org/10.1074/jbc.M302443200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777401	hybrid			2022-12-25	WOS:000184507000089
J	Walton, KA; Hsieh, X; Gharavi, N; Wang, S; Wang, G; Yeh, M; Cole, AL; Berliner, JA				Walton, KA; Hsieh, X; Gharavi, N; Wang, S; Wang, G; Yeh, M; Cole, AL; Berliner, JA			Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero3-phosphorylcholine-mediated synthesis of interleukin-8 - A role for toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; ENDOTHELIAL-CELLS; SCAVENGER RECEPTORS; BACTERIAL LIPOPOLYSACCHARIDE; APOPTOTIC CELLS; LDL BINDS; CLASS-A; PHOSPHOLIPIDS; EXPRESSION	We demonstrated previously that oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (ox-PAPC) and, specifically, the component lipid 1-palmitoyl-2-(5,6-epoxyisoprostane E-2)-sn-glycero-3-phosphorylcholine increase interleukin-8 (IL-8) synthesis in aortic endothelial cells. The goal of the current studies was to characterize the receptor complex mediating the increased transcription of IL-8. We demonstrate that scavenger receptor class A, types I and II, lectin-like ox-LDL receptor-1, macrophage receptor with collagenous structure, and CD36 are not responsible for the increase in IL-8. Using dominant-negative constructs and antisense oligonucleotides, we demonstrate a role for Toll-like receptor 4 (TLR4) as the ox-PAPC receptor mediating IL-8 transcription. We demonstrate that a glycosylphosphatidylinositol (GPI)-anchored protein is also necessary because phosphatidylinositol-specific phospholipase C pretreatment inhibited the effect of ox-PAPC. CD14, a GPI-anchored protein that associates with TLR4 in mediating lipopolysaccharide action, did not appear to mediate ox-PAPC action because ox-PAPC-induced IL-8 transcription was not blocked by anti-CD14 neutralizing antibodies nor was it augmented by the addition of soluble CD14 or overexpression of membrane CD14. Instead, anti-TLR4 antibodies immunoprecipitated a 37-kDa protein that also bound ox-PAPC. A protein of this same size was found in aerolysin overlays used to detect GPI-anchored proteins. Therefore, these studies suggest that ox-PAPC may initially bind to a 37-kDa GPI-anchored protein, which interacts with TLR4 to induce IL-8 transcription.	Univ Calif Los Angeles, Ctr Hlth Sci Pathol 13 229, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Berliner, JA (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci Pathol 13 229, Dept Med, 650 Charles Young Dr S, Los Angeles, CA 90095 USA.		Gharavi, Nima/AAN-7890-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, T32HL069766, R01HL064731] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64731, HL30568, T32HL69766] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boullier A, 2001, ANN NY ACAD SCI, V947, P214; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COLOTTA F, 1984, J IMMUNOL, V132, P936; de Winther MPJ, 2000, ARTERIOSCL THROM VAS, V20, P290, DOI 10.1161/01.ATV.20.2.290; Dhaliwal BS, 1999, CLIN CHIM ACTA, V286, P191, DOI 10.1016/S0009-8981(99)00101-1; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Huber J, 2002, ARTERIOSCL THROM VAS, V22, P101, DOI 10.1161/hq0102.101525; Jersmann HPA, 2001, INFECT IMMUN, V69, P479, DOI 10.1128/IAI.69.1.479-485.2001; Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; KIM JA, 1994, ARTERIOSCLER THROMB, V14, P427, DOI 10.1161/01.ATV.14.3.427; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Linton MF, 2001, CURR OPIN LIPIDOL, V12, P489, DOI 10.1097/00041433-200110000-00003; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Miller YI, 2003, J BIOL CHEM, V278, P1561, DOI 10.1074/jbc.M209634200; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; Pearce SFA, 1998, J BIOL CHEM, V273, P34875, DOI 10.1074/jbc.273.52.34875; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Shi WB, 2000, CIRCULATION, V102, P75, DOI 10.1161/01.CIR.102.1.75; Shi WB, 2000, CIRC RES, V86, P1078, DOI 10.1161/01.RES.86.10.1078; Sotgia F, 2002, MOL CELL BIOL, V22, P3905, DOI 10.1128/MCB.22.11.3905-3926.2002; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Yeh M, 2001, ARTERIOSCL THROM VAS, V21, P1585, DOI 10.1161/hq1001.097027; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	35	143	149	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29661	29666		10.1074/jbc.M300738200	http://dx.doi.org/10.1074/jbc.M300738200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777373	hybrid			2022-12-25	WOS:000184507000036
J	Zheng, XL; Nishio, K; Majerus, EM; Sadler, JE				Zheng, XL; Nishio, K; Majerus, EM; Sadler, JE			Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; HEMOLYTIC-UREMIC SYNDROME; VONWILLEBRAND-FACTOR; IDENTIFICATION; MUTATIONS; BINDING; FAMILY; GENE; ENTEROPEPTIDASE	ADAMTS13 consists of a reprolysin-type metalloprotease domain followed by a disintegrin domain, a thrombospondin type 1 motif (TSP1), Cys-rich and spacer domains, seven more TSP1 motifs, and two CUB domains. ADAMTS13 limits platelet accumulation in microvascular thrombi by cleaving the Tyr(1605)-Met(1606) bond in von Willebrand factor, and ADAMTS13 deficiency causes a lethal syndrome, thrombotic thrombocytopenic purpura. ADAMTS13 domains required for substrate recognition were localized by the characterization of recombinant deletion mutants. Constructs with C-terminal His(6) and V5 epitopes were expressed by transient transfection of COS-7 cells or in a baculovirus system. No association with extracellular matrix or cell surface was detected for any ADAMTS13 variant by immunofluorescence microscopy or chemical modification. Both plasma and recombinant full-length ADAMTS13 cleaved von Willebrand factor subunits into two fragments of 176 kDa and 140 kDa. Recombinant ADAMTS13 was divalent metal ion-dependent and was inhibited by IgG from a patient with idiopathic thrombotic thrombocytopenic purpura. ADAMTS13 that was truncated after the metalloprotease domain, the disintegrin domain, the first TSP1 repeat, or the Cys-rich domain was not able to cleave von Willebrand factor, whereas addition of the spacer region restored protease activity. Therefore, the spacer region is necessary for normal ADAMTS13 activity toward von Willebrand factor, and the more C-terminal TSP1 and CUB domains are dispensable in vitro.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.		Zheng, X. Long/ABD-7362-2021; Sadler, Evan/D-8556-2011	Zheng, X. Long/0000-0003-1680-5295; Sadler, J. Evan/0000-0001-5705-469X				Antoine G, 2003, BRIT J HAEMATOL, V120, P821, DOI 10.1046/j.1365-2141.2003.04183.x; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Furlan M, 2001, BEST PRACT RES CL HA, V14, P437, DOI 10.1053/beha.2001.0142; George JN, 2000, BLOOD, V96, P1223, DOI 10.1182/blood.V96.4.1223.h8001223_1223_1229; Gerritsen HE, 1999, THROMB HAEMOSTASIS, V82, P1386; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Moake JL, 2002, ANNU REV MED, V53, P75, DOI 10.1146/annurev.med.53.082901.103948; Plaimauer B, 2002, BLOOD, V100, P3626, DOI 10.1182/blood-2002-05-1397; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Sadler JE, 2002, P NATL ACAD SCI USA, V99, P11552, DOI 10.1073/pnas.192448999; Schneppenheim R, 2003, BLOOD, V101, P1845, DOI 10.1182/blood-2002-08-2399; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596; Zheng XL, 2003, ANN INTERN MED, V138, P105, DOI 10.7326/0003-4819-138-2-200301210-00011; Zheng XL, 2002, J BIOL CHEM, V277, P6858, DOI 10.1074/jbc.M109857200	36	152	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30136	30141		10.1074/jbc.M305331200	http://dx.doi.org/10.1074/jbc.M305331200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12791682	hybrid			2022-12-25	WOS:000184507000091
J	Sorensen, OE; Gram, L; Johnsen, AH; Andersson, E; Bangsboll, S; Tjabringa, GS; Hiemstra, PS; Malm, J; Egesten, A; Borregaard, N				Sorensen, OE; Gram, L; Johnsen, AH; Andersson, E; Bangsboll, S; Tjabringa, GS; Hiemstra, PS; Malm, J; Egesten, A; Borregaard, N			Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin - A novel mechanism of generating antimicrobial peptides in vagina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTIBACTERIAL CATHELICIDIN; HUMAN NEUTROPHILS; INNATE IMMUNITY; PEPSINOGEN-C; HOST-DEFENSE; PROTEIN; LL-37; FLUID; EXPRESSION; ACTIVATION	The human cathelicidin, hCAP-18, is expressed both in neutrophils and in epithelial cells. hCAP-18 is processed to the antimicrobial peptide LL-37 by proteinase 3 in neutrophils. hCAP-18 is highly expressed in the epididymis with a subsequent high concentration in seminal plasma where the protein is present in its unprocessed and antimicrobially inactive form. We report here that hCAP-18 in seminal plasma is processed to generate a 38-amino acid antimicrobial peptide ALL-38 by the prostate-derived protease gastricsin when incubated at a pH corresponding to the vaginal pH. In accordance with this, seminal plasma derived hCAP-18 was found in its processed form in the vagina following sexual intercourse. The antimicrobial activity of ALL-38 against a variety of microorganisms tested is equal to that of LL37. This enzymatic activation of a proantimicrobial substance in seminal plasma following exposure to the vaginal milieu represents a novel mechanism to prevent infection following sexual intercourse.	Univ Copenhagen Hosp, Granulocyte Res Lab, Dept Hematol, Rigshosp, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Dept Clin Biochem, Rigshosp, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Fertil Clin, Rigshosp, DK-2100 Copenhagen, Denmark; Danish Inst Fisheries Res, Dept Seafood Res, DK-2800 Lyngby, Denmark; Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden; Leiden Univ, Dept Lab Med, Med Ctr, NL-2300 RC Leiden, Netherlands	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Technical University of Denmark; Lund University; Skane University Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Sorensen, OE (corresponding author), Univ Calif Los Angeles, Host Def Res Lab, Dept Med, David Geffen Sch Med, 10833 Le Conte Ave,52-164 CHS, Los Angeles, CA 90095 USA.	sorensen@ucla.edu	; Hiemstra, Pieter/K-8587-2018	Gram, Lone/0000-0002-1076-5723; Hiemstra, Pieter/0000-0002-0238-5982; Sorensen, Ole E./0000-0001-8681-6921				Agerberth B, 1999, AM J RESP CRIT CARE, V160, P283, DOI 10.1164/ajrccm.160.1.9807041; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; BELASZECSI P, 1995, BIOL REPROD, V53, P227, DOI 10.1095/biolreprod53.1.227; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Cole AM, 2001, BLOOD, V97, P297, DOI 10.1182/blood.V97.1.297; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; EGESTEN A, 1994, BLOOD, V83, P2985, DOI 10.1182/blood.V83.10.2985.2985; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; GANZ T, 1994, CIBA F SYMP, V186, P62; Georgalaki MD, 2002, APPL ENVIRON MICROB, V68, P5891, DOI 10.1128/AEM.68.12.5891-5903.2002; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Hammami-Hamza S, 2001, MOL HUM REPROD, V7, P625, DOI 10.1093/molehr/7.7.625; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; MARTIN RC, 1998, MOL REPROD DEV, V49, P286; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P20; Murakami M, 2002, J DENT RES, V81, P845, DOI 10.1177/154405910208101210; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4; REID WA, 1984, CELL TISSUE RES, V236, P597; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; Sambrook J, 2001, MOL CLONING LAB MANU; Smeianov V, 2000, MICROBES INFECT, V2, P773, DOI 10.1016/S1286-4579(00)90359-9; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; Sorensen O, 1999, J BIOL CHEM, V274, P22445, DOI 10.1074/jbc.274.32.22445; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; SZECSI PB, 1988, FEBS LETT, V238, P101, DOI 10.1016/0014-5793(88)80234-5; SZECSI PB, 1989, BIOL REPROD, V40, P653, DOI 10.1095/biolreprod40.3.653; SZECSI PB, 1993, J ANDROL, V14, P351; Tomas MSJ, 2003, AM J OBSTET GYNECOL, V188, P35, DOI 10.1067/mob.2003.123; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	133	145	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28540	28546		10.1074/jbc.M301608200	http://dx.doi.org/10.1074/jbc.M301608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759353	hybrid			2022-12-25	WOS:000184421100026
J	Wang, HX; Hays, JB				Wang, HX; Hays, JB			Mismatch repair in human nuclear extracts - Effects of internal DNA-hairpin structures between mismatches and excision-initiation nicks on mismatch correction and mismatch-provoked excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION MECHANISM; PROTEIN HETERODIMERS; SLIDING CLAMP; MUTS; ATP; EXONUCLEASE; BINDING; COMPLEX; REQUIREMENTS; RECOGNITION	DNA mismatch repair (MMR) couples recognition of base mispairs by MSH2.MSH6 heterodimers to initiation, hundreds of nucleotides away, of nascent strand 3'-5' or 5'-3' excision through the mispair. Mismatch-recognition complexes have been hypothesized to move along DNA to excision-initiation signals, in eukaryotes, perhaps ends of nascent DNA, or to remain at mismatches and search through space for initiation signals. Subsequent MMR excision, whether simple processive digestion of the targeted strand or tracking of an excision complex, remains poorly understood. In human cell-free extracts, we analyzed correction of a mismatch in a 2.2-kilobase pair (kbp) circular plasmid containing a pre-existing excision-initiation nick for initiation, and measured MMR excision (in the absence of exogenous dNTPs) at specific locations. Excision specificities were similar to100:1 for nicked versus continuous strands, 80:1 for mismatched versus homoduplex DNA, and 30:1 for shorter (0.3-kbp) versus longer (1.9-kbp) nick-mispair paths. To test models for recognition-excision coupling and excision progress, we inserted potential blockades, 20-bp hairpins, into nick-mispair paths, using a novel technique to first generate gapped plasmid. Continuous strand longer-path hairpins did not affect mismatch correction, but shorter-path hairpins reduced correction 4-fold, and both together eliminated it. Shorter-path hairpins had little effect on initiation of (3'-5') excision, measured 30-60 nucleotides 5' to the nick, but blocked subsequent progress of excision to the mismatch; longer-path hairpins blocked the (lower level) 5'-3' excision to the mismatch. Thus, (a) MMR excision protein(s) cannot move past DNA hairpins. Hairpins at both ends of substrate-derived 0.5-kbp DNA fragments did not prevent ATP-induced dissociation of mismatch-bound human MSH2.MSH6, so recognition complexes at mismatches might provoke excision at nicks beyond hairpins, or loosely sliding MSH2.MSH6 dimers might move to the nicks.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University	Hays, JB (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009848] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09848] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Culligan KM, 2000, PLANT CELL, V12, P991, DOI 10.1105/tpc.12.6.991; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 2001, J MOL BIOL, V312, P637, DOI 10.1006/jmbi.2001.4958; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iams K, 2002, J BIOL CHEM, V277, P30805, DOI 10.1074/jbc.M200846200; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; Wang HX, 2002, J BIOL CHEM, V277, P26143, DOI 10.1074/jbc.M200358200; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200; Wang HX, 2001, MOL BIOTECHNOL, V19, P133, DOI 10.1385/MB:19:2:133; Wei KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762	27	23	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28686	28693		10.1074/jbc.M302844200	http://dx.doi.org/10.1074/jbc.M302844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756259	hybrid			2022-12-25	WOS:000184421100043
J	Kessler, SP; Senanayake, PD; Scheidemantel, TS; Gomos, JB; Rowe, TM; Sen, GC				Kessler, SP; Senanayake, PD; Scheidemantel, TS; Gomos, JB; Rowe, TM; Sen, GC			Maintenance of normal blood pressure and renal functions are independent effects of angiotensin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACE-DEFICIENT MICE; MALE-FERTILITY; DROSOPHILA-MELANOGASTER; CLEAVAGE-SECRETION; MESSENGER-RNAS; CELL-SURFACE; ACTIVE-SITE; C-DOMAIN; EXPRESSION; GENE	Angiotensin-converting enzyme ( ACE) is expressed in many tissues, including vasculature and renal proximal tubules, and its genetic ablation in mice causes abnormal renal structure and functions, hypotension, and male sterility. To test the hypothesis that specific physiological functions of ACE are mediated by its expression in specific tissues, we generated different mouse strains, each expressing ACE in only one tissue. Here, we report the properties of two such strains of mice that express ACE either in vascular endothelial cells or in renal proximal tubules. Because of the natural cleavage secretion process, both groups also have ACE in the serum. Both groups were as healthy as wild-type mice, having normal kidney structure and fluid homeostasis, though males remained sterile, because they lack ACE expression in sperm. Despite equivalent serum ACE and angiotensin II levels and renal functions, only the group that expressed ACE in vascular endothelial cells had normal blood pressure. Expression of ACE, either in renal proximal tubules or in vasculature, is sufficient for maintaining normal kidney functions. However, for maintaining blood pressure, ACE must be expressed in vascular endothelial cells. These results also demonstrate that ACE-mediated blood pressure maintenance can be dissociated from its role in maintaining renal structure and functions.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Ophthalm Res, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, NC20,9500 Euclid Ave, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL-48258] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELDENT V, 1995, J BIOL CHEM, V270, P28962, DOI 10.1074/jbc.270.48.28962; Cole J, 2000, J CLIN INVEST, V106, P1391, DOI 10.1172/JCI10557; Cole J, 2002, CIRC RES, V90, P87, DOI 10.1161/hh0102.102360; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; Esther CR, 1996, LAB INVEST, V74, P953; Esther CR, 1997, J CLIN INVEST, V99, P2375, DOI 10.1172/JCI119419; FRIEDLAND J, 1978, BIOCHEM BIOPH RES CO, V83, P843, DOI 10.1016/0006-291X(78)91471-7; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; HUBERT C, 1991, J BIOL CHEM, V266, P15377; Isaac RE, 1997, BIOCHEM J, V328, P587, DOI 10.1042/bj3280587; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; Kessler SP, 2002, J BIOL CHEM, V277, P4271, DOI 10.1074/jbc.M109474200; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; Mastrobattista JM, 1997, SEMIN PERINATOL, V21, P124, DOI 10.1016/S0146-0005(97)80055-9; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Safer R. L., 1981, BIOCH REGULATION BLO, P123; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; SEN GC, 1990, J CARDIOVASC PHARM, V16, P14; SEN I, 1991, J BIOL CHEM, V266, P21985; Senanayake PD, 1998, PEPTIDES, V19, P1685, DOI 10.1016/S0196-9781(98)00123-5; Sepulveda AR, 1997, J BIOL CHEM, V272, P11959, DOI 10.1074/jbc.272.18.11959; Sharp MGF, 1996, HYPERTENSION, V28, P1126, DOI 10.1161/01.HYP.28.6.1126; Sigmund CD, 2000, ARTERIOSCL THROM VAS, V20, P1425, DOI 10.1161/01.ATV.20.6.1425; STRITTMATTER SM, 1987, NEUROSCIENCE, V21, P407, DOI 10.1016/0306-4522(87)90131-X; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; Tian BH, 1997, HYPERTENSION, V30, P128, DOI 10.1161/01.HYP.30.1.128; Traynor T, 1999, AM J PHYSIOL-RENAL, V276, pF751, DOI 10.1152/ajprenal.1999.276.5.F751; Tsuchida S, 1998, J CLIN INVEST, V101, P755, DOI 10.1172/JCI1899; WEI L, 1991, J BIOL CHEM, V266, P5540; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; Williams TA, 1996, BIOCHEM J, V318, P125, DOI 10.1042/bj3180125; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875	44	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21105	21112		10.1074/jbc.M3023472000	http://dx.doi.org/10.1074/jbc.M3023472000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12777443	Bronze			2022-12-25	WOS:000183230500086
J	Arlt, A; Gehrz, A; Muerkoster, S; Vorndamm, J; Kruse, ML; Folsch, UR; Schafer, H				Arlt, A; Gehrz, A; Muerkoster, S; Vorndamm, J; Kruse, ML; Folsch, UR; Schafer, H			Role of NF-kappa B and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death	ONCOGENE			English	Article						programmed cell death; DNA damage; transcription factor; chemotherapy; protein kinase	CANCER-CELLS; INDUCED APOPTOSIS; DIRECT INHIBITION; MAMMALIAN TARGET; PROTEIN-KINASE; SOLID TUMORS; K-RAS; ACTIVATION; P53; EXPRESSION	Pancreatic cancer is resistant to almost all cytotoxic drugs. Currently, gemcitabine appears to be the only clinically active drug but, because of pre-existing or acquired chemoresistance of most of the tumor cells, it failed to significantly improve the outcome of pancreatic carcinoma patients. The current study examined the relevance of nuclear factor kappaB (NF-kappaB) and PI3K/Akt in the resistance of five pancreatic carcinoma cell lines towards gemcitabine. Treatment for 24 h with gemcitabine (0.04-20 muM) led to a strong induction of apoptosis in PT45-P1 and T3M4 cells but not in BxPc-3, Capan-1 and PancTu-1 cells. These resistant cell lines exhibited a high basal NF-kappaB activity in contrast to the sensitive cell lines. Furthermore, gemcitabine showed a dose-dependent induction of NF-kappaB. At a dose of 0.04 muM, gemcitabine still induced apoptosis in the sensitive cell lines, but did not induce NF-kappaB. In addition, NF-kappaB inhibition by MG132, sulfasalazine or the IkappaBalpha super-repressor strongly diminished the resistance against gemcitabine (0.04-20 muM). In contrast to this obvious correlation between basal NF-kappaB activity and gemcitabine resistance, PI3K/Akt seems not to be involved in gemcitabine resistance of these cell lines. Neither did the basal Akt activity correlate with the sensitivity towards gemcitabine treatment, nor did the inhibition of PI3K/Akt by LY294002 alter gemcitabine-induced apoptosis. These results indicate that constitutive NF-kappaB activity confers resistance against gemcitabine and that modulation of this activity by pharmacological or genetic approaches may have therapeutical potential when combined with gemcitabine in the treatment of pancreatic carcinoma.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany	University of Kiel	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2002, INT J CLIN PHARM TH, V40, P336; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; BIAN X, 2002, J BIOL CHEM, V26, P26; Brognard J, 2001, CANCER RES, V61, P3986; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Dumontet C, 1999, BRIT J HAEMATOL, V106, P78, DOI 10.1046/j.1365-2141.1999.01509.x; Galmarini CM, 2002, INT J CANCER, V97, P439, DOI 10.1002/ijc.1628; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goan YG, 1999, CANCER RES, V59, P4204; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Ng SSW, 2000, CANCER RES, V60, P5451; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rosenberg L, 1997, INT J PANCREATOL, V22, P81; Rosewicz S, 1997, LANCET, V349, P485; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Sekulic A, 2000, CANCER RES, V60, P3504; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VANHAPEREN VWTR, 1995, SEMIN ONCOL, V22, P35; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458	42	435	452	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3243	3251		10.1038/sj.onc.1206390	http://dx.doi.org/10.1038/sj.onc.1206390			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761494				2022-12-25	WOS:000183040000006
J	Sarna, MK; Ingley, E; Busfield, SJ; Cull, VS; Lepere, W; McCarthy, DJ; Wright, MJ; Palmer, GA; Chappell, D; Sayer, MS; Alexander, WS; Hilton, DJ; Starr, R; Watowich, SS; Bittorf, T; Klinken, SP; Tilbrook, PA				Sarna, MK; Ingley, E; Busfield, SJ; Cull, VS; Lepere, W; McCarthy, DJ; Wright, MJ; Palmer, GA; Chappell, D; Sayer, MS; Alexander, WS; Hilton, DJ; Starr, R; Watowich, SS; Bittorf, T; Klinken, SP; Tilbrook, PA			Differential regulation of SOCS genes in normal and transformed erythroid cells	ONCOGENE			English	Article							PHENYLHYDRAZINE-TREATED MICE; PROTEIN-TYROSINE KINASE; ERYTHROPOIETIN RECEPTOR; C-KIT; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; IN-VIVO; ERYTHROLEUKEMIA DEVELOPMENT; TRANSLATIONAL REPRESSION; TRANSCRIPTION FACTOR	The SOCS family of genes are negative regulators of cytokine signalling with SOCS-1 displaying tumor suppressor activity. SOCS-1, CIS and SOCS-3 have been implicated in the regulation of red blood cell production. In this study, a detailed examination was conducted on the expression patterns of these three SOCS family members in normal erythroid progenitors and a panel of erythroleukemic cell lines. Unexpectedly, differences in SOCS gene expression were observed during maturation of normal red cell progenitors, viz changes to CIS were inversely related to the alterations of SOCS-1 and SOCS-3. Similarly, these SOCS genes were differentially expressed in transformed erythoid cells erythroleukemic cells immortalized at an immature stage of differentiation expressed SOCS-1 and SOCS-3 mRNA constitutively, whereas in more mature cell lines SOCS-1 and CIS were induced only after exposure to erythropoietin (Epo). Significantly, when ectopic expression of the tyrosine kinase Lyn was used to promote differentiation of immature cell lines, constitutive expression of SOCS-1 and SOCS-3 was completely suppressed. Modulation of intracellular signalling via mutated Epo receptors in mature erythroleukemic lines also highlighted different responses by the three SOCS family members. Close scrutiny of SOCS-1 revealed that, despite large increases in mRNA levels, the activity of the promoter did not alter after erythropoietin stimulation; in addition, erythroid cells from SOCS-1-/- mice displayed increased sensitivity to Epo. These observations indicate complex, stage-specific regulation of SOCS genes during normal erythroid maturation and in erythroleukemic cells.	Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6009, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia; Royal Perth Hosp, Western Australian Inst Med Res, Neurotrauma Lab, Perth, WA 6000, Australia; PO Box Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia; PO Box Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic, Australia; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Rostock, Inst Med Biochem, D-2500 Rostock 1, Germany	Royal Perth Hospital; University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Rostock	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, 6th Floor MRF Bldg,Rear,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Fear, Vanessa/A-6876-2013; Fear, Vanessa S/AAF-9805-2020; Hilton, Douglas J/C-7250-2013; Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Sarna, Mohinder/GYR-3271-2022; Fear, Vanessa/O-5618-2019	Fear, Vanessa S/0000-0001-8363-6685; Hilton, Douglas J/0000-0002-7698-2392; Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Watowich, Stephanie/0000-0003-1969-659X	NATIONAL CANCER INSTITUTE [R01CA022556, R01CA077447, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA022556, R37 CA022556, R01 CA077447-03, CA-77447, CA-22556, R01 CA077447-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; BUSFIELD SJ, 1992, BLOOD, V80, P412; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CORY S, 1991, CELL GROWTH DIFFER, V2, P165; Cull V, 2000, ONCOGENE, V19, P953, DOI 10.1038/sj.onc.1203370; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; De Sepulveda P, 1999, EMBO J, V18, P904; DEJONG MO, 1995, BLOOD, V86, P4076, DOI 10.1182/blood.V86.11.4076.bloodjournal86114076; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; HAWLEY RG, 1994, GENE THER, V1, P136; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hodges VM, 1999, BRIT J HAEMATOL, V106, P325, DOI 10.1046/j.1365-2141.1999.01535.x; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANDSCHULZ KT, 1989, BLOOD, V73, P1476; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; MARSHALL CJ, 1988, J CELL SCI, P157; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MIURA O, 1994, BLOOD, V84, P1501; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tilbrook PA, 1999, GROWTH FACTORS, V17, P25, DOI 10.3109/08977199909001060; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, ARCH BIOCHEM BIOPHYS, V396, P128, DOI 10.1006/abbi.2001.2577; Tilbrook PA, 2001, CANCER RES, V61, P2453; TROWBRIDGE IS, 1982, J CELL PHYSIOL, V112, P403, DOI 10.1002/jcp.1041120314; UOSHIMA N, 1995, BRIT J HAEMATOL, V91, P30, DOI 10.1111/j.1365-2141.1995.tb05240.x; Vannucchi AM, 2000, BLOOD, V95, P2559; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Waldmann V, 1996, PATHOL RES PRACT, V192, P883, DOI 10.1016/S0344-0338(96)80067-7; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	66	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3221	3230		10.1038/sj.onc.1206381	http://dx.doi.org/10.1038/sj.onc.1206381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761492	Green Accepted			2022-12-25	WOS:000183040000004
J	Mehta, D; Ahmmed, GU; Paria, BC; Holinstat, M; Voyno-Yasenetskaya, T; Tiruppathi, C; Minshall, RD; Malik, AB				Mehta, D; Ahmmed, GU; Paria, BC; Holinstat, M; Voyno-Yasenetskaya, T; Tiruppathi, C; Minshall, RD; Malik, AB			RhoA interaction with inositol 1,4,5-trisphosphate receptor and transient receptor potential channel-1 regulates Ca2+ entry - Role in signaling increased endothelial permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ENDOGENOUSLY EXPRESSED TRP1; GTP-BINDING PROTEIN; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; BARRIER FUNCTION; HUMAN PLATELETS; DIFFERENTIAL LOCALIZATION; DIFFUSIBLE MESSENGER; MOLECULAR-BASIS	We tested the hypothesis that RhoA, a monomeric GTP-binding protein, induces association of inositol trisphosphate receptor (IP3R) with transient receptor potential channel (TRPC1), and thereby activates store depletion-induced Ca2+ entry in endothelial cells. We showed that RhoA upon activation with thrombin associated with both IP3R and TRPC1. Thrombin also induced translocation of a complex consisting of Rho, IP3R, and TRPC1 to the plasma membrane. IP3R and TRPC1 translocation and association required Rho activation because the response was not seen in C3 transferase (C3)-treated cells. Rho function inhibition using Rho dominant-negative mutant or C3 dampened Ca2+ entry regardless of whether Ca2+ stores were emptied by thrombin, thapsigargin, or inositol trisphosphate. Rho-induced association of IP3R with TRPC1 was dependent on actin filament polymerization because latrunculin ( which inhibits actin polymerization) prevented both the association and Ca2+ entry. We also showed that thrombin produced a sustained Rho-dependent increase in cytosolic Ca2+ concentration [Ca2+](i) in endothelial cells overexpressing TRPC1. We further showed that Rho-activated Ca2+ entry via TRPC1 is important in the mechanism of the thrombin-induced increase in endothelial permeability. In summary, Rho activation signals interaction of IP3R with TRPC1 at the plasma membrane of endothelial cells, and triggers Ca2+ entry following store depletion and the resultant increase in endothelial permeability.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.		voyno-yasenetskaya, tatyana/A-3171-2008	Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL45638, R01 HL071794, HL71794] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045638, R01HL071794] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; BIRD GS, 1993, J BIOL CHEM, V268, P21486; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Borbiev T, 2000, ANAL BIOCHEM, V285, P260, DOI 10.1006/abio.2000.4763; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fernando KC, 1997, BIOCHEM J, V328, P463; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kranenburg O, 1997, J CELL SCI, V110, P2417; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; ROSALES C, 1992, J BIOL CHEM, V267, P1443; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sandoval R, 2001, AM J PHYSIOL-LUNG C, V280, pL239, DOI 10.1152/ajplung.2001.280.2.L239; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Su ZC, 2001, AM J PHYSIOL-CELL PH, V280, pC1284, DOI 10.1152/ajpcell.2001.280.5.C1284; Tanimura A, 2000, J BIOL CHEM, V275, P27488; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wu SW, 2001, J CELL BIOL, V154, P1225, DOI 10.1083/jcb.200106156; Xie Q, 2002, J BIOL CHEM, V277, P16559, DOI 10.1074/jbc.M109518200; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	65	164	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33492	33500		10.1074/jbc.M302401200	http://dx.doi.org/10.1074/jbc.M302401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12766172	hybrid			2022-12-25	WOS:000184901800123
J	Park, JH; Wolff, EC; Folk, JE; Park, MH				Park, JH; Wolff, EC; Folk, JE; Park, MH			Reversal of the deoxyhypusine synthesis reaction - Generation of spermidine or homospermidine from deoxyhypusine by deoxyhypusine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; YEAST SACCHAROMYCES-CEREVISIAE; PYRROLIZIDINE ALKALOID BIOSYNTHESIS; PATHWAY-SPECIFIC ENZYME; CELL VIABILITY; INTERMEDIATE FORMATION; SUBSTRATE-SPECIFICITY; HAMSTER EPIDIDYMIS; HYPUSINE DEPLETION; PROTEIN SUBSTRATE	Deoxyhypusine synthase catalyzes the first step in hypusine (N-epsilon-(4-amino-2-hydroxybutyl) lysine) synthesis in a single cellular protein, eIF5A precursor. The synthesis of deoxyhypusine catalyzed by this enzyme involves transfer of the 4-aminobutyl moiety of spermidine to a specific lysine residue in the eIF5A precursor protein to form a deoxyhypusine-containing eIF5A intermediate, eIF5A(Dhp). We recently discovered the efficient reversal of deoxyhypusine synthesis. When eIF5A([H-3]Dhp), radiolabeled in the 4-aminobutyl portion of its deoxyhypusine residue, was incubated with human deoxyhypusine synthase, NAD, and 1,3-diaminopropane, [H-3] spermidine was formed by a rapid transfer of the radiolabeled 4-aminobutyl side chain of the [H-3] deoxyhypusine residue to 1,3-diaminopropane. No reversal was observed with [H-3] hypusine protein, suggesting that hydroxylation at the 4-aminobutyl side chain of the deoxyhypusine residue prevents deoxyhypusine synthase-mediated reversal of the modification. Purified human deoxyhypusine synthase also exhibited homospermidine synthesis activity when incubated with spermidine, NAD, and putrescine. Thus it was found that [C-14] putrescine can replace eIF5A precursor protein as an acceptor of the 4-aminobutyl moiety of spermidine to form radiolabeled homospermidine. The K-m value for putrescine (1.12 mM) as a 4-aminobutyl acceptor, however, is much higher than that for eIF5A precursor (1.5 muM). Using [C-14] putrescine as an acceptor, various spermidine analogs were evaluated as donor substrates for human deoxyhypusine synthase. Comparison of spermidine analogs as inhibitors of deoxyhypusine synthesis, as donor substrates for synthesis of deoxyhypusine (or its analog), and for synthesis of homospermidine (or its analog) provides new insights into the intricate specificity of this enzyme and versatility of the deoxyhypusine synthase reaction.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Park, MH (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Dept Hlth & Human Serv, Bldg 30,Rm 211, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000608] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abbruzzese A, 1988, Adv Exp Med Biol, V250, P459; ALHONENHONGISTO L, 1982, BIOCHEM BIOPH RES CO, V106, P291, DOI 10.1016/0006-291X(82)91108-1; BAILLON JG, 1988, EUR J BIOCHEM, V176, P237, DOI 10.1111/j.1432-1033.1988.tb14274.x; BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; BOTTCHER F, 1994, CAN J CHEM, V72, P80, DOI 10.1139/v94-013; BOTTCHER F, 1993, PHYTOCHEMISTRY, V32, P679, DOI 10.1016/S0031-9422(00)95154-9; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; Chen KY, 1997, BIOL SIGNAL, V6, P105; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Lee GH, 2001, BIOCHEM J, V355, P841, DOI 10.1042/bj3550841; Lee YB, 1999, BIOCHEM J, V340, P273, DOI 10.1042/0264-6021:3400273; Lee YB, 1998, BIOORGAN MED CHEM, V6, P253, DOI 10.1016/S0968-0896(97)10030-X; LEE YB, 1995, J MED CHEM, V38, P3053, DOI 10.1021/jm00016a008; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; MATSUZAKI S, 1982, BIOCHEM BIOPH RES CO, V107, P307, DOI 10.1016/0006-291X(82)91705-3; MATSUZAKI S, 1987, BIOCHEM INT, V15, P817; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; NAGARAJAN S, 1987, J ORG CHEM, V52, P5044, DOI 10.1021/jo00231a044; Ober D, 2003, J BIOL CHEM, V278, P12805, DOI 10.1074/jbc.M207112200; Ober D, 2003, PHYTOCHEMISTRY, V62, P339, DOI 10.1016/S0031-9422(02)00553-8; Ober D, 1996, J GEN APPL MICROBIOL, V42, P411, DOI 10.2323/jgam.42.411; Ober D, 1999, J BIOL CHEM, V274, P32040, DOI 10.1074/jbc.274.45.32040; Ober D, 1999, P NATL ACAD SCI USA, V96, P14777, DOI 10.1073/pnas.96.26.14777; Ober D, 2000, PHYTOCHEMISTRY, V55, P305, DOI 10.1016/S0031-9422(00)00267-3; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Tome ME, 1997, BIOCHEM J, V328, P847; Wang TW, 2001, J BIOL CHEM, V276, P17541, DOI 10.1074/jbc.M008544200; Wolff EC, 1999, YEAST, V15, P43; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; Wolff EC, 2000, J BIOL CHEM, V275, P9170, DOI 10.1074/jbc.275.13.9170	42	44	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32683	32691		10.1074/jbc.M304247200	http://dx.doi.org/10.1074/jbc.M304247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12788913	hybrid			2022-12-25	WOS:000184901800026
J	Haworth, RS; McCann, C; Snabaitis, AK; Roberts, NA; Avkiran, M				Haworth, RS; McCann, C; Snabaitis, AK; Roberts, NA; Avkiran, M			Stimulation of the plasma membrane Na+/H+ exchanger NHE1 by sustained intracellular acidosis - Evidence for a novel mechanism mediated by the ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; NA-H EXCHANGE; ANGIOTENSIN-II; IN-VIVO; C-SRC; EXPRESSION; PH; MYOCARDIUM; ISOFORM	Activity of the Na+/H+ exchanger ( NHE) isoform 1 (NHE1) is increased by intracellular acidosis through the interaction of intracellular H+ with an allosteric modifier site in the transport domain. Additional regulation is achieved via kinase-mediated modulation of the NHE1 regulatory domain. To determine if intracellular acidosis stimulates NHE1 activity solely by the allosteric mechanism, we subjected cultured neonatal rat ventricular myocytes (NRVM) with native NHE1 expression to intracellular acidosis ( pH(i) similar to 6.6) for up to 6 min by transient exposure to NH4Cl and its washout in the presence of NHE inhibition (by zero [Na+](o) or the NHE1 inhibitor cariporide) in HCO3--free medium. After the desired duration of acidosis, NHE was reactivated (by reintroduction of [Na+](o) or removal of cariporide), and the rate of recovery of pH(i) (dpH(i)/dt) was measured as the index of NHE activity. Regardless of the method used when intracellular acidosis was sustained for greater than or equal to 3 min, subsequent NHE activity was significantly increased (>4-fold). Similar NHE stimulatory effects of sustained acidosis were observed in adult rat ventricular myocytes and COS-7 cells. Sustained ( 3 min) intracellular acidosis activated several NHE1 kinases in NRVM, in an in-gel kinase assay using as substrate a glutathione S-transferase fusion protein of the NHE1 regulatory domain. Detailed investigation of ERK and its downstream effector p90(RSK), two putative NHE1 kinases, revealed time-dependent activation of both by intracellular acidosis in NRVM. Furthermore, inhibition of MEK1/2 by pretreatment of NRVM with two structurally distinct inhibitors, PD98059 ( 30 muM) or UO126 ( 3 muM), inhibited the activation of ERK and p90(RSK) and abolished the stimulation of NHE activity by sustained ( 3 min) intracellular acidosis. Our data show that not only the extent but also the duration of intracellular acidosis regulates NHE1 activity and suggest that the stimulatory effect of sustained intracellular acidosis occurs through a novel mechanism mediated by activation of the ERK pathway.	Univ London Kings Coll, Ctr Cardiovasc Biol & Med, Rayne Inst, St Thomas Hosp, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Haworth, RS (corresponding author), Univ London Kings Coll, Ctr Cardiovasc Biol & Med, Rayne Inst, St Thomas Hosp, Lambeth Palace Rd, London SE1 7EH, England.			snabaitis, andrew/0000-0003-0061-1111; Avkiran, Metin/0000-0003-2392-6343				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Avkiran M, 2003, CARDIOVASC RES, V57, P942, DOI 10.1016/S0008-6363(02)00782-4; Bianchini L, 1997, J BIOL CHEM, V272, P271; BOUNTRA C, 1989, J PHYSIOL-LONDON, V418, P163, DOI 10.1113/jphysiol.1989.sp017833; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DYCK JRB, 1995, CARDIOVASC RES, V29, P203, DOI 10.1016/S0008-6363(96)88571-3; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FLIEGEL L, 1993, MOL CELL BIOCHEM, V125, P137, DOI 10.1007/BF00936442; Gunasegaram S, 1999, CIRC RES, V85, P919; Haworth RS, 1999, AM J PHYSIOL-CELL PH, V277, pC1202, DOI 10.1152/ajpcell.1999.277.6.C1202; Haworth RS, 1997, J MOL CELL CARDIOL, V29, P321, DOI 10.1006/jmcc.1996.0277; Haworth RS, 2000, J MOL CELL CARDIOL, V32, P1013, DOI 10.1006/jmcc.2000.1143; Hayashi H, 2002, J BIOL CHEM, V277, P11090, DOI 10.1074/jbc.M111868200; Ishibashi H, 1999, P NATL ACAD SCI USA, V96, P9949, DOI 10.1073/pnas.96.17.9949; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; Khaled AR, 2001, MOL CELL BIOL, V21, P7545, DOI 10.1128/MCB.21.22.7545-7557.2001; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; Maly K, 2002, FEBS LETT, V521, P205, DOI 10.1016/S0014-5793(02)02867-3; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; Snabaitis AK, 2002, CARDIOVASC RES, V53, P470, DOI 10.1016/S0008-6363(01)00464-3; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; TSE CM, 1992, J BIOL CHEM, V267, P9340; Tsuganezawa H, 2002, KIDNEY INT, V62, P41, DOI 10.1046/j.1523-1755.2002.00418.x; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; Wakabayashi S, 2003, J BIOL CHEM, V278, P11828, DOI 10.1074/jbc.M213243200; WALLERT MA, 1989, AM J PHYSIOL, V257, pC207, DOI 10.1152/ajpcell.1989.257.2.C207; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; Wu ML, 1997, J MOL CELL CARDIOL, V29, P1131, DOI 10.1006/jmcc.1996.0338; Yamaji Y, 1997, AM J PHYSIOL-CELL PH, V272, pC886, DOI 10.1152/ajpcell.1997.272.3.C886; Yasutake M, 1996, CIRC RES, V79, P705, DOI 10.1161/01.RES.79.4.705; Yokoyama H, 2000, J AM COLL CARDIOL, V36, P534, DOI 10.1016/S0735-1097(00)00730-0; Yokoyama H, 1998, CIRC RES, V82, P1078, DOI 10.1161/01.RES.82.10.1078	41	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31676	31684		10.1074/jbc.M304400200	http://dx.doi.org/10.1074/jbc.M304400200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791686	hybrid			2022-12-25	WOS:000184782100028
J	Marchal, S; Shehi, E; Harricane, MC; Fusi, P; Heitz, F; Tortora, P; Lange, R				Marchal, S; Shehi, E; Harricane, MC; Fusi, P; Heitz, F; Tortora, P; Lange, R			Structural instability and fibrillar aggregation of non-expanded human ataxin-3 revealed under high pressure and temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERIVATIVE UV-SPECTROSCOPY; HIGH HYDROSTATIC-PRESSURE; FOLDING INITIATION SITE; CONFORMATIONAL DRIFT; GLUTAMINE REPEATS; MOLTEN-GLOBULE; RIBONUCLEASE-A; NEURODEGENERATIVE DISEASES; INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE DISEASE	Protein misfolding and formation of structured aggregates are considered to be the earliest events in the development of neurodegenerative diseases, but the mechanism of these biological phenomena remains to be elucidated. Here, we report a study of heat- and pressure-induced unfolding of human Q26 and murine Q6 ataxin-3 using spectroscopic methods. UV absorbance and fluorescence revealed that heat and pressure induced a structural transition of both proteins to a molten globule conformation. The unfolding pathway was partly irreversible and led to a protein conformation where tryptophans were more exposed to water. Furthermore, the use of fluorescent probes (8-anilino-1-naphthalenesulfonate and thioflavin T) allowed the identification of different intermediates during the process of pressure-induced unfolding. At high temperature and pressure, human Q26, but not murine Q6, underwent concentration-dependent aggregation. Fourier transform infrared and circular dichroism spectroscopy revealed that these aggregates are characterized by an increased beta-sheet content. As revealed by electron microscopy, heat- and pressure-induced aggregates were different; high temperature treatment led to fibrillar microaggregates (8-10-nm length), whereas high pressure induced oligomeric structures of globular shape (100 nm in diameter), which sometimes aligned to higher order suprastructures. Several intermediate structures were detected in this process. Two factors appear to govern ataxin unfolding and aggregation, the length of the polyglutamine tract and its protein context.	INSERM, U128, IFR 122, F-34293 Montpellier 5, France; Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Inst Federatif Rech 122, Format Rech Evlout 2953, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Milano-Bicocca; Universite de Montpellier	Lange, R (corresponding author), INSERM, U128, IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.		MARCHAL, stéphane/M-4324-2017	MARCHAL, stéphane/0000-0002-1101-7890; Fusi, Paola/0000-0002-2746-1742; Tortora, Paolo/0000-0001-5234-601X	Telethon [1021] Funding Source: Medline	Telethon(Fondazione Telethon)		Albrecht M, 2003, PROTEINS, V50, P355, DOI 10.1002/prot.10280; Balny C, 2002, BBA-PROTEIN STRUCT M, V1595, P3, DOI 10.1016/S0167-4838(01)00331-4; BALNY C, 1998, REV HIGH PRESSURE SC, V7, P1292; Bancel F, 1997, EUR J BIOCHEM, V250, P276, DOI 10.1111/j.1432-1033.1997.0276a.x; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Carrotta R, 2001, PROTEIN SCI, V10, P1312, DOI 10.1110/ps.42501; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 2001, J BIOL CHEM, V276, P44889, DOI 10.1074/jbc.M106575200; Chatani E, 2002, BIOCHEMISTRY-US, V41, P4567, DOI 10.1021/bi011365e; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; Fujigasaki H, 2000, EXP NEUROL, V165, P248, DOI 10.1006/exnr.2000.7479; Fujigasaki H, 2001, J NEUROL NEUROSUR PS, V71, P518, DOI 10.1136/jnnp.71.4.518; Goldsteins G, 1997, BIOCHEMISTRY-US, V36, P5346, DOI 10.1021/bi961649c; Kettner M, 2002, EXP NEUROL, V176, P117, DOI 10.1006/exnr.2002.7916; KING L, 1986, BIOCHEMISTRY-US, V25, P3637, DOI 10.1021/bi00360a024; Kobashigawa Y, 1999, PROTEIN SCI, V8, P2765; KORNBLATT JA, 1990, BIOCHEMISTRY-US, V29, P9370, DOI 10.1021/bi00492a010; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lange R, 1996, EUR BIOPHYS J BIOPHY, V24, P284; Lange R, 1996, EUR BIOPHYS J BIOPHY, V24, P277; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Mombelli E, 1997, BIOCHEMISTRY-US, V36, P8733, DOI 10.1021/bi970467v; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Nandi PK, 2002, BIOCHEMISTRY-US, V41, P11017, DOI 10.1021/bi025886t; ONO S, 1989, ACTA NEUROPATHOL, V77, P350, DOI 10.1007/BF00687369; Orr H T, 2001, Lancet, V358 Suppl, pS35, DOI 10.1016/S0140-6736(01)07048-9; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PENG XD, 1993, P NATL ACAD SCI USA, V90, P1776, DOI 10.1073/pnas.90.5.1776; Perez MK, 1999, HUM MOL GENET, V8, P2377, DOI 10.1093/hmg/8.13.2377; Perrett S, 2002, BBA-PROTEIN STRUCT M, V1595, P210, DOI 10.1016/S0167-4838(01)00345-4; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Roitel O, 2001, BIOCHEM BIOPH RES CO, V283, P347, DOI 10.1006/bbrc.2001.4779; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; RUAN K, 1989, BIOCHEMISTRY-US, V28, P2144, DOI 10.1021/bi00431a028; Ruan KC, 1999, EUR J BIOCHEM, V265, P79, DOI 10.1046/j.1432-1327.1999.00665.x; Ruan KC, 1997, BIOCHEM BIOPH RES CO, V239, P150, DOI 10.1006/bbrc.1997.7313; Ruan KC, 1998, BIOCHEM BIOPH RES CO, V249, P844, DOI 10.1006/bbrc.1998.9231; Ruan KC, 2000, BIOCHEM BIOPH RES CO, V269, P681, DOI 10.1006/bbrc.2000.2345; Ruan KC, 2001, EUR J BIOCHEM, V268, P2742, DOI 10.1046/j.1432-1327.2001.02171.x; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; St John RJ, 2001, J BIOL CHEM, V276, P46856, DOI 10.1074/jbc.M107671200; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; Torrent J, 1999, BIOCHEMISTRY-US, V38, P15952, DOI 10.1021/bi991460b; Torrent J, 2003, BIOCHEMISTRY-US, V42, P1318, DOI 10.1021/bi0269916; Vidugiris GJA, 1998, BIOPHYS J, V75, P463, DOI 10.1016/S0006-3495(98)77534-4; ZHANG J, 1995, BIOCHEMISTRY-US, V34, P8631, DOI 10.1021/bi00027a012; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	57	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31554	31563		10.1074/jbc.M304205200	http://dx.doi.org/10.1074/jbc.M304205200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12766160	hybrid			2022-12-25	WOS:000184782100015
J	Steiner-Mosonyi, M; Leslie, DM; Dehghani, H; Aitchison, JD; Mangroo, D				Steiner-Mosonyi, M; Leslie, DM; Dehghani, H; Aitchison, JD; Mangroo, D			Utp8p is an essential intranuclear component of the nuclear tRNA export machinery of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONYL-TRANSFER-RNA; INITIATOR TRANSFER-RNA; PSEUDOURIDINE SYNTHASE PUS1P; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; BINDING DOMAIN; PORE COMPLEX; IN-VIVO; YEAST; SYNTHETASES	A yeast tRNA three-hybrid interaction approach and an in vivo nuclear tRNA export assay based on amber suppression was used to identify proteins that participate in the nuclear tRNA export process in Saccharomyces cerevisiae. One of the proteins identified by this strategy is Utp8p, an essential 80-kDa nucleolar protein that has been implicated in 18 S ribosomal RNA biogenesis. Our characterization indicated that the major function of Utp8p is in nuclear tRNA export. Like the S. cerevisiae Los1p and the mammalian exportin-t, which are proteins known to facilitate nuclear tRNA export, overexpression of Utp8p restored export of tRNA(am)(Tyr) mutants defective in nuclear export. Furthermore, depletion of Utp8p blocked nuclear export of mature tRNAs derived from both intronless and intron-containing pre-tRNAs but did not affect tRNA and rRNA maturation, nuclear export of mRNA and ribosomes, or nuclear tRNA aminoacylation. Overexpression of Utp8p also alleviated nuclear retention of non-aminoacylated tRNATyr in a tyrosyl-tRNA synthetase mutant strain. Utp8p binds tRNA directly and saturably, indicating that it has a tRNA-binding site. Utp8p does not appear to function as a tRNA export receptor, because it does not shuttle between the nucleus and the cytoplasm. Taken together, the results suggest that Utp8p is an essential intranuclear component of the nuclear tRNA export machinery, which may channel tRNA to the various tRNA export pathways operating in S. cerevisiae.	Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem & Biochem, Guelph, ON N1G 2W1, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Inst Syst Biol, Seattle, WA 98103 USA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry; University of Alberta; Institute for Systems Biology (ISB)	Mangroo, D (corresponding author), Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem & Biochem, Guelph, ON N1G 2W1, Canada.		Dehghani, Hesam/D-1421-2010	Dehghani, Hesam/0000-0001-6750-0040; Leslie Pedrioli, Deena/0000-0003-2342-8010				Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Azad AK, 2001, MOL BIOL CELL, V12, P1381, DOI 10.1091/mbc.12.5.1381; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; Bohnsack MT, 2002, EMBO J, V21, P6205, DOI 10.1093/emboj/cdf613; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; Cleary JD, 2000, BIOCHEM J, V347, P115, DOI 10.1042/0264-6021:3470115; Cullen BR, 2000, MOL CELL BIOL, V20, P4181, DOI 10.1128/MCB.20.12.4181-4187.2000; Deinert K, 2001, J BIOL CHEM, V276, P6000, DOI 10.1074/jbc.M008682200; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; EDWARDS H, 1991, P NATL ACAD SCI USA, V88, P1153, DOI 10.1073/pnas.88.4.1153; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Feng WQ, 2002, P NATL ACAD SCI USA, V99, P5412, DOI 10.1073/pnas.082682699; Garcia-Barrio M, 2002, J BIOL CHEM, V277, P30675, DOI 10.1074/jbc.M203187200; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIRLISH D, 1999, ANNU REV CELL DEV BI, V15, P607; Gite S, 1997, J BIOL CHEM, V272, P5305, DOI 10.1074/jbc.272.8.5305; GOOD PD, 1994, GENE, V151, P209, DOI 10.1016/0378-1119(94)90658-0; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; Grosshans H, 2000, GENE DEV, V14, P830; Grosshans H, 2001, J BIOL CHEM, V276, P46333, DOI 10.1074/jbc.M107141200; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hellmuth K, 2000, NUCLEIC ACIDS RES, V28, P4604, DOI 10.1093/nar/28.23.4604; HURT DJ, 1987, MOL CELL BIOL, V7, P1208, DOI 10.1128/MCB.7.3.1208; Iouk TL, 2001, MOL CELL BIOL, V21, P1260, DOI 10.1128/MCB.21.4.1260-1271.2001; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Lipowsky G, 1999, RNA, V5, P539, DOI 10.1017/S1355838299982134; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Mandal N, 1996, RNA, V2, P473; MANGROO D, 1995, J BIOL CHEM, V270, P12203, DOI 10.1074/jbc.270.20.12203; MANGROO D, 1995, J BACTERIOL, V177, P2858, DOI 10.1128/jb.177.10.2858-2862.1995; Milkereit P, 2003, J BIOL CHEM, V278, P4072, DOI 10.1074/jbc.M208898200; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Nathanson L, 2000, J BIOL CHEM, V275, P31559, DOI 10.1074/jbc.C000385200; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Sharma K, 1996, MOL CELL BIOL, V16, P294; SHEN WC, 1993, J BIOL CHEM, V268, P19436; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; VALLEN EA, 1992, J CELL BIOL, V117, P1277, DOI 10.1083/jcb.117.6.1277; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Wang CC, 2000, J BIOL CHEM, V275, P17180, DOI 10.1074/jbc.M001057200; Wang CC, 1999, J BIOL CHEM, V274, P16508, DOI 10.1074/jbc.274.23.16508; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	59	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32236	32245		10.1074/jbc.M302779200	http://dx.doi.org/10.1074/jbc.M302779200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794079	hybrid			2022-12-25	WOS:000184782100098
J	Bink, RJ; Habuchi, H; Lele, Z; Dolk, E; Joore, J; Rauch, GJ; Geisler, R; Wilson, SW; den Hertog, J; Kimata, K; Zivkovic, D				Bink, RJ; Habuchi, H; Lele, Z; Dolk, E; Joore, J; Rauch, GJ; Geisler, R; Wilson, SW; den Hertog, J; Kimata, K; Zivkovic, D			Heparan sulfate 6-O-sulfotransferase is essential for muscle development in zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC EXPRESSION; SIGNALING PATHWAY; II COLLAGEN; TOUT-VELU; CELL-TYPE; PROTEIN; GENE; PROTEOGLYCANS; MYOD; HEDGEHOG	Heparan sulfate proteoglycans function in development and disease. They consist of a core protein with attached heparan sulfate chains that are altered by a series of carbohydrate-modifying enzymes and sulfotransferases. Here, we report on the identification and characterization of a gene encoding zebrafish heparan sulfate 6-O-sulfotransferase (hs6st) that shows high homology to other heparan sulfate 6-O-sulfotransferases. When expressed as a fusion protein in cultured cells, the protein shows specific 6-O-sulfotransferase activity and preferentially acts on the iduronosyl N-sulfoglycosamine. In the developing embryo, hs6st is expressed in the brain, the somites, and the fins; the same structures that were affected upon morpholino-mediated functional knockdown. Morpholino injections significantly inhibited 6-O- but not 2-O-sulfation as assessed by HPLC. Morphants display disturbed somite specification independent of the somite oscillator mechanism and have impaired muscle differentiation. In conclusion, our results show that transfer of sulfate to specific positions on glycosaminoglycans is essential for muscle development.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Max Planck Inst Entwicklungsbiol, Abt Genet 3, D-72076 Tubingen, Germany	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Aichi Medical University; University of London; University College London; Max Planck Society	Zivkovic, D (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	dana@niob.knaw.nl	Geisler, Robert/K-6201-2013; Wilson, Stephen W/B-9404-2008; Zebrafish, UCL/A-3125-2009	Geisler, Robert/0000-0002-3909-8311; Wilson, Stephen W/0000-0002-8557-5940; Lele, Zsolt/0000-0003-2672-144X; Joore, Jos/0000-0002-2744-4862	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055377] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 R01 DK55377-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Becker CG, 2002, J NEUROSCI, V22, P842, DOI 10.1523/JNEUROSCI.22-03-00842.2002; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Binari RC, 1997, DEVELOPMENT, V124, P2623; Blagden CS, 1997, GENE DEV, V11, P2163, DOI 10.1101/gad.11.17.2163; BLAIR SS, 2001, SCI STKE, V101, P1; Braat AK, 2001, GENESIS, V30, P183, DOI 10.1002/gene.1060; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Bulow HE, 2002, P NATL ACAD SCI USA, V99, P6346, DOI 10.1073/pnas.092128099; Concordet JP, 1996, DEVELOPMENT, V122, P2835; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Coutelle O, 2001, DEV BIOL, V236, P136, DOI 10.1006/dbio.2001.0193; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; Devoto SH, 1996, DEVELOPMENT, V122, P3371; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Durbin L, 2000, DEVELOPMENT, V127, P1703; EKKER M, 1992, DEVELOPMENT, V116, P1001; Ekker SC, 2001, GENESIS, V30, P89, DOI 10.1002/gene.1038; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FJOSE A, 1992, MECH DEVELOP, V39, P51, DOI 10.1016/0925-4773(92)90025-F; FLORINI JR, 1989, AM J PHYSIOL, V256, pC701, DOI 10.1152/ajpcell.1989.256.4.C701; Fuentealba L, 1999, J BIOL CHEM, V274, P37876, DOI 10.1074/jbc.274.53.37876; Geisler R, 1999, NAT GENET, V23, P86, DOI 10.1038/12692; Giraldez AJ, 2002, DEV CELL, V2, P667, DOI 10.1016/S1534-5807(02)00180-6; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haddon C, 1998, DEVELOPMENT, V125, P359; Halfter W, 1997, J COMP NEUROL, V383, P1; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Hirsinger E, 1998, MOL CELL ENDOCRINOL, V140, P83, DOI 10.1016/S0303-7207(98)00033-1; Holley SA, 2000, GENE DEV, V14, P1678; Holley SA, 2002, DEVELOPMENT, V129, P1175; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; Irie A, 2002, DEVELOPMENT, V129, P61; ITOH K, 1994, DEVELOPMENT, V120, P2703; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; Lele Z, 2002, DEVELOPMENT, V129, P3281; Lele Z, 2001, GENESIS, V30, P190, DOI 10.1002/gene.1063; Lele Z, 1997, MECH DEVELOP, V61, P89, DOI 10.1016/S0925-4773(96)00626-0; Lewis KE, 1999, DEV BIOL, V216, P469, DOI 10.1006/dbio.1999.9519; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; Muller M, 1996, DEVELOPMENT, V122, P2071; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nomura-Kitabayashi A, 2002, DEVELOPMENT, V129, P2473; Oates AC, 2002, DEVELOPMENT, V129, P2929; Olguin H, 2001, DEV DYNAM, V221, P106, DOI 10.1002/dvdy.1129; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Sawada A, 2000, DEVELOPMENT, V127, P1691; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Van der Sar AM, 2002, DEV DYNAM, V223, P292, DOI 10.1002/dvdy.10059; Walz A, 1997, DEVELOPMENT, V124, P2421; WANG LS, 1992, NEURON, V8, P701, DOI 10.1016/0896-6273(92)90091-Q; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Westerfield M, 1994, ZEBRAFISH BOOK; Westin J, 1997, DEV GENES EVOL, V207, P51, DOI 10.1007/s004270050091; Xu YF, 2000, DEV DYNAM, V219, P201, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1043>3.3.CO;2-9; YAN YL, 1995, DEV DYNAM, V203, P363, DOI 10.1002/aja.1002030308; Yip GW, 2002, DEVELOPMENT, V129, P2109; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200	81	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31118	31127		10.1074/jbc.M213124200	http://dx.doi.org/10.1074/jbc.M213124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782624	hybrid, Green Published			2022-12-25	WOS:000184658800089
J	Crawford, RM; Jovanovic, S; Budas, GR; Davies, AM; Lad, H; Wenger, RH; Robertson, KA; Roy, DJ; Ranki, HJ; Jovanovic, A				Crawford, RM; Jovanovic, S; Budas, GR; Davies, AM; Lad, H; Wenger, RH; Robertson, KA; Roy, DJ; Ranki, HJ; Jovanovic, A			Chronic mild hypoxia protects heart-derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the SUR2A subunit of the ATP-sensitive K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREVENTS MEMBRANE DEPOLARIZATION; MITOGEN-ACTIVATED PROTEIN; BINDING-PROTEIN; OXYGEN-TENSION; FACTOR-I; KINASE; TRANSCRIPTION; ADAPTATION; INDUCTION; REQUIRES	Chronic exposure to lower oxygen tension may increase cellular resistance to different types of acute metabolic stress. Here, we show that 24-h-long exposure to slightly decreased oxygen tension ( partial pressure of oxygen (PO2) of 100 mm Hg instead of normal 144 mm Hg) confers resistance against acute hypoxia/reoxygenation-induced Ca2+ loading in heart-derived H9c2 cells. The number of ATP-sensitive K+ (K-ATP) channels were increased in cells exposed to PO2 = 100 mm Hg relative to cells exposed to PO2 = 144 mm Hg. This was due to an increase in transcription of SUR2A, a K-ATP channel regulatory subunit, but not Kir6.2, a K-ATP channel poreforming subunit. PO2 = 100 mm Hg also increased the SUR2 gene promoter activity. Experiments with cells overexpressing wild type of hypoxia-inducible factor (HIF)-1alpha and dominant negative HIF-1beta suggested that the HIF-1-signaling pathway did not participate in observed PO2-mediated regulation of SUR2A expression. On the other hand, NADH inhibited the effect of PO2 = 100 mm Hg but not the effect of PO2 = 20 mm Hg. LY 294002 and PD 184 352 prevented PO2-mediated regulation of K-ATP channels, whereas rapamycin was without any effect. HMR 1098 inhibited the cytoprotective effect of PO2 = 100 mm Hg, and a decrease of PO2 from 144 to 100 mm Hg did not change the expression of any other gene, including those involved in stress and hypoxic response, as revealed by Affymetrix high density oligonucleotide arrays. We conclude that slight hypoxia activates HIF-1alpha-independent signaling cascade leading to an increase in SUR2A protein, a higher density of K-ATP channels, and a cellular phenotype more resistant to acute metabolic stress.	Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany; Univ Edinburgh, Scottish Ctr Genom Technol & Informat, Edinburgh EH9 1QH, Midlothian, Scotland	University of Dundee; Leipzig University; University of Edinburgh	Jovanovic, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland.	a.jovanovic@dundee.ac.uk	Wenger, Roland H./B-7953-2009; Jovanovic, Aleksandar/A-4482-2008	Wenger, Roland H./0000-0001-7592-4839; Jovanovic, Aleksandar/0000-0002-1214-9318	Biotechnology and Biological Sciences Research Council [C15048] Funding Source: Medline; British Heart Foundation [PG/02/091/14227] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Ashouri K., 1994, Ethnicity and Disease, V4, P82; Austad SN, 1996, EXP GERONTOL, V31, P453, DOI 10.1016/0531-5565(95)02068-3; Bruzzone S, 2001, FASEB J, V15, P10; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chandrasekar B, 1999, CIRCULATION, V99, P427, DOI 10.1161/01.CIR.99.3.427; Chun YS, 2000, EUR J BIOCHEM, V267, P4198, DOI 10.1046/j.1432-1327.2000.01453.x; Clerk A, 2002, BIOCHEM J, V368, P101, DOI 10.1042/BJ20021083; Crawford RM, 2002, EMBO J, V21, P3936, DOI 10.1093/emboj/cdf388; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Ekhterae D, 1999, CIRC RES, V85, pE70; Englert HC, 2001, J MED CHEM, V44, P1085, DOI 10.1021/jm000985v; Graven KK, 1999, BBA-GENE STRUCT EXPR, V1447, P208, DOI 10.1016/S0167-4781(99)00118-9; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Hutchison SJ, 1997, JAMA-J AM MED ASSOC, V278, P1661, DOI 10.1001/jama.1997.03550200037027; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic S, 2003, AM J RESP CELL MOL, V28, P363, DOI 10.1165/rcmb.2002-0101OC; Jovanovic S, 2001, BIOCHEM BIOPH RES CO, V282, P1098, DOI 10.1006/bbrc.2001.4691; Jovanovic S, 2001, INT J MOL MED, V7, P639; Kaluz S, 2002, CANCER RES, V62, P4469; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Laderoute KR, 2002, MOL CELL BIOL, V22, P2515, DOI 10.1128/MCB.22.8.2515-2523.2002; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lorenz E, 1999, J MOL CELL CARDIOL, V31, P425, DOI 10.1006/jmcc.1998.0876; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Oeckler RA, 2003, CIRC RES, V92, P23, DOI 10.1161/01.RES.0000051860.84509.CE; Ranki HJ, 2002, J AM COLL CARDIOL, V40, P367, DOI 10.1016/S0735-1097(02)01947-2; Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8; Ranki HJ, 2001, J AM COLL CARDIOL, V38, P906, DOI 10.1016/S0735-1097(01)01428-0; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Rustin P, 1996, J BIOL CHEM, V271, P14785, DOI 10.1074/jbc.271.25.14785; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SETA KA, 2002, SCI STKE, V146, pRE11, DOI DOI 10.1126/STKE.2002.146.RE11; Silverman HS, 1997, CIRC RES, V80, P699, DOI 10.1161/01.RES.80.5.699; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Tanaki K, 2001, J AM COLL CARDIOL, V37, P676, DOI 10.1016/S0735-1097(00)01123-2; Teng XW, 2002, CIRC RES, V90, P125, DOI 10.1161/hh0202.103647; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WHITE RL, 1993, BIOPHYS J, V65, P196, DOI 10.1016/S0006-3495(93)81058-0	47	76	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31444	31455		10.1074/jbc.M303051200	http://dx.doi.org/10.1074/jbc.M303051200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12791696	Green Accepted, hybrid			2022-12-25	WOS:000184658800128
J	Master, Z; Tran, J; Bishnoi, A; Chen, SH; Ebos, JML; Van Slyke, P; Kerbel, RS; Dumont, DJ				Master, Z; Tran, J; Bishnoi, A; Chen, SH; Ebos, JML; Van Slyke, P; Kerbel, RS; Dumont, DJ			Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; CELL-ADHESION; SH3 DOMAINS; BCR-ABL; PROCESSIVE PHOSPHORYLATION; P21-ACTIVATED KINASE; NEGATIVE REGULATION; ADAPTER PROTEIN; DOCKING PROTEIN	Dok-R, also known as Dok-2/FRIP, belongs to the DOK family of signaling molecules that become tyrosine-phosphorylated by several different receptor and cytoplasmic tyrosine kinases. Tyrosine phosphorylation of DOK proteins establishes high affinity binding sites for other signaling molecules leading to activation of a signaling cascade. Here we show that Dok-R associates with c-Abl directly via a constitutive SH3-mediated interaction and that this binding requires a PMMP motif in the proline-rich tail of Dok-R. The Dok-R-Abl interaction is further enhanced by an active c-Abl kinase, which requires the presence of its SH2 domain. Interaction of Dok-R with c-Abl also results in an increase in c-Abl tyrosine phosphorylation and kinase activity. Furthermore, we demonstrate that this increase in kinase activity correlates with a concomitant increase in c-Abl-mediated biological activity as measured by the formation of actin microspikes. Our data are the first to demonstrate that Dok-R and c-Abl interact in both a constitutive and inducible fashion and that Dok-R influences the intracellular kinase and biological activity of c-Abl.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Dumont, DJ (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, 2075 Bayview Ave,Res Bldg,S Wing,Room 227, Toronto, ON M4N 3M5, Canada.	dan.dumont@swchsc.on.ca		Ebos, John/0000-0002-7175-9044; Master, Zubin/0000-0002-3462-4546				Amoui M, 2000, CELL SIGNAL, V12, P637, DOI 10.1016/S0898-6568(00)00107-8; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Cong F, 1999, MOL CELL BIOL, V19, P8314; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; DRUKER B, 1992, BLOOD, V79, P2215; Ebos JML, 2002, MOL CANCER RES, V1, P89; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Howe AK, 2002, J BIOL CHEM, V277, P38121, DOI 10.1074/jbc.M205379200; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 2003, MOL CELL BIOL, V23, P2658, DOI 10.1128/MCB.23.8.2658-2668.2003; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Lambrechts A, 2000, J BIOL CHEM, V275, P36143, DOI 10.1074/jbc.M006274200; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Madhani HD, 2001, CELL, V106, P9, DOI 10.1016/S0092-8674(01)00422-6; MASTER Z, 2001, EMBO J; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Skourides PA, 1999, ONCOGENE, V18, P1165, DOI 10.1038/sj.onc.1202407; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; van der Heyden MA, 1997, BBA-MOL CELL RES, V1359, P211, DOI 10.1016/S0167-4889(97)00105-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1988, ONCOGENE RES, V3, P293; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30170	30179		10.1074/jbc.M301339200	http://dx.doi.org/10.1074/jbc.M301339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777393	hybrid			2022-12-25	WOS:000184507000095
J	Patzlaff, JS; van der Heide, T; Poolman, B				Patzlaff, JS; van der Heide, T; Poolman, B			The ATP/Substrate stoichiometry of the ATP-binding cassette (ABC) transporter OpuA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOCOCCUS-LACTIS; CATALYTIC CYCLE; P-GLYCOPROTEIN; DRUG TRANSPORT; HYDROLYSIS; RECONSTITUTION; MECHANISM; SYSTEM; EXPRESSION; PROTEIN	ATP-binding cassette (ABC) transport proteins catalyze the translocation of substrates at the expense of hydrolysis of ATP, but the actual ATP/substrate stoichiometry is still controversial. In the osmoregulated ABC transporter (OpuA) from Lactococcus lactis, ATP hydrolysis and substrate translocation are tightly coupled, and the activity of right-side-in and inside-out reconstituted OpuA can be determined accurately. Although the ATP/ substrate stoichiometry determined from the uptake of glycine betaine and intravesicular ATP hydrolysis tends to increase with decreasing average size of the liposomes, the data from inside-out reconstituted OpuA indicate that the mechanistic stoichiometry is 2. Moreover, the two orientations of OpuA in proteoliposomes allowed possible contributions from substrate ( glycine betaine) inhibition on the trans-side of the membrane and inhibition by ADP to be determined. Here we show that OpuA is not inhibited by up to 400 mM glycine betaine on the trans-side of the membrane. ADP is an inhibitor, but accumulation of ADP was negligible in the assays with inside-out-oriented OpuA, and potential effects of the ATP/ ADP ratio on the ATP/ substrate stoichiometry determinations could be eliminated.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@chem.rug.nl	Poolman, Bert/D-1882-2012					Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AUSSEL C, 1989, J CELL PHYSIOL, V141, P103, DOI 10.1002/jcp.1041410116; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; Glaasker E, 1998, J BACTERIOL, V180, P5540, DOI 10.1128/JB.180.21.5540-5546.1998; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Maresh GA, 2001, LIFE SCI, V69, P67, DOI 10.1016/S0024-3205(01)01093-1; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MUIR M, 1985, J BACTERIOL, V163, P1237, DOI 10.1128/JB.163.3.1237-1242.1985; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; Shapiro AB, 1998, EUR J BIOCHEM, V254, P189, DOI 10.1046/j.1432-1327.1998.2540189.x; Van der Heide T, 2000, J BACTERIOL, V182, P203, DOI 10.1128/JB.182.1.203-206.2000; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2002, EMBO REP, V3, P938, DOI 10.1093/embo-reports/kvf201; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Verheul A, 1997, J BACTERIOL, V179, P6979, DOI 10.1128/jb.179.22.6979-6985.1997	31	100	103	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29546	29551		10.1074/jbc.M304796200	http://dx.doi.org/10.1074/jbc.M304796200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766159	hybrid, Green Published			2022-12-25	WOS:000184507000021
J	Xu, HY; Dembski, M; Yang, Q; Yang, D; Moriarty, A; Tayber, O; Chen, H; Kapeller, R; Tartaglia, LA				Xu, HY; Dembski, M; Yang, Q; Yang, D; Moriarty, A; Tayber, O; Chen, H; Kapeller, R; Tartaglia, LA			Dual specificity mitogen-activated protein (MAP) kinase phosphatase-4 plays a potential role in insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PEPCK GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHATASE-1B; MOLECULAR-CLONING; GLUCOSE-TRANSPORT; TRANSCRIPTION; INHIBITION; ALPHA; TRANSFECTION	Insulin is the key hormone that controls glucose homeostasis. Dysregulation of insulin function causes diabetes mellitus. Among the two major forms of diabetes, type 2 diabetes accounts for over 90% of the affected population. The incidence of type 2 diabetes is highly related to obesity. To find novel proteins potentially involved in obesity-related insulin resistance and type 2 diabetes, a functional expression screen was performed to search for genes that negatively regulate insulin signaling. Specifically, a reporter system comprised of the PEPCK promoter upstream of alkaline phosphatase was used in a hepatocyte cell-based assay to screen an expression cDNA library for genes that reverse insulin-induced repression of PEPCK transcription. The cDNA library used in this study was derived from the white adipose tissue of ob/ob mice, which are highly insulin-resistant. The mitogen-activated dual specificity protein kinase phosphatase 4 (MKP-4) was identified as a candidate gene in this screen. Here we show that MKP-4 is expressed in insulin-responsive tissues and that the expression levels are up-regulated in obese insulin-resistant rodent models. Heterologous expression of MKP-4 in preadipocytes significantly blocked insulin-induced adipogenesis, and overexpression of MKP-4 in adipocytes inhibited insulin-stimulated glucose uptake. Our data suggest that MKP-4 negatively regulates insulin signaling and, consequently, may contribute to the pathogenesis of insulin resistance.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Xu, HY (corresponding author), Millennium Pharmaceut Inc, 75 Sidney St,2288B, Cambridge, MA 02139 USA.							Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; BEALE EG, 1985, J BIOL CHEM, V260, P748; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BENNETT PH, 1990, DIABETES MELLITUS TH, P357; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; Dickinson RJ, 2002, BIOCHEM J, V364, P145, DOI 10.1042/bj3640145; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; LEBOVITZ HE, 2000, DIABETES MELLITUS FU, P769; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/diacare.13.3.327; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Sutherland C, 1996, PHILOS T ROY SOC B, V351, P191, DOI 10.1098/rstb.1996.0016; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Xu HY, 1999, J BIOL CHEM, V274, P26287, DOI 10.1074/jbc.274.37.26287; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	27	52	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30187	30192		10.1074/jbc.M302010200	http://dx.doi.org/10.1074/jbc.M302010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12777378	hybrid			2022-12-25	WOS:000184507000097
J	Yaguchi, S; Tsurugi, K				Yaguchi, S; Tsurugi, K			Gts1p activates SNF1-dependent derepression of HSP104 and TPS1 in the stationary phase of yeast growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; METABOLIC OSCILLATIONS; CONTINUOUS-CULTURE; IN-VIVO; KINASE; THERMOTOLERANCE; EXPRESSION; TRANSCRIPTION	We previously reported that the GTS1 product, Gts1p, plays an important role in the regulation of heat tolerance of yeast under glucose-limited conditions in either batch or continuous culture. Here we show that heat tolerance was decreased in GTS1-deleted and increased in GTS1-overexpressing cells under glucose-derepressed conditions during the batch culture and that the disruption of SNF1, a transcriptional activator of glucose-repressible genes, diminished this effect of GTS1. Intracellular levels of Hsp104 and trehalose, which were reportedly required for the acquisition of heat tolerance in the stationary phase of cell growth, were affected in both GTS1 mutants roughly in proportion to the gene dosage of GTS1, whereas those of other Hsps were less affected. The mRNA levels of genes for Hsp104 and trehalose-6-phosphate synthase 1 changed as a function of GTS1 gene dosage. The Q-rich domain of Gts1p fused with the DNA-binding domain of LexA activated the transcription of the reporter gene LacZ, and Gts1p lacking the Q-rich domain lost the activation activity of HSP104 and TPS1. Furthermore, Gts1p bound to subunits of Snf1 kinase, whereas it did not bind to DNA. Therefore, we suggested that GTS1 increases heat tolerance by mainly activating Snf1 kinase-dependent derepression of HSP104 and TPS1 in the stationary phase of yeast growth.	Univ Yamanashi, Dept Biochem 2, Fac Med, Yamanashi 4093898, Japan	University of Yamanashi	Tsurugi, K (corresponding author), Univ Yamanashi, Dept Biochem 2, Fac Med, 1110 Shimokato, Yamanashi 4093898, Japan.	ktsurugi@res.yamanashi-med.ac.jp						BARNES CA, 1990, J BACTERIOL, V172, P4352, DOI 10.1128/jb.172.8.4352-4358.1990; Blader IJ, 1999, MOL BIOL CELL, V10, P581, DOI 10.1091/mbc.10.3.581; Bossier P, 1997, YEAST, V13, P717, DOI 10.1002/(SICI)1097-0061(19970630)13:8<717::AID-YEA132>3.0.CO;2-2; Conlan RS, 1999, J BIOL CHEM, V274, P205, DOI 10.1074/jbc.274.1.205; Elliott B, 1996, GENETICS, V144, P923; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Escher D, 2000, MOL CELL BIOL, V20, P2774, DOI 10.1128/MCB.20.8.2774-2782.2000; Garrels JI, 1997, ELECTROPHORESIS, V18, P1347, DOI 10.1002/elps.1150180810; Goldstein A, 1975, Methods Enzymol, V42, P504; Grably MR, 2002, MOL MICROBIOL, V44, P21, DOI 10.1046/j.1365-2958.2002.02860.x; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hazell BW, 1997, FEBS LETT, V414, P353, DOI 10.1016/S0014-5793(97)01033-8; HUBBARD EJA, 1992, GENETICS, V130, P71; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Keaveney M, 1999, GENES CELLS, V4, P197, DOI 10.1046/j.1365-2443.1999.00255.x; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kuchin S, 2000, P NATL ACAD SCI USA, V97, P7916, DOI 10.1073/pnas.140109897; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; Liu WD, 2002, EUR J BIOCHEM, V269, P3560, DOI 10.1046/j.1432-1033.2002.03047.x; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MITSUI K, 1994, MOL CELL BIOL, V14, P5569, DOI 10.1128/MCB.14.8.5569; Ozcan S, 1997, YEAST, V13, P127; PIPER P, 1996, YEAST STRESS RESPONS, P75; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; Saito T, 2002, J BIOL CHEM, V277, P33624, DOI 10.1074/jbc.M201909200; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; Tonozuka H, 2001, J BIOCHEM-TOKYO, V130, P589, DOI 10.1093/oxfordjournals.jbchem.a003023; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Uno T, 2002, CHRONOBIOL INT, V19, P361, DOI 10.1081/CBI-120002916; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wang JQ, 2001, FEBS LETT, V489, P81, DOI 10.1016/S0014-5793(01)02083-X; Wang JQ, 2000, FEMS MICROBIOL LETT, V189, P9, DOI 10.1111/j.1574-6968.2000.tb09198.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; Xiao H, 1998, J BIOL CHEM, V273, P22873, DOI 10.1074/jbc.273.36.22873; Yaguchi S, 1996, BIOCHEM BIOPH RES CO, V218, P234, DOI 10.1006/bbrc.1996.0041; Yaguchi S, 2000, FEMS MICROBIOL LETT, V187, P179, DOI 10.1016/S0378-1097(00)00198-1	52	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29760	29768		10.1074/jbc.M301441200	http://dx.doi.org/10.1074/jbc.M301441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12782635	hybrid			2022-12-25	WOS:000184507000047
J	Samoto, H; Shimizu, E; Matsuda-Honjyo, Y; Saito, R; Nakao, S; Yamazaki, M; Furuyama, S; Sugiya, H; Sodek, J; Ogata, Y				Samoto, H; Shimizu, E; Matsuda-Honjyo, Y; Saito, R; Nakao, S; Yamazaki, M; Furuyama, S; Sugiya, H; Sodek, J; Ogata, Y			Prostaglandin E-2 stimulates bone sialoprotein (BSP) expression through cAMP and fibroblast growth factor 2 response elements in the proximal promoter of the rat BSP gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HUMAN GINGIVAL FIBROBLASTS; OSTEOBLASTIC CELL-LINE; E RECEPTOR SUBTYPES; INVERTED CCAAT BOX; PARATHYROID-HORMONE; FORMATION INVITRO; MARROW CELLS; TATA BOX; KAPPA-B	Bone sialoprotein (BSP), an early marker of osteoblast differentiation, has been implicated in the nucleation of hydroxyapatite during de novo bone formation. Prostaglandin E-2 (PGE(2)) has anabolic effects on proliferation and differentiation of osteoblasts via diverse signal transduction systems. Because PGE(2) increases the proportion of functional osteoblasts in fetal rat calvarial cell cultures, we investigated the regulation of BSP, as an osteoblastic marker, by PGE(2). Treatment of rat osteosarcoma UMR 106 cells with 3 muM, 300 nM, and 30 nM PGE(2) increased the steady state levels of BSP mRNA about 2.7-, 2.5-, and 2.4-fold after 12 h. From transient transfection assays, the constructs including the promoter sequence of nucleotides (nt) -116 to +60 (pLUC3) were found to enhance transcriptional activity 3.8- and 2.2-fold treated with 3 muM and 30 nM PGE(2) for 12 h. 2-bp mutations were made in an inverted CCAAT box (between nt -50 and -46), a cAMP response element (CRE; between nt -75 and -68), a fibroblast growth factor 2 response element (FRE; nt -92 to -85), and a pituitary-specific transcription factor-1 motif (between nt -111 and -105) within pLUC3 and pLUC7 constructs. Transcriptional stimulation by PGE(2) was almost completed abrogated in constructs that included 2-bp mutations in either the CRE and FRE. In gel shift analyses an increased binding of nuclear extract components to double-stranded oligonucleotide probes containing CRE and FRE was observed following treatment with PGE(2). These studies show that PGE(2) induces BSP transcription in UMR 106 cells through juxtaposed CRE and FRE elements in the proximal promoter of the BSP gene.	Nihon Univ, Dept Periodontol, Sch Dent Matsudo, Chiba 2718587, Japan; Nihon Univ, Dept Endodont, Sch Dent Matsudo, Chiba 2718587, Japan; Nihon Univ, Dept Pharmacol, Sch Dent Matsudo, Chiba 2718587, Japan; Nihon Univ, Dept Physiol, Sch Dent Matsudo, Chiba 2718587, Japan; Nihon Univ, Res Inst Oral Sci, Sch Dent Matsudo, Chiba 2718587, Japan; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Dent, Canadian Inst Hlth, Res Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada	Nihon University; Nihon University; Nihon University; Nihon University; Nihon University; University of Toronto; University of Toronto	Ogata, Y (corresponding author), Nihon Univ, Dept Periodontol, Sch Dent Matsudo, Chiba 2718587, Japan.							AKATSU T, 1989, J BONE MINER RES, V4, P29; Benson MD, 2000, J BIOL CHEM, V275, P13907, DOI 10.1074/jbc.275.18.13907; Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALL PM, 1994, J BONE MINER RES, V9, P1935; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; Gruber R, 2000, BIOCHEM BIOPH RES CO, V270, P1080, DOI 10.1006/bbrc.2000.2573; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAKEDA Y, 1985, J BIOCHEM, V97, P97, DOI 10.1093/oxfordjournals.jbchem.a135072; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006-291X(91)92015-C; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; Ibrahim T, 2000, CLIN EXP METASTAS, V18, P253, DOI 10.1023/A:1006754605901; Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097-4644(19990401)73:1<36::AID-JCB5>3.3.CO;2-6; Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KERR JM, 1993, GENOMICS, V17, P408, DOI 10.1006/geno.1993.1340; Kim RH, 1999, CANCER RES, V59, P565; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; Kozawa O, 1998, BONE, V22, P355, DOI 10.1016/S8756-3282(97)00293-7; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Millet I, 1998, J BONE MINER RES, V13, P1092, DOI 10.1359/jbmr.1998.13.7.1092; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; Niisato N, 1996, BIOCHEM PHARMACOL, V52, P1015, DOI 10.1016/0006-2952(96)00417-0; Ogata Y, 2000, MATRIX BIOL, V19, P395, DOI 10.1016/S0945-053X(00)00085-8; OGATA Y, 1995, EUR J BIOCHEM, V230, P183; Ogata Y, 1997, J CELL BIOCHEM, V65, P501, DOI 10.1002/(SICI)1097-4644(19970615)65:4<501::AID-JCB6>3.0.CO;2-S; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; Opas EE, 2000, BONE, V26, P27, DOI 10.1016/S8756-3282(99)00235-5; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; PITARU S, 1993, J BONE MINER RES, V8, P919; RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1654, DOI 10.1210/endo-126-3-1654; RAISZ LG, 1993, MOL ENDOCRINOL, V7, P17, DOI 10.1210/me.7.1.17; Sakuma Y, 2000, INFECT IMMUN, V68, P6819, DOI 10.1128/IAI.68.12.6819-6825.2000; Samoto H, 2002, J CELL BIOCHEM, V87, P313, DOI 10.1002/jcb.10301; SCUTT A, 1995, J BONE MINER RES, V10, P474; Shimizu E, 2002, J CELL BIOCHEM, V86, P35, DOI 10.1002/jcb.10194; Shimizu-Sasaki K, 2001, J BIOL CHEM, V276, P5459, DOI 10.1074/jbc.M008971200; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; WATABE A, 1993, J BIOL CHEM, V268, P20175; Weinreb M, 2001, BONE, V28, P275, DOI 10.1016/S8756-3282(00)00447-6; Yamauchi M, 1996, MATRIX BIOL, V15, P119, DOI 10.1016/S0945-053X(96)90153-5; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399	63	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28659	28667		10.1074/jbc.M300671200	http://dx.doi.org/10.1074/jbc.M300671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12766167	hybrid			2022-12-25	WOS:000184421100040
J	Legate, KR; Andrews, DW				Legate, KR; Andrews, DW			The beta-subunit of the signal recognition particle receptor is a novel GTP-binding protein without intrinsic GTPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; GUANINE-NUCLEOTIDE BINDING; H-RAS P21; ADP-RIBOSYLATION; ALPHA-SUBUNIT; NASCENT PREPROLACTIN; RIBOSOME; SEQUENCE; DOMAIN; POLYPEPTIDE	The beta-subunit of the signal recognition particle receptor (SRbeta), a member of the Ras family of small molecular weight GTPases, is involved in the targeting of nascent polypeptide chains to the protein translocation machinery in the endoplasmic reticulum membrane. We purified SRbeta from an expressing strain of Escherichia coli and investigated the properties of the isolated GTPase. We find that, unlike other Ras family GTPases, most SRbeta purifies bound to GTP, and SRbeta-bound GTP is not easily exchanged with solution GTP. SRbeta possesses no detectable GTPase activity. Although a stable interaction between SRbeta and ribosomes is observed, SRbeta is not stimulated to hydrolyze GTP when incubated with ribosomes or ribosome-nascent chains. A GTPase mutant harboring a mutation in a region predicted to be functionally important, based on observations made in related GTPases, binds GTP with faster kinetics and appears to be a less stable protein but otherwise displays similar properties to the wild-type SRbeta GTPase. Our results demonstrate that as an isolated GTPase, SRbeta functions differently from the Arf- and Ras-type GTPases that it is most closely related to by sequence.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Legate, Kyle/0000-0003-3243-579X; Andrews, David/0000-0002-9266-7157				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fulga TA, 2001, EMBO J, V20, P2338, DOI 10.1093/emboj/20.9.2338; HUGHES MJ, 1996, BIOTECHNIQUES, V20, P192; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; Koyama S, 2001, METHOD ENZYMOL, V332, P127; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; Legate KR, 2000, J BIOL CHEM, V275, P27439; Legate KR, 2001, BIOCHEM CELL BIOL, V79, P593, DOI 10.1139/bcb-79-5-593; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARSH RC, 1975, J BIOL CHEM, V250, P8344; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; Millman JS, 1997, CELL, V89, P673, DOI 10.1016/S0092-8674(00)80248-2; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POE M, 1985, J BIOL CHEM, V260, P3906; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Schwartz T, 2003, CELL, V112, P793, DOI 10.1016/S0092-8674(03)00161-2; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHAPIRO AD, 1993, J BIOL CHEM, V268, P6925; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wang Y, 2001, METHOD ENZYMOL, V332, P139; WEISS O, 1989, J BIOL CHEM, V264, P21066; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	43	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27712	27720		10.1074/jbc.M302158200	http://dx.doi.org/10.1074/jbc.M302158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12759365	hybrid			2022-12-25	WOS:000184242700049
J	Akdis, M; Trautmann, A; Klunker, S; Daigle, I; Kucuksezer, UC; Deglmann, W; Disch, R; Blaser, K; Akdis, CA				Akdis, M; Trautmann, A; Klunker, S; Daigle, I; Kucuksezer, UC; Deglmann, W; Disch, R; Blaser, K; Akdis, CA			T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells	FASEB JOURNAL			English	Article						activation-induced cell death; atopic dermatitis; cytokines; T cells; Th1/Th2	ACTIVATION-INDUCED APOPTOSIS; LYMPHOCYTE-ASSOCIATED ANTIGEN; HECA-452 EPITOPE; IN-SITU; DEATH; EXPRESSION; FAS; DERMATITIS; INDUCTION; RECEPTOR	T cells constitute a large population of cellular infiltrate in atopic/allergic inflammation and a dysregulated, Th2-biased peripheral immune response appears to be an important pathogenetic factor. In atopic dermatitis, circulating cutaneous lymphocyte-associated antigen-bearing (CLA(+)) CD45RO(+) T cells with skin-specific homing property represent an activated memory/effector T cell subset. They express high levels of Fas and Fas ligand and undergo activation-induced apoptosis. The freshly purified (CLA(+)) CD45RO(+) T cells of atopic individuals display distinct features of in vivo-triggered apoptosis such as procaspase degradation and active caspase-8 formation. In particular, the Th1 compartment of activated memory/effector T cells selectively undergoes activation-induced cell death, skewing the immune response toward surviving Th2 cells in atopic dermatitis patients. The apoptosis of circulating memory/effector T cells was confined to atopic individuals whereas non-atopic patients such as psoriasis, intrinsic-type asthma, contact dermatitis, intrinsic type of atopic dermatitis, bee venom allergic patients, and healthy controls showed no evidence for enhanced T cell apoptosis in vivo. These results define a novel mechanism for peripheral Th2 response in atopic diseases.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Istanbul Univ, Expt Med Res Inst, TR-34280 Istanbul, Turkey; Clin Dermatol & Allergy, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; Istanbul University	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020; kucuksezer, umut/AAD-5168-2020	Akdis, Cezmi/0000-0001-8020-019X; 				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Akdis CA, 2000, FASEB J, V14, P1666; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 1999, J IMMUNOL, V163, P466; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Belaud-Rotureau MA, 1999, CELL DEATH DIFFER, V6, P788, DOI 10.1038/sj.cdd.4400552; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hunger RE, 1999, BRIT J DERMATOL, V141, P565; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Ledru E, 1998, J IMMUNOL, V160, P3194; Li XC, 2000, J IMMUNOL, V164, P1193, DOI 10.4049/jimmunol.164.3.1193; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MULLER G, 1994, J CLIN INVEST, V94, P1799, DOI 10.1172/JCI117528; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ng TTC, 1997, J IMMUNOL, V158, P2984; Norris DA, 1997, APOPTOSIS, V2, P136, DOI 10.1023/A:1026456229688; PICKER LJ, 1990, AM J PATHOL, V136, P1053; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; SHYRTE J, 1995, NATURE, V373, P444; Stoll S, 1998, EUR J IMMUNOL, V28, P3231, DOI 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Trautmann A, 2001, TRENDS IMMUNOL, V22, P530, DOI 10.1016/S1471-4906(01)02004-X; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; Yawalkar N, 2000, EUR J IMMUNOL, V30, P491, DOI 10.1002/1521-4141(200002)30:2<491::AID-IMMU491>3.3.CO;2-8; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	55	134	147	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1026	1035		10.1096/fj.02-1070com	http://dx.doi.org/10.1096/fj.02-1070com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773485				2022-12-25	WOS:000183818000006
J	Pakneshan, P; Xing, RHM; Rabbani, SA				Pakneshan, P; Xing, RHM; Rabbani, SA			Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo	FASEB JOURNAL			English	Article						urokinase plasminogen activator; CpG dinucleotides; MSP	UROKINASE PLASMINOGEN-ACTIVATOR; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; BREAST-CANCER; EXPRESSION; RECEPTOR; HYPOMETHYLATION; CELLS; METASTASIS; CARCINOMAS	Urokinase plasminogen activator (uPA) promotes tumor invasion and metastasis in several malignancies including prostate cancer, one of the most commonly detected male cancers that result in a high incidence of mortality. In the present study we have examined the differential regulation of uPA gene expression in different stages of prostate cancer by DNA methylation. We determined levels of uPA expression in normal prostate epithelial cells (PrEC) and in hormone-responsive (LNCaP) and -insensitive (PC-3) prostate cancer cell lines. We found that uPA is expressed only in the highly invasive PC-3 cells where the uPA promoter is unmethylated. The lack of uPA expression in PrEC and LNCaP cells, where uPA promoter is highly methylated, is due to suppression of uPA gene transcription by DNA methylation. Treatment of LNCaP cells with 5'-azacytidine, a potent demethylating agent, resulted in induction of uPA mRNA expression, uPA activity, and higher invasive capacity in vitro. Additionally, a marked increase in tumor volume was observed after inoculation of these cells into the flank of male BALB/c (nu/nu) mice. Collectively these studies have demonstrated that DNA methylation is the underlying molecular mechanism responsible for uPA gene silencing in normal and early stages of prostate cancer, which has a direct effect on tumor cell invasion and growth in vitro and in vivo.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, 687 Pine Ave W,Room H4-67, Montreal, PQ H3A 1A1, Canada.	shafaat.rabbani@mcgill.ca		rabbani, shafaat/0000-0001-5594-3899				Ahuja N, 1997, CANCER RES, V57, P3370; Altschmied J, 1997, BIOL CHEM, V378, P1457, DOI 10.1515/bchm.1997.378.12.1457; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Duffy MJ, 1996, ENZYME PROTEIN, V49, P85, DOI 10.1159/000468618; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GRAFF JR, 1995, CANCER RES, V55, P5195; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; GUO Y, 2002, J BIOL CHEM     0826; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; HENDERSON BE, 1988, CANCER RES, V48, P246; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIENERT G, 1988, J UROLOGY, V140, P1466, DOI 10.1016/S0022-5347(17)42074-X; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KIRCHHEIMER J, 1984, BIOCHIM BIOPHYS ACTA, V797, P256, DOI 10.1016/0304-4165(84)90129-6; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; Rabbani SA, 1998, INT J ONCOL, V12, P911; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; Slack A, 2002, J GENE MED, V4, P381, DOI 10.1002/jgm.288; Szyf M, 2002, METHODS, V27, P184, DOI 10.1016/S1046-2023(02)00073-7; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WATT PM, 2000, GENE CHROMOSOME CANC, V29, P371; Xing RH, 1999, INT J CANCER, V81, P443, DOI 10.1002/(SICI)1097-0215(19990505)81:3<443::AID-IJC19>3.0.CO;2-T; Xing RH, 1997, CANCER RES, V57, P3585; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8	37	78	89	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1081	1088		10.1096/fj.02-0973com	http://dx.doi.org/10.1096/fj.02-0973com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773490				2022-12-25	WOS:000183818000011
J	Mimori, K; Shiraishi, T; Mashino, K; Sonoda, H; Yamashita, K; Yoshinaga, K; Masuda, T; Utsunomiya, T; Alonso, MA; Inoue, H; Mori, M				Mimori, K; Shiraishi, T; Mashino, K; Sonoda, H; Yamashita, K; Yoshinaga, K; Masuda, T; Utsunomiya, T; Alonso, MA; Inoue, H; Mori, M			MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway	ONCOGENE			English	Article						T-lymphocyte maturation associated protein; (MAL); esophageal cancer; Fas; apoptosis; motility; tumorigenicity	DARBY CANINE KIDNEY; POLYMERASE-CHAIN-REACTION; HUMAN T-LYMPHOCYTES; APICAL TRANSPORT; CELL-LINES; JUVENILE NEPHRONOPHTHISIS; PROTEIN; MEMBRANE; CARCINOMA; DELETIONS	We isolated the MAL (T-lymphocyte maturation associated protein) gene from differentially expressed products of esophageal epithelium relative to esophageal carcinoma tissues. The Mal protein has been demonstrated as being a component of the protein machinery for apical transport in epithelial polarized cells. In this study, we describe the reduced expression of MAL in all 39 cases of esophageal carcinoma tested and 60 other human carcinomas. MAL gene transcription was induced in three out of 13 esophageal carcinoma cell lines by treatment with the demethylating agent 5-aza-2'-deoxycytidine (DAC), and in nine additional cell lines by simultaneous treatment with trichostatin A, an inhibitor of deacetylation, and DAC. We established a stable MAL gene transfectant whose expression was regulated by subcutaneous doxycycline injection in nude mice. Tumor growth was suppressed in cells expressing TE3-MAL compared with TE3 parent cells or cells not expressing TE3-MAL with doxycycline injection (20mug/body) (P<0.01). Additionally, the TE3-MAL transfectant cells exhibited decreased cellular motility, a G1/S transition block and increased levels of apoptosis, concomitant with increased expression of Fas receptor in vitro. The apoptotic staining in MALexpressing tumors was confirmed by TUNEL assay. Therefore, we conclude that expression of MAL was frequently decreased or diminished in gastrointestinal tract cancers, and that Mal expression confers reduced tumorigenicity in vivo to tumor TE3 cells through the induction of apoptosis via the Fas signaling pathway.	Kyushu Univ, Med Inst Bioregulat, Dept Surg, Beppu, Oita 8740838, Japan; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid, Spain; CSIC, Madrid, Spain	Kyushu University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC)	Mori, M (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Surg, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.		Alonso, Miguel A/J-3945-2016; Mashino, Kohjiro/AAW-7923-2020	Alonso, Miguel A/0000-0002-7001-8826; Mimori, Koshi/0000-0003-3897-9974				Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Konrad M, 1996, HUM MOL GENET, V5, P367, DOI 10.1093/hmg/5.3.367; Martin-Belmonte F, 2001, J BIOL CHEM, V276, P49337, DOI 10.1074/jbc.M106882200; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; Martin-Belmonte F, 2000, MOL BIOL CELL, V11, P2033, DOI 10.1091/mbc.11.6.2033; Matsuyama A, 2001, CANCER RES, V61, P5714; Millan J, 1997, BIOCHEM J, V321, P247, DOI 10.1042/bj3210247; Millan J, 1998, EUR J IMMUNOL, V28, P3675, DOI 10.1002/(SICI)1521-4141(199811)28:11<3675::AID-IMMU3675>3.3.CO;2-X; Mimori K, 1997, BRIT J CANCER, V76, P531, DOI 10.1038/bjc.1997.420; Mori M, 1996, ANN SURG, V224, P183, DOI 10.1097/00000658-199608000-00011; MORI M, 1995, CANCER RES, V55, P3417; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Puertollano R, 1997, J BIOL CHEM, V272, P18311, DOI 10.1074/jbc.272.29.18311; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; Puertollano R, 2001, MOL BIOL CELL, V12, P1869, DOI 10.1091/mbc.12.6.1869; Saunier S, 2000, AM J HUM GENET, V66, P778, DOI 10.1086/302819; Shibata K, 1999, CANCER RES, V59, P1096; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shiraishi T, 1998, INT J CANCER, V79, P175, DOI 10.1002/(SICI)1097-0215(19980417)79:2<175::AID-IJC13>3.3.CO;2-P; SUGIMACHI K, 1988, BRIT J SURG, V75, P1115, DOI 10.1002/bjs.1800751122; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; Wadler S, 1999, ANAL BIOCHEM, V267, P24, DOI 10.1006/abio.1998.2890	27	68	74	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3463	3471		10.1038/sj.onc.1206378	http://dx.doi.org/10.1038/sj.onc.1206378			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776198				2022-12-25	WOS:000183128500013
J	Bartusel, T; Klempnauer, KH				Bartusel, T; Klempnauer, KH			Transactivation mediated by B-Myb is dependent on TAF(II)250	ONCOGENE			English	Article						B-Myb; TAF(II)250; ts13; transactivation	CELL-CYCLE PROGRESSION; V-MYB; ACETYLTRANSFERASE ACTIVITY; SYNERGISTIC ACTIVATION; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; KINASE-ACTIVITY; MIM-1 GENE; C/EBP-BETA; A-MYB	B-Myb is a highly conserved member of the Myb family of transcription factors, which has been implicated in cell cycle regulation. B-Myb is expressed in most proliferating cells and its activity is highly regulated around the G1/S-phase border of the cell cycle. It is generally assumed that B-Myb regulates the expression of genes that are crucial for cell proliferation; however, the identity of these genes, the molecular mechanisms by which B-Myb stimulates their expression and the involvement of other proteins have not been sufficiently clarified. We have employed the hamster cell line ts13 as a tool to demonstrate a functional link between B-Myb and the coactivator TAF(II)250, a key component of the transcriptional machinery which itself is essential for cell proliferation. ts13 cells express a point-mutated version of TAFI,250 whose intrinsic histone acetyl transferase activity is temperature sensitive. Transactivation of Myb-responsive reporter genes by B-Myb is temperature-dependent in ts13 cells but not in ts13 cells, which have been rescued by transfection with an expression vector for wild-type TAF(II)250. Furthermore, B-Myb and TAF(II)250 can be coprecipitated, suggesting that both proteins are present in a complex. The formation of this complex is dependent on the DNA-binding domain of B-Myb and not on its transactivation domain. Taken together, these observations provide the first evidence that the coactivator TAF(II)250 is involved in the activation of Myb responsive promoters by B-Myb. The finding that B-Myb transactivation is dependent on a key coactivator involved in cell cycle control is consistent with and strengthens the idea that B-Myb plays a crucial role as a transcription factor in proliferating cells.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Horstmann S, 2000, ONCOGENE, V19, P5428, DOI 10.1038/sj.onc.1203937; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LEVAILLARD T, 1997, J BIOL CHEM, V272, P30651; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lively TN, 2001, J BIOL CHEM, V276, P25582, DOI 10.1074/jbc.M100278200; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Siegert JL, 2000, ONCOGENE, V19, P5703, DOI 10.1038/sj.onc.1203966; Siegert JL, 1999, MOL CELL BIOL, V19, P846; Sitzmann J, 1996, ONCOGENE, V12, P1889; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wassarman DA, 2001, J CELL SCI, V114, P2895; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	53	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2932	2941		10.1038/sj.onc.1206494	http://dx.doi.org/10.1038/sj.onc.1206494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771944				2022-12-25	WOS:000182824800008
J	Aepfelbacher, M; Trasak, C; Wilharm, G; Wiedemann, A; Trulzsch, K; Krauss, K; Gierschik, P; Heesemann, J				Aepfelbacher, M; Trasak, C; Wilharm, G; Wiedemann, A; Trulzsch, K; Krauss, K; Gierschik, P; Heesemann, J			Characterization of YopT effects on Rho GTPases in Yersinia enterocolitica-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; VIRULENCE PLASMID; PROTEINS; GDI; COMPLEX; FAMILY; KINASE; SYSTEM; PHOSPHORYLATION; TRANSLOCATION	Pathogenic yersiniae employ a type III secretion system for translocating up to six effector proteins (Yersinia outer proteins (Yops)) into eukaryotic target cells. YopT is a cysteine protease that was shown to remove the C-terminal isoprenoid group of RhoA, Rac, and CDC42Hs. Here we characterized the cell biological and biochemical activities of YopT in cells infected with pathogenic Yersinia enterocolitica. Bacterially injected YopT located to cell membranes from which it released RhoA but not Rac or CDC42Hs. In the infected cells RhoA was dissociated from guanine nucleotide dissociation inhibitor-1 (GDI-1) and accumulated as a monomeric protein in the cytosol, whereas Rac and CDC42Hs remained GDI-bound. Direct transfer of isoprenylated RhoA to YopT and RhoA modification could be reconstituted in vitro by guanosine 5'-3-O-(thio) triphosphate loading of a recombinant RhoA . GDI-1 complex. Finally, in macrophages infected with a Yersinia strain selectively translocating YopT podosomal adhesion structures required for chemotaxis as well as phagocytic cups mediating uptake of yersiniae were disrupted. These findings indicate that bacterially translocated YopT acts on membrane-bound and GDI-complexed RhoA but not Rac or CDC42, and this is sufficient for disruption of macrophage immune functions.	Univ Munich, Max von Pettenkofer Inst Med Mikrobiol, D-80336 Munich, Germany; Univ Ulm, Abt Pharmakol & Toxikol, D-89081 Ulm, Germany	University of Munich; Ulm University	Aepfelbacher, M (corresponding author), Univ Munich, Max von Pettenkofer Inst Med Mikrobiol, Pettenkoferstr 9A, D-80336 Munich, Germany.			Trulzsch, Konrad/0000-0002-1937-5043; Wilharm, Gottfried/0000-0002-1771-6799; Wiedemann, Agnes/0000-0001-8237-3545				Aepfelbacher M, 2001, INT J MED MICROBIOL, V291, P269, DOI 10.1078/1438-4221-00130; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Faure J, 2001, BIOCHIMIE, V83, P409, DOI 10.1016/S0300-9084(01)01263-9; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; Grosdent N, 2002, INFECT IMMUN, V70, P4165, DOI 10.1128/IAI.70.8.4165-4176.2002; HEESEMANN J, 1986, INFECT IMMUN, V54, P561, DOI 10.1128/IAI.54.2.561-567.1986; Illenberger D, 2000, METHOD ENZYMOL, V325, P167; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Linder S, 2000, J IMMUNOL, V165, P221, DOI 10.4049/jimmunol.165.1.221; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; Read PW, 2000, PROTEIN SCI, V9, P376; ROGGENKAMP A, 1995, FEMS MICROBIOL LETT, V134, P69, DOI 10.1016/0378-1097(95)00383-G; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Shao F, 2003, P NATL ACAD SCI USA, V100, P904, DOI 10.1073/pnas.252770599; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Sorg I, 2001, INFECT IMMUN, V69, P7535, DOI 10.1128/IAI.69.12.7535-7543.2001; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; VAN AL, 1997, GENE DEV, V11, P2295; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; Wiedemann A, 2001, CELL MICROBIOL, V3, P693, DOI 10.1046/j.1462-5822.2001.00149.x; Zumbihl R, 1999, J BIOL CHEM, V274, P29289, DOI 10.1074/jbc.274.41.29289	33	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33217	33223		10.1074/jbc.M303349200	http://dx.doi.org/10.1074/jbc.M303349200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12791693	hybrid, Green Published			2022-12-25	WOS:000184901800089
J	Tortorici, MA; Broering, TJ; Nibert, ML; Patton, JT				Tortorici, MA; Broering, TJ; Nibert, ML; Patton, JT			Template recognition and formation of initiation complexes by the replicase of a segmented double-stranded RNA virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTAVIRUS MESSENGER-RNA; CONSENSUS SEQUENCE; GENOME REPLICATION; IN-VITRO; POLYMERASE; IDENTIFICATION; MECHANISM; PROTEINS; PROMOTER; REQUIRES	Replication of the segmented double-stranded (ds) RNA genome of viruses belonging to the Reoviridae family requires the RNA-dependent RNA polymerase (RdRP) to use 10-12 different mRNAs as templates for (-) strand synthesis. Rotavirus serves as a model system for study of this process, since its RdRP (VP1) is catalytically active and can specifically recognize template mRNAs in vitro. Here, we have analyzed the requirements for template recognition by the rotavirus RdRP and compared those to the requirements for formation of (-) strand initiation complexes. The results show that multiple functionally independent recognition signals are present at the 3'-end of viral mRNAs, some positioned in nonconserved regions upstream of the highly conserved 3'-terminal consensus sequence. We also found that RdRP recognition signals are distinct from cis-acting signals that promote (-) strand synthesis, because deletions of portions of the 3'-consensus sequence that caused viral mRNAs to be poorly replicated in vitro did not necessarily prevent efficient recognition of the RNA by the RdRP. Although the RdRP alone can specifically bind to viral mRNAs, our analysis reveals that this interaction is not sufficient to generate initiation complexes, even in the presence of nucleotides and divalent cations. Rather, the formation of initiation complexes also requires the core lattice protein (VP2), a virion component that forms a T=1 icosahedral shell that encapsidates the segmented dsRNA genome. The essential role that the core lattice protein has in (-) strand initiation provides a mechanism for the coordination of genome replication and virion assembly.	NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard Medical School	Patton, JT (corresponding author), NIAID, Infect Dis Lab, NIH, 50 South Dr,MSC 8026,Rm 6314, Bethesda, MD 20892 USA.	jpatton@niaid.nih.gov	Patton, John T/P-1390-2014; Patton, John/V-7651-2018	Tortorici, M. Alejandra/0000-0002-2260-2577; Patton, John/0000-0003-1572-0732	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000754, Z01AI000754] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barro M, 2001, VIROLOGY, V288, P71, DOI 10.1006/viro.2001.1054; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Chen D, 1998, J VIROL, V72, P7387, DOI 10.1128/JVI.72.9.7387-7396.1998; Chen D, 2001, VIROLOGY, V282, P221, DOI 10.1006/viro.2001.0825; Chen DY, 2000, RNA, V6, P1455, DOI 10.1017/S1355838200001187; Chen DY, 1999, VIROLOGY, V265, P120, DOI 10.1006/viro.1999.0029; CHEN DY, 1994, J VIROL, V68, P7030, DOI 10.1128/JVI.68.11.7030-7039.1994; Chizhikov V, 2000, RNA, V6, P814, DOI 10.1017/S1355838200992264; Deo RC, 2002, CELL, V108, P71, DOI 10.1016/S0092-8674(01)00632-8; Desselberger U, 1994, Curr Top Microbiol Immunol, V185, P31; Estes M.K., 2001, FIELDS VIROLOGY, V2., P1747; GALLEGOS CO, 1989, VIROLOGY, V172, P616, DOI 10.1016/0042-6822(89)90204-3; Hsu LLM, 2003, BIOCHEMISTRY-US, V42, P3777, DOI 10.1021/bi026954e; Kapikian A. Z., 2001, FIELDS VIROLOGY, V2, P1787; Lawton JA, 1997, J VIROL, V71, P7353, DOI 10.1128/JVI.71.10.7353-7360.1997; MANSELL EA, 1994, VIROLOGY, V204, P69, DOI 10.1006/viro.1994.1511; MITCHELL DB, 1990, VIROLOGY, V177, P324, DOI 10.1016/0042-6822(90)90487-C; Patton JT, 1999, VIROLOGY, V264, P167, DOI 10.1006/viro.1999.9989; Patton JT, 1996, J VIROL, V70, P3961, DOI 10.1128/JVI.70.6.3961-3971.1996; Patton JT, 1999, J VIROL, V73, P1382, DOI 10.1128/JVI.73.2.1382-1391.1999; Patton JT, 1997, J VIROL, V71, P9618, DOI 10.1128/JVI.71.12.9618-9626.1997; Patton JT, 1996, J VIROL, V70, P7940, DOI 10.1128/JVI.70.11.7940-7947.1996; PATTON JT, 1990, J GEN VIROL, V71, P1087, DOI 10.1099/0022-1317-71-5-1087; Patton JT, 2000, VIROLOGY, V277, P217, DOI 10.1006/viro.2000.0645; PONCET D, 1994, EMBO J, V13, P4165, DOI 10.1002/j.1460-2075.1994.tb06734.x; Prasad BVV, 1996, NATURE, V382, P471, DOI 10.1038/382471a0; VALENZUELA S, 1991, J VIROL, V65, P3964, DOI 10.1128/JVI.65.7.3964-3967.1991; Wentz MJ, 1996, J VIROL, V70, P7833, DOI 10.1128/JVI.70.11.7833-7841.1996; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	29	56	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32673	32682		10.1074/jbc.M305358200	http://dx.doi.org/10.1074/jbc.M305358200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12788926	Green Submitted, hybrid			2022-12-25	WOS:000184901800025
J	Bro, C; Regenberg, B; Lagniel, G; Labarre, J; Montero-Lomeli, M; Nielsen, J				Bro, C; Regenberg, B; Lagniel, G; Labarre, J; Montero-Lomeli, M; Nielsen, J			Transcriptional, proteomic, and metabolic responses to lithium in galactose-grown yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; PROTEIN EXPRESSION; SIGNALING PATHWAY; KINASE PATHWAYS; MESSENGER-RNA; TOR; STRESS; ACTIVATOR; RAPAMYCIN	Lithium is highly toxic to yeast when grown in galactose medium mainly because phosphoglucomutase, a key enzyme of galactose metabolism, is inhibited. We studied the global protein and gene expression profiles of Saccharomyces cerevisiae grown in galactose in different time intervals after addition of lithium. These results were related to physiological studies where both secreted and intracellular metabolites were determined. Microarray analysis showed that 664 open reading frames were down-regulated and 725 up-regulated in response to addition of lithium. Genes involved in transcription, translation, and nucleotide metabolism were down-regulated at the transcriptional level, whereas genes responsive to different stresses as well as genes from energy reserve metabolism and monosaccharide metabolism were up-regulated. Compared with the proteomic data, 26% of the down-regulated and 48% of the up-regulated proteins were also identified as being changed on the mRNA level. Functional clusters obtained from proteome data were coincident with transcriptional clusters. Physiological studies showed that acetate, glycerol, and glycogen accumulate in response to lithium, as reflected in expression data, whereas a change from respiro-fermentative to respiratory growth could not be predicted from the expression analyses.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Ctr Ciencias & Saude, BR-21941590 Rio De Janeiro, Brazil; Tech Univ Denmark, Bioctr, Ctr Proc Biotechnol, DK-2800 Lyngby, Denmark; Ctr Energie Atom Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	Universidade Federal do Rio de Janeiro; Technical University of Denmark	Montero-Lomeli, M (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Ctr Ciencias & Saude, Bloco D Subsolo Sala 11, BR-21941590 Rio De Janeiro, Brazil.		Montero-Lomeli, Monica/D-9885-2013; Regenberg, Brigit/C-2699-2009; Nielsen, Jens/Q-1347-2017	Regenberg, Brigit/0000-0003-4996-7012; Nielsen, Jens/0000-0002-9955-6003				Akhtar N, 1997, FEBS LETT, V403, P173, DOI 10.1016/S0014-5793(97)00048-3; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Bhat PJ, 2003, MED HYPOTHESES, V60, P123, DOI 10.1016/S0306-9877(02)00347-X; BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cutler NS, 2001, MOL BIOL CELL, V12, P4103, DOI 10.1091/mbc.12.12.4103; de la Cera T, 2002, J MOL BIOL, V319, P703, DOI 10.1016/S0022-2836(02)00377-7; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Lai K, 2003, GLYCOBIOLOGY, V13, P285, DOI 10.1093/glycob/cwg033; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Maillet I, 1996, J BIOL CHEM, V271, P10263, DOI 10.1074/jbc.271.17.10263; MartinezPastor MT, 1996, FEBS LETT, V390, P319, DOI 10.1016/0014-5793(96)00683-7; Masuda CA, 2001, J BIOL CHEM, V276, P37794; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; Montero-Lomeli M, 2002, J BIOL CHEM, V277, P21542, DOI 10.1074/jbc.M201977200; Navarro-Avino JP, 1999, YEAST, V15, P829, DOI 10.1002/(SICI)1097-0061(199907)15:10A<829::AID-YEA423>3.0.CO;2-9; Ning C, 2001, MOL GENET METAB, V72, P306, DOI 10.1006/mgme.2001.3152; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Rose MD., 1990, METHODS YEAST GENETI; Schou M, 1997, ARCH GEN PSYCHIAT, V54, P9; Smits HP, 1998, ANAL BIOCHEM, V261, P36, DOI 10.1006/abio.1998.2714; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; van Dijken JP, 2000, ENZYME MICROB TECH, V26, P706, DOI 10.1016/S0141-0229(00)00162-9; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; VANURK H, 1988, YEAST, V4, P283, DOI 10.1002/yea.320040406; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; Washburn MP, 2003, P NATL ACAD SCI USA, V100, P3107, DOI 10.1073/pnas.0634629100; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463	48	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32141	32149		10.1074/jbc.M304478200	http://dx.doi.org/10.1074/jbc.M304478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12791685	hybrid			2022-12-25	WOS:000184782100086
J	Ong, LL; Er, CPN; Ho, A; Aung, MT; Yu, H				Ong, LL; Er, CPN; Ho, A; Aung, MT; Yu, H			Kinectin anchors the translation elongation factor-1 delta to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE PROTEIN; MATURATION-PROMOTING FACTOR; KINESIN-BINDING PROTEIN; MOLECULAR-CLONING; VESICLE TRANSPORT; FACTOR EF-1-DELTA; AXONAL-TRANSPORT; MOTOR; KINASE; PHOSPHORYLATION	Kinectin has been proposed to be a membrane anchor for kinesin on intracellular organelles. A kinectin isoform that lacks a major portion of the kinesin-binding domain does not bind kinesin but interacts with another resident of the endoplasmic reticulum, the translation elongation factor-1 delta (EF-1delta). This was shown by yeast two-hybrid analysis and a number of in vitro and in vivo assays. EF-1alpha provides the guanine nucleotide exchange activities on EF-1alpha during elongation step of protein synthesis. The minimal EF-1delta-binding domain on kinectin resides within a conserved region present in all the kinectin isoforms. Overexpression of the kinectin fragments in vivo disrupted the intracellular localization of EF-1delta proteins. This report provides evidence of an alternative kinectin function as the membrane anchor for EF-1delta on the endoplasmic reticulum and provides clues to the EF-1 complex assembly and anchorage on the endoplasmic reticulum.	Natl Univ Med Inst, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore	National University of Singapore; National University of Singapore	Yu, H (corresponding author), Block MD9,03-03,2 Med Dr, Singapore 117597, Singapore.		Yu, Hanry/L-6050-2019; Yu, Hanry/C-7375-2011; Aung-Htut, May/AAF-6826-2019; Yu, Hanry/C-1031-2013	Yu, Hanry/0000-0002-0339-3685; Aung-Htut, May/0000-0002-6379-2303; Yu, Hanry/0000-0002-0339-3685				Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; CORMIER P, 1993, NUCLEIC ACIDS RES, V21, P743, DOI 10.1093/nar/21.3.743; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Furukawa R, 2001, BBA-GEN SUBJECTS, V1527, P130, DOI 10.1016/S0304-4165(01)00157-X; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Inagawa Junichi, 2000, P35; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; Kawaguchi Y, 1998, J VIROL, V72, P1731, DOI 10.1128/JVI.72.3.1731-1736.1998; Kumar J, 1998, J BIOL CHEM, V273, P31738, DOI 10.1074/jbc.273.48.31738; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; Leung E, 1996, IMMUNOL CELL BIOL, V74, P421, DOI 10.1038/icb.1996.72; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MINELLA O, 1994, CELL MOL BIOL, V40, P521; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; MULNERLORILLON O, 1994, J BIOL CHEM, V269, P20201; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Nakazawa M, 1999, FEBS LETT, V453, P29, DOI 10.1016/S0014-5793(99)00692-4; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Ong LL, 2000, J BIOL CHEM, V275, P32854, DOI 10.1074/jbc.M005650200; PRINT CG, 1994, GENE, V144, P221, DOI 10.1016/0378-1119(94)90381-6; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders J, 1996, J CELL SCI, V109, P1113; SANDERS J, 1993, BIOCHIM BIOPHYS ACTA, V1174, P87, DOI 10.1016/0167-4781(93)90097-W; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; Toyoshima I, 1996, NEUROSCI LETT, V211, P171, DOI 10.1016/0304-3940(96)12752-X; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Xu JW, 2002, MOL REPROD DEV, V62, P37, DOI 10.1002/mrd.10066; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171	48	30	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32115	32123		10.1074/jbc.M210917200	http://dx.doi.org/10.1074/jbc.M210917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12773547	hybrid			2022-12-25	WOS:000184782100083
J	Close, BE; Mendiratta, SS; Geiger, KM; Broom, LJ; Ho, LL; Colley, KJ				Close, BE; Mendiratta, SS; Geiger, KM; Broom, LJ; Ho, LL; Colley, KJ			The minimal structural domains required for neural cell adhesion molecule polysialylation by PST/ST8Sia IV and STX/ST8Sia II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; POLYSIALIC ACID UNITS; N-CAM; LUNG-CARCINOMA; PSA-NCAM; COOPERATIVE POLYSIALYLATION; DIFFERENTIAL BIOSYNTHESIS; DEVELOPMENTAL EXPRESSION; SYNAPTIC PLASTICITY; SECRETORY PROTEIN	A limited number of mammalian proteins are modified by polysialic acid, with the neural cell adhesion molecule (NCAM) being the most abundant of these. We hypothesize that polysialylation is a protein-specific glycosylation event and that an initial protein-protein interaction between polysialyltransferases and glycoprotein substrates mediates this specificity. To evaluate the regions of NCAM required for recognition and polysialylation by PST/ST8Sia IV and STX/ST8Sia II, a series of domain deletion proteins were generated, co-expressed with each enzyme, and their polysialylation analyzed. A protein consisting of the fifth immunoglobulin-like domain (Ig5), which contains the reported sites of polysialylation, and the first fibronectin type III repeat (FN1) was polysialylated by both enzymes, whereas a protein consisting of Ig5 alone was not polysialylated by either enzyme. This demonstrates that the Ig5 domain of NCAM and FN1 are sufficient for polysialylation, and suggests that the FN1 may constitute an enzyme recognition and docking site. Two other NCAM mutants, NCAM-6 (Ig1-5) and NCAM-7 (FN1-FN2), were weakly polysialylated by PST/ST8Sia IV, suggesting that a weaker enzyme recognition site may exist within the Ig domains, and that glycans in the FN region are polysialylated. Further analysis indicated that O-linked oligosaccharides in NCAM-7, and O-linked and N-linked glycans in full-length NCAM, are polysialylated when these proteins are co-expressed with the polysialyltransferases in COS-1 cells. Our data support a model in which the polysialyltransferases bind to the FN1 of NCAM to polymerize polysialic acid chains on appropriately presented glycans in adjacent regions.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 1819 W Polk St,M-C 536, Chicago, IL 60612 USA.	karenc@uic.edu			NIGMS NIH HHS [R01 GM 63483, R01 GM 48134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134, R01GM063843, T32GM063483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Angata K, 2002, J BIOL CHEM, V277, P36808, DOI 10.1074/jbc.M204632200; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BONFANTI L, 1992, NEUROSCIENCE, V49, P419, DOI 10.1016/0306-4522(92)90107-D; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Close BE, 2001, GLYCOBIOLOGY, V11, P997, DOI 10.1093/glycob/11.11.997; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; Durbec P, 2001, MOL NEUROBIOL, V24, P53; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; FIGARELLABRANGER DF, 1990, CANCER RES, V50, P6364; FINNE J, 1987, J IMMUNOL, V138, P4402; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Fukuda M, 1996, CANCER RES, V56, P2237; Haltiwanger RS, 2002, CURR OPIN STRUC BIOL, V12, P593, DOI 10.1016/S0959-440X(02)00371-8; Hildebrandt H, 1998, CANCER RES, V58, P779; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; KIBBELAAR RE, 1989, J PATHOL, V159, P23, DOI 10.1002/path.1711590108; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kojima N, 1996, J BIOL CHEM, V271, P22058, DOI 10.1074/jbc.271.36.22058; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOMMINOTH P, 1991, AM J PATHOL, V139, P297; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KWOK SCM, 1983, J BIOL CHEM, V258, P2357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Phillips GR, 1997, DEV BRAIN RES, V102, P143, DOI 10.1016/S0165-3806(97)00069-2; Qian R, 2001, J BIOL CHEM, V276, P28641, DOI 10.1074/jbc.M103664200; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; Suzuki M, 2000, GLYCOBIOLOGY, V10, P1113; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WALSH FS, 1989, DEVELOPMENT, V105, P803; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; ZUBER C, 1992, J BIOL CHEM, V267, P9965	76	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30796	30805		10.1074/jbc.M305390200	http://dx.doi.org/10.1074/jbc.M305390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12791681	hybrid			2022-12-25	WOS:000184658800048
J	Lee, DC; Cottrill, MA; Forsberg, CW; Jia, ZC				Lee, DC; Cottrill, MA; Forsberg, CW; Jia, ZC			Functional insights revealed by the crystal structures of Escherichia coli glucose-1-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2.5 ACID-PHOSPHATASE; NUCLEOTIDE-SEQUENCE; PHYTASE; GENE; AGP; PROGRAM; COMPLEX; HYDROLYSIS; ENZYME	The Escherichia coli periplasmic glucose-1-phosphatase is a member of the histidine acid phosphatase family and acts primarily as a glucose scavenger. Previous substrate profiling studies have demonstrated some of the intriguing properties of the enzyme, including its unique and highly selective inositol phosphatase activity. The enzyme is also potentially involved in pathogenic inositol phosphate signal transduction pathways via type III secretion into the host cell. We have determined the crystal structure of E. coli glucose-1-phosphatase in an effort to unveil the structural mechanism underlying such unique substrate specificity. The structure was determined by the method of multiwavelength anomalous dispersion using a tungstate derivative together with the H18A inactive mutant complex structure with glucose 1-phosphate at 2.4-Angstrom resolution. In the active site of glucose-1-phosphatase, there are two unique gating residues, Glu-196 and Leu-24, in addition to the conserved features of histidine acid phosphatases. Together they create steric and electrostatic constraints responsible for the unique selectivity of the enzyme toward phytate and glucose-1-phosphate as well as its unusually high pH optimum for the latter. Based on the structural characterization, we were able to derive simple structural principles that not only precisely explains the substrate specificity of glucose-1-phosphatase and the hydrolysis products of various inositol phosphate substrates but also rationalizes similar general characteristics across the histidine acid phosphatase family.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	Queens University - Canada; University of Guelph	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	jia@post.queensu.ca						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi HB, 1999, GENOMICS, V56, P324, DOI 10.1006/geno.1998.5736; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Cottrill MA, 2002, CAN J MICROBIOL, V48, P801, DOI 10.1139/W02-076; DASSA J, 1990, J BACTERIOL, V172, P5497, DOI 10.1128/jb.172.9.5497-5500.1990; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeVinney R, 2000, TRENDS MICROBIOL, V8, P29, DOI 10.1016/S0966-842X(99)01657-1; Dvorakova J, 1998, FOLIA MICROBIOL, V43, P323, DOI 10.1007/BF02818571; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Golovan S, 2000, CAN J MICROBIOL, V46, P59, DOI 10.1139/cjm-46-1-59; Greiner R, 2000, J BIOTECHNOL, V84, P53, DOI 10.1016/S0168-1656(00)00331-X; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; IRVING GCJ, 1972, J BACTERIOL, V112, P434, DOI 10.1128/JB.112.1.434-438.1972; Jakob CG, 2000, PROSTATE, V42, P211, DOI 10.1002/(SICI)1097-0045(20000215)42:3<211::AID-PROS7>3.0.CO;2-U; Jia ZC, 2001, ACTA CRYSTALLOGR D, V57, P314, DOI 10.1107/S090744490001979X; Kerovuo J, 2000, BIOCHEM J, V352, P623, DOI 10.1042/0264-6021:3520623; Kostrewa D, 1999, J MOL BIOL, V288, P965, DOI 10.1006/jmbi.1999.2736; Kostrewa D, 1997, NAT STRUCT BIOL, V4, P185, DOI 10.1038/nsb0397-185; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lim D, 2000, NAT STRUCT BIOL, V7, P108; LINDQVIST Y, 1994, EUR J BIOCHEM, V221, P139, DOI 10.1111/j.1432-1033.1994.tb18722.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; PRADEL E, 1988, J BACTERIOL, V170, P4916, DOI 10.1128/jb.170.10.4916-4923.1988; PRADEL E, 1991, RES MICROBIOL, V142, P37, DOI 10.1016/0923-2508(91)90095-R; PRADEL E, 1989, J BACTERIOL, V171, P3511, DOI 10.1128/jb.171.6.3511-3517.1989; PRADEL E, 1990, J BACTERIOL, V172, P802, DOI 10.1128/jb.172.2.802-807.1990; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; ULLAH AHJ, 1994, J AGR FOOD CHEM, V42, P423, DOI 10.1021/jf00038a034; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; Wyss M, 1999, APPL ENVIRON MICROB, V65, P367	42	35	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31412	31418		10.1074/jbc.M213154200	http://dx.doi.org/10.1074/jbc.M213154200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782623	hybrid			2022-12-25	WOS:000184658800124
J	Chovolou, Y; Watjen, W; Kampkotter, A; Kahl, R				Chovolou, Y; Watjen, W; Kampkotter, A; Kahl, R			Resistance to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis in rat hepatoma cells expressing TNF-alpha is linked to low antioxidant enzyme expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANOUS SUPEROXIDE-DISMUTASE; CATALASE ACTIVITY; OXIDATIVE STRESS; IN-VITRO; CYTOTOXICITY; MITOCHONDRIAL; TRANSCRIPTION; LIVER; MNSOD; INTERLEUKIN-1-BETA	In order to study the mechanisms of resistance to tumor necrosis factor-alpha (TNF-alpha), we have constructed two stable transfectants producing TNF-alpha (Yv12-2 and Yv13-44) from the rat hepatoma H4IIE cell, which does not produce TNF-alpha. H4IIE cells were highly sensitive to apoptosis induced by TNF-alpha, whereas Yv2-12 and Yv13-44 cells were resistant. Manganous superoxide dismutase was not up-regulated in Yv2-12 and Yv13-44 cells and was unresponsive to induction by exogenous TNF-alpha and by H2O2 in H4IIE cells and in the transfectants. Catalase expression and activity were lower in Yv2-12 and Yv13-44 cells than in H4IIE cells; furthermore, the transfectants were more susceptible to H2O2. Treatment with exogenous TNF-alpha down-regulated catalase in H4IIE cells but not in Yv2-12 and Yv13-44 cells. Treatment of H4IIE cells with the catalase inhibitor 3-amino-1,2,4-triazole rendered them resistant to exogenous TNF-alpha. These data suggest a causal relationship between resistance to TNF-alpha and low catalase activity. Expression of copper and zinc containing superoxide dismutase was also decreased, whereas expression of glutathione peroxidase-1 was unchanged in Yv2-12 and Yv13-44 cells. Data from a microarray point to a downregulation of genes in the resistant clones that code for antioxidative proteins and proteins involved in glutathione synthesis and function. We assume that a prooxidant signal linked to the down-regulation of antioxidant defense may be associated with resistance to apoptosis induced by TNF-alpha.	Univ Deusseldorf, Inst Toxicol, D-40001 Dusseldorf, Germany		Kahl, R (corresponding author), Univ Deusseldorf, Inst Toxicol, POB 10 10 07, D-40001 Dusseldorf, Germany.	kahl@uni-duesseldorf.de	Wätjen, Wim/G-8339-2015; Wätjen, Wim/AAE-9018-2021					AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; BAEUERLE PA, 2000, ANTIOXIDANT REDOX RE; Bai JX, 2000, J BIOL CHEM, V275, P19241, DOI 10.1074/jbc.M000438200; Beier K, 1997, FEBS LETT, V412, P385, DOI 10.1016/S0014-5793(97)00805-3; Bernard D, 2001, FREE RADICAL BIO MED, V31, P943, DOI 10.1016/S0891-5849(01)00668-2; Beyaert R, 1998, CYTOKINES, P335, DOI 10.1016/B978-012498340-3/50025-7; BORENFREUND E, 1986, TOXICOLOGY, V39, P121, DOI 10.1016/0300-483X(86)90130-7; CLERCH LB, 1991, AM J PHYSIOL, V260, pL428, DOI 10.1152/ajplung.1991.260.6.L428; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; COHEN G, 1970, ANAL BIOCHEM, V34, P30, DOI 10.1016/0003-2697(70)90083-7; El-Bahay C, 1999, TOXICOL APPL PHARM, V158, P253, DOI 10.1006/taap.1999.8705; Goossens V, 1999, ANTIOXID REDOX SIGN, V1, P285, DOI 10.1089/ars.1999.1.3-285; Hentze H, 2000, AM J PATHOL, V156, P2045, DOI 10.1016/S0002-9440(10)65076-6; HILL DB, 1995, HEPATOLOGY, V21, P1114, DOI 10.1002/hep.1840210434; HIMENO T, 1990, CANCER RES, V50, P4941; Kawasaki H, 2002, NAT BIOTECHNOL, V20, P376, DOI 10.1038/nbt0402-376; KRAMER SM, 1986, J IMMUNOL METHODS, V93, P201; LEIST M, 1994, J IMMUNOL, V153, P1778; LINDL T, 2002, CELL TISSUE CULTURE, P161; Luster MI, 1999, CRIT REV TOXICOL, V29, P491, DOI 10.1080/10408449991349258; MAEDA M, 1994, INT J CANCER, V58, P376, DOI 10.1002/ijc.2910580312; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Nenoi M, 2001, CANCER RES, V61, P5885; OKAMOTO T, 1992, CANCER RES, V52, P5278; Pinteaux E, 1996, DEV NEUROSCI-BASEL, V18, P397, DOI 10.1159/000111433; Rogers RJ, 2001, J BIOL CHEM, V276, P20419, DOI 10.1074/jbc.M008915200; Rohrdanz E, 2001, BRAIN RES, V900, P128, DOI 10.1016/S0006-8993(01)02277-6; Rohrdanz E, 1998, FREE RADICAL BIO MED, V24, P27, DOI 10.1016/S0891-5849(97)00159-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sass G, 2002, INFLAMM RES, V51, P229, DOI 10.1007/PL00000298; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Schumann J, 1999, TOXICOLOGY, V138, P103, DOI 10.1016/S0300-483X(99)00087-6; SHEPPARD BC, 1991, SURGERY, V109, P698; SHULL S, 1991, J BIOL CHEM, V266, P24398; Siemankowski LM, 1999, FREE RADICAL BIO MED, V26, P919, DOI 10.1016/S0891-5849(98)00273-1; WALLACH D, 1988, J IMMUNOL, V140, P2994; Watanabe N, 1996, PANCREAS, V13, P395, DOI 10.1097/00006676-199611000-00009; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; YASMINEH WG, 1991, CANCER RES, V51, P3990; ZYAD A, 1994, CANCER RES, V54, P825	42	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29626	29632		10.1074/jbc.M208665200	http://dx.doi.org/10.1074/jbc.M208665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775721	hybrid			2022-12-25	WOS:000184507000031
J	Holowaty, MN; Zeghouf, M; Wu, H; Tellam, J; Athanasopoulos, V; Greenblatt, J; Frappier, L				Holowaty, MN; Zeghouf, M; Wu, H; Tellam, J; Athanasopoulos, V; Greenblatt, J; Frappier, L			Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; VIRUS LATENT ORIGIN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-PROTEIN; DNA-REPLICATION; EBNA1; COMPLEX; DOMAIN; SET; PURIFICATION	The Epstein-Barr nuclear antigen-1 (EBNA1) protein of Epstein-Barr virus is important for the replication, segregation, and transcriptional activation of latent Epstein-Barr virus genomes; has been implicated in host cell immortalization; and avoids proteasomal processing and cell-surface presentation. To gain insight into how EBNA1 fulfills these functions, we have profiled cellular protein interactions with EBNA1 using EBNA1 affinity chromatography and tandem affinity purification ( TAP) of EBNA1 complexes from human cells ( TAP-tagging). We discovered several new specific cellular protein interactions with EBNA1, including interactions with HAUSP/USP7, NAP1, template-activating factor-Ibeta/SET, CK2, and PRMT5, all of which play important cell regulatory roles. The ubiquitin-specific protease USP7 is a known target of herpes simplex virus, and the USP7-binding region of EBNA1 was mapped to amino acids 395 - 450. A mutation in EBNA1 that selectively disrupted binding to USP7 was found to cause a 4-fold increase in EBNA1 replication activity but had no effect on EBNA1 turnover and cell-surface presentation. The results suggest that USP7 can regulate the replication function of EBNA1 and that EBNA1 may influence cellular events by sequestering key regulatory proteins.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 1A8, Canada; Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4029, Australia	University of Toronto; University of Toronto; QIMR Berghofer Medical Research Institute	Frappier, L (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	lori.frappier@utoronto.ca		Zeghouf, Mahel/0000-0003-3686-2510; Athanasopoulos, Vicki/0000-0002-5764-5948				Aiyar A, 1998, EMBO J, V17, P6394, DOI 10.1093/emboj/17.21.6394; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; Avolio-Hunter TM, 1998, NUCLEIC ACIDS RES, V26, P4462, DOI 10.1093/nar/26.19.4462; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Ceccarelli DFJ, 2000, J VIROL, V74, P4939, DOI 10.1128/JVI.74.11.4939-4948.2000; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Fischer N, 1997, J BIOL CHEM, V272, P3999, DOI 10.1074/jbc.272.7.3999; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; Frappier L, 2003, BIOL PLASMIDS; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito S, 2000, VIROLOGY, V266, P110, DOI 10.1006/viro.1999.0054; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Kapoor P, 2001, EMBO J, V20, P222, DOI 10.1093/emboj/20.1.222; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kim AL, 1997, VIROLOGY, V239, P340, DOI 10.1006/viro.1997.8874; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shire K, 1999, J VIROL, V73, P2587, DOI 10.1128/JVI.73.4.2587-2595.1999; SNUDDEN DK, 1994, EMBO J, V13, P4840, DOI 10.1002/j.1460-2075.1994.tb06810.x; SOPTA M, 1985, J BIOL CHEM, V260, P353; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; STERNAS L, 1990, J VIROL, V64, P2407; Van Scoy S, 2000, VIROLOGY, V275, P145, DOI 10.1006/viro.2000.0508; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Wu H, 2002, J VIROL, V76, P2480, DOI 10.1128/JVI.76.5.2480-2490.2002; Wu H, 2000, EMBO REP, V1, P140, DOI 10.1093/embo-reports/kvd026; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Zhang D, 1998, NUCLEIC ACIDS RES, V26, P631, DOI 10.1093/nar/26.2.631	56	178	197	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29987	29994		10.1074/jbc.M303977200	http://dx.doi.org/10.1074/jbc.M303977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12783858	hybrid			2022-12-25	WOS:000184507000073
J	McCann, JAB; Berti, PJ				McCann, JAB; Berti, PJ			Adenine release is fast in MutY-catalyzed hydrolysis of G : A and 8-Oxo-G : A DNA mismatches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; PURINE NUCLEOSIDE PHOSPHORYLASE; TRANSITION-STATE ANALYSIS; C-TERMINAL DOMAIN; GLYCOSYLASE MUTY; SUBSTRATE-ANALOGS; INHIBITORS; REPAIR; BINDING; SPECIFICITY	MutY, a DNA repair enzyme, is unusual in that it binds exceedingly tightly to its products after the chemical steps of catalysis. Until now it was not known whether the product being released in the rate-limiting step was DNA, adenine, or both. MutY hydrolyzes adenine from 8-oxo-G: A (OG: A) base pair mismatches as the first step in the base excision repair pathway, as well as from G: A mismatches. The products are adenine and DNA containing an apurinic (AP) site. Tight product binding may have a physiological role in preventing further damage at the OG: AP site. We developed a rate assay using [8-C-14] adenine in OG: A or G: A mismatches that distinguishes between adenine hydrolysis and adenine release. [8-C-14] Adenine was released quickly from the MutY . AP- DNA . [ 8-C-14] adenine complex, with a rate constant greater than 5 min(-1). This was much faster than the rate-limiting step, at 0.006 - 0.015 min(-1). Gel retardation experiments showed that AP- DNA release was very slow, consistent with it being the rate-limiting step. Thus, the kinetic mechanism involves fast adenine release after hydrolysis followed by rate-limiting AP- DNA release. Adenine appears to be buried deep in the protein . DNA interface, but there is enough flexibility or open space for it to dissociate from the MutY . AP-DNA . adenine complex. These results have implications for the catalytic mechanism of MutY.	McMaster Univ, Dept Biochem, Hamilton, ON L8S 4M1, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada; McMaster Univ, Antimicrobial Res Ctr, Hamilton, ON L8S 4M1, Canada	McMaster University; McMaster University; McMaster University	Berti, PJ (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8S 4M1, Canada.							AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Basso LA, 2001, BIOCHEMISTRY-US, V40, P8196, DOI 10.1021/bi010584x; Bernards AS, 2002, J BIOL CHEM, V277, P20960, DOI 10.1074/jbc.C200181200; Berti PJ, 2002, ADV PHYS ORG CHEM, V37, P239, DOI 10.1016/S0065-3160(02)37004-7; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Chen XY, 2000, J AM CHEM SOC, V122, P6527, DOI 10.1021/ja992751a; Chepanoske CL, 1999, NUCLEIC ACIDS RES, V27, P3197, DOI 10.1093/nar/27.15.3197; Chmiel NH, 2003, J MOL BIOL, V327, P431, DOI 10.1016/S0022-2836(03)00124-4; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; CONNOLLY BA, 1997, OLIGONUCLEOTIDES ANA, P179; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; Deng L, 1997, J AM CHEM SOC, V119, P7865, DOI 10.1021/ja970828u; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HARRIS DC, 1995, QUANTATIVE CHEM ANAL, P635; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P7116, DOI 10.1021/bi025694y; KLINE PC, 1992, BIOCHEMISTRY-US, V31, P5964, DOI 10.1021/bi00141a003; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Lillelund VH, 2002, CHEM REV, V102, P515, DOI 10.1021/cr000433k; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; Schramm VL, 1999, METHOD ENZYMOL, V308, P301; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Tanaka KSE, 2001, BIOCHEMISTRY-US, V40, P6845, DOI 10.1021/bi010499p; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011	31	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29587	29592		10.1074/jbc.M212474200	http://dx.doi.org/10.1074/jbc.M212474200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766151	hybrid			2022-12-25	WOS:000184507000026
J	Rogers, RS; Horvath, CM; Matunis, MJ				Rogers, RS; Horvath, CM; Matunis, MJ			SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; TRANSCRIPTIONAL SYNERGY; SIGNAL-TRANSDUCTION; MODIFIER-1 SUMO-1; UBIQUITIN; MOTIF; CONJUGATION; SUMOYLATION; LIGASES; REQUIRES	The PIAS (protein inhibitors of activated STAT) family of proteins were first discovered as inhibitors of activated signal transducers and activators of transcription (STATs). More recently these proteins have been shown to function as E3 ligases that promote the SUMO modification of a number of transcription regulators. We have investigated the relationship between the effects of PIAS proteins on STAT1 transcriptional activity and the ability of the PIAS proteins to function as SUMO E3 ligases. We demonstrate that STAT1 is a substrate for SUMO modification and that PIASx-alpha, but not PIAS1, functions as an E3 ligase to promote STAT1 modification. In addition, we have mapped the major site for SUMO modification on STAT1 to lysine 703. This lysine residue is in close proximity to the regulatory tyrosine residue at position 701, whose phosphorylation mediates STAT1 activation in response to cytokine signaling. Mutation of lysine 703 to arginine abolishes SUMO modification of STAT1 both in vitro and in vivo. However, this mutation does not affect the activation of STAT1 or the ability of either PIAS1 or PIASx-alpha to function as an inhibitor of STAT1-mediated transcription activation. Our findings demonstrate that inhibition of STAT1 by PIAS proteins does not require SUMO modification of STAT1 itself. SUMO modification of STAT1 may nonetheless be functionally important given the close proximity between the SUMO modification site and tyrosine 701.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Matunis, MJ (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.			Matunis, Michael/0000-0002-9350-6611; Horvath, Curt/0000-0003-2449-225X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002	31	124	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30091	30097		10.1074/jbc.M301344200	http://dx.doi.org/10.1074/jbc.M301344200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764129	hybrid			2022-12-25	WOS:000184507000086
J	Atarashi, R; Nishida, N; Shigematsu, K; Goto, S; Kondo, T; Sakaguchi, S; Katamine, S				Atarashi, R; Nishida, N; Shigematsu, K; Goto, S; Kondo, T; Sakaguchi, S; Katamine, S			Deletion of N-terminal residues 23-88 from prion protein (PrP) abrogates the potential to rescue PrP-deficient mice from PrP-like protein/Doppel-induced neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURKINJE-CELL DEGENERATION; CREUTZFELDT-JAKOB-DISEASE; TRANSGENIC MICE; EXPRESSION LEVEL; BINDS COPPER; WILD-TYPE; IN-VIVO; SCRAPIE; DOPPEL; NEURONS	Accumulating evidence has suggested that prion protein (PrP) is neuroprotective and that a PrP-like protein/ Doppel (PrPLP/Dpl) is neurotoxic. A line of PrP-deficient mice, Ngsk Prnp(0/0), ectopically expressing PrPLP/Dpl in neurons, exhibits late-onset ataxia because of Purkinje cell death that is prevented by a transgene encoding wild-type mouse PrP. To elucidate the mechanisms of neurodegeneration in these mice, we introduced five types of PrP transgene, namely one heterologous hamster, two mouse/hamster chimeric genes, and two mutants, each of which encoded PrP lacking residues 23 - 88 (MHM2.del23-88) or with E199K substitution (Mo.E199K), into Ngsk Prnp(0/0) mice. Only MHM2.del23-88 failed to rescue the mice from the Purkinje cell death. The transgenic mice, MHM2.del23-88/ Ngsk Prnp(0/0), expressed several times more PrP than did wild-type (Prnp(+/+)) mice and PrPLP/Dpl at an equivalent level to Ngsk Prnp(0/0) mice. Little difference was observed in the pathology and onset of ataxia between Ngsk Prnp(0/0) and MHM2.del23-88/Ngsk Prnp(0/0). No detergent-insoluble PrPLP/Dpl was detectable in the central nervous system of Ngsk Prnp(0/0) mice even after the onset of ataxia. Our findings provide evidence that the N-terminal residues 23-88 of PrP containing the unique octapeptide-repeat region is crucial for preventing Purkinje cell death in Prnp(0/0) mice expressing PrPLP/Dpl in the neuron.	Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki 8528523, Japan; Nagasaki Univ, Dept Pathol, Grad Sch Biomed Sci, Nagasaki 8528523, Japan; Nagasaki Univ, Dept Biochem & Mol Biol Dis, Grad Sch Biomed Sci, Inst Atom Bomb Dis, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Katamine, S (corresponding author), Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.							Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Behrens A, 2002, EMBO J, V21, P3652, DOI 10.1093/emboj/cdf386; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Li AM, 2000, CELL MOL NEUROBIOL, V20, P553, DOI 10.1023/A:1007059827541; Li AM, 2000, AM J PATHOL, V157, P1447, DOI 10.1016/S0002-9440(10)64782-7; Linder MC, 1996, AM J CLIN NUTR, V63, P797; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; Murphy RM, 2002, ANNU REV BIOMED ENG, V4, P155, DOI 10.1146/annurev.bioeng.4.092801.094202; Nishida N, 1999, LAB INVEST, V79, P689; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Qin KF, 2003, J BIOL CHEM, V278, P8888, DOI 10.1074/jbc.M210875200; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zhang YB, 2000, J BIOL CHEM, V275, P33650, DOI 10.1074/jbc.C000483200	45	42	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28944	28949		10.1074/jbc.M303655200	http://dx.doi.org/10.1074/jbc.M303655200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759361	hybrid			2022-12-25	WOS:000184421100074
J	Gan-Erdene, T; Nagamalleswari, K; Yin, LM; Wu, K; Pan, ZQ; Wilkinson, KD				Gan-Erdene, T; Nagamalleswari, K; Yin, LM; Wu, K; Pan, ZQ; Wilkinson, KD			Identification and characterization of DEN1, a deneddylase of the ULP family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYMES; UBIQUITIN ALDEHYDE; CRYSTAL-STRUCTURE; 26S PROTEASOME; PROTEINS; NEDD8; YEAST; SUMO; CONJUGATION; COMPLEX	To identify deneddylases, proteases with specificity for hydrolysis of Nedd8 derivatives, a facile method was developed for the synthesis of Nedd8 amidomethylcoumarin ( a substrate) and Nedd8 vinyl sulfone ( an inhibitor). Deneddylase activity is necessary to reverse the conjugation of Nedd8 to cullin, a modification that regulates at least some ubiquitin ligases. The reaction of Nedd8 vinyl sulfone with L-M( TK-) mouse fibroblast lysates identified two deneddylases. The deubiquitinating enzyme UCH-L3 is labeled by both ubiquitin vinyl sulfone and Nedd8 vinyl sulfone. In contrast, a second and more selective enzyme is labeled only by Nedd8 vinyl sulfone. This protein, DEN1, is a 221-amino acid thiol protease that is encoded by an open reading frame previously annotated as SENP8. Recombinant human DEN1 shows significant specificity for Nedd8 and catalyzes the hydrolysis of Nedd8 amidomethylcoumarin with a Km of 51 nM and a k(cat) of 7 s(-1). The catalytic efficiency of DEN1 acting upon ubiquitin amidomethylcoumarin is 6 x 10(-4) that of Nedd8 amidomethylcoumarin and its activity on SUMO-1 amidomethylcoumarin is undetectable. This selectivity was unexpected as DEN1 is most closely related to enzymes that catalyze desumoylation. This observation expands to four the number of DUB families with members that can process the C terminus of Nedd8.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Emory University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wilkinson, KD (corresponding author), Emory Univ, Sch Med, Dept Biochem, 4017 Rollins Bldg, Atlanta, GA 30322 USA.				FOGARTY INTERNATIONAL CENTER [F05TW005461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061051, R01GM030308, R01GM066355] Funding Source: NIH RePORTER; FIC NIH HHS [F05 TW05461] Funding Source: Medline; NIGMS NIH HHS [GM066355, GM061051, GM30308] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Brett TJ, 2000, J CHEM SOC PERK T 2, V6, P1105; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Coux Olivier, 2002, Prog Mol Subcell Biol, V29, P85; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Linghu B, 2002, EUKARYOT CELL, V1, P491, DOI 10.1128/EC.1.3.491-494.2002; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; Melandri F, 1996, BIOCHEMISTRY-US, V35, P12893, DOI 10.1021/bi9612935; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; WILINSON KD, 1998, HDB PROTEOLYTIC ENZY, P660; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; Wilkinson KD, 1999, J MOL BIOL, V291, P1067; WILKINSON KD, 1986, BIOCHEMISTRY-US, V25, P6644, DOI 10.1021/bi00369a047; WILKINSON KD, 1988, UBIQUITIN, P5; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	47	145	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28892	28900		10.1074/jbc.M302890200	http://dx.doi.org/10.1074/jbc.M302890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759362	hybrid			2022-12-25	WOS:000184421100068
J	Giles, N; Forrest, A; Gabrielli, B				Giles, N; Forrest, A; Gabrielli, B			14-3-3 acts as an intramolecular bridge to regulate cdc25B localization and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-CONTROL; CYCLIN A/CDK2; PHOSPHATASE; MITOSIS; PHOSPHORYLATION; ACTIVATION; CHECKPOINT; TRIGGERS; PROTEIN; BINDING	One of the major regulators of mitosis in somatic cells is cdc25B. cdc25B is tightly regulated at multiple levels. The final activation step involves the regulated binding of 14-3-3 proteins. Previous studies have demonstrated that Ser-323 is a primary 14-3-3 binding site in cdc25B, which influences its activity and cellular localization. 14-3-3 binding to this site appeared to interact with the N-terminal domain of cdc25B to regulate its activity. The presence of consensus 14-3-3 binding sites in the N-terminal domain suggested that the interaction is through direct binding of the 14-3-3 dimer to sites in the N-terminal domain. We have identified Ser-151 and Ser-230 in the N-terminal domain as functional 14-3-3 binding sites utilized by cdc25B in vivo. These low affinity sites cooperate to bind the 14-3-3 dimer bound to the high affinity Ser-323 site, thus forming an intramolecular bridge that constrains cdc25B structure to prevent access of the catalytic site. Loss of 14-3-3 binding to either N-terminal site relaxes cdc25B structure sufficiently to permit access to the catalytic site, and the nuclear export sequence located in the N-terminal domain. Mutation of the Ser-323 site was functionally equivalent to the mutation of all three sites, resulting in the complete loss of 14-3-3 binding, increased access of the catalytic site, and access to nuclear localization sequence.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.		Forrest, Alistair/A-6597-2008; Gabrielli, Brian G/B-3655-2011	Forrest, Alistair/0000-0003-4543-1675; Gabrielli, Brian G/0000-0003-3933-1651				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Lammer C, 1998, J CELL SCI, V111, P2445; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	27	67	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28580	28587		10.1074/jbc.M304027200	http://dx.doi.org/10.1074/jbc.M304027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12764136	hybrid			2022-12-25	WOS:000184421100031
J	Sawada, S; Yoshimoto, M; Odintsova, E; Hotchin, NA; Berditchevski, F				Sawada, S; Yoshimoto, M; Odintsova, E; Hotchin, NA; Berditchevski, F			The tetraspanin CD151 functions as a negative regulator in the adhesion-dependent activation of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CELL-MIGRATION; INTEGRIN; KINASE; EXPRESSION; COMPLEXES; ALPHA(3)BETA(1); MOTILITY; ALPHA-3-BETA-1; ASSOCIATION	Transmembrane proteins of the tetraspanin superfamily are associated with integrins and are thought to regulate adhesion-dependent signaling. The molecular mechanisms of this regulation remain unknown. We used rat fibroblasts to analyze the contribution of the tetraspanin CD151 in the adhesion-dependent signaling. Expression of CD151 specifically attenuated adhesion-dependent activation of Ras. Furthermore, activation of PKB/c-Akt and ERK1/2, downstream targets in the Ras signaling pathway, was also diminished in cells expressing CD151. In contrast, adhesion-dependent activation of FAK and c-Src were not affected by CD151. The attenuation of Ras signaling did not correlate with phosphorylation of Tyr925-FAK, tyrosine phosphorylation of Shc, or with assembly of the p120RasGAP-p62Dok complex. Using mutants of CD151 we established that the cytoplasmic C-terminal portion is critical for activity of CD151 toward Ras. Taken together these results identify CD151 as a negative regulator of Ras and suggest a novel mechanism of adhesion- dependent regulation of Ras activity.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TA, W Midlands, England	Cancer Research UK; University of Birmingham; University of Birmingham	Berditchevski, F (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	f.berditchevski@bham.ac.uk		Hotchin, Neil/0000-0002-1844-7607				Ashman LK, 2002, J BIOL REG HOMEOS AG, V16, P223; Baudoux B, 2000, EUR J CELL BIOL, V79, P41, DOI 10.1078/S0171-9335(04)70006-0; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berditchevski F, 2001, J CELL SCI, V114, P4143; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Berditchevski F, 2001, J BIOL CHEM, V276, P41165, DOI 10.1074/jbc.M104041200; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Geary SM, 2001, TISSUE ANTIGENS, V58, P141, DOI 10.1034/j.1399-0039.2001.580301.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hall BE, 2002, FRONT BIOSCI, V7, pD288, DOI 10.2741/hall; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Kohno M, 2002, INT J CANCER, V97, P336, DOI 10.1002/ijc.1605; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Testa JE, 1999, CANCER RES, V59, P3812; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yanez-Mo M, 2001, MICROCIRCULATION, V8, P153; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	32	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26323	26326		10.1074/jbc.C300210200	http://dx.doi.org/10.1074/jbc.C300210200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12782641	hybrid			2022-12-25	WOS:000184155700006
J	Aldred, MA; Morrison, C; Gimm, O; Hoang-Vu, C; Krause, U; Dralle, H; Jhiang, S; Eng, C				Aldred, MA; Morrison, C; Gimm, O; Hoang-Vu, C; Krause, U; Dralle, H; Jhiang, S; Eng, C			Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas	ONCOGENE			English	Article						follicular thyroid cancer; microarray analysis	LONG ARM; TUMORS; MUTATIONS; CANCER; HETEROZYGOSITY; PAPILLARY; INSTABILITY; EXPRESSION; DELETIONS; SUGGESTS	Peroxisome proliferator-activated receptor gamma (PPARgamma) has previously been implicated in the pathogenesis of follicular thyroid carcinoma (FTC), where a translocation with PAX8 has been reported in some 50% of tumors in three small series. The resultant fusion protein inhibits normal PPARgamma function by a dominant-negative mechanism. In a series of 19 FTCs, we identified this translocation in only two tumors (10.5%). However, microarray analysis and semiquantitative RT-PCR demonstrated greatly reduced PPARgamma expression in 13 of 17 (76%) nontranslocation tumors. Immunohistochemical analysis of 142 thyroid tumors showed a statistically significant reduction in PPARgamma immunoreactive protein, not only in FTCs but also in papillary thyroid carcinomas and Hurthle cell carcinomas. This suggests that while the overall frequency of the PAX8-PPARgamma translocation in FTCs may be lower than previously thought, functional downregulation of PPARgamma is a key event in multiple types of thyroid neoplasia and is a possible target for therapeutic intervention.	Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Univ Halle Wittenberg, Dept Surg, Halle Saale, Germany; Univ Halle Wittenberg, Inst Pathol, Halle Saale, Germany; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Leicester, Div Med Genet, Leicester, Leics, England; Univ Cambridge, Canc Res UK, Human Canc Genet Res Grp, Cambridge, England	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; University System of Ohio; Ohio State University; University of Leicester; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Ohio State Univ, Human Canc Genet Program, 420 W 12th Ave,Ste 690 TMRF, Columbus, OH 43210 USA.			Eng, Charis/0000-0002-3693-5145	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Clay CE, 2000, PROSTAG OTH LIPID M, V62, P23, DOI 10.1016/S0090-6980(00)00073-3; Dahia PLM, 1997, CANCER RES, V57, P4710; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Grebe SKG, 1997, J CLIN ENDOCR METAB, V82, P3684, DOI 10.1210/jc.82.11.3684; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Oriola J, 2001, EUR J CANCER, V37, P2470, DOI 10.1016/S0959-8049(01)00302-1; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; Trovato M, 1999, J CLIN ENDOCR METAB, V84, P3235, DOI 10.1210/jcem.84.9.5986; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; Yeh JJ, 1999, GENE CHROMOSOME CANC, V26, P322, DOI 10.1002/(SICI)1098-2264(199912)26:4<322::AID-GCC6>3.0.CO;2-#; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758; Zhou XP, 2000, J MED GENET, V37, P410, DOI 10.1136/jmg.37.6.410	19	48	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3412	3416		10.1038/sj.onc.1206400	http://dx.doi.org/10.1038/sj.onc.1206400			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776192				2022-12-25	WOS:000183128500007
J	An, JB; Sun, YP; Sun, R; Rettig, MB				An, JB; Sun, YP; Sun, R; Rettig, MB			Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappa B and JNK/AP1 pathways	ONCOGENE			English	Article						KSHV; vFLIP; interleukin-6; NF-kappa B; jun N-terminal kinase; AP1	MULTICENTRIC CASTLEMANS-DISEASE; INTERLEUKIN-6 GENE-EXPRESSION; C-JUN; DNA-SEQUENCES; TERMINAL KINASE; NUCLEAR ANTIGEN; GROWTH-FACTOR; UP-REGULATION; ACTIVATION; HUMAN-HERPESVIRUS-8	The Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a FADD-like interferon converting enzyme or caspase 8 (FLICE) inhibitory protein (vFLIP) that prevents death receptor-mediated apoptosis by inhibiting the recruitment and activation of FLICE. Since vFLIP physically interacts with tumor necrosis factor receptor associated factor 2 (TRAF2) and TRAF2 mediates activation of the jun NH2-terminal kinase (JNK)/activation protein 1 (AP1) pathway, we hypothesized that vFLIP might also activate this pathway. To evaluate this hypothesis, we transiently and stably transfected a vFLIP expression construct and performed several complementary assays to document that vFLIP activates the JNK/AP1 pathway and does so in a TRAF-dependent fashion. As vFLIP also activates the nuclear factor kappaB (NF-kappaB) signaling pathway and the NF-kappaB and JNK/AP1 pathways both modulate cellular interleukin-6 (cIL-6) expression, we postulated that vFLIP induces expression of this cytokine. We show that vFLIP induces cIL-6 expression and activates the cIL-6 promoter, and maximal activation of the cIL-6 promoter by vFLIP requires NF-kappaB and AP1 activation. In addition, vFLIP and latency-associated nuclear antigen (LANA), another KSHV-encoded latent protein, potentiate each other's ability to activate the cIL-6 promoter. Gene silencing experiments by RNA interference demonstrate that vFLIP in BCBL-1 endogenously infected primary effusion lymphoma (PEL) cells mediates JNK/AP1 activation and cIL-6 expression. Thus, we conclude that vFLIP, in addition to its known effects on NF-kappaB activation, also modulates the JNK/AP1 pathway and induces gene expression from the cIL-6 promoter in a JNK/AP1-dependent fashion.	VA Greater Los Angeles Healthcare Syst W LA, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rettig, MB (corresponding author), VA Greater Los Angeles Healthcare Syst W LA, Dept Med, 11301 Wilshire Blvd,Bldg 304,Room E1-113, Los Angeles, CA 90073 USA.	matthew.rettig@med.va.gov			NCI NIH HHS [1R01CA80004-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2002, BLOOD, V99, P649, DOI 10.1182/blood.V99.2.649; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BLACK EJ, 1991, ONCOGENE, V6, P1949; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Foussat A, 1999, EUR CYTOKINE NETW, V10, P501; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Glykofrydes D, 2000, J VIROL, V74, P11919, DOI 10.1128/JVI.74.24.11919-11927.2000; Grandadam M, 1997, J INFECT DIS, V175, P1198, DOI 10.1086/593567; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Hu SM, 1997, J BIOL CHEM, V272, P9621; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Keller SA, 2000, BLOOD, V96, P2537; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEGERRAVET MB, 1991, BLOOD, V78, P2923; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Panyutich EA, 1998, AIDS, V12, P467, DOI 10.1097/00002030-199805000-00007; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Talbot SJ, 1999, VIROLOGY, V257, P84, DOI 10.1006/viro.1999.9672; THORNE M, 1997, NATURE, V386, P517	46	101	105	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3371	3385		10.1038/sj.onc.1206407	http://dx.doi.org/10.1038/sj.onc.1206407			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776188	Bronze			2022-12-25	WOS:000183128500003
J	Arlt, A; Kruse, ML; Breitenbroich, M; Gehrz, A; Koc, B; Minkenberg, J; Folsch, UR; Schafer, H				Arlt, A; Kruse, ML; Breitenbroich, M; Gehrz, A; Koc, B; Minkenberg, J; Folsch, UR; Schafer, H			The early response gene IEX-1 attenuates NF-kappa B activation in 293 cells, a possible counter-regulatory process leading to enhanced cell death	ONCOGENE			English	Article						programmed cell death; cytokines; transcription factor; ribozyme	IMMEDIATE-EARLY GENE; TARGET GENE; IMMUNE-RESPONSES; IN-VIVO; APOPTOSIS; GROWTH; IDENTIFICATION; EXPRESSION; P53; KERATINOCYTES	The early response gene IEX-1 is involved in the regulation of cellular growth and survival, and its expression is related to stress-, growth- and death-inducing signals. Addressing the role of IEX-1 in the promotion of apoptosis, we investigated the effect of IEX-1 on nuclear factor-kappaB (NF-kappaB) activation. Stably transfected HEK-293 cells conditionally overexpressing IEX-1 exhibit decreased levels of NF-kappaB activity, either basal or TNFalpha induced, as shown by gel-shift and luciferase reporter gene assay. Furthermore, activated p65 accumulated in the nuclei of 293 cells to a lower degree, if IEX-1 expression was increased. This inhibited NF-kappaB activation was preceded by an altered turnover of IkappaBalpha and phospho-IkappaBalpha. In addition, IEX-1 expression also inhibited the activity of the 26S-proteasome, as shown by a fluorometric proteasome assay. Conversely, disruption of IEX-1 expression in 293 cells by stable transfection with specific anti-IEX-1 hammerhead ribozymes increased NF-kappaB activity, and accelerated the degradation of IkappaBalpha. Along with these opposite effects of IEX-1 expression and IEX-1 disruption on NF-kappaB activation, the sensitivity of 293 cells towards various apoptotic stimuli also changed. In contrast to ribozyme-transduced 293 cells that were significantly less sensitive to apoptosis, this sensitivity was enhanced if IEX-1 expression was increased. Our data suggest that IEX-1 itself an NF-kappaB target gene - inhibits the activation of this transcription factor, and hereby may counteract the antiapoptodc potential of NF-kappaB.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany	University of Kiel	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; CHARLES CH, 1993, ONCOGENE, V8, P797; Chen BC, 2002, J BIOL CHEM, V277, P24169, DOI 10.1074/jbc.M106014200; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; De Keulenaer GW, 2002, CIRC RES, V90, P690, DOI 10.1161/01.RES.0000012922.40318.05; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; IM HJ, 2002, J BIOL CHEM, V21, P3706; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Masdehors P, 2000, BLOOD, V96, P269, DOI 10.1182/blood.V96.1.269.013k10_269_274; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ohki R, 2002, J HYPERTENS, V20, P685, DOI 10.1097/00004872-200204000-00026; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; Seitz CS, 2000, CANCER RES, V60, P4085; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tone Y, 2002, GENE DEV, V16, P3142, DOI 10.1101/gad.1025602; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 2002, ONCOGENE, V21, P4969, DOI 10.1038/sj.onc.1205620; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699	40	37	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3343	3351		10.1038/sj.onc.1206524	http://dx.doi.org/10.1038/sj.onc.1206524			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761504				2022-12-25	WOS:000183040000016
J	Iizuka, N; Oka, M; Yamada-Okabe, H; Mori, N; Tamesa, T; Okada, T; Takemoto, N; Hashimoto, K; Tangoku, A; Hamada, K; Nakayama, H; Miyamoto, T; Uchimura, S; Hamamoto, Y				Iizuka, N; Oka, M; Yamada-Okabe, H; Mori, N; Tamesa, T; Okada, T; Takemoto, N; Hashimoto, K; Tangoku, A; Hamada, K; Nakayama, H; Miyamoto, T; Uchimura, S; Hamamoto, Y			Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis	ONCOGENE			English	Article						DNA chip; gene expression profiles; HCC; HBV; liver cirrhosis	HEPATITIS-B; CDNA MICROARRAY; CANCER; IDENTIFICATION; APOPTOSIS; PROFILES; CARCINOGENESIS; PROGRESSION; INTERACTS; BINDING	Using oligonucleotide microarray data of 45 hepatocellular carcinoma (HCC) samples, we evaluated gene expression in hepatitis B virus-positive and hepatitis C virus-positive HCCs (HBV- and HCV-HCCs) for an association with liver cirrhosis (LC). In all, 89 genes were expressed differentially between HBV-HCCs associated with LC and those not associated with LC. Among them, tumors from LC patients showed significantly lower expression levels of 72 genes and significantly higher levels of 17 genes than the levels found in tumors from non-LC patients. The former included genes responsible for signal transduction, transcription, metabolism, and cell growth. The latter included a tumor suppressor gene and a cell-growth-related gene. Only eight genes were expressed differentially between HCV-HCCs associated with and without LC. Our findings provide as a framework for clarifying the role of LC in HBV- and HCV-related hepatocarcinogenesis.	Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Bioregulat Funct, Yamaguchi 7558505, Japan; Nippon Roche Res Ctr, Dept Oncol, Kanagawa 2478530, Japan; Yamaguchi Univ, Fac Engn, Dept Comp Sci & Syst Engn, Yamaguchi 7558611, Japan	Yamaguchi University; Yamaguchi University; Roche Holding; Yamaguchi University	Oka, M (corresponding author), Yamaguchi Univ, Sch Med, Dept Surg 2, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.							Bode BP, 1999, JPEN-PARENTER ENTER, V23, pS33, DOI 10.1177/014860719902300509; Delpuech O, 2002, ONCOGENE, V21, P2926, DOI 10.1038/sj.onc.1205392; Goldenberg D, 2002, MOL CARCINOGEN, V33, P113, DOI 10.1002/mc.10027.abs; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Huang CJ, 2000, J BIOMED SCI, V7, P160, DOI 10.1159/000025442; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; IIZUKA N, 1995, CANCER RES, V55, P652; Iizuka N, 2002, INT J CANCER, V99, P286, DOI 10.1002/ijc.10338; Iizuka N, 2002, CANCER RES, V62, P3939; Kao JH, 2000, GASTROENTEROLOGY, V118, P554, DOI 10.1016/S0016-5085(00)70261-7; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kim JS, 2002, CANCER RES, V62, P2744; Koike K, 2002, ONCOLOGY-BASEL, V62, P29, DOI 10.1159/000048273; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lau WY, 2000, ONCOL RES, V12, P59; Luo J, 2001, CANCER RES, V61, P4683; Okabe H, 2001, CANCER RES, V61, P2129; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith TAD, 1999, BRIT J BIOMED SCI, V56, P285; Sobin L, 2002, TNM CLASSIFICATION M, P81; van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037; Xu L, 2001, CANCER RES, V61, P3176; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398	26	77	86	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					3007	3014		10.1038/sj.onc.1206401	http://dx.doi.org/10.1038/sj.onc.1206401			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771952				2022-12-25	WOS:000182824800016
J	Murata, Y; Watanabe, T; Sato, M; Momose, Y; Nakahara, T; Oka, S; Iwahashi, H				Murata, Y; Watanabe, T; Sato, M; Momose, Y; Nakahara, T; Oka, S; Iwahashi, H			Dimethyl sulfoxide exposure facilitates phospholipid biosynthesis and cellular membrane proliferation in yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; S-ADENOSYLMETHIONINE; DNA MICROARRAY; DIMETHYLSULFOXIDE REDUCTASE; ENVIRONMENTAL-CHANGES; LIPID BIOSYNTHESIS; WALL PROTEINS; EXPRESSION; DMSO	Me2SO is a polar solvent that is widely used in biochemistry, pharmacology, and industry. Although there are several reports in the literature concerning the biological effects of Me2SO, the total cellular response remains unclear. In this paper, DNA microarray technology combined with the hierarchical clustering bioinformatics tool was used to assess the effects of Me2SO on yeast cells. We found that yeast exposed to Me2SO increased phospholipid biosynthesis through up-regulated gene expression. It was confirmed by Northern blotting that the level of INO1 and OPI3 gene transcripts, encoding key enzymes in phospholipid biosynthesis, were significantly elevated following treatment with Me2SO. Furthermore, the phospholipid content of the cells increased during exposure to Me2SO as shown by conspicuous incorporation of a lipophilic fluorescent dye (3,3'-dihexyloxacarbocyanine iodide) into the cell membranes. From these results we propose that Me2SO treatment induces membrane proliferation in yeast cells to alleviate the adverse affects of this chemical on membrane integrity.	Natl Inst Adv Ind Sci Technol, Int Patent Organism Depositary, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci Technol, Res Inst Biol Resources, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Iwahashi, H (corresponding author), Natl Inst Adv Ind Sci Technol, Int Patent Organism Depositary, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.		Iwahashi, Hitoshi/S-1360-2019	Murata, Yoshinori/0000-0003-4246-659X				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; BLAU HM, 1979, CELL, V17, P95, DOI 10.1016/0092-8674(79)90298-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Block-Alper L, 2002, MOL BIOL CELL, V13, P40, DOI 10.1091/mbc.01-07-0366; Bolduc L, 2001, J BIOL CHEM, V276, P17597, DOI 10.1074/jbc.M011769200; Braley R, 1999, FEMS MICROBIOL LETT, V181, P177, DOI 10.1016/S0378-1097(99)00535-2; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Fuse H, 2000, APPL ENVIRON MICROB, V66, P5527, DOI 10.1128/AEM.66.12.5527-5532.2000; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hansen J, 1999, APPL ENVIRON MICROB, V65, P3915; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; KELLOGG WW, 1972, SCIENCE, V175, P587, DOI 10.1126/science.175.4022.587; Kitagawa E, 2002, ENVIRON SCI TECHNOL, V36, P3908, DOI 10.1021/es015705v; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; Koning AJ, 1996, MOL BIOL CELL, V7, P769, DOI 10.1091/mbc.7.5.769; Kurita S, 2002, BIOSCI BIOTECH BIOCH, V66, P532, DOI 10.1271/bbb.66.532; MADIGAN MT, 1978, ARCH MICROBIOL, V117, P119, DOI 10.1007/BF00402298; MCEWAN AG, 1983, ARCH MICROBIOL, V136, P300, DOI 10.1007/BF00425221; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Momose Y, 2001, ENVIRON TOXICOL CHEM, V20, P2353; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; MURATA Y, 2002, CHEMBIO INFORMATICS; PARRISH ML, 1995, MOL BIOL CELL, V6, P1535, DOI 10.1091/mbc.6.11.1535; POLLERBERG GE, 1986, NATURE, V324, P462, DOI 10.1038/324462a0; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SATOH T, 1987, J BIOCHEM-TOKYO, V102, P191, DOI 10.1093/oxfordjournals.jbchem.a122032; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; Teraoka H, 1996, EXP CELL RES, V222, P218, DOI 10.1006/excr.1996.0027; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; THOMAS D, 1991, MOL GEN GENET, V226, P224, DOI 10.1007/BF00273607; Thomas D, 2000, J BIOL CHEM, V275, P40718, DOI 10.1074/jbc.M005967200; THOMAS D, 1987, J BIOL CHEM, V262, P16704; WANG H, 1993, CELL PROLIFERAT, V26, P55, DOI 10.1111/j.1365-2184.1993.tb00006.x; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; YENOFSKY R, 1983, MOL CELL BIOL, V3, P1197, DOI 10.1128/MCB.3.7.1197; ZINDER SH, 1978, ARCH MICROBIOL, V116, P35, DOI 10.1007/BF00408731	50	66	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33185	33193		10.1074/jbc.M300450200	http://dx.doi.org/10.1074/jbc.M300450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12771156	hybrid			2022-12-25	WOS:000184901800085
J	Singh, A; Venning, JD; Quirk, PG; van Boxel, GI; Rodrigues, DJ; White, SA; Jackson, JB				Singh, A; Venning, JD; Quirk, PG; van Boxel, GI; Rodrigues, DJ; White, SA; Jackson, JB			Interactions between transhydrogenase and thio-nicotinamide analogues of NAD(H) and NADP(H) underline the importance of nucleotide conformational changes in coupling to proton translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM TRANSHYDROGENASE; MACROMOLECULAR STRUCTURE DETERMINATION; NADP(H)-BINDING COMPONENT DIII; BINDING-CHANGE MECHANISM; ESCHERICHIA-COLI; HYDRIDE TRANSFER; DOMAIN-III; CATALYTIC PROPERTIES; CRYSTAL-STRUCTURES; ALTERNATING-SITE	Transhydrogenase couples the reduction of NADP(+) by NADH to inward proton translocation across mitochondrial and bacterial membranes. The coupling reactions occur within the protein by long distance conformational changes. In intact transhydrogenase and in complexes formed from the isolated, nucleotide-binding components, thio-NADP(H) is a good analogue for NADP( H), but thio-NAD(H) is a poor analogue for NAD(H). Crystal structures of the nucleotide-binding components show that the twists of the 3-carbothiamide groups of thio-NADP(+) and of thio-NAD(+) ( relative to the planes of the pyridine rings), which are defined by the dihedral, X-am, are altered relative to the twists of the 3-carboxamide groups of the physiological nucleotides. The finding that thio-NADP(+) is a good substrate despite an increased X-am value shows that approach of the NADH prior to hydride transfer is not obstructed by the S atom in the analogue. That thio-NAD( H) is a poor substrate appears to be the result of failure in the conformational change that establishes the ground state for hydride transfer. This might be a consequence of restricted rotation of the 3-carbothiamide group during the conformational change.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.		White, Scott/C-6684-2008	White, Scott/0000-0002-0202-6154				ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; Bergkvist A, 2000, BIOCHEMISTRY-US, V39, P12595, DOI 10.1021/bi0004091; Bizouam T, 1997, BBA-BIOENERGETICS, V1322, P19, DOI 10.1016/S0005-2728(97)00065-0; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; Bizouarn T, 2000, BBA-BIOENERGETICS, V1457, P211, DOI 10.1016/S0005-2728(00)00103-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLAYTON RK, 1963, BIOCHIM BIOPHYS ACTA, V75, P312, DOI 10.1016/0006-3002(63)90618-8; Cook P.F., 1987, PYRIDINE NUCLEOTID A, P405; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; CUMMINS PL, 1989, J MOL STRUCT THEOCHE, V183, P161; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Evans W, 1997, CHEM BRIT, V33, P22; FISHER RR, 1971, J BIOL CHEM, V246, P4687; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; Gadret M., 1969, B SOC PHARM BORDEAUX, V108, P38; Grosse-Kunstleve RW, 1999, ACTA CRYSTALLOGR D, V55, P1568, DOI 10.1107/S0907444999007763; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; HOEK JB, 1988, BIOCHEM J, V254, P1; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 1999, FEBS LETT, V464, P1, DOI 10.1016/S0014-5793(99)01644-0; Jackson JB, 2002, BIOCHEMISTRY-US, V41, P4173, DOI 10.1021/bi012078d; Jeeves M, 2000, BBA-BIOENERGETICS, V1459, P248, DOI 10.1016/S0005-2728(00)00159-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE CHUAN-PU, 1965, BIOCHIM BIOPHYS BIOPHYS ACTA, V105, P397; MCTIGUE MA, 1993, BIOCHEMISTRY-US, V32, P6855, DOI 10.1021/bi00078a008; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Peake SJ, 1999, BBA-BIOENERGETICS, V1413, P81, DOI 10.1016/S0005-2728(99)00084-5; Peake SJ, 1999, BBA-BIOENERGETICS, V1411, P159, DOI 10.1016/S0005-2728(99)00013-4; Pinheiro TJT, 2001, J BIOL CHEM, V276, P44757, DOI 10.1074/jbc.M109227200; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; Prasad GS, 2002, BIOCHEMISTRY-US, V41, P12745, DOI 10.1021/bi020251f; Quirk PG, 1999, FEBS LETT, V446, P127, DOI 10.1016/S0014-5793(99)00198-2; REDDY BS, 1981, J AM CHEM SOC, V103, P907, DOI 10.1021/ja00394a031; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Rydstrom J, 1979, Methods Enzymol, V55, P261; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; van Boxel GI, 2003, BIOCHEMISTRY-US, V42, P1217, DOI 10.1021/bi027032e; Venning JD, 2000, J BIOL CHEM, V275, P19490, DOI 10.1074/jbc.M000577200; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1999, BIOCHEM J, V341, P329, DOI 10.1042/0264-6021:3410329; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; WU YD, 1995, J AM CHEM SOC, V117, P4100, DOI 10.1021/ja00119a026; WU YD, 1993, J ORG CHEM, V58, P2043, DOI 10.1021/jo00060a017	51	14	17	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33208	33216		10.1074/jbc.M303061200	http://dx.doi.org/10.1074/jbc.M303061200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12791694	hybrid			2022-12-25	WOS:000184901800088
J	Feng, LJ; Arvan, P				Feng, LJ; Arvan, P			The trafficking of alpha(1)-antitrypsin, a post-Golgi secretory pathway marker, in INS-1 pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; PROLINE-RICH PROTEIN; ATT-20 CELLS; INTRACELLULAR DEGRADATION; GRANULE BIOGENESIS; CARBOXYPEPTIDASE-E; LYSOSOMAL-ENZYMES; INSULIN-SECRETION; MEMBRANE-BINDING; HOMOTYPIC FUSION	A sulfated alpha(1)-antitrypsin (AAT), thought to be a default secretory pathway marker, is not stored in secretory granules when expressed in neuroendocrine PC12 cells. In search of a constitutive secretory pathway marker for pancreatic beta cells, we produced INS-1 cells stably expressing wild-type AAT. Because newly synthesized AAT arrives very rapidly in the Golgi complex, kinetics alone cannot resolve AAT release via distinct secretory pathways, although most AAT is secreted within a few hours and virtually none is stored in mature granules. Nevertheless, from pulse-chase analyses, a major fraction of newly synthesized AAT transiently exhibits secretogogue-stimulated exocytosis and localizes within immature secretory granules (ISGs). This trafficking occurs without detectable AAT polymerization or binding to lipid rafts. Remarkably, in a manner not requiring its glycans, all of the newly synthesized AAT is then removed from granules during their maturation, leading mostly to constitutive-like AAT secretion, whereas a smaller fraction (similar to10%) goes on to lysosomes. Secretogogue-stimulated ISG exocytosis reroutes newly synthesized AAT directly into the medium and prevents its arrival in lysosomes. These data are most consistent with the idea that soluble AAT abundantly enters ISGs and then is efficiently relocated to the endosomal system, from which many molecules undergo constitutive-like secretion while a smaller fraction advances to lysosomes.	Yeshiva Univ Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Univ Michigan, Div Endocrinol, MSRB2,Rm 5560,1500 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu			NIDDK NIH HHS [DK48280] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; Blazquez M, 2001, J MOL ENDOCRINOL, V27, P107, DOI 10.1677/jme.0.0270107; BOMMER G, 1976, VIRCHOWS ARCH A, V371, P227, DOI 10.1007/BF00433070; BORG LAH, 1986, DIABETES RES CLIN EX, V3, P277; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Castle AM, 1998, FEBS LETT, V439, P341, DOI 10.1016/S0014-5793(98)01398-2; Castle AM, 1997, J CELL BIOL, V138, P45, DOI 10.1083/jcb.138.1.45; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; Castle JD, 1996, J CELL SCI, V109, P2591; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CLERMONT Y, 1992, ANAT RECORD, V232, P349, DOI 10.1002/ar.1092320304; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; Dumermuth E, 1998, METHODS, V16, P188, DOI 10.1006/meth.1998.0666; El Meskini R, 2001, ENDOCRINOLOGY, V142, P864, DOI 10.1210/endo.142.2.7929; GLASER CB, 1977, BIOCHIM BIOPHYS ACTA, V491, P325, DOI 10.1016/0005-2795(77)90068-X; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; HALBAN PA, 1983, DIABETES, V32, P254, DOI 10.2337/diabetes.32.3.254; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Huang AY, 2001, J BIOL CHEM, V276, P22296, DOI 10.1074/jbc.M100211200; HUANG XF, 1994, J BIOL CHEM, V269, P20838; KELLY RB, 1983, COLD SPRING HARB SYM, V48, P697, DOI 10.1101/SQB.1983.048.01.073; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kuliawat R, 2000, MOL BIOL CELL, V11, P1959, DOI 10.1091/mbc.11.6.1959; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; Millar CA, 2000, TRAFFIC, V1, P141, DOI 10.1034/j.1600-0854.2000.010206.x; MITRA A, 1994, J BIOL CHEM, V269, P19876; Molinete M, 2000, DIABETOLOGIA, V43, P1157, DOI 10.1007/s001250051507; NEERMANARBEZ M, 1993, J BIOL CHEM, V268, P16248; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1984, P NATL ACAD SCI-BIOL, V81, P6743, DOI 10.1073/pnas.81.21.6743; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; RHODES CJ, 1988, BIOCHEM J, V251, P23, DOI 10.1042/bj2510023; Rindler MJ, 2001, BIOCHEM BIOPH RES CO, V288, P1071, DOI 10.1006/bbrc.2001.5889; SAMANDARI T, 1993, PROTEIN SCI, V2, P1400, DOI 10.1002/pro.5560020905; SAWANO F, 1986, EXP CELL RES, V164, P174, DOI 10.1016/0014-4827(86)90464-7; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; Stahl LE, 1996, J CELL SCI, V109, P1637; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Turner MD, 2000, J BIOL CHEM, V275, P14025, DOI 10.1074/jbc.275.19.14025; Urbe S, 1998, J CELL BIOL, V143, P1831, DOI 10.1083/jcb.143.7.1831; Wendler F, 2001, MOL BIOL CELL, V12, P1699, DOI 10.1091/mbc.12.6.1699; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187	62	19	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31486	31494		10.1074/jbc.M305690200	http://dx.doi.org/10.1074/jbc.M305690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12796484	hybrid			2022-12-25	WOS:000184782100007
J	Foreman, PK; Brown, D; Dankmeyer, L; Dean, R; Diener, S; Dunn-Coleman, NS; Goedegebuur, F; Houfek, TD; England, GJ; Kelley, AS; Meerman, HJ; Mitchell, T; Mitchinson, C; Olivares, HA; Teunissen, PJM; Yao, J; Ward, M				Foreman, PK; Brown, D; Dankmeyer, L; Dean, R; Diener, S; Dunn-Coleman, NS; Goedegebuur, F; Houfek, TD; England, GJ; Kelley, AS; Meerman, HJ; Mitchell, T; Mitchinson, C; Olivares, HA; Teunissen, PJM; Yao, J; Ward, M			Transcriptional regulation of biomass-degrading enzymes in the filamentous fungus Trichoderma reesei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULASE GENE-EXPRESSION; BETA-GLUCOSIDASE; CATABOLITE REPRESSION; MOLECULAR-CLONING; SEQUENCE; ENDOGLUCANASE; XYLANASE; INDUCTION; PROTEIN; XYN2	The filamentous fungus Trichoderma reesei produces and secretes profuse quantities of enzymes that act synergistically to degrade cellulase and related biomass components. We partially sequenced over 5100 random T. reesei cDNA clones. Among the sequences whose predicted gene products had significant similarity to known proteins, 12 were identified that encode previously unknown enzymes that likely function in biomass degradation. Microarrays were used to query the expression levels of each of the sequences under different conditions known to induce cellulolytic enzyme synthesis. Most of the genes encoding known and putative biomass-degrading enzymes were transcriptionally coregulated. Moreover, despite the fact that several of these enzymes are not thought to degrade cellulase directly, they were coordinately overexpressed in a cellulase overproducing strain. A variety of additional sequences whose function could not be ascribed using the limited sequence available displayed analogous behavior and may also play a role in biomass degradation or in the synthesis of biomass-degrading enzymes. Sequences exhibiting additional regulatory patterns were observed that might reflect roles in regulation of cellulase biosynthesis. However, genes whose products are involved in protein processing and secretion were not highly regulated during cellulase induction.	Genencor Int Inc, Palo Alto, CA 94304 USA; N Carolina State Univ, Fungal Genom Lab, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Foreman, PK (corresponding author), Genencor Int Inc, 925 Page Mill Rd, Palo Alto, CA 94304 USA.	Pforeman@genencor.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Aurilia V, 2000, MICROBIOL-SGM, V146, P1391, DOI 10.1099/00221287-146-6-1391; BARNETT CC, 1991, BIO-TECHNOL, V9, P562, DOI 10.1038/nbt0691-562; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; Biely P., 1998, TRICHODERMA GLIOCLAD, V2, P25; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; CarleUrioste JC, 1997, J BIOL CHEM, V272, P10169, DOI 10.1074/jbc.272.15.10169; Chambergo FS, 2002, J BIOL CHEM, V277, P13983, DOI 10.1074/jbc.M107651200; Conesa A, 2001, FUNGAL GENET BIOL, V33, P155, DOI 10.1006/fgbi.2001.1276; COUTINHO PM, 1999, GENETICS BIOCH ECOLO, P15; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Den Haan R, 2001, APPL MICROBIOL BIOT, V57, P521, DOI 10.1007/s002530100790; DeRisi J, 1996, NAT GENET, V14, P457; Dove A, 2000, NAT BIOTECHNOL, V18, P490, DOI 10.1038/75341; Durand H., 1998, FEMS S, V43, P135; Gerngross TU, 1999, NAT BIOTECHNOL, V17, P541, DOI 10.1038/9843; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Himmel ME, 1997, ACS SYM SER, V666, P2; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Ilmen M, 1997, APPL ENVIRON MICROB, V63, P1298; KUBICEK CP, 1987, J GEN MICROBIOL, V133, P1481; Mach R.L., 1993, THESIS I BIOCH TECHN; Mach RL, 1996, MOL MICROBIOL, V21, P1273, DOI 10.1046/j.1365-2958.1996.00094.x; MANDELS M, 1962, J BACTERIOL, V83, P400, DOI 10.1128/JB.83.2.400-408.1962; Mannhaupt G, 2003, NUCLEIC ACIDS RES, V31, P1944, DOI 10.1093/nar/gkg293; MargollesClark E, 1996, APPL ENVIRON MICROB, V62, P3840, DOI 10.1128/AEM.62.10.3840-3846.1996; MargollesClark E, 1996, GENE, V172, P171, DOI 10.1016/0378-1119(96)00167-9; MargollesClark E, 1997, J BIOTECHNOL, V57, P167, DOI 10.1016/S0168-1656(97)00097-7; MargollesClark E, 1996, EUR J BIOCHEM, V237, P553, DOI 10.1111/j.1432-1033.1996.0553p.x; MargollesClark E, 1996, EUR J BIOCHEM, V240, P104, DOI 10.1111/j.1432-1033.1996.0104h.x; Mielenz JR, 2001, CURR OPIN MICROBIOL, V4, P324, DOI 10.1016/S1369-5274(00)00211-3; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; Nogawa M, 2001, CURR GENET, V38, P329, DOI 10.1007/s002940000165; Okada H, 1998, APPL ENVIRON MICROB, V64, P555; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; Rose SH, 2002, APPL MICROBIOL BIOT, V58, P461, DOI 10.1007/s00253-001-0922-3; SAARELAINEN R, 1993, MOL GEN GENET, V241, P497, DOI 10.1007/BF00279891; SALOHEIMO A, 1994, MOL MICROBIOL, V13, P219, DOI 10.1111/j.1365-2958.1994.tb00417.x; Saloheimo M, 1997, EUR J BIOCHEM, V249, P584, DOI 10.1111/j.1432-1033.1997.00584.x; SALOHEIMO M, 1988, GENE, V63, P11, DOI 10.1016/0378-1119(88)90541-0; Saloheimo M, 2002, EUR J BIOCHEM, V269, P4202, DOI 10.1046/j.1432-1033.2002.03095.x; Saloheimo M, 2002, APPL ENVIRON MICROB, V68, P4546, DOI 10.1128/AEM.68.9.4546-4553.2002; Saloheimo M, 1999, MOL GEN GENET, V262, P35, DOI 10.1007/s004380051057; Saloheimo M.L.A., 2001, WORLD INTELLECTUAL P; Seiboth B, 1997, J BACTERIOL, V179, P5318, DOI 10.1128/jb.179.17.5318-5320.1997; Sheehan J, 1999, BIOTECHNOL PROGR, V15, P817, DOI 10.1021/bp990110d; SHEIRNEISS G, 1984, APPL MICROBIOL BIOT, V20, P46; SHOEMAKER S, 1983, BIO-TECHNOL, V1, P691, DOI 10.1038/nbt1083-691; STALBRAND H, 1995, APPL ENVIRON MICROB, V61, P1090; Suto M, 2001, J BIOSCI BIOENG, V92, P305, DOI 10.1263/jbb.92.305; Takashima S, 1999, J BIOCHEM-TOKYO, V125, P728, DOI 10.1093/oxfordjournals.jbchem.a022343; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; TORRONEN A, 1992, BIO-TECHNOL, V10, P1461, DOI 10.1038/nbt1192-1461; UDENFRIEND S, 1995, METHOD ENZYMOL, V250, P571; Ward M., 1993, BIOCH GENETICS CELLU, P53; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Wyman CE, 2001, APPL BIOCHEM BIOTECH, V91-3, P5, DOI 10.1385/ABAB:91-93:1-9:5; Xu J, 1998, APPL MICROBIOL BIOT, V49, P718, DOI 10.1007/s002530051237; Zeilinger S, 1996, J BIOL CHEM, V271, P25624, DOI 10.1074/jbc.271.41.25624	63	359	464	0	86	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31988	31997		10.1074/jbc.M304750200	http://dx.doi.org/10.1074/jbc.M304750200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788920				2022-12-25	WOS:000184782100068
J	Colomar, A; Marty, V; Medina, C; Combe, C; Parnet, P; Amedee, T				Colomar, A; Marty, V; Medina, C; Combe, C; Parnet, P; Amedee, T			Maturation and release of interleukin-1 beta by lipopolysaccharide-primed mouse Schwann cells require the stimulation of P2X(7) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; DORSAL-ROOT GANGLIA; NUCLEOTIDE RECEPTOR; IMMUNE REGULATION; ATP; RAT; EXPRESSION; IL-1-BETA; SECRETION	The P2X(7) receptor, mainly expressed by immune cells, is a ionotropic receptor activated by high concentration of extracellular ATP. It is involved in several processes relevant to immunomodulation and inflammation. Among these processes, the production of extracellular interleukin-1beta (IL-1beta), a pro-inflammatory cytokine, plays a major role in the activation of the cytokine network. We have investigated the role of P2X(7) receptor and of an associated calcium-activated potassium conductance (BK channels) in IL-1beta maturation and releasing processes by Schwann cells. Lipopolysaccharide-primed Schwann cells synthesized large amounts of pro-IL-1beta but did not release detectable amounts of pro or mature IL-1beta. ATP on its own had no effect on the synthesis of pro-IL-1beta, but a co-treatment with lipopolysaccharide and ATP led to the maturation and the release of IL-1beta by Schwann cells. Both mechanisms were blocked by oxidized ATP. IL-1beta-converting enzyme (ICE), the caspase responsible for the maturation of pro-IL-1beta in IL-1beta, was activated by P2X(7) receptor stimulation. The specific inhibition of ICE by the caspase inhibitor Ac-Tyr-Val-Ala-Asp-aldehyde blocked the maturation of IL-1beta. In searching for a link between the P2X(7) receptor and the activation of ICE, we found that enhancing potassium efflux from Schwann cells upregulated the production of IL-1beta, while strongly reducing potassium efflux led to opposite effects. Blocking BK channels actually modulated IL-1beta release. Taken together, these results show that P2X(7) receptor stimulation and associated BK channels, through the activation of ICE, leads to the maturation and the release of IL-1beta by immune-challenged Schwann cells.	Inst Francois Magendie, Lab Neurobiol Integrat, INSERM, U394, F-33077 Bordeaux, France; Univ Montreal, Dept Physiol, Ctr Rech Sci Neurol, Montreal, PQ H3C 3J7, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Universite de Montreal	Amedee, T (corresponding author), Inst Francois Magendie, Lab Neurobiol Integrat, INSERM, U394, Rue Camille St Saens, F-33077 Bordeaux, France.		Parnet, Patricia/AAW-5064-2021; Parnet, Patricia/GOH-1209-2022					AMEDEE T, 1995, P ROY SOC B-BIOL SCI, V259, P277, DOI 10.1098/rspb.1995.0041; AMEDEE T, 1991, J PHYSIOL-LONDON, V441, P35, DOI 10.1113/jphysiol.1991.sp018737; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; ARMATI PJ, 1990, MUSCLE NERVE, V13, P106, DOI 10.1002/mus.880130204; BERGSTEINSDOTTIR K, 1991, J NEUROIMMUNOL, V34, P15, DOI 10.1016/0165-5728(91)90094-N; BERGSTEINSDOTTIR K, 1992, P NATL ACAD SCI USA, V89, P9054, DOI 10.1073/pnas.89.19.9054; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; Cheneval D, 1998, J BIOL CHEM, V273, P17846, DOI 10.1074/jbc.273.28.17846; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Colomar A, 2001, EUR J NEUROSCI, V14, P927, DOI 10.1046/j.0953-816x.2001.01714.x; COLOMAR A, 2003, IN PRESS J SOC BIOL; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Gold R, 1999, BRAIN PATHOL, V9, P343; Grafe P, 1999, J PHYSIOL-LONDON, V515, P377, DOI 10.1111/j.1469-7793.1999.377ac.x; GRIFFITHS RJ, 1995, J IMMUNOL, V154, P2821; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Heine H, 2001, J ENDOTOXIN RES, V7, P227, DOI 10.1179/096805101101532729; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Koski CL, 1996, J NEUROCHEM, V66, P303; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Mehta VB, 2001, J BIOL CHEM, V276, P3820, DOI 10.1074/jbc.M006814200; Oliveira RB, 2003, INFECT IMMUN, V71, P1427, DOI 10.1128/IAI.71.3.1427-1433.2003; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615; Pousset F, 2000, EUR CYTOKINE NETW, V11, P682; Rutkowski JL, 1999, J NEUROIMMUNOL, V101, P47, DOI 10.1016/S0165-5728(99)00132-0; Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; Skundric DS, 2001, J NEUROIMMUNOL, V116, P74, DOI 10.1016/S0165-5728(01)00281-8; Solini A, 1999, J CELL SCI, V112, P297; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Takeda K, 2001, JPN J INFECT DIS, V54, P209; Taskinen HS, 2000, J PERIPHER NERV SYST, V5, P75, DOI 10.1046/j.1529-8027.2000.00009.x; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x	49	87	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30732	30740		10.1074/jbc.M304534200	http://dx.doi.org/10.1074/jbc.M304534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12796490	hybrid			2022-12-25	WOS:000184658800040
J	Nagata, D; Mogi, M; Walsh, K				Nagata, D; Mogi, M; Walsh, K			AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; NITRIC-OXIDE SYNTHASE; FATTY-ACID OXIDATION; GROWTH-FACTOR; MALONYL-COA; RAT-LIVER; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; GLYCOGEN-SYNTHASE; UP-REGULATION; AKT	AMP-activated protein kinase (AMPK) is a stress-activated protein kinase that is regulated by hypoxia and other cellular stresses that result in diminished cellular ATP levels. Here, we investigated whether AMPK signaling in endothelial cells has a role in regulating angiogenesis. Hypoxia induced the activating phosphorylation of AMPK in human umbilical vein endothelial cells (HUVECs), and AMPK activation was required for the maintenance of pro-angiogenic Akt signaling under these conditions. Suppression of AMPK signaling inhibited both HUVEC migration to VEGF and in vitro differentiation into tube-like structures in hypoxic, but not normoxic cultures. Dominant-negative AMPK also inhibited in vivo angiogenesis in Matrigel plugs that were implanted subcutaneously in mice. These data identify AMPK signaling as a new regulator of angiogenesis that is specifically required for endothelial cell migration and differentiation under conditions of hypoxia. As such, endothelial AMPK signaling may be a critical determinant of blood vessel recruitment to tissues that are subjected to ischemic stress.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052, R01AG017241] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66957] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, AG17241] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Breier G, 1997, THROMB HAEMOSTASIS, V78, P678; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen ZP, 1999, FEBS LETT, V460, P343, DOI 10.1016/S0014-5793(99)01371-X; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; Dagher Z, 1999, BIOCHEM BIOPH RES CO, V265, P112, DOI 10.1006/bbrc.1999.1635; Dagher Z, 2001, CIRC RES, V88, P1276, DOI 10.1161/hh1201.092998; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hutber CA, 1997, AM J PHYSIOL-ENDOC M, V272, pE262, DOI 10.1152/ajpendo.1997.272.2.E262; Ido Y, 2002, DIABETES, V51, P159, DOI 10.2337/diabetes.51.1.159; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; MUHLHAUSER J, 1995, CIRC RES, V77, P1077, DOI 10.1161/01.RES.77.6.1077; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nagata D, 2000, CIRC RES, V87, P699, DOI 10.1161/01.RES.87.8.699; Nagata D, 1999, KIDNEY INT, V55, P1259, DOI 10.1046/j.1523-1755.1999.00361.x; Noiri E, 1998, AM J PHYSIOL-CELL PH, V274, pC236, DOI 10.1152/ajpcell.1998.274.1.C236; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P108, DOI 10.1161/hq0102.101843; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Semenza GL, 2000, GENE DEV, V14, P1983; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; Tian R, 2001, CIRCULATION, V104, P1664, DOI 10.1161/hc4001.097183; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Velasco G, 1997, ARCH BIOCHEM BIOPHYS, V337, P169, DOI 10.1006/abbi.1996.9784; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	60	292	306	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31000	31006		10.1074/jbc.M300643200	http://dx.doi.org/10.1074/jbc.M300643200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788940	hybrid			2022-12-25	WOS:000184658800075
J	Sasaki, K; Sato, M; Umezawa, Y				Sasaki, K; Sato, M; Umezawa, Y			Fluorescent indicators for Akt/protein kinase B and dynamics of Akt activity visualized in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL NITRIC-OXIDE; ESTROGEN-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; SURVIVAL FACTOR; 14-3-3 PROTEIN; ACTIVATION; SYNTHASE; PHOSPHORYLATION; BAD; MEMBRANE	Akt/protein kinase B (PKB) is a serine/threonine kinase that regulates a variety of cellular responses. To provide information on the spatial and temporal dynamics of Akt/PKB activity, we have developed genetically encoded fluorescent indicators for Akt/PKB. The indicators contain two green fluorescent protein mutants, an Akt/PKB substrate domain, flexible linker sequence, and phosphorylation recognition domain. A phosphorylation of the substrate domain in the indicators caused change in the emission ratio based on fluorescent resonance energy transfer between the two green fluorescent protein mutants. To let the fluorescent indicators behave as endothelial nitric-oxide synthase and Bad, which are endogenous Akt/PKB substrates, they were fused with the Golgi target domain and mitochondria target domain, respectively. The indicators thus colocalized with the endogenous substrates conferred their susceptibilities to phosphorylation by Akt/PKB. We showed that the Golgi-localized indicator responded to the stimulation with 17beta-estradiol (E2) and insulin in endothelial cells. In addition, E2 elicited the phosphorylation of the mitochondria-localized indicator in the endothelial cells, but no phosphorylation was observed by E2 or by insulin of the diffusible indicator that has no targeting domain. The difference in the results with the three indicators suggests that the activated Akt/PKB is localized to subcellular compartments, including the Golgi apparatus and/or mitochondria, rather than diffusing in the cytosol, thereby efficiently phosphorylating its substrate proteins. E2 triggered the phosphorylation of the mitochondria-localized indicator, whereas insulin did not induce this phosphorylation, which suggests that the localization of the activated Akt/PKB to the mitochondria is directed differently between insulin and E2 via distinct mechanisms.	Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Umezawa, Y (corresponding author), Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan.	umezawa@chem.s.u-tokyo.ac.jp	Sato, Moritoshi/O-2735-2018	Sato, Moritoshi/0000-0002-3095-5831				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez RJ, 1997, BIOCHEM BIOPH RES CO, V237, P372, DOI 10.1006/bbrc.1997.7085; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	39	124	127	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30945	30951		10.1074/jbc.M212167200	http://dx.doi.org/10.1074/jbc.M212167200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773546	hybrid			2022-12-25	WOS:000184658800068
J	Arai, M; Yokosuka, O; Chiba, T; Imazeki, F; Kato, M; Hashida, J; Ueda, Y; Sugano, S; Hashimoto, K; Saisho, H; Takiguchi, M; Seki, N				Arai, M; Yokosuka, O; Chiba, T; Imazeki, F; Kato, M; Hashida, J; Ueda, Y; Sugano, S; Hashimoto, K; Saisho, H; Takiguchi, M; Seki, N			Gene expression profiling reveals the mechanism and pathophysiology of mouse liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-RECEPTOR; TRANSCRIPTION FACTOR; RAT-LIVER; INITIATION; MICROARRAY; CLONING; SUBUNIT; FAMILY; GROWTH; PHASE	Comprehensive analysis of the changes in gene expression during liver regeneration was carried out by using an in-house microarray composed of 2,304 distinct mouse liver cDNA clones. Mice were subjected to partial two-thirds hepatectomy, and changes in mRNA levels were monitored up to 48 h. Of the 2,304 genes analyzed, 496 genes showed expression levels measurable at all time points after the partial hepatectomy. 317 genes were up- or down-regulated 2-fold or more at least at one time point during liver regeneration and were classified into eight clusters based on their expression patterns. With a more stringent cut-off value of +/-2 S.D., 68 genes were listed and were classified into five clusters. In these two analyses with different clustering criteria, functionally categorized genes showed similar cluster distributions. Genes involved in protein synthesis and posttranslational processing were significantly enriched in the cluster characterized by rapid gene activation and subsequent persistence. This suggests the importance of modulating the efficiency of protein supply and/or altering the composition of protein population from the early phase of hepatocyte proliferation. Genes for two major liver functions, i.e. plasma protein secretion and intermediate metabolism were enriched in distinct clusters exhibiting the features of gradual gene activation and sustained repression, respectively. Therefore, these genes are differentially regulated during the regeneration, possibly leading to changes in the flow of amino acids and energy from enzyme proteins to plasma proteins in their synthesis. Thus, clustering analysis of expression patterns of functionally classified genes gave insights into mechanism and pathophysiology of liver regeneration.	Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Funct Genom, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chiba 2608670, Japan; Hitachi Software Engn Co Ltd, Dept Life Sci Prod, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Inst Med Sci, Dept Virol, Minato Ku, Tokyo 1088639, Japan; Natl Inst Infect Dis, Div Genet Resources, Shinjuku Ku, Tokyo 1628640, Japan	Chiba University; Chiba University; Chiba University; Hitachi Limited; University of Tokyo; National Institute of Infectious Diseases (NIID)	Yokosuka, O (corresponding author), Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol K1, Inohana 1-8-1, Chiba 2608670, Japan.		Kato, Masaki/B-5846-2018	Kato, Masaki/0000-0002-5184-1841				Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Assy N, 1997, J HEPATOL, V26, P945, DOI 10.1016/S0168-8278(97)80266-8; Benayoun B, 2001, J BIOL CHEM, V276, P13830, DOI 10.1074/jbc.M010933200; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; CARR BI, 1986, CANCER RES, V46, P5106; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Higgins GM, 1931, ARCH PATHOL, V12, P186; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Su AI, 2002, P NATL ACAD SCI USA, V99, P11181, DOI 10.1073/pnas.122359899; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; SWICK RW, 1974, J BIOL CHEM, V249, P6836; Takaki Y, 2001, CELL TISSUE RES, V305, P399, DOI 10.1007/s004410100397; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Tsurumi C, 1996, EUR J BIOCHEM, V239, P912, DOI 10.1111/j.1432-1033.1996.0912u.x; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Yoshikawa T, 2000, BIOCHEM BIOPH RES CO, V275, P532, DOI 10.1006/bbrc.2000.3330	27	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29813	29818		10.1074/jbc.M212648200	http://dx.doi.org/10.1074/jbc.M212648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12782638	hybrid			2022-12-25	WOS:000184507000053
J	Gilleron, M; Quesniaux, VFJ; Puzo, G				Gilleron, M; Quesniaux, VFJ; Puzo, G			Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette Guerin and Mycobacterium tuberculosis H37Rv and its implication in toll-like receptor response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOGLYCAN ANTIGENS; DENDRITIC CELLS; LIPOARABINOMANNAN; BIOSYNTHESIS; INDUCE; BCG; RECOGNITION; LIPOMANNAN; MANNOSIDES; DEFINITION	The dimannoside (PIM2) and hexamannoside (PIM6) phosphatidyl-myo-inositol mannosides are the two most abundant classes of PIM found in Mycobacterium bovis bacillus Calmette Guerin, Mycobacterium tuberculosis H37Rv, and Mycobacterium smegmatis 607. Recently, these long known molecules received a renewed interest due to the fact that PIM2 constitute the anchor motif of an important constituent of the mycobacterial cell wall, the lipoarabinomannans (LAM), and that both LAM (phosphoinositol-capped LAM) and PIM are agonists of Toll-like receptor 2 (TLR2), a pattern recognition receptor involved in innate immunity. Due to the biological importance of these molecules, the chemical structure of PIM was revisited. The structure of PIM2 was recently published ( Gilleron, M., Ronet, C., Mempel, M., Monsarrat, B., Gachelin, G., and Puzo, G. (2001) J. Biol. Chem. 276, 34896- 34904). Here we report the purification and molecular characterization of PIM6 in their native form. For the first time, four acyl forms of this molecule have been purified, using hydrophobic interaction chromatography. Mono- to tetra-acylated molecules were identified in M. bovis bacillus Calmette Guerin, M. tuberculosis H37Rv, and M. smegmatis 607 using a sophisticated combination of analytical tools, including matrix-assisted laser desorption/ionization-time of flight-mass spectrometry and two-dimensional homo- and heteronuclear NMR spectroscopy. These experiments revealed that the major acyl forms are similar to the ones described for PIM2. Finally, we show that PIM6, like PIM2, activate primary macrophages to secrete TNF-alpha through TLR2, irrespective of their acylation pattern, and that they signal through the adaptor MyD88.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; FRE 2358, Expt & Mol Genet, F-45071 Orleans, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Gilleron, M (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.			GILLERON, Martine/0000-0002-2581-3302				Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; BALLOU CE, 1963, J BIOL CHEM, V238, P69; Beatty WL, 2000, TRAFFIC, V1, P235, DOI 10.1034/j.1600-0854.2000.010306.x; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Cywes C, 1997, INFECT IMMUN, V65, P4258, DOI 10.1128/IAI.65.10.4258-4266.1997; Ernst WA, 1998, IMMUNITY, V8, P331, DOI 10.1016/S1074-7613(00)80538-5; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; GILLERON M, 1993, J BIOL CHEM, V268, P3168; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; GOREN MB, 1984, MYCOBACTERIA SOURC A, V15, P379; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Heldwein KA, 2002, MICROBES INFECT, V4, P937, DOI 10.1016/S1286-4579(02)01611-8; HILL DL, 1966, J BIOL CHEM, V241, P895; Hoppe HC, 1997, INFECT IMMUN, V65, P3896, DOI 10.1128/IAI.65.9.3896-3905.1997; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; LEE YC, 1965, BIOCHEMISTRY-US, V4, P1395, DOI 10.1021/bi00883a026; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; Ludwiczak P, 2001, ANAL CHEM, V73, P2323, DOI 10.1021/ac001368h; Means TK, 1999, J IMMUNOL, V163, P3920; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Muller M, 1996, MOL MED, V2, P247, DOI 10.1007/BF03401621; Netea MG, 2002, TRENDS IMMUNOL, V23, P135, DOI 10.1016/S1471-4906(01)02169-X; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; Severn WB, 1998, CARBOHYD RES, V308, P397, DOI 10.1016/S0008-6215(98)00108-6; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; VERCELLONE A, 1989, J BIOL CHEM, V264, P7447; WANG Y, 1995, ANAL BIOCHEM, V225, P242, DOI 10.1006/abio.1995.1149	40	174	182	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29880	29889		10.1074/jbc.M303446200	http://dx.doi.org/10.1074/jbc.M303446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775723	Green Published, hybrid			2022-12-25	WOS:000184507000061
J	Li, Y; Lawrence, A; Zhang, L				Li, Y; Lawrence, A; Zhang, L			Sequences within domain II of the urokinase receptor critical for differential ligand recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY LIGAND; PLASMINOGEN-ACTIVATOR; INTEGRIN ALPHA(M)BETA(2); CELL-SURFACE; IN-VIVO; BINDING; VITRONECTIN; IDENTIFICATION; ADHESION; REGION	The receptor for urokinase-type plasminogen activator ( uPAR) plays important roles in a number of physiological and pathological processes by virtue of its interactions with urokinase-type plasminogen activator (uPA), vitronectin (Vn), and several other proteins. The uPA binding site spans all three domains (D1 to D3) of uPAR. However, the nature of the Vn binding site within uPAR is still not clear. In this study, we conducted homolog-scanning mutagenesis on uPAR by switching 14 individual segments of 4 - 8 residues to their counterpart sequences of a uPAR homolog CD59. All 14 mutants were well expressed, reacted with a panel of monoclonal antibodies, and exhibited correct molecular weights. Of these 14 mutants, six mutants were defective in both uPA and Vn binding. Most importantly, we found two unique mutants uPAR(Asn(172)-Lys(175)) and uPAR(Glu(183) Asn(186)) within the D2 domain, which displayed differential ligand binding activity: both had high affinity uPA binding, but completely lost Vn binding, indicating that these two sequences constitute a novel Vn binding site. Indeed, two peptides, P1 ((153)CPGSNGFHNNDTFHFLKC) and P2 ((171)CNTTKCNEGPILELENLPQ), derived from the sequences of the identified uPA and Vn binding pockets within D2, respectively, behaved like bona fide ligand binding sites: peptide P1 bound uPA but not Vn, whereas peptide P2 bound Vn and inhibited uPAR-mediated cell adhesion, but did not interact with uPA. Altogether, our data demonstrated that uPAR D2 contains two distinct ligand binding sites for uPA and Vn. Such information will help us better understand the complex roles of uPAR in cell adhesion, migration, and tumor metastasis.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, Rockville, MD 20855 USA	American Red Cross	Zhang, L (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, Rockville, MD 20855 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061589, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061589, P01 HL054710, 2P01 HL54710-06, R01 HL61589-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gyetko MR, 2000, J IMMUNOL, V165, P1513, DOI 10.4049/jimmunol.165.3.1513; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; Liang OD, 2001, J BIOL CHEM, V276, P28946, DOI 10.1074/jbc.M011437200; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Memarzedeh S, 2002, P NATL ACAD SCI USA, V99, P10647, DOI 10.1073/pnas.152127499; MILES LA, 1988, BLOOD, V72, P628; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; PLOUG M, 1993, J BIOL CHEM, V268, P17539; Rabbani SA, 2002, CANCER RES, V62, P2390; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558	27	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29925	29932		10.1074/jbc.M300751200	http://dx.doi.org/10.1074/jbc.M300751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761227	hybrid			2022-12-25	WOS:000184507000065
J	Merkle, CJ; Karnitz, LM; Henry-Sanchez, JT; Chen, J				Merkle, CJ; Karnitz, LM; Henry-Sanchez, JT; Chen, J			Cloning and characterization of hCTF18, hCTF8, and hDCC1 - Human homologs of an Saccharomyces cerevisiae complex involved in sister chromatid cohesion establishment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; IDENTIFICATION; MITOSIS; CTF18	A growing body of evidence suggests that establishment of sister chromatid cohesion is dependent on replication fork passage over a precohesion area. In Saccharomyces cerevisiae, this process involves an alternative replication factor C (RFC) complex that contains the four small RFC subunits as well as CTF18, CTF8, and DCC1. Here, we show that an evolutionarily conserved homologous complex exists in the nucleus of human cells. We demonstrate that hCTF18, hCTF8, and hDCC1 interact with each other as well as with the p38 subunit of RFC. This alternative RFC-containing complex interacts with proliferating cell nuclear antigen but not with the Rad9/Rad1/Hus1 complex, a proliferating cell nuclear antigen-like clamp involved in the DNA damage response. hCTF18 preferentially binds chromatin during S phase, suggesting a role during replication. Our data provide evidence for the existence of an alternative RFC complex with a probable role in mammalian sister chromatid cohesion establishment.	Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; Mayo Grad Sch, Grad Program Tumor Biol, Rochester, MN 55905 USA; Mayo Clin, Div Mol Pharmacol & Therapeut, Rochester, MN 55905 USA; Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Chen, J (corresponding author), Mayo Clin, Div Oncol Res, Guggenheim Bldg,Rm 1306,200 1st St SW, Rochester, MN 55905 USA.	chen.junjie@mayo.edu			PHS HHS [T32 75926] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Carson DR, 2001, P NATL ACAD SCI USA, V98, P8270, DOI 10.1073/pnas.131022798; Cohen-Fix O, 2001, CELL, V106, P137, DOI 10.1016/S0092-8674(01)00439-1; Hanna JS, 2001, MOL CELL BIOL, V21, P3144, DOI 10.1128/MCB.21.9.3144-3158.2001; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774	17	38	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30051	30056		10.1074/jbc.M211591200	http://dx.doi.org/10.1074/jbc.M211591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766176	hybrid			2022-12-25	WOS:000184507000081
J	Park, S; Geddes, TJ; Javitch, JA; Kuhn, DM				Park, S; Geddes, TJ; Javitch, JA; Kuhn, DM			Dopamine prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide - Is nitrotyrosine formation an early step in dopamine neuronal damage?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVATES TRYPTOPHAN-HYDROXYLASE; REDOX-CYCLING QUINOPROTEIN; NITRIC-OXIDE SYNTHASE; PARKINSONS-DISEASE; OXIDATIVE STRESS; IN-VIVO; SULFHYDRYL OXIDATION; ASCORBIC-ACID; HUMAN-CELLS; NEUROTOXICITY	Peroxynitrite and nitrogen dioxide (NO2) are reactive nitrogen species that have been implicated as causal factors in neurodegenerative conditions. Peroxynitrite-induced nitration of tyrosine residues in tyrosine hydroxylase (TH) may even be one of the earliest biochemical events associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage to dopamine neurons. Exposure of TH to peroxynitrite or NO2 results in nitration of tyrosine residues and modification of cysteines in the enzyme as well as inactivation of catalytic activity. Dopamine (DA), its precursor 3,4-dihydroxyphenylalanine, and metabolite 3,4-dihydroxyphenylacetic acid completely block the nitrating effects of peroxynitrite and NO2 on TH but do not relieve the enzyme from inhibition. o-Quinones formed in the reaction of catechols with either peroxynitrite or NO2 react with cysteine residues in TH and inhibit catalytic function. Using direct, real-time evaluation of tyrosine nitration with a green fluorescent protein-TH fusion protein stably expressed in intact cells (also stably expressing the human DA transporter), DA was also found to prevent NO2-induced nitration while leaving TH activity inhibited. These results show that peroxynitrite and NO2 react with DA to form quinones at the expense of tyrosine nitration. Endogenous DA may therefore play an important role in determining how DA neurons are affected by reactive nitrogen species by shifting the balance of their effects away from tyrosine nitration and toward o-quinone formation.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; John D Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	Wayne State University; Wayne State University; Columbia University; Columbia University; Columbia University	Kuhn, DM (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, 2125 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.			Javitch, Jonathan/0000-0001-7395-2967	NIDA NIH HHS [DA14692, DA107856, DA11495, DA06067] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA014692, R01DA011495] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Blanchard-Fillion B, 2001, J BIOL CHEM, V276, P46017, DOI 10.1074/jbc.M105564200; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crow JP, 1996, METHOD ENZYMOL, V269, P185; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; Daveu C, 1997, NITRIC OXIDE-BIOL CH, V1, P234, DOI 10.1006/niox.1997.0123; DISCHIA M, 1995, BIOORGAN MED CHEM, V3, P923, DOI 10.1016/0968-0896(95)00083-S; Espey MG, 2002, P NATL ACAD SCI USA, V99, P3481, DOI 10.1073/pnas.062604199; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GIBB JW, 1990, NEUROTOXICOLOGY, V11, P317; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GRAHAM DG, 1978, MOL PHARMACOL, V14, P644; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Hastings T. G., 1999, ROLE CATECHOL QUINON, P69; Hastings TG, 1996, ADV EXP MED BIOL, V387, P97; HASTINGS TG, 1994, J NEUROCHEM, V63, P1126; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Imam SZ, 2001, J NEUROCHEM, V76, P745, DOI 10.1046/j.1471-4159.2001.00029.x; Imam SZ, 1999, BRAIN RES, V837, P15, DOI 10.1016/S0006-8993(99)01663-7; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kerry N, 1998, FEBS LETT, V437, P167, DOI 10.1016/S0014-5793(98)01223-X; Kuhn DM, 1999, J NEUROSCI, V19, P10289; Kuhn DM, 1998, J NEUROSCI, V18, P7111; Kuhn DM, 2002, J BIOL CHEM, V277, P14336, DOI 10.1074/jbc.M200290200; Kuhn DM, 1999, MOL BRAIN RES, V73, P78, DOI 10.1016/S0169-328X(99)00238-7; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaVoie MJ, 1999, J NEUROCHEM, V73, P2546, DOI 10.1046/j.1471-4159.1999.0732546.x; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; LERNER P, 1978, NEUROCHEM RES, V3, P641, DOI 10.1007/BF00963765; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; MONKS TJ, 1992, CRIT REV TOXICOL, V22, P243, DOI 10.3109/10408449209146309; Obata T, 2002, J NEURAL TRANSM, V109, P1159, DOI 10.1007/s00702-001-0683-2; Pannala A, 1997, BIOCHEM BIOPH RES CO, V232, P164, DOI 10.1006/bbrc.1997.6254; Park SU, 2002, J NEUROSCI, V22, P4399, DOI 10.1523/JNEUROSCI.22-11-04399.2002; PAZ MA, 1991, J BIOL CHEM, V266, P689; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Rettori D, 2002, FREE RADICAL BIO MED, V33, P685, DOI 10.1016/S0891-5849(02)00953-X; Rowe DB, 1998, J NEUROSCI RES, V53, P551, DOI 10.1002/(SICI)1097-4547(19980901)53:5<551::AID-JNR5>3.3.CO;2-T; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Stepien K, 2000, BBA-GEN SUBJECTS, V1523, P189, DOI 10.1016/S0304-4165(00)00121-5; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Thomas DD, 2002, METHOD ENZYMOL, V359, P84; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Whitehead RE, 2001, J NEUROCHEM, V76, P1242, DOI 10.1046/j.1471-4159.2001.00125.x; Zhang H, 2003, J BIOL CHEM, V278, P8969, DOI 10.1074/jbc.M211561200; Zhang J, 2000, J NEUROCHEM, V74, P970, DOI 10.1046/j.1471-4159.2000.0740970.x	62	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28736	28742		10.1074/jbc.M304362200	http://dx.doi.org/10.1074/jbc.M304362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12771134	hybrid			2022-12-25	WOS:000184421100049
J	Achison, M; Hupp, TR				Achison, M; Hupp, TR			Hypoxia attenuates the p53 response to cellular damage	ONCOGENE			English	Article						p53; hypoxia; CK2; HIF-1; apoptosis	DNA-BINDING FUNCTION; RNA-POLYMERASE-II; P53-DEPENDENT TRANSCRIPTION; TUMOR-SUPPRESSOR; PHOSPHORYLATION; CANCER; PROTEIN; KINASE; CELLS; MDM2	The tumour suppressor activity of p53 in vivo can be subject to pressure from the physiological stress of hypoxia and we report on the development of a cell system to define the p53-dependent stages in the adaptation of cells to hypoxia. p53(+/+) cells exposed to hypoxia exhibited a transient arrest in G2/M, but escaped from this checkpoint and entered a long-term G(0)/G(1) arrest. By contrast, isogenic p53-null cells exposed to hypoxic conditions exhibited a 6-10-fold higher level of apoptosis, suggesting that p53 acts as a survival factor under limiting oxygen concentrations. Surprisingly, hypoxia-dependent growth arrest in p53(+/+) cells did not result in either p21(WAF1) or HIF-1 protein stabilization, but rather promoted a significant decrease in Ser(392)-site phosphorylation at the CK2/FACT site. However, chemically induced anoxia induced Ser(392)-site phosphorylation as well as stabilization of both p53 and HIF-1 proteins. In contrast to hypoxia, 5-flourouracil (5-FU)-induced p53-dependent cell death correlated with enhanced Ser(392) phosphorylation of p53 and elevated p21(WAF1) protein levels. Hypoxia inhibited 5-FU-induced p53-dependent cell death and attenuated p53 phosphorylation at the ATM and CK2/FACT phosphorylation sites. Although anoxia activates the p53 response, hypoxia silences the p53 transactivation pathway and identifies a physiological signalling model to study mechanisms of p53 inactivation under hypoxic conditions.	Univ Dundee, Dept Mol & Cellular Pathol, Canc Res UK Labs, Dundee DD1 9SY, Scotland	University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Dept Mol & Cellular Pathol, Canc Res UK Labs, Dundee DD1 9SY, Scotland.	t.r.hupp@dundee.ac.uk						Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHAN DA, 2002, J BIOL CHEM, V16, P16; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Hupp TR, 2000, METH MOL B, V99, P465; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kotala V, 2001, CELL MOL LIFE SCI, V58, P1333, DOI 10.1007/PL00000944; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Maxwell PH, 2002, CLIN MED, V2, P356, DOI 10.7861/clinmedicine.2-4-356; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Shieh SY, 2000, GENE DEV, V14, P289; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WENG H, 2002, MOL MED, V16, P1151; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zhao RB, 2000, GENE DEV, V14, P981	57	82	92	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3431	3440		10.1038/sj.onc.1206434	http://dx.doi.org/10.1038/sj.onc.1206434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776195				2022-12-25	WOS:000183128500010
J	Aboulkassim, TO; LaRue, H; Lemieux, P; Rousseau, F; Fradet, Y				Aboulkassim, TO; LaRue, H; Lemieux, P; Rousseau, F; Fradet, Y			Alteration of the PATCHED locus in superficial bladder cancer	ONCOGENE			English	Article						chromosome 9; LOH; bladder cancer tumour-suppressor gene; PATCHED gene; RT-PCR	BASAL-CELL CARCINOMAS; FANCONI-ANEMIA POLYPEPTIDE; TUMOR-SUPPRESSOR; HUMAN HOMOLOG; SIGNALING PATHWAY; SONIC HEDGEHOG; GENE; CANDIDATE; CHROMOSOME-9; MICE	Chromosome 9 alterations are the most frequently encountered cytologic anomalies in urothelial carcinoma (UC). We previously screened 139 low-stage UCs for loss of heterozygosity on chromosome 9, and identified five distinct regions likely to harbour tumour-suppressor genes. The present study focused on deletion mapping in the 9q22 region with 11 additional microsatellite markers. New deletions in the 9q22 region were found in five tumours. Deletion mapping allowed us to identify a 0.5 CM common minimal region of deletion between markers D9S280 and D9S1809, encompassing PATCHED (PTC), a gene identified as a tumour suppressor in basal cell carcinoma and in medulloblastoma. A marker located in the first intron of this gene showed the highest percentage of deletion (45%). cDNA sequencing in 15 tumours with deletion of PTC showed no mutation in the remaining allele. However, average expression of PTC mRNA measured by semiquantitative RT-PCR was significantly decreased in tumours with LOH in the 9q22 region, compared to normal urothelium (P = 0.04), while it showed marked fluctuations in tumours without deletion. Our results suggest that the PTC gene is a putative suppressor at the 9q22 locus and that haploinsufficiency of this gene may be an early event in the development of papillary bladder tumours.	Univ Laval, Hotel Dieu, Ctr Rech & Cancerol, Quebec City, PQ G1K 7P4, Canada; CHU Quebec, Hop St Francois Assise, Unite Rech Genet Humaine & Mol, Quebec City, PQ, Canada	Laval University; Laval University	Fradet, Y (corresponding author), Univ Laval, Hotel Dieu, Ctr Rech & Cancerol, Quebec City, PQ G1K 7P4, Canada.			Fradet, Yves/0000-0002-7581-2500				Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, CANCER RES, V53, P1230; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GIBSON RA, 1993, HUM MOL GENET, V2, P35, DOI 10.1093/hmg/2.1.35; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Simoneau M, 2000, ONCOGENE, V19, P6317, DOI 10.1038/sj.onc.1204022; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TANAKA M, 1995, CANCER RES, V55, P3228; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; Velickovic M, 2002, MODERN PATHOL, V15, P479, DOI 10.1038/modpathol.3880551; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; Xie JW, 1997, CANCER RES, V57, P2369; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	35	49	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2967	2971		10.1038/sj.onc.1206513	http://dx.doi.org/10.1038/sj.onc.1206513			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771948				2022-12-25	WOS:000182824800012
J	Moren, A; Hellman, U; Inada, Y; Imamura, T; Heldin, CH; Moustakas, A				Moren, A; Hellman, U; Inada, Y; Imamura, T; Heldin, CH; Moustakas, A			Differential ubiquitination defines the functional status of the tumor suppressor Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DEPENDENT DEGRADATION; I RECEPTOR; PROTEINS; LIGASE; CELLS; PHOSPHORYLATION; PATHWAY; SMURF2; ACTIVATION	Smad4 is an essential signal transducer of all transforming growth factor-beta (TGF-beta) superfamily pathways that regulate cell growth and differentiation, and it becomes inactivated in human cancers. Receptor-activated (R-) Smads can be poly-ubiquitinated in the cytoplasm or the nucleus, and this regulates their steady state levels or shutdown of the signaling pathway. Oncogenic mutations in Smad4 and other Smads have been linked to protein destabilization and proteasomal degradation. We analyzed a panel of missense mutants derived from human cancers that map in the N-terminal Mad homology (MH) 1 domain of Smad4 and result in protein instability. We demonstrate that all mutants exhibit enhanced poly-ubiquitination and proteasomal degradation. In contrast, wild type Smad4 is a relatively stable protein that undergoes mono- or oligo-ubiquitination, a modification not linked to protein degradation. Analysis of Smad4 deletion mutants indicated efficient mono- or oligo-ubiquitination of the C-terminal MH2 domain. Mass spectrometric analysis of mono- ubiquitinated Smad4 MH2 domain identified lysine 507 as a major target for ubiquitination. Lysine 507 resides in the conserved L3 loop of Smad4 and participates in R- Smad C-terminal phosphoserine recognition. Mono- or oligo-ubiquitinated Smad4 exhibited enhanced ability to oligomerize with R- Smads, whereas mutagenesis of lysine 507 led to inefficient Smad4/R-Smad hetero-oligomerization and defective transcriptional activity. Finally, overexpression of a mutant ubiquitin that only leads to mono- ubiquitination of Smad4 enhanced Smad transcriptional activity. These data suggest that oligo-ubiquitination positively regulates Smad4 function, whereas poly-ubiquitination primarily occurs in unstable cancer mutants and leads to protein degradation.	Biomed Ctr, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	Ludwig Institute for Cancer Research; Japanese Foundation for Cancer Research	Moustakas, A (corresponding author), Biomed Ctr, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.							Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Johnson ES, 2002, NAT CELL BIOL, V4, pE295, DOI 10.1038/ncb1202-e295; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu XB, 2002, FEBS LETT, V519, P93, DOI 10.1016/S0014-5793(02)02718-7; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, J CELL SCI, V112, P4557; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	34	83	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33571	33582		10.1074/jbc.M300159200	http://dx.doi.org/10.1074/jbc.M300159200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12794086	hybrid			2022-12-25	WOS:000184901800130
J	Cowan, CM; Quarto, N; Warren, SM; Salim, A; Longaker, MT				Cowan, CM; Quarto, N; Warren, SM; Salim, A; Longaker, MT			Age-related changes in the biomolecular mechanisms of clvarial osteoblast biology affect fibroblast growth factor-2 signaling and osteogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRANIAL SUTURE FUSION; AUG-INITIATED FORMS; MATURE DURA-MATER; IN-VITRO; BONE-FORMATION; REGIONAL DIFFERENTIATION; OSSEOUS OBLITERATION; TISSUE INTERACTIONS; OSTEOCALCIN GENE; FACTOR BETA-1	The ability of immature animals to orchestrate successful calvarial ossification has been well described. This capacity is markedly attenuated in mature animals and humans greater than 2 years of age. Few studies have investigated biological differences between juvenile and adult osteoblasts that mediate successful osteogenesis. To identify possible mechanisms for this clinical observation, we investigated cellular and molecular differences between primary osteoblasts derived from juvenile (2-day-old) and adult (60-day-old) rat calvaria. Data demonstrated that juvenile osteoblasts contain a subpopulation of less differentiated cells as observed by spindle-like morphology and decreased osteocalcin production. Juvenile, compared with adult, osteoblasts showed increased proliferation and adhesion. Furthermore, following rhFGF-2 stimulation juvenile osteoblasts increased expression of collagen Ialpha1 (5-fold), osteopontin (13-fold), and osteocalcin (16-fold), compared with relatively unchanged adult osteoblasts. Additionally, juvenile osteoblasts organized and produced more matrix proteins and formed 41-fold more bone nodules. Alternatively, adult osteoblasts produced more FGF-2 and preferentially translated the high molecular weight (22 kDa) form. Although adult osteoblasts transcribed more FGF-R1 and juvenile osteoblasts transcribed more FGF-R2 at baseline levels, juvenile osteoblasts translated more FGF-R1 and -R2 and showed increased phosphorylation. Collectively, these findings begin to explain why juvenile, but not adult, osteoblasts successfully heal calvarial defects.	Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA	Stanford University	Longaker, MT (corresponding author), Stanford Univ, Sch Med, Dept Surg, 257 Campus Dr, Stanford, CA 94305 USA.				NIDCR NIH HHS [R01DE-14526] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014526] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; Bradley JP, 1997, PLAST RECONSTR SURG, V100, P1091, DOI 10.1097/00006534-199710000-00001; Bradley JP, 1996, CLEFT PALATE-CRAN J, V33, P150, DOI 10.1597/1545-1569(1996)033<0150:SICSBV>2.3.CO;2; Bradley JP, 1996, PLAST RECONSTR SURG, V98, P1039, DOI 10.1097/00006534-199611000-00018; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Candeliere GA, 2001, BONE, V28, P351, DOI 10.1016/S8756-3282(01)00410-0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; dePollak C, 1997, J CELL BIOCHEM, V64, P128, DOI 10.1002/(SICI)1097-4644(199701)64:1<128::AID-JCB15>3.0.CO;2-H; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; FLORKIEWICZ RZ, 1991, ANN NY ACAD SCI, V638, P109, DOI 10.1111/j.1749-6632.1991.tb49022.x; Greenwald JA, 2000, PLAST RECONSTR SURG, V105, P1382, DOI 10.1097/00006534-200004040-00018; Greenwald JA, 2000, PLAST RECONSTR SURG, V106, P630, DOI 10.1097/00006534-200009030-00016; Greenwald JA, 2000, J BONE MINER RES, V15, P2413, DOI 10.1359/jbmr.2000.15.12.2413; HASSLER W, 1990, NEUROSURGERY, V27, P539, DOI 10.1227/00006123-199010000-00006; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; Iseki S, 1999, DEVELOPMENT, V126, P5611; Iseki S, 1997, DEVELOPMENT, V124, P3375; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; Lebaron RG, 2000, TISSUE ENG, V6, P85, DOI 10.1089/107632700320720; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; Lin CY, 1997, J BIOL CHEM, V272, P9147; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Mehrara BJ, 1999, PLAST RECONSTR SURG, V103, P536, DOI 10.1097/00006534-199902000-00026; Mehrara BJ, 1999, PLAST RECONSTR SURG, V104, P435, DOI 10.1097/00006534-199908000-00017; Mehrara BJ, 1999, PLAST RECONSTR SURG, V104, P1003, DOI 10.1097/00006534-199909040-00016; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Moore R, 2002, DEV BIOL, V243, P99, DOI 10.1006/dbio.2001.0533; Moursi AM, 1997, J CELL SCI, V110, P2187; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; OPPERMAN LA, 1995, J BONE MINER RES, V10, P1978; OPPERMAN LA, 1993, DEV DYNAM, V198, P312, DOI 10.1002/aja.1001980408; OPPERMAN LA, 1996, IN VITRO CELL DEV BI, V32; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Sarkar S, 2001, DEVELOPMENT, V128, P2143; SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143; Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200; SIROLA K, 1960, Ann Med Exp Biol Fenn, V38(Suppl 2), P1; Spector JA, 2002, PLAST RECONSTR SURG, V109, P645, DOI 10.1097/00006534-200202000-00035; Spector JA, 2002, PLAST RECONSTR SURG, V109, P631, DOI 10.1097/00006534-200202000-00033; Stein Gary S., 1996, P69; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tanaka H, 1999, MOL CELL ENDOCRINOL, V150, P1, DOI 10.1016/S0303-7207(99)00046-5; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432-0436.2003.700602.x	57	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32005	32013		10.1074/jbc.M304698200	http://dx.doi.org/10.1074/jbc.M304698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788918	hybrid			2022-12-25	WOS:000184782100070
J	Hermann, A; Schmitt, S; Jeltsch, A				Hermann, A; Schmitt, S; Jeltsch, A			The human Dnmt2 has residual DNA-(Cytosine-C5) methyltransferase activity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO METHYLATION; DNA METHYLATION; ENZYMATIC-PROPERTIES; CLONING; MAINTENANCE; ACTIVATION; COOPERATE; BINDING; CANCER; DOMAIN	The human Dnmt2 protein is one member of a protein family conserved from Schizosaccharomyces pombe and Drosophila Melanogaster to Mus musculus and Homo sapiens. It contains all of the amino acid motifs characteristic for DNA-(Cytosine-C5) methyltransferases, and its structure is very similar to prokaryotic DNA methyltransferases. Nevertheless, so far all attempts to detect catalytic activity of this protein have failed. We show here by two independent assay systems that the purified Dnmt2 protein has weak DNA methyltransferase activity. Methylation was observed a CG sites in a loose ttnCG(ga(g/a)) consensus sequence, suggesting that Dnmt2 has a more specialized role than other mammalian DNA methyltransferases.	Univ Giessen, Inst Biochem, FB 8, D-35392 Giessen, Germany; Univ Giessen, Biochem Inst, FB 11, D-35392 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Jeltsch, A (corresponding author), Univ Giessen, Inst Biochem, FB 8, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	Albert.Jeltsch@chemie.bio.uni-giessen.de	Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290				Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Casari G, 1996, TRENDS GENET, V12, P244, DOI 10.1016/0168-9525(96)30057-7; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dodge JE, 2002, GENE, V289, P41, DOI 10.1016/S0378-1119(02)00469-9; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; Fatemi M, 2002, EUR J BIOCHEM, V269, P4981, DOI 10.1046/j.1432-1033.2002.03198.x; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Gowher H, 2001, FEMS MICROBIOL LETT, V205, P151, DOI 10.1111/j.1574-6968.2001.tb10939.x; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Jeltsch A, 1999, J BIOL CHEM, V274, P19538, DOI 10.1074/jbc.274.28.19538; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Jeltsch Albert, 2002, Methods Mol Biol, V182, P85; Johansson M, 1999, J BIOL CHEM, V274, P23814, DOI 10.1074/jbc.274.34.23814; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Lorincz MC, 2001, P NATL ACAD SCI USA, V98, P10034, DOI 10.1073/pnas.201392598; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pinarbasi E, 1996, J MOL BIOL, V257, P804, DOI 10.1006/jmbi.1996.0203; Reither S, 2003, J MOL BIOL, V329, P675, DOI 10.1016/S0022-2836(03)00509-6; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Van den Wyngaert I, 1998, FEBS LETT, V426, P283, DOI 10.1016/S0014-5793(98)00362-7; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	44	160	171	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31717	31721		10.1074/jbc.M305448200	http://dx.doi.org/10.1074/jbc.M305448200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794065	hybrid			2022-12-25	WOS:000184782100131
J	Maluf, NK; Ali, JA; Lohman, TM				Maluf, NK; Ali, JA; Lohman, TM			Kinetic mechanism for formation of the active, dimeric UvrD helicase-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-UVRD; REP HELICASE; INDUCED DIMERIZATION; IN-VITRO; PROTEIN; REPLICATION; MISMATCH; MUTL	Escherichia coli UvrD protein is a 3' to 5' SF1 helicase required for DNA repair as well as DNA replication of certain plasmids. We have shown previously that UvrD can self-associate to form dimers and tetramers in the absence of DNA, but that a UvrD dimer is required to form an active helicase-DNA complex in vitro. Here we have used pre-steady state, chemical quenched flow methods to examine the kinetic mechanism for formation of the active, dimeric helicase-DNA complex. Experiments were designed to examine the steps leading to formation of the active complex, separate from the subsequent DNA unwinding steps. The results show that the active dimeric complex can form via two pathways. The first, faster path involves direct binding to the DNA substrate of a pre-assembled UvrD dimer (dimer path), whereas the second, slower path proceeds via sequential binding to the DNA substrate of two UvrD monomers (monomer path), which then assemble on the DNA to form the dimeric helicase. The rate-limiting step within the monomer pathway involves dimer assembly on the DNA. These results show that UvrD dimers that pre-assemble in the absence of DNA are intermediates along the pathway to formation of the functional dimeric UvrD helicase.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Lohman, TM (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	lohman@biochem.wustl.edu			NIGMS NIH HHS [T32 GM08492, GM45948, R01 GM045948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008492, R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Bruand C, 2000, MOL MICROBIOL, V35, P204, DOI 10.1046/j.1365-2958.2000.01700.x; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Maluf NK, 2003, J MOL BIOL, V325, P889, DOI 10.1016/S0022-2836(02)01276-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WONG I, 1992, J BIOL CHEM, V267, P7596	26	45	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31930	31940		10.1074/jbc.M304223200	http://dx.doi.org/10.1074/jbc.M304223200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788954	hybrid			2022-12-25	WOS:000184782100061
J	He, J; Tegen, SB; Krawitz, AR; Martin, GS; Luo, KX				He, J; Tegen, SB; Krawitz, AR; Martin, GS; Luo, KX			The transforming activity of ski and SnoN is dependent on their ability to repress the activity of Smad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL REPRESSION; V-SRC; NUCLEAR TRANSLOCATION; ONCOPROTEIN INTERACTS; UBIQUITIN LIGASE; CO-REPRESSOR; CDNA CLONES; L3 LOOP	The regulation of cell growth and differentiation by transforming growth factor-beta (TGF-beta) is mediated by the Smad proteins. In the nucleus, the Smad proteins are negatively regulated by two closely related nuclear proto-oncoproteins, Ski and SnoN. When overexpressed, Ski and SnoN induce oncogenic transformation of chicken embryo fibroblasts. However, the mechanism of transformation by Ski and SnoN has not been defined. We have previously reported that Ski and SnoN interact directly with Smad2, Smad3, and Smad4 and repress their ability to activate TGF-beta target genes through multiple mechanisms. Because Smad proteins are tumor suppressors, we hypothesized that the ability of Ski and SnoN to inactivate Smad function may be responsible for their transforming activity. Here, we show that the receptor regulated Smad proteins (Smad2 and Smad3) and common mediator Smad (Smad4) bind to different regions in Ski and SnoN. Mutation of both regions, but not each region alone, markedly impaired the ability of Ski and SnoN to repress TGF-beta-induced transcriptional activation and cell cycle arrest. Moreover, when expressed in chicken embryo fibroblasts, mutant Ski or SnoN defective in binding to the Smad proteins failed to induce oncogenic transformation. These results suggest that the ability of Ski and SnoN to repress the growth inhibitory function of the Smad proteins is required for their transforming activity. This may account for the resistance to TGF-beta-induced growth arrest in some human cancer cell lines that express high levels of Ski or SnoN.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Luo, KX (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 237 Hildebrand Hall,Mail Code 3206, Berkeley, CA 94720 USA.			Krakowski, Ari/0000-0003-0554-1669; Tegen, Sarah/0000-0001-8618-2666	NCI NIH HHS [CA17542, CA09041, CA87940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087940, R37CA017542, R01CA017542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cohen SB, 1998, ONCOGENE, V17, P2505, DOI 10.1038/sj.onc.1202177; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; Germain S, 2000, GENE DEV, V14, P435; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Reed JA, 2001, CANCER RES, V61, P8074; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	62	87	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30540	30547		10.1074/jbc.M304016200	http://dx.doi.org/10.1074/jbc.M304016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12764135	Green Submitted, hybrid			2022-12-25	WOS:000184658800018
J	M'Barek, S; Lopez-Gonzalez, I; Andreotti, N; di Luccio, E; Visan, V; Grissmer, S; Judge, S; El Ayeb, M; Darbon, H; Rochat, H; Sampieri, F; Beraud, E; Fajloun, Z; De Waard, M; Sabatier, JM				M'Barek, S; Lopez-Gonzalez, I; Andreotti, N; di Luccio, E; Visan, V; Grissmer, S; Judge, S; El Ayeb, M; Darbon, H; Rochat, H; Sampieri, F; Beraud, E; Fajloun, Z; De Waard, M; Sabatier, JM			A maurotoxin with constrained standard disulfide bridging - Innovative strategy of chemical synthesis, pharmacology, and docking on K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCORPION PANDINUS-IMPERATOR; BLOCKING TOXIN; HIGH-AFFINITY; PEPTIDES; MAURUS; MECHANISMS; INHIBITOR; INSIGHTS; VENOM	Maurotoxin (MTX) is a 34-residue toxin that has been isolated initially from the venom of the scorpion Scorpio maurus palmatus. It presents a large number of pharmacological targets, including small conductance Ca2+-activated and voltage-gated K+ channels. Contrary to other toxins of the alpha-KTx6 family (Pi1, Pi4, Pi7, and HsTx1), MTX exhibits a unique disulfide bridge organization of the type C1-C5, C2-C6, C3-C4, and C7-C8 (instead of the conventional C1-C5, C2-C6, C3-C7, and C4-C8, herein referred to as Pi1-like) that does not prevent its folding along the classic alpha/beta scaffold of scorpion toxins. Here, we developed an innovative strategy of chemical peptide synthesis to produce an MTX variant (MTXPi1) with a conventional pattern of disulfide bridging without any alteration of the toxin chemical structure. This strategy was used solely to address the impact of half-cystine pairings on MTX structural properties and pharmacology. The data indicate that MTXPi1 displays some marked changes in affinities toward the target K+ channels. Computed docking analyses using molecular models of both MTXPi1 and the various voltage-gated K+ channel subtypes (Shaker B, K(v)1.2, and K(v)1.3) were found to correlate with MTXPi1 pharmacology. A functional map detailing the interaction between MTXPi1 and Shaker B channel was generated in line with docking experiments.	CNRS, Lab Int Associe Ingn Biomol, UMR 6560, F-13916 Marseille 20, France; INSERM, Dept Rech Dynam Cellulaire Canaux Ion & Signaliza, EMI 9931, Inst Federat Rech 27, F-38054 Grenoble 09, France; Univ Ulm, D-89081 Ulm, Germany; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Inst Pasteur Tunis, Lab Venins & Toxines, Tunis 1002, Tunisia; CNRS, Unite Propre Rech 9039, F-13402 Marseille, France; Fac Med Timone, Immunol Lab, F-13385 Marseille 5, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Ulm University; University System of Maryland; University of Maryland Baltimore; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Sabatier, JM (corresponding author), CNRS, Lab Int Associe Ingn Biomol, UMR 6560, Bd Pierre Dramard, F-13916 Marseille 20, France.	sabatier.jm@jean-roche.univ-mrs.fr	De Waard, Michel/G-7406-2014; di Luccio, Eric/Z-5388-2019; Fajloun, Ziad/AAO-8595-2021	De Waard, Michel/0000-0002-2782-9615; di Luccio, Eric/0000-0002-2256-2157; SABATIER, Jean-Marc/0000-0002-9040-5647; Lopez-Gonzalez, Ignacio/0000-0002-1536-0258				Avdonin V, 2000, BIOPHYS J, V79, P776, DOI 10.1016/S0006-3495(00)76335-1; Blanc E, 1997, PROTEINS, V29, P321, DOI 10.1002/(SICI)1097-0134(199711)29:3&lt;321::AID-PROT6&gt;3.0.CO;2-D; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Carlier E, 2000, J PEPT RES, V55, P419, DOI 10.1034/j.1399-3011.2000.00715.x; Carlier E, 2001, FEBS LETT, V489, P202, DOI 10.1016/S0014-5793(00)02433-9; Castle NA, 2003, MOL PHARMACOL, V63, P409, DOI 10.1124/mol.63.2.409; Darbon H, 1999, PERSPECT DRUG DISCOV, V16, P41; Delepierre M, 1997, BIOCHEMISTRY-US, V36, P2649, DOI 10.1021/bi9617116; Delepierre M, 1998, TOXICON, V36, P1599, DOI 10.1016/S0041-0101(98)00152-4; di Luccio E, 2001, BIOCHEM J, V358, P681, DOI 10.1042/0264-6021:3580681; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; Fajloun Z, 2000, J BIOL CHEM, V275, P39394, DOI 10.1074/jbc.M006810200; Fajloun Z, 2000, J BIOL CHEM, V275, P13605, DOI 10.1074/jbc.275.18.13605; Fajloun Z, 2000, EUR J BIOCHEM, V267, P5149, DOI 10.1046/j.1432-1327.2000.01577.x; Fu W, 2002, BIOPHYS J, V83, P2370, DOI 10.1016/S0006-3495(02)75251-X; GRAY EG, 1962, J ANAT, V96, P79; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; JONHSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61; Kharrat R, 1997, FEBS LETT, V406, P284, DOI 10.1016/S0014-5793(97)00285-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebrun B, 1997, BIOCHEM J, V328, P321, DOI 10.1042/bj3280321; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olamendi-Portugal T, 1998, TOXICON, V36, P759, DOI 10.1016/S0041-0101(97)00163-3; OlamendiPortugal T, 1996, BIOCHEM J, V315, P977, DOI 10.1042/bj3150977; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; Savarin P, 1999, PROTEIN SCI, V8, P2672; Stocker U, 2000, PROTEINS, V40, P145, DOI 10.1002/(SICI)1097-0134(20000701)40:1<145::AID-PROT160>3.0.CO;2-Y; TAM JP, 1986, J AM CHEM SOC, V108, P5242, DOI 10.1021/ja00277a031; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	34	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31095	31104		10.1074/jbc.M304271200	http://dx.doi.org/10.1074/jbc.M304271200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783861	hybrid			2022-12-25	WOS:000184658800086
J	Mueller, S; Wimmer, E				Mueller, S; Wimmer, E			Recruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to alpha(v)beta(3) integrin-containing membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; E-CADHERIN; ALKALINE-PHOSPHATASE; ADHERENS JUNCTIONS; MALIGNANT GLIOMA; EPITHELIAL-CELLS; GENE-EXPRESSION; PROTEIN; BINDING; MEMBER	Nectins present a novel class of Ig superfamily adhesion molecules that, cooperatively with cadherins, establish and maintain cell-cell adherens junctions. CD155, the cognate receptor for poliovirus, undergoes cell-matrix contacts by binding to the extracellular matrix protein vitronectin. The significant homology of nectins with CD155 prompted us to investigate the possibility of their interaction. We determined that nectin-3 binds CD155 and its putative mouse homologue Tage4 in cell-based ligand binding assays. Coculture of nectin-3 and CD155-expressing HeLa cells led to CD155-dependent recruitment of nectin-3 to cell-cell contacts. In a heterologous coculture system with CD155 expressing mouse neuroblastoma cells, HeLa cell-expressed nectin-3 was recruited to contact sites with CD155 bearing neurites. CD155 and nectin-3 colocalized to epithelial cell-cell junctions in renal proximal tubules and in the amniotic membrane. Efficient interaction depended on CD155 dimerization, which appears to be aided by cell type-specific cofactors. We furthermore found CD155 to codistribute with alpha(v) integrin microdomains on the surface of transfected mouse fibroblasts and at amniotic epithelial cell junctions. Our findings demonstrate the possible trans-interaction between the bona fide cell-cell adherens type adhesion system (cadherin/nectin) and the cell-matrix adhesion system (integrin/CD155) by virtue of their nectin-3 and CD155 components, respectively.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wimmer, E (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.		Mueller, Steffen/HGE-0738-2022	Mueller, Steffen/0000-0003-2660-258X	NIAID NIH HHS [AI39485] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI039485, R01AI039485] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Aplin AE, 1998, PHARMACOL REV, V50, P197; Arita M, 1999, J VIROL, V73, P1066, DOI 10.1128/JVI.73.2.1066-1074.1999; Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Baury B, 2001, GENE, V265, P185, DOI 10.1016/S0378-1119(01)00343-2; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; Chatterjee N, 2001, J Environ Pathol Toxicol Oncol, V20, P211; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; GLADSON CL, 1995, J CELL SCI, V108, P947; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Gromeier M, 2001, CURR OPIN MOL THER, V3, P503; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; He YN, 2000, P NATL ACAD SCI USA, V97, P79, DOI 10.1073/pnas.97.1.79; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Iwasaki A, 2002, J INFECT DIS, V186, P585, DOI 10.1086/342682; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P951, DOI 10.1073/pnas.88.3.951; Lange R, 2001, VIROLOGY, V285, P218, DOI 10.1006/viro.2001.0943; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Momose Y, 2002, BIOCHEM BIOPH RES CO, V293, P45, DOI 10.1016/S0006-291X(02)00183-3; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; NOBIS P, 1985, J GEN VIROL, V66, P2563, DOI 10.1099/0022-1317-66-12-2563; Ohka S, 2001, BIOCHEM BIOPH RES CO, V287, P941, DOI 10.1006/bbrc.2001.5660; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; PAULUS W, 1994, J NEUROSURG, V80, P515, DOI 10.3171/jns.1994.80.3.0515; REN R, 1992, J VIROL, V66, P296, DOI 10.1128/JVI.66.1.296-304.1992; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Solecki DJ, 2002, J BIOL CHEM, V277, P25697, DOI 10.1074/jbc.M201378200; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TUCKER SP, 1993, J VIROL, V67, P29, DOI 10.1128/JVI.67.1.29-38.1993; Whittard JD, 2002, MATRIX BIOL, V21, P525, DOI 10.1016/S0945-053X(02)00037-9; Yang WX, 1997, VIROLOGY, V229, P421, DOI 10.1006/viro.1997.8450	55	75	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31251	31260		10.1074/jbc.M304166200	http://dx.doi.org/10.1074/jbc.M304166200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12759359	hybrid			2022-12-25	WOS:000184658800104
J	Shaw, S; Wang, XD; Redd, H; Alexander, GD; Isales, CM; Marrero, MB				Shaw, S; Wang, XD; Redd, H; Alexander, GD; Isales, CM; Marrero, MB			High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; PROLIFERATION; TRANSCRIPTION; INACTIVATION; PHOSPHATASES; PP60(C-SRC); RECEPTORS; ROLES	Angiotensin II (Ang II), protein kinase C (PKC), reactive oxygen species (ROS) generated by NADPH oxidase, the activation of Janus kinase 2 (JAK2), and the polyol pathway play important parts in the hyperproliferation of vascular smooth muscle cells (VSMC), a characteristic feature of diabetic macroangiopathy. The precise mechanism, however, remains unclear. This study investigated the relation between the polyol pathway, PKC-beta, ROS, JAK2, and Ang II in the development of diabetic macroangiopathy. VSMC cultured in high glucose (HG; 25 mM) showed significant increases in the tyrosine phosphorylation of JAK2, production of ROS, and proliferation activities when compared with VSMC cultured in normal glucose (5.5 mM (NG)). Both the aldose reductase specific inhibitor (zopolrestat) or transfection with aldose reductase antisense oligonucleotide blocked the phosphorylation of JAK2, the production of ROS, and proliferation of VSMC induced by HG, but it had no effect on the Ang II-induced activation of these parameters in both NG and HG. However, transfection with PKC-beta antisense oligonucleotide, preincubation with a PKC-beta-specific inhibitor (LY379196) or apocynin (NADPH oxidase-specific inhibitor), or electroporation of NADPH oxidase antibodies blocked the Ang II-induced JAK2 phosphorylation, production of ROS, and proliferation of VSMC in both NG and HG. These observations suggest that the polyol pathway hyperactivity induced by HG contributes to the development of diabetic macroangiopathy through a PKC-beta-ROS activation of JAK2.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Marrero, MB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.	mmarrero@mail.mcg.edu	Isales, Carlos/J-9902-2013	Isales, Carlos/0000-0002-4480-3484	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058139, R01HL058139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58139] Funding Source: Medline; NIDDK NIH HHS [DK50268] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amiri F, 1999, J BIOL CHEM, V274, P32382, DOI 10.1074/jbc.274.45.32382; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Berk Bradford C., 1996, P187; BeyerMears A, 1996, PHARMACOLOGY, V52, P292, DOI 10.1159/000139394; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Chappey O, 1997, EUR J CLIN INVEST, V27, P97, DOI 10.1046/j.1365-2362.1997.710624.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; Kapor-Drezgic J, 1999, J AM SOC NEPHROL, V10, P1193; Korchak HM, 2001, J BIOL CHEM, V276, P8910, DOI 10.1074/jbc.M008326200; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Nakamura J, 2001, DIABETOLOGIA, V44, P480, DOI 10.1007/s001250051646; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Schieffer B, 1997, AM J PHYSIOL-CELL PH, V272, pC2019, DOI 10.1152/ajpcell.1997.272.6.C2019; Schieffer B, 2000, CIRC RES, V87, P1195, DOI 10.1161/01.RES.87.12.1195; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Tardif M, 2002, J BIOL CHEM, V277, P24148, DOI 10.1074/jbc.M109036200; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Venugopal SK, 2002, DIABETES, V51, P3049, DOI 10.2337/diabetes.51.10.3049	28	70	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30634	30641		10.1074/jbc.M305008200	http://dx.doi.org/10.1074/jbc.M305008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777386	hybrid			2022-12-25	WOS:000184658800028
J	Bhave, G; Nadin, BM; Brasier, DJ; Glauner, KS; Shah, RD; Heinemann, SF; Karim, F; Gereau, RW				Bhave, G; Nadin, BM; Brasier, DJ; Glauner, KS; Shah, RD; Heinemann, SF; Karim, F; Gereau, RW			Membrane topology of a metabotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ASPARAGINE-LINKED OLIGOSACCHARIDES; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; AGONIST SELECTIVITY; CALMODULIN-BINDING; IN-VITRO; PHOSPHORYLATION; RHODOPSIN; SITE	The metabotropic glutamate receptors (mGluRs) have been predicted to have a classical seven transmembrane domain structure similar to that seen for members of the G-protein-coupled receptor (GPCR) superfamily. However, the mGluRs (and other members of the family C GPCRs) show no sequence homology to the rhodopsin-like GPCRs, for which this seven transmembrane domain structure has been experimentally confirmed. Furthermore, several transmembrane domain prediction algorithms suggest that the mGluRs have a topology that is distinct from these receptors. In the present study, we set out to test whether mGluR5 has seven true transmembrane domains. Using a variety of approaches in both prokaryotic and eukaryotic systems, our data provide stong support for the proposed seven transmembrane domain model of mGluR5. We propose that this membrane topology can be extended to all members of the family C GPCRs.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA	Baylor College of Medicine; Salk Institute	Gereau, RW (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065766, R01MH060230] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM8507] Funding Source: Medline; NIMH NIH HHS [F32MH65766, MH60230] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LACATENA RM, 1994, P NATL ACAD SCI USA, V91, P10521, DOI 10.1073/pnas.91.22.10521; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Ott CM, 2002, J CELL SCI, V115, P2003; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parmentier ML, 2000, NEUROPHARMACOLOGY, V39, P1119, DOI 10.1016/S0028-3908(99)00204-X; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; Quitterer U, 1999, J BIOL CHEM, V274, P14773, DOI 10.1074/jbc.274.21.14773; Schulein R, 1996, J BIOL CHEM, V271, P28844, DOI 10.1074/jbc.271.46.28844; SEAL AJ, 1994, NEUROPHARMACOLOGY, V33, P1065, DOI 10.1016/0028-3908(94)90144-9; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG HY, 1989, J BIOL CHEM, V264, P14424	36	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30294	30301		10.1074/jbc.M303258200	http://dx.doi.org/10.1074/jbc.M303258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764131	hybrid			2022-12-25	WOS:000184507000109
J	Chatterjee, TK; Fisher, RA				Chatterjee, TK; Fisher, RA			Mild heat and proteotoxic stress promote unique subcellular trafficking and nucleolar accumulation of RGS6 and other RGS proteins - Role of the RGS domain in stress-induced trafficking of RGS proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; TOPOISOMERASE-I; SHOCK FACTOR-1; LOCALIZATION; REGULATOR; NUCLEAR; TRANSCRIPTION; TRANSLOCATION; EXPRESSION	RGS proteins comprise a large family of proteins named for their ability to negatively regulate heterotrimeric G protein signaling. RGS6 is a member of the R7 subfamily of RGS proteins possessing DEP (disheveled/Egl-10/pleckstrin) homology and GGL (G protein gamma-sub-unit-like) domains in addition to the semiconserved RGS domain. Our previous study documented unusual complexity in splicing of the human RGS6 gene, and we demonstrated localization of various RGS6 splice forms at sites other than the plasma membrane, including the cytoplasm and nucleus, where G proteins are not localized (Chatterjee, T. K., Liu, Z., and Fisher, R. A. (2003) J. Biol. Chem. 278, 30261-30271). Here we provide new evidence that mild heat stress, proteasome-mediated proteotoxic stress, and HSF1 expression induces dramatic relocalization of RGS6 proteins from such sites to nucleoli. This response was observed in COS-7 cells expressing various splice forms of RGS6, was not elicited by other forms of cellular stress and was observed in cells treated with various protein kinase inhibitors or co-expressing a dominant-negative kinase inactive SAPK. The RGS domain of RGS6 was identified as a primary structural module providing support for its stress-induced nucleolar trafficking and various other RGS proteins or their isolated RGS domains similarly undergo nucleolar migration in response to heat or proteotoxic stress or during co-expression of HSF1. The atypical RGS domains of axin and AKAP10 also underwent stress-induced nucleolar trafficking while structural domains outside of the RGS domain of some RGS proteins can override nucleolar trafficking in response to stress. Inhibition of rDNA transcription also promoted nucleolar migration of RGS6, a response previously observed in a subset of nucleolar proteins. The DEP domain of RGS6, but not its RGS domain, conferred structural support for its transcription-linked nucleolar migration. RGS6 exhibited trafficking from subnuclear dots to nucleoli in response to heat-, proteotoxic- or transcription-linked stress. These results provide new evidence that mammalian RGS proteins undergo unique subcellular trafficking in response to specific forms of cellular stress and implicate the RGS family of proteins in cellular stress signaling pathways.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.			Fisher, Rory/0000-0003-3108-4836	NHLBI NIH HHS [HL41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NIGMS NIH HHS [GM067881] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041071, R29HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067881] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Burchett SA, 2002, J BIOL CHEM, V277, P22156, DOI 10.1074/jbc.M202254200; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 2003, J BIOL CHEM, V278, P30261, DOI 10.1074/jbc.M212687200; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DERRIEN A, 2003, J BIOL CHEM; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Huang S, 1998, J CELL BIOL, V143, P35, DOI 10.1083/jcb.143.1.35; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Klibanov SA, 2001, J CELL SCI, V114, P1867; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; Martemyanov KA, 2002, J BIOL CHEM, V277, P32843, DOI 10.1074/jbc.M205170200; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Nollen EAA, 2002, J CELL SCI, V115, P2809; Nollen EAA, 2001, P NATL ACAD SCI USA, V98, P12038, DOI 10.1073/pnas.201112398; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Snaar S, 2000, J CELL BIOL, V151, P653, DOI 10.1083/jcb.151.3.653; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199; Wang L, 2001, P NATL ACAD SCI USA, V98, P3220, DOI 10.1073/pnas.051633398; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zmijewski JW, 2001, ARCH BIOCHEM BIOPHYS, V392, P192, DOI 10.1006/abbi.2001.2430	55	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30272	30282		10.1074/jbc.M212688200	http://dx.doi.org/10.1074/jbc.M212688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761220	hybrid			2022-12-25	WOS:000184507000107
J	Gambaryan, S; Butt, E; Marcus, K; Glazova, M; Palmetshofer, A; Guillon, G; Smolenski, A				Gambaryan, S; Butt, E; Marcus, K; Glazova, M; Palmetshofer, A; Guillon, G; Smolenski, A			CGMP-dependent protein kinase type II regulates basal level of aldosterone production by zona glomerulosa cells without increasing expression of the steroidogenic acute regulatory protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HUMAN PLATELETS; TRANSMEMBRANE CONDUCTANCE REGULATOR; SODIUM RESTRICTION; CYCLIC-NUCLEOTIDES; ANGIOTENSIN-II; IN-VITRO; RAT; PHOSPHORYLATION; SECRETION; STAR	The renin-angiotensin-aldosterone system plays a pivotal role in the regulation of salt and water homeostasis. Here, we demonstrate the expression and functional role of cGMP-dependent protein kinases (PKGs) in rat adrenal cortex. Expression of PKG II is restricted to adrenal zona glomerulosa (ZG) cells, whereas PKG I is localized to the adrenal capsule and blood vessels. Activation of the aldosterone system by a low sodium diet up-regulated the expression of PKG II, however, it did not change PKG I expression in adrenal cortex. Both, activation of PKG II in isolated ZG cell and adenoviral gene transfer of wild type PKG II into ZG cells enhanced aldosterone production. In contrast, inhibition of PKG II as well as infection with a PKG II catalytically inactive mutant had an inhibitory effect on aldosterone production. Steroidogenic acute regulatory (StAR) protein that regulates the rate-limiting step in steroidogenesis is a new substrate for PKG II and can be phosphorylated by PKG II in vitro at serine 55/56 and serine 99. Stimulation of aldosterone production by PKG II in contrast to stimulation by PKA did not activate StAR gene expression in ZG cells. The results presented indicate that PKG II activity in ZG cells is important for maintaining basal aldosterone production.	Med Univ Clin Wuerzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Russian Acad Sci, IM Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia; CNRS, INSERM, U469, F-34094 Montpellier 05, France; Med Proteome Ctr, D-44780 Bochum, Germany; Med Univ Clin Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany	University of Wurzburg; North-Western State Medical University named after I.I. Mechnikov; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gambaryan, S (corresponding author), Med Univ Clin Wuerzburg, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	gambarya@klin-biochem.uniwuerzburg.de	Glazova, Margarita/AAN-7567-2020; Glazova, Margarita V/J-9938-2018; Glazova, Margarita/Q-8597-2016; Gambaryan, Stepan/I-3940-2016	Glazova, Margarita/0000-0001-6617-3404; Glazova, Margarita V/0000-0001-6617-3404; Glazova, Margarita/0000-0001-6617-3404; Gambaryan, Stepan/0000-0002-1470-0791; Smolenski, Albert/0000-0001-9210-9406				Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; BARRETT PQ, 1988, ENDOCRINOLOGY, V122, P799, DOI 10.1210/endo-122-3-799; Betancourt-Calle S, 2001, MOL CELL ENDOCRINOL, V173, P87, DOI 10.1016/S0303-7207(00)00411-1; Burkhardt M, 2000, J BIOL CHEM, V275, P33536, DOI 10.1074/jbc.M005670200; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Clark BJ, 1999, ENDOCRINOLOGY, V140, P4390, DOI 10.1210/en.140.10.4390; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; Cote M, 1999, ENDOCRINOLOGY, V140, P3594, DOI 10.1210/en.140.8.3594; De Vente J, 2001, NEUROSCIENCE, V108, P27, DOI 10.1016/S0306-4522(01)00401-8; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; GALLOPAYET N, 1993, CELL SIGNAL, V5, P651, DOI 10.1016/0898-6568(93)90060-Y; Gambaryan S, 1998, P NATL ACAD SCI USA, V95, P9003, DOI 10.1073/pnas.95.15.9003; Gambaryan S, 2002, BIOCHEM BIOPH RES CO, V293, P1438, DOI 10.1016/S0006-291X(02)00412-6; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; Hanke CJ, 1998, ENDOCRINOLOGY, V139, P4053, DOI 10.1210/en.139.10.4053; Hanke CJ, 2000, HYPERTENSION, V35, P324, DOI 10.1161/01.HYP.35.1.324; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hofmann F, 2000, J CELL SCI, V113, P1671; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; Kurtz A, 1998, AM J PHYSIOL-RENAL, V275, pF849, DOI 10.1152/ajprenal.1998.275.6.F849; Lehoux JG, 1997, ENDOCRINOLOGY, V138, P5238, DOI 10.1210/en.138.12.5238; Lehoux JG, 1999, ENDOCRINOLOGY, V140, P5154, DOI 10.1210/en.140.11.5154; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; McEwan PE, 1999, AM J PHYSIOL-ENDOC M, V276, pE303, DOI 10.1152/ajpendo.1999.276.2.E303; Osman H, 2002, J BIOL CHEM, V277, P41259, DOI 10.1074/jbc.M206595200; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Wagner C, 1998, J CLIN INVEST, V102, P1576, DOI 10.1172/JCI4044; Wagner C, 1998, KIDNEY INT, V54, pS78, DOI 10.1046/j.1523-1755.1998.06716.x; Weber KT, 2001, NEW ENGL J MED, V345, P1689, DOI 10.1056/NEJMra000050	42	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29640	29648		10.1074/jbc.M302143200	http://dx.doi.org/10.1074/jbc.M302143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775716	hybrid			2022-12-25	WOS:000184507000033
J	Hassepass, I; Voit, R; Hoffmann, I				Hassepass, I; Voit, R; Hoffmann, I			Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; CELL-CYCLE; G(1)/S TRANSITION; CHK1; ACTIVATION; PATHWAY; KINASE; ATR	The human Cdc25A phosphatase plays a pivotal role at the G(1)/S transition by activating cyclin E and A/Cdk2 complexes through dephosphorylation. In response to ionizing radiation, Cdc25A is phosphorylated by both Chk1 and Chk2 on Ser-123. This in turn leads to ubiquitylation and rapid degradation of Cdc25A by the proteasome resulting in cell cycle arrest. We found that in response to UV irradiation, Cdc25A is phosphorylated at a different serine residue, Ser-75. Significantly, Cdc25A mutants carrying alanine instead of either Ser-75 or Ser-123 demonstrate that only Ser-75 mediates protein stabilization in response to UV-induced DNA damage. As a consequence, cyclin E/Cdk2 kinase activity was high. Furthermore, we find that Cdc25A was phosphorylated by Chk1 on Ser-75 in vitro and that the same site was also phosphorylated in vivo. Taken together, these data strongly suggest that phosphorylation of Cdc25A on Ser-75 by Chk1 and its subsequent degradation is required to delay cell cycle progression in response to UV-induced DNA lesions.	German Canc Res Ctr, D-69120 Heidelberg, Germany; Dept Appl Tumorvirol, D-69120 Heidelberg, Germany; Dep Mol Biol Cell 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoffmann, I (corresponding author), German Canc Res Ctr, Cell Cycle Control & Carcinogenesis F045, Dept Appl Tumorvirol, Neuenheimer Feld 242, D-69115 Heidelberg, Germany.	I.Hoffmann@dkfz.de						Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	20	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29824	29829		10.1074/jbc.M302704200	http://dx.doi.org/10.1074/jbc.M302704200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12759351	hybrid			2022-12-25	WOS:000184507000055
J	Houston, DR; Recklies, AD; Krupa, JC; van Aalten, DMF				Houston, DR; Recklies, AD; Krupa, JC; van Aalten, DMF			Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITINASE PROTEIN FAMILY; SUBSTRATE-ASSISTED CATALYSIS; BACILLUS-CIRCULANS WL-12; HUMAN CARTILAGE GP-39; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; SERUM YKL-40; COCCIDIOIDES-IMMITIS; MAMMALIAN LECTIN; POTENTIAL MARKER	The 39-kDa human cartilage glycoprotein (HCGP39), a member of a novel family of chitinase-like lectins (Chi-lectins), is overexpressed in articular chondrocytes and certain cancers. Proposed functions of this protein include a role in connective tissue remodeling and defense against pathogens. Similar to other Chi-lectins, HCGP39 promotes the growth of connective tissue cells. The ability of HCGP39 to activate cytoplasmic signaling pathways suggests the presence of a ligand for this protein at the cell surface. There is currently no information regarding the identity of any physiological or pathological ligands of the Chi-lectins or the nature of the protein-ligand interaction. Here, we show that HCGP39 is able to bind chitooligosaccharides with micromolar affinity. Crystal structures of the native protein and a complex with GlcNAc(8) show that the ligand is bound in identical fashion to family 18 chitinases. However, unlike the chitinases, binding of the oligosaccharide ligand to HCGP39 induces a large conformational change. Thus, HCGP39 could be a lectin that binds chitin-like oligosaccharide ligands and possibly plays a role in innate responses to chitinous pathogens, such as fungi and nematodes.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Shriners Hosp Children, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada	University of Dundee; McGill University; McGill University	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk		van Aalten, Daan/0000-0002-1499-6908; Houston, Douglas/0000-0002-3469-1546				Bokma E, 2002, EUR J BIOCHEM, V269, P893, DOI 10.1046/j.0014-2956.2001.02721.x; Bortone K, 2002, J MOL BIOL, V320, P293, DOI 10.1016/S0022-2836(02)00444-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Cintin C, 2002, CANCER-AM CANCER SOC, V95, P267, DOI 10.1002/cncr.10644; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P750, DOI 10.1107/S0907444997016247; De Ceuninck F, 2001, BIOCHEM BIOPH RES CO, V285, P926, DOI 10.1006/bbrc.2001.5253; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Johansen JS, 1996, BRIT J RHEUMATOL, V35, P553; Johansen JS, 1997, SCAND J GASTROENTERO, V32, P582, DOI 10.3109/00365529709025104; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawamura K, 1999, DEVELOPMENT, V126, P211; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; MALETTE B, 1995, MOL REPROD DEV, V41, P384, DOI 10.1002/mrd.1080410315; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Rao FV, 2003, J BIOL CHEM, V278, P20110, DOI 10.1074/jbc.M300362200; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Steck E, 2002, BIOCHEM BIOPH RES CO, V299, P109, DOI 10.1016/S0006-291X(02)02585-8; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Tanwar MK, 2002, CANCER RES, V62, P4364; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Varela PF, 2002, J BIOL CHEM, V277, P13229, DOI 10.1074/jbc.M110502200; Volck B, 1999, SCAND J RHEUMATOL, V28, P171; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1994, BIOSCI BIOTECH BIOCH, V58, P2283, DOI 10.1271/bbb.58.2283; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	47	112	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30206	30212		10.1074/jbc.M303371200	http://dx.doi.org/10.1074/jbc.M303371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12775711	hybrid			2022-12-25	WOS:000184507000100
J	Mima, J; Narita, Y; Chiba, H; Hayashi, R				Mima, J; Narita, Y; Chiba, H; Hayashi, R			The multiple site binding of carboxypeptidase Y inhibitor (I-C) to the cognate proteinase - Implications for the biological roles of the phosphatidylethanolamine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; SERINE CARBOXYPEPTIDASE; YEAST CARBOXYPEPTIDASE; ALPHA-THROMBIN; COMPLEX; HIRUDIN; FAMILY; RESOLUTION	The serine carboxypeptidase inhibitor in the cytoplasm of Saccharomyces cerevisiae, I-C, specifically inhibits vacuolar carboxypeptidase Y (CPY) and belongs to a functionally unknown family of phosphatidylethanolamine-binding proteins (PEBPs). In the presence of 1 M guanidine hydrochloride, a CPY-I-C complex is formed and is almost fully activated. The reactivities of phenylmethylsulfonyl fluoride, p-chloromercuribenzoic acid, and diisopropyl fluorophosphate toward the complex are considerably increased in 1 M guanidine hydrochloride, indicating that I-C contains a binding site other than its inhibitory reactive site. I-C is able to form the complex with diisopropyl fluorophosphate-modified CPY. Tryptic digestion of the complex indicates that two fragments from I-C are involved in complex formation with CPY. These findings demonstrate the multiple site binding of I-C with CPY. Considering the fact that mouse PEBP has recently been identified as a novel thrombin inhibitor, the binding that characterizes the CPY-I-C complex could be a common feature of PEBPs.	Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Mima, J (corresponding author), Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan.							BAI Y, 1979, J BIOL CHEM, V254, P8473; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Bruun AW, 1998, BIOCHEMISTRY-US, V37, P3351, DOI 10.1021/bi971286w; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HAYASHI R, 1973, J BIOL CHEM, V248, P8366; Hayashi R, 1976, Methods Enzymol, V45, P568; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Jung G, 1998, J BIOCHEM-TOKYO, V124, P446, DOI 10.1093/oxfordjournals.jbchem.a022133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Marino-Buslje C, 2000, EUR J BIOCHEM, V267, P1502, DOI 10.1046/j.1432-1327.2000.01150.x; MATERN H, 1974, P NATL ACAD SCI USA, V71, P4874, DOI 10.1073/pnas.71.12.4874; MATERN H, 1979, BIOCHIM BIOPHYS ACTA, V567, P503, DOI 10.1016/0005-2744(79)90136-0; Mima J, 2002, J BIOCHEM, V132, P967, DOI 10.1093/oxfordjournals.jbchem.a003311; Mima J, 2002, FEBS LETT, V532, P207, DOI 10.1016/S0014-5793(02)03676-1; Mima J, 2002, EUR J BIOCHEM, V269, P3220, DOI [10.1046/j.1432-1033.2002.02997.x, 10.1111/j.0014-2956.2002.02997.x]; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Reverter D, 1998, J BIOL CHEM, V273, P32927, DOI 10.1074/jbc.273.49.32927; Reverter D, 2000, NAT STRUCT BIOL, V7, P322, DOI 10.1038/74092; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VITALI J, 1992, J BIOL CHEM, V267, P17670; WALLACE A, 1989, BIOCHEMISTRY-US, V28, P10079, DOI 10.1021/bi00452a030	28	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29792	29798		10.1074/jbc.M301859200	http://dx.doi.org/10.1074/jbc.M301859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12791700	hybrid			2022-12-25	WOS:000184507000051
J	Hosui, A; Ohkawa, K; Ishida, H; Sato, A; Nakanishi, F; Ueda, K; Takehara, T; Kasahara, A; Sasaki, Y; Hori, M; Hayashi, N				Hosui, A; Ohkawa, K; Ishida, H; Sato, A; Nakanishi, F; Ueda, K; Takehara, T; Kasahara, A; Sasaki, Y; Hori, M; Hayashi, N			Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE CODING SEQUENCE; RAT EMBRYO FIBROBLASTS; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; CELL-LINES; IFN-GAMMA; HEPATOCELLULAR-CARCINOMA; MEDIATED APOPTOSIS; RECEPTOR FAMILY; TYROSINE KINASE	We established hepatitis C virus (HCV) core-expressing cells and investigated whether HCV core would modify the Janus kinase (JAK)-signal transducer and activator transcription factor (STAT) pathway under interleukin-6 (IL-6) and interferon (IFN)-gamma stimuli. Phosphorylation of JAK1/2 and STAT3, and STAT3-mediated transcription, were prevented by HCV core under IL-6 stimulation. In contrast, HCV core increased phosphorylation of JAK1/2 and STAT1 and STAT1-mediated transcription under IFN-gamma stimulation. Immunoprecipitation/Western blot analysis showed that HCV core could bind to JAK1/2. The PGYPWP sequences at codons 79-84 within HCV core were important for interaction with JAKs by in vitro binding analysis. In the reporter gene assay, HCV core-mediated suppression of JAK-STAT pathway under IL-6 stimulation was not observed by abrogation of PGYPWP sequence, suggesting that HCV core/JAK interaction may directly affect the signal transduction. In contrast, augmentation of JAK-STAT pathway was still seen by HCV core without functional PGYPWP sequence under IFN-gamma stimulation. Flow cytometric analysis revealed that HCV core up-regulated of IFN-gamma receptor 2 expression, which may be responsible for HCV core-mediated enhancement of JAK-STAT pathway under IFN-gamma stimulation. In conclusion, HCV core has different effects on the JAK-STAT pathway under IL-6 and IFN-gamma stimuli. This may be exerted by these two independent mechanisms.	Osaka Univ, Sch Med, Dept Mol Therapeut, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Internal Med & Therapeut, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Microbiol, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Gen Med, Grad Sch Med, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University	Hayashi, N (corresponding author), Osaka Univ, Sch Med, Dept Mol Therapeut, Grad Sch Med, 2-2 Yamadaoka, Osaka 5650871, Japan.		Hosui, Atsushi/AAC-1771-2020	Hosui, Atsushi/0000-0003-0777-8045				Adams NJ, 1997, BIOCHEM BIOPH RES CO, V234, P393, DOI 10.1006/bbrc.1997.6627; ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Chamberlain RW, 1997, BIOCHEM BIOPH RES CO, V236, P44, DOI 10.1006/bbrc.1997.6902; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Cramp ME, 2000, GASTROENTEROLOGY, V118, P346, DOI 10.1016/S0016-5085(00)70217-4; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID SA, 2001, SCIENCE, V296, P1653; DONALD BS, 1995, J HEPATOL S2, V23, P26; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GUIDOTTI LG, 1994, P NATL ACAD SCI USA, V91, P3764, DOI 10.1073/pnas.91.9.3764; Heim MH, 1996, EUR J CLIN INVEST, V26, P1, DOI 10.1046/j.1365-2362.1996.103248.x; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MARKUS HH, 1999, J VIROL, V73, P8469; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; MORI S, 1992, BIOCHEM BIOPH RES CO, V183, P334, DOI 10.1016/0006-291X(92)91648-A; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Muraoka O, 1996, IMMUNOL LETT, V54, P1, DOI 10.1016/S0165-2478(96)02633-8; Naganuma A, 2000, J VIROL, V74, P8744, DOI 10.1128/JVI.74.18.8744-8750.2000; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; Pestka S, 1997, Semin Oncol, V24, pS9; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; SAKAMOTO M, 1994, J GEN VIROL, V75, P1761, DOI 10.1099/0022-1317-75-7-1761; Sakatsume M, 1996, J IMMUNOL, V156, P4160; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Tokushige K, 1997, J VIROL METHODS, V64, P73, DOI 10.1016/S0166-0934(96)02143-X; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Yoshida H, 2001, J BIOL CHEM, V276, P16399, DOI 10.1074/jbc.M006671200; YOSHIMURA M, 1990, J PHYSIOL-LONDON, V430, P315, DOI 10.1113/jphysiol.1990.sp018293; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	56	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28562	28571		10.1074/jbc.M210485200	http://dx.doi.org/10.1074/jbc.M210485200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12764155	hybrid			2022-12-25	WOS:000184421100029
J	Sapunaric, FM; Levy, SB				Sapunaric, FM; Levy, SB			Second-site suppressor mutations for the serine 202 to phenylalanine substitution within the interdomain loop of the tetracycline efflux protein Tet(C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; MAJOR FACILITATOR SUPERFAMILY; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; RESISTANCE PROTEIN; SEQUENCE MOTIF; MEMBRANE INSERTION; CYTOPLASMIC LOOP; TRANSPOSON TN10; ANTIPORTER	The serine 202 to phenylalanine substitution within the cytoplasmic interdomain loop of Tet(C) greatly reduces tetracycline resistance and efflux activity (Saraceni-Richards, C. A., and Levy, S. B. (2000) J. Biol. Chem. 275, 6101-6106). Second-site suppressor mutations were identified following hydroxylamine and nitrosoguanidine mutagenesis. Three mutations, L11F in transmembrane 1 (TM1), A213T in the central interdomain loop, and A270V in cytoplasmic loop 8-9, restored a wild type level of resistance and an active efflux activity in Escherichia coli cells bearing the mutant tet(C) gene. The Tet S202F protein with the additional A270V mutation was expressed in amounts comparable with the original mutant, whereas L11F and A213T Tet(C) protein mutants were overexpressed. Introduction of each single mutation into the wild type tet(C) gene by site-directed mutagenesis did not alter tetracycline resistance or efflux activity. These secondary mutations may restore resistance by promoting a conformational change in the protein to accommodate the S202F mutation. The data demonstrate an interaction of the interdomain loop with other distant regions of the protein and support a role of the interdomain loop in mediating tetracycline resistance.	Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts University; Tufts University	Levy, SB (corresponding author), Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, 136 Harrison Ave, Boston, MA 02111 USA.	stuart.levy@tufts.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055430] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55430] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldema ML, 1996, MOL MICROBIOL, V19, P187, DOI 10.1046/j.1365-2958.1996.359886.x; ALLARD JD, 1992, J BIOL CHEM, V267, P17809; Budowsky E I, 1976, Prog Nucleic Acid Res Mol Biol, V16, P125; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ECKERT B, 1989, J BIOL CHEM, V264, P11663; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; Jewell JE, 1999, J BACTERIOL, V181, P1689, DOI 10.1128/JB.181.5.1689-1693.1999; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; Levy SB, 1999, ANTIMICROB AGENTS CH, V43, P1523, DOI 10.1128/AAC.43.6.1523; LEVY SB, 1978, NATURE, V276, P90, DOI 10.1038/276090a0; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MCMURRY LM, 1981, ANTIMICROB AGENTS CH, V20, P307, DOI 10.1128/AAC.20.3.307; MCNICHOLAS P, 1995, J BACTERIOL, V177, P5355, DOI 10.1128/jb.177.18.5355-5357.1995; MILLER JH, 1972, EXPT MOL GENETICS, P125; MILLER KW, 1993, ANAL BIOCHEM, V215, P118, DOI 10.1006/abio.1993.1563; MOYED HS, 1983, J BACTERIOL, V155, P549, DOI 10.1128/JB.155.2.549-556.1983; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; NAKANO Y, 1995, GENE, V162, P157, DOI 10.1016/0378-1119(95)00320-6; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; RUBIN RA, 1991, J BACTERIOL, V173, P4503, DOI 10.1128/JB.173.14.4503-4509.1991; RUBIN RA, 1990, J BACTERIOL, V172, P2303, DOI 10.1128/jb.172.5.2303-2312.1990; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Sambrook J, 2001, MOL CLONING LAB MANU; Saraceni-Richards CA, 2000, J BIOL CHEM, V275, P6101, DOI 10.1074/jbc.275.9.6101; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; THANASSI DG, 1995, J BACTERIOL, V177, P998, DOI 10.1128/jb.177.4.998-1007.1995; Tuckman M, 2000, MICROB DRUG RESIST, V6, P277, DOI 10.1089/mdr.2000.6.277; Varela MF, 1995, MOL MEMBR BIOL, V12, P313, DOI 10.3109/09687689509072433; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Weinglass AB, 2000, P NATL ACAD SCI USA, V97, P8938, DOI 10.1073/pnas.140224497; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1993, FEBS LETT, V324, P131, DOI 10.1016/0014-5793(93)81378-D; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155	42	5	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28588	28592		10.1074/jbc.M302658200	http://dx.doi.org/10.1074/jbc.M302658200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12766164	hybrid, Green Published			2022-12-25	WOS:000184421100032
J	Wei, XL; Yu, ZK; Ramalingam, A; Grossman, SR; Yu, JH; Bloch, DB; Maki, CG				Wei, XL; Yu, ZK; Ramalingam, A; Grossman, SR; Yu, JH; Bloch, DB; Maki, CG			Physical and functional interactions between PML and MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR-BODY FORMATION; RING-FINGER DOMAIN; PROTEIN PML; RAR-ALPHA; PREMATURE SENESCENCE; ONCOGENIC RAS; P53; BODIES; BINDING	The tumor suppressor protein PML and oncoprotein MDM2 have opposing effects on p53. PML stimulates p53 activity by recruiting it to nuclear foci termed PML nuclear bodies. In contrast, MDM2 inhibits p53 by promoting its degradation. To date, neither a physical nor functional relationship between PML and MDM2 has been described. In this study, we report an in vivo and in vitro interaction between PML and MDM2 which is independent of p53. Two separate regions of PML are recognized which can interact with MDM2. The C-terminal half of PML, encoded by residues 300 - 633, can interact with the central region of MDM2 which includes the MDM2 acidic domain. In addition, PML amino acids 1 - 200, which encode the RING-finger and most of the B box zinc binding motifs, can interact with the C-terminal, RING-finger containing region of MDM2. Interestingly, PML mutants in which sumoylation at lysine 160 was inhibited displayed an increased association with MDM2, suggesting that sumoylation at this site may be a determinant of PML-MDM2 binding. Coexpression with MDM2 caused a redistribution of PML from the nucleus to the cytoplasm, and this required the PML N terminus and the MDM2 RING-finger domain. These results suggest that interaction between the PML N terminus and MDM2 C terminus can promote PML nuclear exclusion. Wild-type MDM2 inhibited the ability of PML to stimulate the transcriptional activity of a GAL4-CBP fusion protein. This inhibition required the central, acidic region of MDM2, but did not require the MDM2 C terminus. Taken together, these studies demonstrate that MDM2 and PML can interact through at least two separate protein regions, and that these interactions can have specific effects on the activity and/or localization of PML.	Univ Chicago, Dept Radiat Oncol, Chicago, IL 60637 USA; Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	University of Chicago; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Maki, CG (corresponding author), Univ Chicago, Dept Radiat Oncol, 5841 S Maryland Ave,MC 1105,Room G-06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu		Bloch, Donald/0000-0002-6828-4754	NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA80918-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Blondel D, 2002, ONCOGENE, V21, P7957, DOI 10.1038/sj.onc.1205931; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chan HM, 2001, J CELL SCI, V114, P2363; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Everett RD, 1999, J CELL SCI, V112, P4581; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GU J, 2001, CANCER RES, V18, P6703; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kawai H, 2001, J BIOL CHEM, V276, P45928, DOI 10.1074/jbc.M107770200; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NEGOREY D, 2001, ONCOGENE, V49, P7234; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yu E, 1999, INT J MOL MED, V3, P591; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	47	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29288	29297		10.1074/jbc.M212215200	http://dx.doi.org/10.1074/jbc.M212215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759344	hybrid, Green Published			2022-12-25	WOS:000184421100114
J	Werner, T; Borge-Renberg, K; Mellroth, P; Steiner, H; Hultmark, D				Werner, T; Borge-Renberg, K; Mellroth, P; Steiner, H; Hultmark, D			Functional diversity of the Drosophila PGRP-LC gene cluster in the response to lipopolysaccharide and peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PROTEIN; INNATE IMMUNITY; INSECT IMMUNITY; CECROPIN; BACTERIA; RECEPTOR; FAMILY; IDENTIFICATION; INFECTION; INDUCTION	The peptidoglycan recognition protein PGRP-LC is a major activator of the imd/Relish pathway in the Drosophila immune response. Three transcripts are generated by alternative splicing of the complex PGRP-LC gene. The encoded transmembrane proteins share an identical intracellular part, but each has a separate extracellular PGRP-domain: x, y, or a. Here we show that two of these isoforms play unique roles in the response to different microorganisms. Using RNA interference in Drosophila mbn-2 cells, we found that PGRP-LCx is the only isoform required to mediate signals from Gram-positive bacteria and purified bacterial peptidoglycan. By contrast, the recognition of Gram-negative bacteria and bacterial lipopolysaccharide requires both PGRP-LCa and LCx. The third isoform, LCy, is expressed at lower levels and may be partially redundant. Two additional PGRP domains in the gene cluster, z and w, are both included in a single transcript of a separate gene, PGRP-LF. Suppression of this transcript does not block the response to any of the microorganisms tested.	Umea Univ, Umea Ctr Mol Pathogenesis, S-90187 Umea, Sweden; Univ Stockholm, Dept Microbiol, S-10691 Stockholm, Sweden	Umea University; Stockholm University	Hultmark, D (corresponding author), Umea Univ, Umea Ctr Mol Pathogenesis, S-90187 Umea, Sweden.		Mellroth, Peter/F-8214-2013; Hultmark, Dan/C-5058-2013	Hultmark, Dan/0000-0002-6506-5855; Mellroth, Peter/0000-0002-3518-1054				ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Ekengren S, 1999, INSECT BIOCHEM MOLEC, V29, P965, DOI 10.1016/S0965-1748(99)00071-5; EKENGREN S, 2001, THESIS STOCKHOLM U S; Engstrom Y, 1999, DEV COMP IMMUNOL, V23, P345, DOI 10.1016/S0145-305X(99)00016-6; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P539, DOI 10.1016/0965-1748(94)90089-2; Kurucz E, 2003, P NATL ACAD SCI USA, V100, P2622, DOI 10.1073/pnas.0436940100; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MORISHIMA I, 1998, TECHNIQUES INSECT IM, P59; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; WICKER C, 1990, J BIOL CHEM, V265, P22493; YOSHIDA H, 1986, BIOCHEM BIOPH RES CO, V141, P1177, DOI 10.1016/S0006-291X(86)80168-1	26	147	162	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26319	26322		10.1074/jbc.C300184200	http://dx.doi.org/10.1074/jbc.C300184200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12777387	hybrid			2022-12-25	WOS:000184155700005
J	Jiang, MR; Lie, YC; Yang, Y; Wu, JR				Jiang, MR; Lie, YC; Yang, Y; Wu, JR			C-Myc degradation induced by DNA damage results in apoptosis of CHO cells	ONCOGENE			English	Article						c-Myc; apoptosis; DNA damage; CHO cell; tripchlorolide	SISTER-CHROMATID EXCHANGE; STRAND-BREAK REPAIR; PROTEIN-DEGRADATION; TRIPTOLIDE; PROTEASOME; EXPRESSION; GROWTH; CHEMOTHERAPY; SUPPRESSION; INHIBITORS	Although tripchlorolide (TC), a compound purified from a Chinese herb Tripterygium Wilfordii Hook, has been demonstrated to be a potent antitumor agent, its mechanisms of action are unknown. The present study shows that TC induces apoptosis of Chinese Hamster Ovary (CHO) cells. Most strikingly, TC was particularly potent in inducing apoptosis of the UV41 mutant CHO cells, which are deficient in the ERCC4 gene encoding a nucleotide excision repair protein. TC caused a higher level of DNA damage in UV41 cells than those in the wildtype CHO cells or EM9 cells, which are deficient in single-strand break repair. These results provided a critical link between apoptotic hypersensitivity and DNA damage in defective nucleotide excision repair pathway of UV41 cells by TC treatment. Further analysis showed that degradation of the c-Myc protein in TC-treated UV41 cells was much stronger than those in the wild-type CHOAA8 and the EM9. A proteasome inhibitor, MG132, reduced both the degradation of c-Myc and apoptosis in TC-treated UV41 cells. Expression of exogenous c-Myc also inhibited apoptosis of TC-treated UV41 cells. These results indicate that c-Myc degradation induced by DNA damage in the presence of TC contributes to induction of apoptosis of UV41 cells.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Mat Med, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS	Wu, JR (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Jiang, Manrong/E-6991-2011					Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Dang CV, 1999, MOL CELL BIOL, V19, P1; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Jiang MR, 2001, BIOCHEM BIOPH RES CO, V287, P775, DOI 10.1006/bbrc.2001.5655; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LU XY, 1990, ACTA ACADEMIAE MED S, V12, P157; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sgonc R, 1998, EXP GERONTOL, V33, P525, DOI 10.1016/S0531-5565(98)00031-X; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tajima K, 2001, FEBS LETT, V490, P59, DOI 10.1016/S0014-5793(01)02138-X; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Thompson LH, 1998, BIOESSAYS, V20, P589, DOI 10.1002/(SICI)1521-1878(199807)20:7<589::AID-BIES11>3.0.CO;2-W; THOMPSON LH, 1981, P NATL ACAD SCI-BIOL, V78, P3734, DOI 10.1073/pnas.78.6.3734; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; THULASI R, 1993, J BIOL CHEM, V268, P18306; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WOOD AC, 1994, BRIT J CANCER, V69, P663, DOI 10.1038/bjc.1994.128; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHANG T-M, 1981, Acta Pharmacologica Sinica, V2, P128	39	21	22	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3252	3259		10.1038/sj.onc.1206501	http://dx.doi.org/10.1038/sj.onc.1206501			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761495				2022-12-25	WOS:000183040000007
J	Schulz, R; Gres, P; Skyschally, A; Duschin, A; Belosjorow, S; Konietzka, I; Heusch, G				Schulz, R; Gres, P; Skyschally, A; Duschin, A; Belosjorow, S; Konietzka, I; Heusch, G			Ischemic preconditioning preserves connexin 43 phosphorylation during sustained ischemia in pig hearts in vivo	FASEB JOURNAL			English	Article						protein kinases; reperfusion; preconditioning	ACTIVATED PROTEIN-KINASE; JUNCTION UNCOUPLER HEPTANOL; INFARCT SIZE-REDUCTION; GAP-JUNCTIONS; INTERCELLULAR COMMUNICATION; MAPK ACTIVATION; PKC-EPSILON; CHANNEL; CONDUCTANCE; CARDIOPROTECTION	During myocardial ischemia, connexin 43 (Cx43) is dephosphorylated in vitro, and the subsequent opening of gap junctions formed by two opposing Cx43 hexamers was suggested to propagate ischemia/reperfusion injury. Reduction of infarct size (IS) by ischemic preconditioning (IP) involves activation of protein kinase C (PKC) and p38 mitogen activated protein kinase (MAPK), both of which can phosphorylate Cx43. We now studied in anesthetized pigs whether IP impacts on Cx43 phosphorylation by measuring the density of non-phosphorylated and total Cx43 (confocal laser) during normoperfusion and 90-min ischemia in non-preconditioned and preconditioned hearts. Co-localization of PKCalpha, p38MAPKalpha and p38MAPKbeta with Cx43 and the activity of p38MAPK were assessed. IP by 10 min ischemia and 15 min reperfusion reduced IS. Non-phosphorylated Cx43 remained unchanged during ischemia in preconditioned hearts, while it increased from 35+/-3 to 75+/-8 AU (P<0.05) in non-preconditioned hearts. Co-localization of PKC alpha, p38MAPK alpha and p38MAPK beta with Cx43 during ischemia increased only in preconditioned hearts. While the ischemia-induced increase in p38MAPK alpha activity was comparable in preconditioned and non-preconditioned hearts, p38MAPK beta activity was increased only in preconditioned hearts. Blockade of p38MAPK by SB203580 attenuated the IS-reduction and the increased p38MAPK-Cx43 co-localization by IP. We conclude that IP increases co-localization of protein kinases with Cx43 and preserves phosphorylation of Cx43 during ischemia.	Univ Klinikum Essen, Zentrum Innere Med, Inst Pathophysiol, D-45122 Essen, Germany	University of Duisburg Essen	Schulz, R (corresponding author), Univ Klinikum Essen, Zentrum Innere Med, Inst Pathophysiol, Hufelandstr 55, D-45122 Essen, Germany.	rainer_schulz@uni-essen.de	Heusch, Gerd/ABE-6675-2020; Schulz, Rainer/ABD-5069-2021	Schulz, Rainer/0000-0003-3017-0476				Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Barancik M, 2000, J CARDIOVASC PHARM, V35, P474, DOI 10.1097/00005344-200003000-00019; Barker RJ, 2002, CIRC RES, V91, P556, DOI 10.1161/01.RES.0000036861.37203.2F; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Behrends M, 2000, AM J PHYSIOL-HEART C, V279, pH1111, DOI 10.1152/ajpheart.2000.279.3.H1111; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; Bowling N, 2001, J MOL CELL CARDIOL, V33, P789, DOI 10.1006/jmcc.2000.1349; BRANDES RP, 2000, BRIT J PHARMACOL, V136, P709; BURT JM, 1988, AM J PHYSIOL, V254, pH1206, DOI 10.1152/ajpheart.1988.254.6.H1206; CAMERON SJ, 2002, CIRCULATION S2, V106; Cleveland JC, 1997, J MOL CELL CARDIOL, V29, P175, DOI 10.1006/jmcc.1996.0262; Daleau P, 2001, CAN J PHYSIOL PHARM, V79, P371, DOI 10.1139/cjpp-79-5-371; Das DK, 1999, MOL CELL BIOCHEM, V196, P59, DOI 10.1023/A:1006966128795; Doble BW, 2000, CIRC RES, V86, P293, DOI 10.1161/01.RES.86.3.293; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; Erdbrugger W, 1997, BRIT J PHARMACOL, V120, P177, DOI 10.1038/sj.bjp.0700877; Garcia-Dorado D, 2002, CARDIOVASC RES, V55, P456, DOI 10.1016/S0008-6363(02)00441-8; GarciaDorado D, 1997, CIRCULATION, V96, P3579; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Gysembergh A, 2001, CARDIOVASC PATHOL, V10, P13, DOI 10.1016/S1054-8807(00)00056-9; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Kwak BR, 1996, MOL CELL BIOCHEM, V157, P93; Ladilov Y, 2002, AM J PHYSIOL-HEART C, V283, pH1092, DOI 10.1152/ajpheart.00318.2001; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAU AF, 1991, J MOL CELL CARDIOL, V23, P659, DOI 10.1016/0022-2828(91)90975-R; Li GH, 2002, CARDIOVASC PATHOL, V11, P158, DOI 10.1016/S1054-8807(02)00102-3; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LUCCHESI BR, 1998, DIALOGUES CARDIOVASC, V3, P3; Michel MC, 2001, N-S ARCH PHARMACOL, V363, P245, DOI 10.1007/s002100000363; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Ping PP, 2002, J CLIN INVEST, V109, P499, DOI 10.1172/JCI200213200; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Polontchouk L, 2001, FASEB J, V15, P87, DOI 10.1096/fj.01-0381fje; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; Saurin AT, 2000, FASEB J, V14, P2237, DOI 10.1096/fj.99-0671com; Schneider S, 2001, AM J PHYSIOL-HEART C, V280, pH499; Schulz R, 2001, CARDIOVASC RES, V52, P181, DOI 10.1016/S0008-6363(01)00384-4; Schulz R, 2002, CARDIOVASC RES, V55, P690, DOI 10.1016/S0008-6363(02)00319-X; Schwanke U, 2002, AM J PHYSIOL-HEART C, V283, pH1740, DOI 10.1152/ajpheart.00442.2002; Shimizu N, 1998, CARDIOVASC RES, V38, P116, DOI 10.1016/S0008-6363(97)00327-1; Skyschally A, 2003, AM J PHYSIOL-HEART C, V284, pH698, DOI 10.1152/ajpheart.00693.2002; SPRAY DC, 1985, AM J PHYSIOL, V248, pH753, DOI 10.1152/ajpheart.1985.248.6.H753; SPRAY DC, 1990, AM J PHYSIOL, V258, pC195, DOI 10.1152/ajpcell.1990.258.2.C195; TAKENSKWAK BR, 1992, PFLUG ARCH EUR J PHY, V422, P198, DOI 10.1007/BF00370421; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; van Veen TAB, 2001, CARDIOVASC RES, V51, P217, DOI 10.1016/S0008-6363(01)00324-8; Vondriska TM, 2001, AM J PHYSIOL-HEART C, V280, pH1434, DOI 10.1152/ajpheart.2001.280.4.H1434; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; Weinbrenner C, 1998, CIRCULATION, V98, P899, DOI 10.1161/01.CIR.98.9.899; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	56	143	155	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1355	+		10.1096/fj.02-0975fje	http://dx.doi.org/10.1096/fj.02-0975fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759340				2022-12-25	WOS:000183165000021
J	Kavurma, MM; Khachigian, LM				Kavurma, MM; Khachigian, LM			Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21(WAF1/Cip1) transcription and cyclin D1-Cdk4-p21(WAF1/Cip1) complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITORS; EXPRESSION; ACTIVATION; PROTEIN; GENE; PROMOTER; ARREST; P53	Atherosclerosis and restenosis are common vascular disorders that involve excess proliferation of smooth muscle cells (SMCs) in the artery wall. In this study we demonstrate the anti-mitogenic, pro-apoptotic role of the zinc finger transcription factor Sp1 in vascular SMCs and define the underlying molecular mechanism via its capacity to repress the expression of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) at the level of transcription, mRNA, and protein. SMC proliferation inducible by a dominant-negative mutant form of Sp1 was abrogated by antisense strategies targeting p21(WAF1/Cip1). Conversely, antisense p21(WAF1/Cip1) induced apoptosis in SMCs overexpressing dominant-negative-Sp1. p21(WAF1/Cip1) overexpression alone stimulated proliferation and inhibited apoptosis. Sp1 down-regulated p21(WAF1/Cip1) expression in SMCs. Sp1 blocked assembly of cyclin D1-Cdk4-p21(WAF1/Cip1) complex formation whose integrity is critical for G(1)->S transition. Moreover, Rb phosphorylation, which lies immediately downstream of the cyclin D1-Cdk4-p21(WAF1/Cip1) complex, was blocked either by Sp1 overexpression or antisense p21(WAF1/Cip1). These findings, using complementary approaches, demonstrate the inverse relationship between Sp1 and p21(WAF1/Cip1) in SMCs and the capacity of Sp1 to regulate SMC proliferation and apoptosis via its repression of p21(WAF1/Cip1).	Univ New S Wales, Dept Pathol, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Dept Pathol, Ctr Vasc Res, Sydney, NSW 2052, Australia.	L.Khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Kavurma, Mary/0000-0001-7353-0932; Khachigian, Levon/0000-0003-3446-0323				Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; HARPER JW, 1993, CELL, V75, P805; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Libby P, 1997, ANN NY ACAD SCI, V811, P134, DOI 10.1111/j.1749-6632.1997.tb51996.x; Pan WJ, 2001, CANCER RES, V61, P2885; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; Santini MP, 2001, P NATL ACAD SCI USA, V98, P9575, DOI 10.1073/pnas.161299698; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; ZHANG C, 2003, IN PRESS J BIOL CHEM	31	72	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32537	32543		10.1074/jbc.M305650200	http://dx.doi.org/10.1074/jbc.M305650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796485	hybrid			2022-12-25	WOS:000184901800009
J	Iqbal, J; Anwar, K; Hussain, MM				Iqbal, J; Anwar, K; Hussain, MM			Multiple, independently regulated pathways of cholesterol transport across the intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; TRIGLYCERIDE TRANSFER PROTEIN; DUCT LYMPH LIPOPROTEINS; NON-HUMAN PRIMATES; CACO-2 CELLS; DIETARY-CHOLESTEROL; ACYL-COENZYME; PLASMA-CHOLESTEROL; RABBIT ENTEROCYTES	The present study provides a new understanding about the mechanisms involved in cholesterol absorption by the intestinal cells. Contrary to general belief, our data show that newly absorbed cholesterol is neither immediately available for secretion with apoB lipoproteins nor exclusively secreted as part of chylomicrons. Based on our data, cholesterol transport by enterocytes can be broadly classified into two independently modulated, apoB-dependent and -independent, pathways. Cholesterol secretion by the apoB-dependent pathway is induced by oleic acid, is repressed by microsomal triglyceride transfer protein inhibitors, and occurs only with larger apoB-containing lipoproteins. ApoB-independent pathways do not require microsomal triglyceride transfer protein and involve efflux mediated by ABCA1, high density lipoprotein assembly, and possibly other unknown mechanisms. There are at least two different metabolic pools of cholesterol. The newly absorbed and pre-absorbed cholesterol are preferentially secreted via apoB-independent and apoB-dependent pathways, respectively. In contrast to compartmentalization for secretion, these two metabolic pools are equally accessible for cellular esterification. The esterified cholesterol is mainly secreted by the apoB-dependent pathway, whereas both the pathways are involved in the secretion of free cholesterol. Thus, enterocytes transport exogenous cholesterol by several independently regulated pathways raising the possibility that targeting of apoB-independent pathways may result in selective inhibition of cholesterol transport without affecting triglyceride transport.	Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Hussain, MM (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cell Biol, 450 Clarkson Ave,Box 5, Brooklyn, NY 11203 USA.		Iqbal, Jahangir/B-3903-2014	Iqbal, Jahangir/0000-0002-9021-2271	NHLBI NIH HHS [HL64727] Funding Source: Medline; NIDDK NIH HHS [DK46900] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046900, R01DK046900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakillah A, 2003, FRONT BIOSCI-LANDMRK, V8, pD294; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Beaumier-Gallon G, 2001, AM J CLIN NUTR, V73, P870; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW JL, 1995, METABOLIC MOL BASES; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; Cartwright IJ, 1999, J LIPID RES, V40, P1357; Cartwright IJ, 2001, J BIOL CHEM, V276, P48048, DOI 10.1074/jbc.M104229200; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200; FIELD FJ, 1995, J LIPID RES, V36, P1533; FIELD FJ, 1987, J LIPID RES, V28, P1057; Field FJ, 1995, J LIPID RES, V36, P2651; FONG LG, 1995, AM J PHYSIOL-GASTR L, V269, pG60, DOI 10.1152/ajpgi.1995.269.1.G60; Glickman R M, 1986, Methods Enzymol, V129, P519; GREEN PHR, 1978, J CLIN INVEST, V61, P528, DOI 10.1172/JCI108963; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; ILLINGWORTH DR, 1980, GASTROENTEROLOGY, V78, P68; KERN F, 1991, NEW ENGL J MED, V324, P896, DOI 10.1056/NEJM199103283241306; KESANIEMI YA, 1987, EUR J CLIN INVEST, V17, P391, DOI 10.1111/j.1365-2362.1987.tb01132.x; KLEIN RL, 1983, J LIPID RES, V24, P343; KLEIN RL, 1983, J LIPID RES, V24, P357; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; MAGUN AM, 1985, J CLIN INVEST, V75, P209, DOI 10.1172/JCI111676; MCGILL HC, 1979, AM J CLIN NUTR, V32, P2664, DOI 10.1093/ajcn/32.12.2664; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mulligan JD, 2003, J BIOL CHEM, V278, P13356, DOI 10.1074/jbc.M212377200; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Nayak N, 2001, J LIPID RES, V42, P272; Ohama T, 2002, BIOCHEM BIOPH RES CO, V296, P625, DOI 10.1016/S0006-291X(02)00853-7; Phan CT, 2001, FRONT BIOSCI-LANDMRK, V6, pD299, DOI 10.2741/Phan; Pinkus L M, 1981, Methods Enzymol, V77, P154; Plump AS, 1997, J LIPID RES, V38, P1033; REDINGER RN, 1972, ARCH INTERN MED, V130, P618, DOI 10.1001/archinte.130.4.618; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; RILEY JW, 1980, J LIPID RES, V21, P942; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; TSO P, 1995, AM J PHYSIOL-GASTR L, V268, pG568, DOI 10.1152/ajpgi.1995.268.4.G568; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WILSON MD, 1994, J LIPID RES, V35, P943; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365	51	83	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31610	31620		10.1074/jbc.M301177200	http://dx.doi.org/10.1074/jbc.M301177200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12775725	hybrid			2022-12-25	WOS:000184782100021
J	Laakko, T; Juliano, RL				Laakko, T; Juliano, RL			Adhesion regulation of stromal cell-derived factor-1 activation of ERK in lymphocytes by phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; INTEGRIN-MEDIATED ACTIVATION; MAP-KINASE; SIGNAL-TRANSDUCTION; CHEMOKINE RECEPTORS; T-LYMPHOCYTES; DEPHOSPHORYLATION; PHOSPHORYLATION; SPECIFICITY; INHIBITION	We have investigated whether chemokine signaling to the extracellular-signal-regulated kinase (ERK) was regulated by beta(1)-integrin-mediated adhesion in B- and T-cell lines. Activation of ERK by the chemokine SDF-1 can be regulated by adhesion to beta(1)-integrin substrates in the T-cell lines MOLT-3, Jurkat, and H9 and in the Daudi B-cell line. In Jurkat T-cells, adhesion to the immobilized alpha(4)beta(1)-integrin ligand VCAM-1 or to the alpha(5)beta(1)-integrin ligand fibronectin regulated stromal-cell derived factor-1 (SDF-1) activation of ERK. Adhesion control of SDF-1 signaling was a rapid event, occurring as early as 10 min after adhesion, and loss of signaling occurred within 10 min of deadhesion. In contrast, SDF-1 activation of the ERK kinase MEK was independent of adhesion. Partial restoration of signaling to ERK in suspension was accomplished by pretreatment with pharmacological inhibitors of serine/threonine or protein-tyrosine phosphatases. In addition, we used a nonradioactive phosphatase assay using phosphorylated ERK as the substrate to determine relative ERK dephosphorylation in whole cell extracts. These results showed greater relative ERK dephosphorylation in extracts from Jurkat cells treated in suspension, as compared with adherent cells. Therefore, these data suggest that adhesion influences SDF-1 activation of ERK by regulating the activity of ERK phosphatases. This identifies a novel locus of adhesion regulation of the ERK cascade.	Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Laakko, T (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, Cb 7365, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aplin AE, 1998, PHARMACOL REV, V50, P197; Aplin AE, 2001, J CELL BIOL, V155, P187, DOI 10.1083/jcb.200107116; Baird AM, 1999, CURR OPIN IMMUNOL, V11, P157, DOI 10.1016/S0952-7915(99)80027-2; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cohen PTW, 2002, J CELL SCI, V115, P241; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kim F, 2000, BIOCHEM BIOPH RES CO, V273, P539, DOI 10.1006/bbrc.2000.2951; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Lataillade JJ, 2002, BLOOD, V99, P1117, DOI 10.1182/blood.V99.4.1117; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MOBLEY JL, 1994, BLOOD, V83, P1039, DOI 10.1182/blood.V83.4.1039.bloodjournal8341039; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Pettiford SM, 2000, ONCOGENE, V19, P858, DOI 10.1038/sj.onc.1203408; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schmeissner PJ, 2001, J IMMUNOL, V167, P3715, DOI 10.4049/jimmunol.167.7.3715; Schumacher MA, 2002, BIOCHEMISTRY-US, V41, P3009, DOI 10.1021/bi015799l; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Young MRI, 2002, INT J CANCER, V100, P276, DOI 10.1002/ijc.10491; Zhang ZY, 2002, PHARMACOL THERAPEUT, V93, P307, DOI 10.1016/S0163-7258(02)00199-7; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	40	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31621	31628		10.1074/jbc.M304700200	http://dx.doi.org/10.1074/jbc.M304700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783869	Green Published, hybrid			2022-12-25	WOS:000184782100022
J	Marini, F; Kim, N; Schuffert, A; Wood, RD				Marini, F; Kim, N; Schuffert, A; Wood, RD			POLN, a nuclear PolA family DNA polymerase homologous to the DNA cross-link sensitivity protein Mus308	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; MESSENGER-RNA; MOUSE; EXPRESSION; MUTANTS; HYBRIDIZATION; RECOMBINATION	The Drosophila Mus308 gene is unusual in encoding both a family A DNA polymerase domain and a DNA/RNA helicase domain. A mus308 mutation was shown to result in increased sensitivity to DNA cross-linking agents, leading to the hypothesis that Mus308 functions in the repair of DNA interstrand cross-links. Recently a mammalian ortholog of Mus308, POLQ, has been identified. We report here the identification, cloning, and characterization of POLN and its gene product, a new mammalian DNA polymerase also related to Mus308. The human cDNA encodes a protein of 900 amino acid residues. The region starting from residue 419 shares 33% identity (48% similarity) with the equivalent region of Escherichia coli DNA polymerase I. POLN is expressed in human cell lines with numerous alternatively spliced transcripts, and a full-length human coding region that comprises 24 exons within 160 kilobases of genomic DNA. Expression analysis by northern blotting and in situ hybridization showed highest expression of full-length POLN in human and mouse testis. POLN localized to the nucleus when expressed as a enhanced green fluorescent protein (GFP)-tagged protein in human fibroblasts. GFP-tagged recombinant POLN had DNA polymerase activity on activated calf thymus DNA and on a singly primed template.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wood, RD (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil,5117 Ctr Ave,Suite 2-6, Pittsburgh, PA 15213 USA.		Wood, Richard D/M-6319-2018; Marini, Federica/A-9841-2017	Wood, Richard D/0000-0002-9495-6892; Marini, Federica/0000-0002-9495-2349	NCI NIH HHS [R01 CA101980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; BOYD JB, 1990, GENETICS, V125, P813; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; Harris PV, 1996, MOL CELL BIOL, V16, P5764; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; HOY CA, 1985, CANCER RES, V45, P1737; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Maga G, 2002, J MOL BIOL, V319, P359, DOI 10.1016/S0022-2836(02)00325-X; Marini F, 2002, J BIOL CHEM, V277, P8716, DOI 10.1074/jbc.M110271200; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SENIOR PV, 1988, DEVELOPMENT, V104, P431; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Shima N, 2003, GENETICS, V163, P1031; Shimazaki N, 2002, GENES CELLS, V7, P639, DOI 10.1046/j.1365-2443.2002.00547.x; Shivapurkar N, 1999, CANCER RES, V59, P3576; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; Thompson LH, 1996, MUTAT RES-DNA REPAIR, V363, P77, DOI 10.1016/0921-8777(96)00008-0; Tissier A, 2000, GENE DEV, V14, P1642; VANHOUTEN B, 1988, J BIOL CHEM, V263, P16553; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1; Zandvliet DWJ, 1996, BBA-GENE STRUCT EXPR, V1307, P239, DOI 10.1016/0167-4781(96)00063-2; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	33	90	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32014	32019		10.1074/jbc.M305646200	http://dx.doi.org/10.1074/jbc.M305646200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794064	hybrid			2022-12-25	WOS:000184782100071
J	Samel, D; Muller, D; Gerspach, J; Assohou-Luty, C; Sass, G; Tiegs, G; Pfizenmaier, K; Wajant, H				Samel, D; Muller, D; Gerspach, J; Assohou-Luty, C; Sass, G; Tiegs, G; Pfizenmaier, K; Wajant, H			Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; DOWN-REGULATION; SOLUBLE FORM; LIGAND; APOPTOSIS; RECEPTOR; EXPRESSION; REGRESSION; INDUCTION	We describe the construction of a FasL fusion protein devoid of systemic toxicity, inducing apoptosis only on cell-surface antigen-positive cells. The fusion protein consists carboxyl-terminally of the extracellular domain of FasL and amino-terminally of a fibroblast activation protein (FAP)-specific single chain antibody fragment (sc40-FasL). The latter allows immobilization-dependent conversion of the inactive soluble FasL fusion protein into an entity with membrane FasL-like activity. Thus, sc40-FasL efficiently induced apoptosis only in FAP-expressing cells. In accordance with a strict target-selective activity of sc40-FasL, the intravenous application of this reagent in mice revealed no signs of systemic toxicity and prevented growth of xenotransplanted FAP-positive (but not FAP-negative) tumor cells. The principle described here for the first time, in which cell-surface antigen-mediated activation of Fas permits local activation of Fas in vivo, opens novel avenues for the use of Fas signaling in cancer therapy.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany	University of Stuttgart; University of Erlangen Nuremberg	Wajant, H (corresponding author), Univ Wurzburg, Med Polyklin, Dept Mol Internal Med, Roentgenring 11, D-97070 Wurzburg, Germany.	harald.wajant@mail.uni-wuerzburg.de	Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949; Mueller, Dafne/0000-0002-1544-3475				Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; ASHER A, 1987, J IMMUNOL, V138, P963; Behrens CK, 2001, J IMMUNOL, V166, P3240, DOI 10.4049/jimmunol.166.5.3240; Bergmeyer H.U., 1984, METHOD ENZYMAT AN, P416; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; MULLER D, 2001, THESIS U STUTTGART S; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Shimizu M, 1999, J IMMUNOL, V162, P7350; Shimizu M, 1996, BIOCHEM BIOPH RES CO, V228, P375, DOI 10.1006/bbrc.1996.1669; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Wuest T, 2002, ONCOGENE, V21, P4257, DOI 10.1038/sj.onc.1205193; Yonehara S, 2002, CYTOKINE GROWTH F R, V13, P393, DOI 10.1016/S1359-6101(02)00024-2	27	61	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32077	32082		10.1074/jbc.M304866200	http://dx.doi.org/10.1074/jbc.M304866200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12773535	hybrid			2022-12-25	WOS:000184782100078
J	Yang, F; Kawedia, JD; Menon, AG				Yang, F; Kawedia, JD; Menon, AG			Cyclic AMP regulates aquaporin 5 expression at both transcriptional and post-transcriptional levels through a protein kinase A pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG FLUID TRANSPORT; WATER CHANNEL; GENE-TRANSCRIPTION; ADENYLATE-CYCLASE; SJOGRENS-SYNDROME; EPITHELIAL-CELLS; TRANSGENIC MICE; KNOCKOUT MICE; MOUSE LUNG; PHOSPHORYLATION	The membrane water channel aquaporin 5 (AQP5) plays an important role in transporting water across the apical surface of the alveolar epithelium and the epithelia of submucosal glands in the upper airway and nasopharynx. It is thus a potentially important target for modulating the fluid content of upper airway and nasopharyngeal secretions in disorders such as cystic fibrosis. Here, we have used an in vitro system to identify a molecular mechanism through which transcriptional and post-transcriptional regulation of AQP5 is accomplished. In a murine lung epithelial cell line (MLE-12), the addition of chlorophenylthio-cAMP (cpt-cAMP) causes a 4-fold increase in AQP5 mRNA and protein levels and induces translocation of AQP5 to the apical plasma membrane. Treatment with forskolin and isoproternol also caused similar increases in AQP5 expression both in vitro and in mouse lung tissue slices. The addition of actinomycin D abolished the cAMP-mediated increase in AQP5 mRNA and showed that there was no increase in the half-life of AQP5 mRNA, and inhibition of protein kinase A by H-89 blocked the cpt-cAMP-mediated increase of AQP5. Pretreatment of cells with cycloheximide blocked the cpt-cAMP-mediated increase of AQP5 mRNA, indicating that de novo protein synthesis is essential for increased AQP5 transcription. Immunofluorescent micrographs of cells treated with cpt-cAMP showed a significantly stronger AQP5 signal at the plasma membrane as compared with untreated cells. These results show that cAMP regulates AQP5 at multiple levels, by increasing synthesis of AQP5 mRNA and by triggering translocation of AQP5 to the plasma membrane.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; City Hope Natl Med Ctr, Dept Diabet Endocrinol & Metab, Duarte, CA 91010 USA	University System of Ohio; University of Cincinnati; City of Hope	Menon, AG (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.			Kawedia, Jitesh/0000-0001-9685-9378	NHLBI NIH HHS [HL61781] Funding Source: Medline; NIDCR NIH HHS [DE138283] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Dibas AI, 1998, P SOC EXP BIOL MED, V219, P183; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Han ZQ, 2000, BIOCHEM BIOPH RES CO, V273, P328, DOI 10.1006/bbrc.2000.2944; KAUMANN AJ, 1989, EUR HEART J, V10, P29, DOI 10.1093/eurheartj/10.suppl_B.29; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Krane CM, 1999, MAMM GENOME, V10, P498, DOI 10.1007/s003359901030; Krane CM, 2001, P NATL ACAD SCI USA, V98, P14114, DOI 10.1073/pnas.231273398; Lorenz D, 2003, EMBO REP, V4, P88, DOI 10.1038/sj.embor.embor711; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Matsumura Y, 1997, J AM SOC NEPHROL, V8, P861; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; Steinfeld S, 2001, LAB INVEST, V81, P143, DOI 10.1038/labinvest.3780221; STOSCHECK CM, 1990, ANAL BIOCHEM, V184, P111, DOI 10.1016/0003-2697(90)90021-Z; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818; Towne JE, 2001, J BIOL CHEM, V276, P18657, DOI 10.1074/jbc.M100322200; Tsubota K, 2001, LANCET, V357, P688, DOI 10.1016/S0140-6736(00)04140-4; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029	30	95	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32173	32180		10.1074/jbc.M305149200	http://dx.doi.org/10.1074/jbc.M305149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783871	hybrid			2022-12-25	WOS:000184782100090
J	Blostein, MD; Furie, BC; Rajotte, I; Furie, B				Blostein, MD; Furie, BC; Rajotte, I; Furie, B			The gla domain of factor IXa binds to factor VIIIa in the tenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BLOOD-COAGULATION FACTOR; MEMBRANE-BINDING; PHOSPHOLIPID-VESICLES; MOLECULAR-BASIS; TISSUE FACTOR; HEMOPHILIA-B; LIGHT-CHAIN; ACTIVE-SITE; RICH DOMAIN	During blood coagulation factor IXa binds to factor VIIIa on phospholipid membranes to form an enzymatic complex, the tenase complex. To test whether there is a protein-protein contact site between the gamma-carboxyglutamic acid (Gla) domain of factor IXa and factor VIIIa, we demonstrated that an antibody to the Gla domain of factor IXa inhibited factor VIIIa-dependent factor IXa activity, suggesting an interaction of the factor IXa Gla domain with factor VIIIa. To study this interaction, we synthesized three analogs of the factor IXa Gla domain (FIX1-47) with Phe-9, Phe-25, or Val-46 replaced, respectively, with benzoylphenylalanine (BPA), a photoactivatable cross-linking reagent. These factor IX Gla domain analogs maintain native tertiary structure, as demonstrated by calcium-induced fluorescence quenching and phospholipid binding studies. In the absence of phospholipid membranes, FIX1-47 was able to inhibit factor IXa activity. This inhibition is dependent on the presence of factor VIIIa, suggesting a contact site between the factor IXa Gla domain and factor VIIIa. To demonstrate a direct interaction we did cross-linking experiments with FIX(1-47)9BPA, FIX(1-47)25BPA, and FIX(1-47)46BPA. Covalent cross-linking to factor VIIIa was observed primarily with FIX(1-47)25BPA and to a much lesser degree with FIX(1-47)46BPA. Immunoprecipitation experiments with an antibody to the C2 domain of factor VIIIa indicate that the factor IX Gla domain crosslinks to the A3-C1-C2 domain of factor VIIIa. These results suggest that the factor IXa Gla domain contacts factor VIIIa in the tenase complex through a contact site that includes phenylalanine 25 and perhaps valine 46.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1A4, Canada; Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis, Boston, MA 02111 USA; Harvard Med Sch, Dept Med, Boston, MA 02111 USA	Lady Davis Institute; McGill University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Blostein, MD (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine, Montreal, PQ H3T 1A4, Canada.				NHLBI NIH HHS [P01-HL44234] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; Bajaj SP, 1999, THROMB HAEMOSTASIS, V82, P218; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brown MA, 2000, J BIOL CHEM, V275, P19795, DOI 10.1074/jbc.M002298200; Celie PHN, 2002, J BIOL CHEM, V277, P20214, DOI 10.1074/jbc.M108446200; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FOSTER PA, 1990, BLOOD, V75, P1999; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FREEDMAN SJ, 1995, J BIOL CHEM, V270, P7980, DOI 10.1074/jbc.270.14.7980; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1992, NEW ENGL J MED, V326, P800; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1990, J BIOL CHEM, V265, P815; JACOBS M, 1994, J BIOL CHEM, V269, P25494; Larson PJ, 1996, J BIOL CHEM, V271, P3869; Lefkowitz JB, 2001, THROMB HAEMOSTASIS, V86, P862; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; OSTERLUND M, 2001, THROMB HEMOST, V86, P1788; Owenius R, 2001, BIOPHYS J, V81, P2357, DOI 10.1016/S0006-3495(01)75882-1; Persson KEM, 2002, J BIOL CHEM, V277, P35616, DOI 10.1074/jbc.M205930200; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; SIMPSON DL, 1974, BIOCHEMISTRY-US, V13, P3487, DOI 10.1021/bi00714a011; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417	38	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31297	31302		10.1074/jbc.M302840200	http://dx.doi.org/10.1074/jbc.M302840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782629	Green Published, hybrid			2022-12-25	WOS:000184658800110
J	Fu, TF; Boja, ES; Safo, MK; Schirch, V				Fu, TF; Boja, ES; Safo, MK; Schirch, V			Role of proline residues in the folding of serine hydroxymethyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; CATALYTIC MECHANISM; PURIFICATION; COMPLEX; LIVER	Previous studies on the folding mechanism of Escherichia coli serine hydroxymethyltransferase (SHMT) showed that the final rate determining folding step was from an intermediate that contained two fully folded domains with N-terminal segments of approximately 55 residues and interdomain segments of approximately 50 residues that were still solvent exposed and subject to proteolysis. The interdomain segment contains 3 Pro residues near its N terminus and 2 Pro residues near its C terminus. The 5 Pro residues were each mutated to both a Gly and Ala residue, and each mutant SHMT was purified and characterized with respect to kinetic properties, stability, secondary structure, and folding mechanism. The results showed that Pro(214) and Pro(218) near the N terminus of the interdomain segment are not critical for folding, stability, or activity. The P216A mutant also retained most of the characteristics of the native enzyme, but its folding rate was altered. However, the P216G mutant was severely compromised in folding into a catalytically competent enzyme. Mutation of both Pro(258) and Pro(264) had altered folding kinetics and resulted in enzymes that expressed little catalytic activity. The Phe(257)-Pro(258) bond is cis in its configuration, and the P258A mutant SHMT showed reduced thermal stability. Pro(216), Pro(258), and Pro264 are conserved in all 53 known sequences of this enzyme. The results are discussed in terms of the role of each Pro residue in maintaining the structure and function of SHMT and a possible role in pyridoxal 5'-phosphate addition to the apo-enzyme.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23219 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA; Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23219 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Schirch, V (corresponding author), Virginia Commonwealth Univ, Dept Biochem, 800 E Leigh St,Biotech 1,Suite 212, Richmond, VA 23219 USA.	Schirch@mail2.vcu.edu	Safo, Martin/AAJ-9833-2020; Fu, Tzu-Fun/G-7820-2011					Cai K, 1996, J BIOL CHEM, V271, P2987, DOI 10.1074/jbc.271.6.2987; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; Cai K, 1996, J BIOL CHEM, V271, P27311, DOI 10.1074/jbc.271.44.27311; Eyles SJ, 2000, J MOL BIOL, V301, P737, DOI 10.1006/jmbi.2000.4002; FRATTE SD, 1994, EUR J BIOCHEM, V225, P395, DOI 10.1111/j.1432-1033.1994.00395.x; Iurescia S, 1996, PROTEIN EXPRES PURIF, V7, P323, DOI 10.1006/prep.1996.0046; MCCORMICK DB, 1997, ENCY MOL BIOL MOL ME, V6, P244; Pal D, 1999, J MOL BIOL, V294, P271, DOI 10.1006/jmbi.1999.3217; Pascarella S, 1998, PROTEIN SCI, V7, P1976, DOI 10.1002/pro.5560070913; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; Scarsdale JN, 2000, J MOL BIOL, V296, P155, DOI 10.1006/jmbi.1999.3453; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; Schirch V, 1997, METHOD ENZYMOL, V281, P146; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SCHMID XF, 1992, PROTEIN FOLDING, P203; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; Talwar R, 2000, BIOCHEM J, V350, P849, DOI 10.1042/0264-6021:3500849; Trivedi V, 2002, J BIOL CHEM, V277, P17161, DOI 10.1074/jbc.M111976200; Wedemeyer WJ, 2002, BIOCHEMISTRY-US, V41, P14637, DOI 10.1021/bi020574b; Wu Y, 2002, J MOL BIOL, V323, P309, DOI 10.1016/S0022-2836(02)00922-1	23	21	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31088	31094		10.1074/jbc.M303779200	http://dx.doi.org/10.1074/jbc.M303779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773539	hybrid			2022-12-25	WOS:000184658800085
J	Heuck, AP; Tweten, RK; Johnson, AE				Heuck, AP; Tweten, RK; Johnson, AE			Assembly and topography of the prepore complex in cholesterol-dependent cytolysins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING TOXINS; STAPHYLOCOCCAL ALPHA-HEMOLYSIN; PERFRINGOLYSIN-O; STREPTOLYSIN-O; CLOSTRIDIUM-PERFRINGENS; THETA-TOXIN; LIPOSOMAL MEMBRANES; STRUCTURAL-CHANGES; FLUORESCENCE; MECHANISM	Cholesterol-dependent cytolysins are a family of pore-forming proteins that have been shown to be virulence factors for a large number of pathogenic bacteria. The mechanism of pore formation for these toxins involves a complex series of events that are known to include binding, oligomerization, and insertion of a transmembrane beta-barrel. Several features of this mechanism remain poorly understood and controversial. Whereas a prepore mechanism has been proposed for perfringolysin O, a very different mechanism has been proposed for the homologous member of the family, streptolysin O. To distinguish between the two models, a novel approach that directly measures the dimension of transmembranes pores was used. Pore formation itself was examined for both cytolysins by encapsulating fluorescein-labeled peptides and proteins of different sizes into liposomes. When these liposomes were re-suspended in a solution containing anti-fluorescein antibodies, toxin-mediated pore formation was monitored directly by the quenching of fluorescein emission as the encapsulated molecules were released, and the dyes were bound by the antibodies. The analysis of pore formation determined using this approach reveals that only large pores are produced by perfringolysin O and streptolysin O during insertion (and not small pores that grow in size). These results are consistent only with the formation of a prepore complex intermediate prior to insertion of the transmembrane beta-barrel into the bilayer. Fluorescence quenching experiments also revealed that PFO in the prepore complex contacts the membrane via domain 4, and that the individual transmembrane beta-hairpins in domain 3 are not exposed to the nonpolar core of the bilayer at this intermediate stage.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Johnson, AE (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, 1114 TAMU,116 Reynolds Med Bldg, College Stn, TX 77843 USA.	aejohnson@tamu.edu	Johnson, Arthur E/G-3457-2012	Heuck, Alejandro/0000-0002-7786-3109	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037657, R37AI037657] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37657, R01 AI037657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayley H, 1997, CURR BIOL, V7, pR763, DOI 10.1016/S0960-9822(06)00399-X; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BROOKS DE, 1973, J COLLOID INTERF SCI, V43, P700, DOI 10.1016/0021-9797(73)90415-3; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; Ghani EA, 1999, BIOCHEMISTRY-US, V38, P15204, DOI 10.1021/bi991678y; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Gilbert RJC, 2002, CELL MOL LIFE SCI, V59, P832, DOI 10.1007/s00018-002-8471-1; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; Heuck AP, 1997, J BIOCHEM BIOPH METH, V34, P213, DOI 10.1016/S0165-022X(97)00014-6; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; Heuck AP, 2002, CELL BIOCHEM BIOPHYS, V36, P89, DOI 10.1385/CBB:36:1:89; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Hotze EM, 2001, J BIOL CHEM, V276, P8261, DOI 10.1074/jbc.M009865200; London E, 2002, CURR TOP MEMBR, V52, P89; MINETTI M, 1978, BIOCHEM BIOPH RES CO, V80, P46, DOI 10.1016/0006-291X(78)91102-6; MORGAN PJ, 1995, FEBS LETT, V371, P77, DOI 10.1016/0014-5793(95)00887-F; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nakamura M, 1998, J BIOCHEM, V123, P1145; NAYAR R, 1989, BIOCHIM BIOPHYS ACTA, V986, P200, DOI 10.1016/0005-2736(89)90468-9; OBERLEY TD, 1971, INFECT IMMUN, V4, P683, DOI 10.1128/IAI.4.6.683-687.1971; OHNOIWASHITA Y, 1988, EUR J BIOCHEM, V176, P95, DOI 10.1111/j.1432-1033.1988.tb14255.x; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALMER M, 1995, EUR J BIOCHEM, V231, P388, DOI 10.1111/j.1432-1033.1995.tb20711.x; Palmer M, 1996, J BIOL CHEM, V271, P26664, DOI 10.1074/jbc.271.43.26664; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Palmer M, 2001, TOXICON, V39, P1681, DOI 10.1016/S0041-0101(01)00155-6; Ramachandran R, 2002, NAT STRUCT BIOL, V9, P823, DOI 10.1038/nsb855; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Sellman BR, 1997, MOL MICROBIOL, V23, P551, DOI 10.1046/j.1365-2958.1997.d01-1876.x; Sharpe JC, 1999, J MEMBRANE BIOL, V171, P209, DOI 10.1007/s002329900572; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; WALKER B, 1992, J BIOL CHEM, V267, P21782; YE J, 1991, J BIOL CHEM, V266, P23016	41	93	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31218	31225		10.1074/jbc.M303151200	http://dx.doi.org/10.1074/jbc.M303151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777381	hybrid			2022-12-25	WOS:000184658800100
J	Rosse, C; L'Hoste, B; Offner, N; Picard, A; Camonis, J				Rosse, C; L'Hoste, B; Offner, N; Picard, A; Camonis, J			RLIP, an effector of the Ral GTPases, is a platform for cdk1 to phosphorylate Epsin during the switch off of endocytosis in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC PHOSPHORYLATION; CELL-CYCLE; PROTEIN; DROSOPHILA; PATHWAY; COMPLEX; KINASE; DEPHOSPHORYLATION; IDENTIFICATION; INVOLVEMENT	The Ral signaling pathway is critically involved in Ras-dependent oncogenesis. One of its key actors, RLIP/RalBP1, which participates in receptor endocytosis during interphase, is also involved in mitotic processes when endocytosis is switched off. During mitosis, RLIP76 is located on the duplicated centrosomes and is required for their proper separation and movement to the poles. We have looked for actors that associate with RLIP during mitosis. We show here that RLIP/RalBP1 interacts with an active p34cdc2.cyclinB1 (cdk1) enzyme and that this interaction is crucial for the mitotic phosphorylation of Epsin that, once phosphorylated, is no longer competent for endocytosis. We show also that this latter phosphorylation is dependent on Ral signaling. We propose that RLIP/RalBP1 is used as a platform by the mitotic cdk1 to facilitate the phosphorylation of Epsin, which makes Epsin incompetent for endocytosis during mitosis, when endocytosis is switched off.	Inst Curie, INSERM, U528, F-75248 Paris 05, France; UMR 7628, F-66651 Banyuls sur Mer, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Camonis, J (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75248 Paris 05, France.		Rosse, Carine/L-4775-2017					BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gildea JJ, 2002, CANCER RES, V62, P982; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; JESSUS C, 1991, DEVELOPMENT, V111, P813; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; Kitazawa H, 2000, CELL STRUCT FUNCT, V25, P33, DOI 10.1247/csf.25.33; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Quaroni A, 1999, J CELL SCI, V112, P707; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Tio M, 1999, J CELL SCI, V112, P1541; Tio M, 2001, NATURE, V409, P1063, DOI 10.1038/35059124; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961	32	87	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30597	30604		10.1074/jbc.M302191200	http://dx.doi.org/10.1074/jbc.M302191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12775724	hybrid			2022-12-25	WOS:000184658800024
J	Anguera, MC; Suh, JR; Ghandour, H; Nasrallah, IM; Selhub, J; Stover, PJ				Anguera, MC; Suh, JR; Ghandour, H; Nasrallah, IM; Selhub, J; Stover, PJ			Methenyltetrahydrofolate synthetase regulates folate turnover and accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; ONE-CARBON METABOLISM; NEURAL-TUBE DEFECTS; FOLIC-ACID; SERINE HYDROXYMETHYLTRANSFERASE; MAMMALIAN-CELLS; BINDING-PROTEIN; HOMOCYSTEINE; DEFICIENCY; CATABOLISM	Cellular folate deficiency impairs one-carbon metabolism, resulting in decreased fidelity of DNA synthesis and inhibition of numerous S-adenosylmethionine-dependent methylation reactions including protein and DNA methylation. Cellular folate concentrations are influenced by folate availability, cellular folate transport efficiency, folate polyglutamylation, and folate turnover specifically through degradation. Folate cofactors are highly susceptible to oxidative degradation in vitro with the exception of 5-formyltetrahydrofolate, which may be a storage form of folate. In this study, we determined the effects of depleting cytoplasmic 5-formyltetrahydrofolate on cellular folate concentrations and folate turnover rates in cell cultures by expressing the human methenyltetrahydrofolate synthetase cDNA in human MCF-7 cells and SH-SY5Y neuroblastoma. Cells with increased methenyltetrahydrofolate synthetase activity exhibited: 1) increased rates of folate turnover, 2) elevated generation of p-aminobenzoylglutamate in culture medium, 3) depressed cellular folate concentrations independent of medium folic acid concentrations, and 4) increased average polyglutamate chain lengths of folate cofactors. These data indicate that folate catabolism and folate polyglutamylation are competitive reactions that influence cellular folate concentrations, and that increased methenyltetrahydrofolate synthetase activity accelerates folate turnover rates, depletes cellular folate concentrations, and may account in part for tissue-specific differences in folate accumulation.	Cornell Univ, Grad Field Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Tufts Univ, USDA, Vitamin Metab Lab, Boston, MA 02111 USA	Cornell University; Cornell University; Tufts University; United States Department of Agriculture (USDA)	Stover, PJ (corresponding author), Cornell Univ, Grad Field Biochem Mol & Cellular Biol, 315 Savage Hall, Ithaca, NY 14853 USA.	PJS13@cornell.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035687] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35687] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; Bagley PJ, 2000, CLIN CHEM, V46, P404; Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779; Bailey LB, 1999, J NUTR, V129, P919, DOI 10.1093/jn/129.5.919; BERTRAND R, 1995, BBA-MOL CELL RES, V1266, P245, DOI 10.1016/0167-4889(95)00020-S; BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Caudill MA, 1998, J NUTR, V128, P204, DOI 10.1093/jn/128.2.204; Caudill MA, 2002, J NUTR, V132, P2613, DOI 10.1093/jn/132.9.2613; Chu E, 1996, BIOESSAYS, V18, P191, DOI 10.1002/bies.950180306; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; EISENGA BH, 1992, J NUTR, V122, P977, DOI 10.1093/jn/122.4.977; Finnell RH, 1998, CRIT REV ORAL BIOL M, V9, P38, DOI 10.1177/10454411980090010201; Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299; GARROW TA, 1993, ADV EXP MED BIOL, V338, P659; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; Higgins JR, 2000, BRIT J OBSTET GYNAEC, V107, P1149, DOI 10.1111/j.1471-0528.2000.tb11115.x; Holmes WB, 2002, J BIOL CHEM, V277, P20205, DOI 10.1074/jbc.M201242200; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; Kim Y, 1999, NUTR REV, V57, P314; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; LEWIS GP, 1979, ANAL BIOCHEM, V93, P91, DOI 10.1016/S0003-2697(79)80121-9; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; Lindenbaum J., 1995, FOLATE HLTH DIS, P43; MARAS B, 1994, J BIOL CHEM, V269, P18429; MCNULTY H, 1993, J NUTR, V123, P1089; MCPARTLIN J, 1993, LANCET, V341, P148, DOI 10.1016/0140-6736(93)90007-4; Meenan J, 1997, GASTROENTEROLOGY, V112, P1163, DOI 10.1016/S0016-5085(97)70127-6; Moran RG, 1999, SEMIN ONCOL, V26, P24; Roje S, 2002, J BIOL CHEM, V277, P42748, DOI 10.1074/jbc.M205632200; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Scott J. M., 2001, V55, P192; SCOTT JM, 1981, LANCET, V2, P337; Scott KC, 1996, J NUTR BIOCHEM, V7, P261, DOI 10.1016/0955-2863(96)00026-5; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; SHANE B, 1989, VITAM HORM, V45, P263; SHANE B, 1983, ADV EXP MED BIOL, V163, P149; Shane B., 1995, FOLATE HLTH DIS, V2, P1; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Suh JR, 2000, J BIOL CHEM, V275, P35646, DOI 10.1074/jbc.M005864200; Titus SA, 2000, J BIOL CHEM, V275, P36811, DOI 10.1074/jbc.M005163200; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; van der Put NMJ, 2001, EXP BIOL MED, V226, P243, DOI 10.1177/153537020122600402; VARELAMOREIRAS G, 1992, J NUTR, V122, P986, DOI 10.1093/jn/122.4.986; Wagner C, 1995, FOLATE HLTH DIS, P23; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200	53	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29856	29862		10.1074/jbc.M302883200	http://dx.doi.org/10.1074/jbc.M302883200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764149	hybrid			2022-12-25	WOS:000184507000058
J	Kelpe, CL; Moore, PC; Parazzoli, SD; Wicksteed, B; Rhodes, CJ; Poitout, V				Kelpe, CL; Moore, PC; Parazzoli, SD; Wicksteed, B; Rhodes, CJ; Poitout, V			Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; ACTIVATED PROTEIN-KINASE; LONG-TERM EXPOSURE; FREE FATTY-ACIDS; SIGNAL-TRANSDUCTION; CONTROL ELEMENT; MALONYL-COA; OBESE RATS; LINE INS-1; GLUCOSE	Chronic exposure to elevated levels of fatty acids impairs pancreatic beta cell function, a phenomenon thought to contribute to the progressive deterioration of insulin secretion in type 2 diabetes. We have previously demonstrated that prolonged exposure of isolated islets to elevated levels of palmitate inhibits preproinsulin mRNA levels in the presence of high glucose concentrations. However, whether this occurs via transcriptional or post-transcriptional mechanisms has not been determined. In addition, the nature of the lipid metabolites involved in palmitate inhibition of insulin gene expression is unknown. In this study, we show that palmitate decreases glucose-stimulated preproinsulin mRNA levels in isolated rat islets, an effect that is not mediated by changes in preproinsulin mRNA stability, but is associated with inhibition of glucose-stimulated insulin promoter activity. Prolonged culture of isolated islets with palmitate is associated with increased levels of intracellular ceramide. Palmitate-induced ceramide generation is prevented by inhibitors of de novo ceramide synthesis. Further, exogenous ceramide inhibits insulin mRNA levels, whereas blockade of de novo ceramide synthesis prevents palmitate inhibition of insulin gene expression. We conclude that prolonged exposure to elevated levels of palmitate affects glucose-stimulated insulin gene expression via transcriptional mechanisms and ceramide synthesis.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Poitout, V (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.		Moore, Patrick/GVR-8294-2022	Poitout, Vincent/0000-0002-6555-5053	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050610, R01DK058096] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK058096, R01-DK50610, R01-DK58096] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; deVargas LM, 1997, J BIOL CHEM, V272, P26573, DOI 10.1074/jbc.272.42.26573; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Furukawa N, 1999, ENDOCR J, V46, P43, DOI 10.1507/endocrj.46.43; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; Ishizuka N, 1999, METABOLISM, V48, P1485, DOI 10.1016/S0026-0495(99)90234-2; Jacqueminet S, 2000, METABOLISM, V49, P532, DOI 10.1016/S0026-0495(00)80021-9; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kelpe CL, 2002, ENDOCRINOLOGY, V143, P3326, DOI 10.1210/en.2002-220402; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kwon G, 1996, BBA-LIPID LIPID MET, V1300, P63, DOI 10.1016/0005-2760(95)00223-5; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Maedler K, 2001, DIABETES, V50, P69, DOI 10.2337/diabetes.50.1.69; Major CD, 1999, DIABETES, V48, P1372, DOI 10.2337/diabetes.48.7.1372; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; POITOUT V, 2002, CURR OPIN ENDOCRINOL, V96, P152; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Ritz-Laser B, 1999, ENDOCRINOLOGY, V140, P4005, DOI 10.1210/en.140.9.4005; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; SJOHOLM A, 1995, FEBS LETT, V367, P283, DOI 10.1016/0014-5793(95)00470-T; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; WELSH M, 1985, J BIOL CHEM, V260, P3590; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; Xiao JZ, 2001, ENDOCRINOLOGY, V142, P4777, DOI 10.1210/en.142.11.4777; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	48	176	179	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30015	30021		10.1074/jbc.M302548200	http://dx.doi.org/10.1074/jbc.M302548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771145	hybrid			2022-12-25	WOS:000184507000076
J	Yada, T; Gotoh, M; Sato, T; Shionyu, M; Go, M; Kaseyama, H; Iwasaki, H; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Watanabe, H; Narimatsu, H; Kimata, K				Yada, T; Gotoh, M; Sato, T; Shionyu, M; Go, M; Kaseyama, H; Iwasaki, H; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Watanabe, H; Narimatsu, H; Kimata, K			Chondroitin sulfate synthase-2 - Molecular cloning and characterization of a novel human glycosyltransferase homologous to chondroitin sulfate glucuronyltransferase, which has dual enzymatic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; N-ACETYLGALACTOSAMINYLTRANSFERASE; GLUCURONIC-ACID; HIGH-AFFINITY; UDP-GLCNAC; BIOSYNTHESIS; EXPRESSION; PROTEOGLYCAN; SERUM; BINDS	Chondroitin sulfate is found in a variety of tissues as proteoglycans and consists of repeating disaccharide units of N-acetylgalactosamine and glucuronic acid residues with sulfate residues at various places. We found a novel human gene (GenBank(TM) accession number AB086063) that possesses a sequence homologous with the human chondroitin sulfate glucuronyltransferase gene which we recently cloned and characterized. The full-length open reading frame encodes a typical type II membrane protein comprising 775 amino acids. The protein had a domain containing beta3-glycosyltransferase motif but lacked a typical beta4-glycosyltransferase motif, which is the same as chondroitin sulfate glucuronyltransferase, whereas chondroitin synthase had both domains. The putative catalytic domain was expressed in COS-7 cells as a soluble enzyme. Surprisingly, both glucuronyltransferase and N-acetylgalactosaminyltransferase activities were observed when chondroitin, chondroitin sulfate, and their oligosaccharides were used as the acceptor substrates. The reaction products were identified to have the linkage of GlcUAbeta1-3GalNAc and GalNAcbeta1-4GlcUA at the non-reducing terminus of chondroitin for glucuronyltransferase activity and N-acetylgalactosaminyltransferase activity, respectively. Quantitative real time PCR analysis revealed that the transcripts were ubiquitously expressed in various human tissues but highly expressed in the pancreas, ovary, placenta, small intestine, and stomach. These results indicate that this enzyme could synthesize chondroitin sulfate chains as a chondroitin sulfate synthase that has both glucuronyltransferase and N-acetylgalactosaminyltransferase activities. Sequence analysis based on three-dimensional structure revealed the presence of not typical but significant beta4-glycosyltransferase architecture.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Tokyo 2070021, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogen Funct Team, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Aichi 4648602, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan	Aichi Medical University; Seikagaku Corporation; National Institute of Advanced Industrial Science & Technology (AIST); Nagoya University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp	Togayachi, Akira/M-4144-2018; Narimatsu, Hisashi/M-4757-2018; Sato, Takashi/M-2577-2018	Togayachi, Akira/0000-0003-3600-9149; Narimatsu, Hisashi/0000-0002-8402-133X; Sato, Takashi/0000-0002-9973-8923; Watanabe, Hideto/0000-0001-5291-0696; Shionyu, Masafumi/0000-0002-0431-3456				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Boeggeman E, 2002, GLYCOBIOLOGY, V12, P395, DOI 10.1093/glycob/cwf045; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Ogata K, 2000, J MOL GRAPH MODEL, V18, P258, DOI 10.1016/S1093-3263(00)00037-1; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Sasai K, 2002, GLYCOBIOLOGY, V12, P119, DOI 10.1093/glycob/12.2.119; Sasai K, 2001, J BIOL CHEM, V276, P759, DOI 10.1074/jbc.M004972200; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	47	65	67	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30235	30247		10.1074/jbc.M303657200	http://dx.doi.org/10.1074/jbc.M303657200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761225	hybrid			2022-12-25	WOS:000184507000104
J	Liu, XQ; Yang, J				Liu, XQ; Yang, J			Split dnaE genes encoding multiple novel inteins in Trichodesmium erythraeum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE; EVOLUTION; AUTOPROTEOLYSIS; PROTEINS; ELEMENTS; DATABASE; DOMAINS; REPEAT	Three inteins were found when analyzing a pair of split dnaE genes encoding the catalytic subunit of DNA polymerase III in the oceanic N-2-fixing cyanobacterium Trichodesmium erythraeum. The three inteins (DnaE-1, DnaE-2, and DnaE-3) were clustered in a 70-amino acid (aa) region of the predicted DnaE protein. The DnaE-1 intein is 1258 aa long and three times as large as a typical intein, due to the presence of large tandem repeats in which a 57-aa sequence is repeated 17 times. The DnaE-2 intein has a more typical size of 428 aa with putative protein splicing and endonuclease domains. The DnaE-3 intein is a split intein consisting of a 102-aa N-terminal part and a 36-aa C-terminal part encoded on the first and second split dnaE genes, respectively. Synthesis of a mature DnaE protein is predicted to involve expression of two split dnaE genes followed by two protein cis-splicing reactions and one protein trans-splicing reaction. Tandem repeats in the DnaE-1 intein inhibited the protein splicing activity of this intein when tested in Escherichia coli cells and may potentially regulate DnaE synthesis in vivo.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Liu, XQ (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.	pxqliu@dal.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; de la Fuente Jose, 2001, Animal Health Research Reviews, V2, P163; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; Gogarten JP, 2002, ANNU REV MICROBIOL, V56, P263, DOI 10.1146/annurev.micro.56.012302.160741; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Mulholland MR, 2000, TRENDS PLANT SCI, V5, P148, DOI 10.1016/S1360-1385(00)01576-4; Orcutt KM, 2002, APPL ENVIRON MICROB, V68, P2236, DOI 10.1128/AEM.68.5.2236-2245.2002; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Staub E, 2002, TRENDS BIOCHEM SCI, V27, P441, DOI 10.1016/S0968-0004(02)02163-1; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	27	19	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26315	26318		10.1074/jbc.C300202200	http://dx.doi.org/10.1074/jbc.C300202200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12766150	hybrid			2022-12-25	WOS:000184155700004
J	Narayan, G; Pulido, HA; Koul, S; Lu, XY; Harris, CP; Yeh, YA; Vargas, H; Posso, H; Terry, MB; Gissmann, L; Schneider, A; Mansukhani, M; Rao, PH; Murty, VVVS				Narayan, G; Pulido, HA; Koul, S; Lu, XY; Harris, CP; Yeh, YA; Vargas, H; Posso, H; Terry, MB; Gissmann, L; Schneider, A; Mansukhani, M; Rao, PH; Murty, VVVS			Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression	ONCOGENE			English	Article						cervical carcinoma; chromosome 2; CGH; gene amplification; LOH; cervical intraepithelial neoplasia	SQUAMOUS-CELL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; UTERINE CERVIX; CHROMOSOMAL-ABERRATIONS; PRECANCEROUS LESIONS; INTRAEPITHELIAL NEOPLASIA; CHILDHOOD NEUROBLASTOMAS; RECURRENT PATTERN; E7 ONCOPROTEINS; OVARIAN-CANCER	We performed comparative genomic hybridization (CGH) and high-resolution deletion mapping of the long arm of chromosome 2 (2q) in invasive cervical carcinoma (CC). The CGH analyses on 52 CCs identified genetic losses at 2q33-q36, gain of 3q26-q29, and frequent chromosomal amplifications. Characterization of 2q deletions by loss of heterozygosity (LOH) in 60 primary tumors identified two sites of minimal deleted regions at 2q35-q36.1 and 2q36.3-q37.1. To delineate the stage at which these genetic alterations occur in CC progression, we analysed 33 cervical intraepithelial neoplasia (CIN) for LOH. We found that 89% of high-grade (CINII and CINIII) and 40% of low-grade (CINI) CINs exhibited LOH at 2q. To identify the target tumor suppressor gene (TSG), we performed an extensive genetic and epigenetic analyses of a number of candidate genes mapped to the deleted regions. We did not find inactivating mutations in CASP10, BARD1, XRCC5, or PPP1R7 genes mapped to the deleted regions. However, we did find evidence of downregulated gene expression in CFLAR, CASP10 and PPPIR7 in CC cell lines. We also found reactivated gene expression in CC cell lines in vitro after exposure to demethylating and histone deacetylase (HDAC) inhibiting agents. Thus, these data identify frequent chromosomal amplifications in CC, and sites of TSGs at 2q35-q36.1 and 2q36.3-q37.1 that are critical in CC development.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Inst Nacl Canerol, Dept Genet, Santa Fe De Bogota, Colombia; Inst Nacl Canerol, Dept Pathol, Santa Fe De Bogota, Colombia; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; Univ Jena, Dept Obstet & Gynecol, D-6900 Jena, Germany	Columbia University; Columbia University; Baylor College of Medicine; Texas Children's Cancer Center; Columbia University; Helmholtz Association; German Cancer Research Center (DKFZ); Friedrich Schiller University of Jena	Murty, VVVS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.		Gissmann, Lutz/H-4688-2011; Arias-Pulido, Hugo/AEN-1741-2022	Arias-Pulido, Hugo/0000-0003-4941-1110; Terry, Mary Beth/0000-0002-4106-5033				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Chatterjee A, 2001, CANCER RES, V61, P2119; Dellas A, 1999, CANCER RES, V59, P3475; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Hidalgo A, 2000, EUR J CANCER, V36, P542, DOI 10.1016/S0959-8049(99)00323-8; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Kersemaekers AMF, 1999, GENE CHROMOSOME CANC, V26, P346, DOI 10.1002/(SICI)1098-2264(199912)26:4<346::AID-GCC9>3.0.CO;2-D; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; KURZROCK R, 1995, CANCER-AM CANCER SOC, V75, P584, DOI 10.1002/1097-0142(19950115)75:2<584::AID-CNCR2820750223>3.0.CO;2-P; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MITRA AB, 1994, CANCER RES, V54, P637; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MUNGER K, 1992, CANCER SURV, V12, P197; MURTHY NS, 1990, BRIT J CANCER, V61, P732, DOI 10.1038/bjc.1990.164; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Pulido HA, 2000, CANCER RES, V60, P6677; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; Ransom DT, 1998, HEAD NECK-J SCI SPEC, V20, P404; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Singh B, 2001, CANCER RES, V61, P4506; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Uejima H, 1998, MOL CARCINOGEN, V22, P34, DOI 10.1002/(SICI)1098-2744(199805)22:1<34::AID-MC5>3.0.CO;2-L; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071; 1996, CERVICAL CANC, V14, P1	51	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3489	3499		10.1038/sj.onc.1206432	http://dx.doi.org/10.1038/sj.onc.1206432			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776201	Green Published			2022-12-25	WOS:000183128500016
J	Misumi, S; Endo, M; Mukai, R; Tachibana, K; Umeda, M; Honda, T; Takamune, N; Shoji, S				Misumi, S; Endo, M; Mukai, R; Tachibana, K; Umeda, M; Honda, T; Takamune, N; Shoji, S			A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CXCR4; PROTEIN-COUPLED RECEPTOR; IN-VITRO; DISEASE PROGRESSION; ANTIVIRAL THERAPY; CORECEPTOR; CCR5; INDIVIDUALS; INHIBITOR	A novel synthetic peptide immunogen targeting the human immunodeficiency virus type-1 (HIV-1) coreceptor CXCR4 was evaluated for its capacity to induce CXCR4-specific antibodies with anti-HIV-1 activity in BALB/c mice and cynomolgus monkeys. A cyclic closed-chain dodecapeptide mimicking the conformation-specific domain of CXCR4 (cDDX4) was prepared in which Gly-Asp, as the dipeptide forming a spacer arm, links the amino and carboxyl termini of the decapeptidyl linear chain (linear DDX4, Asn(176) to Ile(185)) derived from the undecapeptidyl arch (UPA; Asn(176) to Cys(186)) of extracellular loop 2 (ECL-2) in CXCR4. Immunization of BALB/c mice with cDDX4 conjugated with a multiple-antigen peptide (cDDX4-MAP) induced conformational epitope-specific antibodies, and monoclonal antibody IA2-F9 reacted with cDDX4, but not with linear DDX4, as determined by real-time biomolecular interaction analysis using surface plasmon resonance. The antibody also reacted with cells expressing CXCR4 but not with cells expressing the other HIV coreceptor, CCR5. Furthermore, the antibody inhibited the replication of HIV-1 X4 virus (using CXCR4), as shown by an infection assay using both MAGIC-5 cells and MT4 cells, but not that of HIV-1 R5 virus (using CCR5). The antibody weakly interfered with chemotaxis induced by stromal cell-derived factor-1alpha in THP-1 cells or moderately inhibited the chemotaxis of Molt4#8 cells under the same conditions. In addition, immunization of cynomolgus monkeys also induced cDDX4-specific antibodies with anti-HIV activity. Taken together, these results indicate that cDDX4 conjugated with a multi-antigen peptide induces the conformational epitope-specific antibodies to the undecapeptidyl arch of CXCR4 may be a novel candidate immunogen for preventing disease progression in HIV-1-infected individuals.	Kumamoto Univ, Fac Pharmaceut Sci, Dept Biochem, Kumamoto 8620973, Japan; Natl Inst Infect Dis, Tsukuba Primate Ctr Med Sci, Tsukuba, Ibaraki 3050843, Japan; Nissui Pharmaceut Co Ltd, Res Lab, Ibaraki 3070036, Japan	Kumamoto University; National Institute of Infectious Diseases (NIID)	Shoji, S (corresponding author), Kumamoto Univ, Fac Pharmaceut Sci, Dept Biochem, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.							ARNON R, 1992, CURR OPIN IMMUNOL, V4, P449, DOI 10.1016/S0952-7915(06)80037-3; Baribaud F, 2001, J VIROL, V75, P8957, DOI 10.1128/JVI.75.19.8957-8967.2001; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; BERNARD A, 1995, EUR J BIOCHEM, V230, P416; Bieniasz P. D., 1998, FRONT BIOSCI, V3, P44; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Dakappagari NK, 2000, CANCER RES, V60, P3782; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doranz BJ, 2001, AIDS RES HUM RETROV, V17, P475, DOI 10.1089/08892220151126508; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Este JA, 1999, J VIROL, V73, P5577; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Galfre G, 1981, Methods Enzymol, V73, P3; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Gunthard HF, 1999, J VIROL, V73, P9404; Hachiya A, 2001, ANTIMICROB AGENTS CH, V45, P495, DOI 10.1128/AAC.45.2.495-501.2001; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Lehner T, 2001, J IMMUNOL, V166, P7446, DOI 10.4049/jimmunol.166.12.7446; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lopalco L, 2000, J IMMUNOL, V164, P3426, DOI 10.4049/jimmunol.164.6.3426; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; Misumi S, 2001, J VIROL, V75, P11614, DOI 10.1128/JVI.75.23.11614-11620.2001; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; Ockert D, 1999, IMMUNOL TODAY, V20, P63, DOI 10.1016/S0167-5699(98)01388-7; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Philpott S, 2001, J CLIN INVEST, V107, P431, DOI 10.1172/JCI11526; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; Rusconi S, 2000, J VIROL, V74, P9328, DOI 10.1128/JVI.74.19.9328-9332.2000; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741; SZEWCZUK Z, 1992, BIOCHEMISTRY-US, V31, P9132, DOI 10.1021/bi00153a004; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Takamune N, 2002, FEBS LETT, V527, P138, DOI 10.1016/S0014-5793(02)03199-X; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; Tremblay CL, 2000, J ACQ IMMUN DEF SYND, V25, P99, DOI 10.1097/00126334-200010010-00001; Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	44	20	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32335	32343		10.1074/jbc.M301209200	http://dx.doi.org/10.1074/jbc.M301209200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12771150	hybrid			2022-12-25	WOS:000184782100111
J	Oda, Y; Senaha, T; Matsuno, Y; Nakajima, K; Naka, R; Kinoshita, M; Honda, E; Furuta, I; Kakehi, K				Oda, Y; Senaha, T; Matsuno, Y; Nakajima, K; Naka, R; Kinoshita, M; Honda, E; Furuta, I; Kakehi, K			A new fungal lectin recognizing alpha(1-6)-linked fucose in the N-glycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SPECIFICITY; PURIFICATION; PROTEINS; OLIGOSACCHARIDES; ELECTROPHORESIS; HEMAGGLUTININ; AGGLUTININ; PLANT	In this report, we describe a new lectin from the fungus Rhizopus stolonifer that agglutinates rabbit red blood cells. Agglutinating activity was detected in the extract of mycelium-forming spores cultured on agar plates but not in the mycelium-forming no spores from liquid medium. This lectin, which we designated R. stolonifer lectin (RSL), was isolated by affinity chromatography with porcine stomach mucin-Sepharose. SDS-polyacrylamide gel electrophoresis and mass spectral analysis showed that RSL is similar to4.5 kDa, whereas gel filtration indicated a mass of 28 kDa. This indicates that the lectin is a hexamer of noncovalently associated RSL monomers. RSL activity was very stable, since it was insensitive to heat treatment at 70degreesC for 10 min. Analysis of RSL binding specificity by both microtiter plate and precipitation assays showed that N-glycans with L-fucose linked to the reducing terminal GlcNAc residues are the most potent inhibitors of RSL binding, whereas N-glycans without alpha(1-6)-linked fucose residues are similar to100-fold weaker inhibitors of binding. Oligosaccharides with alpha(1-2, -3, and -4) linkages showed no inhibition of binding in these assays. In a mirror resonance biosensor assay, high affinity binding was observed between RSL and the glycopeptide of bovine gamma-globulin, which has N-glycans with alpha(1-6)-linked fucose residues. However, RSL showed only a weak interaction with the glycopeptide of quail ovomucoid, which lacks fucose residues. Finally, capillary affinity electrophoresis studies indicated that RSL binds strongly to N-glycans with alpha(1-6)-linked fucose residues. Together, these results show that RSL recognizes the core structure of N-glycans with alpha(1-6)-linked L-fucose residues. This specificity could make RSL a valuable tool for glycobiological studies.	Kinki Univ, Fac Pharmaceut Sci, Higashiosaka, Osaka 5778502, Japan; Kinki Univ, Life Sci Res Inst, Osaka 5898577, Japan	Kindai University (Kinki University); Kindai University (Kinki University)	Oda, Y (corresponding author), Kinki Univ, Fac Pharmaceut Sci, Kowakae 3-4-1, Higashiosaka, Osaka 5778502, Japan.	y_oda@phar.kindai.ac.jp						ALONSO JM, 1988, EUR J BIOCHEM, V177, P187, DOI 10.1111/j.1432-1033.1988.tb14361.x; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; BUCKLEY PM, 1968, J BACTERIOL, V95, P2365, DOI 10.1128/JB.95.6.2365-2373.1968; COOPER DNW, 1984, DEV BIOL, V105, P59, DOI 10.1016/0012-1606(84)90261-6; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; Gorelik E, 1997, CANCER RES, V57, P332; Guillot J, 1997, BIOCHEM SYST ECOL, V25, P203, DOI 10.1016/S0305-1978(96)00110-X; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; KAWAGISHI H, 1995, FOOD REV INT, V11, P63, DOI 10.1080/87559129509541019; KELLENS JTC, 1989, J GEN MICROBIOL, V135, P3127; KOCHIBE N, 1980, BIOCHEMISTRY-US, V19, P2841, DOI 10.1021/bi00554a004; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LIENER IE, 1986, LECTINS PROPERTIES F, P294; LIYING Y, 1997, GLYCOCONJ J, V14, P45; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MO HQ, 1994, J BIOL CHEM, V269, P7666; Nakajima K, 2003, J PROTEOME RES, V2, P81, DOI 10.1021/pr020009v; ODA Y, 1987, EUR J BIOCHEM, V165, P297, DOI 10.1111/j.1432-1033.1987.tb11441.x; Oda Y, 2000, J BIOL CHEM, V275, P26772; PARENTE JP, 1982, J BIOL CHEM, V257, P13173; PARENTE JP, 1982, J CHROMATOGR, V249, P199, DOI 10.1016/S0021-9673(00)80250-2; PEREIRA MEA, 1974, BIOCHEMISTRY-US, V13, P3184, DOI 10.1021/bi00712a029; ROSEN SD, 1973, P NATL ACAD SCI USA, V70, P2554, DOI 10.1073/pnas.70.9.2554; ROSEN SD, 1974, NATURE, V252, P128, DOI 10.1038/252128a0; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAO MC, 1992, ANAL BIOCHEM, V205, P77, DOI 10.1016/0003-2697(92)90581-Q; STEPHAN EB, 1996, GLYCOCONJ J, V13, P585; Sudakevitz D, 2002, J BIOCHEM, V132, P353, DOI 10.1093/oxfordjournals.jbchem.a003230; Taga A, 1999, J CHROMATOGR A, V837, P221, DOI 10.1016/S0021-9673(99)00104-1; VRANKEN AM, 1987, FEBS LETT, V216, P67, DOI 10.1016/0014-5793(87)80758-5; Wang HX, 1998, MYCOL RES, V102, P897, DOI 10.1017/S0953756298006200; WATKINS WM, 1952, NATURE, V169, P825, DOI 10.1038/169825a0; Wu AM, 2001, LIFE SCI, V69, P2039, DOI 10.1016/S0024-3205(01)01297-8	38	48	53	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32439	32447		10.1074/jbc.M305181200	http://dx.doi.org/10.1074/jbc.M305181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788923	hybrid			2022-12-25	WOS:000184782100124
J	Rasmussen, M; Jacobsson, M; Bjorck, L				Rasmussen, M; Jacobsson, M; Bjorck, L			Genome-based identification and analysis of collagen-related structural motifs in bacterial and viral proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; TRIPLE-HELIX; SURFACE PROTEIN; PLATELET-AGGREGATION; CRYSTAL-STRUCTURE; PEPTIDES; PYOGENES; EXOSPORIUM; SEQUENCE; PLANTS	Collagens are extended trimeric proteins composed of the repetitive sequence glycine-X-Y. A (c) under bar ollagen- related (S) under bar tructural (m) under bar otif (CSM) containing glycine-X-Y repeats is also found in numerous proteins often referred to as collagen-like proteins. Little is known about CSMs in bacteria and viruses, but the occurrence of such motifs has recently been demonstrated. Moreover, bacterial CSMs form collagen-like trimers, even though these organisms cannot synthesize hydroxyproline, a critical residue for the stability of the collagen triple helix. Here we present 100 novel proteins of bacteria and viruses (including bacteriophages) containing CSMs identified by in silico analyses of genomic sequences. These CSMs differ significantly from human collagens in amino acid content and distribution; bacterial and viral CSMs have a lower proline content and a preference for proline in the X position of GXY triplets. Moreover, the CSMs identified contained more threonine than collagens, and in 17 of 53 bacterial CSMs threonine was the dominating amino acid in the Y position. Molecular modeling suggests that threonines in the Y position make direct hydrogen bonds to neighboring backbone carbonyls and thus substitute for hydroxyproline in the stabilization of the collagen-like triple-helix of bacterial CSMs. The majority of the remaining CSMs were either rich in proline or rich in charged residues. The bacterial proteins containing a CSM that could be functionally annotated were either surface structures or spore components, whereas the viral proteins generally could be annotated as structural components of the viral particle. The limited occurrence of CSMs in eubacteria and lower eukaryotes and the absence of CSMs in archaebacteria suggests that DNA encoding CSMs has been transferred horizontally, possibly from multicellular organisms to bacteria.	Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, S-22184 Lund, Sweden; Biovitrum AB, SE-11276 Stockholm, Sweden; Uppsala Univ, Dept Med Chem, SE-75123 Uppsala, Sweden	Lund University; Swedish Orphan Biovitrum; Uppsala University	Rasmussen, M (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, B14,Tornavagen 10, S-22184 Lund, Sweden.	Magnus.Rasmussen@medkem.lu.se		Rasmussen, Magnus/0000-0003-1588-5473				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; BAMFORD DH, 1990, NATURE, V344, P497, DOI 10.1038/344497b0; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Caldentey J, 2000, BIOCHEMISTRY-US, V39, P10566, DOI 10.1021/bi000711+; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; CHARALAMBOUS BM, 1988, EMBO J, V7, P2903, DOI 10.1002/j.1460-2075.1988.tb03148.x; DOI T, 1993, J BIOL CHEM, V268, P2126; Duplessis M, 2001, MOL MICROBIOL, V41, P325, DOI 10.1046/j.1365-2958.2001.02521.x; ERICKSON PR, 1987, J IMMUNOL, V138, P3360; ERICKSON PR, 1993, J BIOL CHEM, V268, P1646; Janulczyk R, 2001, INFECT IMMUN, V69, P4019, DOI 10.1128/IAI.69.6.4019-4026.2001; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; MEDVECZKY MM, 1993, VIRUS GENES, V7, P349, DOI 10.1007/BF01703391; Perret S, 2001, J BIOL CHEM, V276, P43693, DOI 10.1074/jbc.M105507200; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Rasmussen M, 2001, MOL MICROBIOL, V40, P1427, DOI 10.1046/j.1365-2958.2001.02493.x; Ruggiero F, 2000, FEBS LETT, V469, P132, DOI 10.1016/S0014-5793(00)01259-X; Smith MCM, 1998, SCIENCE, V279, P1834; Stanhope MJ, 2001, NATURE, V411, P940, DOI 10.1038/35082058; Sylvestre P, 2003, J BACTERIOL, V185, P1555, DOI 10.1128/JB.185.5.1555-1563.2003; Sylvestre P, 2002, MOL MICROBIOL, V45, P169, DOI 10.1046/j.1365-2958.2000.03000.x; Syvanen M, 2002, TRENDS GENET, V18, P245, DOI 10.1016/S0168-9525(02)02647-1; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	33	110	113	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32313	32316		10.1074/jbc.M304709200	http://dx.doi.org/10.1074/jbc.M304709200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788919	Green Submitted, hybrid			2022-12-25	WOS:000184782100108
J	Xi, SC; Zhang, Q; Dyer, KF; Lerner, EC; Smithgall, TE; Gooding, WE; Kamens, J; Grandis, JR				Xi, SC; Zhang, Q; Dyer, KF; Lerner, EC; Smithgall, TE; Gooding, WE; Kamens, J; Grandis, JR			Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOSAL EPITHELIAL-CELLS; SIGNAL-REGULATED KINASE; FACTOR RECEPTOR; TYROSINE KINASES; C-SRC; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE ACTIVATION; CYTOKINE RECEPTORS; GENE-EXPRESSION; EGF-RECEPTOR	Signal transducer and activator of transcription (STAT) proteins are constitutively activated in many malignancies, including squamous cell carcinoma of the head and neck (SCCHN). Previously, we reported that phosphorylation of the epidermal growth factor receptor (EGFR) is linked to activation of STATs 3 and 5 in SCCHN cells. The present study was undertaken to determine the role of Src family kinases in STAT activation and SCCHN growth. The Src family kinases c-Src, c-Yes, Fyn, and Lyn were expressed and activated by transforming growth factor-alpha stimulation in all four SCCHN cell lines examined but not in corresponding normal epithelial cells. In nine SCCHN cell lines tested, Src phosphotyrosine expression levels were highly correlated with activation levels of STATs 3 and 5. Co-immunoprecipitation analysis demonstrated interaction between c-Src and STATs 3 or 5 and EGFR in SCCHN cells, but no heterodimerization was detected between STAT3 and STAT5. SCCHN cells treated with either of two Src-specific inhibitors or transfected with a dominant-negative c-Src construct demonstrated decreased activation of STATs 3 and 5 and reduced growth rates in vitro. These results demonstrate a role for Src kinases in mediating activation of STATs 3 and 5 in concert with the EGFR in SCCHN cells. Strategies to target Src activation may contribute to the treatment of cancers that demonstrate increased levels of EGFR and STATs, including SCCHN.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Abbott Biores Ctr, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Inst Eye & Ear, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.		ZHANG, QING/AGY-7972-2022	ZHANG, QING/0000-0002-6595-8995; Kamens, Joanne/0000-0002-7000-1477	NATIONAL CANCER INSTITUTE [R01CA077308] Funding Source: NIH RePORTER; NCI NIH HHS [CA77308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hecker TP, 2002, CANCER RES, V62, P2699; HEO DS, 1989, CANCER RES, V49, P5167; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kok SH, 2003, ORAL ONCOL, V39, P19, DOI 10.1016/S1368-8375(01)00129-4; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Leong PL, 2002, ONCOGENE, V21, P2846, DOI 10.1038/sj.onc.1205385; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MORONI MC, 1992, J BIOL CHEM, V267, P2714; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nicolini G, 1996, J BIOL CHEM, V271, P30290, DOI 10.1074/jbc.271.47.30290; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Runge DM, 1999, BIOCHEM BIOPH RES CO, V265, P376, DOI 10.1006/bbrc.1999.1681; SACKS PG, 1988, CANCER RES, V48, P2858; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; van Oijen MGCT, 1998, J ORAL PATHOL MED, V27, P147; VIROLAINEN E, 1983, OTOLARYNG HEAD NECK, V91, P126, DOI 10.1177/019459988309100204; Wang LH, 1999, J IMMUNOL, V162, P3897; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Wisniewski D, 2002, CANCER RES, V62, P4244; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YOKOI T, 1988, Tumor Research, V23, P43; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	64	141	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31574	31583		10.1074/jbc.M303499200	http://dx.doi.org/10.1074/jbc.M303499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12771142	hybrid			2022-12-25	WOS:000184782100017
J	Canamasas, I; Debes, A; Natali, PG; Kurzik-Dumke, U				Canamasas, I; Debes, A; Natali, PG; Kurzik-Dumke, U			Understanding human cancer using Drosophila - Tid47, a cytosolic product of the DnaJ-like tumor suppressor gene l(2)tid, is a novel molecular partner of patched related to skin cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMA; HEDGEHOG SIGNAL-TRANSDUCTION; HEAT-SHOCK PROTEIN; IMAGINAL DISKS; EXPRESSION; MELANOGASTER; CHAPERONE; HOMOLOG; MUTATIONS; INDUCTION	Recessive mutations of the Drosophila gene lethal(2)-tumorous imaginal discs (l(2)tid) cause neoplastic growth of the anlagen of the adult organs, the imaginal discs. Here we report that the three proteins encoded by this evolutionarily conserved gene, Tid50, Tid47, and Tid40, identified as members of the DnaJ cochaperone family, are destined for different cellular compartments, build complexes with many proteins in a developmental stage-specific manner, and are likely to be involved in different cellular processes. We show that the cytosolic Tid47 molecule is a novel component of the Hedgehog (Hh)-Patched (Ptc) signaling regulating cell/tissue polarity and spatial patterning during development and is associated with human tumors such as basal cell carcinoma (BCC) and medulloblastoma. We provide functional evidence for its direct in vivo interaction with the Hh-bound Ptc receptor during signal transmission. Because loss of l(2)tid causes neoplastic transformation of Hh-responsive cells, we suggest that Tid47 may at least act as a guardian of the Hh signaling gradient by regulating Ptc homeostasis in the tissue. Finally, we show that the expression of htid-1, the human counterpart of l(2)tid, is altered in human BCCs. We demonstrate that in BCCs loss of htid expression correlates with loss of differentiation capacity of the neoplastic cells similar to that found in the Drosophila tumor model.	Johannes Gutenberg Univ Mainz, Inst Genet, Lab Comparat Tumor Biol, D-55131 Mainz, Germany; Regina Elena Inst Canc Res, Ctr Ric Sperimentale, Immunol Lab, I-00158 Rome, Italy	Johannes Gutenberg University of Mainz; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Kurzik-Dumke, U (corresponding author), Johannes Gutenberg Univ Mainz, Inst Genet, Lab Comparat Tumor Biol, Obere Zahlbacher Str 63, D-55131 Mainz, Germany.	kurzik@mail.uni-mainz.de						Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Capdevila J, 1999, CURR OPIN GENET DEV, V9, P427, DOI 10.1016/S0959-437X(99)80065-3; Chen Y, 1998, DEVELOPMENT, V125, P4943; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Chuang PT, 2000, CURR OPIN GENET DEV, V10, P515, DOI 10.1016/S0959-437X(00)00121-0; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Green J, 1998, BRIT J DERMATOL, V139, P911; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; KurzikDumke U, 1996, GENE, V171, P163, DOI 10.1016/0378-1119(95)00885-3; KurzikDumke U, 1997, GENE, V200, P45, DOI 10.1016/S0378-1119(97)00373-9; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; LEVER FW, 1963, HISTOPATHOLOGY SKIN, P562; LINDSLEY DL, 1992, GENOME DROSOPHILA ME, P89; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Quirk J, 1997, COLD SPRING HARB SYM, V62, P217; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Shen TL, 1999, HUM PATHOL, V30, P284, DOI 10.1016/S0046-8177(99)90006-0; Soltys BJ, 2000, INT REV CYTOL, V194, P133; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tojo M, 1999, PATHOL INT, V49, P687, DOI 10.1046/j.1440-1827.1999.00938.x; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; TZUMIN L, 1999, NEUROLOGY, V22, P451; Unden AB, 1997, CANCER RES, V57, P2336; VELAZQUEZ JM, 1983, J CELL BIOL, V96, P286, DOI 10.1083/jcb.96.1.286; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; ZUBER U, 1998, MOL CHAPERONES LIFE, P241	52	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30952	30960		10.1074/jbc.M304225200	http://dx.doi.org/10.1074/jbc.M304225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783860	hybrid			2022-12-25	WOS:000184658800069
J	Caretti, G; Salsi, V; Vecchi, C; Imbriano, C; Mantovani, R				Caretti, G; Salsi, V; Vecchi, C; Imbriano, C; Mantovani, R			Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; TRANSCRIPTION FACTOR; G1/S TRANSITION; CDC2 PROMOTER; B1 GENE; C-MYC; BINDING; COMPLEX; CHROMATIN; E2F	Regulation of transcription during the cell-cycle is under the control of E2 factors (E2Fs), often in cooperation with nuclear factor Y (NF-Y), a histone-like CCAAT-binding trimer. NF-Y is paradigmatic of a constitutive, ubiquitous factor that pre-sets the promoter architecture for other regulatory proteins to access it. We analyzed the recruitment of NF-Y, E2F1/4/6, histone acetyltransferases, and histone deacetylase (HDAC) 1/3/4 to several cell-cycle promoters by chromatin immunoprecipitation assays in serum-starved and restimulated NIH3T3 cells. NF-Y binding is not constitutive but timely regulated in all promoters tested, being displaced when promoters are repressed. p300 association correlates with activation, and it is never found in the absence of NF-Y, whereas PCAF/hGCN5 is often found before NF-Y association. E2F4 and E2F6, together with HDACs, are bound to repressed promoters, including the G(2)/M Cyclin B2. As expected, an inverse relationship between HDACs association and histones H3/H4 acetylation is observed. Blocking cells in G(1) with the cyclin-dependent kinase 2 inhibitor R-roscovitine confirms that NF-Y is bound to G(1)/S but not to G(2)/M promoters in G(1). These data indicate that following the release of E2Fs/HDACs, a hierarchy of PCAF-NF-Y-p300 interactions and H3-H4 acetylations are required for activation of cell-cycle promoters.	Univ Milan, Dipartimento Sci Biomol & Biotechnol, I-20133 Milan, Italy; Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy	University of Milan; Universita di Modena e Reggio Emilia	Mantovani, R (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotechnol, Via Celoria 26, I-20133 Milan, Italy.	mantor@unimi.it	Imbriano, Carol/ABD-8204-2021; Vecchi, Chiara/C-1552-2014; Imbriano, Carol/C-9376-2015	Imbriano, Carol/0000-0003-2864-4820; Imbriano, Carol/0000-0003-2864-4820; VECCHI, Chiara/0000-0001-7761-4922; SALSI, Valentina/0000-0002-7133-0360				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; ALDER H, 1992, NUCLEIC ACIDS RES, V20, P1769, DOI 10.1093/nar/20.7.1769; Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Goodman RH, 2000, GENE DEV, V14, P1553; Gowri PM, 2003, MOL CELL BIOL, V23, P815, DOI 10.1128/MCB.23.3.815-825.2003; Hut QH, 2002, J BIOL CHEM, V277, P37191, DOI 10.1074/jbc.M205985200; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Izumi H, 2001, J CELL SCI, V114, P1533; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; MESSEN A, 2002, P NATL ACAD SCI USA, V99, P6274; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Powell CMH, 2000, EMBO J, V19, P4665, DOI 10.1093/emboj/19.17.4665; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Takahashi Y, 2000, GENE DEV, V14, P804; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Wasner M, 2003, FEBS LETT, V536, P66, DOI 10.1016/S0014-5793(03)00028-0; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	49	134	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30435	30440		10.1074/jbc.M304606200	http://dx.doi.org/10.1074/jbc.M304606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12771133	hybrid, Green Published			2022-12-25	WOS:000184658800006
J	Sundberg, LJ; Galante, LM; Bill, HM; Mack, CP; Taylor, JM				Sundberg, LJ; Galante, LM; Bill, HM; Mack, CP; Taylor, JM			An endogenous inhibitor of focal adhesion kinase blocks Rac1/JNK but not Ras/ERK-dependent signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR ACTIVATION; CYCLE PROGRESSION; MAP KINASE; ANGIOTENSIN-II; PHOSPHATIDYLINOSITOL 3-KINASE; P21-ACTIVATED KINASE; STIMULATED MIGRATION; TARGETED MUTATION; TYROSINE KINASES	Humoral factors and extracellular matrix are critical co-regulators of smooth muscle cell (SMC) migration and proliferation. We reported previously that focal adhesion kinase (FAK)-related non-kinase (FRNK) is expressed selectively in SMC and can inhibit platelet-derived growth factor BB homodimer (PDGF-BB)-induced proliferation and migration of SMC by attenuating FAK activity. The goal of the current studies was to identify the mechanism by which FAK/FRNK regulates SMC growth and migration in response to diverse mitogenic signals. Transient overexpression of FRNK in SMC attenuated autophosphorylation of FAK at Tyr-397, reduced Src family-dependent tyrosine phosphorylation of FAK at Tyr-576, Tyr-577, and Tyr-881, and reduced phosphorylation of the FAK/Src substrates Cas and paxillin. However, FRNK expression did not alter the magnitude or dynamics of ERK activation induced by PDGF-BB or angiotensin II. Instead, FRNK expression markedly attenuated PDGF-BB-, angiotensin II-, and integrin-stimulated Rac1 activity and attenuates downstream signaling to JNK. Importantly, constitutively active Rac1 rescued the proliferation defects in FRNK expressing cells. Based on these observations, we hypothesize that FAK activation is required to integrate integrin signals with those from receptor tyrosine kinases and G protein-coupled receptors through downstream activation of Rac1 and that in SMC, FRNK may control proliferation and migration by buffering FAK-dependent Rac1 activation.	Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Taylor, JM (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, 420 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.			Taylor, Joan/0000-0002-8794-5167	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD001441] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081844, R01HL071054, T32HL069768] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071054, T32 HL069768, R01 HL081844, R01-HL71054] Funding Source: Medline; NICHD NIH HHS [K12 HD 01441] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Berrier AL, 2002, J CELL SCI, V115, P4285, DOI 10.1242/jcs.00109; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; CLOWES AW, 1983, LAB INVEST, V49, P327; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; FURUTA Y, 1995, ONCOGENE, V11, P1989; George EL, 1997, BLOOD, V90, P3073, DOI 10.1182/blood.V90.8.3073; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Govindarajan G, 2000, CIRC RES, V87, P710, DOI 10.1161/01.RES.87.8.710; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Lin TH, 1997, J BIOL CHEM, V272, P8849; Liu JF, 1999, ONCOGENE, V18, P6425, DOI 10.1038/sj.onc.1203027; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Nakamura M, 1998, BIOCHEM BIOPH RES CO, V242, P16, DOI 10.1006/bbrc.1997.7899; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Owens GK, 1996, CIRC RES, V79, P1054, DOI 10.1161/01.RES.79.5.1054; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Pukac L, 1998, EXP CELL RES, V242, P548, DOI 10.1006/excr.1998.4138; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmitz U, 2001, J BIOL CHEM, V276, P22003, DOI 10.1074/jbc.M102450200; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; Tombes RM, 1998, BIOCHEM J, V330, P1451; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Yamamoto H, 1999, EUR J BIOCHEM, V264, P110, DOI 10.1046/j.1432-1327.1999.00584.x; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V280, pC1680, DOI 10.1152/ajpcell.2001.280.6.C1680	64	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29783	29791		10.1074/jbc.M303771200	http://dx.doi.org/10.1074/jbc.M303771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12782622	Green Published, hybrid			2022-12-25	WOS:000184507000050
J	Tang, TTL; Lasky, LA				Tang, TTL; Lasky, LA			The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR PROTEIN; ARYL-HYDROCARBON RECEPTOR; E3 UBIQUITIN LIGASE; CELL-CYCLE; GENE-EXPRESSION; FACTOR AFX; KINASE-B; PROLYL HYDROXYLATION/; 3-KINASE/AKT PATHWAY	Tumors utilize hyperactivation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway to cope with deleterious environmental conditions. Activation of the PI3K/AKT pathway has been shown to increase protein expression of the alpha subunit of the hypoxia-inducible factor (HIF) 1, a key regulator of oxygen homeostasis. Elevated levels of HIF-1alpha induce expression of genes with critical roles in angiogenesis, erythropoiesis, and glucose metabolism, processes that are essential for tumor expansion. Here we examine the involvement of FOXO4 (also known as AFX), a member of the forkhead transcription factor superfamily that is negatively regulated by the PI3K/AKT pathway, in the regulation of HIF-1alpha protein expression. Nuclear expression of FOXO4 results in the suppression of various responses to hypoxia, including decreased vascular endothelial growth factor, glucose transporter 1, and erythropoietin expression. Interestingly, FOXO4 down-regulates the HIF-1alpha protein levels, consistent with the lack of hypoxia responsiveness. Previous results have revealed a role for prolyl hydroxylation and resultant von Hippel-Lindau protein (pVHL) interactions in the ubiquitin-proteasome-mediated degradation of HIF-1alpha. However, neither inhibition of prolyl hydroxylases nor mutation of HIF-1alpha-hydroxylated prolines involved with pVHL-mediated binding inhibits the observed FOXO4-mediated down-regulation of HIF-1alpha. These results suggest a novel alternate mechanism for hypoxic regulation that is dependent upon the level of activation of FOXO4-mediated transcription.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Lasky, LA (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.		tang, tina/GRX-7859-2022					Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arora K, 2001, DEV CELL, V1, P441, DOI 10.1016/S1534-5807(01)00067-3; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blancher C, 2001, CANCER RES, V61, P7349; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Chen EY, 2001, CANCER RES, V61, P2429; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li DM, 1997, CANCER RES, V57, P2124; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Neumann F, 1997, EXP CELL RES, V230, P252, DOI 10.1006/excr.1996.3417; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Park H, 1999, MOL CELLS, V9, P172; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ravi R, 2000, GENE DEV, V14, P34; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	66	76	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30125	30135		10.1074/jbc.M302042200	http://dx.doi.org/10.1074/jbc.M302042200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761217	hybrid			2022-12-25	WOS:000184507000090
J	Efendiev, R; Budu, CE; Cinelli, AR; Bertorello, AM; Pedemonte, CH				Efendiev, R; Budu, CE; Cinelli, AR; Bertorello, AM; Pedemonte, CH			Intracellular Na+ regulates dopamine and angiotensin II receptors availability at the plasma membrane and their cellular responses in renal epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROXIMAL TUBULE NA+,K+-ATPASE; SHORT-TERM REGULATION; ALPHA-SUBUNIT; SODIUM-TRANSPORT; OPOSSUM KIDNEY; PKC-BETA; PHOSPHORYLATION; STIMULATION; NA,K-ATPASE	The balance and cross-talk between natruretic and antinatruretic hormone receptors plays a critical role in the regulation of renal Na+ homeostasis, which is a major determinant of blood pressure. Dopamine and angiotensin II have antagonistic effects on renal Na+ and water excretion, which involves regulation of the Na+, K+-ATPase activity. Herein we demonstrate that angiotensin II (Ang II) stimulation of AT1 receptors in proximal tubule cells induces the recruitment of Na+, K+-ATPase molecules to the plasmalemma, in a process mediated by protein kinase Cbeta and interaction of the Na+, K+-ATPase with adaptor protein 1. Ang II stimulation led to phosphorylation of the alpha subunit Ser-11 and Ser-18 residues, and substitution of these amino acids with alanine residues completely abolished the Ang II-induced stimulation of Na+,K+-ATPase-mediated Rb+ transport. Thus, for Ang II-dependent stimulation of Na+,K+-ATPase activity, phosphorylation of these serine residues is essential and may constitute a triggering signal for recruitment of Na+,K+-ATPase molecules to the plasma membrane. When cells were treated simultaneously with saturating concentrations of dopamine and Ang II, either activation or inhibition of the Na+,K+-ATPase activity was produced dependent on the intracellular Na+ concentration, which was varied in a very narrow physiological range (9-19 mM). A small increase in intracellular Na+ concentrations induces the recruitment of D1 receptors to the plasma membrane and a reduction in plasma membrane AT1 receptors. Thus, one or more proteins may act as an intracellular Na+ concentration sensor and play a major regulatory role on the effect of hormones that regulate proximal tubule Na+ reabsorption.	Univ Houston, Coll Pharm, Houston, TX 77204 USA; SUNY, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; Karolinska Hosp, Karolinska Inst, Dept Med, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden	University of Houston System; University of Houston; State University of New York (SUNY) System; SUNY Maritime College; Karolinska Institutet; Karolinska University Hospital	Pedemonte, CH (corresponding author), Univ Houston, Coll Pharm, 4800 Calhoun Rd,Bldg SR2,Rm 555, Houston, TX 77204 USA.	cpedemonte@uh.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053460] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53460] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APERIA A, 1994, FASEB J, V8, P436, DOI 10.1096/fasebj.8.6.8168694; Aperia AC, 2000, ANNU REV PHYSIOL, V62, P621, DOI 10.1146/annurev.physiol.62.1.621; BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; Bharatula M, 1998, CLIN EXP HYPERTENS, V20, P465, DOI 10.3109/10641969809053225; Brismar H, 1998, P NATL ACAD SCI USA, V95, P5573, DOI 10.1073/pnas.95.10.5573; Carey RM, 2001, HYPERTENSION, V38, P297, DOI 10.1161/hy0901.096422; CHEN CJ, 1991, J PHARMACOL EXP THER, V256, P486; Cheng HF, 1996, J CLIN INVEST, V97, P2745, DOI 10.1172/JCI118729; CHENG HF, 1995, J CLIN INVEST, V95, P2012, DOI 10.1172/JCI117886; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; Done SC, 2002, J BIOL CHEM, V277, P17108, DOI 10.1074/jbc.M201326200; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Efendiev R, 2002, J BIOL CHEM, V277, P44108, DOI 10.1074/jbc.M205173200; Efendiev R, 2002, J BIOL CHEM, V277, P11489, DOI 10.1074/jbc.M108182200; EWART HS, 1995, AM J PHYSIOL, V269, pC205; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; GARVIN JL, 1991, J AM SOC NEPHROL, V1, P1146; Guimaraes JT, 1997, INT J BIOCHEM CELL B, V29, P681, DOI 10.1016/S1357-2725(96)00166-5; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; HABER RS, 1987, AM J PHYSIOL, V253, pF26, DOI 10.1152/ajprenal.1987.253.1.F26; HARRIS PJ, 1977, PFLUG ARCH EUR J PHY, V367, P295, DOI 10.1007/BF00581370; Harris PJ, 1996, CLIN EXP PHARMACOL P, V23, pS112, DOI 10.1111/j.1440-1681.1996.tb03071.x; HEGDE SS, 1989, HYPERTENSION, V13, P828, DOI 10.1161/01.HYP.13.6.828; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Hussain T, 1998, HYPERTENSION, V32, P187, DOI 10.1161/01.HYP.32.2.187; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Kowluru RA, 1998, DIABETES, V47, P464, DOI 10.2337/diabetes.47.3.464; KUCHEL OG, 1991, HYPERTENSION, V18, P709, DOI 10.1161/01.HYP.18.6.709; MALSTROM K, 1987, BIOCHIM BIOPHYS ACTA, V902, P269, DOI 10.1016/0005-2736(87)90305-1; Mochly-Rosen D, 1998, FASEB J, V12, P35; NASH SR, 1993, MOL PHARMACOL, V44, P918; Navar LG, 1999, J AM SOC NEPHROL, V10, pS266; NAVAR LG, 1994, J AM SOC NEPHROL, V5, P1153; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Pedemonte CH, 1997, MOL PHARMACOL, V52, P88, DOI 10.1124/mol.52.1.88; Pedemonte CH, 1997, J MEMBRANE BIOL, V155, P219, DOI 10.1007/s002329900174; Pedemonte CH, 2001, J BIOENERG BIOMEMBR, V33, P439, DOI 10.1023/A:1010675708820; PRESSMAN BC, 1983, ADV EXP MED BIOL, V161, P543; Quan A, 1998, AM J PHYSIOL-RENAL, V275, pF74, DOI 10.1152/ajprenal.1998.275.1.F74; RuizOpazo N, 1997, HYPERTENSION, V30, P191, DOI 10.1161/01.HYP.30.2.191; SHEIKHHAMAD D, 1993, AM J PHYSIOL, V264, pF737, DOI 10.1152/ajprenal.1993.264.4.F737; SOARESDASILVA P, 1993, BIOCHEM PHARMACOL, V45, P1791, DOI 10.1016/0006-2952(93)90435-Y; Wong PSK, 1998, BRIT J PHARMACOL, V124, P41, DOI 10.1038/sj.bjp.0701791; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zhuo JL, 2002, HYPERTENSION, V39, P116, DOI 10.1161/hy0102.100780	52	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28719	28726		10.1074/jbc.M303741200	http://dx.doi.org/10.1074/jbc.M303741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759348	hybrid			2022-12-25	WOS:000184421100047
J	Chien, WW; Tidow, N; Williamson, EA; Shih, LY; Krug, U; Kettenbach, A; Fermin, AC; Roifman, CM; Koeffler, HP				Chien, WW; Tidow, N; Williamson, EA; Shih, LY; Krug, U; Kettenbach, A; Fermin, AC; Roifman, CM; Koeffler, HP			Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR; C-ABL; INDUCED TRANSFORMATION; ADAPTER PROTEINS; KINASE-ACTIVITY; GROWTH-FACTORS; IN-VIVO	The Bcr-Abl protein-tyrosine kinase is implicated in the development of chronic myeloid leukemia. The potential role of protein-tyrosine phosphatase in the regulation of Bcr-Abl signaling was explored. First, expression patterns of tyrosine phosphatases in leukemic cell lines were investigated using degenerate primers for reverse transcription-PCR followed by cloning and sequencing of the cDNA. Distinct patterns of distribution of phosphatase were found in erythroid and myeloid leukemic cell lines. Whereas some phosphatases were ubiquitously expressed, others were limited to specific cell types. Surprisingly, a previously cloned "lymphocyte-specific" phosphatase, Lyp, was frequently detected in a number of myeloid cell lines as well as normal granulocytes and monocytes. Lyp was localized to the cytosol, and overexpression of Lyp caused reduction in the phosphorylation levels of multiple proteins in KCL22 chronic myeloid leukemia blast cells including Cbl, Bcr-Abl, Erk1/2, and CrkL. Co-expression of Lyp and Bcr-Abl in Cos-7 cells resulted in decreased levels of Bcr-Abl, Grb2, and Myc. Overexpression of Lyp markedly suppressed anchorage-independent clonal growth of KCL22 cells. Taken together, the data suggest that Lyp may play an antagonistic role in signaling by the Bcr-Abl fusion protein.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Hematol Oncol, Los Angeles, CA 90048 USA; Chang Gung Mem Hosp, Div Hematol Oncol, Taipei 105, Taiwan; Chang Gung Univ, Taipei 105, Taiwan; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chang Gung Memorial Hospital; Chang Gung University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Chien, WW (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Hematol Oncol, 110 George Burns Rd,D5065, Los Angeles, CA 90048 USA.			Kettenbach, Arminja/0000-0003-3979-4576				Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; An WG, 2000, CELL GROWTH DIFFER, V11, P355; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Cohen S, 1999, BLOOD, V93, P2013, DOI 10.1182/blood.V93.6.2013.406k25_2013_2024; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Hill RJ, 2002, EXP HEMATOL, V30, P237, DOI 10.1016/S0301-472X(01)00794-9; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kardinal C, 2001, BLOOD, V98, P1773, DOI 10.1182/blood.V98.6.1773; Kim H, 1999, MOL CELL BIOL, V19, P5326; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; Levkowitz G, 1996, ONCOGENE, V12, P1117; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Million RP, 2000, BLOOD, V96, P664; NOWELL PC, 1960, SCIENCE, V132, P1497; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Salgia R, 1996, EXP HEMATOL, V24, P310; Sasaki T, 2001, INT J BIOCHEM CELL B, V33, P1041, DOI 10.1016/S1357-2725(01)00075-9; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Sattler M, 1996, ONCOGENE, V12, P839; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4	41	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27413	27420		10.1074/jbc.M304575200	http://dx.doi.org/10.1074/jbc.M304575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12764153	hybrid			2022-12-25	WOS:000184242700012
J	Wilhelmsson, U; Eliasson, C; Bjerkvig, R; Pekny, M				Wilhelmsson, U; Eliasson, C; Bjerkvig, R; Pekny, M			Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression	ONCOGENE			English	Article						glial fibrillary acidic protein; astrocytoma; intermediate filaments; gene targeting; p53	FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; HUMAN GLIOMAS; INTERMEDIATE FILAMENTS; PHOSPHORYLATION SITES; COMPLEMENTARY-DNA; BRAIN-TUMORS; IN-VITRO; CELLS; GROWTH	In astrocytic neoplasms, the number of cells expressing glial fibrillary acidic protein (GFAP) is inversely proportional to the extent of anaplasia. The loss of GFAP expression, the principal marker of astroglial cells, in these tumors has been proposed to constitute a step in their development and progression. To test this hypothesis, we crossed p53-negative (p53(-/-)) mice, which frequently develop astrocytomas after intrauterine exposure to ethylnitrosourea, with GFAP-negative (GFAP(-/-)) mice or GFAP(+/+) controls. Brain tumors of glial origin were found in 12 of 35 GFAP(+/+) p53(-/-) mice (34%) and in I I of 27 GFAP(-/-) p53(-/-) mice (41%). The two groups did not differ in the age at which tumors were detected or in tumor histology or progression. Thus, the loss of GFAP expression frequently seen in high-grade astrocytomas does not constitute a step in tumor development. Rather, it may represent the undifferentiated state of these cells.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Univ Bergen, Dept Anat & Cell Biol, Bergen, Norway	University of Gothenburg; University of Bergen	Pekny, M (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.			Wilhelmsson, Ulrika/0000-0003-3227-2687				BIGNER SH, 1998, GENETIC BASIS HUMAN, P661; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECK JHN, 1978, ACTA NEUROPATHOL, V42, P183, DOI 10.1007/BF00690355; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1978, J HISTOCHEM CYTOCHEM, V26, P513, DOI 10.1177/26.7.357640; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Engebraaten O, 1999, J NEUROSURG, V90, P125, DOI 10.3171/jns.1999.90.1.0125; HARA A, 1991, SURG NEUROL, V36, P190, DOI 10.1016/0090-3019(91)90111-L; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; JACQUE CM, 1979, J NATL CANCER I, V62, P479, DOI 10.1093/jnci/62.3.479; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; KAJIWARA K, 1992, BRAIN RES, V572, P314, DOI 10.1016/0006-8993(92)90492-R; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Leonard JR, 2001, ONCOGENE, V20, P8281, DOI 10.1038/sj.onc.1205024; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Oda H, 1997, CANCER RES, V57, P646; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Pekny M, 2001, Prog Brain Res, V132, P23; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TASCOS NA, 1982, HUM PATHOL, V13, P454, DOI 10.1016/S0046-8177(82)80028-2; TODA M, 1994, J NEUROCHEM, V63, P1975; Toda M, 1999, NEUROCHEM RES, V24, P339, DOI 10.1023/A:1022538810581; TSUJIMURA K, 1994, J BIOCHEM, V116, P426, DOI 10.1093/oxfordjournals.jbchem.a124542; VANDERMEULEN JDM, 1978, NEUROPATH APPL NEURO, V4, P177; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; Wechsler W, 1979, Natl Cancer Inst Monogr, P219; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; YONG VW, 1992, J NEUROL SCI, V111, P92; ZHOU Y, 2002, NAT REV CANCER, V8, P616	38	44	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3407	3411		10.1038/sj.onc.1206372	http://dx.doi.org/10.1038/sj.onc.1206372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776191				2022-12-25	WOS:000183128500006
J	Bahamonde, MI; Fernandez-Fernandez, JM; Guix, FX; Vazquez, E; Valverde, MA				Bahamonde, MI; Fernandez-Fernandez, JM; Guix, FX; Vazquez, E; Valverde, MA			Plasma membrane voltage-dependent anion channel mediates antiestrogen-activated Maxi Cl- currents in C1300 neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; CONDUCTANCE CHLORIDE CHANNEL; SKELETAL-MUSCLE; PORIN; VDAC; LOCALIZATION; ESTROGEN; ANTIBODIES; BINDING; VOLUME	The cell membrane large conductance voltage-dependent chloride channel ( Maxi Cl- channel) has been recorded in different cell types following excision of membrane patches or stimulation by antiestrogens under whole-cell recording conditions. However, both its molecular nature and relevance to cell physiology await elucidation. Its electrophysiological properties resemble those of the voltage-dependent anion channel ( VDAC) of the outer mitochondrial membrane. This observation has led to the controversial hypothesis that VDAC could be the molecular correlate of the plasma membrane Maxi Cl- channel. We have investigated the cellular localization of VDAC and its relationship with the antiestrogen-activated Maxi Cl- current in C1300 neuroblastoma cells. The presence of a plasma membrane VDAC was demonstrated by immunoblotting of membrane fractions with monoclonal antibodies against the VDAC and by reverse transcription-PCR using primers that hybridize to a VDAC sequence coding for an N-terminal leader peptide required for its plasma membrane sorting. Besides, VDAC colocalized with markers of plasma membrane lipid rafts ( cholera toxin beta subunit) but not caveolin-1. Transfection of C1300 cells with an antisense oligonucleotide directed against the specific membrane leader sequence of VDAC markedly reduced both VDAC immunostaining and antiestrogen-activated Maxi Cl- currents, suggesting that VDAC forms the plasma membrane Maxi Cl- channel or a part thereof.	Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Unitat Senyalitzacio, Barcelona 08003, Spain	Pompeu Fabra University	Valverde, MA (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Unitat Senyalitzacio, C Dr Aiguader 80, Barcelona 08003, Spain.		Fernández-Fernández, José Manuel M/M-8157-2015; Guix, Francesc/AAA-7462-2020	Fernández-Fernández, José Manuel M/0000-0003-2330-8449; Guix Rafols, Francesc Xavier/0000-0001-5781-3799; Vazquez, Esther/0000-0003-1052-0424; Valverde, Miguel A./0000-0002-6961-3361				BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; Bathori G, 2000, J BIOENERG BIOMEMBR, V32, P79, DOI 10.1023/A:1005516513313; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; Buettner R, 2000, P NATL ACAD SCI USA, V97, P3201, DOI 10.1073/pnas.060242297; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COULOMBE A, 1992, PFLUG ARCH EUR J PHY, V422, P143, DOI 10.1007/BF00370413; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; Diaz M, 2001, J PHYSIOL-LONDON, V536, P79, DOI 10.1111/j.1469-7793.2001.00079.x; Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell.00245.2002; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; GRAESER D, 1992, SIGNAL TRANSDUCTION, P23; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; LEWIS TM, 1994, NEUROSCI LETT, V181, P83, DOI 10.1016/0304-3940(94)90565-7; Li ZY, 2000, J CARDIOVASC PHARM, V35, P506, DOI 10.1097/00005344-200003000-00023; MCGILL JM, 1993, J MEMBRANE BIOL, V133, P253; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Reymann S, 1999, ANAL BIOCHEM, V274, P289, DOI 10.1006/abio.1999.4265; REYMANN S, 1995, BIOCHEM MOL MED, V54, P75, DOI 10.1006/bmme.1995.1011; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; THINNES FP, 1992, J BIOENERG BIOMEMBR, V24, P71, DOI 10.1007/BF00769533; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Valverde MA, 2002, STEROIDS, V67, P439, DOI 10.1016/S0039-128X(01)00174-X; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; Yu WH, 1996, J BIOENERG BIOMEMBR, V28, P93, DOI 10.1007/BF02110638	29	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33284	33289		10.1074/jbc.M302814200	http://dx.doi.org/10.1074/jbc.M302814200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12794078	hybrid			2022-12-25	WOS:000184901800097
J	Haldrup, A; Lunde, C; Scheller, HV				Haldrup, A; Lunde, C; Scheller, HV			Arabidopsis thaliana plants lacking the PSI-D subunit of photosystem I suffer severe photoinhibition, have unstable photosystem I complexes, and altered redox homeostasis in the chloroplast stroma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERREDOXIN-THIOREDOXIN SYSTEM; NADP-MALATE-DEHYDROGENASE; CYCLIC ELECTRON FLOW; IRON-SULFUR PROTEIN; PSAD SUBUNIT; INSERTIONAL INACTIVATION; PHOTOAUTOTROPHIC GROWTH; ATPASE ACTIVITY; CO2 FIXATION; LIGHT	The PSI-D subunit of photosystem I is a hydrophilic subunit of about 18 kDa, which is exposed to the stroma and has an important function in the docking of ferredoxin to photosystem I. We have used an antisense approach to obtain Arabidopsis thaliana plants with only 5 - 60% of PSI-D. No plants were recovered completely lacking PSI-D, suggesting that PSI-D is essential for a functional PSI in plants. Plants with reduced amounts of PSI-D showed a similar decrease in all other subunits of PSI including the light harvesting complex, suggesting that in the absence of PSI-D, PSI cannot be properly assembled and becomes degraded. Plants with reduced amounts of PSI-D became light-stressed even in low light although they exhibited high non-photochemical quenching (NPQ). The high NPQ was generated by upregulating the level of violaxanthin de-epoxidase and PsbS, which are both essential components of NPQ. Interestingly, the lack of PSI-D affected the redox state of thioredoxin. During the normal light cycle thioredoxin became increasingly oxidized, which was observed as decreasing malate dehydrogenase activity over a 4-h light period. This result shows that photosynthesis was close to normal the first 15 min, but after 2 - 4 h photo-inhibition dominated as the stroma progressively became less reduced. The change in the thiol disulfide redox state might be fatal for the PSI-D-less plants, because reduction of thioredoxin is one of the main switches for the initiation of CO2 assimilation and photoprotection upon light exposure.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Haldrup, A (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	anna@kvl.dk	Scheller, Henrik/AAH-4770-2020; Scheller, Henrik V/A-8106-2008	Scheller, Henrik/0000-0002-6702-3560; Scheller, Henrik V/0000-0002-6702-3560; Haldrup, Anna/0000-0002-2348-7072				ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSSON J, 2003, IN PRESS PLANT J; ASADA K, 1978, PHOTOCHEM PHOTOBIOL, V28, P917, DOI 10.1111/j.1751-1097.1978.tb07040.x; Ashton AR, 2000, PHYSIOL PLANTARUM, V110, P314, DOI 10.1034/j.1399-3054.2000.1100305.x; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Bernhard Teicher H, 2000, PHOTOSYNTH RES, V64, P53, DOI 10.1023/A:1026524302191; Bottin H, 2001, BIOCHEM BIOPH RES CO, V287, P833, DOI 10.1006/bbrc.2001.5658; Broin M, 2002, PLANT CELL, V14, P1417, DOI 10.1105/tpc.001644; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Carlberg I, 1999, BIOCHEMISTRY-US, V38, P3197, DOI 10.1021/bi982506o; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COHEN Y, 1992, FEBS LETT, V302, P15, DOI 10.1016/0014-5793(92)80273-J; Cournac L, 1997, FEBS LETT, V416, P65, DOI 10.1016/S0014-5793(97)01170-8; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; CSEKE C, 1986, BIOCHIM BIOPHYS ACTA, V853, P43, DOI 10.1016/0304-4173(86)90004-2; Endo T, 1999, FEBS LETT, V457, P5, DOI 10.1016/S0014-5793(99)00989-8; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Gilmore AM, 1998, BIOCHEMISTRY-US, V37, P13582, DOI 10.1021/bi981384x; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JENSEN PE, 2003, IN PRESS PHYSL PLANT; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kato MC, 2003, PLANT CELL PHYSIOL, V44, P318, DOI 10.1093/pcp/pcg045; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; Kofer W, 1998, MOL GEN GENET, V258, P166, DOI 10.1007/s004380050719; Koike H, 2000, PHOTOSYNTH RES, V65, P207, DOI 10.1023/A:1010734912776; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Lagoutte B, 2001, PLANT PHYSIOL, V126, P307, DOI 10.1104/pp.126.1.307; Lee JW, 1996, SCIENCE, V273, P364, DOI 10.1126/science.273.5273.364; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LOTAN O, 1993, J BIOL CHEM, V268, P16185; Lunde C, 2003, PLANT CELL PHYSIOL, V44, P44, DOI 10.1093/pcp/pcg012; MANNAN RM, 1991, P NATL ACAD SCI USA, V88, P10168, DOI 10.1073/pnas.88.22.10168; MERATI G, 1987, FEBS LETT, V215, P37, DOI 10.1016/0014-5793(87)80109-6; Miginiac-Maslow M, 2000, PHYSIOL PLANTARUM, V110, P322, DOI 10.1034/j.1399-3054.2000.1100306.x; MILLS JD, 1980, FEBS LETT, V112, P173, DOI 10.1016/0014-5793(80)80173-6; Minai L, 1996, P NATL ACAD SCI USA, V93, P6338, DOI 10.1073/pnas.93.13.6338; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; Naver H, 2001, PLANT CELL, V13, P2731, DOI 10.1105/tpc.010253; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Pandini V, 1999, BIOCHEMISTRY-US, V38, P10707, DOI 10.1021/bi990423h; Pesaresi P, 2002, PLANTA, V215, P940, DOI 10.1007/s00425-002-0835-0; Pursiheimo S, 2001, PLANT J, V26, P317, DOI 10.1046/j.1365-313X.2001.01033.x; REBEILLE F, 1986, ARCH BIOCHEM BIOPHYS, V249, P171, DOI 10.1016/0003-9861(86)90572-2; Redding K, 1999, J BIOL CHEM, V274, P10466, DOI 10.1074/jbc.274.15.10466; Rintamaki E, 2000, P NATL ACAD SCI USA, V97, P11644, DOI 10.1073/pnas.180054297; SCHEIBE R, 1981, FEBS LETT, V133, P301, DOI 10.1016/0014-5793(81)80529-7; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; SCHELLER HV, 2003, FUNCTIONAL CHARACTER; SCHREIBE R, 1988, PLANT PHYSIOL BIOCH, V26, P473; Shikanai T, 1998, P NATL ACAD SCI USA, V95, P9705, DOI 10.1073/pnas.95.16.9705; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; Varotto C, 2000, PLANT J, V22, P115, DOI 10.1046/j.1365-313x.2000.00717.x; WALTERS RG, 1994, PLANTA, V195, P248, DOI 10.1007/BF00199685; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; XU Q, 1994, J BIOL CHEM, V269, P21512; YAMAMOTO Y, 1993, PLANT MOL BIOL, V22, P985, DOI 10.1007/BF00028971; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	72	51	56	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33276	33283		10.1074/jbc.M305106200	http://dx.doi.org/10.1074/jbc.M305106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12794067	hybrid			2022-12-25	WOS:000184901800096
J	Hensley, LL; Ranganathan, G; Wagner, EM; Wells, BD; Daniel, JC; Vu, D; Semenkovich, CF; Zechner, R; Kern, PA				Hensley, LL; Ranganathan, G; Wagner, EM; Wells, BD; Daniel, JC; Vu, D; Semenkovich, CF; Zechner, R; Kern, PA			Transgenic mice expressing lipoprotein lipase in adipose tissue - Absence of the proximal 3 '-untranslated region causes translational upregulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; MUSCLE-SPECIFIC OVEREXPRESSION; ISOLATED RAT ADIPOCYTES; 3' UNTRANSLATED REGION; MESSENGER-RNA LEVELS; GENE-EXPRESSION; ENZYME-ACTIVITY; ORNITHINE DECARBOXYLASE; CHOLESTEROL LEVELS; 3T3-L1 ADIPOCYTES	Lipoprotein lipase (LPL) is a key enzyme in lipoprotein and adipocyte metabolism. Defects in LPL can lead to hypertriglyceridemia and the subsequent development of atherosclerosis. The mechanisms of regulation of this enzyme are complex and may occur at multiple levels of gene expression. Because the 3'-untranslated region (UTR) is involved in LPL translational regulation, transgenic mice were generated with adipose tissue expression of an LPL construct either with or without the proximal 3'-UTR and driven by the aP2 promoter. Both transgenic mouse colonies were viable and expressed the transgene, resulting in a 2-fold increase in LPL activity in white adipose tissue. Neither mouse colony exhibited any obvious phenotype in terms of body weight, plasma lipids, glucose, and non-esterified fatty acid levels. In the mice expressing hLPL with an intact 3'-UTR, hLPL mRNA expression approximately paralleled hLPL activity. However in the mice without the proximal 3'-UTR, hLPL mRNA was low in the setting of large amounts of hLPL protein and LPL activity. In previous studies, the 3'-UTR of LPL was critical for the inhibitory effects of constitutively expressed hormones, such as thyroid hormone and catecholamines. Therefore, these data suggest that the absence of the 3'-UTR results in a translationally unrepressed LPL, resulting in a moderate overexpression of adipose LPL activity.	Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Little Rock, AR 72205 USA; Karl Franzens Univ Graz, Inst Mol Biol Biochem & Microbiol, Graz, Austria; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences; University of Graz; Washington University (WUSTL)	Kern, PA (corresponding author), Cent Arkansas Vet Healthcare Syst, 4300 W 7th St, Little Rock, AR 72205 USA.			Zechner, Rudolf/0000-0001-5483-1182; Semenkovich, Clay/0000-0003-1163-1871	NHLBI NIH HHS [HL 58427] Funding Source: Medline; NIDDK NIH HHS [DK 39176] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039176, R29DK039176, R37DK039176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORNTORP P, 1978, J LIPID RES, V19, P316; CHNG JL, 1990, SCIENCE, V245, P1003; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; DESHAIES Y, 1993, HORM METAB RES, V25, P13, DOI 10.1055/s-2007-1002036; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; FRIED SK, 1989, J LIPID RES, V30, P1917; FRIEDMAN G, 1991, BIOCHIM BIOPHYS ACTA, V1082, P27, DOI 10.1016/0005-2760(91)90295-S; GIRALT M, 1990, BIOCHIM BIOPHYS ACTA, V1048, P270, DOI 10.1016/0167-4781(90)90066-B; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GREENWOOD MRC, 1985, INT J OBESITY, V9, P67; GRENS A, 1990, J BIOL CHEM, V265, P11810; Hoefler G, 1997, BIOCHIMIE, V79, P163, DOI 10.1016/S0300-9084(97)81509-X; HOLLENBERG CH, 1966, J CLIN INVEST, V45, P205, DOI 10.1172/JCI105333; JENSEN DR, 1997, AM J PHYSIOL, V273, pT9; KAHANA C, 1985, J BIOL CHEM, V260, P5390; Kern PA, 1996, J LIPID RES, V37, P2332; KERN PA, 1988, J CLIN INVEST, V81, P398, DOI 10.1172/JCI113332; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; Levak-Frank S, 1999, P NATL ACAD SCI USA, V96, P3165, DOI 10.1073/pnas.96.6.3165; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LIU MS, 1992, BIOCHIM BIOPHYS ACTA, V1128, P113, DOI 10.1016/0005-2760(92)90264-V; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1989, J BIOL CHEM, V264, P3177; ONG JM, 1992, ENDOCRINOLOGY, V130, P2310, DOI 10.1210/en.130.4.2310; Ong JM, 1995, METABOLISM, V44, P1596, DOI 10.1016/0026-0495(95)90081-0; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PREVIATO L, 1991, J BIOL CHEM, V266, P18958; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; Ranganathan S, 1998, J BIOL CHEM, V273, P26117, DOI 10.1074/jbc.273.40.26117; SAFFARI B, 1992, J LIPID RES, V33, P241; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SIMSOLO RB, 1992, J LIPID RES, V33, P89; SIMSOLO RB, 1993, J CLIN INVEST, V92, P2124, DOI 10.1172/JCI116813; SIMSOLO RB, 1992, J LIPID RES, V33, P1777; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	49	21	21	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32702	32709		10.1074/jbc.M304200200	http://dx.doi.org/10.1074/jbc.M304200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796491	hybrid			2022-12-25	WOS:000184901800028
J	Corker, H; Poole, RK				Corker, H; Poole, RK			Nitric oxide formation by Escherichia coli - Dependence on nitrite reductase, the NO-sensing regulator FNR, and flavohemoglobin Hmp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC CYTOCHROME-C; NITRATE REDUCTASE; NITROUS-OXIDE; ALKALINE-PHOSPHATASE; FLAVOHAEMOGLOBIN HMP; NITROSATIVE STRESS; ENTERIC BACTERIA; GENE-EXPRESSION; MUTATIONS; CATALYSIS	Nitric oxide (NO) is a key signaling and defense molecule in biological systems. The bactericidal effects of NO produced, for example, by macrophages are resisted by various bacterial NO-detoxifying enzymes, the best understood being the flavohemoglobins exemplified by Escherichia coli Hmp. However, many bacteria, including E. coli, are reported to produce NO by processes that are independent of denitrification in which NO is an obligatory intermediate. We demonstrate using an NO-specific electrode that E. coli cells, grown anaerobically with nitrate as terminal electron acceptor, generate significant NO on adding nitrite. The periplasmic cytochrome c nitrite reductase (Nrf) is shown, by comparing Nrf(+) and Nrf(-) mutants, to be largely responsible for NO generation. Surprisingly, an hmp mutant did not accumulate more NO but, rather, failed to produce detectable NO. Anaerobic growth of the hmp mutant was not stimulated by nitrate, and the mutant failed to produce periplasmic cytochrome(s) c, leading to the hypothesis that accumulating NO in the absence of Hmp inactivates the global anaerobic regulator Fnr by reaction with the [4Fe-4S](2+) cluster (Cruz-Ramos, H., Crack, J., Wu, G., Hughes, M. N., Scott, C., Thomson, A. J., Green, J., and Poole, R. K. (2002) EMBO J. 21, 3235-3244). Fnr thus failed to up-regulate nitrite reductase. The model is supported by the inability of an fnr mutant to generate NO and by the restoration of NO accumulation to hmp mutants upon introducing a plasmid encoding Fnr* (D154A) known to confer activity in the presence of oxygen. A cytochrome bd-deficient mutant retained NO-generating activity. The present study reveals a critical balance between NO-generating and -detoxifying activities during anaerobic growth.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Poole, RK (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.				Biotechnology and Biological Sciences Research Council [P18939] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ANDERSON IC, 1986, APPL ENVIRON MICROB, V51, P938, DOI 10.1128/AEM.51.5.938-945.1986; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BELL AI, 1990, MOL MICROBIOL, V4, P1753, DOI 10.1111/j.1365-2958.1990.tb00553.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BRONS HJ, 1991, ARCH MICROBIOL, V155, P341; CALMELS S, 1987, CARCINOGENESIS, V8, P1085, DOI 10.1093/carcin/8.8.1085; CALMELS S, 1988, J GEN MICROBIOL, V134, P221; CHEN YJ, 1995, J BACTERIOL, V177, P5122, DOI 10.1128/jb.177.17.5122-5128.1995; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; FUJITA T, 1966, J BIOCHEM-TOKYO, V60, P204, DOI 10.1093/oxfordjournals.jbchem.a128420; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; HADDOCK BA, 1976, BIOCHEM J, V154, P285, DOI 10.1042/bj1540285; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Huang X, 2002, PLANT PHYSIOL BIOCH, V40, P625, DOI 10.1016/S0981-9428(02)01401-8; HUBBARD JAM, 1983, FEBS LETT, V164, P241, DOI 10.1016/0014-5793(83)80293-2; HUBBARD JAM, 1985, MICROBIAL GAS METABO, P231; Hutchings MI, 2000, J BACTERIOL, V182, P6434, DOI 10.1128/JB.182.22.6434-6439.2000; JI XB, 1989, BIOCHEM ARCH, V5, P61; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; KALKOWSKI I, 1991, FEMS MICROBIOL LETT, V82, P107, DOI 10.1111/j.1574-6968.1991.tb04848.x; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; Mallick N, 2000, J PLANT PHYSIOL, V157, P40, DOI 10.1016/S0176-1617(00)80133-9; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Metheringham R, 1997, MICROBIOL-UK, V143, P2647, DOI 10.1099/00221287-143-8-2647; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; Mills CE, 2001, BIOCHEM J, V353, P207, DOI 10.1042/0264-6021:3530207; PAGE L, 1990, ARCH MICROBIOL, V154, P349, DOI 10.1007/BF00276530; Pittman MS, 2002, J BIOL CHEM, V277, P49841, DOI 10.1074/jbc.M205615200; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; POOLE RK, 1994, FEMS MICROBIOL LETT, V117, P217, DOI 10.1111/j.1574-6968.1994.tb06768.x; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; POPE NR, 1984, J GEN MICROBIOL, V130, P1279; Potter L, 2001, ADV MICROB PHYSIOL, V45, P51, DOI 10.1016/S0065-2911(01)45002-8; RALT D, 1988, J BACTERIOL, V170, P359, DOI 10.1128/jb.170.1.359-364.1988; Ren T, 2000, APPL ENVIRON MICROB, V66, P3891, DOI 10.1128/AEM.66.9.3891-3897.2000; SMITH MS, 1983, APPL ENVIRON MICROB, V45, P1545, DOI 10.1128/AEM.45.5.1545-1547.1983; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUVEN R, 1992, ARCH MICROBIOL, V158, P439; VASUDEVAN SG, 1995, FEMS MICROBIOL LETT, V125, P219, DOI 10.1016/0378-1097(94)00501-H; Wang HN, 2000, J BACTERIOL, V182, P5813, DOI 10.1128/JB.182.20.5813-5822.2000; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8; Weiss B, 2001, MUTAT RES-DNA REPAIR, V461, P301, DOI 10.1016/S0921-8777(00)00062-8; Weitzberg E, 1998, NITRIC OXIDE-BIOL CH, V2, P1, DOI 10.1006/niox.1997.0162; WU G, 2003, IN PRESS ADV MICROB, V47; Zhang X, 2000, MOD ASP IMMUNOBIOL, V1, P160; ZUMFT WG, 1993, ARCH MICROBIOL, V160, P253, DOI 10.1007/BF00292074; ZUMFT WG, 1997, MICROBIOL MOL BIOL R, V61, P253	66	136	140	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31584	31592		10.1074/jbc.M303282200	http://dx.doi.org/10.1074/jbc.M303282200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783887	hybrid			2022-12-25	WOS:000184782100018
J	Haan, S; Ferguson, P; Sommer, U; Hiremath, M; McVicar, DW; Heinrich, PC; Johnston, JA; Cacalano, NA				Haan, S; Ferguson, P; Sommer, U; Hiremath, M; McVicar, DW; Heinrich, PC; Johnston, JA; Cacalano, NA			Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNALING-3; MEDIATED DEGRADATION; PROTEIN INTERACTS; UBIQUITIN LIGASE; MOLECULAR-BASIS; KINASE-ACTIVITY; BOX MOTIF; SUPPRESSOR; RECEPTOR; VHL	The suppressors of cytokine signaling (SOCS) are negative feedback inhibitors of cytokine and growth factor-induced signal transduction. The C-terminal SOCS box region is thought to regulate SOCS protein stability most likely via an elongin C interaction. In the present study, we have found that phosphorylation of SOCS3 at two tyrosine residues in the conserved SOCS box, Tyr(204) and Tyr(221), can inhibit the SOCS3-elongin C interaction and activate proteasome-mediated SOCS3 degradation. Jak-mediated phosphorylation of SOCS3 decreased SOCS3 protein half-life, and phosphorylation of both Tyr(204) and Tyr(221) was required to fully destabilize SOCS3. In contrast, a phosphorylation-deficient mutant of SOCS3, Y204F, Y221F, remained stable in the presence of activated Jak2 and receptor tyrosine kinases. SOCS3 stability correlated with the relative amount that bound elongin C, because in vitro phosphorylation of a SOCS3-glutathione S-transferase fusion protein abolished its ability to interact with elongin C. In addition, a SOCS3/SOCS1 chimera that co-precipitates with markedly increased elongin C, was significantly more stable than wild-type SOCS3. The data suggest that interaction with elongin C stabilizes SOCS3 protein expression and that phosphorylation of SOCS box tyrosine residues disrupts the complex and enhances proteasome-mediated degradation of SOCS3.	Queens Univ Belfast, Dept Immunol, Belfast BT9 7BL, Antrim, North Ireland; Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Radiat Oncol, Los Angeles, CA 90095 USA	Queens University Belfast; RWTH Aachen University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles	Johnston, JA (corresponding author), Queens Univ Belfast, Sch Med, Dept Microbiol & Immunol, Rm 226,Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	jim.johnston@qub.ac.uk	McVicar, Daniel/G-1970-2015	McVicar, Daniel/0000-0002-1112-5111				Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; Grignani F, 1998, CANCER RES, V58, P14; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Hortner M, 2002, EUR J BIOCHEM, V269, P2516, DOI 10.1046/j.1432-1033.2002.02916.x; Jaleco AC, 1999, BLOOD, V94, P2637, DOI 10.1182/blood.V94.8.2637.420k22_2637_2646; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Onishi M, 1996, EXP HEMATOL, V24, P324; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Staal FJT, 1996, CANCER GENE THER, V3, P345; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Toniato E, 2002, J BIOL CHEM, V277, P37315, DOI 10.1074/jbc.M205900200; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498	53	86	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31972	31979		10.1074/jbc.M303170200	http://dx.doi.org/10.1074/jbc.M303170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12783885	hybrid			2022-12-25	WOS:000184782100066
J	Sot, B; Banuelos, S; Valpuesta, JM; Muga, A				Sot, B; Banuelos, S; Valpuesta, JM; Muga, A			GroEL stability and function - Contribution of the ionic interactions at the inter-ring contact sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHAPERONIN GROEL; SALT BRIDGES; INFRARED-SPECTROSCOPY; THERMAL-DENATURATION; CRYSTAL-STRUCTURE; PROTEIN; ATP; ASYMMETRY; CYCLE	The chaperonin GroEL consists of a double ring structure made of identical subunits that display different modes of allosteric communication. The protein folding cycle requires the simultaneous positive intra-ring and negative inter-ring cooperativities of ATP binding. This ensures GroES binding to one ring and release of the ligands from the opposite one. To better characterize interring allosterism, the thermal stability as well as the temperature dependence of the functional and conformational properties of wild type GroEL, a single ring mutant (SR1) and two single point mutants suppressing one interring salt bridge (E434K and E461K) were studied. The results indicate that ionic interactions at the two interring contact sites are essential to maintain the negative cooperativity for protein substrate binding and to set the protein thermostat at 39degreesC. These electrostatic interactions contribute distinctly to the stability of the inter-ring interface and the overall protein stability, e.g. the E434K thermal inactivation curve is shifted to lower temperatures, and its unfolding temperature and activation energy are also lowered. An analysis of the ionic interactions at the inter-ring contact sites reveals that at the so called "left site" a network of electrostatic interactions involving three charged residues might be established, in contrast to what is found at the "right site" where only two oppositely charged residues interact. Our data suggest that electrostatic interactions stabilize protein-protein interfaces depending on both the number of ionic interactions and the number of residues engaged in each of these interactions. In the case of GroEL, this combination sets the thermostat of the protein so that the chaperonin distinguishes physiological from stress temperatures.	Univ Basque Country, CSIC, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, CSIC, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Muga, A (corresponding author), Univ Basque Country, CSIC, Unidad Biofis, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Muga, Arturo/N-1174-2014; Valpuesta, Jose M/AAA-6002-2019; Sot, Begoña/H-2882-2015; Bañuelos, Sonia/N-9128-2019; Valpuesta, José M/T-1977-2017	Muga, Arturo/0000-0003-0345-6882; Sot, Begoña/0000-0001-8763-0651; Bañuelos, Sonia/0000-0002-1399-381X; Valpuesta, José M/0000-0001-7468-8053				Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Clark AC, 1998, METHOD ENZYMOL, V290, P100; Dong F, 2002, BIOPHYS J, V83, P1341, DOI 10.1016/S0006-3495(02)73904-0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Galan A, 1999, EUR J BIOCHEM, V259, P347, DOI 10.1046/j.1432-1327.1999.00045.x; GALISTEO ML, 1991, BIOCHEMISTRY-US, V30, P2061, DOI 10.1021/bi00222a009; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Horwich AL, 1998, METHOD ENZYMOL, V290, P141, DOI 10.1016/S0076-6879(98)90013-1; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LEPOCK JR, 1992, BIOCHEMISTRY-US, V27, P1648; Llorca O, 1997, J BIOL CHEM, V272, P32925, DOI 10.1074/jbc.272.52.32925; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; PEREZPEREZ J, 1995, GENE, V158, P141, DOI 10.1016/0378-1119(95)00127-R; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; Sanchez Ruiz J. M., 1988, BIOCHEMISTRY-US, V27, P1648; Sheinerman FB, 2002, J MOL BIOL, V318, P161, DOI 10.1016/S0022-2836(02)00030-X; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sot B, 2002, J BIOL CHEM, V277, P34024, DOI 10.1074/jbc.M205733200; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Takano K, 2000, BIOCHEMISTRY-US, V39, P12375, DOI 10.1021/bi000849s; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	30	22	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32083	32090		10.1074/jbc.M303958200	http://dx.doi.org/10.1074/jbc.M303958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12796493	hybrid			2022-12-25	WOS:000184782100079
J	Niedernhofer, LJ; Daniels, JS; Rouzer, CA; Greene, RE; Marnett, LJ				Niedernhofer, LJ; Daniels, JS; Rouzer, CA; Greene, RE; Marnett, LJ			Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTRAND CROSS-LINK; NUCLEOTIDE EXCISION-REPAIR; SHUTTLE VECTOR PLASMID; ESCHERICHIA-COLI; MASS-SPECTROMETRY; POINT MUTATIONS; SALMONELLA-TYPHIMURIUM; DECOMPOSITION PRODUCT; LIQUID-CHROMATOGRAPHY; DEOXYGUANOSINE ADDUCT	Malondialdehyde (MDA) is an endogenous genotoxic product of enzymatic and oxygen radical-induced lipid peroxidation whose adducts are known to exist in DNA isolated from healthy human beings. To evaluate the mutagenic potential of MDA in human cells, we reacted MDA with pSP189 shuttle vector DNA and then transfected them into human fibroblasts for replication. MDA induced up to a 15-fold increase in mutation frequency in the supF reporter gene compared with untreated DNA. Sequence analysis revealed that the majority of MDA-induced mutations occurred at GC base pairs. The most frequent mutations were large insertions and deletions, but base pair substitutions were also detected. MDA-induced mutations were completely abolished when the adducted shuttle vector was replicated in cells lacking nucleotide excision repair. MDA induction of large deletions and the apparent requirement for nucleotide excision repair suggested the possible involvement of a DNA interstrand cross-link as a premutagenic lesion. Indeed, MDA formed interstrand cross-links in duplex plasmids and oligonucleotides. Substrates containing the sequence 5'-d(CG) were preferentially crosslinked, consistent with the observation of base pair substitutions in 5'-d( CG) sites in the MDA-induced mutation spectrum. These experiments provide biological and biochemical evidence for the existence of MDA-induced DNA interstrand cross-links that could result from endogenous oxidative stress and likely have potent biological effects.	Vanderbilt Univ, Sch Med,AB Hancock Jr Mem Lab Canc Res, Vanderbilt Inst Chem Biol,Dept Biochem, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Inst Chem Biol,Dept Chem, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med,AB Hancock Jr Mem Lab Canc Res, Vanderbilt Inst Chem Biol,Dept Biochem, Vanderbilt Ingram Comprehens Canc Ctr, 221 Kirkland Hall, Nashville, TN 37232 USA.			Rouzer, Carol/0000-0001-6827-1534	NATIONAL CANCER INSTITUTE [R35CA047479, R37CA087819, R01CA087819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA87819, CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BASU AK, 1984, MUTAT RES, V129, P39, DOI 10.1016/0027-5107(84)90121-0; BASU AK, 1988, CHEM RES TOXICOL, V1, P53, DOI 10.1021/tx00001a010; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BASU AK, 1984, CANCER RES, V44, P2848; BENAMIRA M, 1995, CARCINOGENESIS, V16, P93, DOI 10.1093/carcin/16.1.93; Bessho T, 2003, J BIOL CHEM, V278, P5250, DOI 10.1074/jbc.M212323200; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; BREDBERG A, 1995, CARCINOGENESIS, V16, P555, DOI 10.1093/carcin/16.3.555; Chaudhary AK, 1996, CARCINOGENESIS, V17, P1167, DOI 10.1093/carcin/17.5.1167; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; Dooley PA, 2001, J AM CHEM SOC, V123, P1730, DOI 10.1021/ja003163w; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; ESTERBAUER H, 1993, AM J CLIN NUTR, V57, P779, DOI 10.1093/ajcn/57.5.779S; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; HARTLEY JA, 1991, ANAL BIOCHEM, V193, P131, DOI 10.1016/0003-2697(91)90052-U; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JABERABOANSARI A, 1991, RADIAT RES, V127, P202, DOI 10.2307/3577966; Johnson KA, 1999, J BIOL CHEM, V274, P27112, DOI 10.1074/jbc.274.38.27112; Kadlubar FF, 1998, MUTAT RES-FUND MOL M, V405, P125, DOI 10.1016/S0027-5107(98)00129-8; KALININA NN, 1962, ZH OBSHCH KHIM+, V32, P2146; KONDO S, 1970, GENETICS, V66, P187; LARGILLIERE C, 1988, ANAL BIOCHEM, V170, P123, DOI 10.1016/0003-2697(88)90098-X; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAH MCM, 1991, P NATL ACAD SCI USA, V88, P10193, DOI 10.1073/pnas.88.22.10193; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MARNETT LJ, 1986, J AM CHEM SOC, V108, P1348, DOI 10.1021/ja00266a065; MARNETT LJ, 1985, MUTAT RES, V148, P25; MARNETT LJ, 1979, ANAL BIOCHEM, V99, P458, DOI 10.1016/S0003-2697(79)80033-0; MILLARD JT, 1991, NUCLEIC ACIDS RES, V19, P1885, DOI 10.1093/nar/19.8.1885; MILLARD JT, 1990, J AM CHEM SOC, V112, P2459, DOI 10.1021/ja00162a079; MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283; Moses RE, 2001, ANNU REV GENOM HUM G, V2, P41, DOI 10.1146/annurev.genom.2.1.41; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; MUKAI FH, 1976, SCIENCE, V191, P868, DOI 10.1126/science.766187; OHARA SM, 1991, MUTAT RES, V247, P45, DOI 10.1016/0027-5107(91)90032-J; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; ROUTLEDGE MN, 1993, CARCINOGENESIS, V14, P1251, DOI 10.1093/carcin/14.7.1251; Rouzer CA, 1997, CHEM RES TOXICOL, V10, P181, DOI 10.1021/tx9601216; Sambrook J., 2002, MOL CLONING LAB MANU; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; SETO H, 1981, CHEM LETT, P707, DOI 10.1246/cl.1981.707; SETO H, 1983, B CHEM SOC JPN, V56, P1799, DOI 10.1246/bcsj.56.1799; Sevilla CL, 1997, CHEM RES TOXICOL, V10, P172, DOI 10.1021/tx960120d; Sharma RA, 2001, CLIN CANCER RES, V7, P1452; SINGER B, 1982, ANNU REV BIOCHEM, V52, P655; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; STONE K, 1990, CHEM RES TOXICOL, V3, P467, DOI 10.1021/tx00017a013; STONE K, 1990, CHEM RES TOXICOL, V3, P33, DOI 10.1021/tx00013a006; TANG MS, 1983, CARCINOGENESIS, V4, P1001, DOI 10.1093/carcin/4.8.1001; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WANG P, 1990, CANCER RES, V50, P7527; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; WEIDNER MF, 1990, BIOCHEMISTRY-US, V29, P9225, DOI 10.1021/bi00491a017; YANG JL, 1987, P NATL ACAD SCI USA, V84, P3787, DOI 10.1073/pnas.84.11.3787; YAU TM, 1979, MECH AGEING DEV, V11, P137, DOI 10.1016/0047-6374(79)90031-9; YEO HC, 1994, ANAL BIOCHEM, V220, P391, DOI 10.1006/abio.1994.1355; YONEI S, 1981, MUTAT RES, V88, P23, DOI 10.1016/0165-1218(81)90086-0; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	62	364	373	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31426	31433		10.1074/jbc.M212549200	http://dx.doi.org/10.1074/jbc.M212549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12775726	hybrid			2022-12-25	WOS:000184658800126
J	Polevoda, B; Cardillo, TS; Doyle, TC; Bedi, GS; Sherman, F				Polevoda, B; Cardillo, TS; Doyle, TC; Bedi, GS; Sherman, F			Nat3p and Mdm20p are required for function of yeast NatB N alpha-terminal acetyltransferase and of actin and tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTOMYOSIN INTERACTIONS; MUTATIONAL ANALYSIS; RIBONUCLEOTIDE REDUCTASE; EUKARYOTIC PROTEINS; CHARGED RESIDUES; SMALL-SUBUNIT; NH2 TERMINUS; ACETYLATION; MYOSIN	NatB Nalpha-terminal acetyltransferase of Saccharomyces cerevisiae acts cotranslationally on proteins with Met-Glu- or Met-Asp-termini and subclasses of proteins with Met-Asn- and Met-Met-termini. NatB is composed of the interacting Nat3p and Mdm20p subunits, both of which are required for acetyltransferase activity. The phenotypes of nat3-Delta and mdm20-Delta mutants are identical or nearly the same and include the following: diminished growth at elevated temperatures and on hyperosmotic and nonfermentable media; diminished mating; defective actin cables formation; abnormal mitochondrial and vacuolar inheritance; inhibition of growth by DNA-damaging agents such as methyl methanesulfonate, bleomycin, camptothecin, and hydroxyurea; and inhibition of growth by the antimitotic drugs benomyl and thiabendazole. The similarity of these phenotypes to the phenotypes of certain act1 and tpm1 mutants suggests that such multiple defects are caused by the lack of acetylation of actin and tropomyosins. However, the lack of acetylation of other unidentified proteins conceivably could cause the same phenotypes. Furthermore, unacetylated actin and certain N-terminally altered actins have comparable defective properties in vitro, particularly actin-activated ATPase activity and sliding velocity.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Inst Mol Biol, Los Angeles, CA 90095 USA	University of Rochester; University of Rochester; University of California System; University of California Los Angeles	Sherman, F (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	Fred_Sherman@urmc.rochester.edu	Polevoda, Bogdan/A-4880-2008	Doyle, Timothy/0000-0002-3899-1239	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014682] Funding Source: NIH RePORTER; NCRR NIH HHS [RR14682] Funding Source: Medline; NIGMS NIH HHS [GM12702] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Chang M, 2002, P NATL ACAD SCI USA, V99, P16934, DOI 10.1073/pnas.262669299; CHO YJ, 1990, J BIOL CHEM, V265, P538; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1993, J BIOL CHEM, V268, P2410; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CROSBIE RH, 1994, BIOCHEMISTRY-US, V33, P3210, DOI 10.1021/bi00177a010; Doyle TC, 2001, BIOPHYS J, V80, P427, DOI 10.1016/S0006-3495(01)76025-0; Doyle Timothy C, 2002, Results Probl Cell Differ, V36, P31; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Evangelista M, 2002, NAT CELL BIOL, V4, P41; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P894, DOI 10.1021/bi00806a026; Hermann GJ, 1997, J CELL BIOL, V137, P141, DOI 10.1083/jcb.137.1.141; HERMANN GJ, 1998, THESIS U UTAH SALT L; HITCHCOCKDEGREGORI SE, 1994, ADV EXP MED BIOL, V358, P85; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; Kimura Y, 2000, J BIOL CHEM, V275, P4635, DOI 10.1074/jbc.275.7.4635; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; LEE FJS, 1989, FEBS LETT, V256, P139, DOI 10.1016/0014-5793(89)81734-X; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; Maytum R, 2000, BIOCHEMISTRY-US, V39, P11913, DOI 10.1021/bi000977g; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P3670, DOI 10.1021/bi952645v; MILLER CJ, 1995, BIOCHEMISTRY-US, V34, P2694, DOI 10.1021/bi00008a037; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; MILLER CJ, 1995, BIOPHYS J S, V68, P50; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Ni L, 2001, MOL BIOL CELL, V12, P2147, DOI 10.1091/mbc.12.7.2147; OGUR M, 1959, GENETICS, V44, P484; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 2001, J BIOL CHEM, V276, P20154, DOI 10.1074/jbc.M011440200; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Singer JM, 2000, GENETICS, V156, P523; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; WERTMAN KF, 1992, GENETICS, V132, P337; Wong WNW, 1999, BIOCHEMISTRY-US, V38, P1365, DOI 10.1021/bi982467g; Yarm F, 2001, CURR OPIN MICROBIOL, V4, P696, DOI 10.1016/S1369-5274(01)00271-5	55	87	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30686	30697		10.1074/jbc.M304690200	http://dx.doi.org/10.1074/jbc.M304690200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12783868	hybrid			2022-12-25	WOS:000184658800034
J	Szczesna-Skorupa, E; Mallah, B; Kemper, B				Szczesna-Skorupa, E; Mallah, B; Kemper, B			Fluorescence resonance energy transfer analysis of cytochromes P4502C2 and 2E1 molecular interactions in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; RAT GABA TRANSPORTER-1; PHOSPHOLIPID-VESICLES; NH2-TERMINAL REGION; TRANSFER MICROSCOPY; PROTEIN ROTATION; LIVER-MICROSOMES; ESCHERICHIA-COLI; P-450 REDUCTASE; RABBIT LIVER	The molecular organization of microsomal cytochromes P450 (P450s) and formation of complexes with P450 reductase have been studied previously with isolated proteins and in reconstituted systems. Although these studies demonstrated that some P450s oligomerize in vitro, neither oligomerization nor interactions of P450 with P450 reductase have been studied in living cells. Here we have used fluorescence resonance energy transfer (FRET) to study P450 oligomerization and binding to P450 reductase in live transfected cells. Cytochrome P450 2C2, but not P450 2E1, forms homo-oligomeric structures, and this self-association is mediated by the signal-anchor sequence. Because P450 2C2, in contrast to P450 2E1, is directly retained in the endoplasmic reticulum (ER), these results could suggest that oligomerization may prevent transport from the ER. However, P450 2C1 signal-anchor sequence chimera defective in ER retention also formed oligomers, and chimera containing the cytoplasmic domain of P450 2C2, which is directly retained in the ER, did not exhibit self-oligomerization, which indicates that oligomerization is not correlated with direct retention. By using FRET, we have also detected binding of P450 2C2 and P450 2E1 to P450 reductase. In contrast to self-oligomerization, the catalytic domain can mediate an interaction of P450 2C2 with P450 reductase. These results suggest that microsomal P450s may differ in their quaternary structure but that these differences do not detectably affect interaction with the reductase or transport from the ER.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 407 S Goodwin Ave, Urbana, IL 61801 USA.	byronkem@life.uiuc.edu			NIGMS NIH HHS [GM35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSTON K, 1991, J BIOL CHEM, V266, P735; Backes WL, 1998, BIOCHEMISTRY-US, V37, P12852, DOI 10.1021/bi980674a; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Cawley GF, 2001, DRUG METAB DISPOS, V29, P1529; Eliasson E, 1996, MOL PHARMACOL, V50, P573; ESTABROOK RW, 1971, METABOLISM, V20, P187, DOI 10.1016/0026-0495(71)90091-6; GUT J, 1982, J BIOL CHEM, V257, P7030; GUT J, 1983, J BIOL CHEM, V258, P8588; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hoa GHB, 2002, BBA-PROTEIN STRUCT M, V1595, P297, DOI 10.1016/S0167-4838(01)00352-1; KANAEVA IP, 1992, ARCH BIOCHEM BIOPHYS, V298, P395, DOI 10.1016/0003-9861(92)90427-X; KAWATO S, 1982, J BIOL CHEM, V257, P7023; KAWATO S, 1991, J BIOCHEM-TOKYO, V109, P587, DOI 10.1093/oxfordjournals.jbchem.a123424; Kucik DF, 1999, BIOPHYS J, V76, P314, DOI 10.1016/S0006-3495(99)77198-5; Latif R, 2001, J BIOL CHEM, V276, P45217, DOI 10.1074/jbc.M103727200; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; Muller-Enoch D, 2000, Z NATURFORSCH C, V55, P747; MYASOEDOVA KN, 1990, FEBS LETT, V275, P235, DOI 10.1016/0014-5793(90)81479-8; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; Omata Y, 2000, J PROTEIN CHEM, V19, P23, DOI 10.1023/A:1007038724874; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; PERNECKY SJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P446, DOI 10.1006/abbi.1995.1253; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; SCHWARZ D, 1990, BIOCHEM BIOPH RES CO, V171, P175, DOI 10.1016/0006-291X(90)91373-Z; SCHWARZ D, 1982, ARCH BIOCHEM BIOPHYS, V216, P322, DOI 10.1016/0003-9861(82)90217-X; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Szczesna-Skorupa E, 2001, J BIOL CHEM, V276, P45009, DOI 10.1074/jbc.M104676200; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; VOZNESENSKY AI, 1994, BIOCHEM BIOPH RES CO, V203, P156, DOI 10.1006/bbrc.1994.2162; WU ES, 1984, BIOCHEMISTRY-US, V23, P28, DOI 10.1021/bi00296a005; Xia ZP, 2001, J BIOL CHEM, V276, P1766, DOI 10.1074/jbc.M008741200; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P10113, DOI 10.1021/bi00032a003; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125	41	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31269	31276		10.1074/jbc.M301489200	http://dx.doi.org/10.1074/jbc.M301489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12766165	hybrid			2022-12-25	WOS:000184658800106
J	Guo, YJ; Philip, F; Scarlata, S				Guo, YJ; Philip, F; Scarlata, S			The pleckstrin homology domains of phospholipases C-beta and -delta confer activation through a common site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING PROPERTIES; HETEROTRIMERIC G-PROTEINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; HIGH-AFFINITY; BILAYER-MEMBRANES; CRYSTAL-STRUCTURE; GAMMA-SUBUNITS; C-BETA(1); C-DELTA(1); IDENTIFICATION	Mammalian inositol-specific phospholipase C-beta(2) (PLCbeta(2)) and PLCdelta(1) differ in their cellular activators. PLCbeta(2) can be activated by Gbetagamma subunits, whereas PLCdelta(1) can be activated by phosphatidylinositol 4,5 bisphosphate (PI(4,5) P-2). For both proteins, the N-terminal pleckstrin homology (PH) domain appears to mediate activation. Here, we have constructed a chimera in which we placed the N-terminal PH domain of PLCdelta(1) into remaining C-terminal regions of PLCbeta(2). The PHdeltaPLCbeta chimera showed PI(4,5)P-2-dependent membrane binding similar to PLCdelta(1) and a Gbetagamma interaction energy close to that of PLCdelta(1). Like PLCdelta(1), the chimera was activated by PI( 4,5) P2 through the PH domain but not by Gbetagamma. Because these and previous results indicate a common site of contact between the PH and catalytic domains in these two enzymes, we computationally docked the known structures of the PH and catalytic domains of PLCdelta(1). A synthetic peptide whose sequence matches a potential interaction site between the two domains inhibited the basal activity of PLCbeta(2), PLCdelta(1), and a Gbetagamma-activable PHbeta(2)-PLCdelta(1) chimera. Also, the peptide was able to inhibit PI(4,5) P-2 and Gbetagamma activation of the PH-PLCdelta(1) PH-PLCbeta(2) enzymes in a concentration-dependent manner, suggesting that this is the region responsible for PH domain-mediated activation of the catalytic core.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Scarlata, S (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.				NIGMS NIH HHS [GM53132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053132] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; Jenco JM, 1997, BIOCHEM J, V327, P431; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE SB, 1993, J BIOL CHEM, V268, P25952; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; PARK DG, 1993, J BIOL CHEM, V268, P3710; Philip F, 2002, FEBS LETT, V531, P28, DOI 10.1016/S0014-5793(02)03411-7; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; Wang T, 1999, P NATL ACAD SCI USA, V96, P7843, DOI 10.1073/pnas.96.14.7843; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; WU DQ, 1993, J BIOL CHEM, V268, P3704	25	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29995	30004		10.1074/jbc.M301438200	http://dx.doi.org/10.1074/jbc.M301438200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761218	hybrid			2022-12-25	WOS:000184507000074
J	Miyamoto, Y; Yamauchi, J; Itoh, H				Miyamoto, Y; Yamauchi, J; Itoh, H			Src kinase regulates the activation of a novel FGD-1-related Cdc42 guanine nucleotide exchange factor in the signaling pathway from the endothelin A receptor to JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; N-TERMINAL KINASE; EZRIN-LIKE DOMAIN; GUANOSINE TRIPHOSPHATASES; P115 RHOGEF; RAC; FAMILY	Small GTPases act as binary switches by cycling between an inactive (GDP-bound) and an active (GTP-bound) state. Upon stimulation with extracellular signals, guanine-nucleotide exchange factors ( GEFs) stimulate the exchange of GDP to GTP to shift toward the active forms of small GTPases, recognizing the downstream targets. Here we show that KIAA0793, containing substantial sequence homology with the catalytic Dbl homology domain of the faciogenital dysplasia gene product (FGD1), is a specific GEF for Cdc42. We, therefore, tentatively named it FRG (FGD1-related Cdc42-GEF). Src kinase directly phosphorylates and activates FRG, as Vav family GEFs. Additionally, FRG is involved in the signaling pathway from the endothelin A receptor to c-Jun N-terminal kinase, resulting in the inhibition of cell motility. These results suggest that FRG is a member of Cdc42-GEF and plays an important role in the signaling pathway downstream of G protein-coupled receptors.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Nara 6300101, Japan; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Nara Institute of Science & Technology; Stanford University	Itoh, H (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, 8916-5 Takayama, Nara 6300101, Japan.	hitoh@bs.aist-nara.ac.jp						Abe Y, 2000, J BIOL CHEM, V275, P8664, DOI 10.1074/jbc.275.12.8664; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HART MJ, 1994, J BIOL CHEM, V270, P18388; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Koyano Y, 2001, OSTEOARTHR CARTILAGE, V9, pS64, DOI 10.1053/joca.2001.0446; Koyano Y, 1997, BIOCHEM BIOPH RES CO, V241, P369, DOI 10.1006/bbrc.1997.7826; Kubo T, 2002, J NEUROSCI, V22, P8504; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Pasteris NG, 2000, GENE, V242, P237, DOI 10.1016/S0378-1119(99)00518-1; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rohrer DK, 1998, PHYSIOL REV, V78, P35, DOI 10.1152/physrev.1998.78.1.35; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; VAN AL, 1997, GENE DEV, V11, P2295; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; WHITEHEAD I, 1995, J BIOL CHEM, V269, P62; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi J, 2002, BIOCHEM BIOPH RES CO, V296, P85, DOI 10.1016/S0006-291X(02)00839-2; Yamauchi J, 2002, FEBS LETT, V527, P284, DOI 10.1016/S0014-5793(02)03231-3; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V288, P1087, DOI 10.1006/bbrc.2001.5891; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V284, P1199, DOI 10.1006/bbrc.2001.5103; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169	61	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29890	29900		10.1074/jbc.M301559200	http://dx.doi.org/10.1074/jbc.M301559200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12771149	hybrid			2022-12-25	WOS:000184507000062
J	Nilsson, I; Johnson, AE; von Heijne, G				Nilsson, I; Johnson, AE; von Heijne, G			How hydrophobic is alanine?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; MODEL TRANSMEMBRANE HELIX; TURN PROPENSITY SCALE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; SIGNAL PEPTIDASE; STOP-TRANSFER; SEGMENTS; SEQUENCE; SITE	By a number of measures, alanine is poised at the threshold between those amino acids that promote the membrane integration of transmembrane alpha-helices and those that do not. We have measured the preference of alanine to partition into the lipid-water interface region over the central acyl chain region of the endoplasmic reticulum (ER) membrane both by its ability to promote the formation of so-called helical hairpins, i.e. a pair of transmembrane helices separated by a tight turn, and by mapping the position relative to the membrane of the lumenal end of a transmembrane alpha-helix that ends with a block of 10 alanines. Both measures show that Ala has a weak but distinct preference for the interface region, which is in agreement with recent biophysical measurements on pentaeptide partitioning in simple water-lipid or water-octanol systems (Jayasinghe, S., Hristova, K., and White, S. H. ( 2001) J. Mol. Biol. 312, 927 - 934). Considering the complexity of the translocon-mediated insertion of membrane proteins into the ER, the agreement between the biochemical and biophysical measurements is striking and suggests that protein-lipid interactions are already important during the very early steps of membrane protein assembly in the ER.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Texas A&M Univ Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Stockholm University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	von Heijne, G (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.		von Heijne, Gunnar/F-5576-2011; Nilsson, IngMarie/H-2887-2012; Johnson, Arthur E/G-3457-2012; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 	NIGMS NIH HHS [GM 26494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arkin IT, 1998, BBA-PROTEIN STRUCT M, V1429, P113, DOI 10.1016/S0167-4838(98)00225-8; Bechinger B, 2001, FEBS LETT, V504, P161, DOI 10.1016/S0014-5793(01)02741-7; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Chen XM, 2001, J BIOL CHEM, V276, P2411, DOI 10.1074/jbc.M007723200; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; Hermansson M, 2001, J MOL BIOL, V313, P1171, DOI 10.1006/jmbi.2001.5108; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Kajava AV, 2002, J BIOL CHEM, V277, P50396, DOI 10.1074/jbc.M205781200; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; LILJESTROM P, 1991, J VIROL, V65, P147; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Monne M, 1999, J MOL BIOL, V288, P141, DOI 10.1006/jmbi.1999.2657; Monne M, 1999, J MOL BIOL, V293, P807, DOI 10.1006/jmbi.1999.3183; Monne M, 2001, FEBS LETT, V496, P96, DOI 10.1016/S0014-5793(01)02415-2; Monne M, 1998, J MOL BIOL, V284, P1177, DOI 10.1006/jmbi.1998.2218; Nilsson I, 1998, J MOL BIOL, V284, P1185, DOI 10.1006/jmbi.1998.2219; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Sheng ZF, 1997, BIOCHEMISTRY-US, V36, P15501; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; von Herrath MG, 2000, ANN MED, V32, P285, DOI 10.3109/07853890008995930; VONHEIJINE G, 1987, SEQUENCE ANAL MOL BI, P98; WALTER P, 1983, METHOD ENZYMOL, V96, P84; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WOLFE PB, 1983, J BIOL CHEM, V258, P2073	33	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29389	29393		10.1074/jbc.M212310200	http://dx.doi.org/10.1074/jbc.M212310200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761228	hybrid			2022-12-25	WOS:000184507000002
J	Winzen, U; Cole, GJ; Halfter, W				Winzen, U; Cole, GJ; Halfter, W			Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; IDENTIFICATION; BINDING; DIFFERENTIATION; RECOGNITION; MECHANISMS; PROTEINS; LIGANDS; SIGNAL; DOMAIN	Agrin is a large extracellular matrix protein that plays a key role in the formation and maintenance of the vertebrate neuromuscular junction. The amino acid sequence of agrin encodes a protein with a molecular size of 220 kDa, whereas SDS-PAGE shows a diffuse band around 400 kDa. Further studies showed that agrin is highly glycosylated and belongs to the family of heparan sulfate proteoglycans. By expressing different protein fragments, we localized the glycosaminoglycan (GAG) attachment sites to two locations within the agrin molecule. One site that is located between the seventh and eight follistatin-like domain includes 3 closely spaced serine-glycine (SG) consensus sequences and carries exclusively heparan sulfate side chains. The second site is located further downstream in the centrally located serine-threonine-rich domain and contains a cluster of 4 closely packed SG consensus sequences. This site predominantly carries chondroitin sulfate side chains. Investigating the contribution of individual serines in GAG priming by site-directed mutagenesis showed that each serine of the two SG clusters has the potential to carry GAGs. In accordance with the mixed GAG glycosylation of agrin peptide fragments, it was found that recombinant and in vivo-derived full-length agrin are not exclusively heparan sulfate proteoglycans but also carry chondroitin sulfate side chains.	Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA; N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; North Carolina State University	Halfter, W (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, E1402 BST, Pittsburgh, PA 15261 USA.				NINDS NIH HHS [NS33981-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033981] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; Bixby JL, 2002, J NEUROBIOL, V50, P164, DOI 10.1002/neu.10025; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Campagna JA, 1995, NEURON, V15, P1365, DOI 10.1016/0896-6273(95)90014-4; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cotman SL, 2000, MOL CELL NEUROSCI, V15, P183, DOI 10.1006/mcne.1999.0816; Cotman SL, 1999, EXP CELL RES, V249, P54, DOI 10.1006/excr.1999.4463; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Halfter W, 1997, J COMP NEUROL, V383, P1; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Meier T, 1998, EUR J NEUROSCI, V10, P3141, DOI 10.1046/j.1460-9568.1998.00320.x; RODEN L, 1985, FED PROC, V44, P373; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	20	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30106	30114		10.1074/jbc.M212676200	http://dx.doi.org/10.1074/jbc.M212676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12773545	hybrid			2022-12-25	WOS:000184507000088
J	Marionnet, C; Lalou, C; Mollier, K; Chazal, M; Delestaing, G; Compan, D; Verola, O; Vilmer, C; Cuminet, J; Dubertret, L; Basset-Seguin, N				Marionnet, C; Lalou, C; Mollier, K; Chazal, M; Delestaing, G; Compan, D; Verola, O; Vilmer, C; Cuminet, J; Dubertret, L; Basset-Seguin, N			Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development	ONCOGENE			English	Article						DNA macroarray; basal cell carcinoma; squamous cell carcinoma	EXPRESSION; CANCER; PATHWAY; CARCINOGENESIS; MUTATIONS; EMMPRIN; RHOC	Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are skin tumors with different invasive potential. In this work, we analysed mRNA differential expression between seven BCC and five SCC and their normal skin counterparts using 1176 cDNA macroarrays and verification by RT-PCR to identify genes modulated in each tumor type. We identified 37 genes commonly modulated in both tumors and four genes specifically modulated in SCC. Among these latter RhoC and EMMPRIN genes seem to be of particular interest and could participate in SCC aggressivity.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Hop St Louis, IRP, Serv Stat, F-75010 Paris, France; Hop St Louis, Serv Anat Pathol, F-75010 Paris, France; Hop St Louis, Serv Chirurg Plast, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Basset-Seguin, N (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	nbs@chu-stlouis.fr		LALOU, Claude/0000-0002-5271-7439				Asch PH, 1999, AM J DERMATOPATH, V21, P146, DOI 10.1097/00000372-199904000-00006; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; BISWAS C, 1995, CANCER RES, V55, P434; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Harris CC, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P115; Kallassy M, 1997, CANCER RES, V57, P4731; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Matsuyoshi N, 1997, J INVEST DERMATOL, V108, P908, DOI 10.1111/1523-1747.ep12292703; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x; PERKINS W, 1992, J CUTAN PATHOL, V19, P476, DOI 10.1111/j.1600-0560.1992.tb01600.x; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; QUINN AG, 1994, CANCER RES, V54, P4756; Ren ZP, 1996, ONCOGENE, V12, P765; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; van Golen KL, 2000, CANCER RES, V60, P5832; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	21	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3500	3505		10.1038/sj.onc.1206571	http://dx.doi.org/10.1038/sj.onc.1206571			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776202				2022-12-25	WOS:000183128500017
J	Hemmerlin, A; Rivera, SB; Erickson, HK; Poulter, CD				Hemmerlin, A; Rivera, SB; Erickson, HK; Poulter, CD			Enzymes encoded by the farnesyl diphosphate synthase gene family in the big sagebrush Artemisia tridentata ssp spiciformis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHASE; SESQUITERPENE CYCLASE; MOLECULAR-CLONING; CHAIN-LENGTH; BIOSYNTHESIS; LOCALIZATION; PURIFICATION; EXPRESSION; PROTEIN; CELLS	Farnesyl diphosphate synthase catalyzes the sequential head-to-tail condensation of two molecules of isopentenyl diphosphate with dimethylallyl diphosphate. In plants the presence of farnesyl diphosphate synthase isozymes offers the possibility of differential regulation. Three full-length cDNAs encoding putative isoprenoid synthases, FDS-1, FDS-2, and FDS-5, with greater than 89% similarity were isolated from a Big Sagebrush Artemisia tridentata cDNA library using a three-step polymerase chain reaction protocol. One of the open reading frames, FDS-5, encoded a protein with an N-terminal amino acid extension that was identified as a plastidial targeting peptide. Recombinant histidine-tagged versions of three proteins were purified, and their enzymatic properties were characterized. FDS-1 and FDS-2 synthesized farnesyl diphosphate as the final chain elongation product, but their kinetic behavior varied. FDS-1 prefers geranyl diphosphate over dimethylallyl diphosphate as an allylic substrate and is active at acidic pH values compared with FDS-2. In contrast, FDS-5 synthesized two irregular monoterpenoids, chrysanthemyl diphosphate and lavandulyl diphosphate, when incubated with dimethylallyl diphosphate and an additional product, the regular monoterpene geranyl diphosphate, when incubated with isopentenyl diphosphate and dimethylallyl diphosphate. Specific cellular functions are proposed for each of the three enzymes, and a scenario for evolution of isoprenyl synthases in plants is presented.	Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Poulter, CD (corresponding author), Univ Utah, Dept Chem, 315 S,1400 E,Rm 2020, Salt Lake City, UT 84112 USA.			Hemmerlin, Andrea/0000-0002-3383-7355	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021328, R01GM021328, R01GM025521, R56GM021328] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25521, GM 21328] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam KP, 1999, ARCH BIOCHEM BIOPHYS, V369, P127, DOI 10.1006/abbi.1999.1346; ALEXANDER K, 1975, J ORG CHEM, V40, P2576, DOI 10.1021/jo00905a053; ATTUCCI S, 1995, ARCH BIOCHEM BIOPHYS, V321, P493, DOI 10.1006/abbi.1995.1422; BARTLETT DL, 1985, METHOD ENZYMOL, V110, P171; Bouvier F, 2000, PLANT J, V24, P241, DOI 10.1046/j.1365-313x.2000.00875.x; Bouwmeester HJ, 1999, PLANT PHYSIOL, V121, P173, DOI 10.1104/pp.121.1.173; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodelius M, 2002, EUR J BIOCHEM, V269, P3570, DOI 10.1046/j.1432-1033.2002.03044.x; Burke C, 2002, ARCH BIOCHEM BIOPHYS, V405, P130, DOI 10.1016/S0003-9861(02)00335-1; Burke CC, 1999, P NATL ACAD SCI USA, V96, P13062, DOI 10.1073/pnas.96.23.13062; BUTLER AR, 1992, CHEM SOC REV, V21, P85, DOI 10.1039/cs9922100085; Byrd DW, 1999, BIOCHEM SYST ECOL, V27, P11, DOI 10.1016/S0305-1978(98)00064-7; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Connolly J. D., 1992, DICT TERPENOIDS; Cunillera N, 1997, J BIOL CHEM, V272, P15381, DOI 10.1074/jbc.272.24.15381; Cunillera N, 1996, J BIOL CHEM, V271, P7774, DOI 10.1074/jbc.271.13.7774; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; Disch A, 1998, BIOCHEM J, V331, P615, DOI 10.1042/bj3310615; Dolence J. M., 1999, COMPREHENSIVE NATURA, V5, P315; Dudareva N, 2000, PLANT PHYSIOL, V122, P627, DOI 10.1104/pp.122.3.627; ELLENBERGER SR, 1995, Patent No. 5443978; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; EPSTEIN WW, 1973, PHYTOCHEMISTRY, V12, P737, DOI 10.1016/0031-9422(73)80670-3; EPSTEIN WW, 1991, J ORG CHEM, V56, P4451, DOI 10.1021/jo00014a023; Gunawardena K, 2002, PHYTOCHEMISTRY, V59, P197, DOI 10.1016/S0031-9422(01)00438-1; Jarstfer MB, 2002, J AM CHEM SOC, V124, P8834, DOI 10.1021/ja020410i; JIANG Y, 1995, J BIOL CHEM, V270, P21793, DOI 10.1074/jbc.270.37.21793; KUNTZ M, 1992, PLANT J, V2, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Matsushita Y, 1996, GENE, V172, P207, DOI 10.1016/0378-1119(96)00054-6; MCGARVEY DJ, 1995, PLANT CELL, V7, P1015, DOI 10.1105/tpc.7.7.1015; NEWMAN JD, 1997, BIOCH FUNCTION STERO, P123; OGURA K, 1972, J BIOCHEM-TOKYO, V72, P1101, DOI 10.1093/oxfordjournals.jbchem.a129997; Okada K, 2000, PLANT PHYSIOL, V122, P1045, DOI 10.1104/pp.122.4.1045; Pan ZQ, 1996, ARCH BIOCHEM BIOPHYS, V332, P196, DOI 10.1006/abbi.1996.0333; Pare PW, 1999, PLANT PHYSIOL, V121, P325, DOI 10.1104/pp.121.2.325; Phillipson JD, 2001, PHYTOCHEMISTRY, V56, P237, DOI 10.1016/S0031-9422(00)00456-8; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; REED BC, 1976, BIOCHEMISTRY-US, V15, P3739, DOI 10.1021/bi00662a015; RIVERA SB, 2001, P NATL ACAD SCI USA, V93, P5888; Rodriguez-Concepcion M, 1999, EMBO J, V18, P1996, DOI 10.1093/emboj/18.7.1996; Roos W, 1998, PLANT PHYSIOL, V118, P349, DOI 10.1104/pp.118.2.349; RUZICKA L, 1953, EXPERIENTIA, V9, P357, DOI 10.1007/BF02167631; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; Sambrook J., 2002, MOL CLONING LAB MANU; Sanmiya K, 1999, PLANT CELL PHYSIOL, V40, P348, DOI 10.1093/oxfordjournals.pcp.a029549; Schwarz M, 1994, THESIS EIDGENOSSISCH; Suire C, 2000, PLANT PHYSIOL, V124, P971, DOI 10.1104/pp.124.3.971; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Turner G, 1999, PLANT PHYSIOL, V120, P879, DOI 10.1104/pp.120.3.879; VOGELI U, 1988, PLANT PHYSIOL, V88, P1291, DOI 10.1104/pp.88.4.1291; Wang K, 1999, TRENDS BIOCHEM SCI, V24, P445, DOI 10.1016/S0968-0004(99)01464-4; WELCH BL, 1981, J RANGE MANAGE, V34, P380, DOI 10.2307/3897909; Wise M. L., 1999, COMPREHENSIVE NATURA, P97, DOI DOI 10.1016/B978-0-08-091283-7.00038-2	57	77	94	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32132	32140		10.1074/jbc.M213045200	http://dx.doi.org/10.1074/jbc.M213045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12782626	hybrid			2022-12-25	WOS:000184782100085
J	Liu, L; Trimarchi, JR; Navarro, P; Blasco, MA; Keefe, DL				Liu, L; Trimarchi, JR; Navarro, P; Blasco, MA; Keefe, DL			Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ACUTE PROMYELOCYTIC LEUKEMIA; CYTOCHROME-C RELEASE; HUMAN TUMOR-CELLS; SODIUM ARSENITE; DEFICIENT MICE; CANCER; MOUSE; CARCINOGENESIS; MITOCHONDRIA	The environmental contaminant arsenic causes cancer, developmental retardation, and other degenerative diseases and, thus, is a serious health concern worldwide. Paradoxically, arsenic also may serve as an antitumor therapy, although the mechanisms of its antineoplastic effects remain unclear. Arsenic exerts its toxicity in part by generating reactive oxygen species. We show that arsenic-induced oxidative stress promotes telomere attrition, chromosome end-to-end fusions, and apoptotic cell death. An antioxidant, N-acetylcysteine, effectively prevents arsenic-induced oxidative stress, telomere erosion, chromosome instability, and apoptosis, suggesting that increasing the intracellular antioxidant level may have preventive or therapeutic effects in arsenic-induced chromosome instability and genotoxicity. Embryos with shortened telomeres from late generation telomerase-deficient mice exhibit increased sensitivity to arsenic-induced oxidative damage, suggesting that telomere attrition mediates arsenic-induced apoptosis. Unexpectedly, arsenite did not cause chromosome end-to-end fusions in telomerase RNA knockout mouse embryos despite progressively damaged telomeres and disrupting embryo viability. Together, these findings may explain why arsenic can initiate oxidative stress and telomere erosion, leading to apoptosis and anti-tumor therapy on the one hand and chromosome instability and carcinogenesis on the other.	Marine Biol Lab, Lab Reprod Med, Woods Hole, MA 02543 USA; Brown Univ, Women & Infants Hosp, Dept Obstet & Gynecol, Providence, RI 02905 USA; Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain	Marine Biological Laboratory - Woods Hole; Brown University; Women & Infants Hospital Rhode Island	Keefe, DL (corresponding author), Marine Biol Lab, Lab Reprod Med, Woods Hole, MA 02543 USA.	dkeefe@wihri.org	Navarro, Paula/G-2744-2012; Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; Navarro, Paula Andrea/0000-0003-2368-4188				BARRETT JC, 1989, BIOL TRACE ELEM RES, V21, P421, DOI 10.1007/BF02917284; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chappell WR, 1997, ENVIRON HEALTH PERSP, V105, P1060, DOI 10.1289/ehp.971051060; Chattopadhyay S, 2001, ARCH ENVIRON CON TOX, V41, P83, DOI 10.1007/s002440010223; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI14064; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Goering PL, 1999, TOXICOL SCI, V49, P5, DOI 10.1093/toxsci/49.1.5; Golub MS, 1998, J TOXICOL ENV HEAL B, V1, P199, DOI 10.1080/10937409809524552; Gonsebatt ME, 1997, MUTAT RES-REV MUTAT, V386, P219, DOI 10.1016/S1383-5742(97)00009-4; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamadeh HK, 1999, BIOCHEM BIOPH RES CO, V263, P446, DOI 10.1006/bbrc.1999.1395; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Huang SY, 2000, LEUKEMIA LYMPHOMA, V38, P283, DOI 10.3109/10428190009087019; Kipling D, 1997, HUM MOL GENET, V6, P1999, DOI 10.1093/hmg/6.12.1999; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kitchin KT, 2001, TOXICOL APPL PHARM, V172, P249, DOI 10.1006/taap.2001.9157; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LEE TC, 1994, ENVIRON HEALTH PERSP, V102, P101, DOI 10.2307/3431770; LEE TC, 1989, IN VITRO CELL DEV B, V25, P442; LEONARD A, 1980, MUTAT RES, V75, P49, DOI 10.1016/0165-1110(80)90027-5; Liu L, 2002, AGING CELL, V1, P40, DOI 10.1046/j.1474-9728.2002.00004.x; Liu L, 2002, DEV BIOL, V249, P74, DOI 10.1006/dbio.2002.0735; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; Mirkes PE, 2000, TOXICOL APPL PHARM, V162, P197, DOI 10.1006/taap.1999.8849; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; MULLER WU, 1986, ARCH TOXICOL, V59, P172, DOI 10.1007/BF00316328; NAKAMURO K, 1981, MUTAT RES, V88, P73, DOI 10.1016/0165-1218(81)90091-4; Oulton R, 2000, CURR OPIN ONCOL, V12, P74, DOI 10.1097/00001622-200001000-00013; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Samper E, 2001, EMBO REP, V2, P800, DOI 10.1093/embo-reports/kve174; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; Tabacova S, 1996, TOXICOL APPL PHARM, V138, P298, DOI 10.1006/taap.1996.0128; TAYLOR PR, 1989, BRIT J IND MED, V46, P881; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; WANG TS, 1994, MUTAGENESIS, V9, P253, DOI 10.1093/mutage/9.3.253; Wang XD, 2001, GENE DEV, V15, P2922; WARNER ML, 1994, CANCER EPIDEM BIOMAR, V3, P583; Waxman S, 2001, ONCOLOGIST, V6, P3, DOI 10.1634/theoncologist.6-suppl_2-3; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	57	156	166	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31998	32004		10.1074/jbc.M303553200	http://dx.doi.org/10.1074/jbc.M303553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12767976	hybrid			2022-12-25	WOS:000184782100069
J	Miller, S; Edwards, MD; Ozdemir, C; Booth, IR				Miller, S; Edwards, MD; Ozdemir, C; Booth, IR			The closed structure of the MscS mechanosensitive channel - Cross-linking of single cysteine mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MSCS; GATING MECHANISM; ION-CHANNEL; K+ CHANNEL; STOICHIOMETRY; RECEPTOR; DYNAMICS; DOMAIN	Mechanosensitive channels must make a large conformational change during the transition from the closed to the open state. The crystal structure of the open form of the Escherichia coli MscS channel was recently solved and depicts a homoheptamer (1). In this study, cross-linking of site-specific cysteine substitutions demonstrates that residues up to 10 - 33 Angstrom apart in the crystal structure readily form disulfide bridges in the closed form and can also be cross-linked by a 10-Angstrom linker. Crosslinking between adjacent subunits stabilizes the heptameric form of the channel providing biochemical evidence to support the crystal structure. The data are consistent with the published model ( 1) in that the membrane domain is highly flexible and that the closed to open transition may involve a significant displacement of transmembrane helices 1 and 2, possibly by as much as 30 Angstrom. The data are also consistent with significant flexibility of the cytoplasmic domain.	Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Booth, IR (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland.		Miller, Samantha/A-4799-2010	Miller, Samantha/0000-0002-8223-9693; Ozdemir, Cafer/0000-0002-5546-983X				Bass RB, 1999, STRUCT FOLD DES, V7, P829, DOI 10.1016/S0969-2126(99)80106-3; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Blount P, 1999, Methods Enzymol, V294, P458; Booth IR, 1999, CURR OPIN MICROBIOL, V2, P166, DOI 10.1016/S1369-5274(99)80029-0; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Hiniker A, 2003, BIOCHEMISTRY-US, V42, P1179, DOI 10.1021/bi027141t; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; Koprowski P, 2003, J BIOL CHEM, V278, P11237, DOI 10.1074/jbc.M212073200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martz E, 2002, TRENDS BIOCHEM SCI, V27, P107, DOI 10.1016/S0968-0004(01)02008-4; McLaggan D, 2002, MOL MICROBIOL, V43, P521, DOI 10.1046/j.1365-2958.2002.02764.x; Miller S, 2003, EMBO J, V22, P36, DOI 10.1093/emboj/cdg011; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SAMBROOK J, 1989, MOL CLONING LAB MANU, pB12; Sukharev S, 2002, BIOPHYS J, V83, P290, DOI 10.1016/S0006-3495(02)75169-2; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; WU JH, 1997, J MOL BIOL, V270, P2852	28	58	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32246	32250		10.1074/jbc.M303188200	http://dx.doi.org/10.1074/jbc.M303188200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12767977	hybrid			2022-12-25	WOS:000184782100099
J	Scott, CC; Furuya, W; Trimble, WS; Grinstein, S				Scott, CC; Furuya, W; Trimble, WS; Grinstein, S			Activation of store-operated calcium channels - Assessment of the role of snare-mediated vesicular transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE RECEPTOR; CAPACITATIVE CA2+ ENTRY; CATION CHANNELS; INFLUX FACTOR; FUNCTIONAL EXPRESSION; BOTULINUM NEUROTOXINS; ACTIN CYTOSKELETON; SIGNALING COMPLEX; COUPLING MODEL; CELLS	Store-operated calcium channels (SOC) play a central role in cellular calcium homeostasis. Although it is well established that SOC are activated by depletion of the endoplasmic reticulum calcium stores, the molecular mechanism underlying this effect remains ill defined. It has been suggested that SOC activation requires fusion of endomembrane vesicles with the plasmalemma. In this model, SNARE-dependent exocytosis is proposed to deliver channels or their activators to the surface membrane to initiate calcium influx. To test this hypothesis, we studied the requirement for membrane fusion events in SOC activation, using a variety of dominant-negative constructs and toxins that interfere with SNARE function. Botulinum neurotoxin A (BotA), which cleaves SNAP-25, did not prevent SOC activation. Moreover, SNAP-25 was not detectable in the cells where BotA was reported earlier to inhibit SOC. Instead, the BotA-insensitive SNAP-23 was present. Impairment of VAMP function was similarly without effect on SOC opening. We also tested the role of N-ethylmaleimide-sensitive factor, a global regulator of SNARE-mediated membrane fusion. Expression of a mutated N-ethylmaleimide-sensitive factor construct inhibited all aspects of membrane traffic tested, including recycling of transferrin receptors to the plasma membrane, fusion of endosomes with lysosomes, and retrograde traffic to the Golgi complex. Despite this global inhibition of vesicular fusion, which was accompanied by gross alterations in cell morphology, SOC activation persisted. These observations cannot be easily reconciled with the vesicle-mediated coupling hypothesis of SOC activation. Our findings imply that the SOC and the machinery necessary to activate them exist in the plasma membrane or are associated with it prior to activation.	Hosp Sick Children, Cell Biol Programme, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Grinstein, S (corresponding author), Hosp Sick Children, Cell Biol Programme, Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Scott, Cameron/0000-0001-5026-3413				Alderton JM, 2000, CELL CALCIUM, V28, P161, DOI 10.1054/ceca.2000.0144; Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Bauer NN, 2002, CELL BIOCHEM BIOPHYS, V37, P53, DOI 10.1385/CBB:37:1:53; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Coppolino MG, 2001, J BIOL CHEM, V276, P4772, DOI 10.1074/jbc.M007792200; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; FORTE JG, 1977, GASTROENTEROLOGY, V73, P921; FORTE TM, 1977, GASTROENTEROLOGY, V73, P941; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Huang XH, 2001, PANCREAS, V23, P125, DOI 10.1097/00006676-200108000-00002; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Leung SM, 1998, J BIOL CHEM, V273, P17732, DOI 10.1074/jbc.273.28.17732; Littleton JT, 2001, P NATL ACAD SCI USA, V98, P12233, DOI 10.1073/pnas.221450198; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Rossetto O, 2001, TOXICON, V39, P27, DOI 10.1016/S0041-0101(00)00163-X; Sabala P, 2002, BIOCHEM BIOPH RES CO, V296, P484, DOI 10.1016/S0006-291X(02)00893-8; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Su ZC, 2001, AM J PHYSIOL-CELL PH, V280, pC1284, DOI 10.1152/ajpcell.2001.280.5.C1284; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Wang YJ, 2002, BIOCHEM J, V363, P117, DOI 10.1042/0264-6021:3630117; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	47	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30534	30539		10.1074/jbc.M304718200	http://dx.doi.org/10.1074/jbc.M304718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12764154	hybrid			2022-12-25	WOS:000184658800017
J	Shetty, J; Wolkowicz, MJ; Digilio, LC; Klotz, KL; Jayes, FL; Diekman, AB; Westbrook, VA; Farris, EM; Hao, ZL; Coonrod, SA; Flickinger, CJ; Herr, JC				Shetty, J; Wolkowicz, MJ; Digilio, LC; Klotz, KL; Jayes, FL; Diekman, AB; Westbrook, VA; Farris, EM; Hao, ZL; Coonrod, SA; Flickinger, CJ; Herr, JC			SAMP14, a novel, acrosomal membrane-associated, glycosylphosphatidylinositol-anchored member of the Ly-6/urokinase-type plasminogen activator receptor superfamily with a role in sperm-egg interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SPERMATOZOA; PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; SURFACE-PROTEINS; ZONA-PELLUCIDA; LIGAND-BINDING; CELL-ADHESION; PH-20 PROTEIN; IN-VITRO; UROKINASE	We report a new member of the Ly-6/urokinase-type plasminogen activator receptor (uPAR) superfamily of receptors, SAMP14, which is retained on the inner acrosomal membrane of the human spermatozoan following the acrosome reaction and may play a role in fertilization. The SAMP14 sequence predicted a glycosylphosphatidylinositol (GPI)-anchored protein with a signal peptide, a transmembrane domain near the carboxyl terminus, and a putative transamidase cleavage site in the proprotein. Attachment of SAMP14 to the membrane by a lipid anchor was confirmed by its sensitivity to phosphatidylinositol phospholipase C. SAMP14 has a single functional domain similar to the Ly-6 and urokinase plasminogen activator receptor superfamily of proteins, and the gene mapped to 19q13.33, near the PLAUR locus for uPAR at 19q13.2. Northern and dot blotting showed that SAMP14 expression was testis-specific. Indirect immunofluorescence and immunoelectron microscopy with antisera to purified recombinant SAMP14 localized the protein to outer and inner acrosomal membranes as well as the acrosomal matrix of ejaculated human sperm. Acrosome-reacted sperm demonstrated SAMP14 immunofluorescence, indicating its retention on the inner acrosomal membrane following the acrosome reaction. However, SAMP14 localized to the entire sperm when unwashed swim-up sperm from the ejaculate were stained, indicating that some SAMP14 is loosely associated with the plasma membrane. Antibodies against recombinant SAMP14 inhibited both the binding and the fusion of human sperm to zona free hamster eggs, suggesting that SAMP14 may have a role in sperm-egg interaction. SAMP14 represents a GPI-anchored putative receptor in the Ly-6/uPAR family that is exposed on the inner acrosomal membrane after the acrosome reaction.	Univ Virginia, Ctr Res Contracept & Reprod Hlth, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Herr, JC (corresponding author), Univ Virginia, Ctr Res Contracept & Reprod Hlth, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.			Westbrook, Anne/0000-0003-4570-0126; Jayes, Friederike/0000-0001-8862-9345	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029099] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000654] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW/HD 00654] Funding Source: Medline; NICHD NIH HHS [HD U54 29099] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORGLUM AD, 1992, AM J HUM GENET, V50, P492; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; CELIS JE, 1992, ELECTROPHORESIS, V13, P893, DOI 10.1002/elps.11501301198; Cherr GN, 2001, MATRIX BIOL, V20, P515, DOI 10.1016/S0945-053X(01)00171-8; Coonrod SA, 1996, J REPROD FERTIL, V107, P287, DOI 10.1530/jrf.0.1070287; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Diekman AB, 2000, AM J REPROD IMMUNOL, V43, P134, DOI 10.1111/j.8755-8920.2000.430302.x; Domagala A, 2001, MED SCI MONITOR, V7, P325; FENICHEL P, 1994, MOL REPROD DEV, V38, P338, DOI 10.1002/mrd.1080380316; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; GUMLEY TP, 1995, IMMUNOL CELL BIOL, V73, P277, DOI 10.1038/icb.1995.45; HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x; Hamatani T, 2000, BIOL REPROD, V62, P1201, DOI 10.1095/biolreprod62.5.1201; Hao ZL, 2002, BIOL REPROD, V66, P735, DOI 10.1095/biolreprod66.3.735; Jiang HX, 1998, AM J REPROD IMMUNOL, V39, P243; Johnson A., 1990, HDB LABORATORY DIAGN, P135; Kirchhoff C, 1996, MOL HUM REPROD, V2, P177, DOI 10.1093/molehr/2.3.177; KLEMM U, 1991, HUM GENET, V87, P635; Mandal A, 1999, BIOL REPROD, V61, P1184, DOI 10.1095/biolreprod61.5.1184; McLeskey SB, 1998, INT REV CYTOL, V177, P57; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OVERSTREET JW, 1995, BIOL REPROD, V52, P105, DOI 10.1095/biolreprod52.1.105; Palfree RGE, 1996, TISSUE ANTIGENS, V48, P71, DOI 10.1111/j.1399-0039.1996.tb02610.x; PHELPS BM, 1987, DEV BIOL, V123, P63, DOI 10.1016/0012-1606(87)90428-3; PHELPS BM, 1988, SCIENCE, V240, P1780, DOI 10.1126/science.3381102; PLESNER T, 1994, BLOOD, V83, P808; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Sabeur K, 1997, J ANDROL, V18, P151; Shetty J, 1999, BIOL REPROD, V61, P61, DOI 10.1095/biolreprod61.1.61; Shetty J, 2001, ELECTROPHORESIS, V22, P3053, DOI 10.1002/1522-2683(200108)22:14<3053::AID-ELPS3053>3.0.CO;2-K; THALER CD, 1995, BIOCHEMISTRY-US, V34, P7788, DOI 10.1021/bi00024a002; Toshimori K, 1998, CELL TISSUE RES, V293, P177, DOI 10.1007/s004410051110; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; WASSARMAN PM, 1995, CURR TOP DEV BIOL, V30, P1, DOI 10.1016/S0070-2153(08)60562-1; WILLIAMS AF, 1991, CELL BIOL INT REP, V15, P769, DOI 10.1016/0309-1651(91)90032-E; Wolkowicz MJ, 2002, BIOL REPROD, V66, P241, DOI 10.1095/biolreprod66.1.241	44	75	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30506	30515		10.1074/jbc.M301713200	http://dx.doi.org/10.1074/jbc.M301713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788941	hybrid			2022-12-25	WOS:000184658800014
J	Sundram, V; Nanda, JS; Rajagopal, K; Dhar, J; Chaudhary, A; Sahni, G				Sundram, V; Nanda, JS; Rajagopal, K; Dhar, J; Chaudhary, A; Sahni, G			Domain truncation studies reveal that the streptokinase-plasmin activator complex utilizes long range protein-protein interactions with macromolecular substrate to maximize catalytic turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CIRCULAR-DICHROISM; BIOMOLECULAR INTERACTIONS; AFFINITY CHROMATOGRAPHY; CONFORMATIONAL-CHANGE; SYNTHETIC PEPTIDES; CRYSTAL-STRUCTURE; MECHANISM; BINDING; SITE	To explore the interdomain co-operativity during human plasminogen (HPG) activation by streptokinase (SK), we expressed the cDNAs corresponding to each SK domain individually (alpha, beta, and gamma), and also their two-domain combinations, viz. alphabeta and betagamma in Escherichia coli. After purification, alpha and beta showed activator activities of approximately 0.4 and 0.05%, respectively, as compared with that of native SK, measured in the presence of human plasmin, but the bi-domain constructs alphabeta and betagamma showed much higher co-factor activities (3.5 and 0.7% of native SK, respectively). Resonant Mirror-based binding studies showed that the single-domain constructs had significantly lower affinities for "partner" HPG, whereas the affinities of the two-domain constructs were remarkably native-like with regards to both binary-mode as well as ternary mode ("substrate") binding with HPG, suggesting that the vast difference in cofactor activity between the two- and three-domain structures did not arise merely from affinity differences between activator species and HPG. Remarkably, when the co-factor activities of the various constructs were measured with microplasminogen, the nearly 50-fold difference in the co-factor activity between the two- and three-domain SK constructs observed with full-length HPG as substrate was found to be dramatically attenuated, with all three types of constructs now exhibiting a low activity of approximately 1-2% compared to that of SK.HPN and HPG. Thus, the docking of substrate through the catalytic domain at the active site of SK-plasmin(ogen) is capable of engendering, at best, only a minimal level of co-factor activity in SK.HPN. Therefore, apart from conferring additional substrate affinity through kringle-mediated interactions, reported earlier (Dhar et al., 2002; J. Biol. Chem. 277, 13257), selective interactions between all three domains of SK and the kringle domains of substrate vastly accelerate the plasminogen activation reaction to near native levels.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Sahni, G (corresponding author), Inst Microbial Technol, Sector 39-A, Chandigarh 160036, India.		Nanda, Jagpreet/F-9833-2011; SUNDRAM, VASUDHA/D-8000-2012	Nanda, Jagpreet/0000-0002-6629-4641				Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; BUCKLE PE, 1993, BIOSENS BIOELECTRON, V8, P355, DOI 10.1016/0956-5663(93)80074-Y; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; CHRISTENSEN LR, 1947, J GEN PHYSIOL, V30, P465, DOI 10.1085/jgp.30.6.465; ConejeroLara F, 1996, PROTEIN SCI, V5, P2583, DOI 10.1002/pro.5560051221; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dhar J, 2002, J BIOL CHEM, V277, P13257, DOI 10.1074/jbc.M108422200; Esmon CT, 1998, NAT STRUCT BIOL, V5, P933, DOI 10.1038/2906; HUNT D, 1992, LANCET, V339, P753; JACKSON KW, 1986, BIOCHEMISTRY-US, V25, P108, DOI 10.1021/bi00349a016; Johnsen LB, 1999, INFECT IMMUN, V67, P1072, DOI 10.1128/IAI.67.3.1072-1078.1999; Johnsen LB, 2000, BIOCHEMISTRY-US, V39, P6440, DOI 10.1021/bi9922502; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARDER VJ, 1993, BLOOD COAGUL FIBRIN, V4, P1039, DOI 10.1097/00001721-199304060-00021; MARKUS G, 1964, J BIOL CHEM, V239, P2637; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nihalani D, 1997, PROTEIN SCI, V6, P1284, DOI 10.1002/pro.5560060616; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RADEK JT, 1989, J BIOL CHEM, V264, P9915; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; ROBBINS KC, 1981, METHOD ENZYMOL, V80, P379; SHI GY, 1988, J BIOL CHEM, V263, P17071; SHIBATA H, 1994, J BIOCHEM-TOKYO, V115, P738, DOI 10.1093/oxfordjournals.jbchem.a124404; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Wang XQ, 1999, FEBS LETT, V459, P85, DOI 10.1016/S0014-5793(99)01214-4; Wang XQ, 2000, J MOL BIOL, V295, P903, DOI 10.1006/jmbi.1999.3397; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WOHL RC, 1977, J BIOL CHEM, V252, P1141; YANG JT, 1986, METHOD ENZYMOL, V130, P208	44	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30569	30577		10.1074/jbc.M303799200	http://dx.doi.org/10.1074/jbc.M303799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773528	hybrid			2022-12-25	WOS:000184658800021
J	Weggen, S; Eriksen, JL; Sagi, SA; Pietrzik, CU; Golde, TE; Koo, EH				Weggen, S; Eriksen, JL; Sagi, SA; Pietrzik, CU; Golde, TE; Koo, EH			A beta 42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE CLEAVAGE; ALZHEIMERS-DISEASE; A-BETA; THYMOCYTE DEVELOPMENT; APH-1 INTERACTS; IN-VIVO; PRESENILIN; NOTCH; COMPLEX; PROTEOLYSIS	Epidemiological studies indicate that long term use of nonsteroidal anti-inflammatory drugs (NSAIDs) confers protection from Alzheimer's disease, and some NSAIDs were shown to specifically decrease production of the amyloidogenic Abeta42 peptide, most likely by direct modulation of gamma-secretase activity. In contrast to gamma-secretase inhibitors, Abeta42-lowering NSAIDs do not impair S3 cleavage in the NOTCH receptor and release of the NOTCH intracellular domain, a finding with conceptual implications for the development of safer drugs targeting Abeta production through gamma-secretase modulation. Intramembrane cleavage and release of an intracellular signaling domain has recently been demonstrated in a number of additional gamma-secretase substrates. We now show in cell-based assays that intramembrane cleavage of APP and ErbB-4 receptor is not impaired by the Abeta42-lowering NSAIDs, sulindac sulfide and ibuprofen. Generation of the APP intracellular domain (AICD) was further not inhibited in a cell-free assay at concentrations far exceeding those effective in reducing Abeta42 production. Closer inspection of AICD signaling showed that stabilization of the AICD peptide by FE65 and AICD-mediated transcription were also retained at Abeta42-lowering concentrations. These results demonstrate that S3-like/intramembrane cleavage is preserved by Abeta42-lowering NSAIDs in at least three substrates of gamma-secretase APP, ErbB-4, and NOTCH and underline the striking specificity by which these drugs target Abeta42 production.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Mayo Clin, Dept Neurosci & Pharmacol, Jacksonville, FL 32224 USA	University of California System; University of California San Diego; Mayo Clinic	Weggen, S (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	sweggen@ucsd.edu	Eriksen, Jason/A-8054-2008	Eriksen, Jason/0000-0003-1549-4165	NATIONAL INSTITUTE ON AGING [P01AG020206] Funding Source: NIH RePORTER; NIA NIH HHS [AG20206] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Citron M, 2002, NAT NEUROSCI, V5, P1055, DOI 10.1038/nn940; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McLendon C, 2000, FASEB J, V14, P2383; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Xia WM, 2000, NEUROBIOL DIS, V7, P673, DOI 10.1006/nbdi.2000.0322; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	59	115	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30748	30754		10.1074/jbc.M304824200	http://dx.doi.org/10.1074/jbc.M304824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777371	hybrid			2022-12-25	WOS:000184658800042
J	Weigel, M; Varotto, C; Pesaresi, P; Finazzi, G; Rappaport, F; Salamini, F; Leister, D				Weigel, M; Varotto, C; Pesaresi, P; Finazzi, G; Rappaport, F; Salamini, F; Leister, D			Plastocyanin is indispensable for photosynthetic electron flow in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-I; CHLAMYDOMONAS-REINHARDTII; CYTOCHROME C(6); GROWTH; GENE; PROTEOME; SUBUNIT	Plastocyanin is a soluble copper-containing protein present in the thylakoid lumen, which transfers electrons to photosystem I. In the chloroplast of the flowering plant Arabidopsis thaliana, a cytochrome c(6)-like protein is present, which was recently suggested to function as an alternative electron carrier to plastocyanin. We show that Arabidopsis plants mutated in both of the two plastocyanin-coding genes and with a functional cytochrome c(6) cannot grow photoautotrophically because of a complete block in light-driven electron transport. Even increased dosage of the gene encoding the cytochrome c(6)-like protein cannot complement the double mutant phenotype. This demonstrates that in Arabidopsis only plastocyanin can donate electrons to photosystem I in vivo.	Max Planck Inst Zuchtungsforsch, Abt Pflanzenzuchtung & Ertragsphysiol, D-50829 Cologne, Germany; Max Planck Inst Zuchtungsforsch, ZIGIA, D-50829 Cologne, Germany; Inst Biol Physicochim, Serv Photosynth, CNRS, UPR 1261, F-75005 Paris, France	Max Planck Society; Max Planck Society; Centre National de la Recherche Scientifique (CNRS)	Leister, D (corresponding author), Max Planck Inst Zuchtungsforsch, Abt Pflanzenzuchtung & Ertragsphysiol, Carl Von Linne Weg 10, D-50829 Cologne, Germany.		Leister, Dario/D-5587-2009; Pesaresi, Paolo/F-9476-2014	Leister, Dario/0000-0003-1897-8421; Pesaresi, Paolo/0000-0002-3236-7005; Rappaport, Fabrice/0000-0001-9377-4934; Varotto, Claudio/0000-0001-5018-087X				Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clarke AK, 1996, PLANT PHYSIOL, V112, P1551, DOI 10.1104/pp.112.4.1551; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gupta R, 2002, NATURE, V417, P567, DOI 10.1038/417567a; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Joliot P, 2002, P NATL ACAD SCI USA, V99, P10209, DOI 10.1073/pnas.102306999; Kautsky H., 1960, BIOCHEM Z, V322, P277; Leister D, 1999, PLANT PHYSIOL BIOCH, V37, P671, DOI 10.1016/S0981-9428(00)80097-2; MALKIN S, 1966, BIOCHIM BIOPHYS ACTA, V126, P413, DOI 10.1016/0926-6585(66)90001-X; MERCHANT S, 1987, EMBO J, V6, P2531, DOI 10.1002/j.1460-2075.1987.tb02540.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURATA N, 1966, BIOCH BIOPHIS ACTA, V126, P26; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; QUINN J, 1993, J BIOL CHEM, V268, P7832; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Varotto C, 2002, PLANT PHYSIOL, V129, P616, DOI 10.1104/pp.002089; Varotto C, 2000, PLANT J, V22, P115, DOI 10.1046/j.1365-313x.2000.00717.x; Wisman E, 1998, P NATL ACAD SCI USA, V95, P12432, DOI 10.1073/pnas.95.21.12432; ZHANG L, 1992, J BIOL CHEM, V267, P19054; ZHANG LL, 1994, J BIOL CHEM, V269, P5036	24	126	132	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31286	31289		10.1074/jbc.M302876200	http://dx.doi.org/10.1074/jbc.M302876200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773541	hybrid			2022-12-25	WOS:000184658800108
J	Lartigue, A; Gruez, A; Spinelli, S; Riviere, S; Brossut, R; Tegoni, M; Cambillau, C				Lartigue, A; Gruez, A; Spinelli, S; Riviere, S; Brossut, R; Tegoni, M; Cambillau, C			The crystal structure of a cockroach pheromone-binding protein suggests a new ligand binding and release mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; NMR STRUCTURE; MOTH; CRYSTALLIZATION	Pheromone-binding proteins (PBPs) are small helical proteins found in sensorial organs, particularly in the antennae, of moth and other insect species. They were proposed to solubilize and carry the hydrophobic pheromonal compounds through the antennal lymph to receptors, participating thus in the peri-receptor events of signal transduction. The x-ray structure of Bombyx mori PBP (BmorPBP), from male antennae, revealed a six-helix fold forming a cavity that contains the pheromone bombykol. We have identified a PBP (LmaPBP) from the cockroach Leucophaea maderae in the antennae of the females, the gender attracted by pheromones in this species. Here we report the crystal structure of LmaPBP alone or in complex with a fluorescent reporter (amino-naphthalen sulfonate, ANS) or with a component of the pheromonal blend, 3-hydroxy-butan-2-one. Both compounds bind in the internal cavity of LmaPBP, which is more hydrophilic than BmorPBP cavity. LmaPBP structure ends just after the sixth helix (helix F). BmorPBP structure extends beyond the sixth helix with a stretch of residues elongated at neutral pH and folding as a seventh internalized helix at low pH. These differences between LmaPBP and BmorPBP structures suggest that different binding and release mechanism may be adapted to the hydrophilicity or hydrophobicity of the pheromonal ligand.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Univ Bourgogne, CNRS, UMR 5548, F-21000 Dijon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne	Cambillau, C (corresponding author), CNRS, UMR 6098, 31 Ch Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Campanacci V, 2001, J BIOL CHEM, V276, P20078, DOI 10.1074/jbc.M100713200; Campanacci V, 2003, P NATL ACAD SCI USA, V100, P5069, DOI 10.1073/pnas.0836654100; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Horst R, 2001, P NATL ACAD SCI USA, V98, P14374, DOI 10.1073/pnas.251532998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krieger J, 2002, EUR J NEUROSCI, V16, P619, DOI 10.1046/j.1460-9568.2002.02109.x; Krieger J, 1996, INSECT BIOCHEM MOLEC, V26, P297, DOI 10.1016/0965-1748(95)00096-8; Krieger MJB, 2002, SCIENCE, V295, P328, DOI 10.1126/science.1065247; Lartigue A, 2003, ACTA CRYSTALLOGR D, V59, P916, DOI 10.1107/S0907444903004116; Lartigue A, 2002, J BIOL CHEM, V277, P32094, DOI 10.1074/jbc.M204371200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee D, 2002, FEBS LETT, V531, P314, DOI 10.1016/S0014-5793(02)03548-2; Mohl Claudia, 2002, Invertebrate Neuroscience, V4, P165, DOI 10.1007/s10158-002-0018-5; Mosbah A, 2003, BIOCHEM J, V369, P39, DOI 10.1042/BJ20021217; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramon R, 2001, J BIOL CHEM, V276, P7150, DOI 10.1074/jbc.M010368200; Riviere S, 2003, BIOCHEM J, V371, P573, DOI 10.1042/BJ20021877; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Sandler BH, 2000, CHEM BIOL, V7, P143, DOI 10.1016/S1074-5521(00)00078-8; SIRUGUE D, 1992, SCI VIE SANTE; Spinelli S, 2002, EUR J BIOCHEM, V269, P2449, DOI 10.1046/j.1432-1033.2002.02901.x; Sulzenbacher G, 2002, ACTA CRYSTALLOGR D, V58, P2109, DOI 10.1107/S0907444902013938; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1991, J NEUROBIOL, V22, P74, DOI 10.1002/neu.480220108; Wojtasek H, 1999, J BIOL CHEM, V274, P30950, DOI 10.1074/jbc.274.43.30950	31	101	112	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30213	30218		10.1074/jbc.M304688200	http://dx.doi.org/10.1074/jbc.M304688200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766173	hybrid			2022-12-25	WOS:000184507000101
J	Dayan, FE; Kagan, IA; Rimando, AM				Dayan, FE; Kagan, IA; Rimando, AM			Elucidation of the biosynthetic pathway of the allelochemical sorgoleone using retrobiosynthetic NMR analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; ROOT EXUDATE; RESORCINOLIC LIPIDS; INHIBITORY-ACTIVITY; CHALCONE SYNTHASE; NATURAL-PRODUCTS; DEVELOPING SEEDS; STRIGA-ASIATICA; PLANT; SORGHUM	NMR analyses of the labeling pattern obtained using various C-13-labeled precursors indicated that both the lipid tail and the quinone head of sorgoleone, the main allelopathic component of the oily root exudate of Sorghum bicolor, were derived from acetate units, but that the two moieties were synthesized in different subcellular compartments. The 16:3 fatty acid precursor of the tail is synthesized by the combined action of fatty-acid synthase and desaturases most likely in the plastids. It is then exported out of the plastids and converted to 5-pentadecatriene resorcinol by a polyketide synthase. This resorcinol intermediate was identified in root hair extracts. The lipid resorcinol intermediate is then methylated by a S-adenosylmethionine-dependent O-methyltransferase and subsequently dihydroxylated by a P450 monooxygenase to yield the reduced form of sorgoleone.	ARS, USDA, Nat Prod Utilizat Res Unit, University, MS 38677 USA	United States Department of Agriculture (USDA)	Dayan, FE (corresponding author), ARS, USDA, Nat Prod Utilizat Res Unit, University, MS 38677 USA.	fdayan@ars.usda.gov	Dayan, Franck E/AAB-6565-2022; Dayan, Franck/A-7592-2009	Dayan, Franck E/0000-0001-6964-2499; Dayan, Franck/0000-0001-6964-2499				Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Bacher A, 1998, FEMS MICROBIOL REV, V22, P567; BORNHEIM LM, 1993, BIOCHEM PHARMACOL, V45, P1323, DOI 10.1016/0006-2952(93)90286-6; CHANG M, 1986, J AM CHEM SOC, V108, P7858, DOI 10.1021/ja00284a074; Czarnota MA, 2001, WEED TECHNOL, V15, P813, DOI 10.1614/0890-037X(2001)015[0813:MOALOP]2.0.CO;2; Deszcz L, 2000, BBA-MOL CELL BIOL L, V1483, P241, DOI 10.1016/S1388-1981(99)00187-0; DEWICK PM, 1997, MED NATURAL PRODUCTS, P73; Dixon RA, 1999, CURR OPIN BIOTECH, V10, P192, DOI 10.1016/S0958-1669(99)80034-2; Duke SO, 2000, ADV BOT RES, V31, P121, DOI 10.1016/S0065-2296(00)31008-4; EINHELLIG FA, 1993, J CHEM ECOL, V19, P369, DOI 10.1007/BF00993702; Engelmann T, 2001, ARCH MICROBIOL, V175, P376, DOI 10.1007/s002030100275; Erickson J, 2001, J AGR FOOD CHEM, V49, P5537, DOI 10.1021/jf0111099; FATE G, 1990, PLANT PHYSIOL, V93, P201, DOI 10.1104/pp.93.1.201; Fate GD, 1996, J AM CHEM SOC, V118, P11369, DOI 10.1021/ja961395i; Flugge UI, 1999, ANNU REV PLANT PHYS, V50, P27, DOI 10.1146/annurev.arplant.50.1.27; Glawischnig E, 1997, PHYTOCHEMISTRY, V45, P715, DOI 10.1016/S0031-9422(96)00832-1; Gonzalez VM, 1997, J AGR FOOD CHEM, V45, P1415, DOI 10.1021/jf960733w; HAJRA AK, 1986, METHOD ENZYMOL, V122, P50; HERBERT RB, 1989, BIOSYNTHESIS SECONDA, P51; HITCHCOCK C, 1971, PLANT LIPID BIOCH, P2; HSIAO C, 1994, GENOME, V37, P112, DOI 10.1139/g94-014; Ibrahim RK, 1998, PLANT MOL BIOL, V36, P1, DOI 10.1023/A:1005939803300; JAMIESON GR, 1971, PHYTOCHEMISTRY, V10, P1837, DOI 10.1016/S0031-9422(00)86447-X; Joshi CP, 1998, PLANT MOL BIOL, V37, P663, DOI 10.1023/A:1006035210889; Kozubek A, 1999, CHEM REV, V99, P1, DOI 10.1021/cr970464o; Latunde-Dada AO, 2001, J BIOL CHEM, V276, P1688, DOI 10.1074/jbc.M006277200; LEETE E, 1976, J AM CHEM SOC, V98, P6321, DOI 10.1021/ja00436a042; Lupien S, 1999, ARCH BIOCHEM BIOPHYS, V368, P181, DOI 10.1006/abbi.1999.1298; Mathews S, 2000, AM J BOT, V87, P96, DOI 10.2307/2656688; McConkey ME, 2000, PLANT PHYSIOL, V122, P215, DOI 10.1104/pp.122.1.215; Meazza G, 2002, PHYTOCHEMISTRY, V60, P281, DOI 10.1016/S0031-9422(02)00121-8; NETZLY DH, 1986, CROP SCI, V26, P775, DOI 10.2135/cropsci1986.0011183X002600040031x; NETZLY DH, 1988, WEED SCI, V36, P441, DOI 10.1017/S0043174500075172; Nimbal CI, 1996, PESTIC BIOCHEM PHYS, V54, P73, DOI 10.1006/pest.1996.0011; OHLROGGE JB, 1978, LIPIDS, V13, P203, DOI 10.1007/BF02533401; Paramashivappa R, 2001, J AGR FOOD CHEM, V49, P2548, DOI 10.1021/jf001222j; POLLARD MR, 1980, PLANT PHYSIOL, V66, P649, DOI 10.1104/pp.66.4.649; POLLARD MR, 1980, PLANT PHYSIOL, V66, P641, DOI 10.1104/pp.66.4.641; RASMUSSEN JA, 1992, J CHEM ECOL, V18, P197, DOI 10.1007/BF00993753; Rawlings BJ, 1998, NAT PROD REP, V15, P275; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Rawsthorne S, 2002, PROG LIPID RES, V41, P182, DOI 10.1016/S0163-7827(01)00023-6; Rimando AM, 2003, J NAT PROD, V66, P42, DOI 10.1021/np0203842; ROHM M, 1987, PHYSIOL PLANTARUM, V69, P129, DOI 10.1111/j.1399-3054.1987.tb01955.x; ROUGHAN G, 1993, PLANT PHYSIOL, V101, P1157, DOI 10.1104/pp.101.4.1157; STRYER L, 1988, BIOCHEMISTRY-US, P622; Suzuki Y, 1999, PHYTOCHEMISTRY, V52, P281, DOI 10.1016/S0031-9422(99)00196-X; Tauberger E, 2000, PLANT J, V23, P43, DOI 10.1046/j.1365-313x.2000.00783.x; Tellez MR, 1999, PHYTOCHEMISTRY, V52, P1035, DOI 10.1016/S0031-9422(99)00308-8; THOMPSON GA, 1986, PLANT PHYSIOL, V82, P357, DOI 10.1104/pp.82.2.357; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; Wang JH, 1999, ARCH BIOCHEM BIOPHYS, V368, P172, DOI 10.1006/abbi.1999.1304; Werck-Reichhart Daniele, 2002, Arabidopsis Book, V1, pe0028, DOI 10.1199/tab.0028; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029	54	53	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28607	28611		10.1074/jbc.M304185200	http://dx.doi.org/10.1074/jbc.M304185200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12771136	hybrid			2022-12-25	WOS:000184421100034
J	Woods, A; Vertommen, D; Neumann, D; Turk, R; Bayliss, J; Schlattner, U; Wallimann, T; Carlling, D; Rider, MH				Woods, A; Vertommen, D; Neumann, D; Turk, R; Bayliss, J; Schlattner, U; Wallimann, T; Carlling, D; Rider, MH			Identification of phosphorylation sites in AMP-activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; FATTY-ACID OXIDATION; RAT-LIVER; POSTTRANSLATIONAL MODIFICATIONS; MASS-SPECTROMETRY; MAMMALIAN-CELLS; SKELETAL-MUSCLE; SUBUNIT; STIMULATION; EXPRESSION	Bacterially expressed heterotrimeric (alpha(1), beta(1), and gamma(1)) wild-type, catalytically inactive, and constitutively active forms of AMP-activated protein kinase ( AMPK) were used to study phosphorylation by an upstream AMPK kinase preparation. Here, we report the identification of two new phosphorylation sites in the alpha-subunit, viz. Thr(258) and Ser(485) (Ser(491) in the alpha(2)-subunit) by mass spectrometry, in addition to the previously characterized Thr(172) site. Also, autophosphorylation sites in the beta(1)-subunit were identified as Ser(96), Ser(101), and Ser(108). Mutagenesis of Thr(172), Thr(258), and Ser(485) to acidic residues to mimic phosphorylation in the recombinant proteins indicated that Thr172 was involved in AMPK activation, whereas Thr258 and Ser485 were not. Transfection of the non-phosphorylatable S485A and T258A mutants in CCL13 cells subjected to stresses known to activate AMPK either by increasing the AMP: ATP ratio ( slow lysis) or without changing adenine nucleotide concentrations (hyperosmolarity) resulted in no significant differences in AMPK activation. All three sites within the alpha-subunit were phosphorylated in vivo, as seen in AMPK immunoprecipitated from anoxic rat liver. In transfected CCL13 cells, the level of Ser(485) phosphorylation did not change upon AMPK activation. The newly identified phosphorylation sites could play a subtle role in the regulation of AMPK, e.g. in subcellular localization or substrate recognition.	Christian De Duve Instl Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Univ Louvain, B-1200 Brussels, Belgium; Univ London Imperial Coll Sci Technol & Med, Ctr Clin Sci,MRC, Cellular Stress Grp, Hammersmith Hosp, London W12 0NN, England; Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Universite Catholique Louvain; Imperial College London; Swiss Federal Institutes of Technology Domain; ETH Zurich	Rider, MH (corresponding author), ICP UCL, HORM Unit, 75-29 Ave Hippocrate 75, B-1200 Brussels, Belgium.		Schlattner, Uwe/D-1267-2009; Carling, David/F-1943-2014; Wallimann, Theo/C-6047-2008	Schlattner, Uwe/0000-0003-1159-5911; Carling, David/0000-0002-2316-1830; Wallimann, Theo/0000-0003-4957-5836; Neumann, Dietbert/0000-0002-4316-684X; Vertommen, Didier/0000-0001-7648-8282				CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZP, 1999, FEBS LETT, V460, P343, DOI 10.1016/S0014-5793(99)01371-X; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Daniel T, 2002, BIOCHEM J, V365, P629, DOI 10.1042/BJ20020124; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DEGNORE JP, 1998, J AM SOC MASS SPECTR, V265, P13818; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; MARLEY A, 1996, BIOCHEM J, V15, P801; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; NEUMANN D, 2003, IN PRESS PROTEIN EXP; RIDER MH, 1992, FEBS LETT, V310, P139, DOI 10.1016/0014-5793(92)81315-D; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	36	175	186	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28434	28442		10.1074/jbc.M303946200	http://dx.doi.org/10.1074/jbc.M303946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12764152	hybrid			2022-12-25	WOS:000184421100013
J	Graeler, MH; Kong, Y; Karliner, JS; Goetzl, EJ				Graeler, MH; Kong, Y; Karliner, JS; Goetzl, EJ			Protein kinase C epsilon dependence of the recovery from down-regulation of S1P(1) G protein-coupled receptors of T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHATIDIC ACID; CUTTING EDGE; EXPRESSION; ACTIVATION	Sphingosine 1-phosphate (S1P) from mononuclear phagocytes and platelets signals T cells predominantly through S1P(1) G protein-coupled receptors (Rs) to enhance survival, stimulate and suppress migration, and inhibit other immunologically relevant responses. Cellular S1P(1) Rs and their signaling functions are rapidly down-regulated by S1P, through a protein kinase C (PKC)-independent mechanism, but characteristics of cell-surface re-expression of down-regulated S1P(1) Rs have not been elucidated. T cell chemotactic responses (CT) to 10 and 100 nM S1P and inhibition of T cell chemotaxis to chemokines (CI) by 1 and 3 muM S1P were suppressed after 1 h of preincubation with 100 nM S1P, but recovered fully after 12-24 h of exposure to S1P. Late recovery of down-regulated CT and CI, but not early down-regulation, was suppressed by PKC and PKCepsilon-selective inhibitors and was absent in T cells from PKCepsilon-null mice. The same PKCepsilon inhibitors blocked S1P-evoked increases in T cell nuclear levels of c-Fos and phosphorylated c-Jun and JunD after 24 h, but not 1 h. A mixture of c-Fos plus c-Jun antisense oligonucleotides prevented late recovery of down-regulated CT and CI, without affecting S1P induction of down-regulation. Similarly, S1P-elicited threonine phosphorylation of S1P(1) Rs was suppressed by a selective inhibitor of PKCepsilon after 24 h, but not 1 h. Biochemical requisites for recovery of down-regulated S1P(1) Rs thus differ from those for S1P induction of down-regulation.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, UB8B,UC Box 0711,53 Parnassus & 4th, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809, P01HL068738] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-68738, HL-31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; GOETZL EJ, 2000, ANN NY ACAD SCI, V905, P1; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Kohno T, 2002, FASEB J, V16, P983, DOI 10.1096/fj.01-0809com; Kondo T, 2000, J BIOL CHEM, V275, P7668, DOI 10.1074/jbc.275.11.7668; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; Zheng YH, 2000, FASEB J, V14, P2387	15	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27737	27741		10.1074/jbc.C300147200	http://dx.doi.org/10.1074/jbc.C300147200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12782628	hybrid			2022-12-25	WOS:000184242700052
J	Maurer, P; T'Sas, F; Coutte, L; Callens, N; Brenner, C; Van Lint, C; de Launoit, Y; Baert, JL				Maurer, P; T'Sas, F; Coutte, L; Callens, N; Brenner, C; Van Lint, C; de Launoit, Y; Baert, JL			FEV acts as a transcriptional repressor through its DNA-binding ETS domain and alanine-rich domain	ONCOGENE			English	Article						Ets; transcription factor; repression	FAMILY MEMBER ERM; SIGNALING CASCADES; GENE-TRANSCRIPTION; FACTOR ER81; PEA3 GROUP; PROTEIN; TEL; CONTAINS; NET; TRANSACTIVATION	Although most Ets transcription factors have been characterized as transcriptional activators, some of them display repressor activity. Here we characterize an Ets-family member, the very specifically expressed human Fifth Ewing Variant (FEV), as a transcriptional repressor. We show that among a broad range of human cell lines, only Dami megakaryocytic cells express FEV. This nuclear protein binds to Ets-binding sites, such as that of the human ICAM-1 promoter. We used this promoter to demonstrate that FEV can repress both basal transcription and, even more strongly, ectopically Ets-activated transcription. We identified two domains responsible for FEV-mediated repression: the ETS domain, responsible for passive repression, and the carboxy-terminal alanine-rich domain, involved in active repression. In the Ets-independent LEXA system also, FEV acts as a transcriptional repressor via its alanine-rich carboxyterminal domain. The mechanism by which FEV actively represses transcription is currently unknown, since FEV-triggered repression is not reversed by the histone deacetylase inhibitor trichostatin A. We also showed that long-term overexpression of FEV proteins containing the alanine-rich domain prevents cell clones from growing, whereas clones expressing a truncated FEV protein lacking this domain develop like control cells. This confirms the importance of this domain in FEV-triggered repression.	Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, Inst Pasteur, CNRS, UMR 8117,Inst Biol Lille, F-59021 Lille, France; Free Univ Brussels, Fac Sci, Inst Biol & Med Mol, Dept Mol Biol, B-6041 Gosselies, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	de Launoit, Y (corresponding author), Free Univ Brussels, Fac Med, Mol Virol Lab, 808 Route Lennik,CP 614, B-1070 Brussels, Belgium.		callens, nathalie/P-2256-2016	callens, nathalie/0000-0002-7508-6596; coutte, laurent/0000-0002-0031-4742				Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Briata P, 1997, FEBS LETT, V402, P131, DOI 10.1016/S0014-5793(96)01512-8; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Courey AJ, 2001, GENE DEV, V15, P2786; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; Goodman FR, 1997, P NATL ACAD SCI USA, V94, P7458, DOI 10.1073/pnas.94.14.7458; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guidez F, 2000, BLOOD, V96, P2557; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hendricks T, 1999, J NEUROSCI, V19, P10348; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Laget MP, 1996, ONCOGENE, V12, P1325; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Pfaar H, 2002, DEV GENES EVOL, V212, P43, DOI 10.1007/s00427-001-0208-x; RAYGALLET D, 1995, ONCOGENE, V11, P303; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	40	25	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3319	3329		10.1038/sj.onc.1206572	http://dx.doi.org/10.1038/sj.onc.1206572			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761502				2022-12-25	WOS:000183040000014
J	Unruh, A; Ressel, A; Mohamed, HG; Johnson, RS; Nadrowitz, R; Richter, E; Katschinski, DM; Wenger, RH				Unruh, A; Ressel, A; Mohamed, HG; Johnson, RS; Nadrowitz, R; Richter, E; Katschinski, DM; Wenger, RH			The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy	ONCOGENE			English	Article						chemotherapy resistance; glycolysis; transcriptional gene regulation; tumor irradiation; tumor oxygenation	SOLID TUMORS; GENE-EXPRESSION; FACTOR 1-ALPHA; UP-REGULATION; HIF-ALPHA; FACTOR-I; CELL; GROWTH; HIF-1-ALPHA; P53	Tumor hypoxia negatively regulates cell growth and causes a more malignant phenotype by increasing the expression of genes encoding angiogenic, metabolic and metastatic factors. Of clinical importance, insufficient tumor oxygenation affects the efficiency of chemotherapy and radiotherapy by poorly understood mechanisms. The hypoxia-inducible factor (HIF)-1 is a master transcriptional activator of oxygen-regulated genes and HIF-1 is constitutively upregulated in several tumor types. HIF-1 might thus be implicated in tumor therapy resistance. We found that transformed mouse embryonic fibroblasts deficient for HIF-1alpha are more susceptible to the treatment with carboplatin, etoposide and ionizing radiation than wild-type cells. Increased cell death in HIF-1alpha-deficient cells was because of apoptosis and did not involve p53 induction. Tumor chemotherapy of experimental fibrosarcoma in immunocompromised mice with carboplatin and etoposide confirmed the enhanced susceptibility of HIF1alpha-deficient cells. Agents that did not cause DNA double-strand breaks, such as DNA-synthesis inhibitors or a DNA single-strand break-causing agent equally impaired cell growth, independent of the HIF-1alpha genotype. Functional repair of a fragmented reporter gene was decreased in HIF-la-deficient cells. Thus, hypoxia-independent basal HIF-1alpha expression in tumor cells, as known from untransformed embryonic stem cells, is sufficient to induce target gene expression, probably including DNA double strand break repair enzymes.	Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Med Univ Lubeck, Clin Radiotherapy & Nucl Med, D-23538 Lubeck, Germany	Leipzig University; University of Lubeck; University of California System; University of California San Diego; University of Lubeck	Wenger, RH (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, Liebigstr 27, D-04103 Leipzig, Germany.	wenr@medizin.uni-leipzig.de	Wenger, Roland H./B-7953-2009; Johnson, Randall/AAM-1189-2021	Wenger, Roland H./0000-0001-7592-4839; Johnson, Randall/0000-0002-4084-6639				Aebersold DM, 2001, CANCER RES, V61, P2911; Alarcon R, 1999, CANCER RES, V59, P6046; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Birner P, 2000, CANCER RES, V60, P4693; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Brown JM, 1998, CANCER RES, V58, P1408; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Comerford KM, 2002, CANCER RES, V62, P3387; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths JR, 2002, CANCER RES, V62, P688; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hopfl G, 2002, CANCER RES, V62, P2962; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Katschinski DM, 1999, CANCER RES, V59, P3404; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; LEDERMAN HM, 1984, BLOOD, V64, P748; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Rapisarda A, 2002, CANCER RES, V62, P4316; Ravi R, 2000, GENE DEV, V14, P34; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	54	295	324	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3213	3220		10.1038/sj.onc.1206385	http://dx.doi.org/10.1038/sj.onc.1206385			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761491				2022-12-25	WOS:000183040000003
J	Dekoninck, A; Calomme, C; Nizet, S; de Launoit, Y; Burny, A; Ghysdael, J; Van Lint, C				Dekoninck, A; Calomme, C; Nizet, S; de Launoit, Y; Burny, A; Ghysdael, J; Van Lint, C			Identification and characterization of a PU.1/Spi-B binding site in the bovine leukemia virus long terminal repeat	ONCOGENE			English	Review						BLV; transcription; PU.1; spi-b	TRANSCRIPTION FACTOR PU.1; NF-KAPPA-B; PERIPHERAL-BLOOD LYMPHOCYTES; SPI-B; ETS-DOMAIN; IN-VIVO; REGULATORY ELEMENTS; PUTATIVE ONCOGENE; GENE-EXPRESSION; NUCLEAR-FACTOR	Bovine leukemia virus (BLV) is a B-lymphotropic oncogenic retrovirus whose transcriptional promoter is located in the viral 5' long terminal repeat (LTR). To date, no B-lymphocyte-specific cis-regulatory element has been identified in this region. Since ETS proteins are known to regulate transcription of numerous retroviruses, we searched for the presence in the BLV promoter region of binding sites for PU.1/Spi-1, a B-cell- and macrophage-specific ETS family member. In this report, nucleotide sequence analysis of the viral LTR identified a PUbox located at -95/-84 bp. We demonstrated by gel shift and supershift assays that PU.1 and the related Ets transcription factor Spi-B interacted specifically with this PUbox. A 2-bp mutation (GGAA --> CCAA) within this motif abrogated PU.1/Spi-B binding. This mutation caused a marked decrease in LTR-driven basal gene expression in transient transfection assays of B-lymphoid cell tines, but did not impair the responsiveness of the BLV promoter to the virus-encoded transactivator Tax(BLV). Moreover, ectopically expressed PU.1 and Spi-B proteins transactivated the BLV promoter in a PUbox-dependent manner. Taken together, our results provide the first demonstration of regulation of the BLV promoter by two B-cell-specific Ets transcription factors, PU.1 and Spi-B. The PU.1/Spi-B binding site identified here could play an important role in BLV replication and B-lymphoid tropism.	Free Univ Brussels, IBMM, Serv Chim Biol, Mol Virol Lab, B-6041 Gosselies, Belgium; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, CNRS, UMR 8117, Inst Biol Lille,Inst Pasteur Lille, F-59021 Lille, France; Ctr Univ Orsay, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Van Lint, C (corresponding author), Free Univ Brussels, IBMM, Serv Chim Biol, Mol Virol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	cvlint@ulb.ac.be	GHYSDAEL, Jacques/F-3377-2013					Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; ADAM E, 1994, J VIROL, V68, P5845, DOI 10.1128/JVI.68.9.5845-5853.1994; AIDA Y, 1989, AM J VET RES, V50, P1946; Aurrekoetxea-Hernandez K, 2000, J VIROL, V74, P4988, DOI 10.1128/JVI.74.11.4988-4998.2000; BLOOM JC, 1979, BLOOD, V53, P899; BLOOM JC, 1980, CANCER RES, V40, P2240; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS PA, 1995, J VIROL, V69, P6005, DOI 10.1128/JVI.69.10.6005-6009.1995; Brooks PA, 1998, VIROLOGY, V243, P94, DOI 10.1006/viro.1998.9035; BURNY A, 1987, CANCER SURV, V6, P139; BURNY A, 1994, SYMP SOC GEN MICROBI, V51, P213; BURNY A, 1987, VIRAL ONCOLOGY, P231; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CARVALHO M, 1993, J VIROL, V67, P6586, DOI 10.1128/JVI.67.11.6586-6595.1993; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; Dahl R, 2002, EMBO J, V21, P2220, DOI 10.1093/emboj/21.9.2220; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1986, SCIENCE, V231, P1437, DOI 10.1126/science.3006241; DJILALI S, 1987, LEUKEMIA, V1, P777; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ERSELIUS JR, 1990, J VIROL, V64, P1657, DOI 10.1128/JVI.64.4.1657-1666.1990; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FERRER JF, 1979, J AM VET MED ASSOC, V175, P1281; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; HROMAS R, 1993, BLOOD, V82, P2998; Hu CJ, 2001, IMMUNITY, V15, P545, DOI 10.1016/S1074-7613(01)00219-9; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; JENSEN WA, 1992, J VIROL, V66, P4427, DOI 10.1128/JVI.66.7.4427-4433.1992; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; Kettmann R., 1994, The retroviridae: Volume 3, P39; Kiermer V, 1998, J VIROL, V72, P5526, DOI 10.1128/JVI.72.7.5526-5534.1998; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LAGARIAS DM, 1989, J VIROL, V63, P2099, DOI 10.1128/JVI.63.5.2099-2107.1989; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Lodie TA, 1997, J IMMUNOL, V158, P1848; Lodie TA, 1998, J IMMUNOL, V161, P268; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Mao C, 1996, ONCOGENE, V12, P863; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Muller S, 1996, ONCOGENE, V13, P1955; Myers GK, 1995, HUMAN RETROVIRUSES A; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Niermann GL, 1997, VIROLOGY, V239, P249, DOI 10.1006/viro.1997.8868; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Posada R, 2000, AIDS RES HUM RETROV, V16, P1981, DOI 10.1089/088922200750054710; QUANG CT, 1995, ONCOGENE, V11, P1229; Rao S, 1999, J BIOL CHEM, V274, P34245, DOI 10.1074/jbc.274.48.34245; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSEN CA, 1986, J VIROL, V57, P738, DOI 10.1128/JVI.57.3.738-744.1986; ROSEN CA, 1985, SCIENCE, V227, P320, DOI 10.1126/science.2981432; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; Tsukada J, 1997, BLOOD, V90, P3142, DOI 10.1182/blood.V90.8.3142; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Verhoef K, 1999, J VIROL, V73, P1331, DOI 10.1128/JVI.73.2.1331-1340.1999; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILLEMS L, 1993, J VIROL, V67, P1086, DOI 10.1128/JVI.67.2.1086-1089.1993; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; WILLEMS L, 1999, CURRENT TOP VIROL, V1, P139; Xiao JQ, 1998, J VIROL, V72, P5994, DOI 10.1128/JVI.72.7.5994-6003.1998; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yamamoto H, 2002, CELL GROWTH DIFFER, V13, P69; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	113	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2882	2896		10.1038/sj.onc.1206392	http://dx.doi.org/10.1038/sj.onc.1206392			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771939				2022-12-25	WOS:000182824800003
J	Zhang, XD; Borrow, JM; Zhang, XY; Nguyen, T; Hersey, P				Zhang, XD; Borrow, JM; Zhang, XY; Nguyen, T; Hersey, P			Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria	ONCOGENE			English	Article						melanoma; TRAIL; Erk1/2; apoptosis; Smac/DIABLO	NF-KAPPA-B; BCL-X-L; ANTITUMOR-ACTIVITY; CYTOCHROME-C; BAX; FAMILY; LIGAND; RECEPTOR; KINASE; MEMBER	We have previously shown that Smac/DIABLO release from mitochondria appears to be the principal pathway by which TRAIL induces apoptosis of human melanoma. We report that TRAIL-induced release of Smac/DIABLO appears to be downregulated by concomitant signaling through the MEK Erk1/2 kinase pathway and that this inhibits TRAIL-induced apoptosis. Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis. The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126. Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126. This was associated with a rapid reduction in mitochondrial transmembrane potential (MMP) and increased release of Smac/DIABLO into the cytosol. Exploration of events leading to the changes in MMP revealed an increased translocation of Bax from the cytosol to mitochondria in the presence of U0126. There was also a delayed decrease in the levels of expression of Mcl-1. Bcl-2 and BCI-X-L. Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126. Cytochrome c appeared not to play a major role in sensitization of melanoma to TRAIL in that caspase-9 activation was not detected in most of the cell lines. These results suggest that Erk1/2 signaling may protect melanoma cells against TRAIL-induced apoptosis by inhibiting the relocation of Bax from the cytosol to mitochondria and that this may reduce TRAIL-mediated release of Smac/DIABLO and induction of apoptosis.	Immunol & Oncol Unit, Newcastle, NSW 2300, Australia		Hersey, P (corresponding author), Immunol & Oncol Unit, Room 443,David Maddison Clin Sci Bldg,Cnr King &, Newcastle, NSW 2300, Australia.	Peter.Hersey@newcastle.edu.au	Zhang, xiaoyu/GXA-3206-2022; zhang, xian/GYA-0290-2022; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022	Zhang, Xu Dong/0000-0001-9457-8003				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Bouillet P, 2002, J CELL SCI, V115, P1567; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dai Y, 2001, CANCER RES, V61, P5106; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ozoren N, 2000, CANCER RES, V60, P6259; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Sabol SL, 1998, BIOCHEM BIOPH RES CO, V253, P151, DOI 10.1006/bbrc.1998.9770; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	43	121	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2869	2881		10.1038/sj.onc.1206427	http://dx.doi.org/10.1038/sj.onc.1206427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771938				2022-12-25	WOS:000182824800002
J	James, DI; Parone, PA; Mattenberger, Y; Martinou, JC				James, DI; Parone, PA; Mattenberger, Y; Martinou, JC			hFis1, a novel component of the mammalian mitochondrial fission machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; MEMBRANE; DIVISION; GTPASE; OPA1; BAX; ELEGANS; DNM1P; DRP1	The balance between the fission and fusion mechanisms regulate the morphology of mitochondria. In this study we have identified a mammalian protein that we call hFis1, which is the orthologue of the yeast Fis1p known to participate in yeast mitochondrial division. hFis1, when overexpressed in various cell types, localized to the outer mitochondrial membrane and induced mitochondrial fission. This event was inhibited by a dominant negative mutant of Drp1 ( Drp1( K38A)), a major component of the fission apparatus. Fragmentation of the mitochondrial network by hFis1 was followed by the release of cytochrome c and ultimately apoptosis. Bcl-x(L) was able to block cytochrome c release and apoptosis but failed to prevent mitochondrial fragmentation. Our studies show that hFis1 is part of the mammalian fission machinery and suggest that regulation of the fission processes might be involved in apoptotic mechanisms.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva, Switzerland	University of Geneva	Martinou, JC (corresponding author), Univ Geneva, Dept Cell Biol, Quai Ernest Ansermet 30, CH-1211 Geneva, Switzerland.	jean-claude.martinou@cellbio.unige.ch	James, Dominic/G-6435-2016	James, Dominic/0000-0002-0452-2178; martinou, Jean-claude/0000-0002-9847-2051; Mattenberger, Yves/0000-0002-1651-7691				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Koch A, 2003, J BIOL CHEM, V278, P8597, DOI 10.1074/jbc.M211761200; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Messerschmitt M, 2003, J CELL BIOL, V160, P553, DOI 10.1083/jcb.200211113; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Nicholls DG, 2002, INT J BIOCHEM CELL B, V34, P1372, DOI 10.1016/S1357-2725(02)00077-8; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Osiewacz HD, 2002, GENE, V286, P65, DOI 10.1016/S0378-1119(01)00804-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; van der Bliek AM, 2000, J CELL BIOL, V151, pF1, DOI 10.1083/jcb.151.2.F1; Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113	24	500	517	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36373	36379		10.1074/jbc.M303758200	http://dx.doi.org/10.1074/jbc.M303758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12783892	hybrid			2022-12-25	WOS:000185318300064
J	Pelletier, M; Thompson, JS; Qian, F; Bixler, SA; Gong, DH; Cachero, T; Gilbride, K; Day, E; Zafari, M; Benjamin, C; Gorelik, L; Whitty, A; Kalled, SL; Ambrose, C; Hsu, YM				Pelletier, M; Thompson, JS; Qian, F; Bixler, SA; Gong, DH; Cachero, T; Gilbride, K; Day, E; Zafari, M; Benjamin, C; Gorelik, L; Whitty, A; Kalled, SL; Ambrose, C; Hsu, YM			Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR FAMILY; B-LYMPHOCYTE STIMULATOR; FACTOR RECEPTOR SUPERFAMILY; CELL MATURATION ANTIGEN; TNF FAMILY; CRYSTAL-STRUCTURE; AUTOIMMUNE-DISEASE; HUMORAL IMMUNITY; SURVIVAL FACTOR; BLYS RECEPTOR	BAFF is considered a therapeutic target because dysregulated production of BAFF can induce systemic lupus erythematosus-like phenotype in mice, and elevated levels of BAFF are associated with disease severity in systemic lupus erythematosus and rheumatoid arthritis patients. Fc fusion decoy receptors, BCMA-Fc and BAFF-R-Fc, are therapeutic candidates for blocking BAFF. While studying their interactions with BAFF, we found that BAFF-R-Fc is more effective than BCMA-Fc for blocking BAFF binding to its receptors. We also found that a trimeric BAFF can bind more than one BAFF-R-Fc but only one BCMA-Fc. Moreover, we show that, in contrast to monovalent BAFF-R-Fc, monovalent BCMA does not form stable complexes with BAFF. Differences in their interaction with BAFF predict BAFF-R-Fc would be a better inhibitor. Indeed, we show BAFF-R-Fc is 10-fold more efficacious than BCMA-Fc for blocking BAFF-induced B cell proliferation in vitro and for blocking BAFF-mediated survival of mouse splenic B lymphocytes in vivo.	Biogen Inc, Dept Prot Engn, Cambridge, MA 02142 USA; Biogen Inc, Dept Genet Discovery, Cambridge, MA 02142 USA; Biogen Inc, Dept Immunol & Inflammat, Cambridge, MA 02142 USA; Biogen Inc, Dept Quantitat Biochem, Cambridge, MA 02142 USA	Biogen; Biogen; Biogen; Biogen	Hsu, YM (corresponding author), Biogen Inc, Dept Prot Engn, 12 Cambridge Ctr, Cambridge, MA 02142 USA.	yen-ming_hsu@biogen.com	Day, Eric S/C-5020-2009					Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cheema GS, 2001, ARTHRITIS RHEUM-US, V44, P1313, DOI 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; GRAS MP, 1995, INT IMMUNOL, V7, P1093, DOI 10.1093/intimm/7.7.1093; Groom J, 2002, J CLIN INVEST, V109, P59, DOI 10.1172/JCI200214121; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Kalled SL, 2003, EXPERT OPIN THER TAR, V7, P115, DOI 10.1517/14728222.7.1.115; Karpusas M, 2002, J MOL BIOL, V315, P1145, DOI 10.1006/jmbi.2001.5296; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Kim HM, 2003, NAT STRUCT BIOL, V10, P342, DOI 10.1038/nsb925; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackenzie IS, 2002, CLIN MED, V2, P465, DOI 10.7861/clinmedicine.2-5-465; Madry C, 1998, INT IMMUNOL, V10, P1693, DOI 10.1093/intimm/10.11.1693; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Oren DA, 2002, NAT STRUCT BIOL, V9, P288, DOI 10.1038/nsb769; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Roschke V, 2002, J IMMUNOL, V169, P4314, DOI 10.4049/jimmunol.169.8.4314; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Stein JV, 2002, J CLIN INVEST, V109, P1587, DOI 10.1172/JCI200215034; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; von Bulow GU, 2000, MAMM GENOME, V11, P628, DOI 10.1007/s003350010125; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802; Zhang J, 2001, J IMMUNOL, V166, P6, DOI 10.4049/jimmunol.166.1.6	42	77	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33127	33133		10.1074/jbc.M305754200	http://dx.doi.org/10.1074/jbc.M305754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796483	hybrid			2022-12-25	WOS:000184901800078
J	Gregory, LA; Thielens, NM; Arlaud, GJ; Fontecilla-Camps, JC; Gaboriaud, C				Gregory, LA; Thielens, NM; Arlaud, GJ; Fontecilla-Camps, JC; Gaboriaud, C			X-ray structure of the Ca2+-binding interaction domain of C1s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT PROTEASE C1R; 1ST COMPONENT; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; FUNCTIONAL-MODEL; CUB DOMAIN; AMINO-ACID; ACTIVATION; CLQ; MODULE	C1, the complex that triggers the classical pathway of complement, is assembled from two modular proteases C1r and C1s and a recognition protein C1q. The N-terminal CUB1-EGF segments of C1r and C1s are key elements of the C1 architecture, because they mediate both Ca2+-dependent C1r-C1s association and interaction with C1q. The crystal structure of the interaction domain of C1s has been solved and refined to 1.5 Angstrom resolution. The structure reveals a head-to-tail homodimer involving interactions between the CUB1 module of one monomer and the epidermal growth factor (EGF) module of its counterpart. A Ca2+ ion is bound to each EGF module and stabilizes both the intra- and inter-monomer interfaces. Unexpectedly, a second Ca2+ ion is bound to the distal end of each CUB1 module, through six ligands contributed by Glu(45), Asp(53), Asp(98), and two water molecules. These acidic residues and Tyr(17) are conserved in approximately two-thirds of the CUB repertoire and define a novel, Ca2+-binding CUB module subset. The C1s structure was used to build a model of the C1r-C1s CUB1- EGF heterodimer, which in C1 connects C1r to C1s and mediates interaction with C1q. A structural model of the C1q/C1r/C1s interface is proposed, where the rod-like collagen triple helix of C1q is accommodated into a groove along the transversal axis of the C1r-C1s heterodimer.	Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France; Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, F-38027 Grenoble 1, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Gaboriaud, C (corresponding author), Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	chris@lccp.ibs.fr	Thielens, Nicole M/F-2512-2013	Thielens, Nicole M/0000-0002-7354-0302				ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; Arlaud GJ, 2002, MOL IMMUNOL, V39, P383, DOI 10.1016/S0161-5890(02)00143-8; Arlaud GJ, 2001, IMMUNOL REV, V180, P136, DOI 10.1034/j.1600-065X.2001.1800112.x; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bersch B, 1998, BIOCHEMISTRY-US, V37, P1204, DOI 10.1021/bi971851v; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budayova-Spano M, 2002, STRUCTURE, V10, P1509, DOI 10.1016/S0969-2126(02)00881-X; Budayova-Spano M, 2002, EMBO J, V21, P231, DOI 10.1093/emboj/21.3.231; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; BUSBY TF, 1987, BIOCHEMISTRY-US, V26, P5564, DOI 10.1021/bi00391a052; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; ILLY C, 1993, J PROTEIN CHEM, V12, P771, DOI 10.1007/BF01024936; INGHAM KC, 1992, MOL IMMUNOL, V29, P45, DOI 10.1016/0161-5890(92)90155-Q; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabsch W., 2001, INT TABLES CRYSTALLO, P730, DOI [10.1107/97809553602060000001, DOI 10.1107/97809553602060000001]; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, P50; LUO C, 1992, BIOCHEMISTRY-US, V31, P4254, DOI 10.1021/bi00132a015; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rainey JK, 2002, PROTEIN SCI, V11, P2748, DOI 10.1110/ps.0218502; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REID KBM, 1979, BIOCHEM J, V179, P367, DOI 10.1042/bj1790367; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; Romao MJ, 1997, J MOL BIOL, V274, P650, DOI 10.1006/jmbi.1997.1423; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SCHUMAKER VN, 1986, MOL IMMUNOL, V23, P557, DOI 10.1016/0161-5890(86)90119-7; SIEGEL RC, 1983, MOL IMMUNOL, V20, P53, DOI 10.1016/0161-5890(83)90105-0; STRANG CJ, 1982, P NATL ACAD SCI-BIOL, V79, P586, DOI 10.1073/pnas.79.2.586; THIELENS NM, 1990, BIOCHEMISTRY-US, V29, P3570, DOI 10.1021/bi00466a021; Thielens NM, 1999, J BIOL CHEM, V274, P9149, DOI 10.1074/jbc.274.14.9149; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; THIELENS NM, 1994, BIOCHEM J, V301, P378; Tsai SW, 1997, MOL IMMUNOL, V34, P1273, DOI 10.1016/S0161-5890(97)00149-1; WEISS V, 1986, J MOL BIOL, V189, P573, DOI 10.1016/0022-2836(86)90325-6; ZICCARDI RJ, 1985, MOL IMMUNOL, V22, P489, DOI 10.1016/0161-5890(85)90133-6	47	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32157	32164		10.1074/jbc.M305175200	http://dx.doi.org/10.1074/jbc.M305175200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12788922	hybrid			2022-12-25	WOS:000184782100088
J	Lymperopoulos, K; Wirblich, C; Brierley, I; Roy, P				Lymperopoulos, K; Wirblich, C; Brierley, I; Roy, P			Sequence specificity in the interaction of Bluetongue virus non-structural protein 2 (NS2) with viral RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED RNA; HEMORRHAGIC-DISEASE VIRUS; INFLUENZA-VIRUS; INFECTED-CELLS; INCLUSION-BODIES; MESSENGER-RNA; BINDING; BACTERIOPHAGE-PHI-6; PHOSPHORYLATION; PHOSPHOPROTEIN	The non-structural protein NS2 of Bluetongue virus (BTV) is synthesized abundantly in virus-infected cells and has been suggested to be involved in virus replication. The protein, with a high content of charged residues, possesses a strong affinity for single-stranded RNA species but, to date, all studies have failed to identify any specificity in the NS2-RNA interaction. In this report, we have examined, through RNA binding assays using highly purified NS2, the specificity of interaction with different single-stranded RNA (ssRNA) species in the presence of appropriate competitors. The data obtained show that NS2 indeed has a preference for BTV ssRNA over nonspecific RNA species and that NS2 recognizes a specific region within the BTV10 segment S10. The secondary structure of this region was determined and found to be a hairpin-loop with substructures within the loop. Modification-inhibition experiments highlighted two regions within this structure that were protected from ribonuclease cleavage in the presence of NS2. Overall, these data imply that a function of NS2 may be to recruit virus messenger RNAs ( that also act as templates for synthesis of genomic RNAs) selectively from other RNA species within the infected cytosol of the cell during virus replication.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	University of London; London School of Hygiene & Tropical Medicine; University of Cambridge; University of Alabama System; University of Alabama Birmingham	Roy, P (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	polly.roy@lshtm.ac.uk		Roy, Polly/0000-0001-6535-6911	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045000] Funding Source: NIH RePORTER; Medical Research Council [MR/M011747/1] Funding Source: Medline; NIAID NIH HHS [R01 AI45000-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bae SH, 2001, P NATL ACAD SCI USA, V98, P10602, DOI 10.1073/pnas.191268798; Beasley BE, 2002, J VIROL, V76, P4950, DOI 10.1128/JVI.76.10.4950-4960.2002; BROOKES SM, 1993, J GEN VIROL, V74, P525, DOI 10.1099/0022-1317-74-3-525; Brown D, 1997, J BIOL CHEM, V272, P14969, DOI 10.1074/jbc.272.23.14969; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; COWLEY JA, 1992, VIRUS GENES, V6, P387, DOI 10.1007/BF01703087; DEVANEY MA, 1988, VIRUS RES, V11, P151, DOI 10.1016/0168-1702(88)90040-8; Eaton B T, 1989, Subcell Biochem, V15, P233; Fillmore GC, 2002, J VIROL, V76, P499, DOI 10.1128/JVI.76.2.499-506.2002; Fujii Y, 2003, P NATL ACAD SCI USA, V100, P2002, DOI 10.1073/pnas.0437772100; FUKUSHO A, 1989, J GEN VIROL, V70, P1677, DOI 10.1099/0022-1317-70-7-1677; Horscroft NJ, 2000, J GEN VIROL, V81, P1961, DOI 10.1099/0022-1317-81-8-1961; HUISMANS H, 1987, J VIROL, V61, P3589, DOI 10.1128/JVI.61.11.3589-3595.1987; Hyatt A. D., 1992, Bluetongue, African horse sickness, and related orbiviruses: Proceedings of the Second International Symposium., P358; HYATT AD, 1988, J GEN VIROL, V69, P805, DOI 10.1099/0022-1317-69-4-805; Kolchanov NA, 1996, PROG NUCLEIC ACID RE, V53, P131, DOI 10.1016/S0079-6603(08)60144-0; Kouznetzoff A, 1998, J GEN VIROL, V79, P1005, DOI 10.1099/0022-1317-79-5-1005; LOUDON PT, 1992, VIROLOGY, V191, P231, DOI 10.1016/0042-6822(92)90184-Q; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; Makeyev EV, 2000, EMBO J, V19, P124, DOI 10.1093/emboj/19.1.124; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mindich L, 1999, MICROBIOL MOL BIOL R, V63, P149, DOI 10.1128/MMBR.63.1.149-160.1999; Najera I, 1999, J MOL BIOL, V285, P1951, DOI 10.1006/jmbi.1998.2473; Napthine S, 1999, J MOL BIOL, V288, P305, DOI 10.1006/jmbi.1999.2688; Patton JT, 2000, VIROLOGY, V277, P217, DOI 10.1006/viro.2000.0645; Pirttimaa MJT, 2000, RNA, V6, P880, DOI 10.1017/S1355838200992598; PONCET D, 1993, J VIROL, V67, P3159, DOI 10.1128/JVI.67.6.3159-3165.1993; Portela A, 2002, J GEN VIROL, V83, P723, DOI 10.1099/0022-1317-83-4-723; RAMIG RF, 1984, J VIROL, V49, P665, DOI 10.1128/JVI.49.3.665-673.1984; Sambrook J, 2001, MOL CLONING LAB MANU; Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+; Taraporewala ZF, 2001, VIROLOGY, V280, P221, DOI 10.1006/viro.2000.0764; Tchatalbachev S, 2001, RNA, V7, P979, DOI 10.1017/S1355838201002424; TENDAM EB, 1995, RNA, V1, P146; THERON J, 1994, J GEN VIROL, V75, P3401, DOI 10.1099/0022-1317-75-12-3401; Theron J, 1996, J GEN VIROL, V77, P129, DOI 10.1099/0022-1317-77-1-129; Theron J, 1997, VIROLOGY, V229, P134, DOI 10.1006/viro.1996.8389; THOMAS CP, 1990, J GEN VIROL, V71, P2073, DOI 10.1099/0022-1317-71-9-2073; UITENWEERDE JM, 1995, VIROLOGY, V209, P624, DOI 10.1006/viro.1995.1294; VANBELKUM A, 1988, NUCLEIC ACIDS RES, V16, P1931, DOI 10.1093/nar/16.5.1931; Varani G, 2002, NAT STRUCT BIOL, V9, P158, DOI 10.1038/nsb0302-158; VLASSOV VV, 1995, NUCLEIC ACIDS RES, V23, P3161, DOI 10.1093/nar/23.16.3161; ZHAO Y, 1994, J VIROL, V68, P2179, DOI 10.1128/JVI.68.4.2179-2185.1994; Zuker M., 1999, V70, P11; [No title captured]	45	39	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31722	31730		10.1074/jbc.M301072200	http://dx.doi.org/10.1074/jbc.M301072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794083	hybrid			2022-12-25	WOS:000184782100033
J	Philippou, H; Rance, J; Myles, T; Hall, SW; Ariens, RA; Grant, PJ; Leung, L; Lane, DA				Philippou, H; Rance, J; Myles, T; Hall, SW; Ariens, RA; Grant, PJ; Leung, L; Lane, DA			Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation - Competition for cofactor sites on thrombin determines its fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FACTOR-XIII; ANTITHROMBIN-III; CATALYZED ACTIVATION; LATERAL AGGREGATION; PROTEIN-C; FIBRINOGEN; BINDING; COAGULATION; HEPARIN; DOMAIN	Factor XIII is activated by thrombin, and this reaction is enhanced by the presence of fibrin(ogen). Using a substrate-based screening assay for factor XIII activity complemented by kinetic analysis of activation peptide cleavage, we show by using thrombin mutants of surface-exposed residues that Arg-178, Arg-180, Asp-183, Glu-229, Arg-233, and Trp-50 of thrombin are necessary for direct activation of factor XIII. These residues define a low specificity site known to be important also for both protein C activation and for inhibition of thrombin by antithrombin. The enhancing effect of fibrinogen occurs as a consequence of its conversion to fibrin and subsequent polymerization. Surface residues of thrombin further involved in high specificity fibrin-enhanced factor XIII activation were identified as His-66, Tyr-71, and Asn-74. These residues represent a distinct interaction site on thrombin (within exosite I) also employed by thrombomodulin in its cofactor-enhanced activation of protein C. In competition experiments, thrombomodulin inhibited fibrin-enhanced factor XIII activation. Based upon these and prior published results, we propose that the polymerization process forms a fibrin cofactor that acts to approximate thrombin and factor XIII bound to separate and complementary domains of fibrinogen. This enables enhanced factor XIII activation to be localized around the fibrin clot. We also conclude that proximity to and competition for cofactor interaction sites primarily directs the fate of thrombin.	Univ Leeds, Sch Med, Leeds Gen Infirm, Acad Unit Mol Vasc Med, Leeds LS1 3EX, W Yorkshire, England; Univ London Imperial Coll Sci Technol & Med, Dept Haematol, London W12 0NN, England; Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA	Leeds General Infirmary; University of Leeds; Imperial College London; Stanford University	Lane, DA (corresponding author), Univ Leeds, Sch Med, Leeds Gen Infirm, Acad Unit Mol Vasc Med, Leeds LS1 3EX, W Yorkshire, England.			Ariens, Robert/0000-0002-6310-5745; Philippou, Helen/0000-0002-9199-4201				Ariens RAS, 2000, BLOOD, V96, P988, DOI 10.1182/blood.V96.3.988.015k57_988_995; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Butenas S, 1999, BLOOD, V94, P2169, DOI 10.1182/blood.V94.7.2169.419k22_2169_2178; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CREDO RB, 1981, BIOCHEMISTRY-US, V20, P3770, DOI 10.1021/bi00516a016; De Candia E, 2001, J BIOL CHEM, V276, P4692, DOI 10.1074/jbc.M008160200; De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FORNACE AJ, 1984, J BIOL CHEM, V259, P2826; GREENBERG CS, 1985, BLOOD, V66, P466; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; ICHINOSE A, 1994, HAEMOSTASIS THROMBOS, P531; JANUS TJ, 1983, BIOCHEMISTRY-US, V22, P6269, DOI 10.1021/bi00295a035; JESTY J, 1979, J BIOL CHEM, V254, P44; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LORAND L, 1974, BIOCHEM BIOPH RES CO, V56, P914, DOI 10.1016/S0006-291X(74)80275-5; Lorand L, 2001, ANN NY ACAD SCI, V936, P291; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; Meh DA, 1996, J BIOL CHEM, V271, P23121, DOI 10.1074/jbc.271.38.23121; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; SONG YQC, 1994, ANAL BIOCHEM, V223, P88, DOI 10.1006/abio.1994.1551; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tsiang M, 1997, J BIOL CHEM, V272, P12024, DOI 10.1074/jbc.272.18.12024; Tsurupa G, 2002, BIOCHEMISTRY-US, V41, P6449, DOI 10.1021/bi025584r; WEISEL JW, 1986, BIOPHYS J, V50, P1079, DOI 10.1016/S0006-3495(86)83552-4; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382	34	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32020	32026		10.1074/jbc.M305364200	http://dx.doi.org/10.1074/jbc.M305364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12794066	hybrid			2022-12-25	WOS:000184782100072
J	Norregaard, L; Loland, CJ; Gether, U				Norregaard, L; Loland, CJ; Gether, U			Evidence for distinct sodium-, dopamine-, and cocaine-dependent conformational changes in transmembrane segments 7 and 8 of the dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTERS; GABA TRANSPORTER-1; BINDING-SITES; ACCESSIBILITY; FLUORESCENCE; EXPRESSION; SUBSTRATE; CELLS	Previously we obtained evidence based on engineering of Zn2+ binding sites that the extracellular parts of transmembrane segment 7 (TM7) and TM8 in the human dopamine transporter are important for transporter function. To further evaluate the role of this domain, we have employed the substituted cysteine accessibility method and performed 10 single cysteine substitutions at the extracellular ends of TM7 and TM8. The mutants were made in background mutants of the human dopamine transporter with either two (E2C) or five endogenous cysteines substituted (X5C) that render the transporter largely insensitive to cysteine modification. In two mutants (M371C and A399C), treatment with the sulfhydryl-reactive reagent [2-( trimethylammonium)ethyl] methanethiosulfonate (MTSET) led to a substantial inhibition of [H-3] dopamine uptake. In M371C this inactivation was enhanced by Na+ and blocked by dopamine. Inhibitors such as cocaine did not alter the effect of MTSET in M371C. The protection of M371C inactivation by dopamine required Na+. Because dopamine binding is believed to be Na+-independent, this suggests that dopamine induces a transport-associated conformational change that decreases the reactivity of M371C with MTSET. In contrast to M371C, cocaine decreased the reaction rate of A399C with MTSET, whereas dopamine had no effect. The protection by cocaine can either reflect that Ala-399 lines the cocaine binding crevice or that cocaine induces a conformational change that decreases the reactivity of A399C. The present findings add new functionality to the TM7/8 region by providing evidence for the occurrence of distinct Na+-, substrate-, and perhaps inhibitor-induced conformational changes critical for the proper function of the transporter.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen N, Denmark.		Loland, Claus/E-5975-2014	Loland, Claus/0000-0002-1773-1446; Gether, Ulrik/0000-0002-0020-3807	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA 12408] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; Chen NH, 2002, J NEUROCHEM, V81, P1383, DOI 10.1046/j.1471-4159.2002.00941.x; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kobilka BK, 2002, METHOD ENZYMOL, V343, P170; Li LB, 2002, N-S ARCH PHARMACOL, V365, P303, DOI 10.1007/s00210-001-0526-6; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; Meinild AK, 2002, BIOCHEMISTRY-US, V41, P1250, DOI 10.1021/bi011661r; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norgaard-Nielsen K, 2002, FEBS LETT, V524, P87, DOI 10.1016/S0014-5793(02)03008-9; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Schwartz JW, 2003, J BIOL CHEM, V278, P9768, DOI 10.1074/jbc.M209824200; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013	37	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30587	30596		10.1074/jbc.M303854200	http://dx.doi.org/10.1074/jbc.M303854200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773538	hybrid			2022-12-25	WOS:000184658800023
J	Volynski, KE; Capogna, M; Ashton, AC; Thomson, D; Orlova, EV; Manser, CF; Ribchester, RR; Ushkaryov, YA				Volynski, KE; Capogna, M; Ashton, AC; Thomson, D; Orlova, EV; Manser, CF; Ribchester, RR; Ushkaryov, YA			Mutant alpha-latrotoxin (LTXN4C) does not form pores and causes secretion by receptor stimulation - This action does not require neurexins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CALCIUM-INDEPENDENT RECEPTOR; FROG NEUROMUSCULAR-JUNCTION; MOTOR-NERVE TERMINALS; TRANSMITTER RELEASE; SYNAPTIC VESICLES; CHROMAFFIN CELLS; MEMBRANE PORES; STORED CA2+; I-ALPHA	alpha-Latrotoxin (LTX) causes massive release of neurotransmitters via a complex mechanism involving (i) activation of receptor(s) and (ii) toxin insertion into the plasma membrane with (iii) subsequent pore formation. Using cryo-electron microscopy, electrophysiological and biochemical methods, we demonstrate here that the recently described toxin mutant (LTXN4C) is unable to insert into membranes and form pores due to its inability to assemble into tetramers. However, this mutant still binds to major LTX receptors (latrophilin and neurexin) and causes strong transmitter exocytosis in synaptosomes, hippocampal slice cultures, neuromuscular junctions, and chromaffin cells. In the absence of mutant incorporation into the membrane, receptor activation must be the only mechanism by which LTXN4C triggers exocytosis. An interesting feature of this receptor-mediated transmitter release is its dependence on extracellular Ca2+. Because Ca2+ is also strictly required for LTX interaction with neurexin, the latter might be the only receptor mediating the LTXN4C action. To test this hypothesis, we used conditions (substitution of Ca2+ in the medium with Sr2+) under which LTXN4C does not bind to any member of the neurexin family but still interacts with latrophilin. We show that, in all the systems tested, Sr2+ fully replaces Ca2+ in supporting the stimulatory effect of LTXN4C. These results indicate that LTXN4C can cause neurotransmitter release just by stimulating a receptor and that neurexins are not critical for this receptor-mediated action.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England; MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; Univ Edinburgh, Dept Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland	Imperial College London; University of Edinburgh	Ushkaryov, YA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England.		Orlova, Elena/CAF-8290-2022; Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Volynski, Kirill/0000-0001-8208-1905; Capogna, Marco/0000-0002-2742-5485; Orlova, Elena/0000-0003-3371-415X				Ashton AC, 2000, BIOCHIMIE, V82, P453, DOI 10.1016/S0300-9084(00)00199-1; Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; Bittner MA, 2000, J BIOL CHEM, V275, P25351, DOI 10.1074/jbc.M004884200; Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 2003, J NEUROSCI, V23, P4044; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Elrick DB, 1999, J NEUROPHYSIOL, V82, P3550, DOI 10.1152/jn.1999.82.6.3550; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Khvotchev M, 2000, EMBO J, V19, P3250, DOI 10.1093/emboj/19.13.3250; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Liu J, 1998, J NEUROSCI, V18, P6113; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; MALLART A, 1985, MUSCLE NERVE, V8, P151, DOI 10.1002/mus.880080211; Matsushita H, 1999, FEBS LETT, V443, P348, DOI 10.1016/S0014-5793(99)00005-8; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; PHELAN P, 1997, NEUROCHEMISTRY PRACT, P1; QUEIROZ LS, 1982, PROC R SOC SER B-BIO, V216, P103, DOI 10.1098/rspb.1982.0063; Rahman MA, 1999, PHILOS T ROY SOC B, V354, P379, DOI 10.1098/rstb.1999.0390; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tobaben S, 2002, J BIOL CHEM, V277, P6359, DOI 10.1074/jbc.M111231200; Tsang CW, 2000, J NEUROSCI, V20, P8685; Ushkaryov Y, 2002, TOXICON, V40, P1, DOI 10.1016/S0041-0101(01)00204-5; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1986, BIOORG KHIM+, V12, P71; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; Volynski KE, 1999, FEBS LETT, V442, P25, DOI 10.1016/S0014-5793(98)01624-X; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; WATANABE O, 1983, NEUROSCIENCE, V10, P1011, DOI 10.1016/0306-4522(83)90239-7	45	33	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31058	31066		10.1074/jbc.M210395200	http://dx.doi.org/10.1074/jbc.M210395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782639	hybrid			2022-12-25	WOS:000184658800082
J	Potter, DA; Srirangam, A; Fiacco, KA; Brocks, D; Hawes, J; Herndon, C; Maki, M; Acheson, D; Herman, IM				Potter, DA; Srirangam, A; Fiacco, KA; Brocks, D; Hawes, J; Herndon, C; Maki, M; Acheson, D; Herman, IM			Calpain regulates enterocyte brush border actin assembly and pathogenic Escherichia coli-mediated effacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; MICROVILLUS CYTOSKELETON; CALMODULIN-BINDING; APICAL MICROVILLI; PROTEASE CALPAIN; PARIETAL-CELLS; MU-CALPAIN; BETA-ACTIN; MEMBRANE; EZRIN	This study identifies calpain as being instrumental for brush border (BB) microvillus assembly during differentiation and effacement during bacterial pathogenesis. Calpain activity is decreased by 25-80% in Caco 2 lines stably overexpressing calpastatin, the physiological inhibitor of calpain, and the effect is proportional to the calpastatin/calpain ratio. These lines exhibit a 2.5-fold reduction in the rate of microvillus extension. Apical microvillus assembly is reduced by up to 50%, as measured by quantitative fluorometric microscopy (QFM) of ezrin, indicating that calpain recruits ezrin to BB microvilli. Calpain inhibitors ZLLYCHN(2), MDL 28170, and PD 150606 block BB assembly and ezrin recruitment to the BB. The HIV protease inhibitor ritonavir, which inhibits calpain at clinically relevant concentrations, also blocks BB assembly, whereas cathepsin and proteasome inhibitors do not. Microvillus effacement is inhibited after exposure of calpastatin-overexpressing cells to enteropathogenic Escherichia coli. These results suggest that calpain regulates BB assembly as well as pathological effacement, and indicate that it is an important regulator involved in HIV protease inhibitor toxicity and host-microbial pathogen interactions.	Indiana Univ, Sch Med, Dept Med, Walther Oncol Ctr,Div Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Nagoya Univ, Grad Sch Bioagr Sci, Dept Mol Appl Biosci, Nagoya, Aichi 46401, Japan; Univ Maryland, Dept Publ Hlth, Baltimore, MD 21201 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University-Purdue University Indianapolis; Nagoya University; University System of Maryland; University of Maryland Baltimore; Tufts University	Herman, IM (corresponding author), Indiana Univ, Sch Med, Dept Med, Walther Oncol Ctr,Div Hematol Oncol, 1044 W Walnut St, Indianapolis, IN 46202 USA.				NATIONAL CANCER INSTITUTE [K08CA001562] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055110, P20GM066402] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA001562-04] Funding Source: Medline; NEI NIH HHS [EY09033] Funding Source: Medline; NIDDK NIH HHS [P30 DK034928, P30 DK34928] Funding Source: Medline; NIGMS NIH HHS [P20 GM66402, GM 55110, P20 GM066402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; Barnoy S, 1998, BBA-MOL CELL RES, V1402, P52, DOI 10.1016/S0167-4889(97)00144-4; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bode H, 2000, ANN NY ACAD SCI, V915, P117; BRETSCHER A, 1983, CIBA F SYMP, V95, P164; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; BURGESS DR, 1982, J CELL BIOL, V94, P97, DOI 10.1083/jcb.94.1.97; BURGESS DR, 1974, J CELL BIOL, V62, P566, DOI 10.1083/jcb.62.2.566; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CROALL DE, 1992, BIOCHIM BIOPHYS ACTA, V1121, P47, DOI 10.1016/0167-4838(92)90335-B; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; DOURDIN N, 2001, J BIOL CHEM, V15, P15; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; FRANCIS CL, 1991, J INFECT DIS, V164, P693, DOI 10.1093/infdis/164.4.693; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; GRIFFITHS JK, 1994, INFECT IMMUN, V62, P4506, DOI 10.1128/IAI.62.10.4506-4514.1994; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HERMAN IM, 1981, J CELL BIOL, V88, P346, DOI 10.1083/jcb.88.2.346; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; IBRAHIM M, 1994, MOL CELL BIOCHEM, V131, P49, DOI 10.1007/BF01075724; Kenny B, 1997, INFECT IMMUN, V65, P2606, DOI 10.1128/IAI.65.7.2606-2612.1997; KNUTTON S, 1993, ZBL BAKT-INT J MED M, V278, P209; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Maki M., 1990, INTRACELLULAR CALCIU, P37; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MATSUDAIRA PT, 1983, CIBA F SYMP, V95, P233; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; Melendez-Vasquez CV, 2001, P NATL ACAD SCI USA, V98, P1235, DOI 10.1073/pnas.98.3.1235; Mellgren RL, 1997, J BIOL CHEM, V272, P29899, DOI 10.1074/jbc.272.47.29899; MOOSEKER MS, 1980, J CELL BIOL, V87, P809, DOI 10.1083/jcb.87.3.809; MOOSEKER MS, 1982, J CELL BIOL, V95, P223, DOI 10.1083/jcb.95.1.223; Mueller BU, 1998, PEDIATRICS, V101, P335, DOI 10.1542/peds.101.3.335; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; PEARL M, 1984, J CELL BIOL, V98, P66, DOI 10.1083/jcb.98.1.66; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; Shuster CB, 1996, CELL MOTIL CYTOSKEL, V35, P175; STIDWILL RP, 1984, J CELL BIOL, V98, P641, DOI 10.1083/jcb.98.2.641; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Wan WS, 2002, BIOCHEM PHARMACOL, V63, P1481, DOI 10.1016/S0006-2952(02)00907-3; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Wang KKW, 1996, ADV EXP MED BIOL, V389, P95; YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825	53	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30403	30412		10.1074/jbc.M304616200	http://dx.doi.org/10.1074/jbc.M304616200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12764139	hybrid, Green Accepted			2022-12-25	WOS:000184507000121
J	Zhang, JH; Wang, SB; Wesley, RA; Danner, RL				Zhang, JH; Wang, SB; Wesley, RA; Danner, RL			Adjacent sequence controls the response polarity of nitric oxide-sensitive Sp factor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; SMOOTH-MUSCLE-CELLS; VASCULAR ENDOTHELIAL-CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR SP1; GENE-EXPRESSION; CYCLIC-AMP; DNA-BINDING; HUMAN NEUTROPHILS; ALPHA PRODUCTION	Nitric oxide (NO.) and cAMP-dependent protein kinase (PKA) inhibitors up-regulate tumor necrosis factor alpha (TNFalpha) by decreasing Sp1 binding to a proximal GC box element. Here, elements flanking GC boxes were tested for their role in determining whether Sp sites act as activators or repressors. Promoter studies in receptive human cell lines demonstrated that NO. down-regulated endothelial NO. synthase ( eNOS) but up-regulated TNFalpha. Like TNFalpha, Sp1 binding to the eNOS promoter was decreased by NO. and a PKA inhibitor, H89, and increased by a PKA activator, dibutyryl cAMP (Bt(2)cAMP). For either promoter, mutation of Sp sites abolished NO. responses. In contrast, mutation of an upstream AP1 site in the TNFalpha promoter ( not present in eNOS) maintained NO. responsiveness, but reversed the direction of NO. and cAMP effects. Using artificial constructs, NO. increased transcription when Sp and AP1 sites were both present (TNFalpha-like response), but decreased it when the adjacent AP1 site was disrupted (eNOS-like response). NO., H89, and Bt2cAMP were found to produce reciprocal protein binding changes at contiguous AP1 and Sp sites ( p < 0.0001 for an interaction). Chromatin immunoprecipitation assays demonstrated that Sp1 and to a lesser extent Sp3 bound to the GC box regions of eNOS and TNF&alpha; in intact cells. Thus, this NO&BULL;- and cAMP-responsive regulatory module has a Sp site sensor variably coupled to an adjacent element that determines response polarity. These results define a composite element that can utilize secondary inputs to convert off signals to on, thereby conferring complex functionalities to the same DNA binding motif.	NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Danner, RL (corresponding author), NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bldg 10,Rm 7D43, Bethesda, MD 20892 USA.							Alroy I, 1999, MOL CELL BIOL, V19, P1961; Bauer PM, 2001, P NATL ACAD SCI USA, V98, P12802, DOI 10.1073/pnas.211443198; Berendji D, 1999, MOL MED, V5, P721, DOI 10.1007/BF03402096; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; Corriveau CC, 1998, J INFECT DIS, V177, P116, DOI 10.1086/513829; Cote F, 2002, J NEUROCHEM, V81, P673, DOI 10.1046/j.1471-4159.2002.00890.x; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; delaTorre A, 1998, SURGERY, V124, P137, DOI 10.1016/S0039-6060(98)70113-8; DiMario JX, 2002, INT J MOL MED, V10, P65; Du BH, 2000, J BIOL CHEM, V275, P39039, DOI 10.1074/jbc.M005159200; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Eigler A, 1998, J LEUKOCYTE BIOL, V63, P101, DOI 10.1002/jlb.63.1.101; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Jeremy JY, 1999, CARDIOVASC RES, V43, P580, DOI 10.1016/S0008-6363(99)00171-6; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kibbe MR, 2000, J VASC SURG, V31, P1214, DOI 10.1016/S0741-5214(00)90112-5; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LANDER HM, 1993, J IMMUNOL, V150, P1509; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Lim SP, 2000, J VIROL, V74, P1632, DOI 10.1128/JVI.74.4.1632-1640.2000; Liu XK, 1998, LIFE SCI, V62, P739, DOI 10.1016/S0024-3205(97)01172-7; Ma PL, 2002, CRIT CARE MED, V30, P947, DOI 10.1097/00003246-200204000-00049; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Melino G, 2000, CANCER RES, V60, P2377; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Ogra Y, 2001, J BIOL CHEM, V276, P16534, DOI 10.1074/jbc.M100570200; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROMAN D, 1990, New Biologist, V2, P642; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; VOLICER L, 1971, EUR J PHARMACOL, V15, P214, DOI 10.1016/0014-2999(71)90176-2; von Knethen A, 2002, J IMMUNOL, V169, P2619, DOI 10.4049/jimmunol.169.5.2619; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wang WH, 2001, AM J PHYSIOL-CELL PH, V281, pC544, DOI 10.1152/ajpcell.2001.281.2.C544; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Yan L, 1997, BLOOD, V90, P1160, DOI 10.1182/blood.V90.3.1160.1160_1160_1167; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927; Zhang JH, 1998, J BIOL CHEM, V273, P23454, DOI 10.1074/jbc.273.36.23454	57	18	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29192	29200		10.1074/jbc.M213043200	http://dx.doi.org/10.1074/jbc.M213043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759366	hybrid			2022-12-25	WOS:000184421100104
J	Macaluso, M; Cinti, C; Russo, G; Russo, A; Giordano, A				Macaluso, M; Cinti, C; Russo, G; Russo, A; Giordano, A			PRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer	ONCOGENE			English	Article						pRb2/p130; chromatin-modifying enzymes; estrogen receptor-alpha; breast carcinoma	HISTONE DEACETYLASE INHIBITION; CHROMATIN-REMODELING COMPLEXES; CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; REPRESSES TRANSCRIPTION; GENE-EXPRESSION; DNA METHYLATION; METHYLTRANSFERASE; RECRUITMENT; ACETYLATION	The estrogen receptor-alpha (ER) plays a crucial role in normal breast development and is also linked to development and progression of mammary carcinoma. The transcriptional repression of ER-alpha gene in breast cancer is an area of active investigation with potential clinical significance. However, the molecular mechanisms that regulate the ER-alpha gene expression are not fully understood. Here we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells. We investigated in vivo occupancy of ER-alpha promoter by pRb2/p130-E2F4/5-HDAC1-SUV39 H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 complexes, and provided a link between pRb2/p130 and chromatin-modifying enzymes in the regulation of ER-alpha transcription in a physiological setting. These findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Palermo, Dept Oncol, Sect Mol Oncol, Reg Reference Ctr Biomol Characterizat Neoplasms, Palermo, Italy; CNR, ITOI, Inst Normal & Pathol Cytomorphol, I-40126 Bologna, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; Consiglio Nazionale delle Ricerche (CNR); University of Siena	Macaluso, M (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369				Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Davis T, 2000, CLIN CANCER RES, V6, P4334; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1998, CANCER RES, V58, P2515; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Parl F.F., 2000, ESTROGENS ESTROGEN R; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Stiegler P, 1998, CANCER RES, V58, P5049; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WEIGEL RJ, 1993, CANCER RES, V53, P3472; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890	34	114	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3511	3517		10.1038/sj.onc.1206578	http://dx.doi.org/10.1038/sj.onc.1206578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789259				2022-12-25	WOS:000183399200001
J	Land, A; Zonneveld, D; Braakman, I				Land, A; Zonneveld, D; Braakman, I			Folding of HIV-1 Envelope glycoprotein involves extensive isomerization of disulfide bonds and conformation-dependent leader peptide cleavage	FASEB JOURNAL			English	Article						gp120; gp160; endoplasmic reticulum; signal sequence; protein processing	IMMUNODEFICIENCY-VIRUS TYPE-1; PANCREATIC TRYPSIN-INHIBITOR; N-ACETYLGLUCOSAMINIDASE-F; ENDOPLASMIC-RETICULUM; SIGNAL-SEQUENCE; TRANSMEMBRANE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; QUALITY-CONTROL; VACCINIA VIRUS	Human immunodeficiency virus binds and enters cells via the Envelope glycoprotein gp160 at its surface. In infected cells, gp160 is found not only on the plasma membrane but also in the endoplasmic reticulum (ER). Our aim was to establish rate-determining steps in the maturation process of gp160, using a radioactive pulse-chase approach. We found that gp160 has an intricate folding process: disulfide bonds start to form during synthesis but undergo extensive isomerization until the correct native conformation is reached. Removal of the leader peptide critically depends on formation of at least some disulfide bonds in subunit gp120 during folding. Envelope folds extremely slowly and therefore resides in the ER longer than other proteins, but the yield of properly folded molecules is high and degradation is undetectable. The large quantity of gp160 in the ER hence is a result of its slow transit through this compartment. We show here that newly synthesized HIV-1 Envelope glycoprotein apparently follows a slow but high-yield folding path in which co- and post-translational formation of disulfide bonds in gp120, disulfide isomerization and conformation dependent removal of the leader sequence are determining and intertwined events.	Univ Utrecht, Dept Bioorgan Chem 1, NL-3584 CH Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	Braakman, I (corresponding author), Univ Utrecht, Dept Bioorgan Chem 1, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	I.Braakman@chem.uu.nl		Braakman, Ineke/0000-0003-1592-4364				ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; Benham AM, 2000, CRIT REV BIOCHEM MOL, V35, P433, DOI 10.1080/10409230091169258; BERMAN PW, 1988, J VIROL, V62, P3135, DOI 10.1128/JVI.62.9.3135-3142.1988; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; Das AT, 1999, VIROLOGY, V263, P55, DOI 10.1006/viro.1999.9898; Dettenhofer M, 2001, J BIOL CHEM, V276, P5985, DOI 10.1074/jbc.M008933200; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FENNIE C, 1989, J VIROL, V63, P639, DOI 10.1128/JVI.63.2.639-646.1989; FENOUILLET E, 1995, J GEN VIROL, V76, P1509, DOI 10.1099/0022-1317-76-6-1509; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; HALLENBERGER S, 1993, VIROLOGY, V193, P510, DOI 10.1006/viro.1993.1156; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; KIENY MP, 1986, BIO-TECHNOL, V4, P790, DOI 10.1038/nbt0986-790; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; LAEMMLI UK, 1970, J MOL BIOL, V49, P99, DOI 10.1016/0022-2836(70)90379-7; Land A, 2001, BIOCHIMIE, V83, P783, DOI 10.1016/S0300-9084(01)01314-1; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LI Y, 1994, VIROLOGY, V204, P266, DOI 10.1006/viro.1994.1531; LI Y, 1993, J VIROL, V67, P584, DOI 10.1128/JVI.67.1.584-588.1993; Li Y, 2000, VIROLOGY, V272, P417, DOI 10.1006/viro.2000.0357; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9; Moulard M, 1999, VIRUS RES, V60, P55, DOI 10.1016/S0168-1702(99)00002-7; Otteken A, 1996, J VIROL, V70, P3407, DOI 10.1128/JVI.70.6.3407-3415.1996; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PAL R, 1989, P NATL ACAD SCI USA, V86, P3384, DOI 10.1073/pnas.86.9.3384; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Rothenberg SM, 2001, J VIROL, V75, P11851, DOI 10.1128/JVI.75.23.11851-11862.2001; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STEUBE K, 1985, BIOCHEMISTRY-US, V24, P5587, DOI 10.1021/bi00341a045; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Tarentino A L, 1978, Methods Enzymol, V50, P574; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	56	78	81	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1058	1067		10.1096/fj.02-0811com	http://dx.doi.org/10.1096/fj.02-0811com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773488	Green Submitted			2022-12-25	WOS:000183818000009
J	Laposa, RR; Henderson, JT; Wells, PG				Laposa, RR; Henderson, JT; Wells, PG			Tetracycline-dependent regulation of formamidopyrimidine DNA glycosylase in transgenic mice conditionally reduces oxidative DNA damage in vivo	FASEB JOURNAL			English	Article						DNA repair; oxidative stress; brain	BASE EXCISION-REPAIR; MAMMALIAN-CELLS; ESCHERICHIA-COLI; ALZHEIMERS-DISEASE; OGG1 PROTEIN; SACCHAROMYCES-CEREVISIAE; CHEMICAL TERATOGENESIS; GENE-EXPRESSION; 8-HYDROXYGUANINE; 8-OXOGUANINE	8-Oxo-deoxyguanosine (8-oxo-dG) is a pervasive oxidative DNA lesion formed by endogenous oxidative stress and enhanced by drugs and environmental chemicals. This lesion results in transcriptional errors and mutations and is linked to neurodegeneration, teratogenesis, cancer, and other pathologies. We demonstrate that the neonatal central nervous system of transgenic mice carrying the tetracycline-regulable DNA repair gene formamidopyrimidine DNA glycosylase (fpg) has a 50% reduction in 8-oxo-dG levels. This enhanced DNA repair is suppressed by treatment with doxycycline. For the first time, this murine model permits the level of a specific DNA oxidation product to be regulated in a temporally and spatially specific manner, allowing its role as a primary or secondary factor in neurodegenerative disease to be determined in vivo.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	pg.wells@utoronto.ca						ACKLANDBERGLUND CE, 1995, BIOTECHNIQUES, V18, P196; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Alamo MJP, 1998, NUCLEIC ACIDS RES, V26, P5199, DOI 10.1093/nar/26.22.5199; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Ames Bruce N., 1995, Microbiologia (Madrid), V11, P305; Asami S, 1996, CANCER RES, V56, P2546; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boiteux S, 1998, FREE RADICAL RES, V29, P487, DOI 10.1080/10715769800300541; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; CUSSAC C, 1996, NUCLEIC ACIDS RES, V24, P1772; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P243, DOI 10.1016/S0921-8777(00)00006-9; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Gill RD, 1996, CANCER RES, V56, P3721; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guibourt N, 2000, BIOCHEMISTRY-US, V39, P1716, DOI 10.1021/bi992262n; HALL J, 1993, INT J CANCER, V54, P728, DOI 10.1002/ijc.2910540504; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; LAVAL F, 1994, NUCLEIC ACIDS RES, V22, P4943, DOI 10.1093/nar/22.23.4943; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lyras L, 1997, J NEUROCHEM, V68, P2061; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Moallem SA, 1998, DEVELOPMENT, V125, P3225; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; QUIN H, 1997, J BIOCHEM BIOPH METH, V36, P63; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Sarao R, 1998, TRANSGENIC RES, V7, P421, DOI 10.1023/A:1008837410485; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; WILSON DM, 1998, DNA REPAIR PROKARYOT; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x; [No title captured]	45	7	7	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1343	+		10.1096/fj.02-0689fje	http://dx.doi.org/10.1096/fj.02-0689fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759334				2022-12-25	WOS:000183165000019
J	Marks, J; Saifudeen, Z; Dipp, S; El-Dahr, SS				Marks, J; Saifudeen, Z; Dipp, S; El-Dahr, SS			Two functionally divergent p53-responsive elements in the rat bradykinin B-2 receptor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DIFFERENTIAL GENE-EXPRESSION; NUCLEAR ANTIGEN PROMOTER; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; DNA-BINDING; MICROARRAY ANALYSIS; CANDIDATE MEDIATOR; TARGET GENES; APOPTOSIS	Although p53 is known to have dual functions as a transcriptional activator and repressor, there has not been an example where both p53-activating and -repressing elements reside within one target promoter. Previous work from this laboratory defined two different p53 response elements, termed P1 and P2, located at nucleotide positions -70 and -707, respectively, in the rat bradykinin B2 receptor promoter. In this study, through manipulation of the DNA sequence and context, we demonstrate opposing roles for P1 and P2 as transcriptional activator and repressor, respectively. Deletion of P1 abrogates p53-mediated activation. P1 maintains its role as an activator upon relocation to the P2 site and activates transcription from a heterologous promoter construct. Thus, P1 is a bona fide positive p53-response element. In contrast, deletion of P2 enhances P1-induced activation. P2 represses transcription when substituted for P1 or when relocated midway between P1 and P2. P2-mediated repression is sequence-dependent, because it is reversed to activation when P2 is substituted by the P1 or p53 consensus sequences. Moreover, site-directed mutagenesis that converts P2 to a higher affinity p53-binding site results in transcriptional activation rather than repression. Surprisingly, P2 strongly activates a heterologous promoter. Thus, P2-mediated transcriptional repression is both sequence- and context-dependent. Investigations into the mechanisms of P2-mediated repression indicate that it is trichostatin-insensitive and unaffected by CBP or mutation of the minimal repression C-terminal domain of p53. However, gel shift assays suggest that p53 competes with other transcriptional activators for binding to overlapping binding sequences within the P2 element. In conclusion, this study provides a rare example of a transcription factor having two divergent functional effects that are sequence- and context-dependent. The interplay of P1 and P2 may be important in the regulation of bradykinin B2 receptor gene expression in response to inflammatory stress and during development.	Tulane Univ, Sect Pediat Nephrol, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70112 USA	Tulane University	El-Dahr, SS (corresponding author), Tulane Univ, Sect Pediat Nephrol, Hlth Sci Ctr, Dept Pediat, SL-37,1430 Tulane Ave, New Orleans, LA 70112 USA.				NIDDK NIH HHS [R01 DK56264, DK-62250, 1F32 DK-61137] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056264, R01DK062250, F32DK061137] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; DEB SP, 1994, ONCOGENE, V9, P1341; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lo PK, 2001, J BIOL CHEM, V276, P37186, DOI 10.1074/jbc.M104701200; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Mitry RR, 1997, LAB INVEST, V77, P369; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ogden SK, 2001, J BIOL CHEM, V276, P42057, DOI 10.1074/jbc.C100381200; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Saifudeen Z, 2002, AM J PHYSIOL-RENAL, V283, pF727, DOI 10.1152/ajprenal.00114.2002; Saifudeen Z, 2002, J CLIN INVEST, V109, P1021, DOI 10.1172/JCI200213972; Saifudeen Z, 2000, J BIOL CHEM, V275, P15557, DOI 10.1074/jbc.M909810199; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Webster NJG, 1996, CANCER RES, V56, P2781; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao RB, 2000, GENE DEV, V14, P981	42	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34158	34166		10.1074/jbc.M304543200	http://dx.doi.org/10.1074/jbc.M304543200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12791684	hybrid			2022-12-25	WOS:000185047500069
J	Wang, CH; Yeung, F; Liu, PC; Attar, RM; Geng, JP; Chung, LWK; Gottardis, M; Kao, CH				Wang, CH; Yeung, F; Liu, PC; Attar, RM; Geng, JP; Chung, LWK; Gottardis, M; Kao, CH			Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; GENE; RECEPTOR; CANCER; GATA; ENHANCER; SEQUENCES; INDUCTION; PROMOTER; PROGRESSION	Prostate-specific antigen (PSA) is the most valuable marker for the evaluation of prostate cancer progression. The expression of PSA is controlled by androgen receptor (AR) through its binding to androgen-response elements (AREs). Several AREs have been identified within the 5.8-kb PSA promoter. The main activity of this 5.8-kb PSA promoter resides in a 455-bp enhancer core region located about 4 kb upstream of the TATA box. Our study suggests that in addition to the four AREs identified in the PSA enhancer core, another regulatory element (GAGATA), which is located at the region designated PSA3.1, also contributes to transcriptional regulation by androgens. Furthermore, electrophoretic mobility shift assay revealed that a putative transcriptional factor bound the GAGATA sequence in the PSA-producing prostate cancer cell. Further studies demonstrated that GAGATA factor preferentially bound the (G/C)(A/C/T)GATA sequence. The replacement of ATA with GGG in the GAGATA sequence completely eliminated the androgen-mediated transcriptional activity of the enhancer core. By using DNA-coupled magnetic beads and the Southwestern method, a 56-60-kDa protein was identified as the putative GAGATA binding factor. EMSA and Western blotting assay suggested that AR is not involved in androgen-mediated activation through PSA3.1. Therefore, we propose that binding of the GAGATA binding factor and AR to GAGATA and AREs, respectively, of the PSA enhancer core are required for the maximum transcriptional response to androgens.	Indiana Univ, Dept Urol, Indianapolis, IN 46202 USA; Kaohsiung Med Univ, Orthoped Res Ctr, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Biol, Kaohsiung 807, Taiwan; Bristol Myers Squibb Co, Dept Oncol, Princeton, NJ 08543 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Emory Univ, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Kaohsiung Medical University; Kaohsiung Medical University; Bristol-Myers Squibb; University of Virginia; Emory University; Emory University	Kao, CH (corresponding author), Indiana Univ, Dept Urol, Indiana Canc Pavil,535 N Barnhill Dr,Suite 420, Indianapolis, IN 46202 USA.		Wang, Chi-Huei/C-9655-2009		NCI NIH HHS [CA74042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074042, R01CA074042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABMAYR SM, 1993, CURRENT PROTOCOLS MO; ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; Bhayani S B, 1999, Semin Urol Oncol, V17, P148; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Castaldo G, 1997, CLIN CHIM ACTA, V265, P65, DOI 10.1016/S0009-8981(97)00105-8; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; DEVOS P, 1991, J BIOL CHEM, V266, P3439; HENTTU P, 1994, ANN MED, V26, P157, DOI 10.3109/07853899409147884; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; KASPER S, 1994, J BIOL CHEM, V269, P31763; Kim J, 1999, UROL CLIN N AM, V26, P281, DOI 10.1016/S0094-0143(05)70068-9; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lin CS, 2000, DNA CELL BIOL, V19, P1, DOI 10.1089/104454900314654; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Moul JW, 2000, J UROLOGY, V163, P1632, DOI 10.1016/S0022-5347(05)67511-8; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; Perez-Stable CM, 2000, MOL CELL ENDOCRINOL, V167, P43, DOI 10.1016/S0303-7207(00)00300-2; Richie JP, 1999, UROLOGY, V54, P15, DOI 10.1016/S0090-4295(99)00449-5; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RUCKLE HC, 1993, WORLD J UROL, V11, P227; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; TAN JA, 1992, J BIOL CHEM, V267, P4456; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Wang CH, 2000, ENDOCRINE, V12, P69, DOI 10.1385/ENDO:12:1:69; WEISS MJ, 1995, EXP HEMATOL, V23, P99	31	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32423	32430		10.1074/jbc.M207862200	http://dx.doi.org/10.1074/jbc.M207862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12782640	hybrid			2022-12-25	WOS:000184782100122
J	Agoulnik, IU; Krause, WC; Bingman, WE; Rahman, HT; Amrikachi, M; Ayala, GE; Weigel, NL				Agoulnik, IU; Krause, WC; Bingman, WE; Rahman, HT; Amrikachi, M; Ayala, GE; Weigel, NL			Repressors of androgen and progesterone receptor action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL HYPOPLASIA CONGENITA; TRANSCRIPTIONAL ACTIVATION; CO-REPRESSOR; N-COR; COREPRESSOR; DAX-1; PHOSPHORYLATION; COACTIVATOR; DOMAINS; BINDING	Androgen and progesterone receptors (AR and PR) are two determining factors in gonadal differentiation that are highly expressed in developing and mature gonads. Loss of AR results in XY sex reversal and mutations causing reduced AR activity lead to varying degrees of defects in masculinization. Female PR knockout mice are infertile due to ovarian defects. While much has been discovered about positive regulation of these receptors by coactivators little is known about repression of the transcriptional activity of AR and PR in the presence of agonists. In this study we assessed the effect of SMRT and DAX-1 on AR and PR activity in the presence of both agonists and partial antagonists. We show that SMRT and DAX-1 repress agonist-dependent activity of both receptors, and the mechanism of repression includes disruption of the receptor dimer interactions rather than recruitment of histone deacetylases. We demonstrate that endogenous agonist-bound PR and DAX-1 in T47D breast cancer cells and endogenous AR and DAX-1 in LNCaP prostate cancer cells can be coimmunoprecipitated suggesting that the interaction is physiological. Surprisingly, although DAX-1 represses partial antagonist activity of AR, it was ineffective in repressing partial antagonist induced activity of PR. In contrast to most reported repressors, the expression of DAX-1 is restricted. We found that although DAX-1 is expressed in normal human prostate, its expression is strongly reduced in benign prostatic hyperplasia suggesting that DAX-1 plays a role in limiting AR activity in prostate.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Weigel, NL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Ayala, Gustavo/ABC-6625-2020; Agoulnik, Irina/AAD-4687-2020	Agoulnik, Irina/0000-0003-4889-0324	NCI NIH HHS [CA 58204] Funding Source: Medline; NICHD NIH HHS [HD 07165] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achermann JC, 2001, MOL CELL ENDOCRINOL, V185, P17, DOI 10.1016/S0303-7207(01)00619-0; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; Bartsch G, 2002, WORLD J UROL, V19, P413, DOI 10.1007/s00345-002-0248-5; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng ST, 2002, MOL ENDOCRINOL, V16, P1492, DOI 10.1210/me.16.7.1492; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Gregory CW, 2001, CANCER RES, V61, P4315; Holter E, 2002, MOL ENDOCRINOL, V16, P515, DOI 10.1210/me.16.3.515; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Liao GQ, 2003, J BIOL CHEM, V278, P5052, DOI 10.1074/jbc.M206374200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; MILAD M, 1995, MOL ENDOCRINOL, V9, P838, DOI 10.1210/me.9.7.838; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Narayanan R, 2002, BONE, V31, P381, DOI 10.1016/S8756-3282(02)00836-0; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P1532, DOI 10.1210/endo-122-4-1532; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nazareth LV, 1999, MOL ENDOCRINOL, V13, P2065, DOI 10.1210/me.13.12.2065; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WHEELER TM, 1994, PROSTATE, V25, P274, DOI 10.1002/pros.2990250507; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	49	108	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31136	31148		10.1074/jbc.M305153200	http://dx.doi.org/10.1074/jbc.M305153200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12771131	hybrid			2022-12-25	WOS:000184658800091
J	Bidere, N; Lorenzo, HK; Carmona, S; Laforge, M; Harper, F; Dumont, C; Senik, A				Bidere, N; Lorenzo, HK; Carmona, S; Laforge, M; Harper, F; Dumont, C; Senik, A			Cathepsin D triggers bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; MITOCHONDRIAL-MEMBRANE; INTRACELLULAR PH; TNF-ALPHA; PATHWAYS; PROTEASE; TRANSLOCATION; DEGRADATION	Activated human T lymphocytes exposed to apoptotic stimuli targeting mitochondria (i.e. staurosporine), enter an early, caspase-independent phase of commitment to apoptosis characterized by cell shrinkage and peripheral chromatin condensation. We show that during this phase, AIF is selectively released from the intermembrane space of mitochondria, and that Bax undergo conformational change, relocation to mitochondria, and insertion into the outer mitochondrial membrane, in a Bid-independent manner. We analyzed the subcellular distribution of cathepsins (Cat) B, D, and L, in a search for caspase-independent factors responsible for Bax activation and AIF release. All were translocated from lysosomes to the cytosol, in correlation with limited destabilization of the lysosomes and release of lysosomal molecules in a size selective manner. However, only inhibition of Cat D activity by pepstatin A inhibited the early apoptotic events and delayed cell death, even in the presence of bafilomycin A(1), an inhibitor of vacuolar type H+-ATPase, which inhibits acidification in lysosomes. Small interfering RNA-mediated gene silencing was used to inactivate Cat D, Bax, and AIF gene expression. This allowed us to define a novel sequence of events in which Cat D triggers Bax activation, Bax induces the selective release of mitochondrial AIF, and the latter is responsible for the early apoptotic phenotype.	Hop Paul Brousse, INSERM, U542, Lab Greffes Epitheliums & Regulat Activat Lymphoc, F-94807 Villejuif, France; CNRS, UPR IAL 1983, Lab Genet Mol & Integrat Fonct Cellulaires, Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Senik, A (corresponding author), Hop Paul Brousse, INSERM, U542, Lab Greffes Epitheliums & Regulat Activat Lymphoc, 14 Ave Paul Vaillant Couturier,Batiment Lavoisier, F-94807 Villejuif, France.		Bidère, Nicolas/K-8887-2015; Lorenzo, Hans-Kristian/GLR-5785-2022	Bidère, Nicolas/0000-0001-9177-0008; Lorenzo, Hans Kristian/0000-0002-7921-177X				Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Bidere N, 2002, J BIOL CHEM, V277, P32339, DOI 10.1074/jbc.M205153200; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Lee AY, 1998, NAT STRUCT BIOL, V5, P866, DOI 10.1038/2306; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Rathmell JC, 2002, NAT IMMUNOL, V3, P932, DOI 10.1038/ni834; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	48	353	365	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31401	31411		10.1074/jbc.M301911200	http://dx.doi.org/10.1074/jbc.M301911200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782632	hybrid			2022-12-25	WOS:000184658800123
J	Bylund, J; Bjorstad, A; Granfeldt, D; Karlsson, A; Woschnagg, C; Dahlgren, C				Bylund, J; Bjorstad, A; Granfeldt, D; Karlsson, A; Woschnagg, C; Dahlgren, C			Reactivation of formyl peptide receptors triggers the neutrophil NADPH-oxidase but not a transient rise in intracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONYL-LEUCYL-PHENYLALANINE; PROTEIN-KINASE ACTIVATION; CHEMOATTRACTANT RECEPTORS; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE; GRANULE MOBILIZATION; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; RESPIRATORY BURST; HL-60 CELLS	In neutrophils, coupling of chemoattractants to their cell surface receptor at low temperature (less than or equal to15 degreesC) leads to receptor deactivation/desensitization without any triggering of the superoxide anion-generating NADPH-oxidase. We show that the deactivated formyl peptide receptors (FPRs) can be reactivated/resensitized by the cytoskeleton-disrupting drug cytochalasin B. Such cytoskeleton-dependent receptor reactivation occurs also with the closely related receptors FPR-like-1 and C5aR but not with the receptors for interleukin-8 and platelet-activating factor. The reactivation state was further characterized with FPR as a model. The signals generated by receptor reactivation induced superoxide production that was terminated in 5-8 min, after which the neutrophils entered a new state of homologous deactivation. FPR antagonists were potent inhibitors of the superoxide production induced by the reactivated receptors, suggesting that the occupied receptors turn into an actively signaling state when the cytoskeleton is disrupted. The signals generated by the reactivated receptor were pertussis toxin-sensitive, indicating involvement of a G-protein. However, no transient elevation of intracellular Ca2+ accompanies the NADPH-oxidase activation. This was not due to a general down-regulation of phospholipase C/Ca2+ signaling, and despite the fact that no intracellular Ca2+ transient was generated, protein kinase C still appeared to be involved in the response. Further, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, and MEK all participated in the generation of second messengers from the reactivated receptors.	Gothenburg Univ, Dept Rheumatol & Inflammat Res, S-41346 Gothenburg, Sweden	University of Gothenburg	Dahlgren, C (corresponding author), Gothenburg Univ, Dept Rheumatol & Inflammat Res, Guldhedsgatan 10, S-41346 Gothenburg, Sweden.	Claes.Dahlgren@microbio.gu.se	TEST-GU, TEST-GU/B-5469-2010; Karlsson, Anna/A-4130-2012	Granfeldt, Daniel/0000-0002-2617-2033; Karlsson, Anna/0000-0001-6796-1154				Almkvist J, 2001, INFECT IMMUN, V69, P832, DOI 10.1128/IAI.69.2.832-837.2001; ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Benard V, 1999, TRENDS PHARMACOL SCI, V20, P365, DOI 10.1016/S0165-6147(99)01367-X; BENGTSSON T, 1991, J LEUKOCYTE BIOL, V49, P236, DOI 10.1002/jlb.49.3.236; Bennett TA, 2001, J BIOL CHEM, V276, P22453, DOI 10.1074/jbc.M009679200; Borregaard N, 2001, CURR OPIN HEMATOL, V8, P23, DOI 10.1097/00062752-200101000-00005; BOYUM A, 1991, SCAND J IMMUNOL, V34, P697, DOI 10.1111/j.1365-3083.1991.tb01594.x; Bylund J, 2002, INFECT IMMUN, V70, P2908, DOI 10.1128/IAI.70.6.2908-2914.2002; Bylund J, 2003, EXP CELL RES, V282, P70, DOI 10.1016/S0014-4827(02)00010-1; Christophe T, 2001, J BIOL CHEM, V276, P21585, DOI 10.1074/jbc.M007769200; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; COLLINS SJ, 1987, BLOOD, V70, P1233; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; FoyouziYoussefi R, 1997, BIOCHEM J, V322, P709, DOI 10.1042/bj3220709; Gilbert TL, 1999, J RECEPT SIGNAL TR R, V19, P327, DOI 10.3109/10799899909036655; GRIPENTROG JM, 2000, BIOCHEM J, V2, P399; Haribabu B, 2000, IMMUNOL RES, V22, P271, DOI 10.1385/IR:22:2-3:271; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; JESAITIS AJ, 1993, EUR J HAEMATOL, V51, P288; JESAITIS AJ, 1986, J BIOL CHEM, V261, P3662; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; JOHNSTON JJ, 1992, BLOOD, V80, P2088; Kardos J, 2001, TRENDS PHARMACOL SCI, V22, P642, DOI 10.1016/S0165-6147(00)01824-1; Katanaev VL, 2001, BIOCHEMISTRY-MOSCOW+, V66, P351, DOI 10.1023/A:1010293809553; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; KLOTZ KN, 1994, BIOESSAYS, V16, P193, DOI 10.1002/bies.950160310; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liu L, 1998, J IMMUNOL, V160, P2463; LUNDQVIST H, 1994, BBA-MOL CELL RES, V1224, P43, DOI 10.1016/0167-4889(94)90111-2; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; Matsukawa A, 2000, Rev Immunogenet, V2, P339; MCPHAIL LC, 1984, J BIOL CHEM, V259, P5768; Mollapour E, 2001, BLOOD, V97, P2469, DOI 10.1182/blood.V97.8.2469; MUKHERJEE G, 1994, J LEUKOCYTE BIOL, V55, P685, DOI 10.1002/jlb.55.6.685; Nusse O, 1998, EMBO J, V17, P1279, DOI 10.1093/emboj/17.5.1279; Potter RM, 2002, J BIOL CHEM, V277, P8970, DOI 10.1074/jbc.M111086200; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; Rane MJ, 2000, BIOCHEM PHARMACOL, V60, P179, DOI 10.1016/S0006-2952(00)00313-0; Riccobene TA, 1999, J THEOR BIOL, V200, P207, DOI 10.1006/jtbi.1999.0988; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; SIMCHOWITZ L, 1990, J BIOL CHEM, V265, P13449; Stossel T., 1999, INFLAMMATION BASIC P, P661; Szaszi K, 1999, FREE RADICAL BIO MED, V27, P764, DOI 10.1016/S0891-5849(99)00126-4; UHING RJ, 1999, INFLAMMATION BASIC P, P607; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3	50	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30578	30586		10.1074/jbc.M209202200	http://dx.doi.org/10.1074/jbc.M209202200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12773548	hybrid			2022-12-25	WOS:000184658800022
J	Hausmann, S; Pei, Y; Shuman, S				Hausmann, S; Pei, Y; Shuman, S			Homodimeric quaternary structure is required for the in vivo function and thermal stability of Saccharomyces cerevisiae and Schizosaccharomyces pombe RNA triphosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; CAPPING ENZYME; POLYMERASE-II; GUANYLYLTRANSFERASE COMPONENT; YEAST; MECHANISM; PHOSPHORYLATION; ASSOCIATION; EFFICIENCY	Saccharomyces cerevisiae Cet1 and Schizosaccharomyces pombe Pct1 are the essential RNA triphosphatase components of the mRNA capping apparatus of budding and fission yeast, respectively. Cet1 and Pct1 share a baroque active site architecture and a homodimeric quaternary structure. The active site is located within a topologically closed hydrophilic beta-barrel (the triphosphate tunnel) that rests on a globular core domain (the pedestal) composed of elements from both protomers of the homodimer. Earlier studies of the effects of alanine cluster mutations at the crystallographic dimer interface of Cet1 suggested that homodimerization is important for triphosphatase function in vivo, albeit not for catalysis. Here, we studied the effects of 14 single-alanine mutations on Cet1 activity and thereby pinpointed Asp(280) as a critical side chain required for dimer formation. We find that disruption of the dimer interface is lethal in vivo and renders Cet1 activity thermolabile at physiological temperatures in vitro. In addition, we identify individual residues within the pedestal domain (Ile(470), Leu(519), Ile(520), Phe(523), Leu(524), and Ile(530)) that stabilize Cet1 in vivo and in vitro. In the case of Pct1, we show that dimerization depends on the peptide segment (VPKIEMNFLN50)-V-41 located immediately prior to the start of the Pct1 catalytic domain. Deletion of this peptide converts Pct1 into a catalytically active monomer that is defective in vivo in S. pombe and hypersensitive to thermal inactivation in vitro. Our findings suggest an explanation for the conservation of quaternary structure in fungal RNA triphosphatases, whereby the delicate tunnel architecture of the active site is stabilized by the homodimeric pedestal domain.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Hausmann S, 2001, J BIOL CHEM, V276, P36116, DOI 10.1074/jbc.M105856200; Ho CK, 2001, J BIOL CHEM, V276, P46182, DOI 10.1074/jbc.M108706200; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lehman K, 2001, J BIOL CHEM, V276, P14996, DOI 10.1074/jbc.M100588200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mukai Y, 2003, J BIOL CHEM, V278, P18895, DOI 10.1074/jbc.M302155200; Myers LC, 2002, MOL CELL, V10, P883, DOI 10.1016/S1097-2765(02)00644-5; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 2003, J BIOL CHEM, V278, P7180, DOI 10.1074/jbc.M211713200; Pei Y, 2001, BMC Microbiol, V1, P29, DOI 10.1186/1471-2180-1-29; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Takagi T, 2001, MOL BIOCHEM PARASIT, V114, P239, DOI 10.1016/S0166-6851(01)00254-7; Takase Y, 2000, MOL CELL BIOL, V20, P9307, DOI 10.1128/MCB.20.24.9307-9316.2000; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	40	11	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30487	30496		10.1074/jbc.M303060200	http://dx.doi.org/10.1074/jbc.M303060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12788946	hybrid			2022-12-25	WOS:000184658800012
J	Kang, S; Spann, NJ; Hui, TY; Davis, RA				Kang, S; Spann, NJ; Hui, TY; Davis, RA			ARP-1/COUP-TF II determines hepatoma phenotype by acting as both a transcriptional repressor of microsomal triglyceride transfer protein and an inducer of CYP7A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; STEROID-RECEPTOR SUPERFAMILY; APOLIPOPROTEIN-B; CHOLESTEROL 7-ALPHA-HYDROXYLASE; COUP-TFII; MESSENGER-RNA; RAT-LIVER; APO-B; GENE; EXPRESSION	L35 and FAO cells were derived as single cell isolates from H35 cells. Whereas L35 cells do not express microsomal triglyceride transfer protein (MTP), which regulates lipoprotein secretion, they express CYP7A1, which regulates bile acid synthesis from cholesterol. FAO cells display the opposite phenotype (i.e. expression of MTP but not CYP7A1). We examined the molecular basis of the transcriptional inactivation of the MTP gene in L35 cells. Nested deletion and mutagenesis studies show that a conserved DR1 element within the 135-bp proximal MTP promoter is responsible for differential expression by L35 and FAO cells. Yeast one-hybrid screening identified apolipoprotein A1 regulatory protein-1/chicken ovalbumin upstream promoter transcription factor II (ARP-1/COUP-TFII) and retinoid X receptor (RXRalpha) as the protein factors that can bind to the conserved DR1 element. Nuclear extracts from L35 cells contained 2-fold more ARP-1/COUP-TFII and 50% less RXRalpha than those from FAO cells. Immunologic studies show that in L35 cells, ARP-1/COUP-TFII is bound to the DR1 element, whereas in FAO cells, a complex containing RXRalpha is bound to the DR1 element. Co-transfection studies show that ARP-1/COUP-TFII repressed MTP promoter activity by similar to70% in FAO hepatoma cells, whereas RXRalpha and its ligand 9-cis-retinoic acid increased MTP promoter activity by 6-fold in L35 cells. The combined data suggest that in the context of the MTP promoter, ARP-1/COUP-TFII (repressor) and a complex containing RXRalpha (inducer) compete for the DR1 element. Analysis of the CYP7A1 promoter revealed that it is similar to5-fold more active in L35 cells than in FAO cells. Co-transfection of an ARP-1/COUP-TFII expression vector showed that it enhances CYP7A1 promoter activity by 6-fold in FAO cells. These combined findings indicate that ARP-1/COUP-TFII acts as both a transcriptional repressor (of MTP) and as a transcription activator (of CYP7A1). This dual function of ARP-1/COUP-TFII may play an important role in determining the metabolic phenotype of individual liver cells.	San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, Inst Mol Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Heart, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Davis, RA (corresponding author), San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, Inst Mol Biol, Life Sci Bldg,LS307,5500 Campanile Dr, San Diego, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051648] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51648] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker DM, 2000, J BIOL CHEM, V275, P19985, DOI 10.1074/jbc.M002351200; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Bernard S, 2000, DIABETOLOGIA, V43, P995, DOI 10.1007/s001250051481; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 2001, ARTERIOSCL THROM VAS, V21, P887, DOI 10.1161/01.ATV.21.6.887; Davis RA, 2002, J LIPID RES, V43, P533; DAVIS RA, 1999, BIOCHIM BIOPHYS ACTA, V1441, P1; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Du EZ, 1996, J LIPID RES, V37, P1309; DUELAND S, 1992, J BIOL CHEM, V267, P22695; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HARDISON WG, 1972, AM J PHYSIOL, V222, P61, DOI 10.1152/ajplegacy.1972.222.1.61; Hui TY, 2002, J LIPID RES, V43, P785; Jamil H, 1998, J LIPID RES, V39, P1448; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Karpe F, 1998, ARTERIOSCL THROM VAS, V18, P756, DOI 10.1161/01.ATV.18.5.756; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Ledmyr H, 2002, J LIPID RES, V43, P51; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; Lindros KO, 1997, CELL BIOL TOXICOL, V13, P257, DOI 10.1023/A:1007479223229; Massimi M, 1998, HEPATOLOGY, V28, P1064, DOI 10.1002/hep.510280422; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Miura K, 2002, J MOL ENDOCRINOL, V29, P223, DOI 10.1677/jme.0.0290223; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Miyake JH, 2002, ARTERIOSCL THROM VAS, V22, P121, DOI 10.1161/hq0102.102588; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Puchowicz MA, 1999, AM J PHYSIOL-ENDOC M, V277, pE1022, DOI 10.1152/ajpendo.1999.277.6.E1022; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Stroup D, 2000, J LIPID RES, V41, P1; Stroup D, 1997, J BIOL CHEM, V272, P9833; Tietge UJF, 1999, J LIPID RES, V40, P2134; Trawick JD, 1997, J BIOL CHEM, V272, P3099, DOI 10.1074/jbc.272.5.3099; Trawick JD, 1996, J LIPID RES, V37, P588; TWISK J, 1995, J CLIN INVEST, V95, P1235, DOI 10.1172/JCI117773; VLAHCEVIC ZR, 1992, SEMIN LIVER DIS, V12, P403, DOI 10.1055/s-2008-1040410; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WETTERAU JR, 1992, SCIENCE, V258, P999; Zhang P, 2002, MECH DEVELOP, V119, P109, DOI 10.1016/S0925-4773(02)00286-1	50	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30478	30486		10.1074/jbc.M304201200	http://dx.doi.org/10.1074/jbc.M304201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12777384	hybrid			2022-12-25	WOS:000184658800011
J	Okada, T; Haze, K; Nadanaka, S; Yoshida, H; Seidah, NG; Hirano, Y; Sato, R; Negishi, M; Mori, K				Okada, T; Haze, K; Nadanaka, S; Yoshida, H; Seidah, NG; Hirano, Y; Sato, R; Negishi, M; Mori, K			A serine protease inhibitor prevents endoplasmic reticulum stress-induced cleavage but not transport of the membrane-bound transcription factor ATF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; NF-Y CBF; REGULATORY ELEMENT; ESCHERICHIA-COLI; ER STRESS; SITE-1 PROTEASE; GENE-PRODUCT; PROTEOLYSIS; GOLGI; IDENTIFICATION	Mammalian cells express several transcription factors embedded in the endoplasmic reticulum (ER) as transmembrane proteins that are activated by proteolysis, and two types of these proteins have been extensively investigated. One type comprises the sterol regulatory element-binding proteins (SREBP-1 and SREBP-2). The other type comprises the activating transcription factors 6 (ATF6alpha and ATF6beta), which are activated in response to ER stress. It was shown previously that both SREBP and ATF6 are cleaved sequentially first by the Site-1 protease (serine protease) and then by the Site-2 protease (metalloprotease) (Ye, J., Rawson, R. B., Komuro, R., Chen, X., Dave, U. P., Prywes, R., Brown, M. S., and Goldstein, J. L. (2000) Mol. Cell 6, 1355-1364). In this study, we examined various protease inhibitors and found that 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), a serine protease inhibitor, prevented ER stress-induced cleavage of ATF6alpha and ATF6beta, resulting in inhibition of transcriptional induction of ATF6-target genes. AEBSF also inhibited production of the mature form of SREBP-2 that was induced in response to sterol depletion, and appeared to directly prevent cleavage of ATF6alpha and ATF6beta by inhibiting Site-1 protease. As the Site-1 protease is localized in the Golgi apparatus, both SREBP and ATF6 must relocate to the Golgi apparatus to be cleaved. We showed here that AEBSF treatment had little effect on ER stress-induced translocation of ATF6 from the ER to the Golgi apparatus, but blocked nuclear localization of ATF6. These results indicate that the transport of ATF6 from the ER to the Golgi apparatus and that from the Golgi apparatus to the nucleus are distinct steps that can be distinguished by treatment with AEBSF.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068304, Japan; Japan Sci & Technol Corp, CREST, Saitama 3320012, Japan; HSP Res Inst, Kyoto 6008813, Japan; Japan Sci & Technol Corp, PRESTO, Saitama 3320012, Japan; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan	Kyoto University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Tokyo	Mori, K (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, 46-29 Yoshida Shimoadachi, Kyoto 6068304, Japan.		Mori, Kazutoshi/K-6106-2015; Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; Yoshida, Hiderou/0000-0002-5773-1408; Okada, Tetsuya/0000-0002-2513-1301				Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bestilny LJ, 2000, EXP CELL RES, V256, P264, DOI 10.1006/excr.2000.4821; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kanehara K, 2001, GENE, V281, P71, DOI 10.1016/S0378-1119(01)00823-X; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lewis AP, 1999, PROTEIN SCI, V8, P439; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PENAS AD, 1997, MOL MICROBIOL, V24, P373, DOI DOI 10.1046/J.1365-2958.1997.3611718.X; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Sambrook J., 2002, MOL CLONING LAB MANU; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Urano F, 2000, J CELL SCI, V113, P3697; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wang Y, 2000, J BIOL CHEM, V275, P27013; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	47	171	174	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31024	31032		10.1074/jbc.M300923200	http://dx.doi.org/10.1074/jbc.M300923200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12782636	hybrid			2022-12-25	WOS:000184658800078
J	Chatterjee, TK; Liu, ZY; Fisher, RA				Chatterjee, TK; Liu, ZY; Fisher, RA			Human RGS6 gene structure, complex alternative splicing, and role of N terminus and G protein gamma-subunit-like (GGL) domain in subcellular localization of RGS6 splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; BETA-SUBUNIT; NUCLEAR-LOCALIZATION; ADENYLYL-CYCLASE; REGULATOR; ACTIVATION; G-BETA-5; BINDING; BRAIN; DESENSITIZATION	RGS proteins are defined by the presence of a semi-conserved RGS domain that confers the GTPase-activating activity of these proteins toward certain Galpha subunits. RGS6 is a member of a subfamily of RGS proteins distinguished by the presence of DEP and GGL domains, the latter a Gbeta5-interacting domain. Here we report identification of 36 distinct transcripts of human RGS6 that arise by unusually complex processing of the RGS6 gene, which spans 630 kilobase pairs of genomic DNA in human chromosome 14 and is interrupted by 19 introns. These transcripts arise by use of two alternative transcription sites and complex alternative splicing mechanisms and encode proteins with long or short N-terminal domains, complete or incomplete GGL domains, 7 distinct C-terminal domains and a common internal domain where the RGS domain is found. The role of structural diversity in the N-terminal and GGL domains of RGS6 splice variants in their interaction with Gbeta5 and subcellular localization and of Gbeta5 on RGS6 protein localization was examined in COS-7 cells expressing various RGS6 splice variant proteins. RGS6 splice variants with complete GGL domains interacted with Gbeta5, irrespective of the type of N-terminal domain, while those lacking a complete GGL domain did not. RGS6 protein variants displayed subcellular distribution patterns ranging from an exclusive cytoplasmic to exclusive nuclear/nucleolar localization, and co-expression of Gbeta5 promoted nuclear localization of RGS6 proteins. Analysis of our results show that the long N-terminal and GGL domain sequences of RGS6 proteins function as cytoplasmic retention sequences to prevent their nuclear/nucleolar accumulation. These findings provide the first evidence for Gbeta5-independent functions of the GGL domain and for a role of Gbeta5 in RGS protein localization. This study reveals extraordinary complexity in processing of the human RGS6 gene and provides new insights into how structural diversity in the RGS6 protein family is involved in their localization and likely function(s) in cells.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.			Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041071, R01HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067881] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NIGMS NIH HHS [GM067881] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 2003, J BIOL CHEM, V278, P30272, DOI 10.1074/jbc.M212688200; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Granneman JG, 1998, MOL PHARMACOL, V54, P687; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Nishizuka M, 2001, J BIOL CHEM, V276, P29625, DOI 10.1074/jbc.C100272200; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang JH, 2000, J NEUROCHEM, V75, P393, DOI 10.1046/j.1471-4159.2000.0750393.x; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200	37	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30261	30271		10.1074/jbc.M212687200	http://dx.doi.org/10.1074/jbc.M212687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12761221	hybrid			2022-12-25	WOS:000184507000106
J	Kwon, YH; Jovanovic, A; Serfas, MS; Tyner, AL				Kwon, YH; Jovanovic, A; Serfas, MS; Tyner, AL			The Cdk inhibitor p21 is required for necrosis, but it inhibits apoptosis following toxin-induced liver injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; P21(WAF1/CIP1) EXPRESSION; MICE; REGENERATION; HEPATOCYTES; PROTEIN; PROLIFERATION; PROGRESSION; MECHANISMS; CANCER	Liver injury and repair were examined in wild type, p21(Waf1/Cip1), and p27(Kip1)-deficient mice following carbon tetrachloride (CCl4) administration. In wild type liver, p21 expression is induced in a biphasic manner following injection of CCl4, with an early peak of p21 expression occurring in pericentral hepatocytes at 6 h, prior to evidence of injury, and a second peak succeeding regenerative proliferation. In contrast, p27 is present throughout the quiescent liver, but its expression decreases following CCl4 injection. Surprisingly, p21-deficient animals were resistant to CCl4-induced necrotic injury, indicating that rapid induction of p21 in pericentral hepatocytes following CCl4 injection contributes to subsequent necrosis. Expression of cytochrome P450 2E1, which plays an essential role in CCl4-induced necrotic injury, was not affected in p21-deficient mice. Although they had the least injury, p21-deficient mice had the highest levels of hepatic proliferation that correlated with increases in hyperphosphorylated retinoblastoma protein and Cyclin A gene expression. Increased replication in p21-deficient livers was counteracted by an increase in hepatocyte apoptosis as detected by caspase-3 activation. p21 plays distinct and opposing roles regulating hepatocyte survival during injury and subsequent repair, with early induction of p21 contributing to necrotic injury and later expression to cessation of proliferation and hepatocyte survival.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-c 669,900 S Ashland Ave, Chicago, IL 60607 USA.			Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056283, R01 DK56283] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeRyckere D, 2002, METHODS, V26, P57, DOI 10.1016/S1046-2023(02)00008-7; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gartel AL, 2002, MOL CANCER THER, V1, P639; GARTEL AL, 1996, P SOC EXP BIOL MED, V213, P137; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Hui AM, 1997, HEPATOLOGY, V25, P575, DOI 10.1002/hep.510250314; Inoue Masayasu, 1994, P443; Jaime M, 2002, HEPATOLOGY, V35, P1063, DOI 10.1053/jhep.2002.32678; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sell S, 2001, HEPATOLOGY, V33, P738, DOI 10.1053/jhep.2001.21900; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLATER TF, 1984, BIOCHEM J, V222, P1; TYNER AL, 2003, G1 PHASE PROGR; Wagayama H, 2002, HUM PATHOL, V33, P429, DOI 10.1053/hupa.2002.124724; Wong FWY, 1998, TOXICOL APPL PHARM, V153, P109, DOI 10.1006/taap.1998.8547	35	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30348	30355		10.1074/jbc.M300996200	http://dx.doi.org/10.1074/jbc.M300996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12759355	hybrid			2022-12-25	WOS:000184507000115
J	Sanzone, S; Zeyda, M; Saemann, MD; Soncini, M; Holter, W; Fritsch, G; Knapp, W; Candotti, F; Stulnig, TM; Parolini, O				Sanzone, S; Zeyda, M; Saemann, MD; Soncini, M; Holter, W; Fritsch, G; Knapp, W; Candotti, F; Stulnig, TM; Parolini, O			SLAM-associated protein deficiency causes imbalanced early signal transduction and blocks downstream activation in T cells from X-linked lymphoproliferative disease patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; GENE-PRODUCT SAP; ACTIN CYTOSKELETON; RECEPTOR; LAT; VIRUS; ADAPTER; TCR; VAV; MOLECULE	Deficiency of SAP ( SLAM ( signaling lymphocyte activation molecule)-associated protein) protein is associated with a severe immunodeficiency, the X-linked lymphoproliferative disease ( XLP) characterized by an inappropriate immune reaction against Epstein-Barr virus infection often resulting in a fatal clinical course. Several studies demonstrated altered NK and T cell function in XLP patients; however, the mechanisms underlying XLP disease are still largely unknown. Here, we show that non-transformed T cell lines obtained from XLP patients were defective in several activation events such as IL-2 production, CD25 expression, and homotypic cell aggregation when cells were stimulated via T cell antigen receptor (TCR).CD3 but not when early TCR-dependent events were bypassed by stimulation with phorbol 12-myristate 13-acetate/ionomycin. Analysis of proximal T cell signaling revealed imbalanced TCR . CD3-induced signaling in SAP-deficient T cells. Although phospholipase Cgamma1 phosphorylation and calcium response were both enhanced in T cells from XLP patients, phosphorylation of VAV and downstream signal transduction events such as mitogen-activated protein kinase phosphorylation and IL-2 production were diminished. Importantly, reconstitution of SAP expression by retroviral-mediated gene transfer completely restored abnormal signaling events in T cell lines derived from XLP patients. In conclusion, SAP mutation or deletion in XLP patients causes profound defects in T cell activation, resulting in immune deficiency. Moreover, these data provide evidence that SAP functions as an essential integrator in early TCR signal transduction.	Osped Poliambulanza, Ctr Ric Parco Sci E Menni, I-25124 Brescia, Italy; Lab Interdisciplinare Tecnol Avanzate, Dipartimento Sci & Tecnol Biomed, I-20090 Milan, Italy; Univ Vienna, Div Endocrinol & Metab, Dept Internal Med 3, A-1090 Vienna, Austria; Univ Vienna, Inst Immunol, A-1090 Vienna, Austria; Childrens Canc Res Inst, A-1090 Vienna, Austria; NHGRI, Disorders Immun Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Austrian Acad Sci, Ctr Mol Med, A-1090 Vienna, Austria	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Vienna; University of Vienna; Saint Anna Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Austrian Academy of Sciences	Parolini, O (corresponding author), Osped Poliambulanza, Ctr Ric Parco Sci E Menni, Via Romiglia 4, I-25124 Brescia, Italy.		PAROLINI, ORNELLA/ABI-7862-2020; PAROLINI, ORNELLA/C-7946-2013	PAROLINI, ORNELLA/0000-0002-5211-6430; PAROLINI, ORNELLA/0000-0002-5211-6430; Stulnig, Thomas/0000-0003-3300-6161; Zeyda, Maximilian/0000-0001-5000-1974; Candotti, Fabio/0000-0001-6399-6042	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000122, Z01HG000122] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Aguado E, 2002, SCIENCE, V296, P2036, DOI 10.1126/science.1069057; Aoukaty A, 2002, J BIOL CHEM, V277, P13331, DOI 10.1074/jbc.M112029200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, SEMIN IMMUNOL, V10, P317, DOI 10.1006/smim.1998.0124; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Henning G, 2001, EUR J IMMUNOL, V31, P2741, DOI 10.1002/1521-4141(200109)31:9<2741::AID-IMMU2741>3.0.CO;2-6; Howie D, 2002, BLOOD, V99, P957, DOI 10.1182/blood.V99.3.957; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Krawczyk C, 2002, IMMUNITY, V16, P331, DOI 10.1016/S1074-7613(02)00291-1; Krawczyk C, 2001, J LEUKOCYTE BIOL, V69, P317; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; LATOUR S, 2003, NAT CELL BIOL; Lewis J, 2001, CLIN IMMUNOL, V100, P15, DOI 10.1006/clim.2001.5035; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; Moller A, 2001, J BIOL CHEM, V276, P20022, DOI 10.1074/jbc.M011139200; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nakamura H, 2001, J IMMUNOL, V167, P2657, DOI 10.4049/jimmunol.167.5.2657; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Parolini O, 2003, IMMUNOGENETICS, V55, P116, DOI 10.1007/s00251-003-0557-x; Parolini O, 2002, ANN HEMATOL, V81, P441, DOI 10.1007/s00277-002-0490-3; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Perez-Villar JJ, 2002, BIOCHEMISTRY-US, V41, P10732, DOI 10.1021/bi025554o; Sayos J, 2001, BLOOD, V97, P3867, DOI 10.1182/blood.V97.12.3867; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Tangye SG, 2000, MOL IMMUNOL, V37, P493, DOI 10.1016/S0161-5890(00)00076-6; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VEILLETTE A, 2002, SCI STKE; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Zeyda M, 2002, J BIOL CHEM, V277, P28418, DOI 10.1074/jbc.M203343200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	52	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29593	29599		10.1074/jbc.M300565200	http://dx.doi.org/10.1074/jbc.M300565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12766168	hybrid			2022-12-25	WOS:000184507000027
J	Fu, XY; Kassim, SY; Parks, WC; Heinecke, JW				Fu, XY; Kassim, SY; Parks, WC; Heinecke, JW			Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin) - An oxidative mechanism for restraining proteolytic activity during inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; LIPOPROTEIN OXIDATION; CYSTEINE SWITCH; ACTIVATION; NEUTROPHILS; GELATINASE; METHIONINE; OXYGEN; CELLS; ATHEROSCLEROSIS	Dysregulation of matrix metalloproteinase (MMP) activity is implicated in tissue destruction under inflammatory conditions. An important mechanism controlling enzymatic activity might involve reactive oxygen species generated by phagocytes. Myeloperoxidase, a heme protein secreted by neutrophils, monocytes, and macrophages, uses hydrogen peroxide to generate hypochlorous acid (HOCl). We demonstrate that HOCl inhibits the activity of human matrilysin (MMP-7) in vitro, suggesting that it might limit proteolytic activity during inflammation. When MMP-7 was exposed to HOCl generated by myeloperoxidase, the proteinase lost activity. High performance liquid chromatographic analysis of the tryptic digest of the HOCl-treated proteinase demonstrated the absence of two peptides that were present in the untreated enzyme. Tandem mass spectrometric analysis revealed that both of the lost peptides contained methionine and tryptophan-glycine residues. The methionine residue of one of the peptides had been oxidized to methionine sulfoxide. In contrast, the major product from the other peptide was 4 atomic mass units smaller than its precursor ( WG-4). This novel oxidation product was derived though modification of adjacent tryptophan and glycine residues in the catalytic domain of the enzyme. Loss of proteolytic activity was associated with conversion of the precursor peptide to WG-4 but not with methionine oxidation. In contrast, hydrogen peroxide failed to oxidize MMP-7 or to inactivate the enzyme. Thus, HOCl inactivates MMP-7, perhaps by site-specific conversion of tryptophan-glycine to WG-4. This inactivation mechanism is distinct from the well studied mechanisms involving tissue inhibitors of metalloproteinases. Our findings suggest that local pericellular production of HOCl by phagocytes is a physiological mechanism for governing MMP activity during inflammation.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Zhejiang Univ, Dept Chem, Hangzhou 310027, Peoples R China; Washington Univ, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Zhejiang University; Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Univ Washington, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu	Parks, William C./AAH-6786-2021		NHLBI NIH HHS [HL56419, HL64344, HL29594] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, P50HL056419, R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carr AC, 2001, FREE RADICAL BIO MED, V31, P62, DOI 10.1016/S0891-5849(01)00552-4; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Finley EL, 1998, PROTEIN SCI, V7, P2391, DOI 10.1002/pro.5560071116; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Heinecke JW, 1999, FASEB J, V13, P1113, DOI 10.1096/fasebj.13.10.1113; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Hope HR, 2000, PROTEIN EXPRES PURIF, V18, P269, DOI 10.1006/prep.1999.1197; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; Owens MW, 1997, AM J PHYSIOL-LUNG C, V273, pL445, DOI 10.1152/ajplung.1997.273.2.L445; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Walling HW, 1998, J CELL PHYSIOL, V177, P563, DOI 10.1002/(SICI)1097-4652(199812)177:4<563::AID-JCP7>3.0.CO;2-B; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Woessner J.F., 2000, PROTEIN PROFILE SER; WOESSNER JF, 1995, METHOD ENZYMOL, V248, P485; Woessner JF, 1998, BIOL EXTRAC, P1	45	107	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28403	28409		10.1074/jbc.M304739200	http://dx.doi.org/10.1074/jbc.M304739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759346	hybrid			2022-12-25	WOS:000184421100009
J	Rumberger, JM; Wu, T; Hering, MA; Marshall, S				Rumberger, JM; Wu, T; Hering, MA; Marshall, S			Role of hexosamine biosynthesis in glucose-mediated up-regulation of lipogenic enzyme mRNA levels - Effects of glucose, glutamine, and glucosamine on glycerophosphate dehydrogenase, fatty acid synthase, and acetyl-CoA carboxylase mRNA levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; WHITE ADIPOSE-TISSUE; GROWTH-FACTOR BETA-1; GENE-EXPRESSION; INSULIN ACTION; TRANSCRIPTIONAL REGULATION; ISOLATED ADIPOCYTES; PATHWAY; CELLS; STIMULATION	Glucose uptake into adipose and liver cells is known to up-regulate mRNA levels for various lipogenic enzymes such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). To determine whether the hexosamine biosynthesis pathway (HBP) mediates glucose regulation of mRNA expression, we treated primary cultured adipocytes for 18 h with insulin ( 25 ng/ml) and either glucose ( 20 mM) or glucosamine ( 2 mM). A ribonuclease protection assay was used to quantitate mRNA levels for FAS, ACC, and glycerol-3-P dehydrogenase (GPDH). Treatment with insulin and various concentrations of D-glucose increased mRNA levels for FAS (280%), ACC (93%), and GPDH (633%) in a dose-dependent manner (ED50 8 - 16 mM). Mannose similarly elevated mRNA levels, but galactose and fructose were only partially effective. L-glucose had no effect. Omission of glutamine from the culture medium markedly diminished the stimulatory effect of glucose on mRNA expression. Since glutamine is a crucial amide donor in hexosamine biosynthesis, we interpret these data to mean that glucose flux through the HBP is linked to regulation of lipogenesis through control of gene expression. Further evidence for hexosamine regulation was obtained using glucosamine, which is readily transported into adipocytes where it directly enters the HBP. Glucosamine was 15 - 30 times more potent than glucose in elevating FAS, ACC, and GPDH mRNA levels (ED50 similar to 0.5 mM). In summary: 1) GPDH, FAS, and ACC mRNA levels are upregulated by glucose; 2) glucose-induced up-regulation requires glutamine; and 3) mRNA levels for lipogenic enzymes are up-regulated by glucosamine. Hyperglycemia is the hallmark of diabetes mellitus and leads to insulin resistance, impaired glucose metabolism, and dyslipidemia. We postulate that disease pathophysiology may have a common underlying factor, excessive glucose flux through the HBP.	Hexos Inc, Woodinville, WA 98072 USA		Marshall, S (corresponding author), Hexos Inc, 18304 NE 153rd St, Woodinville, WA 98072 USA.							CLARKE SD, 1993, J ANIM SCI, V71, P1957, DOI 10.2527/1993.7171957x; Daniels MC, 2000, AM J MED SCI, V319, P138, DOI 10.1097/00000441-200003000-00002; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DUGAIL I, 1992, BIOCHEM J, V281, P607, DOI 10.1042/bj2810607; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; Jones BH, 1998, BIOCHEM J, V335, P405, DOI 10.1042/bj3350405; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; Li QM, 1998, AM J PHYSIOL-ENDOC M, V274, pE577, DOI 10.1152/ajpendo.1998.274.4.E577; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; Marshall S, 2000, DIABETES ANNUAL/13, P97; Marshall S, 2003, ANAL BIOCHEM, V314, P169, DOI 10.1016/S0003-2697(02)00686-3; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; MARSHALL S, 2002, CURR OPIN ENDOCRINOL, V9, P160; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; McClain DA, 2000, ENDOCRINOLOGY, V141, P1999, DOI 10.1210/en.141.6.1999; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; Raclot T, 1998, BIOCHEM BIOPH RES CO, V245, P510, DOI 10.1006/bbrc.1998.8469; RODBELL M, 1964, J BIOL CHEM, V239, P375; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; STIFEL FB, 1969, BIOCHIM BIOPHYS ACTA, V184, P29, DOI 10.1016/0304-4165(69)90094-4; TRAXINGER RR, 1992, J BIOL CHEM, V267, P9718; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474	29	52	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28547	28552		10.1074/jbc.M302793200	http://dx.doi.org/10.1074/jbc.M302793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12759350	hybrid			2022-12-25	WOS:000184421100027
J	Nahoum, V; Gangloff, A; Shi, R; Lin, SX				Nahoum, V; Gangloff, A; Shi, R; Lin, SX			How estrogen-specific proteins discriminate estrogens from androgens: A common steroid-binding site architecture	FASEB JOURNAL			English	Article						"sandwich-like" structure; estrogen-specific; estrogen receptor; 17 beta-HSD1; estrogen sulfotransferase; convergent evolution	HUMAN 17-BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURE; HUMAN-BREAST; ESTRADIOL; RECEPTOR; CANCER; C-19-DELTA-5-STEROIDS; 17-BETA-ESTRADIOL; SULFOTRANSFERASE; INTRACRINOLOGY	Steroid hormones play an essential role in a wide range of physiological and pathological processes, such as growth, metabolism, aging, and hormone-sensitive cancers. Estrogens are no exception and influence growth, differentiation, and functioning of many target tissues, such as the mammary gland, uterus, hypothalamus, pituitary, bone, and liver. Although very similar in structure, each steroid class (i.e., estrogens, androgens, progestins, mineral corticoids, or glucocorticoids) is responsible for distinct physiological processes. To permit specific biological responses for a given steroid class, specific proteins are responsible for steroid bioactivation, action, and inactivation, yet they have low or no affinity to other classes. Estrogens make no exception and possess their own set of related proteins. To understand the molecular basis underlying estrogen recognition from other steroids, structural features of estrogen-specific proteins were analyzed along with their ability to discriminate between steroid hormones belonging to different classes. Hence, the study of all estrogen-specific proteins for which an atomic structure has been determined demonstrated that a common steroid-binding pocket architecture is shared by these proteins. This architecture is composed of the following elements: i) a glutamate residue acting as a proton acceptor coupled with a proton donor that interact with the steroid O3; ii) a proton donor (His or Ser) that interacts with O17; iii) a highly conserved sandwich-like structure providing steric hindrance and preventing C19 steroid from binding; and iv) several amino acid residues interacting with the C18. As these different estrogen-specific proteins are not related in overall sequence, the inference is that the steroid binding site in these proteins has originated by convergent evolution.	CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ, Canada	Laval University; Laval University	Lin, SX (corresponding author), CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Gangloff, Anne/0000-0002-6848-6559; Nahoum, Virginie/0000-0003-3125-6618; Lin, Sheng-Xiang/0000-0001-9149-375X				AAKVAAG A, 1990, CANCER RES, V50, P7806; ADAMS JB, 1985, MOL CELL ENDOCRINOL, V41, P1, DOI 10.1016/0303-7207(85)90138-8; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; Ekena K, 1998, J BIOL CHEM, V273, P693, DOI 10.1074/jbc.273.2.693; Gangloff A, 2002, FASEB J, V16, P274, DOI 10.1096/fj.02-0397fje; Gangloff A, 2001, BIOCHEM J, V356, P269, DOI 10.1042/0264-6021:3560269; Han Q, 2000, J BIOL CHEM, V275, P1105, DOI 10.1074/jbc.275.2.1105; Huang YW, 2001, MOL ENDOCRINOL, V15, P2010, DOI 10.1210/me.15.11.2010; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KATZENELLENBOGEN BS, 1980, ANNU REV PHYSIOL, V42, P17, DOI 10.1146/annurev.ph.42.030180.000313; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; Lamminmaki U, 2001, J BIOL CHEM, V276, P36687, DOI 10.1074/jbc.M102367200; Mazza C, 1998, J BIOL CHEM, V273, P8145, DOI 10.1074/jbc.273.14.8145; Monnet C, 2002, J MOL BIOL, V315, P699, DOI 10.1006/jmbi.2001.5284; MURDOCK GL, 1988, BIOCHEMISTRY-US, V27, P4452, DOI 10.1021/bi00412a036; Petrotchenko EV, 1999, J BIOL CHEM, V274, P30019, DOI 10.1074/jbc.274.42.30019; POULIN R, 1986, CANCER RES, V46, P4933; Puranen T, 1997, MOL ENDOCRINOL, V11, P77, DOI 10.1210/me.11.1.77; READ LD, 1991, CHARACTERIZATION REG; Sarrel P.M., 1994, SCI MED, V1, P44; Sasano H, 2000, ONCOLOGY-BASEL, V59, P5, DOI 10.1159/000055281; SIMARD J, 1988, MOL CELL ENDOCRINOL, V55, P233, DOI 10.1016/0303-7207(88)90138-4; SIMARD J, 1987, J STEROID BIOCHEM, V26, P539, DOI 10.1016/0022-4731(87)90005-7; Suzuki T, 2000, BRIT J CANCER, V82, P518; Trinh CH, 1997, STRUCTURE, V5, P937, DOI 10.1016/S0969-2126(97)00247-5; Yue W, 1998, CANCER RES, V58, P927	31	36	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1334	+		10.1096/fj.02-0524fje	http://dx.doi.org/10.1096/fj.02-0524fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759331				2022-12-25	WOS:000183165000013
